,Unnamed: 0_x,English,Chinese_Google,Dict_Acc_Google,Terms_Google,Correct_Terms_Google,Unnamed: 0_y,Chinese_M2M,Dict_Acc_M2M,Terms_M2M,Correct_Terms_M2M,Human Eval Google,Human Eval M2M
0,0,probably not : analysis suggests minimal effect of HT in maintaining lean body mass .,可能不是：分析表明 HT 在维持瘦体重方面的作用微乎其微。,0.4,"['analysis', 'effect', 'minimal', 'mass', 'body']","['analysis', 'effect']",0,['可能不是:分析表明HT在维持脂肪体重的最小效果。'],0.4,"['analysis', 'effect', 'minimal', 'mass', 'body']","['analysis', 'effect']",10.0,7.0
1,1,investigators identified 12 randomized trials of menopausal HT in which changes in LBM were assessed .,研究人员确定了 12 项评估 LBM 变化的绝经期 HT 随机试验。,0.0,"['menopausal', 'in', 'assessed']",[],1,"['研究人员确定了12次随机测试,其中评估了LBM的变化。']",0.0,"['menopausal', 'in', 'assessed']",[],9.0,8.0
2,2,Intensifying blood pressure regimens at discharge in older adults was associated with excess readmissions and serious adverse events .,老年人出院时强化血压方案与再入院率和严重不良事件有关。,0.0909090909090909,"['discharge', 'excess', 'pressure', 'blood', 'blood pressure', 'adverse', 'associated', 'with', 'serious', 'in', 'and']",['blood pressure'],2,['在老年人排放时的血压强化制度与过度回收和严重的副作用有关。'],0.1818181818181818,"['discharge', 'excess', 'pressure', 'blood', 'blood pressure', 'adverse', 'associated', 'with', 'serious', 'in', 'and']","['pressure', 'blood pressure']",10.0,5.0
3,3,"during hospitalization , patients frequently have transient elevations in blood pressure ( BP ) , which result in modification of their outpatient antihypertensive regimens at discharge .",住院期间，患者的血压 (BP) 经常出现短暂升高，这导致他们在出院时修改门诊降压方案。,0.25,"['transient', 'discharge', 'modification', 'antihypertensive', 'pressure', 'blood', 'frequently', 'blood pressure', 'hospitalization', 'result', 'have', 'in']","['antihypertensive', 'blood pressure', 'hospitalization']",3,"['在入院期间,患者经常有过渡的血压(BP)上升,这导致他们在排放时的病人抗高血压饮食的变化。']",0.25,"['transient', 'discharge', 'modification', 'antihypertensive', 'pressure', 'blood', 'frequently', 'blood pressure', 'hospitalization', 'result', 'have', 'in']","['antihypertensive', 'blood pressure', 'have']",10.0,5.0
4,4,no studies have been designed to evaluate whether this practice improves outcomes .,尚未设计任何研究来评估这种做法是否会改善结果。,0.2,"['no', 'practice', 'have', 'this', 'to']",['this'],4,['没有任何研究旨在评估这种实践是否会改善结果。'],0.6,"['no', 'practice', 'have', 'this', 'to']","['practice', 'have', 'this']",10.0,10.0
5,5,"at 1 year , mean systolic BP and incidence of adverse cardiac events were similar in the two groups .",1 年时，两组的平均收缩压和不良心脏事件的发生率相似。,0.5454545454545454,"['cardiac', 'incidence', 'mean', 'year', '1', 'adverse', 'systolic', 'at', 'and', 'two', 'similar']","['cardiac', 'incidence', 'mean', 'year', '1', 'two']",5,"['在1年,中间系统性BP和不良心脏病发作的发病率在两组中相似。']",0.4545454545454545,"['cardiac', 'incidence', 'mean', 'year', '1', 'adverse', 'systolic', 'at', 'and', 'two', 'similar']","['cardiac', 'incidence', 'year', '1', 'two']",10.0,7.0
6,6,this study highlights a common clinical inpatient scenario .,这项研究突出了一种常见的临床住院情况。,0.1666666666666666,"['a', 'study', 'common', 'clinical', 'inpatient', 'this']",['clinical'],6,['这项研究强调了一个常见的临床病人场景。'],0.1666666666666666,"['a', 'study', 'common', 'clinical', 'inpatient', 'this']",['clinical'],10.0,8.0
7,7,"clinicians often feel compelled to act on elevated BP readings in hospitalized patients , but these results suggest we should do otherwise .",临床医生常常觉得有必要对住院患者的血压读数升高采取行动，但这些结果表明我们不应该这样做。,0.25,"['feel', 'act', 'readings', 'suggest', 'act on', 'but', 'to', 'we']","['act', 'but']",7,"['临床医生经常觉得被迫在入院的患者中采取高BP阅读行动,但这些结果表明我们应该做不一样的事情。']",0.25,"['feel', 'act', 'readings', 'suggest', 'act on', 'but', 'to', 'we']","['act', 'but']",10.0,4.0
8,8,a guideline that addresses asymptomatic BP elevations in hospitalized patients would be helpful .,解决住院患者无症状血压升高的指南会有所帮助。,0.2,"['a', 'be', 'asymptomatic', 'that', 'in']",['asymptomatic'],8,['在入院患者中处理无症状BP上升的指导方针将有助于。'],0.4,"['a', 'be', 'asymptomatic', 'that', 'in']","['be', 'asymptomatic']",10.0,9.0
9,9,there is a recent emphasis in liver disease management on how best to identify individuals at increased risk for clinically significant disease in the primary care setting .,肝病管理最近强调如何在初级保健环境中最好地识别出临床上重要疾病风险增加的个体。,0.5,"['liver', 'disease', 'setting', 'recent', 'liver disease', 'primary', 'risk', 'management', 'identify', 'care', 'emphasis', 'at', 'on', 'to']","['liver', 'disease', 'liver disease', 'risk', 'management', 'identify', 'emphasis']",9,"['在肝脏疾病管理中,最近强调如何最好地识别在初级护理环境中患有临床意义的疾病风险的人。']",0.4285714285714285,"['liver', 'disease', 'setting', 'recent', 'liver disease', 'primary', 'risk', 'management', 'identify', 'care', 'emphasis', 'at', 'on', 'to']","['liver', 'disease', 'risk', 'management', 'identify', 'emphasis']",10.0,10.0
10,10,"many studies have developed risk stratification guidelines , but few have applied them in a primary care population .",许多研究制定了风险分层指南，但很少将其应用于初级保健人群。,0.4444444444444444,"['population', 'stratification', 'primary', 'risk', 'applied', 'care', 'have', 'in', 'but']","['population', 'stratification', 'risk', 'but']",10,"['许多研究已经开发了风险分裂指南,但很少有人在初级护理人口中应用了这些指南。']",0.4444444444444444,"['population', 'stratification', 'primary', 'risk', 'applied', 'care', 'have', 'in', 'but']","['population', 'risk', 'have', 'but']",10.0,9.0
11,11,"in this prospective study , researchers recruited patients from a family medicine practice in an inner city setting in England .",在这项前瞻性研究中，研究人员从英格兰市中心的一家家庭医疗诊所招募了患者。,0.25,"['family', 'setting', 'medicine', 'inner', 'study', 'prospective study', 'practice', 'this']","['family', 'prospective study']",11,"['在这项有前途的研究中,研究人员招募了来自英格兰内部城市的家庭医学实践的患者。']",0.375,"['family', 'setting', 'medicine', 'inner', 'study', 'prospective study', 'practice', 'this']","['family', 'medicine', 'practice']",10.0,9.0
12,12,"adults with one or more risk factors for chronic liver disease ( obesity , type 2 diabetes , and hazardous alcohol use ) were enrolled as a subpopulation of the overall primary care practice .",具有一种或多种慢性肝病危险因素（肥胖、2 型糖尿病和有害饮酒）的成年人被纳入整个初级保健实践的一个亚群。,0.75,"['alcohol', 'diabetes', 'liver', 'type', 'disease', '2', 'subpopulation', 'liver disease', 'obesity', 'chronic', 'primary', 'risk', 'practice', 'care', 'with', 'and']","['alcohol', 'diabetes', 'liver', 'type', 'disease', '2', 'subpopulation', 'liver disease', 'obesity', 'chronic', 'risk', 'practice']",12,['患有慢性肝脏疾病的一个或多个风险因素(肥胖、2型糖尿病和危险酒精使用)的成年人被列为总体初级护理实践的低人口。'],0.625,"['alcohol', 'diabetes', 'liver', 'type', 'disease', '2', 'subpopulation', 'liver disease', 'obesity', 'chronic', 'primary', 'risk', 'practice', 'care', 'with', 'and']","['alcohol', 'diabetes', 'liver', 'type', 'disease', '2', 'obesity', 'chronic', 'risk', 'practice']",10.0,5.0
13,13,"patients underwent transient elastography ( TE ) , from which a reading of ≥ 8 kPa was defined as significant liver disease .",患者接受了瞬时弹性成像 (TE)，其中≥ 8 kPa 的读数被定义为显着肝病。,0.4285714285714285,"['TE', 'transient', 'liver', 'disease', 'defined', 'reading', 'liver disease']","['liver', 'disease', 'liver disease']",13,"['患者接受过渡性艾拉斯托格(TE),从那里读取 ≥ 8 kPa 被定义为严重的肝病。']",0.4285714285714285,"['TE', 'transient', 'liver', 'disease', 'defined', 'reading', 'liver disease']","['liver', 'disease', 'liver disease']",10.0,4.0
14,14,"among 576 patients participating , 533 ( 93 % ) had a reliable TE measurement .",在参与的 576 名患者中，533 名 (93%) 进行了可靠的 TE 测量。,0.3333333333333333,"['TE', 'a', 'measurement']",['measurement'],14,"['在576名患者中,533人(93%)接受了可靠的TE测量。']",0.3333333333333333,"['TE', 'a', 'measurement']",['measurement'],8.0,5.0
15,15,"significant liver disease was found in 12 % of patients , nearly one third of whom had obesity as their only risk factor .",12% 的患者患有严重的肝病，其中将近三分之一的患者肥胖是唯一的危险因素。,0.6666666666666666,"['liver', 'disease', 'factor', 'liver disease', 'obesity', 'risk', 'risk factor', 'in', 'third']","['liver', 'disease', 'factor', 'liver disease', 'obesity', 'risk']",15,"['显著的肝脏疾病在12%的患者中被发现,其中近三分之一患有肥胖,这是他们唯一的风险因素。']",0.6666666666666666,"['liver', 'disease', 'factor', 'liver disease', 'obesity', 'risk', 'risk factor', 'in', 'third']","['liver', 'disease', 'factor', 'obesity', 'risk', 'risk factor']",10.0,10.0
16,16,"also , importantly , not only was obesity or diabetes each individually a driver of significant liver disease , but their combined presence showed a synergistic effect on prevalence .",同样重要的是，不仅肥胖或糖尿病各自单独成为严重肝病的驱动因素，而且它们的共同存在对患病率显示出协同效应。,0.7142857142857143,"['presence', 'diabetes', 'liver', 'disease', 'prevalence', 'liver disease', 'obesity', 'driver', 'synergistic', 'effect', 'synergistic effect', 'on', 'each', 'but']","['presence', 'diabetes', 'liver', 'disease', 'liver disease', 'obesity', 'effect', 'synergistic effect', 'each', 'but']",16,"['此外,重要的是,不僅肥胖或糖尿病,每個人都是一個重大肝病的導致者,但他們的組合存在表明對流行性有相互作用。']",0.6428571428571429,"['presence', 'diabetes', 'liver', 'disease', 'prevalence', 'liver disease', 'obesity', 'driver', 'synergistic', 'effect', 'synergistic effect', 'on', 'each', 'but']","['presence', 'diabetes', 'liver', 'disease', 'prevalence', 'liver disease', 'obesity', 'effect', 'but']",10.0,6.0
17,17,"Helicobacter pylori is a known risk factor for gastric cancer , and its eradication may be protective against the disease .",幽门螺杆菌是胃癌的已知危险因素，根除幽门螺杆菌可预防该病。,0.5,"['eradication', 'disease', 'cancer', 'gastric', 'factor', 'helicobacter', 'be', 'risk', 'risk factor', 'protective', 'gastric cancer', 'and']","['eradication', 'disease', 'cancer', 'factor', 'risk', 'gastric cancer']",17,"['Helicobacter pylori 是一种已知的胃癌风险因素,其消除可能对疾病有保护性。']",0.5,"['eradication', 'disease', 'cancer', 'gastric', 'factor', 'helicobacter', 'be', 'risk', 'risk factor', 'protective', 'gastric cancer', 'and']","['disease', 'cancer', 'factor', 'risk', 'risk factor', 'gastric cancer']",10.0,5.0
18,18,both garlic and vitamin supplementation may also be protective in populations with nutritional deficiencies .,大蒜和维生素补充剂也可能对营养缺乏的人群起到保护作用。,0.2857142857142857,"['vitamin', 'be', 'garlic', 'nutritional', 'protective', 'with', 'and']","['vitamin', 'garlic']",18,['胡萝卜和维生素补充剂在营养缺陷的人群中也可能有保护性。'],0.2857142857142857,"['vitamin', 'be', 'garlic', 'nutritional', 'protective', 'with', 'and']","['vitamin', 'be']",10.0,10.0
19,19,"the 2258 participants with H. pylori infection were assigned in a 2 × 2 × 2 factorial fashion to H. pylori eradication treatment , supplementation with vitamins ( vitamins C , E , and selenium ) , or supplementation with garlic ( extract and oil ) or to placebos for each .",2258名感染幽门螺杆菌的参与者以2 × 2 × 2析因方式被分配到根除幽门螺杆菌治疗、补充维生素（维生素C、E和硒） ，或补充大蒜（提取物和油） ，或每个安慰剂。,0.625,"['infection', 'placebos', 'extract', 'eradication', 'oil', '2', 'garlic', 'treatment', 'selenium', 'with', 'C', 'E', 'vitamins', 'each', 'to', 'and']","['infection', 'placebos', 'extract', 'eradication', 'oil', '2', 'garlic', 'treatment', 'selenium', 'vitamins']",19,['2258名患有H. pylori感染的参与者以2×2×2因子方式被分配给H. pylori消灭治疗、维生素补充(维生素C、E、和<unk>)或加胡萝卜补充(提取物和油)或每种补充。'],0.375,"['infection', 'placebos', 'extract', 'eradication', 'oil', '2', 'garlic', 'treatment', 'selenium', 'with', 'C', 'E', 'vitamins', 'each', 'to', 'and']","['infection', 'extract', 'oil', '2', 'treatment', 'vitamins']",8.0,7.0
20,20,the 1107 participants without H. pylori infection were assigned in a 2 × 2 factorial fashion to vitamin or garlic supplementation or to placebos for each .,1107 名未感染幽门螺杆菌的参与者以 2 × 2 阶乘方式被分配到维生素或大蒜补充剂组或安慰剂组。,0.625,"['infection', 'placebos', 'vitamin', '2', 'garlic', 'each', 'to', 'without']","['infection', 'placebos', 'vitamin', '2', 'garlic']",20,['没有H.pylori感染的1107名参与者以2×2因子方式分配到维生素或胡萝卜补充剂或每人分配到 placebo。'],0.375,"['infection', 'placebos', 'vitamin', '2', 'garlic', 'each', 'to', 'without']","['infection', 'vitamin', '2']",10.0,8.0
21,21,"H. pylori eradication reduced the incidence of gastric cancer ( odds ratio , 0.48 ) and mortality from gastric cancer ( adjusted hazard ratio , 0.62 ) .",根除幽门螺杆菌降低了胃癌的发病率（比值比，0.48）和胃癌死亡率（调整后的风险比，0.62）。,0.7,"['eradication', 'incidence', 'cancer', 'gastric', 'ratio', 'hazard ratio', 'mortality', 'gastric cancer', 'and', 'odds']","['eradication', 'incidence', 'cancer', 'ratio', 'hazard ratio', 'mortality', 'gastric cancer']",21,['H. pylori 消除降低了胃癌的发病率(率为 0.48 )和胃癌的死亡率(调整的危险率为 0.62 )。'],0.4,"['eradication', 'incidence', 'cancer', 'gastric', 'ratio', 'hazard ratio', 'mortality', 'gastric cancer', 'and', 'odds']","['incidence', 'cancer', 'mortality', 'gastric cancer']",10.0,10.0
22,22,"vitamin supplementation also decreased the incidence of gastric cancer ( OR , 0.64 ) and mortality from gastric cancer ( aHR , 0.48 ) .","维生素补充剂还降低了胃癌的发病率 (OR, 0.64) 和胃癌死亡率 (aHR, 0.48)。",0.625,"['incidence', 'cancer', 'gastric', 'vitamin', 'mortality', 'OR', 'gastric cancer', 'and']","['incidence', 'cancer', 'vitamin', 'mortality', 'gastric cancer']",22,"['维生素补充也降低了胃癌的发病率( OR, 0.64 )和胃癌的死亡率( aHR, 0.48 )。']",0.625,"['incidence', 'cancer', 'gastric', 'vitamin', 'mortality', 'OR', 'gastric cancer', 'and']","['incidence', 'cancer', 'vitamin', 'mortality', 'gastric cancer']",10.0,9.0
23,23,"garlic supplementation did not reduce gastric cancer incidence but did reduce mortality from gastric cancer ( aHR , 0.66 ) .","大蒜补充剂并未降低胃癌的发病率，但确实降低了胃癌的死亡率 (aHR, 0.66)。",0.875,"['incidence', 'cancer', 'gastric', 'reduce', 'garlic', 'mortality', 'gastric cancer', 'but']","['incidence', 'cancer', 'reduce', 'garlic', 'mortality', 'gastric cancer', 'but']",23,"['加糖补充剂没有减少胃癌的发病率,但减少了胃癌的死亡率(aHR,0.66)。']",0.625,"['incidence', 'cancer', 'gastric', 'reduce', 'garlic', 'mortality', 'gastric cancer', 'but']","['incidence', 'cancer', 'mortality', 'gastric cancer', 'but']",10.0,8.0
24,24,the beneficial effects of both vitamin and garlic supplementation were seen later than those from H. pylori eradication .,维生素和大蒜补充剂的有益作用晚于根除幽门螺杆菌。,0.6,"['eradication', 'vitamin', 'garlic', 'later', 'and']","['eradication', 'vitamin', 'garlic']",24,['维生素和胡萝卜补充剂的有益效果比H.pylori消灭的效果更晚。'],0.2,"['eradication', 'vitamin', 'garlic', 'later', 'and']",['vitamin'],10.0,8.0
25,25,"although the results reconfirm the benefit of H. pylori eradication at reducing gastric cancer incidence and mortality , the findings of the benefits of vitamin and garlic supplementation required longer observation to become apparent .",虽然结果再次证实了根除幽门螺杆菌对降低胃癌发病率和死亡率的益处，但补充维生素和大蒜的益处的发现需要更长时间的观察才能变得明显。,0.6153846153846154,"['eradication', 'incidence', 'cancer', 'gastric', 'vitamin', 'garlic', 'mortality', 'benefit', 'observation', 'gastric cancer', 'become', 'to', 'and']","['eradication', 'incidence', 'cancer', 'vitamin', 'garlic', 'mortality', 'observation', 'gastric cancer']",25,"['虽然结果证实了H. pylori的消灭对减少胃癌的发病率和死亡率的好处,但维生素和胡萝卜补充的好处的发现需要更长的观察才能显而易见。']",0.5384615384615384,"['eradication', 'incidence', 'cancer', 'gastric', 'vitamin', 'garlic', 'mortality', 'benefit', 'observation', 'gastric cancer', 'become', 'to', 'and']","['incidence', 'cancer', 'vitamin', 'mortality', 'observation', 'gastric cancer', 'and']",,
26,26,"the generalizability of the findings on supplementation may be limited , given that the study population had baseline nutritional deficiencies and a high risk for gastric cancer , but I would consider recommending a multivitamin for my patients at high risk for gastric cancer .",考虑到研究人群基线营养缺乏和胃癌高风险，补充剂研究结果的普遍性可能有限，但我会考虑向我的胃癌高风险患者推荐复合维生素。,0.3333333333333333,"['population', 'cancer', 'gastric', 'baseline', 'high risk', 'study', 'my', 'be', 'nutritional', 'gastric cancer', 'limited', 'I', 'that', 'but', 'and']","['population', 'cancer', 'baseline', 'gastric cancer', 'but']",26,"['关于补充剂的发现的普遍性可能有限,因为研究人口的基本营养缺陷和胃癌的风险很高,但我会考虑推荐一个多维生素给我的患者患胃癌的风险很高。']",0.2666666666666666,"['population', 'cancer', 'gastric', 'baseline', 'high risk', 'study', 'my', 'be', 'nutritional', 'gastric cancer', 'limited', 'I', 'that', 'but', 'and']","['population', 'cancer', 'gastric cancer', 'but']",,
27,27,a large cohort study found higher rates of cancer in children who underwent computed tomography than in those who did not .,一项大型队列研究发现，接受过计算机断层扫描的儿童患癌症的几率高于未接受过计算机断层扫描的儿童。,0.25,"['tomography', 'cancer', 'who', 'study', 'large', 'cohort study', 'computed tomography', 'in']","['tomography', 'cancer']",27,"['一项大型协调研究发现,在受计算 tomography 的儿童中,癌症的发病率高于未经计算的儿童中。']",0.125,"['tomography', 'cancer', 'who', 'study', 'large', 'cohort study', 'computed tomography', 'in']",['cancer'],,
28,28,"concerns about the carcinogenic effects of radiation are largely based on data from atomic bomb survivors , and the effects of ionizing radiation used for medical imaging are less well studied .",对辐射致癌作用的担忧主要基于原子弹爆炸幸存者的数据，而用于医学成像的电离辐射的影响研究较少。,0.5,"['carcinogenic', 'radiation', 'data', 'bomb', 'medical', 'ionizing radiation', 'well', 'atomic', 'imaging', 'and']","['radiation', 'data', 'bomb', 'ionizing radiation', 'and']",28,"['关于辐射的致癌作用的担忧主要是基于原子弹幸存者的数据,用于医学图像的离子辐射的效果不太好研究。']",0.3,"['carcinogenic', 'radiation', 'data', 'bomb', 'medical', 'ionizing radiation', 'well', 'atomic', 'imaging', 'and']","['radiation', 'data', 'bomb']",,
29,29,"to count as an exposure , diagnostic radiation had to have occurred two years before any cancer diagnosis .",要算作一次暴露，诊断性辐射必须在任何癌症诊断前两年发生。,0.5454545454545454,"['count', 'cancer', 'radiation', 'exposure', 'diagnosis', 'diagnostic', 'as', 'have', 'before', 'to', 'two']","['cancer', 'radiation', 'exposure', 'diagnosis', 'before', 'two']",29,"['要计算为曝光,诊断辐射必须在任何癌症诊断之前发生两年。']",0.5454545454545454,"['count', 'cancer', 'radiation', 'exposure', 'diagnosis', 'diagnostic', 'as', 'have', 'before', 'to', 'two']","['cancer', 'radiation', 'exposure', 'diagnosis', 'before', 'two']",,
30,30,"new cancers were diagnosed in 22,000 patients ( 0.02 % ) , including 1444 patients after radiation exposure ( 0.1 % ) .","22,000 名患者 (0.02%) 被诊断出新的癌症，其中包括 1444 名接受辐射照射后的患者 (0.1%)。",0.8,"['radiation', 'exposure', 'after', 'in', 'new']","['radiation', 'exposure', 'after', 'new']",30,"['新的癌症被诊断为22000名患者(0.02%),其中1444名患者在辐射曝光后(0.1%)。']",0.8,"['radiation', 'exposure', 'after', 'in', 'new']","['radiation', 'exposure', 'after', 'new']",,
31,31,"after adjustment for age and sex , radiation exposure was associated with a relative risk of 1.64 for developing a new cancer .",在针对年龄和性别进行调整后，辐射暴露与患上新癌症的相对风险 1.64 相关。,0.5333333333333333,"['a', 'cancer', 'radiation', 'exposure', 'sex', 'adjustment', 'relative', 'developing', 'associated', 'age', 'risk', 'after', 'with', 'and', 'new']","['cancer', 'radiation', 'exposure', 'sex', 'age', 'risk', 'after', 'new']",31,"['在年龄和性别调整后,辐射曝光与新癌症发育的相对风险为1.64相关。']",0.5333333333333333,"['a', 'cancer', 'radiation', 'exposure', 'sex', 'adjustment', 'relative', 'developing', 'associated', 'age', 'risk', 'after', 'with', 'and', 'new']","['cancer', 'radiation', 'exposure', 'sex', 'age', 'risk', 'after', 'new']",,
32,32,"the highest risks were for myelodysplasia , leukemias , and breast , thyroid , and oral and pharyngeal cancers .",风险最高的是骨髓增生异常、白血病、乳腺癌、甲状腺癌、口腔癌和咽癌。,0.2,"['thyroid', 'oral', 'pharyngeal', 'breast', 'and']",['thyroid'],32,"['最高的风险是甲状腺,乳腺,甲状腺和口腔和甲状腺癌。']",0.2,"['thyroid', 'oral', 'pharyngeal', 'breast', 'and']",['thyroid'],,
33,33,"however , the overall risk of cancer was still very low , so when imaging is necessary , we should not hesitate to order it .",但是，整体患癌症的风险仍然很低，因此当需要进行影像学检查时，我们应该毫不犹豫地进行检查。,0.4,"['cancer', 'order', 'still', 'low', 'necessary', 'risk', 'imaging', 'so', 'to', 'we']","['cancer', 'low', 'risk', 'so']",33,"['然而,癌症的总风险仍然很低,所以当图像需要时,我们不应该犹豫地订购它。']",0.4,"['cancer', 'order', 'still', 'low', 'necessary', 'risk', 'imaging', 'so', 'to', 'we']","['cancer', 'low', 'risk', 'so']",,
34,34,"treatment with cool running water was associated with improved outcomes , especially when administered for at least 20 minutes .",用凉爽的自来水治疗与改善结果有关，尤其是在至少持续 20 分钟的情况下。,0.5,"['water', 'running', 'associated', 'treatment', 'cool', 'with']","['water', 'treatment', 'cool']",34,"['冷流水的治疗与改善结果有关,特别是当服用至少20分钟时。']",0.5,"['water', 'running', 'associated', 'treatment', 'cool', 'with']","['water', 'treatment', 'cool']",,
35,35,recent evidence suggests that burns in adults heal better when treated with cool running water ( Burns 2019 ; 45 : 433 ; PLoS One 2016 ; 11 : e0147259 ) .,最近的证据表明，成人烧伤在用凉爽的自来水处理后愈合得更好（Burns 2019；45：433；PLoS One 2016；11：e0147259）。,0.5555555555555556,"['recent', 'water', 'running', 'heal', 'evidence', 'cool', 'with', 'burns', 'that']","['water', 'heal', 'evidence', 'cool', 'burns']",35,"['最近的证据表明,燃烧在成年人治疗时愈合更好(燃烧2019;45:433;PLoS One2016;11:e0147259)。']",0.2222222222222222,"['recent', 'water', 'running', 'heal', 'evidence', 'cool', 'with', 'burns', 'that']","['heal', 'evidence']",,
36,36,"to assess the effect of this treatment for pediatric burns , researchers queried an Australian burn center database that included structured interviews with patients and parents about first aid provided within 3 hours of injury , prior to burn center assessment .",为了评估这种治疗对小儿烧伤的效果，研究人员查询了澳大利亚烧伤中心的数据库，该数据库包括在烧伤中心评估之前对患者和父母进行的关于受伤 3 小时内提供的急救的结构化访谈。,0.5263157894736842,"['injury', 'center', 'parents', 'database', 'first aid', 'pediatric', 'burn', 'assessment', 'treatment', 'prior', 'effect', '3', 'with', 'burns', 'burn center', 'this', 'that', 'to', 'and']","['injury', 'center', 'first aid', 'burn', 'assessment', 'treatment', 'effect', 'burns', 'burn center', 'to']",36,"['为了评估这种治疗对儿科烧伤的影响,研究人员询问了澳大利亚烧伤中心的数据库,其中包括与患者和父母的结构化采访,关于在伤害后3小时内提供的第一援助,在烧伤中心的评估之前。']",0.4210526315789473,"['injury', 'center', 'parents', 'database', 'first aid', 'pediatric', 'burn', 'assessment', 'treatment', 'prior', 'effect', '3', 'with', 'burns', 'burn center', 'this', 'that', 'to', 'and']","['injury', 'center', 'burn', 'assessment', 'treatment', 'burns', 'burn center', 'to']",,
37,37,"patients with friction , electrical , and chemical burns as well as those with missing data were excluded .",有摩擦、电和化学灼伤的患者以及数据缺失的患者被排除在外。,0.3333333333333333,"['data', 'chemical', 'friction', 'well', 'as', 'with', 'burns', 'and', 'missing']","['data', 'friction', 'missing']",37,['被排除患有震动、电气和化学燃烧的患者以及缺乏数据的患者。'],0.2222222222222222,"['data', 'chemical', 'friction', 'well', 'as', 'with', 'burns', 'and', 'missing']","['data', 'missing']",,
38,38,"although observational , this study provides fairly convincing evidence that treatment of pediatric burns with cool running water as soon as possible improves important clinical outcomes .",虽然是观察性研究，但这项研究提供了相当有说服力的证据，证明尽快用凉爽的自来水治疗小儿烧伤可改善重要的临床结果。,0.5384615384615384,"['pediatric', 'study', 'water', 'running', 'treatment', 'clinical', 'evidence', 'cool', 'as', 'with', 'burns', 'this', 'that']","['water', 'treatment', 'clinical', 'evidence', 'cool', 'burns', 'this']",38,"['虽然观察性,但这项研究提供了相当令人信服的证据,儿童烧伤的治疗用冷流水尽快改善重要临床结果。']",0.4615384615384615,"['pediatric', 'study', 'water', 'running', 'treatment', 'clinical', 'evidence', 'cool', 'as', 'with', 'burns', 'this', 'that']","['water', 'treatment', 'clinical', 'evidence', 'cool', 'burns']",,
39,39,"the authors note that durations longer than 20 minutes have not been shown to provide additive benefit and could be harmful , although that was not tested in this study .",作者指出，持续时间超过 20 分钟并没有显示出额外的好处，而且可能有害，尽管本研究并未对此进行测试。,0.0909090909090909,"['study', 'be', 'additive', 'note', 'benefit', 'have not', 'this', 'that', 'in', 'to', 'and']",['and'],39,"['作者指出,超过20分钟的持续时间没有被证明提供添加益处,并且可能有害,尽管这项研究没有测试。']",0.0,"['study', 'be', 'additive', 'note', 'benefit', 'have not', 'this', 'that', 'in', 'to', 'and']",[],,
40,40,"HbA1c was averaged over time for each patient ( mean HbA1c level for the cohort , 8.0 % ) .",对每个患者的 HbA1c 随时间进行平均（队列的平均 HbA1c 水平，8.0%）。,0.5714285714285714,"['mean', 'time', 'patient', 'level', 'cohort', 'each', 'over']","['mean', 'time', 'patient', 'level']",40,['HbA1c 是每個患者的時間平均值(每個患者的 HbA1c 水平平均值為 8.0 % )。'],0.4285714285714285,"['mean', 'time', 'patient', 'level', 'cohort', 'each', 'over']","['mean', 'patient', 'level']",,
41,41,"thus , the authors suggest that an HbA1c target of 6.5 % to 6.9 % is reasonable .",因此，作者建议将 HbA1c 目标设定为 6.5% 至 6.9% 是合理的。,0.4,"['target', 'thus', 'suggest', 'that', 'to']","['target', 'thus']",41,"['因此,作者建议一个HbA1c目标为6.5%至6.9%是合理的。']",0.4,"['target', 'thus', 'suggest', 'that', 'to']","['target', 'thus']",,
42,42,"no ; benefits will outweigh risks for many menopausal patients who , through discussion of research findings and shared decision making , can make informed choices about HT use .",不 ;对于许多绝经期患者而言，收益将大于风险，他们可以通过讨论研究结果和共同决策，就 HT 使用做出明智的选择。,0.5,"['research', 'who', 'shared decision making', 'menopausal', 'will', 'discussion', 'and', 'make']","['research', 'shared decision making', 'discussion', 'and']",42,"['好处将超越许多更年期患者的风险,通过讨论研究结果和共享决策,可以做出关于HT使用的有信息的选择。']",0.25,"['research', 'who', 'shared decision making', 'menopausal', 'will', 'discussion', 'and', 'make']","['research', 'discussion']",,
43,43,hormone therapy ( HT ) is the most effective treatment for bothersome menopausal vasomotor symptoms .,激素疗法 (HT) 是治疗烦人的更年期血管舒缩症状最有效的方法。,0.5,"['hormone', 'vasomotor', 'symptoms', 'therapy', 'menopausal', 'treatment']","['hormone', 'therapy', 'treatment']",43,['荷尔蒙治疗(HT)是最有效的治疗缓慢的更年期血管症状。'],0.3333333333333333,"['hormone', 'vasomotor', 'symptoms', 'therapy', 'menopausal', 'treatment']","['therapy', 'treatment']",,
44,44,both regimens raised risk for stroke and venous thromboembolism but lowered risk for fractures and diabetes .,这两种方案都会增加中风和静脉血栓栓塞的风险，但会降低骨折和糖尿病的风险。,0.6666666666666666,"['diabetes', 'stroke', 'venous', 'thromboembolism', 'risk', 'raised', 'fractures', 'but', 'and']","['diabetes', 'stroke', 'thromboembolism', 'risk', 'fractures', 'but']",44,"['两种饮食都增加了中风和血管肿瘤的风险,但减少了裂缝和糖尿病的风险。']",0.4444444444444444,"['diabetes', 'stroke', 'venous', 'thromboembolism', 'risk', 'raised', 'fractures', 'but', 'and']","['diabetes', 'stroke', 'risk', 'but']",,
45,45,"although observational studies over the past several decades have linked HT to increased breast cancer risk , the specific associations with HT formulation , route of delivery , and duration have been poorly studied .",尽管过去几十年的观察性研究已将 HT 与乳腺癌风险增加联系起来，但与 HT 配方、分娩途径和持续时间的具体关联研究很少。,0.4615384615384615,"['cancer', 'breast cancer', 'delivery', 'risk', 'specific', 'formulation', 'duration', 'with', 'have', 'over', 'to', 'and', 'past']","['cancer', 'breast cancer', 'delivery', 'risk', 'duration', 'over']",45,"['虽然过去几十年的观测研究将HT与乳腺癌风险增加有关,但与HT的具体组成、分娩路径和持续时间的具体联系已被研究不佳。']",0.5384615384615384,"['cancer', 'breast cancer', 'delivery', 'risk', 'specific', 'formulation', 'duration', 'with', 'have', 'over', 'to', 'and', 'past']","['cancer', 'breast cancer', 'delivery', 'risk', 'duration', 'have', 'over']",,
46,46,all systemic HT formulations ( including those using oral conjugated equine estrogens or estradiol or transdermal estradiol ) were associated with excess risk for breast cancer .,所有全身性 HT 制剂（包括使用口服结合马雌激素或雌二醇或透皮雌二醇的制剂）都与患乳腺癌的风险过高有关。,0.3846153846153846,"['excess', 'cancer', 'oral', 'breast cancer', 'associated', 'equine', 'risk', 'systemic', 'estradiol', 'with', 'estrogens', 'transdermal', 'all']","['cancer', 'breast cancer', 'risk', 'estradiol', 'transdermal']",46,['所有系统的HT配方(包括使用口服合并的乙<unk>雌激素或 estradiol或 transdermal estradiol)都与乳腺癌的过度风险有关。'],0.3076923076923077,"['excess', 'cancer', 'oral', 'breast cancer', 'associated', 'equine', 'risk', 'systemic', 'estradiol', 'with', 'estrogens', 'transdermal', 'all']","['cancer', 'breast cancer', 'risk', 'systemic']",,
47,47,type of progestogen did not appear to affect these associations .,孕激素的类型似乎并未影响这些关联。,0.6666666666666666,"['type', 'affect', 'progestogen']","['type', 'affect']",47,['这种类型的蛋白质似乎不会影响这些组合。'],0.6666666666666666,"['type', 'affect', 'progestogen']","['type', 'affect']",,
48,48,vaginal estrogen was not associated with increased risk .,阴道雌激素与风险增加无关。,0.4,"['estrogen', 'vaginal', 'associated', 'risk', 'with']","['estrogen', 'risk']",48,['阴道雌激素与增加风险无关。'],0.4,"['estrogen', 'vaginal', 'associated', 'risk', 'with']","['estrogen', 'risk']",10.0,10.0
49,49,"assuming the reported associations are causal , the authors estimated the absolute risk for breast cancer up to age 70 .",假设报告的关联是因果关系，作者估计了 70 岁以下患乳腺癌的绝对风险。,0.5,"['cancer', 'absolute', 'breast cancer', 'age', 'risk', 'causal', 'up', 'to']","['cancer', 'absolute', 'breast cancer', 'risk']",49,"['假设报告的协会是因果性的,作者估计到70岁之前患乳腺癌的绝对风险。']",0.5,"['cancer', 'absolute', 'breast cancer', 'age', 'risk', 'causal', 'up', 'to']","['cancer', 'absolute', 'breast cancer', 'risk']",10.0,8.0
50,50,"at 10 years of HT use , risks were approximately twice that at 5 years .",使用 HT 10 年时，风险大约是 5 年时的两倍。,0.2,"['5', 'at', 'approximately', 'that', 'twice']",['5'],50,"['在使用10年HT时,风险大约是5年时的两倍。']",0.2,"['5', 'at', 'approximately', 'that', 'twice']",['5'],10.0,10.0
51,51,"for EPT , both the randomized WHI trial and this new Lancet analysis of observational data indicated an increased risk for breast cancer .",对于 EPT，随机 WHI 试验和这项新的柳叶刀观察数据分析均表明患乳腺癌的风险增加。,0.5,"['lancet', 'cancer', 'data', 'analysis', 'breast cancer', 'risk', 'trial', 'observational data', 'EPT', 'this', 'and', 'new']","['cancer', 'data', 'analysis', 'breast cancer', 'risk', 'new']",51,"['对于EPT,无论是随机的WHI测试还是新的Lancet观测数据分析,都表明乳腺癌的风险增加。']",0.6666666666666666,"['lancet', 'cancer', 'data', 'analysis', 'breast cancer', 'risk', 'trial', 'observational data', 'EPT', 'this', 'and', 'new']","['cancer', 'data', 'analysis', 'breast cancer', 'risk', 'observational data', 'this', 'new']",10.0,10.0
52,52,could the excess risk found in observational studies be exaggerated due to inherent limitations of the study design ?,由于研究设计的固有局限性，是否会夸大观察性研究中发现的额外风险？,0.375,"['excess', 'inherent', 'study', 'be', 'risk', 'design', 'due', 'to']","['risk', 'design', 'to']",52,['在观察研究中发现的过度风险是否会由于研究设计的本质限制而被夸张?'],0.5,"['excess', 'inherent', 'study', 'be', 'risk', 'design', 'due', 'to']","['be', 'risk', 'design', 'to']",10.0,10.0
53,53,"in contrast , in the WHI trial ( and in most randomized trials of HT ) , both users and nonusers underwent uniformly standardized mammographic screening .",相比之下，在 WHI 试验（以及大多数 HT 随机试验）中，使用者和非使用者都接受了统一标准化的乳房 X 光检查。,0.0,"['contrast', 'screening', 'trial', 'and']",[],53,"['相反,在WHI试验(和大多数随机试验的HT)中,用户和未使用者都接受了均匀标准化的乳房筛查。']",0.25,"['contrast', 'screening', 'trial', 'and']",['screening'],10.0,10.0
54,54,"thus , the excess breast cancer risk in observational studies could reflect increased mammographic detection of nonlethal cancers .",因此，观察性研究中乳腺癌风险过高可能反映了非致命性癌症的乳房 X 光检查检测率增加。,0.75,"['excess', 'cancer', 'detection', 'breast cancer', 'reflect', 'risk', 'thus', 'in']","['cancer', 'detection', 'breast cancer', 'reflect', 'risk', 'thus']",54,"['因此,在观测研究中,乳腺癌的过度风险可能会反映非乳腺癌的增加乳腺癌检测。']",0.75,"['excess', 'cancer', 'detection', 'breast cancer', 'reflect', 'risk', 'thus', 'in']","['cancer', 'detection', 'breast cancer', 'reflect', 'risk', 'thus']",,
55,55,"accordingly , one advantage that observational studies have over randomized trials ( usually limited to 5 − 7 years of treatment ) is their ability to assess extended use .",因此，观察性研究优于随机试验（通常限于 5-7 年的治疗）的一个优势是它们能够评估延长使用时间。,0.5,"['5', 'treatment', 'advantage', 'ability', 'assess', 'limited', 'have', 'that', 'over', 'to']","['5', 'treatment', 'advantage', 'assess', 'to']",55,"['因此,观察研究对随机试验(通常限于5～7年的治疗)的一个优点是它们能够评估延长使用。']",0.5,"['5', 'treatment', 'advantage', 'ability', 'assess', 'limited', 'have', 'that', 'over', 'to']","['5', 'treatment', 'advantage', 'assess', 'to']",,
56,56,"understandably , women are often concerned about breast cancer risk as they make decisions about HT ; however , such decisions should be guided by the big picture .",可以理解的是，女性在做出关于 HT 的决定时通常会担心患乳腺癌的风险；但是，此类决策应以大局为指导。,0.7142857142857143,"['cancer', 'breast cancer', 'be', 'picture', 'risk', 'by', 'make']","['cancer', 'breast cancer', 'be', 'risk', 'by']",56,"['可以理解的,女性经常担心乳腺癌的风险,因为他们做出关于HT的决定;但是,这样的决定应该由大图像引导。']",0.7142857142857143,"['cancer', 'breast cancer', 'be', 'picture', 'risk', 'by', 'make']","['cancer', 'breast cancer', 'picture', 'risk', 'by']",,
57,57,"on an absolute scale , many of the risks associated with HT are modest .",从绝对规模上看，许多与 HT 相关的风险是适度的。,0.2,"['scale', 'absolute', 'associated', 'with', 'on']",['absolute'],57,"['在绝对范围内,与HT相关的许多风险是微不足道的。']",0.2,"['scale', 'absolute', 'associated', 'with', 'on']",['absolute'],,
58,58,the largest hazard ratio associated with HT use corresponds to an elevated risk for venous thromboembolism - and using transdermal rather than oral estrogen appeared to attenuate this risk .,与 HT 使用相关的最大风险比对应于静脉血栓栓塞风险的升高 - 使用透皮而不是口服雌激素似乎可以降低这种风险。,0.6,"['estrogen', 'ratio', 'hazard ratio', 'oral', 'venous', 'thromboembolism', 'associated', 'attenuate', 'risk', 'with', 'transdermal', '-', 'this', 'to', 'and']","['estrogen', 'ratio', 'hazard ratio', 'thromboembolism', 'risk', 'transdermal', 'this', 'to', 'and']",58,"['与HT使用相关的最大风险比例相当于血管血管肿瘤的风险增加,而使用跨皮质而不是口服雌激素似乎会减轻这种风险。']",0.4666666666666667,"['estrogen', 'ratio', 'hazard ratio', 'oral', 'venous', 'thromboembolism', 'associated', 'attenuate', 'risk', 'with', 'transdermal', '-', 'this', 'to', 'and']","['estrogen', 'ratio', 'hazard ratio', 'risk', 'this', 'to', 'and']",,
59,59,"for many women , risks associated with HT are offset by reductions in symptoms , improved quality of life , and benefits in other health outcomes , such as fractures .",对于许多女性来说，与 HT 相关的风险会被症状减轻、生活质量改善以及骨折等其他健康结果的益处所抵消。,0.5833333333333334,"['life', 'health', 'quality', 'symptoms', 'offset', 'associated', 'quality of life', 'with', 'fractures', 'in', 'by', 'and']","['life', 'health', 'quality', 'offset', 'quality of life', 'fractures', 'by']",59,"['对于许多妇女来说,与HT相关的风险是由症状的减少、生活质量的改善以及其他健康结果的好处,如骨折来补偿的。']",0.5833333333333334,"['life', 'health', 'quality', 'symptoms', 'offset', 'associated', 'quality of life', 'with', 'fractures', 'in', 'by', 'and']","['life', 'health', 'quality', 'offset', 'quality of life', 'fractures', 'by']",,
60,60,"the net effects of HT are most favorable for recently menopausal women who have moderate to severe vasomotor symptoms and low or average risks for breast cancer , cardiovascular disease , and venous thromboembolism .",HT 的净效应最有利于最近绝经的妇女，她们有中度至重度血管舒缩症状，患乳腺癌、心血管疾病和静脉血栓栓塞症的风险较低或一般。,0.5555555555555556,"['disease', 'cancer', 'cardiovascular', 'net', 'average', 'who', 'vasomotor', 'venous', 'breast cancer', 'moderate', 'symptoms', 'thromboembolism', 'menopausal', 'cardiovascular disease', 'low', 'severe', 'have', 'and']","['disease', 'cancer', 'cardiovascular', 'breast cancer', 'thromboembolism', 'menopausal', 'cardiovascular disease', 'low', 'severe', 'have']",60,"['HT的净效应最有利于最近更年期妇女,患有适度至严重的血管发作症状,乳腺癌、心血管疾病和阴道血管肿瘤的风险较低或平均。']",0.4444444444444444,"['disease', 'cancer', 'cardiovascular', 'net', 'average', 'who', 'vasomotor', 'venous', 'breast cancer', 'moderate', 'symptoms', 'thromboembolism', 'menopausal', 'cardiovascular disease', 'low', 'severe', 'have', 'and']","['disease', 'cancer', 'cardiovascular', 'average', 'breast cancer', 'cardiovascular disease', 'low', 'have']",,
61,61,"in sum , women deserve reliable information in order to make informed decisions - aligned with their personal preferences - on whether the potential benefits of HT are likely to outweigh the potential risks .",总而言之，女性应该得到可靠的信息，以便根据她们的个人喜好做出明智的决定，了解 HT 的潜在益处是否可能超过潜在风险。,0.2222222222222222,"['order', 'potential', 'sum', 'personal', 'information', 'with', '-', 'in order to', 'make']","['information', 'in order to']",61,"['总的来说,妇女应获得可靠的信息,以便根据自己的个人偏好做出有意识的决定,关于HT的潜在好处是否可能超越潜在的风险。']",0.4444444444444444,"['order', 'potential', 'sum', 'personal', 'information', 'with', '-', 'in order to', 'make']","['potential', 'personal', 'information', 'in order to']",,
62,62,"the primary outcome was treatment success , defined as a decrease of 50 % or more in the Gastroesophageal Reflux Disease ( GERD ) -Health Related Quality of Life score ( range , 0 to 50 , with higher scores indicating worse symptoms ) at 1 year .",主要结果是治疗成功，定义为 1 年时胃食管反流病 (GERD) 与健康相关的生活质量评分（范围 0 至 50，评分越高表示症状越严重）下降 50% 或更多。,0.6,"['life', 'disease', 'decrease', 'defined', 'range', 'year', '1', 'outcome', 'quality', 'symptoms', 'gastroesophageal', 'treatment', 'primary', 'success', 'reflux', 'quality of life', 'score', 'with', 'gastroesophageal reflux', 'worse']","['life', 'disease', 'range', 'year', '1', 'outcome', 'quality', 'treatment', 'success', 'reflux', 'quality of life', 'gastroesophageal reflux']",62,"['初步结果是治疗成功,定义为Gastroesophageal Reflux Disease(GERD) -Health Related Quality of Life Score(范围,0至50,高得分表明症状恶化)的50%或以上下降1年。']",0.3,"['life', 'disease', 'decrease', 'defined', 'range', 'year', '1', 'outcome', 'quality', 'symptoms', 'gastroesophageal', 'treatment', 'primary', 'success', 'reflux', 'quality of life', 'score', 'with', 'gastroesophageal reflux', 'worse']","['range', 'year', '1', 'outcome', 'treatment', 'success']",,
63,63,"a total of 366 patients ( mean age , 48.5 years ; 280 men ) were enrolled .",共有 366 名患者（平均年龄 48.5 岁；280 名男性）入组。,0.5,"['a', 'mean', 'total', 'age']","['mean', 'age']",63,['共有366名患者(平均年龄、48.5岁、280名男性)被注册。'],0.5,"['a', 'mean', 'total', 'age']","['mean', 'age']",,
64,64,the remaining 78 patients underwent randomization .,其余 78 名患者接受了随机分组。,1.0,['randomization'],['randomization'],64,['其余78名患者遭到随机化。'],1.0,['randomization'],['randomization'],,
65,65,"the difference in the incidence of treatment success between the active medical group and the control medical group was 16 percentage points ( 95 % confidence interval , − 5 to 38 ; P = 0.17 ) .",活性药物组和对照药物组治疗成功率的差异为16个百分点（95%置信区间，-5至38；P=0.17）。,0.5333333333333333,"['group', 'percentage', '5', 'incidence', 'control', 'interval', 'medical', 'active', 'difference', 'treatment', 'success', 'confidence interval', 'P', 'to', 'and']","['group', '5', 'control', 'interval', 'difference', 'treatment', 'success', 'confidence interval']",65,"['活跃医疗组和控制医疗组之间的治疗成功率差异为16个百分点(95%的信任间隔, − 5 至 38; P = 0.17)。']",0.4666666666666667,"['group', 'percentage', '5', 'incidence', 'control', 'interval', 'medical', 'active', 'difference', 'treatment', 'success', 'confidence interval', 'P', 'to', 'and']","['group', '5', 'control', 'interval', 'difference', 'treatment', 'success']",,
66,66,"for that highly selected subgroup , surgery was superior to medical treatment . ( Funded by the Department of Veterans Affairs Cooperative Studies Program ; ClinicalTrials.gov number , NCT01265550 . )",对于那个经过严格挑选的亚组，手术优于药物治疗。 （由退伍军人事务部合作研究计划资助；ClinicalTrials.gov 编号，NCT01265550。）,0.5,"['cooperative', 'program', 'surgery', 'department', 'medical', 'superior', 'medical treatment', 'number', 'subgroup', 'that', 'by', 'to']","['program', 'surgery', 'department', 'number', 'by', 'to']",66,"['对于这个高度选择的子组,手术优于医疗治疗(由退休人员事务合作研究计划资助;ClinicalTrials.gov号,NCT01265550。']",0.4166666666666667,"['cooperative', 'program', 'surgery', 'department', 'medical', 'superior', 'medical treatment', 'number', 'subgroup', 'that', 'by', 'to']","['program', 'surgery', 'number', 'by', 'to']",,
67,67,"in the United States , approximately 20 % of adults regularly have symptoms of gastroesophageal reflux disease ( GERD ) , 1 and annual costs for managing GERD exceed $ 12 billion.2",在美国，大约 20 % 的成年人经常有胃食管反流病 ( GERD ) 的症状 1 ，每年管理 GERD 的费用超过 120 亿美元。 2,0.5,"['annual', 'disease', '1', 'symptoms', 'gastroesophageal', 'reflux', 'gastroesophageal reflux', 'have', 'approximately', 'in', 'and', 'exceed']","['disease', '1', 'reflux', 'gastroesophageal reflux', 'have', 'exceed']",67,"['在美国,大约20%的成年人经常患有胃血管流感疾病(GERD)的症状,1和管理GERD的年度成本超过12亿美元。']",0.3333333333333333,"['annual', 'disease', '1', 'symptoms', 'gastroesophageal', 'reflux', 'gastroesophageal reflux', 'have', 'approximately', 'in', 'and', 'exceed']","['disease', '1', 'have', 'exceed']",,
68,68,PPIs are often continued despite inadequate symptom relief.11,尽管症状缓解不充分，但 PPI 通常会继续使用。 11,0.3333333333333333,"['symptom', 'inadequate', 'despite']",['symptom'],68,"['PPI经常持续,尽管症状缓解不够。']",0.3333333333333333,"['symptom', 'inadequate', 'despite']",['symptom'],,
69,69,"alternatively , for patients with reflux hypersensitivity , surgical reduction of reflux might not relieve symptoms generated by a hypersensitive esophagus .",或者，对于反流过敏的患者，减少反流的手术可能无法缓解由过敏性食管引起的症状。,0.6363636363636364,"['hypersensitivity', 'a', 'relieve', 'esophagus', 'surgical', 'reduction', 'symptoms', 'hypersensitive', 'reflux', 'with', 'by']","['hypersensitivity', 'relieve', 'esophagus', 'reduction', 'hypersensitive', 'reflux', 'by']",69,"['换句话说,对于患有过敏的患者,过敏的手术减少可能不会缓解由过敏性<unk>疹引起的症状。']",0.4545454545454545,"['hypersensitivity', 'a', 'relieve', 'esophagus', 'surgical', 'reduction', 'symptoms', 'hypersensitive', 'reflux', 'with', 'by']","['hypersensitivity', 'relieve', 'reduction', 'hypersensitive', 'by']",,
70,70,"surgeons are reluctant to rely on it to select patients for fundoplication , generally preferring traditional esophageal pH monitoring for that purpose.21",外科医生不愿意依靠它来选择患者进行胃底折叠术，通常更喜欢为此目的进行传统的食管 pH 监测。 21,0.5,"['monitoring', 'ph', 'esophageal', 'that']","['monitoring', 'esophageal']",70,"['外科医生拒绝依赖于选择病人进行补贴,一般偏好传统的尿液pH监测。']",0.25,"['monitoring', 'ph', 'esophageal', 'that']",['monitoring'],,
71,71,this trial was approved by the Veterans Affairs ( VA ) central institutional review board .,该试验得到了退伍军人事务部 (VA) 中央机构审查委员会的批准。,0.1666666666666666,"['review', 'central', 'board', 'trial', 'this', 'by']",['review'],71,['该审判由维特兰事务中央机构审计委员会(VA)批准。'],0.5,"['review', 'central', 'board', 'trial', 'this', 'by']","['review', 'trial', 'by']",,
72,72,"the authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol , available with the full text of this article at NEJM.org .",作者保证数据的完整性和准确性以及试验对方案的忠实度，方案与本文全文可在 NEJM.org 获取。,0.3076923076923077,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",72,"['作者保证数据的完整性和准确性,以及对本议定书的审判忠诚性,可在NEJM.org上提供本文的完整文本。']",0.4615384615384615,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'full']",,
73,73,prerandomization Trial Procedures,随机化前试验程序,0.0,['trial'],[],73,['预先审判程序'],1.0,['trial'],['trial'],,
74,74,all patients who were referred to VA gastroenterology clinics for heartburn refractory to PPIs were screened ( Figure 1 ) .,所有因 PPI 难治性胃灼热而转诊至 VA 胃肠病诊所的患者均接受了筛查（图 1）。,0.2857142857142857,"['who', '1', 'figure', 'heartburn', 'refractory', 'gastroenterology', 'all']","['1', 'heartburn']",74,['所有被转移到 VA 胃肠道诊所的病人对心燃解体的 PPI 进行了检查(图 1 )。'],0.1428571428571428,"['who', '1', 'figure', 'heartburn', 'refractory', 'gastroenterology', 'all']",['1'],,
75,75,"initial slow recruitment of patients resulted in intratrial changes to the protocol , including revised power calculations . ( for details on prerandomization trial procedures , randomization , intratrial changes to the protocol , and the statistical analysis , see the Supplementary Appendix , available at NEJM.org. )",最初缓慢招募患者导致试验中对方案进行了更改，包括修改了功效计算。 （有关随机化前试验程序、随机化、试验方案变更和统计分析的详细信息，请参阅补充附录，可在 NEJM.org 获取。）,0.5454545454545454,"['appendix', 'randomization', 'analysis', 'power', 'protocol', 'supplementary', 'initial', 'recruitment', 'available', 'trial', 'statistical analysis']","['randomization', 'analysis', 'protocol', 'initial', 'recruitment', 'statistical analysis']",75,"['患者的初始缓慢招聘导致协议的内分子变化,包括修订的功率计算(关于预分测试程序、随机化、内分子协议的变化以及统计分析的详细信息,请参见附件,可在NEJM.org上找到)。']",0.6363636363636364,"['appendix', 'randomization', 'analysis', 'power', 'protocol', 'supplementary', 'initial', 'recruitment', 'available', 'trial', 'statistical analysis']","['appendix', 'randomization', 'analysis', 'power', 'protocol', 'initial', 'statistical analysis']",,
76,76,medical Treatment Groups,医疗组,0.0,"['medical', 'medical treatment']",[],76,['医疗治疗组'],0.0,"['medical', 'medical treatment']",[],,
77,77,investigators and patients were unaware of whether medical treatment was active or placebo .,研究人员和患者不知道药物治疗是积极的还是安慰剂。,0.3333333333333333,"['placebo', 'medical', 'active', 'medical treatment', 'unaware', 'and']","['placebo', 'active']",77,['研究人员和患者不知道医疗治疗是否活跃或 placebo。'],0.0,"['placebo', 'medical', 'active', 'medical treatment', 'unaware', 'and']",[],,
78,78,"at all clinic visits , patients were queried about missed medication doses , and medication counts were performed .",在所有门诊就诊时，都会询问患者是否漏服药物，并进行药物计数。,0.0,"['medication', 'clinic', 'all', 'and']",[],78,"['在所有临床访问中,患者被问及错过的药物剂量,并进行药物计算。']",0.25,"['medication', 'clinic', 'all', 'and']",['clinic'],,
79,79,patients in both groups received active omeprazole at a dose of 20 mg twice daily throughout the trial .,在整个试验期间，两组患者均接受每天两次 20 毫克剂量的活性奥美拉唑。,0.1428571428571428,"['a', 'active', 'trial', 'at', 'dose', 'in', 'twice']",['dose'],79,['两组患者在试验期间每天服用20毫克的活性 omeprazole。'],0.0,"['a', 'active', 'trial', 'at', 'dose', 'in', 'twice']",[],,
80,80,"after discontinuation , patients with contraindications to desipramine were declared to have treatment failure .",停药后，对地昔帕明有禁忌症的患者被宣布治疗失败。,0.6666666666666666,"['failure', 'treatment', 'after', 'with', 'have', 'to']","['failure', 'treatment', 'after', 'have']",80,"['在中断后,患有抗示剂的患者被告知患有治疗失败。']",0.6666666666666666,"['failure', 'treatment', 'after', 'with', 'have', 'to']","['failure', 'treatment', 'after', 'have']",,
81,81,surgical Treatment Group,手术治疗组,0.75,"['group', 'surgical', 'treatment', 'treatment group']","['group', 'treatment', 'treatment group']",81,['外科治疗小组'],0.5,"['group', 'surgical', 'treatment', 'treatment group']","['group', 'treatment']",,
82,82,surgical treatment was laparoscopic Nissen fundoplication .,手术治疗为腹腔镜尼森胃底折叠术。,0.5,"['surgical', 'treatment']",['treatment'],82,['手术治疗是Laparoscopic Nissen fundoplication。'],0.5,"['surgical', 'treatment']",['treatment'],10.0,3.0
83,83,heartburn medications were prohibited after fundoplication .,胃底折叠术后禁用胃灼热药物。,1.0,"['heartburn', 'after']","['heartburn', 'after']",83,['心燃药物被禁止在基金投注后。'],0.5,"['heartburn', 'after']",['after'],10.0,5.0
84,84,this article does not include all analyses and outcomes that were prespecified in the protocol and does not include any analyses or outcome measures that were not prespecified in the protocol .,本文不包括方案中预先指定的所有分析和结果，也不包括方案中未预先指定的任何分析或结果测量。,0.125,"['outcome', 'protocol', 'article', 'all', 'this', 'that', 'in', 'and']",['outcome'],84,"['本条不包括在议定书中预定的所有分析和结果,也不包括在议定书中未预定的任何分析或结果措施。']",0.25,"['outcome', 'protocol', 'article', 'all', 'this', 'that', 'in', 'and']","['outcome', 'protocol']",10.0,10.0
85,85,"to keep the overall type I error at 0.05 for the null hypothesis , the alpha level for each of the three comparisons was adjusted with the use of the Hochberg method.25",为了将零假设的总体 I 类错误保持在 0.05，使用 Hochberg 方法调整了三个比较中每一个的 alpha 水平。 25,0.3571428571428571,"['type', 'hypothesis', 'alpha', 'null', 'error', 'keep', 'null hypothesis', 'level', 'with', 'at', 'I', 'three', 'each', 'to']","['hypothesis', 'null', 'error', 'keep', 'level']",85,"['为了在零假设中保持总类型 I 错误为 0.05,每个三种比较的 alpha 水平通过使用 Hochberg 方法进行调整。']",0.4285714285714285,"['type', 'hypothesis', 'alpha', 'null', 'error', 'keep', 'null hypothesis', 'level', 'with', 'at', 'I', 'three', 'each', 'to']","['type', 'hypothesis', 'null', 'error', 'keep', 'level']",10.0,9.0
86,86,"we used SAS software , version 9.4 ( SAS Institute ) , for all analyses .",我们使用 SAS 软件 9.4 版（SAS Institute）进行所有分析。,0.1666666666666666,"['version', 'software', 'institute', 'SAS', 'all', 'we']",['software'],86,"['我们使用SAS软件,版本 9.4(SAS研究所),用于所有分析。']",0.5,"['version', 'software', 'institute', 'SAS', 'all', 'we']","['version', 'software', 'institute']",10.0,10.0
87,87,prerandomization PROCEDURE EXCLUSIONS,随机化前程序排除,,[],[],87,['提前排除程序'],,[],[],,
88,88,"a revised power calculation called for 108 randomly assigned patients , but enrollment was capped at 78 solely because of funding limitations .",修订后的功效计算要求 108 名随机分配的患者，但仅由于资金限制，登记人数上限为 78 人。,0.4,"['a', 'power', 'capped', 'at', 'but']","['at', 'but']",88,"['一个修订的电力计算呼吁108随机分配的病人,但注册被抓到78仅因为融资限制。']",0.4,"['a', 'power', 'capped', 'at', 'but']","['power', 'but']",,
89,89,randomly ASSIGNED PATIENTS,随机分配的患者,,[],[],89,['随机注册的病人'],,[],[],,
90,90,"after trial completion , review of primary data collection forms revealed discrepancies in eligibility criteria data for 5 randomly assigned patients , which raised uncertainty about whether these patients met all eligibility criteria .",试验完成后，对主要数据收集表的审查发现 5 名随机分配患者的资格标准数据存在差异，这增加了对这些患者是否符合所有资格标准的不确定性。,0.4666666666666667,"['5', 'data', 'review', 'collection', 'primary', 'raised', 'after', 'trial', 'completion', 'data collection', 'primary data', 'met', 'uncertainty', 'all', 'revealed']","['5', 'data', 'review', 'collection', 'after', 'completion', 'data collection']",90,"['试验完成后,初级数据收集表格的审查揭示了5名随机分配的患者资格标准数据的差异,这引起了对这些患者是否符合所有资格标准的不确定性。']",0.4666666666666667,"['5', 'data', 'review', 'collection', 'primary', 'raised', 'after', 'trial', 'completion', 'data collection', 'primary data', 'met', 'uncertainty', 'all', 'revealed']","['5', 'data', 'review', 'collection', 'after', 'completion', 'data collection']",,
91,91,analyses that excluded these 5 patients were similar to our primary analyses ( see the Supplementary Appendix ) .,排除这 5 名患者的分析与我们的主要分析相似（见补充附录）。,0.1428571428571428,"['5', 'appendix', 'supplementary', 'primary', 'that', 'to', 'similar']",['5'],91,['排除这些5名患者的分析与我们的初级分析相似(参见附件)。'],0.2857142857142857,"['5', 'appendix', 'supplementary', 'primary', 'that', 'to', 'similar']","['5', 'appendix']",,
92,92,"the relative risk of treatment success was 2.38 ( 95 % CI , 1.20 to 4.71 ) for surgery versus active medical treatment , 5.78 ( 95 % CI , 1.93 to 17.31 ) for surgery versus control medical treatment , and 2.43 ( 95 % CI , 0.71 to 8.35 ) for active medical treatment versus control medical treatment ( unadjusted comparisons ) .",手术与积极药物治疗的治疗成功相对风险分别为 2.38 ( 95 % CI 1.20 至 4.71 ) ，手术与对照药物治疗 5.78 ( 95 % CI 1.93 至 17.31 ) 和 2.43 ( 95 % CI 0.71 至8.35) 积极药物治疗与对照药物治疗（未经调整的比较）。,0.3333333333333333,"['control', 'surgery', 'medical', 'relative', 'active', 'medical treatment', 'success', 'risk', 'unadjusted', 'CI', 'to', 'and']","['control', 'surgery', 'success', 'risk']",92,['治疗成功的相对风险为2.38(95% CI、1.20至4.71 )对手术对活性医疗治疗、5.78(95% CI、1.93至17.31 )对手术对控制医疗治疗、和2.43(95% CI、0.71至8.35 )对活性医疗治疗对控制医疗治疗(不调整的比较)。'],0.3333333333333333,"['control', 'surgery', 'medical', 'relative', 'active', 'medical treatment', 'success', 'risk', 'unadjusted', 'CI', 'to', 'and']","['control', 'surgery', 'success', 'risk']",,
93,93,the incidence of success in the surgery group was 71 % among the 14 patients with reflux hypersensitivity and 62 % among the 13 with abnormal acid reflux .,手术组的成功率在 14 名反流过敏患者中为 71%，在 13 名胃酸反流异常患者中为 62%。,0.6,"['hypersensitivity', 'group', 'incidence', 'surgery', 'abnormal', 'success', 'reflux', 'with', 'acid', 'and']","['group', 'surgery', 'abnormal', 'success', 'reflux', 'acid']",93,['在手术组中成功的发病率为14名患有过敏的患者中71%和13名患有异常酸过敏的患者中62%。'],0.6,"['hypersensitivity', 'group', 'incidence', 'surgery', 'abnormal', 'success', 'reflux', 'with', 'acid', 'and']","['group', 'incidence', 'surgery', 'abnormal', 'success', 'acid']",,
94,94,"there were five serious adverse events in 4 patients in the surgery group , four serious adverse events in 4 patients in the active medical group , and five serious adverse events in 3 patients in the control medical group ( Table S3 ) .",手术组有 4 名患者发生 5 起严重不良事件，积极治疗组有 4 名患者发生 4 起严重不良事件，对照组有 3 名患者发生 5 起严重不良事件（表 S3）。,0.2857142857142857,"['group', 'control', 'table', 'surgery', 'medical', 'active', 'adverse', '3', '4', 'S3', 'serious', 'five', 'in', 'and']","['group', 'control', 'table', 'surgery']",94,"['在手术组中有4名患者发生5件严重的副作用,在活跃医疗组中有4名患者发生4件严重的副作用,在控制医疗组中有3名患者发生5件严重的副作用。']",0.2142857142857142,"['group', 'control', 'table', 'surgery', 'medical', 'active', 'adverse', '3', '4', 'S3', 'serious', 'five', 'in', 'and']","['group', 'control', 'surgery']",,
95,95,"one surgical patient had a herniated Nissen fundoplication that resulted in repeat surgery complicated by postoperative pneumonia ; recovery was complete , and repeat surgery successfully controlled heartburn .",一名手术患者患有突出的 Nissen 胃底折叠术，导致重复手术并发术后肺炎；恢复完全，再次手术成功地控制了胃灼热。,0.4705882352941176,"['repeat', 'heartburn', 'surgery', 'surgical', 'controlled', 'complete', 'complicated', 'postoperative', 'recovery', 'patient', 'herniated', 'pneumonia', 'that', 'in', 'by', 'and', 'complicated by']","['repeat', 'heartburn', 'surgery', 'controlled', 'recovery', 'patient', 'herniated', 'pneumonia']",95,"['一名外科病人患有麻醉的尼森基金,结果是由手术后肺炎复杂的重复手术;恢复完成,并重复手术成功控制心燃。']",0.4705882352941176,"['repeat', 'heartburn', 'surgery', 'surgical', 'controlled', 'complete', 'complicated', 'postoperative', 'recovery', 'patient', 'herniated', 'pneumonia', 'that', 'in', 'by', 'and', 'complicated by']","['repeat', 'surgery', 'controlled', 'complicated', 'recovery', 'patient', 'pneumonia', 'by']",,
96,96,there were no deaths .,没有死亡。,0.0,['no'],[],96,['没有死亡。'],0.0,['no'],[],,
97,97,"in that highly selected group , the incidence of treatment success with laparoscopic Nissen fundoplication at 1 year ( 67 % ) was significantly superior to that with active medical treatment ( 28 % ) or control medical treatment ( 12 % ) .",在这个精心挑选的组中，腹腔镜 Nissen 胃底折叠术在 1 年时的治疗成功率 (67%) 明显优于积极药物治疗 (28%) 或对照药物治疗 (12%)。,0.4615384615384615,"['group', 'incidence', 'control', 'year', '1', 'medical', 'superior', 'active', 'medical treatment', 'success', 'with', 'that', 'to']","['group', 'control', 'year', '1', 'success', 'to']",97,"['在这个精选的群体中,在1年(67%)的拉帕罗斯科尼森药物治疗成功率显著高于活性医疗治疗(28%)或控制医疗治疗(12%)的成功率。']",0.4615384615384615,"['group', 'incidence', 'control', 'year', '1', 'medical', 'superior', 'active', 'medical treatment', 'success', 'with', 'that', 'to']","['group', 'control', 'year', '1', 'success', 'to']",,
98,98,"first , trial patients were given explicit instructions to take omeprazole 30 minutes before meals .",首先，试验患者被明确指示在饭前 30 分钟服用奥美拉唑。,0.3333333333333333,"['trial', 'explicit', 'before', 'to', 'first', 'instructions']","['before', 'first']",98,"['首先,试验患者被明确指示在晚餐前30分钟服用 omeprazole。']",0.3333333333333333,"['trial', 'explicit', 'before', 'to', 'first', 'instructions']","['before', 'first']",,
99,99,this is important because PPIs bind only to gastric proton pumps that are actively secreting acid .,这很重要，因为 PPI 仅与活跃分泌酸的胃质子泵结合。,0.3333333333333333,"['gastric', 'proton', 'acid', 'this', 'that', 'bind']","['proton', 'acid']",99,"['这很重要,因为PPI仅连接到活跃分泌酸的胃<unk>泵。']",0.1666666666666666,"['gastric', 'proton', 'acid', 'this', 'that', 'bind']",['acid'],,
100,100,"fewer than 10 % of those pumps are active during fasting , whereas approximately 70 % are active when stimulated by meals.26",这些泵中只有不到 10 % 在禁食期间处于活动状态，而大约 70 % 在进食时处于活动状态。 26,0.0,"['active', 'fasting', 'approximately', 'by']",[],100,"['在禁食期间,不到10%的这些泵是活跃的,而在食物刺激时,约70%是活跃的。']",0.0,"['active', 'fasting', 'approximately', 'by']",[],,
101,101,"consequently , PPIs are most effective when taken before meals .",因此，PPI 在饭前服用最有效。,1.0,['before'],['before'],101,"['因此,PPI在晚餐前服用时最有效。']",1.0,['before'],['before'],,
102,102,"second , patients taking PPIs other than omeprazole at trial entry were switched to omeprazole .",其次，在试验开始时服用奥美拉唑以外的 PPI 的患者转为服用奥美拉唑。,0.1666666666666666,"['taking', 'trial', 'entry', 'at', 'second', 'to']",['second'],102,"['其次,在试验入口时服用非 omeprazole PPI 的患者被转换为 omeprazole。']",0.1666666666666666,"['taking', 'trial', 'entry', 'at', 'second', 'to']",['second'],,
103,103,"relative potencies of different PPIs vary widely , 27 and individual patients can exhibit considerable variability in response to different PPIs.28",不同 PPI 的相对效力差异很大，27 并且个体患者对不同 PPI 的反应可能表现出相当大的差异。 28,0.2857142857142857,"['variability', 'individual', 'relative', 'response', 'exhibit', 'to', 'and']","['individual', 'response']",103,"['不同PPI的相对强度广泛不同,27个患者在不同PPI的反应中可能显著变化。']",0.1428571428571428,"['variability', 'individual', 'relative', 'response', 'exhibit', 'to', 'and']",['response'],,
104,104,"many patients would not complete this rigorous evaluation , and among those who did , the cause of heartburn in most of them was not GERD .",许多患者不会完成这项严格的评估，而在那些完成的患者中，大多数胃灼热的原因不是 GERD。,0.5,"['who', 'evaluation', 'heartburn', 'complete', 'cause', 'this', 'in', 'and']","['heartburn', 'cause', 'this', 'and']",104,"['许多患者不会完成这项严格的评估,并且在那些这样做的人中,心脏病发作的原因在大多数人中不是GERD。']",0.25,"['who', 'evaluation', 'heartburn', 'complete', 'cause', 'this', 'in', 'and']","['cause', 'this']",,
105,105,"our finding that reflux hypersensitivity can respond to fundoplication is noteworthy because reflux hypersensitivity is considered a functional disorder , which might not be expected to improve with a procedure that eliminates reflux without altering abnormal esophageal pain perception.10",我们发现反流超敏反应可以对胃底折叠术产生反应是值得注意的，因为反流超敏反应被认为是一种功能障碍，可能无法通过消除反流而不改变异常食管疼痛感知的手术来改善这种情况。 10,0.5333333333333333,"['hypersensitivity', 'esophageal', 'procedure', 'disorder', 'functional', 'abnormal', 'be', 'pain', 'reflux', 'functional disorder', 'with', 'that', 'to', 'respond to', 'without']","['hypersensitivity', 'esophageal', 'disorder', 'abnormal', 'pain', 'reflux', 'respond to', 'without']",105,"['我們的發現,反流過敏性可以回應 fundoplication 是值得注意的,因為反流過敏性被認為是一個功能障礙,這可能不會被預計改善一個程序,消除反流,而不改變異常的尿道疼痛感知。']",0.2,"['hypersensitivity', 'esophageal', 'procedure', 'disorder', 'functional', 'abnormal', 'be', 'pain', 'reflux', 'functional disorder', 'with', 'that', 'to', 'respond to', 'without']","['procedure', 'pain', 'reflux']",,
106,106,"for our surgical patients , the incidence of treatment success was 71 % among the 14 with reflux hypersensitivity and 62 % among the 13 with abnormal acid reflux .",对于我们的手术患者，14 名反流过敏患者的治疗成功率为 71%，13 名胃酸反流异常患者的治疗成功率为 62%。,0.5,"['hypersensitivity', 'incidence', 'abnormal', 'surgical', 'treatment', 'success', 'reflux', 'with', 'acid', 'and']","['abnormal', 'treatment', 'success', 'reflux', 'acid']",106,"['对于我们的手术患者,治疗成功的发病率为14人中有过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏性过敏。']",0.4,"['hypersensitivity', 'incidence', 'abnormal', 'surgical', 'treatment', 'success', 'reflux', 'with', 'acid', 'and']","['hypersensitivity', 'incidence', 'treatment', 'success']",,
107,107,"PPIs are inactivated through the hepatic cytochrome P450 isoenzyme CYP2C19 , and CYP2C19 mutations can influence PPI inactivation rates and clinical efficacy.39",PPI 通过肝细胞色素 P450 同工酶 CYP2C19 失活，而 CYP2C19 突变可影响 PPI 失活率和临床疗效。 39,0.75,"['cytochrome', 'isoenzyme', 'inactivation', 'hepatic', 'clinical', 'influence', 'cytochrome P450', 'and']","['cytochrome', 'isoenzyme', 'inactivation', 'clinical', 'influence', 'and']",107,"['PPI 通过肝细胞染色素 P450 以生素 CYP2C19 被禁活,而 CYP2C19 突变可能会影响 PPI 禁活率和临床有效性。']",0.375,"['cytochrome', 'isoenzyme', 'inactivation', 'hepatic', 'clinical', 'influence', 'cytochrome P450', 'and']","['clinical', 'influence', 'and']",,
108,108,limitations of our trial include its relatively small sample size and predominance of white men ( reflecting the veteran patient population ) .,我们试验的局限性包括其相对较小的样本量和白人男性的优势（反映了退伍军人患者群体）。,0.5555555555555556,"['sample', 'population', 'white', 'size', 'patient', 'trial', 'sample size', 'predominance', 'and']","['sample', 'population', 'white', 'patient', 'predominance']",108,['我们试验的限制包括其相对较小的样品大小和白人占主导地位(反映了退休患者人口)。'],0.5555555555555556,"['sample', 'population', 'white', 'size', 'patient', 'trial', 'sample size', 'predominance', 'and']","['sample', 'population', 'white', 'size', 'patient']",,
109,109,another limitation involves the intratrial protocol amendments required to enable trial completion .,另一个局限性涉及为完成试验所需的试验内协议修正案。,0.5,"['protocol', 'limitation', 'trial', 'completion']","['protocol', 'completion']",109,"['另一个限制包括在内议定书中所需的修正案,以便审判完成。']",0.75,"['protocol', 'limitation', 'trial', 'completion']","['protocol', 'trial', 'completion']",,
110,110,"overly restrictive entry criteria that limit trial enrollment , generalizability , and completion are a common problem in trials involving patients with functional gastrointestinal disorders.40,41","限制试验入组、普遍性和完成的过于严格的入组标准是涉及功能性胃肠病患者的试验中的一个常见问题。 40,41",0.3333333333333333,"['a', 'gastrointestinal', 'functional', 'common', 'trial', 'limit', 'completion', 'problem', 'entry', 'with', 'that', 'and']","['gastrointestinal', 'limit', 'completion', 'problem']",110,['限制试验登记、通用性和完成的过度限制性入门标准是涉及功能性肠道障碍患者的试验中常见问题。'],0.25,"['a', 'gastrointestinal', 'functional', 'common', 'trial', 'limit', 'completion', 'problem', 'entry', 'with', 'that', 'and']","['limit', 'completion', 'problem']",,
111,111,"consequently , we amended the protocol to allow the entry of patients with contraindications to desipramine .",因此，我们修改了协议，允许有禁忌症的患者进入地昔帕明。,0.4,"['protocol', 'allow', 'entry', 'with', 'we']","['protocol', 'allow']",111,"['因此,我们修改了议定书,以便允许患有抗指示的患者入院。']",0.4,"['protocol', 'allow', 'entry', 'with', 'we']","['protocol', 'allow']",,
112,112,"we also amended power calculations to detect only large differences between medical and surgical treatments , reasoning that physicians would not recommend surgery unless it were considerably more effective than medical therapy .",我们还修改了功效计算以仅检测药物治疗和手术治疗之间的巨大差异，理由是医生不会推荐手术，除非它比药物治疗有效得多。,0.3076923076923077,"['power', 'surgery', 'medical', 'surgical', 'recommend', 'large', 'therapy', 'detect', 'reasoning', 'that', 'to', 'and', 'physicians']","['surgery', 'recommend', 'therapy', 'detect']",112,"['我们还修改了功率计算,以检测医学和手术治疗之间只有大差异,认为医生不会推荐手术,除非它比医学治疗更有效。']",0.3846153846153846,"['power', 'surgery', 'medical', 'surgical', 'recommend', 'large', 'therapy', 'detect', 'reasoning', 'that', 'to', 'and', 'physicians']","['power', 'surgery', 'recommend', 'therapy', 'detect']",,
113,113,"in that highly selected group , laparoscopic Nissen fundoplication was significantly superior to medical therapy .",在这个经过精心挑选的组中，腹腔镜 Nissen 胃底折叠术明显优于药物治疗。,0.4285714285714285,"['group', 'medical', 'superior', 'therapy', 'that', 'in', 'to']","['group', 'therapy', 'to']",113,"['在这个精选的群体中,Laparoscopic Nissen fundoplication 显著高于医学治疗。']",0.4285714285714285,"['group', 'medical', 'superior', 'therapy', 'that', 'in', 'to']","['group', 'therapy', 'to']",,
114,114,the relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned are uncertain .,对于计划进行侵入性评估的急性冠脉综合征患者，替格瑞洛与普拉格雷相比的相对优势尚不确定。,0.3333333333333333,"['evaluation', 'coronary', 'uncertain', 'relative', 'acute', 'as', 'with', 'prasugrel', 'syndromes']","['coronary', 'prasugrel', 'syndromes']",114,"['与Prasugrel相比,Ticagrelor的相对价值在患有急性冠状综合征的患者中不确定。']",0.2222222222222222,"['evaluation', 'coronary', 'uncertain', 'relative', 'acute', 'as', 'with', 'prasugrel', 'syndromes']","['coronary', 'syndromes']",,
115,115,"the primary end point was the composite of death , myocardial infarction , or stroke at 1 year .",主要终点是 1 年时死亡、心肌梗死或卒中的复合终点。,0.6666666666666666,"['myocardial infarction', 'composite', 'stroke', 'year', '1', 'death', 'primary', 'end', 'point']","['myocardial infarction', 'stroke', 'year', '1', 'death', 'point']",115,"['主要的终点是死亡的组成,心脏病发作,或1年的中风。']",0.6666666666666666,"['myocardial infarction', 'composite', 'stroke', 'year', '1', 'death', 'primary', 'end', 'point']","['stroke', 'year', '1', 'death', 'primary', 'point']",,
116,116,a major secondary end point ( the safety end point ) was bleeding .,一个主要的次要终点（安全终点）是出血。,0.5,"['bleeding', 'safety', 'major', 'secondary', 'end', 'point']","['bleeding', 'safety', 'point']",116,['一个主要的次要终点(安全终点)是出血。'],0.5,"['bleeding', 'safety', 'major', 'secondary', 'end', 'point']","['bleeding', 'safety', 'point']",,
117,117,a total of 4018 patients underwent randomization .,共有 4018 名患者接受了随机分组。,0.3333333333333333,"['a', 'randomization', 'total']",['randomization'],117,['共有4018名患者遭到随机化。'],0.3333333333333333,"['a', 'randomization', 'total']",['randomization'],,
118,118,"the respective incidences of the individual components of the primary end point in the ticagrelor group and the prasugrel group were as follows : death , 4.5 % and 3.7 % ; myocardial infarction , 4.8 % and 3.0 % ; and stroke , 1.1 % and 1.0 % .",替格瑞洛组和普拉格雷组主要终点的各个组成部分的发生率分别如下：死亡，4.5%和3.7%；心肌梗塞，4.8%和3.0%；和中风，1.1% 和 1.0%。,0.6363636363636364,"['group', 'myocardial infarction', 'stroke', 'individual', 'death', 'primary', 'end', 'point', 'as', 'prasugrel', 'and']","['group', 'myocardial infarction', 'stroke', 'death', 'point', 'as', 'prasugrel']",118,['图克格勒群体和图克格勒群体的主要终点组成部分的分别发病率如下:死亡、4.5%和3.7%、心脏病发作、4.8%和 3.0%、中风、1.1%和1.0%。'],0.4545454545454545,"['group', 'myocardial infarction', 'stroke', 'individual', 'death', 'primary', 'end', 'point', 'as', 'prasugrel', 'and']","['group', 'stroke', 'death', 'point', 'as']",,
119,119,"definite or probable stent thrombosis occurred in 1.3 % of patients assigned to ticagrelor and 1.0 % of patients assigned to prasugrel , and definite stent thrombosis occurred in 1.1 % and 0.6 % , respectively .",分配给替格瑞洛组的患者和普拉格雷组分别有 1.3% 和 1.0% 的患者发生明确或可能的支架内血栓形成，明确的支架内血栓形成发生率分别为 1.1% 和 0.6%。,0.3333333333333333,"['thrombosis', 'stent', 'prasugrel', 'in', 'to', 'and']","['thrombosis', 'prasugrel']",119,"['确定的或可能的<unk>血病发生在Ticagrelor患者的1.3%和Prasugrel患者的1.0%中,而确定的<unk>血病发生在1.1%和0.6%分别。']",0.1666666666666666,"['thrombosis', 'stent', 'prasugrel', 'in', 'to', 'and']",['and'],,
120,120,"major bleeding ( as defined by the Bleeding Academic Research Consortium scale ) was observed in 5.4 % of patients in the ticagrelor group and in 4.8 % of patients in the prasugrel group ( hazard ratio , 1.12 ; 95 % CI , 0.83 to 1.51 ; P = 0.46 ) .",替格瑞洛组 5.4% 的患者和普拉格雷组 4.8% 的患者观察到大出血（根据出血学术研究联盟量表定义）（风险比，1.12；95% CI，0.83 至 1.51；P = 0.46）。,0.4705882352941176,"['bleeding', 'group', 'consortium', 'defined', 'research', 'ratio', 'hazard ratio', 'scale', 'major', 'academic research', 'as', 'prasugrel', 'P', 'CI', 'by', 'to', 'and']","['bleeding', 'group', 'research', 'ratio', 'hazard ratio', 'scale', 'academic research', 'prasugrel']",120,"['主要出血(根据血液学术研究协会规模定义)被观察到 5.4% 的患者在 ticagrelor 群体和 4.8% 的患者在 prasugrel 群体(风险比例, 1.12 ; 95% CI, 0.83 到 1.51 ; P = 0.46 ) 。']",0.3529411764705882,"['bleeding', 'group', 'consortium', 'defined', 'research', 'ratio', 'hazard ratio', 'scale', 'major', 'academic research', 'as', 'prasugrel', 'P', 'CI', 'by', 'to', 'and']","['bleeding', 'group', 'research', 'ratio', 'hazard ratio', 'academic research']",,
121,121,"however , data are lacking on the relative merits of treatment for 1 year with ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned .",然而，对于计划进行有创评估的急性冠脉综合征患者，与普拉格雷相比，替格瑞洛治疗 1 年的相对优点尚缺乏数据。,0.5384615384615384,"['data', 'year', '1', 'evaluation', 'coronary', 'relative', 'treatment', 'acute', 'as', 'with', 'prasugrel', 'in', 'syndromes']","['data', 'year', '1', 'coronary', 'treatment', 'prasugrel', 'syndromes']",121,"['然而,与Prasugrel相比,在患有急性冠状综合征的患者中,缺乏对1年的Ticagrelor治疗的相对益处的数据,其中计划进行侵入性评估。']",0.4615384615384615,"['data', 'year', '1', 'evaluation', 'coronary', 'relative', 'treatment', 'acute', 'as', 'with', 'prasugrel', 'in', 'syndromes']","['data', 'year', '1', 'coronary', 'treatment', 'syndromes']",,
122,122,"in these patients , ticagrelor is usually administered as pretreatment before diagnostic angiography , 4 but prasugrel is administered only after the coronary anatomy has been assessed by means of diagnostic angiography , 5 since no advantage has been observed when prasugrel is used as pretreatment.9",在这些患者中，替格瑞洛通常作为诊断性血管造影术前的预处理给药 4 ，但仅在通过诊断性血管造影术评估冠状动脉解剖后才给药普拉格雷 5 ，因为普拉格雷用作预处理时未观察到优势 9 。,0.5555555555555556,"['angiography', '5', 'anatomy', 'coronary', 'no', 'after', 'advantage', 'diagnostic', '4', 'means', 'as', 'prasugrel', 'pretreatment', 'before', 'in', 'by', 'but', 'assessed']","['angiography', '5', 'anatomy', 'coronary', 'after', 'advantage', 'prasugrel', 'pretreatment', 'before', 'but']",122,"['在这些患者中,Ticagrelor通常在诊断安吉格拉之前作为预治疗,4但Prasugrel仅在通过诊断安吉格拉评估冠状解剖后服用,5因为当Prasugrel作为预治疗时没有任何好处。']",0.3888888888888889,"['angiography', '5', 'anatomy', 'coronary', 'no', 'after', 'advantage', 'diagnostic', '4', 'means', 'as', 'prasugrel', 'pretreatment', 'before', 'in', 'by', 'but', 'assessed']","['5', 'anatomy', 'coronary', 'after', 'before', 'in', 'but']",,
123,123,"one strategy is based on ticagrelor , and the other is based on prasugrel .",一种策略基于替格瑞洛，另一种基于普拉格雷。,0.5,"['strategy', 'prasugrel', 'on', 'and']","['strategy', 'prasugrel']",123,"['一个策略是基于ticagrelor,另一个是基于 prasugrel。']",0.25,"['strategy', 'prasugrel', 'on', 'and']",['strategy'],,
124,124,the design and rationale of the trial have been published previously.10,试验的设计和基本原理之前已发表。 10,0.4,"['rationale', 'trial', 'design', 'have', 'and']","['rationale', 'design']",124,['审判的草案和合理性已经公布10'],0.2,"['rationale', 'trial', 'design', 'have', 'and']",['trial'],,
125,125,"the first and last authors , with input from the steering committee , designed the trial .",第一作者和最后一位作者在指导委员会的指导下设计了试验。,0.2857142857142857,"['steering', 'committee', 'input', 'trial', 'with', 'and', 'first']","['committee', 'first']",125,"['第一和最后的作者,由董事会提交,设计了审判。']",0.2857142857142857,"['steering', 'committee', 'input', 'trial', 'with', 'and', 'first']","['trial', 'first']",,
126,126,"the Intracoronary Stenting and Antithrombosis Research Center , which is affiliated with Deutsches Herzzentrum München in Munich , Germany , was the data coordinating center .",隶属于德国慕尼黑的Deutsches Herzzentrum München的冠状动脉内支架置入术和抗血栓形成研究中心是数据协调中心。,0.5714285714285714,"['center', 'research', 'data', 'research center', 'with', 'in', 'and']","['center', 'research', 'data', 'research center']",126,"['Intracoronary Stenting and Antithrombosis Research Center 与德国慕尼黑的 Deutsches Herzzentrum München 附属,是数据协调中心。']",0.2857142857142857,"['center', 'research', 'data', 'research center', 'with', 'in', 'and']","['center', 'data']",,
127,127,data analysis was performed by the trial statistician .,数据分析由试验统计学家进行。,0.75,"['data', 'analysis', 'trial', 'by']","['data', 'analysis', 'by']",127,['数据分析由调查统计学家进行。'],0.75,"['data', 'analysis', 'trial', 'by']","['data', 'analysis', 'by']",,
128,128,"the first and last authors and the trial statistician vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol , which is available with the full text of this article at NEJM.org .",第一作者和最后一位作者以及试验统计学家保证数据的准确性和完整性，以及试验对方案的忠实度，方案与本文全文可在 NEJM.org 获取。,0.3571428571428571,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and', 'first']","['data', 'accuracy', 'completeness', 'full', 'first']",128,"['第一和最后的作者和审查统计学家为数据的准确性和完整性以及审查对议定书的忠诚度,该议定书可在NEJM.org上提供本文的完整文本。']",0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and', 'first']","['data', 'accuracy', 'protocol', 'completeness', 'full', 'first']",,
129,129,the first author wrote the first draft of the manuscript .,第一作者撰写了手稿的初稿。,0.5,"['author', 'manuscript', 'first', 'draft']","['manuscript', 'first']",129,['第一位作者写了手稿的第一个草案。'],0.5,"['author', 'manuscript', 'first', 'draft']","['manuscript', 'first']",,
130,130,all the authors agreed to submit the manuscript for publication .,所有作者均同意投稿发表。,0.25,"['publication', 'manuscript', 'all', 'to']",['publication'],130,['所有作者都同意将手稿提交出版。'],0.5,"['publication', 'manuscript', 'all', 'to']","['publication', 'manuscript']",,
131,131,the funding institutions were not involved in writing the manuscript or interpreting the results .,资助机构没有参与撰写手稿或解释结果。,0.5,"['manuscript', 'writing']",['manuscript'],131,['资助机构不参与编写手稿或解释结果。'],0.5,"['manuscript', 'writing']",['manuscript'],,
132,132,commercially available ticagrelor or prasugrel tablets were prescribed by the treating physician and purchased by the patients .,市售的替格瑞洛或普拉格雷片剂由主治医师开具处方并由患者购买。,0.6,"['physician', 'available', 'prasugrel', 'by', 'and']","['physician', 'prasugrel', 'by']",132,['商用可用的Ticagrelor或Prasugrel药片由治疗医生处方并由患者购买。'],0.6,"['physician', 'available', 'prasugrel', 'by', 'and']","['physician', 'available', 'by']",,
133,133,"a detailed list of participating centers and investigators is provided in the Supplementary Appendix , available at NEJM.org .",补充附录中提供了参与中心和研究者的详细列表，补充附录可在 NEJM.org 获取。,0.0,"['a', 'appendix', 'supplementary', 'available', 'list', 'at', 'in', 'and']",[],133,"['参与中心和调查人员的详细列表在附加附件中提供,可在NEJM.org上找到。']",0.125,"['a', 'appendix', 'supplementary', 'available', 'list', 'at', 'in', 'and']",['appendix'],,
134,134,exclusion criteria were determined predominantly from the summary of medical product characteristics of the trial drugs .,排除标准主要根据试验药物的医疗产品特征的总结确定。,0.5,"['product', 'drugs', 'medical', 'exclusion', 'characteristics', 'trial']","['product', 'drugs', 'characteristics']",134,['排除标准主要由试用药物的医疗产品特征总结确定。'],0.5,"['product', 'drugs', 'medical', 'exclusion', 'characteristics', 'trial']","['product', 'drugs', 'characteristics']",,
135,135,the detailed exclusion criteria are listed in the Supplementary Appendix .,详细的排除标准列于补充附录中。,0.0,"['appendix', 'supplementary', 'exclusion', 'in']",[],135,['详细的排除标准在附件中列出。'],0.25,"['appendix', 'supplementary', 'exclusion', 'in']",['appendix'],,
136,136,"patients who met all the inclusion criteria and none of the exclusion criteria were randomly assigned in consecutive order to either ticagrelor or prasugrel , with a randomization ratio of 1 : 1 .",满足所有纳入标准且未满足任何排除标准的患者按连续顺序随机分配至替格瑞洛或普拉格雷，随机化比例为 1:1。,0.2857142857142857,"['a', 'randomization', 'who', 'inclusion', 'order', '1', 'ratio', 'exclusion', 'consecutive', 'with', 'prasugrel', 'met', 'all', 'to']","['randomization', '1', 'ratio', 'prasugrel']",136,"['满足所有包容标准的患者,并且没有排除标准的患者随机分别分配到Ticagrelor或Prasugrel,随机分配比为1:1。']",0.2142857142857142,"['a', 'randomization', 'who', 'inclusion', 'order', '1', 'ratio', 'exclusion', 'consecutive', 'with', 'prasugrel', 'met', 'all', 'to']","['randomization', '1', 'ratio']",,
137,137,time zero was defined as the time of randomization .,时间零被定义为随机化的时间。,0.6,"['defined', 'randomization', 'time', 'as', 'zero']","['randomization', 'time', 'zero']",137,['零时间被定义为随机化时间。'],0.6,"['defined', 'randomization', 'time', 'as', 'zero']","['randomization', 'time', 'zero']",,
138,138,"randomly permuted block sizes ( of four , six , or eight ) were used in each stratum .",每个层使用随机排列的块大小（四个、六个或八个）。,0.5,"['stratum', 'block', 'each', 'in']","['stratum', 'block']",138,['随机转换的区块大小(四、六、八)在每个层中使用。'],0.5,"['stratum', 'block', 'each', 'in']","['stratum', 'block']",,
139,139,therapy with ticagrelor was started at a loading dose of 180 mg and continued at a maintenance dose of 90 mg twice daily .,替格瑞洛治疗以 180 毫克的负荷剂量开始，并以每天两次 90 毫克的维持剂量继续。,0.4444444444444444,"['loading', 'therapy', 'maintenance', 'with', 'at', 'dose', 'maintenance dose', 'and', 'twice']","['therapy', 'maintenance', 'dose', 'maintenance dose']",139,"['用Ticagrelor治疗开始于180毫克的负载剂量,并在90毫克的维持剂量继续,每天两次。']",0.5555555555555556,"['loading', 'therapy', 'maintenance', 'with', 'at', 'dose', 'maintenance dose', 'and', 'twice']","['therapy', 'maintenance', 'at', 'dose', 'maintenance dose']",,
140,140,patients who were assigned to ticagrelor received the loading dose as soon as possible after randomization .,被分配到替格瑞洛组的患者在随机分组后尽快接受负荷剂量。,0.4285714285714285,"['loading', 'randomization', 'who', 'after', 'as', 'dose', 'to']","['randomization', 'after', 'dose']",140,['被分配到Ticagrelor的患者在随机化后尽快获得充电剂量。'],0.4285714285714285,"['loading', 'randomization', 'who', 'after', 'as', 'dose', 'to']","['randomization', 'after', 'dose']",,
141,141,therapy with prasugrel was started at a loading dose of 60 mg and continued at a maintenance dose of 10 mg once per day .,普拉格雷治疗以 60 毫克的负荷剂量开始，并以每天一次 10 毫克的维持剂量继续。,0.5555555555555556,"['loading', 'therapy', 'maintenance', 'with', 'prasugrel', 'at', 'dose', 'maintenance dose', 'and']","['therapy', 'maintenance', 'prasugrel', 'dose', 'maintenance dose']",141,"['用 prasugrel 治疗开始于 60 毫克的负载剂量,并在 10 毫克的维持剂量每日进行一次。']",0.5555555555555556,"['loading', 'therapy', 'maintenance', 'with', 'prasugrel', 'at', 'dose', 'maintenance dose', 'and']","['therapy', 'maintenance', 'at', 'dose', 'maintenance dose']",,
142,142,a reduced maintenance dose of 5 mg daily was recommended in patients who were 75 years of age or older and in those who had a body weight of less than 60 kg .,对于 75 岁或以上以及体重低于 60 公斤的患者，建议将维持剂量减至每天 5 毫克。,0.6,"['body weight', '5', 'a', 'who', 'age', 'kg', 'maintenance', 'dose', 'maintenance dose', 'and']","['body weight', '5', 'kg', 'maintenance', 'dose', 'maintenance dose']",142,"['在75岁及以上的患者和体重低于60公斤的患者中,建议每天减少5毫克的维持剂量。']",0.6,"['body weight', '5', 'a', 'who', 'age', 'kg', 'maintenance', 'dose', 'maintenance dose', 'and']","['body weight', '5', 'kg', 'maintenance', 'dose', 'maintenance dose']",,
143,143,"in the prasugrel group , timing of the initiation of the trial drug depended on the clinical presentation .",在普拉格雷组中，开始试验药物的时间取决于临床表现。,0.625,"['presentation', 'group', 'initiation', 'clinical', 'trial', 'timing', 'drug', 'prasugrel']","['group', 'initiation', 'clinical', 'drug', 'prasugrel']",143,"['在 prasugrel 组中,试验药物的启动时间取决于临床呈现。']",0.625,"['presentation', 'group', 'initiation', 'clinical', 'trial', 'timing', 'drug', 'prasugrel']","['presentation', 'group', 'initiation', 'clinical', 'drug']",,
144,144,trial END POINTS AND DEFINITIONS,试验终点和定义,0.0,['trial'],[],144,['审判终点和定义'],1.0,['trial'],['trial'],,
145,145,"the primary end point was the composite of death , myocardial infarction , or stroke at 1 year after randomization .",主要终点是随机分组后 1 年时死亡、心肌梗死或卒中的复合终点。,0.7272727272727273,"['myocardial infarction', 'composite', 'stroke', 'randomization', 'year', '1', 'death', 'primary', 'after', 'end', 'point']","['myocardial infarction', 'stroke', 'randomization', 'year', '1', 'death', 'after', 'point']",145,"['主要的终点是死亡的组成,心脏病发作,或1年随机化后的中风。']",0.7272727272727273,"['myocardial infarction', 'composite', 'stroke', 'randomization', 'year', '1', 'death', 'primary', 'after', 'end', 'point']","['stroke', 'randomization', 'year', '1', 'death', 'primary', 'after', 'point']",,
146,146,a detailed description of the end points is included in the Supplementary Appendix .,终点的详细描述包含在补充附录中。,0.4,"['a', 'appendix', 'supplementary', 'end points', 'description']","['end points', 'description']",146,['最终点的详细描述在附件中包含。'],0.6,"['a', 'appendix', 'supplementary', 'end points', 'description']","['appendix', 'end points', 'description']",,
147,147,"in addition , 100 % of source data were checked for at least 10 % of patients in all centers .",此外，对所有中心至少 10% 的患者的 100% 源数据进行了检查。,0.4,"['data', 'addition', 'source', 'all', 'in']","['data', 'source']",147,"['此外,在所有中心至少有10%的病人检查了100%的源数据。']",0.4,"['data', 'addition', 'source', 'all', 'in']","['data', 'source']",,
148,148,"the null hypothesis of the trial states that there is no difference between ticagrelor and prasugrel with respect to the treatment effect in patients with acute coronary syndromes for whom invasive evaluation is planned ( hazard ratio , 1 ) .",该试验的零假设表明，在计划进行侵入性评估的急性冠状动脉综合征患者中，替格瑞洛和普拉格雷之间的治疗效果没有差异（风险比，1）。,0.5217391304347826,"['hypothesis', '1', 'ratio', 'hazard ratio', 'evaluation', 'coronary', 'difference', 'treatment', 'no', 'null', 'trial', 'acute', 'effect', 'null hypothesis', 'treatment effect', 'with', 'respect', 'prasugrel', 'that', 'in', 'to', 'and', 'syndromes']","['hypothesis', '1', 'ratio', 'hazard ratio', 'coronary', 'difference', 'treatment', 'null', 'effect', 'treatment effect', 'prasugrel', 'syndromes']",148,"['试验的零假设表明,对于患有急性冠状综合征的患者的治疗效应,Ticagrelor和Prasugrel之间没有差异(风险比例,1)。']",0.4782608695652174,"['hypothesis', '1', 'ratio', 'hazard ratio', 'evaluation', 'coronary', 'difference', 'treatment', 'no', 'null', 'trial', 'acute', 'effect', 'null hypothesis', 'treatment effect', 'with', 'respect', 'prasugrel', 'that', 'in', 'to', 'and', 'syndromes']","['hypothesis', '1', 'ratio', 'hazard ratio', 'coronary', 'difference', 'treatment', 'null', 'effect', 'to', 'syndromes']",,
149,149,cumulative incidence functions were computed for end points other than death to account for competing risks .,计算死亡以外的终点的累积发生率函数以考虑竞争风险。,0.6,"['incidence', 'death', 'cumulative incidence', 'end points', 'to']","['incidence', 'death', 'end points']",149,"['累积影响函数被计算为死亡以外的终点,以计算竞争风险。']",0.4,"['incidence', 'death', 'cumulative incidence', 'end points', 'to']","['death', 'end points']",,
150,150,effect estimates of the secondary end points are presented along with corresponding 95 % confidence intervals .,次要终点的效果估计与相应的 95% 置信区间一起呈现。,0.375,"['corresponding', 'end points', 'along', 'secondary', 'effect', 'with', 'confidence', 'intervals']","['corresponding', 'end points', 'effect']",150,['二级终点的效应估计与相应的95%信任间隔一起呈现。'],0.375,"['corresponding', 'end points', 'along', 'secondary', 'effect', 'with', 'confidence', 'intervals']","['corresponding', 'end points', 'effect']",,
151,151,the widths of the intervals are not adjusted for multiple comparisons because of the exploratory character of these analyses .,由于这些分析的探索性特征，未针对多重比较调整区间宽度。,0.25,"['character', 'multiple', 'exploratory', 'intervals']",['character'],151,['间隔的宽度因这些分析的探索性质而不适用于多个比较。'],0.25,"['character', 'multiple', 'exploratory', 'intervals']",['character'],,
152,152,"patients were evaluated from randomization until death , withdrawal of consent , or the last contact date .",对患者进行评估，从随机分组到死亡、撤回同意或最后接触日期。,0.8,"['randomization', 'death', 'date', 'withdrawal', 'consent']","['randomization', 'death', 'date', 'consent']",152,"['患者从随机化到死亡,撤销同意,或最后的接触日期被评估。']",0.8,"['randomization', 'death', 'date', 'withdrawal', 'consent']","['randomization', 'death', 'date', 'consent']",,
153,153,"from September 2013 through February 2018 , a total of 4018 patients were recruited in 23 centers ( 21 centers in Germany and 2 centers in Italy ) ; 2012 patients were assigned to ticagrelor and 2006 patients were assigned to prasugrel ( Figure 1 ) .",从2013年9月到2018年2月，在23个中心（德国21个中心和意大利2个中心）共招募了4018名患者； 2012 名患者被分配到替格瑞洛组，2006 名患者被分配到普拉格雷组（图 1）。,0.375,"['a', '1', '2', 'figure', 'total', 'prasugrel', 'in', 'and']","['1', '2', 'prasugrel']",153,"['从2013年9月至2018年2月,共有4018名患者被招募到23个中心(德国21个中心和意大利2个中心);2012年患者被分配到Ticagrelor,2006年患者被分配到Prasugrel(图1)。']",0.25,"['a', '1', '2', 'figure', 'total', 'prasugrel', 'in', 'and']","['1', '2']",,
154,154,the baseline characteristics of the patients are listed in Table 1 .,患者的基线特征见表1。,1.0,"['table', 'baseline', '1', 'characteristics']","['table', 'baseline', '1', 'characteristics']",154,['患者的基本特征在表1中列出。'],0.75,"['table', 'baseline', '1', 'characteristics']","['table', '1', 'characteristics']",,
155,155,"the suspected diagnosis at admission was STEMI in 41.1 % , NSTEMI in 46.2 % , and unstable angina in 12.7 % of the patients .",入院时疑似STEMI占41.1%，NSTEMI占46.2%，不稳定型心绞痛占12.7%。,0.3333333333333333,"['admission', 'angina', 'diagnosis', 'unstable', 'at', 'and']","['angina', 'unstable']",155,"['在入院时,可疑的诊断为41.1%的STEMI,46.2%的NSTEMI,12.7%的患者患有不稳定的腹泻。']",0.3333333333333333,"['admission', 'angina', 'diagnosis', 'unstable', 'at', 'and']","['diagnosis', 'unstable']",,
156,156,"before admission , 34.7 % of patients in the ticagrelor group and 35.6 % of patients in the prasugrel group were receiving aspirin , and 5.0 % of patients in the ticagrelor group and 4.7 % of patients in the prasugrel group were receiving clopidogrel .",入院前，替格瑞洛组34.7%的患者和普拉格雷组35.6%的患者接受阿司匹林治疗，替格瑞洛组5.0%的患者和普拉格雷组4.7%的患者接受氯吡格雷治疗。,0.7142857142857143,"['group', 'aspirin', 'admission', 'clopidogrel', 'prasugrel', 'before', 'and']","['group', 'aspirin', 'clopidogrel', 'prasugrel', 'before']",156,"['在接入之前,34.7%的Ticagrelor患者和35.6%的Prasugrel患者服用阿司匹林,而5.0%的Ticagrelor患者和4.7%的Prasugrel患者服用Clopidogrel。']",0.4285714285714285,"['group', 'aspirin', 'admission', 'clopidogrel', 'prasugrel', 'before', 'and']","['aspirin', 'before', 'and']",,
157,157,"in patients presenting with STEMI , the interval from symptom onset to randomization was 3.2 hours ( interquartile range , 1.8 to 7.7 ) in the ticagrelor group and 3.0 hours ( interquartile range , 1.9 to 8.4 ) in the prasugrel group .",在出现 STEMI 的患者中，替卡格雷组从症状发作到随机分组的间隔时间为 3.2 小时（四分位距，1.8 至 7.7），普拉格雷组为 3.0 小时（四分位距，1.9 至 8.4）。,0.625,"['group', 'symptom', 'interval', 'range', 'randomization', 'onset', 'with', 'prasugrel']","['group', 'symptom', 'interval', 'randomization', 'prasugrel']",157,"['在患有STEMI的患者中,从症状开始到随机化的间隔为3.2小时(四角间范围,1.8至7.7)在蒂卡格勒群体和3.0小时(四角间范围,1.9至8.4)在普拉苏格勒群体。']",0.75,"['group', 'symptom', 'interval', 'range', 'randomization', 'onset', 'with', 'prasugrel']","['group', 'symptom', 'interval', 'range', 'randomization', 'onset']",,
158,158,"a total of 84.1 % of the patients underwent PCI , and 2.1 % underwent CABG .",共有 84.1% 的患者接受了 PCI，2.1% 的患者接受了 CABG。,0.0,"['a', 'total', 'CABG', 'and']",[],158,"['总共有84.1%的患者接受了PCI,而2.1%的患者接受了CABG。']",0.25,"['a', 'total', 'CABG', 'and']",['and'],,
159,159,glycoprotein IIb / IIIa inhibitors were used in 12.3 % of the patients who underwent PCI .,12.3% 接受 PCI 的患者使用了糖蛋白 IIb/IIIa 抑制剂。,0.3333333333333333,"['who', 'glycoprotein', '/']",['glycoprotein'],159,['Glycoprotein IIb / IIIa 抑制剂被用于 12.3% 的患有 PCI 的患者。'],0.0,"['who', 'glycoprotein', '/']",[],,
160,160,"in more than 99 % of the patients who were receiving aspirin at discharge , the daily dose was 100 mg or less . ( angiographic and procedural characteristics are listed in Tables S1 and S2 , respectively , in the Supplementary Appendix . )",在超过 99% 的出院时服用阿司匹林的患者中，日剂量为 100 毫克或更少。 （血管造影和手术特征分别列于补充附录的表 S1 和表 S2 中。）,0.4166666666666667,"['discharge', 'aspirin', 'appendix', 'who', 'supplementary', 'characteristics', 'daily dose', 'at', 'S1', 'S2', 'and', 'angiographic']","['discharge', 'aspirin', 'characteristics', 'at', 'angiographic']",160,"['在接收阿司匹林的患者中,超过99%的患者,每日剂量为100毫克或更少(天文学和程序性特征列入表 S1 和 S2,分别,附件。']",0.3333333333333333,"['discharge', 'aspirin', 'appendix', 'who', 'supplementary', 'characteristics', 'daily dose', 'at', 'S1', 'S2', 'and', 'angiographic']","['discharge', 'aspirin', 'appendix', 'characteristics']",,
161,161,"at discharge , 81.1 % of patients in the ticagrelor group and 80.7 % of patients in the prasugrel group received the randomly assigned trial drug ( Table S3 in the Supplementary Appendix ) .",出院时，替格瑞洛组 81.1% 的患者和普拉格雷组 80.7% 的患者接受了随机分配的试验药物（补充附录表 S3）。,0.3333333333333333,"['group', 'discharge', 'appendix', 'table', 'supplementary', 'trial', 'drug', 'prasugrel', 'at', 'S3', 'in', 'and']","['group', 'table', 'drug', 'prasugrel']",161,"['在排放时,Ticagrelor群体的81.1%患者和Prasugrel群体的80.7%患者接受了随机分配的试用药物(附件中的S3表)。']",0.3333333333333333,"['group', 'discharge', 'appendix', 'table', 'supplementary', 'trial', 'drug', 'prasugrel', 'at', 'S3', 'in', 'and']","['group', 'appendix', 'table', 'drug']",,
162,162,"the median interval from randomization to discontinuation of the trial drug after discharge was 84 days ( interquartile range , 23 to 181 ) in the ticagrelor group and 109 days ( interquartile range , 35 to 220 ) in the prasugrel group ( P = 0.01 ) .",从随机分组到出院后停用试验药物的中位间隔时间，替卡格雷组为 84 天（四分位距，23 至 181 天），普拉格雷组为 109 天（四分位距，35 至 220 天）(P = 0.01)。,0.4285714285714285,"['group', 'discharge', 'median', 'interval', 'range', 'randomization', 'after', 'trial', 'median interval', 'drug', 'prasugrel', 'P', 'after discharge', 'to']","['group', 'interval', 'randomization', 'after', 'drug', 'prasugrel']",162,['从随机化到试用药物排放后的中间间间隔为84天(中间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间间'],0.2857142857142857,"['group', 'discharge', 'median', 'interval', 'range', 'randomization', 'after', 'trial', 'median interval', 'drug', 'prasugrel', 'P', 'after discharge', 'to']","['interval', 'randomization', 'after', 'drug']",,
163,163,the types of antithrombotic therapy received by patients who discontinued the trial medication after discharge are listed in Table S4 in the Supplementary Appendix .,补充附录表 S4 列出了出院后停用试验药物的患者接受的抗血栓治疗类型。,0.2142857142857142,"['discharge', 'appendix', 'table', 'who', 'antithrombotic', 'supplementary', 'therapy', 'medication', 'after', 'trial', 'after discharge', 'S4', 'in', 'by']","['table', 'therapy', 'after']",163,['在排放后停止试用药物的患者接受的抗血管治疗的类型在附件中的S4表中列出。'],0.2857142857142857,"['discharge', 'appendix', 'table', 'who', 'antithrombotic', 'supplementary', 'therapy', 'medication', 'after', 'trial', 'after discharge', 'S4', 'in', 'by']","['appendix', 'table', 'therapy', 'after']",,
164,164,"the composite of death from cardiovascular causes , myocardial infarction , or stroke occurred in 161 of 2012 patients ( 8.1 % ) in the ticagrelor group and 124 of 2006 patients ( 6.3 % ) in the prasugrel group ( hazard ratio , 1.32 ; 95 % CI , 1.04 to 1.66 ) .",替格瑞洛组 2012 名患者中有 161 名 ( 8.1 % ) 和普拉格雷组 2006 名患者中有 124 名 ( 6.3 % ) 发生心血管原因死亡、心肌梗死或卒中的复合事件（风险比 1.32 ； 95 % CI ， 1.04 至 1.66)。,0.6666666666666666,"['group', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'ratio', 'hazard ratio', 'death', 'prasugrel', 'CI', 'to', 'and']","['group', 'myocardial infarction', 'cardiovascular', 'stroke', 'ratio', 'hazard ratio', 'death', 'prasugrel']",164,"['因心血管原因、心脏病发作或中风而死亡的组成情况发生在2012年中161名患者(8.1%)中,2006年中124名患者(6.3%)中(危险比例,1.32;95% CI,1.04至1.66)。']",0.5,"['group', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'ratio', 'hazard ratio', 'death', 'prasugrel', 'CI', 'to', 'and']","['group', 'cardiovascular', 'stroke', 'ratio', 'death', 'and']",,
165,165,the incidences of the individual components of the primary end point are shown in Table 2 .,表 2 显示了主要终点的各个组成部分的发生率。,0.5,"['table', '2', 'individual', 'primary', 'end', 'point']","['table', '2', 'point']",165,['主要终点的各个组件的影响表2中显示。'],0.5,"['table', '2', 'individual', 'primary', 'end', 'point']","['table', '2', 'point']",,
166,166,"the rate of death from any cause at 1 year was 4.5 % in the ticagrelor group and 3.7 % in the prasugrel group ( hazard ratio , 1.23 ; 95 % CI , 0.91 to 1.68 ) .",1 年时任何原因的死亡率在替格瑞洛组和普拉格雷组分别为 4.5% 和 3.7%（风险比，1.23；95% CI，0.91 至 1.68）。,0.6923076923076923,"['group', 'year', 'rate', '1', 'ratio', 'hazard ratio', 'death', 'cause', 'prasugrel', 'CI', 'in', 'to', 'and']","['group', 'year', 'rate', '1', 'ratio', 'hazard ratio', 'death', 'cause', 'prasugrel']",166,"['1年因任何原因死亡率为Ticagrelor群体的4.5%和Prasugrel群体的3.7%(风险比例为1.23;95% CI,0.91至1.68)。']",0.6153846153846154,"['group', 'year', 'rate', '1', 'ratio', 'hazard ratio', 'death', 'cause', 'prasugrel', 'CI', 'in', 'to', 'and']","['group', 'year', 'rate', '1', 'ratio', 'hazard ratio', 'death', 'cause']",,
167,167,"the incidence of myocardial infarction was 4.8 % in the ticagrelor group and 3.0 % in the prasugrel group ( hazard ratio , 1.63 ; 95 % CI , 1.18 to 2.25 ) .",心肌梗死的发生率在替格瑞洛组和普拉格雷组分别为 4.8% 和 3.0%（风险比，1.63；95% CI，1.18 至 2.25）。,0.6666666666666666,"['group', 'myocardial infarction', 'incidence', 'ratio', 'hazard ratio', 'prasugrel', 'CI', 'to', 'and']","['group', 'myocardial infarction', 'incidence', 'ratio', 'hazard ratio', 'prasugrel']",167,"['心脏病发作的发病率在Ticagrelor群体中为4.8%和Prasugrel群体中为3.0%(风险比例为1.63;95% CI,1.18至2.25)。']",0.4444444444444444,"['group', 'myocardial infarction', 'incidence', 'ratio', 'hazard ratio', 'prasugrel', 'CI', 'to', 'and']","['group', 'incidence', 'ratio', 'hazard ratio']",,
168,168,"the incidence of stroke was 1.1 % in the ticagrelor group and 1.0 % in the prasugrel group ( hazard ratio , 1.17 ; 95 % CI , 0.63 to 2.15 ) .",中风的发生率在替格瑞洛组和普拉格雷组分别为 1.1% 和 1.0%（风险比，1.17；95% CI，0.63 至 2.15）。,0.6666666666666666,"['group', 'incidence', 'stroke', 'ratio', 'hazard ratio', 'prasugrel', 'CI', 'to', 'and']","['group', 'incidence', 'stroke', 'ratio', 'hazard ratio', 'prasugrel']",168,"['发作的发病率在Ticagrelor群体中为1.1%和Prasugrel群体中为1.0%(风险比率,1.17;95% CI,0.63至2.15)。']",0.5555555555555556,"['group', 'incidence', 'stroke', 'ratio', 'hazard ratio', 'prasugrel', 'CI', 'to', 'and']","['group', 'incidence', 'stroke', 'ratio', 'hazard ratio']",,
169,169,"the incidence of definite or probable stent thrombosis was 1.3 % in the ticagrelor group and 1.0 % in the prasugrel group ( hazard ratio , 1.30 ; 95 % CI , 0.72 to 2.33 ) .",明确或可能的支架内血栓形成的发生率在替格瑞洛组和普拉格雷组分别为 1.3% 和 1.0%（风险比，1.30；95% CI，0.72 至 2.33）。,0.6,"['group', 'incidence', 'ratio', 'hazard ratio', 'thrombosis', 'stent', 'prasugrel', 'CI', 'to', 'and']","['group', 'incidence', 'ratio', 'hazard ratio', 'thrombosis', 'prasugrel']",169,"['确定的或可能的<unk>血病的发病率在Ticagrelor群体中为1.3%和Prasugrel群体中为1.0%(风险比例为1.30;95% CI,0.72至2.33)。']",0.4,"['group', 'incidence', 'ratio', 'hazard ratio', 'thrombosis', 'stent', 'prasugrel', 'CI', 'to', 'and']","['group', 'incidence', 'ratio', 'hazard ratio']",,
170,170,data from the analysis of the primary end point in the prespecified subgroups are shown in Figure S1 in the Supplementary Appendix .,来自预先指定亚组主要终点分析的数据显示在补充附录图 S1 中。,0.375,"['appendix', 'data', 'analysis', 'figure', 'supplementary', 'primary', 'point', 'S1']","['data', 'analysis', 'point']",170,['预定子组中的主要终点分析数据显示在附件中的图 S1 。'],0.5,"['appendix', 'data', 'analysis', 'figure', 'supplementary', 'primary', 'point', 'S1']","['appendix', 'data', 'analysis', 'point']",,
171,171,the lower incidence of the composite end point was primarily driven by fewer myocardial infarctions in the prasugrel group than in the ticagrelor group .,复合终点的较低发生率主要是由于普拉格雷组的心肌梗死率低于替格瑞洛组。,0.6,"['group', 'composite', 'incidence', 'lower', 'myocardial', 'end', 'point', 'prasugrel', 'by', 'infarctions']","['group', 'incidence', 'point', 'prasugrel', 'by', 'infarctions']",171,['合成终点的较低的发病率主要是由 prasugrel 群体中比 ticagrelor 群体中较少的心脏病发作引起的。'],0.5,"['group', 'composite', 'incidence', 'lower', 'myocardial', 'end', 'point', 'prasugrel', 'by', 'infarctions']","['group', 'incidence', 'lower', 'point', 'by']",,
172,172,the benefit of fewer ischemic events with prasugrel did not occur at the expense of an increased risk of bleeding .,普拉格雷减少缺血事件的好处并没有以增加出血风险为代价。,0.375,"['bleeding', 'risk', 'benefit', 'with', 'occur', 'prasugrel', 'at', 'ischemic']","['bleeding', 'risk', 'prasugrel']",172,['与 prasugrel 较少的催化事件的好处没有发生在增加出血风险的代价。'],0.375,"['bleeding', 'risk', 'benefit', 'with', 'occur', 'prasugrel', 'at', 'ischemic']","['bleeding', 'risk', 'occur']",,
173,173,the results were consistent across the whole spectrum of presentation of acute coronary syndromes .,结果在急性冠脉综合征的整个表现范围内是一致的。,0.4285714285714285,"['presentation', 'spectrum', 'coronary', 'across', 'acute', 'whole', 'syndromes']","['coronary', 'whole', 'syndromes']",173,"['结果在整个频谱中一致,表现出急性冠状综合征。']",0.5714285714285714,"['presentation', 'spectrum', 'coronary', 'across', 'acute', 'whole', 'syndromes']","['spectrum', 'coronary', 'whole', 'syndromes']",,
174,174,a particular feature of this trial is that it did not simply compare two antiplatelet drugs .,该试验的一个特点是它没有简单地比较两种抗血小板药物。,0.4444444444444444,"['feature', 'drugs', 'antiplatelet', 'particular', 'trial', 'compare', 'this', 'that', 'two']","['drugs', 'compare', 'this', 'two']",174,"['这个试验的一个特征是,它不只是比较两个抗膜药物。']",0.5555555555555556,"['feature', 'drugs', 'antiplatelet', 'particular', 'trial', 'compare', 'this', 'that', 'two']","['feature', 'drugs', 'compare', 'this', 'two']",,
175,175,"rather , it compared two antiplatelet treatment strategies involving two different drugs .",相反，它比较了涉及两种不同药物的两种抗血小板治疗策略。,0.75,"['drugs', 'antiplatelet', 'treatment', 'two']","['drugs', 'treatment', 'two']",175,"['相比之下,它比较了两种不同药物的抗细胞治疗策略。']",0.75,"['drugs', 'antiplatelet', 'treatment', 'two']","['drugs', 'treatment', 'two']",,
176,176,the superiority assumption was based on several considerations .,优势假设是基于多种考虑。,0.0,"['superiority', 'on']",[],176,['优越的假设是基于几个考虑。'],0.0,"['superiority', 'on']",[],,
177,177,"on the basis of the rationale that a stronger platelet inhibition at the time of PCI reduces periprocedural thrombotic risk , the pretreatment strategy with ticagrelor was considered to be advantageous .",基于 PCI 时更强的血小板抑制可降低围手术期血栓形成风险的理论基础，替格瑞洛预处理策略被认为是有利的。,0.5714285714285714,"['inhibition', 'a', 'strategy', 'basis', 'time', 'thrombotic', 'rationale', 'be', 'risk', 'with', 'platelet', 'pretreatment', 'that', 'to']","['inhibition', 'strategy', 'time', 'rationale', 'risk', 'platelet', 'pretreatment', 'to']",177,"['基于在 PCI 时期的更强的平板膜抑制会降低周期流动性血管风险的理由,预治疗策略以 ticagrelor 被认为是有益的。']",0.4285714285714285,"['inhibition', 'a', 'strategy', 'basis', 'time', 'thrombotic', 'rationale', 'be', 'risk', 'with', 'platelet', 'pretreatment', 'that', 'to']","['inhibition', 'strategy', 'time', 'be', 'risk', 'to']",,
178,178,"also , previous findings suggest a consistent benefit of ticagrelor but not a consistent benefit of prasugrel in patients with acute coronary syndromes who receive conservative therapy .",此外，之前的研究结果表明，在接受保守治疗的急性冠脉综合征患者中，替格瑞洛的持续获益与普拉格雷的获益不一致。,0.2857142857142857,"['a', 'who', 'previous', 'coronary', 'therapy', 'acute', 'benefit', 'suggest', 'with', 'prasugrel', 'conservative', 'in', 'but', 'syndromes']","['coronary', 'therapy', 'prasugrel', 'syndromes']",178,"['此外,以前的发现表明Ticagrelor的持久益处,但在接受保守治疗的急性冠状综合征患者中,Prasugrel的不持久益处。']",0.3571428571428571,"['a', 'who', 'previous', 'coronary', 'therapy', 'acute', 'benefit', 'suggest', 'with', 'prasugrel', 'conservative', 'in', 'but', 'syndromes']","['previous', 'coronary', 'therapy', 'but', 'syndromes']",,
179,179,"in PLATO , ticagrelor was superior to clopidogrel not only in patients who underwent PCI but also in those who received conservative treatment.13",在 PLATO 中，替卡格雷不仅在接受 PCI 的患者中而且在接受保守治疗的患者中都优于氯吡格雷。 13,0.4285714285714285,"['who', 'superior', 'clopidogrel', 'conservative', 'in', 'but', 'to']","['clopidogrel', 'but', 'to']",179,"['在PLATO中,Ticagrelor高于Clopidogrel,不仅在接受PCI的患者中,而且在接受保守治疗的患者中。']",0.2857142857142857,"['who', 'superior', 'clopidogrel', 'conservative', 'in', 'but', 'to']","['but', 'to']",,
180,180,"whereas in PLATO only 61 % of the patients underwent PCI during the index hospitalization , 4 PCI was performed much more frequently in the present trial ( 84 % ) .",而在 PLATO 中，只有 61% 的患者在首次住院期间接受了 PCI，而在本试验中 4 PCI 的执行频率更高 (84%)。,0.1666666666666666,"['frequently', 'index', 'hospitalization', 'trial', '4', 'present']",['hospitalization'],180,"['在PLATO中,只有61%的患者在指数入院期间接受了PCI,而在目前的研究中,4个PCI进行了更频繁(84%)。']",0.1666666666666666,"['frequently', 'index', 'hospitalization', 'trial', '4', 'present']",['index'],,
181,181,"therefore , the contribution of patients who did not undergo PCI to the overall results was relatively small .",因此，未接受 PCI 的患者对总体结果的贡献相对较小。,0.0,"['who', 'undergo', 'therefore', 'to']",[],181,"['因此,未接受PCI的患者对总体结果的贡献相对较小。']",0.0,"['who', 'undergo', 'therefore', 'to']",[],,
182,182,"finally , pharmacodynamic studies showing a stronger antiplatelet effect of ticagrelor15 and the potential beneficial pleiotropic effects of ticagrelor , particularly those related to increased release of adenosine , 16 favored the expectation of superiority of ticagrelor over prasugrel in the current trial .",最后，药效学研究表明替格瑞洛具有更强的抗血小板作用 15 和替格瑞洛潜在的有益多效性作用，尤其是那些与腺苷释放增加相关的作用 16 ，支持在当前试验中替格瑞洛优于普拉格雷的预期。,0.5333333333333333,"['adenosine', 'pleiotropic', 'potential', 'pharmacodynamic', 'antiplatelet', 'release', 'trial', 'expectation', 'effect', 'superiority', 'current', 'prasugrel', 'over', 'to', 'and']","['adenosine', 'potential', 'pharmacodynamic', 'release', 'expectation', 'effect', 'prasugrel', 'to']",182,"['最后,药物动态研究表明,Ticagrelor15具有更强的抗斑作用,以及Ticagrelor的潜在有益的 pleiotropic效果,特别是与Adenosine的释放增加相关的效果,16在目前的研究中促进了Ticagrelor的优越性预期。']",0.2666666666666666,"['adenosine', 'pleiotropic', 'potential', 'pharmacodynamic', 'antiplatelet', 'release', 'trial', 'expectation', 'effect', 'superiority', 'current', 'prasugrel', 'over', 'to', 'and']","['release', 'expectation', 'effect', 'superiority']",,
183,183,the incidence of the primary composite net clinical end point assessed after 7 days did not differ between the ticagrelor and prasugrel groups .,7 天后评估的主要复合净临床终点的发生率在替格瑞洛和普拉格雷组之间没有差异。,0.4166666666666667,"['composite', 'incidence', 'net', 'primary', 'differ', 'clinical', 'after', 'end', 'point', 'prasugrel', 'and', 'assessed']","['incidence', 'clinical', 'after', 'point', 'prasugrel']",183,['7天后评估的初级合成净临床终点的发病率没有区别于Ticagrelor和Prasugrel群体。'],0.3333333333333333,"['composite', 'incidence', 'net', 'primary', 'differ', 'clinical', 'after', 'end', 'point', 'prasugrel', 'and', 'assessed']","['incidence', 'clinical', 'after', 'point']",,
184,184,an interaction between treatment effect and aspirin dosage has been reported for ticagrelor19 but not for prasugrel.20,据报道，治疗效果和阿司匹林剂量之间的相互作用对替格瑞洛 19 但普拉格雷没有。 20,0.75,"['aspirin', 'dosage', 'treatment', 'interaction', 'effect', 'treatment effect', 'but', 'and']","['aspirin', 'dosage', 'treatment', 'effect', 'treatment effect', 'but']",184,['治疗效果与阿司匹林剂量之间的相互作用已被报告为Ticagrelor19但不是Prasugrel。'],0.75,"['aspirin', 'dosage', 'treatment', 'interaction', 'effect', 'treatment effect', 'but', 'and']","['aspirin', 'dosage', 'treatment', 'effect', 'treatment effect', 'but']",,
185,185,"however , the actual dose of aspirin in the present trial was 100 mg per day or less , as compared with a dose of 300 mg per day or more in 54 % of the U.S. patients in PLATO.19",然而，本试验中阿司匹林的实际剂量为每天 100 毫克或更少，而 PLATO 试验中 54 % 的美国患者的剂量为每天 300 毫克或更多。 19,0.3333333333333333,"['aspirin', 'actual', 'trial', 'present', 'with', 'dose']","['aspirin', 'dose']",185,"['然而,目前的阿司匹林的实际剂量是每日100毫克或更少的,与美国54%的PLATO患者的每日300毫克或更少的剂量相比。']",0.3333333333333333,"['aspirin', 'actual', 'trial', 'present', 'with', 'dose']","['aspirin', 'dose']",,
186,186,"the incidence of the primary end point in the ticagrelor group was close to the predicted event rate for that group ( 9.3 % and 10.0 % , respectively ) .",替格瑞洛组主要终点的发生率接近该组的预测事件率（分别为 9.3% 和 10.0%）。,0.3636363636363636,"['group', 'incidence', 'rate', 'primary', 'end', 'point', 'event', 'that', 'to', 'and', 'close to']","['group', 'incidence', 'rate', 'point']",186,['图克格勒群体的主要终点的影响率接近该群体预测的事件率(分别为9.3%和10.0%)。'],0.2727272727272727,"['group', 'incidence', 'rate', 'primary', 'end', 'point', 'event', 'that', 'to', 'and', 'close to']","['group', 'rate', 'point']",,
187,187,"the incidence of myocardial infarction was lower in the present trial than in previous pivotal trials.4,5","本试验的心肌梗死发生率低于之前的关键试验。 4,5",0.3333333333333333,"['myocardial infarction', 'incidence', 'previous', 'lower', 'trial', 'present']","['myocardial infarction', 'incidence']",187,['心脏病发作的发病率在目前的试验中低于以前的试验中。'],0.3333333333333333,"['myocardial infarction', 'incidence', 'previous', 'lower', 'trial', 'present']","['incidence', 'previous']",,
188,188,this may be explained in part by differences in the definition of myocardial infarction .,部分原因可能是心肌梗死定义的差异。,0.5,"['part', 'myocardial infarction', 'be', 'definition', 'this', 'by']","['myocardial infarction', 'definition', 'this']",188,['这部分可以由心脏病发作的定义中的差异解释。'],0.3333333333333333,"['part', 'myocardial infarction', 'be', 'definition', 'this', 'by']","['definition', 'by']",,
189,189,the incidence of major bleeding was not higher in the prasugrel group than in the ticagrelor group .,普拉格雷组的大出血发生率并不高于替格瑞洛组。,0.8,"['bleeding', 'group', 'incidence', 'major', 'prasugrel']","['bleeding', 'group', 'incidence', 'prasugrel']",189,['主要出血的发病率在 prasugrel 群体中不高于 ticagrelor 群体。'],0.6,"['bleeding', 'group', 'incidence', 'major', 'prasugrel']","['bleeding', 'group', 'incidence']",,
190,190,"patients presented with pulmonary , gastrointestinal , and constitutional symptoms and varying degrees of respiratory failure .",患者表现为肺部、胃肠道和全身症状以及不同程度的呼吸衰竭。,0.3,"['failure', 'gastrointestinal', 'respiratory', 'symptoms', 'pulmonary', 'respiratory failure', 'constitutional', 'with', 'degrees', 'and']","['failure', 'gastrointestinal', 'respiratory failure']",190,['患有肺、肠道和宪法症状和不同程度的呼吸障碍的患者。'],0.0,"['failure', 'gastrointestinal', 'respiratory', 'symptoms', 'pulmonary', 'respiratory failure', 'constitutional', 'with', 'degrees', 'and']",[],,
191,191,"most patients were young men ( median age , 19 ) .",大多数患者是年轻男性（中位年龄 19 岁）。,0.25,"['median', 'age', 'median age', 'young']",['age'],191,"['大多数患者是年轻人(平均年龄,19岁)。']",0.25,"['median', 'age', 'median age', 'young']",['age'],10.0,6.0
192,192,"patients presented with constitutional symptoms ( most commonly , fever ) , dyspnea , cough , chest pain , and gastrointestinal complaints .",患者出现全身症状（最常见的是发烧）、呼吸困难、咳嗽、胸痛和胃肠道不适。,0.5,"['chest', 'gastrointestinal', 'dyspnea', 'chest pain', 'symptoms', 'cough', 'constitutional', 'fever', 'with', 'and']","['chest', 'gastrointestinal', 'dyspnea', 'chest pain', 'cough']",192,"['患有宪法症状(最常见的,发烧), dyspnea, 咳嗽, 胸部疼痛, 和 胃肠道抱怨。']",0.3,"['chest', 'gastrointestinal', 'dyspnea', 'chest pain', 'symptoms', 'cough', 'constitutional', 'fever', 'with', 'and']","['chest', 'gastrointestinal', 'cough']",10.0,8.0
193,193,"more than half of patients were admitted to intensive care units , and one third received invasive mechanical ventilation .",一半以上的患者住进了重症监护病房，三分之一接受了有创机械通气。,0.375,"['ventilation', 'mechanical', 'half', 'mechanical ventilation', 'intensive care', 'to', 'and', 'third']","['ventilation', 'half', 'mechanical ventilation']",193,"['超过一半的病人被录取到强度护理单位,三分之一受到了侵入性机械通风。']",0.375,"['ventilation', 'mechanical', 'half', 'mechanical ventilation', 'intensive care', 'to', 'and', 'third']","['ventilation', 'half', 'mechanical ventilation']",10.0,9.0
194,194,neutrophilic leukocytosis was common ; acute kidney injury was not .,中性粒细胞增多常见；没有急性肾损伤。,0.5,"['injury', 'kidney', 'common', 'kidney injury', 'neutrophilic', 'acute']","['injury', 'kidney', 'kidney injury']",194,['neutrophilic leukocytosis 是常见的; 急性肾损伤没有。'],0.5,"['injury', 'kidney', 'common', 'kidney injury', 'neutrophilic', 'acute']","['injury', 'kidney', 'kidney injury']",8.0,7.0
195,195,"one patient died in this cohort , and additional deaths have been reported in other areas .",该队列中有一名患者死亡，其他地区也报告了其他死亡病例。,0.2857142857142857,"['additional', 'patient', 'cohort', 'have', 'this', 'in', 'and']","['patient', 'have']",195,"['一名病人在此期间死亡,并在其他地区报告了额外的死亡。']",0.2857142857142857,"['additional', 'patient', 'cohort', 'have', 'this', 'in', 'and']","['additional', 'patient']",10.0,10.0
196,196,this approach was better at limiting exacerbations than was daily corticosteroid therapy .,这种方法比每日皮质类固醇治疗更能限制病情加重。,0.3333333333333333,"['approach', 'corticosteroid', 'therapy', 'limiting', 'at', 'this']","['corticosteroid', 'therapy']",196,"['这种方法在限制恶化方面更好,而不是每日治疗甲状腺素。']",0.3333333333333333,"['approach', 'corticosteroid', 'therapy', 'limiting', 'at', 'this']","['therapy', 'this']",10.0,4.0
197,197,inhaler adherence was 76 % .,吸入器依从性为 76%。,0.5,"['inhaler', 'adherence']",['inhaler'],197,['吸入器的粘贴率为76%。'],0.5,"['inhaler', 'adherence']",['inhaler'],10.0,8.0
198,198,we discuss this relatively new approach to mild asthma in more detail in a separate NEJM Journal Watch General MedicineClinical Spotlight feature .,我们在单独的 NEJM Journal Watch General MedicineClinical Spotlight 专题中更详细地讨论了这种相对较新的治疗轻度哮喘的方法。,0.25,"['approach', 'feature', 'asthma', 'general', 'discuss', 'spotlight', 'detail', 'watch', 'journal', 'mild', 'this', 'in', 'separate', 'to', 'new', 'we']","['asthma', 'detail', 'mild', 'new']",198,['我们在一个单独的NEJM杂志观看通用医学临床照明功能中讨论了这种相对较新的轻微哮喘方法。'],0.1875,"['approach', 'feature', 'asthma', 'general', 'discuss', 'spotlight', 'detail', 'watch', 'journal', 'mild', 'this', 'in', 'separate', 'to', 'new', 'we']","['asthma', 'journal', 'new']",10.0,7.0
199,199,vedolizumab was superior to adalimumab for achieving clinical remission of moderately to severely active ulcerative colitis .,在实现中度至重度活动性溃疡性结肠炎的临床缓解方面，维多珠单抗优于阿达木单抗。,0.7,"['colitis', 'superior', 'active', 'moderately', 'ulcerative', 'ulcerative colitis', 'clinical', 'remission', 'vedolizumab', 'to']","['colitis', 'active', 'ulcerative', 'ulcerative colitis', 'clinical', 'remission', 'to']",199,"['vedolizumab 比 adalimumab 优越,以达到适度至严重活性溃<unk>炎的临床复发。']",0.1,"['colitis', 'superior', 'active', 'moderately', 'ulcerative', 'ulcerative colitis', 'clinical', 'remission', 'vedolizumab', 'to']",['clinical'],,
200,200,"standard dosing of vedolizumab and adalimumab were used , with no dose escalation permitted in either group .",使用标准剂量的维多珠单抗和阿达木单抗，两组均不允许增加剂量。,0.4285714285714285,"['group', 'standard', 'no', 'with', 'vedolizumab', 'dose', 'in']","['group', 'standard', 'dose']",200,"['使用了标准剂量的Vedolizumab和Adalimumab,没有允许在任何群体中增加剂量。']",0.4285714285714285,"['group', 'standard', 'no', 'with', 'vedolizumab', 'dose', 'in']","['group', 'standard', 'dose']",,
201,201,"among the 769 participants , clinical remission at week 52 ( the primary outcome ) was more frequently achieved in the vedolizumab group compared with the adalimumab group ( 31.3 % vs. 22.5 % ) ; endoscopic improvement also occurred more frequently in the vedolizumab group ( 39.7 % vs. 27.7 % ) .",在 769 名参与者中，与阿达木单抗组相比，维多珠单抗组在第 52 周（主要结果）达到临床缓解的频率更高（31.3% 对 22.5%）；维多珠单抗组的内窥镜改善也更常见（39.7% 对 27.7%）。,0.5,"['group', 'improvement', 'outcome', 'frequently', 'primary', 'clinical', 'week', 'remission', 'with', 'achieved', 'vedolizumab', 'at']","['group', 'improvement', 'outcome', 'clinical', 'week', 'remission']",201,"['在769名参与者中,在第52周(初始结果)的临床衰退在Vedolizumab群体中比Adalimumab群体更频繁(31.3%与22.5%);在Vedolizumab群体中,内分泌改善也更频繁(39.7%与27.7%)。']",0.4166666666666667,"['group', 'improvement', 'outcome', 'frequently', 'primary', 'clinical', 'week', 'remission', 'with', 'achieved', 'vedolizumab', 'at']","['group', 'improvement', 'outcome', 'clinical', 'week']",,
202,202,a difference of nearly 9 percentage points in the primary outcome translates to a number needed to treat of 11 to achieve one additional remission .,主要结果中将近 9 个百分点的差异转化为需要治疗的数字 11 以实现额外的缓解。,0.6,"['percentage', 'outcome', 'treat', 'difference', 'primary', 'number', 'additional', 'remission', 'in', 'to']","['outcome', 'treat', 'difference', 'number', 'additional', 'remission']",202,"['在初始结果中,几乎9个百分点的差异转化为需要处理的11个数字,以实现额外的折扣。']",0.5,"['percentage', 'outcome', 'treat', 'difference', 'primary', 'number', 'additional', 'remission', 'in', 'to']","['outcome', 'treat', 'difference', 'number', 'additional']",,
203,203,"given its more favorable safety profile , vedolizumab might be the preferable first choice for moderately to severely active ulcerative colitis .",鉴于其更有利的安全性，vedolizumab 可能是中度至重度活动性溃疡性结肠炎的首选。,0.5,"['safety', 'colitis', 'active', 'moderately', 'ulcerative', 'be', 'ulcerative colitis', 'profile', 'choice', 'vedolizumab', 'to', 'first']","['safety', 'colitis', 'active', 'ulcerative', 'ulcerative colitis', 'to']",203,"['由于其更有利的安全性,Vedolizumab可能是适度至严重活性<unk>疹的首选。']",0.1666666666666666,"['safety', 'colitis', 'active', 'moderately', 'ulcerative', 'be', 'ulcerative colitis', 'profile', 'choice', 'vedolizumab', 'to', 'first']","['safety', 'to']",,
204,204,"a case study provides support for pursuing this approach , but much more needs to be learned .",案例研究为追求这种方法提供了支持，但还需要学习更多。,0.4444444444444444,"['approach', 'support', 'study', 'be', 'case', 'case study', 'this', 'but', 'to']","['support', 'study', 'case', 'but']",204,"['一个案例研究为追求这种方法提供支持,但需要了解更多。']",0.3333333333333333,"['approach', 'support', 'study', 'be', 'case', 'case study', 'this', 'but', 'to']","['support', 'case', 'but']",,
205,205,HIV uses the coreceptor CCR5 to infect CD4 + T cells .,HIV 使用辅助受体 CCR5 感染 CD4+ T 细胞。,1.0,"['HIV', 'coreceptor', 'T']","['HIV', 'coreceptor', 'T']",205,['艾滋病毒使用 CCR5 调节器感染 CD4 + T 细胞。'],0.3333333333333333,"['HIV', 'coreceptor', 'T']",['HIV'],,
206,206,two people have been cured of HIV after being treated for malignancy with stem cell transplants from donors who lack this coreceptor .,两个人在接受来自缺乏这种辅助受体的供体的干细胞移植治疗恶性肿瘤后治愈了 HIV。,0.5384615384615384,"['stem cell', 'HIV', 'coreceptor', 'lack', 'malignancy', 'who', 'after', 'transplants', 'being', 'with', 'have', 'this', 'two']","['stem cell', 'HIV', 'coreceptor', 'malignancy', 'after', 'transplants', 'two']",206,"['两人接受了艾滋病毒的治疗后,他们接受了从捐赠者缺乏这种调节剂的干细胞移植的恶性治疗。']",0.4615384615384615,"['stem cell', 'HIV', 'coreceptor', 'lack', 'malignancy', 'who', 'after', 'transplants', 'being', 'with', 'have', 'this', 'two']","['stem cell', 'HIV', 'malignancy', 'after', 'transplants', 'two']",,
207,207,he had been diagnosed with ALL and was in remission after standard chemotherapy .,他被诊断出患有 ALL，经过标准化疗后病情正在缓解。,0.6666666666666666,"['chemotherapy', 'standard', 'after', 'remission', 'with', 'in']","['chemotherapy', 'standard', 'after', 'remission']",207,"['他被诊断为全身,并在标准化疗后处于复发状态。']",0.5,"['chemotherapy', 'standard', 'after', 'remission', 'with', 'in']","['chemotherapy', 'standard', 'after']",,
208,208,"donor cells with ablated CCR5 persisted for at least 19 months in the recipient , accounting for approximately 5 % of bone marrow cells .",去除了 CCR5 的供体细胞在受体体内至少持续存在 19 个月，约占骨髓细胞的 5%。,0.5555555555555556,"['recipient', 'donor', 'bone', 'bone marrow', '5', 'with', 'at', 'approximately', 'in']","['recipient', 'donor', 'bone', 'bone marrow', '5']",208,"['捐赠者细胞在受益者中至少持久了19个月,占骨髓细胞的约5%。']",0.3333333333333333,"['recipient', 'donor', 'bone', 'bone marrow', '5', 'with', 'at', 'approximately', 'in']","['bone', 'bone marrow', '5']",,
209,209,"seven months after engraftment , the recipient underwent an ART interruption , during which his HIV RNA rebounded quickly .",植入七个月后，接受者经历了 ART 中断，在此期间他的 HIV RNA 迅速反弹。,0.8571428571428571,"['RNA', 'HIV', 'recipient', 'interruption', 'after', 'his', 'engraftment']","['RNA', 'HIV', 'recipient', 'interruption', 'after', 'engraftment']",209,"['接收后七个月,接收者经历了ART中断,在此期间他的HIVRNA迅速恢复。']",0.5714285714285714,"['RNA', 'HIV', 'recipient', 'interruption', 'after', 'his', 'engraftment']","['RNA', 'HIV', 'interruption', 'after']",,
210,210,"although insomnia increases risks for suicidality , we know little about whether insomnia treatments might be helpful .",尽管失眠会增加自杀的风险，但我们对失眠治疗是否有帮助知之甚少。,0.25,"['be', 'increases', 'insomnia', 'we']",['insomnia'],210,"['虽然失眠会增加自杀的风险,但我们很少知道失眠治疗是否有用。']",0.25,"['be', 'increases', 'insomnia', 'we']",['insomnia'],,
211,211,"SSRIs were fluoxetine ( 20 mg / day ) , sertraline ( 50 mg / day ) or citalopram ( 20 mg / day ) ; doses could be doubled after 4 weeks .",SSRIs 是氟西汀（20 毫克/天）、舍曲林（50 毫克/天）或西酞普兰（20 毫克/天）； 4周后剂量可加倍。,0.5,"['/', 'be', 'after', '4', 'fluoxetine', 'citalopram']","['after', 'fluoxetine', 'citalopram']",211,"['SSRI 是 fluoxetine (20 mg / 天 ), sertraline (50 mg / 天 ) 或 citalopram (20 mg / 天 ) ; 剂量可以在 4 周后翻倍。']",0.3333333333333333,"['/', 'be', 'after', '4', 'fluoxetine', 'citalopram']","['be', 'after']",,
212,212,"exclusions included bipolar disorder , schizophrenia , substance abuse , positive urine drug screen , severe obesity , and a positive screen for sleep apnea .",排除包括躁郁症、精神分裂症、药物滥用、尿液药物筛查阳性、严重肥胖和睡眠呼吸暂停筛查阳性。,0.5,"['bipolar', 'urine', 'apnea', 'disorder', 'schizophrenia', 'sleep apnea', 'obesity', 'substance abuse', 'screen', 'bipolar disorder', 'drug', 'severe', 'positive', 'and']","['urine', 'apnea', 'schizophrenia', 'sleep apnea', 'obesity', 'screen', 'drug']",212,"['排除包括双极障碍,精神分裂症,物质滥用,积极的尿液药物屏幕,严重的肥胖,以及睡眠失眠的积极屏幕。']",0.5,"['bipolar', 'urine', 'apnea', 'disorder', 'schizophrenia', 'sleep apnea', 'obesity', 'substance abuse', 'screen', 'bipolar disorder', 'drug', 'severe', 'positive', 'and']","['urine', 'disorder', 'schizophrenia', 'obesity', 'substance abuse', 'screen', 'drug']",,
213,213,"at 8 weeks , ratings of insomnia and suicidal ideation fell in all groups .",在第 8 周时，所有组的失眠和自杀意念的评分都下降了。,0.3333333333333333,"['suicidal', 'fell', 'ideation', 'insomnia', 'all', 'and']","['suicidal', 'insomnia']",213,"['在8周,在所有群体中,失眠和自杀思想的评分下降。']",0.3333333333333333,"['suicidal', 'fell', 'ideation', 'insomnia', 'all', 'and']","['suicidal', 'insomnia']",,
214,214,"decades ago , Swiss and German psychiatrists popularized dauerschlaf ( prolonged sleep therapy ) , now long out of favor , for severe psychoses .",几十年前，瑞士和德国的精神病学家推广了 dauerschlaf（延长睡眠疗法），但现在早已失宠，用于治疗严重的精神病。,0.3333333333333333,"['therapy', 'sleep', 'severe', 'prolonged', 'out', 'and']","['therapy', 'sleep']",214,"['几十年前,瑞士和德国精神病学家普及了Dauerschlaf(延长睡眠疗法),现在很久没有支持,严重的精神病。']",0.3333333333333333,"['therapy', 'sleep', 'severe', 'prolonged', 'out', 'and']","['therapy', 'sleep']",,
215,215,this study reminds us that attention to sleep quality might benefit both depression and suicidal ideation .,这项研究提醒我们注意睡眠质量可能对抑郁症和自杀意念都有好处。,0.4166666666666667,"['depression', 'quality', 'study', 'suicidal', 'sleep', 'ideation', 'benefit', 'attention', 'this', 'that', 'to', 'and']","['depression', 'quality', 'suicidal', 'sleep', 'attention']",215,"['这项研究提醒我们,注意睡眠质量可能有利于抑郁和自杀的想法。']",0.5833333333333334,"['depression', 'quality', 'study', 'suicidal', 'sleep', 'ideation', 'benefit', 'attention', 'this', 'that', 'to', 'and']","['depression', 'quality', 'suicidal', 'sleep', 'benefit', 'attention', 'to']",,
216,216,these findings do not support routine hypnotics for depression but do suggest that patients with insomnia and suicidal ideation might well benefit from focused attention to sleep improvement .,这些发现不支持抑郁症的常规催眠药，但确实表明失眠和自杀意念的患者可能会从集中注意力改善睡眠中获益。,0.5294117647058824,"['depression', 'improvement', 'support', 'routine', 'suicidal', 'well', 'sleep', 'ideation', 'insomnia', 'benefit', 'suggest', 'with', 'attention', 'that', 'but', 'to', 'and']","['depression', 'improvement', 'support', 'routine', 'suicidal', 'sleep', 'insomnia', 'attention', 'but']",216,"['这些发现不支持抑郁症的日常催眠,但表明患有失眠和自杀思想的患者可以从专注于睡眠改善的注意力中受益。']",0.5294117647058824,"['depression', 'improvement', 'support', 'routine', 'suicidal', 'well', 'sleep', 'ideation', 'insomnia', 'benefit', 'suggest', 'with', 'attention', 'that', 'but', 'to', 'and']","['depression', 'improvement', 'support', 'suicidal', 'sleep', 'insomnia', 'attention', 'but', 'to']",,
217,217,"current guidelines ( National Asthma Education and Prevention Program and Global Initiative for Asthma ) recommend assessing asthma control using a combination of symptoms , exacerbation history , and lung function .",目前的指南（国家哮喘教育和预防计划和全球哮喘倡议）建议综合使用症状、恶化史和肺功能来评估哮喘控制情况。,0.625,"['asthma', 'combination', 'lung', 'control', 'program', 'global', 'function', 'education', 'exacerbation', 'prevention', 'recommend', 'history', 'symptoms', 'current', 'initiative', 'and']","['asthma', 'lung', 'control', 'program', 'global', 'function', 'education', 'exacerbation', 'prevention', 'recommend']",217,"['目前的指导方针(国家哮喘教育和预防计划和全球哮喘倡议)建议通过症状,恶化历史和肺功能的组合来评估哮喘控制。']",0.75,"['asthma', 'combination', 'lung', 'control', 'program', 'global', 'function', 'education', 'exacerbation', 'prevention', 'recommend', 'history', 'symptoms', 'current', 'initiative', 'and']","['asthma', 'combination', 'lung', 'control', 'program', 'global', 'function', 'education', 'exacerbation', 'prevention', 'recommend', 'history']",,
218,218,"although both reduced lung function and increased symptoms are associated with worsening asthma outcomes , the correlation between the two is unclear .",尽管肺功能下降和症状加重都与哮喘预后恶化有关，但两者之间的相关性尚不清楚。,0.5555555555555556,"['asthma', 'correlation', 'lung', 'function', 'symptoms', 'associated', 'with', 'and', 'two']","['asthma', 'correlation', 'lung', 'function', 'two']",218,"['虽然肺功能下降和症状增加都与哮喘结果的恶化有关,但两者之间的关系不清楚。']",0.4444444444444444,"['asthma', 'correlation', 'lung', 'function', 'symptoms', 'associated', 'with', 'and', 'two']","['asthma', 'lung', 'function', 'two']",,
219,219,"adjustment for socioeconomic status and smoking history improved correlation somewhat , but changes in FEV1 and symptom scores over time still were disparate .",对社会经济地位和吸烟史进行调整后，相关性有所改善，但 FEV1 和症状评分随时间的变化仍然存在差异。,0.4285714285714285,"['correlation', 'symptom', 'adjustment', 'status', 'history', 'time', 'still', 'disparate', 'socioeconomic status', 'FEV1', 'in', 'over', 'but', 'and']","['correlation', 'symptom', 'status', 'time', 'socioeconomic status', 'but']",219,"['对社会经济状况和吸烟历史的调整有所改善,但FEV1和症状成绩的变化随着时间的推移,仍然不一样。']",0.3571428571428571,"['correlation', 'symptom', 'adjustment', 'status', 'history', 'time', 'still', 'disparate', 'socioeconomic status', 'FEV1', 'in', 'over', 'but', 'and']","['symptom', 'status', 'history', 'time', 'but']",,
220,220,"I am often surprised by patients who have few symptoms but very low lung function , and conversely , by those who are very symptomatic but have normal FEV1 .",我经常对症状很少但肺功能很低的患者感到惊讶，相反，对那些症状非常严重但 FEV1 正常的患者感到惊讶。,0.3846153846153846,"['lung', 'who', 'function', 'normal', 'symptoms', 'low', 'symptomatic', 'FEV1', 'I', 'have', 'by', 'but', 'and']","['lung', 'function', 'normal', 'low', 'but']",220,"['我经常被患有少数症状但肺功能非常低的患者惊讶,反之亦然,患有非常症状但正常的FEV1患者。']",0.4615384615384615,"['lung', 'who', 'function', 'normal', 'symptoms', 'low', 'symptomatic', 'FEV1', 'I', 'have', 'by', 'but', 'and']","['lung', 'function', 'normal', 'low', 'have', 'but']",,
221,221,"for patients with few symptoms but surprisingly low FEV1 , I consider alternative causes ( e.g. , poor effort or technique , chronic obstructive pulmonary disease , irreversible obstruction due to chronic remodeling ) .",对于症状很少但 FEV1 出奇低的患者，我会考虑其他原因（例如，努力程度或技术不佳、慢性阻塞性肺病、慢性重塑导致的不可逆阻塞）。,0.4117647058823529,"['disease', 'obstructive', 'obstruction', 'symptoms', 'pulmonary', 'low', 'chronic', 'technique', 'effort', 'due', 'with', 'FEV1', 'alternative', 'I', 'poor', 'but', 'irreversible']","['disease', 'low', 'chronic', 'technique', 'effort', 'but', 'irreversible']",221,"['对于患有少数症状但令人惊讶的低FEV1的患者,我考虑替代原因(例如,不足的努力或技术,慢性阻塞性肺疾病,由于慢性修复而不可逆转的阻塞)。']",0.4117647058823529,"['disease', 'obstructive', 'obstruction', 'symptoms', 'pulmonary', 'low', 'chronic', 'technique', 'effort', 'due', 'with', 'FEV1', 'alternative', 'I', 'poor', 'but', 'irreversible']","['disease', 'low', 'chronic', 'technique', 'effort', 'but', 'irreversible']",,
222,222,but if the low FEV1 appears to be due to asthma - especially if it reversible with a bronchodilator - the patient might be underreporting symptoms and therapy should be stepped up .,但如果低 FEV1 似乎是由于哮喘引起的——尤其是如果它可以用支气管扩张剂逆转——患者可能没有报告症状，应该加强治疗。,0.375,"['asthma', 'reversible', 'symptoms', 'therapy', 'be', 'low', 'bronchodilator', 'patient', 'up', 'due', 'with', 'FEV1', '-', 'if', 'but', 'and']","['asthma', 'therapy', 'low', 'bronchodilator', 'patient', 'but']",222,"['但是,如果低 FEV1 似乎是由于哮喘 - 特别是如果它是逆转的 bronchodilator - 患者可能不报告症状,治疗应该加步。']",0.3125,"['asthma', 'reversible', 'symptoms', 'therapy', 'be', 'low', 'bronchodilator', 'patient', 'up', 'due', 'with', 'FEV1', '-', 'if', 'but', 'and']","['asthma', 'therapy', 'low', 'patient', 'but']",,
223,223,"conversely , for very symptomatic patients with normal FEV1 , I consider alternative diagnoses ( e.g. , heart disease , vocal cord dysfunction , obesity , anxiety ) .",相反，对于 FEV1 正常但症状非常严重的患者，我会考虑其他诊断（例如，心脏病、声带功能障碍、肥胖、焦虑）。,0.4666666666666667,"['heart', 'dysfunction', 'disease', 'anxiety', 'heart disease', 'cord', 'obesity', 'normal', 'vocal', 'vocal cord', 'symptomatic', 'with', 'FEV1', 'alternative', 'I']","['heart', 'disease', 'anxiety', 'heart disease', 'cord', 'obesity', 'vocal cord']",223,"['相反,对于患有正常FEV1的非常症状的患者,我考虑替代诊断(例如,心脏病,语音心脏功能障碍,肥胖,焦虑)。']",0.4,"['heart', 'dysfunction', 'disease', 'anxiety', 'heart disease', 'cord', 'obesity', 'normal', 'vocal', 'vocal cord', 'symptomatic', 'with', 'FEV1', 'alternative', 'I']","['heart', 'disease', 'anxiety', 'heart disease', 'obesity', 'symptomatic']",,
224,224,"if these are ruled out , the patient might require a higher level of therapy despite relatively normal lung function .",如果排除这些，尽管肺功能相对正常，患者可能需要更高水平的治疗。,0.5,"['lung', 'a', 'function', 'normal', 'therapy', 'patient', 'level', 'despite', 'if', 'out']","['lung', 'function', 'therapy', 'patient', 'level']",224,"['如果这些被排除,患者可能需要更高的治疗水平,尽管相对正常的肺功能。']",0.6,"['lung', 'a', 'function', 'normal', 'therapy', 'patient', 'level', 'despite', 'if', 'out']","['lung', 'function', 'normal', 'therapy', 'patient', 'level']",,
225,225,a large study showed excess risk for a number of outcomes .,一项大型研究表明，许多结果的风险过大。,0.1666666666666666,"['excess', 'a', 'study', 'large', 'number', 'risk']",['risk'],225,"['一项大型研究表明,多种结果的风险过高。']",0.1666666666666666,"['excess', 'a', 'study', 'large', 'number', 'risk']",['risk'],,
226,226,survivors of hematologic malignancies had excess risks for all these outcomes ; survivors of other cancers had excess risks for only some outcomes .,血液系统恶性肿瘤的幸存者对所有这些结果都有额外的风险；其他癌症的幸存者仅对某些结果有过高的风险。,0.0,"['excess', 'all', 'hematologic']",[],226,['血病恶性疾病的幸存者对所有这些结果都有过度风险;其他癌症的幸存者只对某些结果有过度风险。'],0.0,"['excess', 'all', 'hematologic']",[],,
227,227,"incidence of VTE decreased with time after diagnosis , whereas incidence of heart failure or cardiomyopathy increased .",VTE的发生率在诊断后随时间降低，而心力衰竭或心肌病的发生率增加。,0.8888888888888888,"['heart', 'incidence', 'failure', 'time', 'diagnosis', 'heart failure', 'cardiomyopathy', 'after', 'with']","['heart', 'incidence', 'failure', 'time', 'diagnosis', 'heart failure', 'cardiomyopathy', 'after']",227,"['VTE的发病率随着诊断后的时间减少,而心脏衰竭或心脏病的发病率增加。']",0.6666666666666666,"['heart', 'incidence', 'failure', 'time', 'diagnosis', 'heart failure', 'cardiomyopathy', 'after', 'with']","['heart', 'incidence', 'failure', 'time', 'diagnosis', 'after']",,
228,228,"in this study , available data were insufficient to identify the risks associated with specific treatment modalities , but some of them are well known ( e.g. , heart failure with anthracycline drugs , coronary disease after chest radiotherapy ) .",在这项研究中，现有数据不足以确定与特定治疗方式相关的风险，但其中一些是众所周知的（例如，蒽环类药物引起的心力衰竭、胸部放疗后的冠心病）。,0.5652173913043478,"['heart', 'disease', 'chest', 'failure', 'data', 'drugs', 'study', 'coronary', 'radiotherapy', 'heart failure', 'associated', 'treatment', 'available', 'well', 'after', 'specific', 'identify', 'with', 'this', 'in', 'but', 'to', 'insufficient']","['heart', 'disease', 'chest', 'failure', 'data', 'drugs', 'coronary', 'heart failure', 'treatment', 'after', 'this', 'but', 'insufficient']",228,"['在这项研究中,可用的数据不足以确定与特定治疗方法相关的风险,但其中一些是众所周知的(例如,心脏衰竭与安特拉西克林药物,乳房放射治疗后的冠状疾病)。']",0.5652173913043478,"['heart', 'disease', 'chest', 'failure', 'data', 'drugs', 'study', 'coronary', 'radiotherapy', 'heart failure', 'associated', 'treatment', 'available', 'well', 'after', 'specific', 'identify', 'with', 'this', 'in', 'but', 'to', 'insufficient']","['heart', 'disease', 'failure', 'data', 'drugs', 'coronary', 'radiotherapy', 'treatment', 'available', 'after', 'this', 'but', 'insufficient']",,
229,229,"genome sequencing is often pivotal in the diagnosis of rare diseases , but many of these conditions lack specific treatments .",基因组测序通常在罕见疾病的诊断中起着关键作用，但其中许多疾病缺乏特异性治疗方法。,0.6666666666666666,"['genome', 'lack', 'sequencing', 'diagnosis', 'specific', 'but']","['genome', 'sequencing', 'diagnosis', 'but']",229,"['基因组序列往往在诊断罕见疾病方面至关重要,但许多这些疾病缺乏具体治疗。']",0.5,"['genome', 'lack', 'sequencing', 'diagnosis', 'specific', 'but']","['genome', 'diagnosis', 'but']",,
230,230,"there were no serious adverse events , and treatment was associated with objective reduction in seizures ( determined by electroencephalography and parental reporting ) .",没有严重的不良事件，治疗与癫痫发作的客观减少有关（由脑电图和父母报告确定）。,0.3571428571428571,"['objective', 'parental', 'reduction', 'electroencephalography', 'adverse', 'associated', 'treatment', 'no', 'with', 'serious', 'in', 'by', 'and', 'seizures']","['reduction', 'electroencephalography', 'treatment', 'by', 'seizures']",230,"['没有严重的副作用,并且治疗与客观减少受伤(由电解体和父母报告确定)有关。']",0.2142857142857142,"['objective', 'parental', 'reduction', 'electroencephalography', 'adverse', 'associated', 'treatment', 'no', 'with', 'serious', 'in', 'by', 'and', 'seizures']","['reduction', 'treatment', 'by']",,
231,231,rare diseases in aggregate affect approximately 30 million persons in the United States alone.1,仅在美国，罕见病总共影响了大约 3000 万人。 1,0.2,"['aggregate', 'affect', 'approximately', 'in', 'million']",['affect'],231,"['稀有疾病总体影响约3000万人,仅在美国1']",0.2,"['aggregate', 'affect', 'approximately', 'in', 'million']",['affect'],,
232,232,this report shows a path to personalized treatment for patients with orphan diseases .,这份报告显示了针对孤儿病患者的个性化治疗途径。,0.5,"['a', 'report', 'treatment', 'orphan', 'path', 'with', 'this', 'to']","['report', 'treatment', 'orphan', 'path']",232,['本报告显示了患有孤儿病患者的个性化治疗的路径。'],0.5,"['a', 'report', 'treatment', 'orphan', 'path', 'with', 'this', 'to']","['report', 'treatment', 'orphan', 'path']",,
233,233,"identification of the mutation was followed by the development and clinical deployment , within 1 year , of a tailored drug to treat the patient ( Figure 1A ) .",在确定突变后，在 1 年内开发并临床部署了一种治疗患者的定制药物（图 1A）。,0.5384615384615384,"['mutation', 'year', '1', 'identification', 'figure', 'treat', 'clinical', 'patient', 'development', 'drug', 'by', 'to', 'and']","['mutation', 'year', '1', 'treat', 'clinical', 'patient', 'drug']",233,"['突变的识别,随后是开发和临床部署,在1年内,个性化药物治疗患者(图1A)。']",0.6153846153846154,"['mutation', 'year', '1', 'identification', 'figure', 'treat', 'clinical', 'patient', 'development', 'drug', 'by', 'to', 'and']","['mutation', 'year', '1', 'identification', 'treat', 'clinical', 'patient', 'drug']",,
234,234,clinical Presentation,临床表现,0.5,"['presentation', 'clinical']",['clinical'],234,['临床介绍'],1.0,"['presentation', 'clinical']","['presentation', 'clinical']",,
235,235,"when she was 4 years of age , her family noticed her pulling books close to her face at bedtime .",当她 4 岁时，她的家人注意到她在睡觉时将书本拉近自己的脸。,0.375,"['face', 'family', 'books', 'age', '4', 'at', 'to', 'close to']","['face', 'family', 'at']",235,"['当她4岁时,她的家人注意到她在睡觉时在她的脸上拉着书。']",0.375,"['face', 'family', 'books', 'age', '4', 'at', 'to', 'close to']","['face', 'family', 'at']",,
236,236,"at 5 years of age , she came to medical attention because of modest language and social regression , as well as increased clumsiness and stumbling .",在 5 岁时，她因语言谦虚和社会退化以及越来越笨拙和跌跌撞撞而就医。,0.3333333333333333,"['5', 'medical', 'regression', 'language', 'well', 'as', 'attention', 'to', 'and']","['5', 'regression', 'and']",236,"['5岁时,她因语言和社会衰退而接受了医学护理,以及增加了同情心和沉默。']",0.2222222222222222,"['5', 'medical', 'regression', 'language', 'well', 'as', 'attention', 'to', 'and']","['5', 'and']",,
237,237,"in the months before she turned 6 years of age , the progression of symptoms accelerated , and she was hospitalized after the rapid development of loss of vision , frequent falls , dysarthria , and dysphagia .",在她 6 岁之前的几个月里，症状进展加速，并在视力丧失、频繁跌倒、构音障碍和吞咽困难的快速发展后入院。,0.5,"['vision', 'symptoms', 'loss', 'progression', 'dysphagia', 'age', 'after', 'development', 'loss of vision', 'before', 'in', 'frequent', 'and', 'rapid']","['vision', 'loss', 'progression', 'dysphagia', 'after', 'development', 'before']",237,"['在她6岁之前的几个月里,症状的进展加速,她在视力损失、频繁衰落、 dysarthria 和 dysphagia 的快速发展后被送往医院。']",0.4285714285714285,"['vision', 'symptoms', 'loss', 'progression', 'dysphagia', 'age', 'after', 'development', 'loss of vision', 'before', 'in', 'frequent', 'and', 'rapid']","['vision', 'loss', 'progression', 'after', 'development', 'before']",,
238,238,"an extensive laboratory workup for mitochondrial or metabolic diseases was initially unrevealing , until a skin biopsy was performed .",对线粒体或代谢疾病进行广泛的实验室检查最初没有发现问题，直到进行了皮肤活检。,0.8,"['mitochondrial', 'biopsy', 'skin', 'laboratory', 'metabolic']","['mitochondrial', 'biopsy', 'skin', 'laboratory']",238,"['对甲状腺或代谢疾病进行了广泛的实验室工作,直到进行皮肤生物检测。']",0.4,"['mitochondrial', 'biopsy', 'skin', 'laboratory', 'metabolic']","['skin', 'laboratory']",,
239,239,no second mutation could be found .,没有发现第二个突变。,0.25,"['mutation', 'be', 'no', 'second']",['mutation'],239,['没有第二次突变。'],0.5,"['mutation', 'be', 'no', 'second']","['mutation', 'second']",,
240,240,the family was offered enrollment in a research study for further diagnostic workup .,该家庭被邀请参加一项研究，以进行进一步的诊断检查。,0.4,"['family', 'research', 'study', 'diagnostic', 'in']","['family', 'research']",240,"['家人被邀请加入研究研究,以进一步诊断工作。']",0.4,"['family', 'research', 'study', 'diagnostic', 'in']","['family', 'research']",,
241,241,a full description of the methods of the subsequent workup is provided in the Supplementary Appendix .,补充附录中提供了后续检查方法的完整说明。,0.1428571428571428,"['a', 'appendix', 'supplementary', 'subsequent', 'description', 'full', 'in']",['full'],241,['随后的工作组的方法的完整描述在附件中提供。'],0.4285714285714285,"['a', 'appendix', 'supplementary', 'subsequent', 'description', 'full', 'in']","['appendix', 'description', 'full']",,
242,242,"all the authors vouch for the accuracy and completeness of the data and for the fidelity of the study to the protocol , available at NEJM.org .",所有作者保证数据的准确性和完整性，以及研究对方案的忠实度，该方案可在 NEJM.org 获取。,0.3333333333333333,"['fidelity', 'data', 'accuracy', 'protocol', 'study', 'available', 'completeness', 'all', 'and']","['data', 'accuracy', 'completeness']",242,"['所有作者都赞扬数据的准确性和完整性以及研究对该协议的忠诚性,可在NEJM.org上找到。']",0.4444444444444444,"['fidelity', 'data', 'accuracy', 'protocol', 'study', 'available', 'completeness', 'all', 'and']","['data', 'accuracy', 'protocol', 'completeness']",,
243,243,mutation IDENTIFICATION,突变鉴定,1.0,['mutation'],['mutation'],243,['突变识别'],1.0,['mutation'],['mutation'],,
244,244,"chimeric breakpoints were offset by 14 bp , suggesting duplication of an endogenous target sequence ( Figure 1B ) .",嵌合断点被 14 bp 抵消，表明内源靶序列的重复（图 1B）。,0.4444444444444444,"['duplication', 'endogenous', 'chimeric', 'sequence', 'bp', 'figure', 'offset', 'target', 'by']","['duplication', 'sequence', 'offset', 'target']",244,"['化学分裂点被折扣为14bp,表明一个内分子目标序列(图1B)的重复。']",0.3333333333333333,"['duplication', 'endogenous', 'chimeric', 'sequence', 'bp', 'figure', 'offset', 'target', 'by']","['duplication', 'sequence', 'target']",,
245,245,the SVA insertion was also correctly detected by automated analysis with the Tea algorithm.5,SVA 插入也通过 Tea 算法的自动分析正确检测到。 5,0.3333333333333333,"['analysis', 'insertion', 'tea', 'with', 'by', 'automated']","['analysis', 'insertion']",245,['SVA 插入也通过使用 Tea 算法进行自动分析正确检测。'],0.3333333333333333,"['analysis', 'insertion', 'tea', 'with', 'by', 'automated']","['analysis', 'insertion']",,
246,246,"this insertion has not been reported in the literature and does not appear in dbRIP , a database of retrotransposon insertions in the human population.6",这种插入没有在文献中报道过，也没有出现在 dbRIP 中，这是一个在人群中插入反转录转座子的数据库。 6,0.7142857142857143,"['retrotransposon', 'database', 'insertion', 'literature', 'human', 'this', 'and']","['retrotransposon', 'insertion', 'literature', 'human', 'this']",246,"['此插入未在文学中报告,并且不出现在 dbRIP,人类人口中 retrotransposon 插入数据库中。']",0.4285714285714285,"['retrotransposon', 'database', 'insertion', 'literature', 'human', 'this', 'and']","['insertion', 'literature', 'human']",,
247,247,development OF AN ANTISENSE OLIGONUCLEOTIDE DRUG,一种反义寡核苷酸药物的开发,0.0,"['development', 'AN']",[],247,['抗氧化药物的发育'],0.5,"['development', 'AN']",['development'],,
248,248,"when we tested these antisense oligonucleotides in patient fibroblasts , we identified three that boosted normal : mutant splicing ratios by a factor of 2.5 to 3 .",当我们在患者成纤维细胞中测试这些反义寡核苷酸时，我们发现了三种将正常：突变剪接比率提高 2.5 至 3 倍的寡核苷酸。,0.1666666666666666,"['antisense', 'splicing', 'mutant', 'factor', 'in patient', 'normal', '3', 'three', 'that', 'by', 'fibroblasts', 'we']","['antisense', 'splicing']",248,"['当我们在患者纤维细胞中测试了这些反敏性聚合物时,我们发现有三种增强正常的因素:突变分裂率为 2.5 至 3 的因素。']",0.1666666666666666,"['antisense', 'splicing', 'mutant', 'factor', 'in patient', 'normal', '3', 'three', 'that', 'by', 'fibroblasts', 'we']","['factor', 'normal']",,
249,249,"fibroblasts from the patient had several cellular phenotypes characteristic of lysosomal dysfunction , including intracellular vacuolation , 16 increased total lysosomal mass , 17 autofluorescence , miscompartmentalization of lysosomal enzyme activity , and reduced autophagic flux18 ( Figure 2D ) .",患者的成纤维细胞具有溶酶体功能障碍的多种细胞表型特征，包括细胞内空泡形成、16 溶酶体总质量增加、17 自发荧光、溶酶体酶活性的错误区室化和自噬通量降低 18（图 2D）。,0.5384615384615384,"['enzyme activity', 'dysfunction', 'characteristic', 'lysosomal', 'cellular', 'autofluorescence', 'figure', 'vacuolation', 'total', 'patient', 'mass', 'and', 'fibroblasts']","['enzyme activity', 'characteristic', 'lysosomal', 'autofluorescence', 'vacuolation', 'patient', 'mass']",249,"['患者的 fibroblasts 有几种细胞现象特征的 lysosomal dysfunction, 包括内细胞 vacuolation, 16 增加的整体 lysosomal 质量, 17 自我氟化, 错误分配的 lysosomal 酶活动, 和 减少的 autophagic 流量(图 2D ) 。']",0.2307692307692307,"['enzyme activity', 'dysfunction', 'characteristic', 'lysosomal', 'cellular', 'autofluorescence', 'figure', 'vacuolation', 'total', 'patient', 'mass', 'and', 'fibroblasts']","['characteristic', 'patient', 'mass']",,
250,250,studies IN SUPPORT OF AN INVESTIGATIONAL NEW DRUG APPLICATION,支持研究性新药应用的研究,0.0,['AN'],[],250,['研究支持研究新药应用'],0.0,['AN'],[],,
251,251,"clinical evaluation at 7 years of age revealed an inability to make discernible words , dysphagia ( prompting gastrostomy tube placement ) , the need for substantial support to walk , and 15 to 30 overt seizures per day .",7 岁时的临床评估显示无法辨认词语、吞咽困难（促使胃造口管放置）、行走需要大量支撑以及每天 15 至 30 次明显癫痫发作。,0.3888888888888889,"['support', 'need', 'evaluation', 'dysphagia', 'clinical', 'gastrostomy', 'age', 'tube', 'walk', 'overt', 'prompting', 'inability', 'placement', 'and', 'substantial', 'make', 'seizures', 'revealed']","['support', 'need', 'dysphagia', 'clinical', 'tube', 'seizures', 'revealed']",251,"['7岁时的临床评估显示,无法做出可识别的词语、 dysphagia(导致 gastrostomy 管放置)、需要有显著的支持走路、每日15至30次冲击。']",0.2777777777777778,"['support', 'need', 'evaluation', 'dysphagia', 'clinical', 'gastrostomy', 'age', 'tube', 'walk', 'overt', 'prompting', 'inability', 'placement', 'and', 'substantial', 'make', 'seizures', 'revealed']","['support', 'need', 'clinical', 'tube', 'revealed']",,
252,252,"she did , however , remain alert and reactive to familiar stimuli and responded happily to hearing her favorite books and songs .",然而，她确实对熟悉的刺激保持警觉和反应，并且对听到她最喜欢的书籍和歌曲做出愉快的反应。,0.625,"['familiar', 'books', 'hearing', 'reactive', 'stimuli', 'alert', 'to', 'and']","['books', 'hearing', 'stimuli', 'alert', 'and']",252,"['然而,她对熟悉的刺激保持警惕和反应,并快乐地响应听到她最喜欢的书籍和歌曲。']",0.5,"['familiar', 'books', 'hearing', 'reactive', 'stimuli', 'alert', 'to', 'and']","['books', 'hearing', 'stimuli', 'and']",,
253,253,milasen drug substance ( 18 g ) was manufactured and formulated for clinical administration .,milasen 原料药 (18 g) 被制造和配制用于临床给药。,0.4,"['administration', 'clinical', 'substance', 'drug', 'and']","['clinical', 'drug']",253,['米拉森药物(18g)已生产并用于临床用途。'],0.4,"['administration', 'clinical', 'substance', 'drug', 'and']","['clinical', 'drug']",,
254,254,"to identify potential hazards , we administered milasen to rats by intrathecal injection at three doses : 0.06 mg , 0.25 mg , and 1.0 mg ( approximately 2.5 times , 10 times , and 42 times , respectively , the typical clinical dose of nusinersen , after compartmental scaling considerations ) .","为了确定潜在的危害，我们通过鞘内注射三种剂量给大鼠注射milasen ： 0.06 mg , 0.25 mg , 和 1.0 mg （分别约为 nusinersen 典型临床剂量的 2.5 倍 , 10 倍 , 和 42 倍，经过间隔缩放后）考虑因素）。",0.3333333333333333,"['injection', 'potential', 'scaling', 'typical', 'clinical', 'after', 'identify', 'nusinersen', 'at', 'dose', 'intrathecal injection', 'rats', 'approximately', 'three', 'by', 'to', 'and', 'we']","['injection', 'potential', 'clinical', 'after', 'dose', 'intrathecal injection']",254,"['为了确定潜在的危险,我们用三剂量: 0.06 mg, 0.25 mg,和 1.0 mg(大约 2.5 次, 10 次,和 42 次,相应,典型的临床剂量,Nusinersen,经过共享扩展考虑)。']",0.2222222222222222,"['injection', 'potential', 'scaling', 'typical', 'clinical', 'after', 'identify', 'nusinersen', 'at', 'dose', 'intrathecal injection', 'rats', 'approximately', 'three', 'by', 'to', 'and', 'we']","['potential', 'typical', 'clinical', 'dose']",,
255,255,no adverse effects were observed in the group that received 0.06 mg .,在接受 0.06 毫克的组中没有观察到不良反应。,0.2,"['group', 'adverse', 'no', 'that', 'in']",['group'],255,['在接受 0.06 mg 的群体中没有发现任何副作用。'],0.2,"['group', 'adverse', 'no', 'that', 'in']",['group'],,
256,256,"at higher doses , some animals ( half of those in the group that received 0.25 mg and most of those in the group that received 1.0 mg ) had hindlimb weakness , which resolved by approximately 24 hours after each dose . ( for additional details , including multidose experiments , see Fig .",在较高剂量下，一些动物（接受 0.25 毫克组中的一半动物和接受 1.0 毫克组中的大多数动物）出现后肢无力，在每次给药后约 24 小时后消失。 （有关更多详细信息，包括多剂量实验，请参见图 1）。,0.3333333333333333,"['group', 'fig', 'half', 'weakness', 'additional', 'after', 'at', 'dose', 'approximately', 'that', 'each', 'in', 'by', 'and', 'hindlimb']","['group', 'half', 'weakness', 'after', 'dose']",256,"['在较高的剂量中,一些动物(受 0.25 mg 的群体中的一半和受 1.0 mg 的群体中的一半)患有抑郁症,在每剂量后大约24小时解决。']",0.2666666666666666,"['group', 'fig', 'half', 'weakness', 'additional', 'after', 'at', 'dose', 'approximately', 'that', 'each', 'in', 'by', 'and', 'hindlimb']","['group', 'half', 'after', 'dose']",,
257,257,S13 and Supplementary Text . ) These results provided translatable indicators of potential toxic effects that could be readily monitored and guided our clinical protocol design .,S13 和补充文本。 ) 这些结果提供了潜在毒性作用的可转化指标，可以很容易地监测和指导我们的临床方案设计。,0.3,"['toxic', 'potential', 'protocol', 'supplementary', 'be', 'clinical', 'text', 'design', 'that', 'and']","['be', 'clinical', 'design']",257,"['S13 和补充文本. ) 这些结果提供了可翻译的潜在毒性影响的指标,可以轻松地监测和指导我们的临床协议设计。']",0.4,"['toxic', 'potential', 'protocol', 'supplementary', 'be', 'clinical', 'text', 'design', 'that', 'and']","['protocol', 'be', 'clinical', 'design']",,
258,258,clinical STUDY,临床研究,1.0,['clinical'],['clinical'],258,['临床研究'],1.0,['clinical'],['clinical'],,
259,259,we initiated a clinical study of milasen in our patient 1 month after we started the toxicology studies in animals ( Figure 1A ) .,在开始动物毒理学研究 1 个月后，我们在患者身上开始了 milasen 的临床研究（图 1A）。,0.6,"['a', '1', 'figure', 'month', 'study', 'toxicology', 'clinical study', 'patient', 'after', 'we']","['1', 'month', 'toxicology', 'clinical study', 'patient', 'after']",259,['我们在动物毒理学研究开始后1个月开始了我们患者的米拉森的临床研究(图1A)。'],0.6,"['a', '1', 'figure', 'month', 'study', 'toxicology', 'clinical study', 'patient', 'after', 'we']","['1', 'month', 'toxicology', 'clinical study', 'patient', 'after']",,
260,260,"a dose of 42 mg was chosen because antisense oligonucleotides administered intrathecally to humans or nonhuman primates distribute to the brain ( the target of milasen ) with approximately one third the efficiency with which they distribute to the spinal cord ( the target of nusinersen ) , 8,13 and 42 mg of milasen is the molar equivalent of 3 times the typical nusinersen dose ( 12 mg ) .","选择 42 mg 的剂量是因为鞘内给予人类或非人类灵长类动物的反义寡核苷酸分布到大脑（milasen 的靶标）的效率约为它们分布到脊髓（nusinersen 的靶标）的三分之一，8, 13 和 42 毫克的 milasen 是典型 nusinersen 剂量（12 毫克）的 3 倍摩尔当量。",0.45,"['antisense', 'primates', 'equivalent', 'molar', 'cord', 'brain', 'spinal', 'typical', 'target', 'efficiency', '3', 'distribute', 'with', 'spinal cord', 'nusinersen', 'dose', 'approximately', 'to', 'and', 'third']","['antisense', 'primates', 'equivalent', 'molar', 'brain', 'target', 'efficiency', 'spinal cord', 'dose']",260,"['42毫克的剂量被选择,因为对人类或非人类原始物体进行内分泌的抗氧化物质分布到大脑(米拉森的目标),大约三分之一的效率分布到脊椎(尼西纳森的目标),8、13和42毫克的米拉森是3倍的典型尼西纳森剂量(12毫克)。']",0.2,"['antisense', 'primates', 'equivalent', 'molar', 'cord', 'brain', 'spinal', 'typical', 'target', 'efficiency', '3', 'distribute', 'with', 'spinal cord', 'nusinersen', 'dose', 'approximately', 'to', 'and', 'third']","['brain', 'target', 'efficiency', 'dose']",,
261,261,"after dose escalation , two additional loading doses were administered , followed by maintenance dosing approximately every 3 months .",剂量递增后，再给予两次负荷剂量，然后大约每 3 个月给予一次维持剂量。,0.4444444444444444,"['loading', 'additional', 'after', '3', 'maintenance', 'dose', 'approximately', 'by', 'two']","['after', 'maintenance', 'dose', 'two']",261,"['剂量升级后,服用了2个额外的加载剂量,随后约每3个月进行维持剂量。']",0.4444444444444444,"['loading', 'additional', 'after', '3', 'maintenance', 'dose', 'approximately', 'by', 'two']","['additional', 'after', 'maintenance', 'dose']",,
262,262,"adverse Events , Pharmacokinetics , and Imaging","不良事件 , 药代动力学 , 和影像学",0.25,"['pharmacokinetics', 'adverse', 'imaging', 'and']",['pharmacokinetics'],262,"['不良事件, 药物素学, 和 图像']",0.0,"['pharmacokinetics', 'adverse', 'imaging', 'and']",[],,
263,263,"through the first year of treatment , no serious adverse events occurred .",通过第一年的治疗，没有发生严重的不良事件。,0.5,"['year', 'adverse', 'treatment', 'no', 'serious', 'first']","['year', 'treatment', 'first']",263,"['在治疗的第一年内,没有发生严重的副作用。']",0.5,"['year', 'adverse', 'treatment', 'no', 'serious', 'first']","['year', 'treatment', 'first']",,
264,264,"no clinically significant adverse changes were observed in vital signs ; in the results of physical examination , including assessments of strength , gait , and sensory testing ; or in clinical laboratory test profiles .",生命体征未见有临床意义的不良变化；在身体检查的结果中，包括力量、步态和感官测试的评估；或在临床实验室测试配置文件中。,0.4,"['vital signs', 'sensory', 'test', 'physical', 'examination', 'physical examination', 'adverse', 'no', 'strength', 'gait', 'clinical', 'laboratory', 'testing', 'laboratory test', 'and']","['vital signs', 'examination', 'physical examination', 'gait', 'clinical', 'laboratory']",264,"['没有临床上显著的负面变化在重要迹象中被观察到;在物理检查的结果中,包括强度、功率和感官测试的评估;或在临床实验室测试档案中。']",0.2666666666666666,"['vital signs', 'sensory', 'test', 'physical', 'examination', 'physical examination', 'adverse', 'no', 'strength', 'gait', 'clinical', 'laboratory', 'testing', 'laboratory test', 'and']","['examination', 'strength', 'clinical', 'laboratory']",,
265,265,"MRI of the head showed continued brain volume loss 7 months after treatment initiation , extending a trend that had been observed over the previous 3 years .",头部 MRI 显示治疗开始后 7 个月脑容量持续减少，延续了过去 3 年观察到的趋势。,0.3846153846153846,"['trend', 'volume', 'a', 'initiation', 'head', 'brain', 'previous', 'MRI', 'after treatment', 'loss', '3', 'that', 'over']","['trend', 'initiation', 'head', 'brain', 'over']",265,"['头部的MRI显示,在治疗开始后7个月的脑体积持续下降,延长了过去3年中观察到的趋势。']",0.4615384615384615,"['trend', 'volume', 'a', 'initiation', 'head', 'brain', 'previous', 'MRI', 'after treatment', 'loss', '3', 'that', 'over']","['trend', 'volume', 'initiation', 'head', 'brain', 'over']",,
266,266,neurologic and Neuropsychological Assessments,神经学和神经心理学评估,0.6666666666666666,"['and', 'neurologic', 'neuropsychological']","['neurologic', 'neuropsychological']",266,['神经和神经心理学评估'],0.6666666666666666,"['and', 'neurologic', 'neuropsychological']","['neurologic', 'neuropsychological']",,
267,267,"of the 4 subscores that did not decline , 2 remained the same and 2 improved in the 3 months before the initiation of the clinical study .",在临床研究开始前的 3 个月内，4 个未下降的分项分数中，2 个保持不变，2 个有所改善。,0.5,"['decline', 'initiation', '2', 'study', 'clinical study', '3', '4', 'that', 'before', 'and']","['decline', 'initiation', '2', 'clinical study', 'before']",267,"['在未下降的4个分数中,2个保持相同,2个在临床研究开始前3个月改善。']",0.5,"['decline', 'initiation', '2', 'study', 'clinical study', '3', '4', 'that', 'before', 'and']","['decline', 'initiation', '2', 'clinical study', 'before']",,
268,268,"subscores tended to stabilize in the period from the start of the clinical study to approximately 3 months ( 3 declined , 6 remained the same , and 2 improved from day − 6 to day 107 ) and from 3 months to 6 months ( 4 declined , 2 remained the same , and 5 improved from day 107 to day 203 ) .",从临床研究开始到大约 3 个月（从第 6 天到第 107 天，3 人下降，6 人保持不变，2 人提高）和从 3 个月到 6 个月（4 人下降，2 人保持不变，从第 107 天到第 203 天有 5 个有所改善）。,0.25,"['period', '5', '2', 'study', 'clinical study', '3', '4', 'stabilize', 'start', 'approximately', 'to', 'and']","['5', '2', 'clinical study']",268,"['从临床研究开始的期间,低分倾向于稳定约为3个月(3下降,6保持相同,2从6到107日改善)和3个月到6个月(4下降,2保持相同,5从107到203日改善)。']",0.5,"['period', '5', '2', 'study', 'clinical study', '3', '4', 'stabilize', 'start', 'approximately', 'to', 'and']","['period', '5', '2', 'clinical study', 'stabilize', 'to']",,
269,269,seizures,癫痫发作,1.0,['seizures'],['seizures'],269,['攻击'],0.0,['seizures'],[],,
270,270,"at baseline , our patient was having approximately 15 to 30 seizures per day , each lasting 1 to 2 minutes ( Figure 3C ) .",在基线时，我们的患者每天大约发作 15 到 30 次，每次持续 1 到 2 分钟（图 3C）。,0.5555555555555556,"['baseline', '1', '2', 'figure', 'patient', 'approximately', 'each', 'to', 'seizures']","['baseline', '1', '2', 'patient', 'seizures']",270,"['在基线上,我们的病人每天大约有15至30次,每次持续1至2分钟(图3C)。']",0.4444444444444444,"['baseline', '1', '2', 'figure', 'patient', 'approximately', 'each', 'to', 'seizures']","['baseline', '1', '2', 'patient']",,
271,271,"over the course of the clinical study , the frequency decreased to between 0 and 20 seizures per day , and the duration of each seizure decreased to less than 1 minute .",在临床研究过程中，频率减少到每天 0 到 20 次癫痫发作，每次癫痫发作的持续时间减少到不到 1 分钟。,0.6923076923076923,"['frequency', '1', 'study', 'minute', 'seizure', 'clinical study', 'duration', 'course', 'each', 'over', 'to', 'and', 'seizures']","['frequency', '1', 'minute', 'seizure', 'clinical study', 'duration', 'course', 'over', 'seizures']",271,"['在临床试验期间,频率下降到每日0至20次,每次接收的持续时间下降到不到1分钟。']",0.3076923076923077,"['frequency', '1', 'study', 'minute', 'seizure', 'clinical study', 'duration', 'course', 'each', 'over', 'to', 'and', 'seizures']","['frequency', '1', 'minute', 'duration']",,
272,272,"these trends were corroborated by overnight electroencephalographic monitoring ( Figure 3D ) , which indicated that both the frequency and duration of seizures decreased by greater than 50 % ( comparing the initial two recordings and the subsequent three recordings ) .",这些趋势得到夜间脑电图监测的证实（图 3D），这表明癫痫发作的频率和持续时间都减少了 50% 以上（比较最初的两次记录和随后的三次记录）。,0.5833333333333334,"['monitoring', 'frequency', 'figure', 'initial', 'subsequent', 'duration', 'three', 'that', 'by', 'and', 'two', 'seizures']","['monitoring', 'frequency', 'initial', 'duration', 'by', 'two', 'seizures']",272,"['这些趋势是由夜间电解体监测(图3D)证实的,这表明捕获的频率和持续时间都减少了50%以上(比较初步两次录制和后来的三次录制)。']",0.5,"['monitoring', 'frequency', 'figure', 'initial', 'subsequent', 'duration', 'three', 'that', 'by', 'and', 'two', 'seizures']","['monitoring', 'frequency', 'initial', 'duration', 'by', 'two']",,
273,273,the percent cumulative time spent in seizure decreased by greater than 80 % .,癫痫发作的累积时间百分比减少了 80% 以上。,0.5,"['time', 'cumulative', 'seizure', 'percent', 'in', 'by']","['time', 'seizure', 'by']",273,['收集时间的百分比减少了80%以上。'],0.3333333333333333,"['time', 'cumulative', 'seizure', 'percent', 'in', 'by']","['time', 'by']",,
274,274,treatment has also been accompanied by objective reductions in the frequency and duration of seizures .,治疗还伴随着癫痫发作频率和持续时间的客观减少。,0.4,"['objective', 'frequency', 'accompanied', 'treatment', 'duration', 'in', 'by', 'and', 'accompanied by', 'seizures']","['frequency', 'treatment', 'duration', 'seizures']",274,['治疗也伴随着对抗的频率和持续时间的客观减少。'],0.3,"['objective', 'frequency', 'accompanied', 'treatment', 'duration', 'in', 'by', 'and', 'accompanied by', 'seizures']","['frequency', 'treatment', 'duration']",,
275,275,"nonetheless , this experience indicates that antisense oligonucleotides may deserve consideration as a platform for the rapid delivery of individualized treatments .",尽管如此，这一经验表明，反义寡核苷酸可能值得考虑作为快速提供个性化治疗的平台。,0.4444444444444444,"['antisense', 'delivery', 'platform', 'experience', 'as', 'this', 'that', 'consideration', 'rapid']","['antisense', 'platform', 'experience', 'as']",275,"['然而,这种经验表明,抗敏性<unk>核酸可能值得考虑,作为快速提供个性化治疗的平台。']",0.2222222222222222,"['antisense', 'delivery', 'platform', 'experience', 'as', 'this', 'that', 'consideration', 'rapid']","['platform', 'experience']",,
276,276,"more generally , this approach is at present probably scalable to only a limited number of patients , given current limitations on systemic and infrastructural issues ( e.g. , regulatory burden , manufacturing capacity , cost , and reimbursement ) .",更一般地说，考虑到目前对系统和基础设施问题（例如，监管负担、制造能力、成本和报销）的限制，这种方法目前可能只能扩展到有限数量的患者。,0.2142857142857142,"['approach', 'capacity', 'number', 'systemic', 'current', 'cost', 'present', 'at', 'on', 'limited', 'this', 'to', 'and', 'burden']","['capacity', 'number', 'cost']",276,"['更普遍地说,这种方法目前可能仅可扩展到有限数量的患者,考虑到系统和基础设施问题(例如,监管负担,制造能力,成本和回报)的当前限制。']",0.2857142857142857,"['approach', 'capacity', 'number', 'systemic', 'current', 'cost', 'present', 'at', 'on', 'limited', 'this', 'to', 'and', 'burden']","['capacity', 'number', 'cost', 'at']",,
277,277,"this study illustrates the ability to rationally design , test , and deploy a novel therapeutic agent for a patient with a rare disease on the basis of an understanding of her specific pathogenic mutation .",这项研究说明了在了解罕见病患者特定致病突变的基础上合理设计、测试和部署新型治疗剂的能力。,0.2941176470588235,"['mutation', 'disease', 'test', 'study', 'basis', 'pathogenic', 'therapeutic', 'patient', 'novel', 'specific', 'ability', 'design', 'with', 'agent', 'this', 'to', 'and']","['mutation', 'disease', 'patient', 'ability', 'design']",277,"['这项研究展示了对一个患有罕见疾病的患者进行理性设计、测试和部署新疗法的能力,基于对其特定的病因突变的理解。']",0.4117647058823529,"['mutation', 'disease', 'test', 'study', 'basis', 'pathogenic', 'therapeutic', 'patient', 'novel', 'specific', 'ability', 'design', 'with', 'agent', 'this', 'to', 'and']","['mutation', 'disease', 'test', 'patient', 'ability', 'design', 'to']",,
278,278,it is an example of individualized genomic medicine .,它是个体化基因组医学的一个例子。,1.0,"['medicine', 'example']","['medicine', 'example']",278,['这是个别化基因医学的例子。'],1.0,"['medicine', 'example']","['medicine', 'example']",,
279,279,"the two primary outcomes were net adverse clinical events - defined as death from any cause , myocardial infarction , definite stent thrombosis , stroke , or major bleeding defined according to Platelet Inhibition and Patient Outcomes ( PLATO ) criteria - at 12 months ( primary combined outcome ; tested for noninferiority , with a noninferiority margin of 2 percentage points for the absolute difference ) and PLATO major or minor bleeding at 12 months ( primary bleeding outcome ) .",两个主要结果是 12 个月时的净不良临床事件——定义为任何原因死亡、心肌梗死、确定的支架内血栓形成、中风或根据血小板抑制和患者结果 (PLATO) 标准定义的大出血（主要综合结果；测试了非劣效性，绝对差的非劣效性界限为 2 个百分点）和 PLATO 12 个月时的大出血或小出血（主要出血结果）。,0.5517241379310345,"['bleeding', 'myocardial infarction', 'percentage', 'inhibition', 'stroke', 'net', 'defined', 'margin', '2', 'outcome', 'death', 'absolute', 'difference', 'thrombosis', 'minor', 'major', 'adverse', 'primary', 'stent', 'cause', 'clinical', 'patient', 'as', 'with', 'platelet', '-', 'to', 'and', 'two']","['bleeding', 'myocardial infarction', 'inhibition', 'stroke', 'defined', 'margin', '2', 'outcome', 'death', 'absolute', 'thrombosis', 'cause', 'clinical', 'patient', 'platelet', 'two']",279,"['两个主要结果是净不良的临床现象 - 定义为死亡的任何原因, 心脏病发作, 定义的<unk>血病, 发作, 或主要出血 根据定义的基准 Platelet Inhibition 和 病人结果 ( PLATO ) - 在 12 个月( 主要组合结果 ; 测试为 noninferiority, 与 noninferiority 边界为 2 个百分点的绝对差异 ) 和 PLATO 大或小出血 在 12 个月( 主要出血结果 ) 。']",0.4137931034482758,"['bleeding', 'myocardial infarction', 'percentage', 'inhibition', 'stroke', 'net', 'defined', 'margin', '2', 'outcome', 'death', 'absolute', 'difference', 'thrombosis', 'minor', 'major', 'adverse', 'primary', 'stent', 'cause', 'clinical', 'patient', 'as', 'with', 'platelet', '-', 'to', 'and', 'two']","['bleeding', 'stroke', 'margin', '2', 'outcome', 'death', 'absolute', 'difference', 'cause', 'clinical', 'patient', 'two']",,
280,280,"in these patients , dual antiplatelet therapy , consisting of aspirin and a P2Y12 inhibitor , is essential to prevent recurrent thrombotic events such as stent thrombosis.1",在这些患者中，由阿司匹林和 P2Y12 抑制剂组成的双重抗血小板治疗对于预防复发性血栓事件（如支架内血栓形成）至关重要。 1,0.3636363636363636,"['inhibitor', 'aspirin', 'antiplatelet', 'essential', 'thrombotic', 'therapy', 'recurrent', 'stent', 'dual', 'prevent', 'and']","['inhibitor', 'aspirin', 'therapy', 'prevent']",280,"['在这些患者中,由阿司匹林和P2Y12抑制剂组成的双重抗斑疗法至关重要,以防止重复的血管现象,如<unk>血病。']",0.2727272727272727,"['inhibitor', 'aspirin', 'antiplatelet', 'essential', 'thrombotic', 'therapy', 'recurrent', 'stent', 'dual', 'prevent', 'and']","['inhibitor', 'aspirin', 'therapy']",,
281,281,"current guidelines1,2 favor the more potent platelet inhibitors ticagrelor and prasugrel over clopidogrel because these drugs are more effective for the prevention of thrombotic events.3,4","目前的指南 1,2 倾向于使用更有效的血小板抑制剂替格瑞洛和普拉格雷，而不是氯吡格雷，因为这些药物在预防血栓事件方面更有效。 3,4",0.6,"['drugs', 'clopidogrel', 'prevention', 'thrombotic', 'potent', 'current', 'platelet', 'prasugrel', 'over', 'and']","['drugs', 'clopidogrel', 'prevention', 'platelet', 'prasugrel', 'and']",281,"['目前的指南1,2 有利于更强大的平板膜抑制剂 ticagrelor 和 prasugrel 超过 clopidogrel 因为这些药物更有效地预防血管事件。']",0.3,"['drugs', 'clopidogrel', 'prevention', 'thrombotic', 'potent', 'current', 'platelet', 'prasugrel', 'over', 'and']","['drugs', 'prevention', 'over']",,
282,282,"however , this greater efficacy comes with a higher risk of bleeding.3,4","然而，这种更高的疗效伴随着更高的出血风险。 3,4",0.2,"['a', 'risk', 'efficacy', 'with', 'this']",['risk'],282,"['然而,这种更高的有效性伴随着出血的风险更高。']",0.4,"['a', 'risk', 'efficacy', 'with', 'this']","['risk', 'efficacy']",,
283,283,"clopidogrel is a prodrug , transformed into its active metabolite by hepatic cytochrome P450 enzymes .",氯吡格雷是一种前药，通过肝细胞色素P450酶转化为活性代谢物。,0.6,"['cytochrome', 'a', 'metabolite', 'hepatic', 'enzymes', 'clopidogrel', 'active', 'prodrug', 'cytochrome P450', 'by']","['cytochrome', 'metabolite', 'enzymes', 'clopidogrel', 'prodrug', 'cytochrome P450']",283,"['克洛皮多格勒是一种药物,由肝细胞染色素P450酶转化为其活性代谢。']",0.2,"['cytochrome', 'a', 'metabolite', 'hepatic', 'enzymes', 'clopidogrel', 'active', 'prodrug', 'cytochrome P450', 'by']","['enzymes', 'by']",,
284,284,"the active metabolite irreversibly inhibits the P2Y12 receptor on platelets , which results in inhibition of platelet aggregation .",活性代谢物不可逆地抑制血小板上的P2Y12受体，从而抑制血小板聚集。,0.8571428571428571,"['aggregation', 'receptor', 'inhibition', 'metabolite', 'active', 'platelets', 'platelet aggregation']","['aggregation', 'receptor', 'inhibition', 'metabolite', 'platelets', 'platelet aggregation']",284,"['活性代谢物不可逆转地抑制板块上的P2Y12受体,从而抑制板块集成。']",0.4285714285714285,"['aggregation', 'receptor', 'inhibition', 'metabolite', 'active', 'platelets', 'platelet aggregation']","['receptor', 'inhibition', 'metabolite']",,
285,285,neither entity had any role in the design or execution of the trial or in the analysis of the data .,这两个实体都没有参与试验的设计或执行，也没有参与数据分析。,0.5714285714285714,"['data', 'analysis', 'entity', 'role', 'trial', 'design', 'in']","['data', 'analysis', 'entity', 'design']",285,['任何实体都没有在审判的设计或执行或数据分析中发挥任何作用。'],0.8571428571428571,"['data', 'analysis', 'entity', 'role', 'trial', 'design', 'in']","['data', 'analysis', 'entity', 'role', 'trial', 'design']",,
286,286,details of the design have been published previously.13,设计细节之前已经发布。 13,0.5,"['design', 'have']",['design'],286,['该项目的详细信息已公布。13'],0.0,"['design', 'have']",[],,
287,287,the trial was approved by the appropriate ethics committees and national authorities in each country .,该试验得到了每个国家相应的伦理委员会和国家当局的批准。,0.3333333333333333,"['country', 'ethics', 'trial', 'committees', 'each', 'in', 'by', 'and', 'appropriate']","['country', 'committees', 'in']",287,['审判由各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國各國'],0.3333333333333333,"['country', 'ethics', 'trial', 'committees', 'each', 'in', 'by', 'and', 'appropriate']","['trial', 'each', 'by']",,
288,288,"the trial was registered after the enrollment of the first 18 patients , as described in the Supplementary Appendix ( available with the full text of this article at NEJM.org ) .",如补充附录（与本文全文可在 NEJM.org 获取）中所述，该试验在前 18 名患者入组后注册。,0.1428571428571428,"['appendix', 'article', 'supplementary', 'available', 'after', 'trial', 'text', 'as', 'with', 'at', 'full', 'this', 'in', 'first']","['after', 'as']",288,"['试验在注册前18名患者后登记,如附件中所描述(可在NEJM.org上提供本文的完整文本)。']",0.2857142857142857,"['appendix', 'article', 'supplementary', 'available', 'after', 'trial', 'text', 'as', 'with', 'at', 'full', 'this', 'in', 'first']","['appendix', 'after', 'as', 'full']",,
289,289,an independent data and safety monitoring board monitored the trial and had full access to all data .,一个独立的数据和安全监督委员会监督了试验并可以完全访问所有数据。,0.3,"['safety', 'monitoring', 'data', 'access', 'board', 'trial', 'independent', 'full', 'all', 'and']","['safety', 'data', 'independent']",289,"['一个独立的数据和安全监测委员会监测了试验,并完全访问了所有数据。']",0.4,"['safety', 'monitoring', 'data', 'access', 'board', 'trial', 'independent', 'full', 'all', 'and']","['safety', 'monitoring', 'data', 'independent']",,
290,290,"trial monitoring was executed by an external service provider ( Research Drive , Norg , the Netherlands ) .",试验监测由外部服务提供商（Research Drive，Norg，荷兰）执行。,0.2857142857142857,"['monitoring', 'external', 'research', 'service', 'drive', 'trial', 'by']","['monitoring', 'by']",290,"['试验监测由一个外部服务提供商(研究驱动,诺格,荷兰)执行。']",0.5714285714285714,"['monitoring', 'external', 'research', 'service', 'drive', 'trial', 'by']","['monitoring', 'research', 'drive', 'by']",,
291,291,major PROTOCOL REVISION,主要协议修订,0.0,['major'],[],291,['主要议定书审查'],0.0,['major'],[],,
292,292,"patients were eligible for enrollment if they had signs or symptoms of STEMI lasting 30 minutes to 12 hours , underwent primary PCI with stent implantation , and were 21 years of age or older .",如果患者有持续 30 分钟至 12 小时的 STEMI 体征或症状，接受直接 PCI 支架植入术，并且年龄在 21 岁或以上，则患者符合入组条件。,0.2,"['implantation', 'symptoms', 'signs', 'primary', 'stent', 'age', 'with', 'if', 'and', 'eligible']","['implantation', 'age']",292,"['患者有资格登记,如果他们有30分钟至12小时的STEMI的迹象或症状,接受了初级PCI与斯坦特植入,并且年龄为21岁或以上。']",0.2,"['implantation', 'symptoms', 'signs', 'primary', 'stent', 'age', 'with', 'if', 'and', 'eligible']","['implantation', 'age']",,
293,293,exclusion criteria are provided in Table S1 in the Supplementary Appendix .,补充附录表 S1 中提供了排除标准。,0.1666666666666666,"['appendix', 'table', 'supplementary', 'exclusion', 'S1', 'in']",['table'],293,['排除标准在附件 S1 表中列出。'],0.3333333333333333,"['appendix', 'table', 'supplementary', 'exclusion', 'S1', 'in']","['appendix', 'table']",,
294,294,"because patients were asked to participate in the trial during the acute phase of myocardial infarction , many provided only oral informed consent before randomization .",由于要求患者在心肌梗死的急性期参加试验，因此许多患者在随机分组前仅提供了口头知情同意书。,0.7,"['myocardial infarction', 'randomization', 'phase', 'oral', 'trial', 'acute', 'consent', 'informed consent', 'before', 'to']","['myocardial infarction', 'randomization', 'phase', 'acute', 'consent', 'before', 'to']",294,"['由于患者在心脏病发作的急性阶段被要求参加试验,许多患者在随机化之前只提供口头通知的同意。']",0.5,"['myocardial infarction', 'randomization', 'phase', 'oral', 'trial', 'acute', 'consent', 'informed consent', 'before', 'to']","['randomization', 'phase', 'consent', 'before', 'to']",,
295,295,such patients were eligible for the final analysis only if written informed consent was subsequently obtained .,只有随后获得书面知情同意书，此类患者才有资格进行最终分析。,0.4,"['analysis', 'consent', 'informed consent', 'if', 'eligible']","['analysis', 'consent']",295,"['这些患者仅有资格进行最终分析,如果随后获得书面通知的同意。']",0.4,"['analysis', 'consent', 'informed consent', 'if', 'eligible']","['analysis', 'consent']",,
296,296,pretrial TREATMENT,审前治疗,,[],[],296,['初级交易'],,[],[],,
297,297,pretrial antithrombotic treatment was administered according to local protocol .,试验前抗血栓治疗根据当地方案进行。,0.25,"['protocol', 'antithrombotic', 'local', 'treatment']",['treatment'],297,['根据本地议定书进行前列抗血管治疗。'],0.5,"['protocol', 'antithrombotic', 'local', 'treatment']","['protocol', 'treatment']",,8.0
298,298,"this usually consisted of a loading dose of aspirin , a P2Y12 inhibitor , and heparin .",这通常包括负荷剂量的阿司匹林、P2Y12 抑制剂和肝素。,0.5714285714285714,"['loading', 'inhibitor', 'aspirin', 'heparin', 'dose', 'this', 'and']","['inhibitor', 'aspirin', 'heparin', 'dose']",298,['这通常由阿司匹林、P2Y12抑制剂和海帕林的负载剂量组成。'],0.4285714285714285,"['loading', 'inhibitor', 'aspirin', 'heparin', 'dose', 'this', 'and']","['inhibitor', 'aspirin', 'dose']",,10.0
299,299,"other antithrombotic periprocedural therapies were chosen at the discretion of the treating physician , as was the P2Y12 inhibitor administered before randomization .",其他围手术期抗血栓治疗由主治医师自行决定，随机分组前使用的 P2Y12 抑制剂也是如此。,0.8333333333333334,"['inhibitor', 'randomization', 'antithrombotic', 'physician', 'as', 'before']","['inhibitor', 'randomization', 'physician', 'as', 'before']",299,"['其他抗血管周期治疗是在治疗医生的判断下选择的,如在随机化之前服用的P2Y12抑制剂。']",0.8333333333333334,"['inhibitor', 'randomization', 'antithrombotic', 'physician', 'as', 'before']","['inhibitor', 'randomization', 'physician', 'as', 'before']",,10.0
300,300,randomization AND TRIAL PROCEDURES,随机化和试验程序,1.0,['randomization'],['randomization'],300,['随机化和试验程序'],1.0,['randomization'],['randomization'],,
301,301,patients were enrolled during or up to 48 hours after primary PCI .,患者在直接 PCI 期间或之后 48 小时内被纳入。,0.25,"['primary', 'after', 'up', 'to']",['after'],301,['患者在初始 PCI 后 48 小时内或最多注册。'],0.25,"['primary', 'after', 'up', 'to']",['after'],,
302,302,use of the Spartan device began during the course of the trial ; not all hospitals started using it simultaneously .,在试验过程中开始使用 Spartan 设备；并非所有医院都同时开始使用它。,0.5,"['device', 'trial', 'course', 'all']","['device', 'course']",302,"['在试验过程中,斯巴达设备的使用开始;不是所有医院都开始同时使用它。']",0.5,"['device', 'trial', 'course', 'all']","['device', 'course']",,
303,303,details of the logistics of these tests in this trial have been published previously.15,该试验中这些测试的详细信息之前已发表。 15,0.0,"['logistics', 'trial', 'have', 'this', 'in']",[],303,['这些试验的物流细节在此试验中已经公布。'],0.0,"['logistics', 'trial', 'have', 'this', 'in']",[],,
304,304,"if patients switched between P2Y12 inhibitors , the use of a loading dose was at the discretion of the treating physician .",如果患者在 P2Y12 抑制剂之间转换，负荷剂量的使用由主治医师决定。,0.4,"['loading', 'physician', 'at', 'dose', 'if']","['physician', 'dose']",304,"['如果患者在 P2Y12 抑制剂之间交换,则使用充电剂量是治疗医生的判断。']",0.4,"['loading', 'physician', 'at', 'dose', 'if']","['physician', 'dose']",,
305,305,all patients were treated with a P2Y12 inhibitor for at least 1 year after primary PCI .,所有患者在直接 PCI 后均接受了至少 1 年的 P2Y12 抑制剂治疗。,0.4444444444444444,"['inhibitor', 'a', 'year', '1', 'primary', 'after', 'with', 'at', 'all']","['inhibitor', 'year', '1', 'after']",305,"['所有患者都接受了P2Y12抑制剂的治疗,至少在初级PCI之后一年。']",0.4444444444444444,"['inhibitor', 'a', 'year', '1', 'primary', 'after', 'with', 'at', 'all']","['inhibitor', 'year', '1', 'after']",,
306,306,"patients were asked to fill out a questionnaire at 1 month , 6 months , and 12 months after primary PCI .",要求患者在直接 PCI 后 1 个月、6 个月和 12 个月时填写问卷。,0.3333333333333333,"['a', '1', 'month', 'primary', 'after', 'at', 'out', 'to', 'and']","['1', 'month', 'after']",306,['患者被要求在初级PCI后1个月、6个月和12个月内填写问卷。'],0.3333333333333333,"['a', '1', 'month', 'primary', 'after', 'at', 'out', 'to', 'and']","['1', 'month', 'after']",,
307,307,questionnaires were used as an additional source of information .,问卷被用作额外的信息来源。,0.75,"['information', 'additional', 'source', 'as']","['information', 'additional', 'source']",307,['问卷被用作额外的信息来源。'],0.75,"['information', 'additional', 'source', 'as']","['information', 'additional', 'source']",,
308,308,there were two primary outcomes .,有两个主要结果。,0.5,"['primary', 'two']",['two'],308,['有两个主要结果。'],0.5,"['primary', 'two']",['two'],,
309,308,there were two primary outcomes .,有两个主要结果。,0.5,"['primary', 'two']",['two'],308,['有两个主要结果。'],0.5,"['primary', 'two']",['two'],,
310,309,a complete list of secondary thrombotic and bleeding outcomes is provided in Tables S2 and S3 in the Supplementary Appendix .,补充附录表 S2 和表 S3 提供了继发性血栓形成和出血结局的完整列表。,0.0909090909090909,"['bleeding', 'a', 'appendix', 'supplementary', 'thrombotic', 'complete', 'secondary', 'list', 'S2', 'S3', 'and']",['bleeding'],309,['二次血管和出血结果的完整列表在附件中的 S2 和 S3 表中提供。'],0.1818181818181818,"['bleeding', 'a', 'appendix', 'supplementary', 'thrombotic', 'complete', 'secondary', 'list', 'S2', 'S3', 'and']","['bleeding', 'appendix']",,
311,310,fewer patients were needed to show superiority for this outcome .,需要更少的患者来显示该结果的优势。,0.25,"['outcome', 'superiority', 'this', 'to']",['outcome'],310,['需要更少的患者来表现出这种结果的优越性。'],0.5,"['outcome', 'superiority', 'this', 'to']","['outcome', 'superiority']",,
312,311,"accounting for withdrawals and for approximately 200 patients enrolled before the May 2012 protocol amendment , we planned to include 2700 patients .",考虑到退出以及 2012 年 5 月方案修订前入组的大约 200 名患者，我们计划纳入 2700 名患者。,0.1666666666666666,"['protocol', 'approximately', 'before', 'and', 'amendment', 'we']",['before'],311,"['考虑到撤销和在2012年5月议定书修正案之前注册的约200名患者,我们计划包括2700名患者。']",0.5,"['protocol', 'approximately', 'before', 'and', 'amendment', 'we']","['protocol', 'before', 'amendment']",,
313,312,"the end of the primary PCI procedure was defined as time 0 , irrespective of when randomization took place .",主要 PCI 程序的结束定义为时间 0，与随机化发生的时间无关。,0.375,"['procedure', 'defined', 'randomization', 'time', 'primary', 'end', 'irrespective', 'as']","['procedure', 'randomization', 'time']",312,"['初始 PCI 程序的结束被定义为时间 0,无论随机化发生什么时候。']",0.375,"['procedure', 'defined', 'randomization', 'time', 'primary', 'end', 'irrespective', 'as']","['procedure', 'randomization', 'time']",,
314,313,"owing to the logistics of obtaining informed consent , obtaining genotyping results , and ( if necessary ) switching the P2Y12 inhibitor , outcome events during the first 24 hours after primary PCI were excluded from the primary analysis .",由于获得知情同意、获得基因分型结果和（如有必要）更换 P2Y12 抑制剂的后勤工作，直接 PCI 后最初 24 小时内的结果事件被排除在主要分析之外。,0.3846153846153846,"['inhibitor', 'analysis', 'outcome', 'primary', 'necessary', 'logistics', 'after', 'consent', 'informed consent', 'switching', 'if', 'and', 'first']","['inhibitor', 'analysis', 'outcome', 'after', 'consent']",313,"['由于获得已知同意的物流,获得基因组结果,并(如有必要)更换P2Y12抑制剂,在初始PCI后的第一个24小时内的结果事件被排除在初始分析中。']",0.4615384615384615,"['inhibitor', 'analysis', 'outcome', 'primary', 'necessary', 'logistics', 'after', 'consent', 'informed consent', 'switching', 'if', 'and', 'first']","['inhibitor', 'analysis', 'outcome', 'after', 'consent', 'first']",,
315,314,"if noninferiority was confirmed , superiority was assessed .",如果确认非劣效性，则评估优效性。,0.0,"['superiority', 'if', 'assessed']",[],314,['如果不低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于低于'],0.0,"['superiority', 'if', 'assessed']",[],,
316,315,both primary outcomes were also assessed in 26 prespecified subgroups .,两项主要结果也在 26 个预先指定的亚组中进行了评估。,0.0,"['primary', 'in', 'assessed']",[],315,['两项初级结果也被评估在26个预定子组中。'],0.0,"['primary', 'in', 'assessed']",[],,
317,316,two sensitivity analyses were planned .,计划进行两项敏感性分析。,0.5,"['sensitivity', 'two']",['two'],316,['有两次敏感性分析。'],0.5,"['sensitivity', 'two']",['two'],,
318,317,"the first included events during the 24 hours after primary PCI , and the second analysis involved stratification according to center .",第一个包括直接 PCI 后 24 小时内的事件，第二个分析涉及根据中心进行分层。,0.5555555555555556,"['center', 'stratification', 'analysis', 'primary', 'after', 'to center', 'second', 'and', 'first']","['center', 'stratification', 'analysis', 'after', 'first']",317,"['首先包括在初始PCI后的24小时内发生的事件,第二次分析涉及根据中心的分裂。']",0.5555555555555556,"['center', 'stratification', 'analysis', 'primary', 'after', 'to center', 'second', 'and', 'first']","['center', 'analysis', 'after', 'second', 'first']",,
319,318,"confidence intervals for secondary outcomes have not been adjusted for multiple comparisons , and therefore inferences drawn from these intervals may not be reproducible .",次要结果的置信区间尚未针对多重比较进行调整，因此从这些区间得出的推论可能无法重现。,0.125,"['multiple', 'be', 'secondary', 'confidence', 'have not', 'therefore', 'and', 'intervals']",['have not'],318,"['二次结果的信任间隔未适用于多次比较,因此从这些间隔中提取的结论可能无法重复。']",0.125,"['multiple', 'be', 'secondary', 'confidence', 'have not', 'therefore', 'and', 'intervals']",['have not'],,
320,319,"data were analyzed with R software , version 3.6.0 ( R Foundation for Statistical Computing ) .",使用 R 软件 3.6.0 版（R 统计计算基金会）分析数据。,0.4,"['data', 'version', 'software', 'with', 'foundation']","['data', 'software']",319,"['数据被分析使用 R 软件,版本 3.6.0 (R 统计计算基金会) 。']",0.6,"['data', 'version', 'software', 'with', 'foundation']","['data', 'version', 'software']",,
321,320,"from June 2011 through April 2018 , a total of 2751 patients were randomly assigned to a treatment group ( Figure 1 ) .",从 2011 年 6 月到 2018 年 4 月，共有 2751 名患者被随机分配到治疗组（图 1）。,0.5714285714285714,"['group', 'a', '1', 'figure', 'total', 'treatment', 'treatment group']","['group', '1', 'treatment', 'treatment group']",320,"['从2011年6月到2018年4月,共有2751名患者随机分配给治疗小组(图1)。']",0.4285714285714285,"['group', 'a', '1', 'figure', 'total', 'treatment', 'treatment group']","['group', '1', 'treatment']",,
322,321,a screening log was kept at only one center ; the records of those patients screened are shown in Table S4 in the Supplementary Appendix .,只有一个中心保存了筛选日志；这些筛查患者的记录见补充附录表 S4。,0.3333333333333333,"['center', 'a', 'appendix', 'table', 'screening', 'supplementary', 'log', 'at', 'S4']","['center', 'table', 'screening']",321,['扫描日志只保留在一个中心;扫描的患者的记录显示在附件中的表 S4 。'],0.3333333333333333,"['center', 'a', 'appendix', 'table', 'screening', 'supplementary', 'log', 'at', 'S4']","['center', 'appendix', 'table']",,
323,322,"patients who underwent duplicate randomization in error , those who withdrew consent , and those who were enrolled before the protocol amendment of May 2012 were excluded from all analyses .",接受错误重复随机分组的患者、撤回同意的患者以及在 2012 年 5 月方案修订前入组的患者均被排除在所有分析之外。,0.4,"['duplicate', 'randomization', 'who', 'protocol', 'error', 'consent', 'all', 'before', 'in', 'amendment']","['randomization', 'error', 'consent', 'before']",322,['经过双重随机化错误的患者、撤回同意的患者以及在2012年5月的议定书修正案之前注册的患者被排除在所有分析中。'],0.6,"['duplicate', 'randomization', 'who', 'protocol', 'error', 'consent', 'all', 'before', 'in', 'amendment']","['randomization', 'protocol', 'error', 'consent', 'before', 'amendment']",,
324,323,"Table S7 in the Supplementary Appendix provides an overview of the genotype results , and Table S8 provides an overview of the intervals from symptom onset to the time that a patient was receiving the recommended therapy .",补充附录中的表 S7 概述了基因型结果，表 S8 概述了从症状发作到患者接受推荐治疗的时间间隔。,0.4285714285714285,"['a', 'symptom', 'appendix', 'table', 'genotype', 'supplementary', 'time', 'therapy', 'onset', 'patient', 'that', 'in', 'and', 'intervals']","['symptom', 'table', 'genotype', 'time', 'therapy', 'patient']",323,"['附件中的S7表提供了基因组结果的概述,S8表提供了从症状开始到患者接受推荐治疗的时间间隔的概述。']",0.5,"['a', 'symptom', 'appendix', 'table', 'genotype', 'supplementary', 'time', 'therapy', 'onset', 'patient', 'that', 'in', 'and', 'intervals']","['symptom', 'appendix', 'table', 'time', 'therapy', 'onset', 'patient']",,
325,324,Table 3 shows a full list of bleeding outcomes .,表 3 显示了完整的出血结果列表。,0.5,"['bleeding', 'a', 'table', 'list', '3', 'full']","['bleeding', 'table', 'full']",324,['图3显示出出血结果的完整列表。'],0.5,"['bleeding', 'a', 'table', 'list', '3', 'full']","['bleeding', 'table', 'full']",,
326,325,analyses of the primary outcomes were performed in prespecified subgroups .,主要结果的分析在预先指定的亚组中进行。,0.0,"['primary', 'in']",[],325,['初始结果的分析是在预定子组中进行的。'],0.0,"['primary', 'in']",[],,
327,326,there are two key findings from this trial .,该试验有两个关键发现。,0.5,"['key', 'trial', 'this', 'two']","['key', 'two']",326,['这次审判中有两个关键结论。'],0.75,"['key', 'trial', 'this', 'two']","['key', 'trial', 'two']",,
328,327,"we chose to incorporate only major bleeding , which has an effect on morbidity and mortality similar to that of thrombotic outcomes.29",我们选择仅纳入大出血，其对发病率和死亡率的影响与血栓形成结果相似。 29,0.2307692307692307,"['bleeding', 'morbidity', 'thrombotic', 'major', 'mortality', 'incorporate', 'effect', 'on', 'that', 'to', 'and', 'similar', 'we']","['bleeding', 'morbidity', 'mortality']",327,"['我们选择只包含重大出血,这对病率和死亡率产生类似于血管结果的影响。']",0.2307692307692307,"['bleeding', 'morbidity', 'thrombotic', 'major', 'mortality', 'incorporate', 'effect', 'on', 'that', 'to', 'and', 'similar', 'we']","['bleeding', 'mortality', 'to']",,
329,328,"furthermore , although earlier trials consistently showed a lower incidence of minor bleeding with clopidogrel than with prasugrel or ticagrelor , this effect was not seen for major bleeding.3,4,22,28","此外，尽管较早的试验一致表明氯吡格雷的小出血发生率低于普拉格雷或替格瑞洛，但在大出血中未见这种效应。 3,4,22,28",0.4166666666666667,"['bleeding', 'incidence', 'a', 'clopidogrel', 'minor', 'lower', 'major', 'effect', 'with', 'prasugrel', 'this', 'earlier']","['bleeding', 'incidence', 'clopidogrel', 'effect', 'prasugrel']",328,"['除此之外,虽然以前的研究一致表明,与克洛皮多格勒相比,较少的出血的发病率较低,但在主要出血的情况下,这种效果并没有被观察到。']",0.25,"['bleeding', 'incidence', 'a', 'clopidogrel', 'minor', 'lower', 'major', 'effect', 'with', 'prasugrel', 'this', 'earlier']","['bleeding', 'incidence', 'effect']",,
330,329,our data confirm this finding .,我们的数据证实了这一发现。,0.5,"['data', 'this']",['data'],329,['我们的数据证实了这一发现。'],0.5,"['data', 'this']",['data'],,
331,330,"moreover , there are more polymorphisms of the CYP2C19 gene , although most are very rare , 13 that may be associated with increased thrombotic or bleeding risk .",此外，CYP2C19 基因还有更多多态性，尽管大多数非常罕见，13 这可能与血栓形成或出血风险增加有关。,0.375,"['bleeding', 'gene', 'thrombotic', 'be', 'associated', 'risk', 'with', 'that']","['bleeding', 'gene', 'risk']",330,"['此外,有更多的CYP2C19基因的聚合物,虽然大多数是非常罕见的,13可能与增加的血管或出血风险有关。']",0.375,"['bleeding', 'gene', 'thrombotic', 'be', 'associated', 'risk', 'with', 'that']","['bleeding', 'gene', 'risk']",,
332,331,"however , data on these other alleles are conflicting.33",然而，关于这些其他等位基因的数据是相互矛盾的。 33,0.6666666666666666,"['data', 'alleles', 'on']","['data', 'alleles']",331,"['但是,这些其他阿尔及利亚的数据是矛盾的。']",0.3333333333333333,"['data', 'alleles', 'on']",['data'],,
333,332,"therefore , our strategy based solely on the CYP2C19 genotype may not be the most useful strategy for some patients .",因此，我们仅基于 CYP2C19 基因型的策略对于某些患者可能不是最有用的策略。,0.4,"['strategy', 'genotype', 'be', 'on', 'therefore']","['strategy', 'genotype']",332,"['因此,我们的基于CYP2C19基因组的策略可能不是一些患者最有用的策略。']",0.2,"['strategy', 'genotype', 'be', 'on', 'therefore']",['strategy'],,
334,333,the primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes .,主要结果是心力衰竭住院总人数和心血管原因死亡的综合结果。,0.6,"['heart', 'composite', 'cardiovascular', 'failure', 'outcome', 'death', 'total', 'heart failure', 'primary', 'and']","['heart', 'cardiovascular', 'failure', 'outcome', 'death', 'heart failure']",333,['主要结果是心脏失败和心血管原因死亡的整体医院的组成部分。'],0.5,"['heart', 'composite', 'cardiovascular', 'failure', 'outcome', 'death', 'total', 'heart failure', 'primary', 'and']","['heart', 'cardiovascular', 'failure', 'outcome', 'death']",,
335,334,heart failure with preserved ejection fraction is common and is associated with substantial morbidity and mortality.1,射血分数保留的心力衰竭很常见，并且与大量的发病率和死亡率相关。 1,0.4166666666666667,"['heart', 'ejection', 'failure', 'morbidity', 'heart failure', 'common', 'associated', 'fraction', 'with', 'ejection fraction', 'and', 'substantial']","['heart', 'failure', 'morbidity', 'heart failure', 'ejection fraction']",334,"['心脏衰竭与保存的排泄分裂是常见的,并与严重的疾病和死亡率有关。']",0.1666666666666666,"['heart', 'ejection', 'failure', 'morbidity', 'heart failure', 'common', 'associated', 'fraction', 'with', 'ejection fraction', 'and', 'substantial']","['heart', 'failure']",,
336,335,"several physiological mechanisms have been postulated , including myocardial hypertrophy and fibrosis , 2 impaired diastolic compliance and relaxation , 3 subclinical systolic dysfunction , 4 and renal dysfunction leading to elevated intracardiac filling pressures , fluid retention , and exercise intolerance .",已经假设了几种生理机制，包括心肌肥大和纤维化、2 舒张顺应性和松弛受损、3 亚临床收缩功能障碍、4 和肾功能障碍导致心内充盈压升高、体液潴留和运动不耐受。,0.4166666666666667,"['dysfunction', 'relaxation', 'filling', 'hypertrophy', 'intolerance', 'retention', '2', 'fibrosis', 'compliance', 'fluid', 'intracardiac', 'exercise', 'subclinical', 'diastolic', 'renal', 'systolic', 'myocardial', '3', '4', 'physiological', 'impaired', 'leading', 'have', 'and']","['relaxation', 'hypertrophy', 'intolerance', 'retention', '2', 'fibrosis', 'compliance', 'fluid', 'exercise', 'impaired']",335,"['多种生理机制已被推断,包括心血管高血压和纤维,2受损的神经合规和放松,3次临床神经功能障碍,4次和肾功能障碍导致上升的心血管填充压力,液体保持和运动不耐受。']",0.2916666666666667,"['dysfunction', 'relaxation', 'filling', 'hypertrophy', 'intolerance', 'retention', '2', 'fibrosis', 'compliance', 'fluid', 'intracardiac', 'exercise', 'subclinical', 'diastolic', 'renal', 'systolic', 'myocardial', '3', '4', 'physiological', 'impaired', 'leading', 'have', 'and']","['relaxation', 'intolerance', 'retention', '2', 'fluid', 'exercise', 'impaired']",,
337,336,"the steering committee designed and oversaw the conduct of the trial and data analysis , in collaboration with the sponsor , Novartis .",指导委员会与申办方诺华公司合作，设计并监督了试验的实施和数据分析。,0.4,"['data', 'analysis', 'sponsor', 'steering', 'committee', 'trial', 'conduct', 'collaboration', 'with', 'and']","['data', 'analysis', 'committee', 'collaboration']",336,"['管理委员会设计并监督审查和数据分析的进行,与赞助商诺瓦蒂斯合作。']",0.4,"['data', 'analysis', 'sponsor', 'steering', 'committee', 'trial', 'conduct', 'collaboration', 'with', 'and']","['data', 'analysis', 'committee', 'collaboration']",,
338,337,ethics committee approval was provided at each trial center .,每个试验中心都提供了伦理委员会的批准。,0.4285714285714285,"['center', 'approval', 'ethics', 'committee', 'trial', 'at', 'each']","['center', 'approval', 'committee']",337,['伦理委员会批准在每个审判中心提供。'],0.5714285714285714,"['center', 'approval', 'ethics', 'committee', 'trial', 'at', 'each']","['center', 'approval', 'committee', 'trial']",,
339,338,an independent data and safety monitoring committee monitored trial conduct and patient safety .,一个独立的数据和安全监督委员会负责监督试验的实施和患者的安全。,0.5555555555555556,"['safety', 'monitoring', 'data', 'committee', 'patient', 'trial', 'independent', 'conduct', 'and']","['safety', 'data', 'committee', 'patient', 'independent']",338,['一个独立的数据和安全监测委员会监测了试验行为和患者安全。'],0.6666666666666666,"['safety', 'monitoring', 'data', 'committee', 'patient', 'trial', 'independent', 'conduct', 'and']","['safety', 'monitoring', 'data', 'committee', 'patient', 'independent']",,
340,339,"data were collected , managed , and analyzed by the sponsor and corroborated by an independent academic statistician .",数据由申办者收集、管理和分析，并由独立的学术统计学家证实。,0.8,"['data', 'sponsor', 'independent', 'by', 'and']","['data', 'sponsor', 'independent', 'by']",339,"['数据由赞助商收集、管理和分析,并由独立的学术统计学家验证。']",0.6,"['data', 'sponsor', 'independent', 'by', 'and']","['data', 'independent', 'by']",,
341,340,"the first draft of the manuscript was prepared by the first author , who had complete access to the data .",手稿的初稿由第一作者编写，他可以完全访问数据。,0.4,"['data', 'who', 'author', 'access', 'complete', 'manuscript', 'by', 'to', 'first', 'draft']","['data', 'manuscript', 'by', 'first']",340,"['手稿的第一个草案是由第一位作者编写的,他完全访问了数据。']",0.4,"['data', 'who', 'author', 'access', 'complete', 'manuscript', 'by', 'to', 'first', 'draft']","['data', 'manuscript', 'by', 'first']",,
342,341,"all the authors made the decision to submit the manuscript for publication and vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol , available with the full text of this article at NEJM.org .",所有作者都决定投稿发表，并保证数据的准确性和完整性以及试验对方案的忠实度，方案与本文全文可在 NEJM.org 获取。,0.3529411764705882,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'publication', 'available', 'manuscript', 'trial', 'text', 'decision', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'publication', 'decision', 'completeness', 'full']",341,"['所有作者都决定提交手稿,以便出版,以确保数据的准确性和完整性以及审判对议定书的忠诚性,并在NEJM.org上提供本文的完整文本。']",0.5294117647058824,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'publication', 'available', 'manuscript', 'trial', 'text', 'decision', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'protocol', 'publication', 'manuscript', 'trial', 'decision', 'completeness', 'full']",,
343,342,"eligibility requirements at screening included an age of 50 years or older , signs and symptoms of heart failure , NYHA class II to IV , an ejection fraction of 45 % or higher within the previous 6 months , elevated level of natriuretic peptides ( with different cutoffs depending on the occurrence of recent hospitalization for heart failure and the presence of atrial fibrillation or flutter ) , evidence of structural heart disease , and diuretic therapy .",筛选的资格要求包括年龄 50 岁或以上，心力衰竭的体征和症状，NYHA II 至 IV 级，射血分数在过去 6 个月内为 45 % 或更高，钠尿肽水平升高（不同的截止值取决于关于最近因心力衰竭住院的发生和心房颤动或扑动的存在）、结构性心脏病的证据和利尿剂治疗。,0.6774193548387096,"['atrial', 'presence', 'heart', 'disease', 'diuretic', 'ejection', 'class', 'failure', 'recent', 'heart disease', 'screening', 'occurrence', 'previous', 'fibrillation', 'symptoms', 'hospitalization', 'therapy', 'heart failure', 'signs', 'atrial fibrillation', 'structural', 'age', 'flutter', 'fraction', 'level', 'evidence', 'with', 'IV', 'ejection fraction', 'and', 'natriuretic']","['presence', 'heart', 'disease', 'diuretic', 'class', 'failure', 'heart disease', 'screening', 'occurrence', 'fibrillation', 'hospitalization', 'therapy', 'heart failure', 'atrial fibrillation', 'structural', 'age', 'flutter', 'level', 'evidence', 'ejection fraction', 'natriuretic']",342,"['筛查资格要求包括50岁及以上的年龄,心脏衰竭的迹象和症状,NYHA II 至 IV 类,在过去 6 个月内排泄率为 45% 或更高,<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>酸<unk>']",0.1290322580645161,"['atrial', 'presence', 'heart', 'disease', 'diuretic', 'ejection', 'class', 'failure', 'recent', 'heart disease', 'screening', 'occurrence', 'previous', 'fibrillation', 'symptoms', 'hospitalization', 'therapy', 'heart failure', 'signs', 'atrial fibrillation', 'structural', 'age', 'flutter', 'fraction', 'level', 'evidence', 'with', 'IV', 'ejection fraction', 'and', 'natriuretic']","['heart', 'failure', 'screening', 'age']",,
344,343,"detailed inclusion and exclusion criteria are provided in Table S1 in the Supplementary Appendix , available at NEJM.org .",补充附录表 S1 中提供了详细的纳入和排除标准，补充附录可在 NEJM.org 获取。,0.1111111111111111,"['appendix', 'table', 'inclusion', 'supplementary', 'exclusion', 'available', 'at', 'S1', 'and']",['table'],343,"['详细的包含和排除标准在附加附件中的表 S1 中提供,可在NEJM.org上找到。']",0.3333333333333333,"['appendix', 'table', 'inclusion', 'supplementary', 'exclusion', 'available', 'at', 'S1', 'and']","['appendix', 'table', 'inclusion']",,
345,344,patients were evaluated at trial visits every 4 to 16 weeks .,每 4 至 16 周在试诊时对患者进行评估。,0.0,"['trial', '4', 'at', 'to']",[],344,['患者每4至16周进行试验访问。'],0.0,"['trial', '4', 'at', 'to']",[],,
346,345,the dose of the trial drugs could be adjusted down if the target dose led to unacceptable side effects .,如果目标剂量导致不可接受的副作用，则可以下调试验药物的剂量。,0.4545454545454545,"['down', 'drugs', 'side effects', 'be', 'target', 'trial', 'unacceptable', 'dose', 'if', 'to', 'led']","['drugs', 'side effects', 'target', 'unacceptable', 'dose']",345,"['测试药物的剂量可以调整,如果目标剂量导致不可接受的副作用。']",0.4545454545454545,"['down', 'drugs', 'side effects', 'be', 'target', 'trial', 'unacceptable', 'dose', 'if', 'to', 'led']","['drugs', 'side effects', 'target', 'unacceptable', 'dose']",,
347,346,the primary outcome was a composite of total ( first and recurrent ) hospitalizations for heart failure and death from cardiovascular causes .,主要结果是因心力衰竭住院总（首次和复发）和心血管原因死亡的综合结果。,0.5,"['heart', 'composite', 'cardiovascular', 'failure', 'outcome', 'death', 'total', 'heart failure', 'recurrent', 'primary', 'and', 'first']","['heart', 'cardiovascular', 'failure', 'outcome', 'death', 'heart failure']",346,['初始结果是心脏衰竭和心血管原因死亡的总体(第一和重复)医院的组成。'],0.5,"['heart', 'composite', 'cardiovascular', 'failure', 'outcome', 'death', 'total', 'heart failure', 'recurrent', 'primary', 'and', 'first']","['heart', 'cardiovascular', 'failure', 'outcome', 'death', 'first']",,
348,347,all the outcomes except KCCQ score and NYHA class were blindly adjudicated according to prespecified criteria ( Section 5 in the Supplementary Appendix ) .,除 KCCQ 评分和 NYHA 分级外，所有结果均根据预先指定的标准（补充附录第 5 部分）进行盲法判定。,0.2,"['5', 'class', 'appendix', 'section', 'supplementary', 'score', 'all', 'in', 'to', 'and']","['5', 'class']",347,"['除 KCCQ 分数和 NYHA 等级外,所有结果都按预定标准(附件第 5 节)进行盲目评估。']",0.4,"['5', 'class', 'appendix', 'section', 'supplementary', 'score', 'all', 'in', 'to', 'and']","['5', 'class', 'appendix', 'score']",,
349,348,"hypotension , renal dysfunction , hyperkalemia , and angioedema were prespecified adverse events of interest ; angioedema was adjudicated by a separate committee .",低血压、肾功能不全、高钾血症和血管性水肿是预先指定的不良事件；血管性水肿由一个单独的委员会裁定。,0.4,"['dysfunction', 'a', 'hypotension', 'adverse', 'hyperkalemia', 'renal', 'committee', 'separate', 'by', 'and']","['hypotension', 'hyperkalemia', 'committee', 'by']",348,['低血压、肾功能障碍、高血压和腹泻被预定为有兴趣的负面事件;腹泻由一个单独的委员会提交。'],0.3,"['dysfunction', 'a', 'hypotension', 'adverse', 'hyperkalemia', 'renal', 'committee', 'separate', 'by', 'and']","['hypotension', 'committee', 'by']",,
350,349,the primary efficacy outcome was evaluated with the use of the semiparametric proportional rates method of Lin et al.13 and a joint gamma frailty model14 stratified according to geographic region .,使用 Lin 等人 13 的半参数比例率方法和根据地理区域分层的联合伽玛衰弱模型 14 评估了主要疗效结果。,0.3333333333333333,"['a', 'joint', 'outcome', 'region', 'primary', 'gamma', 'geographic', 'efficacy', 'method', 'with', 'to', 'and']","['joint', 'outcome', 'region', 'gamma']",349,['初级效能结果通过使用Lin et al.13的半参数比例率方法和根据地理区域分布的组合Gamma frailty模型14进行评估。'],0.25,"['a', 'joint', 'outcome', 'region', 'primary', 'gamma', 'geographic', 'efficacy', 'method', 'with', 'to', 'and']","['outcome', 'region', 'efficacy']",,
351,350,"there was one interim analysis , with an adjusted alpha level of 0.048 for the final analysis .",有一项中期分析，最终分析的调整后 alpha 水平为 0.048。,0.5,"['analysis', 'alpha', 'level', 'with']","['analysis', 'level']",350,"['有一个临时分析,最终分析的调整阿尔法水平为0.048。']",0.5,"['analysis', 'alpha', 'level', 'with']","['analysis', 'level']",,
352,351,we assessed the consistency of the treatment effect among 12 prespecified subgroups that were analyzed individually and then in a multivariable model .,我们评估了 12 个预先指定的亚组的治疗效果的一致性，这些亚组分别进行了分析，然后在多变量模型中进行了分析。,0.4545454545454545,"['a', 'model', 'consistency', 'treatment', 'effect', 'treatment effect', 'that', 'in', 'and', 'assessed', 'we']","['model', 'consistency', 'treatment', 'effect', 'treatment effect']",351,"['我们评估了12个预定子组中的治疗效果的一致性,这些子组单独分析,然后在多样化的模型中进行分析。']",0.4545454545454545,"['a', 'model', 'consistency', 'treatment', 'effect', 'treatment effect', 'that', 'in', 'and', 'assessed', 'we']","['model', 'consistency', 'treatment', 'effect', 'treatment effect']",,
353,352,"if the primary outcome reached significance , a hierarchical , sequentially rejective procedure was planned for the analysis of secondary efficacy outcomes , with the alpha level split equally between KCCQ score and NYHA class , followed by the renal composite outcome .",如果主要结果达到显着性，则计划采用分层、顺序拒绝程序来分析次要疗效结果，α 水平在 KCCQ 评分和 NYHA 分级之间平均分配，然后是肾脏综合结果。,0.3333333333333333,"['composite', 'a', 'procedure', 'class', 'analysis', 'outcome', 'alpha', 'primary', 'renal', 'significance', 'secondary', 'efficacy', 'score', 'level', 'with', 'split', 'by', 'and']","['procedure', 'class', 'analysis', 'outcome', 'alpha', 'level']",352,"['如果初始结果取得了意义,则为分析二进制效率结果进行了序列拒绝程序,阿尔法级别在KCCQ分数和NYHA级别之间均匀分裂,随后由肾合成结果进行。']",0.3888888888888889,"['composite', 'a', 'procedure', 'class', 'analysis', 'outcome', 'alpha', 'primary', 'renal', 'significance', 'secondary', 'efficacy', 'score', 'level', 'with', 'split', 'by', 'and']","['procedure', 'class', 'analysis', 'outcome', 'significance', 'score', 'by']",,
354,353,"confidence intervals for the secondary and exploratory efficacy outcomes have not been adjusted for multiplicity , and therefore inferences drawn from these intervals may not be reproducible .",次要和探索性疗效结果的置信区间尚未针对多重性进行调整，因此从这些区间得出的推论可能无法重现。,0.2,"['be', 'exploratory', 'secondary', 'efficacy', 'multiplicity', 'confidence', 'have not', 'therefore', 'and', 'intervals']","['multiplicity', 'have not']",353,"['二级和探测效能结果的信任间隔未被调整为多样性,因此从这些间隔中提取的结论可能无法重复。']",0.3,"['be', 'exploratory', 'secondary', 'efficacy', 'multiplicity', 'confidence', 'have not', 'therefore', 'and', 'intervals']","['exploratory', 'efficacy', 'have not']",,
355,354,additional information regarding the statistical analysis is provided in the Supplementary Appendix .,补充附录中提供了有关统计分析的更多信息。,0.5714285714285714,"['appendix', 'analysis', 'supplementary', 'regarding', 'information', 'additional', 'statistical analysis']","['analysis', 'regarding', 'information', 'statistical analysis']",354,['有关统计分析的详细信息在附件中提供。'],0.7142857142857143,"['appendix', 'analysis', 'supplementary', 'regarding', 'information', 'additional', 'statistical analysis']","['appendix', 'analysis', 'regarding', 'information', 'statistical analysis']",,
356,355,"from July 18 , 2014 , through December 16 , 2016 , we screened 10,359 patients at 848 centers in 43 countries ( Figure 1 ) .","从 2014 年 7 月 18 日到 2016 年 12 月 16 日，我们在 43 个国家/地区的 848 个中心对 10,359 名患者进行了筛查（图 1）。",0.2,"['1', 'figure', 'at', 'in', 'we']",['1'],355,"['从2014年7月18日至2016年12月16日,我们在43个国家的848个中心检查了10359名患者(图1)。']",0.2,"['1', 'figure', 'at', 'in', 'we']",['1'],,
357,356,"a total of 26 patients were excluded from all efficacy analyses because they had been enrolled at a site that was closed for major violations of Good Clinical Practice , so 4796 patients were included in the efficacy analysis .",共有 26 名患者被排除在所有疗效分析之外，因为他们入组的地点因严重违反良好临床实践而关闭，因此 4796 名患者被纳入疗效分析。,0.1666666666666666,"['a', 'site', 'analysis', 'good clinical practice', 'total', 'major', 'efficacy', 'at', 'closed', 'all', 'that', 'so']","['site', 'analysis']",356,"['总共有26名患者被排除在所有有效性分析中,因为他们被注册在一个被关闭严重违反良好的临床实践的网站上,因此4796名患者被列入有效性分析中。']",0.1666666666666666,"['a', 'site', 'analysis', 'good clinical practice', 'total', 'major', 'efficacy', 'at', 'closed', 'all', 'that', 'so']","['analysis', 'efficacy']",,
358,357,"because this difference did not meet the predetermined level of statistical significance , subsequent analyses were considered to be exploratory .",由于这种差异没有达到预定的统计显着性水平，因此后续分析被认为是探索性的。,0.375,"['difference', 'be', 'exploratory', 'significance', 'subsequent', 'statistical significance', 'level', 'this']","['difference', 'level', 'this']",357,"['由于这种差异不符合预定水平的统计意义,后来的分析被认为是探索性的。']",0.5,"['difference', 'be', 'exploratory', 'significance', 'subsequent', 'statistical significance', 'level', 'this']","['difference', 'significance', 'level', 'this']",,
359,358,components of the primary outcome are shown in Table 2 .,表 2 显示了主要结果的组成部分。,0.6,"['table', '2', 'outcome', 'primary', 'in']","['table', '2', 'outcome']",358,['主要结果的组成部分在图2中显示。'],0.4,"['table', '2', 'outcome', 'primary', 'in']","['2', 'outcome']",,
360,359,the prespecified sensitivity analyses of the primary outcome are shown in Tables S2 and S3 in the Supplementary Appendix .,主要结局的预设敏感性分析见补充附录表 S2 和表 S3。,0.0,"['appendix', 'outcome', 'supplementary', 'primary', 'sensitivity', 'S2', 'S3', 'in', 'and']",[],359,['初始结果的预定敏感性分析在附件中的 S2 和 S3 表中显示。'],0.2222222222222222,"['appendix', 'outcome', 'supplementary', 'primary', 'sensitivity', 'S2', 'S3', 'in', 'and']","['appendix', 'outcome']",,
361,360,the primary outcome in the 12 prespecified subgroups is shown in Figure 3 .,12 个预设亚组的主要结果如图 3 所示。,0.2,"['outcome', 'figure', 'primary', '3', 'in']",['outcome'],360,['预定12个子组的主要结果显示在图3中。'],0.2,"['outcome', 'figure', 'primary', '3', 'in']",['outcome'],,
362,361,"in a multivariable model that accounted for all potential interactions and that used continuous measures when appropriate , there was suggestion of heterogeneity of treatment effect with possible benefit in patients with lower ejection fraction and in women ( Table S4 in the Supplementary Appendix ) .",在一个考虑了所有潜在相互作用并在适当时使用连续测量的多变量模型中，表明治疗效果的异质性可能对射血分数较低的患者和女性有益（补充附录表 S4）。,0.391304347826087,"['suggestion', 'a', 'heterogeneity', 'ejection', 'appendix', 'model', 'table', 'potential', 'continuous', 'supplementary', 'lower', 'treatment', 'fraction', 'effect', 'treatment effect', 'benefit', 'with', 'ejection fraction', 'S4', 'all', 'that', 'and', 'appropriate']","['heterogeneity', 'model', 'table', 'continuous', 'lower', 'treatment', 'effect', 'treatment effect', 'ejection fraction']",361,"['在多样化的模型中,考虑到所有可能的相互作用,并在适当情况下使用持续的措施,在患有较低排泄分的患者和妇女中提出了可能有益的治疗效果的异常性(附件中的S4表)。']",0.3043478260869565,"['suggestion', 'a', 'heterogeneity', 'ejection', 'appendix', 'model', 'table', 'potential', 'continuous', 'supplementary', 'lower', 'treatment', 'fraction', 'effect', 'treatment effect', 'benefit', 'with', 'ejection fraction', 'S4', 'all', 'that', 'and', 'appropriate']","['suggestion', 'appendix', 'model', 'table', 'treatment', 'effect', 'treatment effect']",,
363,362,"the most frequent serious adverse events and adverse events are summarized in Tables S5 and S6 , respectively , in the Supplementary Appendix .",补充附录的表 S5 和表 S6 分别总结了最常见的严重不良事件和不良事件。,0.0,"['appendix', 'supplementary', 'adverse', 'serious', 'in', 'frequent', 'and']",[],362,"['最常见的严重不良事件和不良事件在表 S5 和 S6,分别,在附件中总结。']",0.1428571428571428,"['appendix', 'supplementary', 'adverse', 'serious', 'in', 'frequent', 'and']",['appendix'],,
364,363,the primary composite outcome of total hospitalizations for heart failure and death from cardiovascular causes did not differ significantly between the two groups .,两组因心力衰竭住院总人数和心血管原因死亡的主要复合结局没有显着差异。,0.5,"['heart', 'composite', 'cardiovascular', 'failure', 'outcome', 'death', 'total', 'heart failure', 'primary', 'differ', 'and', 'two']","['heart', 'cardiovascular', 'failure', 'death', 'heart failure', 'two']",363,['心脏衰竭和心血管原因死亡的总入院的主要组成结果在两组之间没有显著的差异。'],0.5,"['heart', 'composite', 'cardiovascular', 'failure', 'outcome', 'death', 'total', 'heart failure', 'primary', 'differ', 'and', 'two']","['heart', 'cardiovascular', 'failure', 'outcome', 'death', 'two']",,
365,364,the findings from nine prespecified supportive and sensitivity analyses were consistent with those from the primary analysis .,九项预先指定的支持性和敏感性分析的结果与主要分析的结果一致。,0.2,"['analysis', 'primary', 'with', 'sensitivity', 'and']",['analysis'],364,['9个预定支持和敏感性分析的结果与初始分析的结果一致。'],0.2,"['analysis', 'primary', 'with', 'sensitivity', 'and']",['analysis'],,
366,365,"patients with heart failure and preserved ejection fraction are phenotypically heterogeneous , 15 and our data raise the possibility of a differential treatment effect in the broad population studied .",心力衰竭和射血分数保留的患者在表型上是异质的， 15 并且我们的数据提高了在所研究的广泛人群中存在差异治疗效果的可能性。,0.6111111111111112,"['heart', 'population', 'differential', 'ejection', 'failure', 'data', 'heterogeneous', 'raise', 'heart failure', 'broad', 'treatment', 'fraction', 'effect', 'treatment effect', 'with', 'ejection fraction', 'in', 'and']","['heart', 'population', 'failure', 'data', 'heterogeneous', 'raise', 'heart failure', 'treatment', 'effect', 'treatment effect', 'ejection fraction']",365,"['患有心脏衰竭和保存的排泄分裂的患者是异常的,15和我们的数据提高了对广泛研究的人口的差异治疗效果的可能性。']",0.4444444444444444,"['heart', 'population', 'differential', 'ejection', 'failure', 'data', 'heterogeneous', 'raise', 'heart failure', 'broad', 'treatment', 'fraction', 'effect', 'treatment effect', 'with', 'ejection fraction', 'in', 'and']","['heart', 'population', 'failure', 'data', 'raise', 'treatment', 'effect', 'treatment effect']",,
367,366,"other diseases , such as amyloid cardiomyopathy , may account for the reduced responsiveness with higher ejection fraction.21",其他疾病，如淀粉样变性心肌病，可能是射血分数较高时反应性降低的原因。 21,0.3333333333333333,"['ejection', 'amyloid', 'cardiomyopathy', 'responsiveness', 'as', 'with']","['cardiomyopathy', 'as']",366,"['其他疾病,如甲状腺心脏病,可能导致低反应性与更高的排泄分裂。']",0.1666666666666666,"['ejection', 'amyloid', 'cardiomyopathy', 'responsiveness', 'as', 'with']",['as'],,
368,367,survival was superior in patients with microsatellite instability versus microsatellite stability .,微卫星不稳定性患者的生存率优于微卫星稳定性患者。,0.5,"['survival', 'superior', 'instability', 'with']","['survival', 'instability']",367,['生存率在微型卫星不稳定性患者比微型卫星稳定性患者更好。'],0.5,"['survival', 'superior', 'instability', 'with']","['survival', 'instability']",,
369,368,microsatellite instability ( MSI ) is a favorable prognostic marker but is present in less than 10 % of gastric cancers .,微卫星不稳定性 (MSI) 是一种有利的预后标志物，但存在于不到 10% 的胃癌中。,0.2857142857142857,"['a', 'gastric', 'marker', 'prognostic', 'present', 'instability', 'but']","['instability', 'but']",368,"['微卫星不稳定性(MSI)是一种有利的预测标志,但在胃癌中存在不到10%。']",0.4285714285714285,"['a', 'gastric', 'marker', 'prognostic', 'present', 'instability', 'but']","['prognostic', 'instability', 'but']",,
370,369,"given the uncommon presence of MSI , its impact on the outcome of adjuvant therapy in locally advanced gastric cancer has not been clearly defined .",鉴于 MSI 并不常见，其对局部晚期胃癌辅助治疗结果的影响尚未明确。,0.4166666666666667,"['presence', 'cancer', 'gastric', 'defined', 'outcome', 'adjuvant', 'therapy', 'impact', 'adjuvant therapy', 'advanced', 'gastric cancer', 'on']","['cancer', 'outcome', 'therapy', 'impact', 'gastric cancer']",369,"['鉴于MSI的异常存在,其对当地先进胃癌补充治疗结果的影响尚未清楚地定义。']",0.5,"['presence', 'cancer', 'gastric', 'defined', 'outcome', 'adjuvant', 'therapy', 'impact', 'adjuvant therapy', 'advanced', 'gastric cancer', 'on']","['presence', 'cancer', 'outcome', 'therapy', 'impact', 'gastric cancer']",,
371,370,MSI status was available from 1556 patients ( 71 % men ; 63 % Asian ; 37 % European ) .,MSI 状态可从 1556 名患者（71% 男性；63% 亚洲人；37% 欧洲人）获得。,0.5,"['status', 'available']",['status'],370,['MSI状态可用于1556名患者(71%男性、63%亚洲人、37%欧洲人)。'],0.5,"['status', 'available']",['status'],,
372,371,MSI was present in 121 ( 7.8 % ) of patients .,121 名 (7.8%) 患者存在 MSI。,0.0,"['present', 'in']",[],371,['MSI在121(7.8%)的患者中存在。'],0.0,"['present', 'in']",[],,
373,372,"of all patients , 45 % had intestinal histology , 71 % underwent surgery and chemotherapy with or without radiation therapy , and 29 % underwent surgery alone .",在所有患者中，45% 有肠道组织学，71% 接受过手术和化疗，有或没有放疗，29% 只接受过手术。,0.2,"['chemotherapy', 'radiation', 'surgery', 'radiation therapy', 'with', 'histology', 'all', 'and', 'alone', 'without']","['chemotherapy', 'surgery']",372,"['在所有患者中,45%患有肠道歇斯托利,71%接受手术和化疗,放射治疗或没有,29%单独接受手术。']",0.4,"['chemotherapy', 'radiation', 'surgery', 'radiation therapy', 'with', 'histology', 'all', 'and', 'alone', 'without']","['chemotherapy', 'radiation', 'surgery', 'alone']",,
374,373,"a benefit for chemotherapy added to surgery was seen in MSS patients compared with MSI patients ( DFS , 77 % vs. 70 % ; OS , 83 % vs , 75 % ) , suggesting a potential survival detriment for chemotherapy in MSI patients .",与 MSI 患者相比，在 MSS 患者中观察到手术联合化疗的获益（DFS，77% 对 70%；OS，83% 对 75%），这表明 MSI 患者化疗可能对生存不利。,0.4444444444444444,"['chemotherapy', 'survival', 'potential', 'surgery', 'detriment', 'benefit', 'with', 'in', 'to']","['chemotherapy', 'survival', 'surgery', 'benefit']",373,"['与 MSI 患者相比,MSS 患者(DFS,77% vs.70%;OS,83% vs.75%)对手术添加的化疗有好处,这表明MSI 患者对化疗有潜在的生存损害。']",0.4444444444444444,"['chemotherapy', 'survival', 'potential', 'surgery', 'detriment', 'benefit', 'with', 'in', 'to']","['chemotherapy', 'survival', 'potential', 'surgery']",,
375,374,there was no difference in survival after recurrence for MSI or MSS cancers .,MSI 或 MSS 癌症复发后的生存率没有差异。,0.5,"['survival', 'difference', 'no', 'after', 'recurrence', 'in']","['survival', 'difference', 'after']",374,['在 MSI 或 MSS 癌症重复后生存中没有差异。'],0.5,"['survival', 'difference', 'no', 'after', 'recurrence', 'in']","['survival', 'difference', 'after']",,
376,375,"MSI should now be tested in all patients with locally advanced gastric cancer who are considered for adjuvant chemotherapy , and surgery alone should be considered for MSI patients .",现在应该对所有考虑接受辅助化疗的局部晚期胃癌患者进行 MSI 检测，并且应该考虑对 MSI 患者进行单纯手术。,0.3571428571428571,"['chemotherapy', 'cancer', 'gastric', 'who', 'adjuvant', 'surgery', 'be', 'advanced', 'with', 'gastric cancer', 'all', 'in', 'and', 'alone']","['chemotherapy', 'cancer', 'surgery', 'be', 'gastric cancer']",375,"['MSI 现在应在所有被视为辅助化疗的本地先进胃癌患者进行测试,而单独的手术应被视为 MSI 患者。']",0.5,"['chemotherapy', 'cancer', 'gastric', 'who', 'adjuvant', 'surgery', 'be', 'advanced', 'with', 'gastric cancer', 'all', 'in', 'and', 'alone']","['chemotherapy', 'cancer', 'surgery', 'be', 'gastric cancer', 'and', 'alone']",,
377,376,"pregnancy can be considered a physiologic stress test ; as such , it could have value for cardiovascular ( CV ) risk prediction .",怀孕可以被认为是一种生理压力测试；因此，它可能对心血管 (CV) 风险预测具有价值。,0.7,"['pregnancy', 'cardiovascular', 'test', 'value', 'stress', 'be', 'risk', 'stress test', 'physiologic', 'have']","['pregnancy', 'cardiovascular', 'value', 'stress', 'risk', 'stress test', 'have']",376,"['怀孕可以被视为生理压力测试;因此,它可能对心血管(CV)风险预测有价值。']",0.7,"['pregnancy', 'cardiovascular', 'test', 'value', 'stress', 'be', 'risk', 'stress test', 'physiologic', 'have']","['pregnancy', 'cardiovascular', 'value', 'stress', 'risk', 'stress test', 'have']",,
378,377,monitor blood pressure per the most recent American Heart Association guidelines,根据最新的美国心脏协会指南监测血压,0.2857142857142857,"['heart', 'pressure', 'monitor', 'recent', 'association', 'blood', 'blood pressure']","['heart', 'blood pressure']",377,['根据美国心脏协会最新指南监测血压'],0.2857142857142857,"['heart', 'pressure', 'monitor', 'recent', 'association', 'blood', 'blood pressure']","['heart', 'blood pressure']",,
379,378,promote healthy lifestyle and weight,促进健康的生活方式和体重,0.6666666666666666,"['weight', 'and', 'healthy']","['weight', 'healthy']",378,['促进健康的生活方式和体重'],0.6666666666666666,"['weight', 'and', 'healthy']","['weight', 'healthy']",,
380,379,"assess lipid profiles and fasting glucose levels , with lifestyle modification if abnormal , followed by medication management as appropriate",评估血脂和空腹血糖水平，如果异常则改变生活方式，然后酌情进行药物管理,0.25,"['modification', 'glucose', 'lipid', 'abnormal', 'medication', 'fasting', 'assess', 'management', 'with', 'by', 'and', 'appropriate']","['abnormal', 'assess', 'management']",379,"['评估脂肪配置和禁食糖水平,如果不正常的话,生活方式的变化,随后适当的药物管理。']",0.1666666666666666,"['modification', 'glucose', 'lipid', 'abnormal', 'medication', 'fasting', 'assess', 'management', 'with', 'by', 'and', 'appropriate']","['assess', 'management']",,
381,380,perform oral glucose tolerance testing for women with histories of gestational diabetes,对有妊娠糖尿病病史的妇女进行口服葡萄糖耐量试验,0.2857142857142857,"['diabetes', 'glucose', 'oral', 'tolerance', 'gestational', 'testing', 'with']","['diabetes', 'glucose']",380,['在怀孕糖尿病史的妇女进行口服葡萄糖容忍测试'],0.4285714285714285,"['diabetes', 'glucose', 'oral', 'tolerance', 'gestational', 'testing', 'with']","['diabetes', 'glucose', 'tolerance']",,
382,381,"apply postpartum screening practices from multiple disciplines ( i.e. , obstetrics , maternal fetal medicine , primary care , cardiology , nutrition , exercise physiology )",应用来自多个学科的产后筛查实践（即产科、母胎医学、初级保健、心脏病学、营养学、运动生理学）,0.6666666666666666,"['maternal', 'physiology', 'nutrition', 'medicine', 'screening', 'fetal', 'exercise', 'multiple', 'obstetrics', 'primary', 'postpartum', 'cardiology', 'apply', 'care', 'exercise physiology']","['maternal', 'physiology', 'nutrition', 'medicine', 'screening', 'exercise', 'obstetrics', 'postpartum', 'cardiology', 'apply']",381,"['应用来自多学科的产后筛查实践(即,生育学,母胎医学,初级护理,心脏学,营养学,锻炼生理学)']",0.6,"['maternal', 'physiology', 'nutrition', 'medicine', 'screening', 'fetal', 'exercise', 'multiple', 'obstetrics', 'primary', 'postpartum', 'cardiology', 'apply', 'care', 'exercise physiology']","['maternal', 'physiology', 'nutrition', 'medicine', 'screening', 'exercise', 'postpartum', 'cardiology', 'apply']",,
383,382,"although CV disease is the leading cause of death among U.S. women , risk factors often are modifiable .",尽管心血管疾病是美国女性死亡的主要原因，但风险因素通常是可以改变的。,0.6666666666666666,"['disease', 'death', 'cause', 'risk', 'cause of death', 'leading']","['disease', 'death', 'cause', 'risk']",382,"['虽然CV疾病是美国妇女死亡的主要原因,但风险因素往往是可改变的。']",0.6666666666666666,"['disease', 'death', 'cause', 'risk', 'cause of death', 'leading']","['disease', 'death', 'cause', 'risk']",,
384,383,"however , spironolactone causes hyperkalemia - and thus is relatively contraindicated - in patients with renal dysfunction .",然而，螺内酯会引起高钾血症，因此在肾功能不全的患者中是相对禁忌的。,0.5,"['dysfunction', 'contraindicated', 'hyperkalemia', 'renal', 'thus', 'with', '-', 'and']","['contraindicated', 'hyperkalemia', 'thus', 'and']",383,"['然而,Spironolactone在患有肾功能障碍的患者中会导致高血压 - 因此相对应。']",0.25,"['dysfunction', 'contraindicated', 'hyperkalemia', 'renal', 'thus', 'with', '-', 'and']","['thus', 'and']",,
385,384,the primary endpoint - the proportion of patients still taking spironolactone at 12 weeks - occurred significantly more frequently with patiromer than with placebo ( 86 % vs. 66 % ) .,主要终点——12 周时仍在服用螺内酯的患者比例——在 patiromer 组中发生的频率明显高于安慰剂组（86% 对 66%）。,0.3,"['proportion', 'placebo', 'taking', 'frequently', 'still', 'primary', 'with', 'endpoint', 'at', '-']","['proportion', 'placebo', 'at']",384,['初级终点 - 患者在12周内仍然服用Spironolactone的比例 - 与Pirodomer相比显著更频繁(86%与66%)。'],0.1,"['proportion', 'placebo', 'taking', 'frequently', 'still', 'primary', 'with', 'endpoint', 'at', '-']",['proportion'],,
386,385,"spironolactone was stopped due to hyperkalemia ( persistent potassium level , ≥ 5.5 mmol / L ) less frequently with patiromer than with placebo ( 7 % vs. 23 % ) .",螺内酯因高钾血症（持续钾水平，≥ 5.5 mmol/L）而停药的频率低于安慰剂组（7% 对 23%）。,0.5,"['persistent', 'placebo', 'potassium', '/', 'frequently', 'hyperkalemia', 'level', 'due', 'with', 'to']","['placebo', 'potassium', 'hyperkalemia', 'level', 'to']",385,"['spironolactone 因高<unk>症(持久的<unk>含量 ≥ 5.5 mmol / L )而被停止,比Pirodomer更少(7 % vs. 23 % )。']",0.0,"['persistent', 'placebo', 'potassium', '/', 'frequently', 'hyperkalemia', 'level', 'due', 'with', 'to']",[],,
387,386,mean systolic blood pressure decreased by about 11 mm Hg during the study .,研究期间平均收缩压降低了约 11 毫米汞柱。,0.1428571428571428,"['pressure', 'mean', 'blood', 'study', 'blood pressure', 'systolic', 'by']",['mean'],386,['研究期间平均血压下降约11毫米Hg。'],0.2857142857142857,"['pressure', 'mean', 'blood', 'study', 'blood pressure', 'systolic', 'by']","['mean', 'blood pressure']",,
388,387,these results indicate that patiromer could facilitate spironolactone use in some patients with resistant hypertension and CKD .,这些结果表明，patiromer 可以促进某些顽固性高血压和 CKD 患者使用螺内酯。,0.1666666666666666,"['hypertension', 'indicate', 'resistant', 'with', 'that', 'and']",['hypertension'],387,"['这些结果表明,Pirodomer可能会在某些患有抵抗性高血压和CKD的患者中促进Spironolactone的使用。']",0.1666666666666666,"['hypertension', 'indicate', 'resistant', 'with', 'that', 'and']",['hypertension'],,
389,388,"toddlers and parents were more likely to have controlling , intrusive , and isolating behaviors when trying to read a tablet together .",当尝试一起阅读平板电脑时，蹒跚学步的幼儿和父母更有可能产生控制、侵入和孤立行为。,0.3333333333333333,"['parents', 'tablet', 'read', 'have', 'to', 'and']","['read', 'have']",388,['婴儿和父母在试图一起阅读平板电脑时更有可能有控制、侵入和隔离行为。'],0.3333333333333333,"['parents', 'tablet', 'read', 'have', 'to', 'and']","['read', 'have']",,
390,389,"the American Academy of Pediatrics recommends that parents interact with children using digital devices such as smartphones and tablets , but the character of those interactions has not been described well .",美国儿科学会建议父母使用智能手机和平板电脑等数字设备与孩子互动，但这些互动的特点并未得到很好的描述。,0.25,"['character', 'parents', 'pediatrics', 'digital', 'well', 'academy', 'as', 'with', 'interact', 'that', 'but', 'and']","['character', 'pediatrics', 'but']",389,"['美国儿科学院建议父母使用智能手机和平板电脑等数字设备与孩子互动,但这些互动的性质尚未被描述得很好。']",0.25,"['character', 'parents', 'pediatrics', 'digital', 'well', 'academy', 'as', 'with', 'interact', 'that', 'but', 'and']","['character', 'pediatrics', 'but']",,
391,390,the order of books varied randomly among dyads .,书籍的顺序在二人组之间随机变化。,0.3333333333333333,"['order', 'books', 'varied']",['books'],390,['书籍的顺序随机在迪亚德之间有所不同。'],0.3333333333333333,"['order', 'books', 'varied']",['books'],,
392,391,the behaviors observed in this study will be recognizable to anyone who has tried to share a digital device with a young child .,任何试图与幼儿共用数字设备的人都会认出本研究中观察到的行为。,0.2307692307692307,"['a', 'who', 'device', 'child', 'study', 'digital', 'be', 'will', 'with', 'young', 'this', 'in', 'to']","['device', 'child', 'young']",391,['在这项研究中观察到的行为将被任何试图与一个年轻的孩子分享一个数字设备的人认可。'],0.2307692307692307,"['a', 'who', 'device', 'child', 'study', 'digital', 'be', 'will', 'with', 'young', 'this', 'in', 'to']","['device', 'child', 'be']",,
393,392,"of these patients , 30 % had class 2 mutations and 70 % had class 3 mutations .",在这些患者中，30% 有 2 类突变，70% 有 3 类突变。,0.25,"['class', '2', '3', 'and']",['2'],392,"['在这些患者中,30%有2级突变,70%有3级突变。']",0.5,"['class', '2', '3', 'and']","['class', '2']",,
394,393,oral immunotherapy produces temporary desensitization in most patients but does not cure peanut allergy .,口服免疫疗法可使大多数患者暂时脱敏，但不能治愈花生过敏。,0.5555555555555556,"['peanut', 'desensitization', 'cure', 'temporary', 'immunotherapy', 'allergy', 'oral', 'in', 'but']","['desensitization', 'cure', 'immunotherapy', 'allergy', 'but']",393,"['口服免疫疗法在大多数患者中产生暂时的抑敏,但不治愈胡萝卜过敏。']",0.5555555555555556,"['peanut', 'desensitization', 'cure', 'temporary', 'immunotherapy', 'allergy', 'oral', 'in', 'but']","['cure', 'temporary', 'immunotherapy', 'allergy', 'but']",,
395,394,patients were randomized to one of three groups :,患者被随机分配到三组中的一组：,0.0,"['three', 'to']",[],394,['病人被随机分配到三组之一:'],0.0,"['three', 'to']",[],,
396,395,placebo for 3 years,安慰剂 3 年,0.5,"['placebo', '3']",['placebo'],395,['可口可乐3年'],0.0,"['placebo', '3']",[],,
397,396,"however , during the months after stopping OIT , most patients gradually lost their ability to consume large amounts of peanut protein .",然而，在停止 OIT 后的几个月里，大多数患者逐渐失去了摄入大量花生蛋白的能力。,0.4285714285714285,"['peanut', 'protein', 'large', 'after', 'ability', 'stopping', 'consume']","['protein', 'after', 'ability']",396,"['然而,在停止OIT之后的几个月里,大多数患者逐渐失去了大量的胡萝卜蛋白的消耗能力。']",0.5714285714285714,"['peanut', 'protein', 'large', 'after', 'ability', 'stopping', 'consume']","['protein', 'after', 'ability', 'consume']",,
398,397,"on September 13 , 2019 , an FDA advisory committee recommended approval of a peanut OIT .",2019 年 9 月 13 日，FDA 咨询委员会建议批准花生 OIT。,0.4,"['peanut', 'approval', 'FDA', 'committee', 'on']","['approval', 'committee']",397,"['2019年9月13日,一届FDA咨询委员会建议批准一项小麦OIT。']",0.4,"['peanut', 'approval', 'FDA', 'committee', 'on']","['approval', 'committee']",,
399,398,"and now , these findings suggest that patients might have to continue OIT indefinitely to maintain their desensitization .",而现在，这些发现表明患者可能必须无限期地继续 OIT 以维持其脱敏作用。,0.5,"['desensitization', 'maintain', 'suggest', 'continue', 'have', 'that', 'to', 'and']","['desensitization', 'maintain', 'continue', 'and']",398,"['现在,这些发现表明,病人可能不得不无限地继续OIT,以保持他们的消毒。']",0.125,"['desensitization', 'maintain', 'suggest', 'continue', 'have', 'that', 'to', 'and']",['continue'],,
400,399,the two primary end points were overall survival and the percentage of patients who had complete remission with full or partial hematologic recovery .,两个主要终点是总生存期和完全缓解且血液学完全或部分恢复的患者百分比。,0.4285714285714285,"['percentage', 'who', 'survival', 'end points', 'complete', 'recovery', 'primary', 'partial', 'remission', 'with', 'full', 'and', 'two', 'hematologic']","['percentage', 'survival', 'end points', 'recovery', 'remission', 'two']",399,['两个主要终点是整体生存和患有完全或部分血液恢复的患者的百分比。'],0.3571428571428571,"['percentage', 'who', 'survival', 'end points', 'complete', 'recovery', 'primary', 'partial', 'remission', 'with', 'full', 'and', 'two', 'hematologic']","['percentage', 'survival', 'end points', 'recovery', 'two']",,
401,400,"of 371 eligible patients , 247 were randomly assigned to the gilteritinib group and 124 to the salvage chemotherapy group .",在 371 名符合条件的患者中，247 名被随机分配到 gilteritinib 组，124 名分配到挽救化疗组。,0.3333333333333333,"['group', 'chemotherapy', 'salvage', 'to', 'and', 'eligible']","['group', 'chemotherapy']",400,"['在371名合格患者中,247人随机分配给吉尔特里蒂尼布群体,124人分配给救生化疗群体。']",0.5,"['group', 'chemotherapy', 'salvage', 'to', 'and', 'eligible']","['group', 'chemotherapy', 'eligible']",,
402,401,"the percentage of patients who had complete remission with full or partial hematologic recovery was 34.0 % in the gilteritinib group and 15.3 % in the chemotherapy group ( risk difference , 18.6 percentage points ; 95 % CI , 9.8 to 27.4 ) ; the percentages with complete remission were 21.1 % and 10.5 % , respectively ( risk difference , 10.6 percentage points ; 95 % CI , 2.8 to 18.4 ) .",完全缓解且血液学完全或部分恢复的患者百分比在吉尔特替尼组为 34.0%，在化疗组为 15.3%（风险差异，18.6 个百分点；95% CI，9.8 至 27.4）；完全缓解的百分比分别为 21.1% 和 10.5%（风险差异，10.6 个百分点；95% CI，2.8 至 18.4）。,0.4117647058823529,"['group', 'percentage', 'chemotherapy', 'who', 'difference', 'complete', 'recovery', 'risk', 'partial', 'remission', 'with', 'CI', 'full', 'in', 'to', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', 'difference', 'recovery', 'risk', 'remission']",401,"['患有完全或部分血液康复的患者的百分比在吉尔特里蒂尼布群体中为34.0%,在化疗群体中为15.3%(风险差异、18.6个百分点、95%的CI、9.8到27.4);与完全康复的患者的百分比分别为21.1%和10.5%(风险差异、10.6个百分点、95%的CI、2.8到18.4)。']",0.2941176470588235,"['group', 'percentage', 'chemotherapy', 'who', 'difference', 'complete', 'recovery', 'risk', 'partial', 'remission', 'with', 'CI', 'full', 'in', 'to', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', 'difference', 'risk']",,
403,402,"in an analysis that was adjusted for therapy duration , adverse events of grade 3 or higher and serious adverse events occurred less frequently in the gilteritinib group than in the chemotherapy group ; the most common adverse events of grade 3 or higher in the gilteritinib group were febrile neutropenia ( 45.9 % ) , anemia ( 40.7 % ) , and thrombocytopenia ( 22.8 % ) .",在针对治疗持续时间进行调整的分析中，gilteritinib 组发生 3 级或更高级别不良事件和严重不良事件的频率低于化疗组； gilteritinib 组最常见的 3 级或更高级别不良事件是发热性中性粒细胞减少症 (45.9%)、贫血 (40.7%) 和血小板减少症 (22.8%)。,0.4117647058823529,"['anemia', 'group', 'chemotherapy', 'febrile', 'analysis', 'grade', 'frequently', 'neutropenia', 'thrombocytopenia', 'common', 'adverse', '3', 'duration', 'serious', 'that', 'in', 'and']","['anemia', 'group', 'chemotherapy', 'analysis', 'neutropenia', 'thrombocytopenia', 'duration']",402,"['在对治疗时间进行调整的分析中,三级或更高的副作用和严重的副作用在吉尔特里蒂尼布群体中比化疗群体中更少发生;在吉尔特里蒂尼布群体中,三级或更高的副作用最常见的是发烧性中风(45.9%)、贫血(40.7%)和血管细胞(22.8%)。']",0.2941176470588235,"['anemia', 'group', 'chemotherapy', 'febrile', 'analysis', 'grade', 'frequently', 'neutropenia', 'thrombocytopenia', 'common', 'adverse', '3', 'duration', 'serious', 'that', 'in', 'and']","['anemia', 'group', 'chemotherapy', 'analysis', 'that']",,
404,403,"however , for patients with relapsed or refractory AML , neither midostaurin nor lestaurtinib has conferred durable clinical benefit as a single agent.13,14,20","然而，对于复发性或难治性 AML 患者，米哚妥林和来他替尼作为单一药物均未带来持久的临床益处。 13,14,20",0.2857142857142857,"['a', 'refractory', 'clinical', 'benefit', 'as', 'with', 'single']","['clinical', 'single']",403,"['然而,对于患有逆转或逆转性AML的患者,没有 midostaurin 或 lestaurtinib 作为单一药物提供可持续的临床益处。']",0.2857142857142857,"['a', 'refractory', 'clinical', 'benefit', 'as', 'with', 'single']","['clinical', 'single']",,
405,404,"sorafenib showed clinical activity in patients with AML that was positive for the FLT3 ITD mutation , but data from randomized trials that support its use in that context are scarce.16",索拉非尼在 FLT3 ITD 突变呈阳性的 AML 患者中显示出临床活性，但支持其在这种情况下使用的随机试验数据很少。 16,0.6363636363636364,"['mutation', 'support', 'context', 'data', 'activity', 'clinical', 'with', 'sorafenib', 'positive', 'that', 'but']","['mutation', 'support', 'data', 'activity', 'clinical', 'sorafenib', 'but']",404,"['sorafenib在患有AML的患者中表现出临床活动,这对FLT3 ITD突变是积极的,但在这种情况下支持其使用的随机试验的数据很少。']",0.5454545454545454,"['mutation', 'support', 'context', 'data', 'activity', 'clinical', 'with', 'sorafenib', 'positive', 'that', 'but']","['mutation', 'support', 'data', 'activity', 'clinical', 'but']",,
406,405,similar resistance is seen with sorafenib.23,类似的耐药性见于索拉非尼。23,0.3333333333333333,"['resistance', 'with', 'similar']",['resistance'],405,['相似的抵抗可见于 sorafenib.23'],0.6666666666666666,"['resistance', 'with', 'similar']","['resistance', 'similar']",,
407,406,"gilteritinib also inhibits the tyrosine kinase AXL , which is implicated in FLT3 inhibitor resistance.26,27","gilteritinib 还抑制酪氨酸激酶 AXL，这与 FLT3 抑制剂耐药性有关。 26,27",1.0,"['inhibitor', 'tyrosine', 'tyrosine kinase']","['inhibitor', 'tyrosine', 'tyrosine kinase']",406,['gilteritinib 还抑制甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺'],0.0,"['inhibitor', 'tyrosine', 'tyrosine kinase']",[],,
408,407,"the randomized , phase 3 ADMIRAL trial was conducted at 107 centers in 14 countries and was sponsored by Astellas Pharma .",这项随机的 3 期 ADMIRAL 试验在 14 个国家的 107 个中心进行，由 Astellas Pharma 赞助。,0.2857142857142857,"['phase', 'trial', '3', 'at', 'in', 'by', 'and']","['phase', 'by']",407,"['随机,第三阶段的ADMIRAL试验在14个国家的107个中心进行,由Astellas Pharma赞助。']",0.2857142857142857,"['phase', 'trial', '3', 'at', 'in', 'by', 'and']","['phase', 'by']",,
409,408,the trial was reviewed and approved by the institutional review board or ethics committee at each participating center and was conducted in accordance with the principles of the Declaration of Helsinki .,该试验由每个参与中心的机构审查委员会或伦理委员会审查和批准，并根据赫尔辛基宣言的原则进行。,0.3333333333333333,"['center', 'review', 'ethics', 'board', 'committee', 'trial', 'with', 'at', 'each', 'in', 'by', 'and']","['center', 'review', 'committee', 'by']",408,"['审判由各参与中心的机构审查委员会或伦理委员会审查和批准,并按照赫尔辛基宣言的原则进行。']",0.5,"['center', 'review', 'ethics', 'board', 'committee', 'trial', 'with', 'at', 'each', 'in', 'by', 'and']","['center', 'review', 'committee', 'trial', 'each', 'by']",,
410,409,all the patients provided written informed consent at enrollment .,所有患者在入组时均提供了书面知情同意书。,0.25,"['consent', 'informed consent', 'at', 'all']",['consent'],409,['所有患者在注册时提供书面通知的同意。'],0.25,"['consent', 'informed consent', 'at', 'all']",['consent'],,
411,410,two authors who were employees of the sponsor designed the trial in collaboration with four academic authors .,作为申办者雇员的两位作者与四位学术作者合作设计了该试验。,0.4285714285714285,"['who', 'sponsor', 'trial', 'collaboration', 'with', 'in', 'two']","['sponsor', 'collaboration', 'two']",410,"['两位作家是赞助商的员工,与四位学术作家合作设计了审判。']",0.4285714285714285,"['who', 'sponsor', 'trial', 'collaboration', 'with', 'in', 'two']","['trial', 'collaboration', 'two']",,
412,411,all the authors had access to the trial data and were involved in data interpretation .,所有作者都可以访问试验数据并参与数据解释。,0.2857142857142857,"['data', 'access', 'interpretation', 'trial', 'all', 'to', 'and']","['data', 'interpretation']",411,"['所有作者都访问了审判数据,并参与了数据的解释。']",0.4285714285714285,"['data', 'access', 'interpretation', 'trial', 'all', 'to', 'and']","['data', 'interpretation', 'trial']",,
413,412,the authors and the sponsor vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol ( available with the full text of this article at NEJM.org ) .,作者和申办方保证数据的完整性和准确性，以及试验对方案的忠实度（与本文全文可在 NEJM.org 获取）。,0.2857142857142857,"['fidelity', 'data', 'accuracy', 'protocol', 'sponsor', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",412,['作者和赞助商为数据的完整性和准确性以及审判对议定书的忠诚度(可在NEJM.org上提供本文的完整文本)。'],0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'sponsor', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'full']",,
414,413,"the first and last authors wrote the manuscript , with additional writing and editorial assistance provided by medical writers who were funded by the sponsor .",第一作者和最后一位作者撰写了手稿，由申办者资助的医学作家提供额外的写作和编辑协助。,0.5454545454545454,"['who', 'sponsor', 'medical', 'manuscript', 'writing', 'additional', 'assistance', 'with', 'by', 'and', 'first']","['sponsor', 'manuscript', 'writing', 'additional', 'by', 'first']",413,"['第一位和最后一位作家写了手稿,由赞助商资助的医学作家提供的额外写作和编辑援助。']",0.4545454545454545,"['who', 'sponsor', 'medical', 'manuscript', 'writing', 'additional', 'assistance', 'with', 'by', 'and', 'first']","['manuscript', 'writing', 'assistance', 'by', 'first']",,
415,414,enrollment on the basis of local testing for the FLT3 mutation was permitted for patients with rapidly proliferative disease .,对于患有快速增殖性疾病的患者，允许根据对 FLT3 突变的本地检测进行登记。,0.2857142857142857,"['mutation', 'disease', 'basis', 'local', 'proliferative', 'testing', 'with']","['mutation', 'disease']",414,"['基于本地测试的注册,FLT3突变已被允许在患有快速繁殖性疾病的患者。']",0.4285714285714285,"['mutation', 'disease', 'basis', 'local', 'proliferative', 'testing', 'with']","['mutation', 'disease', 'proliferative']",,
416,415,FLT3 MUTATIONS,FLT3 突变,,[],[],415,['FLT3 转换'],,[],[],,
417,416,patients were required to have FLT3 ITD or TKD D835 or I836 mutations .,要求患者具有 FLT3 ITD 或 TKD D835 或 I836 突变。,0.3333333333333333,"['TKD', 'have', 'to']",['have'],416,['患者需要 FLT3 ITD 或 TKD D835 或 I836 突变。'],0.0,"['TKD', 'have', 'to']",[],,
418,417,"the median FLT3 ITD allelic ratio was established at 0.77 , with a high FLT3 ITD allelic ratio defined as 0.77 or greater and a low ratio as less than 0.77 .",中位 FLT3 ITD 等位基因比率确定为 0.77，高 FLT3 ITD 等位基因比率定义为 0.77 或更高，低比率定义为小于 0.77。,0.3333333333333333,"['median', 'defined', 'ratio', 'low', 'allelic', 'as', 'with', 'and', 'high']","['ratio', 'low', 'high']",417,"['平均 FLT3 ITD Allelic 比率为 0.77,高 FLT3 ITD Allelic 比率为 0.77 或更高,低比率为 0.77 。']",0.3333333333333333,"['median', 'defined', 'ratio', 'low', 'allelic', 'as', 'with', 'and', 'high']","['ratio', 'low', 'high']",,
419,418,no crossover between treatment groups was permitted .,治疗组之间不允许交叉。,0.5,"['treatment', 'no']",['treatment'],418,['治疗小组之间没有交叉。'],0.5,"['treatment', 'no']",['treatment'],,
420,419,complete remission with full or partial hematologic recovery was evaluated in an interim analysis in the gilteritinib group only and was summarized in the final analysis for both treatment groups .,完全缓解和完全或部分血液学恢复仅在 gilteritinib 组的中期分析中进行评估，并在两个治疗组的最终分析中进行总结。,0.4166666666666667,"['group', 'analysis', 'complete', 'recovery', 'treatment', 'partial', 'remission', 'with', 'full', 'in', 'and', 'hematologic']","['group', 'analysis', 'recovery', 'treatment', 'remission']",419,"['完全或部分血液恢复的复发仅在吉尔特里蒂尼布群体中进行临时分析,并在两组治疗的最终分析中总结。']",0.3333333333333333,"['group', 'analysis', 'complete', 'recovery', 'treatment', 'partial', 'remission', 'with', 'full', 'in', 'and', 'hematologic']","['group', 'analysis', 'recovery', 'treatment']",,
421,420,best response was noted at any postbaseline visit .,在任何基线后访视中记录了最佳反应。,0.3333333333333333,"['response', 'at', 'visit']",['response'],420,['最好的答案在任何邮政访问中都被注意到。'],0.0,"['response', 'at', 'visit']",[],,
422,421,"treatment response was assessed with the use of modified International Working Group criteria ( Table S1 in the Supplementary Appendix , available at NEJM.org ) .31",使用修改后的国际工作组标准（补充附录中的表 S1，可在 NEJM.org 获取）评估治疗反应。31,0.3636363636363636,"['group', 'appendix', 'table', 'supplementary', 'treatment', 'available', 'response', 'with', 'S1', 'in', 'assessed']","['group', 'table', 'treatment', 'response']",421,"['处理答案通过修改的国际工作组标准进行评估(附件中的表 S1,可在NEJM.org上找到)。']",0.3636363636363636,"['group', 'appendix', 'table', 'supplementary', 'treatment', 'available', 'response', 'with', 'S1', 'in', 'assessed']","['group', 'appendix', 'table', 'treatment']",,
423,422,minimal residual disease was not assessed .,未评估微小残留病。,0.25,"['disease', 'minimal', 'residual', 'assessed']",['disease'],422,['最低残留性疾病未被评估。'],0.25,"['disease', 'minimal', 'residual', 'assessed']",['disease'],,
424,423,"safety was assessed by evaluating the incidence of adverse events , including evaluation of vital signs , and results from clinical laboratory tests , electrocardiograms , and ophthalmologic examinations .",安全性是通过评估不良事件的发生率来评估的，包括评估生命体征，以及临床实验室测试、心电图和眼科检查的结果。,0.5384615384615384,"['safety', 'vital signs', 'incidence', 'evaluation', 'ophthalmologic', 'adverse', 'clinical', 'examinations', 'laboratory', 'by', 'and', 'electrocardiograms', 'assessed']","['safety', 'vital signs', 'incidence', 'clinical', 'laboratory', 'by', 'electrocardiograms']",423,"['安全性通过评估不良事件的发病率,包括对重要迹象的评估,以及临床实验室测试、电心图和眼科检查的结果进行评估。']",0.3846153846153846,"['safety', 'vital signs', 'incidence', 'evaluation', 'ophthalmologic', 'adverse', 'clinical', 'examinations', 'laboratory', 'by', 'and', 'electrocardiograms', 'assessed']","['safety', 'incidence', 'clinical', 'laboratory', 'by']",,
425,424,expression of AXL ( a receptor tyrosine kinase associated with drug resistance ) was analyzed by means of flow cytometry .,采用流式细胞术分析AXL（一种与耐药相关的受体酪氨酸激酶）的表达。,0.5,"['receptor', 'drug resistance', 'tyrosine', 'flow cytometry', 'expression', 'tyrosine kinase', 'associated', 'means', 'with', 'by']","['receptor', 'tyrosine', 'flow cytometry', 'expression', 'tyrosine kinase']",424,['AXL(受体甲状腺基纳斯与药物抵抗性相关)的表达通过流量细胞测量进行分析。'],0.3,"['receptor', 'drug resistance', 'tyrosine', 'flow cytometry', 'expression', 'tyrosine kinase', 'associated', 'means', 'with', 'by']","['receptor', 'drug resistance', 'expression']",,
426,425,the first planned interim analysis - to evaluate the primary end point of the percentage of patients who had complete remission with full or partial hematologic recovery - occurred when approximately 141 patients in the gilteritinib group reached the time point of at least 112 days ( four treatment cycles ) after the receipt of first dose or after randomization ; the interim evaluation of complete remission with full or partial hematologic recovery rate had no effect on trial conduct .,第一个计划的中期分析——评估完全缓解且血液学完全或部分恢复的患者百分比的主要终点——发生在 gilteritinib 组约 141 名患者达到至少 112 天（四个治疗周期）的时间点时) 接受第一剂后或随机化后；具有完全或部分血液学恢复率的完全缓解的中期评估对试验的进行没有影响。,0.4137931034482758,"['group', 'percentage', 'randomization', 'who', 'analysis', 'rate', 'evaluation', 'time', 'complete', 'recovery', 'treatment', 'primary', 'no', 'partial', 'after', 'trial', 'effect', 'end', 'point', 'conduct', 'remission', 'with', 'dose', 'full', '-', 'approximately', 'to', 'first', 'hematologic']","['group', 'percentage', 'randomization', 'analysis', 'rate', 'time', 'recovery', 'treatment', 'after', 'point', 'remission', 'first']",425,"['第一次计划的临时分析 - 以评估患有全血病恢复或部分血病恢复的患者的百分比的初端终点 - 发生时,约有141患者在吉尔特里蒂尼布群体达到至少112天的时间点(四个治疗周期)接收第一次剂量或随机化后;临时评估全血病恢复率或部分血病恢复率没有影响试验行为。']",0.4137931034482758,"['group', 'percentage', 'randomization', 'who', 'analysis', 'rate', 'evaluation', 'time', 'complete', 'recovery', 'treatment', 'primary', 'no', 'partial', 'after', 'trial', 'effect', 'end', 'point', 'conduct', 'remission', 'with', 'dose', 'full', '-', 'approximately', 'to', 'first', 'hematologic']","['group', 'percentage', 'randomization', 'analysis', 'rate', 'time', 'recovery', 'treatment', 'after', 'point', 'dose', 'first']",,
427,426,the planned final analysis was performed when approximately 258 deaths had occurred .,计划的最终分析是在大约 258 人死亡时进行的。,0.5,"['analysis', 'approximately']",['analysis'],426,['计划的最终分析是在大约258人死亡时进行的。'],0.5,"['analysis', 'approximately']",['analysis'],,
428,427,the statistical analysis plan excluded provisions for multiplicity correction in the evaluation of secondary and other outcomes .,统计分析计划排除了在评估次要结果和其他结果时进行多重校正的规定。,0.375,"['correction', 'analysis', 'evaluation', 'secondary', 'multiplicity', 'statistical analysis', 'in', 'and']","['correction', 'analysis', 'statistical analysis']",427,['统计分析计划排除在二级和其他结果的评估中对多样性纠正的规定。'],0.25,"['correction', 'analysis', 'evaluation', 'secondary', 'multiplicity', 'statistical analysis', 'in', 'and']","['analysis', 'statistical analysis']",,
429,428,these results are reported as point estimates and 95 % confidence intervals without adjustment for multiplicity and should not be used to infer definitive treatment effects .,这些结果报告为点估计值和 95% 置信区间，未对多重性进行调整，不应用于推断确定的治疗效果。,0.4166666666666667,"['definitive', 'adjustment', 'be', 'treatment', 'multiplicity', 'point', 'as', 'confidence', 'to', 'and', 'without', 'intervals']","['definitive', 'treatment', 'multiplicity', 'point', 'to']",428,"['这些结果被报告为点估计和95%的信任间隔,没有对多样性进行调整,并且不应用于确定最终的治疗效果。']",0.25,"['definitive', 'adjustment', 'be', 'treatment', 'multiplicity', 'point', 'as', 'confidence', 'to', 'and', 'without', 'intervals']","['treatment', 'point', 'to']",,
430,429,"from October 20 , 2015 , to February 20 , 2018 , a total of 625 patients entered screening .",2015年10月20日至2018年2月20日，共有625名患者进入筛查。,0.3333333333333333,"['a', 'screening', 'total']",['screening'],429,"['从2015年10月20日至2018年2月20日,共有625名患者接受了筛查。']",0.3333333333333333,"['a', 'screening', 'total']",['screening'],,
431,430,"the event cutoff of 258 deaths , which triggered the final analysis , occurred on September 17 , 2018 ; the database was locked on October 19 , 2018 .",最终分析触发的258人死亡事件截止发生在2018年9月17日；该数据库于 2018 年 10 月 19 日被锁定。,0.2,"['cutoff', 'database', 'analysis', 'event', 'on']",['analysis'],430,['最终分析引发的258起死亡事件发生于2018年9月17日;数据库于2018年10月19日关闭。'],0.2,"['cutoff', 'database', 'analysis', 'event', 'on']",['analysis'],,
432,431,a total of 371 eligible patients underwent randomization ; 247 were assigned to the gilteritinib group and 124 to the chemotherapy group ( Figure 1 and Table 1 ) .,共有 371 名符合条件的患者接受了随机分组； 247 人被分配到 gilteritinib 组，124 人被分配到化疗组（图 1 和表 1）。,0.625,"['group', 'chemotherapy', 'randomization', 'table', '1', 'figure', 'total', 'eligible']","['group', 'chemotherapy', 'randomization', 'table', '1']",431,"['总共有371名合格的患者遭到随机化;247人被分配给吉尔特里蒂尼布组,124人被分配给化疗组(图1和图1)。']",0.625,"['group', 'chemotherapy', 'randomization', 'table', '1', 'figure', 'total', 'eligible']","['group', 'chemotherapy', 'randomization', '1', 'eligible']",,
433,432,"overall , 60.6 % of the patients had relapsed AML ( median duration of first remission , 6.0 months ; range , 0.3 to 60.0 ) , and 39.4 % had primary refractory disease .",总体而言，60.6% 的患者患有复发性 AML（首次缓解的中位持续时间为 6.0 个月；范围为 0.3 至 60.0 个月），39.4% 的患者患有原发性难治性疾病。,0.5555555555555556,"['median', 'disease', 'range', 'refractory', 'primary', 'duration', 'remission', 'and', 'first']","['disease', 'range', 'duration', 'remission', 'and']",432,"['总体而言,60.6 %的患者患有AML(第一次放松的平均寿命为6.0 个月;范围为 0.3 至 60.0),而39.4 %的患者患有初级放松性疾病。']",0.4444444444444444,"['median', 'disease', 'range', 'refractory', 'primary', 'duration', 'remission', 'and', 'first']","['disease', 'range', 'and', 'first']",,
434,433,most patients ( 83.8 % ) had received previous induction therapy with anthracyclines but not FLT3 inhibitors ( 87.6 % ) ; 21 patients ( 5.7 % ) had received the FLT3 inhibitor midostaurin .,大多数患者 (83.8%) 之前接受过蒽环类药物诱导治疗，但未接受 FLT3 抑制剂 (87.6%)； 21 名患者 (5.7%) 接受了 FLT3 抑制剂米哚妥林。,0.6666666666666666,"['inhibitor', 'induction', 'previous', 'therapy', 'with', 'but']","['inhibitor', 'induction', 'therapy', 'but']",433,"['大多数患者(83.8%)接受了先前的引导治疗,但不使用FLT3抑制剂(87.6%);21患者(5.7%)接受了FLT3抑制剂Midostaurine。']",0.6666666666666666,"['inhibitor', 'induction', 'previous', 'therapy', 'with', 'but']","['inhibitor', 'induction', 'therapy', 'but']",,
435,434,"the median number of cycles of gilteritinib therapy received was 5 ( range , 1 to 33 ) .",接受的 gilteritinib 治疗周期的中位数为 5（范围，1 至 33）。,0.7142857142857143,"['median', '5', 'range', '1', 'therapy', 'number', 'to']","['5', 'range', '1', 'therapy', 'number']",434,"['接受吉尔特里蒂尼布治疗的平均周期数量为5(范围,1至33)。']",0.7142857142857143,"['median', '5', 'range', '1', 'therapy', 'number', 'to']","['5', 'range', '1', 'therapy', 'number']",,
436,435,"at the time of this analysis , 110 patients remained alive and 38 were continuing therapy with gilteritinib .",在进行此项分析时，有 110 名患者还活着，其中 38 名患者继续使用吉替替尼进行治疗。,0.4285714285714285,"['analysis', 'time', 'therapy', 'with', 'at', 'this', 'and']","['analysis', 'time', 'therapy']",435,"['在此分析时,110名患者仍然活着,38人继续接受吉尔特里蒂尼布治疗。']",0.4285714285714285,"['analysis', 'time', 'therapy', 'with', 'at', 'this', 'and']","['analysis', 'time', 'therapy']",,
437,436,"common reasons for the discontinuation of gilteritinib were relapse , progression , or lack of efficacy ( 50.2 % ) , death ( 14.6 % ) , and adverse events ( 11.3 % ) .",停用 gilteritinib 的常见原因是复发、进展或缺乏疗效 (50.2%)、死亡 (14.6%) 和不良事件 (11.3%)。,0.375,"['lack', 'relapse', 'death', 'common', 'adverse', 'progression', 'efficacy', 'and']","['relapse', 'death', 'progression']",436,"['停止使用Gilteritinib的常见原因是衰退、进展或缺乏有效性(50.2 %),死亡(14.6 %)和副作用(11.3 %)。']",0.375,"['lack', 'relapse', 'death', 'common', 'adverse', 'progression', 'efficacy', 'and']","['death', 'progression', 'efficacy']",,
438,437,"common reasons for the discontinuation of chemotherapy were relapse , progression , or lack of efficacy ( 39.5 % ) , withdrawal by the patient ( 8.1 % ) , physician decision ( 8.9 % ) , and death ( 8.1 % ) .",停止化疗的常见原因是复发、进展或缺乏疗效 (39.5%)、患者退出 (8.1%)、医生决定 (8.9%) 和死亡 (8.1%)。,0.5384615384615384,"['chemotherapy', 'lack', 'relapse', 'death', 'withdrawal', 'physician', 'common', 'progression', 'patient', 'efficacy', 'decision', 'by', 'and']","['chemotherapy', 'relapse', 'death', 'physician', 'progression', 'patient', 'decision']",437,['停止化疗的常见原因是逆转、进展或缺乏有效性(39.5%)、患者退出(8.1%)、医生的决定(8.9%)和死亡(8.1%)。'],0.5384615384615384,"['chemotherapy', 'lack', 'relapse', 'death', 'withdrawal', 'physician', 'common', 'progression', 'patient', 'efficacy', 'decision', 'by', 'and']","['chemotherapy', 'death', 'physician', 'progression', 'patient', 'efficacy', 'decision']",,
439,438,the percentages of patients who were alive at 1 year were 37.1 % in the gilteritinib group and 16.7 % in the chemotherapy group .,gilteritinib 组 1 年时存活的患者百分比为 37.1%，化疗组为 16.7%。,0.5,"['group', 'chemotherapy', 'year', 'who', '1', 'at', 'in', 'and']","['group', 'chemotherapy', 'year', '1']",438,['1年生存的患者比例为吉尔特里蒂尼布群体的37.1%和化疗群体的16.7%。'],0.5,"['group', 'chemotherapy', 'year', 'who', '1', 'at', 'in', 'and']","['group', 'chemotherapy', 'year', '1']",,
440,439,"among patients with primary refractory AML , the median overall survival was 10.4 months in the gilteritinib group and 6.9 months in the chemotherapy group ( hazard ratio for death , 0.99 ; 95 % CI , 0.63 to 1.55 ) ( Table S3 ) .",在原发性难治性 AML 患者中，gilteritinib 组的中位总生存期为 10.4 个月，化疗组为 6.9 个月（死亡风险比，0.99；95% CI，0.63 至 1.55）（表 S3）。,0.4666666666666667,"['group', 'chemotherapy', 'median', 'table', 'survival', 'ratio', 'hazard ratio', 'death', 'refractory', 'primary', 'with', 'CI', 'S3', 'in', 'and']","['group', 'chemotherapy', 'table', 'survival', 'ratio', 'hazard ratio', 'death']",439,"['在患有初级分裂性AML的患者中,平均生存时间在吉尔特里蒂尼布群体中为10.4个月,化疗群体中为6.9个月(死亡风险比例为0.99;95%的CI,0.63至1.55)。']",0.4,"['group', 'chemotherapy', 'median', 'table', 'survival', 'ratio', 'hazard ratio', 'death', 'refractory', 'primary', 'with', 'CI', 'S3', 'in', 'and']","['group', 'chemotherapy', 'survival', 'ratio', 'hazard ratio', 'death']",,
441,440,"the percentage of patients who had complete remission with full or partial hematologic recovery was 34.0 % in the gilteritinib group and 15.3 % in the chemotherapy group ( risk difference , 18.6 percentage points ; 95 % CI , 9.8 to 27.4 ) ; the percentages of patients with complete remission were 21.1 % and 10.5 % , respectively ( risk difference , 10.6 percentage points ; 95 % CI , 2.8 to 18.4 ) ( Table 2 ) .",完全缓解且血液学完全或部分恢复的患者百分比在吉尔特替尼组为 34.0%，在化疗组为 15.3%（风险差异，18.6 个百分点；95% CI，9.8 至 27.4）；完全缓解患者的百分比分别为 21.1% 和 10.5%（风险差异，10.6 个百分点；95% CI，2.8 至 18.4）（表 2）。,0.4736842105263157,"['group', 'percentage', 'chemotherapy', 'table', 'who', '2', 'difference', 'complete', 'recovery', 'risk', 'partial', 'remission', 'with', 'CI', 'full', 'in', 'to', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', 'table', '2', 'difference', 'recovery', 'risk', 'remission']",440,"['患有完全或部分血液康复的患者的百分比在吉尔特里蒂尼布群体中为34.0%,在化疗群体中为15.3%(风险差异、18.6个百分点、95%的CI、9.8到27.4);患有完全康复的患者的百分比为21.1%和10.5%(风险差异、10.6个百分点、95%的CI、2.8到18.4)。']",0.3157894736842105,"['group', 'percentage', 'chemotherapy', 'table', 'who', '2', 'difference', 'complete', 'recovery', 'risk', 'partial', 'remission', 'with', 'CI', 'full', 'in', 'to', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', '2', 'difference', 'risk']",,
442,441,the median duration of complete remission with full or partial hematologic recovery was 11.0 months in the gilteritinib group but could not be evaluated in the chemotherapy group because of censoring .,gilteritinib 组完全缓解和血液学部分恢复的中位持续时间为 11.0 个月，但由于删失，无法在化疗组中进行评估。,0.5,"['group', 'chemotherapy', 'median', 'complete', 'be', 'recovery', 'partial', 'duration', 'remission', 'with', 'full', 'in', 'but', 'hematologic']","['group', 'chemotherapy', 'be', 'recovery', 'duration', 'remission', 'but']",441,"['在吉尔特里蒂尼布群体中,完全或部分血液恢复的中间期为11.0个月,但由于审查而无法在化疗群体中进行评估。']",0.3571428571428571,"['group', 'chemotherapy', 'median', 'complete', 'be', 'recovery', 'partial', 'duration', 'remission', 'with', 'full', 'in', 'but', 'hematologic']","['group', 'chemotherapy', 'be', 'recovery', 'but']",,
443,442,the percentages of patients who had remission after an increase in the dose of gilteritinib ( 78 patients ) or a decrease in the dose ( 58 patients ) are shown in Table S5 .,在增加 gilteritinib 剂量（78 名患者）或减少剂量（58 名患者）后获得缓解的患者百分比显示在表 S5 中。,0.625,"['a', 'decrease', 'table', 'who', 'after', 'remission', 'increase', 'dose']","['decrease', 'table', 'after', 'remission', 'dose']",442,['在增加吉尔特里蒂尼布剂量(78名患者)或减少剂量(58名患者)后患有复发的患者的百分比显示在表S5中。'],0.5,"['a', 'decrease', 'table', 'who', 'after', 'remission', 'increase', 'dose']","['decrease', 'table', 'after', 'dose']",,
444,443,"when we excluded remissions that occurred after transplantation during the trial , the percentage of patients who had complete remission with full or partial hematologic recovery was 26.3 % in the gilteritinib group and 15.3 % in the chemotherapy group ( risk difference , 10.9 percentage points ; 95 % CI , 2.4 to 19.5 ) .",当我们在试验期间排除移植后出现的缓解时，完全缓解且血液学完全或部分恢复的患者百分比在 gilteritinib 组中为 26.3 % ，在化疗组中为 15.3 % （风险差异， 10.9 个百分点； 95 % ） CI，2.4 至 19.5）。,0.4545454545454545,"['group', 'percentage', 'chemotherapy', 'transplantation', 'who', 'difference', 'complete', 'recovery', 'risk', 'partial', 'after', 'trial', 'remission', 'with', 'CI', 'full', 'that', 'in', 'to', 'and', 'hematologic', 'we']","['group', 'percentage', 'chemotherapy', 'transplantation', 'difference', 'recovery', 'risk', 'after', 'remission', 'in']",443,"['当我们排除在试验期间移植后发生的移植时,患有完全或部分血液恢复的患者的百分比为吉尔特里蒂尼布群体的 26.3% 和化疗群体的 15.3% (风险差异, 10.9 个百分点 ; 95 % CI, 2.4 到 19.5 ) 。']",0.4545454545454545,"['group', 'percentage', 'chemotherapy', 'transplantation', 'who', 'difference', 'complete', 'recovery', 'risk', 'partial', 'after', 'trial', 'remission', 'with', 'CI', 'full', 'that', 'in', 'to', 'and', 'hematologic', 'we']","['group', 'percentage', 'chemotherapy', 'transplantation', 'difference', 'recovery', 'risk', 'after', 'that', 'in']",,
445,444,"among patients with primary refractory AML , the percentage of patients who had complete remission with full or partial hematologic recovery was 32 % ( 31 of 98 patients ) in the gilteritinib group and 21 % ( 10 of 48 patients ) in the chemotherapy group ( Table S3 ) .",在原发难治性 AML 患者中，完全缓解且血液学完全或部分恢复的患者百分比在吉特替尼组为 32 %（98 名患者中的 31 名），在化疗组中为 21 %（48 名患者中的 10 名）（表 S3） ) 。,0.3529411764705882,"['group', 'percentage', 'chemotherapy', 'table', 'who', 'refractory', 'complete', 'recovery', 'primary', 'partial', 'remission', 'with', 'full', 'S3', 'in', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', 'table', 'recovery', 'remission']",444,"['在患有初级分裂性AML的患者中,患有完全或部分血液康复的患者的百分比为32%(98人中31人)在吉尔特里蒂尼布群体和21%(48人中10人)在化疗群体(S3表)。']",0.2352941176470588,"['group', 'percentage', 'chemotherapy', 'table', 'who', 'refractory', 'complete', 'recovery', 'primary', 'partial', 'remission', 'with', 'full', 'S3', 'in', 'and', 'hematologic']","['group', 'percentage', 'chemotherapy', 'table']",,
446,445,the percentages of patients with a remission according to chemotherapy intensity and receipt or nonreceipt of previous transplantation are presented in Table S4 .,根据化疗强度和接受或未接受既往移植获得缓解的患者百分比见表 S4。,0.4,"['chemotherapy', 'transplantation', 'table', 'previous', 'intensity', 'remission', 'with', 'S4', 'to', 'and']","['chemotherapy', 'transplantation', 'table', 'remission']",445,['根据化疗强度和接收或未接收前移植的患者的百分比在表 S4 中显示。'],0.3,"['chemotherapy', 'transplantation', 'table', 'previous', 'intensity', 'remission', 'with', 'S4', 'to', 'and']","['chemotherapy', 'transplantation', 'table']",,
447,446,"among patients with FLT3 ITD mutations who had been randomly assigned to the gilteritinib group , 20.5 % had a complete remission ; among those who had been randomly assigned to chemotherapy , 9.7 % had a complete remission ( Table S6 ) .",在随机分配到吉替尼组的 FLT3 ITD 突变患者中，20.5% 的患者获得完全缓解；在被随机分配接受化疗的患者中，9.7% 的患者获得完全缓解（表 S6）。,0.5,"['group', 'chemotherapy', 'table', 'who', 'complete', 'remission', 'with', 'to']","['group', 'chemotherapy', 'table', 'remission']",446,"['在患有 FLT3 ITD 突变的患者中,有 20.5 % 随机分配给 gilteritinib 组,有完整的复发;在随机分配给化疗的患者中,有 9.7 % 有完整的复发(表 S6 )。']",0.5,"['group', 'chemotherapy', 'table', 'who', 'complete', 'remission', 'with', 'to']","['group', 'chemotherapy', 'table', 'complete']",,
448,447,"although the percentages of patients with complete remission were similar across the treatment groups among patients with FLT3 TKD mutations , gilteritinib therapy resulted in similar percentages of complete remission among patients with FLT3 TKD mutations alone ( 19.0 % ) and among those with FLT3 ITD mutations alone ( 20.5 % ) ( Table S6 ) .",尽管完全缓解患者的百分比在具有 FLT3 TKD 突变的患者中在整个治疗组中相似，但吉利替尼治疗在仅具有 FLT3 TKD 突变的患者 (19.0%) 和仅具有 FLT3 ITD 突变的患者中导致完全缓解的百分比相似 ( 20.5%）（表 S6）。,0.3333333333333333,"['table', 'therapy', 'complete', 'treatment', 'across', 'TKD', 'remission', 'with', 'in', 'and', 'alone', 'similar']","['table', 'therapy', 'treatment', 'remission']",447,"['虽然患有FLT3 TKD突变的患者的百分比在治疗群体中是相似的,但Gilteritinib治疗导致FLT3 TKD突变的患者(仅19.0%)和FLT3 ITD突变的患者(仅20,5%)的完全突变的百分比相似。']",0.25,"['table', 'therapy', 'complete', 'treatment', 'across', 'TKD', 'remission', 'with', 'in', 'and', 'alone', 'similar']","['therapy', 'treatment', 'similar']",,
449,448,"among patients treated with gilteritinib , the median overall survival was similar among those with FLT3 ITD mutations alone ( 9.3 months ) and those with FLT3 TKD mutations alone ( 8.0 months ) .",在接受 gilteritinib 治疗的患者中，仅具有 FLT3 ITD 突变的患者（9.3 个月）和仅具有 FLT3 TKD 突变的患者（8.0 个月）的中位总生存期相似。,0.1428571428571428,"['median', 'survival', 'TKD', 'with', 'and', 'alone', 'similar']",['survival'],448,"['在接受吉尔特里蒂尼布治疗的患者中,平均生存率相当于只有FLT3 ITD突变(9.3个月)和只有FLT3 TKD突变(8.0个月)的患者中。']",0.1428571428571428,"['median', 'survival', 'TKD', 'with', 'and', 'alone', 'similar']",['survival'],,
450,449,"similar results were observed regarding adverse events that occurred during the first 30 days of treatment , except for elevations of the liver aminotransferase levels . ( details are provided in Tables S7 and S8 . )",除了肝脏转氨酶水平升高外，在治疗的前 30 天内发生的不良事件也观察到了类似的结果。 （详情见表 S7 和 S8。）,0.2222222222222222,"['liver', 'aminotransferase', 'regarding', 'adverse', 'treatment', 'that', 'and', 'first', 'similar']","['liver', 'treatment']",449,"['相似的结果被观察到发生在治疗的前30天内发生的副作用,除了肝脏氨基转移素水平的上升(详细信息显示在表 S7 和 S8 。']",0.3333333333333333,"['liver', 'aminotransferase', 'regarding', 'adverse', 'treatment', 'that', 'and', 'first', 'similar']","['liver', 'treatment', 'similar']",,
451,450,"common adverse events of grade 3 or higher in the gilteritinib group were febrile neutropenia ( 45.9 % ) , anemia ( 40.7 % ) , and thrombocytopenia ( 22.8 % ) ( Table 3 and Table S9 ) ; these were also the most common adverse events of grade 3 or higher that were considered by the investigators to be related to gilteritinib therapy ( Table S10 ) .",gilteritinib 组中 3 级或更高级别的常见不良事件为发热性中性粒细胞减少症 (45.9%)、贫血 (40.7%) 和血小板减少症 (22.8%)（表 3 和表 S9）；这些也是研究人员认为与 gilteritinib 治疗相关的最常见的 3 级或更高级别不良事件（表 S10）。,0.3529411764705882,"['anemia', 'group', 'febrile', 'table', 'grade', 'neutropenia', 'thrombocytopenia', 'therapy', 'be', 'common', 'adverse', '3', 'S10', 'that', 'in', 'by', 'and']","['anemia', 'group', 'table', 'neutropenia', 'thrombocytopenia', 'therapy']",450,['在Gilteritinib群体中3级或更高的常见副作用是发烧性中风(45.9%)、贫血(40.7%)和血管细胞(22.8%);这些也是研究人员认为与Gilteritinib治疗相关的3级或更高的常见副作用(S10)。'],0.2352941176470588,"['anemia', 'group', 'febrile', 'table', 'grade', 'neutropenia', 'thrombocytopenia', 'therapy', 'be', 'common', 'adverse', '3', 'S10', 'that', 'in', 'by', 'and']","['anemia', 'group', 'therapy', 'be']",,
452,451,adverse events of grade 3 or higher that occurred during the first 30 days of treatment are presented in Table S8 .,表 S8 列出了治疗前 30 天内发生的 3 级或更高级别的不良事件。,0.25,"['table', 'grade', 'adverse', 'treatment', '3', 'that', 'in', 'first']","['table', 'treatment']",451,"['在治疗前30天发生的3级或更高类别的副作用,如表 S8所示。']",0.25,"['table', 'grade', 'adverse', 'treatment', '3', 'that', 'in', 'first']","['table', 'treatment']",,
453,452,dose reductions occurred in 6 patients who had a mean change from the baseline QTcF interval of more than 60 msec .,6 名患者发生剂量减少，其 QTcF 间期相对于基线的平均变化超过 60 毫秒。,0.7142857142857143,"['a', 'interval', 'mean', 'who', 'baseline', 'change', 'dose']","['interval', 'mean', 'baseline', 'change', 'dose']",452,"['剂量减少发生在6名患者中,从基线QTcF间隔超过60 msec的平均变化。']",0.7142857142857143,"['a', 'interval', 'mean', 'who', 'baseline', 'change', 'dose']","['interval', 'mean', 'baseline', 'change', 'dose']",,
454,453,"there were 251 deaths in the safety population of 355 patients , including 170 deaths among 246 patients ( 69.1 % ) in the gilteritinib group and 81 deaths among 109 patients ( 74.3 % ) in the chemotherapy group .",355例患者的安全人群中有251例死亡，其中gilteritinib组246例患者中有170例死亡（69.1%），化疗组109例患者中有81例死亡（74.3%）。,0.6666666666666666,"['safety', 'group', 'chemotherapy', 'population', 'in', 'and']","['safety', 'group', 'chemotherapy', 'population']",453,"['在355名患者的安全人口中,有251人死亡,其中有246名患者(69.1%)在吉尔特里丁群中死亡,109名患者(74.3%)在化疗群中死亡81人死亡。']",0.6666666666666666,"['safety', 'group', 'chemotherapy', 'population', 'in', 'and']","['safety', 'group', 'chemotherapy', 'population']",,
455,454,"we found that in this population of patients , gilteritinib resulted in superior overall survival and percentages of remission as compared with salvage chemotherapy .",我们发现，在这一患者群体中，与挽救性化疗相比，gilteritinib 的总生存期和缓解率更高。,0.3076923076923077,"['chemotherapy', 'population', 'survival', 'superior', 'remission', 'as', 'with', 'salvage', 'this', 'that', 'in', 'and', 'we']","['chemotherapy', 'population', 'survival', 'remission']",454,"['我们发现,在这种患者群体中,吉尔特里蒂尼布产生了比救生化疗更高的总生存率和放松率。']",0.3076923076923077,"['chemotherapy', 'population', 'survival', 'superior', 'remission', 'as', 'with', 'salvage', 'this', 'that', 'in', 'and', 'we']","['chemotherapy', 'population', 'survival', 'that']",,
456,455,the present trial enrolled patients with FLT3 ITD or FLT3 TKD mutations .,本试验纳入了具有 FLT3 ITD 或 FLT3 TKD 突变的患者。,0.0,"['trial', 'TKD', 'present', 'with']",[],455,['目前的研究记录了患有 FLT3 ITD 或 FLT3 TKD 突变的患者。'],0.0,"['trial', 'TKD', 'present', 'with']",[],,
457,456,"although FLT3 TKD mutations are uncommon at disease recurrence , they consistently and rapidly emerge during FLT3 inhibitor therapy to confer secondary resistance.22,34","尽管 FLT3 TKD 突变在疾病复发时并不常见，但它们在 FLT3 抑制剂治疗期间持续且迅速地出现并赋予继发性耐药性。 22,34",0.375,"['inhibitor', 'disease', 'therapy', 'secondary', 'TKD', 'recurrence', 'at', 'and']","['inhibitor', 'disease', 'therapy']",456,"['虽然 FLT3 TKD 突变在疾病重复情况下是异常的,但它们在 FLT3 抑制剂治疗期间连续迅速出现,以提供二次抵抗性。']",0.375,"['inhibitor', 'disease', 'therapy', 'secondary', 'TKD', 'recurrence', 'at', 'and']","['inhibitor', 'disease', 'therapy']",,
458,457,gilteritinib had clinical activity in all studied FLT3 mutation types .,gilteritinib 在所有研究的 FLT3 突变类型中均具有临床活性。,0.75,"['mutation', 'activity', 'clinical', 'all']","['mutation', 'activity', 'clinical']",457,['吉尔特里蒂尼布在所有研究的FLT3突变类型中都具有临床活动。'],0.75,"['mutation', 'activity', 'clinical', 'all']","['mutation', 'activity', 'clinical']",,
459,458,"not only were the percentages of patients with complete remission similar in the FLT3 TKD and ITD cohorts , but the median overall survival in these two cohorts was also similar .",不仅完全缓解的患者百分比在 FLT3 TKD 和 ITD 队列中相似，而且这两个队列的中位总生存期也相似。,0.4166666666666667,"['median', 'survival', 'complete', 'TKD', 'cohorts', 'remission', 'with', 'in', 'but', 'and', 'two', 'similar']","['survival', 'remission', 'but', 'and', 'two']",458,"['不仅患者的百分比在FLT3 TKD和ITD组中完全放松相似,但这两个组中平均总生存也相似。']",0.25,"['median', 'survival', 'complete', 'TKD', 'cohorts', 'remission', 'with', 'in', 'but', 'and', 'two', 'similar']","['survival', 'but', 'two']",,
460,459,"overall , gilteritinib showed a consistent survival benefit across many subgroups .",总体而言，gilteritinib 在许多亚组中显示出一致的生存益处。,0.25,"['a', 'survival', 'across', 'benefit']",['survival'],459,"['总体而言,Gilteritinib在许多子群中表现出一致的生存好处。']",0.25,"['a', 'survival', 'across', 'benefit']",['survival'],,
461,460,"although gilteritinib therapy resulted in 63 patients being able to undergo transplantation , the contribution of the transplantation to the survival benefit from gilteritinib is difficult to assess .",尽管 gilteritinib 治疗使 63 名患者能够接受移植，但移植对 gilteritinib 生存获益的贡献难以评估。,0.5555555555555556,"['transplantation', 'survival', 'undergo', 'therapy', 'being', 'assess', 'benefit', 'to', 'difficult']","['transplantation', 'survival', 'therapy', 'assess', 'difficult']",460,"['虽然Gilteritinib治疗导致63名患者能够接受移植,但移植对Gilteritinib的生存益的贡献很难评估。']",0.5555555555555556,"['transplantation', 'survival', 'undergo', 'therapy', 'being', 'assess', 'benefit', 'to', 'difficult']","['transplantation', 'survival', 'therapy', 'assess', 'difficult']",,
462,461,the main toxic effect was myelosuppression .,主要毒性作用为骨髓抑制。,0.3333333333333333,"['toxic', 'effect', 'toxic effect']",['effect'],461,['主要的毒性效应是神经抑郁症。'],0.3333333333333333,"['toxic', 'effect', 'toxic effect']",['effect'],,
463,462,a small signal regarding hepatic toxic effects bears attention in future studies .,关于肝毒性作用的一个小信号在未来的研究中值得关注。,0.3333333333333333,"['a', 'hepatic', 'toxic', 'regarding', 'signal', 'attention']","['regarding', 'signal']",462,['关于肝脏毒性影响的小信号在未来的研究中引起了注意。'],0.5,"['a', 'hepatic', 'toxic', 'regarding', 'signal', 'attention']","['regarding', 'signal', 'attention']",,
464,463,"the primary outcome was the percentage of time that the blood glucose level was within the target range of 70 to 180 mg per deciliter ( 3.9 to 10.0 mmol per liter ) , as measured by continuous glucose monitoring .",主要结果是血糖水平在 70 到 180 毫克每分升（3.9 到 10.0 毫摩尔每升）目标范围内的时间百分比，这是通过连续血糖监测测量的。,0.5882352941176471,"['monitoring', 'percentage', 'glucose', 'liter', 'range', 'outcome', 'continuous', 'blood', 'deciliter', 'time', 'primary', 'target', 'blood glucose', 'level', 'as', 'that', 'by']","['monitoring', 'liter', 'range', 'outcome', 'continuous', 'time', 'target', 'blood glucose', 'level', 'that']",463,"['主要结果是血糖水平在目标范围内达到70至180毫克(每升3.9至10.0毫米)的时间比例,根据持续的血糖监测测测量。']",0.4705882352941176,"['monitoring', 'percentage', 'glucose', 'liter', 'range', 'outcome', 'continuous', 'blood', 'deciliter', 'time', 'primary', 'target', 'blood glucose', 'level', 'as', 'that', 'by']","['monitoring', 'liter', 'range', 'outcome', 'time', 'target', 'blood glucose', 'level']",,
465,464,"the age range of the patients was 14 to 71 years , and the glycated hemoglobin level ranged from 5.4 to 10.6 % .",患者年龄范围为14～71岁，糖化血红蛋白水平为5.4～10.6%。,0.5,"['range', 'hemoglobin', 'hemoglobin level', 'age', 'to', 'and']","['range', 'hemoglobin', 'age']",464,"['患者的年龄范围为14至71岁,血糖血糖水平为5.4%至10.6%。']",0.3333333333333333,"['range', 'hemoglobin', 'hemoglobin level', 'age', 'to', 'and']","['range', 'age']",,
466,465,all 168 patients completed the trial .,全部 168 名患者完成了试验。,0.0,"['trial', 'all']",[],465,['所有168名患者完成了试验。'],0.0,"['trial', 'all']",[],,
467,466,"the mean adjusted difference in glycated hemoglobin level after 6 months was − 0.33 percentage points ( 95 % CI , − 0.53 to − 0.13 ; P = 0.001 ) .",6 个月后糖化血红蛋白水平的平均调整差异为 − 0.33 个百分点（95% CI，− 0.53 至 − 0.13；P = 0.001）。,0.4444444444444444,"['percentage', 'mean', 'hemoglobin', 'difference', 'hemoglobin level', 'after', 'P', 'CI', 'to']","['mean', 'hemoglobin', 'difference', 'after']",466,"['6个月后,血糖血糖水平的平均调整差异为 − 0.33 个百分点(95 % CI, − 0.53 到 − 0.13 ; P = 0.001 )。']",0.3333333333333333,"['percentage', 'mean', 'hemoglobin', 'difference', 'hemoglobin level', 'after', 'P', 'CI', 'to']","['mean', 'difference', 'after']",,
468,467,"despite advances in care , attaining good glycemic outcomes in patients with type 1 diabetes remains challenging ; the targets set by the American Diabetes Association are met in only a minority of patients.1,2","尽管在护理方面取得了进步，但要使 1 型糖尿病患者获得良好的血糖结果仍然具有挑战性；只有少数患者达到了美国糖尿病协会设定的目标。 1,2",0.3333333333333333,"['diabetes', 'type', '1', 'association', 'set', 'care', 'with', 'despite', 'good', 'met', 'in', 'by']","['diabetes', 'type', '1', 'good']",467,"['尽管在护理方面取得了进展,但在患有1型糖尿病的患者中取得良好的血糖结果仍然具有挑战性;美国糖尿病协会设定的目标仅在少数患者中实现。']",0.3333333333333333,"['diabetes', 'type', '1', 'association', 'set', 'care', 'with', 'despite', 'good', 'met', 'in', 'by']","['diabetes', 'type', '1', 'good']",,
469,468,an investigational device exemption was approved by the Food and Drug Administration .,一项试验性器械豁免获得了食品和药物管理局的批准。,0.25,"['food and drug administration', 'device', 'exemption', 'by']",['device'],468,['调查设备豁免已由食品和药物管理局批准。'],0.5,"['food and drug administration', 'device', 'exemption', 'by']","['device', 'by']",,
470,469,an independent data and safety monitoring board provided trial oversight .,一个独立的数据和安全监督委员会提供试验监督。,0.4285714285714285,"['safety', 'monitoring', 'data', 'board', 'trial', 'independent', 'and']","['safety', 'data', 'independent']",469,['一个独立的数据和安全监测委员会提供审查监督。'],0.5714285714285714,"['safety', 'monitoring', 'data', 'board', 'trial', 'independent', 'and']","['safety', 'monitoring', 'data', 'independent']",,
471,469,an independent data and safety monitoring board provided trial oversight .,一个独立的数据和安全监督委员会提供试验监督。,0.4285714285714285,"['safety', 'monitoring', 'data', 'board', 'trial', 'independent', 'and']","['safety', 'data', 'independent']",469,['一个独立的数据和安全监测委员会提供审查监督。'],0.5714285714285714,"['safety', 'monitoring', 'data', 'board', 'trial', 'independent', 'and']","['safety', 'monitoring', 'data', 'independent']",,
472,470,"the first , second , and last authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol .",第一、第二和最后一位作者保证数据的完整性和准确性以及试验对方案的忠实度。,0.4444444444444444,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'second', 'and', 'first']","['data', 'accuracy', 'completeness', 'first']",470,['第一、第二、最后的作者对数据的完整性和准确性以及审判对议定书的忠诚性表示赞扬。'],0.6666666666666666,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'second', 'and', 'first']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'first']",,
473,471,funding was provided by the National Institute of Diabetes and Digestive and Kidney Diseases .,资金由国家糖尿病、消化和肾脏疾病研究所提供。,0.6666666666666666,"['diabetes', 'kidney', 'digestive', 'institute', 'by', 'and']","['diabetes', 'kidney', 'institute', 'by']",471,['该基金由国家糖尿病和消化和肾脏疾病研究所提供。'],0.6666666666666666,"['diabetes', 'kidney', 'digestive', 'institute', 'by', 'and']","['diabetes', 'kidney', 'institute', 'by']",,
474,472,"tandem Diabetes Care reviewed the manuscript but was not otherwise involved in the trial design , conduct , data analysis , or manuscript preparation .",tandem Diabetes Care 审阅了手稿，但未参与试验设计、实施、数据分析或手稿准备。,0.5,"['tandem', 'diabetes', 'data', 'analysis', 'preparation', 'manuscript', 'trial', 'conduct', 'care', 'design', 'in', 'but']","['data', 'analysis', 'preparation', 'manuscript', 'design', 'but']",472,"['tandem Diabetes Care 审查了手稿,但没有其他参与试验设计、行为、数据分析或手稿编制。']",0.4166666666666667,"['tandem', 'diabetes', 'data', 'analysis', 'preparation', 'manuscript', 'trial', 'conduct', 'care', 'design', 'in', 'but']","['data', 'analysis', 'manuscript', 'design', 'but']",,
475,473,"to be included in the trial , patients had to be at least 14 years old and have a clinical diagnosis of type 1 diabetes ; they also had to have been treated with insulin for at least 1 year by means of a pump or multiple daily injections , without a restriction on the glycated hemoglobin level ( complete eligibility criteria are described in Table S1 in the Supplementary Appendix , available at NEJM.org ) .",被纳入试验的患者必须至少年满 14 岁，并且有 1 型糖尿病的临床诊断；他们还必须通过胰岛素泵或每日多次注射接受胰岛素治疗至少 1 年，且糖化血红蛋白水平不受限制（完整的资格标准见补充附录表 S1，补充附录可在 NEJM 获取。组织）。,0.4666666666666667,"['insulin', 'diabetes', 'type', 'appendix', 'table', 'year', '1', 'hemoglobin', 'multiple', 'supplementary', 'years old', 'complete', 'diagnosis', 'hemoglobin level', 'restriction', 'available', 'clinical', 'clinical diagnosis', 'trial', 'means', 'with', 'at', 'injections', 'pump', 'S1', 'have', 'by', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', 'table', 'year', '1', 'hemoglobin', 'years old', 'complete', 'diagnosis', 'clinical', 'clinical diagnosis', 'pump', 'have']",473,"['要参与试验,患者必须至少14岁,并具有1型糖尿病的临床诊断;他们也必须用胰岛素治疗至少1年,通过泵或多次每日注射,没有对血糖血糖水平的限制(完整的可选性标准如表S1所描述的补充附件,可在NEJM.org上找到)。']",0.4666666666666667,"['insulin', 'diabetes', 'type', 'appendix', 'table', 'year', '1', 'hemoglobin', 'multiple', 'supplementary', 'years old', 'complete', 'diagnosis', 'hemoglobin level', 'restriction', 'available', 'clinical', 'clinical diagnosis', 'trial', 'means', 'with', 'at', 'injections', 'pump', 'S1', 'have', 'by', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', 'appendix', 'table', 'year', '1', 'years old', 'complete', 'diagnosis', 'clinical', 'clinical diagnosis', 'pump', 'have']",,
476,474,patients in the control group received a continuous glucose monitor ; patients who had used a pump before participating in the trial used their personal pumps .,对照组患者接受连续血糖监测；在参与试验前使用过泵的患者使用了他们的个人泵。,0.5,"['group', 'a', 'glucose', 'control', 'monitor', 'who', 'continuous', 'personal', 'control group', 'trial', 'pump', 'before']","['group', 'control', 'continuous', 'control group', 'pump', 'before']",474,['控制组的患者接受了持续的葡萄糖监测;在参加试验之前使用泵的患者使用了自己的个人泵。'],0.5,"['group', 'a', 'glucose', 'control', 'monitor', 'who', 'continuous', 'personal', 'control group', 'trial', 'pump', 'before']","['group', 'glucose', 'control', 'personal', 'pump', 'before']",,
477,475,data from the devices were downloaded and reviewed at each visit and during telephone contacts .,每次访问和电话联系时，都会下载和审查来自设备的数据。,0.4,"['data', 'telephone', 'each', 'and', 'visit']","['data', 'telephone']",475,['设备上的数据在每次访问和电话接触时都被下载和审查。'],0.4,"['data', 'telephone', 'each', 'and', 'visit']","['data', 'telephone']",,
478,476,glycated hemoglobin also was measured at randomization and after 13 and 26 weeks at a central laboratory at the University of Minnesota Advanced Research and Diagnostic Laboratory .,还在明尼苏达大学高级研究与诊断实验室的中心实验室随机化以及 13 周和 26 周后测量了糖化血红蛋白。,0.6,"['a', 'research', 'randomization', 'hemoglobin', 'university', 'central', 'after', 'advanced', 'laboratory', 'diagnostic']","['research', 'randomization', 'hemoglobin', 'university', 'after', 'laboratory']",476,['血糖血糖也被测量在随机化和13和26周后在密内索塔大学先进研究和诊断实验室的中央实验室。'],0.5,"['a', 'research', 'randomization', 'hemoglobin', 'university', 'central', 'after', 'advanced', 'laboratory', 'diagnostic']","['research', 'randomization', 'university', 'after', 'laboratory']",,
479,477,reporting of adverse events was solicited throughout the trial .,在整个试验过程中征求不良事件的报告。,0.0,"['adverse', 'trial']",[],477,"['在审判期间,被要求报告不良事件。']",0.5,"['adverse', 'trial']",['trial'],,
480,478,"reportable adverse events included serious adverse events , adverse events occurring in association with a trial device or procedure , severe hypoglycemia ( defined as hypoglycemia leading to the need for assistance because of altered consciousness ) , diabetic ketoacidosis as defined by the Diabetes Control and Complications Trial , 11 or hyperglycemia with ketonemia for which a health care provider was contacted .",可报告的不良事件包括严重不良事件、与试验装置或程序相关的不良事件、严重低血糖（定义为因意识改变而导致需要帮助的低血糖）、糖尿病控制和并发症试验定义的糖尿病酮症酸中毒、 11 或高血糖伴酮血症，为此联系了医疗保健提供者。,0.4347826086956521,"['diabetes', 'procedure', 'control', 'defined', 'need', 'hypoglycemia', 'device', 'consciousness', 'association', 'health', 'diabetic', 'adverse', 'hyperglycemia', 'health care', 'trial', 'leading', 'assistance', 'with', 'severe', 'serious', 'by', 'to', 'and']","['diabetes', 'procedure', 'control', 'need', 'device', 'consciousness', 'association', 'hyperglycemia', 'health care', 'and']",478,"['报告可能的不良事件包括严重的不良事件,与测试设备或程序相结合发生的不良事件,严重的低血糖(定义为由于意识变化的帮助需要导致的低血糖),糖尿病细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞']",0.3478260869565217,"['diabetes', 'procedure', 'control', 'defined', 'need', 'hypoglycemia', 'device', 'consciousness', 'association', 'health', 'diabetic', 'adverse', 'hyperglycemia', 'health care', 'trial', 'leading', 'assistance', 'with', 'severe', 'serious', 'by', 'to', 'and']","['diabetes', 'procedure', 'need', 'device', 'consciousness', 'association', 'by', 'to']",,
481,479,"the primary outcome was the percentage of time that the glucose level , as measured by the continuous glucose monitor , was in the target range of 70 to 180 mg per deciliter ( 3.9 to 10.0 mmol per liter ) .",主要结果是连续血糖监测仪测量的血糖水平处于 70 至 180 毫克/分升（3.9 至 10.0 毫摩尔/升）目标范围内的时间百分比。,0.5333333333333333,"['percentage', 'glucose', 'monitor', 'liter', 'range', 'outcome', 'continuous', 'deciliter', 'time', 'primary', 'target', 'level', 'as', 'that', 'by']","['liter', 'range', 'outcome', 'continuous', 'time', 'target', 'level', 'that']",479,"['主要结果是糖水平在持续的糖监测器测量的时间比例,在每分升70至180毫克(每升3.9至10.0毫莫尔)的目标范围内。']",0.4666666666666667,"['percentage', 'glucose', 'monitor', 'liter', 'range', 'outcome', 'continuous', 'deciliter', 'time', 'primary', 'target', 'level', 'as', 'that', 'by']","['liter', 'range', 'outcome', 'time', 'target', 'level', 'that']",,
482,480,"the main secondary outcomes , which were tested in a hierarchical fashion to maintain a type I error rate of 5 % , were the percentage of time that the glucose level was greater than 180 mg per deciliter , the mean glucose concentration , the glycated hemoglobin level at 26 weeks , the percentage of time that the glucose level was less than 70 mg per deciliter , and the percentage of time that the glucose level was less than 54 mg per deciliter ( 3.0 mmol per liter ) .",主要的次要结局是血糖水平高于 180 mg/dL 的时间百分比、平均血糖浓度、糖化血红蛋白水平26 周时，血糖水平低于 70 毫克/分升的时间百分比，以及血糖水平低于 54 毫克/分升（3.0 毫摩尔/升）的时间百分比。,0.4,"['percentage', 'type', '5', 'glucose', 'concentration', 'mean', 'liter', 'rate', 'hemoglobin', 'deciliter', 'maintain', 'time', 'hemoglobin level', 'secondary', 'error', 'I', 'that', 'to', 'and', 'error rate']","['5', 'concentration', 'mean', 'liter', 'hemoglobin', 'time', 'that', 'to']",480,"['主要的次要结果,以序列的方式进行测试,以保持类型I错误率为5%,是葡萄糖水平超过180毫克每分,平均葡萄糖浓度26周,葡萄糖水平低于70毫克每分,葡萄糖水平低于54毫克每分,葡萄糖水平低于54毫克每分,葡萄糖水平低于30毫克每分。']",0.45,"['percentage', 'type', '5', 'glucose', 'concentration', 'mean', 'liter', 'rate', 'hemoglobin', 'deciliter', 'maintain', 'time', 'hemoglobin level', 'secondary', 'error', 'I', 'that', 'to', 'and', 'error rate']","['type', '5', 'glucose', 'concentration', 'mean', 'rate', 'error', 'to', 'error rate']",,
483,481,"additional secondary outcomes , for which the type I error was controlled with the use of the false discovery rate , are listed in the statistical analysis plan .",使用错误发现率控制 I 类错误的其他次要结果列在统计分析计划中。,0.4166666666666667,"['type', 'analysis', 'rate', 'false', 'controlled', 'additional', 'secondary', 'error', 'statistical analysis', 'with', 'I', 'in']","['analysis', 'rate', 'controlled', 'error', 'statistical analysis']",481,"['额外的次要结果,以便使用虚假发现率控制 I 类错误,在统计分析计划中列出。']",0.5,"['type', 'analysis', 'rate', 'false', 'controlled', 'additional', 'secondary', 'error', 'statistical analysis', 'with', 'I', 'in']","['analysis', 'rate', 'controlled', 'additional', 'error', 'statistical analysis']",,
484,482,"safety outcomes included the frequency of severe hypoglycemia , diabetic ketoacidosis , and other serious adverse events .",安全性结果包括严重低血糖、糖尿病酮症酸中毒和其他严重不良事件的发生率。,0.125,"['safety', 'frequency', 'hypoglycemia', 'diabetic', 'adverse', 'severe', 'serious', 'and']",['safety'],482,['安全结果包括严重的低血糖、糖尿病细菌和其他严重的副作用的频率。'],0.25,"['safety', 'frequency', 'hypoglycemia', 'diabetic', 'adverse', 'severe', 'serious', 'and']","['safety', 'frequency']",,
485,483,modification of the treatment effect according to baseline variables was assessed by including an interaction term in the models described above .,根据基线变量对治疗效果的修改是通过在上述模型中包含一个交互项来评估的。,0.5,"['modification', 'baseline', 'treatment', 'term', 'interaction', 'effect', 'treatment effect', 'by', 'to', 'assessed']","['baseline', 'treatment', 'term', 'effect', 'treatment effect']",483,"['根据基线变量对治疗效应的修改,通过在上述模型中包含互动术语来评估。']",0.3,"['modification', 'baseline', 'treatment', 'term', 'interaction', 'effect', 'treatment effect', 'by', 'to', 'assessed']","['baseline', 'treatment', 'effect']",,
486,484,the analyses of the data at 13 weeks paralleled those of the data at 26 weeks .,13 周时的数据分析与 26 周时的数据分析平行。,1.0,['data'],['data'],484,['13周的数据分析与26周的数据分析相匹配。'],1.0,['data'],['data'],,
487,485,"descriptive statistics include means with standard deviations and medians with interquartile ranges , depending on the distribution of data .",描述性统计包括具有标准差的均值和具有四分位数间距的中位数，具体取决于数据的分布。,0.625,"['standard', 'statistics', 'descriptive', 'data', 'distribution', 'means', 'descriptive statistics', 'with']","['standard', 'statistics', 'descriptive', 'data', 'distribution']",485,"['描述统计包括具有标准偏差的媒体和跨方范围的媒体,取决于数据的分布。']",0.5,"['standard', 'statistics', 'descriptive', 'data', 'distribution', 'means', 'descriptive statistics', 'with']","['standard', 'statistics', 'data', 'distribution']",,
488,486,"analyses were performed with SAS software , version 9.4 ( SAS Institute ) .",使用 SAS 软件 9.4 版（SAS Institute）进行分析。,0.2,"['version', 'software', 'institute', 'with', 'SAS']",['software'],486,"['分析是用SAS软件进行的,版本 9.4(SAS研究所)。']",0.6,"['version', 'software', 'institute', 'with', 'SAS']","['version', 'software', 'institute']",,
489,486,"analyses were performed with SAS software , version 9.4 ( SAS Institute ) .",使用 SAS 软件 9.4 版（SAS Institute）进行分析。,0.2,"['version', 'software', 'institute', 'with', 'SAS']",['software'],486,"['分析是用SAS软件进行的,版本 9.4(SAS研究所)。']",0.6,"['version', 'software', 'institute', 'with', 'SAS']","['version', 'software', 'institute']",,
490,487,"insulin pumps were used by 133 patients ( 79 % ) , and multiple daily insulin injections were used by 35 ( 21 % ) ; 118 ( 70 % ) were using continuous glucose monitoring , and 102 ( 86 % ) of these were using pumps .",133 名患者 (79%) 使用了胰岛素泵，35 名患者 (21%) 使用了每日多次胰岛素注射； 118 人 (70%) 使用连续血糖监测，其中 102 人 (86%) 使用泵。,0.375,"['monitoring', 'insulin', 'glucose', 'continuous', 'multiple', 'injections', 'by', 'and']","['monitoring', 'insulin', 'continuous']",487,"['胰岛素泵由133名患者(79%)使用,35名患者(21%)每天使用多种胰岛素注射;118名患者(70%)使用持续的葡萄糖监测,其中102名患者(86%)使用泵。']",0.5,"['monitoring', 'insulin', 'glucose', 'continuous', 'multiple', 'injections', 'by', 'and']","['monitoring', 'insulin', 'glucose', 'by']",,
491,488,the treatment effect was evident in the first month and was consistent over the 6 months ( Figure 1A ) .,治疗效果在第一个月就很明显，并且在 6 个月内保持一致（图 1A）。,0.5555555555555556,"['figure', 'month', 'treatment', 'effect', 'treatment effect', 'in', 'over', 'and', 'first']","['month', 'treatment', 'effect', 'treatment effect', 'first']",488,"['治疗效果在第一个月显而易见,并在6个月内保持一致(图1A)。']",0.6666666666666666,"['figure', 'month', 'treatment', 'effect', 'treatment effect', 'in', 'over', 'and', 'first']","['month', 'treatment', 'effect', 'treatment effect', 'and', 'first']",,
492,489,"this diurnal pattern , shown in Figure 1B , is a result of the increased aggressiveness of the algorithm to meet a lower glucose target during the second half of the night .",如图 1B 所示，这种昼夜模式是算法在后半夜为满足较低葡萄糖目标而增加攻击性的结果。,0.5,"['a', 'glucose', 'pattern', 'algorithm', 'figure', 'half', 'lower', 'target', 'diurnal', 'result', 'aggressiveness', 'second', 'this', 'in', 'to', 'night']","['glucose', 'pattern', 'algorithm', 'half', 'target', 'result', 'this', 'night']",489,"['这个日常模式,显示在图1B,是由于算法的侵略性增加的结果,以满足低血糖目标在第二半夜间。']",0.5625,"['a', 'glucose', 'pattern', 'algorithm', 'figure', 'half', 'lower', 'target', 'diurnal', 'result', 'aggressiveness', 'second', 'this', 'in', 'to', 'night']","['pattern', 'algorithm', 'half', 'target', 'result', 'aggressiveness', 'this', 'to', 'night']",,
493,490,there was no significant difference between the groups in the daily insulin amount ( P = 0.83 ) or in weight change ( P = 0.83 ) ( Table S8 ) .,每日胰岛素用量 (P = 0.83) 或体重变化 (P = 0.83) 组间无显着差异（表 S8）。,0.6666666666666666,"['insulin', 'weight', 'table', 'difference', 'amount', 'no', 'change', 'P', 'significant difference']","['insulin', 'weight', 'table', 'difference', 'amount', 'change']",490,"['在每日胰岛素量(P = 0.83 )或体重变化(P = 0.83 )中,群体之间没有显著的差异(表 S8)。']",0.6666666666666666,"['insulin', 'weight', 'table', 'difference', 'amount', 'no', 'change', 'P', 'significant difference']","['insulin', 'weight', 'table', 'difference', 'amount', 'change']",,
494,491,system USE,系统使用,1.0,['system'],['system'],491,['系统使用'],1.0,['system'],['system'],,
495,492,severe hypoglycemia did not occur in either group .,两组均未发生严重低血糖。,0.4,"['group', 'hypoglycemia', 'occur', 'severe', 'in']","['group', 'occur']",492,['严重的甲状腺炎在任何群体中都没有发生。'],0.4,"['group', 'hypoglycemia', 'occur', 'severe', 'in']","['group', 'occur']",,
496,493,no severe hypoglycemic events occurred in either group .,两组均未发生严重低血糖事件。,0.2,"['group', 'no', 'severe', 'hypoglycemic', 'in']",['group'],493,['在任何一个群体中都没有发生过严重的催眠现象。'],0.2,"['group', 'no', 'severe', 'hypoglycemic', 'in']",['group'],,
497,494,"in our trial , 70 % of the patients were using a continuous glucose monitor and 79 % were using an insulin pump at the time of enrollment , percentages that are substantially higher than the reported usage in the general population of patients with type 1 diabetes.2",在我们的试验中，70 % 的患者在入组时使用连续血糖监测仪，而 79 % 的患者在使用胰岛素泵，这些百分比大大高于报告的 1 型糖尿病患者一般人群的使用率。 2,0.6,"['insulin', 'population', 'type', 'glucose', 'monitor', '1', 'continuous', 'general', 'time', 'usage', 'trial', 'with', 'pump', 'that', 'and']","['insulin', 'population', 'type', '1', 'continuous', 'time', 'usage', 'pump', 'and']",494,"['在我们的研究中,70%的患者使用持续的葡萄糖监测器,79%在注册时使用胰岛素泵,比1型糖尿病患者的总体人口所报告的使用量要高得多。']",0.5333333333333333,"['insulin', 'population', 'type', 'glucose', 'monitor', '1', 'continuous', 'general', 'time', 'usage', 'trial', 'with', 'pump', 'that', 'and']","['insulin', 'population', 'type', 'glucose', '1', 'time', 'usage', 'pump']",,
498,495,"however , our results appeared to be similar in patients who were not using a pump or a continuous glucose monitor before the trial .",然而，在试验前未使用泵或连续血糖监测仪的患者中，我们的结果似乎相似。,0.4,"['a', 'glucose', 'monitor', 'who', 'continuous', 'be', 'trial', 'pump', 'before', 'similar']","['continuous', 'be', 'pump', 'before']",495,"['然而,我们的结果似乎与在测试之前没有使用泵或持续的葡萄糖监测器的患者相似。']",0.4,"['a', 'glucose', 'monitor', 'who', 'continuous', 'be', 'trial', 'pump', 'before', 'similar']","['glucose', 'be', 'pump', 'before']",,
499,496,"strengths of the present trial include the inclusion of patients across a wide range of baseline characteristics , 100 % patient retention , and a high level of adherence to the use of the assigned devices in both treatment groups .",本试验的优势包括纳入具有广泛基线特征的患者、100% 的患者保留率以及两个治疗组对指定设备使用的高度依从性。,0.3529411764705882,"['a', 'range', 'baseline', 'retention', 'inclusion', 'wide', 'treatment', 'across', 'characteristics', 'patient', 'trial', 'present', 'level', 'adherence', 'to', 'and', 'high']","['baseline', 'retention', 'treatment', 'characteristics', 'patient', 'high']",496,"['本次研究的优点包括患者在广泛的基因特征中参与,患者的百分之百保留,以及在两组治疗中使用所分配的设备的高度坚持。']",0.3529411764705882,"['a', 'range', 'baseline', 'retention', 'inclusion', 'wide', 'treatment', 'across', 'characteristics', 'patient', 'trial', 'present', 'level', 'adherence', 'to', 'and', 'high']","['retention', 'wide', 'treatment', 'characteristics', 'patient', 'high']",,
500,497,"continuous glucose monitoring was used by both groups , with minimal reliance on blood glucose measurements .",两组均使用连续血糖监测，对血糖测量的依赖最小。,0.375,"['monitoring', 'glucose', 'continuous', 'blood', 'minimal', 'blood glucose', 'with', 'by']","['monitoring', 'continuous', 'blood glucose']",497,"['持续的葡萄糖监测是由两组使用的,与血糖测量的最低依赖。']",0.5,"['monitoring', 'glucose', 'continuous', 'blood', 'minimal', 'blood glucose', 'with', 'by']","['monitoring', 'glucose', 'blood glucose', 'by']",,
501,498,our trial also had certain limitations .,我们的试验也有一定的局限性。,0.0,"['trial', 'certain']",[],498,['我们的审判也有一些限制。'],0.5,"['trial', 'certain']",['trial'],,
502,499,outcomes were similar in a randomized comparison of these approaches .,这些方法的随机比较结果相似。,0.25,"['a', 'comparison', 'in', 'similar']",['comparison'],499,['结果在这些方法的随机比较中相似。'],0.25,"['a', 'comparison', 'in', 'similar']",['comparison'],,
503,500,hemiarthroplasty ( replacement of only the femoral head ) and total hip arthroplasty ( replacement of both the femoral head and acetabulum ) are both options for patients with displaced fractures of the femoral neck ; each approach has certain advantages and disadvantages .,半髋关节置换术（仅置换股骨头）和全髋关节置换术（置换股骨头和髋臼）都是股骨颈移位骨折患者的选择；每种方法都有一定的优点和缺点。,0.5294117647058824,"['approach', 'neck', 'head', 'femoral', 'acetabulum', 'total', 'hip', 'arthroplasty', 'replacement', 'options', 'with', 'certain', 'femoral head', 'hemiarthroplasty', 'fractures', 'each', 'and']","['neck', 'head', 'femoral', 'acetabulum', 'hip', 'arthroplasty', 'replacement', 'femoral head', 'fractures']",500,['hemiarthroplasty(只替代阴道头)和整体头骨动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动脉动'],0.0588235294117647,"['approach', 'neck', 'head', 'femoral', 'acetabulum', 'total', 'hip', 'arthroplasty', 'replacement', 'options', 'with', 'certain', 'femoral head', 'hemiarthroplasty', 'fractures', 'each', 'and']",['head'],,
504,501,"in this international randomized trial , researchers compared the two procedures in 1495 patients .",在这项国际随机试验中，研究人员对 1495 名患者的两种手术进行了比较。,0.25,"['trial', 'this', 'in', 'two']",['two'],501,"['在这项国际随机研究中,研究人员在1495名患者中比较了两种程序。']",0.25,"['trial', 'this', 'in', 'two']",['two'],,
505,502,the primary endpoint - another hip procedure required and performed within 24 months - occurred in 8 % of patients in both groups .,主要终点——在 24 个月内需要并进行的另一次髋关节手术——发生在两组中 8% 的患者中。,0.1666666666666666,"['procedure', 'hip', 'primary', 'endpoint', '-', 'and']",['hip'],502,['初级终点 - 另一个需要并在24个月内进行的手术 - 发生在两组患者的8%。'],0.0,"['procedure', 'hip', 'primary', 'endpoint', '-', 'and']",[],,
506,503,"conversely , some measures of pain and function favored total hip arthroplasty compared with hemiarthroplasty , but differences were small and did not meet standard thresholds for clinical importance .",相反，与股骨头置换术相比，一些疼痛和功能指标有利于全髋关节置换术，但差异很小，不符合临床重要性的标准阈值。,0.7,"['standard', 'function', 'total', 'hip', 'pain', 'arthroplasty', 'clinical', 'with', 'hemiarthroplasty', 'but']","['standard', 'function', 'hip', 'pain', 'arthroplasty', 'clinical', 'but']",503,"['相比之下,某些疼痛和功能的测量有利于整体甲状腺炎与甲状腺炎相比,但差异很小,并且不符合临床意义的标准限制。']",0.5,"['standard', 'function', 'total', 'hip', 'pain', 'arthroplasty', 'clinical', 'with', 'hemiarthroplasty', 'but']","['standard', 'function', 'pain', 'clinical', 'but']",,
507,504,"most children received breast milk , alone or with formula ; only 70 received formula alone .",大多数儿童单独或与配方奶粉一起吃母乳；只有 70 人收到了配方奶粉。,0.5,"['milk', 'formula', 'breast', 'breast milk', 'with', 'alone']","['milk', 'breast milk', 'alone']",504,['大多数儿童单独或服用乳制品;只有70人单独服用乳制品。'],0.3333333333333333,"['milk', 'formula', 'breast', 'breast milk', 'with', 'alone']","['milk', 'alone']",,
508,505,median gestational age was 29 weeks .,中位孕龄为 29 周。,0.25,"['median', 'gestational', 'age', 'gestational age']",['gestational age'],505,['平均生育年龄为29周。'],0.25,"['median', 'gestational', 'age', 'gestational age']",['age'],,
509,506,approximately 95 % of participants in each group survived to 24 months ( corrected for gestational age ) .,每组中大约 95% 的参与者存活到 24 个月（校正胎龄）。,0.1,"['group', 'gestational', 'age', 'gestational age', 'survived', 'approximately', 'each', 'in', 'to', 'corrected']",['group'],506,['大约95%的参与者在每个群体中幸存到24个月(修正为怀孕年龄)。'],0.2,"['group', 'gestational', 'age', 'gestational age', 'survived', 'approximately', 'each', 'in', 'to', 'corrected']","['group', 'age']",,
510,507,few adverse events occurred .,很少发生不良事件。,0.0,['adverse'],[],507,['有几个不良事件发生。'],0.0,['adverse'],[],,
511,508,"although this important study does not help define a preferred feeding protocol for very premature infants , it offers reassurance that careful feeding with daily increases of either 30 or 18 mL / kg has comparable outcomes .",尽管这项重要的研究无助于为极早产儿确定首选的喂养方案，但它提供了保证，每天增加 30 或 18 mL/kg 的小心喂养具有可比的结果。,0.0769230769230769,"['a', 'protocol', '/', 'study', 'feeding', 'increases', 'kg', 'premature', 'ml', 'with', 'careful', 'this', 'that']",['premature'],508,"['虽然这项重要研究并没有帮助确定非常早期婴儿的偏好营养协议,但它提供了重新保证,每天增加30或18毫升/公斤的谨慎营养有相似的结果。']",0.3076923076923077,"['a', 'protocol', '/', 'study', 'feeding', 'increases', 'kg', 'premature', 'ml', 'with', 'careful', 'this', 'that']","['protocol', 'kg', 'premature', 'careful']",,
512,509,"dupilumab now is approved for patients with chronic sinusitis and polyps , asthma , and eczema .",dupilumab 现在被批准用于患有慢性鼻窦炎和息肉、哮喘和湿疹的患者。,0.5714285714285714,"['asthma', 'sinusitis', 'eczema', 'chronic', 'with', 'dupilumab', 'and']","['asthma', 'sinusitis', 'eczema', 'chronic']",509,['dupilumab现在已被批准为患有慢性阴道炎和聚合物、哮喘和<unk>疹的患者。'],0.2857142857142857,"['asthma', 'sinusitis', 'eczema', 'chronic', 'with', 'dupilumab', 'and']","['asthma', 'chronic']",,
513,510,"researchers examined whether dupilumab ( Dupixent ) , a monoclonal antibody that targets interleukin ( IL ) -4 and 13 and is approved for asthma and eczema , is effective for CRSwNP .",研究人员检查了 dupilumab (Dupixent)，一种靶向白细胞介素 (IL) -4 和 13 的单克隆抗体，被批准用于治疗哮喘和湿疹，是否对 CRSwNP 有效。,0.5555555555555556,"['asthma', 'interleukin', 'antibody', 'monoclonal antibody', 'eczema', 'IL', 'dupilumab', 'that', 'and']","['asthma', 'interleukin', 'antibody', 'monoclonal antibody', 'eczema']",510,"['研究人员检查是否Dupilumab(Dupixent),一个针对Interleukin(IL) -4和13的单细胞抗体,并被批准为哮喘和<unk>疹,对CRSwNP有效。']",0.2222222222222222,"['asthma', 'interleukin', 'antibody', 'monoclonal antibody', 'eczema', 'IL', 'dupilumab', 'that', 'and']","['asthma', 'antibody']",,
514,511,dupilumab generally was well tolerated .,dupilumab 通常耐受性良好。,0.0,"['well', 'dupilumab']",[],511,['dupilumab 一般被很好地容忍。'],0.0,"['well', 'dupilumab']",[],,
515,512,patients with CRSwNP tend to have poor quality of life .,CRSwNP 患者的生活质量往往较差。,0.375,"['life', 'quality', 'quality of life', 'with', 'have', 'poor', 'tend', 'to']","['life', 'quality', 'quality of life']",512,['患有CRSwNP的患者往往生活质量不佳。'],0.5,"['life', 'quality', 'quality of life', 'with', 'have', 'poor', 'tend', 'to']","['life', 'quality', 'quality of life', 'have']",,
516,513,"treatment is suboptimal , consisting of nasal corticosteroids and saline rinses , frequent bursts of systemic corticosteroids , and sinus surgery .",治疗效果欠佳，包括鼻皮质类固醇和生理盐水冲洗、全身性皮质类固醇的频繁爆发和鼻窦手术。,0.4444444444444444,"['sinus', 'saline', 'surgery', 'nasal', 'treatment', 'suboptimal', 'systemic', 'frequent', 'and']","['sinus', 'saline', 'surgery', 'treatment']",513,"['治疗是微优的,由鼻子和盐肾脏组成,经常出现系统性皮质和阴道手术。']",0.2222222222222222,"['sinus', 'saline', 'surgery', 'nasal', 'treatment', 'suboptimal', 'systemic', 'frequent', 'and']","['surgery', 'treatment']",,
517,514,"dupilumab already has gained FDA approval for managing CRSwNP but probably will be prescribed only by otolaryngologists , allergists , and pulmonologists .",dupilumab 已获得 FDA 批准用于管理 CRSwNP，但可能只会由耳鼻喉科医生、过敏症科医生和肺科医生开处方。,0.375,"['approval', 'be', 'FDA', 'will', 'dupilumab', 'by', 'but', 'and']","['approval', 'by', 'but']",514,['dupilumab 已经获得了 FDA 批准来管理 CRSwNP 但可能只会由肿瘤学家、过敏学家和肺学家处方。'],0.375,"['approval', 'be', 'FDA', 'will', 'dupilumab', 'by', 'but', 'and']","['approval', 'by', 'but']",,
518,515,"and at a cost of US $ 43,000 annually , the drug could be a hard sell , especially when symptoms return after therapy stops .","并且每年花费 43,000 美元，这种药物可能很难销售，尤其是当治疗停止后症状再次出现时。",0.4166666666666667,"['a', 'hard', 'symptoms', 'therapy', 'be', 'after', 'cost', 'sell', 'drug', 'at', 'return', 'and']","['therapy', 'after', 'sell', 'drug', 'at']",515,"['每年43000美元的价格,该药物可能是一个艰难的销售,特别是当症状在治疗停止后回来时。']",0.5833333333333334,"['a', 'hard', 'symptoms', 'therapy', 'be', 'after', 'cost', 'sell', 'drug', 'at', 'return', 'and']","['hard', 'therapy', 'be', 'after', 'sell', 'drug', 'at']",,
519,516,"hemorrhage remains a leading cause of death after trauma , and resuscitation strategies continue to evolve .",出血仍然是创伤后死亡的主要原因，复苏策略也在不断发展。,0.5,"['trauma', 'death', 'hemorrhage', 'resuscitation', 'cause', 'cause of death', 'after', 'evolve', 'leading', 'continue', 'to', 'and']","['trauma', 'death', 'hemorrhage', 'resuscitation', 'cause', 'after']",516,"['出血仍然是创伤后死亡的主要原因,复兴策略仍在不断发展。']",0.4166666666666667,"['trauma', 'death', 'hemorrhage', 'resuscitation', 'cause', 'cause of death', 'after', 'evolve', 'leading', 'continue', 'to', 'and']","['trauma', 'death', 'hemorrhage', 'cause', 'after']",,
520,517,"using a French trauma registry , researchers retrospectively compared outcomes between patients who received at least two units of FFP for every three units of PRBC and patients who received a lower ratio of FFP to PRBC .",使用法国创伤登记，研究人员回顾性地比较了每三个单位的 PRBC 接受至少两个单位的 FFP 的患者与接受较低的 FFP 与 PRBC 比率的患者之间的结果。,0.4444444444444444,"['trauma', 'who', 'ratio', 'lower', 'registry', 'three', 'to', 'and', 'two']","['trauma', 'ratio', 'lower', 'two']",517,"['使用法国创伤记录,研究人员回顾地比较了接受至少两单位FFP的患者和接受较低的FFP与PRBC的患者之间的结果。']",0.4444444444444444,"['trauma', 'who', 'ratio', 'lower', 'registry', 'three', 'to', 'and', 'two']","['trauma', 'ratio', 'lower', 'two']",,
521,518,"of 897 patients , 34 % died within 30 days ( the primary outcome ) .",在 897 名患者中，34% 的患者在 30 天内死亡（主要结果）。,0.5,"['outcome', 'primary']",['outcome'],518,"['在897名患者中,34%在30天内死亡(初始结果)。']",0.5,"['outcome', 'primary']",['outcome'],,
522,519,"an exsanguinating patient is losing whole blood , so resuscitation strategies resembling whole blood replacement have face validity .",失血的病人正在失去全血，因此像全血置换这样的复苏策略具有表面有效性。,0.6666666666666666,"['face', 'blood', 'validity', 'resuscitation', 'patient', 'replacement', 'whole blood', 'have', 'so']","['face', 'resuscitation', 'patient', 'replacement', 'whole blood', 'have']",519,"['一个流血的病人正在失去整个血液,因此复活策略类似于整个血液的替代具有面对面有效性。']",0.4444444444444444,"['face', 'blood', 'validity', 'resuscitation', 'patient', 'replacement', 'whole blood', 'have', 'so']","['face', 'blood', 'patient', 'have']",,
523,520,"however , this study should not be used as part of the evidence supporting ( or refuting ) any transfusion strategy .",然而，这项研究不应被用作支持（或反驳）任何输血策略的证据的一部分。,0.5,"['part', 'transfusion', 'strategy', 'study', 'be', 'evidence', 'as', 'this']","['part', 'transfusion', 'strategy', 'evidence']",520,"['然而,这项研究不应作为支持(或拒绝)任何转移策略的证据的一部分。']",0.375,"['part', 'transfusion', 'strategy', 'study', 'be', 'evidence', 'as', 'this']","['part', 'strategy', 'evidence']",,
524,521,"until better evidence is available , clinicians should continue to provide care tailored for each patient encounter .",在获得更好的证据之前，临床医生应继续为每位患者提供量身定制的护理。,0.375,"['encounter', 'available', 'patient', 'evidence', 'care', 'continue', 'each', 'to']","['patient', 'evidence', 'continue']",521,"['直到有更好的证据,临床医生应该继续为每个病人提供适当的护理。']",0.375,"['encounter', 'available', 'patient', 'evidence', 'care', 'continue', 'each', 'to']","['patient', 'evidence', 'continue']",,
525,522,"ticagrelor monotherapy was associated with less bleeding at 1 year than continued dual antiplatelet therapy and no higher risks for death , myocardial infarction , or stroke .",与持续的双重抗血小板治疗相比，替格瑞洛单药治疗与 1 年时的出血较少相关，并且死亡、心肌梗死或中风的风险没有增加。,0.5384615384615384,"['bleeding', 'myocardial infarction', 'stroke', 'year', '1', 'death', 'antiplatelet', 'therapy', 'associated', 'no', 'dual', 'with', 'and']","['bleeding', 'myocardial infarction', 'stroke', 'year', '1', 'death', 'therapy']",522,"['Ticagrelor 单治疗与 1 年内较少的出血有关,而持续的双重抗膜治疗,并且没有死亡、心脏病发作或中风的风险更高。']",0.5384615384615384,"['bleeding', 'myocardial infarction', 'stroke', 'year', '1', 'death', 'antiplatelet', 'therapy', 'associated', 'no', 'dual', 'with', 'and']","['bleeding', 'stroke', 'year', '1', 'death', 'therapy', 'and']",,
526,523,"at 3 months , 7119 patients underwent randomization ( mean age , 65 ; diabetes , 37 % ; PCI for acute coronary syndrome , 65 % ) to continue this regimen or to receive ticagrelor alone .",在 3 个月时，7119 名患者被随机分组（平均年龄 65 岁；糖尿病，37%；急性冠状动脉综合征行 PCI，65%）以继续该方案或单独接受替格瑞洛。,0.6666666666666666,"['diabetes', 'mean', 'randomization', 'syndrome', 'coronary', 'age', 'acute', '3', 'continue', 'this', 'to', 'alone']","['diabetes', 'mean', 'randomization', 'syndrome', 'coronary', 'age', 'continue', 'alone']",523,"['在3個月內,7119名患者經歷了偶然化(平均年齡,65歲,糖尿病,37%;急性冠<unk>症候群的PCI,65%)以繼續這種治療或單獨接收Ticagrelor。']",0.25,"['diabetes', 'mean', 'randomization', 'syndrome', 'coronary', 'age', 'acute', '3', 'continue', 'this', 'to', 'alone']","['diabetes', 'mean', 'coronary']",,
527,524,"ischemic events were similar between groups , including a composite endpoint of death , nonfatal myocardial infarction , and nonfatal stroke ( 4 % in both ) .",各组间的缺血事件相似，包括死亡、非致死性心肌梗塞和非致死性中风的复合终点（均为 4%）。,0.3333333333333333,"['myocardial infarction', 'composite', 'stroke', 'death', '4', 'endpoint', 'and', 'ischemic', 'similar']","['myocardial infarction', 'stroke', 'death']",524,"['伊斯基米事件类似于群体之间,包括复合死亡点、非致命心脏病发作和非致命中风(两者中有4%)。']",0.2222222222222222,"['myocardial infarction', 'composite', 'stroke', 'death', '4', 'endpoint', 'and', 'ischemic', 'similar']","['stroke', 'death']",,
528,525,"stent thrombosis was nonsignificantly different between groups ( ticagrelor alone , 0.4 % ; ticagrelor plus aspirin , 0.6 % ) .",支架内血栓形成在各组之间无显着差异（单独替格瑞洛，0.4%；替格瑞洛联合阿司匹林，0.6%）。,0.6,"['aspirin', 'plus', 'thrombosis', 'stent', 'alone']","['aspirin', 'thrombosis', 'alone']",525,"['甲状腺肿瘤在群体之间毫无意义地不同(单独的ticagrelor,0.4%;ticagrelor plus aspirin,0.6%)。']",0.2,"['aspirin', 'plus', 'thrombosis', 'stent', 'alone']",['alone'],,
529,526,"in the search for ways to reduce bleeding risks without increasing ischemic events after PCI with a DES , the drug regimen of ticagrelor plus aspirin for 3 months followed by ticagrelor alone appears to be a winner .",在使用 DES 进行 PCI 后寻找降低出血风险而不增加缺血事件的方法时，替格瑞洛加阿司匹林 3 个月然后单独替格瑞洛的药物治疗方案似乎是赢家。,0.5333333333333333,"['bleeding', 'aspirin', 'reduce', 'plus', 'be', 'search', 'after', '3', 'with', 'drug', 'by', 'to', 'alone', 'without', 'ischemic']","['bleeding', 'aspirin', 'reduce', 'plus', 'be', 'after', 'drug', 'alone']",526,"['在寻找减少出血风险的途径,而不增加 PCI 后的化学事件,DES 药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充药物补充']",0.3333333333333333,"['bleeding', 'aspirin', 'reduce', 'plus', 'be', 'search', 'after', '3', 'with', 'drug', 'by', 'to', 'alone', 'without', 'ischemic']","['bleeding', 'plus', 'be', 'after', 'drug']",,
530,527,"as the authors note , these findings differ from the GLOBAL LEADERS trial ( NEJM JW Cardiol Oct 2018 and Lancet 2018 ; 392 : 940 ) , which failed to demonstrate a bleeding benefit with early discontinuation of aspirin , possibly due to differences in patients and study design .",正如作者所指出的，这些发现不同于 GLOBAL LEADERS 试验（ NEJM JW Cardiol Oct 2018 和 Lancet 2018 ； 392 : 940 ），后者未能证明早期停用阿司匹林对出血有益，这可能是由于患者和研究设计的差异.,0.3333333333333333,"['bleeding', 'aspirin', 'lancet', 'study', 'early', 'differ', 'note', 'trial', 'benefit', 'design', 'due', 'with', 'possibly', 'to', 'and']","['bleeding', 'aspirin', 'early', 'design', 'to']",527,"['作者指出,这些发现与全球领袖试验(NEJM JW Cardiol Oct 2018 和 Lancet 2018 ; 392 : 940 )不同,由于患者和研究设计的差异可能导致早期停止使用阿司匹林的出血益处。']",0.3333333333333333,"['bleeding', 'aspirin', 'lancet', 'study', 'early', 'differ', 'note', 'trial', 'benefit', 'design', 'due', 'with', 'possibly', 'to', 'and']","['bleeding', 'aspirin', 'early', 'design', 'to']",,
531,528,"in contrast , approaches using clopidogrel have demonstrated benefits , but these studies were underpowered for ischemic endpoints .",相比之下，使用氯吡格雷的方法已显示出益处，但这些研究对缺血终点的效力不足。,0.2857142857142857,"['demonstrated', 'contrast', 'clopidogrel', 'have', 'in', 'but', 'ischemic']","['clopidogrel', 'but']",528,"['相比之下,使用 clopidogrel 的方法已经证明了好处,但这些研究被支持以化学终点。']",0.1428571428571428,"['demonstrated', 'contrast', 'clopidogrel', 'have', 'in', 'but', 'ischemic']",['but'],,
532,529,"further studies are needed to compare agents , timing , and different risk populations .",需要进一步的研究来比较药物、时间和不同的风险人群。,0.4,"['risk', 'compare', 'timing', 'to', 'and']","['risk', 'compare']",529,['需要进一步的研究来比较因素、时间和不同风险人口。'],0.4,"['risk', 'compare', 'timing', 'to', 'and']","['risk', 'compare']",,
533,530,"in the meantime , stopping aspirin after 3 months of dual antiplatelet therapy with ticagrelor in patients at risk for bleeding seems reasonable .",与此同时，有出血风险的患者在使用替格瑞洛进行双重抗血小板治疗 3 个月后停用阿司匹林似乎是合理的。,0.5,"['bleeding', 'aspirin', 'antiplatelet', 'therapy', 'risk', 'after', '3', 'dual', 'with', 'stopping']","['bleeding', 'aspirin', 'therapy', 'risk', 'after']",530,"['与此同时,在患有出血风险的患者中,在3个月的双重抗细胞治疗后停止阿司匹林似乎是合理的。']",0.5,"['bleeding', 'aspirin', 'antiplatelet', 'therapy', 'risk', 'after', '3', 'dual', 'with', 'stopping']","['bleeding', 'aspirin', 'therapy', 'risk', 'after']",,
534,531,"a similar number of grade 3 or greater adverse events occurred in the cabazitaxel and abiraterone / enzalutamide groups ( 56 % and 52 % , respectively ) .",卡巴他赛组和阿比特龙/恩杂鲁胺组发生了相似数量的 3 级或更高级别的不良事件（分别为 56% 和 52%）。,0.2727272727272727,"['a', 'grade', '/', 'adverse', 'number', '3', 'cabazitaxel', 'enzalutamide', 'in', 'and', 'similar']","['number', 'cabazitaxel', 'enzalutamide']",531,['类似数量的3级或更大的副作用发生在cabazitaxel 和 abiraterone / enzalutamide 群体( 56 % 和 52 % 相应 ) 。'],0.0909090909090909,"['a', 'grade', '/', 'adverse', 'number', '3', 'cabazitaxel', 'enzalutamide', 'in', 'and', 'similar']",['number'],,
535,532,patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke are at high risk for cardiovascular events .,没有心肌梗死或中风的稳定性冠状动脉疾病和糖尿病患者发生心血管事件的风险很高。,0.5714285714285714,"['myocardial infarction', 'diabetes', 'disease', 'cardiovascular', 'stroke', 'who', 'high risk', 'coronary', 'diabetes mellitus', 'with', 'coronary artery', 'at', 'have not', 'and']","['myocardial infarction', 'diabetes', 'disease', 'cardiovascular', 'stroke', 'coronary', 'diabetes mellitus', 'coronary artery']",532,"['患有稳定的冠状动脉疾病和糖尿病患者,没有心脏病发作或中风,患有高心血管事件的风险。']",0.5,"['myocardial infarction', 'diabetes', 'disease', 'cardiovascular', 'stroke', 'who', 'high risk', 'coronary', 'diabetes mellitus', 'with', 'coronary artery', 'at', 'have not', 'and']","['diabetes', 'disease', 'cardiovascular', 'stroke', 'coronary', 'diabetes mellitus', 'coronary artery']",,
536,533,whether adding ticagrelor to aspirin improves outcomes in this population is unclear .,在阿司匹林中加入替格瑞洛是否能改善这一人群的结局尚不清楚。,0.75,"['aspirin', 'population', 'this', 'to']","['aspirin', 'population', 'this']",533,['是否添加Ticagrelor到阿司匹林改善结果在这个人口是不清楚的。'],0.75,"['aspirin', 'population', 'this', 'to']","['aspirin', 'population', 'this']",,
537,534,patients with previous myocardial infarction or stroke were excluded .,既往有心肌梗塞或中风的患者被排除在外。,0.5,"['myocardial infarction', 'stroke', 'previous', 'with']","['myocardial infarction', 'stroke']",534,['以前患有心脏病发作或中风的患者被排除。'],0.25,"['myocardial infarction', 'stroke', 'previous', 'with']",['stroke'],,
538,535,"the primary efficacy outcome was a composite of cardiovascular death , myocardial infarction , or stroke .",主要疗效结果是心血管死亡、心肌梗死或中风的复合结果。,0.625,"['myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'outcome', 'death', 'primary', 'efficacy']","['myocardial infarction', 'cardiovascular', 'stroke', 'outcome', 'death']",535,['主要效力结果是心血管死亡、心脏病发作或中风的组成。'],0.5,"['myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'outcome', 'death', 'primary', 'efficacy']","['cardiovascular', 'stroke', 'outcome', 'death']",,
539,536,the primary safety outcome was major bleeding as defined by the Thrombolysis in Myocardial Infarction ( TIMI ) criteria .,主要安全性结果是心肌梗死溶栓 (TIMI) 标准定义的大出血。,0.5,"['bleeding', 'safety', 'myocardial infarction', 'defined', 'outcome', 'thrombolysis', 'major', 'primary', 'as', 'by']","['bleeding', 'safety', 'myocardial infarction', 'outcome', 'thrombolysis']",536,"['主要的安全结果是主要的出血,根据心脏病发作(TIMI)中的血管炎(Trompolysis in Myocardial Infarction)定义。']",0.4,"['bleeding', 'safety', 'myocardial infarction', 'defined', 'outcome', 'thrombolysis', 'major', 'primary', 'as', 'by']","['bleeding', 'safety', 'outcome', 'primary']",,
540,537,permanent treatment discontinuation was more frequent with ticagrelor than placebo ( 34.5 % vs. 25.4 % ) .,与安慰剂组相比，替格瑞洛组永久性停药的发生率更高（34.5% 对 25.4%）。,0.2,"['placebo', 'permanent', 'treatment', 'with', 'frequent']",['placebo'],537,['永久性治疗中断比 placebo 更常见(34.5% 与 25.4% )。'],0.2,"['placebo', 'permanent', 'treatment', 'with', 'frequent']",['treatment'],,
541,538,"there was no significant difference in the incidence of fatal bleeding ( 0.2 % vs. 0.1 % ; hazard ratio , 1.90 ; 95 % CI , 0.87 to 4.15 ; P = 0.11 ) .",致命性出血的发生率没有显着差异（0.2% 对 0.1%；风险比，1.90；95% CI，0.87 至 4.15；P = 0.11）。,0.4545454545454545,"['bleeding', 'incidence', 'ratio', 'hazard ratio', 'difference', 'fatal', 'no', 'P', 'significant difference', 'CI', 'to']","['bleeding', 'incidence', 'ratio', 'hazard ratio', 'difference']",538,"['致命出血的发病率没有显著的差异( 0.2% 与 0.1% ; 危险比例, 1.90 ; 95 % CI, 0.87 至 4.15 ; P = 0.11 )。']",0.3636363636363636,"['bleeding', 'incidence', 'ratio', 'hazard ratio', 'difference', 'fatal', 'no', 'P', 'significant difference', 'CI', 'to']","['bleeding', 'incidence', 'ratio', 'difference']",,
542,539,"the incidence of an exploratory composite outcome of irreversible harm ( death from any cause , myocardial infarction , stroke , fatal bleeding , or intracranial hemorrhage ) was similar in the ticagrelor group and the placebo group ( 10.1 % vs. 10.8 % ; hazard ratio , 0.93 ; 95 % CI , 0.86 to 1.02 ) .",不可逆伤害（全因死亡、心肌梗死、卒中、致命性出血或颅内出血）的探索性复合结局的发生率在替格瑞洛组和安慰剂组中相似（10.1 % 对 10.8 % ；风险比 0.93 ） ；95% CI，0.86 至 1.02）。,0.5714285714285714,"['bleeding', 'group', 'myocardial infarction', 'composite', 'placebo', 'incidence', 'stroke', 'ratio', 'hazard ratio', 'outcome', 'death', 'hemorrhage', 'intracranial', 'intracranial hemorrhage', 'exploratory', 'fatal', 'cause', 'CI', 'and', 'similar', 'irreversible']","['bleeding', 'group', 'myocardial infarction', 'placebo', 'incidence', 'stroke', 'ratio', 'hazard ratio', 'death', 'hemorrhage', 'intracranial hemorrhage', 'irreversible']",539,"['探测组合的不可逆转损害(任何原因的死亡、心脏病发作、中风、致命出血或内分泌出血)的发病率在Ticagrelor群体和Placebo群体中是相似的(10.1% vs.10.8%;风险比例,0.93;95% CI,0.86 至 1.02)。']",0.5714285714285714,"['bleeding', 'group', 'myocardial infarction', 'composite', 'placebo', 'incidence', 'stroke', 'ratio', 'hazard ratio', 'outcome', 'death', 'hemorrhage', 'intracranial', 'intracranial hemorrhage', 'exploratory', 'fatal', 'cause', 'CI', 'and', 'similar', 'irreversible']","['bleeding', 'group', 'incidence', 'stroke', 'ratio', 'hazard ratio', 'death', 'hemorrhage', 'exploratory', 'cause', 'similar', 'irreversible']",,
543,540,"in patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke , those who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin . ( Funded by AstraZeneca ; THEMIS ClinicalTrials.gov number , NCT01991795 . )",在没有心肌梗死或中风病史的稳定型冠状动脉疾病和糖尿病患者中，接受替格瑞洛联合阿司匹林治疗的患者与接受安慰剂联合阿司匹林治疗的患者相比，缺血性心血管事件发生率较低，但大出血发生率较高。 （由阿斯利康资助；THEMIS ClinicalTrials.gov 编号，NCT01991795。）,0.6086956521739131,"['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'placebo', 'incidence', 'disease', 'cardiovascular', 'stroke', 'who', 'plus', 'coronary', 'history', 'lower', 'major', 'number', 'with', 'coronary artery', 'by', 'but', 'and', 'without', 'ischemic']","['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'placebo', 'incidence', 'disease', 'cardiovascular', 'stroke', 'coronary', 'number', 'coronary artery', 'by', 'but']",540,"['在患有稳定的冠状动脉疾病和没有心脏病发作或中风史的糖尿病患者中,接受Ticagrelor加上阿司匹林的人比接受 placebo加上阿司匹林的人更少发病,但发病率较高(由AstraZeneca资助;TEMIS ClinicalTrials.gov号,NCT01991795 )。']",0.4782608695652174,"['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'placebo', 'incidence', 'disease', 'cardiovascular', 'stroke', 'who', 'plus', 'coronary', 'history', 'lower', 'major', 'number', 'with', 'coronary artery', 'by', 'but', 'and', 'without', 'ischemic']","['diabetes', 'aspirin', 'incidence', 'disease', 'stroke', 'plus', 'coronary', 'number', 'coronary artery', 'by', 'but']",,
544,541,"therefore , aspirin alone , the standard therapy in this population , may not provide fully effective antithrombotic protection .",因此，单独使用阿司匹林作为这一人群的标准疗法，可能无法提供完全有效的抗血栓形成保护。,0.7777777777777778,"['aspirin', 'population', 'standard', 'protection', 'antithrombotic', 'therapy', 'therefore', 'this', 'alone']","['aspirin', 'population', 'standard', 'protection', 'antithrombotic', 'therapy', 'alone']",541,"['因此,只有阿司匹林,这个人口的标准治疗,可能无法提供完全有效的抗血管保护。']",0.5555555555555556,"['aspirin', 'population', 'standard', 'protection', 'antithrombotic', 'therapy', 'therefore', 'this', 'alone']","['aspirin', 'population', 'standard', 'protection', 'therapy']",,
545,542,"ticagrelor , a reversible antagonist of the platelet P2Y12 receptor , has been shown to provide more consistent platelet inhibition than aspirin or clopidogrel.6",替格瑞洛是一种可逆的血小板 P2Y12 受体拮抗剂，已被证明可提供比阿司匹林或氯吡格雷更一致的血小板抑制作用。 6,1.0,"['antagonist', 'receptor', 'aspirin', 'inhibition', 'reversible', 'platelet']","['antagonist', 'receptor', 'aspirin', 'inhibition', 'reversible', 'platelet']",542,"['ticagrelor 是 P2Y12 受体的可逆转反对剂,已被证明提供比 aspirin 或 clopidogrel 更一致的平板抑制。']",0.3333333333333333,"['antagonist', 'receptor', 'aspirin', 'inhibition', 'reversible', 'platelet']","['receptor', 'inhibition']",,
546,543,the relative benefit of ticagrelor in these patients has been consistent regardless of the presence of diabetes .,无论是否存在糖尿病，替格瑞洛对这些患者的相对益处都是一致的。,0.4,"['presence', 'diabetes', 'relative', 'benefit', 'in']","['presence', 'diabetes']",543,"['在这些患者中,Ticagrelor的相对好处无论糖尿病的存在如何,都保持一致。']",0.4,"['presence', 'diabetes', 'relative', 'benefit', 'in']","['presence', 'diabetes']",,
547,544,"however , since patients with diabetes are at high baseline risk , they have had a large absolute benefit from the addition of ticagrelor to aspirin.9,10","然而，由于糖尿病患者的基线风险很高，他们从阿司匹林中加入替格瑞洛获得了很大的绝对益处。 9,10",0.6666666666666666,"['diabetes', 'baseline', 'addition', 'absolute', 'large', 'risk', 'benefit', 'with', 'at', 'have', 'to', 'high']","['diabetes', 'baseline', 'addition', 'absolute', 'risk', 'at', 'to', 'high']",544,"['然而,由于糖尿病患者患有高基因风险,他们从添加Ticagrelor到阿司匹林中获得了巨大的绝对好处。']",0.6666666666666666,"['diabetes', 'baseline', 'addition', 'absolute', 'large', 'risk', 'benefit', 'with', 'at', 'have', 'to', 'high']","['diabetes', 'addition', 'absolute', 'risk', 'at', 'have', 'to', 'high']",,
548,545,whether patients with stable coronary artery disease and diabetes who do not have a history of myocardial infarction or stroke also derive benefit from dual antiplatelet therapy with ticagrelor plus aspirin is unclear .,没有心肌梗死或卒中病史的稳定型冠状动脉疾病和糖尿病患者是否也能从替格瑞洛联合阿司匹林的双重抗血小板治疗中获益尚不清楚。,0.5294117647058824,"['myocardial infarction', 'diabetes', 'aspirin', 'disease', 'stroke', 'who', 'plus', 'antiplatelet', 'coronary', 'history', 'therapy', 'benefit', 'dual', 'with', 'coronary artery', 'have', 'and']","['myocardial infarction', 'diabetes', 'aspirin', 'disease', 'stroke', 'coronary', 'therapy', 'coronary artery', 'have']",545,"['是否患有稳定的冠状动脉疾病和糖尿病的患者,谁没有心脏病发作或中风的历史也受益从双重抗板治疗与Ticagrelor加上阿司匹林不清楚。']",0.5882352941176471,"['myocardial infarction', 'diabetes', 'aspirin', 'disease', 'stroke', 'who', 'plus', 'antiplatelet', 'coronary', 'history', 'therapy', 'benefit', 'dual', 'with', 'coronary artery', 'have', 'and']","['diabetes', 'aspirin', 'disease', 'stroke', 'plus', 'coronary', 'history', 'therapy', 'coronary artery', 'have']",,
549,546,"the Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study ( THEMIS ) was designed to test the efficacy and safety of ticagrelor , as compared with placebo , in addition to aspirin in this population .",在糖尿病患者干预研究 (THEMIS) 中，替格瑞洛对健康结果的影响旨在测试替格瑞洛与安慰剂以及阿司匹林在该人群中的疗效和安全性。,0.4117647058823529,"['safety', 'diabetes', 'aspirin', 'population', 'placebo', 'test', 'health', 'addition', 'study', 'diabetes mellitus', 'intervention', 'effect', 'efficacy', 'with', 'this', 'to', 'and']","['safety', 'diabetes', 'aspirin', 'population', 'placebo', 'health', 'diabetes mellitus']",546,"['甲状腺糖尿病患者干预研究(THEMIS)对健康结果的影响,旨在测试甲状腺糖尿病的有效性和安全性,与 placebo 相比,除了阿司匹林在这个人口。']",0.4117647058823529,"['safety', 'diabetes', 'aspirin', 'population', 'placebo', 'test', 'health', 'addition', 'study', 'diabetes mellitus', 'intervention', 'effect', 'efficacy', 'with', 'this', 'to', 'and']","['safety', 'diabetes', 'aspirin', 'population', 'health', 'diabetes mellitus', 'efficacy']",,
550,547,"AstraZeneca funded the trial , which was designed and overseen by an academic executive committee .",阿斯利康资助了该试验，该试验由学术执行委员会设计和监督。,0.5,"['committee', 'trial', 'by', 'and']","['committee', 'by']",547,"['AstraZeneca资助了审判,该审判由学术执行委员会设计和监督。']",0.75,"['committee', 'trial', 'by', 'and']","['committee', 'trial', 'by']",,
551,548,all the trial centers obtained ethical approval according to local regulations .,所有试验中心均按当地法规获得伦理批准。,0.1666666666666666,"['approval', 'ethical', 'local', 'trial', 'all', 'to']",['approval'],548,['所有审判中心根据当地法规获得道德批准。'],0.3333333333333333,"['approval', 'ethical', 'local', 'trial', 'all', 'to']","['approval', 'trial']",,
552,549,"site selection was conducted jointly by the national lead investigators and representatives of AstraZeneca , who performed site monitoring and supervision and handled the collection , storage , and analysis of the data .",选址由国家首席调查员和阿斯利康代表共同进行，他们负责现场监测和监督，并处理数据的收集、存储和分析。,0.6363636363636364,"['monitoring', 'lead', 'site', 'data', 'who', 'analysis', 'collection', 'supervision', 'storage', 'by', 'and']","['monitoring', 'site', 'data', 'analysis', 'collection', 'storage', 'by']",549,"['网站选择由国家领先的调查人员和AstraZeneca的代表共同进行,他们进行了网站监测和监督,处理数据的收集、存储和分析。']",0.5454545454545454,"['monitoring', 'lead', 'site', 'data', 'who', 'analysis', 'collection', 'supervision', 'storage', 'by', 'and']","['monitoring', 'data', 'analysis', 'collection', 'storage', 'by']",,
553,550,"the Baim Clinical Research Institute independently validated all the data that are reported , with funding from AstraZeneca .",Baim 临床研究所在阿斯利康的资助下独立验证了所有报告的数据。,0.5714285714285714,"['research', 'data', 'clinical', 'institute', 'with', 'all', 'that']","['research', 'data', 'clinical', 'institute']",550,"['Baim临床研究所独立验证了所有报告的数据,由AstraZeneca资助。']",0.5714285714285714,"['research', 'data', 'clinical', 'institute', 'with', 'all', 'that']","['research', 'data', 'clinical', 'institute']",,
554,551,all the authors contributed to the writing of the manuscript and made the decision to submit the manuscript for publication .,所有作者都对文稿的撰写做出了贡献，并做出了投稿发表的决定。,0.4285714285714285,"['publication', 'manuscript', 'writing', 'decision', 'all', 'to', 'and']","['publication', 'writing', 'decision']",551,"['所有作者都参与了手稿的写作,并决定将手稿提交出版。']",0.5714285714285714,"['publication', 'manuscript', 'writing', 'decision', 'all', 'to', 'and']","['publication', 'manuscript', 'writing', 'decision']",,
555,552,the authors vouch for the completeness and accuracy of the data and the analyses and for the fidelity of the trial to the protocol .,作者保证数据和分析的完整性和准确性，并保证试验对方案的忠实度。,0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'completeness']",552,"['作者保证数据和分析的完整性和准确性,以及审判对议定书的忠诚性。']",0.7142857142857143,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
556,553,the trial population consisted of patients who were 50 years of age or older and who had stable coronary artery disease and type 2 diabetes mellitus .,试验人群包括年龄在 50 岁或以上且患有稳定性冠状动脉疾病和 2 型糖尿病的患者。,0.75,"['diabetes', 'population', 'type', 'disease', 'who', '2', 'coronary', 'diabetes mellitus', 'age', 'trial', 'coronary artery', 'and']","['diabetes', 'population', 'type', 'disease', '2', 'coronary', 'diabetes mellitus', 'age', 'coronary artery']",553,"['研究人口由50岁以上的患者组成,并且患有稳定的冠状动脉疾病和2型糖尿病。']",0.6666666666666666,"['diabetes', 'population', 'type', 'disease', 'who', '2', 'coronary', 'diabetes mellitus', 'age', 'trial', 'coronary artery', 'and']","['diabetes', 'population', 'type', 'disease', '2', 'coronary', 'diabetes mellitus', 'coronary artery']",,
557,554,the presence of type 2 diabetes mellitus was determined by the receipt of an antihyperglycemic medication for at least 6 months .,2 型糖尿病的存在是通过接受抗高血糖药物治疗至少 6 个月来确定的。,0.75,"['presence', 'diabetes', 'type', '2', 'diabetes mellitus', 'medication', 'antihyperglycemic', 'by']","['presence', 'diabetes', 'type', '2', 'diabetes mellitus', 'antihyperglycemic']",554,['二型糖尿病的存在是通过服用抗高血糖药物至少6个月的确定。'],0.625,"['presence', 'diabetes', 'type', '2', 'diabetes mellitus', 'medication', 'antihyperglycemic', 'by']","['presence', 'diabetes', 'type', 'diabetes mellitus', 'antihyperglycemic']",,
558,555,"patients with known history of myocardial infarction or stroke were excluded , as were patients who were receiving dual antiplatelet therapy .",已知有心肌梗塞或中风病史的患者被排除在外，接受双重抗血小板治疗的患者也被排除在外。,0.3333333333333333,"['myocardial infarction', 'stroke', 'who', 'antiplatelet', 'history', 'therapy', 'as', 'dual', 'with']","['myocardial infarction', 'stroke', 'therapy']",555,"['已知心脏病发作或中风史的患者被排除,如接受双重抗甲状腺治疗的患者。']",0.3333333333333333,"['myocardial infarction', 'stroke', 'who', 'antiplatelet', 'history', 'therapy', 'as', 'dual', 'with']","['stroke', 'therapy', 'as']",,
559,556,randomization AND TREATMENT GROUPS,随机化和治疗组,1.0,['randomization'],['randomization'],556,['随机化和处理组'],1.0,['randomization'],['randomization'],,
560,557,patients were initially assigned to receive ticagrelor at a dose of 90 mg twice daily or matching placebo .,患者最初被分配接受每日两次 90 毫克剂量的替格瑞洛或匹配的安慰剂。,0.6,"['placebo', 'matching', 'dose', 'to', 'twice']","['placebo', 'matching', 'dose']",557,"['患者最初被处以90毫克的剂量,每天两次或相匹配的 placebo。']",0.4,"['placebo', 'matching', 'dose', 'to', 'twice']","['matching', 'dose']",,
561,558,"secondary efficacy outcomes were tested hierarchically according to the following sequence : cardiovascular death , myocardial infarction , ischemic stroke , and death from any cause .",次要疗效结果按照以下顺序进行分层测试：心血管死亡、心肌梗死、缺血性卒中和全因死亡。,0.4166666666666667,"['myocardial infarction', 'cardiovascular', 'stroke', 'sequence', 'death', 'cause', 'secondary', 'efficacy', 'to', 'and', 'ischemic', 'following']","['myocardial infarction', 'cardiovascular', 'stroke', 'sequence', 'death']",558,['二次有效性结果按下列序列进行层次测试:心血管死亡、心脏病发作、心脏病发作和任何原因死亡。'],0.5,"['myocardial infarction', 'cardiovascular', 'stroke', 'sequence', 'death', 'cause', 'secondary', 'efficacy', 'to', 'and', 'ischemic', 'following']","['cardiovascular', 'stroke', 'sequence', 'death', 'cause', 'efficacy']",,
562,559,"the primary safety outcome was major bleeding , which was defined according to the TIMI classification .",主要安全性结果是大出血，这是根据 TIMI 分类定义的。,0.5,"['bleeding', 'safety', 'defined', 'classification', 'outcome', 'major', 'primary', 'to']","['bleeding', 'safety', 'classification', 'outcome']",559,"['主要的安全结果是主要的出血,根据TIMI分类定义。']",0.625,"['bleeding', 'safety', 'defined', 'classification', 'outcome', 'major', 'primary', 'to']","['bleeding', 'safety', 'classification', 'outcome', 'primary']",,
563,560,"an exploratory outcome of net irreversible harm was prespecified as a composite of death from any cause , myocardial infarction , stroke , fatal bleeding , or intracranial hemorrhage .",净不可逆伤害的探索性结果被预先指定为全因死亡、心肌梗死、中风、致命性出血或颅内出血的复合结果。,0.5333333333333333,"['bleeding', 'myocardial infarction', 'composite', 'stroke', 'net', 'outcome', 'death', 'hemorrhage', 'intracranial', 'intracranial hemorrhage', 'exploratory', 'fatal', 'cause', 'as', 'irreversible']","['bleeding', 'myocardial infarction', 'stroke', 'outcome', 'death', 'hemorrhage', 'intracranial hemorrhage', 'irreversible']",560,['净不可逆转的损害的探测结果被预定为任何原因、心脏病发作、中风、致命出血或内膜出血的死亡组成部分。'],0.5333333333333333,"['bleeding', 'myocardial infarction', 'composite', 'stroke', 'net', 'outcome', 'death', 'hemorrhage', 'intracranial', 'intracranial hemorrhage', 'exploratory', 'fatal', 'cause', 'as', 'irreversible']","['bleeding', 'stroke', 'outcome', 'death', 'hemorrhage', 'exploratory', 'cause', 'irreversible']",,
564,561,the definitions of all trial outcomes are provided in the Supplementary Appendix .,补充附录中提供了所有试验结果的定义。,0.0,"['appendix', 'supplementary', 'trial', 'all', 'in']",[],561,['所有审查结果的定义在附件中列出。'],0.2,"['appendix', 'supplementary', 'trial', 'all', 'in']",['appendix'],,
565,562,we estimated that the annual event rate in the placebo group would be 2.5 % .,我们估计安慰剂组的年事件发生率为 2.5%。,0.3333333333333333,"['annual', 'group', 'placebo', 'rate', 'be', 'event', 'that', 'in', 'we']","['group', 'placebo', 'rate']",562,"['我们估计,在 placebo 组的年度事件率将为 2.5 % 。']",0.3333333333333333,"['annual', 'group', 'placebo', 'rate', 'be', 'event', 'that', 'in', 'we']","['group', 'rate', 'be']",,
566,563,"we determined that the occurrence of 1385 primary outcome events would provide the trial with a power of 90 % , assuming a 16 % lower risk of a primary outcome event in the ticagrelor group than in the placebo group.11",我们确定 1385 次主要结果事件的发生将为试验提供 90 % 的功效，假设替格瑞洛组中主要结果事件的风险比安慰剂组低 16 % 11。,0.4615384615384615,"['group', 'placebo', 'outcome', 'power', 'occurrence', 'lower', 'primary', 'risk', 'trial', 'with', 'event', 'that', 'in']","['group', 'placebo', 'outcome', 'occurrence', 'risk', 'event']",563,"['我们确定,1385个初始结果事件的发生将为测试提供90%的功率,假设在Ticagrelor群体中出现初始结果事件的风险比在Placebo群体中低16%。']",0.4615384615384615,"['group', 'placebo', 'outcome', 'power', 'occurrence', 'lower', 'primary', 'risk', 'trial', 'with', 'event', 'that', 'in']","['group', 'outcome', 'power', 'occurrence', 'risk', 'event']",,
567,564,"safety analyses were performed in the safety analysis set , which included all the patients who had received at least one dose of ticagrelor or placebo , with patients evaluated according to the one they actually received .",安全性分析在安全性分析集中进行，其中包括接受过至少一剂替格瑞洛或安慰剂的所有患者，并根据实际接受的剂量对患者进行评估。,0.3333333333333333,"['safety', 'placebo', 'who', 'analysis', 'set', 'safety analysis', 'with', 'at', 'dose', 'all', 'in', 'to']","['safety', 'placebo', 'analysis', 'dose']",564,"['安全分析是在安全分析组中进行的,其中包括所有接受至少一剂Ticagrelor或Placebo的患者,并根据他们实际接受的患者进行评估。']",0.25,"['safety', 'placebo', 'who', 'analysis', 'set', 'safety analysis', 'with', 'at', 'dose', 'all', 'in', 'to']","['safety', 'analysis', 'safety analysis']",,
568,565,"confidence intervals for secondary and exploratory efficacy end points have not been adjusted for multiple comparisons , so inferences drawn from these intervals may not be reproducible .",次要和探索性疗效终点的置信区间尚未针对多重比较进行调整，因此从这些区间得出的推论可能无法重现。,0.1818181818181818,"['multiple', 'end points', 'be', 'exploratory', 'secondary', 'efficacy', 'confidence', 'have not', 'so', 'and', 'intervals']","['end points', 'have not']",565,"['二级和探测效率终点的信任间隔未适用于多个比较,因此从这些间隔中提取的结论可能无法重复。']",0.2727272727272727,"['multiple', 'end points', 'be', 'exploratory', 'secondary', 'efficacy', 'confidence', 'have not', 'so', 'and', 'intervals']","['end points', 'exploratory', 'have not']",,
569,566,"to assess possible effects of missing data in the ticagrelor group , the event rate in the placebo group was used to estimate the intensity of a Poisson process .",为了评估替格瑞洛组缺失数据的可能影响，安慰剂组的事件发生率用于估计泊松过程的强度。,0.7272727272727273,"['group', 'placebo', 'data', 'rate', 'process', 'intensity', 'estimate', 'assess', 'event', 'to', 'missing']","['group', 'placebo', 'data', 'rate', 'process', 'assess', 'to', 'missing']",566,"['为了评估Ticagrelor组缺乏数据的可能影响,Placebo组的事件率被用来估计Poisson过程的强度。']",0.5454545454545454,"['group', 'placebo', 'data', 'rate', 'process', 'intensity', 'estimate', 'assess', 'event', 'to', 'missing']","['group', 'data', 'rate', 'process', 'assess', 'missing']",,
570,567,the comparison between ticagrelor and placebo was recalculated with these additional events .,替格瑞洛和安慰剂之间的比较是根据这些额外的事件重新计算的。,0.6,"['placebo', 'comparison', 'additional', 'with', 'and']","['placebo', 'comparison', 'additional']",567,['Ticagrelor 和 placebo 的比较与这些额外事件进行了重新计算。'],0.2,"['placebo', 'comparison', 'additional', 'with', 'and']",['comparison'],,
571,568,"to estimate the interaction between the trial group and prespecified subgroups , we added to the model the trial group , subgroup , and interaction term between trial group and subgroup .",为了估计试验组和预先指定的亚组之间的相互作用，我们在模型中添加了试验组、亚组以及试验组和亚组之间的相互作用项。,0.3,"['group', 'model', 'term', 'interaction', 'trial', 'estimate', 'subgroup', 'to', 'and', 'we']","['group', 'model', 'term']",568,"['为了估计试验组和预定子组之间的互动,我们将试验组、子组和试验组和子组之间的互动术语添加到模型中。']",0.2,"['group', 'model', 'term', 'interaction', 'trial', 'estimate', 'subgroup', 'to', 'and', 'we']","['group', 'model']",,
572,569,specific analyses were also prespecified to test the consistency of effect for the two doses of ticagrelor .,还预先指定了具体分析，以测试两种替格瑞洛剂量的效果一致性。,0.5,"['test', 'consistency', 'effect', 'specific', 'to', 'two']","['consistency', 'effect', 'two']",569,"['具体的分析也被预定,以测试两剂Ticagrelor的效果一致性。']",0.5,"['test', 'consistency', 'effect', 'specific', 'to', 'two']","['consistency', 'effect', 'two']",,
573,570,primary efficacy and safety analyses were repeated in the subgroup of patients who had undergone randomization after the reduction in the dose of ticagrelor .,在替格瑞洛剂量减少后接受随机分组的患者亚组中重复了主要疗效和安全性分析。,0.4545454545454545,"['safety', 'randomization', 'who', 'reduction', 'primary', 'after', 'efficacy', 'subgroup', 'dose', 'repeated', 'in']","['safety', 'randomization', 'reduction', 'after', 'dose']",570,['初级有效性和安全性分析在细菌剂量减少后随机化患者的子组中重复。'],0.5454545454545454,"['safety', 'randomization', 'who', 'reduction', 'primary', 'after', 'efficacy', 'subgroup', 'dose', 'repeated', 'in']","['safety', 'randomization', 'reduction', 'after', 'efficacy', 'dose']",,
574,571,"from February 10 , 2014 , to May 24 , 2016 , a total of 20,108 patients were enrolled .",2014年2月10日至2016年5月24日，共纳入20108例患者。,0.0,"['a', 'total']",[],571,"['从2014年2月10日至2016年5月24日,共有20108名病人被注册。']",0.0,"['a', 'total']",[],,
575,572,"of these patients , 19,271 underwent randomization at 1315 sites in 42 countries in North America , South America , Asia , Africa , Australia , and Europe .","在这些患者中，有 19,271 人在北美、南美、亚洲、非洲、澳大利亚和欧洲 42 个国家的 1315 个地点接受了随机分组。",0.6,"['australia', 'randomization', 'america', 'north', 'in']","['australia', 'randomization', 'north']",572,"['在这些患者中,有19271人在北美、南美、亚洲、非洲、澳大利亚和欧洲42个国家的1315个地点进行了随机诊断。']",0.6,"['australia', 'randomization', 'america', 'north', 'in']","['australia', 'randomization', 'north']",,
576,573,one site that had enrolled 51 patients was closed by the sponsor before unblinding owing to inadequate adherence to good clinical practice in a different trial.11,由于在另一项试验中未能充分遵守良好的临床实践，一个已招募 51 名患者的研究中心在揭盲前被申办者关闭。 11,0.3636363636363636,"['a', 'site', 'good clinical practice', 'sponsor', 'inadequate', 'adherence', 'closed', 'that', 'before', 'by', 'to']","['sponsor', 'before', 'by', 'to']",573,"['一家注册51名患者的网站被赞助商关闭,因为在另一个试验中不适当遵守良好的临床实践。']",0.0,"['a', 'site', 'good clinical practice', 'sponsor', 'inadequate', 'adherence', 'closed', 'that', 'before', 'by', 'to']",[],,
577,574,"the last visit with a trial patient was conducted on January 25 , 2019 .",对试验患者的最后一次访问是在 2019 年 1 月 25 日进行的。,0.1666666666666666,"['a', 'patient', 'trial', 'with', 'on', 'visit']",['patient'],574,['与试验患者的最后一次访问是在2019年1月25日进行的。'],0.1666666666666666,"['a', 'patient', 'trial', 'with', 'on', 'visit']",['patient'],,
578,575,"the censoring date for the efficacy analyses was October 29 , 2018 .",疗效分析的审查日期为 2018 年 10 月 29 日。,0.5,"['date', 'efficacy']",['date'],575,['对效率分析的审查日期为2018年10月29日。'],0.5,"['date', 'efficacy']",['date'],,
579,576,the characteristics of the patients were well balanced between the two groups ( Table 1 ) .,两组患者的特征均衡（表1）。,0.8,"['table', '1', 'well', 'characteristics', 'two']","['table', '1', 'characteristics', 'two']",576,['患者的特征在两组之间平衡良好(图1)。'],0.6,"['table', '1', 'well', 'characteristics', 'two']","['1', 'characteristics', 'two']",,
580,577,"the median age was 66 years , and 31.4 % of the patients were women .",中位年龄为 66 岁，31.4% 的患者为女性。,0.25,"['median', 'age', 'median age', 'and']",['age'],577,"['平均年龄为66岁,31%的患者是女性。']",0.25,"['median', 'age', 'median age', 'and']",['age'],,
581,578,"a total of 58.0 % of the patients had undergone PCI ( with or without stent placement ) , 21.8 % had undergone CABG but not PCI , and 7.0 % had undergone both PCI and CABG ; 20.2 % had no history of coronary revascularization and had received only medical treatment .",共有58.0%的患者接受了PCI（有或没有放置支架），21.8%的患者接受了CABG但未接受PCI，7.0%的患者同时接受了PCI和CABG。 20.2% 没有冠状动脉血运重建史，只接受过药物治疗。,0.2,"['a', 'medical', 'coronary', 'total', 'history', 'medical treatment', 'revascularization', 'CABG', 'stent', 'no', 'with', 'placement', 'but', 'and', 'without']","['coronary', 'revascularization', 'but']",578,"['总共有58,0%的患者接受了PCI(有或没有放置),21.8%的患者接受了CABG但不接受PCI,7.0%的患者接受了PCI和CABG;20.2%的患者没有冠状复发史,只接受了医疗治疗。']",0.1333333333333333,"['a', 'medical', 'coronary', 'total', 'history', 'medical treatment', 'revascularization', 'CABG', 'stent', 'no', 'with', 'placement', 'but', 'and', 'without']","['coronary', 'but']",,
582,579,patients had received a diagnosis of diabetes a median of 10.0 years before randomization .,患者在随机分组前被诊断为糖尿病的时间中位数为 10.0 年。,0.8,"['diabetes', 'median', 'randomization', 'diagnosis', 'before']","['diabetes', 'randomization', 'diagnosis', 'before']",579,['患者在随机化前10年中间接受了糖尿病的诊断。'],0.8,"['diabetes', 'median', 'randomization', 'diagnosis', 'before']","['diabetes', 'randomization', 'diagnosis', 'before']",,
583,580,most of the patients were receiving two or more antihyperglycemic medications ( Table S2 in the Supplementary Appendix ) .,大多数患者正在接受两种或更多种降糖药（补充附录表 S2）。,0.2857142857142857,"['appendix', 'table', 'supplementary', 'antihyperglycemic', 'S2', 'in', 'two']","['table', 'two']",580,['大多数患者接受了两种或多种抗高血糖药物(附件中的S2表)。'],0.5714285714285714,"['appendix', 'table', 'supplementary', 'antihyperglycemic', 'S2', 'in', 'two']","['appendix', 'table', 'antihyperglycemic', 'two']",,
584,581,"more than half the patients were taking metformin , and more than 20 % were receiving insulin .",超过一半的患者服用二甲双胍，超过 20% 的患者服用胰岛素。,0.6,"['insulin', 'taking', 'half', 'metformin', 'and']","['insulin', 'half', 'metformin']",581,"['超过一半的患者服用了甲状腺素,超过20%的患者服用了胰岛素。']",0.4,"['insulin', 'taking', 'half', 'metformin', 'and']","['insulin', 'half']",,
585,582,efficacy outcomes are summarized in Table 2 .,表 2 总结了疗效结果。,0.5,"['table', '2', 'efficacy', 'in']","['table', '2']",582,['有效性结果在表2中总结。'],0.75,"['table', '2', 'efficacy', 'in']","['table', '2', 'efficacy']",,
586,583,the number of patients who would need to be treated to prevent one primary event at 36 months was 138 .,在 36 个月时需要接受治疗以预防一次主要事件的患者人数为 138 人。,0.5,"['need', 'who', 'be', 'primary', 'number', 'prevent', 'at', 'to']","['need', 'be', 'number', 'prevent']",583,['在36个月内预防一个初始事件需要治疗的患者数量为138人。'],0.5,"['need', 'who', 'be', 'primary', 'number', 'prevent', 'at', 'to']","['need', 'be', 'number', 'prevent']",,
587,584,the lower frequency of the primary composite outcome in the ticagrelor group was driven by lower incidences of myocardial infarction and stroke than in the placebo group .,与安慰剂组相比，替格瑞洛组主要复合结局发生率较低是由于心肌梗死和中风的发生率较低。,0.4545454545454545,"['group', 'myocardial infarction', 'composite', 'frequency', 'placebo', 'stroke', 'outcome', 'lower', 'primary', 'by', 'and']","['group', 'myocardial infarction', 'placebo', 'stroke', 'by']",584,"['基克格勒群体的初始合成结果的频率较低,是由心脏病发作和中风的频率较低而导致的,而不是 placebo群体。']",0.5454545454545454,"['group', 'myocardial infarction', 'composite', 'frequency', 'placebo', 'stroke', 'outcome', 'lower', 'primary', 'by', 'and']","['group', 'frequency', 'stroke', 'outcome', 'by', 'and']",,
588,585,secondary efficacy outcomes were analyzed according to a prespecified hierarchy that started with cardiovascular death .,根据从心血管死亡开始的预设等级分析次要疗效结局。,0.3333333333333333,"['a', 'cardiovascular', 'death', 'hierarchy', 'secondary', 'efficacy', 'with', 'that', 'to']","['cardiovascular', 'death', 'hierarchy']",585,"['二次有效性结果根据预定的序列分析,开始于心血管死亡。']",0.4444444444444444,"['a', 'cardiovascular', 'death', 'hierarchy', 'secondary', 'efficacy', 'with', 'that', 'to']","['cardiovascular', 'death', 'efficacy', 'to']",,
589,586,additional secondary efficacy outcomes are presented in Table 2 ; there were fewer myocardial infarctions and fewer ischemic strokes in the ticagrelor group than in the placebo group .,其他次要疗效结果见表 2；与安慰剂组相比，替格瑞洛组的心肌梗死和缺血性卒中发生率更低。,0.4166666666666667,"['group', 'placebo', 'table', '2', 'additional', 'secondary', 'efficacy', 'myocardial', 'in', 'and', 'infarctions', 'ischemic']","['group', 'placebo', 'table', '2', 'infarctions']",586,"['在图2中显示了额外的次要效益结果;在Ticagrelor群体中有较少的心脏病发作和较少的催化性发作,而不是在Placebo群体中。']",0.3333333333333333,"['group', 'placebo', 'table', '2', 'additional', 'secondary', 'efficacy', 'myocardial', 'in', 'and', 'infarctions', 'ischemic']","['group', '2', 'additional', 'and']",,
590,587,adjudicated causes of death are provided in Table S3 in the Supplementary Appendix .,补充附录表 S3 提供了裁定死因。,0.4285714285714285,"['appendix', 'table', 'death', 'supplementary', 'causes of death', 'S3', 'in']","['table', 'death', 'causes of death']",587,['投诉死亡原因在附件 S3 表中列出。'],0.4285714285714285,"['appendix', 'table', 'death', 'supplementary', 'causes of death', 'S3', 'in']","['appendix', 'table', 'death']",,
591,588,"fatal myocardial infarction and fatal strokes accounted for 51 and 52 deaths , respectively , out of a total 1166 deaths .",在 1166 例死亡病例中，致命性心肌梗死和致命性中风分别占 51 例和 52 例。,0.2,"['myocardial infarction', 'total', 'fatal', 'out', 'and']",['myocardial infarction'],588,"['致命心脏病发作和致命心脏病发作分别为51和52人死亡,共1166人死亡。']",0.0,"['myocardial infarction', 'total', 'fatal', 'out', 'and']",[],,
592,589,"in a prespecified exploratory analysis , the number of events of the composite of acute limb ischemia or major amputation was lower with ticagrelor than with placebo ( hazard ratio , 0.45 ; 95 % CI , 0.23 to 0.86 ) .",在预先指定的探索性分析中，替格瑞洛组的急性肢体缺血或重大截肢复合事件的数量低于安慰剂组（风险比，0.45；95% CI，0.23 至 0.86）。,0.5,"['composite', 'placebo', 'limb', 'analysis', 'ratio', 'hazard ratio', 'ischemia', 'amputation', 'lower', 'major', 'exploratory', 'number', 'acute', 'with', 'CI', 'in']","['placebo', 'limb', 'analysis', 'ratio', 'hazard ratio', 'ischemia', 'amputation', 'number']",589,"['在预先确定的探测分析中,急性肢体腹泻或主要解剖的组合发生的事件数量与<unk>血病相比较低(风险比率为0.45;95%的CI,0.23至0.86)。']",0.375,"['composite', 'placebo', 'limb', 'analysis', 'ratio', 'hazard ratio', 'ischemia', 'amputation', 'lower', 'major', 'exploratory', 'number', 'acute', 'with', 'CI', 'in']","['limb', 'analysis', 'ratio', 'hazard ratio', 'exploratory', 'number']",,
593,590,we conducted a prespecified sensitivity analysis of the primary outcome to account for the reduction in the ticagrelor dose during the trial ; the results were consistent with those of the primary analysis ( Table S4 in the Supplementary Appendix ) .,我们对主要结局进行了预先指定的敏感性分析，以说明试验期间替格瑞洛剂量的减少；结果与主要分析的结果一致（补充附录表S4）。,0.3125,"['a', 'appendix', 'table', 'analysis', 'outcome', 'supplementary', 'reduction', 'primary', 'trial', 'with', 'sensitivity', 'dose', 'S4', 'in', 'to', 'we']","['table', 'analysis', 'outcome', 'reduction', 'dose']",590,"['我们进行了初始结果的预定敏感性分析,以便在测试期间考虑到细菌剂量的减少;结果与初始分析的结果一致(附件中的S4表)。']",0.375,"['a', 'appendix', 'table', 'analysis', 'outcome', 'supplementary', 'reduction', 'primary', 'trial', 'with', 'sensitivity', 'dose', 'S4', 'in', 'to', 'we']","['appendix', 'table', 'analysis', 'outcome', 'reduction', 'dose']",,
594,591,"in a sensitivity analysis performed to assess the possible effects of missing data , it was estimated that 757 primary outcome events ( 7.9 % ) would have occurred in the ticagrelor group , resulting in a hazard ratio of 0.93 ( 95 % CI , 0.84 to 1.02 ) .",在为评估缺失数据的可能影响而进行的敏感性分析中，估计替格瑞洛组会发生 757 次主要结果事件 ( 7.9 % ) ，导致风险比为 0.93 （ 95 % CI ， 0.84 至 1.02 ） .,0.5,"['group', 'a', 'data', 'analysis', 'ratio', 'hazard ratio', 'outcome', 'primary', 'assess', 'sensitivity', 'CI', 'have', 'that', 'in', 'to', 'missing']","['group', 'data', 'analysis', 'ratio', 'hazard ratio', 'outcome', 'assess', 'missing']",591,"['在对失踪数据的可能影响进行的敏感性分析中,估计757个初始结果事件(7.9%)会发生在图克格勒群体中,导致危险比例为0.93(95%CI,0.84至1.02)。']",0.3125,"['group', 'a', 'data', 'analysis', 'ratio', 'hazard ratio', 'outcome', 'primary', 'assess', 'sensitivity', 'CI', 'have', 'that', 'in', 'to', 'missing']","['group', 'data', 'analysis', 'ratio', 'outcome']",,
595,592,selected prespecified subgroup analyses for the primary efficacy outcome are provided in Figure S4 in the Supplementary Appendix .,主要疗效结局的选定预设亚组分析见补充附录图 S4。,0.0,"['appendix', 'outcome', 'figure', 'supplementary', 'primary', 'efficacy', 'subgroup', 'S4', 'in']",[],592,"['对初级效能结果的选择预定子组分析,在附加附件的图 S4 中提供。']",0.3333333333333333,"['appendix', 'outcome', 'figure', 'supplementary', 'primary', 'efficacy', 'subgroup', 'S4', 'in']","['appendix', 'outcome', 'efficacy']",,
596,593,there was a modest variation in treatment benefit according to the date of censoring of events relative to last dose of ticagrelor or placebo ( Table S6 in the Supplementary Appendix ) .,根据与替格瑞洛或安慰剂末次剂量相关的事件删失日期，治疗获益略有不同（补充附录表 S6）。,0.4166666666666667,"['placebo', 'appendix', 'table', 'variation', 'date', 'supplementary', 'relative', 'treatment', 'benefit', 'dose', 'in', 'to']","['placebo', 'table', 'date', 'treatment', 'dose']",593,"['根据审查事件的日期,治疗益处有所微不足道的变化,与最后一剂Ticagrelor或Placebo有关(附件中的S6表)。']",0.4166666666666667,"['placebo', 'appendix', 'table', 'variation', 'date', 'supplementary', 'relative', 'treatment', 'benefit', 'dose', 'in', 'to']","['appendix', 'table', 'variation', 'date', 'treatment']",,
597,594,serious adverse events were slightly less frequent with ticagrelor than with placebo ( 31.9 % vs. 33.7 % ) .,替格瑞洛组的严重不良事件发生率略低于安慰剂组（31.9% 对 33.7%）。,0.2,"['placebo', 'adverse', 'with', 'serious', 'frequent']",['placebo'],594,['严重的副作用在Ticagrelor与Placebo相比略有较少(31.9%与33.7%)。'],0.0,"['placebo', 'adverse', 'with', 'serious', 'frequent']",[],,
598,595,"adverse events of interest occurred more frequently with ticagrelor than with placebo , a difference that was driven by a greater frequency of dyspnea in the ticagrelor group ( Table 3 ) .",与安慰剂组相比，替格瑞洛组感兴趣的不良事件发生频率更高，这是由替格瑞洛组呼吸困难频率更高所致（表 3）。,0.4615384615384615,"['group', 'frequency', 'placebo', 'table', 'dyspnea', 'frequently', 'difference', 'adverse', '3', 'with', 'that', 'in', 'by']","['group', 'frequency', 'placebo', 'table', 'dyspnea', 'by']",595,"['与Ticagrelor发生的不良兴趣事件更频繁,而不是与Placebo发生的差异,这是由Ticagrelor群体中更频繁的 dyspnea(图3)引发的差异。']",0.2307692307692307,"['group', 'frequency', 'placebo', 'table', 'dyspnea', 'frequently', 'difference', 'adverse', '3', 'with', 'that', 'in', 'by']","['group', 'difference', 'by']",,
599,596,results that were consistent with the primary safety analysis were observed for other bleeding definitions .,对于其他出血定义，观察到与主要安全性分析一致的结果。,0.4285714285714285,"['bleeding', 'safety', 'analysis', 'primary', 'safety analysis', 'with', 'that']","['bleeding', 'safety', 'analysis']",596,['与初级安全分析一致的结果被观察到其他出血定义。'],0.5714285714285714,"['bleeding', 'safety', 'analysis', 'primary', 'safety analysis', 'with', 'that']","['bleeding', 'safety', 'analysis', 'safety analysis']",,
600,597,"intracranial hemorrhage was more frequent with ticagrelor than with placebo , with 70 events and 46 events , respectively ( 0.7 % vs. 0.5 % ; hazard ratio , 1.71 ; 95 % CI , 1.18 to 2.48 ; P = 0.005 ) .",替格瑞洛组的颅内出血发生率高于安慰剂组，分别为 70 起事件和 46 起事件（0.7% 对 0.5%；风险比，1.71；95% CI，1.18 至 2.48；P = 0.005）。,0.5,"['placebo', 'ratio', 'hazard ratio', 'hemorrhage', 'intracranial', 'intracranial hemorrhage', 'with', 'P', 'CI', 'frequent', 'to', 'and']","['placebo', 'ratio', 'hazard ratio', 'hemorrhage', 'intracranial hemorrhage', 'to']",597,"['甲状腺内出血比 placebo 更常见,有 70 个事件和 46 个事件,分别( 0.7 % 与 0.5 % ; 危险比例, 1.71 ; 95 % CI, 1.18 至 2.48 ; P = 0.005 )。']",0.1666666666666666,"['placebo', 'ratio', 'hazard ratio', 'hemorrhage', 'intracranial', 'intracranial hemorrhage', 'with', 'P', 'CI', 'frequent', 'to', 'and']","['ratio', 'hemorrhage']",,
601,598,selected prespecified subgroup analyses for the primary safety outcome are presented in Figure S5 in the Supplementary Appendix .,主要安全性结局的选定预设亚组分析见补充附录图 S5。,0.125,"['safety', 'appendix', 'outcome', 'figure', 'supplementary', 'primary', 'subgroup', 'in']",['safety'],598,"['对于初级安全结果的选择预定子组分析,在附加附件中的图 S5 中呈现。']",0.375,"['safety', 'appendix', 'outcome', 'figure', 'supplementary', 'primary', 'subgroup', 'in']","['safety', 'appendix', 'outcome']",,
602,599,"rates of discontinuation were high in the two groups but were higher in the ticagrelor group , primarily due to an increased risk of bleeding and dyspnea .",两组的停药率都很高，但替格瑞洛组的停药率更高，这主要是由于出血和呼吸困难的风险增加。,0.8,"['bleeding', 'group', 'dyspnea', 'risk', 'due', 'but', 'to', 'and', 'two', 'high']","['bleeding', 'group', 'dyspnea', 'risk', 'but', 'to', 'two', 'high']",599,"['两组中断率很高,但在蒂卡格勒群体中较高,主要是由于出血和甲状腺炎的风险增加。']",0.7,"['bleeding', 'group', 'dyspnea', 'risk', 'due', 'but', 'to', 'and', 'two', 'high']","['bleeding', 'group', 'risk', 'but', 'to', 'two', 'high']",,
603,600,prespecified analyses that were performed according to dose provided results consistent with those in the primary analysis .,根据剂量进行的预设分析提供的结果与主要分析中的结果一致。,0.2857142857142857,"['analysis', 'primary', 'with', 'dose', 'that', 'in', 'to']","['analysis', 'dose']",600,"['根据剂量进行的预定分析,结果与初始分析的结果一致。']",0.2857142857142857,"['analysis', 'primary', 'with', 'dose', 'that', 'in', 'to']","['analysis', 'dose']",,
604,601,"however , the prevention of ischemic events did not translate into a lower risk of cardiovascular death , presumably because fatal myocardial infarction and fatal stroke accounted for only a small fraction of all deaths ( 4.4 % and 4.5 % , respectively ) .",然而，预防缺血性事件并未转化为心血管死亡风险的降低，这可能是因为致命性心肌梗死和致命性中风仅占所有死亡的一小部分（分别为 4.4% 和 4.5%）。,0.6153846153846154,"['myocardial infarction', 'cardiovascular', 'stroke', 'death', 'prevention', 'lower', 'fatal', 'risk', 'fraction', 'translate', 'all', 'and', 'ischemic']","['myocardial infarction', 'cardiovascular', 'stroke', 'death', 'prevention', 'risk', 'fraction', 'and']",601,"['然而,预防化学事件并没有将其转化为心血管死亡的风险较低,可能是因为致命心脏病发作和致命中风仅占所有死亡人数的一小部分(相应为4.4%和4.5%)。']",0.5384615384615384,"['myocardial infarction', 'cardiovascular', 'stroke', 'death', 'prevention', 'lower', 'fatal', 'risk', 'fraction', 'translate', 'all', 'and', 'ischemic']","['cardiovascular', 'stroke', 'death', 'prevention', 'risk', 'fraction', 'and']",,
605,602,"the observed 10 % lower incidence of ischemic events in the ticagrelor group , although significant , was less than the 16 % lower incidence assumed at the time of the trial design .",在替格瑞洛组观察到的缺血事件发生率降低了 10%，尽管意义重大，但低于试验设计时假定的 16% 发生率。,0.625,"['group', 'incidence', 'time', 'lower', 'trial', 'design', 'at', 'ischemic']","['group', 'incidence', 'time', 'design', 'at']",602,"['虽然显著,但在图卡格勒群体中发现的10%较低的异化现象的发病率低于试验设计时的16%较低的发病率。']",0.75,"['group', 'incidence', 'time', 'lower', 'trial', 'design', 'at', 'ischemic']","['group', 'incidence', 'time', 'lower', 'design', 'at']",,
606,603,"in THEMIS , dual antiplatelet therapy with ticagrelor was associated with a higher frequency of intracranial hemorrhage than placebo .",在 THEMIS 中，与安慰剂相比，使用替格瑞洛的双重抗血小板治疗与更高的颅内出血频率相关。,0.5,"['frequency', 'placebo', 'hemorrhage', 'antiplatelet', 'intracranial', 'intracranial hemorrhage', 'therapy', 'associated', 'dual', 'with']","['frequency', 'placebo', 'hemorrhage', 'intracranial hemorrhage', 'therapy']",603,"['在TEMIS中,双重抗斑疗法与Ticagrelor相结合,内分泌出血的频率比 placebo更高。']",0.3,"['frequency', 'placebo', 'hemorrhage', 'antiplatelet', 'intracranial', 'intracranial hemorrhage', 'therapy', 'associated', 'dual', 'with']","['frequency', 'hemorrhage', 'therapy']",,
607,604,"in the past , increases in the incidence of intracranial hemorrhage with dual antiplatelet therapy have been reported with ticagrelor , 7 clopidogrel , 24 and prasugrel.22,25","过去曾有报道称，使用替卡格雷 7 氯吡格雷 24 和普拉格雷 22, 25 进行双重抗血小板治疗会增加颅内出血的发生率。",0.4615384615384615,"['incidence', 'hemorrhage', 'antiplatelet', 'intracranial', 'intracranial hemorrhage', 'clopidogrel', 'therapy', 'increases', 'dual', 'with', 'have', 'and', 'past']","['incidence', 'hemorrhage', 'intracranial hemorrhage', 'clopidogrel', 'therapy', 'have']",604,"['在过去,双血管治疗的内分泌出血的发病率增加已被提卡格勒勒、7克洛皮多格勒、24和普拉苏格勒报告。']",0.2307692307692307,"['incidence', 'hemorrhage', 'antiplatelet', 'intracranial', 'intracranial hemorrhage', 'clopidogrel', 'therapy', 'increases', 'dual', 'with', 'have', 'and', 'past']","['incidence', 'hemorrhage', 'therapy']",,
608,605,the ongoing TWILIGHT trial is testing a similar strategy.32,正在进行的 TWILIGHT 试验正在测试一种类似的策略。 32,0.0,"['a', 'trial', 'testing', 'similar']",[],605,['目前的TWILIGHT审判正在测试类似策略。'],0.25,"['a', 'trial', 'testing', 'similar']",['trial'],,
609,606,"in conclusion , in patients with stable coronary artery disease and type 2 diabetes who did not have a history of myocardial infarction or stroke , ticagrelor plus aspirin was associated with a lower incidence of ischemic events than placebo plus aspirin at the expense of a higher incidence of major bleeding , including intracranial hemorrhage .",总之，在没有心肌梗死或中风病史的稳定型冠状动脉疾病和2型糖尿病患者中，替格瑞洛加阿司匹林与安慰剂加阿司匹林相比，缺血事件发生率较低，但代价是缺血事件发生率较高。大出血，包括颅内出血。,0.6153846153846154,"['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'type', 'placebo', 'incidence', 'disease', 'stroke', 'who', '2', 'hemorrhage', 'plus', 'intracranial', 'intracranial hemorrhage', 'coronary', 'history', 'lower', 'major', 'associated', 'conclusion', 'with', 'coronary artery', 'have', 'and', 'ischemic']","['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'type', 'placebo', 'incidence', 'disease', 'stroke', '2', 'hemorrhage', 'plus', 'intracranial hemorrhage', 'coronary', 'coronary artery', 'have']",606,"['结论是,在患有稳定的冠状动脉疾病和2型糖尿病的患者,没有心脏病发作或中风的历史,Ticagrelor plus aspirin与比 placebo plus aspirin更低的催化事件的发病率相结合,而更高的发病率主要出血,包括内分泌出血。']",0.5384615384615384,"['bleeding', 'myocardial infarction', 'diabetes', 'aspirin', 'type', 'placebo', 'incidence', 'disease', 'stroke', 'who', '2', 'hemorrhage', 'plus', 'intracranial', 'intracranial hemorrhage', 'coronary', 'history', 'lower', 'major', 'associated', 'conclusion', 'with', 'coronary artery', 'have', 'and', 'ischemic']","['bleeding', 'diabetes', 'type', 'incidence', 'disease', 'stroke', '2', 'hemorrhage', 'coronary', 'history', 'conclusion', 'coronary artery', 'have', 'and']",,
610,607,"as a result , there was no significantly lower incidence of the exploratory composite outcome of efficacy and safety with ticagrelor than with placebo .",因此，与安慰剂相比，替格瑞洛的有效性和安全性探索性复合结果的发生率没有显着降低。,0.4615384615384615,"['safety', 'composite', 'placebo', 'incidence', 'outcome', 'lower', 'exploratory', 'no', 'efficacy', 'result', 'as', 'with', 'and']","['safety', 'placebo', 'incidence', 'outcome', 'efficacy', 'result']",607,"['因此,与Ticagrelor的有效性和安全性研究组合结果的发病率与Placebo相比没有显著较低。']",0.3846153846153846,"['safety', 'composite', 'placebo', 'incidence', 'outcome', 'lower', 'exploratory', 'no', 'efficacy', 'result', 'as', 'with', 'and']","['safety', 'incidence', 'outcome', 'efficacy', 'result']",,
611,608,hypertension is a powerful risk factor for ischemic and hemorrhagic stroke .,高血压是缺血性和出血性中风的重要危险因素。,0.4444444444444444,"['a', 'stroke', 'hypertension', 'factor', 'risk', 'hemorrhagic', 'risk factor', 'and', 'ischemic']","['stroke', 'hypertension', 'factor', 'risk']",608,['高血压是伊斯基米和血管中风的强大风险因素。'],0.5555555555555556,"['a', 'stroke', 'hypertension', 'factor', 'risk', 'hemorrhagic', 'risk factor', 'and', 'ischemic']","['stroke', 'hypertension', 'factor', 'risk', 'risk factor']",,
612,609,"the effects of blood pressure ( BP ) values and trajectories in midlife on subsequent brain morphologic changes are less clear , as is the effect of midlife hypertension on later cognitive decline .",中年时期的血压 (BP) 值和轨迹对随后的大脑形态变化的影响不太清楚，中年高血压对后来认知能力下降的影响也是如此。,0.4,"['decline', 'pressure', 'clear', 'hypertension', 'brain', 'blood', 'blood pressure', 'effect', 'subsequent', 'values', 'as', 'cognitive', 'midlife', 'later', 'and']","['decline', 'hypertension', 'brain', 'blood pressure', 'as', 'later']",609,"['中期血压(BP)值和轨道对后来的大脑形状变化的影响不太明显,正如中期高血压对后来的认知衰退的影响。']",0.4,"['decline', 'pressure', 'clear', 'hypertension', 'brain', 'blood', 'blood pressure', 'effect', 'subsequent', 'values', 'as', 'cognitive', 'midlife', 'later', 'and']","['decline', 'hypertension', 'brain', 'blood pressure', 'as', 'later']",,
613,610,participants also underwent amyloid PET scanning and cognitive testing .,参与者还接受了淀粉样蛋白 PET 扫描和认知测试。,0.0,"['amyloid', 'PET', 'scanning', 'testing', 'cognitive', 'and']",[],610,['参与者也接受了AMYLOID PET扫描和认知测试。'],0.0,"['amyloid', 'PET', 'scanning', 'testing', 'cognitive', 'and']",[],,
614,611,"of 465 participants ( mean age , 71 ; 51 % men ) who completed imaging and cognitive testing , 18 % were amyloid positive on PET imaging and 29 % were carriers of the Apo E ℇ4 allele .",在完成成像和认知测试的 465 名参与者（平均年龄 71 岁；51% 为男性）中，18% 的淀粉样蛋白在 PET 成像中呈阳性，29% 是 Apo Eℇ4 等位基因的携带者。,0.25,"['allele', 'mean', 'who', 'amyloid', 'PET', 'age', 'testing', 'cognitive', 'positive', 'on', 'imaging', 'and']","['allele', 'mean', 'age']",611,"['在完成图像和认知测试的465名参与者(平均年龄,71;51%)中,有18%对PET图像有益,29%是Apo E <unk>4 Allele的携带者。']",0.1666666666666666,"['allele', 'mean', 'who', 'amyloid', 'PET', 'age', 'testing', 'cognitive', 'positive', 'on', 'imaging', 'and']","['mean', 'age']",,
615,612,"at age 69 , mean BP was 132 / 73 mm Hg and 40 % of participants were taking antihypertensive medication .",69 岁时，平均血压为 132 / 73 毫米汞柱，40% 的参与者正在服用抗高血压药物。,0.2857142857142857,"['antihypertensive', 'mean', 'taking', '/', 'medication', 'age', 'and']","['antihypertensive', 'mean']",612,"['在69歲時,平均BP為132 / 73 mm Hg,40%的參與者服用抗高血壓藥物。']",0.1428571428571428,"['antihypertensive', 'mean', 'taking', '/', 'medication', 'age', 'and']",['mean'],,
616,613,"higher systolic or diastolic BP at age 53 years , and higher BP increases between ages 43 and 53 , were associated with increases in later WMHV .",53 岁时较高的收缩压或舒张压以及 43 岁和 53 岁之间较高的血压增幅与后期 WMHV 的增高有关。,0.125,"['diastolic', 'associated', 'age', 'increases', 'systolic', 'with', 'later', 'and']",['later'],613,"['53岁时的更高的系统性或神经性BP,43岁至53岁之间的更高的BP增加,与后期WMHV的增加有关。']",0.125,"['diastolic', 'associated', 'age', 'increases', 'systolic', 'with', 'later', 'and']",['later'],,
617,614,"for every 10 mm Hg increase in systolic BP at age 53 , subsequent WMHV increased by 7 % ; for comparable increases in diastolic BP , WMHV increased by 15 % .",53 岁时收缩压每增加 10 毫米汞柱，随后的 WMHV 就会增加 7%；对于可比较的舒张压增加，WMHV 增加了 15%。,0.1428571428571428,"['diastolic', 'age', 'increases', 'systolic', 'subsequent', 'at', 'by']",['at'],614,"['每10毫米Hg增加在53岁时的系统性BP,随后的WMHV增加了7%;对于相似的增加在二元性BP,WMHV增加了15%。']",0.1428571428571428,"['diastolic', 'age', 'increases', 'systolic', 'subsequent', 'at', 'by']",['at'],,
618,615,"the greater the increase in BP between ages 36 and 43 , the smaller the hippocampal volume at ages 69 to 71 years .",36 岁至 43 岁之间血压升高越大，69 至 71 岁时海马体积越小。,0.3333333333333333,"['volume', 'increase', 'at', 'to', 'and', 'hippocampal']","['volume', 'hippocampal']",615,"['年龄在36岁至43岁之间的BP增加越大,年龄在69岁至71岁时的催眠体积越小。']",0.1666666666666666,"['volume', 'increase', 'at', 'to', 'and', 'hippocampal']",['volume'],,
619,616,absolute BP values or BP changes were not linked with amyloid positivity or overall cognitive scores .,绝对血压值或血压变化与淀粉样蛋白阳性或总体认知评分无关。,0.2,"['amyloid', 'absolute', 'values', 'with', 'cognitive']",['absolute'],616,['绝对的 BP 值或 BP 变化与 amyloid 积极性或整体认知分数无关。'],0.2,"['amyloid', 'absolute', 'values', 'with', 'cognitive']",['absolute'],,
620,617,BP screening and control in early adulthood could have important benefits .,在成年早期筛查和控制血压可能有重要的好处。,0.6666666666666666,"['adulthood', 'control', 'screening', 'early', 'have', 'and']","['control', 'screening', 'early', 'have']",617,['早期成年时的BP筛查和控制可能有很大的好处。'],0.6666666666666666,"['adulthood', 'control', 'screening', 'early', 'have', 'and']","['control', 'screening', 'early', 'have']",,
621,618,"these lesions are thought to represent small vessel disease , and accumulation of WMLs has been associated with cognitive impairment and gait disorders .",这些病变被认为代表小血管疾病，而 WMLs 的积累与认知障碍和步态障碍有关。,0.3846153846153846,"['vessel', 'disease', 'represent', 'thought', 'associated', 'gait', 'disorders', 'impairment', 'with', 'cognitive', 'accumulation', 'to', 'and']","['disease', 'represent', 'gait', 'disorders', 'and']",618,"['这些伤害被认为代表小型船舶疾病,并且WML的积累已与认知障碍和通道障碍有关。']",0.2307692307692307,"['vessel', 'disease', 'represent', 'thought', 'associated', 'gait', 'disorders', 'impairment', 'with', 'cognitive', 'accumulation', 'to', 'and']","['disease', 'represent', 'disorders']",,
622,619,the objective of the substudy was to evaluate the effect of different BP treatments on the progression of WMLs of presumed ischemic origin .,该子研究的目的是评估不同 BP 治疗对推测为缺血性起源的 WML 进展的影响。,0.3333333333333333,"['objective', 'origin', 'progression', 'effect', 'to', 'ischemic']","['origin', 'progression']",619,['该研究的目的是评估不同 BP 治疗对假设以色列起源的 WML 的进展的影响。'],0.3333333333333333,"['objective', 'origin', 'progression', 'effect', 'to', 'ischemic']","['origin', 'progression']",,
623,620,effect on brain volume was a secondary goal .,对脑容量的影响是次要目标。,0.3333333333333333,"['volume', 'a', 'brain', 'secondary', 'effect', 'goal']","['brain', 'goal']",620,['对大脑体积的影响是次要目标。'],0.5,"['volume', 'a', 'brain', 'secondary', 'effect', 'goal']","['volume', 'brain', 'goal']",,
624,621,neurologists should support achievement of lower BP targets .,神经科医生应该支持实现较低的血压目标。,0.6666666666666666,"['support', 'lower', 'achievement']","['support', 'lower']",621,['神经学家应该支持实现较低的BP目标。'],0.6666666666666666,"['support', 'lower', 'achievement']","['support', 'lower']",,
625,622,participants were enrolled at a relatively advanced age ; it would be of interest to know if intensive BP control has greater benefits in midlife .,参加者年龄相对较大；了解强化 BP 控制是否对中年人有更大的益处将很有意义。,0.2222222222222222,"['a', 'control', 'be', 'intensive', 'age', 'advanced', 'at', 'midlife', 'to']","['control', 'age']",622,['參與者在一個相對先進的年齡被註冊;有興趣知道是否強烈的BP控制在中期有更大的好處。'],0.2222222222222222,"['a', 'control', 'be', 'intensive', 'age', 'advanced', 'at', 'midlife', 'to']","['control', 'be']",,
626,623,"also , SPRINT excluded patients with diabetes mellitus and those with previous strokes .",此外，SPRINT 还排除了患有糖尿病和既往中风的患者。,0.4,"['diabetes', 'previous', 'diabetes mellitus', 'with', 'and']","['diabetes', 'diabetes mellitus']",623,"['此外,SPRINT排除患有糖尿病患者和以前的中风患者。']",0.6,"['diabetes', 'previous', 'diabetes mellitus', 'with', 'and']","['diabetes', 'previous', 'diabetes mellitus']",,
627,624,"because BMI does not differentiate between fat and lean body mass , researchers in another Mendelian randomization study have now ascertained whether fat per se is causally associated with depression .",由于 BMI 不能区分脂肪和瘦体重，另一项孟德尔随机研究的研究人员现已确定脂肪本身是否与抑郁症有因果关系。,0.5,"['depression', 'randomization', 'fat', 'BMI', 'study', 'associated', 'differentiate', 'mass', 'body', 'with', 'have', 'in']","['depression', 'randomization', 'fat', 'differentiate', 'body', 'have']",624,"['由于BMI不区分脂肪和脂肪体重,另一个Mendelian随机化研究的研究人员现在确定脂肪是否因原因与抑郁症有关。']",0.5,"['depression', 'randomization', 'fat', 'BMI', 'study', 'associated', 'differentiate', 'mass', 'body', 'with', 'have', 'in']","['depression', 'randomization', 'fat', 'differentiate', 'body', 'have']",,
628,625,the two data sources shared approximately 6.5 million single nucleotide polymorphisms ( SNPs ) .,这两个数据源共享大约 650 万个单核苷酸多态性 (SNP)。,0.6666666666666666,"['nucleotide', 'data', 'approximately', 'single', 'two', 'million']","['nucleotide', 'data', 'single', 'two']",625,['这两个数据来源共享了约650万个单核分子聚合物(SNPs)。'],0.5,"['nucleotide', 'data', 'approximately', 'single', 'two', 'million']","['data', 'single', 'two']",,
629,626,"conversely , depression was not a risk factor for any of the anthropometric measures .",相反，抑郁症不是任何人体测量指标的危险因素。,0.6,"['depression', 'a', 'factor', 'risk', 'risk factor']","['depression', 'factor', 'risk']",626,"['相反,抑郁症并不是任何人类测量的风险因素。']",0.8,"['depression', 'a', 'factor', 'risk', 'risk factor']","['depression', 'factor', 'risk', 'risk factor']",,
630,627,SNPs associated with short stature contributed causally but modestly to risk for depression .,与身材矮小相关的 SNP 对抑郁症的风险有一定的因果作用，但影响不大。,0.4444444444444444,"['depression', 'short', 'associated', 'stature', 'risk', 'with', 'short stature', 'but', 'to']","['depression', 'stature', 'risk', 'but']",627,['与短期相关的SNPs因果但温和地有助于抑郁症的风险。'],0.4444444444444444,"['depression', 'short', 'associated', 'stature', 'risk', 'with', 'short stature', 'but', 'to']","['depression', 'risk', 'but', 'to']",,
631,628,"based on the reasonable assumption that SNPs associated with anthropometric traits are causal for those traits , these findings suggest that body fat mass contributes causally to the risk for depression .",基于与人体测量特征相关的 SNP 是这些特征的因果关系的合理假设，这些发现表明体脂肪量与抑郁症的风险有因果关系。,0.5454545454545454,"['depression', 'fat', 'associated', 'risk', 'causal', 'mass', 'body', 'suggest', 'with', 'that', 'to']","['depression', 'fat', 'risk', 'causal', 'body', 'to']",628,"['基于合理的假设,与人类学特征相关的SNPs是这些特征的原因,这些发现表明身体脂肪质量有助于抑郁症的风险。']",0.5454545454545454,"['depression', 'fat', 'associated', 'risk', 'causal', 'mass', 'body', 'suggest', 'with', 'that', 'to']","['depression', 'fat', 'risk', 'mass', 'body', 'to']",,
632,629,clinicians can be alert to these connections in assessing and managing patients struggling with weight and mood .,临床医生在评估和管理与体重和情绪作斗争的患者时可以警惕这些联系。,0.25,"['mood', 'weight', 'be', 'alert', 'with', 'in', 'to', 'and']","['weight', 'be']",629,['临床医生可以警告这些联系在评估和管理与体重和情绪斗争的患者。'],0.25,"['mood', 'weight', 'be', 'alert', 'with', 'in', 'to', 'and']","['weight', 'be']",,
633,630,"in the face of preeclampsia , a central clinical decision is when to plan delivery .",面对先兆子痫，一个主要的临床决定是何时计划分娩。,0.7142857142857143,"['face', 'preeclampsia', 'delivery', 'central', 'clinical', 'decision', 'to']","['face', 'preeclampsia', 'delivery', 'clinical', 'decision']",630,"['在预发症面前,一个中心的临床决定是什么时候计划分娩。']",0.7142857142857143,"['face', 'preeclampsia', 'delivery', 'central', 'clinical', 'decision', 'to']","['face', 'delivery', 'central', 'clinical', 'decision']",,
634,631,"to assess delivery strategy , U.K. investigators randomized 900 women with preeclampsia without severe features ( median gestational age at diagnosis , 35.6 weeks ) to immediate delivery or expectant management .",为评估分娩策略，英国研究人员将 900 名没有严重特征（诊断时的中位孕龄为 35.6 周）的先兆子痫妇女随机分为立即分娩或期待治疗。,0.4,"['median', 'strategy', 'preeclampsia', 'delivery', 'diagnosis', 'gestational', 'age', 'assess', 'management', 'immediate', 'with', 'severe', 'gestational age', 'to', 'without']","['strategy', 'preeclampsia', 'delivery', 'diagnosis', 'assess', 'gestational age']",631,"['为了评估生育策略,英国研究人员随机调查了900名患有无严重特征的妇女(诊断时平均生育年龄为35.6周),即时生育或预期管理。']",0.4,"['median', 'strategy', 'preeclampsia', 'delivery', 'diagnosis', 'gestational', 'age', 'assess', 'management', 'immediate', 'with', 'severe', 'gestational age', 'to', 'without']","['strategy', 'diagnosis', 'age', 'assess', 'management', 'without']",,
635,632,"median gestational age at birth was 36.0 weeks ( immediate delivery ) and 36.7 weeks ( expectant management ) , and cesarean delivery rates were 55 % and 61 % , respectively .",出生时的中位胎龄为 36.0 周（立即分娩）和 36.7 周（期待治疗），剖宫产率分别为 55% 和 61%。,0.1818181818181818,"['median', 'cesarean', 'birth', 'delivery', 'gestational', 'cesarean delivery', 'age', 'management', 'immediate', 'gestational age', 'and']","['birth', 'delivery']",632,"['出生时的平均生育年龄为36.0周(即时分娩)和36.7周(预期管理),凯撒分娩率为55%和61%,分别。']",0.3636363636363636,"['median', 'cesarean', 'birth', 'delivery', 'gestational', 'cesarean delivery', 'age', 'management', 'immediate', 'gestational age', 'and']","['birth', 'delivery', 'age', 'management']",,
636,633,expectant management is an option if maternal blood pressure and laboratory testing are stable .,如果产妇血压和实验室检查稳定，期待治疗是一种选择。,0.2,"['pressure', 'maternal', 'blood', 'blood pressure', 'option', 'laboratory', 'management', 'testing', 'if', 'and']","['blood pressure', 'laboratory']",633,"['预期管理是一种选择,如果母亲的血压和实验室测试是稳定的。']",0.4,"['pressure', 'maternal', 'blood', 'blood pressure', 'option', 'laboratory', 'management', 'testing', 'if', 'and']","['maternal', 'blood pressure', 'laboratory', 'management']",,
637,634,"immediate delivery is warranted if the preeclampsia progresses ( e.g. , rising maternal blood pressure , worrisome findings upon maternal or fetal testing ) or at the onset of preeclampsia with severe features .",如果先兆子痫进展（例如，母体血压升高，母体或胎儿检测结果令人担忧）或具有严重特征的先兆子痫发作，则需要立即分娩。,0.2857142857142857,"['pressure', 'maternal', 'blood', 'fetal', 'preeclampsia', 'delivery', 'blood pressure', 'onset', 'immediate', 'testing', 'with', 'severe', 'rising', 'if']","['maternal', 'preeclampsia', 'delivery', 'blood pressure']",634,"['即时分娩是保证的,如果前<unk>症进展(例如,母亲血压上升,在母亲或胎儿测试时令人担忧的发现)或在前<unk>症的发起时具有严重特征。']",0.2142857142857142,"['pressure', 'maternal', 'blood', 'fetal', 'preeclampsia', 'delivery', 'blood pressure', 'onset', 'immediate', 'testing', 'with', 'severe', 'rising', 'if']","['maternal', 'delivery', 'blood pressure']",,
638,635,"based on these results , increasing intake of PUFAs for preventing or treating diabetes is not recommended .",基于这些结果，不建议为了预防或治疗糖尿病而增加多不饱和脂肪酸的摄入量。,0.3333333333333333,"['diabetes', 'intake', 'on']",['diabetes'],635,"['基于这些结果,不建议增加PUFAs的摄入,以预防或治疗糖尿病。']",0.3333333333333333,"['diabetes', 'intake', 'on']",['diabetes'],,
639,636,Obverse differences were noted for sedentary time .,久坐时间存在显着差异。,0.5,"['sedentary', 'time']",['time'],636,['可见的差异被注意到在座位时间。'],0.5,"['sedentary', 'time']",['time'],,
640,637,the maximum risk reductions occurred at 375 minutes of light activity and 24 minutes of vigorous activity daily .,最大的风险降低发生在每天 375 分钟的轻度活动和 24 分钟的剧烈活动中。,0.4285714285714285,"['activity', 'risk', 'light', 'vigorous', 'maximum', 'at', 'and']","['activity', 'risk', 'maximum']",637,['最大风险减少发生在375分钟的轻度活动和24分钟的强度活动每日。'],0.2857142857142857,"['activity', 'risk', 'light', 'vigorous', 'maximum', 'at', 'and']","['activity', 'risk']",,
641,638,"however , some residual confounding ( in which low levels of activity resulted in part from medical conditions that accelerate mortality ) seems likely in this analysis , despite statistical adjustment for some comorbidities .",然而，尽管对一些合并症进行了统计调整，但在该分析中似乎可能存在一些残留混杂因素（其中低水平的活动部分是由加速死亡率的医疗条件导致的）。,0.3846153846153846,"['part', 'analysis', 'activity', 'medical', 'adjustment', 'low', 'mortality', 'residual', 'despite', 'this', 'that', 'in', 'accelerate']","['analysis', 'activity', 'low', 'mortality', 'this']",638,"['然而,某些残留的混乱(其中活动水平较低部分是由加速死亡率的医疗条件产生的)似乎在这一分析中很有可能,尽管对某些复杂性进行了统计调整。']",0.3846153846153846,"['part', 'analysis', 'activity', 'medical', 'adjustment', 'low', 'mortality', 'residual', 'despite', 'this', 'that', 'in', 'accelerate']","['analysis', 'activity', 'low', 'mortality', 'this']",,
642,639,"a retrospective study suggests that we should look at overall cardiovascular risk , regardless of baseline BP .",一项回顾性研究表明，无论基线血压如何，我们都应该关注总体心血管风险。,0.4,"['a', 'cardiovascular', 'baseline', 'study', 'retrospective study', 'risk', 'at', 'that', 'look', 'we']","['cardiovascular', 'baseline', 'retrospective study', 'risk']",639,"['一项回顾性研究表明,无论基线BP如何,我们都应该考虑整体心血管风险。']",0.4,"['a', 'cardiovascular', 'baseline', 'study', 'retrospective study', 'risk', 'at', 'that', 'look', 'we']","['cardiovascular', 'baseline', 'retrospective study', 'risk']",,
643,640,"should treatment to lower blood pressure ( BP ) be initiated based on baseline BP , overall cardiovascular ( CV ) risk , or a combination of the two ?",是否应该根据基线血压、总体心血管 (CV) 风险或两者的组合来开始降低血压 (BP) 的治疗？,0.6153846153846154,"['combination', 'pressure', 'cardiovascular', 'baseline', 'blood', 'blood pressure', 'lower', 'be', 'treatment', 'risk', 'lower blood pressure', 'to', 'two']","['combination', 'cardiovascular', 'baseline', 'blood pressure', 'treatment', 'risk', 'lower blood pressure', 'two']",640,"['低血压(BP)的治疗应该是基于基线BP,总心血管(CV)风险,还是两者的组合?']",0.6153846153846154,"['combination', 'pressure', 'cardiovascular', 'baseline', 'blood', 'blood pressure', 'lower', 'be', 'treatment', 'risk', 'lower blood pressure', 'to', 'two']","['combination', 'cardiovascular', 'baseline', 'blood pressure', 'treatment', 'risk', 'to', 'two']",,
644,641,"more patients were eligible for treatment based on high BP alone than with any of the other strategies ( 39 % vs. 22 % , 27 % , and 29 % ) .",与任何其他策略相比，更多的患者有资格接受仅基于高血压的治疗（39% 对 22%、27% 和 29%）。,0.2857142857142857,"['treatment', 'with', 'on', 'and', 'alone', 'high', 'eligible']","['treatment', 'high']",641,"['与其他任何策略相比,仅基于高BP治疗的患者有更多的资格(39%对22%,27%和29%)。']",0.2857142857142857,"['treatment', 'with', 'on', 'and', 'alone', 'high', 'eligible']","['treatment', 'high']",,
645,642,"these data suggest that treatment to lower BP is most efficient when it is targeted to patients with elevated CV risk , regardless of baseline BP .",这些数据表明，无论基线血压如何，当针对心血管风险升高的患者时，降低血压的治疗最有效。,0.4,"['data', 'targeted', 'baseline', 'lower', 'treatment', 'risk', 'suggest', 'with', 'that', 'to']","['data', 'baseline', 'treatment', 'risk']",642,"['这些数据表明,降低BP的治疗是最有效的,当它针对患有高CV风险的患者,无论基线BP。']",0.4,"['data', 'targeted', 'baseline', 'lower', 'treatment', 'risk', 'suggest', 'with', 'that', 'to']","['data', 'baseline', 'treatment', 'risk']",,
646,643,the differences in secondary end points were generally in the same direction as those of the primary end point .,次要终点的差异与主要终点的差异大致相同。,0.2,"['end points', 'primary', 'secondary', 'as', 'direction']",['end points'],643,['二级终点的差异通常与初级终点的差异相同。'],0.2,"['end points', 'primary', 'secondary', 'as', 'direction']",['end points'],,
647,644,there were no serious adverse events .,没有严重的不良事件。,0.0,"['adverse', 'no', 'serious']",[],644,['没有严重的不良事件。'],0.0,"['adverse', 'no', 'serious']",[],,
648,645,"Neurosteroids , which are synthesized from cholesterol in the brain , are potent modulators of GABA and glutamate.16",由大脑中的胆固醇合成的神经类固醇是 GABA 和谷氨酸的有效调节剂。 16,0.6666666666666666,"['cholesterol', 'GABA', 'brain', 'potent', 'modulators', 'and']","['cholesterol', 'GABA', 'brain', 'modulators']",645,['由大脑中的胆固醇合成的神经激素是GABA和葡萄糖的强大调节剂。'],0.6666666666666666,"['cholesterol', 'GABA', 'brain', 'potent', 'modulators', 'and']","['cholesterol', 'GABA', 'brain', 'modulators']",,
649,646,"despite their steroid structure , their target activity and pharmacologic characteristics are distinct from those of glucocorticoids and differ in both genomic and nongenomic effects.17,18","尽管它们具有类固醇结构，但它们的目标活性和药理学特征与糖皮质激素不同，并且在基因组和非基因组效应方面也不同。 17,18",0.5454545454545454,"['steroid', 'activity', 'differ', 'target', 'characteristics', 'structure', 'despite', 'glucocorticoids', 'pharmacologic', 'distinct', 'and']","['steroid', 'activity', 'target', 'characteristics', 'structure', 'pharmacologic']",646,"['尽管它们的类固醇结构,但它们的目标活动和药物特征与葡萄糖的特征有所不同,并且在基因和非基因效应方面有所不同。']",0.4545454545454545,"['steroid', 'activity', 'differ', 'target', 'characteristics', 'structure', 'despite', 'glucocorticoids', 'pharmacologic', 'distinct', 'and']","['steroid', 'activity', 'target', 'characteristics', 'structure']",,
650,647,"preclinical studies have shown that the naturally occurring neurosteroid allopregnanolone is a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors that affects both phasic and tonic inhibition of neurons.16,19","临床前研究表明，天然存在的神经类固醇四氢孕酮是突触和突触外 GABAA 受体的正变构调节剂，可影响神经元的阶段性和强直性抑制。 16,19",0.2,"['allosteric modulator', 'tonic', 'inhibition', 'synaptic', 'receptors', 'preclinical', 'positive', 'have', 'that', 'and']","['inhibition', 'preclinical']",647,"['临床前研究表明,自然出现的神经元阿洛普雷格纳诺隆是一种积极的神经元调节器,对神经元的临床和外观GABAA受体产生影响。']",0.1,"['allosteric modulator', 'tonic', 'inhibition', 'synaptic', 'receptors', 'preclinical', 'positive', 'have', 'that', 'and']",['preclinical'],,
651,648,"with experimental chronic stress , however , levels of allopregnanolone in the brain decrease , and behavioral changes normalize after treatments that increase allopregnanolone levels.19,22,23","然而，随着实验性慢性应激，大脑中四氢孕酮的水平会降低，而在提高四氢孕酮水平的治疗后，行为变化会恢复正常。 19,22,23",0.5,"['decrease', 'brain', 'stress', 'experimental', 'chronic', 'after', 'increase', 'with', 'that', 'and']","['brain', 'stress', 'chronic', 'after', 'and']",648,"['然而,在实验性慢性压力下,大脑中的阿洛弗雷根诺隆水平下降,行为变化在增加阿洛弗雷根诺隆水平的治疗后正常化。']",0.5,"['decrease', 'brain', 'stress', 'experimental', 'chronic', 'after', 'increase', 'with', 'that', 'and']","['brain', 'stress', 'chronic', 'after', 'and']",,
652,649,reduced levels of allopregnanolone in the cerebrospinal fluid normalize after successful treatment of depression with antidepressants.24,在用抗抑郁药成功治疗抑郁症后，脑脊液中四氢孕酮水平的降低会恢复正常。 24,0.8,"['depression', 'cerebrospinal fluid', 'treatment', 'after', 'with']","['depression', 'cerebrospinal fluid', 'treatment', 'after']",649,"['在抑郁症成功治疗后,脑血管液中的阿洛普雷根诺隆的低水平正常化。']",0.6,"['depression', 'cerebrospinal fluid', 'treatment', 'after', 'with']","['depression', 'treatment', 'after']",,
653,650,"the results of the pilot trial are provided in the Supplementary Appendix , available at NEJM.org .",试点试验的结果见补充附录，补充附录可在 NEJM.org 获取。,0.0,"['appendix', 'supplementary', 'available', 'pilot', 'trial', 'at', 'in']",[],650,"['试点试验的结果在附件中提供,可在NEJM.org上找到。']",0.1428571428571428,"['appendix', 'supplementary', 'available', 'pilot', 'trial', 'at', 'in']",['appendix'],,
654,651,this phase 2 trial was conducted at eight sites in the United States from April 2017 through October 2017 .,该 2 期试验于 2017 年 4 月至 2017 年 10 月在美国的八个地点进行。,0.5,"['phase', '2', 'trial', 'at', 'this', 'in']","['phase', '2', 'at']",651,['这次第二阶段审查是在2017年4月至2017年10月期间在美国8个地点进行的。'],0.5,"['phase', '2', 'trial', 'at', 'this', 'in']","['phase', '2', 'this']",,
655,652,a list of sites and principal investigators is provided in the Supplementary Appendix .,补充附录中提供了研究中心和主要研究者的列表。,0.0,"['a', 'appendix', 'supplementary', 'principal', 'list', 'and']",[],652,['网站和主要调查人员的列表在附件中提供。'],0.1666666666666666,"['a', 'appendix', 'supplementary', 'principal', 'list', 'and']",['appendix'],,
656,653,"approval was obtained from the institutional review board at each site , and written informed consent was obtained from each patient .",获得各研究中心机构审查委员会的批准，并获得每位患者的书面知情同意书。,0.5555555555555556,"['site', 'review', 'approval', 'board', 'patient', 'consent', 'informed consent', 'each', 'and']","['review', 'approval', 'patient', 'consent', 'each']",653,"['批准是从每个网站的机构审查委员会获得的,并从每个患者获得了书面信息的同意。']",0.4444444444444444,"['site', 'review', 'approval', 'board', 'patient', 'consent', 'informed consent', 'each', 'and']","['review', 'approval', 'patient', 'consent']",,
657,654,confidentiality agreements exist between the authors and Sage Therapeutics .,作者与 Sage Therapeutics 之间存在保密协议。,0.3333333333333333,"['confidentiality', 'agreements', 'therapeutics', 'exist', 'sage', 'and']","['confidentiality', 'exist']",654,['作者和Sage Therapeutics之间存在隐私协议。'],0.1666666666666666,"['confidentiality', 'agreements', 'therapeutics', 'exist', 'sage', 'and']",['exist'],,
658,655,we recruited patients from outpatient clinics and by using advertising materials approved by the institutional review boards .,我们从门诊诊所招募患者，并使用机构审查委员会批准的广告材料。,0.6,"['review', 'advertising', 'by', 'and', 'we']","['review', 'advertising', 'by']",655,"['我们从外科诊所招募病人,并使用由机构审查委员会批准的广告材料。']",0.6,"['review', 'advertising', 'by', 'and', 'we']","['review', 'advertising', 'by']",,
659,656,patients were admitted as inpatients for the first week of the trial to facilitate daily assessments .,患者在试验的第一周作为住院患者入院，以促进日常评估。,0.3333333333333333,"['week', 'trial', 'as', 'to', 'first', 'inpatients']","['week', 'first']",656,"['患者在试验的第一周被接受为病人,以便日常进行评估。']",0.3333333333333333,"['week', 'trial', 'as', 'to', 'first', 'inpatients']","['week', 'first']",,
660,657,"during the 4 weeks after the treatment period , primary psychiatrists or investigators could adjust the dose of existing antidepressants or prescribe new antidepressants for patients as appropriate .",在治疗期结束后的4周内，初级精神科医生或研究者可酌情调整现有抗抑郁药的剂量或开出新的抗抑郁药给患者。,0.5,"['period', 'adjust', 'treatment', 'primary', 'prescribe', 'after', '4', 'as', 'antidepressants', 'dose', 'appropriate', 'new']","['period', 'treatment', 'after', 'antidepressants', 'dose', 'new']",657,"['在治疗期后的4周内,初级精神科医生或研究人员可以适当调整现有抗抑郁剂的剂量或给患者处方新的抗抑郁剂。']",0.5,"['period', 'adjust', 'treatment', 'primary', 'prescribe', 'after', '4', 'as', 'antidepressants', 'dose', 'appropriate', 'new']","['period', 'treatment', 'after', 'antidepressants', 'dose', 'new']",,
661,658,"the diagnosis of depression was made with the use of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders , fifth edition , Axis I disorders.35",抑郁症的诊断是使用《精神疾病诊断和统计手册结构化临床访谈》第五版，Axis I disorders.35,0.5,"['depression', 'mental', 'axis', 'diagnosis', 'edition', 'clinical', 'disorders', 'diagnostic', 'interview', 'manual', 'with', 'I', 'and', 'fifth']","['depression', 'mental', 'diagnosis', 'edition', 'clinical', 'interview', 'fifth']",658,"['抑郁症的诊断是通过使用结构化临床面试的诊断和统计手册的精神疾病,第五版, 轴 I 疾病。']",0.4285714285714285,"['depression', 'mental', 'axis', 'diagnosis', 'edition', 'clinical', 'disorders', 'diagnostic', 'interview', 'manual', 'with', 'I', 'and', 'fifth']","['depression', 'mental', 'diagnosis', 'edition', 'clinical', 'fifth']",,
662,659,patients were eligible to participate if they had been receiving stable doses of antidepressants for at least 30 days or if they were not taking antidepressants .,如果患者已经接受稳定剂量的抗抑郁药至少 30 天，或者如果他们没有服用抗抑郁药，则他们有资格参加。,0.1666666666666666,"['taking', 'antidepressants', 'at', 'if', 'to', 'eligible']",['antidepressants'],659,"['患者有资格参加,如果他们至少30天接受了稳定的抗抑郁剂剂量,或者如果他们不服用抗抑郁剂。']",0.1666666666666666,"['taking', 'antidepressants', 'at', 'if', 'to', 'eligible']",['antidepressants'],,
663,660,a full list of inclusion and exclusion criteria is provided in the Supplementary Appendix .,补充附录中提供了包含和排除标准的完整列表。,0.25,"['a', 'appendix', 'inclusion', 'supplementary', 'exclusion', 'list', 'full', 'and']","['inclusion', 'full']",660,['包含和排除标准的完整列表在附件中提供。'],0.375,"['a', 'appendix', 'inclusion', 'supplementary', 'exclusion', 'list', 'full', 'and']","['appendix', 'inclusion', 'full']",,
664,661,"safety was assessed on the basis of the frequency and severity of adverse events , vital signs , changes in clinical laboratory measurements , physical examinations , electrocardiography , the Stanford Sleepiness Scale , and assessment of suicidal ideation and behavior with the use of the Columbia Suicide Severity Rating Scale .",安全性的评估依据是不良事件的频率和严重程度、生命体征、临床实验室测量值的变化、身体检查、心电图、斯坦福嗜睡量表，以及使用哥伦比亚自杀严重程度等级对自杀意念和行为的评估。规模 。,0.5714285714285714,"['behavior', 'safety', 'vital signs', 'frequency', 'scale', 'electrocardiography', 'physical', 'basis', 'adverse', 'assessment', 'suicidal', 'clinical', 'examinations', 'laboratory', 'ideation', 'suicide', 'with', 'rating scale', 'sleepiness', 'and', 'assessed']","['behavior', 'safety', 'vital signs', 'frequency', 'scale', 'electrocardiography', 'assessment', 'suicidal', 'clinical', 'laboratory', 'suicide', 'sleepiness']",661,"['安全性是基于不良事件的频率和严重性,重要迹象,临床实验室测量的变化,物理检查,电心,斯坦福睡眠尺度,以及使用哥伦比亚自杀频率评级尺度的自杀思想和行为的评估。']",0.3809523809523809,"['behavior', 'safety', 'vital signs', 'frequency', 'scale', 'electrocardiography', 'physical', 'basis', 'adverse', 'assessment', 'suicidal', 'clinical', 'examinations', 'laboratory', 'ideation', 'suicide', 'with', 'rating scale', 'sleepiness', 'and', 'assessed']","['behavior', 'safety', 'frequency', 'assessment', 'suicidal', 'clinical', 'laboratory', 'suicide']",,
665,662,"continuous variables are reported as means and standard deviations , and categorical variables as numbers and percentages .",连续变量报告为均值和标准差，分类变量报告为数字和百分比。,0.4,"['standard', 'continuous', 'means', 'as', 'categorical']","['standard', 'continuous']",662,"['连续变量被称为手段和标准偏差,类别变量被称为数字和百分比。']",0.6,"['standard', 'continuous', 'means', 'as', 'categorical']","['standard', 'continuous', 'means']",,
666,663,"statistical analyses were performed with the use of SAS software , version 9.3 ( SAS Institute ) .",使用 SAS 软件 9.3 版（SAS Institute）进行统计分析。,0.2,"['version', 'software', 'institute', 'with', 'SAS']",['software'],663,"['统计分析使用SAS软件,版本 9.3(SAS研究所)进行。']",0.6,"['version', 'software', 'institute', 'with', 'SAS']","['version', 'software', 'institute']",,
667,663,"statistical analyses were performed with the use of SAS software , version 9.3 ( SAS Institute ) .",使用 SAS 软件 9.3 版（SAS Institute）进行统计分析。,0.2,"['version', 'software', 'institute', 'with', 'SAS']",['software'],663,"['统计分析使用SAS软件,版本 9.3(SAS研究所)进行。']",0.6,"['version', 'software', 'institute', 'with', 'SAS']","['version', 'software', 'institute']",,
668,664,"there was no plan for imputation of missing data , but sensitivity analyses were performed to assess the effect of missing data .",没有填补缺失数据的计划，但进行了敏感性分析以评估缺失数据的影响。,0.5,"['data', 'no', 'effect', 'assess', 'sensitivity', 'but', 'to', 'missing']","['data', 'assess', 'but', 'missing']",664,"['没有错过的数据的计算计划,但敏感性分析进行,以评估错过的数据的影响。']",0.375,"['data', 'no', 'effect', 'assess', 'sensitivity', 'but', 'to', 'missing']","['data', 'assess', 'but']",,
669,665,the statistical analysis plan did not include a provision for correction for multiplicity when the analyses of secondary end points were performed .,统计分析计划不包括在执行次要终点分析时对多重性进行校正的规定。,0.75,"['a', 'correction', 'analysis', 'provision', 'end points', 'secondary', 'multiplicity', 'statistical analysis']","['correction', 'analysis', 'provision', 'end points', 'multiplicity', 'statistical analysis']",665,['统计分析计划不包括在进行二级终点分析时对多样性进行纠正的规定。'],0.5,"['a', 'correction', 'analysis', 'provision', 'end points', 'secondary', 'multiplicity', 'statistical analysis']","['analysis', 'provision', 'end points', 'statistical analysis']",,
670,666,"therefore , the results are reported as point estimates and unadjusted 95 % confidence intervals and should not be used to infer treatment effects .",因此，结果报告为点估计值和未调整的 95% 置信区间，不应用于推断治疗效果。,0.4,"['be', 'treatment', 'unadjusted', 'point', 'as', 'confidence', 'therefore', 'to', 'and', 'intervals']","['treatment', 'unadjusted', 'point', 'to']",666,"['因此,结果被报告为点估计和不调整的95%信任间隔,不应用于估计治疗效果。']",0.3,"['be', 'treatment', 'unadjusted', 'point', 'as', 'confidence', 'therefore', 'to', 'and', 'intervals']","['treatment', 'point', 'to']",,
671,667,"a total of 169 patients were screened , of whom 89 were enrolled and underwent randomization .",总共筛选了 169 名患者，其中 89 名被纳入并接受了随机分组。,0.3333333333333333,"['a', 'randomization', 'total']",['randomization'],667,"['总共有169名患者被检查,其中89人被注册并经历了随机化。']",0.3333333333333333,"['a', 'randomization', 'total']",['randomization'],,
672,668,results for secondary end points are shown in Table 2 .,表 2 显示了次要终点的结果。,0.75,"['table', '2', 'end points', 'secondary']","['table', '2', 'end points']",668,['二级终点的结果显示在图2中。'],0.5,"['table', '2', 'end points', 'secondary']","['2', 'end points']",,
673,669,there were no serious adverse events and no deaths during this trial .,在该试验期间没有严重的不良事件，也没有死亡。,0.0,"['adverse', 'no', 'trial', 'serious', 'this', 'and']",[],669,"['在此审判期间,没有严重的不良事件和死亡。']",0.1666666666666666,"['adverse', 'no', 'trial', 'serious', 'this', 'and']",['trial'],,
674,670,"subjective sleepiness , as assessed with the use of the Stanford Sleepiness Scale , was similar in the two groups .",使用斯坦福嗜睡量表评估的主观嗜睡在两组中相似。,0.375,"['scale', 'subjective', 'as', 'with', 'sleepiness', 'two', 'assessed', 'similar']","['scale', 'sleepiness', 'two']",670,"['根据Stanford Sleepiness Scale的使用,客观的睡眠率在两组中是相似的。']",0.25,"['scale', 'subjective', 'as', 'with', 'sleepiness', 'two', 'assessed', 'similar']","['two', 'similar']",,
675,671,no patients in the placebo group had dose reductions .,安慰剂组中没有患者剂量减少。,0.6,"['group', 'placebo', 'no', 'dose', 'in']","['group', 'placebo', 'dose']",671,['没有 placebo 群体的患者有剂量减少。'],0.4,"['group', 'placebo', 'no', 'dose', 'in']","['group', 'dose']",,
676,672,"these findings may support a role for GABAA receptors in the pathophysiology of depression.4,38","这些发现可能支持 GABAA 受体在抑郁症病理生理学中的作用。 4,38",0.5,"['a', 'support', 'receptors', 'pathophysiology', 'role', 'in']","['support', 'pathophysiology', 'role']",672,['这些发现可能支持GABAA受体在抑郁症病理学中的作用。'],0.3333333333333333,"['a', 'support', 'receptors', 'pathophysiology', 'role', 'in']","['support', 'role']",,
677,673,"data were missing for approximately 5 % of patients in each group , but sensitivity analyses suggested that this did not alter the conclusions with respect to the primary end point of the trial .",每组中约有 5% 的患者数据缺失，但敏感性分析表明这不会改变试验主要终点的结论。,0.3529411764705882,"['group', '5', 'data', 'primary', 'trial', 'end', 'point', 'with', 'respect', 'sensitivity', 'approximately', 'this', 'that', 'each', 'but', 'to', 'missing']","['group', '5', 'data', 'point', 'but', 'missing']",673,"['每个群体中约有5%的患者缺乏数据,但敏感性分析表明,这并没有改变研究的主要结论。']",0.2941176470588235,"['group', '5', 'data', 'primary', 'trial', 'end', 'point', 'with', 'respect', 'sensitivity', 'approximately', 'this', 'that', 'each', 'but', 'to', 'missing']","['group', '5', 'data', 'but', 'missing']",,
678,674,"the current trial did not include an active comparator group , which limits comparison of the results with those of available antidepressants .",目前的试验不包括一个积极的比较组，这限制了结果与现有抗抑郁药的比较。,0.4,"['group', 'comparison', 'active', 'available', 'trial', 'current', 'limits', 'with', 'antidepressants', 'comparator']","['group', 'comparison', 'active', 'antidepressants']",674,"['目前的研究不包括一个活跃的比较组,这限制了结果与可用的抗抑郁剂的比较。']",0.4,"['group', 'comparison', 'active', 'available', 'trial', 'current', 'limits', 'with', 'antidepressants', 'comparator']","['group', 'comparison', 'available', 'antidepressants']",,
679,675,the diagnosis of atrial fibrillation ( AF ) requires an electrocardiogram ( ECG ) during an AF episode although structural atrial changes and grossly abnormal ECG findings such as left atrial enlargement can also point to AF .,心房颤动 (AF) 的诊断需要在 AF 发作期间进行心电图 (ECG)，但结构性心房变化和严重异常的 ECG 结果（如左心房扩大）也可能指向 AF。,0.7142857142857143,"['atrial', 'electrocardiogram', 'ECG', 'fibrillation', 'abnormal', 'enlargement', 'episode', 'diagnosis', 'atrial fibrillation', 'structural', 'point', 'as', 'to', 'and']","['electrocardiogram', 'ECG', 'fibrillation', 'abnormal', 'enlargement', 'episode', 'diagnosis', 'atrial fibrillation', 'structural', 'as']",675,"['甲状腺纤维化(AF)的诊断需要在AF事件中进行电心图(ECG),尽管结构性甲状腺变化和严重异常的ECG发现,如左甲状腺扩张,也可以指向AF。']",0.2857142857142857,"['atrial', 'electrocardiogram', 'ECG', 'fibrillation', 'abnormal', 'enlargement', 'episode', 'diagnosis', 'atrial fibrillation', 'structural', 'point', 'as', 'to', 'and']","['abnormal', 'diagnosis', 'structural', 'as']",,
680,676,"however , if ECGs in normal sinus rhythm provided clues to the risk for AF , then more individuals could be evaluated closely for AF before the clinical diagnosis and receive treatment .",然而，如果正常窦性心律的 ECG 提供了 AF 风险的线索，那么更多的人可以在临床诊断和接受治疗之前仔细评估 AF。,0.7857142857142857,"['sinus', 'rhythm', 'normal', 'sinus rhythm', 'be', 'diagnosis', 'treatment', 'clinical', 'clinical diagnosis', 'risk', 'before', 'if', 'to', 'and']","['sinus', 'rhythm', 'sinus rhythm', 'be', 'diagnosis', 'treatment', 'clinical', 'clinical diagnosis', 'risk', 'before', 'and']",676,"['然而,如果正常的阴道节奏的ECG提供了对AF风险的提示,那么在临床诊断和接受治疗之前,更多的人可以对AF进行仔细评估。']",0.7142857142857143,"['sinus', 'rhythm', 'normal', 'sinus rhythm', 'be', 'diagnosis', 'treatment', 'clinical', 'clinical diagnosis', 'risk', 'before', 'if', 'to', 'and']","['rhythm', 'normal', 'be', 'diagnosis', 'treatment', 'clinical', 'clinical diagnosis', 'risk', 'before', 'and']",,
681,677,these researchers hypothesized that more subtle ECG findings during normal sinus rhythm are also associated with AF .,这些研究人员假设在正常窦性心律期间更细微的心电图发现也与 AF 相关。,0.4444444444444444,"['sinus', 'ECG', 'rhythm', 'normal', 'sinus rhythm', 'associated', 'subtle', 'with', 'that']","['sinus', 'ECG', 'rhythm', 'sinus rhythm']",677,['这些研究人员假设在正常阴道节奏期间更微妙的ECG发现也与AF相关。'],0.1111111111111111,"['sinus', 'ECG', 'rhythm', 'normal', 'sinus rhythm', 'associated', 'subtle', 'with', 'that']",['rhythm'],,
682,678,"in a retrospective ECG database of 180,922 patients with 649,931 ECGs , machine learning through artificial intelligence ( AI ) was used to develop a predictive model for AF from a single , normal sinus rhythm ECG .","在一个包含 180,922 名患者和 649,931 个心电图的回顾性心电图数据库中，通过人工智能 (AI) 进行的机器学习被用于从单个正常窦性心律心电图开发 AF 预测模型。",0.5555555555555556,"['sinus', 'ECG', 'rhythm', 'a', 'model', 'database', 'normal', 'intelligence', 'develop', 'sinus rhythm', 'artificial', 'predictive', 'artificial intelligence', 'machine', 'with', 'learning', 'single', 'to']","['sinus', 'ECG', 'rhythm', 'model', 'sinus rhythm', 'artificial intelligence', 'machine', 'learning', 'single', 'to']",678,"['在180922名患有64931 ECG的回顾性ECG数据库中,通过人工智能(AI)的机器学习被用来开发一个从一个单一的正常阴道节奏ECG的预测模型。']",0.3333333333333333,"['sinus', 'ECG', 'rhythm', 'a', 'model', 'database', 'normal', 'intelligence', 'develop', 'sinus rhythm', 'artificial', 'predictive', 'artificial intelligence', 'machine', 'with', 'learning', 'single', 'to']","['rhythm', 'model', 'artificial intelligence', 'machine', 'learning', 'single']",,
683,679,"approximately two thirds of ECGs were used for the training set , and the remainder were used for validation and testing .",大约三分之二的心电图用于训练集，其余用于验证和测试。,0.1428571428571428,"['training', 'validation', 'set', 'testing', 'approximately', 'and', 'two']",['training'],679,"['大约三分之二的ECG用于培训组,其余用于验证和测试。']",0.0,"['training', 'validation', 'set', 'testing', 'approximately', 'and', 'two']",[],,
684,680,"about 8 % of patients in the testing cohort had verified AF diagnoses , based on earlier ECGs .",根据早期的心电图，测试队列中约有 8% 的患者证实了 AF 诊断。,0.0,"['testing', 'cohort', 'on', 'earlier']",[],680,"['大约有8%的患者在测试组中确认了AF诊断,基于以前的ECG。']",0.0,"['testing', 'cohort', 'on', 'earlier']",[],,
685,681,the AI algorithm performed quite well .,AI算法表现相当不错。,0.5,"['algorithm', 'well']",['algorithm'],681,['AI算法表现得非常好。'],0.5,"['algorithm', 'well']",['algorithm'],,
686,682,the area under the curve of the receiver operating characteristic curve for detecting AF was 0.87 in the derivation and validation sets .,在推导和验证集中，用于检测 AF 的接受者操作特征曲线的曲线下面积为 0.87。,0.5,"['derivation', 'characteristic', 'validation', 'area', 'curve', 'characteristic curve', 'area under the curve', 'in', 'and', 'receiver']","['derivation', 'characteristic', 'area', 'curve', 'characteristic curve']",682,['接收器操作特性曲线的曲线下的区域在衍生和验证集中为0.87。'],0.4,"['derivation', 'characteristic', 'validation', 'area', 'curve', 'characteristic curve', 'area under the curve', 'in', 'and', 'receiver']","['derivation', 'characteristic', 'area', 'curve']",,
687,683,"when applied to the testing group , the sensitivity was 79.0 % , the specificity was 79.5 % , and the overall accuracy was 79.4 % .",应用于试验组时，灵敏度为79.0%，特异度为79.5%，总准确率为79.4%。,0.375,"['group', 'specificity', 'accuracy', 'applied', 'testing', 'sensitivity', 'to', 'and']","['group', 'sensitivity', 'to']",683,"['当应用于测试组时,敏感度为79.0%,特性为79.5%和总准确度为79.4%。']",0.375,"['group', 'specificity', 'accuracy', 'applied', 'testing', 'sensitivity', 'to', 'and']","['group', 'accuracy', 'to']",,
688,684,AF can be intermittent for many years and is often not diagnosed until patients have progressed to longer episodes .,AF 可以间歇性持续多年，并且通常直到患者发展到更长时间的发作时才被诊断出来。,0.3333333333333333,"['intermittent', 'be', 'episodes', 'have', 'to', 'and']","['intermittent', 'episodes']",684,"['AF可以暂停多年,并且经常没有诊断,直到病人进展到更长的事件。']",0.1666666666666666,"['intermittent', 'be', 'episodes', 'have', 'to', 'and']",['have'],,
689,685,diagnosing AF earlier would allow treatment that could reduce the risk for cryptogenic stroke .,早期诊断 AF 将允许进行治疗以降低隐源性中风的风险。,0.625,"['cryptogenic', 'stroke', 'reduce', 'allow', 'treatment', 'risk', 'that', 'earlier']","['stroke', 'reduce', 'allow', 'treatment', 'risk']",685,"['早期诊断AF将允许治疗,这可能会降低加密性中风的风险。']",0.625,"['cryptogenic', 'stroke', 'reduce', 'allow', 'treatment', 'risk', 'that', 'earlier']","['stroke', 'reduce', 'allow', 'treatment', 'risk']",,
690,686,the AI algorithm developed here is reasonably accurate .,这里开发的 AI 算法相当准确。,0.5,"['algorithm', 'accurate']",['algorithm'],686,['在这里开发的AI算法是合理准确的。'],1.0,"['algorithm', 'accurate']","['algorithm', 'accurate']",,
691,687,"certainly , at this time , treatment decisions should not be based on the algorithm , but it would enable more intense ECG monitoring for people predicted to be at heightened AF risk .",当然，在这个时候，治疗决定不应该基于算法，但它可以对预测为 AF 风险增加的人进行更严格的 ECG 监测。,0.7,"['monitoring', 'ECG', 'algorithm', 'time', 'be', 'treatment', 'risk', 'intense', 'this', 'but']","['monitoring', 'algorithm', 'time', 'be', 'treatment', 'risk', 'but']",687,"['当时,治疗决策不应该基于算法,但它将允许更强烈的ECG监测,人们预计会患有更高的AF风险。']",0.7,"['monitoring', 'ECG', 'algorithm', 'time', 'be', 'treatment', 'risk', 'intense', 'this', 'but']","['monitoring', 'algorithm', 'time', 'treatment', 'risk', 'intense', 'but']",,
692,688,cognitive activities throughout the lifespan and social activities in later life were associated with lower risk .,整个生命周期的认知活动和晚年的社会活动都与较低的风险相关。,0.3,"['life', 'social activities', 'lower', 'associated', 'risk', 'with', 'cognitive', 'later', 'in', 'and']","['life', 'lower', 'risk']",688,['终身认知活动和后期生活中的社会活动与较低的风险有关。'],0.4,"['life', 'social activities', 'lower', 'associated', 'risk', 'with', 'cognitive', 'later', 'in', 'and']","['life', 'lower', 'risk', 'later']",,
693,689,"this information , along with years of education , was used to construct a cognitive reserve score .",此信息连同受教育年限被用于构建认知储备分数。,0.5,"['a', 'reserve', 'education', 'information', 'along', 'score', 'with', 'cognitive', 'this', 'to']","['reserve', 'education', 'information', 'score', 'to']",689,"['这些信息,以及多年的教育,被用来构建一个认知储备分数。']",0.4,"['a', 'reserve', 'education', 'information', 'along', 'score', 'with', 'cognitive', 'this', 'to']","['reserve', 'education', 'information', 'score']",,
694,690,"after multivariable adjustment , participants in the highest tertile of cognitive reserve scores had a 39 % lower risk for dementia diagnosis than those in the lowest tertile .",多变量调整后，认知储备分数最高三分位数的参与者患痴呆症的风险比最低三分位数的参与者低 39%。,0.4,"['a', 'reserve', 'adjustment', 'dementia', 'lower', 'diagnosis', 'risk', 'after', 'cognitive', 'in']","['reserve', 'dementia', 'risk', 'after']",690,"['经过多变的调整,认知备份得分最高的受访者患痴呆症诊断的风险比最低的受访者低39%。']",0.3,"['a', 'reserve', 'adjustment', 'dementia', 'lower', 'diagnosis', 'risk', 'after', 'cognitive', 'in']","['dementia', 'diagnosis', 'risk']",,
695,691,the risk reduction was significant even in participants with high Alzheimer disease and vascular pathologies .,即使在患有高阿尔茨海默病和血管病变的参与者中，风险降低也很显着。,0.5555555555555556,"['disease', 'alzheimer disease', 'vascular', 'reduction', 'risk', 'with', 'in', 'and', 'high']","['disease', 'alzheimer disease', 'reduction', 'risk', 'high']",691,"['风险降低是显著的,即使在患有高阿尔茨海默病和血管疾病的参与者。']",0.5555555555555556,"['disease', 'alzheimer disease', 'vascular', 'reduction', 'risk', 'with', 'in', 'and', 'high']","['disease', 'alzheimer disease', 'reduction', 'risk', 'high']",,
696,692,comment - NEUROLOGY,评论 - 神经病学,0.0,['-'],[],692,['评论 - 神经'],0.0,['-'],[],,
697,692,comment - NEUROLOGY,评论 - 神经病学,0.0,['-'],[],692,['评论 - 神经'],0.0,['-'],[],,
698,693,"participating in cognitive and social activities throughout the lifespan may decrease dementia risk , even in the presence of Alzheimer disease and vascular pathologies on autopsy .",在整个生命周期中参与认知和社会活动可能会降低痴呆风险，即使在尸检中存在阿尔茨海默病和血管病变。,0.3846153846153846,"['presence', 'disease', 'decrease', 'alzheimer disease', 'autopsy', 'vascular', 'social activities', 'dementia', 'risk', 'cognitive', 'on', 'in', 'and']","['presence', 'disease', 'alzheimer disease', 'dementia', 'risk']",693,"['在整个生命中参与认知和社会活动可能会降低痴呆症的风险,即使在阿尔茨海默病和血管疾病在自闭症时存在。']",0.3846153846153846,"['presence', 'disease', 'decrease', 'alzheimer disease', 'autopsy', 'vascular', 'social activities', 'dementia', 'risk', 'cognitive', 'on', 'in', 'and']","['presence', 'disease', 'alzheimer disease', 'dementia', 'risk']",,
699,694,"cognitive activities during nearly the entire lifespan that were queried in the study included reading , writing letters , and visiting the library .",研究中询问的几乎整个生命周期的认知活动包括阅读、写信和访问图书馆。,0.1428571428571428,"['library', 'reading', 'study', 'writing', 'cognitive', 'that', 'and']",['library'],694,"['几乎整个生命的认知活动,在研究中被要求,包括阅读、写信和参观图书馆。']",0.1428571428571428,"['library', 'reading', 'study', 'writing', 'cognitive', 'that', 'and']",['library'],,
700,695,a machine learning technique was noninferior to traditional immunohistochemistry in predicting molecular biomarker expression .,机器学习技术在预测分子生物标志物表达方面不劣于传统的免疫组织化学。,0.875,"['a', 'biomarker', 'expression', 'molecular', 'immunohistochemistry', 'technique', 'machine', 'learning']","['biomarker', 'expression', 'molecular', 'immunohistochemistry', 'technique', 'machine', 'learning']",695,['机器学习技术在预测分子生物标记表达时不低于传统免疫物质化学。'],0.625,"['a', 'biomarker', 'expression', 'molecular', 'immunohistochemistry', 'technique', 'machine', 'learning']","['expression', 'molecular', 'technique', 'machine', 'learning']",,
701,696,"the pathological review of tumor samples , even for common molecular biomarkers such as estrogen receptor ( ER ) , progesterone receptor ( PR ) , and human epidermal growth factor receptor 2 ( HER2 ) , is time consuming .",肿瘤样本的病理检查，即使是常见的分子生物标志物，如雌激素受体 (ER)、孕激素受体 (PR) 和人表皮生长因子受体 2 (HER2)，也是非常耗时的。,0.7058823529411765,"['ER', 'growth factor', 'receptor', 'epidermal growth factor', 'estrogen', 'progesterone', '2', 'review', 'tumor', 'molecular', 'time', 'common', 'pathological', 'human', 'as', 'estrogen receptor', 'and']","['growth factor', 'receptor', 'epidermal growth factor', 'estrogen', '2', 'review', 'tumor', 'molecular', 'time', 'human', 'as', 'estrogen receptor']",696,"['肿瘤样本的病理审查,即使是常见的分子生物标记,如雌激素受体(ER),<unk>酮受体(PR)和人类肾上腺生长因子受体2(HER2),是时间消耗。']",0.6470588235294118,"['ER', 'growth factor', 'receptor', 'epidermal growth factor', 'estrogen', 'progesterone', '2', 'review', 'tumor', 'molecular', 'time', 'common', 'pathological', 'human', 'as', 'estrogen receptor', 'and']","['growth factor', 'receptor', 'estrogen', '2', 'review', 'tumor', 'molecular', 'time', 'human', 'as', 'estrogen receptor']",,
702,697,"moreover , there is not always concordance between pathologists on the interpretation of samples .",此外，病理学家之间对样本的解释并不总是一致的。,0.5,"['concordance', 'interpretation']",['interpretation'],697,"['除此之外,病理学家对样品的解释并不总是一致。']",0.5,"['concordance', 'interpretation']",['interpretation'],,
703,698,"for example , it has been estimated that there is a discrepancy of up to 19 % for ER estimation between central laboratories and local pathology laboratories .",例如，据估计，中心实验室和地方病理实验室之间的 ER 估计差异高达 19%。,0.3333333333333333,"['ER', 'a', 'estimation', 'pathology', 'local', 'central', 'discrepancy', 'up', 'example', 'that', 'to', 'and']","['estimation', 'pathology', 'discrepancy', 'example']",698,"['例如,估计在中央实验室和本地病理实验室之间对ER估计存在高达19%的差异。']",0.3333333333333333,"['ER', 'a', 'estimation', 'pathology', 'local', 'central', 'discrepancy', 'up', 'example', 'that', 'to', 'and']","['estimation', 'pathology', 'discrepancy', 'example']",,
704,699,artificial intelligence ( AI ) and machine learning technologies are being applied to address this variation as well as to improve reliability and add efficiency .,人工智能 (AI) 和机器学习技术正被应用于应对这种变化，并提高可靠性和效率。,0.4375,"['variation', 'reliability', 'intelligence', 'artificial', 'well', 'efficiency', 'applied', 'being', 'artificial intelligence', 'machine', 'as', 'learning', 'this', 'to', 'and', 'add']","['variation', 'reliability', 'efficiency', 'artificial intelligence', 'machine', 'learning', 'to']",699,"['人工智能(AI)和机器学习技术正在应用,以应对这种变化,以及提高可靠性和提高效率。']",0.375,"['variation', 'reliability', 'intelligence', 'artificial', 'well', 'efficiency', 'applied', 'being', 'artificial intelligence', 'machine', 'as', 'learning', 'this', 'to', 'and', 'add']","['variation', 'reliability', 'efficiency', 'artificial intelligence', 'machine', 'learning']",,
705,700,"currently , such technology can differentiate between cancerous and noncancerous tissue as well as determine presence of metastases in lymph nodes and perform tumor grading .",目前，这种技术可以区分癌组织和非癌组织，以及确定淋巴结中是否存在转移并进行肿瘤分级。,0.5,"['presence', 'lymph', 'lymph nodes', 'tissue', 'tumor', 'cancerous', 'well', 'technology', 'differentiate', 'as', 'in', 'and', 'determine', 'grading']","['presence', 'lymph', 'lymph nodes', 'tissue', 'tumor', 'technology', 'differentiate']",700,"['目前,这种技术可以区分癌症和非癌症组织,并确定淋巴腺中的转化物的存在,并进行肿瘤分类。']",0.4285714285714285,"['presence', 'lymph', 'lymph nodes', 'tissue', 'tumor', 'cancerous', 'well', 'technology', 'differentiate', 'as', 'in', 'and', 'determine', 'grading']","['presence', 'lymph', 'tissue', 'tumor', 'technology', 'differentiate']",,
706,701,"histology and biomarkers were found to be significantly correlated with all 19 assessed biomarkers , including most clinically relevant ER , PR , and HER2 .",发现组织学和生物标志物与所有 19 种评估的生物标志物显着相关，包括大多数临床相关的 ER、PR 和 HER2。,0.0,"['ER', 'be', 'with', 'histology', 'all', 'and', 'assessed']",[],701,"['历史学和生物标志被发现与所有19个评估的生物标志相关,其中包括最临床相关的ER、PR和HER2。']",0.0,"['ER', 'be', 'with', 'histology', 'all', 'and', 'assessed']",[],,
707,702,"for approximately half of the patients , the machine learning technique was able to predict biomarker expression with noninferiority to immunohistochemistry ( IHC ) in two validation cohorts with positive predictive values of 97 % and 98 % .",对于大约一半的患者，机器学习技术能够预测两个验证队列中的生物标志物表达，且不劣于免疫组织化学 (IHC)，阳性预测值为 97% 和 98%。,0.5294117647058824,"['biomarker', 'expression', 'validation', 'half', 'predict', 'immunohistochemistry', 'technique', 'values', 'predictive', 'cohorts', 'machine', 'with', 'learning', 'positive', 'approximately', 'and', 'two']","['biomarker', 'expression', 'half', 'predict', 'immunohistochemistry', 'technique', 'machine', 'learning', 'two']",702,"['对于大约一半的患者,机械学习技术能够预测生物标志表达,不低于免疫神经学(IHC)在两个验证协调,有97%和98%的积极预测值。']",0.4117647058823529,"['biomarker', 'expression', 'validation', 'half', 'predict', 'immunohistochemistry', 'technique', 'values', 'predictive', 'cohorts', 'machine', 'with', 'learning', 'positive', 'approximately', 'and', 'two']","['expression', 'half', 'predict', 'technique', 'machine', 'learning', 'two']",,
708,703,"AI and machine learning are emerging technologies that are finding a role in many aspects of modern life , including medicine .",人工智能和机器学习是新兴技术，正在现代生活的许多方面发挥作用，包括医学。,0.625,"['life', 'a', 'medicine', 'role', 'machine', 'learning', 'that', 'and']","['life', 'medicine', 'role', 'machine', 'learning']",703,"['人工智能和机器学习是新兴的技术,在现代生活的许多方面,包括医学,正在发挥作用。']",0.625,"['life', 'a', 'medicine', 'role', 'machine', 'learning', 'that', 'and']","['life', 'medicine', 'role', 'machine', 'learning']",,
709,704,these data represent a first effort to utilize a training set to gauge utility for pathological review of samples .,这些数据代表了第一次尝试利用训练集来衡量样本病理检查的效用。,0.4545454545454545,"['a', 'data', 'review', 'training', 'gauge', 'represent', 'set', 'pathological', 'effort', 'to', 'first']","['data', 'review', 'training', 'represent', 'first']",704,"['这些数据代表了第一次尝试使用一项培训,以确保对样品的病理审查有用。']",0.3636363636363636,"['a', 'data', 'review', 'training', 'gauge', 'represent', 'set', 'pathological', 'effort', 'to', 'first']","['data', 'review', 'represent', 'first']",,
710,705,"large doses of ibuprofen are often used for emergency department ( ED ) patients , despite evidence that doses above 400 mg increase rates of side effects without improving pain control .",大剂量的布洛芬通常用于急诊科 (ED) 患者，尽管有证据表明超过 400 毫克的剂量会增加副作用的发生率而不会改善疼痛控制。,0.4615384615384615,"['control', 'department', 'emergency', 'side effects', 'large', 'pain', 'emergency department', 'evidence', 'increase', 'despite', 'ibuprofen', 'that', 'without']","['control', 'department', 'side effects', 'pain', 'evidence', 'ibuprofen']",705,"['大剂量的伊布普罗芬经常用于紧急部门(ED)患者,尽管有证据表明,超过400毫克的剂量增加副作用率,而无需改善疼痛控制。']",0.5384615384615384,"['control', 'department', 'emergency', 'side effects', 'large', 'pain', 'emergency department', 'evidence', 'increase', 'despite', 'ibuprofen', 'that', 'without']","['control', 'department', 'emergency', 'side effects', 'pain', 'evidence', 'without']",,
711,706,"to test the hypothesis that the analgesic ceiling of ibuprofen is 400 mg in an ED population , researchers randomized a convenience sample of 225 adults with acute pain to doses of 400 mg , 600 mg , or 800 mg .",为了检验布洛芬在急诊人群中的镇痛上限为 400 毫克的假设，研究人员随机抽取了 225 名患有急性疼痛的成年人的方便样本，分别服用 400 毫克、600 毫克或 800 毫克的剂量。,0.6923076923076923,"['sample', 'analgesic', 'population', 'hypothesis', 'test', 'pain', 'convenience', 'acute pain', 'ceiling', 'with', 'ibuprofen', 'that', 'to']","['sample', 'population', 'hypothesis', 'test', 'pain', 'convenience', 'acute pain', 'ceiling', 'ibuprofen']",706,"['为了测试伊布普罗芬的麻醉天花板在ED人口中为400毫克的假设,研究人员随机测试了225名患有急性疼痛的成年人的舒适样本,达到400毫克、600毫克或800毫克的剂量。']",0.3846153846153846,"['sample', 'analgesic', 'population', 'hypothesis', 'test', 'pain', 'convenience', 'acute pain', 'ceiling', 'with', 'ibuprofen', 'that', 'to']","['sample', 'population', 'hypothesis', 'pain', 'acute pain']",,
712,707,most patients had musculoskeletal or cutaneous pain .,大多数患者有肌肉骨骼或皮肤疼痛。,0.3333333333333333,"['musculoskeletal', 'pain', 'cutaneous']",['pain'],707,['大多数患者患有肌肉骨骼或皮肤疼痛。'],0.3333333333333333,"['musculoskeletal', 'pain', 'cutaneous']",['pain'],,
713,708,"at 60 minutes , mean pain scores and the change from baseline were similar among groups ( mean scores at 60 minutes , 4.4 , 4.5 , and 4.5 , respectively ) .",在 60 分钟时，各组的平均疼痛评分和相对于基线的变化相似（60 分钟时的平均评分分别为 4.4、4.5 和 4.5）。,0.7142857142857143,"['mean', 'baseline', 'pain', 'change', 'at', 'and', 'similar']","['mean', 'baseline', 'pain', 'change', 'at']",708,"['在60分钟,平均疼痛得分和基线的变化是类似的群体(平均得分在60分钟,4.4,4.5和4.5分别)。']",0.5714285714285714,"['mean', 'baseline', 'pain', 'change', 'at', 'and', 'similar']","['mean', 'baseline', 'pain', 'change']",,
714,709,no side effects were reported .,没有副作用的报道。,0.5,"['side effects', 'no']",['side effects'],709,['没有报告的副作用。'],0.5,"['side effects', 'no']",['side effects'],,
715,710,"although this study was otherwise well done , patients were followed for only 60 minutes , which minimizes the ability to identify adverse events .",尽管这项研究在其他方面做得很好，但仅对患者进行了 60 分钟的随访，这最大限度地降低了识别不良事件的能力。,0.2857142857142857,"['study', 'adverse', 'well', 'ability', 'identify', 'this', 'to']","['ability', 'identify']",710,"['尽管这项研究是顺利进行的,但患者仅追踪了60分钟,这减少了识别不良事件的能力。']",0.4285714285714285,"['study', 'adverse', 'well', 'ability', 'identify', 'this', 'to']","['ability', 'identify', 'this']",,
716,711,"the authors point out that a single dose of ibuprofen at any of these doses is unlikely to cause harm , but prescriptions for ongoing treatment may be more problematic .",作者指出，任何这些剂量的单剂量布洛芬都不太可能造成伤害，但持续治疗的处方可能会有更多问题。,0.4615384615384615,"['a', 'be', 'treatment', 'cause', 'point', 'ibuprofen', 'dose', 'prescriptions', 'that', 'out', 'single', 'but', 'to']","['treatment', 'ibuprofen', 'dose', 'prescriptions', 'single', 'but']",711,"['作者指出,在这些剂量中的任何一份单一剂量可能不会造成伤害,但持续治疗的处方可能更有问题。']",0.4615384615384615,"['a', 'be', 'treatment', 'cause', 'point', 'ibuprofen', 'dose', 'prescriptions', 'that', 'out', 'single', 'but', 'to']","['be', 'treatment', 'dose', 'prescriptions', 'single', 'but']",,
717,712,"since there is consistent evidence that doses above 400 mg do not provide additional pain control , we should avoid prescribing higher doses of ibuprofen .",由于有一致的证据表明超过 400 毫克的剂量不能提供额外的疼痛控制，我们应该避免开出更高剂量的布洛芬。,0.75,"['control', 'pain', 'additional', 'evidence', 'ibuprofen', 'that', 'avoid', 'we']","['control', 'pain', 'additional', 'evidence', 'ibuprofen', 'avoid']",712,"['由于有一致的证据表明,超过400毫克的剂量不提供额外的疼痛控制,我们应该避免处方更高的剂量的伊布普罗芬。']",0.625,"['control', 'pain', 'additional', 'evidence', 'ibuprofen', 'that', 'avoid', 'we']","['control', 'pain', 'additional', 'evidence', 'avoid']",,
718,713,daily calcium intake averaged 469 mg in the lowest quintile and 1361 mg in the highest quintile and changed only minimally over time .,最低五分位数的每日钙摄入量平均为 469 毫克，最高五分位数的平均每日钙摄入量为 1361 毫克，并且随着时间的推移变化很小。,0.4,"['calcium', 'intake', 'time', 'over', 'and']","['calcium', 'time']",713,"['每日钙摄入量平均为最低量量469毫克,最高量量1361毫克,并且随着时间的推移,只有少量变化。']",0.4,"['calcium', 'intake', 'time', 'over', 'and']","['calcium', 'time']",,
719,714,"at baseline , BMD was similar across all quintiles of calcium intake .",在基线时，BMD 在钙摄入量的所有五分位数中是相似的。,0.4285714285714285,"['calcium', 'intake', 'baseline', 'across', 'at', 'all', 'similar']","['calcium', 'baseline', 'similar']",714,"['在基线上,BMD在所有的钙摄入量中都是相似的。']",0.4285714285714285,"['calcium', 'intake', 'baseline', 'across', 'at', 'all', 'similar']","['calcium', 'baseline', 'similar']",,
720,715,"at 6 years , gradual decline in BMD was virtually identical in all quintiles .",在 6 岁时，BMD 的逐渐下降在所有五分位数中几乎是相同的。,0.6,"['decline', 'identical', 'at', 'gradual', 'all']","['decline', 'identical', 'gradual']",715,"['在6岁时,BMI的逐步下降几乎在所有基因蒂尔中都是相同的。']",0.4,"['decline', 'identical', 'at', 'gradual', 'all']","['decline', 'identical']",,
721,716,all analyses were adjusted for numerous potentially confounding variables .,所有分析都针对许多潜在的混杂变量进行了调整。,0.5,"['confounding variables', 'all']",['confounding variables'],716,['所有的分析都被调整到许多潜在混乱的变量。'],0.0,"['confounding variables', 'all']",[],,
722,717,"although this study was not a randomized trial of different amounts of dietary calcium , it provides fairly compelling evidence that high intake of dietary calcium does not protect against bone loss in older osteopenic women .",尽管这项研究不是对不同膳食钙含量的随机试验，但它提供了相当有说服力的证据，证明高膳食钙摄入量并不能防止骨质疏松的老年女性骨质流失。,0.5,"['bone', 'calcium', 'intake', 'study', 'loss', 'dietary', 'trial', 'evidence', 'this', 'that', 'protect against', 'high']","['bone', 'calcium', 'evidence', 'this', 'protect against', 'high']",717,"['虽然这项研究不是各种饮食钙量的随机测试,但它提供了相当强迫的证据,高饮食钙摄入量不会保护老年女性免受骨损。']",0.4166666666666667,"['bone', 'calcium', 'intake', 'study', 'loss', 'dietary', 'trial', 'evidence', 'this', 'that', 'protect against', 'high']","['bone', 'calcium', 'evidence', 'this', 'high']",,
723,718,researchers evaluated performance of these tools in a retrospective chart review of 380 patients with malignancy at a single oncology emergency department who underwent computed tomographic pulmonary angiography ( CTPA ) .,研究人员在一个肿瘤急诊科对 380 名接受了计算机断层扫描肺血管造影 (CTPA) 的恶性肿瘤患者进行了回顾性图表审查，评估了这些工具的性能。,0.5,"['chart', 'angiography', 'malignancy', 'tools', 'who', 'review', 'department', 'emergency', 'pulmonary', 'emergency department', 'performance', 'with', 'at', 'in', 'single', 'tomographic']","['chart', 'angiography', 'malignancy', 'tools', 'review', 'department', 'performance', 'tomographic']",718,"['研究人员评估了这些工具的性能,在380名患有恶性疾病的患者的回顾图表中,他们在一个单一的肿瘤紧急部门接受了计算 tomographic 肺结核(CTPA)。']",0.4375,"['chart', 'angiography', 'malignancy', 'tools', 'who', 'review', 'department', 'emergency', 'pulmonary', 'emergency department', 'performance', 'with', 'at', 'in', 'single', 'tomographic']","['chart', 'malignancy', 'tools', 'department', 'emergency', 'performance', 'single']",,
724,719,"overall , PE was diagnosed in 11 % of patients and ACP guidelines were followed in 56 % of patients .",总体而言，11% 的患者被诊断为 PE，56% 的患者遵循了 ACP 指南。,0.3333333333333333,"['PE', 'in', 'and']",['and'],719,"['总体而言,11%的患者接受了PE诊断,56%的患者接受了ACP指南。']",0.3333333333333333,"['PE', 'in', 'and']",['and'],,
725,720,the use of PERC would have resulted in avoidance of further testing in only few patients ( 3.4 % ) .,只有少数患者 (3.4%) 使用 PERC 可以避免进一步检测。,0.3333333333333333,"['avoidance', 'testing', 'have']",['have'],720,['使用 PERC 会导致少数患者避免进行进一步的测试(3.4%)。'],0.0,"['avoidance', 'testing', 'have']",[],,
726,721,"only one PE would have been missed had the guidelines been followed ( sensitivity 97 % , negative predictive value 99 % ) .",如果遵循指南（敏感性 97%，阴性预测值 99%），只会漏掉一次 PE。,0.0,"['value', 'negative', 'predictive', 'sensitivity', 'predictive value', 'PE', 'have']",[],721,"['如果遵循指令,只会错过一个PE(97%的敏感性,99%的负预测值)。']",0.0,"['value', 'negative', 'predictive', 'sensitivity', 'predictive value', 'PE', 'have']",[],,
727,722,"if the association is causal , the absolute incidence is exceedingly rare .",如果关联是因果关系，则绝对发生率极其罕见。,0.6,"['incidence', 'association', 'absolute', 'causal', 'if']","['incidence', 'association', 'absolute']",722,"['如果合并是因果性的,绝对的发病率是过于罕见的。']",0.4,"['incidence', 'association', 'absolute', 'causal', 'if']","['incidence', 'absolute']",,
728,723,"patients with diabetes were excluded , given the strong associations between diabetes and both antibiotic use and neuropathy .",糖尿病患者被排除在外，因为糖尿病与抗生素使用和神经病变之间存在密切关联。,0.5,"['diabetes', 'antibiotic', 'neuropathy', 'strong', 'with', 'and']","['diabetes', 'antibiotic', 'neuropathy']",723,"['糖尿病患者被排除,因为糖尿病和抗生素使用和神经病之间的强烈联系。']",0.6666666666666666,"['diabetes', 'antibiotic', 'neuropathy', 'strong', 'with', 'and']","['diabetes', 'antibiotic', 'neuropathy', 'strong']",,
729,724,"fluoroquinolone exposure within 30 days was associated with excess risk for incident peripheral neuropathy compared with nonexposure ( rate ratio , 1.47 ) ; risk persisted when the window of exposure was extended to 180 days before diagnosis of neuropathy .",与未接触氟喹诺酮相比，30 天内接触氟喹诺酮类药物与发生周围神经病变的风险增加相关（比率 1.47）；当暴露窗口延长至神经病变诊断前 180 天时，风险仍然存在。,0.5714285714285714,"['excess', 'peripheral', 'rate', 'exposure', 'ratio', 'neuropathy', 'window', 'diagnosis', 'associated', 'risk', 'with', 'incident', 'before', 'to']","['rate', 'exposure', 'ratio', 'neuropathy', 'window', 'diagnosis', 'risk', 'before']",724,"['在30天内与过度风险发生周边神经病相比不暴露(率比率为1.47),风险持续,当暴露窗口延长到神经病的诊断前180天。']",0.5714285714285714,"['excess', 'peripheral', 'rate', 'exposure', 'ratio', 'neuropathy', 'window', 'diagnosis', 'associated', 'risk', 'with', 'incident', 'before', 'to']","['rate', 'exposure', 'ratio', 'neuropathy', 'window', 'diagnosis', 'risk', 'before']",,
730,725,analyses were adjusted for alcohol abuse and several diseases and medications known to cause peripheral neuropathy .,分析针对酗酒和已知会导致周围神经病变的几种疾病和药物进行了调整。,0.2857142857142857,"['alcohol', 'peripheral', 'neuropathy', 'cause', 'abuse', 'to', 'and']","['alcohol', 'neuropathy']",725,['分析适用于酒精滥用和多种疾病和药物已知导致周边神经病。'],0.4285714285714285,"['alcohol', 'peripheral', 'neuropathy', 'cause', 'abuse', 'to', 'and']","['alcohol', 'neuropathy', 'to']",,
731,726,"these findings strengthen the case for an association between fluoroquinolones and neuropathy ; however , limitations include the possibility of residual confounding and inaccurate diagnosis of peripheral neuropathy in this primary care database .",这些发现加强了氟喹诺酮类药物与神经病之间的关联；然而，局限性包括在这个初级保健数据库中可能存在残留混杂和周围神经病变的不准确诊断。,0.3846153846153846,"['database', 'peripheral', 'neuropathy', 'association', 'diagnosis', 'primary', 'case', 'care', 'residual', 'inaccurate', 'this', 'strengthen', 'and']","['neuropathy', 'association', 'diagnosis', 'strengthen', 'and']",726,"['这些发现加强了Fluoroquinolones与神经病之间的联系;然而,限制包括残留混乱和周边神经病的不准确诊断在这个初级护理数据库中的可能性。']",0.3846153846153846,"['database', 'peripheral', 'neuropathy', 'association', 'diagnosis', 'primary', 'case', 'care', 'residual', 'inaccurate', 'this', 'strengthen', 'and']","['neuropathy', 'association', 'diagnosis', 'strengthen', 'and']",,
732,727,"if this association is causal , it appears to be a very rare adverse event .",如果这种关联是因果关系，那么这似乎是一种非常罕见的不良事件。,0.3333333333333333,"['a', 'association', 'be', 'adverse', 'causal', 'adverse event', 'this', 'if', 'to']","['association', 'adverse event', 'this']",727,"['如果这种结合是因果性的,它似乎是一个非常罕见的不良事件。']",0.3333333333333333,"['a', 'association', 'be', 'adverse', 'causal', 'adverse event', 'this', 'if', 'to']","['association', 'adverse event', 'this']",,
733,728,"in phase 2 studies involving patients with chronic kidney disease , roxadustat increased levels of endogenous erythropoietin to within or near the physiologic range , along with increasing hemoglobin levels and improving iron homeostasis .",在涉及慢性肾病患者的 2 期研究中，roxadustat 将内源性促红细胞生成素水平提高到生理范围内或接近生理范围，同时增加血红蛋白水平并改善铁稳态。,0.5555555555555556,"['endogenous', 'kidney', 'disease', 'homeostasis', 'erythropoietin', 'range', 'phase', '2', 'hemoglobin', 'chronic', 'along', 'in phase', 'physiologic', 'with', 'roxadustat', 'iron', 'to', 'and']","['kidney', 'disease', 'homeostasis', 'erythropoietin', 'range', 'phase', '2', 'hemoglobin', 'chronic', 'iron']",728,"['在2阶段的研究中,涉及患有慢性肾脏疾病的患者,Roxadustat增加了内分泌的Erythropoietin水平到生理范围内或附近,以及增加了血球水平,并改善了铁同位素。']",0.3888888888888889,"['endogenous', 'kidney', 'disease', 'homeostasis', 'erythropoietin', 'range', 'phase', '2', 'hemoglobin', 'chronic', 'along', 'in phase', 'physiologic', 'with', 'roxadustat', 'iron', 'to', 'and']","['kidney', 'disease', 'range', 'phase', '2', 'chronic', 'iron']",,
734,729,additional data are needed regarding the efficacy and safety of roxadustat for the treatment of anemia in patients with chronic kidney disease who are not undergoing dialysis .,需要更多关于罗沙司他治疗未接受透析的慢性肾病患者贫血的疗效和安全性的数据。,0.6666666666666666,"['anemia', 'safety', 'dialysis', 'kidney', 'disease', 'data', 'who', 'regarding', 'treatment', 'chronic', 'additional', 'efficacy', 'with', 'roxadustat', 'and']","['anemia', 'safety', 'dialysis', 'kidney', 'disease', 'data', 'regarding', 'treatment', 'chronic', 'roxadustat']",729,['有关Roxadustat在慢性肾脏疾病患者中治疗贫血的有效性和安全性需要额外的数据。'],0.6666666666666666,"['anemia', 'safety', 'dialysis', 'kidney', 'disease', 'data', 'who', 'regarding', 'treatment', 'chronic', 'additional', 'efficacy', 'with', 'roxadustat', 'and']","['anemia', 'safety', 'kidney', 'disease', 'data', 'regarding', 'treatment', 'chronic', 'additional', 'efficacy']",,
735,730,all the patients had a hemoglobin level of 7.0 to 10.0 g per deciliter at baseline .,所有患者的基线血红蛋白水平均为 7.0 至 10.0 g/dL。,0.25,"['a', 'baseline', 'hemoglobin', 'deciliter', 'hemoglobin level', 'at', 'all', 'to']","['baseline', 'hemoglobin']",730,['所有患者在基线上每分升7.0至10.0g的血糖水平。'],0.125,"['a', 'baseline', 'hemoglobin', 'deciliter', 'hemoglobin level', 'at', 'all', 'to']",['baseline'],,
736,731,"the primary end point was the mean change from baseline in the hemoglobin level , averaged over weeks 7 through 9 .",主要终点是血红蛋白水平相对于基线的平均变化，是第 7 周到第 9 周的平均值。,0.5555555555555556,"['mean', 'baseline', 'hemoglobin', 'hemoglobin level', 'primary', 'end', 'point', 'change', 'over']","['mean', 'baseline', 'hemoglobin', 'point', 'change']",731,"['初级终点是血球水平的基线的平均变化,平均为7至9周。']",0.4444444444444444,"['mean', 'baseline', 'hemoglobin', 'hemoglobin level', 'primary', 'end', 'point', 'change', 'over']","['mean', 'baseline', 'point', 'change']",,
737,732,the mean reduction from baseline in the hepcidin level ( associated with greater iron availability ) was 56.14 ± 63.40 ng per milliliter in the roxadustat group and 15.10 ± 48.06 ng per milliliter in the placebo group .,roxadustat 组铁调素水平（与更高的铁可用性相关）相对于基线的平均降低为 56.14 ± 63.40 ng/mL，安慰剂组为 15.10 ± 48.06 ng/mL。,0.5833333333333334,"['group', 'placebo', 'mean', 'baseline', 'reduction', 'associated', 'availability', 'level', 'with', 'roxadustat', 'iron', 'and']","['group', 'placebo', 'mean', 'baseline', 'reduction', 'level', 'iron']",732,"['基因水平的平均下降(与较高的铁可用性相结合)在Roxadustat组为56.14 ± 63.40 ng/毫升,在 placebo组为 15.10 ± 48.06 ng/毫升。']",0.3333333333333333,"['group', 'placebo', 'mean', 'baseline', 'reduction', 'associated', 'availability', 'level', 'with', 'roxadustat', 'iron', 'and']","['group', 'mean', 'level', 'iron']",,
738,733,the reduction from baseline in the total cholesterol level was 40.6 mg per deciliter in the roxadustat group and 7.7 mg per deciliter in the placebo group .,罗沙司他组总胆固醇水平较基线降低 40.6 毫克/分升，安慰剂组降低 7.7 毫克/分升。,0.7,"['cholesterol', 'group', 'placebo', 'baseline', 'deciliter', 'reduction', 'total', 'level', 'roxadustat', 'and']","['cholesterol', 'group', 'placebo', 'baseline', 'reduction', 'level', 'roxadustat']",733,"['总胆固醇水平从基层下降为Roxadustat组每分升40.6 mg,在 placebo组每分升7.7 mg。']",0.3,"['cholesterol', 'group', 'placebo', 'baseline', 'deciliter', 'reduction', 'total', 'level', 'roxadustat', 'and']","['cholesterol', 'group', 'level']",,
739,734,hyperkalemia and metabolic acidosis occurred more frequently in the roxadustat group than in the placebo group .,与安慰剂组相比，罗沙司他组高钾血症和代谢性酸中毒的发生率更高。,0.6,"['group', 'placebo', 'frequently', 'acidosis', 'hyperkalemia', 'metabolic', 'roxadustat', 'metabolic acidosis', 'in', 'and']","['group', 'placebo', 'acidosis', 'hyperkalemia', 'roxadustat', 'metabolic acidosis']",734,"['甲状腺高血病和代谢酸化发生在罗克萨德斯塔特群体中更频繁,而不是在 placebo群体中。']",0.2,"['group', 'placebo', 'frequently', 'acidosis', 'hyperkalemia', 'metabolic', 'roxadustat', 'metabolic acidosis', 'in', 'and']","['group', 'and']",,
740,735,"in Chinese patients with chronic kidney disease who were not undergoing dialysis , those in the roxadustat group had a higher mean hemoglobin level than those in the placebo group after 8 weeks .",在未接受透析的中国慢性肾病患者中，8 周后，roxadustat 组患者的平均血红蛋白水平高于安慰剂组患者。,0.6428571428571429,"['group', 'dialysis', 'placebo', 'kidney', 'disease', 'mean', 'who', 'hemoglobin', 'hemoglobin level', 'chronic', 'after', 'with', 'roxadustat', 'chinese']","['group', 'dialysis', 'placebo', 'kidney', 'disease', 'mean', 'hemoglobin', 'chronic', 'after']",735,"['在中国患有慢性肾脏疾病的患者中,在8周后,罗克萨多斯塔特群体中的人比 placebo群体中的人水平更高。']",0.3571428571428571,"['group', 'dialysis', 'placebo', 'kidney', 'disease', 'mean', 'who', 'hemoglobin', 'hemoglobin level', 'chronic', 'after', 'with', 'roxadustat', 'chinese']","['group', 'kidney', 'disease', 'chronic', 'after']",,
741,736,"chronic kidney disease is a global public health challenge that affects approximately 10 % of the population worldwide , including 120 million people in China.1",慢性肾病是全球公共卫生挑战，影响全球约 10 % 的人口，其中包括中国的 1.2 亿人。 1,0.5833333333333334,"['population', 'kidney', 'disease', 'global', 'health', 'public', 'chronic', 'challenge', 'approximately', 'that', 'in', 'million']","['population', 'kidney', 'disease', 'global', 'health', 'chronic', 'challenge']",736,"['慢性肾脏疾病是一个全球公共卫生挑战,影响全球约10%的人口,包括中国120万人。']",0.5833333333333334,"['population', 'kidney', 'disease', 'global', 'health', 'public', 'chronic', 'challenge', 'approximately', 'that', 'in', 'million']","['population', 'kidney', 'disease', 'global', 'health', 'chronic', 'challenge']",,
742,737,"in China , this situation is reflected by low hemoglobin levels in patients who initiate dialysis , with mean levels of 7.3 g per deciliter reported in Guangzhou , 8.2 g per deciliter in Beijing , and 7.7 g per deciliter in Shanghai.8,9","在中国，这种情况反映在开始透析的患者血红蛋白水平较低，广州报告的平均水平为每分升 7.3 克，北京为每分升 8.2 克，上海为每分升 7.7 克。 8,9",0.4166666666666667,"['dialysis', 'situation', 'mean', 'who', 'hemoglobin', 'deciliter', 'low', 'china', 'with', 'this', 'by', 'and']","['dialysis', 'mean', 'hemoglobin', 'low', 'china']",737,"['在中国,这种情况被低血球水平反映在开始腹泻的患者中,平均水平在广州报告为7.3g,在北京报告为8.2g,在上海报告为7.7g。']",0.25,"['dialysis', 'situation', 'mean', 'who', 'hemoglobin', 'deciliter', 'low', 'china', 'with', 'this', 'by', 'and']","['mean', 'low', 'china']",,
743,738,"among the patients who initiated dialysis in rural China , those with a mean ( ± SD ) hemoglobin level of 5.9 ± 4.7 g per deciliter had twice the rates of heart failure and death as those living in urban areas , who had a mean level of 8.4 ± 4.5 g per deciliter ; in these two groups , rates of heart failure were 34.4 % and 16.2 % , respectively , and rates of death were 42.9 % and 21.9 % , respectively.10",在中国农村开始透析的患者中，平均 ( ± SD ) 血红蛋白水平为 5.9 ± 4.7 g/dL 的患者的心力衰竭和死亡率是生活在城市地区的患者的两倍，后者的平均水平为 8.4 ± 4.5 克每分升；在这两组中，心衰率分别为 34.4 % 和 16.2 % ，死亡率分别为 42.9 % 和 21.9 % 10。,0.4736842105263157,"['heart', 'dialysis', 'mean', 'failure', 'who', 'death', 'hemoglobin', 'deciliter', 'hemoglobin level', 'heart failure', 'rural', 'china', 'living', 'as', 'with', 'SD', 'and', 'twice', 'two']","['heart', 'dialysis', 'mean', 'failure', 'death', 'hemoglobin', 'heart failure', 'china', 'two']",738,"['在农村中国启动腹泻的患者中,平均(±SD)血球水平为5.9 ± 4.7 克每分升的患者患有心脏衰竭和死亡率的两倍,而居住在城市地区的患者中,平均水平为8.4 ± 4.5 克每分升;在这两个群体中,心脏衰竭率为 34.4% 和 16.2% 相应,死亡率为 42.9% 和 21.9% 相应。']",0.3684210526315789,"['heart', 'dialysis', 'mean', 'failure', 'who', 'death', 'hemoglobin', 'deciliter', 'hemoglobin level', 'heart failure', 'rural', 'china', 'living', 'as', 'with', 'SD', 'and', 'twice', 'two']","['heart', 'mean', 'failure', 'death', 'china', 'and', 'two']",,
744,739,"the trial was conducted in accordance with the principles of the Declaration of Helsinki , Chinese Good Clinical Practice , and the International Conference on Harmonization E6 guidelines .",该试验是根据赫尔辛基宣言、中国临床试验质量管理规范和国际协调会议 E6 指南的原则进行的。,0.0,"['good clinical practice', 'trial', 'with', 'on', 'chinese', 'and']",[],739,['根据《赫尔辛基宣言、中国良好临床实践》和《国际协调会议E6指令》的原则进行审查。'],0.0,"['good clinical practice', 'trial', 'with', 'on', 'chinese', 'and']",[],,
745,740,"the first two authors designed the trial in collaboration with representatives of the sponsor , FibroGen ; company representatives were responsible for the collection and analysis of the data .",前两位作者与申办方 FibroGen 的代表合作设计了该试验；公司代表负责数据的收集和分析。,0.4545454545454545,"['data', 'analysis', 'sponsor', 'collection', 'trial', 'collaboration', 'with', 'in', 'and', 'first', 'two']","['data', 'analysis', 'collection', 'collaboration', 'two']",740,"['最初的两位作者与赞助商FibroGen的代表合作设计了审判,公司代表负责收集和分析数据。']",0.5454545454545454,"['data', 'analysis', 'sponsor', 'collection', 'trial', 'collaboration', 'with', 'in', 'and', 'first', 'two']","['data', 'analysis', 'collection', 'trial', 'collaboration', 'two']",,
746,741,"all the authors contributed to the analysis and interpretation of the data and to the conduct of the trial , along with having full access to the data and analyses and full review of the manuscript .",所有作者都对数据的分析和解释以及试验的实施做出了贡献，同时能够完全访问数据和分析以及对手稿进行全面审查。,0.3571428571428571,"['data', 'analysis', 'review', 'access', 'interpretation', 'manuscript', 'along', 'trial', 'conduct', 'with', 'full', 'all', 'to', 'and']","['data', 'analysis', 'review', 'interpretation', 'manuscript']",741,"['所有作者都参与了数据的分析和解释,以及审判的进行,并获得了数据和分析的完整访问和手稿的完整审查。']",0.5,"['data', 'analysis', 'review', 'access', 'interpretation', 'manuscript', 'along', 'trial', 'conduct', 'with', 'full', 'all', 'to', 'and']","['data', 'analysis', 'review', 'interpretation', 'manuscript', 'trial', 'full']",,
747,742,all the authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol ( available with the full text of this article at NEJM.org ) .,所有作者保证数据的完整性和准确性，以及试验对方案的忠实度（与本文全文可在 NEJM.org 获取）。,0.2857142857142857,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",742,"['所有作者保证数据的完整性和准确性,以及对议定书的审判忠诚性(可在NEJM.org上提供本文的完整文本)。']",0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'full']",,
748,743,"eligible patients were between the ages of 18 and 75 years , had chronic kidney disease of stage 3 to 5 , and were not currently undergoing dialysis .",符合条件的患者年龄在 18 至 75 岁之间，患有 3 至 5 期慢性肾病，目前未接受透析。,0.6,"['stage', 'dialysis', '5', 'kidney', 'disease', 'chronic', '3', 'to', 'and', 'eligible']","['stage', 'dialysis', '5', 'kidney', 'disease', 'chronic']",743,"['有资格的患者年龄在18至75岁之间,患有3至5阶段的慢性肾脏疾病,并且目前不接受诊断。']",0.4,"['stage', 'dialysis', '5', 'kidney', 'disease', 'chronic', '3', 'to', 'and', 'eligible']","['5', 'kidney', 'disease', 'chronic']",,
749,744,"during screening , the mean of the two most recent hemoglobin values was in the range of 7.0 g per deciliter to less than 10.0 g per deciliter in all the patients . ( details regarding inclusion and exclusion criteria are provided in Table S1 in the Supplementary Appendix , available at NEJM.org. )",在筛选期间，所有患者的两个最近血红蛋白值的平均值在每分升 7.0 克到低于每分升 10.0 克的范围内。 （有关纳入和排除标准的详细信息见补充附录表 S1，补充附录可在 NEJM.org 获取。）,0.45,"['appendix', 'mean', 'range', 'table', 'inclusion', 'recent', 'screening', 'hemoglobin', 'deciliter', 'supplementary', 'exclusion', 'regarding', 'available', 'values', 'at', 'S1', 'all', 'to', 'and', 'two']","['mean', 'range', 'table', 'screening', 'hemoglobin', 'regarding', 'at', 'to', 'two']",744,"['在筛查期间,最新的两种血球值的平均值在每个分数的7.0g到每个分数的10.0g以下范围,所有患者(包括和排除标准的详细信息在附加附件中的S1表中提供,可在NEJM.org上找到。']",0.3,"['appendix', 'mean', 'range', 'table', 'inclusion', 'recent', 'screening', 'hemoglobin', 'deciliter', 'supplementary', 'exclusion', 'regarding', 'available', 'values', 'at', 'S1', 'all', 'to', 'and', 'two']","['appendix', 'mean', 'range', 'table', 'screening', 'two']",,
750,745,the dose of roxadustat was escalated every 4 weeks to maintain a hemoglobin level ranging from 10.0 to 12.0 g per deciliter ( Table S2 in the Supplementary Appendix ) .,罗沙司他的剂量每 4 周增加一次，以将血红蛋白水平维持在 10.0 至 12.0 g/dL（补充附录表 S2）。,0.3846153846153846,"['a', 'appendix', 'table', 'hemoglobin', 'deciliter', 'maintain', 'supplementary', 'hemoglobin level', '4', 'roxadustat', 'dose', 'S2', 'to']","['table', 'hemoglobin', 'maintain', 'roxadustat', 'dose']",745,"['每4周,Roxadustat的剂量增加,以保持每分升10.0至12.0g的血球水平(附件中的S2表)。']",0.2307692307692307,"['a', 'appendix', 'table', 'hemoglobin', 'deciliter', 'maintain', 'supplementary', 'hemoglobin level', '4', 'roxadustat', 'dose', 'S2', 'to']","['appendix', 'table', 'dose']",,
751,746,the adjustment of the placebo dose was carried out in the same manner .,安慰剂剂量的调整同法进行。,0.3333333333333333,"['placebo', 'adjustment', 'manner', 'dose', 'in', 'out']","['placebo', 'dose']",746,['placebo 剂量的调整也以相同的方式进行。'],0.1666666666666666,"['placebo', 'adjustment', 'manner', 'dose', 'in', 'out']",['dose'],,
752,747,"investigators were asked to record abnormal , clinically significant laboratory results , physical examination findings , and electrocardiographic results as adverse events if such findings were deemed to meet the criteria for adverse events .",研究人员被要求将异常的、具有临床意义的实验室结果、体格检查结果和心电图结果记录为不良事件，如果这些发现被认为符合不良事件的标准。,0.5454545454545454,"['record', 'physical', 'examination', 'abnormal', 'physical examination', 'adverse', 'laboratory', 'as', 'if', 'and', 'electrocardiographic']","['record', 'examination', 'abnormal', 'laboratory', 'as', 'electrocardiographic']",747,"['研究人员被要求记录异常、临床上有意义的实验室结果、物理检查结果和电心学结果作为不良事件,如果这些发现被认为符合不良事件的标准。']",0.4545454545454545,"['record', 'physical', 'examination', 'abnormal', 'physical examination', 'adverse', 'laboratory', 'as', 'if', 'and', 'electrocardiographic']","['record', 'examination', 'abnormal', 'laboratory', 'as']",,
753,748,"we performed an analysis of covariance to estimate and compare the difference between the groups in the change from baseline in the hemoglobin level , with missing data handled with the use of multiple imputations in a sensitivity analysis .",我们进行了协方差分析，以估计和比较各组之间血红蛋白水平相对于基线的变化差异，并在敏感性分析中使用多重插补处理缺失数据。,0.5555555555555556,"['covariance', 'data', 'analysis', 'baseline', 'hemoglobin', 'multiple', 'difference', 'hemoglobin level', 'estimate', 'compare', 'change', 'with', 'sensitivity', 'analysis of covariance', 'to', 'and', 'missing', 'we']","['covariance', 'data', 'analysis', 'baseline', 'hemoglobin', 'difference', 'compare', 'change', 'to', 'missing']",748,"['我们进行了可视性分析,以估计和比较从基层到血球水平的变化中的群体之间的差异,缺少的数据处理了在敏感性分析中使用多种假设。']",0.3333333333333333,"['covariance', 'data', 'analysis', 'baseline', 'hemoglobin', 'multiple', 'difference', 'hemoglobin level', 'estimate', 'compare', 'change', 'with', 'sensitivity', 'analysis of covariance', 'to', 'and', 'missing', 'we']","['data', 'analysis', 'difference', 'compare', 'change', 'missing']",,
754,749,we performed an analysis of covariance to calculate the change from baseline in hepcidin at week 9 .,我们进行了协方差分析，以计算第 9 周铁调素相对于基线的变化。,0.8888888888888888,"['covariance', 'analysis', 'baseline', 'week', 'change', 'at', 'analysis of covariance', 'calculate', 'to']","['covariance', 'analysis', 'baseline', 'week', 'change', 'at', 'calculate', 'to']",749,"['我们进行了一项可视性分析,以计算从基线到Hepcidin的变化,在第9周。']",0.5555555555555556,"['covariance', 'analysis', 'baseline', 'week', 'change', 'at', 'analysis of covariance', 'calculate', 'to']","['analysis', 'baseline', 'week', 'change', 'calculate']",,
755,750,we report the values for the secondary analyses as point estimates and 95 % confidence intervals .,我们将二次分析的值报告为点估计值和 95% 置信区间。,0.2222222222222222,"['report', 'secondary', 'values', 'point', 'as', 'confidence', 'and', 'intervals', 'we']","['report', 'point']",750,['我们将二次分析的值报告为点估计和95%的信任间隔。'],0.2222222222222222,"['report', 'secondary', 'values', 'point', 'as', 'confidence', 'and', 'intervals', 'we']","['report', 'point']",,
756,751,"the confidence intervals have not been adjusted for multiple comparisons , so inferences drawn from them may not be reproducible .",置信区间未针对多重比较进行调整，因此从中得出的推论可能无法重现。,0.1666666666666666,"['multiple', 'be', 'confidence', 'have not', 'so', 'intervals']",['have not'],751,"['信任间隔未适用于多个比较,因此从中提取的结论可能无法重复。']",0.1666666666666666,"['multiple', 'be', 'confidence', 'have not', 'so', 'intervals']",['have not'],,
757,752,"of these patients , 2 did not receive a trial regimen , leaving 152 in the safety population .",在这些患者中，有 2 名未接受试验方案，剩下 152 名在安全人群中。,0.6,"['safety', 'population', '2', 'trial', 'in']","['safety', 'population', '2']",752,"['这些病人中有2人没有接受试验制度,在安全人口中留下了152人。']",0.6,"['safety', 'population', '2', 'trial', 'in']","['safety', 'population', '2']",,
758,753,the baseline characteristics were similar in the two groups ( Table 1 ) .,两组的基线特征相似（表 1）。,0.8333333333333334,"['table', 'baseline', '1', 'characteristics', 'two', 'similar']","['table', 'baseline', '1', 'characteristics', 'two']",753,['基线特征在两组中是相似的(图1)。'],0.8333333333333334,"['table', 'baseline', '1', 'characteristics', 'two', 'similar']","['baseline', '1', 'characteristics', 'two', 'similar']",,
759,754,the mean baseline hemoglobin level was 8.9 ± 0.8 g per deciliter in the roxadustat group and 8.9 ± 0.7 g per deciliter in the placebo group .,罗沙司他组的平均基线血红蛋白水平为每分升 8.9 ± 0.8 克，安慰剂组为每分升 8.9 ± 0.7 克。,0.6666666666666666,"['group', 'placebo', 'mean', 'baseline', 'hemoglobin', 'deciliter', 'hemoglobin level', 'roxadustat', 'and']","['group', 'placebo', 'mean', 'baseline', 'hemoglobin', 'roxadustat']",754,"['平均基因血糖水平在Roxadustat组中为8.9 ± 0.8 克,在 placebo组中为8.9 ± 0.7 克。']",0.2222222222222222,"['group', 'placebo', 'mean', 'baseline', 'hemoglobin', 'deciliter', 'hemoglobin level', 'roxadustat', 'and']","['group', 'mean']",,
760,755,"of note , 82 of 152 patients ( 54 % ) had a transferrin saturation of 20 % or more , and 58 patients ( 38 % ) had a ferritin level of 200 μg per liter or more .",值得注意的是，152 名患者中有 82 名 (54%) 的转铁蛋白饱和度为 20% 或更高，58 名患者 (38%) 的铁蛋白水平为 200 μg/L 或更高。,0.625,"['ferritin', 'a', 'transferrin', 'liter', 'saturation', 'note', 'level', 'and']","['ferritin', 'transferrin', 'saturation', 'note', 'level']",755,"['值得注意的是,152名患者中有82人(54%)患有20%或以上的转移林饱和,58人(38%)患有200 μg或以上的费里丁。']",0.25,"['ferritin', 'a', 'transferrin', 'liter', 'saturation', 'note', 'level', 'and']","['saturation', 'note']",,
761,756,randomized PHASE,随机阶段,,[],[],756,['随机阶段'],,[],[],,
762,757,"rescue therapy was administered to 3 patients ( 3 % ) in the roxadustat group and 6 patients ( 12 % ) in the placebo group ( hazard ratio , 0.11 ; 95 % CI , 0.02 to 0.51 ) .",对罗沙司他组的 3 名患者 (3%) 和安慰剂组的 6 名患者 (12%) 进行了挽救治疗（风险比，0.11；95% CI，0.02 至 0.51）。,0.5,"['group', 'placebo', 'ratio', 'hazard ratio', 'therapy', '3', 'roxadustat', 'CI', 'in', 'to', 'and', 'rescue']","['group', 'placebo', 'ratio', 'hazard ratio', 'therapy', 'roxadustat']",757,"['救生疗法适用于Roxadustat群体的3名患者(3%)和 placebo群体的6名患者(12%)(风险比例,0.11;95% CI,0.02至0.51)。']",0.4166666666666667,"['group', 'placebo', 'ratio', 'hazard ratio', 'therapy', '3', 'roxadustat', 'CI', 'in', 'to', 'and', 'rescue']","['group', 'ratio', 'hazard ratio', 'therapy', 'to']",,
763,758,hepcidin and Iron Levels,铁调素和铁水平,0.5,"['iron', 'and']",['iron'],758,['Hepcidin 和 Iron 水平'],0.0,"['iron', 'and']",[],,
764,759,"among patients in the roxadustat group , the serum iron level was clinically stable during the randomized phase and did not differ significantly from the level in the placebo group , despite robust erythropoiesis ( Table 2 ) .",在罗沙司他组的患者中，血清铁水平在随机阶段临床稳定，与安慰剂组的水平无显着差异，尽管红细胞生成强劲（表 2）。,0.7142857142857143,"['group', 'erythropoiesis', 'placebo', 'table', 'phase', '2', 'serum', 'differ', 'level', 'despite', 'roxadustat', 'iron', 'in', 'and']","['group', 'erythropoiesis', 'placebo', 'table', 'phase', '2', 'serum', 'level', 'roxadustat', 'iron']",759,"['在Roxadustat群体的患者中,血清铁水平在随机阶段临床上稳定,并且与 placebo群体的水平没有显著差异,尽管强烈的甲状腺炎(图2)。']",0.4285714285714285,"['group', 'erythropoiesis', 'placebo', 'table', 'phase', '2', 'serum', 'differ', 'level', 'despite', 'roxadustat', 'iron', 'in', 'and']","['group', 'phase', '2', 'serum', 'level', 'iron']",,
765,760,"in the roxadustat group , transferrin levels and total iron binding capacity increased , with a temporary decrease in the transferrin saturation from 20.6 % to 15.6 % at week 9 during a period of increased iron utilization in which the mean increase in hemoglobin was 1.9 g per deciliter .",在roxadustat组中，转铁蛋白水平和总铁结合力增加，转铁蛋白饱和度在第9周从20.6 %暂时下降至15.6 %，期间铁利用增加，血红蛋白平均增加1.9 g/dL。 .,0.5263157894736842,"['group', 'capacity', 'period', 'transferrin', 'decrease', 'mean', 'utilization', 'temporary', 'hemoglobin', 'deciliter', 'total', 'saturation', 'week', 'increase', 'with', 'roxadustat', 'binding', 'iron', 'and']","['group', 'period', 'transferrin', 'mean', 'utilization', 'hemoglobin', 'saturation', 'week', 'binding', 'iron']",760,"['在Roxadustat群体中,转移素水平和总铁粘容量增加,转移素饱和量从9周的20.6%减少到15.6%在增加铁使用期间,平均血球含量增加为1.9g每分升。']",0.4210526315789473,"['group', 'capacity', 'period', 'transferrin', 'decrease', 'mean', 'utilization', 'temporary', 'hemoglobin', 'deciliter', 'total', 'saturation', 'week', 'increase', 'with', 'roxadustat', 'binding', 'iron', 'and']","['group', 'capacity', 'period', 'decrease', 'mean', 'saturation', 'week', 'iron']",,
766,761,"in the placebo group , iron levels and related measures on average were stable during the randomized phase .",在安慰剂组中，铁水平和相关指标在随机阶段平均保持稳定。,0.7142857142857143,"['group', 'placebo', 'average', 'phase', 'iron', 'in', 'and']","['group', 'placebo', 'average', 'phase', 'iron']",761,"['在 placebo 群体中,铁水平和相关测量平均在随机阶段保持稳定。']",0.5714285714285714,"['group', 'placebo', 'average', 'phase', 'iron', 'in', 'and']","['group', 'average', 'phase', 'iron']",,
767,762,cholesterol Levels,胆固醇水平,1.0,['cholesterol'],['cholesterol'],762,['胆固醇水平'],1.0,['cholesterol'],['cholesterol'],,
768,763,"at baseline , the mean total cholesterol level was 172.8 ± 45.8 mg per deciliter ( 4.5 ± 1.2 mmol per liter ) in the roxadustat group and 181.4 ± 49.0 mg per deciliter ( 4.7 ± 1.3 mmol per liter ) in the placebo group .",基线时，罗沙司他组的平均总胆固醇水平为 172.8 ± 45.8 毫克每分升（4.5 ± 1.2 毫摩尔每升），安慰剂组为 181.4 ± 49.0 毫克每分升（4.7 ± 1.3 毫摩尔每升）。,0.7272727272727273,"['cholesterol', 'group', 'placebo', 'mean', 'liter', 'baseline', 'deciliter', 'total', 'level', 'roxadustat', 'and']","['cholesterol', 'group', 'placebo', 'mean', 'liter', 'baseline', 'level', 'roxadustat']",763,"['在基线上,平均总胆固醇水平为172.8 ± 45.8 毫克(4.5 ± 1.2 mmol 每升)在 roxadustat 组和181.4 ± 49.0 毫克(4.7 ± 1.3 mmol 每升)在 placebo 组。']",0.5454545454545454,"['cholesterol', 'group', 'placebo', 'mean', 'liter', 'baseline', 'deciliter', 'total', 'level', 'roxadustat', 'and']","['cholesterol', 'group', 'mean', 'liter', 'baseline', 'level']",,
769,764,safety and Adverse Events,安全和不良事件,0.3333333333333333,"['safety', 'adverse', 'and']",['safety'],764,['安全和不良事件'],0.3333333333333333,"['safety', 'adverse', 'and']",['safety'],,
770,765,one patient in each group discontinued participation in the trial because of hyperkalemia .,每组中有一名患者因高钾血症而停止参与试验。,0.5714285714285714,"['group', 'hyperkalemia', 'patient', 'trial', 'participation', 'each', 'in']","['group', 'hyperkalemia', 'patient', 'participation']",765,['每个群体中有1名患者因催眠症而停止参加试验。'],0.2857142857142857,"['group', 'hyperkalemia', 'patient', 'trial', 'participation', 'each', 'in']","['group', 'patient']",,
771,766,local laboratory values were not collected .,未收集当地实验室值。,0.3333333333333333,"['local', 'laboratory', 'values']",['laboratory'],766,['當地實驗室價值未被收集。'],0.0,"['local', 'laboratory', 'values']",[],,
772,767,"in the roxadustat group , the percentages of patients with a serum bicarbonate level of 21 mmol per liter or less were 92 % at baseline and 91 % at 9 weeks .",在罗沙司他组中，血清碳酸氢盐水平为 21 毫摩尔/升或更低的患者百分比在基线时为 92%，在 9 周时为 91%。,0.7,"['group', 'a', 'liter', 'bicarbonate', 'baseline', 'serum', 'level', 'with', 'roxadustat', 'and']","['group', 'liter', 'bicarbonate', 'baseline', 'serum', 'level', 'roxadustat']",767,"['在 roxadustat 群体中,血清二氧化碳含量为 21 mmol 或低于 1 升的患者的百分比在基线上为 92%,在 9 周内为 91 %.']",0.4,"['group', 'a', 'liter', 'bicarbonate', 'baseline', 'serum', 'level', 'with', 'roxadustat', 'and']","['group', 'liter', 'baseline', 'serum']",,
773,768,"in the placebo group , the percentages were 96 % at baseline and 89 % at 9 weeks ( Table S4 in the Supplementary Appendix ) .",在安慰剂组中，该百分比在基线时为 96%，在 9 周时为 89%（补充附录表 S4）。,0.4444444444444444,"['group', 'placebo', 'appendix', 'table', 'baseline', 'supplementary', 'at', 'S4', 'and']","['group', 'placebo', 'table', 'baseline']",768,"['在 placebo 群体中,百分比为 96% 基线和 89% 9 周(附件中的 S4 表)。']",0.4444444444444444,"['group', 'placebo', 'appendix', 'table', 'baseline', 'supplementary', 'at', 'S4', 'and']","['group', 'appendix', 'table', 'baseline']",,
774,769,"serious adverse events , which were consistent with those generally seen in patients with chronic kidney disease , were reported in 9 patients ( 9 % ) in the roxadustat group and in 6 patients ( 12 % ) in the placebo group ( Table 3 ) .",罗沙司他组 9 名患者 (9%) 和安慰剂组 6 名患者 (12%) 报告了与慢性肾病患者常见的严重不良事件（表 3）。,0.5384615384615384,"['group', 'placebo', 'kidney', 'disease', 'table', 'adverse', 'chronic', '3', 'with', 'roxadustat', 'serious', 'in', 'and']","['group', 'placebo', 'kidney', 'disease', 'table', 'chronic', 'roxadustat']",769,"['严重的副作用,与患有慢性肾脏疾病的患者常见相一致,报告了9名患者(9%)在Roxadustat群体和6名患者(12%)在 placebo群体(图3)。']",0.3076923076923077,"['group', 'placebo', 'kidney', 'disease', 'table', 'adverse', 'chronic', '3', 'with', 'roxadustat', 'serious', 'in', 'and']","['group', 'kidney', 'disease', 'chronic']",,
775,770,there were no deaths during the randomized phase of the trial .,在试验的随机阶段没有死亡。,0.3333333333333333,"['phase', 'no', 'trial']",['phase'],770,['在审判的随机阶段没有死亡。'],0.6666666666666666,"['phase', 'no', 'trial']","['phase', 'trial']",,
776,771,an increase in the level of alanine aminotransferase ( ALT ) or aspartate aminotransferase ( AST ) occurred in 2 patients in the roxadustat group and 1 patient in the placebo group ( 2 % in each group ) .,丙氨酸氨基转移酶 (ALT) 或天冬氨酸氨基转移酶 (AST) 水平升高发生在罗沙司他组 2 名患者和安慰剂组 1 名患者（每组 2%）。,0.6,"['group', 'placebo', 'alanine', '1', '2', 'alanine aminotransferase', 'AST', 'ALT', 'aspartate aminotransferase', 'patient', 'level', 'increase', 'roxadustat', 'each', 'and']","['group', 'placebo', 'alanine', '1', '2', 'alanine aminotransferase', 'patient', 'level', 'roxadustat']",771,['阿拉丁氨基转移剂(ALT)或阿斯帕特氨基转移剂(AST)的水平增加发生在罗克萨多斯塔特群体的2名患者和 placebo群体的1名患者(每个群体的2%)。'],0.3333333333333333,"['group', 'placebo', 'alanine', '1', '2', 'alanine aminotransferase', 'AST', 'ALT', 'aspartate aminotransferase', 'patient', 'level', 'increase', 'roxadustat', 'each', 'and']","['group', '1', '2', 'patient', 'level']",,
777,772,"in the roxadustat group , 1 patient who had a grade 1 elevation in ALT and AST had a spontaneous normalization in the level without any change in the drug regimen ; a second patient had a grade 2 elevation in ALT and AST that was reported 2 days after receipt of the last dose of roxadustat during the trial while the patient was receiving concomitant medications known to be associated with an elevation in liver enzyme levels .",在罗沙司他组中，1 名 ALT 和 AST 出现 1 级升高的患者在药物治疗方案没有任何变化的情况下自发恢复正常；第二名患者的 ALT 和 AST 出现 2 级升高，在试验期间接受最后一剂 roxadustat 后 2 天报告，当时该患者正在接受已知与肝酶水平升高相关的伴随药物治疗。,0.4333333333333333,"['group', 'liver', 'elevation', 'enzyme', 'who', '1', '2', 'spontaneous', 'AST', 'grade', 'ALT', 'be', 'concomitant', 'associated', 'normalization', 'patient', 'after', 'trial', 'level', 'change', 'with', 'drug', 'roxadustat', 'dose', 'second', 'that', 'in', 'to', 'and', 'without']","['group', 'liver', 'enzyme', '1', '2', 'be', 'patient', 'after', 'level', 'change', 'drug', 'roxadustat', 'in']",772,"['在Roxadustat群体中,1名患有1级 ALT 和 AST 的患者在药物制度中没有任何变化的情况下在水平上自发正常化;2名患有2级 ALT 和 AST 的患者在测试期间接收Roxadustat的最后剂量后近2天,而患者在接受同步药物时已知与肝酶水平的上升有关。']",0.5333333333333333,"['group', 'liver', 'elevation', 'enzyme', 'who', '1', '2', 'spontaneous', 'AST', 'grade', 'ALT', 'be', 'concomitant', 'associated', 'normalization', 'patient', 'after', 'trial', 'level', 'change', 'with', 'drug', 'roxadustat', 'dose', 'second', 'that', 'in', 'to', 'and', 'without']","['group', 'liver', 'elevation', 'enzyme', '1', '2', 'grade', 'be', 'normalization', 'patient', 'after', 'level', 'change', 'drug', 'dose', 'and']",,
778,773,"among the patients who had initially received placebo , the mean hemoglobin level increased from baseline by 2.0 ± 1.5 g per deciliter after crossover to receive roxadustat ; 31 of 43 patients ( 72 % ) had a hemoglobin level of more than 11.0 g per deciliter , and 37 ( 86 % ) had a hemoglobin level of 10.0 g per deciliter or more during weeks 23 through 27 .",在最初接受安慰剂的患者中，平均血红蛋白水平在交叉接受罗沙司他后较基线增加了 2.0 ± 1.5 g/dL； 43 名患者中有 31 名 (72%) 的血红蛋白水平超过 11.0 g/dL，37 名 (86%) 在第 23 至 27 周期间血红蛋白水平为 10.0 g/dL 或更高。,0.5,"['placebo', 'mean', 'who', 'baseline', 'hemoglobin', 'deciliter', 'hemoglobin level', 'after', 'roxadustat', 'by', 'to', 'and']","['placebo', 'mean', 'baseline', 'hemoglobin', 'after', 'roxadustat']",773,"['在接受 placebo 的患者中,平均血球水平从基线上增加了 2.0 ± 1.5 克每分克后交叉接收Roxadustat;在 43 名患者中,31 名患者( 72% )的血球水平超过 11.0 克每分克;在 37 名患者( 86%)的血球水平在 23 至 27 周内超过 10.0 克每分克。']",0.3333333333333333,"['placebo', 'mean', 'who', 'baseline', 'hemoglobin', 'deciliter', 'hemoglobin level', 'after', 'roxadustat', 'by', 'to', 'and']","['mean', 'baseline', 'after', 'by']",,
779,774,the primary efficacy analysis showed a significantly larger increase in the hemoglobin level from baseline over weeks 7 to 9 in the roxadustat group than in the placebo group ( an increase of 1.9 ± 1.2 g per deciliter vs. a decrease of 0.4 ± 0.8 g per deciliter ) .,主要疗效分析显示，与安慰剂组相比，在第 7 周至第 9 周期间，罗沙司他组的血红蛋白水平相对于基线的增幅明显更大（增加 1.9 ± 1.2 g/dL 对比减少 0.4 ± 0.8 g/dL ) 。,0.5714285714285714,"['group', 'placebo', 'decrease', 'analysis', 'baseline', 'hemoglobin', 'deciliter', 'hemoglobin level', 'primary', 'efficacy', 'increase', 'roxadustat', 'over', 'to']","['group', 'placebo', 'decrease', 'analysis', 'baseline', 'hemoglobin', 'roxadustat', 'to']",774,"['初级效能分析显示,在Roxadustat组的7至9周内,血球水平显著增加(每分克增加1.9 ± 1.2 克,每分克减少0.4 ± 0.8 克)。']",0.2857142857142857,"['group', 'placebo', 'decrease', 'analysis', 'baseline', 'hemoglobin', 'deciliter', 'hemoglobin level', 'primary', 'efficacy', 'increase', 'roxadustat', 'over', 'to']","['group', 'decrease', 'analysis', 'efficacy']",,
780,775,"similarly , other hemoglobin end points , such as the percentage of patients who had a hemoglobin response ( i.e. , an increase of ≥ 1.0 g per deciliter from baseline ) or who did not receive rescue therapy , were greater in the roxadustat group than in the placebo group .",类似地，其他血红蛋白终点，例如有血红蛋白反应（即从基线增加≥1.0 g/dL）或未接受挽救治疗的患者百分比，罗沙司他组高于安慰剂组。团体 。,0.6153846153846154,"['group', 'percentage', 'placebo', 'who', 'baseline', 'hemoglobin', 'deciliter', 'therapy', 'end points', 'response', 'increase', 'roxadustat', 'rescue']","['group', 'placebo', 'baseline', 'hemoglobin', 'therapy', 'end points', 'response', 'roxadustat']",775,"['同樣,其他血球結末點,例如患有血球反應(即從基線增加 ≥ 1.0 g 每分鐘)或沒有接受救援治療的患者的比例,在Roxadustat群體中比在 placebo群體中更高。']",0.1538461538461538,"['group', 'percentage', 'placebo', 'who', 'baseline', 'hemoglobin', 'deciliter', 'therapy', 'end points', 'response', 'increase', 'roxadustat', 'rescue']","['group', 'rescue']",,
781,776,"in spite of the robust erythropoiesis and the restriction of intravenous administration of iron in the roxadustat group , serum iron levels remained stable .",尽管 roxadustat 组红细胞生成旺盛且静脉注射铁剂受到限制，但血清铁水平仍保持稳定。,0.4444444444444444,"['group', 'erythropoiesis', 'administration', 'serum', 'restriction', 'intravenous', 'roxadustat', 'iron', 'and']","['group', 'erythropoiesis', 'serum', 'iron']",776,"['尽管坚固的甲状腺炎和罗克萨多斯塔特群体中的铁的内分泌限制,但血清铁的水平仍然稳定。']",0.3333333333333333,"['group', 'erythropoiesis', 'administration', 'serum', 'restriction', 'intravenous', 'roxadustat', 'iron', 'and']","['group', 'serum', 'iron']",,
782,777,"we found that in addition to the erythropoietic effects of roxadustat , the drug was associated with reduced levels of hepcidin and cholesterol .",我们发现除了 roxadustat 的红细胞生成作用外，该药物还与铁调素和胆固醇水平降低有关。,0.1666666666666666,"['cholesterol', 'addition', 'erythropoietic', 'associated', 'with', 'drug', 'roxadustat', 'that', 'in', 'to', 'and', 'we']","['cholesterol', 'drug']",777,"['我们发现,除了Roxadustat的勃起作用之外,该药物与低水平的肝炎和胆固醇有关。']",0.1666666666666666,"['cholesterol', 'addition', 'erythropoietic', 'associated', 'with', 'drug', 'roxadustat', 'that', 'in', 'to', 'and', 'we']","['cholesterol', 'drug']",,
783,778,"we speculate that the stability of serum iron levels in the roxadustat group may have been driven by reductions in hepcidin levels , which permitted the gut absorption of iron and improved the release of macrophage iron onto transferrin.26",我们推测，roxadustat 组血清铁水平的稳定可能是由于 hepcidin 水平降低所致，这允许肠道吸收铁并促进巨噬细胞将铁释放到转铁蛋白上。 26,0.5333333333333333,"['group', 'gut', 'absorption', 'macrophage', 'release', 'serum', 'roxadustat', 'iron', 'stability', 'have', 'that', 'in', 'by', 'and', 'we']","['group', 'gut', 'absorption', 'macrophage', 'release', 'serum', 'iron', 'by']",778,"['我们猜测,罗克萨德斯塔特群体的血清铁水平的稳定性可能被肝素水平的下降所驱动,这使得肠道吸收铁,并改善转移铁的释放。']",0.4666666666666667,"['group', 'gut', 'absorption', 'macrophage', 'release', 'serum', 'roxadustat', 'iron', 'stability', 'have', 'that', 'in', 'by', 'and', 'we']","['group', 'gut', 'absorption', 'release', 'serum', 'iron', 'stability']",,
784,779,"previous studies involving patients with chronic kidney disease who were not undergoing dialysis have shown that roxadustat increased hemoglobin levels with stable serum iron levels , despite robust erythropoiesis in the absence of intravenous administration of iron.23,25","先前对未接受透析的慢性肾病患者的研究表明，尽管在没有静脉注射铁剂的情况下红细胞生成旺盛，罗沙司他仍可增加血红蛋白水平和稳定的血清铁水平。 23,25",0.5555555555555556,"['dialysis', 'erythropoiesis', 'kidney', 'disease', 'who', 'hemoglobin', 'administration', 'previous', 'serum', 'chronic', 'absence', 'intravenous', 'with', 'despite', 'roxadustat', 'iron', 'have', 'that']","['dialysis', 'erythropoiesis', 'kidney', 'disease', 'hemoglobin', 'serum', 'chronic', 'roxadustat', 'iron', 'have']",779,"['以前的研究涉及患有慢性肾脏疾病的患者,他们没有接受诊断,发现Roxadustat增加了血球水平与稳定的血清铁水平,尽管在缺乏血管内铁的强度勃起。']",0.4444444444444444,"['dialysis', 'erythropoiesis', 'kidney', 'disease', 'who', 'hemoglobin', 'administration', 'previous', 'serum', 'chronic', 'absence', 'intravenous', 'with', 'despite', 'roxadustat', 'iron', 'have', 'that']","['kidney', 'disease', 'previous', 'serum', 'chronic', 'absence', 'iron', 'have']",,
785,780,"in our trial , initial measures of iron suggested adequate baseline iron stores in only half the patients .",在我们的试验中，铁的初步测量表明只有一半的患者有足够的基线铁储存。,0.7142857142857143,"['baseline', 'half', 'initial', 'trial', 'adequate', 'iron', 'stores']","['baseline', 'half', 'initial', 'adequate', 'iron']",780,"['在我们的研究中,铁的初步测量表明,只有半数患者有足够的基铁仓库。']",0.5714285714285714,"['baseline', 'half', 'initial', 'trial', 'adequate', 'iron', 'stores']","['half', 'initial', 'adequate', 'iron']",,
786,781,"despite the absolute need for iron for erythropoiesis , roxadustat therapy corrected anemia and maintained hemoglobin levels in spite of lower transferrin saturation and progressive reduction in ferritin levels with only oral iron in moderate doses .",尽管红细胞生成绝对需要铁，但罗沙司他疗法纠正了贫血并维持了血红蛋白水平，尽管转铁蛋白饱和度较低，铁蛋白水平逐渐降低，仅口服中等剂量的铁。,0.6,"['anemia', 'erythropoiesis', 'ferritin', 'transferrin', 'need', 'hemoglobin', 'oral', 'absolute', 'reduction', 'progressive', 'moderate', 'lower', 'therapy', 'saturation', 'with', 'despite', 'roxadustat', 'iron', 'and', 'corrected']","['anemia', 'erythropoiesis', 'ferritin', 'transferrin', 'need', 'hemoglobin', 'absolute', 'reduction', 'therapy', 'saturation', 'roxadustat', 'iron']",781,"['尽管对甲状腺炎的铁的绝对需要,但Roxadustat治疗修复了贫血和维持了血球水平,尽管过渡素的饱和度较低,并且费里丁水平的逐步下降,只有适度剂量的口腔铁。']",0.3,"['anemia', 'erythropoiesis', 'ferritin', 'transferrin', 'need', 'hemoglobin', 'oral', 'absolute', 'reduction', 'progressive', 'moderate', 'lower', 'therapy', 'saturation', 'with', 'despite', 'roxadustat', 'iron', 'and', 'corrected']","['anemia', 'need', 'absolute', 'therapy', 'saturation', 'iron']",,
787,782,"serum iron , the more important component of the plasma iron content , can remain constant or increase even if the level of carrier protein increases .",血清铁是血浆铁含量中更重要的组成部分，即使载体蛋白水平升高，它也可以保持不变或升高。,0.6363636363636364,"['carrier', 'component', 'carrier protein', 'plasma', 'content', 'serum', 'constant', 'increases', 'level', 'iron', 'if']","['carrier', 'carrier protein', 'plasma', 'content', 'serum', 'level', 'iron']",782,"['血清铁,血清铁含量最重要的组成部分,可以保持稳定或增加,即使携带蛋白质的水平增加。']",0.3636363636363636,"['carrier', 'component', 'carrier protein', 'plasma', 'content', 'serum', 'constant', 'increases', 'level', 'iron', 'if']","['content', 'serum', 'level', 'iron']",,
788,783,"in this trial and in the phase 2 studies of roxadustat , 25 transferrin levels increased in patients receiving roxadustat but not in those receiving placebo .",在该试验和 roxadustat 的 2 期研究中，25 转铁蛋白水平在接受 roxadustat 的患者中增加，但在接受安慰剂的患者中没有增加。,0.5555555555555556,"['placebo', 'transferrin', 'phase', '2', 'trial', 'roxadustat', 'this', 'but', 'and']","['placebo', 'transferrin', 'phase', '2', 'but']",783,"['在这项研究和Roxadustat的第二阶段研究中,在Roxadustat患者中,25个转移素水平增加,但不适用于 placebo患者。']",0.3333333333333333,"['placebo', 'transferrin', 'phase', '2', 'trial', 'roxadustat', 'this', 'but', 'and']","['phase', '2', 'but']",,
789,784,this increase is probably a direct effect of the stabilization in the HIF level by roxadustat .,这种增加可能是 roxadustat 稳定 HIF 水平的直接影响。,0.4444444444444444,"['a', 'stabilization', 'effect', 'level', 'increase', 'direct', 'roxadustat', 'this', 'by']","['stabilization', 'level', 'direct', 'this']",784,['这种增加可能是Roxadustat在HIF水平的稳定性的直接影响。'],0.4444444444444444,"['a', 'stabilization', 'effect', 'level', 'increase', 'direct', 'roxadustat', 'this', 'by']","['stabilization', 'level', 'direct', 'this']",,
790,785,serum hepcidin levels were reduced in the patients who received roxadustat .,接受罗沙司他治疗的患者血清铁调素水平降低。,0.5,"['who', 'serum', 'roxadustat', 'in']","['serum', 'roxadustat']",785,['血清 hepcidin 水平在接受 roxadustat 的患者中降低。'],0.25,"['who', 'serum', 'roxadustat', 'in']",['serum'],,
791,786,maintenance of total serum iron levels permits adequate iron delivery and avoidance of functional iron deficiency .,维持血清总铁水平可以提供足够的铁并避免功能性缺铁。,0.4444444444444444,"['iron deficiency', 'functional', 'total', 'delivery', 'serum', 'adequate', 'avoidance', 'maintenance', 'and']","['iron deficiency', 'serum', 'adequate', 'maintenance']",786,"['保持整体血清铁水平,可提供适当的铁供应,避免功能铁缺乏。']",0.3333333333333333,"['iron deficiency', 'functional', 'total', 'delivery', 'serum', 'adequate', 'avoidance', 'maintenance', 'and']","['iron deficiency', 'serum', 'adequate']",,
792,787,this factor may indicate the need to reconsider the threshold of iron measures below which patients are considered to have iron depletion in order to determine which level will be most useful if HIF prolyl hydroxylase inhibitors become clinically available in the future .,这一因素可能表明需要重新考虑铁测量的阈值，低于该阈值的患者被认为铁耗竭，以确定如果 HIF 脯氨酰羟化酶抑制剂在未来临床上可用，哪个水平最有用。,0.5789473684210527,"['depletion', 'threshold', 'prolyl', 'need', 'factor', 'order', 'hydroxylase', 'indicate', 'be', 'available', 'level', 'will', 'iron', 'have', 'this', 'if', 'in order to', 'become', 'determine']","['depletion', 'threshold', 'prolyl', 'need', 'factor', 'hydroxylase', 'be', 'level', 'iron', 'have', 'in order to']",787,"['这种因素可能表明需要重新考虑患者被认为患有铁衰竭的铁措施的边界,以确定如果HIF prolyl hydroxylase 抑制剂在未来临床上可用,该水平将是最有用的。']",0.4210526315789473,"['depletion', 'threshold', 'prolyl', 'need', 'factor', 'order', 'hydroxylase', 'indicate', 'be', 'available', 'level', 'will', 'iron', 'have', 'this', 'if', 'in order to', 'become', 'determine']","['need', 'factor', 'be', 'level', 'iron', 'have', 'this', 'in order to']",,
793,788,"in our trial , total cholesterol levels decreased by 23 % during the initial 8 weeks of roxadustat therapy .",在我们的试验中，在罗沙司他治疗的最初 8 周内，总胆固醇水平降低了 23%。,0.5714285714285714,"['cholesterol', 'total', 'therapy', 'initial', 'trial', 'roxadustat', 'by']","['cholesterol', 'therapy', 'initial', 'roxadustat']",788,"['在我们的研究中,总胆固醇水平在Roxadustat治疗的初始8周期间下降了23%。']",0.4285714285714285,"['cholesterol', 'total', 'therapy', 'initial', 'trial', 'roxadustat', 'by']","['cholesterol', 'therapy', 'initial']",,
794,789,"among patients with chronic kidney disease , a high total cholesterol level is a major risk factor for cardiovascular disease.33",在患有慢性肾病的患者中，高总胆固醇水平是心血管疾病的主要危险因素。 33,0.6923076923076923,"['cholesterol', 'kidney', 'disease', 'cardiovascular', 'factor', 'total', 'major', 'chronic', 'risk', 'risk factor', 'level', 'with', 'high']","['cholesterol', 'kidney', 'disease', 'cardiovascular', 'factor', 'chronic', 'risk', 'level', 'high']",789,"['在患有慢性肾脏疾病的患者中,高胆固醇水平是心血管疾病的主要风险因素。']",0.7692307692307693,"['cholesterol', 'kidney', 'disease', 'cardiovascular', 'factor', 'total', 'major', 'chronic', 'risk', 'risk factor', 'level', 'with', 'high']","['cholesterol', 'kidney', 'disease', 'cardiovascular', 'factor', 'chronic', 'risk', 'risk factor', 'level', 'high']",,
795,790,there is evidence that statins reduce the risk of cardiovascular disease among patients with chronic kidney disease who are not undergoing dialysis.34,有证据表明，他汀类药物可降低未接受透析的慢性肾病患者患心血管疾病的风险。 34,0.75,"['kidney', 'disease', 'cardiovascular', 'who', 'reduce', 'statins', 'cardiovascular disease', 'chronic', 'risk', 'evidence', 'with', 'that']","['kidney', 'disease', 'cardiovascular', 'reduce', 'statins', 'cardiovascular disease', 'chronic', 'risk', 'evidence']",790,"['有证据表明,静脉在慢性肾脏疾病患者中降低了心血管疾病的风险,而不接受分泌。']",0.6666666666666666,"['kidney', 'disease', 'cardiovascular', 'who', 'reduce', 'statins', 'cardiovascular disease', 'chronic', 'risk', 'evidence', 'with', 'that']","['kidney', 'disease', 'cardiovascular', 'reduce', 'cardiovascular disease', 'chronic', 'risk', 'evidence']",,
796,791,the frequencies of hyperkalemia and metabolic acidosis that were reported as adverse events were higher in the roxadustat group than in the placebo group .,罗沙司他组中作为不良事件报告的高钾血症和代谢性酸中毒的频率高于安慰剂组。,0.5,"['group', 'placebo', 'acidosis', 'adverse', 'hyperkalemia', 'metabolic', 'as', 'roxadustat', 'metabolic acidosis', 'that', 'in', 'and']","['group', 'placebo', 'acidosis', 'hyperkalemia', 'roxadustat', 'metabolic acidosis']",791,['被报告为副作用的催眠和代谢酸化频率在Roxadustat群体中高于 placebo群体。'],0.0833333333333333,"['group', 'placebo', 'acidosis', 'adverse', 'hyperkalemia', 'metabolic', 'as', 'roxadustat', 'metabolic acidosis', 'that', 'in', 'and']",['group'],,
797,792,the Kidney Disease Improving Global Outcomes ( KDIGO ) guidelines suggest that patients with chronic kidney disease who have a serum bicarbonate level of less than 22 mmol per liter ( associated with metabolic acidosis ) should begin oral bicarbonate supplementation to maintain a serum bicarbonate level within the normal range.35,肾脏病改善全球预后 (KDIGO) 指南建议，血清碳酸氢盐水平低于 22 mmol/L（伴有代谢性酸中毒）的慢性肾脏病患者应开始口服碳酸氢盐补充剂，以将血清碳酸氢盐水平维持在正常范围内范围.35,0.5909090909090909,"['kidney', 'disease', 'liter', 'who', 'global', 'bicarbonate', 'oral', 'maintain', 'normal', 'serum', 'acidosis', 'associated', 'chronic', 'metabolic', 'level', 'suggest', 'with', 'metabolic acidosis', 'have', 'that', 'begin', 'to']","['kidney', 'disease', 'global', 'bicarbonate', 'maintain', 'serum', 'acidosis', 'chronic', 'level', 'metabolic acidosis', 'have', 'begin', 'to']",792,"['肾病改善全球结果(KDIGO)指南指出,患有慢性肾病的患者,每升血清二氧化碳水平低于22 mmol(与代谢酸化相关)应开始口服二氧化碳补充,以保持血清二氧化碳水平在正常范围内。']",0.4545454545454545,"['kidney', 'disease', 'liter', 'who', 'global', 'bicarbonate', 'oral', 'maintain', 'normal', 'serum', 'acidosis', 'associated', 'chronic', 'metabolic', 'level', 'suggest', 'with', 'metabolic acidosis', 'have', 'that', 'begin', 'to']","['kidney', 'disease', 'liter', 'global', 'serum', 'chronic', 'level', 'have', 'begin', 'to']",,
798,793,"in a similar study involving patients with chronic kidney disease receiving dialysis , hyperkalemia was reported as an adverse event more often in patients treated with roxadustat than in those treated with epoetin alfa.36",在一项涉及接受透析的慢性肾病患者的类似研究中，与接受阿法依泊汀治疗的患者相比，接受罗沙司他治疗的患者高钾血症作为不良事件的发生率更高。 36,0.5833333333333334,"['dialysis', 'kidney', 'disease', 'study', 'adverse', 'chronic', 'hyperkalemia', 'adverse event', 'with', 'roxadustat', 'in', 'similar']","['dialysis', 'kidney', 'disease', 'chronic', 'hyperkalemia', 'adverse event', 'roxadustat']",793,"['在类似的研究中,涉及患有慢性肾脏疾病的患者接受腹泻,高<unk>病被报告为患有Roxadustat的患者比接受Epoetin alfa的患者更频繁的副作用。']",0.25,"['dialysis', 'kidney', 'disease', 'study', 'adverse', 'chronic', 'hyperkalemia', 'adverse event', 'with', 'roxadustat', 'in', 'similar']","['kidney', 'disease', 'chronic']",,
799,794,"it should be noted that our findings are limited by the small sample size and short trial duration relative to the ongoing large , international , phase 3 studies ( ClinicalTrials.gov numbers , NCT01750190 , NCT02052310 , and NCT02273726 ) .",应该指出的是，相对于正在进行的大型国际 3 期研究（ClinicalTrials.gov 编号，NCT01750190、NCT02052310 和 NCT02273726），我们的研究结果受到样本量小和试验持续时间短的限制。,0.3125,"['sample', 'phase', 'short', 'relative', 'large', 'be', 'size', 'trial', '3', 'sample size', 'duration', 'limited', 'that', 'by', 'to', 'and']","['sample', 'phase', 'be', 'duration', 'to']",794,"['值得注意的是,我们的发现仅限于小型样品大小和与正在进行的大型、国际、阶段3研究(ClinicalTrials.gov 号码、NCT01750190、NCT02052310、和NCT02273726)的短期试验时间。']",0.3125,"['sample', 'phase', 'short', 'relative', 'large', 'be', 'size', 'trial', '3', 'sample size', 'duration', 'limited', 'that', 'by', 'to', 'and']","['sample', 'phase', 'be', 'size', 'to']",,
800,795,additional data are needed regarding the effectiveness and safety of roxadustat as compared with standard therapy ( epoetin alfa ) for the treatment of anemia in patients undergoing dialysis .,需要更多关于罗沙司他与标准疗法 (epoetin alfa) 相比治疗透析患者贫血的有效性和安全性的数据。,0.7142857142857143,"['anemia', 'safety', 'dialysis', 'standard', 'effectiveness', 'data', 'therapy', 'regarding', 'treatment', 'additional', 'as', 'with', 'roxadustat', 'epoetin alfa']","['anemia', 'safety', 'dialysis', 'standard', 'effectiveness', 'data', 'therapy', 'regarding', 'treatment', 'roxadustat']",795,"['有关Roxadustat的有效性和安全性,如与标准治疗(epoetin alfa)相比,需要进一步的数据,以治疗患有腹泻的患者。']",0.5714285714285714,"['anemia', 'safety', 'dialysis', 'standard', 'effectiveness', 'data', 'therapy', 'regarding', 'treatment', 'additional', 'as', 'with', 'roxadustat', 'epoetin alfa']","['safety', 'standard', 'effectiveness', 'data', 'therapy', 'regarding', 'treatment', 'as']",,
801,796,parenteral iron was withheld except as rescue therapy .,除作为挽救疗法外，不使用肠外铁剂。,0.6,"['parenteral', 'therapy', 'as', 'iron', 'rescue']","['parenteral', 'therapy', 'iron']",796,"['除救援治疗外,已被放弃。']",0.4,"['parenteral', 'therapy', 'as', 'iron', 'rescue']","['therapy', 'rescue']",,
802,797,the primary end point was the mean change in hemoglobin level from baseline to the average level during weeks 23 through 27 .,主要终点是第 23 周至第 27 周期间血红蛋白水平从基线到平均水平的平均变化。,0.6363636363636364,"['mean', 'average', 'baseline', 'hemoglobin', 'hemoglobin level', 'primary', 'average level', 'end', 'point', 'change', 'to']","['mean', 'average', 'baseline', 'hemoglobin', 'average level', 'point', 'change']",797,['主要的终点是从基层到平均水平的血球水平在23至27周的平均变化。'],0.5454545454545454,"['mean', 'average', 'baseline', 'hemoglobin', 'hemoglobin level', 'primary', 'average level', 'end', 'point', 'change', 'to']","['mean', 'average', 'primary', 'average level', 'point', 'change']",,
803,798,patients in each group had doses adjusted to reach a hemoglobin level of 10.0 to 12.0 g per deciliter .,每组患者的剂量都经过调整，使血红蛋白水平达到每分升 10.0 至 12.0 克。,0.25,"['group', 'a', 'hemoglobin', 'deciliter', 'hemoglobin level', 'each', 'to', 'reach']","['group', 'hemoglobin']",798,['每个群体的患者均有调整剂量达到10.0至12.0g的血糖水平。'],0.125,"['group', 'a', 'hemoglobin', 'deciliter', 'hemoglobin level', 'each', 'to', 'reach']",['group'],,
804,799,safety was assessed by analysis of adverse events and clinical laboratory values .,通过分析不良事件和临床实验室值评估安全性。,0.4444444444444444,"['safety', 'analysis', 'adverse', 'clinical', 'laboratory', 'values', 'by', 'and', 'assessed']","['safety', 'analysis', 'clinical', 'laboratory']",799,['安全性通过分析不良事件和临床实验室值进行评估。'],0.4444444444444444,"['safety', 'analysis', 'adverse', 'clinical', 'laboratory', 'values', 'by', 'and', 'assessed']","['safety', 'analysis', 'clinical', 'laboratory']",,
805,800,the mean baseline hemoglobin level was 10.4 g per deciliter .,平均基线血红蛋白水平为每分升 10.4 克。,0.6,"['mean', 'baseline', 'hemoglobin', 'deciliter', 'hemoglobin level']","['mean', 'baseline', 'hemoglobin']",800,['平均基因血糖水平为每分升10.4g。'],0.2,"['mean', 'baseline', 'hemoglobin', 'deciliter', 'hemoglobin level']",['mean'],,
806,801,"as compared with epoetin alfa , roxadustat increased the transferrin level ( difference , 0.43 g per liter ; 95 % CI , 0.32 to 0.53 ) , maintained the serum iron level ( difference , 25 μg per deciliter ; 95 % CI , 17 to 33 ) , and attenuated decreases in the transferrin saturation ( difference , 4.2 percentage points ; 95 % CI , 1.5 to 6.9 ) .",与阿法依泊汀相比，罗沙司他增加转铁蛋白水平（差异，0.43 g/L；95 % CI，0.32至0.53），维持血清铁水平（差异，25 μg/dL；95 % CI，17至33） ，并且转铁蛋白饱和度降低减弱（差异，4.2 个百分点；95% CI，1.5 至 6.9）。,0.4375,"['percentage', 'transferrin', 'liter', 'deciliter', 'difference', 'serum', 'saturation', 'level', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron', 'CI', 'to', 'and']","['transferrin', 'difference', 'serum', 'saturation', 'level', 'roxadustat', 'iron']",801,"['与epoetin alfa 相比,roxadustat 增加了 transferrin 水平(差异, 0.43 g 每升; 95 % CI, 0.32 至 0.53 ),保持了血清铁水平(差异, 25 μg 每分升; 95 % CI, 17 至 33 ),并减轻了 transferrin 饱和度(差异, 4.2 百分点; 95 % CI, 1.5 至 6.9 ) 。']",0.375,"['percentage', 'transferrin', 'liter', 'deciliter', 'difference', 'serum', 'saturation', 'level', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron', 'CI', 'to', 'and']","['liter', 'difference', 'serum', 'saturation', 'level', 'iron']",,
807,802,"roxadustat was associated with a mean reduction in hepcidin of 30.2 ng per milliliter ( 95 % CI , − 64.8 to − 13.6 ) , as compared with 2.3 ng per milliliter ( 95 % CI , − 51.6 to 6.2 ) in the epoetin alfa group .",罗沙司他与铁调素平均降低 30.2 ng/mL（95% CI，-64.8 至-13.6）相关，而 epoetin alfa 组为 2.3 ng/mL（95% CI，-51.6 至 6.2）。,0.4,"['group', 'a', 'mean', 'reduction', 'associated', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to']","['group', 'mean', 'reduction', 'roxadustat']",802,"['roxadustat 与每毫升的 hepcidin 的平均减少为 30.2 ng(95 % CI, − 64.8 至 − 13.6) 相似,与每毫升的 2.3 ng(95 % CI, − 51.6 至 6.2) 相比。']",0.2,"['group', 'a', 'mean', 'reduction', 'associated', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to']","['mean', 'reduction']",,
808,803,"hyperkalemia and upper respiratory infection occurred at a higher frequency in the roxadustat group , and hypertension occurred at a higher frequency in the epoetin alfa group .",roxadustat组高钾血症和上呼吸道感染发生率较高，epoetin alfa组高血压发生率较高。,0.3636363636363636,"['infection', 'group', 'frequency', 'a', 'hypertension', 'upper', 'respiratory', 'hyperkalemia', 'roxadustat', 'epoetin alfa', 'and']","['infection', 'group', 'hypertension', 'hyperkalemia']",803,"['甲状腺高血压和上呼吸道感染发生在较高的频率在 roxadustat 群体,高血压发生在较高的频率在 epoetin alfa 群体。']",0.3636363636363636,"['infection', 'group', 'frequency', 'a', 'hypertension', 'upper', 'respiratory', 'hyperkalemia', 'roxadustat', 'epoetin alfa', 'and']","['infection', 'group', 'frequency', 'hypertension']",,
809,804,"in China , 120 million persons have chronic kidney disease , a prevalence that is projected to increase.1,2","在中国，有 1.2 亿人患有慢性肾病，而且这一患病率预计还会增加。 1,2",0.5555555555555556,"['kidney', 'disease', 'prevalence', 'china', 'chronic', 'have', 'that', 'to', 'million']","['kidney', 'disease', 'china', 'chronic', 'have']",804,"['在中国,120万人患有慢性肾脏疾病,这种发病率预计会增加。']",0.5555555555555556,"['kidney', 'disease', 'prevalence', 'china', 'chronic', 'have', 'that', 'to', 'million']","['kidney', 'disease', 'china', 'chronic', 'have']",,
810,805,only half the patients undergoing dialysis in China reach a hemoglobin level of 10.0 g per deciliter or greater using recombinant erythropoietin therapy .,在中国接受重组促红细胞生成素治疗的透析患者中，只有一半的血红蛋白水平达到 10.0 克/分升或更高。,0.6,"['dialysis', 'erythropoietin', 'recombinant', 'hemoglobin', 'half', 'deciliter', 'therapy', 'hemoglobin level', 'china', 'reach']","['dialysis', 'erythropoietin', 'hemoglobin', 'half', 'therapy', 'china']",805,"['在中国,只有半数患有分裂症的患者达到10.0g或更高的血糖水平,使用 recombinant erythropoietin 治疗。']",0.3,"['dialysis', 'erythropoietin', 'recombinant', 'hemoglobin', 'half', 'deciliter', 'therapy', 'hemoglobin level', 'china', 'reach']","['half', 'therapy', 'china']",,
811,806,"this apparent undertreatment may result from the cost of the medication , hyporesponsiveness due to inflammation , or iron depletion.12",这种明显的治疗不足可能是由于药物成本、炎症引起的反应迟钝或缺铁造成的。 12,0.625,"['inflammation', 'medication', 'result', 'cost', 'due', 'iron', 'this', 'to']","['inflammation', 'cost', 'iron', 'this', 'to']",806,['这种显而易见的过度治疗可能导致药物的成本、由于炎症而过度响应性或铁的枯竭。'],0.5,"['inflammation', 'medication', 'result', 'cost', 'due', 'iron', 'this', 'to']","['inflammation', 'cost', 'iron', 'to']",,
812,807,"the kidneys of patients with kidney disease retain the ability to produce erythropoietin.13,14","肾病患者的肾脏保留了产生促红细胞生成素的能力。 13,14",0.5,"['kidney', 'disease', 'produce', 'ability', 'with', 'to']","['kidney', 'disease', 'ability']",807,['患有肾疾病的患者的肾保持生成Erythropoietin的能力。'],0.5,"['kidney', 'disease', 'produce', 'ability', 'with', 'to']","['kidney', 'disease', 'ability']",,
813,808,"the protocol , available with the full text of this article at NEJM.org , was approved by regulatory authorities and ethics committees , and the trial was conducted in accordance with local regulatory and ethics requirements .",该方案与本文全文可在 NEJM.org 获取，已获得监管机构和伦理委员会的批准，试验是根据当地监管和伦理要求进行的。,0.2666666666666666,"['protocol', 'article', 'ethics', 'local', 'available', 'trial', 'text', 'committees', 'with', 'at', 'full', 'this', 'in', 'by', 'and']","['committees', 'at', 'this', 'in']",808,"['该议定书与本条的完整文本在NEJM.org上可用,由监管机构和伦理委员会批准,审判按照当地的监管和伦理要求进行。']",0.5333333333333333,"['protocol', 'article', 'ethics', 'local', 'available', 'trial', 'text', 'committees', 'with', 'at', 'full', 'this', 'in', 'by', 'and']","['protocol', 'local', 'trial', 'committees', 'at', 'full', 'in', 'by']",,
814,809,the trial was designed by the first two authors and the sponsor ( FibroGen ) .,该试验由前两位作者和赞助商 (FibroGen) 设计。,0.3333333333333333,"['sponsor', 'trial', 'by', 'and', 'first', 'two']","['by', 'two']",809,['试验是由前两位作者和赞助商(FibroGen)设计的。'],0.3333333333333333,"['sponsor', 'trial', 'by', 'and', 'first', 'two']","['by', 'two']",,
815,810,the sponsor provided financial support and was responsible for data collection and analysis .,申办者提供资金支持并负责数据收集和分析。,0.8571428571428571,"['support', 'data', 'analysis', 'sponsor', 'collection', 'data collection', 'and']","['support', 'data', 'analysis', 'sponsor', 'collection', 'data collection']",810,"['赞助商提供财务支持,负责数据收集和分析。']",0.7142857142857143,"['support', 'data', 'analysis', 'sponsor', 'collection', 'data collection', 'and']","['support', 'data', 'analysis', 'collection', 'data collection']",,
816,811,all the authors had full access to the trial data and analyses and contributed to data analysis and interpretation and to the conduct of the trial .,所有作者都可以完全访问试验数据和分析，并为数据分析和解释以及试验的实施做出了贡献。,0.3,"['data', 'analysis', 'access', 'interpretation', 'trial', 'conduct', 'full', 'all', 'to', 'and']","['data', 'analysis', 'interpretation']",811,"['所有作者都有充分的访问审判数据和分析,并有助于数据分析和解释以及审判的进行。']",0.5,"['data', 'analysis', 'access', 'interpretation', 'trial', 'conduct', 'full', 'all', 'to', 'and']","['data', 'analysis', 'interpretation', 'trial', 'to']",,
817,812,an author who is an employee of the sponsor wrote the first draft of the manuscript .,作为申办方雇员的作者撰写了手稿的初稿。,0.2857142857142857,"['who', 'author', 'sponsor', 'manuscript', 'employee', 'first', 'draft']","['manuscript', 'employee']",812,"['作者是赞助商的员工,写了手稿的第一个草案。']",0.4285714285714285,"['who', 'author', 'sponsor', 'manuscript', 'employee', 'first', 'draft']","['manuscript', 'employee', 'first']",,
818,813,"a list of inclusion and exclusion criteria is provided in Table S1 in the Supplementary Appendix , available at NEJM.org .",补充附录表 S1 中提供了纳入和排除标准列表，补充附录可在 NEJM.org 获取。,0.0909090909090909,"['a', 'appendix', 'table', 'inclusion', 'supplementary', 'exclusion', 'available', 'list', 'at', 'S1', 'and']",['table'],813,"['包含和排除的标准列表在附加附件中的S1表中,可在NEJM.org上找到。']",0.2727272727272727,"['a', 'appendix', 'table', 'inclusion', 'supplementary', 'exclusion', 'available', 'list', 'at', 'S1', 'and']","['appendix', 'table', 'inclusion']",,
819,814,patients who had been randomly assigned to receive epoetin alfa continued their prerandomization doses .,被随机分配接受 epoetin alfa 治疗的患者继续其随机化前的剂量。,0.0,"['who', 'epoetin alfa', 'to']",[],814,['随机服用epoetin alfa的患者继续服用预先剂量。'],0.0,"['who', 'epoetin alfa', 'to']",[],,
820,815,both epoetin alfa and roxadustat were supplied by the sponsor .,epoetin alfa 和 roxadustat 均由申办方提供。,0.2,"['sponsor', 'roxadustat', 'epoetin alfa', 'by', 'and']",['by'],815,['Epoetin alfa 和 roxadustat 都是由赞助商提供的。'],0.2,"['sponsor', 'roxadustat', 'epoetin alfa', 'by', 'and']",['by'],,
821,816,doses were adjusted so that the patient would have a hemoglobin level of 10.0 to 12.0 g per deciliter ( Table S2 in the Supplementary Appendix ) .,调整剂量，使患者的血红蛋白水平达到 10.0 至 12.0 g/dL（补充附录表 S2）。,0.2307692307692307,"['a', 'appendix', 'table', 'hemoglobin', 'deciliter', 'supplementary', 'hemoglobin level', 'patient', 'S2', 'have', 'that', 'so', 'to']","['table', 'hemoglobin', 'patient']",816,"['剂量被调整,以便患者每分升10.0至12.0g的血糖水平(附件中的S2表)。']",0.2307692307692307,"['a', 'appendix', 'table', 'hemoglobin', 'deciliter', 'supplementary', 'hemoglobin level', 'patient', 'S2', 'have', 'that', 'so', 'to']","['appendix', 'table', 'patient']",,
822,817,the use of oral iron therapy was allowed ; intravenous iron therapy was prohibited except as rescue therapy .,允许使用口服铁剂疗法；除非作为补救治疗，否则禁止静脉铁剂治疗。,0.3333333333333333,"['oral', 'therapy', 'intravenous', 'as', 'iron', 'rescue']","['therapy', 'iron']",817,"['使用口腔铁疗法被允许;除救援疗法外,禁止内膜铁疗法。']",0.5,"['oral', 'therapy', 'intravenous', 'as', 'iron', 'rescue']","['therapy', 'iron', 'rescue']",,
823,818,the primary efficacy end point was the mean change in the hemoglobin level from baseline to the average level during weeks 23 through 27 .,主要疗效终点是第 23 周至第 27 周期间血红蛋白水平从基线到平均水平的平均变化。,0.5833333333333334,"['mean', 'average', 'baseline', 'hemoglobin', 'hemoglobin level', 'primary', 'efficacy', 'average level', 'end', 'point', 'change', 'to']","['mean', 'average', 'baseline', 'hemoglobin', 'average level', 'point', 'change']",818,"['初级有效性终点是从基层到平均水平的血球水平的平均变化,在23至27周。']",0.5,"['mean', 'average', 'baseline', 'hemoglobin', 'hemoglobin level', 'primary', 'efficacy', 'average level', 'end', 'point', 'change', 'to']","['mean', 'average', 'efficacy', 'average level', 'point', 'change']",,
824,819,the baseline hemoglobin level was defined as the mean of the last three hemoglobin levels before the first dose of a trial drug .,基线血红蛋白水平定义为试验药物首次给药前最后三个血红蛋白水平的平均值。,0.4166666666666667,"['a', 'defined', 'mean', 'baseline', 'hemoglobin', 'hemoglobin level', 'trial', 'drug', 'dose', 'three', 'before', 'first']","['mean', 'baseline', 'hemoglobin', 'drug', 'before']",819,"['基因血球水平被定义为前三血球水平的平均水平,在试用药物的第一剂量之前。']",0.4166666666666667,"['a', 'defined', 'mean', 'baseline', 'hemoglobin', 'hemoglobin level', 'trial', 'drug', 'dose', 'three', 'before', 'first']","['mean', 'drug', 'dose', 'before', 'first']",,
825,820,"in order for the trial to show the noninferiority of roxadustat to epoetin alfa , the lower boundary of the 95 % confidence interval for the treatment difference in the change in hemoglobin level had to be greater than or equal to − 1.0 g per deciliter .",为了让试验显示罗沙司他对阿法依泊汀的非劣效性，血红蛋白水平变化的治疗差异的 95% 置信区间下限必须大于或等于 − 1.0 g/dL。,0.5294117647058824,"['boundary', 'interval', 'order', 'hemoglobin', 'deciliter', 'difference', 'lower', 'be', 'hemoglobin level', 'treatment', 'trial', 'confidence interval', 'change', 'equal', 'roxadustat', 'epoetin alfa', 'to']","['interval', 'hemoglobin', 'difference', 'treatment', 'confidence interval', 'change', 'equal', 'roxadustat', 'to']",820,"['为了在试验中显示Roxadustat对Epoetin alfa的非低度,对治疗差异的95%信任间隔的低限度在血球水平的变化中应该超过或相当于 − 1.0 g 每分。']",0.3529411764705882,"['boundary', 'interval', 'order', 'hemoglobin', 'deciliter', 'difference', 'lower', 'be', 'hemoglobin level', 'treatment', 'trial', 'confidence interval', 'change', 'equal', 'roxadustat', 'epoetin alfa', 'to']","['interval', 'difference', 'be', 'treatment', 'change', 'to']",,
826,821,"sensitivity analyses with analysis of covariance ( ANCOVA ) were performed in which missing hemoglobin values were imputed with the use of the Markov chain Monte Carlo method , 28,29 which assumes multivariate normal distribution of hemoglobin values , to create a data set of observed plus imputed data .","进行了具有协方差分析 ( ANCOVA ) 的敏感性分析，其中使用马尔可夫链蒙特卡洛方法 28,29 估算了缺失的血红蛋白值，该方法假设血红蛋白值呈多变量正态分布，以创建观察值和估算值的数据集数据 。",0.5,"['covariance', 'normal distribution', 'chain', 'data', 'analysis', 'hemoglobin', 'plus', 'set', 'method', 'values', 'monte carlo method', 'multivariate normal distribution', 'with', 'sensitivity', 'analysis of covariance', 'to', 'missing', 'create', 'data set', 'markov chain']","['covariance', 'normal distribution', 'chain', 'data', 'analysis', 'hemoglobin', 'missing', 'create', 'data set', 'markov chain']",821,"['敏感性分析与可视性分析(ANCOVA)进行了,在其中缺乏的血球值被指示使用马尔科夫链蒙特卡洛方法28,29,假设多变的血球值的正常分布,创建一个数据集的观察加上指示的数据。']",0.35,"['covariance', 'normal distribution', 'chain', 'data', 'analysis', 'hemoglobin', 'plus', 'set', 'method', 'values', 'monte carlo method', 'multivariate normal distribution', 'with', 'sensitivity', 'analysis of covariance', 'to', 'missing', 'create', 'data set', 'markov chain']","['chain', 'data', 'analysis', 'plus', 'missing', 'create', 'data set']",,
827,822,"the number of patients , proportion of patients with a response , and treatment differences were averaged from the multiple imputations .",患者人数、有反应的患者比例和治疗差异均通过多重插补计算平均。,0.5,"['proportion', 'a', 'multiple', 'treatment', 'number', 'response', 'with', 'and']","['proportion', 'treatment', 'number', 'response']",822,['病人数量、患有反应的病人比例和治疗差异是从多种指征中平均的。'],0.5,"['proportion', 'a', 'multiple', 'treatment', 'number', 'response', 'with', 'and']","['proportion', 'treatment', 'number', 'response']",,
828,823,"since the analyses of secondary end points were not adjusted for multiple comparisons , we report point estimates and 95 % confidence intervals without P values .",由于次要终点的分析未针对多重比较进行调整，因此我们报告了没有 P 值的点估计值和 95% 置信区间。,0.1818181818181818,"['report', 'multiple', 'end points', 'secondary', 'values', 'confidence', 'P', 'and', 'without', 'intervals', 'we']","['report', 'end points']",823,"['由于二级终点的分析没有适用于多个比较,我们报告点估计和95%的信任间隔没有P值。']",0.1818181818181818,"['report', 'multiple', 'end points', 'secondary', 'values', 'confidence', 'P', 'and', 'without', 'intervals', 'we']","['report', 'end points']",,
829,824,"the 95 % confidence intervals have not been adjusted for multiple comparisons , and inference drawn from them may not be reproducible .",95% 置信区间未针对多重比较进行调整，从中得出的推论可能无法重现。,0.2857142857142857,"['multiple', 'be', 'inference', 'confidence', 'have not', 'and', 'intervals']","['inference', 'have not']",824,"['95%的信任间隔未适用于多个比较,并可能无法重复的结论。']",0.1428571428571428,"['multiple', 'be', 'inference', 'confidence', 'have not', 'and', 'intervals']",['have not'],,
830,825,"safety was monitored by assessment of adverse events and serious adverse events during treatment for 28 days after the discontinuation of trial drug , by review of clinical laboratory values , and by physical examinations .",通过评估停药后 28 天内治疗期间的不良事件和严重不良事件、审查临床实验室值和体格检查来监测安全性。,0.4375,"['safety', 'review', 'physical', 'adverse', 'assessment', 'treatment', 'clinical', 'examinations', 'after', 'trial', 'laboratory', 'values', 'drug', 'serious', 'by', 'and']","['safety', 'review', 'assessment', 'treatment', 'clinical', 'after', 'laboratory']",825,"['安全性通过在试用药物停止后28天进行治疗期间的副作用和严重副作用的评估,通过临床实验室值的审查和物理检查进行监测。']",0.5,"['safety', 'review', 'physical', 'adverse', 'assessment', 'treatment', 'clinical', 'examinations', 'after', 'trial', 'laboratory', 'values', 'drug', 'serious', 'by', 'and']","['safety', 'review', 'assessment', 'treatment', 'clinical', 'after', 'laboratory', 'drug']",,
831,826,the number and proportion of patients who received rescue therapy during trial treatment and the time to rescue therapy from the first dose during treatment were also reported .,还报告了试验治疗期间接受挽救治疗的患者人数和比例，以及治疗期间从第一次给药到挽救治疗的时间。,0.5,"['proportion', 'who', 'time', 'therapy', 'treatment', 'number', 'trial', 'dose', 'to', 'and', 'rescue', 'first']","['proportion', 'time', 'therapy', 'treatment', 'number', 'first']",826,['还报告了在试验期间接受救生疗法的患者数量和比例以及在治疗期间从第一剂量救生疗法的时间。'],0.5833333333333334,"['proportion', 'who', 'time', 'therapy', 'treatment', 'number', 'trial', 'dose', 'to', 'and', 'rescue', 'first']","['proportion', 'time', 'therapy', 'treatment', 'number', 'dose', 'first']",,
832,827,baseline CHARACTERISTICS OF THE PATIENTS,患者的基线特征,1.0,['baseline'],['baseline'],827,['病人的基本特征'],0.0,['baseline'],[],,
833,828,a total of 48 patients ( 42 in the roxadustat group and 6 in the epoetin alfa group ) discontinued the assigned medication .,共有 48 名患者（roxadustat 组 42 名和 epoetin alfa 组 6 名）停止了分配的药物治疗。,0.1428571428571428,"['group', 'a', 'total', 'medication', 'roxadustat', 'epoetin alfa', 'and']",['group'],828,['总共48名患者(Roxadustat组中有42人和Epoetin alfa组中有6人)停止服用药物。'],0.1428571428571428,"['group', 'a', 'total', 'medication', 'roxadustat', 'epoetin alfa', 'and']",['group'],,
834,829,the baseline characteristics of the patients were similar in the two groups ( Table 1 ) .,两组患者的基线特征相似（表1）。,0.8333333333333334,"['table', 'baseline', '1', 'characteristics', 'two', 'similar']","['table', 'baseline', '1', 'characteristics', 'two']",829,['患者的基本特征在两组中是相似的(图1)。'],0.6666666666666666,"['table', 'baseline', '1', 'characteristics', 'two', 'similar']","['1', 'characteristics', 'two', 'similar']",,
835,830,"overall , the mean hemoglobin level of the patients was 10.4 g per deciliter , and the mean dose of epoetin alfa was approximately 7500 units per week .",总体而言，患者的平均血红蛋白水平为 10.4 g/dL，而 epoetin alfa 的平均剂量约为每周 7500 单位。,0.5555555555555556,"['mean', 'hemoglobin', 'deciliter', 'hemoglobin level', 'week', 'epoetin alfa', 'dose', 'approximately', 'and']","['mean', 'hemoglobin', 'week', 'dose', 'and']",830,"['总体而言,患者的平均血糖水平为每分升104克,平均Epoetin alfa的剂量每周约为7500个单位。']",0.4444444444444444,"['mean', 'hemoglobin', 'deciliter', 'hemoglobin level', 'week', 'epoetin alfa', 'dose', 'approximately', 'and']","['mean', 'week', 'dose', 'and']",,
836,831,hemoglobin LEVELS,血红蛋白水平,1.0,['hemoglobin'],['hemoglobin'],831,['血球水平'],0.0,['hemoglobin'],[],,
837,832,"the percentage of patients with a mean hemoglobin level of at least 10.0 g per deciliter was 87.0 % in the roxadustat group ( 178 patients ) and 88.5 % in the epoetin alfa group ( 88 patients ) in weeks 23 through 27 ( treatment difference , − 0.1 percentage point ; 95 % CI , − 8.6 to 8.5 ) .",在第 23 周至第 27 周期间，罗沙司他组（178 名患者）平均血红蛋白水平至少为 10.0 g/dL 的患者百分比为 87.0%，阿法依泊汀组（88 名患者）为 88.5%（治疗差异，- 0.1个百分点；95% CI，- 8.6 至 8.5)。,0.4666666666666667,"['group', 'percentage', 'mean', 'hemoglobin', 'deciliter', 'difference', 'hemoglobin level', 'treatment', 'point', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to', 'and']","['group', 'mean', 'hemoglobin', 'difference', 'treatment', 'point', 'roxadustat']",832,"['在23至27周期间,平均血糖水平至少为10.0g的患者比例在Roxadustat群体(178名患者)和Epoetin alfa群体(88名患者)中为88.5%(治疗差异, − 0.1 个百分点, − 95 % CI, − 8.6 到 8.5 )。']",0.3333333333333333,"['group', 'percentage', 'mean', 'hemoglobin', 'deciliter', 'difference', 'hemoglobin level', 'treatment', 'point', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to', 'and']","['group', 'mean', 'difference', 'treatment', 'point']",,
838,833,"the treatment difference in the change in hemoglobin level was similar according to the ANCOVA multiple imputations ( increase in hemoglobin level , 0.7 ± 1.1 g per deciliter in the roxadustat group and 0.5 ± 1.0 g per deciliter in the epoetin alfa group ) .",根据 ANCOVA 多重插补，血红蛋白水平变化的治疗差异相似（血红蛋白水平增加，roxadustat 组为 0.7 ± 1.1 g/dL，epoetin alfa 组为 0.5 ± 1.0 g/dL）。,0.3571428571428571,"['group', 'hemoglobin', 'deciliter', 'multiple', 'difference', 'hemoglobin level', 'treatment', 'change', 'increase', 'roxadustat', 'epoetin alfa', 'to', 'and', 'similar']","['group', 'hemoglobin', 'difference', 'treatment', 'change']",833,"['血球水平的治疗差异是相似的,根据 ANCOVA 多种催化物(血球水平的增加,在 roxadustat 组中 0.7 ± 1.1 g 每分,在 epoetin alfa 组中 0.5 ± 1.0 g 每分)。']",0.2857142857142857,"['group', 'hemoglobin', 'deciliter', 'multiple', 'difference', 'hemoglobin level', 'treatment', 'change', 'increase', 'roxadustat', 'epoetin alfa', 'to', 'and', 'similar']","['group', 'difference', 'treatment', 'similar']",,
839,834,"at baseline , the mean hepcidin level was 180.7 ± 136.8 ng per milliliter in the roxadustat group and 148.3 ± 104.2 ng per milliliter in the epoetin alfa group .",基线时，roxadustat 组的平均铁调素水平为 180.7 ± 136.8 ng/mL，而 epoetin alfa 组为 148.3 ± 104.2 ng/mL。,0.7142857142857143,"['group', 'mean', 'baseline', 'level', 'roxadustat', 'epoetin alfa', 'and']","['group', 'mean', 'baseline', 'level', 'and']",834,"['在基线上,每毫升的平均肝素水平为180.7 ± 136.8 ng 在罗克萨多斯塔特群体和148.3 ± 104.2 ng 在阿尔法群体中。']",0.5714285714285714,"['group', 'mean', 'baseline', 'level', 'roxadustat', 'epoetin alfa', 'and']","['group', 'mean', 'baseline', 'level']",,
840,835,"at week 27 , the change from baseline was − 30.2 ± 113.3 ng per milliliter ( 95 % CI , − 64.8 to − 13.6 ) in the roxadustat group and − 2.3 ± 130.7 ng per milliliter ( 95 % CI , − 51.6 to 6.2 ) in the epoetin alfa group ( Figure 1B ) .",第 27 周时，罗沙司他组相对于基线的变化为 − 30.2 ± 113.3 ng/mL（ 95 % CI ， − 64.8 至 − 13.6 ），而epoetin alfa 组（图 1B）。,0.7,"['group', 'baseline', 'figure', 'week', 'change', 'roxadustat', 'epoetin alfa', 'CI', 'to', 'and']","['group', 'baseline', 'week', 'change', 'roxadustat', 'to', 'and']",835,"['在第27周,从基线的变化是 − 30.2 ± 113.3 ng 每毫升(95 % CI, − 64.8 至 − 13.6)在 roxadustat 组和 − 2.3 ± 130.7 ng 每毫升(95 % CI, − 51.6 至 6.2)在 epoetin 阿尔法 组(图 1B ) 。']",0.4,"['group', 'baseline', 'figure', 'week', 'change', 'roxadustat', 'epoetin alfa', 'CI', 'to', 'and']","['group', 'baseline', 'week', 'change']",,
841,836,this resulted in a greater decline in transferrin saturation in the epoetin alfa group than in the roxadustat group .,这导致 epoetin alfa 组的转铁蛋白饱和度下降幅度大于罗沙司他组。,0.625,"['group', 'decline', 'a', 'transferrin', 'saturation', 'roxadustat', 'epoetin alfa', 'this']","['group', 'decline', 'transferrin', 'saturation', 'roxadustat']",836,"['这导致在epoetin alfa群体中的转移林饱和度下降,而不是在roxadustat群体中。']",0.5,"['group', 'decline', 'a', 'transferrin', 'saturation', 'roxadustat', 'epoetin alfa', 'this']","['group', 'decline', 'saturation', 'this']",,
842,837,"the mean change in the mean arterial pressure from baseline to the average value during weeks 23 through 27 was − 2.1 mm Hg in the roxadustat group and − 0.7 mm Hg in the epoetin alfa group ( difference , − 1.4 mm Hg ; 95 % CI , − 3.7 to 1.0 ) .",在第 23 周至第 27 周期间，平均动脉压从基线到平均值的平均变化在罗沙司他组为 − 2.1 mm Hg，在阿法依泊汀组为 − 0.7 mm Hg（差异，− 1.4 mm Hg；95% CI， − 3.7 至 1.0)。,0.6666666666666666,"['group', 'arterial pressure', 'mean', 'average', 'baseline', 'value', 'difference', 'change', 'average value', 'roxadustat', 'epoetin alfa', 'mean arterial pressure', 'CI', 'to', 'and']","['group', 'arterial pressure', 'mean', 'average', 'baseline', 'difference', 'change', 'average value', 'roxadustat', 'mean arterial pressure']",837,"['从基线到平均值的平均血压在23至27周的平均变化是 − 2.1 mm Hg 在 roxadustat 组和 − 0.7 mm Hg 在 epoetin alfa 组(差异, − 1.4 mm Hg ; 95 % CI, − 3.7 至 1.0 ) 。']",0.4666666666666667,"['group', 'arterial pressure', 'mean', 'average', 'baseline', 'value', 'difference', 'change', 'average value', 'roxadustat', 'epoetin alfa', 'mean arterial pressure', 'CI', 'to', 'and']","['group', 'mean', 'average', 'baseline', 'difference', 'change', 'average value']",,
843,838,"during treatment , 67 patients ( 32.8 % ) in the roxadustat group received oral iron therapy , as compared with 43 ( 43.0 % ) in the epoetin alfa group .",在治疗期间，roxadustat 组中有 67 名患者 (32.8%) 接受了口服铁剂治疗，而 epoetin alfa 组中有 43 名患者 (43.0%) 接受了口服铁剂治疗。,0.4444444444444444,"['group', 'oral', 'therapy', 'treatment', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron']","['group', 'therapy', 'treatment', 'iron']",838,"['在治疗期间,Roxadustat组的67名患者(32.8%)接受了口服铁治疗,与Epoetin alfa组的43名患者(43.0%)相比。']",0.4444444444444444,"['group', 'oral', 'therapy', 'treatment', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron']","['group', 'therapy', 'treatment', 'iron']",,
844,839,"there was a 14 % improvement from baseline in the LDL : HDL cholesterol ratio with roxadustat as compared with epoetin alfa ( − 0.32 ± 0.89 ; 95 % CI for treatment difference , − 0.50 to − 0.17 ) .",与 epoetin alfa 相比，罗沙司他的低密度脂蛋白：高密度脂蛋白胆固醇比基线有 14% 的改善（- 0.32 ± 0.89；治疗差异的 95% CI，- 0.50 至 - 0.17）。,0.6428571428571429,"['cholesterol', 'improvement', 'a', 'baseline', 'ratio', 'HDL', 'difference', 'LDL', 'treatment', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to']","['cholesterol', 'improvement', 'baseline', 'ratio', 'HDL', 'difference', 'LDL', 'treatment', 'roxadustat']",839,"['在 LDL 的基线上有 14% 的改善: HDL 与 roxadustat 的胆固醇比例与 epoetin alfa 相比( − 0.32 ± 0.89 ; 治疗差异的 95% CI, − 0.50 至 − 0.17 ) 。']",0.4285714285714285,"['cholesterol', 'improvement', 'a', 'baseline', 'ratio', 'HDL', 'difference', 'LDL', 'treatment', 'with', 'roxadustat', 'epoetin alfa', 'CI', 'to']","['cholesterol', 'improvement', 'baseline', 'ratio', 'difference', 'treatment']",,
845,840,"in addition , there was a mean treatment difference between the roxadustat group and the epoetin alfa group of − 12.4 ± 9.7 mg per deciliter ( − 0.14 ± 0.11 mmol per liter ) in the decrease in triglyceride level .",此外，roxadustat 组和 epoetin alfa 组之间在甘油三酯水平降低方面的平均治疗差异为 − 12.4 ± 9.7 mg/dL（− 0.14 ± 0.11 mmol/L）。,0.4285714285714285,"['triglyceride', 'group', 'a', 'decrease', 'mean', 'liter', 'deciliter', 'addition', 'difference', 'treatment', 'level', 'roxadustat', 'epoetin alfa', 'and']","['triglyceride', 'group', 'mean', 'difference', 'treatment', 'level']",840,"['除此之外,Roxadustat 组和 Epoetin 阿尔法 组之间的治疗差异为 − 12.4 ± 9.7 mg 每分升( − 0.14 ± 0.11 mmol 每升)的三酯水平下降。']",0.3571428571428571,"['triglyceride', 'group', 'a', 'decrease', 'mean', 'liter', 'deciliter', 'addition', 'difference', 'treatment', 'level', 'roxadustat', 'epoetin alfa', 'and']","['group', 'liter', 'difference', 'treatment', 'level']",,
846,841,markers OF INFLAMMATION,炎症标志物,,[],[],841,['炎症标志'],,[],[],,
847,842,a total of 159 of 204 patients ( 77.9 % ) treated with roxadustat and 63 of 100 patients ( 63.0 % ) treated with epoetin alfa reported having at least one adverse event during treatment .,接受 roxadustat 治疗的 204 名患者中的 159 名 (77.9%) 和接受 epoetin alfa 治疗的 100 名患者中的 63 名 (63.0%) 报告在治疗期间至少有一次不良事件。,0.2222222222222222,"['a', 'total', 'adverse', 'treatment', 'adverse event', 'with', 'roxadustat', 'epoetin alfa', 'and']","['treatment', 'adverse event']",842,['共有159名204名(77.9%)用Roxadustat治疗的患者和100名(63.0%)用Epoetin alfa治疗的患者中有63名报告在治疗期间至少有1个副作用。'],0.1111111111111111,"['a', 'total', 'adverse', 'treatment', 'adverse event', 'with', 'roxadustat', 'epoetin alfa', 'and']",['treatment'],,
848,843,"the most frequently reported event was upper respiratory infection , which occurred in 37 patients ( 18.1 % ) in the roxadustat group and in 11 ( 11.0 % ) in the epoetin alfa group .",最常报告的事件是上呼吸道感染，罗沙司他组有 37 名患者 (18.1%)，阿法依泊汀组有 11 名患者 (11.0%)。,0.3333333333333333,"['infection', 'group', 'frequently', 'upper', 'respiratory', 'roxadustat', 'epoetin alfa', 'event', 'and']","['infection', 'group', 'roxadustat']",843,"['最常报告的事件是上呼吸道感染,发生在37名患者(18.1%)在罗克萨多斯特群体和11名患者(11.0%)在阿尔法群体中。']",0.2222222222222222,"['infection', 'group', 'frequently', 'upper', 'respiratory', 'roxadustat', 'epoetin alfa', 'event', 'and']","['infection', 'group']",,
849,844,a total of 29 patients ( 14.2 % ) treated with roxadustat and 10 ( 10.0 % ) treated with epoetin alfa reported having at least one serious adverse event during treatment .,共有 29 名接受 roxadustat 治疗的患者 (14.2%) 和 10 名 (10.0%) 接受 epoetin alfa 治疗的患者报告在治疗期间至少发生一次严重不良事件。,0.25,"['a', 'serious adverse event', 'total', 'treatment', 'with', 'roxadustat', 'epoetin alfa', 'and']","['serious adverse event', 'treatment']",844,['共 29 名( 14.2 % )用 roxadustat 和 10 (10.0 % )用 epoetin alfa 治疗的患者报告在治疗期间至少有 1 个严重的副作用。'],0.125,"['a', 'serious adverse event', 'total', 'treatment', 'with', 'roxadustat', 'epoetin alfa', 'and']",['treatment'],,
850,845,adverse events that occurred in at least 5 % of the patients in either group are listed in Table 3 .,表 3 列出了两组中至少 5% 的患者发生的不良事件。,0.375,"['group', '5', 'table', 'adverse', '3', 'at', 'that', 'in']","['group', '5', 'table']",845,"['在任何群体中至少有5%的患者中发生的副作用,列入表3。']",0.375,"['group', '5', 'table', 'adverse', '3', 'at', 'that', 'in']","['group', '5', 'table']",,
851,846,"on the basis of central laboratory assessments of blood samples obtained at baseline ( week 1 ) and every 4 weeks , the mean changes in potassium level were as follows : at week 5 , a change of 0.12 mmol per liter in the roxadustat group and 0.01 mmol per liter in the epoetin alfa group ; at week 13 , a change of − 0.04 mmol per liter and − 0.01 mmol per liter , respectively ; and at week 21 , a change of − 0.07 mmol per liter and − 0.02 mmol per liter , respectively .",根据中央实验室对基线（第 1 周）和每 4 周采集的血样进行的评估，血钾水平的平均变化如下：第 5 周时，roxadustat 组每升变化 0.12 毫摩尔，每升变化 0.01 毫摩尔每升在 epoetin alfa 组中；在第 13 周，变化分别为 − 0.04 mmol/L 和 − 0.01 mmol/L ；在第 21 周，变化分别为 − 0.07 mmol/L 和 − 0.02 mmol/L。,0.55,"['group', '5', 'a', 'mean', 'liter', 'baseline', '1', 'potassium', 'blood', 'basis', 'central', 'week', 'laboratory', '4', 'level', 'change', 'roxadustat', 'epoetin alfa', 'on', 'and']","['group', '5', 'mean', 'liter', 'baseline', '1', 'potassium', 'week', 'laboratory', 'level', 'change']",846,"['基于基线(第1周)和每4周获得的血液样本的中央实验室评估,<unk>水平的平均变化如下:第5周,<unk>分组每升 0.12 mmol 和<unk>分组每升 0.01 mmol;第13周,每升 - 0.04 mmol 和每升 - 0.01 mmol 分别;第21周,每升 - 0.07 mmol 和每升 - 0.02 mmol 分别。']",0.55,"['group', '5', 'a', 'mean', 'liter', 'baseline', '1', 'potassium', 'blood', 'basis', 'central', 'week', 'laboratory', '4', 'level', 'change', 'roxadustat', 'epoetin alfa', 'on', 'and']","['group', '5', 'mean', 'liter', 'baseline', '1', 'blood', 'week', 'laboratory', 'level', 'change']",,
852,847,"the proportion of patients with potassium values within categories from 5.5 mmol per liter or less , more than 5.5 to 6.0 mmol per liter , more than 6.0 to 6.5 mmol per liter , and more than 6.5 mmol per liter at baseline and at weeks 13 and 27 were generally similar in the treatment groups ( Table S4 in the Supplementary Appendix ) .",在基线以及第 13 周和第 27 周时钾值在 5.5 毫摩尔/升或以下、超过 5.5 至 6.0 毫摩尔/升、超过 6.0 至 6.5 毫摩尔/升以及超过 6.5 毫摩尔/升的类别中的患者比例治疗组的总体相似性（补充附录表 S4）。,0.4,"['proportion', 'appendix', 'liter', 'table', 'baseline', 'potassium', 'categories', 'supplementary', 'treatment', 'values', 'with', 'S4', 'to', 'and', 'similar']","['proportion', 'liter', 'table', 'baseline', 'potassium', 'treatment']",847,"['在每升5,5 mmol或更少的类别内,<unk>值患者的比例,每升5,5 mmol以上至6.0 mmol以上,每升6.0 mmol以上至6,5 mmol以上,在基线上每升6,5 mmol以上,在13周和27周,一般类似于治疗小组(附件中的S4表)。']",0.4666666666666667,"['proportion', 'appendix', 'liter', 'table', 'baseline', 'potassium', 'categories', 'supplementary', 'treatment', 'values', 'with', 'S4', 'to', 'and', 'similar']","['proportion', 'appendix', 'liter', 'table', 'baseline', 'treatment', 'to']",,
853,848,the percentage of patients who received rescue therapy or who did not reach the lower end of the hemoglobin target range ( 10 g per deciliter ) did not differ substantially between groups .,接受挽救治疗或未达到血红蛋白目标范围下限（10 克/分升）的患者百分比在各组之间没有显着差异。,0.3333333333333333,"['percentage', 'range', 'who', 'hemoglobin', 'deciliter', 'lower', 'therapy', 'differ', 'target', 'end', 'rescue', 'reach']","['range', 'hemoglobin', 'therapy', 'target']",848,['接受救生疗法或未达到血球目标范围(每分克10g)的低端患者的比例在群体之间没有显著差异。'],0.25,"['percentage', 'range', 'who', 'hemoglobin', 'deciliter', 'lower', 'therapy', 'differ', 'target', 'end', 'rescue', 'reach']","['range', 'therapy', 'target']",,
854,849,"inflammation is known to increase the hepcidin level , resulting in functional iron deficiency .",众所周知，炎症会增加铁调素水平，导致功能性缺铁。,0.5,"['iron deficiency', 'inflammation', 'functional', 'level', 'increase', 'to']","['iron deficiency', 'inflammation', 'level']",849,"['炎症已知增加肝炎水平,导致功能铁缺乏。']",0.5,"['iron deficiency', 'inflammation', 'functional', 'level', 'increase', 'to']","['iron deficiency', 'inflammation', 'level']",,
855,850,the use of intravenous iron therapy was restricted in both groups - a design that was based on the previous observation that oral iron therapy provided results equivalent to those of intravenous iron therapy with roxadustat.34,两组均限制静脉铁剂治疗的使用——这一设计基于之前的观察结果，即口服铁剂治疗提供的结果与罗沙司他静脉铁剂治疗的结果相同。 34,0.3846153846153846,"['a', 'equivalent', 'oral', 'previous', 'therapy', 'intravenous', 'design', 'observation', 'with', 'iron', '-', 'that', 'to']","['therapy', 'design', 'observation', 'iron', 'to']",850,"['在两组中使用 intravenous iron therapy 是有限的 - 一个设计是基于以前的观察,口腔铁疗法提供了与 roxadustat 的 intravenous iron therapy 相同的结果。']",0.4615384615384615,"['a', 'equivalent', 'oral', 'previous', 'therapy', 'intravenous', 'design', 'observation', 'with', 'iron', '-', 'that', 'to']","['previous', 'therapy', 'design', 'observation', 'iron', 'to']",,
856,851,the mechanism of action of epoetin alfa is limited to stimulation of the erythropoietin receptor ; oral iron is expected to be ineffective relative to intravenous iron with epoetin alfa in the treatment of anemia in patients undergoing dialysis.35,epoetin alfa 的作用机制仅限于刺激促红细胞生成素受体；在治疗透析患者的贫血方面，口服铁剂预计与静脉注射铁剂和阿法依泊汀相比无效。 35,0.625,"['anemia', 'receptor', 'stimulation', 'mechanism', 'erythropoietin', 'oral', 'relative', 'action', 'be', 'mechanism of action', 'treatment', 'intravenous', 'with', 'epoetin alfa', 'iron', 'limited']","['anemia', 'receptor', 'stimulation', 'mechanism', 'erythropoietin', 'action', 'be', 'mechanism of action', 'treatment', 'iron']",851,['epoetin alfa的作用机制仅限于激发 erythropoietin 受体;预计口腔铁与 intravenous 铁与 epoetin alfa 无血病患者的治疗中将不有效。'],0.375,"['anemia', 'receptor', 'stimulation', 'mechanism', 'erythropoietin', 'oral', 'relative', 'action', 'be', 'mechanism of action', 'treatment', 'intravenous', 'with', 'epoetin alfa', 'iron', 'limited']","['receptor', 'mechanism', 'action', 'mechanism of action', 'treatment', 'iron']",,
857,852,"overall , changes in iron biomarker levels showed improvement with roxadustat as compared with epoetin alfa .",总体而言，与阿法依泊汀相比，罗沙司他铁生物标志物水平的变化有所改善。,0.5714285714285714,"['improvement', 'biomarker', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron']","['improvement', 'biomarker', 'roxadustat', 'iron']",852,"['总体而言,铁生物标记水平的变化表明,与epoetin alfa相比,roxadustat有所改善。']",0.2857142857142857,"['improvement', 'biomarker', 'as', 'with', 'roxadustat', 'epoetin alfa', 'iron']","['improvement', 'iron']",,
858,853,"the serum iron level is strongly affected by the serum transferrin level , which is increased with roxadustat .",血清铁水平受血清转铁蛋白水平的强烈影响，而罗沙司他会增加血清铁水平。,0.7142857142857143,"['transferrin', 'serum', 'level', 'with', 'roxadustat', 'iron', 'by']","['transferrin', 'serum', 'level', 'roxadustat', 'iron']",853,"['血清铁的水平受到血清转移素的水平的强烈影响,这与罗克萨德斯塔特增加。']",0.4285714285714285,"['transferrin', 'serum', 'level', 'with', 'roxadustat', 'iron', 'by']","['serum', 'level', 'iron']",,
859,854,"the attenuation of the decrease in transferrin saturation with roxadustat as compared with epoetin alfa , despite the increase in transferrin level , supports an effect on enteric iron absorption with roxadustat .",尽管转铁蛋白水平增加，但与阿法依泊汀相比，罗沙司他转铁蛋白饱和度降低的减弱支持罗沙司他对肠内铁吸收的影响。,0.4285714285714285,"['attenuation', 'transferrin', 'decrease', 'absorption', 'enteric', 'saturation', 'effect', 'level', 'increase', 'with', 'despite', 'roxadustat', 'epoetin alfa', 'iron']","['transferrin', 'absorption', 'saturation', 'level', 'roxadustat', 'iron']",854,"['与epoetin alfa相比,转移林饱和量下降的减轻,尽管转移林水平上升,但支持与 roxadustat的内在铁吸收的影响。']",0.2857142857142857,"['attenuation', 'transferrin', 'decrease', 'absorption', 'enteric', 'saturation', 'effect', 'level', 'increase', 'with', 'despite', 'roxadustat', 'epoetin alfa', 'iron']","['absorption', 'saturation', 'level', 'iron']",,
860,855,improvements in iron delivery to the bone marrow could result in a reduced use of intravenous iron therapy and an increased efficacy of oral iron therapy .,铁输送到骨髓的改善可能会减少静脉铁剂治疗的使用，并提高口服铁剂治疗的疗效。,0.3636363636363636,"['bone', 'bone marrow', 'oral', 'delivery', 'therapy', 'efficacy', 'intravenous', 'result', 'iron', 'to', 'and']","['bone', 'bone marrow', 'therapy', 'iron']",855,"['向骨头发送铁的改进可能导致 intravenous iron therapy 的使用减少,以及口服 iron therapy 的有效性增加。']",0.2727272727272727,"['bone', 'bone marrow', 'oral', 'delivery', 'therapy', 'efficacy', 'intravenous', 'result', 'iron', 'to', 'and']","['bone', 'efficacy', 'iron']",,
861,856,the adverse events during treatment that we observed are consistent with those expected in patients undergoing dialysis .,我们在治疗期间观察到的不良事件与透析患者的预期一致。,0.2857142857142857,"['dialysis', 'adverse', 'treatment', 'with', 'that', 'in', 'we']","['dialysis', 'treatment']",856,['我们所观察到的治疗期间的副作用与患有分裂症患者的预期相一致。'],0.1428571428571428,"['dialysis', 'adverse', 'treatment', 'with', 'that', 'in', 'we']",['treatment'],,
862,857,hyperkalemia was reported more often in patients who received roxadustat than in those who received epoetin alfa .,接受罗沙司他治疗的患者比接受阿法依泊汀治疗的患者更常报告高钾血症。,0.5,"['who', 'hyperkalemia', 'roxadustat', 'epoetin alfa']","['hyperkalemia', 'roxadustat']",857,"['甲状腺高血病在Roxadustat患者中更为常见,而在Epoetin alfa患者中更为常见。']",0.0,"['who', 'hyperkalemia', 'roxadustat', 'epoetin alfa']",[],,
863,858,analyses of central laboratory data did not show any clinically significant changes in the mean potassium levels over time or between groups .,对中心实验室数据的分析未显示平均钾水平随时间或组间发生任何临床显着变化。,0.625,"['mean', 'data', 'potassium', 'time', 'central', 'laboratory', 'in', 'over']","['mean', 'data', 'potassium', 'time', 'laboratory']",858,['中央实验室数据的分析没有显示中间<unk>水平的临床上有意义的变化。'],0.25,"['mean', 'data', 'potassium', 'time', 'central', 'laboratory', 'in', 'over']","['data', 'laboratory']",,
864,859,"the intermittent central laboratory monitoring may not have detected potassium elevations , and therefore continued evaluation will be important in presently ongoing trials ( ClinicalTrials.gov numbers , NCT02052310and NCT02273726 ) and as wider experience with roxadustat occurs .",间歇性中央实验室监测可能未检测到钾升高，因此在目前正在进行的试验（ClinicalTrials.gov 编号，NCT02052310 和 NCT02273726）中以及随着罗沙司他的更广泛经验的出现，持续评估将很重要。,0.5,"['monitoring', 'potassium', 'evaluation', 'intermittent', 'be', 'central', 'laboratory', 'experience', 'will', 'with', 'roxadustat', 'have', 'therefore', 'and']","['monitoring', 'potassium', 'intermittent', 'be', 'laboratory', 'experience', 'roxadustat']",859,"['中央实验室间隔监测可能没有发现<unk>升高,因此在目前正在进行的试验(ClinicalTrials.gov 号码、NCT02052310和NCT02273726 )中,继续进行评估,并且由于与 roxadustat 更广泛的经验发生。']",0.3571428571428571,"['monitoring', 'potassium', 'evaluation', 'intermittent', 'be', 'central', 'laboratory', 'experience', 'will', 'with', 'roxadustat', 'have', 'therefore', 'and']","['monitoring', 'be', 'laboratory', 'experience', 'have']",,
865,860,more patients receiving roxadustat discontinued treatment owing to adverse events than did patients receiving epoetin alfa .,接受 roxadustat 的患者因不良事件而停止治疗的患者多于接受 epoetin alfa 的患者。,0.4,"['adverse', 'treatment', 'roxadustat', 'epoetin alfa', 'to']","['treatment', 'to']",860,['因不良事件而接受Roxadustat的患者比接受Epoetin alfa的患者中断了治疗。'],0.2,"['adverse', 'treatment', 'roxadustat', 'epoetin alfa', 'to']",['treatment'],,
866,861,no clustering of severe adverse events during treatment was observed in either group .,两组在治疗期间均未观察到聚集性严重不良事件。,0.3333333333333333,"['group', 'clustering', 'adverse', 'treatment', 'no', 'severe']","['group', 'treatment']",861,"['在任何群体中,在治疗期间没有出现严重的副作用。']",0.3333333333333333,"['group', 'clustering', 'adverse', 'treatment', 'no', 'severe']","['group', 'treatment']",,
867,862,"in conclusion , this phase 3 trial comparing 26 weeks of roxadustat therapy with epoetin alfa therapy in patients undergoing dialysis showed the noninferiority of roxadustat in the treatment of anemia .",总之，这项在接受透析的患者中比较 26 周罗沙司他疗法与阿法依泊汀疗法的 3 期试验表明，罗沙司他在治疗贫血方面具有非劣效性。,0.5,"['anemia', 'dialysis', 'phase', 'therapy', 'treatment', 'trial', '3', 'conclusion', 'with', 'roxadustat', 'epoetin alfa', 'this']","['anemia', 'dialysis', 'phase', 'therapy', 'treatment', 'roxadustat']",862,"['在结论中,这段阶段3试验与26周的罗克萨多斯特治疗与阿尔法治疗的病人进行对话,表明罗克萨多斯特在治疗贫血时不低。']",0.4166666666666667,"['anemia', 'dialysis', 'phase', 'therapy', 'treatment', 'trial', '3', 'conclusion', 'with', 'roxadustat', 'epoetin alfa', 'this']","['anemia', 'phase', 'therapy', 'treatment', 'conclusion']",,
868,863,"antibiotics are associated with CRC risk , but the effect depends on anatomical location and type of antibiotic .",抗生素与 CRC 风险相关，但效果取决于解剖位置和抗生素类型。,0.6363636363636364,"['anatomical', 'type', 'antibiotic', 'location', 'associated', 'risk', 'effect', 'antibiotics', 'with', 'but', 'and']","['type', 'antibiotic', 'location', 'risk', 'effect', 'antibiotics', 'but']",863,"['抗生素与CRC风险有关,但效果取决于抗生素的解剖位置和类型。']",0.6363636363636364,"['anatomical', 'type', 'antibiotic', 'location', 'associated', 'risk', 'effect', 'antibiotics', 'with', 'but', 'and']","['type', 'antibiotic', 'location', 'risk', 'effect', 'antibiotics', 'but']",,
869,864,alterations of the gut microbiome can increase colorectal cancer ( CRC ) risk via bacteria that cause local inflammation and promote carcinogenesis .,肠道微生物组的改变可以通过引起局部炎症和促进癌变的细菌增加结直肠癌 (CRC) 的风险。,0.5333333333333333,"['microbiome', 'carcinogenesis', 'bacteria', 'cancer', 'gut', 'gut microbiome', 'inflammation', 'via', 'colorectal cancer', 'local', 'cause', 'risk', 'increase', 'that', 'and']","['microbiome', 'bacteria', 'cancer', 'gut', 'gut microbiome', 'inflammation', 'local', 'risk']",864,['肠道微生物的变化可以通过导致本地炎症并促进癌症的细菌来增加染色性癌症(CRC)的风险。'],0.3333333333333333,"['microbiome', 'carcinogenesis', 'bacteria', 'cancer', 'gut', 'gut microbiome', 'inflammation', 'via', 'colorectal cancer', 'local', 'cause', 'risk', 'increase', 'that', 'and']","['bacteria', 'cancer', 'gut', 'inflammation', 'risk']",,
870,865,"previous studies suggest an association between CRC and exposure to antibiotics , but this remains insufficiently characterized .",先前的研究表明 CRC 与接触抗生素之间存在关联，但这仍未得到充分表征。,0.3333333333333333,"['exposure', 'association', 'previous', 'antibiotics', 'suggest', 'this', 'but', 'to', 'and']","['association', 'antibiotics', 'but']",865,"['以前的研究表明CRC与抗生素暴露之间的联系,但这一点仍然不够特征。']",0.5555555555555556,"['exposure', 'association', 'previous', 'antibiotics', 'suggest', 'this', 'but', 'to', 'and']","['exposure', 'association', 'previous', 'antibiotics', 'but']",,
871,866,"using a large clinical research database in the U.K. , researchers compared antibiotic exposure in 28,980 sporadic CRC cases and 137,077 matched controls .","使用英国的大型临床研究数据库，研究人员比较了 28,980 例散发性 CRC 病例和 137,077 例匹配对照的抗生素暴露情况。",0.4444444444444444,"['antibiotic', 'research', 'database', 'exposure', 'large', 'clinical', 'sporadic', 'controls', 'and']","['antibiotic', 'research', 'exposure', 'clinical']",866,"['使用在英国的大型临床研究数据库,研究人员比较了抗生素暴露在28980例随机的CRC病例和13777匹配的检查。']",0.4444444444444444,"['antibiotic', 'research', 'database', 'exposure', 'large', 'clinical', 'sporadic', 'controls', 'and']","['antibiotic', 'research', 'exposure', 'clinical']",,
872,867,the analysis was adjusted for demographic and clinical factors associated with CRC risk .,该分析针对与 CRC 风险相关的人口统计和临床因素进行了调整。,0.5,"['analysis', 'associated', 'clinical', 'risk', 'with', 'and']","['analysis', 'clinical', 'risk']",867,['分析对与CRC风险相关的人口和临床因素进行了调整。'],0.5,"['analysis', 'associated', 'clinical', 'risk', 'with', 'and']","['analysis', 'clinical', 'risk']",,
873,868,antibiotic exposure was comparable between those with rectal cancer and controls ( 67.1 % and 67.2 % ) .,直肠癌患者和对照组的抗生素暴露情况相当（67.1% 和 67.2%）。,0.5714285714285714,"['antibiotic', 'cancer', 'exposure', 'rectal cancer', 'controls', 'with', 'and']","['antibiotic', 'cancer', 'exposure', 'rectal cancer']",868,['抗生素暴露在直肠癌和控制症(67.1%和67.2%)的人之间是相似的。'],0.5714285714285714,"['antibiotic', 'cancer', 'exposure', 'rectal cancer', 'controls', 'with', 'and']","['antibiotic', 'cancer', 'exposure', 'rectal cancer']",,
874,869,tetracyclines were associated with decreased rectal cancer risk .,四环素与直肠癌风险降低有关。,0.6,"['cancer', 'rectal cancer', 'associated', 'risk', 'with']","['cancer', 'rectal cancer', 'risk']",869,['泰特拉西克林与直肠癌风险降低有关。'],0.6,"['cancer', 'rectal cancer', 'associated', 'risk', 'with']","['cancer', 'rectal cancer', 'risk']",,
875,870,these results provide useful information for patients who are contemplating quitting .,这些结果为正在考虑戒烟的患者提供了有用的信息。,0.5,"['who', 'information']",['information'],870,['这些结果为正在考虑退休的患者提供有用的信息。'],0.5,"['who', 'information']",['information'],,
876,871,"moreover , recent retrospective studies have suggested that lipophilic statins ( atorvastatin , lovastatin , simvastatin ) prevent HCC more effectively than hydrophilic statins ( pravastatin , rosuvastatin ) .",此外，最近的回顾性研究表明，亲脂性他汀类药物（阿托伐他汀、洛伐他汀、辛伐他汀）比亲水性他汀类药物（普伐他汀、瑞舒伐他汀）更能有效地预防 HCC。,0.5384615384615384,"['lipophilic', 'recent', 'statins', 'pravastatin', 'retrospective studies', 'prevent', 'rosuvastatin', 'simvastatin', 'lovastatin', 'atorvastatin', 'hydrophilic', 'have', 'that']","['statins', 'prevent', 'rosuvastatin', 'simvastatin', 'lovastatin', 'atorvastatin', 'have']",871,"['此外,最近的回顾研究表明,脂肪静脉(Atorvastatin、Lovastatin、Symvastatin)比水素静脉(Pravastatin、Rosuvastatin)更有效地预防HCC。']",0.1538461538461538,"['lipophilic', 'recent', 'statins', 'pravastatin', 'retrospective studies', 'prevent', 'rosuvastatin', 'simvastatin', 'lovastatin', 'atorvastatin', 'hydrophilic', 'have', 'that']","['prevent', 'have']",,
877,872,statin use data were obtained from the Swedish Prescribed Drug Register .,他汀类药物使用数据来自瑞典处方药登记处。,0.5,"['statin', 'data', 'drug', 'register']","['data', 'drug']",872,['斯塔丁使用数据从瑞典处方药登记簿中获取。'],0.25,"['statin', 'data', 'drug', 'register']",['data'],,
878,873,"this nationwide Swedish registry study showed that among patients with viral hepatitis , lipophilic statin use reduced HCC risk but hydrophilic statin use did not .",这项全国范围的瑞典登记研究表明，在病毒性肝炎患者中，使用亲脂性他汀类药物可降低 HCC 风险，但使用亲水性他汀类药物则不能。,0.3076923076923077,"['statin', 'lipophilic', 'study', 'hepatitis', 'registry', 'risk', 'viral', 'with', 'viral hepatitis', 'hydrophilic', 'this', 'that', 'but']","['hepatitis', 'risk', 'viral hepatitis', 'but']",873,"['这项全国性瑞典注册表研究表明,患有病毒性肝炎的患者中,<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性']",0.1538461538461538,"['statin', 'lipophilic', 'study', 'hepatitis', 'registry', 'risk', 'viral', 'with', 'viral hepatitis', 'hydrophilic', 'this', 'that', 'but']","['hepatitis', 'viral hepatitis']",,
879,874,future studies should focus on the feasibility of lipophilic statins as an HCC prevention tool in patients with chronic liver disease .,未来的研究应侧重于亲脂性他汀类药物作为慢性肝病患者 HCC 预防工具的可行性。,0.6363636363636364,"['focus', 'liver', 'disease', 'lipophilic', 'statins', 'prevention', 'liver disease', 'chronic', 'tool', 'with', 'feasibility']","['liver', 'disease', 'statins', 'prevention', 'liver disease', 'chronic', 'tool']",874,['未来的研究应专注于患有慢性肝脏疾病的患者的HCC预防工具的脂肪静脉的可行性。'],0.4545454545454545,"['focus', 'liver', 'disease', 'lipophilic', 'statins', 'prevention', 'liver disease', 'chronic', 'tool', 'with', 'feasibility']","['liver', 'disease', 'prevention', 'chronic', 'tool']",,
880,875,past and present studies now not only confirm the safety of statin use in liver disease but also its potential benefit in reducing HCC risk .,过去和现在的研究现在不仅证实了他汀类药物在肝病中使用的安全性，而且证实了它在降低 HCC 风险方面的潜在益处。,0.6666666666666666,"['safety', 'statin', 'liver', 'disease', 'potential', 'liver disease', 'risk', 'present', 'benefit', 'but', 'and', 'past']","['safety', 'liver', 'disease', 'liver disease', 'risk', 'present', 'but', 'and']",875,"['过去和目前的研究现在不仅证实了在肝脏疾病中使用静素的安全性,而且降低HCC风险的潜在好处。']",0.5833333333333334,"['safety', 'statin', 'liver', 'disease', 'potential', 'liver disease', 'risk', 'present', 'benefit', 'but', 'and', 'past']","['safety', 'liver', 'disease', 'risk', 'present', 'but', 'and']",,
881,876,dietary factors have been implicated for many years as potential pathophysiologic triggers in the development of type 1 diabetes ( T1D ) .,多年来，饮食因素一直被认为是 1 型糖尿病 (T1D) 发展的潜在病理生理诱因。,0.4444444444444444,"['diabetes', 'type', '1', 'potential', 'dietary', 'development', 'as', 'have', 'in']","['diabetes', 'type', '1', 'development']",876,"['多年来,营养因素参与了1型糖尿病(T1D)的发展潜在的病理发育因素。']",0.5555555555555556,"['diabetes', 'type', '1', 'potential', 'dietary', 'development', 'as', 'have', 'in']","['diabetes', 'type', '1', 'potential', 'development']",,
882,877,this is the first study to report associations between intake of specific cereals and IA in children genetically predisposed to T1D .,这是第一项报告遗传易患 T1D 的儿童摄入特定谷物与 IA 之间关联的研究。,0.3333333333333333,"['intake', 'report', 'study', 'IA', 'specific', 'this', 'to', 'and', 'first']","['report', 'this', 'first']",877,['这是第一项研究报告特定的谷物摄入与基因偏向T1D儿童的AI之间的联系。'],0.3333333333333333,"['intake', 'report', 'study', 'IA', 'specific', 'this', 'to', 'and', 'first']","['report', 'this', 'first']",,
883,878,"of concern is that some of the dietary components implicated , such as fiber , are promoted for their health benefits .",令人担忧的是，一些相关的膳食成分，如纤维，因其健康益处而得到推广。,0.5,"['health', 'fiber', 'dietary', 'concern', 'as', 'that']","['health', 'fiber', 'as']",878,"['令人担忧的是,其中的一些营养成分,如纤维,为其健康益处而受益。']",0.5,"['health', 'fiber', 'dietary', 'concern', 'as', 'that']","['health', 'fiber', 'as']",,
884,879,"until more is understood , encouraging moderate intake , not exceeding standard recommended amounts , of gluten , fiber , and selected grains might be reasonable , especially in the child who has a known strong family history of autoimmune disease .",在了解更多之前，鼓励适度摄入面筋、纤维和精选谷物，但不要超过标准推荐量，这可能是合理的，尤其是对于已知有明显自身免疫性疾病家族史的儿童。,0.5384615384615384,"['autoimmune', 'family', 'intake', 'standard', 'disease', 'grains', 'who', 'child', 'family history', 'fiber', 'moderate', 'strong', 'autoimmune disease']","['autoimmune', 'family', 'standard', 'disease', 'child', 'family history', 'fiber']",879,"['更明白,鼓励适度的摄入量,不超过标准推荐量,葡萄糖,纤维和选择的谷物可能是合理的,特别是在儿童谁有已知的强烈的家庭历史的免疫疾病。']",0.5384615384615384,"['autoimmune', 'family', 'intake', 'standard', 'disease', 'grains', 'who', 'child', 'family history', 'fiber', 'moderate', 'strong', 'autoimmune disease']","['family', 'standard', 'disease', 'child', 'family history', 'fiber', 'strong']",,
885,880,"we cardiologists have long lived with the idea that the assessment of myocardial viability should inform decisions about revascularization , particularly in patients with ischemic cardiomyopathy , but some studies have questioned this reasonable assumption .",我们心脏病专家长期以来一直认为，心肌活力评估应为血运重建决策提供信息，尤其是在缺血性心肌病患者中，但一些研究质疑这一合理假设。,0.3571428571428571,"['viability', 'revascularization', 'inform', 'assessment', 'idea', 'cardiomyopathy', 'myocardial', 'with', 'have', 'this', 'that', 'but', 'ischemic', 'we']","['revascularization', 'assessment', 'cardiomyopathy', 'this', 'but']",880,"['我们心脏病学家长期以来一直生活在这个想法中,评估心脏病的可行性应该告知关于复发的决策,特别是在患有心脏病的患者,但一些研究质疑了这个合理的假设。']",0.3571428571428571,"['viability', 'revascularization', 'inform', 'assessment', 'idea', 'cardiomyopathy', 'myocardial', 'with', 'have', 'this', 'that', 'but', 'ischemic', 'we']","['inform', 'assessment', 'have', 'this', 'but']",,
886,881,"of the 1212 patients enrolled in STICH , 601 had myocardial viability testing , of whom 19 % were classified as having no viability .",在参加 STICH 的 1212 名患者中，有 601 名进行了心肌活力测试，其中 19% 被归类为无活力。,0.0,"['viability', 'no', 'myocardial', 'testing', 'classified']",[],881,"['在1212名入学的患者中,601人接受了心血管可行性测试,其中19%被认为没有可行性。']",0.0,"['viability', 'no', 'myocardial', 'testing', 'classified']",[],,
887,882,the incidence of death at 10 years did not differ significantly between patients with or without myocardial viability .,10 年的死亡率在有或没有心肌存活的患者之间没有显着差异。,0.1428571428571428,"['incidence', 'death', 'viability', 'differ', 'myocardial', 'with', 'without']",['death'],882,['10岁时死亡的发病率在患有或没有心脏病的患者之间没有显著的差异。'],0.2857142857142857,"['incidence', 'death', 'viability', 'differ', 'myocardial', 'with', 'without']","['incidence', 'death']",,
888,883,CABG was not more effective for patients with viability than those without viability .,CABG 对于有生存力的患者并不比没有生存力的患者更有效。,0.0,"['viability', 'CABG', 'with', 'without']",[],883,['CABG在可行性患者中并不比不可行性患者更有效。'],0.0,"['viability', 'CABG', 'with', 'without']",[],,
889,884,LVEF was measured in 318 participants at baseline and 4 months .,在基线和 4 个月时测量了 318 名参与者的 LVEF。,0.25,"['baseline', '4', 'at', 'and']",['baseline'],884,['LVEF在基线上的318名参与者和4个月进行了测量。'],0.25,"['baseline', '4', 'at', 'and']",['baseline'],,
890,885,"patients with myocardial viability had a significant increase in LVEF at 4 months , whereas those without viability did not .",有心肌活力的患者在 4 个月时 LVEF 显着增加，而没有心肌活力的患者则没有。,0.0,"['a', 'viability', 'myocardial', '4', 'increase', 'with', 'at', 'without']",[],885,"['患有心血管生存率的患者在4个月内在LVEF中显著增加,而没有生存率的患者则没有。']",0.0,"['a', 'viability', 'myocardial', '4', 'increase', 'with', 'at', 'without']",[],,
891,886,mortality did not correlate with LVEF change .,死亡率与 LVEF 变化无关。,0.6666666666666666,"['mortality', 'change', 'with']","['mortality', 'change']",886,['死亡率与LVEF的变化无关。'],0.6666666666666666,"['mortality', 'change', 'with']","['mortality', 'change']",,
892,887,"in this population , myocardial viability did not dictate the likelihood of benefit from surgical revascularization .",在这个人群中，心肌活力并不决定从手术血运重建中获益的可能性。,0.25,"['population', 'viability', 'surgical', 'revascularization', 'myocardial', 'benefit', 'this', 'in']","['population', 'revascularization']",887,"['在这个人口中,心脏病的可行性并没有定义从手术复发中受益的可能性。']",0.125,"['population', 'viability', 'surgical', 'revascularization', 'myocardial', 'benefit', 'this', 'in']",['population'],,
893,888,"also , change in LVEF , a surrogate outcome , failed to correspond with benefit .",此外，作为替代结果的 LVEF 的变化与获益不符。,0.3333333333333333,"['a', 'surrogate', 'outcome', 'change', 'benefit', 'with', 'correspond', 'in', 'to']","['surrogate', 'outcome', 'change']",888,"['此外,LVEF的变化,一个超越的结果,未能与利润相匹配。']",0.3333333333333333,"['a', 'surrogate', 'outcome', 'change', 'benefit', 'with', 'correspond', 'in', 'to']","['outcome', 'change', 'benefit']",,
894,889,I have some concerns about testing for interactions in relatively small groups .,我对在相对较小的群体中测试交互有一些担忧。,0.3333333333333333,"['testing', 'I', 'have']",['have'],889,['我对对相对较小群体的互动进行测试的一些担忧。'],0.0,"['testing', 'I', 'have']",[],,
895,890,we need larger studies to be certain about these findings .,我们需要更大规模的研究来确定这些发现。,0.2,"['need', 'be', 'certain', 'to', 'we']",['need'],890,['我们需要更大的研究来确定这些发现。'],0.2,"['need', 'be', 'certain', 'to', 'we']",['need'],,
896,891,"nevertheless , until people can demonstrate the value of testing for myocardial viability in patients with ischemic cardiomyopathy , we should hold off using these tests for similar patients to inform decisions .",尽管如此，在人们能够证明检测缺血性心肌病患者心肌活力的价值之前，我们应该推迟对类似患者使用这些检测来做出决定。,0.1666666666666666,"['value', 'viability', 'inform', 'cardiomyopathy', 'myocardial', 'testing', 'with', 'to', 'hold', 'ischemic', 'similar', 'we']","['value', 'cardiomyopathy']",891,"['然而,直到人们能够在患有催化性心脏病的患者中证明心脏病可行性测试的价值,我们应该停止使用这些类似患者的测试来告知决策。']",0.1666666666666666,"['value', 'viability', 'inform', 'cardiomyopathy', 'myocardial', 'testing', 'with', 'to', 'hold', 'ischemic', 'similar', 'we']","['value', 'inform']",,
897,892,more patients receiving the standard dose versus dose escalation had KRAS mutation ( 55 % vs. 39 % ) .,更多接受标准剂量与剂量递增的患者有 KRAS 突变（55% 对 39%）。,1.0,"['standard', 'mutation', 'dose']","['standard', 'mutation', 'dose']",892,"['接收标准剂量对剂量升级的患者多,患有KRAS突变(55%对39%)。']",1.0,"['standard', 'mutation', 'dose']","['standard', 'mutation', 'dose']",,
898,893,these results show that dose escalation of regorafenib does not appear to compromise the modest efficacy of this agent and support the use of this strategy in clinical practice .,这些结果表明，瑞戈非尼的剂量增加似乎不会损害该药物的适度疗效，并支持在临床实践中使用该策略。,0.4615384615384615,"['support', 'strategy', 'clinical', 'practice', 'efficacy', 'compromise', 'agent', 'dose', 'regorafenib', 'this', 'that', 'to', 'and']","['support', 'strategy', 'clinical', 'practice', 'dose', 'regorafenib']",893,"['这些结果表明,regorafenib的剂量升级似乎不会损害这种药物的微妙有效性,并支持在临床实践中使用这种策略。']",0.4615384615384615,"['support', 'strategy', 'clinical', 'practice', 'efficacy', 'compromise', 'agent', 'dose', 'regorafenib', 'this', 'that', 'to', 'and']","['support', 'strategy', 'clinical', 'practice', 'efficacy', 'dose']",,
899,894,a small multicenter study shows durable improvement in T2D indicators at 1 year after endoscopic duodenal mucosal resurfacing .,一项小型多中心研究表明，在内窥镜十二指肠粘膜表面重修术后 1 年，T2D 指标得到持久改善。,0.4,"['improvement', 'a', 'year', '1', 'mucosal', 'duodenal', 'study', 'after', 'at', 'in']","['improvement', 'year', '1', 'after']",894,"['一项小多中心研究显示,在内分泌双膜粘膜复发后1年,T2D指标的持续改善。']",0.4,"['improvement', 'a', 'year', '1', 'mucosal', 'duodenal', 'study', 'after', 'at', 'in']","['improvement', 'year', '1', 'after']",,
900,895,"exclusion of the duodenum through bariatric surgery has shown immediate benefit of improved glycemic control , independent of weight loss , in obese patients with type 2 diabetes mellitus ( T2D ) .",通过减肥手术切除十二指肠已显示，在患有 2 型糖尿病 (T2D) 的肥胖患者中，独立于体重减轻，可以直接改善血糖控制。,0.5,"['diabetes', 'type', 'control', 'weight', '2', 'surgery', 'exclusion', 'diabetes mellitus', 'loss', 'obese', 'duodenum', 'independent', 'immediate', 'benefit', 'with', 'weight loss']","['diabetes', 'type', 'control', 'weight', '2', 'surgery', 'diabetes mellitus', 'duodenum']",895,"['通过 bariatric 手术排除双胞胎表明,在肥胖患者患有2型糖尿病(T2D)的体重损失独立的改善血糖控制的即时好处。']",0.5625,"['diabetes', 'type', 'control', 'weight', '2', 'surgery', 'exclusion', 'diabetes mellitus', 'loss', 'obese', 'duodenum', 'independent', 'immediate', 'benefit', 'with', 'weight loss']","['diabetes', 'type', 'control', 'weight', '2', 'surgery', 'diabetes mellitus', 'loss', 'independent']",,
901,896,endoscopic duodenal mucosal resurfacing ( DMR ) - a new minimally invasive technique that involves circumferential hydrothermal ablation of the postampullary duodenal mucosa - might present a novel approach to improving glycemic control in T2D .,内窥镜十二指肠粘膜表面重修术 (DMR) - 一种新的微创技术，涉及壶腹后十二指肠粘膜的环状水热消融 - 可能会提供一种改善 T2D 血糖控制的新方法。,0.4,"['approach', 'mucosa', 'control', 'mucosal', 'duodenal', 'hydrothermal', 'ablation', 'novel', 'technique', 'present', '-', 'that', 'in', 'to', 'new']","['mucosa', 'control', 'mucosal', 'ablation', 'technique', 'new']",896,"['内分泌双胞胎粘膜复发(DMR) - 一个新的最小侵入性技术,涉及周围的水热消化后双胞胎粘膜 - 可能提出一个新的方法,以改善血糖控制在T2D。']",0.2666666666666666,"['approach', 'mucosa', 'control', 'mucosal', 'duodenal', 'hydrothermal', 'ablation', 'novel', 'technique', 'present', '-', 'that', 'in', 'to', 'new']","['mucosa', 'control', 'technique', 'new']",,
902,897,"at 24 weeks postprocedure , there were improvements in parameters of T2D , including glycated hemoglobin ( HbA1c ) level ( − 10 mmol / mol ) , fasting plasma glucose ( − 1.7 mmol / L ) , and homeostatic model assessment for insulin resistance ( − 2.9 ) , which were each sustained at 12 months .",术后 24 周，T2D 参数有所改善，包括糖化血红蛋白 ( HbA1c ) 水平 ( − 10 mmol / mol ) 、空腹血糖 ( − 1.7 mmol / L ) 和胰岛素抵抗的稳态模型评估 ( − 2.9 ) ，每一个持续 12 个月。,0.4,"['insulin', 'resistance', 'glucose', 'plasma', 'model', 'hemoglobin', '/', 'assessment', 'fasting', 'insulin resistance', 'level', 'at', 'mol', 'each', 'and']","['insulin', 'resistance', 'model', 'hemoglobin', 'assessment', 'level']",897,"['在24周后程序中,T2D的参数有所改善,包括血糖血糖(HbA1c)水平( − 10 mmol / mol ),禁食血糖( − 1.7 mmol / L ),以及对胰岛素抵抗性( − 2.9 )的同位素模型评估,每分为12个月。']",0.3333333333333333,"['insulin', 'resistance', 'glucose', 'plasma', 'model', 'hemoglobin', '/', 'assessment', 'fasting', 'insulin resistance', 'level', 'at', 'mol', 'each', 'and']","['insulin', 'resistance', 'model', 'assessment', 'level']",,
903,898,change in HbA1c did not correlate with weight loss .,HbA1c 的变化与体重减轻无关。,0.3333333333333333,"['weight', 'loss', 'change', 'with', 'weight loss', 'in']","['weight', 'change']",898,['HbA1c的变化与减肥无关。'],0.1666666666666666,"['weight', 'loss', 'change', 'with', 'weight loss', 'in']",['change'],,
904,899,it is fascinating that the duodenum has such an important role in T2D and potential role in insulin regulation .,令人着迷的是，十二指肠在 T2D 中具有如此重要的作用，并且在胰岛素调节中具有潜在作用。,0.5714285714285714,"['insulin', 'regulation', 'potential', 'role', 'duodenum', 'that', 'and']","['insulin', 'regulation', 'role', 'duodenum']",899,"['令人兴奋的是,双胞胎在T2D中扮演着如此重要的角色,以及在胰岛素调节中的潜在角色。']",0.4285714285714285,"['insulin', 'regulation', 'potential', 'role', 'duodenum', 'that', 'and']","['insulin', 'regulation', 'role']",,
905,900,further research is needed to define which patients with T2D would most benefit from this approach and to standardize endoscopic DMR technique .,需要进一步的研究来确定哪些 T2D 患者最能从这种方法中受益，并使内窥镜 DMR 技术标准化。,0.25,"['approach', 'research', 'technique', 'benefit', 'with', 'this', 'to', 'and']","['research', 'technique']",900,"['需要进一步的研究来确定哪些患有T2D的患者会从这种方法中受益,并标准化内分泌DMR技术。']",0.25,"['approach', 'research', 'technique', 'benefit', 'with', 'this', 'to', 'and']","['research', 'technique']",,
906,901,"moreover , carefully controlled studies are needed before DMR is used clinically in T2D .",此外，在将 DMR 临床用于 T2D 之前，需要进行仔细的对照研究。,0.3333333333333333,"['controlled', 'before', 'in']",['before'],901,"['此外,在 DMR 在 T2D 中临床使用之前需要仔细控制的研究。']",0.6666666666666666,"['controlled', 'before', 'in']","['controlled', 'before']",,
907,902,"however , these results support the concept of an effective endoscopic intervention to favorably alter metabolism .",然而，这些结果支持有效的内窥镜干预以有利地改变新陈代谢的概念。,0.6,"['metabolism', 'support', 'intervention', 'concept', 'to']","['metabolism', 'support', 'concept']",902,"['然而,这些结果支持有效的内分泌干预的概念,有利于改变代谢。']",0.8,"['metabolism', 'support', 'intervention', 'concept', 'to']","['metabolism', 'support', 'concept', 'to']",,
908,903,"compared with placebo , ursodeoxycholic acid modestly improved pruritis but did not reduce adverse perinatal outcomes .",与安慰剂相比，熊去氧胆酸适度改善了瘙痒症，但并未减少不良的围产期结局。,0.4285714285714285,"['placebo', 'perinatal', 'reduce', 'ursodeoxycholic acid', 'adverse', 'with', 'but']","['placebo', 'ursodeoxycholic acid', 'but']",903,"['与 placebo 相比, ursodeoxycholic 酸温和地改善了 pruritis 但并没有减少不良的阴道结果。']",0.1428571428571428,"['placebo', 'perinatal', 'reduce', 'ursodeoxycholic acid', 'adverse', 'with', 'but']",['but'],,
909,904,"ursodeoxycholic acid and placebo resulted in similar rates of preterm birth ( 17 % and 20 % ; risk ratio , 0.79 ) and admission to the neonatal intensive care unit ( 14 % and 17 % ; RR , 0.81 ) .",熊去氧胆酸和安慰剂导致相似的早产率（17% 和 20%；风险比，0.79）和进入新生儿重症监护病房的比率（14% 和 17%；RR，0.81）。,0.5833333333333334,"['placebo', 'neonatal', 'ratio', 'unit', 'admission', 'birth', 'ursodeoxycholic acid', 'intensive care unit', 'risk', 'to', 'and', 'similar']","['placebo', 'ratio', 'admission', 'ursodeoxycholic acid', 'intensive care unit', 'risk', 'similar']",904,"['ursodeoxycholic acid and placebo resulted in similar rates of premature birth ( 17 % and 20 % ; risk ratio, 0.79 ) and admission to the neonatal intensive care unit ( 14 % and 17 % ; RR, 0.81 ) 。']",0.0,"['placebo', 'neonatal', 'ratio', 'unit', 'admission', 'birth', 'ursodeoxycholic acid', 'intensive care unit', 'risk', 'to', 'and', 'similar']",[],,
910,905,there are limited data from randomized trials evaluating the use of antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease .,评估房颤和稳定性冠状动脉疾病患者使用抗血栓治疗的随机试验数据有限。,0.4615384615384615,"['atrial', 'disease', 'data', 'antithrombotic', 'fibrillation', 'coronary', 'therapy', 'atrial fibrillation', 'with', 'coronary artery', 'limited', 'in', 'and']","['disease', 'data', 'fibrillation', 'coronary', 'therapy', 'coronary artery']",905,['有有限的数据从随机测试评估使用抗血管治疗的患者和稳定的冠状动脉疾病。'],0.4615384615384615,"['atrial', 'disease', 'data', 'antithrombotic', 'fibrillation', 'coronary', 'therapy', 'atrial fibrillation', 'with', 'coronary artery', 'limited', 'in', 'and']","['disease', 'data', 'coronary', 'therapy', 'coronary artery', 'limited']",,
911,906,"the primary efficacy end point was a composite of stroke , systemic embolism , myocardial infarction , unstable angina requiring revascularization , or death from any cause ; this end point was analyzed for noninferiority with a noninferiority margin of 1.46 .",主要疗效终点是卒中、全身性栓塞、心肌梗死、需要血运重建的不稳定型心绞痛或全因死亡的复合终点。对这一终点进行了非劣效性分析，非劣效性界值为 1.46。,0.5294117647058824,"['myocardial infarction', 'composite', 'stroke', 'margin', 'death', 'angina', 'revascularization', 'primary', 'cause', 'unstable', 'systemic', 'efficacy', 'end', 'point', 'embolism', 'with', 'this']","['myocardial infarction', 'stroke', 'death', 'angina', 'revascularization', 'unstable', 'point', 'embolism', 'this']",906,"['初级有效性终点是中风、系统性胚胎、心脏病发作、不稳定的腹泻,需要复发或因任何原因而死亡的组成部分;这一终点被分析为不低于不低于不低于不低于不低于不低于不低于不低于不低于不低于不低。']",0.4117647058823529,"['myocardial infarction', 'composite', 'stroke', 'margin', 'death', 'angina', 'revascularization', 'primary', 'cause', 'unstable', 'systemic', 'efficacy', 'end', 'point', 'embolism', 'with', 'this']","['stroke', 'death', 'cause', 'unstable', 'efficacy', 'point', 'this']",,
912,907,"the primary safety end point was major bleeding , according to the criteria of the International Society on Thrombosis and Hemostasis ; this end point was analyzed for superiority .",根据国际血栓形成和止血学会的标准，主要安全终点是大出血；对该终点进行优效性分析。,0.5,"['bleeding', 'safety', 'thrombosis', 'hemostasis', 'major', 'society', 'primary', 'superiority', 'end', 'point', 'on', 'this', 'to', 'and']","['bleeding', 'safety', 'thrombosis', 'hemostasis', 'society', 'point', 'this']",907,"['主要安全终点是主要出血,根据国际血管和血管疾病协会的标准;这一终点被分析为优越性。']",0.4285714285714285,"['bleeding', 'safety', 'thrombosis', 'hemostasis', 'major', 'society', 'primary', 'superiority', 'end', 'point', 'on', 'this', 'to', 'and']","['bleeding', 'safety', 'society', 'superiority', 'point', 'this']",,
913,908,"as antithrombotic therapy , rivaroxaban monotherapy was noninferior to combination therapy for efficacy and superior for safety in patients with atrial fibrillation and stable coronary artery disease . ( Funded by the Japan Cardiovascular Research Foundation ; AFIRE UMIN Clinical Trials Registry number , UMIN000016612 ; and ClinicalTrials.gov number , NCT02642419 . )",作为抗血栓治疗，利伐沙班单药治疗在心房颤动和稳定性冠状动脉疾病患者中的疗效不劣于联合疗法，安全性优于联合疗法。 （由日本心血管研究基金会资助；AFIRE UMIN 临床试验注册号 UMIN000016612；ClinicalTrials.gov 号 NCT02642419。）,0.5652173913043478,"['atrial', 'safety', 'combination therapy', 'disease', 'cardiovascular', 'research', 'antithrombotic', 'fibrillation', 'coronary', 'superior', 'atrial fibrillation', 'registry', 'number', 'clinical', 'japan', 'efficacy', 'with', 'coronary artery', 'rivaroxaban', 'foundation', 'by', 'to', 'and']","['safety', 'disease', 'cardiovascular', 'research', 'fibrillation', 'coronary', 'atrial fibrillation', 'number', 'clinical', 'coronary artery', 'rivaroxaban', 'by', 'to']",908,"['作为抗血管疗法,Rivaroxaban单疗法不低于结合疗法的有效性和安全性高于患有甲状腺纤维和稳定的冠状动脉疾病的患者(由日本心血管研究基金会资助;AFIRE UMIN临床试验登记号,UMIN000016612;和ClinicalTrials.gov号,NCT02642419。']",0.4782608695652174,"['atrial', 'safety', 'combination therapy', 'disease', 'cardiovascular', 'research', 'antithrombotic', 'fibrillation', 'coronary', 'superior', 'atrial fibrillation', 'registry', 'number', 'clinical', 'japan', 'efficacy', 'with', 'coronary artery', 'rivaroxaban', 'foundation', 'by', 'to', 'and']","['safety', 'disease', 'cardiovascular', 'research', 'coronary', 'number', 'clinical', 'efficacy', 'coronary artery', 'by', 'to']",,
914,909,"the use of dual antiplatelet therapy ( a P2Y12 inhibitor plus aspirin ) after percutaneous coronary intervention ( PCI ) reduces the risk of ischemic or atherothrombotic events , including stent thrombosis , recurrent myocardial infarction , and cardiovascular death.1",经皮冠状动脉介入治疗 (PCI) 后使用双重抗血小板治疗（P2Y12 抑制剂加阿司匹林）可降低缺血或动脉粥样硬化血栓形成事件的风险，包括支架内血栓形成、复发性心肌梗死和心血管死亡。 1,0.5555555555555556,"['inhibitor', 'myocardial infarction', 'aspirin', 'cardiovascular', 'plus', 'antiplatelet', 'coronary', 'thrombosis', 'therapy', 'recurrent', 'stent', 'intervention', 'risk', 'after', 'dual', 'percutaneous', 'and', 'ischemic']","['inhibitor', 'myocardial infarction', 'aspirin', 'cardiovascular', 'plus', 'coronary', 'thrombosis', 'therapy', 'risk', 'after']",909,"['二重抗板膜治疗(P2Y12抑制剂加上阿司匹林)的使用后,皮层干预(PCI)减少了伊斯基米或甲状腺炎事件的风险,包括<unk>血病,重复的心脏病发作和心血管死亡。']",0.3888888888888889,"['inhibitor', 'myocardial infarction', 'aspirin', 'cardiovascular', 'plus', 'antiplatelet', 'coronary', 'thrombosis', 'therapy', 'recurrent', 'stent', 'intervention', 'risk', 'after', 'dual', 'percutaneous', 'and', 'ischemic']","['inhibitor', 'aspirin', 'cardiovascular', 'plus', 'therapy', 'risk', 'after']",,
915,910,"the use of antiplatelet agents in combination with anticoagulation results in an increased risk of bleeding events , as shown recently in a nationwide Danish cohort study.3",最近一项全国性的丹麦队列研究显示，抗血小板药物与抗凝药物联合使用会增加出血事件的风险。 3,0.5,"['bleeding', 'combination', 'anticoagulation', 'antiplatelet', 'risk', 'cohort', 'as', 'with']","['bleeding', 'combination', 'anticoagulation', 'risk']",910,"['与抗凝固剂相结合的抗阴膜药物的使用导致出血事件的风险增加,如最近在全国范围内的丹麦凝固研究中所示。']",0.625,"['bleeding', 'combination', 'anticoagulation', 'antiplatelet', 'risk', 'cohort', 'as', 'with']","['bleeding', 'combination', 'anticoagulation', 'risk', 'as']",,
916,911,"as a consequence , the selection of the most effective antithrombotic treatment for patients with atrial fibrillation and stable coronary artery disease is a clinical challenge requiring careful assessment of the risks of ischemia and bleeding in each patient.2",因此，为心房颤动和稳定性冠状动脉疾病患者选择最有效的抗血栓治疗是一项临床挑战，需要仔细评估每位患者的缺血和出血风险。 2,0.6111111111111112,"['bleeding', 'atrial', 'disease', 'ischemia', 'antithrombotic', 'fibrillation', 'coronary', 'atrial fibrillation', 'assessment', 'treatment', 'clinical', 'challenge', 'consequence', 'with', 'careful', 'coronary artery', 'each', 'and']","['bleeding', 'disease', 'ischemia', 'fibrillation', 'coronary', 'atrial fibrillation', 'assessment', 'treatment', 'clinical', 'challenge', 'coronary artery']",911,"['因此,在患有甲状腺纤维和稳定的冠状动脉疾病的患者中选择最有效的抗血管治疗是一种临床挑战,需要仔细评估每个患者的腹泻和出血风险。']",0.4444444444444444,"['bleeding', 'atrial', 'disease', 'ischemia', 'antithrombotic', 'fibrillation', 'coronary', 'atrial fibrillation', 'assessment', 'treatment', 'clinical', 'challenge', 'consequence', 'with', 'careful', 'coronary artery', 'each', 'and']","['bleeding', 'disease', 'coronary', 'assessment', 'treatment', 'clinical', 'challenge', 'coronary artery']",,
917,912,"such treatment is followed by combination therapy with an oral anticoagulant plus a P2Y12 inhibitor for 4 to 6 weeks8 or up to 12 months in selected patients.9,10","这种治疗之后是口服抗凝剂和 P2Y12 抑制剂联合治疗 4 至 6 周8，或在选定患者中长达 12 个月。 9,10",0.4,"['inhibitor', 'combination therapy', 'anticoagulant', 'plus', 'oral', 'treatment', '4', 'up', 'with', 'by']","['inhibitor', 'combination therapy', 'anticoagulant', 'treatment']",912,['这种治疗由口服抗凝固剂和P2Y12抑制剂进行4至6周8或最多12个月的组合治疗。'],0.3,"['inhibitor', 'combination therapy', 'anticoagulant', 'plus', 'oral', 'treatment', '4', 'up', 'with', 'by']","['inhibitor', 'treatment', 'by']",,
918,913,"after 12 months of combination therapy , or in patients with atrial fibrillation and stable coronary artery disease not requiring intervention , current guidelines recommend monotherapy with an oral anticoagulant.9,10","经过 12 个月的联合治疗后，或对于不需要干预的心房颤动和稳定型冠状动脉疾病患者，目前的指南建议使用口服抗凝剂进行单药治疗。 9,10",0.5714285714285714,"['atrial', 'combination therapy', 'disease', 'oral', 'fibrillation', 'coronary', 'recommend', 'atrial fibrillation', 'intervention', 'after', 'current', 'with', 'coronary artery', 'and']","['combination therapy', 'disease', 'fibrillation', 'coronary', 'recommend', 'atrial fibrillation', 'after', 'coronary artery']",913,"['经过12个月的组合治疗,或在不需要干预的静脉动脉和静脉动脉疾病的患者中,现行指导方针建议用口服抗凝固剂单治疗。']",0.1428571428571428,"['atrial', 'combination therapy', 'disease', 'oral', 'fibrillation', 'coronary', 'recommend', 'atrial fibrillation', 'intervention', 'after', 'current', 'with', 'coronary artery', 'and']","['disease', 'recommend']",,
919,914,"however , this approach has yet to be supported by evidence from randomized , controlled trials .",然而，这种方法尚未得到随机对照试验证据的支持。,0.1428571428571428,"['approach', 'controlled', 'be', 'evidence', 'this', 'by', 'to']",['evidence'],914,"['然而,这种方法尚未得到随机、控制的试验的证据的支持。']",0.2857142857142857,"['approach', 'controlled', 'be', 'evidence', 'this', 'by', 'to']","['controlled', 'evidence']",,
920,915,"furthermore , substantial numbers of patients in this situation continue to be treated with combination therapy , which indicates a gap between guidelines and clinical practice.11",此外，大量处于这种情况的患者继续接受联合治疗，这表明指南与临床实践之间存在差距。 11,0.4545454545454545,"['combination therapy', 'situation', 'gap', 'be', 'clinical', 'with', 'continue', 'this', 'to', 'and', 'substantial']","['combination therapy', 'be', 'clinical', 'continue', 'to']",915,"['此外,在这种情况下,大量的患者仍在用结合疗法进行治疗,这表明指导方针与临床实践之间的差距。']",0.1818181818181818,"['combination therapy', 'situation', 'gap', 'be', 'clinical', 'with', 'continue', 'this', 'to', 'and', 'substantial']","['be', 'clinical']",,
921,916,"one previous randomized , controlled trial has evaluated the efficacy and safety of monotherapy with an oral anticoagulant as compared with combination therapy with an oral anticoagulant plus a single antiplatelet agent in patients with atrial fibrillation and stable coronary artery disease more than 1 year after stenting , but this trial was underpowered and inconclusive because of the premature termination of enrollment.12",先前的一项随机对照试验评估了在支架置入术后 1 年以上的心房颤动和稳定型冠状动脉疾病患者中，口服抗凝剂单一疗法与口服抗凝剂加单一抗血小板药物联合疗法的疗效和安全性，但是由于提前终止入组，该试验的功效不足且不确定。 12,0.6666666666666666,"['atrial', 'safety', 'combination therapy', 'anticoagulant', 'disease', 'year', '1', 'plus', 'oral', 'antiplatelet', 'previous', 'fibrillation', 'coronary', 'controlled', 'atrial fibrillation', 'termination', 'after', 'efficacy', 'premature', 'with', 'coronary artery', 'agent', 'controlled trial', 'this', 'single', 'but', 'and']","['safety', 'anticoagulant', 'disease', 'year', '1', 'plus', 'fibrillation', 'coronary', 'atrial fibrillation', 'termination', 'after', 'efficacy', 'premature', 'coronary artery', 'controlled trial', 'this', 'single', 'but']",916,"['此前一项随机控制的研究评估了口服抗凝固剂单疗法的有效性和安全性,与口服抗凝固剂的结合疗法相比,并在关节炎和稳定的冠状动脉疾病1年以上的患者中进行单一抗凝固剂的单一抗凝固剂,但这项研究由于提前终止登记而被支持和无关紧要。']",0.4814814814814814,"['atrial', 'safety', 'combination therapy', 'anticoagulant', 'disease', 'year', '1', 'plus', 'oral', 'antiplatelet', 'previous', 'fibrillation', 'coronary', 'controlled', 'atrial fibrillation', 'termination', 'after', 'efficacy', 'premature', 'with', 'coronary artery', 'agent', 'controlled trial', 'this', 'single', 'but', 'and']","['safety', 'disease', 'year', '1', 'coronary', 'controlled', 'termination', 'efficacy', 'premature', 'coronary artery', 'single', 'but', 'and']",,
922,917,details regarding the trial design have been described previously.13,有关试验设计的详细信息已在前面描述过。 13,0.75,"['regarding', 'trial', 'design', 'have']","['regarding', 'design', 'have']",917,['关于试验设计的细节已被描述。13'],0.5,"['regarding', 'trial', 'design', 'have']","['regarding', 'design']",,
923,918,funding was provided by the Japan Cardiovascular Research Foundation under a contract with Bayer Yakuhin .,日本心血管研究基金会根据与 Bayer Yakuhin 的合同提供资金。,0.375,"['a', 'cardiovascular', 'research', 'contract', 'japan', 'with', 'foundation', 'by']","['cardiovascular', 'research', 'foundation']",918,['该资金由日本心血管研究基金会根据与Bayer Yakuhin的合同提供。'],0.5,"['a', 'cardiovascular', 'research', 'contract', 'japan', 'with', 'foundation', 'by']","['cardiovascular', 'research', 'foundation', 'by']",,
924,919,"the company had no role in the design of the trial , in the collection or analysis of the data , in the interpretation of the trial results , or in the writing of the manuscript .",该公司未参与试验设计、数据收集或分析、试验结果解释或文稿撰写。,0.6,"['data', 'analysis', 'collection', 'interpretation', 'role', 'no', 'manuscript', 'writing', 'trial', 'design']","['data', 'analysis', 'collection', 'interpretation', 'writing', 'design']",919,['公司在审查的设计、数据收集或分析、审查结果的解释或手稿的写作中没有任何作用。'],0.8,"['data', 'analysis', 'collection', 'interpretation', 'role', 'no', 'manuscript', 'writing', 'trial', 'design']","['data', 'analysis', 'collection', 'interpretation', 'role', 'manuscript', 'writing', 'design']",,
925,920,"under the guidance of the authors , Mebix , a contract research organization , provided assistance in the selection of the participating centers , supervision or monitoring of the centers , collection and storage of trial data , data analysis , interpretation of the trial results , and preparation of the manuscript .",在作者的指导下，合同研究机构Mebix在参与中心的选择、中心的监督或监测、试验数据的收集和存储、数据分析、试验结果的解释以及准备手稿。,0.5625,"['monitoring', 'organization', 'research', 'data', 'analysis', 'preparation', 'collection', 'interpretation', 'supervision', 'contract', 'manuscript', 'storage', 'trial', 'assistance', 'and', 'guidance']","['monitoring', 'research', 'data', 'analysis', 'preparation', 'collection', 'interpretation', 'manuscript', 'storage']",920,"['在作者的指导下,Mebix是一家合同研究组织,在参与中心的选择、监督或监测中心、审查数据的收集和存储、数据分析、审查结果的解释和手稿的编制方面提供了协助。']",0.5625,"['monitoring', 'organization', 'research', 'data', 'analysis', 'preparation', 'collection', 'interpretation', 'supervision', 'contract', 'manuscript', 'storage', 'trial', 'assistance', 'and', 'guidance']","['monitoring', 'organization', 'research', 'data', 'analysis', 'collection', 'interpretation', 'manuscript', 'storage']",,
926,921,the trial was designed and led by an executive steering committee .,该试验由执行指导委员会设计和领导。,0.3333333333333333,"['steering', 'committee', 'trial', 'by', 'and', 'led']","['committee', 'by']",921,['审判是由执行管理委员会设计和领导的。'],0.5,"['steering', 'committee', 'trial', 'by', 'and', 'led']","['committee', 'trial', 'by']",,
927,922,"the trial was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the institutional review board of the National Cerebral and Cardiovascular Center , Japan , along with the institutional review boards of all participating institutions .",该试验是根据赫尔辛基宣言的原则进行的，并获得了日本国家脑心血管中心的机构审查委员会以及所有参与机构的机构审查委员会的批准。,0.3076923076923077,"['center', 'cardiovascular', 'review', 'cerebral', 'board', 'along', 'japan', 'trial', 'with', 'all', 'in', 'by', 'and']","['center', 'cardiovascular', 'review', 'by']",922,"['审查按照赫尔辛基宣言的原则进行,由日本国家大脑和心血管中心的机构审查委员会和所有参与机构的机构审查委员会批准。']",0.3846153846153846,"['center', 'cardiovascular', 'review', 'cerebral', 'board', 'along', 'japan', 'trial', 'with', 'all', 'in', 'by', 'and']","['center', 'cardiovascular', 'review', 'cerebral', 'by']",,
928,923,data were reviewed by an independent data and safety monitoring committee .,数据由一个独立的数据和安全监测委员会审查。,0.8571428571428571,"['safety', 'monitoring', 'data', 'committee', 'independent', 'by', 'and']","['safety', 'monitoring', 'data', 'committee', 'independent', 'by']",923,['数据由独立的数据和安全监测委员会审查。'],0.8571428571428571,"['safety', 'monitoring', 'data', 'committee', 'independent', 'by', 'and']","['safety', 'monitoring', 'data', 'committee', 'independent', 'by']",,
929,924,"the authors vouch for the completeness and accuracy of the data and all analyses , and for the fidelity of the trial to the protocol , available with the full text of this article at NEJM.org .",作者保证数据和所有分析的完整性和准确性，以及试验对方案的忠实度，方案与本文全文可在 NEJM.org 获取。,0.2857142857142857,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",924,"['作者保证数据和所有分析的完整性和准确性,以及审判对议定书的忠诚性,可在NEJM.org上提供本文的完整文本。']",0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'full']",,
930,925,trial POPULATION AND ELIGIBILITY CRITERIA,试验人群和资格标准,0.0,['trial'],[],925,['审判人口和可行性标准'],1.0,['trial'],['trial'],,
931,926,men and women who were 20 years of age or older and had received a diagnosis of atrial fibrillation and stable coronary artery disease were enrolled in Japan .,在日本，年龄在 20 岁或以上并被诊断为心房颤动和稳定型冠状动脉疾病的男性和女性被纳入研究。,0.5833333333333334,"['atrial', 'disease', 'who', 'fibrillation', 'coronary', 'diagnosis', 'atrial fibrillation', 'age', 'japan', 'coronary artery', 'in', 'and']","['disease', 'fibrillation', 'coronary', 'diagnosis', 'atrial fibrillation', 'age', 'coronary artery']",926,"['20岁及以上的男性和女性,并接受了甲状腺纤维化和稳定的冠状动脉疾病的诊断,被注册在日本。']",0.3333333333333333,"['atrial', 'disease', 'who', 'fibrillation', 'coronary', 'diagnosis', 'atrial fibrillation', 'age', 'japan', 'coronary artery', 'in', 'and']","['disease', 'coronary', 'diagnosis', 'coronary artery']",,
932,927,"during screening , we evaluated the patients on a CHADS2 scale , which ranges from 0 to 6 , with a higher score indicating a greater risk of stroke ; congestive heart failure , hypertension , diabetes , and an age of 75 years or older are each assigned 1 point , and prior stroke or transient ischemic attack is assigned 2 points .",在筛查期间，我们根据 CHADS2 量表对患者进行了评估，该量表的范围为 0 至 6，分数越高表明中风的风险越大；充血性心力衰竭、高血压、糖尿病和 75 岁或以上的患者各得 1 分，既往中风或短暂性脑缺血发作史得 2 分。,0.68,"['attack', 'transient', 'heart', 'diabetes', 'stroke', 'failure', 'hypertension', '1', '2', 'screening', 'scale', 'heart failure', 'congestive', 'age', 'risk', 'prior', 'score', 'point', 'with', 'congestive heart failure', 'transient ischemic attack', 'each', 'to', 'and', 'we']","['attack', 'transient', 'heart', 'diabetes', 'stroke', 'failure', 'hypertension', '1', '2', 'screening', 'scale', 'heart failure', 'risk', 'score', 'congestive heart failure', 'transient ischemic attack', 'each']",927,"['在筛查期间,我们评估了一个CHADS2规模的患者,从0到6的,一个更高的分数表明一个更大的心脏病发作风险;凝固性心脏衰竭,高血压,糖尿病,和75岁或以上的年龄,每人分为1分,并分为前进或过渡性心脏病发作2分。']",0.52,"['attack', 'transient', 'heart', 'diabetes', 'stroke', 'failure', 'hypertension', '1', '2', 'screening', 'scale', 'heart failure', 'congestive', 'age', 'risk', 'prior', 'score', 'point', 'with', 'congestive heart failure', 'transient ischemic attack', 'each', 'to', 'and', 'we']","['attack', 'heart', 'diabetes', 'stroke', 'failure', 'hypertension', '1', '2', 'screening', 'scale', 'age', 'risk', 'score']",,
933,928,the patients were required to have a score of at least 1 on the scale .,要求患者的评分至少为 1 分。,0.25,"['a', '1', 'scale', 'score', 'at', 'on', 'have', 'to']","['1', 'scale']",928,['患者必须在规模上获得至少1分的成绩。'],0.125,"['a', '1', 'scale', 'score', 'at', 'on', 'have', 'to']",['1'],,
934,929,"key exclusion criteria were a history of stent thrombosis , coexisting active tumor , and poorly controlled hypertension .",关键的排除标准是支架内血栓病史、共存的活动性肿瘤和控制不佳的高血压。,0.5454545454545454,"['a', 'key', 'hypertension', 'tumor', 'active', 'thrombosis', 'history', 'exclusion', 'controlled', 'stent', 'and']","['key', 'hypertension', 'tumor', 'active', 'thrombosis', 'controlled']",929,['关键排除标准是<unk>血管病史、共同存在的活性肿瘤和不受控制的高血压。'],0.3636363636363636,"['a', 'key', 'hypertension', 'tumor', 'active', 'thrombosis', 'history', 'exclusion', 'controlled', 'stent', 'and']","['key', 'hypertension', 'tumor', 'controlled']",,
935,930,other RISK EVALUATIONS,其他风险评估,,[],[],930,['其他风险评估'],,[],[],,
936,931,"patients are evaluated on the basis of the five criteria of the CHADS2 scale plus three additional criteria : the presence of vascular disease , an age of 64 to 74 years , and sex .",患者根据 CHADS2 量表的五个标准加上三个附加标准进行评估：存在血管疾病、年龄在 64 至 74 岁之间以及性别。,0.5,"['presence', 'disease', 'sex', 'vascular', 'scale', 'plus', 'vascular disease', 'basis', 'age', 'additional', 'three', 'five', 'to', 'and']","['presence', 'disease', 'sex', 'scale', 'plus', 'vascular disease', 'age']",931,"['基于 CHADS2 尺寸的五个标准以及三个额外的标准进行评估:血管疾病的存在,年龄为 64 至 74 岁,性别。']",0.5,"['presence', 'disease', 'sex', 'vascular', 'scale', 'plus', 'vascular disease', 'basis', 'age', 'additional', 'three', 'five', 'to', 'and']","['presence', 'disease', 'sex', 'vascular disease', 'age', 'additional', 'to']",,
937,932,"this score ranges from 0 to 9 , with 2 points for an age of 75 years or older ; higher scores indicate a greater risk .",该分数范围为 0 至 9，75 岁或以上为 2 分；分数越高表示风险越大。,0.3333333333333333,"['a', '2', 'indicate', 'age', 'risk', 'score', 'with', 'this', 'to']","['2', 'risk', 'score']",932,"['这个分数从 0 到 9,为 75 岁及以上的 2 个分数;更高的分数表明更大的风险。']",0.3333333333333333,"['a', '2', 'indicate', 'age', 'risk', 'score', 'with', 'this', 'to']","['2', 'risk', 'score']",,
938,933,"we randomly assigned the patients in a 1 : 1 ratio to receive either monotherapy with rivaroxaban ( 10 mg once daily for patients with a creatinine clearance of 15 to 49 ml per minute or 15 mg once daily for patients with a creatinine clearance of ≥ 50 ml per minute ) or combination therapy with rivaroxaban at the previously stated doses plus an antiplatelet agent ( either aspirin or a P2Y12 inhibitor , according to the discretion of the treating physician ) .",我们以 1 : 1 的比例随机分配患者接受利伐沙班单药治疗（肌酐清除率为每分钟 15 至 49 毫升的患者每天一次 10 毫克，肌酐清除率≥ 50 毫升的患者每天一次 15 毫克每分钟）或与先前规定剂量的利伐沙班联合抗血小板药物（阿司匹林或 P2Y12 抑制剂，由主治医师决定）联合治疗。,0.5625,"['inhibitor', 'combination therapy', 'creatinine', 'aspirin', '1', 'ratio', 'plus', 'antiplatelet', 'physician', 'minute', 'clearance', 'ml', 'with', 'rivaroxaban', 'agent', 'we']","['inhibitor', 'combination therapy', 'aspirin', '1', 'ratio', 'physician', 'minute', 'clearance', 'rivaroxaban']",933,"['我们随机分配给患者1:1的比例,以接受无论是单疗法与Rivaroxaban(每分钟15至49毫升或每分钟15毫升的克里亚丁清洁剂的患者每日10毫克或每分钟50毫克的克里亚丁清洁剂的患者每日15毫克)或与Rivaroxaban的结合疗法在前面提到的剂量加上抗平板剂(无论是阿司匹林或P2Y12抑制剂,根据治疗医生的判断)。']",0.4375,"['inhibitor', 'combination therapy', 'creatinine', 'aspirin', '1', 'ratio', 'plus', 'antiplatelet', 'physician', 'minute', 'clearance', 'ml', 'with', 'rivaroxaban', 'agent', 'we']","['inhibitor', 'aspirin', '1', 'ratio', 'plus', 'physician', 'minute']",,
939,934,"details regarding the randomization procedure and the administration of the trial drugs are provided in the Supplementary Appendix , available at NEJM.org .",有关随机化程序和试验药物给药的详细信息，请参见补充附录，补充附录可在 NEJM.org 获取。,0.4444444444444444,"['procedure', 'appendix', 'randomization', 'administration', 'drugs', 'supplementary', 'regarding', 'available', 'trial']","['procedure', 'randomization', 'drugs', 'regarding']",934,"['关于随机化程序和试用药物的处方的详细信息在附件中提供,可在NEJM.org上找到。']",0.5555555555555556,"['procedure', 'appendix', 'randomization', 'administration', 'drugs', 'supplementary', 'regarding', 'available', 'trial']","['procedure', 'appendix', 'randomization', 'drugs', 'regarding']",,
940,935,"the primary efficacy end point was the composite of stroke , systemic embolism , myocardial infarction , unstable angina requiring revascularization , or death from any cause .",主要疗效终点是中风、全身性栓塞、心肌梗塞、需要血运重建的不稳定型心绞痛或任何原因死亡的复合终点。,0.6428571428571429,"['myocardial infarction', 'composite', 'stroke', 'death', 'angina', 'revascularization', 'primary', 'cause', 'unstable', 'systemic', 'efficacy', 'end', 'point', 'embolism']","['myocardial infarction', 'stroke', 'death', 'angina', 'revascularization', 'cause', 'unstable', 'point', 'embolism']",935,"['初级有效性终点是中风、系统性胚胎、心脏病发作、不稳定的腹泻,需要复发或因任何原因而死亡的组成。']",0.4285714285714285,"['myocardial infarction', 'composite', 'stroke', 'death', 'angina', 'revascularization', 'primary', 'cause', 'unstable', 'systemic', 'efficacy', 'end', 'point', 'embolism']","['stroke', 'death', 'cause', 'unstable', 'efficacy', 'point']",,
941,936,"originally , the end point included only death from cardiovascular causes , but this composite was changed to include death from any cause in August 2015 .",最初，终点仅包括心血管原因死亡，但该复合终点在 2015 年 8 月更改为包括全因死亡。,0.5,"['composite', 'cardiovascular', 'death', 'cause', 'end', 'point', 'this', 'originally', 'but', 'to']","['cardiovascular', 'death', 'cause', 'point', 'but']",936,"['起初,终点仅包括心血管原因死亡,但该组成部分于2015年8月更改,包括任何原因死亡。']",0.6,"['composite', 'cardiovascular', 'death', 'cause', 'end', 'point', 'this', 'originally', 'but', 'to']","['cardiovascular', 'death', 'cause', 'point', 'but', 'to']",,
942,937,"the primary safety end point was major bleeding , as defined according to the criteria of the International Society on Thrombosis and Hemostasis .",主要安全性终点是根据国际血栓形成和止血学会的标准定义的大出血。,0.4615384615384615,"['bleeding', 'safety', 'defined', 'thrombosis', 'hemostasis', 'major', 'society', 'primary', 'end', 'point', 'on', 'to', 'and']","['bleeding', 'safety', 'thrombosis', 'hemostasis', 'society', 'point']",937,"['主要安全终点是主要出血,根据国际血管和血管疾病协会的标准定义。']",0.3076923076923077,"['bleeding', 'safety', 'defined', 'thrombosis', 'hemostasis', 'major', 'society', 'primary', 'end', 'point', 'on', 'to', 'and']","['bleeding', 'safety', 'society', 'point']",,
943,938,"secondary end points were the individual components of the primary end point ; death from any cause ; a composite of ischemic cardiovascular events or death ( death from any cause , myocardial infarction , unstable angina requiring revascularization , stroke , transient ischemic attack , systemic arterial embolism , venous thromboembolism , revascularization , or stent thrombosis ) ; net adverse clinical events ( death from any cause , myocardial infarction , stroke , and major bleeding ) ; and any bleeding events .",次要终点是主要终点的各个组成部分；因任何原因死亡；缺血性心血管事件或死亡（全因死亡、心肌梗死、需要血运重建的不稳定型心绞痛、中风、短暂性脑缺血发作、全身性动脉栓塞、静脉血栓栓塞、血运重建或支架内血栓形成）的复合事件；净不良临床事件（全因死亡、心肌梗死、中风和大出血）；以及任何出血事件。,0.5925925925925926,"['bleeding', 'attack', 'transient', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'net', 'individual', 'death', 'venous', 'angina', 'thrombosis', 'thromboembolism', 'major', 'end points', 'revascularization', 'adverse', 'primary', 'stent', 'cause', 'clinical', 'unstable', 'systemic', 'secondary', 'transient ischemic attack', 'and']","['bleeding', 'attack', 'transient', 'myocardial infarction', 'cardiovascular', 'stroke', 'death', 'angina', 'thrombosis', 'thromboembolism', 'end points', 'revascularization', 'cause', 'clinical', 'unstable', 'transient ischemic attack']",938,"['二级终点是初级终点的个体组成部分;因任何原因而死亡;因任何原因而死亡或死亡的组成部分(因任何原因而死亡,心脏病发作,不稳定的腹泻,需要复发,中风,过渡性腹泻攻击,系统性血管胚胎,阴道血管,复发,或静脉血管);因任何原因而死亡(因任何原因而死亡,心脏病发作,中风和主要出血);以及任何出血事件。']",0.3703703703703703,"['bleeding', 'attack', 'transient', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'net', 'individual', 'death', 'venous', 'angina', 'thrombosis', 'thromboembolism', 'major', 'end points', 'revascularization', 'adverse', 'primary', 'stent', 'cause', 'clinical', 'unstable', 'systemic', 'secondary', 'transient ischemic attack', 'and']","['bleeding', 'attack', 'transient', 'stroke', 'individual', 'death', 'end points', 'cause', 'unstable', 'and']",,
944,939,the definitions of cardiovascular and bleeding events are provided in Table S1 in the Supplementary Appendix .,补充附录表 S1 中提供了心血管事件和出血事件的定义。,0.4285714285714285,"['bleeding', 'cardiovascular', 'appendix', 'table', 'supplementary', 'S1', 'and']","['bleeding', 'cardiovascular', 'table']",939,['心血管和出血事件的定义在附加附件中的表 S1 中提供。'],0.5714285714285714,"['bleeding', 'cardiovascular', 'appendix', 'table', 'supplementary', 'S1', 'and']","['bleeding', 'cardiovascular', 'appendix', 'table']",,
945,940,blinded adjudication of the end points was conducted by an independent clinical events committee .,终点的盲裁定由一个独立的临床事件委员会进行。,1.0,"['end points', 'clinical', 'committee', 'independent', 'by']","['end points', 'clinical', 'committee', 'independent', 'by']",940,['最终点的盲目交付由独立的临床活动委员会进行。'],1.0,"['end points', 'clinical', 'committee', 'independent', 'by']","['end points', 'clinical', 'committee', 'independent', 'by']",,
946,941,"the trial was powered to assess the noninferiority of rivaroxaban monotherapy , as compared with combination therapy , for the primary efficacy end point .",该试验旨在评估利伐沙班单药治疗与联合治疗相比在主要疗效终点方面的非劣效性。,0.4,"['combination therapy', 'primary', 'trial', 'efficacy', 'assess', 'end', 'point', 'with', 'rivaroxaban', 'to']","['combination therapy', 'assess', 'point', 'rivaroxaban']",941,"['试验被授权评估Rivaroxaban单疗法的非低效性,与组合疗法相比,为初级有效性终点。']",0.3,"['combination therapy', 'primary', 'trial', 'efficacy', 'assess', 'end', 'point', 'with', 'rivaroxaban', 'to']","['efficacy', 'assess', 'point']",,
947,942,the calculation of the trial sample size is provided in the Supplementary Appendix .,补充附录中提供了试验样本量的计算。,0.1428571428571428,"['sample', 'appendix', 'supplementary', 'size', 'trial', 'sample size', 'in']",['sample'],942,['测试样品尺寸的计算在附件中提供。'],0.4285714285714285,"['sample', 'appendix', 'supplementary', 'size', 'trial', 'sample size', 'in']","['sample', 'appendix', 'size']",,
948,943,we estimated that the enrollment of 2200 patients and the occurrence of at least 219 primary efficacy end points were required .,我们估计需要纳入 2200 名患者并出现至少 219 个主要疗效终点。,0.25,"['occurrence', 'end points', 'primary', 'efficacy', 'at', 'that', 'and', 'we']","['occurrence', 'end points']",943,"['我们估计,需要2200名患者的注册和至少219个初级有效性终点的出现。']",0.375,"['occurrence', 'end points', 'primary', 'efficacy', 'at', 'that', 'and', 'we']","['occurrence', 'end points', 'efficacy']",,
949,944,this population included all the patients who had undergone randomization after the exclusion of patients who had a technical reason for not participating in the trial .,该人群包括排除因技术原因未参加试验的患者后接受随机分组的所有患者。,0.3636363636363636,"['population', 'randomization', 'who', 'reason', 'exclusion', 'technical', 'after', 'trial', 'all', 'this', 'in']","['population', 'randomization', 'reason', 'after']",944,"['该人口包括所有经过随机化后排除患者的患者,他们有技术理由不参加试验。']",0.3636363636363636,"['population', 'randomization', 'who', 'reason', 'exclusion', 'technical', 'after', 'trial', 'all', 'this', 'in']","['population', 'randomization', 'reason', 'after']",,
950,945,"if noninferiority was shown for the primary efficacy end point , a closed testing procedure was to be conducted to determine superiority for the primary safety end point .",如果主要疗效终点显示非劣效性，则将进行封闭测试程序以确定主要安全终点的优效性。,0.2307692307692307,"['safety', 'procedure', 'be', 'primary', 'efficacy', 'superiority', 'end', 'testing procedure', 'point', 'closed', 'if', 'to', 'determine']","['safety', 'procedure', 'point']",945,"['如果对初级效能终点显示不低,则应进行关闭测试程序,以确定初级安全终点的优越性。']",0.3846153846153846,"['safety', 'procedure', 'be', 'primary', 'efficacy', 'superiority', 'end', 'testing procedure', 'point', 'closed', 'if', 'to', 'determine']","['safety', 'procedure', 'efficacy', 'superiority', 'point']",,
951,946,"an assessment of superiority for the primary efficacy end point , which was not prespecified before the database lock , was performed after the demonstration of noninferiority for efficacy and superiority for the primary safety end point .",主要疗效终点的优效性评估在数据库锁定前未预先指定，是在证明疗效的非劣效性和主要安全性终点的优效性后进行的。,0.4615384615384615,"['safety', 'database', 'demonstration', 'assessment', 'primary', 'after', 'efficacy', 'superiority', 'lock', 'end', 'point', 'before', 'and']","['safety', 'assessment', 'after', 'lock', 'point', 'before']",946,"['对初级效率终点的优越性评估,在数据库锁之前没有预定,在对初级安全终点的效率和优越性表现后进行。']",0.5384615384615384,"['safety', 'database', 'demonstration', 'assessment', 'primary', 'after', 'efficacy', 'superiority', 'lock', 'end', 'point', 'before', 'and']","['safety', 'assessment', 'after', 'superiority', 'lock', 'point', 'before']",,
952,947,secondary end points are reported with hazard ratios and 95 % confidence intervals .,次要终点报告有风险比和 95% 置信区间。,0.1428571428571428,"['end points', 'hazard', 'secondary', 'with', 'confidence', 'and', 'intervals']",['end points'],947,['二级终点与危险率和95%的信任间隔报告。'],0.2857142857142857,"['end points', 'hazard', 'secondary', 'with', 'confidence', 'and', 'intervals']","['end points', 'hazard']",,
953,948,"the confidence intervals have not been adjusted for multiple comparisons , so inferences drawn from these intervals may not be reproducible .",置信区间未针对多重比较进行调整，因此从这些区间得出的推论可能无法重现。,0.1666666666666666,"['multiple', 'be', 'confidence', 'have not', 'so', 'intervals']",['have not'],948,"['信任间隔未适用于多个比较,因此从这些间隔中提取的结论可能无法重复。']",0.1666666666666666,"['multiple', 'be', 'confidence', 'have not', 'so', 'intervals']",['have not'],,
954,949,"all the statistical analyses were performed with the use of SAS software , version 9.4 for Windows ( SAS Institute ) .",所有统计分析均使用适用于 Windows 的 SAS 软件 9.4 版（SAS Institute）进行。,0.1666666666666666,"['version', 'software', 'institute', 'with', 'SAS', 'all']",['software'],949,"['所有统计分析都使用SAS软件,版本 9.4 for Windows(SAS Institute)进行。']",0.3333333333333333,"['version', 'software', 'institute', 'with', 'SAS', 'all']","['version', 'software']",,
955,950,"at baseline , the characteristics of the patients were similar in the two treatment groups ( Table 1 , and Table S2 in the Supplementary Appendix ) .",基线时，两个治疗组的患者特征相似（表1和补充附录表S2）。,0.5454545454545454,"['appendix', 'table', 'baseline', '1', 'supplementary', 'treatment', 'characteristics', 'S2', 'and', 'two', 'similar']","['table', 'baseline', '1', 'treatment', 'characteristics', 'two']",950,"['在基线上,患者的特征在两组治疗中是相似的(表1和附件S2的表)。']",0.7272727272727273,"['appendix', 'table', 'baseline', '1', 'supplementary', 'treatment', 'characteristics', 'S2', 'and', 'two', 'similar']","['appendix', 'table', 'baseline', '1', 'treatment', 'characteristics', 'two', 'similar']",,
956,951,"the mean age was 74 years , and 79 % of the patients were men .",平均年龄为 74 岁，79% 的患者为男性。,0.6666666666666666,"['mean', 'age', 'and']","['mean', 'age']",951,"['平均年龄为74岁,79%的患者是男性。']",0.6666666666666666,"['mean', 'age', 'and']","['mean', 'age']",,
957,952,"a total of 1564 patients ( 70.6 % ) had undergone previous PCI , and 252 ( 11.4 % ) had undergone previous CABG .",共有1564名患者(70.6%)曾接受过PCI，252名(11.4%)患者曾接受过CABG。,0.0,"['a', 'previous', 'total', 'CABG', 'and']",[],952,"['总共有1564名患者(70.6%)经历过以前的PCI,252名患者(11.4%)经历过以前的CABG。']",0.2,"['a', 'previous', 'total', 'CABG', 'and']",['previous'],,
958,953,early TERMINATION OF THE TRIAL,提前终止试验,0.0,['early'],[],953,['特里亚尔的早期终结'],1.0,['early'],['early'],,
959,954,the evaluation of the patients was planned to continue until September 2018 .,对患者的评估计划持续到 2018 年 9 月。,0.3333333333333333,"['evaluation', 'continue', 'to']",['continue'],954,['预计患者的评估将持续到2018年9月。'],0.3333333333333333,"['evaluation', 'continue', 'to']",['continue'],,
960,955,the trial database was locked in January 2019 .,试验数据库已于 2019 年 1 月锁定。,0.0,"['database', 'trial', 'in']",[],955,['测试数据库于2019年1月关闭。'],0.0,"['database', 'trial', 'in']",[],,
961,956,primary EFFICACY AND SAFETY END POINTS,主要疗效和安全性终点,0.0,['primary'],[],956,['首要效率和安全终点'],0.0,['primary'],[],,
962,957,"in the assessment of superiority for the primary efficacy end point ( which was not a prespecified analysis ) , the P value was 0.02 .",在主要疗效终点（不是预设分析）的优效性评估中，P 值为 0.02。,0.3,"['a', 'analysis', 'value', 'assessment', 'primary', 'efficacy', 'superiority', 'end', 'point', 'P']","['analysis', 'assessment', 'point']",957,"['在对初级效率终点的优越性评估(这不是预定分析),P值为0.02。']",0.4,"['a', 'analysis', 'value', 'assessment', 'primary', 'efficacy', 'superiority', 'end', 'point', 'P']","['analysis', 'assessment', 'superiority', 'point']",,
963,958,a sensitivity analysis using the original efficacy end point also showed consistent results ( Table S6 in the Supplementary Appendix ) .,使用原始疗效终点的敏感性分析也显示出一致的结果（补充附录表 S6）。,0.3333333333333333,"['a', 'appendix', 'table', 'analysis', 'supplementary', 'efficacy', 'original', 'point', 'sensitivity']","['table', 'analysis', 'point']",958,['使用原始效率终点的敏感性分析也显示了一致的结果(附件中的S6表)。'],0.4444444444444444,"['a', 'appendix', 'table', 'analysis', 'supplementary', 'efficacy', 'original', 'point', 'sensitivity']","['appendix', 'table', 'analysis', 'point']",,
964,959,the incidence of individual components of the primary end point in the two groups are provided in Table 2 .,表 2 提供了两组中主要终点的各个组成部分的发生率。,0.625,"['incidence', 'table', '2', 'individual', 'primary', 'end', 'point', 'two']","['incidence', 'table', '2', 'point', 'two']",959,['主要终点的各个组成部分在两组中的影响表2中表明。'],0.5,"['incidence', 'table', '2', 'individual', 'primary', 'end', 'point', 'two']","['table', '2', 'point', 'two']",,
965,960,detailed information regarding bleeding sites is provided in Table S8 in the Supplementary Appendix .,补充附录表 S8 中提供了有关出血部位的详细信息。,0.6666666666666666,"['bleeding', 'appendix', 'table', 'supplementary', 'regarding', 'information']","['bleeding', 'table', 'regarding', 'information']",960,['有关出血场所的详细信息在附加附件中的表 S8 中提供。'],0.8333333333333334,"['bleeding', 'appendix', 'table', 'supplementary', 'regarding', 'information']","['bleeding', 'appendix', 'table', 'regarding', 'information']",,
966,961,there were two fatal bleeding events in each group ( Table S9 in the Supplementary Appendix ) .,每组均有两起致命性出血事件（补充附录表 S9）。,0.5,"['bleeding', 'group', 'appendix', 'table', 'supplementary', 'fatal', 'each', 'two']","['bleeding', 'group', 'table', 'two']",961,['每个群体中有两起致命的出血事件(附件中的S9表)。'],0.75,"['bleeding', 'group', 'appendix', 'table', 'supplementary', 'fatal', 'each', 'two']","['bleeding', 'group', 'appendix', 'table', 'fatal', 'two']",,
967,962,selected SUBGROUP ANALYSES,选定的子组分析,,[],[],962,['选择的子组分析'],,[],[],,
968,963,"with respect to the primary efficacy end point , the effect of monotherapy , as compared with combination therapy , was generally consistent across all prespecified subgroups , including those defined according to sex , age , stroke and bleeding risk scores , and renal function ( Figure 3 ) .",关于主要疗效终点，与联合治疗相比，单一疗法的效果在所有预先指定的亚组中基本一致，包括根据性别、年龄、中风和出血风险评分以及肾功能定义的亚组（图 3 ） .,0.4583333333333333,"['bleeding', 'combination therapy', 'stroke', 'defined', 'sex', 'figure', 'function', 'primary', 'across', 'renal', 'age', 'risk', 'effect', 'efficacy', '3', 'end', 'point', 'as', 'with', 'respect', 'all', 'to', 'and', 'renal function']","['bleeding', 'combination therapy', 'stroke', 'sex', 'function', 'age', 'risk', 'effect', 'point', 'to', 'renal function']",963,"['至于初级有效性终点,与结合疗法相比,单疗法的效果在所有预定子群中都是一致的,包括根据性别、年龄、中风和出血风险分数和肾功能定义的子群。']",0.4583333333333333,"['bleeding', 'combination therapy', 'stroke', 'defined', 'sex', 'figure', 'function', 'primary', 'across', 'renal', 'age', 'risk', 'effect', 'efficacy', '3', 'end', 'point', 'as', 'with', 'respect', 'all', 'to', 'and', 'renal function']","['bleeding', 'stroke', 'sex', 'function', 'age', 'risk', 'effect', 'efficacy', 'point', 'to', 'renal function']",,
969,964,"the trial met its primary objective of showing the noninferiority of rivaroxaban monotherapy , as compared with combination therapy with rivaroxaban plus antiplatelet therapy , for the composite of cardiovascular events or death from any cause .",该试验达到了其主要目标，即显示利伐沙班单一疗法与利伐沙班加抗血小板疗法的联合疗法相比，对于心血管事件或全因死亡的复合疗法具有非劣效性。,0.3846153846153846,"['combination therapy', 'composite', 'objective', 'cardiovascular', 'death', 'plus', 'antiplatelet', 'primary', 'cause', 'trial', 'with', 'rivaroxaban', 'met']","['cardiovascular', 'death', 'plus', 'cause', 'rivaroxaban']",964,"['该研究满足了其主要目标,表明Rivaroxaban单疗法与Rivaroxaban加上抗斑疗法的结合疗法相比,对心血管事件的组成或因任何原因而导致的死亡不低。']",0.3076923076923077,"['combination therapy', 'composite', 'objective', 'cardiovascular', 'death', 'plus', 'antiplatelet', 'primary', 'cause', 'trial', 'with', 'rivaroxaban', 'met']","['cardiovascular', 'death', 'plus', 'cause']",,
970,965,"in an analysis that was not prespecified , monotherapy was superior to combination therapy for this same end point .",在一项未预先指定的分析中，就同一终点而言，单一疗法优于联合疗法。,0.375,"['combination therapy', 'analysis', 'superior', 'end', 'point', 'this', 'that', 'to']","['analysis', 'point', 'to']",965,"['在没有预定的分析中,单疗法比同一终点的结合疗法优越。']",0.25,"['combination therapy', 'analysis', 'superior', 'end', 'point', 'this', 'that', 'to']","['analysis', 'point']",,
971,966,"the trial also met its primary safety end point , with use of monotherapy associated with a significantly lower rate of major bleeding events .",该试验还达到了主要安全终点，使用单一疗法可显着降低大出血事件的发生率。,0.3333333333333333,"['bleeding', 'safety', 'rate', 'lower', 'major', 'associated', 'primary', 'trial', 'end', 'point', 'with', 'met']","['bleeding', 'safety', 'rate', 'point']",966,"['试验也满足了其主要安全终点,使用单治疗与重大出血事件的显著较低率有关。']",0.3333333333333333,"['bleeding', 'safety', 'rate', 'lower', 'major', 'associated', 'primary', 'trial', 'end', 'point', 'with', 'met']","['bleeding', 'safety', 'rate', 'point']",,
972,967,the trial was based on the concept that an antithrombotic regimen for patients with both atrial fibrillation and coronary artery disease should be less intensive than would be required if the regimens for both conditions were combined .,该试验基于这样的概念，即对于同时患有心房颤动和冠状动脉疾病的患者，抗血栓形成方案的强度应低于两种情况联合方案所需的强度。,0.5,"['atrial', 'disease', 'antithrombotic', 'fibrillation', 'coronary', 'be', 'atrial fibrillation', 'intensive', 'concept', 'with', 'coronary artery', 'that', 'if', 'and']","['disease', 'antithrombotic', 'fibrillation', 'coronary', 'atrial fibrillation', 'concept', 'coronary artery']",967,"['该研究基于对患有甲状腺纤维和冠状动脉疾病的患者的抗血管制应比如果两种疾病的制应相结合,则所需的要少强度。']",0.2142857142857142,"['atrial', 'disease', 'antithrombotic', 'fibrillation', 'coronary', 'be', 'atrial fibrillation', 'intensive', 'concept', 'with', 'coronary artery', 'that', 'if', 'and']","['disease', 'coronary', 'coronary artery']",,
973,968,"these trials have shaped current guidelines and consensus documents , which recommend combination therapy with an anticoagulant plus a P2Y12 inhibitor for up to 1 year after PCI in patients with atrial fibrillation.8,10,14","这些试验形成了目前的指南和共识文件，建议在房颤患者 PCI 后使用抗凝剂和 P2Y12 抑制剂联合治疗长达 1 年。 8,10,14",0.5333333333333333,"['atrial', 'inhibitor', 'combination therapy', 'anticoagulant', 'consensus', 'year', '1', 'plus', 'recommend', 'after', 'current', 'up', 'with', 'have', 'and']","['inhibitor', 'combination therapy', 'anticoagulant', 'consensus', 'year', '1', 'recommend', 'after']",968,"['这些试验已经形成了当前的指导方针和共识文件,建议与抗凝固剂以及P2Y12抑制剂的结合治疗,在患有甲状腺纤维炎的患者中,PCI后1年。']",0.5333333333333333,"['atrial', 'inhibitor', 'combination therapy', 'anticoagulant', 'consensus', 'year', '1', 'plus', 'recommend', 'after', 'current', 'up', 'with', 'have', 'and']","['inhibitor', 'consensus', 'year', '1', 'recommend', 'after', 'current', 'have']",,
974,969,"after 1 year following PCI , guidelines in western countries recommend oral anticoagulant monotherapy.9,10","PCI 术后 1 年后，西方国家的指南推荐口服抗凝剂单一疗法。 9,10",0.625,"['anticoagulant', 'year', '1', 'oral', 'recommend', 'after', 'in', 'following']","['anticoagulant', 'year', '1', 'recommend', 'after']",969,"['PCI之后1年后,西方国家的指南建议口服抗凝固剂单治疗。']",0.5,"['anticoagulant', 'year', '1', 'oral', 'recommend', 'after', 'in', 'following']","['year', '1', 'recommend', 'after']",,
975,970,"this recommendation was based on the findings of a national Danish cohort study.3,15","该建议基于丹麦全国队列研究的结果。 3,15",0.0,"['a', 'cohort', 'on', 'this']",[],970,['该建议是基于国家丹麦联盟研究的结果。'],0.25,"['a', 'cohort', 'on', 'this']",['this'],,
976,971,"however , this recommendation has yet to be supported by evidence from randomized clinical trials .",然而，这一建议尚未得到随机临床试验证据的支持。,0.3333333333333333,"['be', 'clinical', 'evidence', 'this', 'by', 'to']","['clinical', 'evidence']",971,"['然而,这一建议尚未得到随机临床试验的证据支持。']",0.3333333333333333,"['be', 'clinical', 'evidence', 'this', 'by', 'to']","['clinical', 'evidence']",,
977,972,"these anticoagulants have several advantages over warfarin , including an improved efficacy and safety profile , a predictable anticoagulant effect without the need for routine coagulation monitoring , and lower risks of food and drug interactions , intracranial hemorrhage , and death.16,17","与华法林相比，这些抗凝剂有几个优点，包括提高疗效和安全性、无需常规凝血监测即可预测抗凝效果，以及食物和药物相互作用、颅内出血和死亡的风险较低。 16,17",0.6666666666666666,"['safety', 'monitoring', 'anticoagulant', 'coagulation', 'food', 'need', 'hemorrhage', 'routine', 'intracranial', 'intracranial hemorrhage', 'lower', 'warfarin', 'effect', 'efficacy', 'profile', 'drug', 'have', 'over', 'and', 'without', 'anticoagulants']","['safety', 'monitoring', 'anticoagulant', 'coagulation', 'food', 'hemorrhage', 'routine', 'intracranial hemorrhage', 'warfarin', 'effect', 'drug', 'have', 'without', 'anticoagulants']",972,"['这些抗凝固剂对瓦法林有几个好处,包括提高效率和安全性,预测性抗凝固剂效应,无需日常凝固监测,降低食物和药物相互作用的风险,内分泌出血和死亡。']",0.4285714285714285,"['safety', 'monitoring', 'anticoagulant', 'coagulation', 'food', 'need', 'hemorrhage', 'routine', 'intracranial', 'intracranial hemorrhage', 'lower', 'warfarin', 'effect', 'efficacy', 'profile', 'drug', 'have', 'over', 'and', 'without', 'anticoagulants']","['safety', 'monitoring', 'coagulation', 'food', 'hemorrhage', 'effect', 'drug', 'have', 'without']",,
978,973,our results support the general concept that rivaroxaban monotherapy without antiplatelet therapy is the better approach in this population on the basis of both efficacy and safety .,我们的结果支持这样的一般概念，即在有效性和安全性的基础上，利伐沙班单药治疗而不进行抗血小板治疗是该人群的更好方法。,0.5882352941176471,"['approach', 'safety', 'population', 'support', 'antiplatelet', 'general', 'basis', 'therapy', 'efficacy', 'concept', 'general concept', 'rivaroxaban', 'this', 'that', 'in', 'and', 'without']","['safety', 'population', 'support', 'therapy', 'efficacy', 'concept', 'general concept', 'rivaroxaban', 'this', 'and']",973,"['我们的结果支持普遍的概念,Rivaroxaban单治疗没有抗细胞治疗是这个人口的最佳方法,基于有效性和安全性。']",0.4705882352941176,"['approach', 'safety', 'population', 'support', 'antiplatelet', 'general', 'basis', 'therapy', 'efficacy', 'concept', 'general concept', 'rivaroxaban', 'this', 'that', 'in', 'and', 'without']","['safety', 'population', 'support', 'general', 'therapy', 'efficacy', 'concept', 'this']",,
979,974,some limitations of our trial should be noted .,应注意我们试验的一些局限性。,0.0,"['be', 'trial']",[],974,['请注意我们审判的某些限制。'],0.5,"['be', 'trial']",['trial'],,
980,975,"however , these values were within the 5 % rate of discontinuation that was anticipated ( Table S12 in the Supplementary Appendix ) and were consistent between the two groups .",然而，这些值在预期的 5% 停药率范围内（补充附录中的表 S12），并且在两组之间是一致的。,0.5,"['5', 'appendix', 'table', 'rate', 'supplementary', 'values', 'that', 'in', 'and', 'two']","['5', 'table', 'rate', 'and', 'two']",975,"['然而,这些值在预期的5%中断率(附件中的S12表)之内,并在两组之间一致。']",0.6,"['5', 'appendix', 'table', 'rate', 'supplementary', 'values', 'that', 'in', 'and', 'two']","['5', 'appendix', 'table', 'rate', 'and', 'two']",,
981,976,"the choice of antiplatelet regimen , either aspirin or a P2Y12 inhibitor , was at the discretion of the treating physicians , a factor that makes it uncertain whether the benefit of rivaroxaban monotherapy applies equally to the two combination regimens .",抗血小板治疗方案（阿司匹林或 P2Y12 抑制剂）的选择由主治医师自行决定，这一因素导致不确定利伐沙班单一疗法的益处是否同样适用于两种联合治疗方案。,0.6666666666666666,"['inhibitor', 'combination', 'aspirin', 'factor', 'antiplatelet', 'uncertain', 'benefit', 'choice', 'rivaroxaban', 'that', 'two', 'physicians']","['inhibitor', 'combination', 'aspirin', 'factor', 'benefit', 'choice', 'rivaroxaban', 'two']",976,"['抗乳腺治疗方案的选择,无论是阿司匹林还是P2Y12抑制剂,在治疗医生的判断下,这是一个因素,使它不确定Rivaroxaban单治疗的好处是否同样适用于两种组合治疗方案。']",0.5,"['inhibitor', 'combination', 'aspirin', 'factor', 'antiplatelet', 'uncertain', 'benefit', 'choice', 'rivaroxaban', 'that', 'two', 'physicians']","['inhibitor', 'combination', 'aspirin', 'factor', 'choice', 'two']",,
982,977,"finally , the reductions in the rate of ischemic events and death from any cause with rivaroxaban monotherapy were unanticipated and are difficult to explain on the basis of the biologic effects of antithrombotic therapy ; these findings may be due to the play of chance .",最后，利伐沙班单一疗法可降低缺血事件发生率和全因死亡率，这是出乎意料的，而且很难根据抗血栓治疗的生物学效应来解释；这些发现可能是偶然的结果。,0.3529411764705882,"['rate', 'death', 'biologic', 'antithrombotic', 'basis', 'therapy', 'be', 'cause', 'due', 'with', 'rivaroxaban', 'on', 'in', 'to', 'and', 'difficult', 'ischemic']","['rate', 'death', 'therapy', 'rivaroxaban', 'and', 'difficult']",977,"['最后,与Rivaroxaban单治疗的任何原因导致的催化事件和死亡率的下降是意想不到的,很难根据抗血管治疗的生物效应来解释;这些发现可能是由于偶然的作用。']",0.3529411764705882,"['rate', 'death', 'biologic', 'antithrombotic', 'basis', 'therapy', 'be', 'cause', 'due', 'with', 'rivaroxaban', 'on', 'in', 'to', 'and', 'difficult', 'ischemic']","['rate', 'death', 'therapy', 'cause', 'to', 'difficult']",,
983,978,"in conclusion , the AFIRE trial evaluated antithrombotic regimens in patients with atrial fibrillation and stable coronary artery disease more than 1 year after revascularization or in those with angiographically confirmed coronary artery disease not requiring revascularization .",总之，AFIRE 试验评估了血运重建后 1 年以上心房颤动和稳定性冠状动脉疾病患者或血管造影证实的冠状动脉疾病不需要血运重建患者的抗血栓治疗方案。,0.625,"['atrial', 'disease', 'year', '1', 'antithrombotic', 'fibrillation', 'coronary', 'revascularization', 'atrial fibrillation', 'after', 'conclusion', 'with', 'coronary artery', 'in', 'and', 'angiographically']","['disease', 'year', '1', 'fibrillation', 'coronary', 'revascularization', 'atrial fibrillation', 'after', 'coronary artery', 'angiographically']",978,"['在结论中,AFIRE研究评估了患有甲状腺纤维和稳定的冠状动脉疾病超过1年后的患者的抗血管疾病,或在没有需要重血的冠状动脉疾病的患者中。']",0.4375,"['atrial', 'disease', 'year', '1', 'antithrombotic', 'fibrillation', 'coronary', 'revascularization', 'atrial fibrillation', 'after', 'conclusion', 'with', 'coronary artery', 'in', 'and', 'angiographically']","['disease', 'year', '1', 'coronary', 'after', 'conclusion', 'coronary artery']",,
984,979,we found that rivaroxaban monotherapy was noninferior to combination therapy with rivaroxaban plus antiplatelet therapy with respect to cardiovascular events and death from any cause and superior with respect to major bleeding .,我们发现，在心血管事件和全因死亡方面，利伐沙班单药疗法不劣于利伐沙班加抗血小板疗法的联合疗法，在大出血方面优于利伐沙班。,0.375,"['bleeding', 'combination therapy', 'cardiovascular', 'death', 'plus', 'antiplatelet', 'superior', 'major', 'cause', 'with', 'respect', 'rivaroxaban', 'that', 'to', 'and', 'we']","['bleeding', 'cardiovascular', 'death', 'plus', 'rivaroxaban', 'to']",979,"['我们发现,Rivaroxaban的单疗法与Rivaroxaban的结合疗法以及与心血管事件和任何原因导致的死亡以及与主要出血相比不低。']",0.25,"['bleeding', 'combination therapy', 'cardiovascular', 'death', 'plus', 'antiplatelet', 'superior', 'major', 'cause', 'with', 'respect', 'rivaroxaban', 'that', 'to', 'and', 'we']","['bleeding', 'cardiovascular', 'death', 'cause']",,
985,980,additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials .,额外的吉西他滨和顺铂诱导化疗在 2 期试验中显示出有前途的疗效。,0.7,"['chemotherapy', 'induction', 'phase', 'cisplatin', '2', 'additional', 'in phase', 'efficacy', 'gemcitabine', 'and']","['chemotherapy', 'induction', 'phase', 'cisplatin', '2', 'additional', 'gemcitabine']",980,['额外的吉姆西塔宾和西斯普拉丁引导化疗在阶段2试验中表现出有前途的有效性。'],0.6,"['chemotherapy', 'induction', 'phase', 'cisplatin', '2', 'additional', 'in phase', 'efficacy', 'gemcitabine', 'and']","['chemotherapy', 'induction', 'phase', '2', 'additional', 'efficacy']",,
986,981,"secondary end points included overall survival , treatment adherence , and safety .",次要终点包括总生存期、治疗依从性和安全性。,0.5714285714285714,"['safety', 'survival', 'end points', 'treatment', 'secondary', 'adherence', 'and']","['safety', 'survival', 'end points', 'treatment']",981,['二级终点包括整体生存、治疗和安全。'],0.5714285714285714,"['safety', 'survival', 'end points', 'treatment', 'secondary', 'adherence', 'and']","['safety', 'survival', 'end points', 'treatment']",,
987,982,"overall survival at 3 years was 94.6 % and 90.3 % , respectively ( stratified hazard ratio for death , 0.43 ; 95 % CI , 0.24 to 0.77 ) .",3 年总生存率分别为 94.6% 和 90.3%（死亡的分层风险比为 0.43；95% CI 为 0.24 至 0.77）。,0.5,"['survival', 'ratio', 'hazard ratio', 'death', '3', 'CI', 'to', 'and']","['survival', 'ratio', 'hazard ratio', 'death']",982,"['3年的总生存率为94.6%和90.3%,分别(分裂死亡风险比例为0.43;95% CI,0.24至0.77)。']",0.5,"['survival', 'ratio', 'hazard ratio', 'death', '3', 'CI', 'to', 'and']","['survival', 'ratio', 'hazard ratio', 'death']",,
988,983,a total of 96.7 % of the patients completed three cycles of induction chemotherapy .,共有96.7%的患者完成了三个周期的诱导化疗。,0.5,"['chemotherapy', 'induction', 'total', 'three']","['chemotherapy', 'induction']",983,['96.7%的患者完成了3个引发化疗周期。'],0.25,"['chemotherapy', 'induction', 'total', 'three']",['chemotherapy'],,
989,984,nasopharyngeal carcinoma is a head and neck cancer with a specific geographic distribution .,鼻咽癌是一种具有特定地理分布的头颈癌。,0.5,"['a', 'carcinoma', 'cancer', 'neck', 'head', 'nasopharyngeal', 'nasopharyngeal carcinoma', 'distribution', 'geographic', 'specific', 'with', 'and']","['carcinoma', 'cancer', 'neck', 'head', 'nasopharyngeal carcinoma', 'distribution']",984,['鼻孔癌是一种具有特定的地理分布的头部和脖子癌症。'],0.3333333333333333,"['a', 'carcinoma', 'cancer', 'neck', 'head', 'nasopharyngeal', 'nasopharyngeal carcinoma', 'distribution', 'geographic', 'specific', 'with', 'and']","['carcinoma', 'cancer', 'head', 'distribution']",,
990,985,"it affected an estimated 130,000 patients worldwide in 2018 , with the highest rates occurring in regions in South China , Southeastern Asia , and North Africa.1","2018 年全球估计有 130,000 名患者受到影响，其中华南、东南亚和北非地区的发病率最高。 1",0.25,"['north', 'china', 'with', 'and']",['north'],985,"['它影响了全球估计130,000名患者在2018年,最高率发生在南中国、东南亚和北非地区。']",0.5,"['north', 'china', 'with', 'and']","['north', 'china']",,
991,986,"the toxicity of systemic therapy after chemoradiotherapy remains a pertinent issue.6,10","放化疗后全身治疗的毒性仍然是一个相关问题。 6,10",0.6,"['a', 'toxicity', 'therapy', 'systemic', 'after']","['toxicity', 'therapy', 'after']",986,['化疗后系统治疗的毒性仍然是一个相关问题。'],0.6,"['a', 'toxicity', 'therapy', 'systemic', 'after']","['toxicity', 'therapy', 'after']",,
992,987,"however , in the context of newly diagnosed , nonmetastatic , locoregionally advanced disease , the efficacy and safety profile of induction therapy with gemcitabine plus cisplatin to chemoradiotherapy is unclear .",然而，在新诊断的、非转移性、局部晚期疾病的情况下，吉西他滨联合顺铂诱导治疗对化放疗的疗效和安全性尚不清楚。,0.5,"['safety', 'induction', 'disease', 'context', 'cisplatin', 'plus', 'therapy', 'advanced', 'efficacy', 'profile', 'with', 'gemcitabine', 'to', 'and']","['safety', 'induction', 'disease', 'cisplatin', 'therapy', 'gemcitabine', 'and']",987,"['然而,在新诊断、非甲状腺疾病、区域先进疾病的背景下,用吉姆西塔宾加西斯普拉丁进行化学放射治疗的有效性和安全性不清楚。']",0.4285714285714285,"['safety', 'induction', 'disease', 'context', 'cisplatin', 'plus', 'therapy', 'advanced', 'efficacy', 'profile', 'with', 'gemcitabine', 'to', 'and']","['safety', 'disease', 'plus', 'therapy', 'efficacy', 'and']",,
993,988,"we therefore conducted a multicenter , randomized , controlled , phase 3 clinical trial to investigate the efficacy and safety of adding gemcitabine plus cisplatin to chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma .",因此，我们开展了一项多中心、随机、对照的 3 期临床试验，以研究在局部晚期鼻咽癌患者中将吉西他滨联合顺铂加入放化疗的疗效和安全性。,0.4444444444444444,"['clinical trial', 'safety', 'carcinoma', 'phase', 'cisplatin', 'plus', 'nasopharyngeal', 'nasopharyngeal carcinoma', 'controlled', 'advanced', 'efficacy', '3', 'with', 'gemcitabine', 'therefore', 'to', 'and', 'we']","['clinical trial', 'safety', 'carcinoma', 'phase', 'cisplatin', 'plus', 'nasopharyngeal carcinoma', 'gemcitabine']",988,"['因此,我们进行了多中心、随机、控制、第三阶段的临床试验,以调查在患有区域先进的鼻孔癌的患者中添加吉姆西塔宾加西斯普拉丁的有效性和安全性。']",0.3888888888888889,"['clinical trial', 'safety', 'carcinoma', 'phase', 'cisplatin', 'plus', 'nasopharyngeal', 'nasopharyngeal carcinoma', 'controlled', 'advanced', 'efficacy', '3', 'with', 'gemcitabine', 'therefore', 'to', 'and', 'we']","['clinical trial', 'safety', 'carcinoma', 'phase', 'plus', 'controlled', 'efficacy']",,
994,989,"the institutional ethics review board at each participating center approved the trial protocol , available at NEJM.org .",每个参与中心的机构伦理审查委员会批准了试验方案，可在 NEJM.org 获取。,0.3333333333333333,"['center', 'review', 'protocol', 'ethics', 'available', 'board', 'trial', 'at', 'each']","['center', 'review', 'protocol']",989,"['各參與中心的機構倫理評論委員會批准了試驗議定書,可在NEJM.org上找到。']",0.2222222222222222,"['center', 'review', 'protocol', 'ethics', 'available', 'board', 'trial', 'at', 'each']","['center', 'each']",,
995,990,the trial was performed according to the principles of the Declaration of Helsinki and Good Clinical Practice guidelines as defined by the International Conference on Harmonisation .,该试验是根据赫尔辛基宣言的原则和国际协调会议定义的良好临床实践指南进行的。,0.0,"['defined', 'good clinical practice', 'trial', 'as', 'on', 'by', 'to', 'and']",[],990,['根据《赫尔辛基宣言》和《国际协调会议》所定义的良好临床实践指南的原则进行审查。'],0.0,"['defined', 'good clinical practice', 'trial', 'as', 'on', 'by', 'to', 'and']",[],,
996,991,written informed consent was obtained from all the patients before enrollment .,入组前已获得所有患者的书面知情同意书。,0.5,"['consent', 'informed consent', 'all', 'before']","['consent', 'before']",991,"['在注册之前,所有患者都获得了书面信息的同意。']",0.5,"['consent', 'informed consent', 'all', 'before']","['consent', 'before']",,
997,992,patients could withdraw consent at any time after enrollment and could discontinue the trial if disease progression or severe coexisting conditions occurred during treatment .,患者可以在入组后随时撤回同意，如果在治疗期间出现疾病进展或严重合并症，患者可以终止试验。,0.5454545454545454,"['disease', 'withdraw', 'time', 'treatment', 'progression', 'after', 'trial', 'consent', 'severe', 'if', 'and']","['disease', 'time', 'treatment', 'progression', 'after', 'consent']",992,"['患者可以在注册后随时撤回同意,如果病情进展或治疗期间发生严重的共同存在条件,则可以停止检查。']",0.5454545454545454,"['disease', 'withdraw', 'time', 'treatment', 'progression', 'after', 'trial', 'consent', 'severe', 'if', 'and']","['disease', 'time', 'treatment', 'progression', 'after', 'consent']",,
998,993,"the last author designed , wrote , and implemented the trial protocol and managed the trial .",最后一位作者设计、撰写和实施了试验方案并管理了试验。,0.25,"['author', 'protocol', 'trial', 'and']",['protocol'],993,['最后的作者设计、写作、实施审判协议并管理审判。'],0.5,"['author', 'protocol', 'trial', 'and']","['protocol', 'trial']",,
999,994,lead investigators from each center gathered the data and ensured its accuracy and completeness .,每个中心的首席调查员收集数据并确保其准确性和完整性。,0.5714285714285714,"['center', 'lead', 'data', 'accuracy', 'completeness', 'each', 'and']","['center', 'data', 'accuracy', 'completeness']",994,"['各中心的主要调查人员收集了数据,并确保其准确性和完整性。']",0.7142857142857143,"['center', 'lead', 'data', 'accuracy', 'completeness', 'each', 'and']","['center', 'data', 'accuracy', 'completeness', 'each']",,
1000,995,one of the authors conducted the statistical analyses .,其中一位作者进行了统计分析。,,[],[],995,['其中一位作者进行了统计分析。'],,[],[],,
1001,996,no one who is not an author contributed to the writing of the manuscript .,没有非作者参与手稿的撰写。,0.1666666666666666,"['who', 'author', 'no', 'manuscript', 'writing', 'to']",['manuscript'],996,"['没有人是作家,没有人参与了手稿的写作。']",0.3333333333333333,"['who', 'author', 'no', 'manuscript', 'writing', 'to']","['manuscript', 'writing']",,
1002,996,no one who is not an author contributed to the writing of the manuscript .,没有非作者参与手稿的撰写。,0.1666666666666666,"['who', 'author', 'no', 'manuscript', 'writing', 'to']",['manuscript'],996,"['没有人是作家,没有人参与了手稿的写作。']",0.3333333333333333,"['who', 'author', 'no', 'manuscript', 'writing', 'to']","['manuscript', 'writing']",,
1003,996,no one who is not an author contributed to the writing of the manuscript .,没有非作者参与手稿的撰写。,0.1666666666666666,"['who', 'author', 'no', 'manuscript', 'writing', 'to']",['manuscript'],996,"['没有人是作家,没有人参与了手稿的写作。']",0.3333333333333333,"['who', 'author', 'no', 'manuscript', 'writing', 'to']","['manuscript', 'writing']",,
1004,997,"the first author wrote the first draft of manuscript , which was reviewed by all the authors .",第一作者撰写了初稿，并由所有作者审阅。,0.3333333333333333,"['author', 'manuscript', 'all', 'by', 'first', 'draft']","['by', 'first']",997,"['第一位作者写了第一本手稿草案,所有作者都审查了。']",0.3333333333333333,"['author', 'manuscript', 'all', 'by', 'first', 'draft']","['manuscript', 'first']",,
1005,998,all the authors approved the final content of the manuscript .,所有作者都认可了手稿的最终内容。,0.3333333333333333,"['content', 'manuscript', 'all']",['manuscript'],998,['所有作者都批准了手稿的最终内容。'],0.3333333333333333,"['content', 'manuscript', 'all']",['manuscript'],,
1006,999,the trial sponsors had no access to the data and were not involved in the data interpretation or the manuscript preparation or review .,试验发起人无法访问数据，也不参与数据解释或手稿准备或审查。,0.5,"['data', 'preparation', 'review', 'access', 'interpretation', 'no', 'manuscript', 'trial', 'to', 'and']","['data', 'preparation', 'review', 'interpretation', 'manuscript']",999,"['审判赞助商没有访问数据,并未参与数据解释或手稿编制或审查。']",0.5,"['data', 'preparation', 'review', 'access', 'interpretation', 'no', 'manuscript', 'trial', 'to', 'and']","['data', 'review', 'interpretation', 'manuscript', 'trial']",,
1007,1000,"Qilu Pharmaceutical provided gemcitabine and cisplatin free of charge and was not involved in the trial design , data collection or analysis , or manuscript preparation or review .",齐鲁制药免费提供吉西他滨和顺铂，未参与试验设计、数据收集或分析、文稿准备或审阅。,0.625,"['charge', 'data', 'analysis', 'pharmaceutical', 'preparation', 'cisplatin', 'review', 'collection', 'free', 'free of charge', 'manuscript', 'trial', 'data collection', 'design', 'gemcitabine', 'and']","['data', 'analysis', 'preparation', 'cisplatin', 'review', 'collection', 'free of charge', 'data collection', 'design', 'gemcitabine']",1000,['Qilu Pharmaceutical 免费提供 gemcitabine 和 cisplatin 并未参与试验设计、数据收集或分析、手稿制作或审查。'],0.5,"['charge', 'data', 'analysis', 'pharmaceutical', 'preparation', 'cisplatin', 'review', 'collection', 'free', 'free of charge', 'manuscript', 'trial', 'data collection', 'design', 'gemcitabine', 'and']","['data', 'analysis', 'review', 'collection', 'free of charge', 'manuscript', 'data collection', 'design']",,
1008,1001,the last author vouches for the completeness and accuracy of the data and for the adherence of the trial to the protocol .,最后一位作者保证数据的完整性和准确性以及试验对方案的依从性。,0.375,"['data', 'author', 'accuracy', 'protocol', 'trial', 'completeness', 'adherence', 'and']","['data', 'accuracy', 'completeness']",1001,['最后的作者为数据的完整性和准确性以及审判对议定书的遵守提供优惠。'],0.625,"['data', 'author', 'accuracy', 'protocol', 'trial', 'completeness', 'adherence', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
1009,1002,"for this trial , essential pretreatment evaluations included the following : complete history ; physical examination ; hematologic and biochemical analyses ; flexible nasopharyngoscopy ; histopathological diagnosis ; and magnetic resonance imaging ( MRI ) or enhanced computed tomography ( CT ) ( if patients had contraindications to MRI ) of the nasopharynx and neck for primary tumor staging .",对于该试验，基本的治疗前评估包括以下内容：完整的病史；身体检查；血液学和生化分析；可弯曲鼻咽镜检查；组织病理学诊断；鼻咽部和颈部的磁共振成像 (MRI) 或增强型计算机断层扫描 (CT)（如果患者有 MRI 禁忌证）用于原发肿瘤分期。,0.36,"['resonance', 'tomography', 'nasopharynx', 'neck', 'primary tumor', 'physical', 'examination', 'history', 'essential', 'physical examination', 'MRI', 'magnetic resonance imaging', 'complete', 'diagnosis', 'trial', 'flexible', 'CT', 'biochemical', 'pretreatment', 'computed tomography', 'this', 'if', 'and', 'hematologic', 'following']","['resonance', 'tomography', 'nasopharynx', 'neck', 'examination', 'physical examination', 'magnetic resonance imaging', 'complete', 'diagnosis']",1002,"['对于此试验,基本的预治疗评估包括以下:完整的历史;物理检查;血液学和生物化学分析;灵活的鼻孔筛查;歇斯托病学诊断;和磁响图像(MRI)或增强计算图像(CT)(如果患者有MRI的对抗迹象)的鼻孔和颈部的初始肿瘤排序。']",0.24,"['resonance', 'tomography', 'nasopharynx', 'neck', 'primary tumor', 'physical', 'examination', 'history', 'essential', 'physical examination', 'MRI', 'magnetic resonance imaging', 'complete', 'diagnosis', 'trial', 'flexible', 'CT', 'biochemical', 'pretreatment', 'computed tomography', 'this', 'if', 'and', 'hematologic', 'following']","['neck', 'examination', 'history', 'magnetic resonance imaging', 'complete', 'diagnosis']",,
1010,1003,distant metastasis staging was completed with CT examination of the chest and abdomen and with skeletal scintigraphy .,远处转移的分期是通过胸部和腹部的 CT 检查以及骨骼闪烁扫描完成的。,0.4444444444444444,"['abdomen', 'metastasis', 'chest', 'examination', 'skeletal', 'distant', 'CT', 'with', 'and']","['abdomen', 'metastasis', 'chest', 'examination']",1003,"['遥远的转移阶段完成了胸部和腹部的CT检查,以及骨骼阴道。']",0.5555555555555556,"['abdomen', 'metastasis', 'chest', 'examination', 'skeletal', 'distant', 'CT', 'with', 'and']","['abdomen', 'metastasis', 'chest', 'examination', 'distant']",,
1011,1004,a computer program was used to generate the assignment list .,使用计算机程序生成分配列表。,0.2857142857142857,"['a', 'program', 'computer', 'list', 'generate', 'assignment', 'to']","['program', 'computer']",1004,['一个计算机程序被用来创建任务列表。'],0.2857142857142857,"['a', 'program', 'computer', 'list', 'generate', 'assignment', 'to']","['program', 'computer']",,
1012,1005,treatment group assignment was not masked .,治疗组分配未设盲。,0.75,"['group', 'treatment', 'treatment group', 'assignment']","['group', 'treatment', 'treatment group']",1005,['治疗小组任务没有面具。'],0.5,"['group', 'treatment', 'treatment group', 'assignment']","['group', 'treatment']",,
1013,1006,"cisplatin that was concurrent with radiotherapy was then administered intravenously at a dose of 100 mg per square meter every 3 weeks on days 1 , 22 , and 43 .",然后在第 1、22 和 43 天每 3 周静脉内给予与放疗同步的顺铂，剂量为每平方米 100 毫克。,0.4615384615384615,"['a', 'cisplatin', '1', 'meter', 'radiotherapy', 'intravenously', 'concurrent', '3', 'with', 'dose', 'that', 'and', 'square']","['cisplatin', '1', 'meter', 'intravenously', 'dose', 'square']",1006,['随后与放射治疗相匹配的西斯普拉丁在1日、22日和43日每3周服用100毫克每平方米的内分泌剂。'],0.3076923076923077,"['a', 'cisplatin', '1', 'meter', 'radiotherapy', 'intravenously', 'concurrent', '3', 'with', 'dose', 'that', 'and', 'square']","['1', 'meter', 'radiotherapy', 'square']",,
1014,1007,details of the chemotherapy dose modifications and supportive measures are provided in the Supplementary Appendix .,补充附录中提供了化疗剂量调整和支持措施的详细信息。,0.3333333333333333,"['chemotherapy', 'appendix', 'supplementary', 'dose', 'in', 'and']","['chemotherapy', 'dose']",1007,['化疗剂量修改和支持措施的详细信息在附件中提供。'],0.5,"['chemotherapy', 'appendix', 'supplementary', 'dose', 'in', 'and']","['chemotherapy', 'appendix', 'dose']",,
1015,1008,"the guidelines regarding radiotherapy3,17 are provided in the Supplementary Appendix .","补充附录中提供了有关放疗的指南3,17。",0.3333333333333333,"['appendix', 'supplementary', 'regarding']",['regarding'],1008,['关于放射治疗的指南3、17在附件中列出。'],0.6666666666666666,"['appendix', 'supplementary', 'regarding']","['appendix', 'regarding']",,
1016,1009,it was recommended that patients in the induction chemotherapy group commence chemoradiotherapy within 21 to 28 days after the first day of the last cycle of induction chemotherapy .,建议诱导化疗组患者在诱导化疗末周期第一天后21～28天内开始放化疗。,0.75,"['group', 'chemotherapy', 'induction', 'cycle', 'after', 'that', 'to', 'first']","['group', 'chemotherapy', 'induction', 'cycle', 'after', 'first']",1009,['建议患者在因子化疗周期的第一天后21至28天内开始化疗。'],0.5,"['group', 'chemotherapy', 'induction', 'cycle', 'after', 'that', 'to', 'first']","['chemotherapy', 'cycle', 'after', 'first']",,
1017,1010,tumors were assessed with the use of flexible nasopharyngoscopy and MRI of the nasopharyngeal and neck areas at 1 week after the completion of induction chemotherapy and 16 weeks after chemoradiotherapy .,在诱导化疗完成后 1 周和放化疗后 16 周，使用可弯曲鼻咽镜和鼻咽及颈部 MRI 评估肿瘤。,0.5,"['chemotherapy', 'induction', 'neck', '1', 'nasopharyngeal', 'MRI', 'week', 'after', 'flexible', 'completion', 'with', 'at', 'and', 'assessed']","['chemotherapy', 'induction', 'neck', '1', 'week', 'after', 'completion']",1010,"['肿瘤被评估使用灵活的鼻<unk>和鼻<unk>和脖子区域的MRI在完成引发化疗后1周,并在化疗后16周。']",0.3571428571428571,"['chemotherapy', 'induction', 'neck', '1', 'nasopharyngeal', 'MRI', 'week', 'after', 'flexible', 'completion', 'with', 'at', 'and', 'assessed']","['chemotherapy', '1', 'week', 'after', 'completion']",,
1018,1011,"we used the Common Terminology Criteria for Adverse Events , version 4.0 , to grade acute toxic effects during treatment , and late toxic effects that were associated with radiotherapy were graded according to the Late Radiation Morbidity Scoring Scheme of the Radiation Therapy Oncology Group.18",我们使用不良事件通用术语标准 4.0 版对治疗期间的急性毒性反应进行分级，并根据放射治疗肿瘤组的晚期放射发病率评分方案对与放疗相关的晚期毒性反应进行分级。 18,0.25,"['radiation', 'toxic', 'morbidity', 'grade', 'version', 'radiotherapy', 'common', 'late', 'adverse', 'associated', 'treatment', 'terminology', 'scheme', 'acute', 'radiation therapy', 'scoring', 'with', 'that', 'and', 'we']","['radiation', 'morbidity', 'radiotherapy', 'treatment', 'terminology']",1011,"['我们使用的常用术语对不良事件的标准,版本 4.0,以评分治疗期间的急性毒性效果,以及与辐射治疗相关的晚期毒性效果,根据放射治疗肿瘤学集团的晚期辐射病度评分计划进行了评分。']",0.3,"['radiation', 'toxic', 'morbidity', 'grade', 'version', 'radiotherapy', 'common', 'late', 'adverse', 'associated', 'treatment', 'terminology', 'scheme', 'acute', 'radiation therapy', 'scoring', 'with', 'that', 'and', 'we']","['radiation', 'grade', 'version', 'radiotherapy', 'treatment', 'terminology']",,
1019,1012,all end points were assessed or confirmed by the physician in charge .,所有终点均由主治医师评估或确认。,0.5,"['charge', 'physician', 'end points', 'all', 'by', 'assessed']","['physician', 'end points', 'by']",1012,['所有终点都由负责的医生评估或确认。'],0.5,"['charge', 'physician', 'end points', 'all', 'by', 'assessed']","['physician', 'end points', 'by']",,
1020,1013,this yielded a final sample size of 476 ( 238 patients per group ) .19,这产生了 476 的最终样本量（每组 238 名患者）.19,0.4,"['sample', 'group', 'size', 'sample size', 'this']","['sample', 'group']",1013,['最终样品大小为476(每组238名患者)。'],0.6,"['sample', 'group', 'size', 'sample size', 'this']","['sample', 'group', 'size']",,
1021,1014,the safety population comprised patients who started treatment in each group .,安全人群包括每组开始治疗的患者。,0.5714285714285714,"['safety', 'group', 'population', 'who', 'treatment', 'each', 'in']","['safety', 'group', 'population', 'treatment']",1014,['安全人口包括在每个群体开始治疗的患者。'],0.5714285714285714,"['safety', 'group', 'population', 'who', 'treatment', 'each', 'in']","['safety', 'group', 'population', 'treatment']",,
1022,1015,"for each chemotherapy drug , we calculated the relative dose intensity as the total dose actually received during treatment , divided by the dose defined by the protocol .",对于每种化疗药物，我们将相对剂量强度计算为治疗期间实际接受的总剂量除以方案规定的剂量。,0.3076923076923077,"['chemotherapy', 'defined', 'protocol', 'relative', 'total', 'treatment', 'total dose', 'intensity', 'as', 'drug', 'each', 'by', 'we']","['chemotherapy', 'treatment', 'drug', 'by']",1015,"['对于每种化疗药物,我们计算了相对剂量强度,作为治疗期间实际获得的总剂量,分为协议定义的剂量。']",0.3076923076923077,"['chemotherapy', 'defined', 'protocol', 'relative', 'total', 'treatment', 'total dose', 'intensity', 'as', 'drug', 'each', 'by', 'we']","['chemotherapy', 'protocol', 'treatment', 'drug']",,
1023,1016,an independent data monitoring committee monitored the trial and made decisions regarding possible early trial stoppage .,一个独立的数据监测委员会监测了试验并就可能的早期试验停止做出了决定。,0.5555555555555556,"['monitoring', 'data', 'early', 'regarding', 'committee', 'trial', 'independent', 'stoppage', 'and']","['monitoring', 'data', 'early', 'committee', 'independent']",1016,"['一个独立的数据监测委员会对审判进行了监测,并就可能早期审判中断作出决定。']",0.6666666666666666,"['monitoring', 'data', 'early', 'regarding', 'committee', 'trial', 'independent', 'stoppage', 'and']","['monitoring', 'data', 'early', 'committee', 'trial', 'independent']",,
1024,1017,"an interim analysis was performed on October 30 , 2016 , when the trial reached approximately half the expected number of disease recurrences or deaths ( i.e. , 38 events ) .",2016 年 10 月 30 日进行了中期分析，当时试验达到了预期疾病复发或死亡人数的大约一半（即 38 起事件）。,0.4444444444444444,"['disease', 'analysis', 'half', 'number', 'of disease', 'trial', 'expected number', 'on', 'approximately']","['disease', 'analysis', 'half', 'number']",1017,"['临时分析是在2016年10月30日进行的,当调查达到预期的疾病重复或死亡人数(即38起事件)的约一半时。']",0.4444444444444444,"['disease', 'analysis', 'half', 'number', 'of disease', 'trial', 'expected number', 'on', 'approximately']","['disease', 'analysis', 'half', 'number']",,
1025,1018,the data monitoring committee reviewed the analyses and approved the continuation of the trial .,数据监测委员会审查了分析并批准继续试验。,0.6,"['monitoring', 'data', 'committee', 'trial', 'and']","['monitoring', 'data', 'committee']",1018,"['数据监测委员会审查了分析,并批准了审判的继续。']",0.8,"['monitoring', 'data', 'committee', 'trial', 'and']","['monitoring', 'data', 'committee', 'trial']",,
1026,1019,"the database was locked on April 15 , 2019 , and here we report the survival and toxicity analyses .",该数据库于 2019 年 4 月 15 日被锁定，我们在此报告生存和毒性分析。,0.4285714285714285,"['toxicity', 'database', 'survival', 'report', 'on', 'and', 'we']","['toxicity', 'survival', 'report']",1019,"['数据库于2019年4月15日关闭,我们在这里报告生存和毒性分析。']",0.4285714285714285,"['toxicity', 'database', 'survival', 'report', 'on', 'and', 'we']","['toxicity', 'survival', 'report']",,
1027,1020,"analyses were conducted with the use of SPSS software , version 22.0 ( IBM ) , and Stata software , version 14.2 ( StataCorp ) .",使用 SPSS 软件 22.0 版 (IBM) 和 Stata 软件 14.2 版 (StataCorp) 进行分析。,0.25,"['version', 'software', 'with', 'and']",['software'],1020,"['分析是使用SPSS软件,版本 22.0(IBM)和Stata软件,版本 14.2(StataCorp)进行的。']",0.5,"['version', 'software', 'with', 'and']","['version', 'software']",,
1028,1021,"from December 2013 through September 2016 , we enrolled 480 patients across 12 sites .",从 2013 年 12 月到 2016 年 9 月，我们在 12 个地点招募了 480 名患者。,0.0,"['across', 'we']",[],1021,"['从2013年12月到2016年9月,我们在12个网站上注册了480名患者。']",0.0,"['across', 'we']",[],,
1029,1022,the characteristics of the patients at baseline were well balanced between the two groups ( Table 1 ) .,两组患者的基线特征非常均衡（表 1）。,0.7142857142857143,"['table', 'baseline', '1', 'well', 'characteristics', 'at', 'two']","['table', 'baseline', '1', 'characteristics', 'two']",1022,['基层患者的特点在两组之间平衡得很好(图1)。'],0.2857142857142857,"['table', 'baseline', '1', 'well', 'characteristics', 'at', 'two']","['1', 'two']",,
1030,1023,"a total of 3 patients withdrew from the trial before the initiation of trial treatment ( 1 patient received chemoradiotherapy alone , and 2 received different induction chemotherapy plus chemoradiotherapy ) .",共有3例患者在试验治疗开始前退出试验（1例患者接受单纯放化疗，2例患者接受不同的诱导化疗加放化疗）。,0.6428571428571429,"['chemotherapy', 'induction', 'initiation', '1', '2', 'plus', 'total', 'treatment', 'patient', 'trial', '3', 'before', 'and', 'alone']","['chemotherapy', 'induction', 'initiation', '1', '2', 'plus', 'treatment', 'patient', 'before']",1023,"['总共3名患者在试验开始前退出试验(1名患者仅接受化疗,2名患者接受不同的引导化疗以及化疗)。']",0.5,"['chemotherapy', 'induction', 'initiation', '1', '2', 'plus', 'total', 'treatment', 'patient', 'trial', '3', 'before', 'and', 'alone']","['chemotherapy', 'induction', 'initiation', '1', '2', 'patient', 'before']",,
1031,1024,"a total of 231 of the 239 patients ( 96.7 % ) completed three cycles of induction chemotherapy ; 8 patients ( 3.3 % ) did not complete all three cycles of induction chemotherapy ( 3 patients received two cycles and 5 received one cycle ; the reasons included a case of the patient declining the treatment , a case of disease progression , and discontinuation due to adverse events in the remaining six cases ) ( Table S2 in the Supplementary Appendix ) .",239例患者中共有231例(96.7%)完成了3个周期的诱导化疗。 8例（ 3.3 % ）未完成全部3个周期的诱导化疗（3例2周期，5例1周期；原因包括1例患者拒绝治疗，1例疾病进展，1例因不良反应停药）其余六例中的事件）（补充附录中的表 S2）。,0.391304347826087,"['chemotherapy', 'induction', '5', 'disease', 'appendix', 'table', 'supplementary', 'total', 'cycle', 'complete', 'adverse', 'treatment', 'progression', 'case', 'patient', 'of disease', '3', 'due', 'S2', 'all', 'three', 'and', 'two']","['chemotherapy', 'induction', '5', 'disease', 'table', 'cycle', 'treatment', 'progression', 'patient']",1024,"['共231名239名患者(96.7%)完成了3个引发化疗周期;8名患者(3.3%)未完成所有3个引发化疗周期(3名患者接受了2个周期,5名患者接受了1个周期;原因包括患者中断治疗的案例,疾病进展的案例,以及由于其他6个案例发生的不良事件的中断)。']",0.3478260869565217,"['chemotherapy', 'induction', '5', 'disease', 'appendix', 'table', 'supplementary', 'total', 'cycle', 'complete', 'adverse', 'treatment', 'progression', 'case', 'patient', 'of disease', '3', 'due', 'S2', 'all', 'three', 'and', 'two']","['chemotherapy', '5', 'disease', 'cycle', 'treatment', 'progression', 'case', 'patient']",,
1032,1025,"a total of 31 of the 239 patients ( 13.0 % ) had dose reductions of gemcitabine or cisplatin , mainly because of hematologic toxic effects ( in 21 patients ) .",239 名患者中共有 31 名 (13.0%) 减少了吉西他滨或顺铂的剂量，主要是因为血液学毒性作用（21 名患者）。,0.4285714285714285,"['a', 'cisplatin', 'toxic', 'total', 'gemcitabine', 'dose', 'hematologic']","['cisplatin', 'gemcitabine', 'dose']",1025,"['在239名患者中,总共31名患者(13.0%)因血液毒性影响(21名患者)导致血糖或西斯普拉丁的剂量减少。']",0.1428571428571428,"['a', 'cisplatin', 'toxic', 'total', 'gemcitabine', 'dose', 'hematologic']",['dose'],,
1033,1026,"overall , the median relative dose intensity was 100 % ( interquartile range , 100 to 100 ) for gemcitabine and 100 % ( interquartile range , 100 to 100 ) for cisplatin .",总体而言，吉西他滨的中位相对剂量强度为 100%（四分位距，100 至 100），顺铂为 100%（四分位距，100 至 100）。,0.4444444444444444,"['median', 'range', 'cisplatin', 'relative', 'intensity', 'gemcitabine', 'dose', 'to', 'and']","['cisplatin', 'gemcitabine', 'dose', 'and']",1026,"['总体而言,中间相对剂量强度为100%(四分之一范围,100至100)为gemsitabine和100%(四分之一范围,100至100)为cisplatin。']",0.3333333333333333,"['median', 'range', 'cisplatin', 'relative', 'intensity', 'gemcitabine', 'dose', 'to', 'and']","['range', 'dose', 'and']",,
1034,1027,"in the induction chemotherapy group , 234 of 239 patients ( 97.9 % ) received concurrent chemoradiotherapy after induction chemotherapy , and 5 patients ( 2.1 % ) did not ( Figure 1 ) .",诱导化疗组239例患者中有234例(97.9%)在诱导化疗后接受同步放化疗，5例(2.1%)未接受同步放化疗(图1)。,0.6666666666666666,"['group', 'chemotherapy', 'induction', '5', '1', 'figure', 'concurrent', 'after', 'and']","['group', 'chemotherapy', 'induction', '5', '1', 'after']",1027,"['在因子化疗组中,234名239名患者(97.9%)在因子化疗后接受了同步化疗,而5名患者(2.1%)则没有(图1)。']",0.6666666666666666,"['group', 'chemotherapy', 'induction', '5', '1', 'figure', 'concurrent', 'after', 'and']","['group', 'chemotherapy', '5', '1', 'after', 'and']",,
1035,1028,"a total of 93 patients ( 38.9 % ) completed three cycles of concurrent cisplatin , 127 ( 53.1 % ) received two cycles , and 14 ( 5.9 % ) received one cycle .",共有93例患者（38.9%）完成了三个周期的顺铂同步治疗，127例患者（53.1%）完成了两个周期，14例患者（5.9%）完成了一个周期。,0.375,"['a', 'cisplatin', 'total', 'cycle', 'concurrent', 'three', 'and', 'two']","['cisplatin', 'cycle', 'two']",1028,"['总共93名患者(38.9%)完成了3个循环,127人(53.1%)接受了2个循环,14人(5.9%)接受了1个循环。']",0.125,"['a', 'cisplatin', 'total', 'cycle', 'concurrent', 'three', 'and', 'two']",['cycle'],,
1036,1029,"a total of 177 of 237 patients ( 74.7 % ) completed three cycles of concurrent cisplatin , 56 ( 23.6 % ) received two cycles , and 4 ( 1.7 % ) received one cycle .",237例患者中共有177例(74.7%)完成了3个周期的顺铂同步化疗，56例(23.6%)完成了2个周期，4例(1.7%)完成了1个周期。,0.2222222222222222,"['a', 'cisplatin', 'total', 'cycle', 'concurrent', '4', 'three', 'and', 'two']","['cisplatin', 'cycle']",1029,"['在237名患者中,共有177名患者(74.7%)完成了3个循环,56名患者(23.6%)接受了2个循环,4名患者(1.7%)接受了1个循环。']",0.1111111111111111,"['a', 'cisplatin', 'total', 'cycle', 'concurrent', '4', 'three', 'and', 'two']",['cycle'],,
1037,1030,"the median cumulative dose of cisplatin was 440 mg per square meter ( interquartile range , 440 to 540 ) in the induction chemotherapy group ; only 63 of 239 patients ( 26.4 % ) received the full cumulative dose of 540 mg per square meter .",诱导化疗组顺铂的中位累积剂量为440 mg/m（四分位距，440至540）； 239 名患者中只有 63 名 (26.4%) 接受了每平方米 540 毫克的全累积剂量。,0.5833333333333334,"['group', 'chemotherapy', 'induction', 'median', 'range', 'cisplatin', 'meter', 'cumulative', 'dose', 'full', 'to', 'square']","['group', 'chemotherapy', 'induction', 'cisplatin', 'meter', 'dose', 'square']",1030,"['基斯普拉丁的平均累积剂量为440毫克每平方米(四方范围,440至540)在引导化疗组;只有63名239名患者(264%)获得了每平方米540毫克的全部累积剂量。']",0.6666666666666666,"['group', 'chemotherapy', 'induction', 'median', 'range', 'cisplatin', 'meter', 'cumulative', 'dose', 'full', 'to', 'square']","['group', 'chemotherapy', 'induction', 'range', 'meter', 'dose', 'full', 'square']",,
1038,1031,"the median time from the start of the last induction chemotherapy cycle to the commencement of chemoradiotherapy was 25 days ( interquartile range , 22 to 28 ) .",从最后一个诱导化疗周期开始到放化疗开始的中位时间为 25 天（四分位距，22 到 28）。,0.5,"['chemotherapy', 'induction', 'median', 'range', 'time', 'cycle', 'start', 'to']","['chemotherapy', 'induction', 'time', 'cycle']",1031,"['从最后一次引发化疗周期开始到开始化疗的平均时间为25天(四分之一间范围,22至28天)。']",0.5,"['chemotherapy', 'induction', 'median', 'range', 'time', 'cycle', 'start', 'to']","['chemotherapy', 'range', 'time', 'cycle']",,
1039,1032,the time to the completion of radiotherapy and the radiotherapy doses received were similar in the two groups ( Table S3 in the Supplementary Appendix ) .,两组完成放疗的时间和接受的放疗剂量相似（补充附录表S3）。,0.3333333333333333,"['appendix', 'table', 'supplementary', 'radiotherapy', 'time', 'completion', 'S3', 'in', 'to', 'and', 'two', 'similar']","['table', 'time', 'completion', 'two']",1032,['放射治疗完成的时间和收到的放射治疗剂量在两组中是相似的(附件中的S3表)。'],0.5833333333333334,"['appendix', 'table', 'supplementary', 'radiotherapy', 'time', 'completion', 'S3', 'in', 'to', 'and', 'two', 'similar']","['appendix', 'table', 'radiotherapy', 'time', 'completion', 'two', 'similar']",,
1040,1033,"overall , 94.6 % of the patients ( 226 of 239 ) had a response after induction chemotherapy before the start of chemoradiotherapy ; 24 patients ( 10.0 % ) had a complete response , and 202 ( 84.5 % ) had a partial response .",总体而言，94.6% 的患者（239 人中的 226 人）在化放疗开始前的诱导化疗后有反应； 24例（10.0%）完全缓解，202例（84.5%）部分缓解。,0.6666666666666666,"['chemotherapy', 'induction', 'complete', 'response', 'partial', 'after', 'start', 'before', 'and']","['chemotherapy', 'induction', 'response', 'after', 'before', 'and']",1033,"['总体而言,94.6%的患者(239人中226人)在开始化疗之前接受了引发化疗后的反应;24人(10.0%)接受了完整的反应,202人(84.5%)接受了部分反应。']",0.6666666666666666,"['chemotherapy', 'induction', 'complete', 'response', 'partial', 'after', 'start', 'before', 'and']","['chemotherapy', 'complete', 'response', 'after', 'before', 'and']",,
1041,1034,details regarding the patterns of relapse and subsequent therapies after relapse are provided in Tables S5 and S6 in the Supplementary Appendix .,有关复发模式和复发后后续治疗的详细信息，请参见补充附录表 S5 和表 S6。,0.4285714285714285,"['relapse', 'appendix', 'supplementary', 'regarding', 'after', 'subsequent', 'and']","['relapse', 'regarding', 'after']",1034,['关于回归模式和后续回归治疗的详细信息在附件中的 S5 和 S6 表中提供。'],0.4285714285714285,"['relapse', 'appendix', 'supplementary', 'regarding', 'after', 'subsequent', 'and']","['appendix', 'regarding', 'after']",,
1042,1035,details regarding the cause of death are provided in Table S5 in the Supplementary Appendix .,补充附录表 S5 提供了有关死因的详细信息。,0.5714285714285714,"['appendix', 'table', 'death', 'supplementary', 'regarding', 'cause', 'cause of death']","['table', 'death', 'regarding', 'cause of death']",1035,['关于死亡原因的详细信息在附件 S5 表中提供。'],0.7142857142857143,"['appendix', 'table', 'death', 'supplementary', 'regarding', 'cause', 'cause of death']","['appendix', 'table', 'death', 'regarding', 'cause']",,
1043,1036,"during induction chemotherapy , 93 of 239 patients ( 38.9 % ) had acute adverse events of grade 3 or 4 ( Table S4 in the Supplementary Appendix ) .",在诱导化疗期间，239 名患者中有 93 名 (38.9%) 出现了 3 级或 4 级的急性不良事件（补充附录表 S4）。,0.2727272727272727,"['chemotherapy', 'induction', 'appendix', 'table', 'grade', 'supplementary', 'adverse', 'acute', '3', '4', 'S4']","['chemotherapy', 'induction', 'table']",1036,"['在引发化疗期间,239名患者中有93人(38.9%)患有3级或4级的急性副作用(附件中的S4表)。']",0.2727272727272727,"['chemotherapy', 'induction', 'appendix', 'table', 'grade', 'supplementary', 'adverse', 'acute', '3', '4', 'S4']","['chemotherapy', 'appendix', 'table']",,
1044,1037,"the majority of patients had unfavorable prognostic features of N2 or N3 disease or bulky primary tumors ( T3 or T4 ) , all of which are surrogates for occult metastasis.23",大多数患者具有 N2 或 N3 疾病或大块原发性肿瘤（T3 或 T4）的不良预后特征，所有这些都是隐匿性转移的替代物。 23,0.25,"['disease', 'occult', 'primary', 'prognostic', 'T4', 'majority', 'all', 'unfavorable']","['disease', 'majority']",1037,"['大多数患者患有N2或N3疾病或重型初级肿瘤(T3或T4)的不良预测特征,所有这些肿瘤都是对阴道转移的过敏。']",0.375,"['disease', 'occult', 'primary', 'prognostic', 'T4', 'majority', 'all', 'unfavorable']","['disease', 'prognostic', 'majority']",,
1045,1038,this clinical advantage was evident when the outcomes of the two treatment groups were analyzed in patients who completed the planned course of treatment ( three cycles of chemotherapy plus two or three cycles of concurrent cisplatin and radiotherapy vs. three cycles of concurrent cisplatin and radiotherapy alone ) ( see the Supplementary Appendix ) .,当在完成计划治疗过程的患者中分析两个治疗组的结果时，这种临床优势是显而易见的（三个周期的化疗加上两个或三个周期的同步顺铂和放疗对比三个周期的同步顺铂和放疗） （见补充附录）。,0.5882352941176471,"['chemotherapy', 'appendix', 'who', 'cisplatin', 'plus', 'supplementary', 'radiotherapy', 'concurrent', 'treatment', 'clinical', 'advantage', 'course', 'three', 'this', 'and', 'alone', 'two']","['chemotherapy', 'cisplatin', 'plus', 'treatment', 'clinical', 'advantage', 'course', 'this', 'and', 'two']",1038,"['这种临床优势是显而易见的,当两组治疗的结果被分析在完成计划治疗的患者(三个化疗周期加上两个或三个周期相同的西斯普拉丁和放射治疗与三个周期相同的西斯普拉丁和放射治疗单独 )(参见补充附件 )。']",0.7058823529411765,"['chemotherapy', 'appendix', 'who', 'cisplatin', 'plus', 'supplementary', 'radiotherapy', 'concurrent', 'treatment', 'clinical', 'advantage', 'course', 'three', 'this', 'and', 'alone', 'two']","['chemotherapy', 'appendix', 'plus', 'radiotherapy', 'treatment', 'clinical', 'advantage', 'three', 'this', 'and', 'alone', 'two']",,
1046,1039,it remains unclear whether these regimens differ significantly with regard to efficacy or toxicity .,目前尚不清楚这些方案在疗效或毒性方面是否存在显着差异。,0.25,"['toxicity', 'differ', 'efficacy', 'with']",['toxicity'],1039,['目前尚不清楚这些饮食是否在效率或毒性方面有显著差异。'],0.25,"['toxicity', 'differ', 'efficacy', 'with']",['toxicity'],,
1047,1040,"we noted a higher overall incidence of acute adverse events among patients treated with induction chemotherapy than among those treated with chemoradiotherapy alone ; in particular , the incidence of severe neutropenia , thrombocytopenia , anemia , nausea , and vomiting was higher in the induction chemotherapy group .",我们注意到接受诱导化疗的患者的急性不良事件总体发生率高于仅接受化放疗的患者；特别是诱导化疗组中严重粒细胞减少、血小板减少、贫血、恶心、呕吐的发生率较高。,0.4705882352941176,"['anemia', 'group', 'chemotherapy', 'induction', 'incidence', 'neutropenia', 'thrombocytopenia', 'particular', 'nausea', 'adverse', 'vomiting', 'acute', 'with', 'severe', 'and', 'alone', 'we']","['anemia', 'group', 'chemotherapy', 'induction', 'incidence', 'thrombocytopenia', 'nausea', 'vomiting']",1040,"['我们注意到,在接受引导化疗的患者中,急性副作用的总体发病率高于接受引导化疗的患者中,而在接受引导化疗的患者中,特别是严重的中风、血管细胞炎、贫血、恶心和呕吐的发病率在引导化疗群体中高。']",0.5294117647058824,"['anemia', 'group', 'chemotherapy', 'induction', 'incidence', 'neutropenia', 'thrombocytopenia', 'particular', 'nausea', 'adverse', 'vomiting', 'acute', 'with', 'severe', 'and', 'alone', 'we']","['anemia', 'group', 'chemotherapy', 'induction', 'incidence', 'nausea', 'vomiting', 'acute', 'and']",,
1048,1041,"the incidence of acute grade 1 or 2 nephrotoxic effects was also greater with the higher cumulative dose of cisplatin in the induction chemotherapy group , although the frequencies of late nephrotoxic effects and ototoxic effects were similar in the treatment groups , with the exception of grade 1 or 2 peripheral neuropathy .",在诱导化疗组中，随着顺铂累积剂量的增加，急性 1 级或 2 级肾毒性作用的发生率也更高，尽管除 1 级或2周围神经病变。,0.4736842105263157,"['group', 'chemotherapy', 'induction', 'incidence', 'peripheral', 'cisplatin', '1', '2', 'grade', 'neuropathy', 'cumulative', 'late', 'treatment', 'acute', 'exception', 'with', 'dose', 'and', 'similar']","['group', 'chemotherapy', 'induction', 'incidence', 'cisplatin', '1', '2', 'neuropathy', 'dose']",1041,"['急性1级或2级甲状腺作用的发病率也较高,在引发化疗组中,西斯普拉丁的累积剂量较高,尽管晚期甲状腺作用和甲状腺作用的发病率在治疗组中相似,除1级或2级周边神经病外。']",0.4210526315789473,"['group', 'chemotherapy', 'induction', 'incidence', 'peripheral', 'cisplatin', '1', '2', 'grade', 'neuropathy', 'cumulative', 'late', 'treatment', 'acute', 'exception', 'with', 'dose', 'and', 'similar']","['group', 'chemotherapy', 'incidence', '1', '2', 'neuropathy', 'treatment', 'dose']",,
1049,1042,"in our previous chemotherapy trial ( which investigated docetaxel plus cisplatin plus fluorouracil ) , 7 a high incidence of grade 3 or 4 acute adverse events such as neutropenia ( 35.5 % ) , leukopenia ( 27.2 % ) , and diarrhea ( 8.0 % ) was observed despite the modified doses ( a 20 % reduction of each drug as compared with the other trials26,27 ) ; in that trial , four patients ( 2 % ) had leukopenic fever , and one patient died from neutropenic sepsis ( Table S7 in the Supplementary Appendix ) .","在我们之前的化疗试验（研究多西紫杉醇加顺铂加氟尿嘧啶） 7 中，观察到中性粒细胞减少症 ( 35.5 % ) 、白细胞减少症 ( 27.2 % ) 和腹泻 ( 8.0 % ) 等 3 级或 4 级急性不良事件的高发生率，尽管修改后的剂量（与其他试验相比，每种药物减少 20%26,27）；在该试验中，4 名患者 (2%) 出现白细胞减少性发热，1 名患者死于中性粒细胞减少性败血症（补充附录表 S7）。",0.53125,"['chemotherapy', 'incidence', 'appendix', 'table', 'cisplatin', '2', 'grade', 'plus', 'previous', 'supplementary', 'neutropenia', 'reduction', 'sepsis', 'diarrhea', 'adverse', 'leukopenia', 'fever', 'patient', 'trial', 'acute', '3', '4', 'as', 'with', 'despite', 'drug', 'fluorouracil', 'docetaxel', 'that', 'each', 'and', 'high']","['chemotherapy', 'incidence', 'table', 'cisplatin', '2', 'plus', 'neutropenia', 'reduction', 'sepsis', 'diarrhea', 'leukopenia', 'fever', 'patient', 'drug', 'fluorouracil', 'docetaxel', 'high']",1042,"['在我们之前的化疗试验(研究Docetaxel plus Cisplatin plus Fluorouracil)中,尽管有修改剂量(与其他试验相比,每种药物的20%减少26,27%),但观察到3级或4级急性副作用,如中风(35.5%),白血病(27.2%)和腹泻(8.0%)的发病率高;在试验中,有4名患者(2%)患有白血病发病,其中1名患者死于中风<unk>症(附件表S7)。']",0.34375,"['chemotherapy', 'incidence', 'appendix', 'table', 'cisplatin', '2', 'grade', 'plus', 'previous', 'supplementary', 'neutropenia', 'reduction', 'sepsis', 'diarrhea', 'adverse', 'leukopenia', 'fever', 'patient', 'trial', 'acute', '3', '4', 'as', 'with', 'despite', 'drug', 'fluorouracil', 'docetaxel', 'that', 'each', 'and', 'high']","['chemotherapy', 'incidence', 'appendix', 'table', '2', 'reduction', 'diarrhea', 'patient', 'as', 'drug', 'high']",,
1050,1043,"a quarter of patients responded to the oral agent selinexor , an inhibitor of the nuclear export protein exportin 1 .",四分之一的患者对口服药物 selinexor 有反应，selinexor 是核输出蛋白输出 1 的抑制剂。,0.5,"['inhibitor', 'a', '1', 'protein', 'oral', 'quarter', 'nuclear', 'agent']","['inhibitor', '1', 'protein', 'nuclear']",1043,"['四分之一的病人对口服药物塞林克索(Selinexor)作出回应,这是核出口蛋白质出口1的抑制剂。']",0.625,"['inhibitor', 'a', '1', 'protein', 'oral', 'quarter', 'nuclear', 'agent']","['inhibitor', '1', 'protein', 'quarter', 'nuclear']",,
1051,1044,"the overall response rate ( ≥ 50 % decrease in myeloma paraprotein level ; the primary endpoint ) was 26 % , with 2 patients achieving complete remission ; an additional 13 % achieved minimal response .",总体缓解率（骨髓瘤副蛋白水平降低 ≥ 50%；主要终点）为 26%，其中 2 名患者达到完全缓解；另有 13% 的人获得了最低限度的回应。,0.3333333333333333,"['decrease', 'rate', '2', 'myeloma', 'complete', 'primary', 'response', 'additional', 'minimal', 'level', 'remission', 'response rate', 'with', 'achieved', 'endpoint']","['rate', '2', 'myeloma', 'level', 'remission']",1044,['总反应率(甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺'],0.2,"['decrease', 'rate', '2', 'myeloma', 'complete', 'primary', 'response', 'additional', 'minimal', 'level', 'remission', 'response rate', 'with', 'achieved', 'endpoint']","['rate', 'response', 'response rate']",,
1052,1045,"grade 3 or 4 adverse events included thrombocytopenia , anemia , hyponatremia , and neutropenia .",3 级或 4 级不良事件包括血小板减少症、贫血、低钠血症和中性粒细胞减少症。,0.4444444444444444,"['anemia', 'grade', 'hyponatremia', 'neutropenia', 'thrombocytopenia', 'adverse', '3', '4', 'and']","['anemia', 'hyponatremia', 'neutropenia', 'thrombocytopenia']",1045,"['等级3或4的副作用包括血管细胞,贫血,催眠,和中性。']",0.2222222222222222,"['anemia', 'grade', 'hyponatremia', 'neutropenia', 'thrombocytopenia', 'adverse', '3', '4', 'and']","['anemia', 'grade']",,
1053,1046,"most participants ( 89 % ) had no history of CV disease , but half had known hypertension .",大多数参与者 (89%) 没有 CV 病史，但一半有高血压病史。,0.6666666666666666,"['disease', 'hypertension', 'half', 'history', 'no', 'but']","['disease', 'hypertension', 'half', 'but']",1046,"['大多数参与者(89%)没有CV病史,但一半已知高血压。']",0.6666666666666666,"['disease', 'hypertension', 'half', 'history', 'no', 'but']","['disease', 'hypertension', 'half', 'but']",,
1054,1047,only one third of participants had been taking any CV drug .,只有三分之一的参与者服用过任何心血管药物。,0.3333333333333333,"['taking', 'drug', 'third']",['drug'],1047,['只有三分之一的参与者曾经服用任何CV药物。'],0.3333333333333333,"['taking', 'drug', 'third']",['drug'],,
1055,1048,"the difference was driven largely by fewer coronary events ( and not strokes , heart failure , or sudden deaths ) .",这种差异主要是由于冠状动脉事件较少（而不是中风、心力衰竭或猝死）。,1.0,"['heart', 'failure', 'coronary', 'difference', 'heart failure', 'sudden', 'by', 'and']","['heart', 'failure', 'coronary', 'difference', 'heart failure', 'sudden', 'by', 'and']",1048,['差异主要是由较少的冠状事件引起的(而不是中风、心脏衰竭或突然死亡)。'],0.75,"['heart', 'failure', 'coronary', 'difference', 'heart failure', 'sudden', 'by', 'and']","['heart', 'failure', 'coronary', 'difference', 'by', 'and']",,
1056,1049,overall mortality ( 5.9 % and 6.5 % ; P = 0.43 ) and side effects were similar in the two groups .,两组的总体死亡率（5.9% 和 6.5%；P = 0.43）和副作用相似。,0.4285714285714285,"['side effects', 'mortality', 'P', 'in', 'and', 'two', 'similar']","['side effects', 'mortality', 'two']",1049,['总死亡率( 5.9 % 和 6.5 % ; P = 0.43 )和副作用在两组都相似。'],0.4285714285714285,"['side effects', 'mortality', 'P', 'in', 'and', 'two', 'similar']","['side effects', 'mortality', 'two']",,
1057,1050,"these results support the polypill concept , but the study has limitations .",这些结果支持复方药丸的概念，但该研究有局限性。,0.75,"['support', 'study', 'concept', 'but']","['support', 'concept', 'but']",1050,"['这些结果支持聚合物的概念,但研究有限制。']",0.75,"['support', 'study', 'concept', 'but']","['support', 'concept', 'but']",,
1058,1051,"for example , nearly 14,000 people were randomized originally , but half of them subsequently were excluded for various reasons - some of which could have biased the results .","例如，最初有将近 14,000 人被随机分组，但后来有一半人由于各种原因被排除在外——其中一些原因可能会使结果产生偏差。",0.5714285714285714,"['half', 'various', 'example', '-', 'have', 'originally', 'but']","['half', 'example', 'have', 'but']",1051,"['例如,大约有14000人最初是随机的,但其中一半后来因各种原因被排除 - 其中一些可能偏见了结果。']",0.5714285714285714,"['half', 'various', 'example', '-', 'have', 'originally', 'but']","['half', 'example', 'have', 'but']",,
1059,1052,"in a commentary in the New York Times on Aug 22 , 2019 , a reporter interviewed several experts who favor the polypill and others who were skeptical .",在 2019 年 8 月 22 日纽约时报的评论中，记者采访了几位支持复方药丸的专家和其他持怀疑态度的人。,0.0,"['a', 'who', 'on', 'reporter', 'in', 'and', 'new']",[],1052,"['在2019年8月22日的《纽约时报》的一篇评论中,一名记者采访了多位支持聚合物的专家和其他人,他们是怀疑的。']",0.0,"['a', 'who', 'on', 'reporter', 'in', 'and', 'new']",[],,
1060,1053,left ventricular ejection fraction ( LVEF ) is a commonly used prognostic indicator of cardiovascular disease risk and outcomes .,左心室射血分数 (LVEF) 是心血管疾病风险和结果的常用预后指标。,0.5454545454545454,"['disease', 'cardiovascular', 'ejection', 'indicator', 'cardiovascular disease', 'ventricular', 'prognostic', 'risk', 'fraction', 'ejection fraction', 'and']","['disease', 'cardiovascular', 'indicator', 'cardiovascular disease', 'risk', 'ejection fraction']",1053,['左<unk>排泄分裂(LVEF)是一种常用的心血管疾病风险和结果的预测指标。'],0.5454545454545454,"['disease', 'cardiovascular', 'ejection', 'indicator', 'cardiovascular disease', 'ventricular', 'prognostic', 'risk', 'fraction', 'ejection fraction', 'and']","['disease', 'cardiovascular', 'indicator', 'cardiovascular disease', 'prognostic', 'risk']",,
1061,1054,"the primary analysis was performed on 403,977 echocardiograms from 1998 to 2018 in 203,135 unique patients in a U.S. regional health system ( mean age , 64 ; 52 % men ) .","主要分析是对 1998 年至 2018 年美国区域卫生系统中 203,135 名独特患者的 403,977 份超声心动图进行的（平均年龄 64 岁；52% 为男性）。",0.5,"['a', 'mean', 'analysis', 'system', 'health', 'regional', 'primary', 'unique', 'age', 'in', 'to', 'echocardiograms']","['mean', 'analysis', 'system', 'health', 'age', 'echocardiograms']",1054,"['初步分析是在1998年至2018年间在美国区域卫生系统的203,135个单一患者(平均年龄,64;男性52%)进行的403,977个心血管。']",0.4166666666666667,"['a', 'mean', 'analysis', 'system', 'health', 'regional', 'primary', 'unique', 'age', 'in', 'to', 'echocardiograms']","['mean', 'analysis', 'system', 'health', 'age']",,
1062,1055,"indications for echocardiograms varied widely , with the top five being chest pain , dyspnea / fatigue , coronary artery disease , aortic valve disease , and heart failure .",超声心动图的适应症千差万别，排在前五位的是胸痛、呼吸困难/疲劳、冠状动脉疾病、主动脉瓣疾病和心力衰竭。,0.6190476190476191,"['aortic', 'valve', 'heart', 'disease', 'chest', 'failure', 'fatigue', '/', 'dyspnea', 'chest pain', 'coronary', 'top', 'heart failure', 'aortic valve', 'being', 'with', 'coronary artery', 'five', 'and', 'varied', 'echocardiograms']","['valve', 'heart', 'disease', 'chest', 'failure', 'fatigue', 'dyspnea', 'chest pain', 'coronary', 'heart failure', 'aortic valve', 'coronary artery', 'echocardiograms']",1055,"['甲状腺炎的指示多样化,前五种是胸部疼痛、 dyspnea/疲劳、冠状动脉疾病、 aortic valve 疾病和心脏衰竭。']",0.3809523809523809,"['aortic', 'valve', 'heart', 'disease', 'chest', 'failure', 'fatigue', '/', 'dyspnea', 'chest pain', 'coronary', 'top', 'heart failure', 'aortic valve', 'being', 'with', 'coronary artery', 'five', 'and', 'varied', 'echocardiograms']","['aortic', 'heart', 'disease', 'chest', 'failure', 'fatigue', 'coronary', 'coronary artery']",,
1063,1056,the adjusted hazard ratio for mortality was 1.71 when the LVEF ≥ 70 % and 1.73 with LVEFs in the 35 % -40 % range .,当 LVEF ≥ 70% 时，调整后的死亡率风险比为 1.71，而 LVEF 在 35%-40% 范围内时为 1.73。,0.8571428571428571,"['range', 'ratio', 'hazard ratio', 'mortality', 'with', 'in', 'and']","['range', 'ratio', 'hazard ratio', 'mortality', 'in', 'and']",1056,['对死亡率的调整风险比例为1.71 LVEF ≥ 70 % 和 1.73 LVEF 在 35 % 至 40 % 范围内。'],0.5714285714285714,"['range', 'ratio', 'hazard ratio', 'mortality', 'with', 'in', 'and']","['range', 'ratio', 'hazard ratio', 'mortality']",,
1064,1057,"clinicians emphasize LVEF , despite its imprecision , in treatment decisions .",临床医生在治疗决策中强调 LVEF，尽管其不精确。,0.3333333333333333,"['treatment', 'despite', 'in']",['treatment'],1057,"['临床医生在治疗决策中强调LVEF,尽管不准确。']",0.3333333333333333,"['treatment', 'despite', 'in']",['treatment'],,
1065,1058,this study had clear confounders that could not be fully adjusted for .,这项研究有明显的混杂因素，无法完全调整。,0.0,"['clear', 'study', 'be', 'this', 'that']",[],1058,"['这项研究有明显的混乱,无法完全调整。']",0.0,"['clear', 'study', 'be', 'this', 'that']",[],,
1066,1059,"as an example , the structured fields in the database for indications for the echocardiogram could fail to capture the complete clinical picture of the patient undergoing the test .",例如，数据库中用于超声心动图指示的结构化字段可能无法捕捉接受测试的患者的完整临床图像。,0.6363636363636364,"['database', 'capture', 'test', 'complete', 'picture', 'clinical', 'patient', 'fail', 'example', 'to', 'echocardiogram']","['capture', 'picture', 'clinical', 'patient', 'example', 'to', 'echocardiogram']",1059,"['作为一个例子,数据库中的结构化领域可能无法捕获接受测试的患者的完整临床图像。']",0.4545454545454545,"['database', 'capture', 'test', 'complete', 'picture', 'clinical', 'patient', 'fail', 'example', 'to', 'echocardiogram']","['capture', 'picture', 'clinical', 'patient', 'example']",,
1067,1060,"Hyperdynamic LV function ( LVEF , ≥ 70 % ) is likely associated with other clinical comorbidities that confer increased risk ( e.g. , liver failure ) but were not fully accounted for in the study .","高动态 LV 功能 (LVEF, ≥ 70%) 可能与其他导致风险增加的临床合并症（例如，肝衰竭）有关，但在研究中没有得到充分考虑。",0.5454545454545454,"['liver', 'failure', 'function', 'study', 'associated', 'clinical', 'risk', 'with', 'that', 'but', 'LV']","['liver', 'failure', 'function', 'clinical', 'risk', 'but']",1060,"['超动态LV功能(LVEF, ≥70%)可能与其他临床复杂性相关联,导致风险增加(例如,肝衰竭),但在研究中并未充分考虑。']",0.5454545454545454,"['liver', 'failure', 'function', 'study', 'associated', 'clinical', 'risk', 'with', 'that', 'but', 'LV']","['liver', 'failure', 'function', 'clinical', 'risk', 'but']",,
1068,1061,"in a large observational study , statin discontinuers were vulnerable to later cardiovascular hospitalizations .",在一项大型观察性研究中，停用他汀类药物的人很容易因心血管疾病住院治疗。,0.2857142857142857,"['statin', 'cardiovascular', 'observational study', 'large', 'vulnerable', 'later', 'to']","['cardiovascular', 'observational study']",1061,"['在一项大型观察研究中,静素中断剂对后来的心血管医院受伤。']",0.2857142857142857,"['statin', 'cardiovascular', 'observational study', 'large', 'vulnerable', 'later', 'to']","['cardiovascular', 'later']",,
1069,1062,there remains uncertainty as to whether people who reach a certain age can discontinue a statin without facing additional risks .,对于达到一定年龄的人是否可以在不面临额外风险的情况下停用他汀类药物，仍存在不确定性。,0.2727272727272727,"['statin', 'who', 'age', 'additional', 'as', 'certain', 'facing', 'uncertainty', 'to', 'reach', 'without']","['age', 'facing', 'to']",1062,['仍然不确定是否达到一定年龄的人可以停止服用静素而不面临额外的风险。'],0.1818181818181818,"['statin', 'who', 'age', 'additional', 'as', 'certain', 'facing', 'uncertainty', 'to', 'reach', 'without']","['age', 'additional']",,
1070,1063,the little existing trial evidence has suggested a benefit from statins into older age .,现有的少量试验证据表明他汀类药物对老年人有益。,0.3333333333333333,"['a', 'statins', 'age', 'trial', 'evidence', 'benefit']","['statins', 'evidence']",1063,"['现有很少的试验证据表明,从老年人到老年人有好处。']",0.1666666666666666,"['a', 'statins', 'age', 'trial', 'evidence', 'benefit']",['evidence'],,
1071,1064,"the 120,173 participants had no history of cardiovascular disease and had filled prescriptions for statins for 2 years ( medication possession ratio , ≥ 80 % ) .","这 120,173 名参与者没有心血管疾病史，并且已按处方服用他汀类药物 2 年（药物占有率≥ 80%）。",0.5833333333333334,"['disease', 'cardiovascular', '2', 'ratio', 'statins', 'history', 'medication', 'cardiovascular disease', 'no', 'possession', 'prescriptions', 'and']","['disease', 'cardiovascular', '2', 'statins', 'medication', 'cardiovascular disease', 'prescriptions']",1064,"['120173名参与者没有心血管疾病的历史,并在2年内填写了静素的处方(药物持有比例, ≥80%)。']",0.6666666666666666,"['disease', 'cardiovascular', '2', 'ratio', 'statins', 'history', 'medication', 'cardiovascular disease', 'no', 'possession', 'prescriptions', 'and']","['disease', 'cardiovascular', '2', 'ratio', 'history', 'medication', 'cardiovascular disease', 'prescriptions']",,
1072,1065,statin discontinuation was defined as 3 consecutive months without medication .,停用他汀类药物定义为连续 3 个月未服药。,0.0,"['statin', 'defined', 'consecutive', 'medication', '3', 'as', 'without']",[],1065,['静素中断被定义为连续3个月没有药物。'],0.0,"['statin', 'defined', 'consecutive', 'medication', '3', 'as', 'without']",[],,
1073,1066,a total of 3243 people died .,共有3243人死亡。,0.0,"['a', 'total']",[],1066,['总共有3243人死亡。'],0.0,"['a', 'total']",[],,
1074,1067,the statin discontinuation rate was 14.3 % .,他汀类药物停药率为 14.3%。,0.5,"['statin', 'rate']",['rate'],1067,['静态中断率为14.3%。'],0.5,"['statin', 'rate']",['rate'],,
1075,1068,"factors associated with statin discontinuation were hospital admission , admission to a skilled nursing facility , metastatic solid tumor , and initiation of enteral or oral feeding .",与停用他汀类药物相关的因素包括入院、入住专业护理机构、转移性实体瘤以及开始肠内或经口喂养。,0.125,"['statin', 'initiation', 'tumor', 'oral', 'admission', 'feeding', 'nursing', 'solid', 'metastatic', 'associated', 'facility', 'hospital', 'with', 'skilled', 'to', 'and']","['initiation', 'nursing']",1068,['与静素中断相关的因素包括入院、入院到熟练的护理设施、甲状腺固体肿瘤以及内科或口服营养的启动。'],0.375,"['statin', 'initiation', 'tumor', 'oral', 'admission', 'feeding', 'nursing', 'solid', 'metastatic', 'associated', 'facility', 'hospital', 'with', 'skilled', 'to', 'and']","['initiation', 'tumor', 'nursing', 'solid', 'facility', 'skilled']",,
1076,1069,"a question remains as to whether statin withdrawal was a marker of higher risk ; ideally , a trial will resolve that .",关于停用他汀类药物是否是高风险标志的问题仍然存在；理想情况下，审判将解决这个问题。,0.4545454545454545,"['statin', 'marker', 'question', 'withdrawal', 'resolve', 'risk', 'trial', 'as', 'will', 'that', 'to']","['question', 'resolve', 'risk', 'trial', 'to']",1069,"['一个问题仍然是,是否 statin 撤销是更高的风险标志;理想情况下,一个审查将解决这个问题。']",0.2727272727272727,"['statin', 'marker', 'question', 'withdrawal', 'resolve', 'risk', 'trial', 'as', 'will', 'that', 'to']","['question', 'resolve', 'risk']",,
1077,1070,studies suggest that fluoride exposure during brain development might negatively affect neurocognitive outcomes in children .,研究表明，在大脑发育过程中接触氟化物可能会对儿童的神经认知结果产生负面影响。,0.5714285714285714,"['fluoride', 'exposure', 'brain', 'affect', 'development', 'suggest', 'that']","['fluoride', 'brain', 'affect', 'development']",1070,"['研究表明,在大脑发育期间的氟化物曝光可能会对儿童的神经认知结果产生负面影响。']",0.7142857142857143,"['fluoride', 'exposure', 'brain', 'affect', 'development', 'suggest', 'that']","['fluoride', 'exposure', 'brain', 'affect', 'development']",,
1078,1071,"analyses included multiple covariates , such as maternal education , household income , parity , and exposure to other chemicals , as well as child gestational age , birth weight , and sex .",分析包括多个协变量，例如母亲教育程度、家庭收入、产次和接触其他化学品，以及儿童胎龄、出生体重和性别。,0.4736842105263157,"['maternal', 'weight', 'exposure', 'sex', 'birth weight', 'child', 'education', 'multiple', 'gestational', 'well', 'age', 'household', 'as', 'income', 'parity', 'gestational age', 'chemicals', 'to', 'and']","['maternal', 'weight', 'sex', 'child', 'education', 'household', 'as', 'income', 'parity']",1071,"['分析包括多种差异,如母亲教育、家庭收入、平等和对其他化学物质的暴露以及儿童的怀孕年龄、出生体重和性别。']",0.5263157894736842,"['maternal', 'weight', 'exposure', 'sex', 'birth weight', 'child', 'education', 'multiple', 'gestational', 'well', 'age', 'household', 'as', 'income', 'parity', 'gestational age', 'chemicals', 'to', 'and']","['maternal', 'weight', 'exposure', 'sex', 'child', 'education', 'age', 'household', 'as', 'income']",,
1079,1072,"but methodologies are improving in this area , making these findings potentially concerning , particularly at the population level .",但该领域的方法正在改进，使这些调查结果可能令人担忧，尤其是在人口层面。,0.5,"['population', 'area', 'level', 'this', 'in', 'but']","['population', 'this', 'but']",1072,"['但在这个领域的方法正在改善,使这些发现可能涉及,特别是在人口水平。']",0.6666666666666666,"['population', 'area', 'level', 'this', 'in', 'but']","['population', 'level', 'this', 'but']",,
1080,1073,"clinicians should be prepared to discuss the possible positive and negative effects of fluoride exposure , since parents may ask whether they should avoid giving fluoridated water to their young children or drinking it during pregnancy .",临床医生应该准备好讨论接触氟化物可能产生的正面和负面影响，因为父母可能会问他们是否应该避免给年幼的孩子喝含氟水或在怀孕期间饮用。,0.5,"['pregnancy', 'parents', 'fluoride', 'exposure', 'negative', 'water', 'drinking', 'be', 'discuss', 'positive', 'young', 'to', 'and', 'avoid']","['pregnancy', 'fluoride', 'water', 'drinking', 'be', 'young', 'avoid']",1073,"['临床医生应该准备讨论氟化物曝光的潜在积极和负面影响,因为父母可能会问他们是否应该避免给小孩子氟化水或在怀孕期间喝水。']",0.5,"['pregnancy', 'parents', 'fluoride', 'exposure', 'negative', 'water', 'drinking', 'be', 'discuss', 'positive', 'young', 'to', 'and', 'avoid']","['pregnancy', 'fluoride', 'exposure', 'water', 'drinking', 'be', 'avoid']",,
1081,1074,"because prenatal fluoride is not believed to benefit the fetus , it is reasonable to recommend that women reduce fluoride intake during pregnancy .",由于产前氟化物不被认为对胎儿有益，因此建议女性在怀孕期间减少氟化物摄入量是合理的。,0.5,"['pregnancy', 'intake', 'fetus', 'fluoride', 'reduce', 'recommend', 'prenatal', 'benefit', 'that', 'to']","['pregnancy', 'fetus', 'fluoride', 'recommend', 'to']",1074,"['由于预产氟化物不被认为对胎儿有好处,因此建议妇女在怀孕期间减少氟化物摄入量。']",0.5,"['pregnancy', 'intake', 'fetus', 'fluoride', 'reduce', 'recommend', 'prenatal', 'benefit', 'that', 'to']","['pregnancy', 'fetus', 'fluoride', 'recommend', 'to']",,
1082,1075,diagnoses of chronic obstructive pulmonary disease were incorrect in about 62 % of cases .,在大约 62% 的病例中，慢性阻塞性肺病的诊断是不正确的。,0.4,"['disease', 'obstructive', 'pulmonary', 'chronic', 'in']","['disease', 'chronic']",1075,['慢性抑制性肺疾病的诊断在约62%的病例中是错误的。'],0.4,"['disease', 'obstructive', 'pulmonary', 'chronic', 'in']","['disease', 'chronic']",,
1083,1076,"previously , it showed that as many as 81 % of COPD cases worldwide are undiagnosed ( Chest 2015 ; 148 : 971 ) .",此前，它表明全世界多达 81% 的 COPD 病例未得到诊断（Chest 2015；148：971）。,0.25,"['COPD', 'chest', 'as', 'that']",['COPD'],1076,"['此前,它表明,全球大约有81%的COPD病例未经诊断(Cest 2015;148:971)。']",0.25,"['COPD', 'chest', 'as', 'that']",['COPD'],,
1084,1077,"now , researchers have examined the rate of COPD overdiagnosis .",现在，研究人员已经检查了 COPD 过度诊断率。,0.6666666666666666,"['COPD', 'rate', 'have']","['COPD', 'rate']",1077,"['现在,研究人员已经检查了COPD过度诊断的速度。']",0.3333333333333333,"['COPD', 'rate', 'have']",['COPD'],,
1085,1078,performing spirometry before and after administration of a bronchodilator is essential before making a diagnosis .,在进行诊断之前，在使用支气管扩张剂之前和之后进行肺活量测定是必不可少的。,0.4,"['a', 'administration', 'essential', 'diagnosis', 'bronchodilator', 'after', 'spirometry', 'performing', 'before', 'and']","['diagnosis', 'bronchodilator', 'after', 'before']",1078,"['在服用 bronchodilator 之前和服用 bronchodilator 后进行螺旋测量,在进行诊断之前至关重要。']",0.3,"['a', 'administration', 'essential', 'diagnosis', 'bronchodilator', 'after', 'spirometry', 'performing', 'before', 'and']","['diagnosis', 'after', 'before']",,
1086,1079,patients with lower levels might not need 5 days of oral steroids for chronic obstructive pulmonary disease exacerbations .,较低水平的患者可能不需要 5 天的口服类固醇治疗慢性阻塞性肺疾病恶化。,0.4444444444444444,"['5', 'disease', 'need', 'obstructive', 'oral', 'lower', 'pulmonary', 'chronic', 'with']","['5', 'disease', 'need', 'chronic']",1079,['低水平的患者可能不需要5天的口服类固醇慢性阻塞性肺病恶化。'],0.4444444444444444,"['5', 'disease', 'need', 'obstructive', 'oral', 'lower', 'pulmonary', 'chronic', 'with']","['5', 'disease', 'need', 'chronic']",,
1087,1080,GOLD guidelines recommend use of prednisone ( 40 mg daily ) for 5 days for acute exacerbations of chronic obstructive pulmonary disease ( COPD ; NEJM JW Gen Med Jun 15 2017 and Am J Respir Crit Care Med 2017 ; 195 : 557 ) .,GOLD 指南建议使用强的松（每天 40 毫克）治疗 5 天慢性阻塞性肺疾病急性加重期（COPD；NEJM JW Gen Med 2017 年 6 月 15 日和 Am J Respir Crit Care Med 2017；195：557）。,0.3846153846153846,"['COPD', '5', 'disease', 'obstructive', 'prednisone', 'recommend', 'pulmonary', 'chronic', 'acute', 'gen', 'care', 'and', 'med']","['COPD', '5', 'disease', 'recommend', 'chronic']",1080,['黄金指南建议使用<unk>(每日40毫克)为5天的慢性阻塞性肺疾病急剧加剧(COPD;NEJM JW Gen Med Jun 15 2017和Am J Respir Crit Care Med 2017;195:557 )。'],0.3846153846153846,"['COPD', '5', 'disease', 'obstructive', 'prednisone', 'recommend', 'pulmonary', 'chronic', 'acute', 'gen', 'care', 'and', 'med']","['COPD', '5', 'disease', 'recommend', 'chronic']",,
1088,1081,"all patients received 80 mg of methylprednisolone on day 1 , followed by either 37.5 mg of prednisolone daily for 4 days or prednisolone just on the days when peripheral eosinophil count was ≥ 300 cell / mL .",所有患者均在第 1 天接受 80 mg 甲泼尼龙，随后每天接受 37.5 mg 泼尼松龙治疗 4 天，或仅在外周嗜酸性粒细胞计数≥ 300 个细胞/mL 时才接受泼尼松龙治疗。,0.4615384615384615,"['prednisolone', 'cell', 'count', 'eosinophil', 'peripheral', '1', '/', 'methylprednisolone', '4', 'ml', 'all', 'by', 'just']","['prednisolone', 'cell', 'count', '1', 'methylprednisolone', 'just']",1081,"['所有患者在第一天服用了80毫克甲基<unk><unk>,随后每日服用了37.5毫克甲基<unk>4天或甲基<unk>仅在周边甲基<unk>数为≥300细胞/毫升的日子。']",0.0769230769230769,"['prednisolone', 'cell', 'count', 'eosinophil', 'peripheral', '1', '/', 'methylprednisolone', '4', 'ml', 'all', 'by', 'just']",['cell'],,
1089,1082,this study raises questions about whether all patients with COPD exacerbations need a full 5 days of systemic corticosteroids .,这项研究提出了一个问题，即是否所有患有 COPD 恶化的患者都需要整整 5 天的全身性皮质类固醇。,0.4,"['COPD', '5', 'a', 'need', 'study', 'systemic', 'with', 'full', 'all', 'this']","['COPD', '5', 'need', 'this']",1082,['这项研究提出了关于所有患有COPD加剧的患者是否需要一个完整的5天系统类固醇的疑问。'],0.5,"['COPD', '5', 'a', 'need', 'study', 'systemic', 'with', 'full', 'all', 'this']","['COPD', '5', 'need', 'full', 'this']",,
1090,1083,the slight excess of COPD readmissions and the cumbersome regimen of changing treatment daily based on eosinophil counts does not make this an attractive approach as yet .,COPD 再入院人数略多，以及根据嗜酸性粒细胞计数每天更换治疗的繁琐方案，目前还不能使该方法成为一种有吸引力的方法。,0.1818181818181818,"['approach', 'eosinophil', 'COPD', 'excess', 'slight', 'treatment', 'as', 'on', 'this', 'and', 'make']","['COPD', 'treatment']",1083,"['微不足道的COPD复发和基于eosinophil数的日常治疗变化的累积模式,这一点尚未成为一个有吸引力的方法。']",0.1818181818181818,"['approach', 'eosinophil', 'COPD', 'excess', 'slight', 'treatment', 'as', 'on', 'this', 'and', 'make']","['COPD', 'treatment']",,
1091,1084,a larger trial in which therapy was based on a single eosinophil count at presentation would be welcome .,欢迎进行一项更大规模的试验，其中治疗基于就诊时的单个嗜酸性粒细胞计数。,0.4285714285714285,"['presentation', 'count', 'eosinophil', 'therapy', 'be', 'trial', 'single']","['count', 'therapy', 'single']",1084,"['一个更大的试验,其中治疗是基于一个单一的eosinophil 计算在演示会将是欢迎的。']",0.4285714285714285,"['presentation', 'count', 'eosinophil', 'therapy', 'be', 'trial', 'single']","['therapy', 'be', 'single']",,
1092,1085,data do not support routine use of vitamin E in this population .,数据不支持在该人群中常规使用维生素 E。,0.7142857142857143,"['population', 'support', 'vitamin', 'data', 'routine', 'vitamin E', 'this']","['population', 'support', 'vitamin', 'data', 'routine']",1085,['数据不支持在这个人口中常规使用维生素E。'],0.8571428571428571,"['population', 'support', 'vitamin', 'data', 'routine', 'vitamin E', 'this']","['population', 'support', 'vitamin', 'data', 'routine', 'vitamin E']",,
1093,1086,"vitamin E has shown some benefit for treating nonalcoholic steatohepatitis ( NASH ) in patients without type 2 diabetes mellitus ( T2DM ) , but there are few data from patients with T2DM .",维生素 E 已显示对治疗非 2 型糖尿病 (T2DM) 患者的非酒精性脂肪性肝炎 (NASH) 有一定益处，但来自 T2DM 患者的数据很少。,0.5833333333333334,"['diabetes', 'type', 'vitamin', 'data', '2', 'diabetes mellitus', 'steatohepatitis', 'benefit', 'with', 'vitamin E', 'but', 'without']","['diabetes', 'type', 'vitamin', 'data', '2', 'diabetes mellitus', 'but']",1086,"['维生素E在没有2型糖尿病(T2DM)患者治疗非酒精性甲状腺炎(NASH)方面表现出一些好处,但患有T2DM患者的数据很少。']",0.6666666666666666,"['diabetes', 'type', 'vitamin', 'data', '2', 'diabetes mellitus', 'steatohepatitis', 'benefit', 'with', 'vitamin E', 'but', 'without']","['diabetes', 'type', 'vitamin', 'data', '2', 'diabetes mellitus', 'vitamin E', 'but']",,
1094,1087,"patients were randomized in a 1 : 1 : 1 fashion to receive vitamin E 400 IU twice daily , vitamin E plus pioglitazone ( starting at 30 mg daily and titrated to 45 mg daily ) , or placebo for 18 months .",患者以 1:1:1 的方式随机接受维生素 E 400 IU，每天两次，维生素 E 加吡格列酮（从每天 30 毫克开始，逐渐增加到每天 45 毫克），或安慰剂，为期 18 个月。,0.5,"['placebo', 'vitamin', '1', 'plus', 'vitamin E', 'pioglitazone', 'at', 'to', 'and', 'twice']","['placebo', 'vitamin', '1', 'plus', 'pioglitazone']",1087,"['病人随机以1:1:1的方式接收维生素E400U每天两次,维生素E加上皮奥格利塔森(从每日30毫克开始,每日45毫克推特),或18个月的 placebo。']",0.4,"['placebo', 'vitamin', '1', 'plus', 'vitamin E', 'pioglitazone', 'at', 'to', 'and', 'twice']","['vitamin', '1', 'plus', 'vitamin E']",,
1095,1088,the primary endpoint was reduction in the nonalcoholic fatty liver disease activity score of ≥ 2 points without worsening of fibrosis .,主要终点是非酒精性脂肪性肝病活动评分降低 ≥ 2 分且纤维化没有恶化。,0.5833333333333334,"['liver', 'disease', 'fatty liver', '2', 'fibrosis', 'activity', 'reduction', 'liver disease', 'primary', 'score', 'endpoint', 'without']","['liver', 'disease', '2', 'fibrosis', 'activity', 'reduction', 'liver disease']",1088,"['主要的终点是减少非酒精脂肪肝疾病活动分数 ≥ 2 点,没有恶化纤维炎。']",0.6666666666666666,"['liver', 'disease', 'fatty liver', '2', 'fibrosis', 'activity', 'reduction', 'liver disease', 'primary', 'score', 'endpoint', 'without']","['liver', 'disease', 'fatty liver', '2', 'activity', 'reduction', 'primary', 'score']",,
1096,1089,baseline characteristics were similar between groups .,组间的基线特征相似。,0.6666666666666666,"['baseline', 'characteristics', 'similar']","['baseline', 'characteristics']",1089,['基层特征在群体之间是相似的。'],0.6666666666666666,"['baseline', 'characteristics', 'similar']","['characteristics', 'similar']",,
1097,1090,several patients discontinued treatment in each group .,每组都有几名患者停止治疗。,0.5,"['group', 'treatment', 'each', 'in']","['group', 'treatment']",1090,['几名患者在每个群体中停止治疗。'],0.5,"['group', 'treatment', 'each', 'in']","['group', 'treatment']",,
1098,1091,the primary endpoint was achieved at a significantly higher rate with combination therapy compared with placebo ( 54 % vs. 19 % ) but not with vitamin E alone compared with placebo ( 31 % vs. 19 % ; P = 0.26 ) .,与安慰剂相比，联合治疗的主要终点达到率显着更高（54% 对 19%），但与安慰剂相比，单独使用维生素 E 则没有达到主要终点（31% 对 19%；P = 0.26）。,0.5,"['combination therapy', 'placebo', 'vitamin', 'rate', 'primary', 'with', 'achieved', 'endpoint', 'vitamin E', 'P', 'but', 'alone']","['combination therapy', 'placebo', 'vitamin', 'rate', 'but', 'alone']",1091,"['与 placebo 相比,初级终点率显著高(54 % vs. 19 %),而不仅仅是维生素 E 与 placebo 相比(31 % vs. 19 % ; P = 0.26 )。']",0.25,"['combination therapy', 'placebo', 'vitamin', 'rate', 'primary', 'with', 'achieved', 'endpoint', 'vitamin E', 'P', 'but', 'alone']","['vitamin', 'rate', 'but']",,
1099,1092,no significant improvement in fibrosis was seen in either treatment group .,两个治疗组均未见纤维化明显改善。,0.7142857142857143,"['group', 'improvement', 'fibrosis', 'treatment', 'no', 'treatment group', 'in']","['group', 'improvement', 'fibrosis', 'treatment', 'treatment group']",1092,['在任何治疗组中都没有显著改善纤维炎。'],0.5714285714285714,"['group', 'improvement', 'fibrosis', 'treatment', 'no', 'treatment group', 'in']","['group', 'improvement', 'treatment', 'treatment group']",,
1100,1093,the safety of CRISPR ( clustered regularly interspaced short palindromic repeats ) -based genome editing in the context of human gene therapy is largely unknown .,在人类基因治疗的背景下，基于 CRISPR（成簇规则间隔短回文重复序列）的基因组编辑的安全性在很大程度上是未知的。,0.6,"['genome', 'safety', 'gene', 'editing', 'gene therapy', 'context', 'genome editing', 'clustered regularly interspaced short palindromic repeats', 'CRISPR', 'human gene therapy']","['genome', 'safety', 'gene', 'gene therapy', 'genome editing', 'human gene therapy']",1093,['CRISPR(基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基于基。'],0.0,"['genome', 'safety', 'gene', 'editing', 'gene therapy', 'context', 'genome editing', 'clustered regularly interspaced short palindromic repeats', 'CRISPR', 'human gene therapy']",[],,
1101,1094,"at diagnosis , the HIV viral load was 8.5 × 106 copies per milliliter , and the CD4 + cell count was 528 × 106 per liter .",诊断时，HIV 病毒载量为每毫升 8.5 × 106 个拷贝，CD4+ 细胞计数为每升 528 × 106 个。,0.5,"['HIV', 'cell', 'count', 'liter', 'cell count', 'load', 'diagnosis', 'viral', 'at', 'and']","['HIV', 'cell', 'count', 'liter', 'diagnosis']",1094,"['在诊断时,HIV病毒负载为每毫升8,5×106副本,CD4+细胞数量为每升528×106。']",0.5,"['HIV', 'cell', 'count', 'liter', 'cell count', 'load', 'diagnosis', 'viral', 'at', 'and']","['HIV', 'cell', 'liter', 'load', 'diagnosis']",,
1102,1095,"the patient received six courses of standard chemotherapy for acute lymphoblastic leukemia ( see the Methods : chemotherapeutic Regimens section in the Supplementary Appendix , available with the full text of this article at NEJM.org ) , which led to morphologic complete remission .",该患者接受了六个疗程的急性淋巴细胞白血病标准化疗（见补充附录中的方法：化疗方案部分，补充附录与本文全文可在 NEJM.org 获取），导致形态学完全缓解。,0.238095238095238,"['chemotherapy', 'standard', 'appendix', 'section', 'leukemia', 'article', 'courses', 'acute lymphoblastic leukemia', 'supplementary', 'complete', 'available', 'patient', 'text', 'remission', 'with', 'chemotherapeutic', 'full', 'this', 'in', 'to', 'led']","['chemotherapy', 'standard', 'leukemia', 'patient', 'remission']",1095,"['患者接受了六个标准化疗课程的急性淋巴细胞白血病(参见方法:化疗规则部分,附件,可用完整的文章在NEJM.org ),导致morphologic完整的复发。']",0.3333333333333333,"['chemotherapy', 'standard', 'appendix', 'section', 'leukemia', 'article', 'courses', 'acute lymphoblastic leukemia', 'supplementary', 'complete', 'available', 'patient', 'text', 'remission', 'with', 'chemotherapeutic', 'full', 'this', 'in', 'to', 'led']","['chemotherapy', 'standard', 'appendix', 'leukemia', 'complete', 'patient', 'full']",,
1103,1096,"the patient had an undetectable plasma HIV RNA level and had lymphopenia ( CD4 + cell count , 201.31 × 106 per liter ) .",该患者的血浆 HIV RNA 水平检测不到，并且有淋巴细胞减少症（CD4+ 细胞计数，每升 201.31 × 106 个）。,0.8,"['RNA', 'HIV', 'cell', 'count', 'liter', 'plasma', 'cell count', 'patient', 'level', 'and']","['RNA', 'HIV', 'cell', 'count', 'liter', 'plasma', 'patient', 'level']",1096,"['病人患有无法检测的血浆HIVRNA水平,并且患有淋巴<unk>(CD4 + 细胞数量,每升 201.31 × 106 )。']",0.7,"['RNA', 'HIV', 'cell', 'count', 'liter', 'plasma', 'cell count', 'patient', 'level', 'and']","['RNA', 'HIV', 'cell', 'liter', 'plasma', 'patient', 'level']",,
1104,1097,written informed consent was provided by the patient .,患者提供了书面知情同意书。,0.5,"['patient', 'consent', 'informed consent', 'by']","['patient', 'consent']",1097,['由病人提供的书面通知同意。'],0.75,"['patient', 'consent', 'informed consent', 'by']","['patient', 'consent', 'by']",,
1105,1098,no commercial sponsor was involved .,没有商业赞助商参与。,0.0,"['sponsor', 'no']",[],1098,['没有商业赞助商参与。'],0.0,"['sponsor', 'no']",[],,
1106,1099,all experiments were performed in accordance with the protocol ( available at NEJM.org ) .,所有实验均按照方案（可在 NEJM.org 获得）进行。,0.0,"['protocol', 'available', 'with', 'at', 'all', 'in']",[],1099,['所有实验都按照协议进行(在NEJM.org上可用)。'],0.1666666666666666,"['protocol', 'available', 'with', 'at', 'all', 'in']",['protocol'],,
1107,1100,the study was designed by the last three authors .,该研究由最后三位作者设计。,0.3333333333333333,"['study', 'three', 'by']",['by'],1100,['这项研究是由最后三位作家设计的。'],0.3333333333333333,"['study', 'three', 'by']",['by'],,
1108,1101,"the manuscript was written and revised by the first , third , and last two authors and was approved by all the authors .",手稿由第一、第三和最后两位作者撰写和修改，并得到所有作者的认可。,0.7142857142857143,"['manuscript', 'all', 'by', 'and', 'third', 'first', 'two']","['manuscript', 'by', 'third', 'first', 'two']",1101,"['手稿由第一、第三、最后两位作家撰写和修订,并由所有作家批准。']",0.7142857142857143,"['manuscript', 'all', 'by', 'and', 'third', 'first', 'two']","['manuscript', 'by', 'third', 'first', 'two']",,
1109,1102,the authors performed the data analysis and vouch for the completeness and accuracy of the data and for the adherence of the study to the protocol .,作者进行了数据分析并保证数据的完整性和准确性以及研究对方案的依从性。,0.5,"['data', 'analysis', 'accuracy', 'protocol', 'study', 'completeness', 'adherence', 'and']","['data', 'analysis', 'accuracy', 'completeness']",1102,['作者对数据的完整性和准确性以及研究与议定书的遵守进行了数据分析和审查。'],0.625,"['data', 'analysis', 'accuracy', 'protocol', 'study', 'completeness', 'adherence', 'and']","['data', 'analysis', 'accuracy', 'protocol', 'completeness']",,
1110,1103,gene EDITING AND PREINFUSION CELL PREPARATION,基因编辑和灌注前细胞制备,1.0,['gene'],['gene'],1103,['基因编辑和预防细胞准备'],1.0,['gene'],['gene'],,
1111,1104,"the sorted population was 95 % CD34 + cells , equivalent to 71.2 % of the total CD34 + cells ( Table S1 in the Supplementary Appendix ) .",分选的细胞群为 95% 的 CD34+ 细胞，相当于总 CD34+ 细胞的 71.2%（补充附录表 S1）。,0.375,"['population', 'equivalent', 'appendix', 'table', 'supplementary', 'total', 'S1', 'in']","['population', 'table', 'in']",1104,"['分类人口为95%的CD34+细胞,相当于总CD34+细胞的71.2%(附件中的S1表)。']",0.5,"['population', 'equivalent', 'appendix', 'table', 'supplementary', 'total', 'S1', 'in']","['population', 'appendix', 'table', 'in']",,
1112,1105,recipient ENGRAFTMENT AND ACUTE LYMPHOBLASTIC LEUKEMIA ASSAY,接受者植入和急性淋巴细胞白血病检测,1.0,['recipient'],['recipient'],1105,['接收器 和 急性 LYMPHOBLASTIC LEUKEMIA ASSAY'],0.0,['recipient'],[],,
1113,1106,"neutrophil and platelet engraftment occurred on days 13 and 27 , respectively , after transplantation ( see the Methods : allogeneic Transplantation section in the Supplementary Appendix ) .",中性粒细胞和血小板植入分别发生在移植后第 13 天和第 27 天（参见补充附录中的方法：同种异体移植部分）。,0.4545454545454545,"['transplantation', 'appendix', 'neutrophil', 'section', 'supplementary', 'after', 'platelet', 'allogeneic', 'in', 'and', 'engraftment']","['transplantation', 'neutrophil', 'after', 'platelet', 'engraftment']",1106,"['甲状腺和甲状腺移植发生在13日和27日,分别,移植后(参见方法:附加附件中的异常移植部分)。']",0.2727272727272727,"['transplantation', 'appendix', 'neutrophil', 'section', 'supplementary', 'after', 'platelet', 'allogeneic', 'in', 'and', 'engraftment']","['transplantation', 'appendix', 'after']",,
1114,1107,"although the platelet count transiently decreased at month 3 , the count spontaneously recovered and stabilized in a normal range ( Figure 1A ) .",尽管血小板计数在第 3 个月出现短暂下降，但计数自发恢复并稳定在正常范围内（图 1A）。,0.5,"['transiently', 'count', 'range', 'figure', 'month', 'normal', '3', 'normal range', 'platelet', 'in', 'and', 'spontaneously']","['count', 'range', 'figure', 'month', 'normal range', 'platelet']",1107,"['虽然平板电脑数量在3个月内过时下降,但数字自发恢复并在正常范围内稳定(图1A)。']",0.3333333333333333,"['transiently', 'count', 'range', 'figure', 'month', 'normal', '3', 'normal range', 'platelet', 'in', 'and', 'spontaneously']","['range', 'figure', 'month', 'normal range']",,
1115,1108,"full donor chimerism was achieved at week 4 after transplantation and persisted through the most recent time point , 19 months after transplantation .",完全供体嵌合体在移植后第 4 周实现，并持续到最近的时间点，即移植后 19 个月。,0.5833333333333334,"['donor', 'chimerism', 'transplantation', 'recent', 'time', 'week', 'after', '4', 'point', 'achieved', 'full', 'and']","['donor', 'chimerism', 'transplantation', 'time', 'week', 'after', 'point']",1108,"['全捐赠者化学在移植后的第4周实现,并持续到最新的时间点,移植后的19个月。']",0.4166666666666667,"['donor', 'chimerism', 'transplantation', 'recent', 'time', 'week', 'after', '4', 'point', 'achieved', 'full', 'and']","['transplantation', 'time', 'week', 'after', 'point']",,
1116,1109,CCR5 GENE EDITING,CCR5基因编辑,,[],[],1109,['CCR5 编辑'],,[],[],,
1117,1110,the representative types of CCR5 gene mutation are shown in Figure S1 in the Supplementary Appendix .,CCR5基因突变的代表性类型见补充附录图S1。,0.2857142857142857,"['gene', 'mutation', 'appendix', 'figure', 'supplementary', 'S1', 'in']","['gene', 'mutation']",1110,['CCR5基因突变的代表性类型在附件中的图 S1 显示。'],0.4285714285714285,"['gene', 'mutation', 'appendix', 'figure', 'supplementary', 'S1', 'in']","['gene', 'mutation', 'appendix']",,
1118,1111,safety ANALYSIS,安全分析,1.0,['safety'],['safety'],1111,['安全分析'],1.0,['safety'],['safety'],,
1119,1112,"the patient presented with predictable side effects after preconditioning , including anemia ( hemoglobin level , 79 g per liter at day 22 ) , neutropenia ( undetectable neutrophils at day 0 ) , and thrombocytopenia ( platelet count , 12 × 109 per liter at day 6 ) .",患者在预处理后出现了可预测的副作用，包括贫血（血红蛋白水平，第 22 天时每升 79 克）、中性粒细胞减少症（第 0 天时检测不到中性粒细胞）和血小板减少症（血小板计数，第 6 天时每升 12 × 109）。,0.7857142857142857,"['anemia', 'count', 'liter', 'preconditioning', 'hemoglobin', 'neutropenia', 'side effects', 'thrombocytopenia', 'hemoglobin level', 'patient', 'after', 'with', 'platelet', 'and']","['anemia', 'count', 'liter', 'preconditioning', 'hemoglobin', 'neutropenia', 'side effects', 'thrombocytopenia', 'patient', 'after', 'platelet']",1112,"['患者在预测后出现可预测的副作用,包括贫血(血球水平,22日每升79克),中性<unk>(0日未检测中性<unk>)和血细胞<unk>(6日每升12×109克)。']",0.3571428571428571,"['anemia', 'count', 'liter', 'preconditioning', 'hemoglobin', 'neutropenia', 'side effects', 'thrombocytopenia', 'hemoglobin level', 'patient', 'after', 'with', 'platelet', 'and']","['anemia', 'liter', 'side effects', 'patient', 'after']",,
1120,1113,no acute immune response was observed after the infusion of donor cells .,输注供体细胞后未观察到急性免疫反应。,0.6666666666666666,"['donor', 'infusion', 'immune', 'response', 'after', 'acute']","['donor', 'infusion', 'response', 'after']",1113,['捐献细胞注射后没有急性免疫反应。'],0.5,"['donor', 'infusion', 'immune', 'response', 'after', 'acute']","['infusion', 'response', 'after']",,
1121,1114,"febrile neutropenia ( grade 3 ) and bacteremia ( Staphylococcus epidermidis ; grade 3 ) developed in the first 2 weeks , which resolved with the use of standard antibiotic therapy .",头 2 周内出现发热性中性粒细胞减少症（3 级）和菌血症（表皮葡萄球菌；3 级），使用标准抗生素治疗可缓解。,0.4615384615384615,"['bacteremia', 'standard', 'antibiotic', 'febrile', '2', 'grade', 'staphylococcus epidermidis', 'antibiotic therapy', 'neutropenia', '3', 'with', 'in', 'first']","['bacteremia', 'standard', 'antibiotic', '2', 'staphylococcus epidermidis', 'neutropenia']",1114,"['发烧性中性(三级)和细菌(三级)在前两周内发育,并通过使用标准抗生素治疗解决。']",0.1538461538461538,"['bacteremia', 'standard', 'antibiotic', 'febrile', '2', 'grade', 'staphylococcus epidermidis', 'antibiotic therapy', 'neutropenia', '3', 'with', 'in', 'first']","['standard', 'antibiotic']",,
1122,1115,all these events resolved .,所有这些事件都解决了。,0.0,['all'],[],1115,['所有这些事件都解决了。'],0.0,['all'],[],,
1123,1116,no adverse events that were related to CCR5 gene editing were noted ( Table S2 in the Supplementary Appendix ) .,未发现与 CCR5 基因编辑相关的不良事件（补充附录表 S2）。,0.2727272727272727,"['gene', 'editing', 'appendix', 'table', 'gene editing', 'supplementary', 'adverse', 'no', 'S2', 'that', 'to']","['gene', 'table', 'gene editing']",1116,['没有与 CCR5 基因编辑相关的副作用被注意到(附件中的 S2 表)。'],0.3636363636363636,"['gene', 'editing', 'appendix', 'table', 'gene editing', 'supplementary', 'adverse', 'no', 'S2', 'that', 'to']","['gene', 'appendix', 'table', 'gene editing']",,
1124,1117,"the serum viral load increased to 3 × 107 copies per milliliter at week 4 during the interruption of antiretroviral therapy , and the drugs were then resumed ( Figure 2A ) .",在抗逆转录病毒治疗中断的第 4 周，血清病毒载量增加到 3×107 拷贝/毫升，然后恢复药物治疗（图 2A）。,0.3846153846153846,"['figure', 'drugs', 'interruption', 'load', 'therapy', 'serum', 'viral', 'week', '3', '4', 'at', 'to', 'and']","['drugs', 'interruption', 'therapy', 'serum', 'week']",1117,"['血清病毒负载在4周中停止治疗时增加到每毫升3×107副本,然后重新服用药物(图2A)。']",0.3846153846153846,"['figure', 'drugs', 'interruption', 'load', 'therapy', 'serum', 'viral', 'week', '3', '4', 'at', 'to', 'and']","['drugs', 'load', 'therapy', 'serum', 'week']",,
1125,1118,the viral load gradually decreased to an undetectable level during the following months .,在接下来的几个月里，病毒载量逐渐下降到检测不到的水平。,0.2,"['load', 'viral', 'level', 'to', 'following']",['level'],1118,['病毒负载在接下来的几个月内逐渐下降到无法检测的水平。'],0.4,"['load', 'viral', 'level', 'to', 'following']","['load', 'level']",,
1126,1119,"during the interruption of antiretroviral therapy , the peripheral CD4 + cell count decreased from 575 × 106 per liter to 250 × 106 per liter , and the same trend was observed in the ratio of CD4 + cells to CD8 + cells .",抗逆转录病毒治疗中断期间，外周血CD4+细胞计数从575×106/L下降到250×106/L，CD4+细胞与CD8+细胞的比例也有相同趋势。,0.5454545454545454,"['cell', 'count', 'trend', 'liter', 'peripheral', 'ratio', 'cell count', 'interruption', 'therapy', 'to', 'and']","['cell', 'count', 'trend', 'ratio', 'interruption', 'therapy']",1119,"['在中断抗病毒治疗期间,周边CD4+细胞数量从575×106每升降至250×106每升,并在CD4+细胞与CD8+细胞的比例中观察到相同的趋势。']",0.5454545454545454,"['cell', 'count', 'trend', 'liter', 'peripheral', 'ratio', 'cell count', 'interruption', 'therapy', 'to', 'and']","['cell', 'trend', 'liter', 'ratio', 'interruption', 'therapy']",,
1127,1120,"in addition , the level of CCR5 disruption in peripheral CD4 + cells before the interruption was 2.96 % .",此外，中断前外周CD4+细胞的CCR5中断水平为2.96%。,0.5,"['peripheral', 'addition', 'interruption', 'disruption', 'level', 'before']","['interruption', 'level', 'before']",1120,"['除此之外,在中断之前的周边CD4 +细胞中,CCR5中断的水平为2.96%。']",0.5,"['peripheral', 'addition', 'interruption', 'disruption', 'level', 'before']","['interruption', 'level', 'before']",,
1128,1121,"the level of CCR5 disruption in CD4 + cells peaked ( 4.39 % ) during the interruption , at a level that was 1.6 times as great as the mean level , and was accompanied by a decrease in the CD4 + cell count ( 360 × 106 per liter ) .",CD4 + 细胞中的 CCR5 破坏水平在中断期间达到峰值 ( 4.39 % )，是平均水平的 1.6 倍，并且伴随着 CD4 + 细胞计数的减少（ 360 × 106 每升) 。,0.4117647058823529,"['cell', 'count', 'a', 'decrease', 'mean', 'liter', 'cell count', 'interruption', 'accompanied', 'disruption', 'level', 'at', 'that', 'great', 'by', 'and', 'accompanied by']","['cell', 'count', 'decrease', 'mean', 'liter', 'interruption', 'level']",1121,"['在中断期间,CD4 + 细胞中 CCR5 干扰的水平上升( 4.39 % ),达到平均水平的 1.6 倍,并伴随着 CD4 + 细胞数量的下降( 360 × 106 每升)。']",0.2941176470588235,"['cell', 'count', 'a', 'decrease', 'mean', 'liter', 'cell count', 'interruption', 'accompanied', 'disruption', 'level', 'at', 'that', 'great', 'by', 'and', 'accompanied by']","['cell', 'mean', 'liter', 'interruption', 'level']",,
1129,1122,their quick rebound after the interruption of antiretroviral therapy coincided with the appearance of a measurable viral load .,它们在抗逆转录病毒治疗中断后迅速反弹，同时出现可测量的病毒载量。,0.3,"['a', 'rebound', 'interruption', 'load', 'therapy', 'viral', 'after', 'quick', 'appearance', 'with']","['interruption', 'therapy', 'after']",1122,['其快速恢复后中断的反病毒治疗与出现可测量的病毒负载相匹配。'],0.4,"['a', 'rebound', 'interruption', 'load', 'therapy', 'viral', 'after', 'quick', 'appearance', 'with']","['interruption', 'load', 'therapy', 'after']",,
1130,1123,"the donor cells engrafted with full chimerism , and the acute lymphoblastic leukemia was in complete remission for 19 months after transplantation , during which time the cells with the modified CCR5 gene persisted , and the CCR5 disruption ranged from 5.20 to 8.28 % in bone marrow cells ( Figure 1B ) .",移植完全嵌合的供体细胞，急性淋巴细胞白血病在移植后 19 个月内完全缓解，在此期间，具有修饰的 CCR5 基因的细胞持续存在，骨髓细胞中的 CCR5 破坏范围为 5.20 至 8.28 % (图 1B）。,0.4736842105263157,"['donor', 'gene', 'bone', 'chimerism', 'transplantation', 'bone marrow', 'leukemia', 'figure', 'acute lymphoblastic leukemia', 'disruption', 'time', 'complete', 'after', 'remission', 'with', 'full', 'in', 'to', 'and']","['donor', 'gene', 'bone', 'chimerism', 'transplantation', 'bone marrow', 'leukemia', 'after', 'remission']",1123,"['捐献细胞充满了化学,而急性淋巴细胞白血病在移植后的19个月内处于完整的复发状态,在此期间,有修改的CCR5基因的细胞持续了,而CCR5的干扰率在骨头细胞中从5.20%到8.28%(图1B)。']",0.4736842105263157,"['donor', 'gene', 'bone', 'chimerism', 'transplantation', 'bone marrow', 'leukemia', 'figure', 'acute lymphoblastic leukemia', 'disruption', 'time', 'complete', 'after', 'remission', 'with', 'full', 'in', 'to', 'and']","['gene', 'bone', 'transplantation', 'leukemia', 'complete', 'after', 'full', 'to', 'and']",,
1131,1124,"when antiretroviral therapy was interrupted at 7 months after transplantation , a small increase in the percentage of CCR5 indels was observed 2 weeks after the initiation of the interruption ( Figure 2C ) .",当移植后 7 个月中断抗逆转录病毒治疗时，在中断开始 2 周后观察到 CCR5 插入缺失百分比的小幅增加（图 2C）。,0.6,"['percentage', 'transplantation', 'initiation', '2', 'figure', 'interruption', 'therapy', 'interrupted', 'after', 'increase']","['transplantation', 'initiation', '2', 'interruption', 'therapy', 'after']",1124,"['如果在移植后7个月中断抗逆转病毒治疗,则在中断开始后2周内观察到CCR5的百分比略有增加(图2C)。']",0.6,"['percentage', 'transplantation', 'initiation', '2', 'figure', 'interruption', 'therapy', 'interrupted', 'after', 'increase']","['transplantation', 'initiation', '2', 'interruption', 'therapy', 'after']",,
1132,1125,biologic therapies are widely used in patients with ulcerative colitis .,生物疗法广泛用于溃疡性结肠炎患者。,0.5,"['biologic', 'colitis', 'ulcerative', 'ulcerative colitis', 'with', 'in']","['colitis', 'ulcerative', 'ulcerative colitis']",1125,['生物疗法在患有<unk>性<unk>炎的患者中广泛使用。'],0.0,"['biologic', 'colitis', 'ulcerative', 'ulcerative colitis', 'with', 'in']",[],,
1133,1126,previous exposure to a tumor necrosis factor inhibitor other than adalimumab was allowed in up to 25 % of patients .,允许多达 25% 的患者既往接触过阿达木单抗以外的肿瘤坏死因子抑制剂。,0.5555555555555556,"['inhibitor', 'a', 'necrosis', 'factor', 'exposure', 'tumor', 'previous', 'up', 'tumor necrosis factor']","['inhibitor', 'necrosis', 'factor', 'tumor', 'tumor necrosis factor']",1126,"['在25%的患者中,除了阿达利穆巴以外的肿瘤尼克罗斯因子抑制剂之前的曝光被允许。']",0.4444444444444444,"['inhibitor', 'a', 'necrosis', 'factor', 'exposure', 'tumor', 'previous', 'up', 'tumor necrosis factor']","['inhibitor', 'factor', 'exposure', 'tumor']",,
1134,1127,"the patients were assigned to receive infusions of 300 mg of vedolizumab on day 1 and at weeks 2 , 6 , 14 , 22 , 30 , 38 , and 46 ( plus injections of placebo ) or subcutaneous injections of 40 mg of adalimumab , with a total dose of 160 mg at week 1 , 80 mg at week 2 , and 40 mg every 2 weeks thereafter until week 50 ( plus infusions of placebo ) .",患者被分配在第 1 天和第 2 周、第 6 周、第 14 周、第 22 周、第 30 周、第 38 周和第 46 周（加上安慰剂注射）或皮下注射 40 mg 阿达木单抗，总共第 1 周剂量为 160 mg，第 2 周剂量为 80 mg，此后每 2 周剂量为 40 mg，直至第 50 周（加上输注安慰剂）。,0.3846153846153846,"['placebo', '1', '2', 'plus', 'total', 'subcutaneous', 'total dose', 'week', 'with', 'vedolizumab', 'at', 'injections', 'and']","['placebo', '1', '2', 'plus', 'week']",1127,"['患者在第1天和第2周、第6周、第14周、第22周、第30周、第38周和第46周(加上 placebo 注射)或下皮注射40 mg的 adalimumab,总剂量为第1周160 mg、第2周80 mg,随后每2周40 mg,直到第50周(加上 placebo 注射)。']",0.3076923076923077,"['placebo', '1', '2', 'plus', 'total', 'subcutaneous', 'total dose', 'week', 'with', 'vedolizumab', 'at', 'injections', 'and']","['1', '2', 'plus', 'week']",,
1135,1128,dose escalation was not permitted in either group .,两组均不允许增加剂量。,0.6666666666666666,"['group', 'dose', 'in']","['group', 'dose']",1128,['剂量升级不允许在任何群体中。'],0.6666666666666666,"['group', 'dose', 'in']","['group', 'dose']",,
1136,1129,a total of 769 patients underwent randomization and received at least one dose of vedolizumab ( 383 patients ) or adalimumab ( 386 patients ) .,共有 769 名患者接受了随机分组并接受了至少一剂维多珠单抗（383 名患者）或阿达木单抗（386 名患者）。,0.2,"['a', 'randomization', 'total', 'vedolizumab', 'dose']",['randomization'],1129,"['共 769 名患者遭到随机化,并获得至少 1 份 Vedolizumab (383 名患者) 或 Adalimumab (386 名患者) 。']",0.2,"['a', 'randomization', 'total', 'vedolizumab', 'dose']",['randomization'],,
1137,1130,"ulcerative colitis is a chronic inflammatory disorder of the large bowel characterized by abdominal pain , bloody diarrhea , and fecal urgency.1",溃疡性结肠炎是大肠的一种慢性炎症性疾病，其特征是腹痛、血性腹泻和便急。 1,0.5333333333333333,"['a', 'disorder', 'colitis', 'abdominal pain', 'fecal', 'large', 'bowel', 'ulcerative', 'diarrhea', 'large bowel', 'ulcerative colitis', 'chronic', 'inflammatory', 'characterized by', 'and']","['colitis', 'abdominal pain', 'bowel', 'ulcerative', 'diarrhea', 'large bowel', 'ulcerative colitis', 'chronic']",1130,"['溃<unk>性<unk>炎是一种慢性大肠炎症疾病,其特点是腹部疼痛、血液腹泻和排泄急性。']",0.2666666666666666,"['a', 'disorder', 'colitis', 'abdominal pain', 'fecal', 'large', 'bowel', 'ulcerative', 'diarrhea', 'large bowel', 'ulcerative colitis', 'chronic', 'inflammatory', 'characterized by', 'and']","['bowel', 'diarrhea', 'large bowel', 'chronic']",,
1138,1131,"adalimumab , a humanized monoclonal antibody that binds and neutralizes TNF , is widely used to treat ulcerative colitis .",阿达木单抗是一种结合并中和 TNF 的人源化单克隆抗体，广泛用于治疗溃疡性结肠炎。,0.7,"['antibody', 'monoclonal antibody', 'colitis', 'treat', 'ulcerative', 'ulcerative colitis', 'TNF', 'that', 'to', 'and']","['antibody', 'monoclonal antibody', 'colitis', 'treat', 'ulcerative', 'ulcerative colitis', 'to']",1131,"['阿达利穆巴(Adalimumab)是一种人文化单细胞抗体,连接和中立化TNF,广泛用于治疗<unk>疹<unk>疹。']",0.3,"['antibody', 'monoclonal antibody', 'colitis', 'treat', 'ulcerative', 'ulcerative colitis', 'TNF', 'that', 'to', 'and']","['antibody', 'treat', 'to']",,
1139,1132,"adults 18 to 85 years of age were eligible for inclusion in the trial if they had moderately to severely active ulcerative colitis , defined as a total score of 6 to 12 on the Mayo scale8 ( total Mayo scores range from 0 to 12 , with higher scores indicating more severe disease ) and a subscore of at least 2 on the endoscopic component of the Mayo scale ( subscores on each of the four components of the Mayo scale range from 0 to 3 ) ; colonic involvement of at least 15 cm ; and had a confirmed diagnosis of ulcerative colitis at least 3 months before screening .",18 至 85 岁的成年人如果患有中度至重度活动性溃疡性结肠炎，则有资格参加试验，定义为梅奥量表总分 6 至 12 分 8（梅奥总分范围为 0 至 12 分，分数较高表示更严重的疾病）和 Mayo 量表内窥镜部分的分项分数至少为 2（Mayo 量表四个部分中每个部分的分项分数范围为 0 至 3）；结肠受累至少 15 厘米 ;并在筛选前至少 3 个月确诊为溃疡性结肠炎。,0.3870967741935484,"['component', 'disease', 'defined', 'range', 'inclusion', '2', 'cm', 'screening', 'scale', 'colitis', 'active', 'total', 'moderately', 'ulcerative', 'colonic', 'diagnosis', 'ulcerative colitis', 'age', 'trial', 'scale range', '3', 'score', 'involvement', 'with', 'severe', 'severe disease', 'before', 'each', 'if', 'and', 'eligible']","['disease', 'range', '2', 'screening', 'scale', 'colitis', 'active', 'ulcerative', 'ulcerative colitis', 'score', 'severe', 'before']",1132,"['18 至 85 歲的成年人有資格參加試驗,如果他們有中等到嚴重活性<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>疹<unk>']",0.0,"['component', 'disease', 'defined', 'range', 'inclusion', '2', 'cm', 'screening', 'scale', 'colitis', 'active', 'total', 'moderately', 'ulcerative', 'colonic', 'diagnosis', 'ulcerative colitis', 'age', 'trial', 'scale range', '3', 'score', 'involvement', 'with', 'severe', 'severe disease', 'before', 'each', 'if', 'and', 'eligible']",[],,
1140,1133,patients who had not previously used a TNF inhibitor and had no response or loss of response to conventional treatments were eligible .,以前没有使用过 TNF 抑制剂并且对常规治疗没有反应或反应丧失的患者符合条件。,0.3333333333333333,"['inhibitor', 'a', 'who', 'loss', 'no', 'response', 'TNF', 'and', 'eligible']","['inhibitor', 'loss', 'response']",1133,['未曾使用过 TNF 抑制剂并且没有对常规治疗的反应或反应损失的患者有资格。'],0.3333333333333333,"['inhibitor', 'a', 'who', 'loss', 'no', 'response', 'TNF', 'and', 'eligible']","['inhibitor', 'loss', 'response']",,
1141,1134,"patients who had discontinued treatment with a TNF inhibitor ( except adalimumab ) because of documented reasons other than safety were also eligible , with enrollment capped at 25 % .",因安全性以外的有据可查的原因而停止使用 TNF 抑制剂（阿达木单抗除外）治疗的患者也符合条件，入组率上限为 25%。,0.375,"['safety', 'inhibitor', 'who', 'treatment', 'capped', 'with', 'TNF', 'eligible']","['safety', 'inhibitor', 'treatment']",1134,"['因其安全原因而停止使用 TNF 抑制剂(除了 adalimumab 除外)的患者也可接受,注册率为 25%。']",0.25,"['safety', 'inhibitor', 'who', 'treatment', 'capped', 'with', 'TNF', 'eligible']","['safety', 'inhibitor']",,
1142,1135,all patients had not previously received vedolizumab .,所有患者之前均未接受过维多珠单抗。,0.0,"['vedolizumab', 'all']",[],1135,['所有患者都没有提前服用Vedolizumab。'],0.0,"['vedolizumab', 'all']",[],,
1143,1136,screening ASSESSMENTS,筛选评估,1.0,['screening'],['screening'],1136,['扫描助理'],0.0,['screening'],[],,
1144,1137,"screening assessments included a physical examination , endoscopy ( findings were read at a central location ) , the total Mayo score , blood and stool tests , tuberculosis screening , the score on the Inflammatory Bowel Disease Questionnaire ( IBDQ ; scores range from 32 to 224 , with higher scores indicating a better quality of life ) , 9 and a questionnaire to identify possible symptoms of progressive multifocal leukoencephalopathy .",筛选评估包括身体检查、内窥镜检查（结果在中央位置读取） 、梅奥总分、血液和粪便检查、肺结核筛查、炎症性肠病问卷（ IBDQ ；分数范围从 32 到 224 ，以及更高的分数表明更好的生活质量），9 和一份问卷调查，以确定进行性多灶性脑白质病的可能症状。,0.5769230769230769,"['tuberculosis', 'life', 'disease', 'range', 'screening', 'blood', 'quality', 'physical', 'examination', 'location', 'total', 'progressive', 'physical examination', 'symptoms', 'bowel', 'read', 'central', 'endoscopy', 'stool', 'inflammatory', 'quality of life', 'score', 'identify', 'with', 'inflammatory bowel disease', 'and']","['tuberculosis', 'life', 'disease', 'range', 'screening', 'blood', 'quality', 'examination', 'location', 'physical examination', 'bowel', 'read', 'stool', 'quality of life', 'score']",1137,"['扫描评估包括物理检查,内分泌(发现在一个中心位置阅读),梅奥总分,血液和血管测试,结核病筛查,在炎症肠道疾病问卷(IBDQ;分数范围为32至224,与更高的分数表明更好的生活质量),9和一个问卷,以确定可能的症状的进步多点白血病。']",0.5,"['tuberculosis', 'life', 'disease', 'range', 'screening', 'blood', 'quality', 'physical', 'examination', 'location', 'total', 'progressive', 'physical examination', 'symptoms', 'bowel', 'read', 'central', 'endoscopy', 'stool', 'inflammatory', 'quality of life', 'score', 'identify', 'with', 'inflammatory bowel disease', 'and']","['tuberculosis', 'life', 'disease', 'range', 'screening', 'blood', 'quality', 'examination', 'location', 'bowel', 'read', 'quality of life', 'score']",,
1145,1138,"patients who were assigned to the vedolizumab group received intravenous infusions of 300 mg of vedolizumab on day 1 and at weeks 2 , 6 , 14 , 22 , 30 , 38 , and 46 plus subcutaneous injections of placebo on day 1 ( four injections ) , at week 2 ( two injections ) , and every 2 weeks thereafter ( single injections ) until week 50 .",被分配到维多珠单抗组的患者在第 1 天和第 2 周、第 6 周、第 14 周、第 22 周、第 30 周、第 38 周和第 46 周接受静脉输注 300 mg 维多珠单抗，并在第 1 天皮下注射安慰剂（四次注射） ，第 2 周（两次注射），此后每 2 周一次（单次注射），直至第 50 周。,0.4375,"['group', 'placebo', 'who', '1', '2', 'plus', 'subcutaneous', 'week', 'intravenous', 'vedolizumab', 'at', 'injections', 'single', 'to', 'and', 'two']","['group', 'placebo', '1', '2', 'week', 'single', 'two']",1138,"['被分配给Vedolizumab群体的患者在第1天和第2周、第6周、第14周、第22周、第30周、第38周和第46周接受了300mg的Vedolizumab注射,并在第1天(四次注射),第2周(两次注射),随后每2周(单次注射)直到第50周。']",0.375,"['group', 'placebo', 'who', '1', '2', 'plus', 'subcutaneous', 'week', 'intravenous', 'vedolizumab', 'at', 'injections', 'single', 'to', 'and', 'two']","['group', '1', '2', 'week', 'single', 'two']",,
1146,1139,dose escalation was not permitted in either treatment group .,两个治疗组都不允许增加剂量。,0.8,"['group', 'treatment', 'treatment group', 'dose', 'in']","['group', 'treatment', 'treatment group', 'dose']",1139,['剂量升级在任何治疗组都未允许。'],0.8,"['group', 'treatment', 'treatment group', 'dose', 'in']","['group', 'treatment', 'treatment group', 'dose']",,
1147,1140,"among the patients who were receiving an oral corticosteroid at baseline , the dose must have been stable ( ≤ 30 mg per day of prednisone or equivalent ) for at least 2 weeks before the first dose of a trial drug .",在基线时接受口服皮质类固醇治疗的患者中，剂量必须在试验药物首次给药前至少 2 周保持稳定（≤ 30 mg/d 泼尼松或同等药物）。,0.4375,"['corticosteroid', 'must', 'a', 'equivalent', 'who', 'baseline', '2', 'oral', 'prednisone', 'trial', 'drug', 'at', 'dose', 'have', 'before', 'first']","['corticosteroid', 'baseline', '2', 'prednisone', 'drug', 'dose', 'before']",1140,"['在接受口服甲状腺素的患者中,该剂量必须在试用药物的第一剂量前至少2周保持稳定(每日<30毫克或同等剂量)。']",0.3125,"['corticosteroid', 'must', 'a', 'equivalent', 'who', 'baseline', '2', 'oral', 'prednisone', 'trial', 'drug', 'at', 'dose', 'have', 'before', 'first']","['2', 'drug', 'dose', 'before', 'first']",,
1148,1141,"the corticosteroid dose remained unaltered through week 6 of the trial , and after week 6 , the dose was tapered intermittently if the patient had a response .",皮质类固醇的剂量在试验的第 6 周内保持不变，并且在第 6 周后，如果患者有反应，则剂量会间歇性地减少。,0.6,"['corticosteroid', 'a', 'response', 'week', 'patient', 'after', 'trial', 'dose', 'if', 'and']","['corticosteroid', 'response', 'week', 'patient', 'after', 'dose']",1141,"['甲状腺素的剂量在试验的第6周内保持不变,如果患者有反应,则在第6周后,剂量被中间切断。']",0.5,"['corticosteroid', 'a', 'response', 'week', 'patient', 'after', 'trial', 'dose', 'if', 'and']","['response', 'week', 'patient', 'after', 'dose']",,
1149,1142,patients who had a loss of response during the tapering period were permitted to receive the baseline corticosteroid dose one time only before tapering was restarted .,在减量期间失去反应的患者仅在重新开始减量前允许接受一次基线皮质类固醇剂量。,0.5454545454545454,"['corticosteroid', 'period', 'a', 'who', 'baseline', 'time', 'loss', 'response', 'dose', 'before', 'to']","['corticosteroid', 'period', 'baseline', 'response', 'dose', 'before']",1142,['在切割期间患有反应损失的患者只能在切割重新启动之前一次接收基因类固醇剂量。'],0.4545454545454545,"['corticosteroid', 'period', 'a', 'who', 'baseline', 'time', 'loss', 'response', 'dose', 'before', 'to']","['period', 'loss', 'response', 'dose', 'before']",,
1150,1143,"in accordance with the protocol , patients in whom the corticosteroid dose could not be tapered were withdrawn from the trial and were considered to have treatment failures with respect to each of the outcomes .",根据方案，皮质类固醇剂量不能逐渐减少的患者退出试验，并被认为在每项结果方面均治疗失败。,0.3333333333333333,"['corticosteroid', 'protocol', 'be', 'treatment', 'trial', 'with', 'respect', 'dose', 'have', 'each', 'in', 'and']","['corticosteroid', 'be', 'treatment', 'dose']",1143,"['根据该议定书,患有甲状腺素剂量无法吸收的患者被撤销,并被认为对每个结果都有治疗失败。']",0.3333333333333333,"['corticosteroid', 'protocol', 'be', 'treatment', 'trial', 'with', 'respect', 'dose', 'have', 'each', 'in', 'and']","['protocol', 'treatment', 'dose', 'have']",,
1151,1144,patients who were not receiving corticosteroids at baseline but who initiated corticosteroid treatment during the trial were withdrawn because of lack of efficacy .,基线时未接受皮质类固醇但在试验期间开始皮质类固醇治疗的患者因缺乏疗效而退出。,0.5,"['corticosteroid', 'lack', 'who', 'baseline', 'treatment', 'trial', 'efficacy', 'but']","['corticosteroid', 'baseline', 'treatment', 'but']",1144,['未在基线上服用甲状腺素但在试验期间开始治疗甲状腺素的患者因缺乏有效性而被撤回。'],0.5,"['corticosteroid', 'lack', 'who', 'baseline', 'treatment', 'trial', 'efficacy', 'but']","['baseline', 'treatment', 'efficacy', 'but']",,
1152,1145,patients who were receiving an aminosalicylate or an immunomodulator at baseline maintained stable doses throughout the trial .,在基线时接受氨基水杨酸盐或免疫调节剂的患者在整个试验期间保持稳定的剂量。,0.25,"['immunomodulator', 'who', 'baseline', 'trial']",['baseline'],1145,['在基线上服用氨基酸或免疫调节剂的患者在整个测试期间保持了稳定的剂量。'],0.25,"['immunomodulator', 'who', 'baseline', 'trial']",['baseline'],,
1153,1146,"adverse events ( classified according to the Medical Dictionary for Regulatory Activities , version 21.0 ) , results of laboratory tests and safety assessments , and concomitant medications were recorded throughout the trial .",不良事件（根据《监管活动医学词典》21.0 版分类）、实验室测试和安全性评估的结果以及合并用药在整个试验过程中均有记录。,0.2222222222222222,"['safety', 'version', 'medical', 'concomitant', 'adverse', 'trial', 'laboratory', 'classified', 'and']","['safety', 'laboratory']",1146,"['副作用(根据《医学规则活动词典》第21版分类),实验室测试和安全评估的结果以及同步药物在整个测试中被记录。']",0.2222222222222222,"['safety', 'version', 'medical', 'concomitant', 'adverse', 'trial', 'laboratory', 'classified', 'and']","['safety', 'laboratory']",,
1154,1147,"the total Mayo score was calculated at weeks 14 and 52 , when endoscopy was performed .",在第 14 周和第 52 周进行内窥镜检查时计算 Mayo 总分。,0.0,"['total', 'endoscopy', 'score', 'at', 'and']",[],1147,"['梅奥的总分数在14周和52周计算,当进行内分镜时。']",0.4,"['total', 'endoscopy', 'score', 'at', 'and']","['score', 'at']",,
1155,1148,"measurements of the fecal calprotectin level were performed at weeks 14 , 30 , and 52 .",在第 14、30 和 52 周时测量粪便钙卫蛋白水平。,0.25,"['fecal', 'level', 'at', 'and']",['level'],1148,"['在14周、30周和52周内,测量了分子卡尔蛋白素水平。']",0.25,"['fecal', 'level', 'at', 'and']",['level'],,
1156,1149,IBDQ assessments were performed at weeks 30 and 52 .,IBDQ 评估在第 30 周和第 52 周进行。,0.0,"['at', 'and']",[],1149,['IBDQ评估是在30周和52周进行的。'],0.0,"['at', 'and']",[],,
1157,1150,the trial sponsor ( Takeda ) designed the trial in conjunction with the principal academic investigators and provided the trial drugs and placebo .,试验发起人 (Takeda) 与主要学术研究人员一起设计试验并提供试验药物和安慰剂。,0.25,"['placebo', 'sponsor', 'drugs', 'principal', 'trial', 'conjunction', 'with', 'and']","['placebo', 'drugs']",1150,"['试验赞助商(Takeda)与主要学术调查人员共同设计了试验,并提供了试验药物和 placebo。']",0.125,"['placebo', 'sponsor', 'drugs', 'principal', 'trial', 'conjunction', 'with', 'and']",['drugs'],,
1158,1151,"a clinical research organization ( IQVIA ) , funded by the sponsor , managed all the collection of the data , maintained the trial database in a blinded manner , and performed the data analyses .",由申办方资助的临床研究机构 (IQVIA) 管理所有数据收集，以盲法维护试验数据库，并进行数据分析。,0.3636363636363636,"['organization', 'research', 'database', 'sponsor', 'collection', 'clinical', 'trial', 'manner', 'all', 'by', 'and']","['research', 'collection', 'clinical', 'by']",1151,"['由赞助商资助的临床研究组织(IQVIA)管理了所有数据收集,以盲目的方式维持了测试数据库,并进行了数据分析。']",0.4545454545454545,"['organization', 'research', 'database', 'sponsor', 'collection', 'clinical', 'trial', 'manner', 'all', 'by', 'and']","['organization', 'research', 'collection', 'clinical', 'by']",,
1159,1152,"the trial investigators , the participating institutions , the clinical research organization , and the sponsor agreed to maintain data confidentiality .",试验研究者、参与机构、临床研究组织和申办方同意对数据保密。,0.5,"['organization', 'confidentiality', 'research', 'data', 'sponsor', 'maintain', 'clinical', 'trial', 'to', 'and']","['organization', 'confidentiality', 'research', 'data', 'clinical']",1152,['调查调查人员、参与机构、临床研究组织和赞助商同意保持数据的机密性。'],0.4,"['organization', 'confidentiality', 'research', 'data', 'sponsor', 'maintain', 'clinical', 'trial', 'to', 'and']","['organization', 'research', 'data', 'clinical']",,
1160,1153,the initial draft of the manuscript was written by one of the authors employed by the sponsor in collaboration with the first and last authors .,手稿的初稿由申办方聘请的一位作者与第一作者和最后一位作者合作撰写。,0.5,"['sponsor', 'initial', 'manuscript', 'collaboration', 'with', 'by', 'and', 'first', 'employed', 'draft']","['initial', 'manuscript', 'collaboration', 'by', 'first']",1153,['手稿的初始草案是由赞助商与第一和最后的作者合作雇用的作者之一写的。'],0.5,"['sponsor', 'initial', 'manuscript', 'collaboration', 'with', 'by', 'and', 'first', 'employed', 'draft']","['initial', 'manuscript', 'collaboration', 'by', 'first']",,
1161,1154,"a medical writer , funded by the sponsor , assisted with the preparation of subsequent drafts .",一位由申办者资助的医学作家协助准备了后续的草稿。,0.375,"['a', 'preparation', 'sponsor', 'medical', 'writer', 'subsequent', 'with', 'by']","['preparation', 'sponsor', 'by']",1154,"['由赞助商资助的医学作家,协助下列草案的编制。']",0.125,"['a', 'preparation', 'sponsor', 'medical', 'writer', 'subsequent', 'with', 'by']",['by'],,
1162,1155,"all the authors interpreted the data , contributed to subsequent drafts , and made the decision to submit the manuscript for publication .",所有作者都解释了数据，为随后的草稿做出了贡献，并做出了投稿发表的决定。,0.375,"['data', 'publication', 'manuscript', 'subsequent', 'decision', 'all', 'to', 'and']","['data', 'publication', 'decision']",1155,"['所有作者都解释了数据,为随后的草案做出了贡献,并决定提交手稿出版。']",0.5,"['data', 'publication', 'manuscript', 'subsequent', 'decision', 'all', 'to', 'and']","['data', 'publication', 'manuscript', 'decision']",,
1163,1156,the academic authors had access to the data and vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol .,学术作者可以访问数据并保证数据的准确性和完整性以及试验对方案的忠实度。,0.375,"['fidelity', 'data', 'accuracy', 'protocol', 'access', 'trial', 'completeness', 'and']","['data', 'accuracy', 'completeness']",1156,"['学术作家可以访问数据,并为数据的准确性和完整性以及审判对议定书的忠诚度提供服务。']",0.625,"['fidelity', 'data', 'accuracy', 'protocol', 'access', 'trial', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
1164,1157,we performed a prespecified sensitivity analysis of the primary efficacy outcome that used a hybrid imputation approach to assess the effect of discontinuation under different missing data mechanisms .,我们对主要疗效结果进行了预先指定的敏感性分析，该分析使用混合插补方法来评估不同缺失数据机制下停药的影响。,0.3571428571428571,"['approach', 'hybrid', 'data', 'analysis', 'outcome', 'primary', 'effect', 'efficacy', 'assess', 'sensitivity', 'that', 'to', 'missing', 'we']","['data', 'analysis', 'outcome', 'assess', 'missing']",1157,"['我们对初级效率结果进行了预先确定的敏感性分析,使用了混合催化方法来评估不同缺乏数据机制的中断效应。']",0.4285714285714285,"['approach', 'hybrid', 'data', 'analysis', 'outcome', 'primary', 'effect', 'efficacy', 'assess', 'sensitivity', 'that', 'to', 'missing', 'we']","['data', 'analysis', 'outcome', 'effect', 'assess', 'missing']",,
1165,1158,"first , under the assumption that data were not missing at random , missing data for patients who discontinued vedolizumab or adalimumab because of an adverse event or lack of efficacy were imputed as nonresponses .",首先，在数据不是随机缺失的假设下，因不良事件或缺乏疗效而停用 vedolizumab 或 adalimumab 的患者的缺失数据被归因为无反应。,0.4166666666666667,"['lack', 'data', 'who', 'adverse', 'adverse event', 'efficacy', 'random', 'as', 'vedolizumab', 'that', 'missing', 'first']","['data', 'adverse event', 'random', 'missing', 'first']",1158,"['首先,假设数据不是随机缺少的,因不良事件或缺乏有效性而停止Vedolizumab或Adalimumab的患者缺少的数据被视为不响应。']",0.5833333333333334,"['lack', 'data', 'who', 'adverse', 'adverse event', 'efficacy', 'random', 'as', 'vedolizumab', 'that', 'missing', 'first']","['lack', 'data', 'adverse event', 'efficacy', 'random', 'missing', 'first']",,
1166,1159,"second , under the assumption that data were missing at random , data that were missing for other reasons were imputed with the use of multiple imputation .",其次，在数据随机缺失的假设下，对因其他原因缺失的数据采用多重插补法进行插补。,0.5714285714285714,"['data', 'multiple', 'random', 'with', 'second', 'that', 'missing']","['data', 'random', 'second', 'missing']",1159,"['其次,假设数据是随机缺失的,由于其他原因而缺失的数据是用多种假设来归因的。']",0.5714285714285714,"['data', 'multiple', 'random', 'with', 'second', 'that', 'missing']","['data', 'random', 'second', 'missing']",,
1167,1160,this sensitivity analysis was repeated post hoc for the two secondary efficacy outcomes .,事后对两项次要疗效结果重复了这种敏感性分析。,0.25,"['analysis', 'post', 'secondary', 'efficacy', 'sensitivity', 'repeated', 'this', 'two']","['analysis', 'two']",1160,['这种敏感性分析在两次二次有效性结果后重复。'],0.375,"['analysis', 'post', 'secondary', 'efficacy', 'sensitivity', 'repeated', 'this', 'two']","['analysis', 'efficacy', 'two']",,
1168,1161,efficacy was also assessed in prespecified subgroup analyses that were performed on the basis of disease characteristics and previous use of a TNF inhibitor ( yes or no ) .,疗效也在预先指定的亚组分析中进行了评估，这些分析是根据疾病特征和既往使用 TNF 抑制剂（是或否）进行的。,0.2142857142857142,"['inhibitor', 'disease', 'previous', 'basis', 'no', 'characteristics', 'of disease', 'efficacy', 'subgroup', 'TNF', 'on', 'that', 'and', 'assessed']","['inhibitor', 'disease', 'characteristics']",1161,['有效性也被评估在基于疾病特征和以前使用TNF抑制剂(是或没有)进行的预定子组分析。'],0.2857142857142857,"['inhibitor', 'disease', 'previous', 'basis', 'no', 'characteristics', 'of disease', 'efficacy', 'subgroup', 'TNF', 'on', 'that', 'and', 'assessed']","['inhibitor', 'disease', 'characteristics', 'efficacy']",,
1169,1162,"a total of 1285 patients were screened for eligibility , and 771 were enrolled in the trial , of whom 769 underwent randomization and received at least one dose of vedolizumab ( 383 patients ) or adalimumab ( 386 patients ) .",共有 1285 名患者接受了资格筛选，771 名患者参加了试验，其中 769 名接受了随机分组并接受了至少一剂维多珠单抗（383 名患者）或阿达木单抗（386 名患者）。,0.1428571428571428,"['a', 'randomization', 'total', 'trial', 'vedolizumab', 'dose', 'in']",['randomization'],1162,"['总共1285名患者被审查可接受,771名患者被注册,其中769人遭到随机化,并获得至少1剂Vedolizumab(383名患者)或Adalimumab(386名患者)。']",0.1428571428571428,"['a', 'randomization', 'total', 'trial', 'vedolizumab', 'dose', 'in']",['randomization'],,
1170,1163,the characteristics of the patients were generally similar between the treatment groups ( Table 1 ) .,治疗组之间患者的特征大体相似（表 1）。,0.8,"['table', '1', 'treatment', 'characteristics', 'similar']","['table', '1', 'treatment', 'characteristics']",1163,['患者的特性一般在治疗组之间相似(图1)。'],0.6,"['table', '1', 'treatment', 'characteristics', 'similar']","['1', 'treatment', 'characteristics']",,
1171,1164,clinical Remission,临床缓解,1.0,"['clinical', 'remission']","['clinical', 'remission']",1164,['临床复发'],0.5,"['clinical', 'remission']",['clinical'],,
1172,1165,"a sensitivity analysis to evaluate the effect of withdrawals showed that clinical remission at week 52 occurred in 37.2 % of the patients in the vedolizumab group and in 25.9 % in the adalimumab group ( adjusted difference , 11.3 percentage points ; 95 % CI , 4.6 to 18.0 ) . ( see Tables S3 and S4 in the Supplementary Appendix . )",评估退出影响的敏感性分析显示，在第 52 周时，维多珠单抗组 37.2 % 的患者和阿达木单抗组 25.9 % 的患者出现临床缓解（调整后的差异，11.3 个百分点； 95 % CI，4.6 至 18.0 ) 。 （见补充附录中的表 S3 和 S4。）,0.3157894736842105,"['group', 'percentage', 'appendix', 'analysis', 'supplementary', 'difference', 'clinical', 'week', 'effect', 'remission', 'sensitivity', 'vedolizumab', 'at', 'CI', 'S3', 'S4', 'that', 'to', 'and']","['group', 'analysis', 'difference', 'clinical', 'week', 'remission']",1165,"['一项敏感性分析,以评估撤销的效果,表明,在第52周的临床衰退发生在37.2%的患者在Vedolizumab组和25.9%的患者在Adalimumab组(调整差异,11.3个百分点;95%的CI,4.6到18.0)。']",0.3157894736842105,"['group', 'percentage', 'appendix', 'analysis', 'supplementary', 'difference', 'clinical', 'week', 'effect', 'remission', 'sensitivity', 'vedolizumab', 'at', 'CI', 'S3', 'S4', 'that', 'to', 'and']","['group', 'analysis', 'difference', 'clinical', 'week', 'effect']",,
1173,1166,"among the patients who had not previously used a TNF inhibitor , clinical remission at week 52 was observed in 34.2 % in the vedolizumab group and in 24.3 % in the adalimumab group ; among the patients who had previous exposure to a TNF inhibitor other than adalimumab , the corresponding percentages were 20.3 % and 16.0 % ( Figure 1A ) .",在之前未使用过 TNF 抑制剂的患者中，维多珠单抗组 34.2% 和阿达木单抗组 24.3% 在第 52 周观察到临床缓解；在既往接触过阿达木单抗以外的 TNF 抑制剂的患者中，相应的百分比分别为 20.3% 和 16.0%（图 1A）。,0.4,"['group', 'inhibitor', 'corresponding', 'a', 'who', 'exposure', 'figure', 'previous', 'clinical', 'week', 'remission', 'vedolizumab', 'at', 'TNF', 'and']","['group', 'inhibitor', 'corresponding', 'clinical', 'week', 'remission']",1166,"['在未使用 TNF 抑制剂的患者中,在第 52 周,在 Vedolizumab 群体中有 34.2% 和 Adalimumab 群体中有 24.3% 的临床衰退;在未使用 TNF 抑制剂而不是 Adalimumab 的患者中,相应的百分比为 20.3% 和 16.0% (图 1A ) 。']",0.4,"['group', 'inhibitor', 'corresponding', 'a', 'who', 'exposure', 'figure', 'previous', 'clinical', 'week', 'remission', 'vedolizumab', 'at', 'TNF', 'and']","['group', 'inhibitor', 'corresponding', 'clinical', 'week', 'and']",,
1174,1167,"durable clinical remission occurred in 18.3 % of the patients ( 70 of 383 ) in the vedolizumab group and in 11.9 % ( 46 of 386 ) in the adalimumab group ( difference , 6.3 percentage points ; 95 % CI , 1.3 to 11.3 ) .",维多珠单抗组 18.3% 的患者（383 人中的 70 人）和阿达木单抗组 11.9% 的患者（386 人中的 46 人）实现了持久临床缓解（差异，6.3 个百分点；95% CI，1.3 至 11.3）。,0.4444444444444444,"['group', 'percentage', 'difference', 'clinical', 'remission', 'vedolizumab', 'CI', 'to', 'and']","['group', 'difference', 'clinical', 'remission']",1167,"['持久的临床衰退发生在 18.3% 的患者(70 的 383 )在 vedolizumab 组和 11.9% ( 46 的 386 )在 adalimumab 组(差异, 6.3 个百分点 ; 95 % CI, 1.3 到 11.3 ) 。']",0.3333333333333333,"['group', 'percentage', 'difference', 'clinical', 'remission', 'vedolizumab', 'CI', 'to', 'and']","['group', 'difference', 'clinical']",,
1175,1168,endoscopic Improvement,内窥镜改善,1.0,['improvement'],['improvement'],1168,['内分泌改善'],1.0,['improvement'],['improvement'],,
1176,1169,"a sensitivity analysis to evaluate the effect of withdrawals showed that endoscopic improvement at week 52 occurred in 46.8 % of the patients in the vedolizumab group and in 33.6 % in the adalimumab group ( adjusted difference , 13.2 percentage points ; 95 % CI , 6.0 to 20.3 ) .",评估停药影响的敏感性分析显示，在第 52 周时，维多珠单抗组 46.8 % 的患者和阿达木单抗组 33.6 % 的患者发生了内镜改善（调整后的差异，13.2 个百分点； 95 % CI，6.0 至 20.3 ) 。,0.3333333333333333,"['group', 'percentage', 'improvement', 'analysis', 'difference', 'week', 'effect', 'sensitivity', 'vedolizumab', 'at', 'CI', 'that', 'in', 'to', 'and']","['group', 'improvement', 'analysis', 'difference', 'week']",1169,"['一项敏感性分析,以评估撤销的效果,表明52周内内分泌改善发生在46.8%的病人在Vedolizumab群体和33.6%在Adalimumab群体(调整差异,13.2个百分点;95%的CI,6.0到20.3)。']",0.4,"['group', 'percentage', 'improvement', 'analysis', 'difference', 'week', 'effect', 'sensitivity', 'vedolizumab', 'at', 'CI', 'that', 'in', 'to', 'and']","['group', 'improvement', 'analysis', 'difference', 'week', 'effect']",,
1177,1170,"among the patients who had not previously used a TNF inhibitor , endoscopic improvement at week 52 occurred in 43.1 % in the vedolizumab group and in 29.5 % in the adalimumab group , and among the patients who had previous exposure to a TNF inhibitor other than adalimumab , the corresponding percentages were 26.6 % and 21.0 % ( Figure 1B ) .",在既往未使用过 TNF 抑制剂的患者中，第 52 周内镜下改善发生率在维多珠单抗组为 43.1 %，在阿达木单抗组为 29.5 %，在既往使用过阿达木单抗以外的 TNF 抑制剂的患者中，相应的百分比为 26.6% 和 21.0%（图 1B）。,0.3571428571428571,"['group', 'inhibitor', 'corresponding', 'improvement', 'a', 'who', 'exposure', 'figure', 'previous', 'week', 'vedolizumab', 'at', 'TNF', 'and']","['group', 'inhibitor', 'corresponding', 'improvement', 'week']",1170,"['在未使用 TNF 抑制剂的患者中,在第 52 周内,内分泌改善发生在 vedolizumab 群体中的 43.1% 和 adalimumab 群体中的 29.5%,并且在以前接触 TNF 抑制剂而不是 adalimumab 的患者中,相应的百分比为 26.6% 和 21.0% (图 1B ) 。']",0.4285714285714285,"['group', 'inhibitor', 'corresponding', 'improvement', 'a', 'who', 'exposure', 'figure', 'previous', 'week', 'vedolizumab', 'at', 'TNF', 'and']","['group', 'inhibitor', 'corresponding', 'improvement', 'week', 'and']",,
1178,1171,the median change in the oral corticosteroid dose from baseline to week 52 was -10.0 mg in the vedolizumab group and -7.0 mg in the adalimumab group .,从基线到第 52 周，口服皮质类固醇剂量的中位变化在维多珠单抗组中为 -10.0 mg，在阿达木单抗组中为 -7.0 mg。,0.5454545454545454,"['group', 'corticosteroid', 'median', 'baseline', 'oral', 'week', 'change', 'vedolizumab', 'dose', 'to', 'and']","['group', 'corticosteroid', 'baseline', 'week', 'change', 'dose']",1171,['从基线到52周的口服甲状腺素剂量中间变化是10.0 mg在Vedolizumab组和7.0 mg在Adalimumab组。'],0.4545454545454545,"['group', 'corticosteroid', 'median', 'baseline', 'oral', 'week', 'change', 'vedolizumab', 'dose', 'to', 'and']","['group', 'baseline', 'week', 'change', 'dose']",,
1179,1172,"the percentage of patients who were in clinical remission at week 52 and who also had a subscore of 0 on both the rectal bleeding and endoscopic components of the Mayo scale was 22.2 % ( 85 of 383 ) in the vedolizumab group and 14.0 % ( 54 of 386 ) in the adalimumab group ( difference , 8.2 percentage points ; 95 % CI , 2.8 to 13.5 ) .",在第 52 周达到临床缓解并且梅奥量表的直肠出血和内窥镜检查项目子评分均为 0 的患者百分比在维多珠单抗组为 22.2 %（ 383 人中的 85 人）和 14.0 %（ 54 人） 386）在阿达木单抗组（差异，8.2 个百分点；95% CI，2.8 至 13.5）。,0.4666666666666667,"['bleeding', 'group', 'percentage', 'who', 'scale', 'difference', 'rectal', 'clinical', 'week', 'remission', 'vedolizumab', 'at', 'CI', 'to', 'and']","['bleeding', 'group', 'scale', 'difference', 'clinical', 'week', 'remission']",1172,"['在第52周临床衰退的患者的百分比,并且在梅奥尺度的直肠出血和内分泌组成部分的下分为0的百分比为22.2%(383分之85分)在维多利苏马布群体和14.0%(386分之54分)在阿达利苏马布群体(差异、8.2分点、95%CI、2.8至13,5分)。']",0.4,"['bleeding', 'group', 'percentage', 'who', 'scale', 'difference', 'rectal', 'clinical', 'week', 'remission', 'vedolizumab', 'at', 'CI', 'to', 'and']","['bleeding', 'group', 'percentage', 'difference', 'clinical', 'week']",,
1180,1173,patient Quality of Life,患者生活质量,1.0,"['life', 'quality', 'patient', 'quality of life']","['life', 'quality', 'patient', 'quality of life']",1173,['患者生活质量'],1.0,"['life', 'quality', 'patient', 'quality of life']","['life', 'quality', 'patient', 'quality of life']",,
1181,1174,"quality of life improved from baseline to week 52 ( as indicated by an increase of ≥ 16 points in the IBDQ score ) in 52.0 % of the patients in the vedolizumab group and in 42.2 % in the adalimumab group ( difference , 9.7 percentage points ; 95 % CI , 2.7 to 16.7 ) .",维多珠单抗组 52.0 % 的患者和阿达木单抗组 42.2 % 的患者的生活质量从基线到第 52 周有所改善（如 IBDQ 评分增加 ≥ 16 分所示）（差异， 9.7 个百分点； 95 %CI，2.7 至 16.7)。,0.5333333333333333,"['group', 'percentage', 'life', 'baseline', 'quality', 'difference', 'week', 'quality of life', 'score', 'increase', 'vedolizumab', 'CI', 'by', 'to', 'and']","['group', 'life', 'baseline', 'quality', 'difference', 'week', 'quality of life', 'by']",1174,"['从基线到52周的生活质量改善(根据IBDQ分数增加 ≥16点)在52.0%的病人在Vedolizumab组和42.2%在Adalimumab组(差异,9.7个百分点;95%的CI,2.7到16.7)。']",0.6,"['group', 'percentage', 'life', 'baseline', 'quality', 'difference', 'week', 'quality of life', 'score', 'increase', 'vedolizumab', 'CI', 'by', 'to', 'and']","['group', 'life', 'baseline', 'quality', 'difference', 'week', 'quality of life', 'score', 'by']",,
1182,1175,histologic Remission,组织学缓解,1.0,['remission'],['remission'],1175,['歇斯底里复发'],0.0,['remission'],[],,
1183,1176,"minimal histologic disease activity as indicated by a Geboes score lower than 3.2 at week 52 was observed in 33.4 % of the patients in the vedolizumab group and in 13.7 % in the adalimumab group ( difference , 19.6 percentage points ; 95 % CI , 13.8 to 25.5 ) .",在第 52 周时，维多珠单抗组 33.4% 的患者和阿达木单抗组 13.7% 的患者观察到 Geboes 评分低于 3.2 表示的最小组织学疾病活动（差异，19.6 个百分点；95% CI，13.8 至 25.5） ) 。,0.4666666666666667,"['group', 'percentage', 'disease', 'activity', 'difference', 'lower', 'week', 'minimal', 'score', 'vedolizumab', 'at', 'CI', 'by', 'to', 'and']","['group', 'disease', 'activity', 'difference', 'week', 'at', 'to']",1176,"['根据 Geboes 得分低于 3.2 在 52 周,在 Vedolizumab 群体的 33.4% 患者和 Adalimumab 群体的 13.7% 患者(差异, 19.6 个百分点, 95 % CI, 13.8 到 25.5 ) 观察。']",0.3333333333333333,"['group', 'percentage', 'disease', 'activity', 'difference', 'lower', 'week', 'minimal', 'score', 'vedolizumab', 'at', 'CI', 'by', 'to', 'and']","['group', 'difference', 'week', 'at', 'to']",,
1184,1177,clinical Response,临床反应,1.0,"['clinical', 'response']","['clinical', 'response']",1177,['临床回应'],0.5,"['clinical', 'response']",['clinical'],,
1185,1178,the percentages of patients who had a clinical response according to the partial Mayo score are shown in Figure 3 .,图 3 显示了根据部分 Mayo 评分具有临床反应的患者百分比。,0.2222222222222222,"['a', 'who', 'figure', 'clinical', 'response', 'partial', '3', 'score', 'to']","['clinical', 'response']",1178,['根据部分梅奥分数进行临床反应的患者的百分比显示在图3中。'],0.3333333333333333,"['a', 'who', 'figure', 'clinical', 'response', 'partial', '3', 'score', 'to']","['clinical', 'response', 'score']",,
1186,1179,adverse events occurred in 62.7 % of the patients ( 240 of 383 ) in the vedolizumab group and in 69.2 % ( 267 of 386 ) in the adalimumab group ( Table 2 ) .,维多珠单抗组 62.7%（383 人中的 240 人）和阿达木单抗组 69.2%（386 人中的 267 人）发生了不良事件（表 2）。,0.4285714285714285,"['group', 'table', '2', 'adverse', 'vedolizumab', 'in', 'and']","['group', 'table', '2']",1179,['副作用发生在62.7%的患者(240的383)在Vedolizumab群体和69.2%(267的386)在Adalimumab群体(图2)。'],0.2857142857142857,"['group', 'table', '2', 'adverse', 'vedolizumab', 'in', 'and']","['group', '2']",,
1187,1180,the most frequent adverse events are presented in Table S6 .,表 S6 列出了最常见的不良事件。,0.25,"['table', 'adverse', 'in', 'frequent']",['table'],1180,['最常见的不良事件在表 S6 中呈现。'],0.25,"['table', 'adverse', 'in', 'frequent']",['table'],,
1188,1181,serious adverse events occurred in 11.0 % of the patients ( 42 of 383 ) in the vedolizumab group and in 13.7 % ( 53 of 386 ) in the adalimumab group ( Table S7 in the Supplementary Appendix ) .,严重不良事件发生在维多珠单抗组 11.0% 的患者（383 例中的 42 例）和阿达木单抗组 13.7%（386 例中的 53 例）（补充附录表 S7）。,0.2222222222222222,"['group', 'appendix', 'table', 'supplementary', 'adverse', 'vedolizumab', 'serious', 'in', 'and']","['group', 'table']",1181,['严重的副作用发生在病人群中的11.0%(383人中42人)和病人群中的13.7%(386人中53人)(附件中的S7表)。'],0.3333333333333333,"['group', 'appendix', 'table', 'supplementary', 'adverse', 'vedolizumab', 'serious', 'in', 'and']","['group', 'appendix', 'table']",,
1189,1182,no patient received a diagnosis of progressive multifocal leukoencephalopathy .,没有患者被诊断为进行性多灶性脑白质病。,0.5,"['a', 'progressive', 'diagnosis', 'patient']","['diagnosis', 'patient']",1182,['没有一个患者被诊断为进步多点白血病。'],0.5,"['a', 'progressive', 'diagnosis', 'patient']","['diagnosis', 'patient']",,
1190,1183,one patient in the vedolizumab group died because of an exacerbation of ulcerative colitis and postoperative complications that were considered by the trial site investigator to be unrelated to vedolizumab or adalimumab ( Table 2 ) .,维多珠单抗组的一名患者死于溃疡性结肠炎恶化和术后并发症，试验现场研究者认为这些并发症与维多珠单抗或阿达木单抗无关（表 2）。,0.5882352941176471,"['group', 'site', 'table', '2', 'investigator', 'colitis', 'exacerbation', 'ulcerative', 'be', 'postoperative', 'ulcerative colitis', 'patient', 'trial', 'vedolizumab', 'that', 'by', 'and']","['group', 'site', 'table', '2', 'investigator', 'colitis', 'exacerbation', 'ulcerative', 'ulcerative colitis', 'patient']",1183,"['一个病人在Vedolizumab群体死于严重的<unk>疹和手术后并发症,被试验现场调查人员认为与Vedolizumab或Adalimumab无关(图2)。']",0.2941176470588235,"['group', 'site', 'table', '2', 'investigator', 'colitis', 'exacerbation', 'ulcerative', 'be', 'postoperative', 'ulcerative colitis', 'patient', 'trial', 'vedolizumab', 'that', 'by', 'and']","['group', 'site', '2', 'be', 'patient']",,
1191,1184,"as in the VARSITY trial , the ULTRA2 trial maintained blinding and randomization throughout the treatment period .",与 VARSITY 试验一样，ULTRA2 试验在整个治疗期间保持盲法和随机化。,0.5,"['period', 'randomization', 'treatment', 'trial', 'as', 'in']","['period', 'randomization', 'treatment']",1184,"['与VARSITY试验一样,ULTRA2试验在整个治疗期间保持了盲目和随机化。']",0.5,"['period', 'randomization', 'treatment', 'trial', 'as', 'in']","['period', 'randomization', 'treatment']",,
1192,1185,"the higher percentages of patients who had a response to active therapy in the GEMINI 1 trial than in the ULTRA2 trial and our trial may have reflected differences in trial design ; patients who had a clinical response underwent an additional randomization at week 6 in the GEMINI 1 trial , but the patients in the ULTRA2 trial and our trial underwent randomization only at baseline .",GEMINI 1 试验中对积极治疗有反应的患者百分比高于 ULTRA2 试验，我们的试验可能反映了试验设计的差异；在 GEMINI 1 试验中，出现临床反应的患者在第 6 周接受了额外的随机分组，但 ULTRA2 试验和我们的试验中的患者仅在基线时接受了随机分组。,0.75,"['a', 'randomization', 'who', 'baseline', '1', 'active', 'therapy', 'clinical', 'response', 'additional', 'week', 'trial', 'design', 'have', 'but', 'to']","['randomization', 'baseline', '1', 'therapy', 'clinical', 'response', 'additional', 'week', 'design', 'have', 'but', 'to']",1185,"['GEMINI 1 试验中对活性治疗的患者比 ULTRA2 试验和我们的试验中更高的百分比可能反映了试验设计的差异;在 GEMINI 1 试验中有临床反应的患者在第 6 周进行了额外的随机化,但在 ULTRA2 试验和我们的试验中患者仅在基线上进行了随机化。']",0.6875,"['a', 'randomization', 'who', 'baseline', '1', 'active', 'therapy', 'clinical', 'response', 'additional', 'week', 'trial', 'design', 'have', 'but', 'to']","['randomization', 'baseline', '1', 'therapy', 'clinical', 'response', 'additional', 'week', 'design', 'have', 'but']",,
1193,1186,"in addition , the ULTRA2 trial and the GEMINI 1 trial included a higher percentage of patients who had previously received treatment with a TNF inhibitor than the VARSITY trial .",此外，与 VARSITY 试验相比，ULTRA2 试验和 GEMINI 1 试验纳入了更高比例的既往接受过 TNF 抑制剂治疗的患者。,0.3,"['inhibitor', 'percentage', 'who', '1', 'addition', 'treatment', 'trial', 'with', 'TNF', 'and']","['inhibitor', '1', 'treatment']",1186,"['此外,ULTRA2测试和GEMINI 1测试包括比VARSITY测试之前接受TNF抑制剂治疗的患者比例更高。']",0.3,"['inhibitor', 'percentage', 'who', '1', 'addition', 'treatment', 'trial', 'with', 'TNF', 'and']","['inhibitor', '1', 'treatment']",,
1194,1187,it is difficult to explain the inconsistency of the results between this secondary remission outcome and the primary remission outcome .,很难解释这种次要缓解结果与主要缓解结果之间的结果不一致。,0.3333333333333333,"['outcome', 'primary', 'secondary', 'remission', 'inconsistency', 'this', 'to', 'and', 'difficult']","['outcome', 'remission', 'difficult']",1187,['很难解释二次投降结果与初级投降结果之间的结果的不一致性。'],0.3333333333333333,"['outcome', 'primary', 'secondary', 'remission', 'inconsistency', 'this', 'to', 'and', 'difficult']","['outcome', 'inconsistency', 'difficult']",,
1195,1188,"the trial did not require a specific schedule for corticosteroid tapering , which can vary among practitioners .",该试验不需要具体的皮质类固醇逐渐减量时间表，这可能因从业者而异。,0.2,"['corticosteroid', 'a', 'schedule', 'trial', 'specific']",['corticosteroid'],1188,"['试验不需要一个特定的日程安排,可在实践者中有所不同。']",0.2,"['corticosteroid', 'a', 'schedule', 'trial', 'specific']",['schedule'],,
1196,1189,"however , this limitation should not have resulted in differential effects in the two treatment groups .",然而，这种限制不应该导致两个治疗组的不同效果。,0.2857142857142857,"['differential', 'treatment', 'limitation', 'have', 'this', 'in', 'two']","['treatment', 'two']",1189,"['然而,这种限制不应在两组治疗中产生差异效应。']",0.2857142857142857,"['differential', 'treatment', 'limitation', 'have', 'this', 'in', 'two']","['treatment', 'two']",,
1197,1190,there were no notable treatment differences between patients who were receiving concomitant immunomodulator therapy and those who were not .,接受伴随免疫调节剂治疗的患者与未接受免疫调节剂治疗的患者之间没有显着的治疗差异。,0.3333333333333333,"['immunomodulator', 'who', 'therapy', 'concomitant', 'treatment', 'and']","['therapy', 'treatment']",1190,['在接受同步免疫调节治疗的患者和未接受的患者之间没有显著的治疗差异。'],0.3333333333333333,"['immunomodulator', 'who', 'therapy', 'concomitant', 'treatment', 'and']","['therapy', 'treatment']",,
1198,1191,"in the VARSITY trial , a subgroup of patients who had previous use of infliximab or golimumab were enrolled , and therefore the results observed among these patients in the adalimumab group reflect the efficacy in clinical practice among patients who switched to adalimumab from a drug within the same drug class .",在VARSITY试验中，纳入了先前使用过英夫利昔单抗或戈利木单抗的患者亚组，因此在阿达木单抗组的这些患者中观察到的结果反映了临床实践中从同一药物转为阿达木单抗的患者的疗效。毒品类。,0.3125,"['group', 'a', 'class', 'who', 'previous', 'reflect', 'clinical', 'trial', 'practice', 'efficacy', 'subgroup', 'drug', 'infliximab', 'therefore', 'to', 'and']","['group', 'reflect', 'clinical', 'practice', 'drug']",1191,"['在VARSITY研究中,被列入以前使用Infliximab或Golimumab的患者的子组,因此这些患者在Adalimumab群体中观察到的结果反映了从同一药物类内的药物中转移到Adalimumab的患者在临床实践中的有效性。']",0.375,"['group', 'a', 'class', 'who', 'previous', 'reflect', 'clinical', 'trial', 'practice', 'efficacy', 'subgroup', 'drug', 'infliximab', 'therefore', 'to', 'and']","['group', 'reflect', 'clinical', 'practice', 'efficacy', 'drug']",,
1199,1192,histologic remission was an exploratory outcome of this trial and was assessed with the Geboes score and the Robarts Histopathologic Index score .,组织学缓解是该试验的探索性结果，并通过 Geboes 评分和 Robarts 组织病理学指数评分进行评估。,0.4,"['outcome', 'index', 'exploratory', 'trial', 'score', 'remission', 'with', 'this', 'and', 'assessed']","['outcome', 'index', 'remission', 'this']",1192,"['歇斯底里的回报是这项试验的探索结果,并通过Geboes分数和Robarts Histopathologic Index分数进行评估。']",0.3,"['outcome', 'index', 'exploratory', 'trial', 'score', 'remission', 'with', 'this', 'and', 'assessed']","['outcome', 'score', 'this']",,
1200,1193,the results for the outcomes of histologic remission were consistent with the findings for clinical remission and endoscopic improvement .,组织学缓解的结果与临床缓解和内镜改善的结果一致。,0.6,"['improvement', 'clinical', 'remission', 'with', 'and']","['improvement', 'clinical', 'remission']",1193,['基因移植的结果与临床移植和内分泌改善的结果一致。'],0.4,"['improvement', 'clinical', 'remission', 'with', 'and']","['improvement', 'clinical']",,
1201,1194,few differences were observed between the trial groups in terms of the most commonly reported adverse events .,在最常报告的不良事件方面，试验组之间几乎没有差异。,0.0,"['adverse', 'trial', 'in']",[],1194,"['在审查小组中,在最常见的报告不良事件方面,观察到很少的差异。']",0.0,"['adverse', 'trial', 'in']",[],,
1202,1195,the dosing regimens selected for this trial were based on a conservative approach and use according to U.S. labels .,为该试验选择的给药方案是基于保守的方法并根据美国标签使用。,0.3333333333333333,"['approach', 'trial', 'conservative', 'this', 'to', 'and']","['this', 'to']",1195,['为此测试选择的剂量制度是基于美国标签的保守方法和使用。'],0.3333333333333333,"['approach', 'trial', 'conservative', 'this', 'to', 'and']","['this', 'to']",,
1203,1196,"data from ongoing trials of adalimumab ( ClinicalTrials.gov number , NCT02065622 ) and vedolizumab ( NCT03029143 ) may further characterize the effect of higher doses on efficacy outcomes .",来自正在进行的阿达木单抗（ClinicalTrials.gov 编号，NCT02065622）和维多珠单抗 (NCT03029143) 试验的数据可能进一步表征较高剂量对疗效结果的影响。,0.2857142857142857,"['data', 'number', 'effect', 'efficacy', 'vedolizumab', 'on', 'and']","['data', 'number']",1196,"['目前正在进行的 Adalimumab ( ClinicalTrials.gov 号, NCT02065622 ) 和 Vedolizumab ( NCT03029143 ) 的数据可能会进一步描述高剂量对效率结果的影响。']",0.2857142857142857,"['data', 'number', 'effect', 'efficacy', 'vedolizumab', 'on', 'and']","['data', 'number']",,
1204,1197,update recommends that providers use a risk assessment tool for all women with personal or family history of breast and ovarian cancer .,更新建议提供者对所有有乳腺癌和卵巢癌个人史或家族史的女性使用风险评估工具。,0.5384615384615384,"['family', 'cancer', 'personal', 'family history', 'ovarian cancer', 'assessment', 'breast', 'risk', 'tool', 'with', 'all', 'that', 'and']","['family', 'cancer', 'family history', 'ovarian cancer', 'assessment', 'risk', 'tool']",1197,"['更新建议供应商使用风险评估工具,适用于所有有乳腺和卵巢癌的个人或家庭史的女性。']",0.4615384615384615,"['family', 'cancer', 'personal', 'family history', 'ovarian cancer', 'assessment', 'breast', 'risk', 'tool', 'with', 'all', 'that', 'and']","['family', 'cancer', 'ovarian cancer', 'assessment', 'risk', 'tool']",,
1205,1198,sponsoring Organization : U.S. Preventive Services Task Force ( USPSTF ),主办机构：美国预防服务工作组 (USPSTF),0.2,"['organization', 'force', 'task', 'preventive', 'task force']",['task'],1198,['美国预防服务工作组(USPSTF)'],0.2,"['organization', 'force', 'task', 'preventive', 'task force']",['task'],,
1206,1198,sponsoring Organization : U.S. Preventive Services Task Force ( USPSTF ),主办机构：美国预防服务工作组 (USPSTF),0.2,"['organization', 'force', 'task', 'preventive', 'task force']",['task'],1198,['美国预防服务工作组(USPSTF)'],0.2,"['organization', 'force', 'task', 'preventive', 'task force']",['task'],,
1207,1198,sponsoring Organization : U.S. Preventive Services Task Force ( USPSTF ),主办机构：美国预防服务工作组 (USPSTF),0.2,"['organization', 'force', 'task', 'preventive', 'task force']",['task'],1198,['美国预防服务工作组(USPSTF)'],0.2,"['organization', 'force', 'task', 'preventive', 'task force']",['task'],,
1208,1198,sponsoring Organization : U.S. Preventive Services Task Force ( USPSTF ),主办机构：美国预防服务工作组 (USPSTF),0.2,"['organization', 'force', 'task', 'preventive', 'task force']",['task'],1198,['美国预防服务工作组(USPSTF)'],0.2,"['organization', 'force', 'task', 'preventive', 'task force']",['task'],,
1209,1199,BRCA1 / 2 mutations account for 5 % -10 % of breast cancer cases and 15 % of ovarian cancer cases .,BRCA1/2 突变占乳腺癌病例的 5%-10% 和卵巢癌病例的 15%。,0.7142857142857143,"['5', 'cancer', '2', '/', 'breast cancer', 'ovarian cancer', 'and']","['5', 'cancer', '2', 'breast cancer', 'ovarian cancer']",1199,['BRCA1 / 2 突变占乳腺癌病例的 5% - 10% 和卵巢癌病例的 15% 。'],0.7142857142857143,"['5', 'cancer', '2', '/', 'breast cancer', 'ovarian cancer', 'and']","['5', 'cancer', '2', 'breast cancer', 'ovarian cancer']",,
1210,1200,"in 2013 , the U.S. Preventive Services Task Force ( USPSTF ) recommended referral to genetic counseling only for women with a family history of breast , ovarian , tubal , or peritoneal cancer .",2013 年，美国预防服务工作组 (USPSTF) 建议仅将有乳腺癌、卵巢癌、输卵管癌或腹膜癌家族史的女性转诊至遗传咨询。,0.3846153846153846,"['family', 'cancer', 'genetic counseling', 'force', 'tubal', 'task', 'family history', 'preventive', 'breast', 'peritoneal', 'referral', 'task force', 'with']","['family', 'cancer', 'genetic counseling', 'task', 'family history']",1200,"['2013年,美国预防服务工作小组(USPSTF)建议仅对乳腺、卵巢、管道或周围癌症家族史的妇女进行遗传咨询。']",0.3846153846153846,"['family', 'cancer', 'genetic counseling', 'force', 'tubal', 'task', 'family history', 'preventive', 'breast', 'peritoneal', 'referral', 'task force', 'with']","['family', 'cancer', 'genetic counseling', 'task', 'family history']",,
1211,1201,"now , these updated guidelines reflect the latest evidence regarding benefits and harms of risk assessment and genetic testing .",现在，这些更新后的指南反映了有关风险评估和基因检测的益处和危害的最新证据。,0.625,"['genetic', 'reflect', 'regarding', 'assessment', 'risk', 'evidence', 'testing', 'and']","['reflect', 'regarding', 'assessment', 'risk', 'evidence']",1201,"['现在,这些更新的指南反映了关于风险评估和遗传测试的好处和损害的最新证据。']",0.625,"['genetic', 'reflect', 'regarding', 'assessment', 'risk', 'evidence', 'testing', 'and']","['reflect', 'regarding', 'assessment', 'risk', 'evidence']",,
1212,1202,primary care providers should screen patients who have a personal history or family history of breast and ovarian / peritoneal / tubal cancers .,初级保健提供者应筛查有乳腺癌和卵巢癌/腹膜癌/输卵管癌个人史或家族史的患者。,0.3571428571428571,"['family', 'who', '/', 'tubal', 'personal', 'family history', 'personal history', 'primary', 'breast', 'peritoneal', 'care', 'screen', 'have', 'and']","['family', 'family history', 'personal history', 'screen', 'have']",1202,['初级护理提供商应检查患有乳腺和卵巢/卵巢/管癌的个人或家庭史的患者。'],0.1428571428571428,"['family', 'who', '/', 'tubal', 'personal', 'family history', 'personal history', 'primary', 'breast', 'peritoneal', 'care', 'screen', 'have', 'and']","['family', 'have']",,
1213,1203,one of the seven available risk assessment tools should be used to estimate the likelihood of carrying a pathogenic BRCA mutation .,应使用七种可用的风险评估工具之一来估计携带致病性 BRCA 突变的可能性。,0.625,"['mutation', 'tools', 'pathogenic', 'be', 'assessment', 'available', 'risk', 'estimate']","['mutation', 'tools', 'assessment', 'available', 'risk']",1203,['使用七种可用的风险评估工具之一来估计患有病原性BRCA突变的可能性。'],0.625,"['mutation', 'tools', 'pathogenic', 'be', 'assessment', 'available', 'risk', 'estimate']","['mutation', 'tools', 'assessment', 'available', 'risk']",,
1214,1204,"women with a positive screen should be referred for genetic counseling and , if indicated , testing .",筛查呈阳性的女性应转诊进行遗传咨询，如果有指征，还应进行检测。,0.2222222222222222,"['a', 'genetic counseling', 'be', 'screen', 'testing', 'with', 'positive', 'if', 'and']","['genetic counseling', 'screen']",1204,"['有积极的屏幕的妇女应该被提到遗传咨询和,如果指示,测试。']",0.2222222222222222,"['a', 'genetic counseling', 'be', 'screen', 'testing', 'with', 'positive', 'if', 'and']","['genetic counseling', 'screen']",,
1215,1205,routine screening and genetic testing are not recommended among the general population without a history suggestive of BRCA mutation .,不建议在没有提示 BRCA 突变病史的一般人群中进行常规筛查和基因检测。,0.4,"['population', 'mutation', 'screening', 'routine', 'general', 'genetic', 'history', 'testing', 'and', 'without']","['population', 'mutation', 'screening', 'routine']",1205,['常规筛查和遗传测试不推荐在一般人口中没有一个提议的历史的BRCA突变。'],0.5,"['population', 'mutation', 'screening', 'routine', 'general', 'genetic', 'history', 'testing', 'and', 'without']","['population', 'mutation', 'screening', 'routine', 'history']",,
1216,1206,"many professional oncology societies have already adopted genetic testing guidelines that address family history and personal history of cancer ; now , this USPSTF update expands the obligation to the primary care arena .",许多专业肿瘤学会已经采用了涉及癌症家族史和个人史的基因检测指南；现在，这个 USPSTF 更新将义务扩展到初级保健领域。,0.25,"['family', 'cancer', 'obligation', 'personal', 'family history', 'genetic', 'arena', 'personal history', 'primary', 'professional', 'care', 'testing', 'have', 'this', 'that', 'and']","['family', 'cancer', 'family history', 'personal history']",1206,"['许多专业的肿瘤学社会已经采用了对癌症的家庭历史和个人历史的遗传测试指南;现在,这个USPSTF更新将义务扩展到初级护理领域。']",0.1875,"['family', 'cancer', 'obligation', 'personal', 'family history', 'genetic', 'arena', 'personal history', 'primary', 'professional', 'care', 'testing', 'have', 'this', 'that', 'and']","['family', 'cancer', 'family history']",,
1217,1207,"among assessment tools , the Gail Model is not appropriate for calculating risk for BRCA mutation ; either the Referral Screening Tool or Tyrer Cuzick is preferable .",在评估工具中，盖尔模型不适用于计算 BRCA 突变的风险； Referral Screening Tool 或 Tyrer Cuzick 是首选。,0.625,"['mutation', 'tools', 'model', 'screening', 'assessment', 'risk', 'referral', 'appropriate']","['mutation', 'tools', 'model', 'assessment', 'risk']",1207,"['在评估工具中,Gail 模型不适合计算 BRCA 突变的风险;无论是参考扫描工具还是 Tyrer Cuzick 都是优先的。']",0.625,"['mutation', 'tools', 'model', 'screening', 'assessment', 'risk', 'referral', 'appropriate']","['mutation', 'tools', 'model', 'assessment', 'risk']",,
1218,1208,"direct to consumer genetic testing ( e.g. , 23andMe ) only looks for 3 Ashkenazi Jewish founder mutations in BRCA genes and does not identify the other 98 % of BRCA mutations .",直接面向消费者的基因检测（例如 23andMe）仅在 BRCA 基因中寻找 3 个 Ashkenazi Jewish founder 突变，而不会识别其他 98% 的 BRCA 突变。,0.4285714285714285,"['genetic', '3', 'identify', 'testing', 'direct', 'to', 'and']","['identify', 'direct', 'and']",1208,"['直接到消费者基因测试(例如,23andMe)仅在BRCA基因中寻找3个Ashkenazi犹太创始人突变,并且不确定其他98%的BRCA突变。']",0.1428571428571428,"['genetic', '3', 'identify', 'testing', 'direct', 'to', 'and']",['direct'],,
1219,1209,"these days , genetic testing typically involves multiple gene panels beyond BRCA ; the National Comprehensive Cancer Network provides guidelines for such tests .",如今，基因检测通常涉及 BRCA 以外的多个基因组；国家综合癌症网络为此类测试提供指南。,0.4285714285714285,"['gene', 'cancer', 'comprehensive', 'network', 'multiple', 'genetic', 'testing']","['gene', 'cancer', 'network']",1209,"['今天,基因测试通常涉及多个基因板在BRCA之外;国家全面癌症网络为这些测试提供指导方针。']",0.4285714285714285,"['gene', 'cancer', 'comprehensive', 'network', 'multiple', 'genetic', 'testing']","['gene', 'cancer', 'network']",,
1220,1210,"the USPSTF recommends that providers discuss use of tamoxifen , raloxifene , or aromatase inhibitors with women at excess risk for breast cancer and low risk for adverse effects .",USPSTF 建议提供者与乳腺癌高危和不良反应风险低的女性讨论他莫昔芬、雷洛昔芬或芳香化酶抑制剂的使用。,0.4166666666666667,"['excess', 'cancer', 'aromatase', 'breast cancer', 'adverse', 'low', 'risk', 'discuss', 'with', 'tamoxifen', 'that', 'and']","['cancer', 'breast cancer', 'low', 'risk', 'tamoxifen']",1210,['USPSTF 建议供应商讨论使用 tamoxifen、raloxifen 或 aromatase 抑制剂的妇女患乳腺癌的过度风险和负面影响的低风险。'],0.3333333333333333,"['excess', 'cancer', 'aromatase', 'breast cancer', 'adverse', 'low', 'risk', 'discuss', 'with', 'tamoxifen', 'that', 'and']","['cancer', 'breast cancer', 'low', 'risk']",,
1221,1211,aromatase inhibitors are now among the recommended chemoprophylactic agents .,芳香化酶抑制剂现在是推荐的化学预防剂之一。,0.0,['aromatase'],[],1211,['aromatase 抑制剂现在是推荐的化疗药物之一。'],0.0,['aromatase'],[],,
1222,1212,"first , the absolute risk reduction achieved is incremental at best : for example , in the tamoxifen trials , the number needed to treat with 5 years of chemoprophylaxis to prevent one case of breast cancer was 143 .",首先，所实现的绝对风险降低充其量是递增的：例如，在他莫昔芬试验中，预防一例乳腺癌需要 5 年化学预防治疗的人数为 143 人。,0.7222222222222222,"['5', 'cancer', 'chemoprophylaxis', 'treat', 'absolute', 'reduction', 'breast cancer', 'number', 'case', 'risk', 'with', 'prevent', 'achieved', 'tamoxifen', 'example', 'in', 'to', 'first']","['5', 'cancer', 'chemoprophylaxis', 'treat', 'absolute', 'reduction', 'breast cancer', 'number', 'risk', 'prevent', 'tamoxifen', 'example', 'first']",1212,"['首先,实现的绝对风险减少在最佳情况下是增加的:例如,在塔米克西芬试验中,用5年的化学预防治疗所需的数量,以预防乳腺癌的一个案例为143。']",0.7222222222222222,"['5', 'cancer', 'chemoprophylaxis', 'treat', 'absolute', 'reduction', 'breast cancer', 'number', 'case', 'risk', 'with', 'prevent', 'achieved', 'tamoxifen', 'example', 'in', 'to', 'first']","['5', 'cancer', 'chemoprophylaxis', 'treat', 'absolute', 'reduction', 'breast cancer', 'number', 'case', 'risk', 'prevent', 'example', 'first']",,
1223,1213,"third , tamoxifen and raloxifene raise risk for venous thromboembolism - and tamoxifen raises risk for endometrial cancer , uterine bleeding , and endometrial polyps , making this medication less desirable for women with an intact uterus .",第三，他莫昔芬和雷洛昔芬会增加静脉血栓栓塞的风险，而他莫昔芬会增加子宫内膜癌、子宫出血和子宫内膜息肉的风险，因此对于子宫完好的女性而言，这种药物不太理想。,0.5555555555555556,"['bleeding', 'cancer', 'uterus', 'uterine', 'venous', 'endometrial', 'raise', 'thromboembolism', 'medication', 'risk', 'intact', 'with', 'tamoxifen', '-', 'this', 'and', 'third', 'uterine bleeding']","['bleeding', 'cancer', 'uterus', 'raise', 'thromboembolism', 'risk', 'tamoxifen', 'and', 'third', 'uterine bleeding']",1213,"['第三,tamoxifen和raloxifen增加了阴道血管肿瘤的风险,而tamoxifen增加了内分泌癌症、子宫出血和内分泌聚合物的风险,这使得这种药物对患有无菌子宫的女性更不受欢迎。']",0.5,"['bleeding', 'cancer', 'uterus', 'uterine', 'venous', 'endometrial', 'raise', 'thromboembolism', 'medication', 'risk', 'intact', 'with', 'tamoxifen', '-', 'this', 'and', 'third', 'uterine bleeding']","['bleeding', 'cancer', 'uterus', 'uterine', 'raise', 'risk', 'and', 'third', 'uterine bleeding']",,
1224,1214,aromatase inhibitors cause arthralgias and other musculoskeletal symptoms and may raise risk for bone fractures .,芳香化酶抑制剂会引起关节痛和其他肌肉骨骼症状，并可能增加骨折的风险。,0.4444444444444444,"['bone', 'aromatase', 'raise', 'symptoms', 'musculoskeletal', 'cause', 'risk', 'fractures', 'and']","['bone', 'raise', 'risk', 'fractures']",1214,"['香水抑制剂会导致关节炎和其他肌肉骨骼症状,并可能增加骨折的风险。']",0.4444444444444444,"['bone', 'aromatase', 'raise', 'symptoms', 'musculoskeletal', 'cause', 'risk', 'fractures', 'and']","['bone', 'raise', 'risk', 'fractures']",,
1225,1215,all these agents cause vasomotor symptoms .,所有这些药物都会引起血管舒缩症状。,0.0,"['vasomotor', 'symptoms', 'cause', 'all']",[],1215,['所有这些物质都会导致血管症状。'],0.0,"['vasomotor', 'symptoms', 'cause', 'all']",[],,
1226,1216,"the effects of current antidepressants are variable and generally emerge within 4 to 8 weeks ; thus , the search continues for antidepressants with novel mechanisms of action .",目前抗抑郁药的效果各不相同，一般会在 4 到 8 周内出现；因此，人们仍在继续寻找具有新作用机制的抗抑郁药。,0.2727272727272727,"['variable', 'action', 'search', 'thus', 'novel', '4', 'current', 'with', 'antidepressants', 'to', 'and']","['action', 'thus', 'antidepressants']",1216,"['目前抗抑郁药的作用是多样化的,通常在4至8周内出现;因此,新的作用机制的抗抑郁药的搜索仍在继续。']",0.2727272727272727,"['variable', 'action', 'search', 'thus', 'novel', '4', 'current', 'with', 'antidepressants', 'to', 'and']","['action', 'thus', 'antidepressants']",,
1227,1217,"at day 28 , these outcomes no longer significantly differed between groups .",在第 28 天，这些结果在组间不再有显着差异。,0.0,"['no', 'at']",[],1217,"['在28日,这些结果不再在群体之间显著差异。']",0.0,"['no', 'at']",[],,
1228,1218,"the most common adverse events were headache , dizziness , nausea , and somnolence ( 53 % and 45 % of each group experienced at least 1 event ) .",最常见的不良事件是头痛、头晕、恶心和嗜睡（每组分别有 53% 和 45% 的人经历过至少 1 次事件）。,0.5,"['group', 'headache', '1', 'somnolence', 'nausea', 'common', 'dizziness', 'adverse', 'at', 'event', 'each', 'and']","['group', 'headache', '1', 'somnolence', 'nausea', 'dizziness']",1218,['最常见的副作用是头痛、恶心、恶心和失眠(每个群体的53%和45%至少经历了1个事件)。'],0.3333333333333333,"['group', 'headache', '1', 'somnolence', 'nausea', 'common', 'dizziness', 'adverse', 'at', 'event', 'each', 'and']","['group', 'headache', '1', 'nausea']",,
1229,1219,no serious adverse events occurred .,没有发生严重不良事件。,0.0,"['adverse', 'no', 'serious']",[],1219,['没有发生严重的不良事件。'],0.0,"['adverse', 'no', 'serious']",[],,
1230,1220,"metabolic factors , such as hypertension , are the largest contributors to CVD risk , and behavioral factors , such as tobacco use , are the largest contributors to mortality risk .",代谢因素，如高血压，是导致心血管疾病风险的最大因素，而行为因素，如吸烟，是导致死亡风险的最大因素。,0.5,"['hypertension', 'tobacco', 'mortality', 'risk', 'metabolic', 'as', 'CVD', 'and']","['hypertension', 'risk', 'as', 'and']",1220,"['代谢因素,如高血压,是CVD风险最大的贡献者,行为因素,如烟草使用,是死亡风险最大的贡献者。']",0.5,"['hypertension', 'tobacco', 'mortality', 'risk', 'metabolic', 'as', 'CVD', 'and']","['hypertension', 'tobacco', 'risk', 'as']",,
1231,1221,"the authors evaluated associations of 14 modifiable risk factors with total mortality and CVD ( CV death , myocardial infarction , stroke , and heart failure ) in over 150,000 people without CVD at baseline .","作者评估了 14 种可变风险因素与总死亡率和 CVD（CV 死亡、心肌梗死、中风和心力衰竭）之间的关联，研究对象为超过 150,000 名基线时没有 CVD 的人。",0.6,"['heart', 'myocardial infarction', 'stroke', 'failure', 'baseline', 'death', 'total', 'total mortality', 'heart failure', 'risk', 'with', 'CVD', 'over', 'and', 'without']","['heart', 'myocardial infarction', 'stroke', 'failure', 'baseline', 'death', 'heart failure', 'risk', 'over']",1221,"['作者评估了14个可改变的风险因素与总死亡率和CVD(CV死亡、心脏病发作、中风和心脏衰竭)在150,000多人中没有CVD。']",0.3333333333333333,"['heart', 'myocardial infarction', 'stroke', 'failure', 'baseline', 'death', 'total', 'total mortality', 'heart failure', 'risk', 'with', 'CVD', 'over', 'and', 'without']","['heart', 'stroke', 'failure', 'death', 'risk']",,
1232,1222,"overall , about 70 % of cardiovascular disease and deaths were attributed to modifiable risk factors .",总体而言，大约 70% 的心血管疾病和死亡归因于可改变的危险因素。,1.0,"['disease', 'cardiovascular', 'cardiovascular disease', 'risk', 'to', 'and']","['disease', 'cardiovascular', 'cardiovascular disease', 'risk', 'to', 'and']",1222,"['总体而言,大约70%的心血管疾病和死亡被归因于可改变的风险因素。']",1.0,"['disease', 'cardiovascular', 'cardiovascular disease', 'risk', 'to', 'and']","['disease', 'cardiovascular', 'cardiovascular disease', 'risk', 'to', 'and']",,
1233,1223,"for CVD , metabolic risk factors ( lipid levels , blood pressure , diabetes , obesity ) accounted for about 40 % of risk ; hypertension was the largest factor .",对于心血管疾病，代谢风险因素（血脂水平、血压、糖尿病、肥胖）约占风险的 40%；高血压是最大的因素。,0.5454545454545454,"['diabetes', 'pressure', 'lipid', 'hypertension', 'factor', 'blood', 'obesity', 'blood pressure', 'risk', 'metabolic', 'CVD']","['diabetes', 'hypertension', 'factor', 'obesity', 'blood pressure', 'risk']",1223,"['对于CVD,代谢风险因素(脂肪水平、血压、糖尿病、肥胖)约为40%的风险;高血压是最大的因素。']",0.5454545454545454,"['diabetes', 'pressure', 'lipid', 'hypertension', 'factor', 'blood', 'obesity', 'blood pressure', 'risk', 'metabolic', 'CVD']","['diabetes', 'hypertension', 'factor', 'obesity', 'blood pressure', 'risk']",,
1234,1224,"for mortality , behavioral risk factors ( tobacco and alcohol use , diet , physical activity , and sodium intake ) accounted for about 25 % of risk , with tobacco use the largest factor .",对于死亡率，行为风险因素（烟草和酒精使用、饮食、身体活动和钠摄入量）约占风险的 25%，其中烟草使用是最大的因素。,0.5714285714285714,"['alcohol', 'intake', 'tobacco', 'factor', 'sodium', 'diet', 'activity', 'physical', 'sodium intake', 'mortality', 'risk', 'with', 'physical activity', 'and']","['alcohol', 'tobacco', 'factor', 'sodium', 'diet', 'activity', 'mortality', 'risk']",1224,"['死亡率、行为风险因素(烟草和酒精使用、饮食、身体活动和<unk>摄入)约为25%的风险,烟草使用是最大的风险因素。']",0.5,"['alcohol', 'intake', 'tobacco', 'factor', 'sodium', 'diet', 'activity', 'physical', 'sodium intake', 'mortality', 'risk', 'with', 'physical activity', 'and']","['alcohol', 'tobacco', 'factor', 'diet', 'activity', 'mortality', 'risk']",,
1235,1225,ambient air pollution was associated with 14 % of risk for CVD .,环境空气污染与 14% 的 CVD 风险有关。,0.5714285714285714,"['ambient', 'air pollution', 'associated', 'risk', 'with', 'ambient air', 'CVD']","['ambient', 'air pollution', 'risk', 'ambient air']",1225,['环境空气污染与14%的CVD风险有关。'],0.5714285714285714,"['ambient', 'air pollution', 'associated', 'risk', 'with', 'ambient air', 'CVD']","['ambient', 'air pollution', 'risk', 'ambient air']",,
1236,1226,"in MICs and LICs , household air pollution , poor diet , low education , and low grip strength had stronger associations with CVD and mortality than in HICs .",在中等收入国家和低收入国家，家庭空气污染、不良饮食、低教育程度和低握力与心血管疾病和死亡率的相关性高于高收入国家。,0.5384615384615384,"['grip', 'air pollution', 'diet', 'education', 'low', 'mortality', 'strength', 'household', 'with', 'CVD', 'poor', 'in', 'and']","['grip', 'air pollution', 'diet', 'education', 'low', 'mortality', 'household']",1226,"['在MIC和LIC,家庭空气污染,营养不良,低教育和低吸引力与CVD和死亡率有更强的联系,而不是在HIC。']",0.4615384615384615,"['grip', 'air pollution', 'diet', 'education', 'low', 'mortality', 'strength', 'household', 'with', 'CVD', 'poor', 'in', 'and']","['air pollution', 'education', 'low', 'mortality', 'household', 'and']",,
1237,1227,"pure suggests that most cardiovascular morbidity and mortality can be attributed to a small number of common , modifiable risk factors .",pure 表明大多数心血管疾病的发病率和死亡率可归因于少数常见的、可改变的危险因素。,0.5,"['a', 'cardiovascular', 'morbidity', 'be', 'common', 'mortality', 'number', 'risk', 'pure', 'that', 'to', 'and']","['cardiovascular', 'morbidity', 'mortality', 'number', 'risk', 'to']",1227,"['纯暗示,大多数心血管疾病和死亡率可以归因于少数常见、可改变的风险因素。']",0.5,"['a', 'cardiovascular', 'morbidity', 'be', 'common', 'mortality', 'number', 'risk', 'pure', 'that', 'to', 'and']","['cardiovascular', 'mortality', 'number', 'risk', 'pure', 'to']",,
1238,1228,disease prevalence and clinical outcomes are known to be associated with income .,众所周知，疾病患病率和临床结果与收入有关。,0.3333333333333333,"['disease', 'prevalence', 'be', 'associated', 'clinical', 'with', 'income', 'to', 'and']","['disease', 'clinical', 'income']",1228,['疾病的发病率和临床结果已知与收入有关。'],0.3333333333333333,"['disease', 'prevalence', 'be', 'associated', 'clinical', 'with', 'income', 'to', 'and']","['disease', 'clinical', 'income']",,
1239,1229,"7.0 % of participants died : 5.7 % had cardiovascular disease ( CVD ) , 3.2 % had cancer , 2.7 % suffered injuries requiring hospitalization , 1.8 % had pneumonia , and 1.1 % had chronic obstructive pulmonary disease ( COPD ) .",7.0% 的参与者死亡：5.7% 患有心血管疾病 (CVD)，3.2% 患有癌症，2.7% 受伤需要住院治疗，1.8% 患有肺炎，1.1% 患有慢性阻塞性肺病 (COPD)。,0.6666666666666666,"['COPD', 'disease', 'cancer', 'cardiovascular', 'obstructive', 'hospitalization', 'pulmonary', 'cardiovascular disease', 'chronic', 'CVD', 'pneumonia', 'and']","['COPD', 'disease', 'cancer', 'cardiovascular', 'hospitalization', 'cardiovascular disease', 'chronic', 'pneumonia']",1229,"['7.0%的参与者死亡: 5.7%患有心血管疾病(CVD),3.2%患有癌症,2.7%患有需要入院的伤害,1.8%患有肺炎,1.1%患有慢性阻塞性肺疾病(COPD)。']",0.5833333333333334,"['COPD', 'disease', 'cancer', 'cardiovascular', 'obstructive', 'hospitalization', 'pulmonary', 'cardiovascular disease', 'chronic', 'CVD', 'pneumonia', 'and']","['COPD', 'disease', 'cancer', 'cardiovascular', 'cardiovascular disease', 'chronic', 'pneumonia']",,
1240,1230,"this was true for all causes of death except cancer , from which mortality was similar across all country income levels .",对于癌症以外的所有死因都是如此，癌症死亡率在所有收入水平的国家都相似。,0.6363636363636364,"['cancer', 'death', 'true', 'country', 'causes of death', 'mortality', 'across', 'income', 'all', 'this', 'similar']","['cancer', 'death', 'country', 'causes of death', 'mortality', 'income', 'this']",1230,"['这适用于除了癌症以外的所有死亡原因,其中死亡率在所有国家的收入水平上都是相同的。']",0.5454545454545454,"['cancer', 'death', 'true', 'country', 'causes of death', 'mortality', 'across', 'income', 'all', 'this', 'similar']","['cancer', 'death', 'country', 'mortality', 'income', 'this']",,
1241,1231,"CVD , the most common cause of mortality , accounted for 40 % of deaths overall but for only 23 % of deaths in HICs .",CVD 是最常见的死亡原因，占总死亡人数的 40%，但在高收入国家死亡人数中仅占 23%。,0.3333333333333333,"['common', 'mortality', 'cause', 'CVD', 'in', 'but']","['cause', 'but']",1231,"['CVD,死亡率最常见的原因,占总死亡率的40%,但仅占HIC死亡率的23%。']",0.5,"['common', 'mortality', 'cause', 'CVD', 'in', 'but']","['mortality', 'cause', 'but']",,
1242,1232,"the ratio of death from CVD to death from cancer was 0.4 in HICs , 1.3 in MICs , and 3.0 in LICs .",心血管疾病死亡与癌症死亡的比率在高收入国家为 0.4，在中等收入国家为 1.3，在低收入国家为 3.0。,0.4285714285714285,"['cancer', 'ratio', 'death', 'CVD', 'in', 'to', 'and']","['cancer', 'ratio', 'death']",1232,['CVD死亡与癌症死亡的比例在HIC中为0.4、MIC中为1.3、LIC中为3.0。'],0.4285714285714285,"['cancer', 'ratio', 'death', 'CVD', 'in', 'to', 'and']","['cancer', 'ratio', 'death']",,
1243,1233,these data highlight the influence of income in combating largely preventable diseases such as CVD .,这些数据突出了收入在抗击 CVD 等基本上可预防的疾病方面的影响。,0.6,"['data', 'influence', 'as', 'income', 'CVD']","['data', 'influence', 'income']",1233,"['这些数据强调了收入对抗主要可预防的疾病,如CVD的影响。']",0.8,"['data', 'influence', 'as', 'income', 'CVD']","['data', 'influence', 'as', 'income']",,
1244,1234,the high mortality in poorer countries was likely related to poorer access to health care .,较贫穷国家的高死亡率可能与较差的医疗保健机会有关。,0.4285714285714285,"['health', 'access', 'mortality', 'health care', 'in', 'to', 'high']","['mortality', 'health care', 'high']",1234,['贫困国家的死亡率很可能与贫困国家的医疗保健接入有关。'],0.2857142857142857,"['health', 'access', 'mortality', 'health care', 'in', 'to', 'high']","['mortality', 'health care']",,
1245,1235,"not surprisingly , medication use was lowest in LICs and highest in HICs .",毫不奇怪，低收入国家的药物使用率最低，而高收入国家的药物使用率最高。,0.3333333333333333,"['medication', 'in', 'and']",['and'],1235,"['不令人惊讶的是,药物使用量在LIC中最低,在HIC中最高。']",0.0,"['medication', 'in', 'and']",[],,
1246,1236,"at baseline , mean serum 25 ( OH ) D was 32 ng / mL ( 79 nmol / L ) .",基线时，平均血清 25 (OH) D 为 32 ng/mL (79 nmol/L)。,0.4285714285714285,"['mean', 'baseline', '/', 'serum', 'D', 'ml', 'at']","['mean', 'baseline', 'serum']",1236,"['在基线上,平均血清25(OH)D为32 ng / mL(79 nmol / L)。']",0.4285714285714285,"['mean', 'baseline', '/', 'serum', 'D', 'ml', 'at']","['mean', 'baseline', 'serum']",,
1247,1237,dietary calcium intake was supplemented to recommended levels .,将膳食钙摄入量补充至推荐水平。,0.25,"['calcium', 'intake', 'dietary', 'to']",['calcium'],1237,['饮食摄入量加到推荐的水平。'],0.0,"['calcium', 'intake', 'dietary', 'to']",[],,
1248,1238,participants were assessed serially through 36 months .,在 36 个月内对参与者进行连续评估。,0.0,"['serially', 'assessed']",[],1238,['參與者在36個月內進行了嚴重評估。'],0.0,"['serially', 'assessed']",[],,
1249,1239,"serum 25 ( OH ) D levels increased significantly for participants who received 4000 IU or 10,000 IU daily but not for participants who received 400 IU daily .","每天接受 4000 IU 或 10,000 IU 的参与者的血清 25 (OH) D 水平显着升高，但每天接受 400 IU 的参与者则没有。",0.5,"['who', 'serum', 'D', 'but']","['serum', 'but']",1239,"['血清25(OH)D水平在每日接收4000 IU或10,000 IU的参与者中显著增加,但不是每日接收400 IU的参与者。']",0.5,"['who', 'serum', 'D', 'but']","['serum', 'but']",,
1250,1240,"at 3 years , declines in BMD at the radius were significantly steeper in the 4000 IU and 10,000 IU groups ( − 2.4 % and − 3.5 % , respectively ) than in the 400 IU group ( − 1.2 % ) .","3 年时，4000 IU 和 10,000 IU 组（分别为 - 2.4% 和 - 3.5%）的桡骨 BMD 下降幅度明显大于 400 IU 组（-1.2%）。",0.4285714285714285,"['group', 'radius', '3', 'at', 'steeper', 'in', 'and']","['group', 'radius', 'at']",1240,"['在3年,在4000 IU和10,000 IU群体( − 2.4 % 和 − 3.5 % 相应)中,比400 IU群体( − 1.2 % )显著下降。']",0.1428571428571428,"['group', 'radius', '3', 'at', 'steeper', 'in', 'and']",['group'],,
1251,1241,a similar pattern was noted in the tibia .,在胫骨中发现了类似的模式。,0.4,"['a', 'pattern', 'tibia', 'in', 'similar']","['pattern', 'tibia']",1241,['类似的模型在Tibia中被注意到。'],0.2,"['a', 'pattern', 'tibia', 'in', 'similar']",['pattern'],,
1252,1242,the authors speculate that this somewhat unexpected finding might be due to increased bone resorption secondary to parathyroid hormone suppression .,作者推测，这一有点出乎意料的发现可能是由于甲状旁腺激素抑制继发的骨吸收增加所致。,0.7272727272727273,"['parathyroid hormone', 'bone', 'suppression', 'resorption', 'bone resorption', 'be', 'secondary', 'due', 'this', 'that', 'to']","['parathyroid hormone', 'bone', 'suppression', 'resorption', 'bone resorption', 'secondary', 'this', 'to']",1242,"['作者猜测,这种有点意想不到的发现可能是由于增加的骨质吸收二次到甲状腺激素抑制。']",0.4545454545454545,"['parathyroid hormone', 'bone', 'suppression', 'resorption', 'bone resorption', 'be', 'secondary', 'due', 'this', 'that', 'to']","['bone', 'suppression', 'resorption', 'this', 'to']",,
1253,1243,"in relatively healthy diabetic patients , this drug showed promise for primary prevention .",在相对健康的糖尿病患者中，这种药物有望用于一级预防。,0.7142857142857143,"['prevention', 'diabetic', 'primary prevention', 'drug', 'this', 'in', 'healthy']","['prevention', 'diabetic', 'primary prevention', 'drug', 'healthy']",1243,"['在相对健康的糖尿病患者中,这种药物表现出初级预防的承诺。']",0.5714285714285714,"['prevention', 'diabetic', 'primary prevention', 'drug', 'this', 'in', 'healthy']","['prevention', 'diabetic', 'drug', 'healthy']",,
1254,1244,"in trials with primary CV outcomes , liraglutide and semaglutide also prevented some prespecified chronic renal outcomes .",在具有主要 CV 结果的试验中，利拉鲁肽和索马鲁肽还可以预防一些预先指定的慢性肾脏结果。,0.375,"['chronic', 'primary', 'renal', 'with', 'semaglutide', 'liraglutide', 'in', 'and']","['chronic', 'semaglutide', 'liraglutide']",1244,"['在初级CV结果的试验中,Liraglutide和Semaglutide也预防了一些预定慢性肾脏结果。']",0.125,"['chronic', 'primary', 'renal', 'with', 'semaglutide', 'liraglutide', 'in', 'and']",['chronic'],,
1255,1245,the difference was driven primarily by nonfatal strokes .,这种差异主要是由非致命性中风造成的。,1.0,"['difference', 'by']","['difference', 'by']",1245,['这种差异主要是由非致命的发作引起的。'],1.0,"['difference', 'by']","['difference', 'by']",,
1256,1246,hazard ratios were similar for patients with and without prior CV disease .,有和没有既往心血管疾病的患者的风险比相似。,0.1428571428571428,"['disease', 'hazard', 'prior', 'with', 'and', 'without', 'similar']",['disease'],1246,['风险比例类似于患有和没有先前的CV疾病的患者。'],0.2857142857142857,"['disease', 'hazard', 'prior', 'with', 'and', 'without', 'similar']","['disease', 'prior']",,
1257,1247,a composite microvascular ( retinal and renal ) outcome also occurred significantly less frequently in the dulaglutide group .,dulaglutide 组复合微血管（视网膜和肾脏）结果的发生频率也显着降低。,0.2222222222222222,"['group', 'composite', 'a', 'retinal', 'outcome', 'frequently', 'renal', 'dulaglutide', 'and']","['group', 'outcome']",1247,['合成微血管(网膜和肾脏)的结果也发生在杜拉格卢蒂德群体中显著较少。'],0.2222222222222222,"['group', 'composite', 'a', 'retinal', 'outcome', 'frequently', 'renal', 'dulaglutide', 'and']","['group', 'outcome']",,
1258,1248,"recent advances in molecular technology have made whole genome sequencing ( WGS ) widely available to microbiology laboratories , enabling resistance testing at the molecular level .",分子技术的最新进展已使全基因组测序 (WGS) 广泛应用于微生物实验室，从而能够在分子水平上进行耐药性测试。,0.5714285714285714,"['genome', 'microbiology', 'resistance', 'sequencing', 'recent', 'molecular', 'available', 'technology', 'level', 'testing', 'at', 'have', 'whole', 'to']","['genome', 'resistance', 'sequencing', 'molecular', 'technology', 'level', 'at', 'to']",1248,"['最近在分子技术的进步使整体基因组序列(WGS)广泛可用于微生物学实验室,允许在分子层面进行抵抗测试。']",0.5714285714285714,"['genome', 'microbiology', 'resistance', 'sequencing', 'recent', 'molecular', 'available', 'technology', 'level', 'testing', 'at', 'have', 'whole', 'to']","['genome', 'microbiology', 'resistance', 'molecular', 'technology', 'at', 'whole', 'to']",,
1259,1249,"resistance testing by WGS is particularly attractive for mycobacteria , as all resistance is coded in the mycobacterial genome and not in plasmids .",WGS 的耐药性测试对分枝杆菌特别有吸引力，因为所有耐药性都编码在分枝杆菌基因组中，而不是在质粒中。,0.5,"['genome', 'mycobacteria', 'resistance', 'testing', 'as', 'all', 'by', 'and']","['genome', 'mycobacteria', 'resistance', 'and']",1249,"['WGS的抵抗测试对微细菌特别有吸引力,因为所有的抵抗都在微细菌基因组中编码,而不是在血浆中。']",0.375,"['genome', 'mycobacteria', 'resistance', 'testing', 'as', 'all', 'by', 'and']","['genome', 'resistance', 'and']",,
1260,1250,MGIT retesting at additional antimycobacterial drug concentrations could be performed on 48 isolates .,可以对 48 个分离株进行额外抗分枝杆菌药物浓度的 MGIT 重新测试。,0.1666666666666666,"['be', 'additional', 'drug', 'at', 'concentrations', 'isolates']",['drug'],1250,['MGIT在额外的抗微细菌药物浓度的重新测试可以在48个隔离器上进行。'],0.5,"['be', 'additional', 'drug', 'at', 'concentrations', 'isolates']","['be', 'additional', 'drug']",,
1261,1251,"of 80 patients enrolled , 88 % achieved complete remission after 12 cycles ; 61 % were minimal residual disease ( MRD ) -negative by multicolor flow cytometry , increasing to 89 % after 18 cycles .",在入组的 80 名患者中，88% 在 12 个周期后达到完全缓解；多色流式细胞术显示 61% 为微小残留病 (MRD) 阴性，18 个周期后增加到 89%。,0.4,"['disease', 'flow cytometry', 'multicolor', 'complete', 'after', 'minimal', 'remission', 'residual', 'achieved', 'by']","['disease', 'flow cytometry', 'after', 'remission']",1251,"['在80名病人中,88%在12个周期后获得了完整的康复;61%是由多色流量细胞测量负的最低残留性疾病(MRD),增加到18个周期后89%。']",0.4,"['disease', 'flow cytometry', 'multicolor', 'complete', 'after', 'minimal', 'remission', 'residual', 'achieved', 'by']","['disease', 'complete', 'after', 'by']",,
1262,1252,there were no unexpected toxicities ; three patients had laboratory but not clinical evidence of tumor lysis syndrome .,没有意外的毒性；三名患者有肿瘤溶解综合征的实验室证据，但没有临床证据。,0.7777777777777778,"['lysis', 'syndrome', 'tumor', 'no', 'clinical', 'laboratory', 'evidence', 'three', 'but']","['lysis', 'syndrome', 'tumor', 'clinical', 'laboratory', 'evidence', 'but']",1252,['没有意想不到的毒性;三名患者有实验室但没有临床证据的肿瘤利西斯综合征。'],0.6666666666666666,"['lysis', 'syndrome', 'tumor', 'no', 'clinical', 'laboratory', 'evidence', 'three', 'but']","['syndrome', 'tumor', 'clinical', 'laboratory', 'evidence', 'but']",,
1263,1253,the immunomodulatory drug lenalidomide ( L ) plus weekly dexamethasone ( d ) is a standard induction regimen ( Ld ) for patients with myeloma who are ineligible for autologous stem cell transplant ( SCT ) consolidation therapy .,免疫调节药物来那度胺 (L) 加每周一次地塞米松 (d) 是标准诱导方案 (Ld)，适用于不适合自体干细胞移植 (SCT) 巩固治疗的骨髓瘤患者。,0.6,"['stem cell', 'induction', 'standard', 'transplant', 'who', 'myeloma', 'consolidation', 'plus', 'therapy', 'autologous', 'with', 'drug', 'dexamethasone', 'SCT', 'ld']","['stem cell', 'induction', 'standard', 'myeloma', 'consolidation', 'plus', 'therapy', 'drug', 'dexamethasone']",1253,"['免疫调节药物Lenalidomide(L)加上每周的dexamethasone(d)是一种标准的引导制度(Ld)对于患有甲状腺炎的患者,他们无法接受自闭性干细胞移植(SCT)的巩固治疗。']",0.4666666666666667,"['stem cell', 'induction', 'standard', 'transplant', 'who', 'myeloma', 'consolidation', 'plus', 'therapy', 'autologous', 'with', 'drug', 'dexamethasone', 'SCT', 'ld']","['stem cell', 'induction', 'standard', 'consolidation', 'plus', 'therapy', 'drug']",,
1264,1254,a total of 737 patients were randomized equally to receive a median of 27 LdD cycles versus 22 Ld cycles .,共有 737 名患者被平均随机分配接受 27 个 LdD 周期和 22 个 Ld 周期的中位数。,0.0,"['median', 'total', 'ld']",[],1254,['总共737名患者被随机分配到27个Ld周期对22个Ld周期的平均水平。'],0.0,"['median', 'total', 'ld']",[],,
1265,1255,"rates of complete response , patient survival at 30 months , and achievement of minimal residual disease negativity were all significantly higher with LdD .",LdD 的完全缓解率、患者 30 个月存活率和微小残留病阴性率均显着提高。,0.2727272727272727,"['disease', 'survival', 'complete', 'response', 'patient', 'minimal', 'achievement', 'residual', 'with', 'all', 'and']","['disease', 'survival', 'patient']",1255,['完全回应率、30个月的患者生存率和最低残留性疾病负度的实现率都显著高于LdD。'],0.2727272727272727,"['disease', 'survival', 'complete', 'response', 'patient', 'minimal', 'achievement', 'residual', 'with', 'all', 'and']","['disease', 'survival', 'patient']",,
1266,1256,the intervention group also had more frequent grade 3 to 4 neutropenia ( 50 % vs. 35.3 % ) and pneumonia ( 13.7 % vs. 7.9 % ),干预组也更频繁地出现 3 至 4 级中性粒细胞减少症（ 50 % 对 35.3 % ）和肺炎（ 13.7 % 对 7.9 % ）,0.3,"['group', 'grade', 'neutropenia', 'intervention', '3', '4', 'pneumonia', 'frequent', 'to', 'and']","['group', 'neutropenia', 'pneumonia']",1256,['干预小组也患有更频繁的3至4级中风(50%与35.3%)和肺炎(13.7%与7.9%)。'],0.2,"['group', 'grade', 'neutropenia', 'intervention', '3', '4', 'pneumonia', 'frequent', 'to', 'and']","['group', 'pneumonia']",,
1267,1257,the FDA recently approved daratumumab in combination with lenalidomide and dexamethasone for treating newly diagnosed multiple myeloma in patients ineligible for SCT .,FDA 最近批准了 daratumumab 联合来那度胺和地塞米松用于治疗不适合 SCT 的新诊断多发性骨髓瘤患者。,0.4444444444444444,"['combination', 'myeloma', 'multiple myeloma', 'FDA', 'with', 'daratumumab', 'dexamethasone', 'SCT', 'and']","['combination', 'myeloma', 'multiple myeloma', 'dexamethasone']",1257,"['FDA最近批准了Daratumumab与Lenalidomide和Dexamethasone相结合,用于治疗新诊断的多发性甲状腺肿瘤在不适用于SCT的患者。']",0.1111111111111111,"['combination', 'myeloma', 'multiple myeloma', 'FDA', 'with', 'daratumumab', 'dexamethasone', 'SCT', 'and']",['combination'],,
1268,1258,demonstration of airway obstruction ( by spirometry ) is required for diagnosing chronic obstructive pulmonary disease ( COPD ) .,诊断慢性阻塞性肺病 (COPD) 需要证明气道阻塞（通过肺量计）。,0.4545454545454545,"['COPD', 'disease', 'obstructive', 'obstruction', 'pulmonary', 'demonstration', 'chronic', 'airway', 'spirometry', 'airway obstruction', 'by']","['COPD', 'disease', 'chronic', 'airway', 'airway obstruction']",1258,['空气阻塞的表现(通过螺旋测量)是必要的诊断慢性阻塞性肺疾病(COPD)。'],0.2727272727272727,"['COPD', 'disease', 'obstructive', 'obstruction', 'pulmonary', 'demonstration', 'chronic', 'airway', 'spirometry', 'airway obstruction', 'by']","['COPD', 'disease', 'chronic']",,
1269,1259,current Global Initiative for Chronic Obstructive Lung Disease ( GOLD ) guidelines recommend use of a fixed threshold of forced expiratory volume in 1 second to forced vital capacity ( FEV1 : FVC ) of 0.70 .,目前全球慢性阻塞性肺疾病倡议 (GOLD) 指南建议使用 0.70 的固定阈值，即 1 秒内用力呼气容积至用力肺活量 (FEV1:FVC)。,0.5263157894736842,"['capacity', 'lung', 'threshold', 'volume', 'disease', 'global', '1', 'obstructive', 'expiratory', 'vital', 'recommend', 'vital capacity', 'chronic', 'fixed', 'forced', 'current', 'initiative', 'FEV1', 'second']","['lung', 'threshold', 'volume', 'disease', 'global', '1', 'recommend', 'vital capacity', 'chronic', 'second']",1259,['现行《慢性阻塞性肺病全球倡议(GOLD)指南》建议在1秒内使用强制性生命容量(FEV1:FVC)的固定限度为0.70。'],0.4210526315789473,"['capacity', 'lung', 'threshold', 'volume', 'disease', 'global', '1', 'obstructive', 'expiratory', 'vital', 'recommend', 'vital capacity', 'chronic', 'fixed', 'forced', 'current', 'initiative', 'FEV1', 'second']","['capacity', 'lung', 'disease', 'global', '1', 'recommend', 'chronic', 'second']",,
1270,1260,"researchers studied more than 24,000 patients ( mean age , 63 ) from four large U.S. cohorts to identify the appropriate FEV1 : FVC threshold for COPD diagnosis .","研究人员对来自美国四大队列的 24,000 多名患者（平均年龄 63 岁）进行了研究，以确定适合 COPD 诊断的 FEV1:FVC 阈值。",0.4545454545454545,"['threshold', 'COPD', 'mean', 'large', 'diagnosis', 'age', 'identify', 'cohorts', 'FEV1', 'to', 'appropriate']","['threshold', 'COPD', 'mean', 'diagnosis', 'age']",1260,"['研究人员研究了来自美国四大联盟的24000多名患者(平均年龄,63岁),以确定适当的FEV1:FVC对COPD诊断的边界。']",0.3636363636363636,"['threshold', 'COPD', 'mean', 'large', 'diagnosis', 'age', 'identify', 'cohorts', 'FEV1', 'to', 'appropriate']","['COPD', 'mean', 'diagnosis', 'age']",,
1271,1261,"when the LLN was used , COPD was diagnosed in 15 % of patients .",使用 LLN 时，15% 的患者被诊断为 COPD。,0.5,"['COPD', 'in']",['COPD'],1261,"['当使用LLN时,COPD被诊断为15%的患者。']",1.0,"['COPD', 'in']","['COPD', 'in']",,
1272,1262,more than a quarter of the population showed obstruction with a threshold ratio of 0.70 .,超过四分之一的人口表现出障碍，阈值比为 0.70。,0.6666666666666666,"['population', 'threshold', 'ratio', 'quarter', 'obstruction', 'with']","['population', 'threshold', 'ratio', 'obstruction']",1262,"['超过四分之一的人口表现出障碍,边界比率为0.70。']",0.6666666666666666,"['population', 'threshold', 'ratio', 'quarter', 'obstruction', 'with']","['population', 'ratio', 'quarter', 'obstruction']",,
1273,1263,"in subgroup analyses based on height and sociodemographic criteria , the threshold of 0.70 was consistently accurate .",在基于身高和社会人口学标准的亚组分析中，0.70 的阈值始终是准确的。,0.2857142857142857,"['threshold', 'height', 'accurate', 'subgroup', 'on', 'in', 'and']","['threshold', 'accurate']",1263,"['在基于高度和社会人口学标准的子组分析中,0.70的边界是一致准确的。']",0.2857142857142857,"['threshold', 'height', 'accurate', 'subgroup', 'on', 'in', 'and']","['height', 'accurate']",,
1274,1264,it should encourage clinicians to stop using LLN for this purpose .,它应该鼓励临床医生停止为此目的使用 LLN。,0.5,"['encourage', 'purpose', 'this', 'stop']","['encourage', 'purpose']",1264,['应该鼓励诊所医生停止使用LLN为此目的。'],0.5,"['encourage', 'purpose', 'this', 'stop']","['encourage', 'purpose']",,
1275,1265,"using height and sex , along with race , which is problematic for a variety of reasons , does not help and probably results in missing patients who would benefit from COPD care .",使用身高、性别以及种族（出于各种原因而存在问题）无济于事，而且可能会导致错过可从 COPD 护理中受益的患者。,0.2857142857142857,"['height', 'COPD', 'a', 'who', 'sex', 'variety', 'along', 'race', 'care', 'benefit', 'with', 'in', 'and', 'missing']","['COPD', 'sex', 'race', 'and']",1265,"['使用高度和性别,以及种族,这是有问题的各种原因,没有帮助,并可能导致缺席的患者谁将受益于COPD护理。']",0.3571428571428571,"['height', 'COPD', 'a', 'who', 'sex', 'variety', 'along', 'race', 'care', 'benefit', 'with', 'in', 'and', 'missing']","['height', 'COPD', 'sex', 'race', 'missing']",,
1276,1266,approximately 10 % to 15 % of strokes occur in adults younger than 50 years .,大约 10% 到 15% 的中风发生在 50 岁以下的成年人身上。,0.25,"['occur', 'approximately', 'in', 'to']",['occur'],1266,['大约10%至15%的发作发生在50岁以下的成年人。'],0.25,"['occur', 'approximately', 'in', 'to']",['occur'],,
1277,1267,"to provide such information , investigators examined outcomes among 15,257 survivors of stroke at age 18 through 49 ( median age , 44 ; 53 % women ) , identified from nationwide hospital and population registries in the Netherlands .","为提供此类信息，研究人员检查了 15,257 名年龄在 18 岁至 49 岁之间的中风幸存者（中位年龄为 44 岁；53% 为女性）的结果，这些幸存者来自荷兰的全国性医院和人口登记处。",0.5555555555555556,"['population', 'median', 'stroke', 'information', 'age', 'hospital', 'median age', 'to', 'and']","['population', 'stroke', 'information', 'age', 'hospital']",1267,"['为了提供此类信息,调查人员对18至49岁的15257名中风幸存者(平均年龄44%;女性53%)的结果进行了调查,这些结果来自荷兰全国医院和人口记录。']",0.5555555555555556,"['population', 'median', 'stroke', 'information', 'age', 'hospital', 'median age', 'to', 'and']","['population', 'stroke', 'information', 'age', 'hospital']",,
1278,1268,stroke patients who had their first stroke in the years 1998 through 2010 were followed until 2017 .,对 1998 年至 2010 年间首次中风的中风患者进行了随访，直至 2017 年。,0.25,"['stroke', 'who', 'in', 'first']",['stroke'],1268,['在1998年至2010年间首次发病的中风患者一直在追踪到2017年。'],0.25,"['stroke', 'who', 'in', 'first']",['stroke'],,
1279,1269,"secondary endpoints were mortality according to stroke subtype ( ischemic , hemorrhagic ) and observed mortality compared with expected mortality in a population of comparable age .",次要终点是根据中风亚型（缺血性、出血性）分类的死亡率，以及在可比年龄人群中观察到的死亡率与预期死亡率的比较。,0.3636363636363636,"['population', 'stroke', 'mortality', 'age', 'hemorrhagic', 'secondary', 'with', 'in', 'to', 'and', 'ischemic']","['population', 'stroke', 'mortality', 'age']",1269,['其次的终点是根据中风子型死亡率(以化学、血管)和观察到死亡率与相似年龄的人口的预期死亡率相比。'],0.3636363636363636,"['population', 'stroke', 'mortality', 'age', 'hemorrhagic', 'secondary', 'with', 'in', 'to', 'and', 'ischemic']","['population', 'stroke', 'mortality', 'age']",,
1280,1270,"in the first 30 days after stroke , 1776 of the patients died .",在中风后的头30天内，有1776名患者死亡。,0.5,"['stroke', 'after', 'in', 'first']","['stroke', 'after']",1270,"['在发作后的前30天,1776名病人死亡。']",0.5,"['stroke', 'after', 'in', 'first']","['stroke', 'after']",,
1281,1271,SMR was similar for men and women .,男性和女性的 SMR 相似。,0.0,"['and', 'similar']",[],1271,['SMR对男性和女性来说是相似的。'],0.5,"['and', 'similar']",['similar'],,
1282,1272,the decrease in mortality over the study period could be due to more widespread use of antihypertensive medications and statins .,研究期间死亡率的下降可能是由于更广泛地使用抗高血压药物和他汀类药物。,0.4545454545454545,"['antihypertensive', 'period', 'decrease', 'statins', 'study', 'be', 'mortality', 'due', 'over', 'to', 'and']","['antihypertensive', 'period', 'statins', 'mortality', 'to']",1272,['研究期间死亡率的下降可能是由于抗高血压药物和静素的广泛使用。'],0.3636363636363636,"['antihypertensive', 'period', 'decrease', 'statins', 'study', 'be', 'mortality', 'due', 'over', 'to', 'and']","['antihypertensive', 'period', 'mortality', 'to']",,
1283,1273,deoxygenated sickle hemoglobin ( HbS ) polymerization drives the pathophysiology of sickle cell disease .,脱氧镰状血红蛋白 (HbS) 聚合驱动镰状细胞病的病理生理学。,0.75,"['cell', 'disease', 'pathophysiology', 'hemoglobin', 'sickle', 'sickle cell', 'polymerization', 'hbs']","['cell', 'disease', 'pathophysiology', 'hemoglobin', 'sickle cell', 'polymerization']",1273,['脱氧化<unk>血球(HbS)聚合物化推动<unk>细胞疾病的病理学。'],0.375,"['cell', 'disease', 'pathophysiology', 'hemoglobin', 'sickle', 'sickle cell', 'polymerization', 'hbs']","['cell', 'disease', 'polymerization']",,
1284,1274,"therefore , direct inhibition of HbS polymerization has potential to favorably modify disease outcomes .",因此，直接抑制 HbS 聚合有可能改善疾病结果。,0.4444444444444444,"['inhibition', 'disease', 'potential', 'polymerization', 'direct', 'modify', 'therefore', 'to', 'hbs']","['inhibition', 'disease', 'polymerization', 'direct']",1274,"['因此,HbS聚合物的直接抑制有可能有利于改变疾病的结果。']",0.5555555555555556,"['inhibition', 'disease', 'potential', 'polymerization', 'direct', 'modify', 'therefore', 'to', 'hbs']","['inhibition', 'disease', 'polymerization', 'direct', 'to']",,
1285,1275,voxelotor is an HbS polymerization inhibitor .,voxelotor 是一种 HbS 聚合抑制剂。,0.6666666666666666,"['inhibitor', 'polymerization', 'hbs']","['inhibitor', 'polymerization']",1275,['voxelotor 是一种 HbS 聚合物抑制剂。'],0.6666666666666666,"['inhibitor', 'polymerization', 'hbs']","['inhibitor', 'polymerization']",,
1286,1276,anemia worsened between baseline and week 24 in fewer participants in each voxelotor dose group than in those receiving placebo .,在基线和第 24 周之间，每个 voxelotor 剂量组的参与者比接受安慰剂的参与者更少贫血恶化。,0.75,"['anemia', 'group', 'placebo', 'baseline', 'week', 'dose', 'each', 'and']","['anemia', 'group', 'placebo', 'baseline', 'week', 'dose']",1276,"['贫血在基因和24周之间恶化,在每个Voxelotor剂量组的参与者较少,而不是接受 placebo的人。']",0.625,"['anemia', 'group', 'placebo', 'baseline', 'week', 'dose', 'each', 'and']","['anemia', 'group', 'week', 'dose', 'and']",,
1287,1277,the percentage of participants with an adverse event that occurred or worsened during the treatment period was similar across the trial groups .,在治疗期间发生或恶化不良事件的参与者百分比在各试验组中相似。,0.3,"['percentage', 'period', 'adverse', 'treatment', 'across', 'adverse event', 'trial', 'with', 'that', 'similar']","['period', 'treatment', 'adverse event']",1277,['治疗期间发生或恶化不良事件的参与者比例在试验组中相似。'],0.3,"['percentage', 'period', 'adverse', 'treatment', 'across', 'adverse event', 'trial', 'with', 'that', 'similar']","['period', 'treatment', 'adverse event']",,
1288,1278,"most adverse events were not related to the trial drug or placebo , as determined by the investigators .",经研究人员确定，大多数不良事件与试验药物或安慰剂无关。,0.2857142857142857,"['placebo', 'adverse', 'trial', 'as', 'drug', 'by', 'to']","['placebo', 'drug']",1278,"['大多数不良事件与试验药物或 placebo 无关,根据调查人员的确定。']",0.1428571428571428,"['placebo', 'adverse', 'trial', 'as', 'drug', 'by', 'to']",['drug'],,
1289,1279,"sickle cell disease affects approximately 100,000 persons in the United States and reduces life expectancy by approximately 30 years.1","在美国，镰状细胞病影响了大约 100,000 人，预期寿命减少了大约 30 年。 1",0.4,"['cell', 'life', 'disease', 'life expectancy', 'sickle', 'sickle cell', 'approximately', 'in', 'by', 'and']","['cell', 'disease', 'life expectancy', 'sickle cell']",1279,"['甲状腺细胞疾病影响美国约10万人,寿命减少约30年。']",0.2,"['cell', 'life', 'disease', 'life expectancy', 'sickle', 'sickle cell', 'approximately', 'in', 'by', 'and']","['cell', 'disease']",,
1290,1280,the disease is caused by a single amino acid substitution resulting in the production of sickle hemoglobin ( HbS ) .2,该疾病是由导致镰状血红蛋白 (HbS) 产生的单一氨基酸替代引起的 .2,0.7,"['production', 'substitution', 'amino', 'disease', 'amino acid', 'hemoglobin', 'sickle', 'single', 'by', 'hbs']","['substitution', 'amino', 'disease', 'amino acid', 'hemoglobin', 'single', 'by']",1280,"['这种疾病是由单一的氨基酸替代引起的,导致细胞血球(HbS)的产生。']",0.6,"['production', 'substitution', 'amino', 'disease', 'amino acid', 'hemoglobin', 'sickle', 'single', 'by', 'hbs']","['substitution', 'amino', 'disease', 'amino acid', 'single', 'by']",,
1291,1281,"in particular , chronic organ dysfunction has become a leading cause of death in adults with sickle cell disease in the United States.10,11","特别是，慢性器官功能障碍已成为美国镰状细胞病成人的主要死因。 10,11",0.5714285714285714,"['organ', 'cell', 'dysfunction', 'disease', 'death', 'sickle', 'particular', 'sickle cell', 'chronic', 'cause', 'cause of death', 'leading', 'with', 'become']","['organ', 'cell', 'disease', 'death', 'sickle cell', 'chronic', 'cause of death', 'become']",1281,"['特别是,慢性器官功能障碍已成为美国患有<unk>细胞疾病的成年人死亡的主要原因。']",0.5,"['organ', 'cell', 'dysfunction', 'disease', 'death', 'sickle', 'particular', 'sickle cell', 'chronic', 'cause', 'cause of death', 'leading', 'with', 'become']","['organ', 'cell', 'disease', 'death', 'chronic', 'cause', 'become']",,
1292,1282,"because the rate of HbS polymerization is extremely sensitive to deoxygenated HbS concentration , small changes in concentration can have substantial effects on polymerization.12,13","由于 HbS 聚合速率对脱氧 HbS 浓度极其敏感，因此浓度的微小变化会对聚合产生重大影响。 12,13",0.4444444444444444,"['concentration', 'rate', 'polymerization', 'sensitive', 'have', 'in', 'to', 'substantial', 'hbs']","['concentration', 'rate', 'polymerization', 'to']",1282,"['由于HbS聚合物的速度对氧化HbS浓度非常敏感,所以浓度的小变化可能会对聚合物产生重大影响。']",0.3333333333333333,"['concentration', 'rate', 'polymerization', 'sensitive', 'have', 'in', 'to', 'substantial', 'hbs']","['concentration', 'polymerization', 'to']",,
1293,1283,"this hypothesis is supported by the absence of symptoms of sickle cell disease in persons who are compound heterozygotes for HbS and deletional hereditary persistence of fetal hemoglobin , who have antisickling fetal hemoglobin levels of approximately 30 % .13",这一假说得到以下证据的支持：在 HbS 复合杂合子和胎儿血红蛋白缺失遗传性持续存在的人群中没有镰状细胞病的症状，这些人的抗镰状细胞胎儿血红蛋白水平约为 30 % .13,0.55,"['cell', 'persistence', 'disease', 'who', 'hereditary', 'hypothesis', 'compound', 'hemoglobin', 'fetal', 'fetal hemoglobin', 'sickle', 'symptoms', 'sickle cell', 'absence', 'have', 'approximately', 'this', 'by', 'and', 'hbs']","['cell', 'persistence', 'disease', 'hereditary', 'hypothesis', 'compound', 'hemoglobin', 'fetal hemoglobin', 'sickle cell', 'have', 'by']",1283,"['这种假设是由缺乏细胞细胞疾病的症状支持,在HbS和胎儿血球的遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗传性遗']",0.35,"['cell', 'persistence', 'disease', 'who', 'hereditary', 'hypothesis', 'compound', 'hemoglobin', 'fetal', 'fetal hemoglobin', 'sickle', 'symptoms', 'sickle cell', 'absence', 'have', 'approximately', 'this', 'by', 'and', 'hbs']","['cell', 'disease', 'hereditary', 'hypothesis', 'absence', 'this', 'by']",,
1294,1284,"voxelotor is an HbS polymerization inhibitor that reversibly binds to hemoglobin to stabilize the oxygenated hemoglobin state.14,15","voxelotor 是一种 HbS 聚合抑制剂，可逆地结合血红蛋白以稳定氧合血红蛋白状态。 14,15",0.7142857142857143,"['inhibitor', 'hemoglobin', 'polymerization', 'stabilize', 'oxygenated', 'that', 'hbs']","['inhibitor', 'hemoglobin', 'polymerization', 'stabilize', 'oxygenated']",1284,"['voxelotor 是一种 HbS 聚合物抑制剂,可逆转连接到血球,以稳定氧化血球状态。']",0.4285714285714285,"['inhibitor', 'hemoglobin', 'polymerization', 'stabilize', 'oxygenated', 'that', 'hbs']","['inhibitor', 'polymerization', 'stabilize']",,
1295,1285,"the phase 3 HOPE ( Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization ) trial was designed to evaluate the efficacy and safety of voxelotor , as compared with placebo , in adolescents and adults with sickle cell disease .",3 期 HOPE（血红蛋白氧亲和力调节抑制 HbS 聚合）试验旨在评估与安慰剂相比，voxelotor 在患有镰状细胞病的青少年和成人中的疗效和安全性。,0.5789473684210527,"['modulation', 'safety', 'cell', 'affinity', 'placebo', 'disease', 'phase', 'hemoglobin', 'sickle', 'sickle cell', 'trial', 'efficacy', 'polymerization', '3', 'oxygen', 'with', 'to', 'and', 'hbs']","['modulation', 'safety', 'cell', 'affinity', 'placebo', 'disease', 'phase', 'hemoglobin', 'sickle cell', 'polymerization', 'oxygen']",1285,"['第三阶段的HOPE(Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization)试验旨在评估与 placebo 相比,在青少年和成年人患有<unk>细胞疾病的Voxelotor的有效性和安全性。']",0.2631578947368421,"['modulation', 'safety', 'cell', 'affinity', 'placebo', 'disease', 'phase', 'hemoglobin', 'sickle', 'sickle cell', 'trial', 'efficacy', 'polymerization', '3', 'oxygen', 'with', 'to', 'and', 'hbs']","['safety', 'cell', 'disease', 'phase', 'efficacy']",,
1296,1286,"global Blood Therapeutics , the trial sponsor , provided the investigational agent and collaborated with academic investigators on the design of the trial and the analysis and interpretation of the data .",试验赞助商 global Blood Therapeutics 提供了研究药物，并与学术研究人员合作设计试验以及分析和解释数据。,0.3333333333333333,"['data', 'global', 'analysis', 'sponsor', 'blood', 'interpretation', 'therapeutics', 'trial', 'design', 'with', 'agent', 'and']","['data', 'analysis', 'interpretation', 'design']",1286,"['全球血液疗法(Global Blood Therapeutics),审判赞助商,提供调查代理,并与学术调查人员合作,设计审判,分析和数据的解释。']",0.6666666666666666,"['data', 'global', 'analysis', 'sponsor', 'blood', 'interpretation', 'therapeutics', 'trial', 'design', 'with', 'agent', 'and']","['data', 'global', 'analysis', 'blood', 'interpretation', 'therapeutics', 'trial', 'design']",,
1297,1287,"all the authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol , available with the full text of this article at NEJM.org .",所有作者保证数据的准确性和完整性以及试验对方案的忠实度，方案与本文全文可在 NEJM.org 获取。,0.2857142857142857,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",1287,"['所有作者对数据的准确性和完整性以及对议定书的审判的忠诚性,可在NEJM.org上提供本文的完整文本。']",0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'full']",,
1298,1288,"the conduct of the trial was overseen by IQVIA , a contract research organization , and an independent data and safety monitoring board performed periodic assessments .",试验的进行由合同研究机构 IQVIA 监督，独立的数据和安全监督委员会进行定期评估。,0.4166666666666667,"['safety', 'monitoring', 'organization', 'research', 'data', 'contract', 'board', 'trial', 'independent', 'conduct', 'by', 'and']","['safety', 'research', 'data', 'independent', 'by']",1288,"['调查的进展由合同研究组织IQVIA监督,独立的数据和安全监测委员会进行定期评估。']",0.5833333333333334,"['safety', 'monitoring', 'organization', 'research', 'data', 'contract', 'board', 'trial', 'independent', 'conduct', 'by', 'and']","['safety', 'monitoring', 'organization', 'research', 'data', 'independent', 'by']",,
1299,1289,written informed consent was obtained from the adult participants ( 18 to 65 years of age ) and from the parents or guardians of the adolescent participants ( 12 to 17 years of age ) .,已从成年参与者（18 至 65 岁）和青少年参与者（12 至 17 岁）的父母或监护人处获得书面知情同意书。,0.375,"['parents', 'adolescent', 'adult', 'age', 'consent', 'informed consent', 'to', 'and']","['adolescent', 'adult', 'consent']",1289,['由成年参与者(年龄为18至65岁)以及青少年参与者的父母或监护人(年龄为12至17岁)获得书面信息同意。'],0.5,"['parents', 'adolescent', 'adult', 'age', 'consent', 'informed consent', 'to', 'and']","['adolescent', 'adult', 'age', 'consent']",,
1300,1290,the protocol and consent form were approved by an independent ethics committee at each participating trial site .,方案和知情同意书由每个参与试验地点的独立伦理委员会批准。,0.3333333333333333,"['form', 'site', 'protocol', 'ethics', 'committee', 'trial', 'independent', 'consent', 'at', 'each', 'by', 'and']","['site', 'committee', 'consent', 'by']",1290,['议定书和同意表格由一个独立的伦理委员会在每个参与审判场所批准。'],0.5833333333333334,"['form', 'site', 'protocol', 'ethics', 'committee', 'trial', 'independent', 'consent', 'at', 'each', 'by', 'and']","['site', 'protocol', 'committee', 'trial', 'independent', 'consent', 'by']",,
1301,1291,"all drafts of the manuscript were prepared by the authors , with writing assistance from a medical writer funded by the sponsor .",手稿的所有草稿均由作者编写，并得到申办方资助的医学作家的写作协助。,0.4,"['a', 'sponsor', 'medical', 'manuscript', 'writer', 'writing', 'assistance', 'with', 'all', 'by']","['manuscript', 'writer', 'writing', 'by']",1291,"['手稿的所有草案都是由作者编写的,由赞助商资助的医学作家的书面协助。']",0.3,"['a', 'sponsor', 'medical', 'manuscript', 'writer', 'writing', 'assistance', 'with', 'all', 'by']","['manuscript', 'writer', 'by']",,
1302,1292,the sponsor and all authors and institutions agreed to data confidentiality during manuscript development .,赞助商和所有作者和机构同意在手稿开发过程中对数据保密。,0.375,"['confidentiality', 'data', 'sponsor', 'manuscript', 'development', 'all', 'to', 'and']","['confidentiality', 'data', 'manuscript']",1292,['赞助商和所有作者和机构在手稿开发期间同意数据的保密性。'],0.375,"['confidentiality', 'data', 'sponsor', 'manuscript', 'development', 'all', 'to', 'and']","['confidentiality', 'data', 'manuscript']",,
1303,1293,participants who were receiving hydroxyurea at a dose that had been stable for at least 3 months before they provided informed consent were eligible .,在提供知情同意书之前以稳定至少 3 个月的剂量接受羟基脲的参与者符合条件。,0.3636363636363636,"['a', 'who', 'hydroxyurea', '3', 'consent', 'informed consent', 'at', 'dose', 'that', 'before', 'eligible']","['hydroxyurea', 'consent', 'dose', 'before']",1293,['在提交已知同意之前至少3个月保持稳定的剂量服用水氧化剂的参与者有资格。'],0.2727272727272727,"['a', 'who', 'hydroxyurea', '3', 'consent', 'informed consent', 'at', 'dose', 'that', 'before', 'eligible']","['consent', 'dose', 'before']",,
1304,1294,participants could be rescreened at the discretion of an investigator .,参与者可以根据研究者的判断重新筛选。,0.5,"['investigator', 'be']",['investigator'],1294,['参与者可以在调查员的判断下重新审查。'],0.5,"['investigator', 'be']",['be'],,
1305,1295,"the primary end point was the percentage of participants who had a hemoglobin response , which was defined as an increase from baseline of more than 1.0 g per deciliter at week 24 .",主要终点是有血红蛋白反应的参与者百分比，血红蛋白反应定义为在第 24 周时从基线增加超过 1.0 g/dL。,0.3846153846153846,"['percentage', 'defined', 'who', 'baseline', 'hemoglobin', 'deciliter', 'primary', 'response', 'week', 'end', 'point', 'increase', 'at']","['baseline', 'hemoglobin', 'response', 'week', 'point']",1295,"['主要的终点是对血球反应的参与者的百分比,这被定义为从基线上增加超过10g每分钟24周。']",0.3846153846153846,"['percentage', 'defined', 'who', 'baseline', 'hemoglobin', 'deciliter', 'primary', 'response', 'week', 'end', 'point', 'increase', 'at']","['baseline', 'primary', 'response', 'week', 'point']",,
1306,1296,"clinical assessments were performed at screening , at baseline , every 2 weeks for the first 8 weeks of the treatment period , every 4 weeks up to week 24 , and every 3 months until the end of the treatment period .",临床评估在筛选时、基线时、治疗期前 8 周每 2 周一次、直至第 24 周每 4 周一次、以及每 3 个月一次直至治疗期结束时进行。,0.5,"['period', 'baseline', '2', 'screening', 'treatment', 'clinical', 'week', '3', '4', 'end', 'up', 'to', 'and', 'first']","['period', 'baseline', '2', 'screening', 'treatment', 'clinical', 'week']",1296,"['临床评估是在检查时进行的,在基线上,每2周,在治疗期间的第一个8周,每4周到24周,每3个月,直到治疗期间结束。']",0.5,"['period', 'baseline', '2', 'screening', 'treatment', 'clinical', 'week', '3', '4', 'end', 'up', 'to', 'and', 'first']","['period', 'baseline', '2', 'treatment', 'clinical', 'week', 'first']",,
1307,1297,serum erythropoietin levels were assessed at baseline and every 3 months until the end of the treatment period .,在基线和每 3 个月评估一次血清促红细胞生成素水平，直至治疗期结束。,0.5555555555555556,"['period', 'erythropoietin', 'baseline', 'serum', 'treatment', '3', 'end', 'and', 'assessed']","['period', 'erythropoietin', 'baseline', 'serum', 'treatment']",1297,"['血清甲状腺素水平在基线上进行评估,每3个月,直到治疗期结束。']",0.4444444444444444,"['period', 'erythropoietin', 'baseline', 'serum', 'treatment', '3', 'end', 'and', 'assessed']","['period', 'baseline', 'serum', 'treatment']",,
1308,1298,all laboratory studies were performed at a central laboratory .,所有实验室研究均在中央实验室进行。,0.25,"['a', 'central', 'laboratory', 'all']",['laboratory'],1298,['所有的实验室研究都在一个中央实验室进行。'],0.25,"['a', 'central', 'laboratory', 'all']",['laboratory'],,
1309,1299,"pharmacokinetic and pharmacodynamic modeling was used to correlate voxelotor exposure and response ( e.g. , changes in the levels of hemoglobin and markers of hemolysis ) .",药代动力学和药效学模型被用来关联 voxelotor 暴露和反应（例如，血红蛋白水平和溶血标志物的变化）。,0.6666666666666666,"['hemolysis', 'exposure', 'hemoglobin', 'pharmacodynamic', 'response', 'modeling', 'pharmacokinetic', 'to', 'and']","['hemolysis', 'exposure', 'hemoglobin', 'pharmacodynamic', 'response', 'pharmacokinetic']",1299,"['药物学和药物动态模型用于与伏克索托尔的曝光和反应(例如,血球水平和血球标志的变化)相连。']",0.3333333333333333,"['hemolysis', 'exposure', 'hemoglobin', 'pharmacodynamic', 'response', 'modeling', 'pharmacokinetic', 'to', 'and']","['exposure', 'response', 'to']",,
1310,1300,"hemoglobin occupancy was defined as the percentage of hemoglobin bound by voxelotor , calculated as the concentration of voxelotor in red cells divided by the concentration of hemoglobin in red cells , as previously described.17,18","血红蛋白占有率被定义为与 voxelotor 结合的血红蛋白百分比，计算方法为红细胞中 voxelotor 浓度除以红细胞中血红蛋白浓度，如前所述。 17, 18",0.625,"['percentage', 'concentration', 'defined', 'hemoglobin', 'red', 'bound', 'as', 'by']","['concentration', 'hemoglobin', 'bound', 'as', 'by']",1300,"['血球占据被定义为由 voxelotor 连接的血球的百分比,计算为红细胞中的 voxelotor 的浓度,分为红细胞中的血球浓度,如上所述。']",0.375,"['percentage', 'concentration', 'defined', 'hemoglobin', 'red', 'bound', 'as', 'by']","['concentration', 'as', 'by']",,
1311,1301,participants who received at least one dose of the trial drug or placebo were assessed for safety .,对接受至少一剂试验药物或安慰剂的参与者进行安全性评估。,0.375,"['safety', 'placebo', 'who', 'trial', 'drug', 'at', 'dose', 'assessed']","['safety', 'placebo', 'drug']",1301,['接受至少一剂试用药物或 placebo 的参与者被评估为安全。'],0.25,"['safety', 'placebo', 'who', 'trial', 'drug', 'at', 'dose', 'assessed']","['safety', 'drug']",,
1312,1302,"adverse events that occurred on or after initiation of the trial drug or placebo or preexisting adverse events that worsened during the treatment period for up to 28 days after the last dose were assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events , version 4.03 .",在试验药物或安慰剂开始时或之后发生的不良事件或在最后一次给药后长达 28 天的治疗期间恶化的既往不良事件根据美国国家癌症研究所不良事件通用术语标准进行评估和分级，版本 4.03 。,0.5263157894736842,"['period', 'placebo', 'cancer', 'initiation', 'version', 'common', 'adverse', 'treatment', 'terminology', 'institute', 'after', 'trial', 'up', 'drug', 'dose', 'that', 'to', 'and', 'assessed']","['period', 'placebo', 'cancer', 'initiation', 'version', 'treatment', 'terminology', 'institute', 'after', 'drug']",1302,['试用药物或 placebo 或预先存在的试用药物或 placebo 或试用药物或 placebo 或试用药物或 placebo 或试用药物或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或 placebo 或'],0.0526315789473684,"['period', 'placebo', 'cancer', 'initiation', 'version', 'common', 'adverse', 'treatment', 'terminology', 'institute', 'after', 'trial', 'up', 'drug', 'dose', 'that', 'to', 'and', 'assessed']",['drug'],,
1313,1303,the relationship of an adverse event to the trial drug or placebo was adjudicated by the investigators .,不良事件与试验药物或安慰剂的关系由研究者判定。,0.5,"['relationship', 'placebo', 'adverse', 'adverse event', 'trial', 'drug', 'by', 'to']","['placebo', 'adverse event', 'drug', 'by']",1303,['与试验药物或 placebo 发生不良事件的关系由调查人员提交。'],0.375,"['relationship', 'placebo', 'adverse', 'adverse event', 'trial', 'drug', 'by', 'to']","['adverse event', 'drug', 'by']",,
1314,1304,adverse events not related to sickle cell disease and those related to sickle cell disease were tabulated separately .,与镰状细胞病无关的不良事件和与镰状细胞病相关的不良事件单独列出。,0.375,"['cell', 'disease', 'sickle', 'sickle cell', 'adverse', 'separately', 'to', 'and']","['cell', 'disease', 'sickle cell']",1304,['与<unk>细胞疾病无关的不良事件和与<unk>细胞疾病有关的事件分别表。'],0.25,"['cell', 'disease', 'sickle', 'sickle cell', 'adverse', 'separately', 'to', 'and']","['cell', 'disease']",,
1315,1305,attribution of an adverse event to a cause other than a new therapeutic agent may be inexact .,将不良事件归因于新治疗药物以外的原因可能是不准确的。,0.5,"['a', 'be', 'adverse', 'cause', 'therapeutic', 'adverse event', 'attribution', 'agent', 'to', 'new']","['cause', 'adverse event', 'attribution', 'to', 'new']",1305,"['将不良事件归因于另一种原因,而不是新治疗药物,可能不准确。']",0.5,"['a', 'be', 'adverse', 'cause', 'therapeutic', 'adverse event', 'attribution', 'agent', 'to', 'new']","['cause', 'adverse event', 'attribution', 'to', 'new']",,
1316,1306,"baseline values were calculated as the mean values of the data collected at screening and on the day of randomization , and the values at week 24 were calculated as the mean values of the data collected at weeks 20 and 24 .",基线值计算为筛选时和随机化当天收集的数据的平均值，第 24 周的值计算为第 20 周和第 24 周收集的数据的平均值。,0.8571428571428571,"['mean', 'randomization', 'data', 'baseline', 'screening', 'week', 'values']","['mean', 'randomization', 'data', 'baseline', 'screening', 'week']",1306,"['基线值被计算为扫描和随机化日收集的数据的平均值,24周的值被计算为20周和24周收集的数据的平均值。']",0.7142857142857143,"['mean', 'randomization', 'data', 'baseline', 'screening', 'week', 'values']","['mean', 'randomization', 'data', 'baseline', 'week']",,
1317,1307,"if one time point was missing , data from the other time point were used .",如果一个时间点缺失，则使用另一个时间点的数据。,0.8,"['data', 'time', 'point', 'if', 'missing']","['data', 'time', 'point', 'missing']",1307,"['如果一个时间点失踪,则从另一个时间点的数据被使用。']",0.6,"['data', 'time', 'point', 'if', 'missing']","['data', 'time', 'point']",,
1318,1308,"absolute change in hemoglobin level , relative change in indirect bilirubin level , absolute reticulocyte count and percentage of reticulocytes , and lactate dehydrogenase level from baseline to week 24 were analyzed with the use of a regression model for repeated measures .",血红蛋白水平的绝对变化、间接胆红素水平的相对变化、网织红细胞绝对计数和网织红细胞百分比，以及从基线到第 24 周的乳酸脱氢酶水平使用重复测量回归模型进行分析。,0.6363636363636364,"['count', 'percentage', 'reticulocyte', 'lactate', 'model', 'dehydrogenase', 'bilirubin', 'baseline', 'hemoglobin', 'absolute', 'relative', 'indirect', 'hemoglobin level', 'regression', 'lactate dehydrogenase', 'week', 'relative change', 'with', 'repeated', 'to', 'and', 'regression model']","['count', 'reticulocyte', 'lactate', 'model', 'dehydrogenase', 'bilirubin', 'baseline', 'hemoglobin', 'absolute', 'regression', 'lactate dehydrogenase', 'week', 'relative change', 'regression model']",1308,"['血糖水平的绝对变化、间接 bilirubin 水平的相对变化、绝对 reticulocyte 数量和 reticulocyte 的百分比以及从基线到 24 周的乳糖脱水素水平的分析,使用重复测量的 regression 模型。']",0.2272727272727272,"['count', 'percentage', 'reticulocyte', 'lactate', 'model', 'dehydrogenase', 'bilirubin', 'baseline', 'hemoglobin', 'absolute', 'relative', 'indirect', 'hemoglobin level', 'regression', 'lactate dehydrogenase', 'week', 'relative change', 'with', 'repeated', 'to', 'and', 'regression model']","['model', 'baseline', 'absolute', 'week', 'relative change']",,
1319,1309,intrapatient variability was modeled with the use of an unstructured covariance matrix .,使用非结构化协方差矩阵对患者内部变异性进行建模。,0.75,"['matrix', 'covariance', 'variability', 'with']","['matrix', 'covariance', 'variability']",1309,"['intrapatient variability 被模拟,使用一个未结构化的covariance 矩阵。']",0.25,"['matrix', 'covariance', 'variability', 'with']",['matrix'],,
1320,1310,baseline characteristics of the three trial groups were generally well balanced ( Table 1 ) .,三个试验组的基线特征总体均衡（表 1）。,0.5714285714285714,"['table', 'baseline', '1', 'well', 'characteristics', 'trial', 'three']","['table', 'baseline', '1', 'characteristics']",1310,['三个试验组的基本特征一般均衡良好(图1)。'],0.2857142857142857,"['table', 'baseline', '1', 'well', 'characteristics', 'trial', 'three']","['1', 'characteristics']",,
1321,1311,hemoglobin RESPONSE AND MARKERS OF HEMOLYSIS,血红蛋白反应和溶血标志物,1.0,['hemoglobin'],['hemoglobin'],1311,['血球反应与血球的标志'],0.0,['hemoglobin'],[],,
1322,1312,"the mean increase in hemoglobin level among the participants receiving voxelotor was consistent across patient subgroups , regardless of concurrent hydroxyurea use or baseline anemia severity ( Table S1 in the Supplementary Appendix ) .",无论是否同时使用羟基脲或基线贫血严重程度如何，接受 voxelotor 的参与者血红蛋白水平的平均增加在所有患者亚组中都是一致的（补充附录表 S1）。,0.5,"['anemia', 'appendix', 'mean', 'table', 'baseline', 'hydroxyurea', 'hemoglobin', 'supplementary', 'concurrent', 'hemoglobin level', 'across', 'patient', 'increase', 'S1']","['anemia', 'mean', 'table', 'baseline', 'hydroxyurea', 'hemoglobin', 'patient']",1312,"['接受Voxelotor的参与者中血糖水平的平均增加在患者子群中是一致的,无论是同步使用Hydroxyurea或基因贫血的严重性(附件中的S1表)。']",0.3571428571428571,"['anemia', 'appendix', 'mean', 'table', 'baseline', 'hydroxyurea', 'hemoglobin', 'supplementary', 'concurrent', 'hemoglobin level', 'across', 'patient', 'increase', 'S1']","['anemia', 'appendix', 'mean', 'table', 'patient']",,
1323,1313,"the most common adverse events , with an incidence of at least 20 % , were headache and diarrhea ( Table 3 ) .",最常见的不良事件（发生率至少为 20%）是头痛和腹泻（表 3）。,0.4,"['incidence', 'headache', 'table', 'diarrhea', 'common', 'adverse', '3', 'with', 'at', 'and']","['incidence', 'headache', 'table', 'diarrhea']",1313,"['最常见的副作用,其发病率至少为20%,是头痛和腹泻(图3)。']",0.3,"['incidence', 'headache', 'table', 'diarrhea', 'common', 'adverse', '3', 'with', 'at', 'and']","['incidence', 'headache', 'diarrhea']",,
1324,1314,"the majority of adverse events were grade 1 or 2 ; the percentages of participants who had an adverse event of at least grade 3 , a serious adverse event , and treatment discontinuation because of an adverse event did not differ substantially among the three trial groups .",大多数不良事件为 1 级或 2 级；发生至少 3 级不良事件、严重不良事件和因不良事件而停止治疗的参与者的百分比在三个试验组中没有显着差异。,0.5384615384615384,"['a', 'who', '1', '2', 'serious adverse event', 'grade', 'treatment', 'differ', 'trial', '3', 'majority', 'three', 'and']","['1', '2', 'serious adverse event', 'treatment', 'majority', 'three', 'and']",1314,['大多数不良事件是1级或2级;至少有3级不良事件、严重不良事件和因不良事件而停止治疗的参与者比例在三组中没有显著差异。'],0.5384615384615384,"['a', 'who', '1', '2', 'serious adverse event', 'grade', 'treatment', 'differ', 'trial', '3', 'majority', 'three', 'and']","['1', '2', 'serious adverse event', 'treatment', 'majority', 'three', 'and']",,
1325,1315,most adverse events were judged by the investigators to be unrelated to the trial drug or placebo .,大多数不良事件被研究者判断为与试验药物或安慰剂无关。,0.2857142857142857,"['placebo', 'be', 'adverse', 'trial', 'drug', 'by', 'to']","['placebo', 'drug']",1315,['大多数不良事件被调查人员认为与试验药物或 placebo 无关。'],0.1428571428571428,"['placebo', 'be', 'adverse', 'trial', 'drug', 'by', 'to']",['drug'],,
1326,1316,additional details are provided in Tables S5 and S6 in the Supplementary Appendix .,补充附录表 S5 和表 S6 中提供了更多详细信息。,0.0,"['appendix', 'supplementary', 'additional', 'in', 'and']",[],1316,['更多详细信息在附件中的 S5 和 S6 表中提供。'],0.2,"['appendix', 'supplementary', 'additional', 'in', 'and']",['appendix'],,
1327,1317,"the increase in hemoglobin level and reduction in hemolysis occurred within 2 weeks after initiation of the trial drug , indicating a rapid pharmacodynamic and biologic effect .",血红蛋白水平升高和溶血减少发生在试验药物开始后 2 周内，表明药效学和生物学效应迅速。,0.5625,"['hemolysis', 'a', 'initiation', '2', 'hemoglobin', 'biologic', 'pharmacodynamic', 'reduction', 'hemoglobin level', 'after', 'trial', 'effect', 'increase', 'drug', 'and', 'rapid']","['hemolysis', 'initiation', '2', 'hemoglobin', 'pharmacodynamic', 'reduction', 'after', 'effect', 'drug']",1317,"['血糖水平的增加和血糖下降发生在试用药物开始后2周内,表明快速的药物动态和生物效应。']",0.3125,"['hemolysis', 'a', 'initiation', '2', 'hemoglobin', 'biologic', 'pharmacodynamic', 'reduction', 'hemoglobin level', 'after', 'trial', 'effect', 'increase', 'drug', 'and', 'rapid']","['initiation', '2', 'after', 'effect', 'drug']",,
1328,1318,"subsequently , a steady state was reached that was sustained throughout the treatment period .",随后，达到稳定状态，并在整个治疗期间持续。,0.5,"['period', 'a', 'state', 'steady state', 'treatment', 'that']","['period', 'state', 'treatment']",1318,"['随后,实现了一个稳定的状态,在整个治疗期间保持。']",0.5,"['period', 'a', 'state', 'steady state', 'treatment', 'that']","['period', 'state', 'treatment']",,
1329,1319,"a clear relationship was observed between voxelotor exposure and all hematologic measures of efficacy , including lactate dehydrogenase level and absolute reticulocyte count .",在 voxelotor 暴露与所有血液学疗效指标（包括乳酸脱氢酶水平和绝对网织红细胞计数）之间观察到明确的关系。,0.5714285714285714,"['count', 'reticulocyte', 'relationship', 'lactate', 'clear', 'dehydrogenase', 'exposure', 'absolute', 'lactate dehydrogenase', 'efficacy', 'level', 'all', 'and', 'hematologic']","['count', 'reticulocyte', 'lactate', 'dehydrogenase', 'exposure', 'absolute', 'lactate dehydrogenase', 'level']",1319,"['观察到伏克索托特曝光与所有血液效能测量之间的明显关系,包括乳糖脱水素水平和绝对 reticulocyte 数量。']",0.2857142857142857,"['count', 'reticulocyte', 'relationship', 'lactate', 'clear', 'dehydrogenase', 'exposure', 'absolute', 'lactate dehydrogenase', 'efficacy', 'level', 'all', 'and', 'hematologic']","['exposure', 'absolute', 'efficacy', 'level']",,
1330,1320,the percentage of participants who had adverse events of at least grade 3 and serious adverse events were similar in both voxelotor and placebo groups .,发生至少 3 级不良事件和严重不良事件的参与者百分比在 voxelotor 和安慰剂组中相似。,0.0909090909090909,"['percentage', 'placebo', 'who', 'grade', 'adverse', '3', 'at', 'serious', 'in', 'and', 'similar']",['placebo'],1320,['至少有3级和严重的不良事件的参与者的比例在Voxelotor和Placebo群体中都是相似的。'],0.0909090909090909,"['percentage', 'placebo', 'who', 'grade', 'adverse', '3', 'at', 'serious', 'in', 'and', 'similar']",['similar'],,
1331,1321,"the hemoglobin occupancy target was based on the pancellular fetal hemoglobin level of approximately 30 % observed in persons who are compound heterozygotes for HbS and hereditary persistence of fetal hemoglobin , who generally have no symptoms of sickle cell disease.13",血红蛋白占有率目标是基于在 HbS 复合杂合子和胎儿血红蛋白遗传持续性人群中观察到的全细胞胎儿血红蛋白水平约为 30 %，这些人通常没有镰状细胞病的症状。 13,0.4210526315789473,"['cell', 'persistence', 'who', 'hereditary', 'compound', 'hemoglobin', 'fetal', 'fetal hemoglobin', 'sickle', 'symptoms', 'hemoglobin level', 'sickle cell', 'no', 'target', 'on', 'have', 'approximately', 'and', 'hbs']","['cell', 'persistence', 'compound', 'hemoglobin', 'fetal hemoglobin', 'sickle cell', 'target', 'have']",1321,"['血球占据目标是基于细胞胎儿血球水平约30%,在HbS和胎儿血球的遗传持久性化合物催化物的人中观察到,一般没有<unk>细胞疾病的症状。']",0.2105263157894736,"['cell', 'persistence', 'who', 'hereditary', 'compound', 'hemoglobin', 'fetal', 'fetal hemoglobin', 'sickle', 'symptoms', 'hemoglobin level', 'sickle cell', 'no', 'target', 'on', 'have', 'approximately', 'and', 'hbs']","['cell', 'compound', 'target', 'have']",,
1332,1322,"this finding was supported by the similar erythropoietin levels observed with voxelotor and placebo , a reduction in the percentage of reticulocytes with voxelotor , and no pattern of adverse events suggestive of impaired tissue oxygenation .",这一发现得到了使用 voxelotor 和安慰剂观察到的相似促红细胞生成素水平、使用 voxelotor 的网织红细胞百分比降低以及没有提示组织氧合作用受损的不良事件模式的支持。,0.5333333333333333,"['percentage', 'placebo', 'tissue', 'oxygenation', 'erythropoietin', 'pattern', 'reduction', 'adverse', 'no', 'impaired', 'with', 'this', 'by', 'and', 'similar']","['placebo', 'tissue', 'oxygenation', 'erythropoietin', 'pattern', 'reduction', 'impaired', 'by']",1322,"['这种发现是由类似的Erythropoietin水平观察到Voxelotor和Placebo,减少的百分比的Reticulocytes与Voxelotor,和没有模式的副作用暗示损坏的组织氧化。']",0.4,"['percentage', 'placebo', 'tissue', 'oxygenation', 'erythropoietin', 'pattern', 'reduction', 'adverse', 'no', 'impaired', 'with', 'this', 'by', 'and', 'similar']","['tissue', 'oxygenation', 'pattern', 'reduction', 'this', 'by']",,
1333,1323,we specifically chose to use an increase in hemoglobin level of more than 1 g per deciliter as a primary end point because validated natural history studies indicated that an increase in hemoglobin level significantly decreases the rate of multiorgan failure and death .,我们特别选择将血红蛋白水平升高超过 1 克/分升作为主要终点，因为经过验证的自然历史研究表明，血红蛋白水平升高可显着降低多器官衰竭和死亡率。,0.3529411764705882,"['a', 'natural history', 'failure', 'rate', '1', 'death', 'hemoglobin', 'deciliter', 'hemoglobin level', 'primary', 'end', 'point', 'as', 'increase', 'that', 'and', 'we']","['failure', 'rate', '1', 'death', 'hemoglobin', 'point']",1323,"['我们具体选择使用超过1g的血球水平作为一个主要终点,因为验证的自然历史研究表明,血球水平的增加显著降低多器官失败和死亡率。']",0.2941176470588235,"['a', 'natural history', 'failure', 'rate', '1', 'death', 'hemoglobin', 'deciliter', 'hemoglobin level', 'primary', 'end', 'point', 'as', 'increase', 'that', 'and', 'we']","['failure', 'rate', '1', 'death', 'point']",,
1334,1324,"in conclusion , voxelotor provided a significant , sustained increase in hemoglobin level and reduced the incidence of worsening anemia and hemolysis in persons with sickle cell disease .",总之，voxelotor 显着、持续地提高了镰状细胞病患者的血红蛋白水平，降低了贫血恶化和溶血的发生率。,0.5384615384615384,"['anemia', 'cell', 'hemolysis', 'incidence', 'disease', 'hemoglobin', 'sickle', 'hemoglobin level', 'sickle cell', 'conclusion', 'increase', 'with', 'and']","['anemia', 'cell', 'hemolysis', 'incidence', 'disease', 'hemoglobin', 'sickle cell']",1324,"['在结论中,voxelotor提供了一个显著的,持续的血球水平增加,并减少了患有细胞细胞疾病的人的贫血和血球的恶化发病率。']",0.3846153846153846,"['anemia', 'cell', 'hemolysis', 'incidence', 'disease', 'hemoglobin', 'sickle', 'hemoglobin level', 'sickle cell', 'conclusion', 'increase', 'with', 'and']","['anemia', 'cell', 'incidence', 'disease', 'conclusion']",,
1335,1325,"however , whether vitamin D supplementation lowers the risk of diabetes is unknown .",然而，补充维生素 D 是否会降低患糖尿病的风险尚不清楚。,0.6,"['diabetes', 'vitamin', 'risk', 'D', 'vitamin D']","['diabetes', 'vitamin', 'risk']",1325,"['然而,维生素D补充是否降低糖尿病的风险尚不清楚。']",0.8,"['diabetes', 'vitamin', 'risk', 'D', 'vitamin D']","['diabetes', 'vitamin', 'risk', 'vitamin D']",,
1336,1326,a total of 2423 participants underwent randomization ( 1211 to the vitamin D group and 1212 to the placebo group ) .,共有 2423 名参与者被随机分组（维生素 D 组 1211 人，安慰剂组 1212 人）。,0.5714285714285714,"['group', 'placebo', 'vitamin', 'randomization', 'total', 'D', 'vitamin D']","['group', 'placebo', 'vitamin', 'randomization']",1326,['共有2423名参与者经历了随机化(1211对维生素D组和1212对 placebo组)。'],0.5714285714285714,"['group', 'placebo', 'vitamin', 'randomization', 'total', 'D', 'vitamin D']","['group', 'vitamin', 'randomization', 'vitamin D']",,
1337,1327,"the hazard ratio for vitamin D as compared with placebo was 0.88 ( 95 % confidence interval , 0.75 to 1.04 ; P = 0.12 ) .",与安慰剂相比，维生素 D 的风险比为 0.88（95% 置信区间，0.75 至 1.04；P = 0.12）。,0.5,"['placebo', 'interval', 'vitamin', 'ratio', 'hazard ratio', 'D', 'confidence interval', 'as', 'with', 'vitamin D', 'P', 'to']","['placebo', 'interval', 'vitamin', 'ratio', 'hazard ratio', 'confidence interval']",1327,"['与 placebo 相比,维生素 D 的风险比例为 0.88 (95% 信任间隔, 0.75 至 1.04 ; P = 0.12 ) 。']",0.3333333333333333,"['placebo', 'interval', 'vitamin', 'ratio', 'hazard ratio', 'D', 'confidence interval', 'as', 'with', 'vitamin D', 'P', 'to']","['interval', 'vitamin', 'ratio', 'hazard ratio']",,
1338,1328,the incidence of adverse events did not differ significantly between the two groups .,不良事件的发生率在两组之间没有显着差异。,0.5,"['incidence', 'adverse', 'differ', 'two']","['incidence', 'two']",1328,['副作用的发病率在两组之间没有显著的差异。'],0.5,"['incidence', 'adverse', 'differ', 'two']","['incidence', 'two']",,
1339,1329,"among persons at high risk for type 2 diabetes not selected for vitamin D insufficiency , vitamin D3 supplementation at a dose of 4000 IU per day did not result in a significantly lower risk of diabetes than placebo . ( Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others ; D2d ClinicalTrials.gov number , NCT01942694 . )",在没有选择维生素 D 不足的 2 型糖尿病高危人群中，每天补充 4000 IU 剂量的维生素 D3 并没有导致患糖尿病的风险显着低于安慰剂。 （由国家糖尿病、消化和肾脏疾病研究所等资助；D2d ClinicalTrials.gov 编号，NCT01942694。）,0.6842105263157895,"['diabetes', 'type', 'placebo', 'kidney', 'vitamin', 'insufficiency', '2', 'high risk', 'digestive', 'lower', 'number', 'institute', 'D', 'result', 'vitamin D', 'at', 'dose', 'by', 'and']","['diabetes', 'type', 'placebo', 'kidney', 'vitamin', 'insufficiency', '2', 'high risk', 'number', 'institute', 'at', 'dose', 'by']",1329,"['在患2型糖尿病的风险较高的人中,维生素D3补充剂每天4000IU的剂量不会导致糖尿病的风险比 placebo 显著低(由国家糖尿病和消化和肾脏疾病和其他机构资助;D2d ClinicalTrials.gov号,NCT01942694 )。']",0.4736842105263157,"['diabetes', 'type', 'placebo', 'kidney', 'vitamin', 'insufficiency', '2', 'high risk', 'digestive', 'lower', 'number', 'institute', 'D', 'result', 'vitamin D', 'at', 'dose', 'by', 'and']","['diabetes', 'type', 'kidney', 'vitamin', '2', 'number', 'vitamin D', 'dose', 'by']",,
1340,1330,"more than 84 million adults in the United States have an increased risk of type 2 diabetes , based on a fasting glucose or glycated hemoglobin level above the normal range but below the threshold for diabetes.1",根据空腹血糖或糖化血红蛋白水平高于正常范围但低于糖尿病阈值，美国有超过 8400 万成年人患 2 型糖尿病的风险增加。 1,0.625,"['diabetes', 'type', 'threshold', 'glucose', 'range', '2', 'hemoglobin', 'normal', 'hemoglobin level', 'fasting', 'risk', 'normal range', 'on', 'have', 'but', 'million']","['diabetes', 'type', 'threshold', 'range', '2', 'hemoglobin', 'risk', 'normal range', 'have', 'but']",1330,"['美国有超过84百万成年人患2型糖尿病的风险增加,基于禁食糖或血糖血糖水平高于正常范围,但低于糖尿病的限制。']",0.5,"['diabetes', 'type', 'threshold', 'glucose', 'range', '2', 'hemoglobin', 'normal', 'hemoglobin level', 'fasting', 'risk', 'normal range', 'on', 'have', 'but', 'million']","['diabetes', 'type', 'range', '2', 'risk', 'normal range', 'have', 'but']",,
1341,1331,"however , achieving and maintaining sufficient lifestyle change is challenging , and the residual risk of diabetes remains elevated , even after successful weight loss .",然而，实现并维持充分的生活方式改变具有挑战性，即使在成功减肥后，糖尿病的残余风险仍然很高。,0.5555555555555556,"['diabetes', 'weight', 'loss', 'risk', 'after', 'change', 'residual', 'weight loss', 'and']","['diabetes', 'risk', 'after', 'residual', 'and']",1331,"['然而,实现和维持足够的生活方式变化是挑战性的,而糖尿病的剩余风险仍然高,即使成功减肥后。']",0.6666666666666666,"['diabetes', 'weight', 'loss', 'risk', 'after', 'change', 'residual', 'weight loss', 'and']","['diabetes', 'risk', 'after', 'change', 'residual', 'and']",,
1342,1332,the Vitamin D and Type 2 Diabetes ( D2d ) trial was conducted to test whether vitamin D supplementation reduces the risk of type 2 diabetes among adults at high risk for the disorder .,维生素 D 和 2 型糖尿病 (D2d) 试验的目的是测试补充维生素 D 是否可以降低高风险成人患 2 型糖尿病的风险。,0.3846153846153846,"['diabetes', 'type', 'vitamin', 'disorder', '2', 'test', 'high risk', 'trial', 'D', 'vitamin D', 'at', 'to', 'and']","['diabetes', 'type', 'vitamin', '2', 'test']",1332,"['维生素D和2型糖尿病(D2d)的测试进行了测试,以测试维生素D补充是否降低患2型糖尿病的风险在患有高疾病风险的成年人中。']",0.4615384615384615,"['diabetes', 'type', 'vitamin', 'disorder', '2', 'test', 'high risk', 'trial', 'D', 'vitamin D', 'at', 'to', 'and']","['diabetes', 'type', 'vitamin', '2', 'test', 'vitamin D']",,
1343,1333,the trial protocol ( available with the full text of this article at NEJM.org ) was designed by the planning committee and the primary sponsor ( National Institute of Diabetes and Digestive and Kidney Diseases ) without input from manufacturers11 and involved collaboration among 22 academic medical centers in the United States ( https : / / d2dstudy.org / sites ) .,试验方案（与本文全文可在 NEJM.org 上获取）由规划委员会和主要申办方（国家糖尿病、消化和肾脏疾病研究所）设计，没有制造商的参与11，涉及 22 个学术医学中心之间的合作在美国 (https://d2dstudy.org/sites)。,0.3181818181818182,"['diabetes', 'kidney', 'protocol', '/', 'sponsor', 'digestive', 'article', 'medical', 'primary', 'available', 'committee', 'input', 'institute', 'trial', 'text', 'collaboration', 'with', 'full', 'this', 'by', 'and', 'without']","['diabetes', 'kidney', 'protocol', 'committee', 'institute', 'collaboration', 'by']",1333,"['试验协议(可在NEJM.org上提供本文的完整文本)由规划委员会和主要赞助商(国家糖尿病和消化和肾脏疾病研究所)没有来自制造商的提交,并参与了美国22个学术医疗中心的合作(https: / d2dstudy.org / 网站 )。']",0.3636363636363636,"['diabetes', 'kidney', 'protocol', '/', 'sponsor', 'digestive', 'article', 'medical', 'primary', 'available', 'committee', 'input', 'institute', 'trial', 'text', 'collaboration', 'with', 'full', 'this', 'by', 'and', 'without']","['diabetes', 'kidney', 'protocol', 'committee', 'institute', 'collaboration', 'full', 'by']",,
1344,1334,"the institutional review board at each clinical site also approved the protocol , and all the participants provided written informed consent .",每个临床中心的机构审查委员会也批准了该方案，所有参与者都提供了书面知情同意书。,0.2727272727272727,"['site', 'review', 'protocol', 'board', 'clinical', 'consent', 'informed consent', 'at', 'all', 'each', 'and']","['review', 'clinical', 'consent']",1334,"['每个临床场所的机构审查委员会也批准了协议,所有参与者都提供了书面通知的同意。']",0.4545454545454545,"['site', 'review', 'protocol', 'board', 'clinical', 'consent', 'informed consent', 'at', 'all', 'each', 'and']","['site', 'review', 'protocol', 'clinical', 'consent']",,
1345,1335,the statistical team at the coordinating center analyzed the data and vouches for its accuracy .,协调中心的统计小组对数据进行了分析，并保证其准确性。,0.8,"['center', 'data', 'accuracy', 'team', 'and']","['center', 'data', 'accuracy', 'team']",1335,"['协调中心的统计团队分析了数据和优惠,以确保其准确性。']",0.8,"['center', 'data', 'accuracy', 'team', 'and']","['center', 'data', 'accuracy', 'team']",,
1346,1336,"they also contributed to the interpretation of the results and the preparation , review , and approval of the manuscript and made the decision to submit the manuscript for publication .",他们还对结果的解释以及手稿的准备、审查和批准做出了贡献，并做出了投稿发表的决定。,0.7777777777777778,"['preparation', 'review', 'approval', 'interpretation', 'publication', 'manuscript', 'decision', 'to', 'and']","['preparation', 'review', 'approval', 'interpretation', 'publication', 'manuscript', 'decision']",1336,"['他们还为结果的解释和手稿的准备、审查和批准做出了贡献,并决定将手稿提交出版。']",0.7777777777777778,"['preparation', 'review', 'approval', 'interpretation', 'publication', 'manuscript', 'decision', 'to', 'and']","['preparation', 'review', 'approval', 'interpretation', 'publication', 'manuscript', 'decision']",,
1347,1337,"no pharmaceutical manufacturers contributed to the planning , design , or conduct of the trial .",没有制药商参与试验的规划、设计或实施。,0.1666666666666666,"['pharmaceutical', 'no', 'trial', 'conduct', 'design', 'to']",['design'],1337,['任何制药制造商都没有参与试验的规划、设计或进行。'],0.1666666666666666,"['pharmaceutical', 'no', 'trial', 'conduct', 'design', 'to']",['design'],,
1348,1338,"for a complete list of eligibility criteria , see the Supplementary Appendix ( available at NEJM.org ) .",有关资格标准的完整列表，请参阅补充附录（可在 NEJM.org 获取）。,0.0,"['a', 'appendix', 'supplementary', 'complete', 'available', 'list', 'at']",[],1338,"['有关资格准则的完整列表,请参见附件(可在NEJM.org上找到)。']",0.1428571428571428,"['a', 'appendix', 'supplementary', 'complete', 'available', 'list', 'at']",['appendix'],,
1349,1339,intervention AND PROCEDURES,干预和程序,0.0,['intervention'],[],1339,['干预与程序'],0.0,['intervention'],[],,
1350,1340,participants received a bottle of trial pills at the time of randomization and every 6 months thereafter .,参与者在随机分组时收到一瓶试验药片，此后每 6 个月收到一次。,0.5,"['a', 'randomization', 'bottle', 'time', 'trial', 'pills']","['randomization', 'bottle', 'time']",1340,"['參與者在偶然化時收到一瓶試用藥片,然後每6個月。']",0.1666666666666666,"['a', 'randomization', 'bottle', 'time', 'trial', 'pills']",['bottle'],,
1351,1341,bottles with unused pills were returned at each visit to estimate adherence .,每次就诊时将装有未使用药丸的瓶子归还，以估计依从性。,0.1428571428571428,"['estimate', 'with', 'adherence', 'pills', 'each', 'to', 'visit']",['pills'],1341,"['未使用的药片的瓶子每次访问都返回,以估计合并。']",0.0,"['estimate', 'with', 'adherence', 'pills', 'each', 'to', 'visit']",[],,
1352,1342,"because of concern that high intake of calcium from supplements may be associated with adverse outcomes , participants were asked to limit calcium supplements to 600 mg per day .",由于担心从补充剂中摄入大量钙可能会导致不良后果，因此要求参与者将钙补充剂的摄入量限制在每天 600 毫克。,0.3636363636363636,"['calcium', 'intake', 'be', 'adverse', 'associated', 'limit', 'concern', 'with', 'that', 'to', 'high']","['calcium', 'be', 'limit', 'to']",1342,"['由于担心从补充剂中摄入高钙可能与不良结果有关,参与者被要求将钙补充剂限制为每日600毫克。']",0.3636363636363636,"['calcium', 'intake', 'be', 'adverse', 'associated', 'limit', 'concern', 'with', 'that', 'to', 'high']","['calcium', 'limit', 'to', 'high']",,
1353,1343,"if two or three of the glycemic measures met the 2010 ADA thresholds for diabetes , 12 the participant was considered to have met the diabetes outcome .",如果两项或三项血糖测量指标达到 2010 年 ADA 糖尿病阈值，12 则认为参与者达到了糖尿病结果。,0.5,"['diabetes', 'outcome', 'met', 'have', 'three', 'if', 'to', 'two']","['diabetes', 'outcome', 'three', 'two']",1343,"['如果两个或三个糖尿病测量满足了2010年糖尿病 ADA 限制,12 参与者被认为满足了糖尿病结果。']",0.5,"['diabetes', 'outcome', 'met', 'have', 'three', 'if', 'to', 'two']","['diabetes', 'outcome', 'three', 'two']",,
1354,1344,"when only the measure for fasting plasma glucose or glycated hemoglobin met the threshold , confirmatory testing was performed for the positive measure within 8 weeks .",当只有空腹血糖或糖化血红蛋白的测量值达到阈值时，在 8 周内对阳性测量值进行确认测试。,0.4,"['threshold', 'glucose', 'plasma', 'hemoglobin', 'fasting', 'measure', 'testing', 'positive', 'met', 'confirmatory']","['threshold', 'hemoglobin', 'measure', 'confirmatory']",1344,"['当只有<unk>血糖或<unk>血糖的禁食测量达到边界时,在8周内对积极测量进行确认测试。']",0.2,"['threshold', 'glucose', 'plasma', 'hemoglobin', 'fasting', 'measure', 'testing', 'positive', 'met', 'confirmatory']","['measure', 'confirmatory']",,
1355,1345,"during the trial , research staff , caregivers , and participants were unaware of glycemic test results until a participant met the diabetes outcome .",在试验期间，研究人员、护理人员和参与者在参与者出现糖尿病结果之前都不知道血糖测试结果。,0.4,"['diabetes', 'research', 'test', 'outcome', 'staff', 'trial', 'unaware', 'met', 'and', 'caregivers']","['diabetes', 'research', 'test', 'outcome']",1345,"['在试验期间,研究人员、护理人员和参与者不知道糖尿病测试结果,直到参与者发现糖尿病结果。']",0.4,"['diabetes', 'research', 'test', 'outcome', 'staff', 'trial', 'unaware', 'met', 'and', 'caregivers']","['diabetes', 'research', 'test', 'outcome']",,
1356,1346,"safety was assessed by means of participant report and annual fasting measurements of serum calcium , serum creatinine , and morning spot urine calcium : creatinine ratio ( a rough estimate of urine calcium excretion ) .14",安全性是通过参与者报告和年度空腹测量血清钙、血清肌酐和晨间尿钙：肌酐比（尿钙排泄的粗略估计） .14 来评估的。,0.4444444444444444,"['annual', 'safety', 'calcium', 'creatinine', 'excretion', 'urine', 'report', 'ratio', 'calcium excretion', 'serum', 'fasting', 'spot', 'estimate', 'means', 'by', 'and', 'morning', 'assessed']","['safety', 'calcium', 'excretion', 'urine', 'report', 'ratio', 'calcium excretion', 'serum']",1346,['安全性通过参与者报告和每年的禁食测量来评估血清钙、血清克里亚丁和早晨点尿液钙:克里亚丁比例(尿液钙排泄的严格估计)。'],0.5555555555555556,"['annual', 'safety', 'calcium', 'creatinine', 'excretion', 'urine', 'report', 'ratio', 'calcium excretion', 'serum', 'fasting', 'spot', 'estimate', 'means', 'by', 'and', 'morning', 'assessed']","['safety', 'calcium', 'excretion', 'urine', 'report', 'ratio', 'calcium excretion', 'serum', 'spot', 'morning']",,
1357,1347,"serum calcium and creatinine were analyzed locally at each site , and the estimated glomerular filtration rate was calculated.15",在每个部位局部分析血清钙和肌酸酐，并计算估计的肾小球滤过率。 15,0.625,"['calcium', 'creatinine', 'site', 'rate', 'glomerular filtration rate', 'serum', 'each', 'and']","['calcium', 'creatinine', 'rate', 'glomerular filtration rate', 'serum']",1347,"['血清钙和克里亚丁在每个区域进行了本地分析,并计算了估计的血清过滤率。']",0.375,"['calcium', 'creatinine', 'site', 'rate', 'glomerular filtration rate', 'serum', 'each', 'and']","['calcium', 'rate', 'serum']",,
1358,1348,other blood and urine specimens were processed locally and shipped to the central laboratory .,其他血液和尿液标本在当地处理并运往中央实验室。,0.4285714285714285,"['urine', 'blood', 'specimens', 'central', 'laboratory', 'processed', 'and']","['urine', 'blood', 'laboratory']",1348,['其他血液和尿液样本被本地处理并发送到中央实验室。'],0.5714285714285714,"['urine', 'blood', 'specimens', 'central', 'laboratory', 'processed', 'and']","['urine', 'blood', 'specimens', 'laboratory']",,
1359,1349,plasma glucose was measured with the use of a hexokinase method .,使用己糖激酶法测量血浆葡萄糖。,0.5,"['a', 'glucose', 'plasma', 'method', 'with', 'hexokinase']","['glucose', 'plasma', 'hexokinase']",1349,"['血糖在血糖中被测量,使用 hexokinase 方法。']",0.0,"['a', 'glucose', 'plasma', 'method', 'with', 'hexokinase']",[],,
1360,1350,"no imputation was performed for missing data , but we conducted a sensitivity analysis to assess for noninformative censoring of incomplete data ( see the Supplementary Appendix ) .",没有对缺失数据进行填补，但我们进行了敏感性分析以评估对不完整数据的非信息删失（见补充附录）。,0.3571428571428571,"['a', 'appendix', 'data', 'analysis', 'supplementary', 'no', 'incomplete', 'assess', 'incomplete data', 'sensitivity', 'but', 'to', 'missing', 'we']","['data', 'analysis', 'assess', 'but', 'missing']",1350,"['没有对缺乏数据进行指控,但我们进行了敏感性分析,以评估非信息性审查不完整的数据(参见附件)。']",0.4285714285714285,"['a', 'appendix', 'data', 'analysis', 'supplementary', 'no', 'incomplete', 'assess', 'incomplete data', 'sensitivity', 'but', 'to', 'missing', 'we']","['appendix', 'data', 'analysis', 'assess', 'but', 'missing']",,
1361,1351,"all events that occurred during the trial , including those that occurred after the target of 508 events was reached , were used to generate the primary results .",试验期间发生的所有事件，包括达到 508 事件目标后发生的事件，均用于生成主要结果。,0.375,"['primary', 'target', 'after', 'trial', 'generate', 'all', 'that', 'to']","['target', 'after', 'to']",1351,"['所有在试验期间发生的事件,包括在达到508事件目标后发生的事件,都被用来产生初始结果。']",0.25,"['primary', 'target', 'after', 'trial', 'generate', 'all', 'that', 'to']","['target', 'after']",,
1362,1352,"the model included group assignment as its main predictor variable and the stratification variables ( trial site , BMI , and race ) .",该模型包括作为其主要预测变量的分组和分层变量（试验地点、BMI 和种族）。,0.5,"['variable', 'group', 'stratification', 'model', 'site', 'BMI', 'trial', 'race', 'as', 'assignment', 'and', 'predictor']","['variable', 'group', 'stratification', 'model', 'site', 'race']",1352,['该模型包括组分配作为其主要预测变量和分裂变量(测试地点、BMI和赛车)。'],0.3333333333333333,"['variable', 'group', 'stratification', 'model', 'site', 'BMI', 'trial', 'race', 'as', 'assignment', 'and', 'predictor']","['variable', 'group', 'model', 'site']",,
1363,1353,we also show a model without the stratification variables .,我们还展示了一个没有分层变量的模型。,0.5,"['stratification', 'model', 'without', 'we']","['stratification', 'model']",1353,"['我们还展示了一个模型,没有分裂变量。']",0.25,"['stratification', 'model', 'without', 'we']",['model'],,
1364,1354,variability of response to vitamin D supplementation was assessed in prespecified subgroups defined by key baseline variables .,在由关键基线变量定义的预先指定的亚组中评估了对维生素 D 补充剂反应的变异性。,0.5454545454545454,"['key', 'defined', 'vitamin', 'baseline', 'variability', 'response', 'D', 'vitamin D', 'by', 'to', 'assessed']","['key', 'vitamin', 'baseline', 'variability', 'response', 'by']",1354,['对维生素D补充反应的变量在由关键基因变量定义的预定子组中被评估。'],0.4545454545454545,"['key', 'defined', 'vitamin', 'baseline', 'variability', 'response', 'D', 'vitamin D', 'by', 'to', 'assessed']","['key', 'vitamin', 'response', 'vitamin D', 'by']",,
1365,1355,rates of adverse events were compared between the two groups .,比较两组不良事件发生率。,0.5,"['adverse', 'two']",['two'],1355,['对不起事件的率在两组之间进行了比较。'],0.5,"['adverse', 'two']",['two'],,
1366,1356,"when evaluating the significance of the prespecified subgroup analyses , we used the Hochberg sequential procedure to adjust for multiple comparisons , if necessary .",在评估预先指定的亚组分析的显着性时，如有必要，我们使用 Hochberg 序贯程序针对多重比较进行调整。,0.125,"['procedure', 'multiple', 'adjust', 'necessary', 'significance', 'subgroup', 'to', 'we']",['procedure'],1356,"['在评估预定子组分析的重要性时,我们使用霍赫伯格序列程序进行调整,以便在必要时进行多次比较。']",0.25,"['procedure', 'multiple', 'adjust', 'necessary', 'significance', 'subgroup', 'to', 'we']","['procedure', 'significance']",,
1367,1357,"no adjustments were made for the safety analyses or the planned exploratory or post hoc analyses for the primary outcome ; therefore , only point estimates and 95 % confidence intervals are presented without P values .",未对主要结局的安全性分析或计划的探索性或事后分析进行调整；因此，仅提供点估计值和 95% 置信区间，而没有 P 值。,0.2142857142857142,"['safety', 'outcome', 'post', 'exploratory', 'primary', 'no', 'values', 'point', 'confidence', 'P', 'therefore', 'and', 'without', 'intervals']","['safety', 'point', 'and']",1357,"['对于安全分析或初始结果的计划探测或后考分析没有进行调整;因此,只有点估计和95%的信任间隔没有P值。']",0.2857142857142857,"['safety', 'outcome', 'post', 'exploratory', 'primary', 'no', 'values', 'point', 'confidence', 'P', 'therefore', 'and', 'without', 'intervals']","['safety', 'outcome', 'exploratory', 'point']",,
1368,1358,"a total of 44.8 % of the participants were women , 33.3 % were of nonwhite race , and 9.3 % were of Hispanic ethnic background.24",总共 44.8 % 的参与者是女性， 33.3 % 是非白人种族， 9.3 % 是西班牙裔。 24,0.25,"['a', 'total', 'race', 'and']",['race'],1358,"['总共有44.8%的参与者是女性,33.3%是非白人,9.3%是西班牙人。']",0.0,"['a', 'total', 'race', 'and']",[],,
1369,1359,"the participants had a mean age of 60.0 years , a mean BMI of 32.1 , and a mean glycated hemoglobin level of 5.9 % ( 48 mmol per mole ) .",参与者的平均年龄为 60.0 岁，平均 BMI 为 32.1，平均糖化血红蛋白水平为 5.9%（48 毫摩尔/摩尔）。,0.5,"['a', 'mean', 'hemoglobin', 'BMI', 'hemoglobin level', 'mole', 'age', 'and']","['mean', 'hemoglobin', 'mole', 'age']",1359,"['参与者平均年龄为60.0岁,平均BMI为32.1岁,平均血糖血糖水平为5.9%(每粒48mmol)。']",0.25,"['a', 'mean', 'hemoglobin', 'BMI', 'hemoglobin level', 'mole', 'age', 'and']","['mean', 'age']",,
1370,1360,a total of 84.2 % of the participants met the glycemic criteria for both fasting plasma glucose and glycated hemoglobin ; approximately one third met all three glycemic criteria .,共有 84.2% 的参与者符合空腹血糖和糖化血红蛋白的血糖标准；大约三分之一符合所有三个血糖标准。,0.1666666666666666,"['a', 'glucose', 'plasma', 'hemoglobin', 'total', 'fasting', 'met', 'approximately', 'all', 'three', 'and', 'third']","['hemoglobin', 'three']",1360,['共有84.2%的参与者满足了禁食血糖和血糖血糖的血糖基准;约三分之一满足了三分之一的血糖基准。'],0.0833333333333333,"['a', 'glucose', 'plasma', 'hemoglobin', 'total', 'fasting', 'met', 'approximately', 'all', 'three', 'and', 'third']",['three'],,
1371,1361,the last trial encounter was in November 2018 .,最后一次试探是在2018年11月。,0.0,"['encounter', 'november', 'trial', 'in']",[],1361,['最后一次审判是在2018年11月。'],0.25,"['encounter', 'november', 'trial', 'in']",['trial'],,
1372,1362,"before reaching a primary outcome event , 10 participants ( 5 in each group ) died , and 62 ( 34 in the vitamin D group and 28 in the placebo group ) withdrew consent ( Figure 1 ) .",在达到主要结果事件之前，10 名参与者（每组 5 名）死亡，62 名（维生素 D 组 34 名，安慰剂组 28 名）撤回同意（图 1）。,0.6,"['group', '5', 'placebo', 'vitamin', '1', 'outcome', 'figure', 'primary', 'D', 'consent', 'vitamin D', 'event', 'before', 'each', 'and']","['group', '5', 'placebo', 'vitamin', '1', 'outcome', 'consent', 'event', 'before']",1362,"['在到达一个主要结果事件之前,10名参与者(每个组5人)死亡,62人(维生素D组34人和 placebo组28人)撤回了同意(图1)。']",0.6,"['group', '5', 'placebo', 'vitamin', '1', 'outcome', 'figure', 'primary', 'D', 'consent', 'vitamin D', 'event', 'before', 'each', 'and']","['group', '5', 'vitamin', '1', 'outcome', 'consent', 'vitamin D', 'event', 'before']",,
1373,1363,"by the end of the trial , diabetes had developed in 616 patients .",到试验结束时，已有 616 名患者患上了糖尿病。,0.2,"['diabetes', 'trial', 'end', 'in', 'by']",['diabetes'],1363,"['在试验结束时,糖尿病在616名患者中出现。']",0.2,"['diabetes', 'trial', 'end', 'in', 'by']",['diabetes'],,
1374,1364,"when the stratification variables were not included in the model , the hazard ratio in the vitamin D group was 0.87 ( 95 % CI , 0.75 to 1.02 ) .",当模型中未包括分层变量时，维生素 D 组的风险比为 0.87（95% CI，0.75 至 1.02）。,0.5454545454545454,"['group', 'stratification', 'vitamin', 'model', 'ratio', 'hazard ratio', 'D', 'vitamin D', 'CI', 'not included', 'to']","['group', 'stratification', 'vitamin', 'model', 'ratio', 'hazard ratio']",1364,"['当分裂变量不包括在模型中时,维生素D组的危险比例为0.87(95% CI,0.75 至 1.02)。']",0.4545454545454545,"['group', 'stratification', 'vitamin', 'model', 'ratio', 'hazard ratio', 'D', 'vitamin D', 'CI', 'not included', 'to']","['group', 'vitamin', 'model', 'ratio', 'vitamin D']",,
1375,1365,"in a sensitivity analysis to account for missing data , the hazard ratio did not change substantially ( see the Supplementary Appendix ) .",在解释缺失数据的敏感性分析中，风险比没有显着变化（见补充附录）。,0.5,"['a', 'appendix', 'data', 'analysis', 'ratio', 'hazard ratio', 'supplementary', 'change', 'sensitivity', 'in', 'to', 'missing']","['data', 'analysis', 'ratio', 'hazard ratio', 'change', 'missing']",1365,"['在对失踪数据的敏感性分析中,风险比例没有显著变化(参见附件)。']",0.5,"['a', 'appendix', 'data', 'analysis', 'ratio', 'hazard ratio', 'supplementary', 'change', 'sensitivity', 'in', 'to', 'missing']","['appendix', 'data', 'analysis', 'ratio', 'hazard ratio', 'change']",,
1376,1366,the results of the subgroup analyses were consistent with the findings of the main analysis ; there was no apparent heterogeneity of treatment effect across the prespecified subgroups ( Figure 3 ) .,亚组分析结果与主要分析结果一致；预先指定的亚组之间的治疗效果没有明显的异质性（图 3）。,0.4545454545454545,"['heterogeneity', 'analysis', 'figure', 'treatment', 'no', 'across', 'effect', '3', 'treatment effect', 'subgroup', 'with']","['heterogeneity', 'analysis', 'treatment', 'effect', 'treatment effect']",1366,['子组分析的结果与主要分析的发现一致;在预定子组中没有显而易见的治疗效应异性(图3)。'],0.2727272727272727,"['heterogeneity', 'analysis', 'figure', 'treatment', 'no', 'across', 'effect', '3', 'treatment effect', 'subgroup', 'with']","['analysis', 'treatment', 'effect']",,
1377,1367,"overall , 47 participants ( 3.9 % ) in the vitamin D group stopped the trial pills because of an adverse event , as compared with 37 ( 3.1 % ) in the placebo group ( difference , 0.8 percentage points ; 95 % CI , − 0.7 to 2.3 ) .",总体而言，维生素 D 组中有 47 名参与者 (3.9%) 因不良事件停止了试验药物，而安慰剂组中有 37 名 (3.1%) 参与者（差异，0.8 个百分点；95% CI，- 0.7 至 2.3 ) 。,0.3333333333333333,"['group', 'percentage', 'placebo', 'vitamin', 'difference', 'adverse', 'adverse event', 'trial', 'D', 'as', 'with', 'vitamin D', 'CI', 'pills', 'to']","['group', 'placebo', 'vitamin', 'difference', 'adverse event']",1367,"['总体而言,维生素D组的47名参与者(3.9%)因副作用而停止了试用药丸,与 placebo组的37名(3.1%)相比(差异,0.8个百分点;95%的CI, −0.7到2.3)。']",0.3333333333333333,"['group', 'percentage', 'placebo', 'vitamin', 'difference', 'adverse', 'adverse event', 'trial', 'D', 'as', 'with', 'vitamin D', 'CI', 'pills', 'to']","['group', 'vitamin', 'difference', 'vitamin D', 'pills']",,
1378,1368,"while our trial was being conducted , two other trials that were designed to test whether vitamin D supplementation lowers the risk of type 2 diabetes among persons at risk showed hazard ratios with vitamin D that were similar to those in our trial.25,26","在我们进行试验的同时，另外两项旨在测试维生素 D 补充剂是否能降低高危人群患 2 型糖尿病风险的试验表明，维生素 D 的风险比与我们试验中的风险比相似。 25,26",0.4117647058823529,"['diabetes', 'type', 'vitamin', '2', 'test', 'hazard', 'risk', 'trial', 'D', 'being', 'with', 'vitamin D', 'at', 'that', 'to', 'two', 'similar']","['diabetes', 'type', 'vitamin', '2', 'test', 'risk', 'two']",1368,"['虽然我们的研究正在进行中,还有两项研究,旨在测试维生素D补充是否降低患2型糖尿病的风险,并显示与我们研究中的类似的维生素D的风险比例。']",0.4705882352941176,"['diabetes', 'type', 'vitamin', '2', 'test', 'hazard', 'risk', 'trial', 'D', 'being', 'with', 'vitamin D', 'at', 'that', 'to', 'two', 'similar']","['diabetes', 'type', 'vitamin', '2', 'test', 'risk', 'vitamin D', 'two']",,
1379,1369,"in the Tromsø Vitamin D and T2DM Trial ( Norway ) , which randomly assigned 511 white adults with prediabetes to 20,000 IU per week ( approximately 2900 IU per day ) of vitamin D3 or placebo , the risk of diabetes was numerically lower in the vitamin D group than in the placebo group , but the difference was not significant ( hazard ratio , 0.90 ; 95 % CI , 0.69 to 1.18 ) .25","在特罗姆瑟维生素 D 和 T2DM 试验（挪威）中，该试验将 511 名患有糖尿病前期的白人成人随机分配至每周服用 20,000 IU（每天约 2900 IU）的维生素 D3 或安慰剂，维生素 D 组患糖尿病的风险在数值上较低与安慰剂组相比，但差异不显着（危险比，0.90 ； 95 % CI，0.69 至 1.18 ） .25",0.5,"['group', 'diabetes', 'placebo', 'vitamin', 'ratio', 'hazard ratio', 'white', 'difference', 'lower', 'risk', 'week', 'trial', 'D', 'with', 'vitamin D', 'CI', 'approximately', 'but', 'to', 'and']","['group', 'diabetes', 'placebo', 'vitamin', 'ratio', 'white', 'difference', 'risk', 'week', 'but']",1369,"['在 Tromsø 维生素 D 和 T2DM 试验( 挪威 ),随机分配 511 白人成年人 预糖尿病 每周 20,000 IU ( 约 2900 IU 每日 ) 维生素 D3 或 placebo, 糖尿病的风险在 维生素 D 组 比在  placebo 组, 但差异 没有显著( 风险比例, 0.90 ; 95 % CI, 0.69 到 1.18 ).25']",0.5,"['group', 'diabetes', 'placebo', 'vitamin', 'ratio', 'hazard ratio', 'white', 'difference', 'lower', 'risk', 'week', 'trial', 'D', 'with', 'vitamin D', 'CI', 'approximately', 'but', 'to', 'and']","['group', 'diabetes', 'vitamin', 'ratio', 'hazard ratio', 'white', 'difference', 'risk', 'week', 'but']",,
1380,1370,"in the Diabetes Prevention with Active Vitamin D study ( Japan ) , which randomly assigned 1256 adults with prediabetes to an active form of vitamin D analogue ( eldecalcitol ) or placebo , the risk of diabetes was also lower in the vitamin D group than in the placebo group , but the difference was again not significant ( hazard ratio , 0.87 ; 95 % CI , 0.68 to 1.09 ) .27",在用活性维生素 D 预防糖尿病的研究（日本）中，该研究随机分配了 1256 名患有前驱糖尿病的成年人服用活性形式的维生素 D 类似物（eldecalcitol）或安慰剂，维生素 D 组患糖尿病的风险也低于安慰剂组组，但差异同样不显着（危险比，0.87 ； 95 % CI，0.68 至 1.09 ） .27,0.5454545454545454,"['group', 'diabetes', 'placebo', 'analogue', 'form', 'vitamin', 'ratio', 'hazard ratio', 'study', 'active', 'difference', 'prevention', 'lower', 'risk', 'japan', 'D', 'with', 'vitamin D', 'CI', 'but', 'to', 'again']","['group', 'diabetes', 'placebo', 'analogue', 'form', 'vitamin', 'ratio', 'difference', 'prevention', 'risk', 'but', 'to']",1370,"['在糖尿病预防与活性维生素D研究(日本),随机分配1256名患有前糖尿病的成年人到活性维生素D类似( eldecalcitol )或 placebo的形式,糖尿病的风险也低于维生素D组,而不是 placebo组,但差异再次不显著(风险比例,0.87;95% CI,0.68到1.09 )。']",0.5909090909090909,"['group', 'diabetes', 'placebo', 'analogue', 'form', 'vitamin', 'ratio', 'hazard ratio', 'study', 'active', 'difference', 'prevention', 'lower', 'risk', 'japan', 'D', 'with', 'vitamin D', 'CI', 'but', 'to', 'again']","['group', 'diabetes', 'form', 'vitamin', 'ratio', 'hazard ratio', 'difference', 'prevention', 'risk', 'vitamin D', 'but', 'to', 'again']",,
1381,1371,we powered our trial to detect a 25 % lower risk of diabetes with vitamin D than with placebo .,我们为试验提供动力，发现服用维生素 D 比服用安慰剂可降低 25% 的糖尿病风险。,0.4545454545454545,"['diabetes', 'placebo', 'vitamin', 'lower', 'risk', 'detect', 'trial', 'D', 'with', 'vitamin D', 'to']","['diabetes', 'placebo', 'vitamin', 'risk', 'detect']",1371,"['我们强化了我们的试验,以检测与维生素D相比糖尿病的风险降低25%。']",0.4545454545454545,"['diabetes', 'placebo', 'vitamin', 'lower', 'risk', 'detect', 'trial', 'D', 'with', 'vitamin D', 'to']","['diabetes', 'vitamin', 'risk', 'detect', 'vitamin D']",,
1382,1372,"on the basis of the results from all three trials , vitamin D supplementation may decrease diabetes risk among persons at risk for diabetes not selected for vitamin D insufficiency by a smaller effect size ( 10 to 15 % ) , but none of these trials were powered to test this effect size .",根据所有三项试验的结果，维生素 D 补充剂可能会以较小的效应量（ 10 至 15 % ） 降低未被选为维生素 D 不足的糖尿病风险人群的糖尿病风险，但这些试验均无统计学意义测试这个效果大小。,0.4736842105263157,"['diabetes', 'decrease', 'vitamin', 'insufficiency', 'test', 'basis', 'size', 'risk', 'D', 'effect', 'vitamin D', 'at', 'on', 'all', 'three', 'this', 'by', 'but', 'to']","['diabetes', 'vitamin', 'insufficiency', 'test', 'size', 'risk', 'effect', 'by', 'but']",1372,"['基于所有三项研究的结果,维生素D补充可以降低患不维生素D不足的糖尿病风险的人的糖尿病风险较小(10至15%),但这些研究中没有一个能够测试这种效果大小。']",0.5789473684210527,"['diabetes', 'decrease', 'vitamin', 'insufficiency', 'test', 'basis', 'size', 'risk', 'D', 'effect', 'vitamin D', 'at', 'on', 'all', 'three', 'this', 'by', 'but', 'to']","['diabetes', 'vitamin', 'insufficiency', 'size', 'risk', 'effect', 'vitamin D', 'at', 'by', 'but', 'to']",,
1383,1373,our trial has several strengths .,我们的审判有几个优势。,1.0,['trial'],['trial'],1373,['我们的审判有几个力量。'],1.0,['trial'],['trial'],,
1384,1373,our trial has several strengths .,我们的审判有几个优势。,1.0,['trial'],['trial'],1373,['我们的审判有几个力量。'],1.0,['trial'],['trial'],,
1385,1373,our trial has several strengths .,我们的审判有几个优势。,1.0,['trial'],['trial'],1373,['我们的审判有几个力量。'],1.0,['trial'],['trial'],,
1386,1374,"we used contemporary glycemic criteria to assemble a diverse cohort at high risk for diabetes with a hyperglycemic pattern closely matching how prediabetes is diagnosed in clinical practice , most commonly with fasting plasma glucose and glycated hemoglobin .",我们使用现代血糖标准收集了一个多样化的糖尿病高风险队列，其高血糖模式与临床实践中糖尿病前期的诊断方式非常匹配，最常见的是空腹血糖和糖化血红蛋白。,0.4375,"['diabetes', 'glucose', 'plasma', 'pattern', 'high risk', 'hemoglobin', 'fasting', 'clinical', 'matching', 'practice', 'cohort', 'with', 'assemble', 'to', 'and', 'we']","['diabetes', 'pattern', 'hemoglobin', 'clinical', 'matching', 'practice', 'assemble']",1374,"['我们使用了当代的血糖标准,以结合糖尿病高风险的多样性,与超血糖模式密切相匹配,在临床实践中如何诊断前糖尿病,最常见的是禁食的血糖和血糖化血糖。']",0.3125,"['diabetes', 'glucose', 'plasma', 'pattern', 'high risk', 'hemoglobin', 'fasting', 'clinical', 'matching', 'practice', 'cohort', 'with', 'assemble', 'to', 'and', 'we']","['diabetes', 'pattern', 'clinical', 'matching', 'practice']",,
1387,1375,"our cohort was recruited at a constant rate throughout the calendar year , which reduced the potential of confounding by seasonal variability .",我们的队列在整个日历年中以恒定的速度招募，这减少了季节性变化造成混淆的可能性。,0.4,"['a', 'year', 'rate', 'variability', 'potential', 'constant', 'seasonal', 'calendar', 'cohort', 'by']","['year', 'constant', 'calendar', 'by']",1375,"['我们的联盟在整个日历年间以稳定的速度招募,从而减少了季节性变化的潜力。']",0.4,"['a', 'year', 'rate', 'variability', 'potential', 'constant', 'seasonal', 'calendar', 'cohort', 'by']","['year', 'potential', 'calendar', 'by']",,
1388,1376,the high percentage of participants with adequate levels of vitamin D may have limited the ability of the trial to detect a significant effect .,维生素 D 水平充足的高比例参与者可能限制了试验检测显着效果的能力。,0.3571428571428571,"['percentage', 'vitamin', 'detect', 'trial', 'D', 'effect', 'adequate', 'ability', 'with', 'vitamin D', 'limited', 'have', 'to', 'high']","['vitamin', 'detect', 'effect', 'ability', 'high']",1376,"['具有足够的维生素D水平的参与者的高比例可能限制了试验的能力,以检测显著的效果。']",0.5714285714285714,"['percentage', 'vitamin', 'detect', 'trial', 'D', 'effect', 'adequate', 'ability', 'with', 'vitamin D', 'limited', 'have', 'to', 'high']","['vitamin', 'detect', 'effect', 'adequate', 'ability', 'vitamin D', 'have', 'high']",,
1389,1377,"the vitamin D dose of 4000 IU per day is the recommended upper intake level to avert potential toxicity , 23 although data from large trials on the safety on this dose have been scant .",每天 4000 IU 的维生素 D 剂量是避免潜在毒性的推荐摄入量上限，23 尽管有关该剂量安全性的大型试验数据很少。,0.5333333333333333,"['safety', 'intake', 'toxicity', 'vitamin', 'data', 'potential', 'upper', 'large', 'D', 'level', 'vitamin D', 'dose', 'on', 'have', 'this']","['safety', 'toxicity', 'vitamin', 'data', 'D', 'dose', 'have', 'this']",1377,"['维生素D的每日剂量为4000 IU,是预防潜在毒性的建议上级摄入量,23虽然对该剂量的安全性进行了大规模测试的数据已经被扫描。']",0.5333333333333333,"['safety', 'intake', 'toxicity', 'vitamin', 'data', 'potential', 'upper', 'large', 'D', 'level', 'vitamin D', 'dose', 'on', 'have', 'this']","['safety', 'toxicity', 'vitamin', 'data', 'D', 'vitamin D', 'dose', 'this']",,
1390,1378,"in conclusion , among persons at high risk for type 2 diabetes not selected for vitamin D insufficiency , vitamin D3 supplementation at a dose of 4000 IU per day did not result in a significantly lower risk of diabetes than placebo .",总之，在没有选择维生素 D 不足的 2 型糖尿病高风险人群中，每天补充 4000 IU 剂量的维生素 D3 并没有导致患糖尿病的风险显着低于安慰剂。,0.5714285714285714,"['diabetes', 'type', 'placebo', 'vitamin', 'insufficiency', '2', 'high risk', 'lower', 'D', 'result', 'conclusion', 'vitamin D', 'at', 'dose']","['diabetes', 'type', 'placebo', 'vitamin', 'insufficiency', '2', 'at', 'dose']",1378,"['在结论中,在患2型糖尿病的风险较高的人中,维生素D3补充剂的剂量每天4000 IU并不导致糖尿病的风险显著低于 placebo。']",0.5714285714285714,"['diabetes', 'type', 'placebo', 'vitamin', 'insufficiency', '2', 'high risk', 'lower', 'D', 'result', 'conclusion', 'vitamin D', 'at', 'dose']","['diabetes', 'type', 'vitamin', '2', 'conclusion', 'vitamin D', 'at', 'dose']",,
1391,1379,"to examine this potential association further , investigators studied data from more than 500,000 participants in the multinational European Prospective Investigation into Cancer and Nutrition ( EPIC ) study .","为了进一步研究这种潜在关联，研究人员研究了欧洲癌症与营养前瞻性跨国调查 (EPIC) 研究中超过 500,000 名参与者的数据。",0.4545454545454545,"['cancer', 'data', 'investigation', 'nutrition', 'potential', 'association', 'study', 'this', 'to', 'and', 'examine']","['cancer', 'data', 'investigation', 'nutrition', 'association']",1379,"['为了进一步研究这种潜在的协会,研究人员研究了超过500000名参与者对癌症和营养的跨国欧洲展望调查(EPIC)的数据。']",0.4545454545454545,"['cancer', 'data', 'investigation', 'nutrition', 'potential', 'association', 'study', 'this', 'to', 'and', 'examine']","['cancer', 'data', 'investigation', 'nutrition', 'potential']",,
1392,1380,the inverse dietary associations were strongest for colon cancer .,结肠癌的反向饮食关联最强。,0.6,"['cancer', 'colon', 'dietary', 'inverse', 'colon cancer']","['cancer', 'colon', 'colon cancer']",1380,['相反的饮食协会是肠道癌最强的。'],0.4,"['cancer', 'colon', 'dietary', 'inverse', 'colon cancer']","['cancer', 'inverse']",,
1393,1381,"regular consumption of fish has several health benefits , and CRC prevention can now be added to the list .",经常食用鱼有多种健康益处，现在可以将 CRC 预防添加到列表中。,0.4444444444444444,"['consumption', 'fish', 'health', 'prevention', 'be', 'regular', 'list', 'to', 'and']","['fish', 'health', 'prevention', 'be']",1381,"['经常吃鱼有几个健康益处,CRC预防现在可以添加到列表中。']",0.4444444444444444,"['consumption', 'fish', 'health', 'prevention', 'be', 'regular', 'list', 'to', 'and']","['fish', 'health', 'prevention', 'be']",,
1394,1382,"practically , patients seeking to modify their CRC risk should consider the Mediterranean diet , which includes whole grains , fruits , vegetables , nuts , olive oil , fish , and seafood and restricts consumption of red meat .",实际上，寻求降低 CRC 风险的患者应考虑地中海饮食，其中包括全麦、水果、蔬菜、坚果、橄榄油、鱼和海鲜，并限制红肉的摄入。,0.4666666666666667,"['oil', 'grains', 'consumption', 'fish', 'diet', 'seafood', 'olive oil', 'red', 'risk', 'mediterranean diet', 'modify', 'whole', 'to', 'and', 'vegetables']","['oil', 'fish', 'diet', 'seafood', 'olive oil', 'risk', 'mediterranean diet']",1382,"['實際上,尋求改變他們的CRC風險的患者應該考慮地中海飲食,其中包括整個穀物、水果、蔬菜、果汁、橄欖油、魚類和海鮮,並限制紅肉的消費。']",0.1333333333333333,"['oil', 'grains', 'consumption', 'fish', 'diet', 'seafood', 'olive oil', 'red', 'risk', 'mediterranean diet', 'modify', 'whole', 'to', 'and', 'vegetables']","['oil', 'whole']",,
1395,1383,measurements of nonfasting total and HDL cholesterol levels seem to be enough to obtain an accurate estimate of cardiovascular risk .,非空腹总胆固醇和 HDL 胆固醇水平的测量似乎足以准确估计心血管风险。,0.3,"['cholesterol', 'cardiovascular', 'HDL', 'total', 'accurate', 'be', 'risk', 'estimate', 'obtain', 'and']","['cholesterol', 'cardiovascular', 'risk']",1383,['不损失总和HDL胆固醇水平的测量似乎足以获得心血管风险的准确估计。'],0.4,"['cholesterol', 'cardiovascular', 'HDL', 'total', 'accurate', 'be', 'risk', 'estimate', 'obtain', 'and']","['cholesterol', 'cardiovascular', 'risk', 'obtain']",,
1396,1384,"most calculators of cardiovascular disease ( CVD ) risk include measures of total cholesterol , HDL cholesterol , or their combination in risk prediction models .",大多数心血管疾病 (CVD) 风险计算器包括总胆固醇、高密度脂蛋白胆固醇或它们在风险预测模型中的组合。,0.7777777777777778,"['cholesterol', 'combination', 'disease', 'cardiovascular', 'HDL', 'total', 'cardiovascular disease', 'risk', 'CVD']","['cholesterol', 'combination', 'disease', 'cardiovascular', 'HDL', 'cardiovascular disease', 'risk']",1384,['大多数心血管疾病(CVD)风险计算器包括总胆固醇、HDL胆固醇或风险预测模型的测量。'],0.5555555555555556,"['cholesterol', 'combination', 'disease', 'cardiovascular', 'HDL', 'total', 'cardiovascular disease', 'risk', 'CVD']","['cholesterol', 'disease', 'cardiovascular', 'cardiovascular disease', 'risk']",,
1397,1385,"debate continues , however , about whether other lipid parameters can improve prediction of CVD and about the usefulness of nonfasting measurements .",然而，关于其他脂质参数是否可以提高 CVD 的预测以及非空腹测量的有用性的争论仍在继续。,0.5,"['lipid', 'debate', 'CVD', 'and']","['lipid', 'and']",1385,"['然而,讨论是否有其他脂肪参数可以改善CVD的预测,以及不损害测量的有用性。']",0.25,"['lipid', 'debate', 'CVD', 'and']",['and'],,
1398,1386,"during a median of 9 years , an incident CVD event was reported in 6216 participants not taking a statin ( 1656 fatal events ) and in 3515 patients taking a statin .",在中位数 9 年期间，6216 名未服用他汀类药物的参与者（1656 例死亡事件）和 3515 名服用他汀类药物的患者报告了 CVD 事件。,0.125,"['statin', 'median', 'taking', 'fatal', 'incident', 'event', 'CVD', 'and']",['incident'],1386,"['在中期9年内,在6216名不服用静素的参与者(1656个致命事件)和3515名服用静素的患者中报告了一起CVD事件。']",0.125,"['statin', 'median', 'taking', 'fatal', 'incident', 'event', 'CVD', 'and']",['incident'],,
1399,1387,"each SD increase in HDL and ApoA1 had a similar association with reduced CVD events ( HR , 0.81 ) .",HDL 和 ApoA1 的每一个 SD 增加都与 CVD 事件减少有相似的关联（HR，0.81）。,0.2,"['a', 'association', 'HDL', 'increase', 'with', 'SD', 'CVD', 'each', 'and', 'similar']","['association', 'similar']",1387,"['HDL 和 ApoA1 的每個 SD 增長都與減少的 CVD 事件( HR, 0.81 )相似。']",0.0,"['a', 'association', 'HDL', 'increase', 'with', 'SD', 'CVD', 'each', 'and', 'similar']",[],,
1400,1388,"in the model using classical risk factors plus total cholesterol and HDL , the investigators found that risk prediction did not further improve with the addition of ApoB or any other LDL measure .",在使用经典风险因素加上总胆固醇和 HDL 的模型中，研究人员发现风险预测并没有随着 ApoB 或任何其他 LDL 指标的增加而进一步改善。,0.5384615384615384,"['cholesterol', 'model', 'plus', 'addition', 'HDL', 'total', 'LDL', 'risk', 'measure', 'with', 'that', 'in', 'and']","['cholesterol', 'model', 'plus', 'addition', 'risk', 'measure', 'and']",1388,"['在使用经典风险因素以及整体胆固醇和HDL的模型中,研究人员发现风险预测与添加ApoB或其他LDL测量没有进一步改善。']",0.4615384615384615,"['cholesterol', 'model', 'plus', 'addition', 'HDL', 'total', 'LDL', 'risk', 'measure', 'with', 'that', 'in', 'and']","['cholesterol', 'model', 'plus', 'addition', 'risk', 'measure']",,
1401,1389,findings were similar in participants taking a statin .,服用他汀类药物的参与者的研究结果相似。,0.0,"['statin', 'taking', 'similar']",[],1389,['结果类似于参加者服用一个静素。'],0.0,"['statin', 'taking', 'similar']",[],,
1402,1390,"these data suggest that incorporation of parameters beyond classical variables , HDL , and total cholesterol does not improve risk prediction .",这些数据表明，结合经典变量、HDL 和总胆固醇以外的参数并不能改善风险预测。,0.4444444444444444,"['cholesterol', 'incorporation', 'data', 'HDL', 'total', 'risk', 'suggest', 'that', 'and']","['cholesterol', 'incorporation', 'data', 'risk']",1390,"['这些数据表明,超越经典变量、HDL和整体胆固醇的参数的集成不会改善风险预测。']",0.3333333333333333,"['cholesterol', 'incorporation', 'data', 'HDL', 'total', 'risk', 'suggest', 'that', 'and']","['cholesterol', 'data', 'risk']",,
1403,1391,"furthermore , no data suggest that measurement of additional parameters would change therapeutic recommendations .",此外，没有数据表明额外参数的测量会改变治疗建议。,0.25,"['data', 'no', 'therapeutic', 'measurement', 'additional', 'change', 'suggest', 'that']","['data', 'measurement']",1391,"['此外,没有数据表明测量额外的参数会改变治疗建议。']",0.375,"['data', 'no', 'therapeutic', 'measurement', 'additional', 'change', 'suggest', 'that']","['data', 'measurement', 'additional']",,
1404,1392,resection of additional tissue around the tumor cavity significantly reduces the need to return to surgery for margin control .,切除肿瘤腔周围的额外组织显着减少了返回手术以控制边缘的需要。,0.6666666666666666,"['tissue', 'control', 'cavity', 'margin', 'need', 'tumor', 'surgery', 'resection', 'additional', 'return', 'around', 'to']","['tissue', 'control', 'cavity', 'margin', 'need', 'tumor', 'surgery', 'resection']",1392,['肿瘤洞周围的额外组织的恢复显著减少了返回外科手术的必要性。'],0.3333333333333333,"['tissue', 'control', 'cavity', 'margin', 'need', 'tumor', 'surgery', 'resection', 'additional', 'return', 'around', 'to']","['tissue', 'cavity', 'tumor', 'surgery']",,
1405,1393,randomization occurred intraoperatively after completion of standard PM .,随机化发生在术中完成标准 PM 后。,1.0,"['standard', 'randomization', 'after', 'completion']","['standard', 'randomization', 'after', 'completion']",1393,['随机化发生在标准PM完成后内手术。'],1.0,"['standard', 'randomization', 'after', 'completion']","['standard', 'randomization', 'after', 'completion']",,
1406,1394,"as expected , significantly more tissue was removed with CSM resection than without it .",正如预期的那样，CSM 切除术切除的组织明显多于未切除的组织。,0.6,"['tissue', 'resection', 'as', 'with', 'without']","['tissue', 'resection', 'as']",1394,"['正如预期的那样,通过CSM复制,有显著更多的组织被移除,而不是没有它。']",0.4,"['tissue', 'resection', 'as', 'with', 'without']","['tissue', 'as']",,
1407,1395,longer durations were acceptable if patients had not met clinical stability criteria by the end of the shortest effective duration .,如果患者在最短有效持续时间结束时未达到临床稳定性标准，则可以接受更长的持续时间。,0.5,"['clinical', 'end', 'duration', 'acceptable', 'met', 'stability', 'if', 'by']","['clinical', 'duration', 'stability', 'by']",1395,"['更长的寿命是可接受的,如果患者在最短有效期结束时未满足临床稳定性标准。']",0.375,"['clinical', 'end', 'duration', 'acceptable', 'met', 'stability', 'if', 'by']","['clinical', 'acceptable', 'stability']",,
1408,1396,"discharge summary documentation of total recommended antibiotic duration was associated with significantly less excess therapy ( adjusted rate ratio , 0.78 ) .",总推荐抗生素持续时间的出院总结文件与显着减少的过量治疗相关（调整后的比率，0.78）。,0.5833333333333334,"['discharge', 'antibiotic', 'excess', 'documentation', 'rate', 'ratio', 'total', 'therapy', 'associated', 'duration', 'with', 'adjusted rate']","['discharge', 'antibiotic', 'excess', 'rate', 'ratio', 'therapy', 'duration']",1396,"['排放总体建议的抗生素寿命的总结文件与显著较少的过量治疗(调整率比例,0.78 )有关。']",0.5,"['discharge', 'antibiotic', 'excess', 'documentation', 'rate', 'ratio', 'total', 'therapy', 'associated', 'duration', 'with', 'adjusted rate']","['discharge', 'antibiotic', 'excess', 'rate', 'ratio', 'therapy']",,
1409,1397,"excess antibiotic duration did not lead to more Clostridium difficile infections , hospital revisits , or deaths .",抗生素使用时间过长并没有导致更多的艰难梭菌感染、再次住院或死亡。,0.25,"['antibiotic', 'excess', 'lead', 'clostridium', 'clostridium difficile', 'duration', 'hospital', 'to']","['antibiotic', 'clostridium difficile']",1397,"['过量抗生素的持续时间不会导致更多的Clostridium difficile感染,医院检查,或死亡。']",0.5,"['antibiotic', 'excess', 'lead', 'clostridium', 'clostridium difficile', 'duration', 'hospital', 'to']","['antibiotic', 'excess', 'duration', 'hospital']",,
1410,1398,a large analysis found that both measurements were independent predictors of adverse outcomes .,一项大型分析发现，这两项测量都是不良结果的独立预测因子。,0.1666666666666666,"['a', 'analysis', 'large', 'adverse', 'independent', 'that']",['analysis'],1398,"['一项大型分析发现,这两项测量都是独立预测不良结果。']",0.1666666666666666,"['a', 'analysis', 'large', 'adverse', 'independent', 'that']",['analysis'],,
1411,1399,"fifty years ago , diastolic blood pressure ( BP ) was thought to be more predictive of adverse cardiovascular ( CV ) events than systolic BP , but epidemiologic studies eventually overturned that idea .",五十年前，人们认为舒张压 (BP) 比收缩压更能预测不良心血管 (CV) 事件，但流行病学研究最终推翻了这一观点。,0.1538461538461538,"['pressure', 'cardiovascular', 'blood', 'blood pressure', 'thought', 'be', 'diastolic', 'adverse', 'idea', 'systolic', 'predictive', 'that', 'but']","['cardiovascular', 'but']",1399,"['五十年前,神经血压(BP)被认为比神经血压(BP)更有预测,但流行病学研究最终推翻了这个想法。']",0.1538461538461538,"['pressure', 'cardiovascular', 'blood', 'blood pressure', 'thought', 'be', 'diastolic', 'adverse', 'idea', 'systolic', 'predictive', 'that', 'but']","['blood pressure', 'but']",,
1412,1400,"more recently , systolic BP has been deemed more important , although both systolic and diastolic BP targets are recommended in guidelines ( NEJM JW Gen Med Dec 15 2017 and J Am Coll Cardiol 2018 ; 71 : e127 ) .",最近，收缩压被认为更重要，尽管指南中推荐了收缩压和舒张压目标（NEJM JW Gen Med 2017 年 12 月 15 日和 J Am Coll Cardiol 2018；71：e127）。,0.0,"['coll', 'diastolic', 'systolic', 'gen', 'in', 'and', 'med']",[],1400,"['最近,系统性BP被认为更重要,尽管系统性和神经性BP目标在指南中推荐(NEJM JW Gen Med Dec 15 2017和J Am Coll Cardiol 2018;71:e127)。']",0.0,"['coll', 'diastolic', 'systolic', 'gen', 'in', 'and', 'med']",[],,
1413,1401,"in multivariable analyses , systolic and diastolic BP were each associated independently with increased risk for CV events , but the effect was greater for systolic than for diastolic BP .",在多变量分析中，收缩压和舒张压均与 CV 事件风险增加独立相关，但收缩压的影响大于舒张压。,0.2,"['diastolic', 'associated', 'risk', 'systolic', 'effect', 'with', 'each', 'in', 'but', 'and']","['risk', 'but']",1401,"['在多变的分析中,系统性和神经性BP分别与CV事件的风险增加有关,但对神经性比神经性BP的影响更大。']",0.2,"['diastolic', 'associated', 'risk', 'systolic', 'effect', 'with', 'each', 'in', 'but', 'and']","['risk', 'but']",,
1414,1402,"for diastolic BPs of 81 and 96 mm Hg , CV event rates were 1.9 % and 3.6 % , respectively .",对于 81 和 96 mm Hg 的舒张压，CV 事件发生率分别为 1.9% 和 3.6%。,0.0,"['diastolic', 'event', 'and']",[],1402,['对于 81 和 96 毫米 Hg 的 Diastolic BP 的 CV 事件率为 1.9% 和 3.6% 相应。'],0.0,"['diastolic', 'event', 'and']",[],,
1415,1403,relative risks for CV events ( but not necessarily absolute risks ) were similar regardless of use of antihypertensive medication .,无论是否使用抗高血压药物，心血管事件的相对风险（但不一定是绝对风险）都是相似的。,0.6666666666666666,"['antihypertensive', 'absolute', 'relative', 'medication', 'but', 'similar']","['antihypertensive', 'absolute', 'but', 'similar']",1403,['CV事件的相对风险(但不一定是绝对的风险)与使用抗高血压药物相似。'],0.5,"['antihypertensive', 'absolute', 'relative', 'medication', 'but', 'similar']","['antihypertensive', 'absolute', 'but']",,
1416,1404,"this interesting study is more than an assessment of a single blood pressure value , but also an evaluation of the weighted average BP over time , indicating the BP burden .",这项有趣的研究不仅仅是对单一血压值的评估，也是对随时间推移的加权平均血压的评估，表明血压负担。,0.4117647058823529,"['a', 'pressure', 'average', 'evaluation', 'value', 'blood', 'study', 'blood pressure', 'time', 'assessment', 'interesting', 'weighted average', 'this', 'single', 'over', 'but', 'burden']","['average', 'blood pressure', 'time', 'assessment', 'interesting', 'this', 'single']",1404,"['这项有趣的研究不仅仅是一项单血压值的评估,而且还是一项时间重量的平均BP的评估,表明BP的负担。']",0.4705882352941176,"['a', 'pressure', 'average', 'evaluation', 'value', 'blood', 'study', 'blood pressure', 'time', 'assessment', 'interesting', 'weighted average', 'this', 'single', 'over', 'but', 'burden']","['average', 'blood pressure', 'time', 'assessment', 'interesting', 'this', 'single', 'but']",,
1417,1405,I wonder if variations in the patterns of BP carry additional prognostic importance and whether certain treatments were more effective in mitigating risk .,我想知道 BP 模式的变化是否具有额外的预后重要性，以及某些治疗是否能更有效地降低风险。,0.2222222222222222,"['wonder', 'prognostic', 'risk', 'additional', 'certain', 'I', 'carry', 'if', 'and']","['risk', 'additional']",1405,"['我想知道BP模式的变化是否具有额外的预测意义,以及某些治疗是否在降低风险方面更有效。']",0.3333333333333333,"['wonder', 'prognostic', 'risk', 'additional', 'certain', 'I', 'carry', 'if', 'and']","['prognostic', 'risk', 'additional']",,
1418,1406,"I would have liked to see how the prognostic importance of the weighted average compared with a single measurement at the beginning of the study period , which is how many studies are conducted .",我很想看看加权平均数与研究期开始时的单一测量相比的预后重要性如何，即进行了多少研究。,0.3076923076923077,"['period', 'a', 'average', 'study', 'measurement', 'prognostic', 'weighted average', 'with', 'at', 'I', 'have', 'single', 'to']","['period', 'average', 'measurement', 'single']",1406,"['我想看到重量平均值的预测重要性与研究期间开始时单一测量相比,这就是进行的研究数量。']",0.3846153846153846,"['period', 'a', 'average', 'study', 'measurement', 'prognostic', 'weighted average', 'with', 'at', 'I', 'have', 'single', 'to']","['period', 'average', 'measurement', 'prognostic', 'single']",,
1419,1407,"to stratify risks , it may be that we should be using weighted averages , which could be calculated from electronic medical records .",为了对风险进行分层，我们可能应该使用加权平均数，这可以从电子病历中计算出来。,0.0,"['medical', 'be', 'electronic', 'that', 'to', 'we']",[],1407,"['要分裂风险,我们可能应该使用重量平均值,可以从电子医学记录中计算。']",0.0,"['medical', 'be', 'electronic', 'that', 'to', 'we']",[],,
1420,1408,"as new agents become incorporated into neoadjuvant and adjuvant regimens , patients who develop disease recurrence continue to need other options .",随着新药物被纳入新辅助和辅助治疗方案，出现疾病复发的患者继续需要其他选择。,0.3333333333333333,"['disease', 'need', 'who', 'adjuvant', 'develop', 'recurrence', 'options', 'continue', 'become', 'to', 'and', 'new']","['disease', 'need', 'continue', 'new']",1408,"['随着新物质被纳入新添加剂和添加剂的饮食,患有疾病重复的患者仍然需要其他选项。']",0.25,"['disease', 'need', 'who', 'adjuvant', 'develop', 'recurrence', 'options', 'continue', 'become', 'to', 'and', 'new']","['disease', 'need', 'new']",,
1421,1409,trastuzumab duocarmazine was administered intravenously on day 1 every 3 weeks and continued until disease progression or unacceptable toxicity .,trastuzumab duocarmazine 在每 3 周的第 1 天静脉内给药，一直持续到疾病进展或出现不可接受的毒性。,0.75,"['disease', 'toxicity', '1', 'intravenously', 'progression', '3', 'unacceptable', 'and']","['disease', 'toxicity', '1', 'intravenously', 'progression', 'unacceptable']",1409,"['trastuzumab duocarmazine 每 3 周每 1 天内服用,直到疾病进展或不可接受的毒性。']",0.625,"['disease', 'toxicity', '1', 'intravenously', 'progression', '3', 'unacceptable', 'and']","['disease', 'toxicity', '1', 'progression', 'unacceptable']",,
1422,1410,"among the 48 breast cancer patients , 16 ( 33 % ) had a partial response .",在 48 名乳腺癌患者中，16 名 (33%) 有部分反应。,0.6,"['a', 'cancer', 'breast cancer', 'response', 'partial']","['cancer', 'breast cancer', 'response']",1410,"['在48名乳腺癌患者中,16(33%)有部分反应。']",0.6,"['a', 'cancer', 'breast cancer', 'response', 'partial']","['cancer', 'breast cancer', 'response']",,
1423,1411,"most breast cancer patients had received prior trastuzumab or trastuzumab emtansine , and a smaller fraction had received pertuzumab and lapatinib .",大多数乳腺癌患者之前接受过曲妥珠单抗或曲妥珠单抗emtansine，一小部分患者接受过帕妥珠单抗和拉帕替尼。,0.5714285714285714,"['a', 'cancer', 'breast cancer', 'fraction', 'prior', 'pertuzumab', 'and']","['cancer', 'breast cancer', 'fraction', 'pertuzumab']",1411,"['大多数乳腺癌患者早已服用过 trastuzumab 或 trastuzumab emtansine,而较小的分数则服用过 pertuzumab 和 lapatinib。']",0.4285714285714285,"['a', 'cancer', 'breast cancer', 'fraction', 'prior', 'pertuzumab', 'and']","['cancer', 'breast cancer', 'and']",,
1424,1412,"for patients who develop disease recurrence , additional options are needed .",对于疾病复发的患者，需要额外的选择。,0.3333333333333333,"['disease', 'who', 'develop', 'additional', 'recurrence', 'options']","['disease', 'additional']",1412,"['对于患有疾病重复的患者,需要额外的选项。']",0.3333333333333333,"['disease', 'who', 'develop', 'additional', 'recurrence', 'options']","['disease', 'additional']",,
1425,1413,"patients with incidental PE , including those with subsegmental involvement , had increased recurrence rates , despite treatment .",尽管进行了治疗，但偶发 PE 的患者，包括亚节段受累的患者，复发率增加。,0.1428571428571428,"['incidental', 'treatment', 'recurrence', 'involvement', 'with', 'despite', 'PE']",['treatment'],1413,"['患有偶然的PE的患者,包括患有子部分参与的患者,尽管接受治疗,但重复率有所增加。']",0.2857142857142857,"['incidental', 'treatment', 'recurrence', 'involvement', 'with', 'despite', 'PE']","['incidental', 'treatment']",,
1426,1414,pulmonary embolism ( PE ) is often discovered incidentally in oncology patients during their cancer staging and surveillance .,肺栓塞 (PE) 通常是在肿瘤患者的癌症分期和监测过程中偶然发现的。,0.5,"['cancer', 'pulmonary', 'surveillance', 'embolism', 'pulmonary embolism', 'PE', 'in', 'and']","['cancer', 'surveillance', 'embolism', 'pulmonary embolism']",1414,['肺胚胎(PE)经常在癌症阶段和监测期间在肿瘤病人中偶然发现。'],0.25,"['cancer', 'pulmonary', 'surveillance', 'embolism', 'pulmonary embolism', 'PE', 'in', 'and']","['cancer', 'surveillance']",,
1427,1415,"treatment recommendations are typically based on retrospective data , and it is unclear whether outcomes in patients with subsegmental PE differ from those with more proximal PEs .",治疗建议通常基于回顾性数据，尚不清楚亚段 PE 患者的结局是否与近端 PE 患者不同。,0.3,"['pes', 'data', 'proximal', 'treatment', 'differ', 'with', 'on', 'PE', 'in', 'and']","['data', 'proximal', 'treatment']",1415,"['治疗建议通常是基于逆转数据的,并且不清楚患有分子PE的患者的结果是否不同于患有更接近PE的患者。']",0.2,"['pes', 'data', 'proximal', 'treatment', 'differ', 'with', 'on', 'PE', 'in', 'and']","['data', 'treatment']",,
1428,1416,subgroup analyses were conducted by site of PE ( subsegmental vs. more proximal ) and intensity of anticoagulation ( prophylactic / intermediate vs. therapeutic dosing ) .,亚组分析是根据 PE 部位（亚节段与更近端）和抗凝强度（预防/中间与治疗剂量）进行的。,0.1666666666666666,"['anticoagulation', 'site', '/', 'proximal', 'therapeutic', 'intensity', 'subgroup', 'intermediate', 'prophylactic', 'PE', 'by', 'and']","['anticoagulation', 'proximal']",1416,['子组分析是由PE(分区对比更接近)和抗凝固强度(预防性/中间对比治疗剂量)进行的。'],0.1666666666666666,"['anticoagulation', 'site', '/', 'proximal', 'therapeutic', 'intensity', 'subgroup', 'intermediate', 'prophylactic', 'PE', 'by', 'and']","['anticoagulation', 'by']",,
1429,1417,"eligible patients were those with active malignancy ( colorectal 21 % , lung 15 % , gynecological 11 % ; 64 % with metastatic disease ) , and a first incidental PE within 2 months of inclusion .",符合条件的患者是患有活动性恶性肿瘤（结直肠癌 21%，肺部 15%，妇科疾病 11%；64% 有转移性疾病），并且在入组后 2 个月内首次发生 PE 的患者。,0.3333333333333333,"['lung', 'disease', 'malignancy', 'inclusion', '2', 'gynecological', 'incidental', 'active', 'metastatic', 'with', 'PE', 'and', 'first', 'colorectal', 'eligible']","['lung', 'disease', 'malignancy', '2', 'active']",1417,"['合格的患者是活性恶性症(染色体21%,肺15%,妇科11%;甲状腺疾病64%),并在接入后2个月内获得第一次偶然的PE。']",0.4666666666666667,"['lung', 'disease', 'malignancy', 'inclusion', '2', 'gynecological', 'incidental', 'active', 'metastatic', 'with', 'PE', 'and', 'first', 'colorectal', 'eligible']","['lung', 'disease', 'malignancy', '2', 'incidental', 'first', 'eligible']",,
1430,1418,most patients ( 97 % ) were anticoagulated ; median duration of treatment was 216 days .,大多数患者 (97%) 进行了抗凝治疗；中位治疗持续时间为 216 天。,0.6666666666666666,"['median', 'treatment', 'duration']","['treatment', 'duration']",1418,"['大多数患者(97%)是抗凝固剂,平均治疗时间为216天。']",0.3333333333333333,"['median', 'treatment', 'duration']",['treatment'],,
1431,1419,bleeding and PE were the cause of death in 3.8 % of patients .,出血和肺栓塞是 3.8% 患者的死因。,0.5,"['bleeding', 'death', 'cause', 'cause of death', 'PE', 'and']","['bleeding', 'death', 'cause of death']",1419,['出血和PE是患者3.8%的死亡原因。'],0.5,"['bleeding', 'death', 'cause', 'cause of death', 'PE', 'and']","['bleeding', 'death', 'cause']",,
1432,1420,recurrence rates were increased despite treatment ( 4.9 % ) ; rates were comparable between patients with subsegmental and proximal PE and did not differ by intensity of anticoagulation .,尽管接受了治疗，复发率还是增加了 (4.9%)；亚段和近端 PE 患者的发生率相当，并且抗凝强度没有差异。,0.2727272727272727,"['anticoagulation', 'proximal', 'treatment', 'differ', 'intensity', 'recurrence', 'with', 'despite', 'PE', 'by', 'and']","['anticoagulation', 'proximal', 'treatment']",1420,"['尽管治疗,重复率增加了(4.9%);在患有子分子和近分子PE的患者中,重复率是相似的,并且不因抗凝固的强度而有所不同。']",0.2727272727272727,"['anticoagulation', 'proximal', 'treatment', 'differ', 'intensity', 'recurrence', 'with', 'despite', 'PE', 'by', 'and']","['anticoagulation', 'treatment', 'and']",,
1433,1421,this prospective study supports the current practice of anticoagulating cancer patients with incidental PE .,这项前瞻性研究支持目前对伴有 PE 的癌症患者进行抗凝治疗的做法。,0.2222222222222222,"['cancer', 'incidental', 'study', 'prospective study', 'practice', 'current', 'with', 'PE', 'this']","['cancer', 'prospective study']",1421,['这项有前途的研究支持患有偶然的PE的抗凝固癌症患者的当前实践。'],0.3333333333333333,"['cancer', 'incidental', 'study', 'prospective study', 'practice', 'current', 'with', 'PE', 'this']","['cancer', 'incidental', 'practice']",,
1434,1422,"here , the majority were treated with LMWHs ; moving forward , more patients with incidental PE will be treated with direct oral anticoagulants , which can improve quality of life , as patients can avoid the burden of injections .",在这里，大多数人接受了 LMWHs 治疗；今后，更多的偶发 PE 患者将接受直接口服抗凝剂治疗，这可以提高生活质量，因为患者可以避免注射的负担。,0.4705882352941176,"['life', 'quality', 'oral', 'incidental', 'be', 'forward', 'quality of life', 'majority', 'as', 'will', 'with', 'direct', 'injections', 'PE', 'avoid', 'anticoagulants', 'burden']","['life', 'quality', 'be', 'quality of life', 'majority', 'direct', 'avoid', 'anticoagulants']",1422,"['在这里,大多数人用LMWH治疗;前进,更多患有偶然的PE的患者将用直接口服抗凝固剂治疗,这可以改善生活质量,因为患者可以避免注射的负担。']",0.4705882352941176,"['life', 'quality', 'oral', 'incidental', 'be', 'forward', 'quality of life', 'majority', 'as', 'will', 'with', 'direct', 'injections', 'PE', 'avoid', 'anticoagulants', 'burden']","['life', 'quality', 'incidental', 'be', 'quality of life', 'majority', 'direct', 'avoid']",,
1435,1423,"however , early loss of glycemic control has been observed with metformin monotherapy .",然而，已观察到二甲双胍单药治疗会导致血糖早期失控。,0.6,"['control', 'early', 'loss', 'with', 'metformin']","['control', 'early', 'metformin']",1423,"['然而,早期损失的血糖控制已被观察到与甲状腺素单治疗。']",0.6,"['control', 'early', 'loss', 'with', 'metformin']","['control', 'early', 'loss']",,
1436,1424,whether liraglutide added to metformin ( with or without basal insulin treatment ) is safe and effective in youth with type 2 diabetes is unknown .,liraglutide 添加到二甲双胍（有或没有基础胰岛素治疗）中是否对患有 2 型糖尿病的青少年安全有效尚不清楚。,0.4615384615384615,"['insulin', 'diabetes', 'type', 'basal', '2', 'treatment', 'youth', 'with', 'liraglutide', 'metformin', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', '2', 'treatment', 'metformin']",1424,['是否添加到甲状腺素(与或没有基本胰岛素治疗)是安全和有效的青少年2型糖尿病尚不清楚。'],0.3846153846153846,"['insulin', 'diabetes', 'type', 'basal', '2', 'treatment', 'youth', 'with', 'liraglutide', 'metformin', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', '2', 'treatment']",,
1437,1425,all the patients received metformin during the trial .,所有患者在试验期间都接受了二甲双胍。,0.3333333333333333,"['trial', 'metformin', 'all']",['metformin'],1425,['所有患者在测试期间都接受了甲状腺素。'],0.0,"['trial', 'metformin', 'all']",[],,
1438,1426,the primary end point was the change from baseline in the glycated hemoglobin level after 26 weeks .,主要终点是 26 周后糖化血红蛋白水平相对于基线的变化。,0.625,"['baseline', 'hemoglobin', 'hemoglobin level', 'primary', 'after', 'end', 'point', 'change']","['baseline', 'hemoglobin', 'after', 'point', 'change']",1426,['主要的终点是从基线到血糖血糖水平的变化26周后。'],0.625,"['baseline', 'hemoglobin', 'hemoglobin level', 'primary', 'after', 'end', 'point', 'change']","['baseline', 'primary', 'after', 'point', 'change']",,
1439,1427,secondary end points included the change in fasting plasma glucose level .,次要终点包括空腹血糖水平的变化。,0.4285714285714285,"['glucose', 'plasma', 'end points', 'fasting', 'secondary', 'level', 'change']","['end points', 'level', 'change']",1427,['二级终点包括禁食血糖水平的变化。'],0.4285714285714285,"['glucose', 'plasma', 'end points', 'fasting', 'secondary', 'level', 'change']","['end points', 'level', 'change']",,
1440,1428,safety was assessed throughout the course of the trial .,在整个试验过程中评估了安全性。,0.5,"['safety', 'trial', 'course', 'assessed']","['safety', 'course']",1428,"['整个审判期间,安全被评估。']",0.5,"['safety', 'trial', 'course', 'assessed']","['safety', 'trial']",,
1441,1429,"of 135 patients who underwent randomization , 134 received at least one dose of liraglutide ( 66 patients ) or placebo ( 68 patients ) .",在接受随机分组的 135 名患者中，134 名接受了至少一剂利拉鲁肽（66 名患者）或安慰剂（68 名患者）。,0.6,"['placebo', 'randomization', 'who', 'liraglutide', 'dose']","['placebo', 'randomization', 'liraglutide']",1429,"['在135名随机诊断的患者中,134人获得至少1剂Liraglutide(66名患者)或Placebo(68名患者)。']",0.2,"['placebo', 'randomization', 'who', 'liraglutide', 'dose']",['randomization'],,
1442,1430,"demographic characteristics were similar in the two groups ( mean age , 14.6 years ) .",两组的人口统计学特征相似（平均年龄 14.6 岁）。,0.5,"['mean', 'demographic characteristics', 'age', 'in', 'two', 'similar']","['mean', 'age', 'two']",1430,"['人口特征在两个群体中是相似的(平均年龄, 14.6 年)。']",0.6666666666666666,"['mean', 'demographic characteristics', 'age', 'in', 'two', 'similar']","['mean', 'age', 'two', 'similar']",,
1443,1431,the fasting plasma glucose level had decreased at both time points in the liraglutide group but had increased in the placebo group .,利拉鲁肽组的两个时间点的空腹血糖水平均降低，但安慰剂组的空腹血糖水平升高。,0.6,"['group', 'placebo', 'glucose', 'plasma', 'time', 'fasting', 'level', 'liraglutide', 'at', 'but']","['group', 'placebo', 'time', 'level', 'liraglutide', 'but']",1431,"['禁食的血糖水平在Liraglutide群体的两个时间点下降,但在 placebo群体中增加。']",0.4,"['group', 'placebo', 'glucose', 'plasma', 'time', 'fasting', 'level', 'liraglutide', 'at', 'but']","['group', 'time', 'level', 'but']",,
1444,1432,"in children and adolescents with type 2 diabetes , liraglutide , at a dose of up to 1.8 mg per day ( added to metformin , with or without basal insulin ) , was efficacious in improving glycemic control over 52 weeks .",在患有 2 型糖尿病的儿童和青少年中，每天 1.8 毫克剂量的利拉鲁肽（添加到二甲双胍中，有或没有基础胰岛素）在 52 周内有效改善血糖控制。,0.5,"['insulin', 'diabetes', 'type', 'basal', 'control', '2', 'up', 'with', 'liraglutide', 'at', 'metformin', 'dose', 'over', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', 'control', '2', 'liraglutide', 'metformin', 'dose']",1432,"['在患有2型糖尿病的儿童和青少年中,每天高达1.8毫克的利拉格卢蒂德(添加到甲状腺素,含有或没有基因胰岛素)在52周内有效地改善血糖控制。']",0.3125,"['insulin', 'diabetes', 'type', 'basal', 'control', '2', 'up', 'with', 'liraglutide', 'at', 'metformin', 'dose', 'over', 'to', 'and', 'without']","['insulin', 'diabetes', 'type', 'control', '2']",,
1445,1433,"this efficacy came at the cost of an increased frequency of gastrointestinal adverse events . ( Funded by Novo Nordisk ; Ellipse ClinicalTrials.gov number , NCT01541215 . )",这种疗效是以胃肠道不良事件发生频率增加为代价的。 （由 Novo Nordisk 资助；Ellipse ClinicalTrials.gov 编号，NCT01541215。）,0.6,"['frequency', 'gastrointestinal', 'ellipse', 'adverse', 'number', 'efficacy', 'cost', 'at', 'this', 'by']","['frequency', 'gastrointestinal', 'number', 'cost', 'this', 'by']",1433,"['这种有效性是由于增加胃肠不良事件的频率而产生的(由Novo Nordisk资助;Ellipse ClinicalTrials.gov号,NCT01541215 )。']",0.7,"['frequency', 'gastrointestinal', 'ellipse', 'adverse', 'number', 'efficacy', 'cost', 'at', 'this', 'by']","['frequency', 'gastrointestinal', 'number', 'efficacy', 'at', 'this', 'by']",,
1446,1434,"insulin is the only drug class approved for use in youth who do not have an adequate response to metformin monotherapy , 4,5 whereas a large number of oral and injectable agents of different classes are approved for adults.7","胰岛素是唯一批准用于对二甲双胍单一疗法没有足够反应的青少年的药物类别，4,5 而大量不同类别的口服和注射剂已获准用于成人。 7",0.3888888888888889,"['insulin', 'a', 'class', 'who', 'oral', 'large', 'number', 'response', 'injectable', 'adequate', 'youth', 'classes', 'adequate response', 'drug', 'metformin', 'have', 'to', 'and']","['insulin', 'response', 'drug', 'metformin', 'have', 'to', 'and']",1434,"['胰岛素是唯一批准的药物类,适用于未成年人,对甲状腺素单治疗没有足够的反应,而成年人则接受了大量的口服和不同类的注射剂。']",0.3888888888888889,"['insulin', 'a', 'class', 'who', 'oral', 'large', 'number', 'response', 'injectable', 'adequate', 'youth', 'classes', 'adequate response', 'drug', 'metformin', 'have', 'to', 'and']","['insulin', 'response', 'adequate', 'drug', 'have', 'to', 'and']",,
1447,1435,this discrepancy in available treatments for youth as compared with adults persists because of a lack of successfully completed trials needed for approval of new drugs for the treatment of type 2 diabetes in children since a trial of metformin was completed in 1999.8,由于自 1999 年完成二甲双胍试验以来，缺乏批准用于治疗儿童 2 型糖尿病的新药所需的成功完成的试验，因此青少年可用治疗方法与成人的这种差异持续存在。 8,0.5,"['diabetes', 'lack', 'type', '2', 'approval', 'drugs', 'new drugs', 'treatment', 'available', 'trial', 'discrepancy', 'youth', 'as', 'with', 'metformin', 'this']","['diabetes', 'type', '2', 'approval', 'new drugs', 'treatment', 'discrepancy', 'metformin']",1435,"['与成年人相比,青少年可用的治疗方法的这种差异仍然存在,因为自1999年完成的甲状腺素试验以来,缺乏成功完成的试验需要批准2型糖尿病儿童的新药物。']",0.5625,"['diabetes', 'lack', 'type', '2', 'approval', 'drugs', 'new drugs', 'treatment', 'available', 'trial', 'discrepancy', 'youth', 'as', 'with', 'metformin', 'this']","['diabetes', 'type', '2', 'approval', 'drugs', 'new drugs', 'treatment', 'available', 'discrepancy']",,
1448,1436,"regulatory agencies mandate that new drugs that have been approved for use in adults with type 2 diabetes undergo efficacy and safety trials in youth with the disease.9,10","监管机构要求已获准用于成人 2 型糖尿病的新药在患有该病的青少年中进行疗效和安全性试验。 9,10",0.4285714285714285,"['safety', 'diabetes', 'type', '2', 'undergo', 'drugs', 'new drugs', 'efficacy', 'youth', 'with', 'have', 'that', 'in', 'and']","['safety', 'diabetes', 'type', '2', 'new drugs', 'have']",1436,['监管机构委托在患有2型糖尿病的成年人使用已批准的新药物在患有2型糖尿病的青少年中进行有效性和安全性测试。'],0.5714285714285714,"['safety', 'diabetes', 'type', '2', 'undergo', 'drugs', 'new drugs', 'efficacy', 'youth', 'with', 'have', 'that', 'in', 'and']","['safety', 'diabetes', 'type', '2', 'drugs', 'new drugs', 'efficacy', 'have']",,
1449,1437,"the Evaluation of Liraglutide in Pediatrics with Diabetes ( Ellipse ) phase 3 trial of liraglutide was launched in 2012 , enrolled patients for a period of 4 years and 4 months , and was successfully completed in 2018 .",利拉鲁肽在儿科糖尿病中的评价（椭圆） 利拉鲁肽3期试验于2012年启动，入组患者，为期4年4个月，2018年顺利完成。,0.4615384615384615,"['diabetes', 'period', 'phase', 'evaluation', 'pediatrics', 'ellipse', 'trial', '3', '4', 'with', 'liraglutide', 'in', 'and']","['diabetes', 'period', 'phase', 'evaluation', 'ellipse', 'liraglutide']",1437,"['2012年启动了《糖尿病儿童医学利拉格卢蒂德评估》(Evaluation of Liraglutide in Pediatrics with Diabetes, Ellipse)阶段3的利拉格卢蒂德试验,为期4年4个月,并于2018年成功完成。']",0.2307692307692307,"['diabetes', 'period', 'phase', 'evaluation', 'pediatrics', 'ellipse', 'trial', '3', '4', 'with', 'liraglutide', 'in', 'and']","['diabetes', 'period', 'phase']",,
1450,1438,here we report the efficacy and safety outcomes of this trial .,我们在此报告该试验的有效性和安全性结果。,0.4285714285714285,"['safety', 'report', 'trial', 'efficacy', 'this', 'and', 'we']","['safety', 'report', 'efficacy']",1438,"['在这里,我们报告了这次试验的有效性和安全性结果。']",0.4285714285714285,"['safety', 'report', 'trial', 'efficacy', 'this', 'and', 'we']","['safety', 'report', 'efficacy']",,
1451,1439,we aimed to confirm the superiority of liraglutide to placebo in controlling glycemia in children and adolescents when added to treatment with metformin with or without insulin .,我们的目的是确认利拉鲁肽在控制儿童和青少年血糖时与二甲双胍联合使用或不联合胰岛素治疗时优于安慰剂。,0.5833333333333334,"['insulin', 'glycemia', 'placebo', 'treatment', 'superiority', 'with', 'liraglutide', 'metformin', 'to', 'and', 'without', 'we']","['insulin', 'glycemia', 'placebo', 'treatment', 'liraglutide', 'metformin', 'to']",1439,"['我们致力于确认Liraglutide对 placebo在儿童和青少年糖尿病控制的优越性,当添加到与或没有胰岛素的甲状腺素治疗时。']",0.3333333333333333,"['insulin', 'glycemia', 'placebo', 'treatment', 'superiority', 'with', 'liraglutide', 'metformin', 'to', 'and', 'without', 'we']","['insulin', 'treatment', 'superiority', 'to']",,
1452,1440,"written informed consent was obtained from a legally acceptable representative of all participants , and assent from all child participants was obtained except in Israel , where the assent form was not applicable .",从所有参与者的合法代表处获得了书面知情同意书，并获得了所有儿童参与者的同意，但在以色列除外，那里的同意书不适用。,0.3333333333333333,"['a', 'form', 'child', 'assent', 'consent', 'informed consent', 'acceptable', 'all', 'and']","['child', 'assent', 'consent']",1440,"['书面通知的同意是从合法接受的代表所有参与者获得的,并从所有儿童参与者获得的许可,除了在以色列,在那里许可表格不适用。']",0.3333333333333333,"['a', 'form', 'child', 'assent', 'consent', 'informed consent', 'acceptable', 'all', 'and']","['child', 'assent', 'consent']",,
1453,1441,the trial protocol and statistical analysis plan ( available with the full text of this article at NEJM.org ) were designed by the sponsor ( Novo Nordisk ) .,试验方案和统计分析计划（与本文全文可在 NEJM.org 获取）由申办方 (Novo Nordisk) 设计。,0.3076923076923077,"['analysis', 'protocol', 'sponsor', 'article', 'available', 'trial', 'text', 'statistical analysis', 'with', 'full', 'this', 'by', 'and']","['analysis', 'protocol', 'statistical analysis', 'by']",1441,['试验协议和统计分析计划(可在NEJM.org上提供本文的完整文本)由赞助商(Novo Nordisk)设计。'],0.3846153846153846,"['analysis', 'protocol', 'sponsor', 'article', 'available', 'trial', 'text', 'statistical analysis', 'with', 'full', 'this', 'by', 'and']","['analysis', 'protocol', 'statistical analysis', 'full', 'by']",,
1454,1442,the protocol ( without the statistical analysis plan ) was developed in accordance with local regulations and was reviewed and approved by an independent ethics committee or institutional review board at each site .,该方案（不含统计分析计划）是根据当地法规制定的，并由每个研究中心的独立伦理委员会或机构审查委员会审查和批准。,0.3333333333333333,"['site', 'analysis', 'review', 'protocol', 'ethics', 'local', 'board', 'committee', 'independent', 'statistical analysis', 'with', 'each', 'by', 'and', 'without']","['analysis', 'review', 'committee', 'statistical analysis', 'by']",1442,"['该议定书(没有统计分析计划)按照当地法规制定,并由独立的伦理委员会或各个网站的机构审查委员会审查和批准。']",0.5333333333333333,"['site', 'analysis', 'review', 'protocol', 'ethics', 'local', 'board', 'committee', 'independent', 'statistical analysis', 'with', 'each', 'by', 'and', 'without']","['analysis', 'review', 'protocol', 'committee', 'independent', 'statistical analysis', 'each', 'by']",,
1455,1443,an independent data monitoring committee had access to all unblinded data for the purpose of ensuring patient safety .,一个独立的数据监测委员会可以访问所有非盲数据，以确保患者安全。,0.6666666666666666,"['safety', 'monitoring', 'data', 'access', 'committee', 'patient', 'independent', 'purpose', 'all']","['safety', 'monitoring', 'data', 'committee', 'patient', 'independent']",1443,"['一个独立的数据监测委员会可以访问所有未透露的数据,以确保患者的安全。']",0.6666666666666666,"['safety', 'monitoring', 'data', 'access', 'committee', 'patient', 'independent', 'purpose', 'all']","['safety', 'monitoring', 'data', 'committee', 'patient', 'independent']",,
1456,1444,"amendments to the protocol are listed in the Supplementary Appendix , available at NEJM.org .",方案的修正案列在补充附录中，补充附录可在 NEJM.org 获取。,0.0,"['appendix', 'protocol', 'supplementary', 'available', 'at', 'in']",[],1444,"['该协议的修正案列入附件中,可在NEJM.org上找到。']",0.3333333333333333,"['appendix', 'protocol', 'supplementary', 'available', 'at', 'in']","['appendix', 'protocol']",,
1457,1445,"site investigators gathered the data , and the sponsor performed site monitoring , collected the data , and performed the analyses .",研究中心调查人员收集数据，申办方进行研究中心监测、收集数据并进行分析。,0.4,"['monitoring', 'site', 'data', 'sponsor', 'and']","['monitoring', 'data']",1445,"['网站调查人员收集了数据,赞助商进行了网站监测,收集了数据,并进行了分析。']",0.4,"['monitoring', 'site', 'data', 'sponsor', 'and']","['monitoring', 'data']",,
1458,1446,all the authors had access to the trial results and vouch for the fidelity of the trial to the protocol .,所有作者都可以查看试验结果并保证试验对方案的忠实度。,0.0,"['fidelity', 'protocol', 'access', 'trial', 'all', 'and']",[],1446,"['所有作家都可以访问审判结果,并为审判对议定书的忠诚度提供支票。']",0.3333333333333333,"['fidelity', 'protocol', 'access', 'trial', 'all', 'and']","['protocol', 'trial']",,
1459,1447,"the first author wrote the first draft of the manuscript , and the manuscript was subsequently revised and approved by all the authors , who agreed to submit the manuscript for publication .",第一作者撰写了手稿的初稿，随后对手稿进行了修改并获得所有作者的认可，他们同意投稿发表。,0.3,"['who', 'author', 'publication', 'manuscript', 'all', 'by', 'to', 'and', 'first', 'draft']","['publication', 'manuscript', 'first']",1447,"['第一位作者写了手稿的第一个草案,手稿随后被所有作者审查并批准,他们同意提交手稿出版。']",0.3,"['who', 'author', 'publication', 'manuscript', 'all', 'by', 'to', 'and', 'first', 'draft']","['publication', 'manuscript', 'first']",,
1460,1448,the first author also vouches for the accuracy and completeness of the data .,第一作者同时保证数据的准确性和完整性。,0.6666666666666666,"['data', 'author', 'accuracy', 'completeness', 'and', 'first']","['data', 'accuracy', 'completeness', 'first']",1448,['第一位作者也保证了数据的准确性和完整性。'],0.6666666666666666,"['data', 'author', 'accuracy', 'completeness', 'and', 'first']","['data', 'accuracy', 'completeness', 'first']",,
1461,1449,"an independent medical writer , funded by the sponsor , provided editorial support , with guidance from the authors .",一位独立的医学作家，由申办方资助，在作者的指导下提供编辑支持。,0.5,"['support', 'sponsor', 'medical', 'writer', 'independent', 'with', 'by', 'guidance']","['support', 'writer', 'independent', 'by']",1449,"['由赞助商资助的独立医学作家,提供编辑支持,由作者指导。']",0.375,"['support', 'sponsor', 'medical', 'writer', 'independent', 'with', 'by', 'guidance']","['support', 'writer', 'by']",,
1462,1450,"other exclusion criteria were the use of any antidiabetic agent other than metformin or basal insulin within 90 days before screening ; a history of pancreatitis ; serum calcitonin levels of 50 ng or more per liter ; a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2 ; an alanine aminotransferase level 2.5 times the upper limit of the normal range or higher ; serum creatinine levels greater than the upper limit of the normal range for age ; a recent history of heart disease , proliferative retinopathy or maculopathy ; and recurrent severe hypoglycemia or hypoglycemic unawareness .",其他排除标准是在筛选前 90 天内使用除二甲双胍或基础胰岛素以外的任何抗糖尿病药物；胰腺炎病史；血清降钙素水平为每升 50 纳克或更多；甲状腺髓样癌或多发性内分泌肿瘤的个人史或家族史 2 ；丙氨酸氨基转移酶水平是正常范围上限的 2.5 倍或更高；血清肌酐水平高于年龄正常范围的上限；最近有心脏病、增生性视网膜病变或黄斑病史；反复发作的严重低血糖或低血糖意识不清。,0.6222222222222222,"['heart', 'medullary', 'insulin', 'creatinine', 'family', 'calcitonin', 'thyroid', 'basal', 'alanine', 'disease', 'cancer', 'liter', 'range', 'hypoglycemia', '2', 'recent', 'alanine aminotransferase', 'heart disease', 'endocrine', 'screening', 'personal', 'upper', 'family history', 'multiple', 'pancreatitis', 'normal', 'exclusion', 'serum', 'multiple endocrine neoplasia', 'recurrent', 'thyroid cancer', 'proliferative', 'age', 'limit', 'level', 'normal range', 'upper limit', 'severe', 'metformin', 'agent', 'hypoglycemic', 'antidiabetic', 'retinopathy', 'before', 'and']","['heart', 'insulin', 'family', 'calcitonin', 'thyroid', 'alanine', 'disease', 'cancer', 'liter', 'range', '2', 'alanine aminotransferase', 'heart disease', 'endocrine', 'screening', 'family history', 'pancreatitis', 'serum', 'recurrent', 'proliferative', 'age', 'level', 'normal range', 'upper limit', 'metformin', 'antidiabetic', 'retinopathy', 'before']",1450,"['其他排除标准包括在筛查前90天内使用任何非甲状腺素或基因胰岛素的抗糖药物;胰岛素史;血清钙素水平为每升50英<unk>或以上;甲状腺癌或多重内分泌肿瘤2的个人或家庭史;阿兰素氨基转移素水平为正常范围的 2.5 倍或更高;血清基因素水平高于正常范围的上限;心脏病史,繁殖性网膜炎或宏观病史;重复严重的催眠或催眠不良。']",0.4222222222222222,"['heart', 'medullary', 'insulin', 'creatinine', 'family', 'calcitonin', 'thyroid', 'basal', 'alanine', 'disease', 'cancer', 'liter', 'range', 'hypoglycemia', '2', 'recent', 'alanine aminotransferase', 'heart disease', 'endocrine', 'screening', 'personal', 'upper', 'family history', 'multiple', 'pancreatitis', 'normal', 'exclusion', 'serum', 'multiple endocrine neoplasia', 'recurrent', 'thyroid cancer', 'proliferative', 'age', 'limit', 'level', 'normal range', 'upper limit', 'severe', 'metformin', 'agent', 'hypoglycemic', 'antidiabetic', 'retinopathy', 'before', 'and']","['heart', 'insulin', 'family', 'thyroid', 'disease', 'cancer', 'liter', 'range', '2', 'heart disease', 'endocrine', 'screening', 'serum', 'thyroid cancer', 'proliferative', 'level', 'normal range', 'upper limit', 'before']",,
1463,1451,complete inclusion and exclusion criteria are listed in the Supplementary Appendix .,完整的纳入和排除标准列于补充附录中。,0.1666666666666666,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'complete', 'and']",['complete'],1451,['完整的包含和排除标准在附件中列出。'],0.5,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'complete', 'and']","['appendix', 'inclusion', 'complete']",,
1464,1452,"eligibility criteria included a fasting plasma glucose level between 126 mg and 220 mg per deciliter ( between 7.0 mmol and 12.2 mmol per liter ) and a stable metformin dose ( in most patients , 1000 mg to 2000 mg per day ) for at least 8 weeks .",合格标准包括空腹血糖水平在 126 mg 到 220 mg/dL（7.0 mmol 到 12.2 mmol/L）之间，二甲双胍剂量稳定（在大多数患者中，每天 1000 mg 到 2000 mg）至少 8 周。,0.25,"['a', 'glucose', 'liter', 'plasma', 'deciliter', 'fasting', 'level', 'at', 'metformin', 'dose', 'to', 'and']","['level', 'metformin', 'dose']",1452,"['合格性标准包括禁食的血糖水平为126 mg至220 mg每分升(每升7.0 mmol至12.2 mmol)和稳定的甲状腺素剂量(在大多数患者中,每日1000 mg至2000 mg)至少8周。']",0.25,"['a', 'glucose', 'liter', 'plasma', 'deciliter', 'fasting', 'level', 'at', 'metformin', 'dose', 'to', 'and']","['liter', 'level', 'dose']",,
1465,1453,patients who were receiving metformin at a dose of more than 2000 mg when they entered the trial continued receiving that dose .,进入试验时接受二甲双胍剂量超过 2000 毫克的患者继续接受该剂量。,0.2857142857142857,"['a', 'who', 'trial', 'at', 'metformin', 'dose', 'that']","['metformin', 'dose']",1453,"['当他们进入试验时,在2000毫克以上的剂量服用甲状腺素的患者继续服用该剂量。']",0.2857142857142857,"['a', 'who', 'trial', 'at', 'metformin', 'dose', 'that']","['at', 'dose']",,
1466,1454,patients who were being treated with basal insulin had to have been on a stable dose for at least 8 weeks .,正在接受基础胰岛素治疗的患者必须接受至少 8 周的稳定剂量。,0.2,"['insulin', 'basal', 'who', 'being', 'with', 'at', 'dose', 'on', 'have', 'to']","['insulin', 'dose']",1454,['接受基因胰岛素治疗的患者必须在稳定的剂量至少8周。'],0.2,"['insulin', 'basal', 'who', 'being', 'with', 'at', 'dose', 'on', 'have', 'to']","['insulin', 'dose']",,
1467,1455,"diet and exercise counseling was provided , according to local standards , at several visits .",根据当地标准，在几次访问中提供了饮食和运动咨询。,0.5714285714285714,"['diet', 'exercise', 'local', 'counseling', 'at', 'to', 'and']","['diet', 'exercise', 'counseling', 'at']",1455,"['根据当地标准,在几次访问中提供饮食和锻炼咨询。']",0.5714285714285714,"['diet', 'exercise', 'local', 'counseling', 'at', 'to', 'and']","['diet', 'exercise', 'counseling', 'at']",,
1468,1456,"eligible patients were randomly assigned , in a 1 : 1 ratio , to receive subcutaneous liraglutide or placebo for 26 weeks , in combination with metformin , with or without basal insulin , on a background of a diet and exercise regimen .",符合条件的患者被随机分配，以 1:1 的比例接受皮下注射利拉鲁肽或安慰剂 26 周，联合二甲双胍，有或没有基础胰岛素，在饮食和运动方案的背景下。,0.5882352941176471,"['insulin', 'combination', 'background', 'placebo', 'basal', '1', 'ratio', 'diet', 'exercise', 'subcutaneous', 'with', 'liraglutide', 'metformin', 'to', 'and', 'without', 'eligible']","['insulin', 'combination', 'background', 'placebo', '1', 'ratio', 'diet', 'exercise', 'liraglutide', 'metformin']",1456,"['合格的患者随机分配,在1:1的比例,接受下皮利拉格卢蒂德或 placebo26周,与甲状腺素,与或没有基因胰岛素,在饮食和锻炼计划的背景下。']",0.4117647058823529,"['insulin', 'combination', 'background', 'placebo', 'basal', '1', 'ratio', 'diet', 'exercise', 'subcutaneous', 'with', 'liraglutide', 'metformin', 'to', 'and', 'without', 'eligible']","['insulin', 'background', '1', 'ratio', 'diet', 'exercise', 'eligible']",,
1469,1457,"after randomization , administration of liraglutide or placebo by subcutaneous injection ( with visually identical prefilled pen injectors ) was initiated at a dose of 0.6 mg per day , and the dose was escalated in both groups in increments of approximately 0.6 mg each week over the course of 2 to 3 weeks .",随机分组后，皮下注射利拉鲁肽或安慰剂（使用视觉上相同的预填充笔式注射器）的起始剂量为每天 0.6 毫克，并且在整个治疗过程中，两组的剂量均以每周约 0.6 毫克的增量递增。 2 到 3 周。,0.65,"['injection', 'placebo', 'subcutaneous injection', 'randomization', '2', 'administration', 'pen', 'week', 'after', '3', 'identical', 'course', 'with', 'liraglutide', 'dose', 'approximately', 'each', 'by', 'over', 'to']","['injection', 'placebo', 'subcutaneous injection', 'randomization', '2', 'week', 'after', 'identical', 'course', 'liraglutide', 'dose', 'by', 'over']",1457,"['随机化后,用皮下注射(视觉上相同的预注金注射器)启动了Liraglutide或Placebo的剂量,每日剂量为0.6 mg,并在两组中增加了每周约0.6 mg的剂量,在2至3周内。']",0.4,"['injection', 'placebo', 'subcutaneous injection', 'randomization', '2', 'administration', 'pen', 'week', 'after', '3', 'identical', 'course', 'with', 'liraglutide', 'dose', 'approximately', 'each', 'by', 'over', 'to']","['injection', 'subcutaneous injection', 'randomization', '2', 'week', 'after', 'identical', 'dose']",,
1470,1458,dose adjustment was based on side effects and the efficacy of the lower dose .,剂量调整是根据副作用和较低剂量的疗效。,0.2857142857142857,"['adjustment', 'side effects', 'lower', 'efficacy', 'dose', 'on', 'and']","['side effects', 'dose']",1458,['剂量调整是基于副作用和低剂量的有效性。'],0.4285714285714285,"['adjustment', 'side effects', 'lower', 'efficacy', 'dose', 'on', 'and']","['side effects', 'efficacy', 'dose']",,
1471,1459,prespecified criteria for rescue treatment with insulin that were based on fasting plasma glucose levels were applied to ensure acceptable glycemic control in both treatment groups .,应用基于空腹血糖水平的胰岛素抢救治疗的预设标准，以确保两个治疗组的血糖控制在可接受范围内。,0.3333333333333333,"['insulin', 'glucose', 'control', 'plasma', 'treatment', 'fasting', 'applied', 'acceptable', 'with', 'that', 'to', 'rescue']","['insulin', 'control', 'treatment', 'to']",1459,"['基于禁食的血糖水平的胰岛素救援治疗的预定标准被应用,以确保在两组治疗中可接受的血糖控制。']",0.5,"['insulin', 'glucose', 'control', 'plasma', 'treatment', 'fasting', 'applied', 'acceptable', 'with', 'that', 'to', 'rescue']","['insulin', 'control', 'treatment', 'acceptable', 'to', 'rescue']",,
1472,1460,the primary efficacy end point was the change from baseline in glycated hemoglobin level at week 26 .,主要疗效终点是第 26 周时糖化血红蛋白水平相对于基线的变化。,0.6,"['baseline', 'hemoglobin', 'hemoglobin level', 'primary', 'week', 'efficacy', 'end', 'point', 'change', 'at']","['baseline', 'hemoglobin', 'week', 'point', 'change', 'at']",1460,['初级效率的终点是从基线到血糖血糖水平的变化26周。'],0.4,"['baseline', 'hemoglobin', 'hemoglobin level', 'primary', 'week', 'efficacy', 'end', 'point', 'change', 'at']","['baseline', 'week', 'point', 'change']",,
1473,1461,"additional secondary end points included the changes from baseline in body weight , fasting lipid levels , and systolic and diastolic blood pressure .",其他次要终点包括体重、空腹血脂水平以及收缩压和舒张压相对于基线的变化。,0.2307692307692307,"['body weight', 'pressure', 'lipid', 'baseline', 'blood', 'blood pressure', 'end points', 'diastolic', 'fasting', 'additional', 'systolic', 'secondary', 'and']","['body weight', 'baseline', 'end points']",1461,"['额外的次要终点包括体重基线的变化,禁食脂肪水平,以及系统和二进制血压。']",0.3846153846153846,"['body weight', 'pressure', 'lipid', 'baseline', 'blood', 'blood pressure', 'end points', 'diastolic', 'fasting', 'additional', 'systolic', 'secondary', 'and']","['body weight', 'baseline', 'blood pressure', 'end points', 'additional']",,
1474,1462,"adverse events , serious adverse events , and medical events of special interest were assessed throughout the trial ( definitions are provided in the Supplementary Appendix ) .",在整个试验过程中评估了不良事件、严重不良事件和特别关注的医学事件（定义见补充附录）。,0.1,"['appendix', 'medical', 'supplementary', 'adverse', 'trial', 'serious', 'in', 'and', 'special', 'assessed']",['special'],1462,['试验期间对不良事件、严重不良事件和特殊兴趣的医学事件进行了评估(定义在附件中提供)。'],0.2,"['appendix', 'medical', 'supplementary', 'adverse', 'trial', 'serious', 'in', 'and', 'special', 'assessed']","['appendix', 'special']",,
1475,1463,hypoglycemic episodes were classified according to the Novo Nordisk and American Diabetes Association definitions ( see the Supplementary Appendix ) .,根据诺和诺德和美国糖尿病协会的定义（见补充附录）对低血糖发作进行分类。,0.2222222222222222,"['diabetes', 'appendix', 'association', 'supplementary', 'episodes', 'classified', 'hypoglycemic', 'to', 'and']","['diabetes', 'episodes']",1463,['催眠性病例根据Novo Nordisk和美国糖尿病协会的定义分类(参见补充附件)。'],0.2222222222222222,"['diabetes', 'appendix', 'association', 'supplementary', 'episodes', 'classified', 'hypoglycemic', 'to', 'and']","['diabetes', 'appendix']",,
1476,1464,"lipase , amylase , and calcitonin levels at baseline and during the trial were evaluated with standard laboratory tests .",基线和试验期间的脂肪酶、淀粉酶和降钙素水平通过标准实验室测试进行评估。,0.75,"['amylase', 'calcitonin', 'standard', 'lipase', 'baseline', 'trial', 'laboratory', 'with']","['amylase', 'calcitonin', 'standard', 'lipase', 'baseline', 'laboratory']",1464,['基线和测试期间的脂肪、阿米拉斯和钙素水平通过标准实验室测试进行评估。'],0.375,"['amylase', 'calcitonin', 'standard', 'lipase', 'baseline', 'trial', 'laboratory', 'with']","['standard', 'baseline', 'laboratory']",,
1477,1465,"the sample size was calculated for the primary glycated hemoglobin end point alone ; we determined that a sample size of 47 patients in each treatment group would give the study 80 % power , assuming a mean ( ± SD ) difference of 0.9 ± 1.2 percentage points between the liraglutide group and the placebo group ( a difference of 0.7 percentage points after adjustment for a 22 % withdrawal rate ) .",仅针对主要糖化血红蛋白终点计算样本量；我们确定每个治疗组中 47 名患者的样本量将为研究提供 80 % 的功效，假设利拉鲁肽组和安慰剂组之间的平均 ( ± SD ) 差异为 0.9 ± 1.2 个百分点（差异为 0.7 个百分点调整为 22% 的退出率后）。,0.4444444444444444,"['sample', 'group', 'percentage', 'placebo', 'mean', 'rate', 'power', 'hemoglobin', 'withdrawal', 'study', 'adjustment', 'difference', 'size', 'treatment', 'primary', 'after', 'sample size', 'end', 'point', 'treatment group', 'liraglutide', 'SD', 'give', 'that', 'each', 'and', 'alone']","['sample', 'group', 'placebo', 'mean', 'rate', 'hemoglobin', 'difference', 'treatment', 'after', 'point', 'treatment group', 'liraglutide']",1465,"['样品大小仅计算为初级格利克化血球的终点;我们确定,每个治疗组的47名患者的样品大小将给研究80%的功率,假设在利拉格卢蒂德组和 placebo组之间的平均(±SD)差距为0.9 ±1.2 百分点(调整后差距为0.7 百分点为22%退缩率)。']",0.3703703703703703,"['sample', 'group', 'percentage', 'placebo', 'mean', 'rate', 'power', 'hemoglobin', 'withdrawal', 'study', 'adjustment', 'difference', 'size', 'treatment', 'primary', 'after', 'sample size', 'end', 'point', 'treatment group', 'liraglutide', 'SD', 'give', 'that', 'each', 'and', 'alone']","['sample', 'group', 'mean', 'rate', 'power', 'size', 'treatment', 'after', 'point', 'treatment group']",,
1478,1466,"according to regulatory requirements , at least 30 % of patients who underwent randomization were to be 10 to 14 years of age , at least 40 % were to be female , and at least 30 % were to be from the European Union or from countries with lifestyle and diabetes care similar to those in European Union countries .",根据法规要求，接受随机分组的患者中至少有 30 % 年龄在 10 至 14 岁之间，至少 40 % 为女性，至少 30 % 来自欧盟或具有生活方式的国家。和欧盟国家的糖尿病护理相似。,0.3636363636363636,"['diabetes', 'randomization', 'female', 'who', 'age', 'care', 'with', 'union', 'in', 'to', 'similar']","['diabetes', 'randomization', 'female', 'age']",1466,"['根据监管要求,至少有30%的随机诊断患者年龄为10至14岁,至少有40%是女性,至少有30%来自欧盟或与欧盟国家相似的生活方式和糖尿病护理国家。']",0.4545454545454545,"['diabetes', 'randomization', 'female', 'who', 'age', 'care', 'with', 'union', 'in', 'to', 'similar']","['diabetes', 'randomization', 'female', 'age', 'similar']",,
1479,1467,the full analysis set ( patients as randomly assigned ) and the safety analysis set ( patients as treated ) included all patients who received at least one dose of liraglutide or placebo .,全分析集（随机分配的患者）和安全性分析集（接受治疗的患者）包括接受至少一剂利拉鲁肽或安慰剂的所有患者。,0.3076923076923077,"['safety', 'placebo', 'who', 'analysis', 'set', 'safety analysis', 'as', 'liraglutide', 'at', 'dose', 'full', 'all', 'and']","['safety', 'placebo', 'analysis', 'liraglutide']",1467,['完整的分析组(随机分配的患者)和安全分析组(接受治疗的患者)包括接受至少一剂Liraglutide或Placebo的所有患者。'],0.3076923076923077,"['safety', 'placebo', 'who', 'analysis', 'set', 'safety analysis', 'as', 'liraglutide', 'at', 'dose', 'full', 'all', 'and']","['safety', 'analysis', 'safety analysis', 'full']",,
1480,1468,"missing data at week 26 were imputed with the use of a regression model that was based on data from patients in the placebo group who completed week 26 , with missing data for patients in the placebo group imputed from data throughout the trial and missing data for patients in the liraglutide group imputed from baseline data .",第26周的缺失数据使用回归模型进行估算，该模型基于完成第26周的安慰剂组患者的数据，安慰剂组患者的缺失数据是根据整个试验的数据估算的，患者的缺失数据在根据基线数据估算的利拉鲁肽组中。,0.6666666666666666,"['group', 'placebo', 'model', 'data', 'who', 'baseline', 'regression', 'week', 'trial', 'with', 'liraglutide', 'that', 'and', 'missing', 'regression model']","['group', 'placebo', 'model', 'data', 'baseline', 'regression', 'week', 'liraglutide', 'missing', 'regression model']",1468,"['26周失踪的数据被归因于使用基于26周完成的 placebo 群体患者的数据的 regression 模型,在整个测试期间从数据中归因于 placebo 群体患者的失踪数据,以及从基准数据中归因于 liraglutide 群体患者的失踪数据。']",0.2666666666666666,"['group', 'placebo', 'model', 'data', 'who', 'baseline', 'regression', 'week', 'trial', 'with', 'liraglutide', 'that', 'and', 'missing', 'regression model']","['group', 'model', 'data', 'week']",,
1481,1469,"missing data at week 26 were imputed 10,000 times , and for each of the 10,000 imputed data sets , the change in glycated hemoglobin level from baseline to week 26 was assessed with an analysis of covariance , with treatment and stratification groups ( sex and age group ) as categorical fixed effects and baseline glycated hemoglobin level as a covariate .","第26周的缺失数据被估算了10,000次，对于10,000个估算数据集中的每一个，糖化血红蛋白水平从基线到第26周的变化通过协方差分析、治疗组和分层组（性别和年龄组）进行了评估。作为分类固定效应和基线糖化血红蛋白水平作为协变量。",0.6363636363636364,"['group', 'covariance', 'stratification', 'data', 'analysis', 'baseline', 'sex', 'hemoglobin', 'hemoglobin level', 'treatment', 'age', 'week', 'fixed', 'change', 'categorical', 'with', 'analysis of covariance', 'each', 'to', 'and', 'missing', 'assessed']","['group', 'covariance', 'stratification', 'data', 'analysis', 'baseline', 'sex', 'hemoglobin', 'treatment', 'age', 'week', 'change', 'to', 'missing']",1469,"['缺失的数据在26周被归因于10万次,并为每1万个归因的数据集,从基线到26周的血糖血糖水平的变化被评估,通过分析,与治疗和分裂组(性别和年龄组)作为类别固定效应和基线血糖血糖血糖水平作为科瓦里亚特。']",0.5,"['group', 'covariance', 'stratification', 'data', 'analysis', 'baseline', 'sex', 'hemoglobin', 'hemoglobin level', 'treatment', 'age', 'week', 'fixed', 'change', 'categorical', 'with', 'analysis of covariance', 'each', 'to', 'and', 'missing', 'assessed']","['group', 'data', 'analysis', 'baseline', 'sex', 'treatment', 'age', 'week', 'change', 'to', 'missing']",,
1482,1470,"to be able to claim superiority for the listed end points , we first needed to show superiority with respect to the primary end point .",为了能够宣称对所列终点的优效性，我们首先需要展示对主要终点的优效性。,0.2,"['end points', 'be', 'primary', 'claim', 'superiority', 'with', 'respect', 'to', 'first', 'we']","['end points', 'first']",1470,"['为了能够对列出的终点提出优越性,我们首先需要对初级终点提出优越性。']",0.3,"['end points', 'be', 'primary', 'claim', 'superiority', 'with', 'respect', 'to', 'first', 'we']","['end points', 'superiority', 'first']",,
1483,1471,a sensitivity analysis ( mixed model of repeated measurements ) in which data after initiation of rescue treatment were excluded was completed for all end points .,对所有终点完成敏感性分析（重复测量的混合模型），其中排除了开始救援治疗后的数据。,0.6153846153846154,"['a', 'initiation', 'model', 'data', 'analysis', 'mixed', 'end points', 'treatment', 'after', 'sensitivity', 'repeated', 'all', 'rescue']","['initiation', 'model', 'data', 'analysis', 'end points', 'treatment', 'after', 'rescue']",1471,"['一项敏感性分析(重复测量的混合模型),在救援处理开始后被排除的数据为所有终点完成。']",0.6153846153846154,"['a', 'initiation', 'model', 'data', 'analysis', 'mixed', 'end points', 'treatment', 'after', 'sensitivity', 'repeated', 'all', 'rescue']","['initiation', 'model', 'data', 'analysis', 'end points', 'treatment', 'after', 'rescue']",,
1484,1472,details of the other sensitivity analyses are provided in the Supplementary Appendix .,补充附录中提供了其他敏感性分析的详细信息。,0.0,"['appendix', 'supplementary', 'sensitivity', 'in']",[],1472,['其他敏感性分析的详细信息在附件中提供。'],0.25,"['appendix', 'supplementary', 'sensitivity', 'in']",['appendix'],,
1485,1473,post hoc analyses of the primary end point and two of the confirmatory secondary end points were performed with data stratified by sex and age group .,使用按性别和年龄组分层的数据对主要终点和两个确认性次要终点进行事后分析。,0.5384615384615384,"['group', 'data', 'sex', 'end points', 'post', 'primary', 'age', 'secondary', 'with', 'by', 'and', 'two', 'confirmatory']","['group', 'data', 'sex', 'end points', 'age', 'two', 'confirmatory']",1473,['初级终点和确认二级终点的后期分析以性别和年龄组分类的数据进行。'],0.5384615384615384,"['group', 'data', 'sex', 'end points', 'post', 'primary', 'age', 'secondary', 'with', 'by', 'and', 'two', 'confirmatory']","['group', 'data', 'sex', 'end points', 'age', 'by', 'confirmatory']",,
1486,1474,proportions of patients who attained specified glycated hemoglobin levels were analyzed with the use of logistic regression ( with missing data imputed as in the primary analysis ) .,使用逻辑回归分析达到特定糖化血红蛋白水平的患者比例（在主要分析中对缺失数据进行估算）。,0.4444444444444444,"['logistic regression', 'data', 'who', 'analysis', 'hemoglobin', 'primary', 'as', 'with', 'missing']","['data', 'analysis', 'hemoglobin', 'missing']",1474,"['达到指定的血糖血糖水平的患者的比例被分析,使用物流回归(如在初始分析中所表明的缺乏数据)。']",0.4444444444444444,"['logistic regression', 'data', 'who', 'analysis', 'hemoglobin', 'primary', 'as', 'with', 'missing']","['data', 'analysis', 'as', 'missing']",,
1487,1475,safety end points were summarized with descriptive statistics .,用描述性统计总结安全性终点。,0.6666666666666666,"['safety', 'statistics', 'descriptive', 'end points', 'descriptive statistics', 'with']","['safety', 'statistics', 'descriptive', 'end points']",1475,['安全终点被总结为描述性统计。'],0.6666666666666666,"['safety', 'statistics', 'descriptive', 'end points', 'descriptive statistics', 'with']","['safety', 'statistics', 'descriptive', 'end points']",,
1488,1476,testing of the supportive secondary end points ( all secondary end points other than the end points in the hierarchy ) and post hoc subgroup analyses were not adjusted for multiplicity .,对支持性次要终点（除层次结构中的终点以外的所有次要终点）和事后亚组分析的测试未针对多重性进行调整。,0.2222222222222222,"['end points', 'post', 'hierarchy', 'secondary', 'multiplicity', 'subgroup', 'testing', 'all', 'and']","['end points', 'multiplicity']",1476,['支持的二级终点测试(所有二级终点不同于 hierarchy 的终点)和后 hoc 子组分析没有调整为多样性。'],0.1111111111111111,"['end points', 'post', 'hierarchy', 'secondary', 'multiplicity', 'subgroup', 'testing', 'all', 'and']",['end points'],,
1489,1477,"results are reported as point estimates with 95 % confidence intervals , and widths of these confidence intervals should not be used to infer definitive treatment effects .",结果报告为具有 95% 置信区间的点估计值，这些置信区间的宽度不应用于推断确定的治疗效果。,0.4,"['definitive', 'be', 'treatment', 'point', 'as', 'with', 'confidence', 'to', 'and', 'intervals']","['definitive', 'treatment', 'point', 'to']",1477,"['结果报告为95%的信任间隔的点估计,这些信任间隔的宽度不应用于确定最终的治疗效果。']",0.3,"['definitive', 'be', 'treatment', 'point', 'as', 'with', 'confidence', 'to', 'and', 'intervals']","['treatment', 'point', 'to']",,
1490,1478,patient DEMOGRAPHICS AND CLINICAL CHARACTERISTICS,患者人口统计学和临床特征,1.0,['patient'],['patient'],1478,['患者人口学和临床特征'],1.0,['patient'],['patient'],,
1491,1479,enrollment began in November 2012 and was completed in May 2018 .,2012年11月开始招生，2018年5月结束。,0.0,"['november', 'in', 'and']",[],1479,"['注册开始于2012年11月,并于2018年5月完成。']",0.0,"['november', 'in', 'and']",[],,
1492,1480,"of 307 patients screened , 135 were randomly assigned to a trial group , of whom 134 received at least one dose of either liraglutide ( 66 patients ) or placebo ( 68 patients ; 1 patient in this group did not received any dose ) ( Figure 1 , and Table S1 in the Supplementary Appendix ) .",在筛选的 307 名患者中，135 名被随机分配到试验组，其中 134 名接受了至少一剂利拉鲁肽（66 名患者）或安慰剂（68 名患者；该组中有 1 名患者未接受任何剂量）（图 1，和补充附录中的表 S1）。,0.4375,"['group', 'placebo', 'appendix', 'table', '1', 'figure', 'supplementary', 'patient', 'trial', 'liraglutide', 'dose', 'S1', 'this', 'in', 'to', 'and']","['group', 'placebo', 'table', '1', 'patient', 'liraglutide', 'dose']",1480,"['在307名受试患者中,135人随机分配给一个试验组,其中134人获得至少一剂Liraglutide(66名患者)或 placebo(68名患者,其中1名患者没有接受任何剂量)(图1和附件中的S1表)。']",0.375,"['group', 'placebo', 'appendix', 'table', '1', 'figure', 'supplementary', 'patient', 'trial', 'liraglutide', 'dose', 'S1', 'this', 'in', 'to', 'and']","['group', 'appendix', 'table', '1', 'patient', 'dose']",,
1493,1481,these 134 patients made up the full and safety analysis sets .,这 134 名患者构成了完整和安全性分析集。,0.5,"['safety', 'analysis', 'up', 'safety analysis', 'full', 'and']","['safety', 'analysis', 'full']",1481,['这些134名患者完成了完整和安全分析套件。'],0.6666666666666666,"['safety', 'analysis', 'up', 'safety analysis', 'full', 'and']","['safety', 'analysis', 'safety analysis', 'full']",,
1494,1482,"among all patients who underwent randomization , 118 patients ( 87.4 % ) - 60 ( 90.9 % ) in the liraglutide group and 58 ( 84.1 % ) in the placebo group - completed 26 weeks of treatment .",在接受随机分组的所有患者中，利拉鲁肽组 118 例 (87.4%) 至 60 例 (90.9%) 和安慰剂组 58 例 (84.1%) 完成了 26 周的治疗。,0.5555555555555556,"['group', 'placebo', 'randomization', 'who', 'treatment', 'liraglutide', '-', 'all', 'in']","['group', 'placebo', 'randomization', 'treatment', 'liraglutide']",1482,"['在所有经过随机诊断的患者中,118名患者(87.4%) - 利拉格卢蒂德群体的60(90.9%)和 placebo群体的58(84.1%) - 完成了26周的治疗。']",0.3333333333333333,"['group', 'placebo', 'randomization', 'who', 'treatment', 'liraglutide', '-', 'all', 'in']","['group', 'randomization', 'treatment']",,
1495,1483,"subsequently , 109 patients ( 80.7 % ) completed 52 weeks of treatment - 56 ( 84.8 % ) in the liraglutide group and 53 ( 76.8 % ) in the placebo group .",随后，109 名患者 (80.7%) 完成了 52 周的治疗——利拉鲁肽组 56 名 (84.8%) 和安慰剂组 53 名 (76.8%)。,0.5714285714285714,"['group', 'placebo', 'treatment', 'liraglutide', '-', 'in', 'and']","['group', 'placebo', 'treatment', 'liraglutide']",1483,"['随后,109名患者(80.7%)完成了52周的治疗 - 56(84.8%)在利拉格卢蒂德群体和53(76.8%)在 placebo群体。']",0.2857142857142857,"['group', 'placebo', 'treatment', 'liraglutide', '-', 'in', 'and']","['group', 'treatment']",,
1496,1484,"a total of 86.4 % of the patients in the liraglutide group and 66.7 % in the placebo group completed the assigned regimen until week 26 without rescue medication , and 71.2 % and 50.7 % , respectively , completed the assigned regimen until week 52 without rescue medication .",利拉鲁肽组中共有 86.4% 的患者和安慰剂组中有 66.7% 的患者在第 26 周之前完成了指定的治疗方案，并且没有使用救援药物，而分别有 71.2% 和 50.7% 的患者在没有使用救援药物的情况下完成了指定的治疗方案直到第 52 周。,0.6,"['group', 'placebo', 'total', 'medication', 'week', 'liraglutide', 'in', 'and', 'rescue', 'without']","['group', 'placebo', 'week', 'liraglutide', 'and', 'rescue']",1484,"['总共86.4%的利拉格卢蒂德群体和66.7%的 placebo群体在第26周之前没有救援药,71.2%和50.7%分别在第52周之前没有救援药。']",0.3,"['group', 'placebo', 'total', 'medication', 'week', 'liraglutide', 'in', 'and', 'rescue', 'without']","['group', 'week', 'rescue']",,
1497,1485,the baseline characteristics were balanced between the two groups ( Table 1 ) .,两组之间的基线特征平衡（表 1）。,1.0,"['table', 'baseline', '1', 'characteristics', 'two']","['table', 'baseline', '1', 'characteristics', 'two']",1485,['基线特征在两组之间均衡(图1)。'],0.8,"['table', 'baseline', '1', 'characteristics', 'two']","['baseline', '1', 'characteristics', 'two']",,
1498,1486,dose ESCALATION PERIOD,剂量递增期,1.0,['dose'],['dose'],1486,['剂量延伸时间'],1.0,['dose'],['dose'],,
1499,1487,"throughout the remainder of the trial , doses in both groups remained relatively stable .",在整个试验的剩余时间里，两组的剂量都保持相对稳定。,0.0,"['trial', 'in']",[],1487,"['在剩余的试验期间,两组的剂量保持相对稳定。']",0.0,"['trial', 'in']",[],,
1500,1488,most patients did not receive the maximum dose of liraglutide or placebo because fasting plasma glucose levels of 110 mg or less per deciliter were achieved with the lower dose .,大多数患者没有接受最大剂量的利拉鲁肽或安慰剂，因为使用较低剂量可达到 110 mg/dL 或更低的空腹血糖水平。,0.2,"['placebo', 'maximum dose', 'glucose', 'plasma', 'deciliter', 'lower', 'fasting', 'with', 'achieved', 'liraglutide']","['placebo', 'liraglutide']",1488,"['大多数患者没有获得最大剂量的利拉格卢蒂德或<unk>,因为禁食的血糖水平为110毫克或低于每分升,以较低的剂量实现。']",0.1,"['placebo', 'maximum dose', 'glucose', 'plasma', 'deciliter', 'lower', 'fasting', 'with', 'achieved', 'liraglutide']",['lower'],,
1501,1489,"only six patients who received liraglutide and four who received placebo were unable to increase the dose , owing to unacceptable side effects .",由于不可接受的副作用，只有 6 名接受利拉鲁肽的患者和 4 名接受安慰剂的患者无法增加剂量。,0.6,"['placebo', 'who', 'side effects', 'unacceptable', 'increase', 'liraglutide', 'dose', 'to', 'and', 'unable to']","['placebo', 'side effects', 'unacceptable', 'liraglutide', 'dose', 'to']",1489,"['只有6名接受Liraglutide的患者和4名接受 placebo的患者无法增加剂量,因为不接受的副作用。']",0.2,"['placebo', 'who', 'side effects', 'unacceptable', 'increase', 'liraglutide', 'dose', 'to', 'and', 'unable to']","['side effects', 'dose']",,
1502,1490,this finding showed the superiority of liraglutide to placebo .,这一发现表明利拉鲁肽优于安慰剂。,0.6,"['placebo', 'superiority', 'liraglutide', 'this', 'to']","['placebo', 'liraglutide', 'to']",1490,"['這些發現表明,Liraglutide對 placebo的優越性。']",0.0,"['placebo', 'superiority', 'liraglutide', 'this', 'to']",[],,
1503,1491,"the estimated treatment difference increased at week 52 ( − 1.30 percentage points ; 95 % CI , − 1.89 to − 0.70 ) ( Figure 2A ) .",估计的治疗差异在第 52 周时增加（- 1.30 个百分点；95% CI，- 1.89 至 - 0.70）（图 2A）。,0.5714285714285714,"['percentage', 'figure', 'difference', 'treatment', 'week', 'CI', 'to']","['figure', 'difference', 'treatment', 'week']",1491,"['估计的治疗差异增加了52周( − 1.30 百分点; 95 % CI, − 1.89 到 − 0.70 )(图 2A )。']",0.5714285714285714,"['percentage', 'figure', 'difference', 'treatment', 'week', 'CI', 'to']","['figure', 'difference', 'treatment', 'week']",,
1504,1492,the superiority of liraglutide to placebo in reducing fasting plasma glucose levels by 26 weeks and by 52 weeks was also shown ( Figure 2B ) .,还显示了利拉鲁肽在降低 26 周和 52 周空腹血糖水平方面优于安慰剂（图 2B）。,0.3,"['placebo', 'glucose', 'plasma', 'figure', 'fasting', 'superiority', 'liraglutide', 'by', 'to', 'and']","['placebo', 'liraglutide', 'to']",1492,"['此外,Liraglutide对禁食血糖水平降低26周和52周的 placebo的优越性也被证明(图2B)。']",0.1,"['placebo', 'glucose', 'plasma', 'figure', 'fasting', 'superiority', 'liraglutide', 'by', 'to', 'and']",['superiority'],,
1505,1493,"in contrast , the statistical superiority of liraglutide to placebo in lowering the BMI z score was not shown ; the estimated treatment difference at week 26 was − 0.05 ( 95 % CI , − 0.15 to 0.06 ) , which subsequently increased at week 52 to − 0.18 ( 95 % CI , − 0.33 to − 0.03 ) ( Figure 2C ) .",相比之下，利拉鲁肽在降低 BMI z 评分方面优于安慰剂的统计学优势并未显示出来；第 26 周时估计的治疗差异为 − 0.05（95% CI，− 0.15 至 0.06），随后在第 52 周增加至 − 0.18（95% CI，− 0.33 至 − 0.03）（图 2C）。,0.5384615384615384,"['placebo', 'contrast', 'figure', 'BMI', 'difference', 'treatment', 'week', 'superiority', 'score', 'liraglutide', 'lowering', 'CI', 'to']","['placebo', 'figure', 'difference', 'treatment', 'week', 'liraglutide', 'to']",1493,"['相比之下,Liraglutide 对 placebo 的统计优越性在降低 BMI z 分数方面没有显示;26 周的估计治疗差距为 − 0.05 (95 % CI, − 0.15 至 0.06 ),随后在 52 周增加至 − 0.18 ( 95 % CI, − 0.33 至 − 0.03 ) ( 图 2C ) 。']",0.3846153846153846,"['placebo', 'contrast', 'figure', 'BMI', 'difference', 'treatment', 'week', 'superiority', 'score', 'liraglutide', 'lowering', 'CI', 'to']","['figure', 'treatment', 'week', 'superiority', 'score']",,
1506,1494,"similarly , mean body weight decreased in both groups at week 26 ( − 2.3 kg with liraglutide and − 0.99 kg with placebo ) but was maintained only with liraglutide at week 52 ( − 1.91 kg with liraglutide vs. 0.87 kg with placebo ) .",同样，在第 26 周时，两组的平均体重均有所下降（利拉鲁肽组为 − 2.3 kg，安慰剂组为 − 0.99 kg），但仅在第 52 周时使用利拉鲁肽维持体重（利拉鲁肽组为 − 1.91 kg，安慰剂组为 0.87 kg）。,0.5454545454545454,"['body weight', 'placebo', 'mean', 'week', 'kg', 'with', 'liraglutide', 'at', 'in', 'but', 'and']","['body weight', 'placebo', 'mean', 'week', 'liraglutide', 'but']",1494,"['同样,在26周的两组中,平均体重下降( − 2.3 公斤与Liraglutide和 − 0.99 公斤与Placebo),但仅在52周与Liraglutide保持( − 1.91 公斤与Liraglutide相比 0.87 公斤与Placebo)。']",0.4545454545454545,"['body weight', 'placebo', 'mean', 'week', 'kg', 'with', 'liraglutide', 'at', 'in', 'but', 'and']","['body weight', 'mean', 'week', 'kg', 'but']",,
1507,1495,"the percentage of patients with adverse events with an onset ( or increase in severity ) on or after the first day of exposure to the trial drug and no later than 7 days after the last day of receipt of the trial drug was similar in the liraglutide and placebo groups ( Table 2 , and Table S5 in the Supplementary Appendix ) .",在暴露于试验药物的第一天或之后以及不迟于接受试验药物的最后一天后 7 天内发生不良事件（或严重程度增加）的患者百分比在利拉鲁肽中相似，并且安慰剂组（补充附录中的表 2 和表 S5）。,0.4761904761904761,"['percentage', 'placebo', 'appendix', 'table', 'exposure', '2', 'supplementary', 'adverse', 'onset', 'no', 'after', 'trial', 'increase', 'with', 'drug', 'liraglutide', 'later', 'to', 'and', 'first', 'similar']","['placebo', 'table', 'exposure', '2', 'after', 'drug', 'liraglutide', 'later', 'to', 'first']",1495,"['试用药物接触的第一天或之后出现(或重度增加)的副作用的患者的百分比,试用药物接收的最后一天后最迟7天,在Liraglutide和Placebo群体中是相似的(图2和附件中的S5表)。']",0.3809523809523809,"['percentage', 'placebo', 'appendix', 'table', 'exposure', '2', 'supplementary', 'adverse', 'onset', 'no', 'after', 'trial', 'increase', 'with', 'drug', 'liraglutide', 'later', 'to', 'and', 'first', 'similar']","['appendix', 'table', '2', 'after', 'drug', 'later', 'first', 'similar']",,
1508,1496,"nausea was the most frequently reported adverse event ( Table 2 ) , and the majority of all adverse events were mild in severity , resolved , and were considered by the investigators to be unrelated to liraglutide or placebo .",恶心是最常报告的不良事件（表 2），所有不良事件中的大多数严重程度较轻，已经解决，并且被研究人员认为与利拉鲁肽或安慰剂无关。,0.4375,"['placebo', 'table', '2', 'frequently', 'be', 'nausea', 'adverse', 'adverse event', 'majority', 'mild', 'liraglutide', 'all', 'in', 'by', 'to', 'and']","['placebo', 'table', '2', 'nausea', 'adverse event', 'majority', 'liraglutide']",1496,"['恶心是最常见的报告不良事件(图2),大多数所有不良事件是轻度的严重性,解决,并被研究人员认为与 liraglutide 或 placebo 无关。']",0.3125,"['placebo', 'table', '2', 'frequently', 'be', 'nausea', 'adverse', 'adverse event', 'majority', 'mild', 'liraglutide', 'all', 'in', 'by', 'to', 'and']","['2', 'nausea', 'adverse event', 'majority', 'mild']",,
1509,1497,a higher percentage of patients in the liraglutide group than in the placebo group had serious adverse events and medical events of special interest ( Table 2 ) .,与安慰剂组相比，利拉鲁肽组中发生严重不良事件和特殊医学事件的患者比例更高（表 2）。,0.5,"['group', 'percentage', 'placebo', 'table', '2', 'medical', 'adverse', 'liraglutide', 'serious', 'in', 'and', 'special']","['group', 'placebo', 'table', '2', 'liraglutide', 'special']",1497,"['利拉格卢蒂德群体的患者比 placebo群体的患者比例较高,患有严重的副作用和特殊兴趣的医学事件(图2)。']",0.25,"['group', 'percentage', 'placebo', 'table', '2', 'medical', 'adverse', 'liraglutide', 'serious', 'in', 'and', 'special']","['group', '2', 'special']",,
1510,1498,there was no clustering of serious adverse events ( Table S6 in the Supplementary Appendix ) .,没有聚集严重不良事件（补充附录中的表 S6）。,0.1428571428571428,"['appendix', 'clustering', 'table', 'supplementary', 'adverse', 'no', 'serious']",['table'],1498,['没有严重不良事件的分类(附件中的S6表)。'],0.2857142857142857,"['appendix', 'clustering', 'table', 'supplementary', 'adverse', 'no', 'serious']","['appendix', 'table']",,
1511,1499,no deaths were reported .,没有死亡报告。,0.0,['no'],[],1499,['没有死亡报告。'],0.0,['no'],[],,
1512,1500,the percentage of patients who had hypoglycemic episodes and the incidence of hypoglycemia were higher with liraglutide than with placebo ( Table 2 ) .,发生低血糖事件的患者百分比和低血糖发生率在利拉鲁肽组高于安慰剂组（表 2）。,0.4166666666666667,"['percentage', 'placebo', 'incidence', 'table', 'who', 'hypoglycemia', '2', 'episodes', 'with', 'liraglutide', 'hypoglycemic', 'and']","['placebo', 'incidence', 'table', '2', 'liraglutide']",1500,['患有催眠性病毒的患者比例和催眠性病毒的发病率比Liraglutide更高(图2)。'],0.1666666666666666,"['percentage', 'placebo', 'incidence', 'table', 'who', 'hypoglycemia', '2', 'episodes', 'with', 'liraglutide', 'hypoglycemic', 'and']","['incidence', '2']",,
1513,1501,"however , lipase levels were higher with liraglutide than with placebo at week 26 ( treatment ratio 1.20 ; 95 % CI , 1.08 to 1.32 ) and at week 52 ( treatment ratio , 1.11 ; 95 % CI , 1.01 to 1.23 ) , whereas amylase levels were similar in the two treatment groups at week 26 and week 52 .",然而，在第 26 周（治疗比率 1.20 ； 95 % CI ， 1.08 至 1.32 ）和第 52 周（治疗比率 1.11 ； 95 % CI ， 1.01 至 1.23 ），利拉鲁肽组的脂肪酶水平高于安慰剂组，而淀粉酶水平为两个治疗组在第 26 周和第 52 周时相似。,0.7142857142857143,"['amylase', 'placebo', 'lipase', 'ratio', 'treatment', 'week', 'with', 'liraglutide', 'CI', 'in', 'to', 'and', 'two', 'similar']","['amylase', 'placebo', 'lipase', 'ratio', 'treatment', 'week', 'liraglutide', 'to', 'and', 'two']",1501,"['然而,利拉格卢蒂德的脂肪含量比26周(治疗比例为1.20、95%的CI、1.08至1.32),52周(治疗比例为1.11、95%的CI、1.01至1.23),而在26周和52周的两组治疗中,氨基酸含量相似。']",0.3571428571428571,"['amylase', 'placebo', 'lipase', 'ratio', 'treatment', 'week', 'with', 'liraglutide', 'CI', 'in', 'to', 'and', 'two', 'similar']","['ratio', 'treatment', 'week', 'and', 'two']",,
1514,1502,"liraglutide also lowered fasting plasma glucose more than placebo , and almost twice as many patients in the liraglutide group than in the placebo group reached glycated hemoglobin levels less than 7.0 % .",利拉鲁肽还比安慰剂更能降低空腹血糖，利拉鲁肽组达到糖化血红蛋白水平低于 7.0% 的患者人数几乎是安慰剂组的两倍。,0.4444444444444444,"['group', 'placebo', 'glucose', 'plasma', 'hemoglobin', 'fasting', 'liraglutide', 'and', 'twice']","['group', 'placebo', 'hemoglobin', 'liraglutide']",1502,"['liraglutide 也降低了禁食的血糖比 placebo 多,而 liraglutide 群体的患者数量比 placebo 群体的患者数量几乎是两倍,血糖血糖水平低于 7.0 % 。']",0.2222222222222222,"['group', 'placebo', 'glucose', 'plasma', 'hemoglobin', 'fasting', 'liraglutide', 'and', 'twice']","['group', 'and']",,
1515,1503,"moreover , over the course of 52 weeks , a decrease of 0.50 percentage points in mean glycated hemoglobin levels was observed with liraglutide , whereas an increase of 0.80 percentage points was observed with placebo - an increase similar to previously reported changes in glycated hemoglobin levels observed over 12 months in youth with type 2 diabetes treated with metformin with or without insulin.14,15","此外，在52周的过程中，观察到利拉鲁肽的平均糖化血红蛋白水平下降了0.50个百分点，而安慰剂组则增加了0.80个百分点——这种增加与之前报道的糖化血红蛋白水平的变化相似。使用二甲双胍联合或不联合胰岛素治疗的 2 型糖尿病青年 12 个月。 14,15",0.5789473684210527,"['diabetes', 'percentage', 'type', 'placebo', 'decrease', 'mean', '2', 'hemoglobin', 'youth', 'course', 'increase', 'with', 'liraglutide', 'metformin', '-', 'over', 'to', 'without', 'similar']","['diabetes', 'type', 'placebo', 'mean', '2', 'hemoglobin', 'youth', 'course', 'liraglutide', 'metformin', 'over']",1503,"['此外,在52周内,利拉格卢蒂德的平均血糖水平下降了0.50个百分点,而在 placebo中出现了0.80个百分点的增加,类似于12个月以上的青少年患有2型糖尿病的血糖水平的变化。']",0.2631578947368421,"['diabetes', 'percentage', 'type', 'placebo', 'decrease', 'mean', '2', 'hemoglobin', 'youth', 'course', 'increase', 'with', 'liraglutide', 'metformin', '-', 'over', 'to', 'without', 'similar']","['diabetes', 'type', 'mean', '2', 'to']",,
1516,1504,"an unexpected finding of this trial was the lack of difference between the groups in BMI z score or body weight at week 26 , a finding that differs from the results of trials in adults.16,17","该试验的一个意外发现是第 26 周时各组之间的 BMI z 评分或体重没有差异，这一发现不同于成人试验的结果。 16,17",0.4545454545454545,"['body weight', 'lack', 'BMI', 'difference', 'week', 'trial', 'score', 'at', 'this', 'that', 'in']","['body weight', 'difference', 'week', 'at', 'this']",1504,"['这项试验的一个意想不到的发现是26周的BMI z分数或体重组之间的差异不足,与成人试验结果不同。']",0.4545454545454545,"['body weight', 'lack', 'BMI', 'difference', 'week', 'trial', 'score', 'at', 'this', 'that', 'in']","['body weight', 'difference', 'week', 'score', 'this']",,
1517,1505,"although the mean difference in weight loss between these treatment groups was similar to that in trials involving adults , 16,17 the relatively small number of patients in the current study and the fact that some children were probably still growing may explain the findings .","虽然这些治疗组之间体重减轻的平均差异与涉及成人的试验中的相似，16,17 但当前研究中的患者数量相对较少以及一些儿童可能仍在生长的事实可能解释了这些发现。",0.4,"['mean', 'weight', 'study', 'difference', 'still', 'loss', 'treatment', 'number', 'current', 'weight loss', 'that', 'in', 'to', 'and', 'similar']","['mean', 'weight', 'difference', 'treatment', 'number', 'in']",1505,"['虽然这些治疗组之间的体重减肥的平均差异类似于涉及成年人的研究,但目前研究中的患者数量相对较小,以及某些儿童可能仍然成长的事实,可以解释这些发现。']",0.4,"['mean', 'weight', 'study', 'difference', 'still', 'loss', 'treatment', 'number', 'current', 'weight loss', 'that', 'in', 'to', 'and', 'similar']","['mean', 'weight', 'difference', 'treatment', 'number', 'to']",,
1518,1506,another explanation may be the fact that only approximately 50 % of the liraglutide group received the full dose of 1.8 mg per day during the trial .,另一种解释可能是，在试验期间，只有大约 50% 的利拉鲁肽组接受了每天 1.8 mg 的全剂量。,0.4444444444444444,"['group', 'be', 'trial', 'explanation', 'liraglutide', 'dose', 'full', 'approximately', 'that']","['group', 'be', 'liraglutide', 'dose']",1506,"['另一个解释可能是,只有大约50%的利拉格卢蒂德群体在试验期间获得了每日1.8毫克的完整剂量。']",0.4444444444444444,"['group', 'be', 'trial', 'explanation', 'liraglutide', 'dose', 'full', 'approximately', 'that']","['group', 'be', 'dose', 'full']",,
1519,1507,"as was the case in studies involving adults with type 2 diabetes , 16,17 mild gastrointestinal complaints were the main cause of increased rates of adverse events with liraglutide .","与涉及成人 2 型糖尿病的研究一样，16,17 轻度胃肠道不适是利拉鲁肽不良事件发生率增加的主要原因。",0.7,"['diabetes', 'type', '2', 'gastrointestinal', 'adverse', 'cause', 'case', 'with', 'mild', 'liraglutide']","['diabetes', 'type', '2', 'gastrointestinal', 'cause', 'mild', 'liraglutide']",1507,"['在涉及2型糖尿病的成年人研究中,1617个轻微的肠道投诉是利拉格卢蒂德的副作用增加率的主要原因。']",0.4,"['diabetes', 'type', '2', 'gastrointestinal', 'adverse', 'cause', 'case', 'with', 'mild', 'liraglutide']","['diabetes', 'type', '2', 'cause']",,
1520,1508,"the observed incidence of hypoglycemia in the liraglutide group was low as compared with the previously reported incidence of clinically important hypoglycemia in youth with type 1 diabetes , 18,19 and many of the reported hypoglycemic episodes were due to low plasma glucose levels , without any symptoms .","在利拉鲁肽组观察到的低血糖发生率低于先前报道的 1 型糖尿病青年临床重要低血糖发生率， 18,19 并且许多报道的低血糖事件是由于血浆葡萄糖水平低，没有任何症状。 .",0.5555555555555556,"['group', 'diabetes', 'type', 'incidence', 'glucose', 'plasma', 'hypoglycemia', '1', 'symptoms', 'low', 'episodes', 'youth', 'due', 'with', 'liraglutide', 'hypoglycemic', 'and', 'without']","['group', 'diabetes', 'type', 'incidence', 'glucose', 'plasma', '1', 'low', 'youth', 'liraglutide']",1508,"['在利拉格卢蒂德群体中观察到的催眠症的发病率低于与患有1型糖尿病的青少年临床重要催眠症的发病率相比,18、19和许多报告的催眠症的发病率是由于低血糖水平,没有任何症状。']",0.3333333333333333,"['group', 'diabetes', 'type', 'incidence', 'glucose', 'plasma', 'hypoglycemia', '1', 'symptoms', 'low', 'episodes', 'youth', 'due', 'with', 'liraglutide', 'hypoglycemic', 'and', 'without']","['group', 'diabetes', 'type', 'incidence', '1', 'low']",,
1521,1509,the fact that approximately half the patients did not receive the highest dose may have limited data collection related to the safety profile of liraglutide .,大约一半的患者没有接受最高剂量这一事实可能限制了与利拉鲁肽安全性相关的数据收集。,0.6153846153846154,"['safety', 'data', 'half', 'collection', 'profile', 'data collection', 'liraglutide', 'dose', 'limited', 'have', 'approximately', 'that', 'to']","['safety', 'data', 'half', 'collection', 'data collection', 'liraglutide', 'dose', 'have']",1509,"['事实上,大约一半的患者没有获得最高剂量,可能有与利拉格卢蒂德的安全性相关的有限数据收集。']",0.5384615384615384,"['safety', 'data', 'half', 'collection', 'profile', 'data collection', 'liraglutide', 'dose', 'limited', 'have', 'approximately', 'that', 'to']","['safety', 'data', 'half', 'collection', 'data collection', 'dose', 'have']",,
1522,1510,"the trial was also limited by the long recruitment period ( owing to problems inherent in clinical trials of youth with type 2 diabetes2 ) , which necessitated some protocol amendments .",该试验还受到招募期长的限制（由于 2 型糖尿病青年临床试验中固有的问题2），这需要对方案进行一些修正。,0.5833333333333334,"['type', 'period', 'inherent', '2', 'protocol', 'recruitment', 'clinical', 'trial', 'youth', 'with', 'limited', 'by']","['type', 'period', 'inherent', '2', 'clinical', 'youth', 'by']",1510,"['审查也受到长期招聘期限的限制(由于患有2型糖尿病的青少年临床试验中存在的问题),这需要一些议定书修正案。']",0.5,"['type', 'period', 'inherent', '2', 'protocol', 'recruitment', 'clinical', 'trial', 'youth', 'with', 'limited', 'by']","['type', 'period', '2', 'protocol', 'clinical', 'by']",,
1523,1511,"in addition , because of the somewhat limited diversity of the trial population , the results may not be generalizable to all other populations .",此外，由于试验人群的多样性有限，结果可能无法推广到所有其他人群。,0.3333333333333333,"['diversity', 'population', 'addition', 'be', 'trial', 'limited', 'all', 'in', 'to']","['diversity', 'population', 'to']",1511,"['除此之外,由于试验人口的多样性略有有限,结果可能对所有其他人口都无法普遍化。']",0.3333333333333333,"['diversity', 'population', 'addition', 'be', 'trial', 'limited', 'all', 'in', 'to']","['diversity', 'population', 'to']",,
1524,1512,"in summary , the current study showed the superiority of liraglutide to placebo , when added to metformin , with or without basal insulin , with respect to glycemic control in children and adolescents .",总而言之，当前的研究表明，在儿童和青少年的血糖控制方面，利拉鲁肽在添加到二甲双胍（有或没有基础胰岛素）时优于安慰剂。,0.5714285714285714,"['insulin', 'placebo', 'basal', 'control', 'study', 'superiority', 'current', 'with', 'respect', 'liraglutide', 'metformin', 'to', 'and', 'without']","['insulin', 'placebo', 'control', 'current', 'liraglutide', 'metformin', 'to', 'and']",1512,"['总而言之,目前的研究表明,当添加到甲状腺素时,利拉格卢蒂德对 placebo的优越性,与基因胰岛素或没有,与儿童和青少年的血糖控制有关。']",0.2857142857142857,"['insulin', 'placebo', 'basal', 'control', 'study', 'superiority', 'current', 'with', 'respect', 'liraglutide', 'metformin', 'to', 'and', 'without']","['insulin', 'control', 'superiority', 'and']",,
1525,1513,gastrointestinal adverse events were more common in the liraglutide group .,胃肠道不良事件在利拉鲁肽组更为常见。,0.6,"['group', 'gastrointestinal', 'common', 'adverse', 'liraglutide']","['group', 'gastrointestinal', 'liraglutide']",1513,['胃肠不良事件在Liraglutide群体中更常见。'],0.4,"['group', 'gastrointestinal', 'common', 'adverse', 'liraglutide']","['group', 'gastrointestinal']",,
1526,1514,"male sex , older age , mutations in MLH1 or MSH2 , and family history are associated with increased risk .",男性、年龄较大、MLH1 或 MSH2 突变以及家族史与风险增加有关。,0.6,"['family', 'sex', 'male', 'family history', 'associated', 'age', 'risk', 'with', 'in', 'and']","['family', 'sex', 'male', 'family history', 'age', 'risk']",1514,['男性性别、老年、MLH1或MSH2的突变和家庭史与风险增加有关。'],0.4,"['family', 'sex', 'male', 'family history', 'associated', 'age', 'risk', 'with', 'in', 'and']","['family', 'sex', 'male', 'risk']",,
1527,1515,the cumulative risk for gastric cancer in patients with Lynch syndrome ( LS ) is estimated to be 7 % to 8 % .,林奇综合征 (LS) 患者患胃癌的累积风险估计为 7% 至 8%。,0.4,"['cancer', 'gastric', 'syndrome', 'be', 'cumulative', 'risk', 'with', 'gastric cancer', 'in', 'to']","['cancer', 'syndrome', 'risk', 'gastric cancer']",1515,"['在患有林奇综合征(LS)的患者中,胃癌的累积风险估计为7%至8%。']",0.5,"['cancer', 'gastric', 'syndrome', 'be', 'cumulative', 'risk', 'with', 'gastric cancer', 'in', 'to']","['cancer', 'syndrome', 'be', 'risk', 'gastric cancer']",,
1528,1516,"however , there are sparse data regarding risk factors and the impact of screening on patient outcomes , resulting in disparate guideline recommendations .",然而，关于风险因素和筛查对患者结果的影响的数据很少，导致指南建议各不相同。,0.7,"['data', 'sparse', 'screening', 'regarding', 'impact', 'risk', 'disparate', 'patient', 'on', 'and']","['data', 'screening', 'regarding', 'impact', 'risk', 'patient', 'and']",1516,"['然而,关于风险因素和筛查对患者结果的影响的数据差不多,导致不同的指导方针建议。']",0.8,"['data', 'sparse', 'screening', 'regarding', 'impact', 'risk', 'disparate', 'patient', 'on', 'and']","['data', 'screening', 'regarding', 'impact', 'risk', 'disparate', 'patient', 'and']",,
1529,1517,clinical and family histories were obtained by referring providers .,临床和家族史是通过转诊提供者获得的。,0.5,"['family', 'clinical', 'by', 'and']","['family', 'clinical']",1517,['临床和家庭史由参考供应商获取。'],0.75,"['family', 'clinical', 'by', 'and']","['family', 'clinical', 'by']",,
1530,1518,"in multivariate analysis , the following factors were associated with gastric cancer :",在多变量分析中，以下因素与胃癌有关：,0.4444444444444444,"['cancer', 'gastric', 'analysis', 'associated', 'multivariate analysis', 'with', 'gastric cancer', 'in', 'following']","['cancer', 'analysis', 'multivariate analysis', 'gastric cancer']",1518,"['在多元化分析中,以下因素与胃癌有关:']",0.3333333333333333,"['cancer', 'gastric', 'analysis', 'associated', 'multivariate analysis', 'with', 'gastric cancer', 'in', 'following']","['cancer', 'analysis', 'gastric cancer']",,
1531,1519,"male sex ( odds ratio , 2.8 )",男性（比值比，2.8）,0.75,"['sex', 'ratio', 'male', 'odds']","['sex', 'ratio', 'male']",1519,"['男性性别(比率,2.8 )']",0.75,"['sex', 'ratio', 'male', 'odds']","['sex', 'ratio', 'male']",,
1532,1520,"older age ( OR , 2.1 per 10 years )",年龄较大（或，每 10 年 2.1）,0.5,"['age', 'OR']",['age'],1520,"['老年人(或,每 10 年 2.1 )']",0.0,"['age', 'OR']",[],,
1533,1521,"mutations in MLH1 ( OR , 6.5 ) or MSH2 ( OR , 5.2 ) compared with mutations in MSH6 , PMS2 , or EPCAM","MLH1 ( OR , 6.5 ) 或 MSH2 ( OR , 5.2 ) 突变与 MSH6 、 PMS2 或 EPCAM 突变相比较",0.0,"['OR', 'with', 'in']",[],1521,['MLH1(OR、6.5)或MSH2(OR、5.2)的突变与MSH6、PMS2或EPCAM的突变相比'],0.0,"['OR', 'with', 'in']",[],,
1534,1522,"although the concept of tailoring LS screening recommendations is not new , most of the available evidence has pertained to colorectal cancer , with less focus on rarer but potentially highly lethal malignancies .",尽管定制 LS 筛查建议的概念并不新鲜，但大多数可用证据都与结直肠癌有关，较少关注更罕见但可能具有高致命性的恶性肿瘤。,0.5,"['focus', 'cancer', 'screening', 'lethal', 'colorectal cancer', 'available', 'evidence', 'concept', 'with', 'but', 'to', 'new']","['cancer', 'screening', 'evidence', 'concept', 'but', 'new']",1522,"['虽然调整 LS 筛查建议的概念并不新鲜,但大多数可用的证据都涉及到染色性癌症,重点较少的是更罕见但潜在的致命恶性疾病。']",0.5833333333333334,"['focus', 'cancer', 'screening', 'lethal', 'colorectal cancer', 'available', 'evidence', 'concept', 'with', 'but', 'to', 'new']","['cancer', 'screening', 'available', 'evidence', 'concept', 'but', 'new']",,
1535,1523,other studies have also identified Asian ancestry as a risk factor for gastric cancer in LS .,其他研究也已将亚洲血统确定为 LS 胃癌的危险因素。,0.4444444444444444,"['a', 'cancer', 'gastric', 'factor', 'risk', 'risk factor', 'gastric cancer', 'have', 'in']","['cancer', 'factor', 'risk', 'gastric cancer']",1523,['其他研究还确定了亚洲祖先作为胃癌的风险因素。'],0.5555555555555556,"['a', 'cancer', 'gastric', 'factor', 'risk', 'risk factor', 'gastric cancer', 'have', 'in']","['cancer', 'factor', 'risk', 'risk factor', 'gastric cancer']",,
1536,1524,"the presence of one or more of these factors should mandate endoscopic screening and regular surveillance , although the frequency of the latter requires additional prospective study .",这些因素中的一种或多种的存在应该要求进行内镜筛查和定期监测，尽管后者的频率需要额外的前瞻性研究。,0.6666666666666666,"['presence', 'frequency', 'screening', 'study', 'prospective study', 'surveillance', 'regular', 'additional', 'and']","['presence', 'frequency', 'screening', 'prospective study', 'surveillance', 'additional']",1524,"['其中一个或多个因素的存在应要求进行内分泌筛查和定期监测,尽管其频率需要进一步的预期研究。']",0.4444444444444444,"['presence', 'frequency', 'screening', 'study', 'prospective study', 'surveillance', 'regular', 'additional', 'and']","['presence', 'frequency', 'screening', 'surveillance']",,
1537,1525,new evidence indicates that smoking cessation might blunt risk for developing RA .,新的证据表明，戒烟可能会降低患 RA 的风险。,0.5,"['developing', 'risk', 'smoking cessation', 'evidence', 'blunt', 'RA', 'that', 'new']","['risk', 'smoking cessation', 'evidence', 'new']",1525,"['新的证据表明,戒烟可能会导致 RA 发育的风险。']",0.5,"['developing', 'risk', 'smoking cessation', 'evidence', 'blunt', 'RA', 'that', 'new']","['risk', 'smoking cessation', 'evidence', 'new']",,
1538,1526,"previous epidemiologic studies have demonstrated that cigarette smoking is an important risk factor for rheumatoid arthritis ( RA ) , especially seropositive RA .",以往的流行病学研究表明，吸烟是类风湿性关节炎（RA），尤其是血清阳性RA的重要危险因素。,0.4615384615384615,"['arthritis', 'demonstrated', 'factor', 'rheumatoid', 'previous', 'cigarette', 'seropositive', 'risk', 'risk factor', 'RA', 'rheumatoid arthritis', 'have', 'that']","['arthritis', 'demonstrated', 'factor', 'risk', 'RA', 'rheumatoid arthritis']",1526,"['以前的流行病学研究表明,吸烟是 rheumatoid arthritis (RA ) 的重要风险因素,尤其是血清积极的RA。']",0.3846153846153846,"['arthritis', 'demonstrated', 'factor', 'rheumatoid', 'previous', 'cigarette', 'seropositive', 'risk', 'risk factor', 'RA', 'rheumatoid arthritis', 'have', 'that']","['demonstrated', 'factor', 'previous', 'risk', 'risk factor']",,
1539,1527,"however , whether smoking cessation lowers risk for developing RA is unclear .",然而，戒烟是否会降低患 RA 的风险尚不清楚。,0.5,"['developing', 'risk', 'smoking cessation', 'RA']","['risk', 'smoking cessation']",1527,"['然而,是否戒烟会降低 RA 发育的风险是不清楚的。']",0.5,"['developing', 'risk', 'smoking cessation', 'RA']","['risk', 'smoking cessation']",,
1540,1528,"between 1976 and 2015 , 1528 new cases of RA ( 63 % seropositive ) were identified in 230,000 women .","1976 年至 2015 年间，在 230,000 名女性中发现了 1528 例新的类风湿性关节炎病例（63% 为血清阳性）。",0.4,"['seropositive', 'RA', 'in', 'and', 'new']","['RA', 'new']",1528,"['在1976年至2015年间,在230,000名妇女中发现了1528例新病例(63%)。']",0.2,"['seropositive', 'RA', 'in', 'and', 'new']",['new'],,
1541,1529,"compared with never smoking , current smoking significantly raised risk for all RA and seropositive RA .",与从不吸烟相比，当前吸烟会显着增加所有 RA 和血清阳性 RA 的风险。,0.125,"['seropositive', 'risk', 'raised', 'current', 'with', 'RA', 'all', 'and']",['risk'],1529,"['与从未吸烟相比,目前的吸烟对所有 RA 和 seropositive RA 的风险显著增加。']",0.125,"['seropositive', 'risk', 'raised', 'current', 'with', 'RA', 'all', 'and']",['risk'],,
1542,1530,"however , compared with risk in never smokers , risk for all RA and seropositive RA remained slightly elevated in former smokers , even those who had stopped the longest .",然而，与从不吸烟者的风险相比，所有 RA 和血清阳性 RA 的风险在前吸烟者中仍然略有升高，即使是那些戒烟时间最长的人。,0.2222222222222222,"['who', 'seropositive', 'former', 'risk', 'with', 'RA', 'all', 'in', 'and']","['risk', 'and']",1530,"['然而,与从未吸烟者的风险相比,所有 RA 和血清积极的 RA 的风险在以前的吸烟者中仍然稍微上升,即使是那些最长时间停止过的吸烟者。']",0.2222222222222222,"['who', 'seropositive', 'former', 'risk', 'with', 'RA', 'all', 'in', 'and']","['risk', 'and']",,
1543,1531,this study adds to our understanding of RA development .,这项研究增加了我们对 RA 发展的理解。,0.2,"['study', 'development', 'RA', 'this', 'to']",['development'],1531,['这项研究增加了我们对RA发展的理解。'],0.2,"['study', 'development', 'RA', 'this', 'to']",['development'],,
1544,1532,"in previously treated patients with FGFR alterations , the response rate with erdafitinib was 40 % .",在既往接受过 FGFR 改变治疗的患者中，erdafitinib 的缓解率为 40%。,0.2,"['rate', 'response', 'response rate', 'with', 'in']",['rate'],1532,"['在患有FGFR变异的患者中,对Erdafitinib的反应率为40%。']",0.6,"['rate', 'response', 'response rate', 'with', 'in']","['rate', 'response', 'response rate']",,
1545,1533,"among the 99 patients assigned to the optimal dose group ( 8 mg / day escalated to 9 mg / day ) , the confirmed response rate ( the primary endpoint ) was 40 % ; an additional 39 % achieved stable disease .",在分配到最佳剂量组（8 毫克/天增加到 9 毫克/天）的 99 名患者中，确认的反应率（主要终点）为 40%；另有 39% 的患者病情稳定。,0.4615384615384615,"['group', 'disease', 'rate', '/', 'primary', 'optimal', 'response', 'additional', 'response rate', 'achieved', 'endpoint', 'dose', 'to']","['group', 'disease', 'rate', 'response', 'response rate', 'dose']",1533,"['在99名患者中,被分配到最佳剂量组(8 mg / 日升至9 mg / 日),确认的反应率(初级终点)为40%;额外的39%实现了稳定的疾病。']",0.5384615384615384,"['group', 'disease', 'rate', '/', 'primary', 'optimal', 'response', 'additional', 'response rate', 'achieved', 'endpoint', 'dose', 'to']","['group', 'disease', 'rate', 'response', 'additional', 'response rate', 'dose']",,
1546,1534,response rates were similar regardless of prior therapy or of the presence or absence of visceral metastases .,无论先前的治疗或是否存在内脏转移，反应率都是相似的。,0.7142857142857143,"['presence', 'therapy', 'visceral', 'absence', 'response', 'prior', 'similar']","['presence', 'therapy', 'response', 'prior', 'similar']",1534,"['答案率是相似的,无论是预先治疗或存在或缺席的阴道转移。']",0.5714285714285714,"['presence', 'therapy', 'visceral', 'absence', 'response', 'prior', 'similar']","['presence', 'therapy', 'absence', 'similar']",,
1547,1535,response rates were 49 % in the 74 patients with FGFR mutations and 16 % in the 25 with FGFR fusions .,74 名 FGFR 突变患者的反应率为 49%，25 名 FGFR 融合患者的反应率为 16%。,0.25,"['response', 'with', 'in', 'and']",['response'],1535,"['答案率为74名患有FGFR突变的患者中49%,25名患有FGFR合并的患者中16%。']",0.0,"['response', 'with', 'in', 'and']",[],,
1548,1536,"in the 22 patients with prior CPI therapy , the response rate was 59 % .",在 22 名既往接受过 CPI 治疗的患者中，反应率为 59%。,0.5714285714285714,"['rate', 'therapy', 'response', 'prior', 'response rate', 'with', 'in']","['rate', 'therapy', 'response', 'response rate']",1536,"['在22名患有先前CPI治疗的患者中,反应率为59%。']",0.7142857142857143,"['rate', 'therapy', 'response', 'prior', 'response rate', 'with', 'in']","['rate', 'therapy', 'response', 'prior', 'response rate']",,
1549,1537,"on the basis of this study , erdafitinib was granted FDA approval for patients with selected FGFR mutations .",在此研究的基础上，erdafitinib 被 FDA 批准用于具有特定 FGFR 突变的患者。,0.1428571428571428,"['approval', 'study', 'basis', 'FDA', 'with', 'on', 'this']",['approval'],1537,"['基于这项研究,Erdafitinib被授予FDA批准的患者与选择的FGFR突变。']",0.1428571428571428,"['approval', 'study', 'basis', 'FDA', 'with', 'on', 'this']",['approval'],,
1550,1538,"although erdafitinib may be an important development for patients with advanced urothelial cancer , a number of issues remain .",尽管 erdafitinib 可能是晚期尿路上皮癌患者的一项重要进展，但仍存在许多问题。,0.2857142857142857,"['a', 'cancer', 'be', 'number', 'advanced', 'development', 'with']","['cancer', 'be']",1538,"['虽然 erdafitinib 可能是患有先进的尿道癌的患者的重要发展,但仍然存在一些问题。']",0.4285714285714285,"['a', 'cancer', 'be', 'number', 'advanced', 'development', 'with']","['cancer', 'be', 'development']",,
1551,1539,"more than 60 % of pneumonias were due to viruses , predominantly respiratory syncytial virus ; the most common bacterial causes were Streptococcus pneumoniae , Haemophilus influenzae , and Mycobacterium tuberculosis .",超过 60% 的肺炎是由病毒引起的，主要是呼吸道合胞病毒；最常见的细菌性病因是肺炎链球菌、流感嗜血杆菌和结核分枝杆菌。,0.6153846153846154,"['virus', 'tuberculosis', 'influenzae', 'syncytial', 'streptococcus', 'mycobacterium tuberculosis', 'haemophilus', 'respiratory syncytial virus', 'haemophilus influenzae', 'common', 'streptococcus pneumoniae', 'due', 'and']","['virus', 'tuberculosis', 'influenzae', 'streptococcus', 'mycobacterium tuberculosis', 'haemophilus', 'haemophilus influenzae', 'streptococcus pneumoniae']",1539,"['超过60%的肺炎是由于病毒,主要是呼吸合成病毒;最常见的细菌原因是Streptococcus pneumoniae,Haemophilus influenzae,和Mycobacterium tuberculosis。']",0.0769230769230769,"['virus', 'tuberculosis', 'influenzae', 'syncytial', 'streptococcus', 'mycobacterium tuberculosis', 'haemophilus', 'respiratory syncytial virus', 'haemophilus influenzae', 'common', 'streptococcus pneumoniae', 'due', 'and']",['virus'],,
1552,1540,"Haemophilus influenzae type B vaccine was routinely used in most sites , pneumococcal conjugate vaccine in about half .",大多数场所常规使用B型流感嗜血杆菌疫苗，约一半使用肺炎球菌结合疫苗。,1.0,"['type', 'influenzae', 'haemophilus', 'haemophilus influenzae', 'conjugate', 'half', 'haemophilus influenzae type B', 'vaccine']","['type', 'influenzae', 'haemophilus', 'haemophilus influenzae', 'conjugate', 'half', 'haemophilus influenzae type B', 'vaccine']",1540,"['Haemophilus influenzae 型 B 疫苗在大多数地方常用,肺结核疫苗在大约一半。']",0.375,"['type', 'influenzae', 'haemophilus', 'haemophilus influenzae', 'conjugate', 'half', 'haemophilus influenzae type B', 'vaccine']","['type', 'half', 'vaccine']",,
1553,1541,Streptococcus pneumoniae was the most common bacterial cause ; it caused more than one third of very severe pneumonia cases .,肺炎链球菌是最常见的细菌性病因；它引起了三分之一以上的非常严重的肺炎病例。,0.3333333333333333,"['streptococcus', 'common', 'cause', 'streptococcus pneumoniae', 'severe', 'third']","['streptococcus', 'streptococcus pneumoniae']",1541,['Streptococcus pneumoniae 是最常见的细菌原因;它导致超过三分之一的非常严重的肺炎病例。'],0.1666666666666666,"['streptococcus', 'common', 'cause', 'streptococcus pneumoniae', 'severe', 'third']",['cause'],,
1554,1542,"among all pathogens , respiratory syncytial virus ( RSV ) accounted for the most cases ( 31 % ) .",在所有病原体中，呼吸道合胞病毒（RSV）占病例数最多（31%）。,0.4,"['virus', 'syncytial', 'RSV', 'respiratory syncytial virus', 'all']","['virus', 'RSV']",1542,"['在所有病原体中,呼吸合成病毒(RSV)是最常见的病例(31%)。']",0.2,"['virus', 'syncytial', 'RSV', 'respiratory syncytial virus', 'all']",['virus'],,
1555,1543,prevalence of pneumonia and predominant causes varied widely by age and geographic location .,肺炎的患病率和主要原因因年龄和地理位置而异。,0.4444444444444444,"['location', 'prevalence', 'age', 'geographic', 'predominant', 'pneumonia', 'by', 'and', 'varied']","['location', 'age', 'pneumonia', 'and']",1543,['肺炎的发病率和主要原因因年龄和地理位置而异。'],0.4444444444444444,"['location', 'prevalence', 'age', 'geographic', 'predominant', 'pneumonia', 'by', 'and', 'varied']","['location', 'age', 'pneumonia', 'and']",,
1556,1544,TEN pathogens together accounted for about 80 % of the cases .,十种病原体合计约占病例的80%。,,[],[],1544,['TEN病原体共占约80%的病例。'],,[],[],,
1557,1545,"of the case pathogens , vaccines exist for 14 % .",在病原体的情况下，疫苗存在的比例为 14%。,0.5,"['case', 'exist']",['exist'],1545,"['在病原体的情况下,疫苗存在14%。']",0.5,"['case', 'exist']",['exist'],,
1558,1546,"the low number of common pathogens identified should allow more targeted development of interventions , including vaccines .",查明的常见病原体数量很少，应该可以更有针对性地开发干预措施，包括疫苗。,0.2,"['targeted', 'allow', 'common', 'number', 'development']",['number'],1546,"['发现的常见病原体数量较低,应允许更有针对性的干预,包括疫苗。']",0.4,"['targeted', 'allow', 'common', 'number', 'development']","['allow', 'number']",,
1559,1547,RSV should be a primary target ; this study clearly documents the key role of RSV in serious respiratory infections .,RSV 应该是主要目标；这项研究清楚地记录了 RSV 在严重呼吸道感染中的关键作用。,0.4166666666666667,"['a', 'key', 'RSV', 'respiratory', 'study', 'be', 'role', 'primary', 'target', 'serious', 'this', 'in']","['key', 'be', 'role', 'target', 'this']",1547,['RSV应该是主要目标;这项研究清楚地证明了RSV在严重的呼吸道感染中的关键作用。'],0.4166666666666667,"['a', 'key', 'RSV', 'respiratory', 'study', 'be', 'role', 'primary', 'target', 'serious', 'this', 'in']","['key', 'be', 'role', 'target', 'this']",,
1560,1548,"in addition to wider use of existing vaccines , other strategies to reduce the burden of respiratory infections include exclusive breastfeeding , better nutrition , and protection from indoor air pollution .",除了更广泛地使用现有疫苗外，其他减轻呼吸道感染负担的策略包括纯母乳喂养、更好的营养和防止室内空气污染。,0.2727272727272727,"['air pollution', 'nutrition', 'protection', 'reduce', 'addition', 'respiratory', 'indoor', 'exclusive', 'breastfeeding', 'and', 'burden']","['air pollution', 'nutrition', 'breastfeeding']",1548,"['除了广泛使用现有疫苗之外,减少呼吸道感染的负担的其他策略还包括独家哺乳、营养和防室空气污染的保护。']",0.2727272727272727,"['air pollution', 'nutrition', 'protection', 'reduce', 'addition', 'respiratory', 'indoor', 'exclusive', 'breastfeeding', 'and', 'burden']","['air pollution', 'nutrition', 'protection']",,
1561,1549,"as an editorialist notes , given high percentage of cases caused by viruses , strategies should be implemented to limit antibiotic use for viral infections .",正如一位社论所指出的那样，鉴于病毒引起的病例比例很高，应实施策略以限制抗生素在病毒感染中的使用。,0.7777777777777778,"['percentage', 'antibiotic', 'be', 'viral', 'limit', 'as', 'by', 'to', 'high']","['antibiotic', 'be', 'limit', 'as', 'by', 'to', 'high']",1549,"['作为编辑的注意事项,考虑到病毒引起的病例的比例很高,应实施限制抗生素对病毒感染的使用策略。']",0.3333333333333333,"['percentage', 'antibiotic', 'be', 'viral', 'limit', 'as', 'by', 'to', 'high']","['antibiotic', 'limit', 'high']",,
1562,1550,CRC risk associated with nonadvanced adenomas or small serrated polyps is no different than having no polyps .,与非晚期腺瘤或小锯齿状息肉相关的 CRC 风险与没有息肉没有什么不同。,0.2,"['serrated', 'associated', 'no', 'risk', 'with']",['risk'],1550,['与不先进的肾上腺素或小粘膜聚合物相关的CRC风险与没有聚合物没有不同。'],0.2,"['serrated', 'associated', 'no', 'risk', 'with']",['risk'],,
1563,1551,surveillance colonoscopy for colorectal cancer ( CRC ) is recommended at intervals determined by the most advanced lesions at baseline examinations .,建议根据基线检查时最晚期病变确定的时间间隔对结直肠癌 (CRC) 进行监测结肠镜检查。,0.4444444444444444,"['cancer', 'baseline', 'colorectal cancer', 'surveillance', 'examinations', 'advanced', 'by', 'intervals', 'colonoscopy']","['cancer', 'baseline', 'surveillance', 'colonoscopy']",1551,['对染色性癌症(CRC)的监测科隆斯科建议在基线检查中最先进的伤害确定的间隔进行。'],0.3333333333333333,"['cancer', 'baseline', 'colorectal cancer', 'surveillance', 'examinations', 'advanced', 'by', 'intervals', 'colonoscopy']","['cancer', 'baseline', 'surveillance']",,
1564,1552,"nonadvanced adenomas : aHR , 1.21 ; P = 0.52",非晚期腺瘤：aHR，1.21； P = 0.52,0.0,['P'],[],1552,"['未进展的肾上腺素 : aHR, 1.21 ; P = 0.52']",0.0,['P'],[],,
1565,1553,"any serrated polyp : aHR , 1.52 ; P = 0.05",任何锯齿状息肉：aHR，1.52； P = 0.05,0.3333333333333333,"['polyp', 'serrated', 'P']",['polyp'],1553,"['任何粘膜聚合物 : aHR, 1.52 ; P = 0.05']",0.0,"['polyp', 'serrated', 'P']",[],,
1566,1554,"large serrated polyps ( ≥ 10 mm ) : aHR , 3.35 ; P = 0.008",大锯齿状息肉（≥10 毫米）：aHR，3.35； P = 0.008,0.0,"['large', 'serrated', 'P']",[],1554,"['大粘膜聚合物( ≥ 10 毫米 ) : aHR, 3.35 ; P = 0.008']",0.0,"['large', 'serrated', 'P']",[],,
1567,1555,"however , the most notable findings in this study pertain to the much more prevalent nonadvanced adenomas and small serrated polyps , for which metachronous CRC risks were not significantly different than having no polyps at baseline .",然而，这项研究中最值得注意的发现与更普遍的非晚期腺瘤和小锯齿状息肉有关，对于这些，异时性 CRC 风险与基线时没有息肉没有显着差异。,0.375,"['baseline', 'study', 'serrated', 'no', 'prevalent', 'this', 'to', 'and']","['baseline', 'to', 'and']",1555,"['然而,这项研究中最显著的发现属于更常见的非先进的肾上腺素和小细胞聚合物,对这些聚合物的甲状腺疾病风险并不大不同于没有聚合物在基线上。']",0.375,"['baseline', 'study', 'serrated', 'no', 'prevalent', 'this', 'to', 'and']","['baseline', 'to', 'and']",,
1568,1556,identifying predictive markers would allow for enhanced treatment protocols for these infants .,确定预测标记将有助于加强对这些婴儿的治疗方案。,0.3333333333333333,"['allow', 'treatment', 'predictive']",['treatment'],1556,['识别预测标记将允许这些婴儿的增强治疗协议。'],0.6666666666666666,"['allow', 'treatment', 'predictive']","['allow', 'treatment']",,
1569,1557,"in a secondary analysis of data from the Multicenter Airway Research Collaboration , researchers assessed the association between serum albumin level and apnea in 1016 infants ( median age , 3 months ) hospitalized with bronchiolitis and without confounding heart and lung conditions .",在对来自多中心气道研究协作组织的数据进行的二次分析中，研究人员评估了 1016 名因毛细支气管炎住院且没有混杂心肺疾病的婴儿（中位年龄，3 个月）的血清白蛋白水平与呼吸暂停之间的关联。,0.5909090909090909,"['heart', 'lung', 'median', 'albumin', 'research', 'apnea', 'data', 'serum albumin', 'analysis', 'association', 'bronchiolitis', 'airway', 'age', 'secondary', '3', 'level', 'collaboration', 'with', 'median age', 'and', 'without', 'assessed']","['heart', 'lung', 'albumin', 'research', 'apnea', 'data', 'serum albumin', 'analysis', 'association', 'bronchiolitis', 'airway', 'age', 'level']",1557,"['在Multicenter Airway Research Collaboration的数据的次要分析中,研究人员评估了1016名婴儿(中年3个月)患有 bronchiolitis和没有混乱的心脏和肺部疾病的血清阿尔博丁水平和<unk>疹之间的联系。']",0.3181818181818182,"['heart', 'lung', 'median', 'albumin', 'research', 'apnea', 'data', 'serum albumin', 'analysis', 'association', 'bronchiolitis', 'airway', 'age', 'secondary', '3', 'level', 'collaboration', 'with', 'median age', 'and', 'without', 'assessed']","['heart', 'lung', 'research', 'data', 'analysis', 'association', 'level']",,
1570,1558,apnea occurred in 25 infants during hospitalization and in 44 infants before but not during hospitalization .,25 名婴儿在住院期间发生呼吸暂停，44 名婴儿在住院前但未在住院期间发生。,0.6666666666666666,"['apnea', 'hospitalization', 'before', 'in', 'but', 'and']","['apnea', 'hospitalization', 'before', 'but']",1558,"['在入院期间的25名婴儿和在入院前的44名婴儿中,但在入院期间没有出现失眠。']",0.3333333333333333,"['apnea', 'hospitalization', 'before', 'in', 'but', 'and']","['before', 'but']",,
1571,1559,among the findings :,其中的调查结果：,,[],[],1559,['在这些发现中:'],,[],[],,
1572,1559,among the findings :,其中的调查结果：,,[],[],1559,['在这些发现中:'],,[],[],,
1573,1560,"among the 25 infants with apnea during hospitalization , the median serum albumin level was 3.5 g / dL and 22 infants ( 88 % ) had low levels .",住院期间出现呼吸暂停的25例患儿血清白蛋白中位值为3.5 g/dL，22例(88%)低。,0.5454545454545454,"['median', 'albumin', 'apnea', 'serum albumin', '/', 'hospitalization', 'low', 'level', 'with', 'and', 'g']","['median', 'albumin', 'apnea', 'serum albumin', 'hospitalization', 'low']",1560,"['在入院期间患有腹泻的25名婴儿中,中间血清 albumin 水平为 3.5 g / dL,22名婴儿(88%) 水平低。']",0.1818181818181818,"['median', 'albumin', 'apnea', 'serum albumin', '/', 'hospitalization', 'low', 'level', 'with', 'and', 'g']","['low', 'level']",,
1574,1561,overall prevalence of apnea was 5.7 % in infants with low albumin versus 0.5 % in those with normal albumin .,低白蛋白婴儿的呼吸暂停总患病率为 5.7%，而白蛋白正常的婴儿为 0.5%。,0.6666666666666666,"['albumin', 'apnea', 'prevalence', 'normal', 'low', 'with']","['albumin', 'apnea', 'normal', 'low']",1561,['一般腹泻的发病率在低 albumin 婴儿中为 5.7% 与正常 albumin 婴儿中为 0.5%.'],0.1666666666666666,"['albumin', 'apnea', 'prevalence', 'normal', 'low', 'with']",['low'],,
1575,1562,"low albumin was significantly associated with apnea ( odds ratio , 12.7 ) .",低白蛋白与呼吸暂停显着相关（比值比，12.7）。,0.5714285714285714,"['albumin', 'apnea', 'ratio', 'associated', 'low', 'with', 'odds']","['albumin', 'apnea', 'ratio', 'low']",1562,"['低 albumin 与 apnea ( odds ratio, 12.7 ) 显著相关。']",0.1428571428571428,"['albumin', 'apnea', 'ratio', 'associated', 'low', 'with', 'odds']",['low'],,
1576,1563,"younger age , preterm birth , and low weight for age also were associated with apnea .",年龄较小、早产和年龄体重偏低也与呼吸暂停有关。,0.5,"['weight', 'apnea', 'birth', 'associated', 'low', 'age', 'with', 'and']","['weight', 'apnea', 'low', 'age']",1563,['年轻的年龄、早产和年龄较低的体重也与失眠有关。'],0.375,"['weight', 'apnea', 'birth', 'associated', 'low', 'age', 'with', 'and']","['weight', 'low', 'age']",,
1577,1564,"after adjustment for the above risk factors , low serum albumin remained statistically associated with apnea ( OR , 4.4 ) .","调整上述危险因素后，低血清白蛋白与呼吸暂停仍存在统计学相关性 (OR, 4.4)。",0.6,"['albumin', 'apnea', 'serum albumin', 'adjustment', 'associated', 'low', 'risk', 'after', 'OR', 'with']","['albumin', 'apnea', 'serum albumin', 'low', 'risk', 'after']",1564,"['在对上述风险因素进行调整后,低血清阿尔博丁仍然与<unk>症统计相关( OR, 4.4)。']",0.3,"['albumin', 'apnea', 'serum albumin', 'adjustment', 'associated', 'low', 'risk', 'after', 'OR', 'with']","['low', 'risk', 'after']",,
1578,1565,risk for apnea was similar in infants with and without respiratory syncytial virus infection .,感染和未感染呼吸道合胞病毒的婴儿发生呼吸暂停的风险相似。,0.3636363636363636,"['infection', 'virus', 'apnea', 'syncytial', 'respiratory syncytial virus', 'virus infection', 'risk', 'with', 'and', 'without', 'similar']","['infection', 'virus', 'apnea', 'risk']",1565,['患失眠的风险类似于患有和没有呼吸道合成病毒感染的婴儿。'],0.3636363636363636,"['infection', 'virus', 'apnea', 'syncytial', 'respiratory syncytial virus', 'virus infection', 'risk', 'with', 'and', 'without', 'similar']","['infection', 'virus', 'virus infection', 'risk']",,
1579,1566,"low serum albumin seems to be another warning sign for apnea risk in infants with bronchiolitis , along with prematurity and low weight for age .",低血清白蛋白似乎是毛细支气管炎婴儿呼吸暂停风险的另一个警告信号，以及早产和低体重。,0.5625,"['albumin', 'weight', 'apnea', 'serum albumin', 'sign', 'bronchiolitis', 'warning', 'be', 'low', 'prematurity', 'along', 'age', 'risk', 'with', 'to', 'and']","['albumin', 'weight', 'apnea', 'serum albumin', 'sign', 'bronchiolitis', 'warning', 'low', 'risk']",1566,"['低血清 albumin 似乎是另一个警告信号,在患有 bronchiolitis 的婴儿中患有<unk>疹的风险,以及早产和年龄较低的体重。']",0.4375,"['albumin', 'weight', 'apnea', 'serum albumin', 'sign', 'bronchiolitis', 'warning', 'be', 'low', 'prematurity', 'along', 'age', 'risk', 'with', 'to', 'and']","['weight', 'sign', 'warning', 'be', 'low', 'age', 'risk']",,
1580,1567,"however , unfortunately the sensitivity of low serum albumin for predicting apnea is not great , as most children with low levels did not develop apnea .",然而，不幸的是，低血清白蛋白预测呼吸暂停的敏感性并不高，因为大多数低水平的儿童没有发生呼吸暂停。,0.5555555555555556,"['albumin', 'apnea', 'serum albumin', 'develop', 'low', 'as', 'with', 'sensitivity', 'great']","['albumin', 'apnea', 'serum albumin', 'low', 'great']",1567,"['然而,不幸的是,低血清阿尔博丁对预测腹泻的敏感性并不大,因为大多数低水平的儿童没有发育腹泻。']",0.2222222222222222,"['albumin', 'apnea', 'serum albumin', 'develop', 'low', 'as', 'with', 'sensitivity', 'great']","['low', 'great']",,
1581,1568,the authors ( and I ) do not recommend routine monitoring of albumin in infants with bronchiolitis based on this study .,基于这项研究，作者（和我）不建议对患有毛细支气管炎的婴儿进行白蛋白的常规监测。,0.5,"['monitoring', 'albumin', 'bronchiolitis', 'routine', 'study', 'recommend', 'with', 'I', 'this', 'and']","['monitoring', 'albumin', 'bronchiolitis', 'routine', 'recommend']",1568,"['作者(和我)不建议基于这项研究,在患有 bronchiolitis 的婴儿中定期监测阿尔博明。']",0.2,"['monitoring', 'albumin', 'bronchiolitis', 'routine', 'study', 'recommend', 'with', 'I', 'this', 'and']","['monitoring', 'recommend']",,
1582,1569,sponsoring Organization : British Society of Gastroenterology,主办机构：英国胃肠病学会,0.6666666666666666,"['organization', 'society', 'gastroenterology']","['society', 'gastroenterology']",1569,['赞助组织:英国胃肠道学协会'],0.6666666666666666,"['organization', 'society', 'gastroenterology']","['organization', 'society']",,
1583,1570,IEE is also the most accurate imaging modality for diagnosing and staging gastric dysplasia and early cancer .,IEE 也是诊断和分期胃发育不良和早期癌症的最准确的成像方式。,0.5555555555555556,"['cancer', 'gastric', 'early', 'accurate', 'dysplasia', 'modality', 'early cancer', 'imaging', 'and']","['cancer', 'early', 'accurate', 'dysplasia', 'early cancer']",1570,"['IEE 也是最准确的图像模式,用于诊断和预测胃 dysplasia 和早期癌症。']",0.4444444444444444,"['cancer', 'gastric', 'early', 'accurate', 'dysplasia', 'modality', 'early cancer', 'imaging', 'and']","['cancer', 'early', 'accurate', 'early cancer']",,
1584,1571,grade the location and extent of AG and GIM as distal gastric ( affecting antrum or incisura ; low risk ) or proximal gastric ( affecting the body with or without the antrum and incisura ; high risk ) .,将 AG 和 GIM 的位置和范围分级为远端胃（影响胃窦或切迹；低风险）或近端胃（影响有或没有胃窦和切迹的身体；高风险）。,0.4615384615384615,"['antrum', 'gastric', 'grade', 'high risk', 'location', 'proximal', 'distal', 'low', 'extent', 'body', 'with', 'and', 'without']","['antrum', 'location', 'proximal', 'distal', 'low', 'body']",1571,['等級 AG 和 GIM 的位置和範圍為 distal gastric (影響 antrum 或 incisura ; 低風險 ) 或 proximal gastric (影響身體與或沒有 antrum 和 incisura ; 高風險 ) 。'],0.1538461538461538,"['antrum', 'gastric', 'grade', 'high risk', 'location', 'proximal', 'distal', 'low', 'extent', 'body', 'with', 'and', 'without']","['location', 'low']",,
1585,1572,"perform endoscopic surveillance every 3 years in patients diagnosed with extensive AG or GIM ( i.e. , affecting the antrum and body ) , but not in patients with AG or GIM limited to the antrum ( unless there is a strong family history of gastric adenocarcinoma or persistent Helicobacter pylori ) .",对诊断为广泛 AG 或 GIM（即影响胃窦和身体）的患者每 3 年进行一次内窥镜监测，但对局限于胃窦的 AG 或 GIM 患者不进行（除非有胃腺癌或持续性幽门螺杆菌的强烈家族史幽门螺杆菌）。,0.5625,"['antrum', 'persistent', 'family', 'gastric', 'helicobacter', 'adenocarcinoma', 'family history', 'strong', 'surveillance', 'gastric adenocarcinoma', '3', 'body', 'with', 'limited', 'but', 'and']","['antrum', 'family', 'adenocarcinoma', 'family history', 'strong', 'surveillance', 'gastric adenocarcinoma', 'body', 'but']",1572,"['每3年进行内分泌监测,在患有广泛的 AG 或 GIM 诊断的患者(即影响 antrum 和 身体),但不限于 antrum 的 AG 或 GIM 患者(除非有强烈的胃肾癌病史或持久的 Helicobacter pylori )。']",0.25,"['antrum', 'persistent', 'family', 'gastric', 'helicobacter', 'adenocarcinoma', 'family history', 'strong', 'surveillance', 'gastric adenocarcinoma', '3', 'body', 'with', 'limited', 'but', 'and']","['strong', 'surveillance', 'body', 'but']",,
1586,1573,sponsoring Organization : American Academy of Pediatrics and American Academy of Obstetricians and Gynecologists ( ACOG ),主办机构：美国儿科学会和美国妇产科医师学会 (ACOG),0.25,"['organization', 'pediatrics', 'academy', 'and']",['pediatrics'],1573,['赞助组织:美国儿科学院和美国妇科医学家和妇科医学家学院(ACOG)'],0.5,"['organization', 'pediatrics', 'academy', 'and']","['organization', 'pediatrics']",,
1587,1574,guidelines to reduce neonatal infection with Group B Streptococcus ( GBS ) were first developed in 1996 and were most recently revised and updated in 2010 .,减少新生儿 B 型链球菌 (GBS) 感染的指南于 1996 年首次制定，最近一次修订和更新是在 2010 年。,0.2,"['infection', 'group', 'neonatal', 'streptococcus', 'reduce', 'B', 'with', 'group B streptococcus', 'and', 'first']","['infection', 'streptococcus']",1574,"['针对减少新生儿B型Streptococcus(GBS)感染的指导方针于1996年首次开发,并于2010年最近修订和更新。']",0.1,"['infection', 'group', 'neonatal', 'streptococcus', 'reduce', 'B', 'with', 'group B streptococcus', 'and', 'first']",['infection'],,
1588,1575,the current update is based on a review of epidemiology and practice standards .,目前的更新是基于对流行病学和实践标准的审查。,0.5714285714285714,"['epidemiology', 'a', 'review', 'practice', 'current', 'on', 'and']","['epidemiology', 'review', 'practice', 'current']",1575,['目前的更新是基于流行病学和实践标准的审查。'],0.5714285714285714,"['epidemiology', 'a', 'review', 'practice', 'current', 'on', 'and']","['epidemiology', 'review', 'practice', 'current']",,
1589,1576,key Findings and Recommendations,主要发现和建议,0.0,"['key', 'and']",[],1576,['关键结论和建议'],0.5,"['key', 'and']",['key'],,
1590,1577,intrapartum antibiotic prophylaxis is recommended for all women with positive screening cultures .,建议所有筛查培养阳性的妇女在产时预防性使用抗生素。,0.5,"['cultures', 'antibiotic', 'screening', 'prophylaxis', 'intrapartum', 'with', 'positive', 'all']","['antibiotic', 'screening', 'prophylaxis', 'intrapartum']",1577,['生育内抗生素预防是推荐给所有有积极的筛查文化的女性。'],0.375,"['cultures', 'antibiotic', 'screening', 'prophylaxis', 'intrapartum', 'with', 'positive', 'all']","['antibiotic', 'screening', 'prophylaxis']",,
1591,1578,this detailed document reviews updated epidemiology of neonatal GBS disease and provides guidance for the management of both pregnant women and infants with signs of sepsis in the newborn period .,这份详细的文件回顾了新生儿 GBS 疾病的最新流行病学，并为新生儿期有败血症迹象的孕妇和婴儿的管理提供了指导。,0.3571428571428571,"['epidemiology', 'period', 'disease', 'neonatal', 'newborn', 'sepsis', 'document', 'signs', 'management', 'with', 'this', 'in', 'and', 'guidance']","['epidemiology', 'period', 'disease', 'sepsis', 'management']",1578,"['这份详细的文件评论更新了新生儿GBS疾病的流行病学,并提供了对怀孕妇女和婴儿在新生儿期间塞普西斯的迹象的管理的指导。']",0.2857142857142857,"['epidemiology', 'period', 'disease', 'neonatal', 'newborn', 'sepsis', 'document', 'signs', 'management', 'with', 'this', 'in', 'and', 'guidance']","['epidemiology', 'period', 'disease', 'management']",,
1592,1579,daily data on mortality and air pollution were collected from 652 cities in 24 countries or regions .,从 24 个国家或地区的 652 个城市收集有关死亡率和空气污染的每日数据。,0.6,"['air pollution', 'data', 'mortality', 'in', 'and']","['air pollution', 'data', 'mortality']",1579,['每日关于死亡率和空气污染的数据从24个国家或地区的652个城市收集。'],0.6,"['air pollution', 'data', 'mortality', 'in', 'and']","['air pollution', 'data', 'mortality']",,
1593,1580,"the corresponding increases in daily mortality for the same change in PM2.5 concentration were 0.68 % ( 95 % CI , 0.59 to 0.77 ) , 0.55 % ( 95 % CI , 0.45 to 0.66 ) , and 0.74 % ( 95 % CI , 0.53 to 0.95 ) .",PM2.5 浓度发生相同变化时，每日死亡率的相应增加分别为 0.68 % ( 95 % CI 0.59 至 0.77 ) 、 0.55 % ( 95 % CI 0.45 至 0.66 ) 和 0.74 % ( 95 % CI 0.53 至 0.53 至0.95）。,0.375,"['corresponding', 'concentration', 'mortality', 'increases', 'change', 'CI', 'to', 'and']","['concentration', 'mortality', 'change']",1580,"['相应的每日死亡率增加相同的 PM2.5 浓度变化为 0.68 % (95 % CI, 0.59 至 0.77 ), 0.55 % ( 95 % CI, 0.45 至 0.66 ), 和 0.74 % ( 95 % CI, 0.53 至 0.95 ) 。']",0.5,"['corresponding', 'concentration', 'mortality', 'increases', 'change', 'CI', 'to', 'and']","['corresponding', 'concentration', 'mortality', 'change']",,
1594,1581,these associations remained significant after adjustment for gaseous pollutants .,在对气态污染物进行调整后，这些关联仍然显着。,0.3333333333333333,"['gaseous', 'adjustment', 'after']",['after'],1581,['这些化合物在气体污染物调整后仍然是显著的。'],0.3333333333333333,"['gaseous', 'adjustment', 'after']",['after'],,
1595,1582,associations were stronger in locations with lower annual mean PM concentrations and higher annual mean temperatures .,在年平均 PM 浓度较低和年平均气温较高的地区，这种关联更强。,0.1428571428571428,"['annual', 'mean', 'lower', 'with', 'concentrations', 'in', 'and']",['mean'],1582,['协会在低年平均PM浓度和高年平均温度的地方更强大。'],0.1428571428571428,"['annual', 'mean', 'lower', 'with', 'concentrations', 'in', 'and']",['mean'],,
1596,1583,these data reinforce the evidence of a link between mortality and PM concentration established in regional and local studies . ( Funded by the National Natural Science Foundation of China and others . ),这些数据强化了区域和地方研究中建立的死亡率和 PM 浓度之间联系的证据。 （国家自然科学基金等资助。）,0.4666666666666667,"['a', 'concentration', 'data', 'science', 'regional', 'natural', 'local', 'china', 'mortality', 'link', 'evidence', 'natural science', 'foundation', 'by', 'and']","['concentration', 'data', 'science', 'mortality', 'evidence', 'natural science', 'foundation']",1583,['这些数据强化了在区域和地方研究中建立的死亡率和 PM 浓度之间的联系的证据(由中国国家自然科学基金会和其他机构资助)。'],0.6,"['a', 'concentration', 'data', 'science', 'regional', 'natural', 'local', 'china', 'mortality', 'link', 'evidence', 'natural science', 'foundation', 'by', 'and']","['concentration', 'data', 'science', 'china', 'mortality', 'evidence', 'natural science', 'foundation', 'by']",,
1597,1584,"particulate matter ( PM ) , especially , arouses public health concerns because of its toxicity and the widespread human exposure to this pollutant .",颗粒物 (PM) 尤其引起公众健康关注，因为它具有毒性并且人类广泛接触这种污染物。,0.3636363636363636,"['pollutant', 'toxicity', 'exposure', 'health', 'public', 'particulate', 'matter', 'human', 'particulate matter', 'this', 'and']","['pollutant', 'toxicity', 'health', 'human']",1584,"['粒子物质(PM),特别是,因其毒性和人类对这种污染物的广泛暴露而引起公众健康的担忧。']",0.7272727272727273,"['pollutant', 'toxicity', 'exposure', 'health', 'public', 'particulate', 'matter', 'human', 'particulate matter', 'this', 'and']","['pollutant', 'toxicity', 'exposure', 'health', 'matter', 'human', 'this', 'and']",,
1598,1585,"PM , which includes inhalable particles with an aerodynamic diameter of 10 μm or less ( PM10 ) and fine particles with an aerodynamic diameter of 2.5 μm or less ( PM2.5 ) , is emitted from combustion sources or formed through atmospheric chemical transformation .",PM 包括空气动力学直径为 10 μm 或更小的可吸入颗粒物 (PM10) 和空气动力学直径为 2.5 μm 或更小的细颗粒物 (PM2.5)，从燃烧源排放或通过大气化学转化形成。,0.5,"['transformation', 'chemical', 'combustion', 'atmospheric', 'aerodynamic', 'with', 'diameter', 'and']","['transformation', 'combustion', 'aerodynamic', 'diameter']",1585,"['PM(含有10 μm或更小的空气动态直径(PM10)和 2.5 μm或更小的空气动态直径(PM2.5 )的微粒,是从燃烧来源发出或通过大气化学转型形成的。']",0.25,"['transformation', 'chemical', 'combustion', 'atmospheric', 'aerodynamic', 'with', 'diameter', 'and']","['combustion', 'diameter']",,
1599,1586,"given the extensive evidence regarding their effects of health , the daily and annual mean concentrations of PM10 and PM2.5 are regulated according to the World Health Organization ( WHO ) Air Quality Guidelines4 and standards in major countries .",鉴于关于它们对健康影响的广泛证据，PM10 和 PM2.5 的日平均浓度和年平均浓度是根据世界卫生组织 (WHO) 空气质量指南 4 和主要国家的标准进行监管的。,0.6666666666666666,"['annual', 'organization', 'mean', 'health', 'quality', 'world health organization', 'major', 'regarding', 'air', 'WHO', 'evidence', 'concentrations', 'regulated', 'to', 'and']","['organization', 'mean', 'health', 'quality', 'world health organization', 'regarding', 'air', 'WHO', 'evidence', 'to']",1586,"['鉴于对其对健康的影响的广泛证据,每日和每年的PM10和PM2.5的平均浓度按照世界卫生组织(WHO)的空气质量指南4和主要国家的标准进行调节。']",0.6,"['annual', 'organization', 'mean', 'health', 'quality', 'world health organization', 'major', 'regarding', 'air', 'WHO', 'evidence', 'concentrations', 'regulated', 'to', 'and']","['organization', 'mean', 'health', 'quality', 'world health organization', 'air', 'WHO', 'evidence', 'to']",,
1600,1587,"however , most evidence has been obtained from studies in single cities , regions , or countries , and there are challenges in comparing these results and in synthesizing effect estimates because of different modeling approaches and potential publication bias .",然而，大多数证据是从单个城市、地区或国家的研究中获得的，由于不同的建模方法和潜在的发表偏倚，在比较这些结果和综合效果估计方面存在挑战。,0.875,"['bias', 'potential', 'publication', 'effect', 'evidence', 'modeling', 'single', 'and']","['bias', 'potential', 'publication', 'effect', 'evidence', 'single', 'and']",1587,"['然而,大多数证据都来自单个城市、地区或国家的研究,并且由于不同的模型方法和潜在的出版差异,比较这些结果和合成效应估计存在挑战。']",0.75,"['bias', 'potential', 'publication', 'effect', 'evidence', 'modeling', 'single', 'and']","['potential', 'publication', 'effect', 'evidence', 'single', 'and']",,
1601,1588,"these limitations can be addressed by performing international , multicenter studies that adopt the same analytic protocol and model specifications to estimate globally representative associations of PM10 and PM2.5 exposures with daily mortality .",这些局限性可以通过开展国际多中心研究来解决，这些研究采用相同的分析协议和模型规范来估计全球代表性的 PM10 和 PM2.5 暴露与每日死亡率之间的关联。,0.3846153846153846,"['model', 'protocol', 'analytic', 'be', 'mortality', 'adopt', 'estimate', 'specifications', 'performing', 'with', 'that', 'by', 'and']","['model', 'protocol', 'mortality', 'adopt', 'by']",1588,"['这些限制可以通过进行国际、多中心研究,采用相同的分析协议和模型规格来估计全球代表性 PM10 和 PM2.5 曝光与日常死亡率。']",0.3846153846153846,"['model', 'protocol', 'analytic', 'be', 'mortality', 'adopt', 'estimate', 'specifications', 'performing', 'with', 'that', 'by', 'and']","['model', 'protocol', 'mortality', 'adopt', 'by']",,
1602,1589,"we obtained health and environmental data from the MCC database , which has been described previously.10,12","我们从 MCC 数据库中获取了健康和环境数据，该数据库已在之前描述过。 10,12",0.25,"['database', 'health', 'and', 'we']",['health'],1589,"['我们从 MCC 数据库中获取了健康和环境数据,此前已被描述。']",0.25,"['database', 'health', 'and', 'we']",['health'],,
1603,1590,"the current analysis was limited to locations that had available data on air pollution ( 652 urban areas in 24 countries or regions , with the data covering the period from 1986 through 2015 ) ( Table S1 in the Supplementary Appendix , available with the full text of this article at NEJM.org ) .",目前的分析仅限于有可用空气污染数据的地点（24 个国家或地区的 652 个城市地区，数据涵盖 1986 年至 2015 年期间）（补充附录中的表 S1，可与本文全文一起获取） NEJM.org 上的文章）。,0.3157894736842105,"['period', 'air pollution', 'appendix', 'table', 'data', 'analysis', 'article', 'supplementary', 'available', 'text', 'current', 'with', 'covering', 'full', 'limited', 'S1', 'this', 'that', 'to']","['period', 'air pollution', 'table', 'data', 'analysis', 'to']",1590,"['目前的分析仅限于有空气污染数据的地点(24个国家或地区的652个城市区域,包括1986年至2015年期间的数据)(附件中的S1表,可在NEJM.org上找到本文的完整文本)。']",0.4210526315789473,"['period', 'air pollution', 'appendix', 'table', 'data', 'analysis', 'article', 'supplementary', 'available', 'text', 'current', 'with', 'covering', 'full', 'limited', 'S1', 'this', 'that', 'to']","['period', 'air pollution', 'appendix', 'table', 'data', 'analysis', 'full', 'to']",,
1604,1591,data on mortality were obtained from local authorities within each country .,死亡率数据是从每个国家的地方当局获得的。,0.5,"['data', 'country', 'local', 'mortality', 'on', 'each']","['data', 'country', 'mortality']",1591,['死亡率数据来自各国地方当局。'],0.5,"['data', 'country', 'local', 'mortality', 'on', 'each']","['data', 'mortality', 'each']",,
1605,1592,we obtained daily data on PM10 in 598 cities and on PM2.5 in 499 cities .,我们获得了 598 个城市的 PM10 和 499 个城市的 PM2.5 的每日数据。,0.2,"['data', 'on', 'in', 'and', 'we']",['data'],1592,['我们每天收集了598个城市的PM10和499个城市的PM2.5的数据。'],0.2,"['data', 'on', 'in', 'and', 'we']",['data'],,
1606,1593,data on both pollutants were available in 445 cities in 16 countries or regions .,16 个国家或地区的 445 个城市提供了这两种污染物的数据。,0.25,"['data', 'available', 'on', 'in']",['data'],1593,['两种污染物的数据在16个国家或地区的445个城市可用。'],0.25,"['data', 'available', 'on', 'in']",['data'],,
1607,1594,we also collected data on the daily mean temperature and daily mean relative humidity .,我们还收集了日平均温度和日平均相对湿度的数据。,0.5,"['relative humidity', 'mean temperature', 'data', 'on', 'and', 'we']","['relative humidity', 'mean temperature', 'data']",1594,['我们还收集了每日平均温度和每日平均相对湿度的数据。'],0.5,"['relative humidity', 'mean temperature', 'data', 'on', 'and', 'we']","['relative humidity', 'mean temperature', 'data']",,
1608,1595,"to avoid potential consequences of including outlying values of exposure data , we used trimmed data , in which the highest 5 % and lowest 5 % of PM10 and PM2.5 measurements were excluded.14",为了避免包含暴露数据的异常值的潜在后果，我们使用了修整后的数据，其中排除了 PM10 和 PM2.5 测量值中最高的 5 % 和最低的 5 %。 14,0.3636363636363636,"['5', 'data', 'exposure', 'potential', 'values', 'in', 'outlying', 'to', 'and', 'avoid', 'we']","['5', 'data', 'exposure', 'avoid']",1595,"['为了避免包括曝光数据的外观值的潜在后果,我们使用压缩数据,其中最高5 %和最低5 %的PM10和PM2.5测量被排除。']",0.3636363636363636,"['5', 'data', 'exposure', 'potential', 'values', 'in', 'outlying', 'to', 'and', 'avoid', 'we']","['5', 'data', 'exposure', 'avoid']",,
1609,1596,we performed several sensitivity analyses .,我们进行了多项敏感性分析。,0.0,"['sensitivity', 'we']",[],1596,['我们进行了多种敏感性分析。'],0.0,"['sensitivity', 'we']",[],,
1610,1597,"third , we restricted the analyses to data available after the year 2000 .",第三，我们将分析限制在 2000 年之后可用的数据。,0.7142857142857143,"['data', 'year', 'available', 'after', 'to', 'third', 'we']","['data', 'year', 'available', 'after', 'third']",1597,"['第三,我们将分析限制到2000年以后可用的数据。']",0.7142857142857143,"['data', 'year', 'available', 'after', 'to', 'third', 'we']","['data', 'year', 'available', 'after', 'third']",,
1611,1598,a P value of less than 0.05 was considered to indicate statistical significance .,小于 0.05 的 P 值被认为表明具有统计学意义。,0.2857142857142857,"['a', 'value', 'indicate', 'significance', 'statistical significance', 'P', 'to']","['significance', 'to']",1598,['低于 0.05 的 P 值被认为表明统计意义。'],0.2857142857142857,"['a', 'value', 'indicate', 'significance', 'statistical significance', 'P', 'to']","['significance', 'to']",,
1612,1599,more details are presented in the Methods section in the Supplementary Appendix .,补充附录的“方法”部分提供了更多详细信息。,0.0,"['appendix', 'section', 'supplementary', 'in']",[],1599,['更多详细信息在附件中的方法部分中呈现。'],0.25,"['appendix', 'section', 'supplementary', 'in']",['appendix'],,
1613,1600,descriptive ANALYSES,描述性分析,1.0,['descriptive'],['descriptive'],1600,['描述分析'],0.0,['descriptive'],[],,
1614,1601,"PM10 was strongly correlated with PM2.5 , with a mean Pearson correlation coefficient of 0.78 .",PM10与PM2.5密切相关，平均皮尔逊相关系数为0.78。,0.75,"['correlation', 'mean', 'correlation coefficient', 'with']","['correlation', 'mean', 'correlation coefficient']",1601,"['PM10 与 PM2.5 密切相关,平均为 0.78 的 Pearson 相关率。']",0.5,"['correlation', 'mean', 'correlation coefficient', 'with']","['correlation', 'mean']",,
1615,1602,"the mean Pearson correlation coefficients between PM10 and gaseous pollutants were 0.46 with nitrogen dioxide , 0.20 with ozone , 0.38 with sulfur dioxide , and 0.40 with carbon monoxide .",PM10与气态污染物的平均皮尔逊相关系数分别为二氧化氮0.46、臭氧0.20、二氧化硫0.38、一氧化碳0.40。,0.6666666666666666,"['correlation', 'nitrogen', 'mean', 'dioxide', 'ozone', 'carbon monoxide', 'sulfur', 'gaseous', 'nitrogen dioxide', 'with', 'sulfur dioxide', 'and']","['correlation', 'nitrogen', 'mean', 'ozone', 'carbon monoxide', 'sulfur', 'nitrogen dioxide', 'sulfur dioxide']",1602,"['皮尔森的 PM10 和气体污染物之间的平均相对比为 0.46 与氮二氧化物, 0.20 与臭氧, 0.38 与硫二氧化物, 0.40 与碳二氧化物。']",0.4166666666666667,"['correlation', 'nitrogen', 'mean', 'dioxide', 'ozone', 'carbon monoxide', 'sulfur', 'gaseous', 'nitrogen dioxide', 'with', 'sulfur dioxide', 'and']","['nitrogen', 'mean', 'dioxide', 'ozone', 'sulfur']",,
1616,1603,"the corresponding coefficients between PM2.5 and gaseous pollutants were 0.48 , 0.22 , 0.40 , and 0.45 .",PM2.5与气态污染物的对应系数分别为0.48、0.22、0.40和0.45。,0.0,"['corresponding', 'gaseous', 'and']",[],1603,"['PM2.5 和气体污染物之间的相应比例为 0.48, 0.22, 0.40, 和 0.45 。']",0.0,"['corresponding', 'gaseous', 'and']",[],,
1617,1604,other descriptive statistics and the correlations between daily mean PM concentrations and weather variables are summarized in the Results section in the Supplementary Appendix .,其他描述性统计数据以及每日平均 PM 浓度与天气变量之间的相关性在补充附录的结果部分进行了总结。,0.3636363636363636,"['statistics', 'descriptive', 'appendix', 'mean', 'section', 'weather', 'supplementary', 'descriptive statistics', 'concentrations', 'in', 'and']","['statistics', 'descriptive', 'mean', 'weather']",1604,['其他描述统计和每日平均 PM 浓度和天气变量之间的关系在附件中的结果部分中总结。'],0.3636363636363636,"['statistics', 'descriptive', 'appendix', 'mean', 'section', 'weather', 'supplementary', 'descriptive statistics', 'concentrations', 'in', 'and']","['statistics', 'appendix', 'mean', 'weather']",,
1618,1605,regression ANALYSES,回归分析,1.0,['regression'],['regression'],1605,['回归分析'],1.0,['regression'],['regression'],,
1619,1606,these moving averages were then applied in subsequent analyses .,然后将这些移动平均数应用于后续分析。,0.0,"['applied', 'subsequent', 'in']",[],1606,['这些移动平均值随后在后续分析中被应用。'],0.0,"['applied', 'subsequent', 'in']",[],,
1620,1607,"for both PM10 and PM2.5 , the associations were significant on lag 0 day and then attenuated substantially on lag 1 to 2 days ; the estimates of the associations were strongest on lag 0 to 1 day ( Table S4 in the Supplementary Appendix ) .",对于 PM10 和 PM2.5，相关性在滞后 0 天显着，然后在滞后 1 至 2 天显着减弱；关联的估计值在滞后 0 到 1 天时最强（补充附录中的表 S4）。,0.4545454545454545,"['appendix', 'lag', 'table', '1', '2', 'supplementary', 'on', 'S4', 'in', 'to', 'and']","['lag', 'table', '1', '2', 'to']",1607,"['对于 PM10 和 PM2.5 两者,合并在 0 天下显著,然后在 1 至 2 天下显著减轻;合并的估计在 0 至 1 天下最强(附件中的 S4 表)。']",0.4545454545454545,"['appendix', 'lag', 'table', '1', '2', 'supplementary', 'on', 'S4', 'in', 'to', 'and']","['appendix', 'table', '1', '2', 'to']",,
1621,1608,"estimates of the effect in France , Estonia , and Switzerland were close to the global median estimate of 0.46 % in association with PM10 concentration ; estimates of the effect in Switzerland and South Africa were close to the global median estimate of 0.80 % in association with PM2.5 concentration .",对法国、爱沙尼亚和瑞士影响的估计值与 PM10 浓度相关的全球中值估计值 0.46% 接近；对瑞士和南非影响的估计值接近与 PM2.5 浓度相关的全球中值估计值 0.80%。,0.3636363636363636,"['estonia', 'median', 'concentration', 'global', 'association', 'effect', 'estimate', 'with', 'in', 'and', 'close to']","['estonia', 'concentration', 'global', 'estimate']",1608,"['法国、爱沙尼亚和瑞士的影响估计接近与PM10浓度相结合的全球平均估计为0.46%,瑞士和南非的影响估计接近与PM2.5浓度相结合的全球平均估计为0.80%。']",0.3636363636363636,"['estonia', 'median', 'concentration', 'global', 'association', 'effect', 'estimate', 'with', 'in', 'and', 'close to']","['estonia', 'concentration', 'global', 'association']",,
1622,1609,"regional analyses indicated differences between areas ( Table S6 in the Supplementary Appendix ) , with higher estimates of the effect in the region of the Americas and smaller estimates in the Western Pacific region .",区域分析表明区域之间存在差异（补充附录中的表 S6），美洲区域的影响估计值较高，西太平洋区域的估计值较小。,0.125,"['appendix', 'table', 'regional', 'supplementary', 'effect', 'with', 'in', 'and']",['table'],1609,"['区域分析表明区域之间的差异(附件中的S6表),在美国地区的影响估计更高,在西太平洋地区的估计更小。']",0.25,"['appendix', 'table', 'regional', 'supplementary', 'effect', 'with', 'in', 'and']","['appendix', 'table']",,
1623,1610,the slopes for both curves were steeper at concentrations lower than 40 μg per cubic meter for PM10 and lower than 20 μg per cubic meter for PM2.5 .,两条曲线的斜率在 PM10 浓度低于 40 微克/立方米和 PM2.5 浓度低于 20 微克/立方米时更陡。,0.2857142857142857,"['meter', 'lower', 'cubic', 'at', 'concentrations', 'steeper', 'and']","['meter', 'at']",1610,['兩個曲線的曲線在 PM10 的每立方米低於 40 μg 的濃度和 PM2.5 的每立方米低於 20 μg 的濃度。'],0.1428571428571428,"['meter', 'lower', 'cubic', 'at', 'concentrations', 'steeper', 'and']",['meter'],,
1624,1611,the slopes seemed to flatten at high ranges .,斜坡似乎在高处变平了。,0.3333333333333333,"['at', 'to', 'high']",['high'],1611,['它们似乎在高层上浮动。'],0.3333333333333333,"['at', 'to', 'high']",['high'],,
1625,1612,sensitivity analyses confirmed these results .,敏感性分析证实了这些结果。,0.0,['sensitivity'],[],1612,['敏感性分析证实了这些结果。'],0.0,['sensitivity'],[],,
1626,1613,"finally , the analysis in which the subset of data since the year 2000 was used provided similar estimates .",最后，使用 2000 年以来数据子集的分析提供了类似的估计。,0.5,"['data', 'year', 'analysis', 'subset', 'in', 'similar']","['data', 'year', 'analysis']",1613,"['最后,分析自2000年以来使用的数据子组提供了类似的估计。']",0.5,"['data', 'year', 'analysis', 'subset', 'in', 'similar']","['data', 'year', 'analysis']",,
1627,1614,estimates based on nontrimmed PM data are provided in Table S8 in the Supplementary Appendix .,补充附录表 S8 中提供了基于非修正 PM 数据的估计值。,0.3333333333333333,"['appendix', 'table', 'data', 'supplementary', 'on', 'in']","['table', 'data']",1614,['基于非期限 PM 数据的估计在附件 S8 表中提供。'],0.5,"['appendix', 'table', 'data', 'supplementary', 'on', 'in']","['appendix', 'table', 'data']",,
1628,1615,"our study analyzed multisite data on air pollution and mortality in 652 cities across different countries and regions , although most countries and cities were in the northern hemisphere .",我们的研究分析了不同国家和地区 652 个城市的空气污染和死亡率的多站点数据，尽管大多数国家和城市位于北半球。,0.5,"['air pollution', 'data', 'hemisphere', 'study', 'mortality', 'across', 'in', 'and']","['air pollution', 'data', 'hemisphere', 'mortality']",1615,"['我们的研究分析了652个不同国家和地区的空气污染和死亡率的多网站数据,尽管大多数国家和城市位于北半球。']",0.5,"['air pollution', 'data', 'hemisphere', 'study', 'mortality', 'across', 'in', 'and']","['air pollution', 'data', 'hemisphere', 'mortality']",,
1629,1616,"the percentage increase in mortality for the same increase in PM10 concentration was 0.77 % in the Multicity Study of Air Pollution and Mortality in Latin America ( ESCALA ) , 8 0.55 % in the Public Health and Air Pollution in Asia ( PAPA ) study , 7 and 0.19 % in the reanalysis of the U.S. National Morbidity Mortality Air Pollution Study ( NMMAPS ) .21",在拉丁美洲空气污染和死亡率多城市研究 ( ESCALA ) 8 中，相同 PM10 浓度增加导致的死亡率增加百分比为 0.77 % ，在亚洲公共卫生和空气污染 ( PAPA ) 研究 7 中为 0.55 % ，并且美国国家发病率死亡率空气污染研究 (NMMAPS) .21 再分析中的 0.19%,0.5,"['percentage', 'air pollution', 'concentration', 'morbidity', 'america', 'health', 'public', 'study', 'mortality', 'increase', 'PAPA', 'and']","['air pollution', 'concentration', 'morbidity', 'america', 'health', 'mortality']",1616,"['相同增加的PM10浓度死亡率的百分比增加在拉丁美洲的多元性空气污染和死亡率研究(ESCALA)中为0.77%,在亚洲的公共卫生和空气污染研究(PAPA)中为8.55%,在美国国家疾病死亡率空气污染研究(NMMAPS)的重新分析中为7和0.19%。']",0.4166666666666667,"['percentage', 'air pollution', 'concentration', 'morbidity', 'america', 'health', 'public', 'study', 'mortality', 'increase', 'PAPA', 'and']","['air pollution', 'concentration', 'america', 'health', 'mortality']",,
1630,1617,"in addition , we found that the associations of mortality with PM concentrations were slightly stronger with PM2.5 than with PM10 in most countries and regions , which added to the evidence that PM2.5 accounted for a larger proportion of the effects of PM10 and PM2.5 combined.6",此外，我们发现，在大多数国家和地区，PM2.5 与 PM10 的死亡率与 PM 浓度的相关性略强于 PM10，这进一步证明 PM2.5 在 PM10 和 PM2 的影响中所占比例更大。 .5 组合.6,0.25,"['proportion', 'a', 'addition', 'mortality', 'evidence', 'with', 'concentrations', 'that', 'in', 'to', 'and', 'we']","['proportion', 'mortality', 'to']",1617,"['此外,我们发现,与 PM 浓度的死亡率的联系在大多数国家和地区的 PM2.5 比 PM10 稍微强大,这增加了 PM2.5 与 PM10 和 PM2.5 相结合的影响的比例。']",0.25,"['proportion', 'a', 'addition', 'mortality', 'evidence', 'with', 'concentrations', 'that', 'in', 'to', 'and', 'we']","['proportion', 'addition', 'mortality']",,
1631,1618,the stronger effects of PM2.5 may also be supported by the abundant evidence that this particulate fraction contains more small particles that can absorb toxic components from the air and penetrate deep into the lungs.24,PM2.5 的更强影响也可能得到大量证据的支持，这些证据表明该颗粒部分包含更多可以从空气中吸收有毒成分并深入肺部的小颗粒。 24,0.2857142857142857,"['toxic', 'abundant', 'penetrate', 'be', 'air', 'particulate', 'fraction', 'evidence', 'deep', 'absorb', 'this', 'that', 'by', 'and']","['air', 'fraction', 'evidence', 'by']",1618,"['PM2.5 的有效性也可能受到丰富的证据的支持,表明该粒子部分含有较小的粒子,可以从空气中吸收有毒组件并深入渗透到肺部。']",0.4285714285714285,"['toxic', 'abundant', 'penetrate', 'be', 'air', 'particulate', 'fraction', 'evidence', 'deep', 'absorb', 'this', 'that', 'by', 'and']","['abundant', 'penetrate', 'air', 'fraction', 'evidence', 'by']",,
1632,1619,"furthermore , the higher proportion of young people in developing countries may decrease population susceptibility to PM , and less outdoor activity during days with high pollution levels may decrease exposure .",此外，发展中国家年轻人比例较高可能会降低人口对 PM 的易感性，而在高污染水平的日子里减少户外活动可能会减少暴露。,0.6428571428571429,"['proportion', 'population', 'decrease', 'pollution', 'exposure', 'susceptibility', 'activity', 'developing', 'with', 'young', 'to', 'and', 'susceptibility to', 'high']","['proportion', 'population', 'decrease', 'pollution', 'exposure', 'susceptibility', 'activity', 'and', 'high']",1619,"['此外,发展中国家的年轻人比例较高可能会降低人口对 PM 的敏感性,在高污染水平的日子里,户外活动较少可能会降低暴露。']",0.5,"['proportion', 'population', 'decrease', 'pollution', 'exposure', 'susceptibility', 'activity', 'developing', 'with', 'young', 'to', 'and', 'susceptibility to', 'high']","['proportion', 'population', 'pollution', 'exposure', 'susceptibility', 'activity', 'high']",,
1633,1620,"however , associations estimated for extreme PM concentrations are characterized by wider confidence intervals , with greater uncertainty about the actual mortality risk at such values .",然而，极端 PM 浓度估计的相关性具有更宽的置信区间，在这些值下实际死亡风险的不确定性更大。,0.1666666666666666,"['actual', 'mortality', 'risk', 'values', 'with', 'confidence', 'at', 'concentrations', 'uncertainty', 'extreme', 'characterized by', 'intervals']","['risk', 'extreme']",1620,"['然而,对极端 PM 浓度估计的协会具有更广泛的信任间隔,对这些值的实际死亡风险的不确定性更大。']",0.1666666666666666,"['actual', 'mortality', 'risk', 'values', 'with', 'confidence', 'at', 'concentrations', 'uncertainty', 'extreme', 'characterized by', 'intervals']","['risk', 'extreme']",,
1634,1621,we found significant evidence of spatial heterogeneity in the associations between PM concentration and daily mortality across countries and regions .,我们发现了各个国家和地区 PM 浓度与每日死亡率之间关联的空间异质性的重要证据。,0.4444444444444444,"['heterogeneity', 'concentration', 'mortality', 'across', 'spatial', 'evidence', 'in', 'and', 'we']","['heterogeneity', 'concentration', 'mortality', 'evidence']",1621,['我们在 PM 浓度和各个国家和地区的日常死亡率之间的关系中发现了显著的空间异性证据。'],0.3333333333333333,"['heterogeneity', 'concentration', 'mortality', 'across', 'spatial', 'evidence', 'in', 'and', 'we']","['concentration', 'mortality', 'evidence']",,
1635,1622,"we also found that higher annual mean concentrations of PM10 and PM2.5 were accompanied by weaker associations with daily mortality , a finding that has been reported in previous studies.16,25","我们还发现，较高的 PM10 和 PM2.5 年平均浓度与每日死亡率的相关性较弱，这一发现已在之前的研究中报道过。 16,25",0.1538461538461538,"['annual', 'mean', 'previous', 'accompanied', 'mortality', 'with', 'concentrations', 'that', 'in', 'by', 'and', 'accompanied by', 'we']","['mean', 'mortality']",1622,"['我们还发现,高年平均 PM10 和 PM2.5 的浓度伴随着与日常死亡率的较弱联系,这是在以前的研究中报告的发现。']",0.3076923076923077,"['annual', 'mean', 'previous', 'accompanied', 'mortality', 'with', 'concentrations', 'that', 'in', 'by', 'and', 'accompanied by', 'we']","['mean', 'previous', 'mortality', 'by']",,
1636,1623,"the estimates of the association between PM and mortality in some countries ( e.g. , France , Finland , Sweden , and the United Kingdom ) were smaller and not significant .",在一些国家（例如法国、芬兰、瑞典和英国），对 PM 与死亡率之间关联的估计较小且不显着。,0.5,"['association', 'mortality', 'kingdom', 'and']","['association', 'mortality']",1623,"['某些国家(例如,法国、芬兰、瑞典和英国)的总理与死亡率之间的联系的估计较小而不大。']",0.75,"['association', 'mortality', 'kingdom', 'and']","['association', 'mortality', 'and']",,
1637,1624,"these countries had fewer cities included and shorter periods evaluated , which may increase the statistical uncertainty in the estimation of the effect .",这些国家包括的城市较少，评估的时间较短，这可能会增加影响估计的统计不确定性。,0.1666666666666666,"['estimation', 'effect', 'increase', 'periods', 'uncertainty', 'and']",['estimation'],1624,"['这些国家包括更少的城市和更短的评估期,这可能会增加统计不确定性在估计效果。']",0.3333333333333333,"['estimation', 'effect', 'increase', 'periods', 'uncertainty', 'and']","['estimation', 'effect']",,
1638,1625,more interpretations on this issue are provided in the Discussion section in the Supplementary Appendix .,补充附录的讨论部分提供了关于这个问题的更多解释。,0.1428571428571428,"['appendix', 'section', 'issue', 'supplementary', 'discussion', 'this', 'in']",['discussion'],1625,['更多关于此事的解释在附件的讨论部分中提供。'],0.2857142857142857,"['appendix', 'section', 'issue', 'supplementary', 'discussion', 'this', 'in']","['appendix', 'discussion']",,
1639,1626,this study has several limitations .,这项研究有几个局限性。,0.0,"['study', 'this']",[],1626,['这项研究有几个限制。'],0.0,"['study', 'this']",[],,
1640,1627,"first , although the analysis included 24 major countries and regions on six continents , our findings cannot be interpreted as fully globally representative because the 652 cities were mainly located in East Asia , Europe , and North America , with a smaller number of cities in Latin America and Africa .",首先，虽然分析涵盖了六大洲的24个主要国家和地区，但我们的研究结果并不能解释为具有完全的全球代表性，因为这652个城市主要分布在东亚、欧洲和北美，拉丁美洲的城市数量较少。和非洲。,0.4285714285714285,"['a', 'analysis', 'america', 'north', 'major', 'be', 'number', 'as', 'with', 'on', 'in', 'and', 'first', 'east']","['analysis', 'north', 'be', 'number', 'first', 'east']",1627,"['首先,虽然分析包括六大洲的24个主要国家和地区,但我们的发现不能被解释为完全全球代表性,因为652个城市主要位于东亚、欧洲和北美,拉丁美洲和非洲的城市数量较小。']",0.3571428571428571,"['a', 'analysis', 'america', 'north', 'major', 'be', 'number', 'as', 'with', 'on', 'in', 'and', 'first', 'east']","['analysis', 'north', 'number', 'first', 'east']",,
1641,1628,"fourth , there are some missing data , but their influence on our estimates was not substantial ( see the Discussion section and Table S9 in the Supplementary Appendix ) .",第四，有一些数据缺失，但它们对我们的估计影响不大（见讨论部分和补充附录表S9）。,0.5454545454545454,"['appendix', 'table', 'data', 'section', 'supplementary', 'influence', 'discussion', 'but', 'and', 'substantial', 'missing']","['table', 'data', 'influence', 'discussion', 'but', 'missing']",1628,"['第四,有些数据缺乏,但它们对我们的估计的影响并不大(参见附件中的讨论部分和表S9)。']",0.6363636363636364,"['appendix', 'table', 'data', 'section', 'supplementary', 'influence', 'discussion', 'but', 'and', 'substantial', 'missing']","['appendix', 'table', 'data', 'influence', 'discussion', 'but', 'missing']",,
1642,1629,this study indicated independent associations of PM10 and PM2.5 concentrations with daily mortality after adjustment for gaseous pollutants .,这项研究表明，在调整气态污染物后，PM10 和 PM2.5 浓度与每日死亡率之间存在独立关联。,0.2,"['gaseous', 'study', 'adjustment', 'mortality', 'after', 'independent', 'with', 'concentrations', 'this', 'and']","['mortality', 'after']",1629,"['这项研究表明,在适用于气体污染物的调整后,每日死亡率的PM10和PM2.5浓度的独立结合。']",0.2,"['gaseous', 'study', 'adjustment', 'mortality', 'after', 'independent', 'with', 'concentrations', 'this', 'and']","['mortality', 'after']",,
1643,1630,the role of assessment of myocardial viability in identifying patients with ischemic cardiomyopathy who might benefit from surgical revascularization remains controversial .,评估心肌活力在确定可能受益于手术血运重建的缺血性心肌病患者中的作用仍然存在争议。,0.3333333333333333,"['who', 'viability', 'surgical', 'role', 'revascularization', 'assessment', 'cardiomyopathy', 'myocardial', 'benefit', 'with', 'in', 'ischemic']","['role', 'revascularization', 'assessment', 'cardiomyopathy']",1630,['评估心脏病的可行性在识别患有催化心脏病的患者的作用可能受益于手术复发仍然有争议。'],0.1666666666666666,"['who', 'viability', 'surgical', 'role', 'revascularization', 'assessment', 'cardiomyopathy', 'myocardial', 'benefit', 'with', 'in', 'ischemic']","['role', 'assessment']",,
1644,1631,"furthermore , although improvement in left ventricular function is one of the goals of revascularization , its relationship to subsequent outcomes is unclear .",此外，尽管左心室功能的改善是血运重建的目标之一，但其与后续结果的关系尚不清楚。,0.375,"['improvement', 'relationship', 'function', 'revascularization', 'ventricular', 'subsequent', 'in', 'to']","['improvement', 'function', 'revascularization']",1631,"['除此之外,尽管左<unk>功能的改善是重振的目标之一,但其与随后的结果的关系不清楚。']",0.25,"['improvement', 'relationship', 'function', 'revascularization', 'ventricular', 'subsequent', 'in', 'to']","['improvement', 'function']",,
1645,1632,patients were randomly assigned to undergo CABG and receive medical therapy or to receive medical therapy alone .,患者被随机分配接受 CABG 并接受药物治疗或仅接受药物治疗。,0.1428571428571428,"['undergo', 'medical', 'therapy', 'CABG', 'to', 'and', 'alone']",['therapy'],1632,['病人随机被授予接受CABG并接受医疗治疗或单独接受医疗治疗。'],0.2857142857142857,"['undergo', 'medical', 'therapy', 'CABG', 'to', 'and', 'alone']","['therapy', 'alone']",,
1646,1633,the primary end point was death from any cause .,主要终点是全因死亡。,0.4,"['death', 'primary', 'cause', 'end', 'point']","['death', 'point']",1633,['主要的终点是任何原因的死亡。'],0.8,"['death', 'primary', 'cause', 'end', 'point']","['death', 'primary', 'cause', 'point']",,
1647,1634,"however , no significant interaction was observed between the presence or absence of myocardial viability and the beneficial effect of CABG plus medical therapy over medical therapy alone ( P = 0.34 for interaction ) .",然而，在存在或不存在心肌活力与 CABG 加药物治疗相对于单独药物治疗的有益效果之间没有观察到显着的相互作用（相互作用 P = 0.34）。,0.4,"['presence', 'plus', 'viability', 'medical', 'therapy', 'CABG', 'absence', 'no', 'interaction', 'effect', 'myocardial', 'P', 'over', 'and', 'alone']","['presence', 'plus', 'therapy', 'effect', 'and', 'alone']",1634,"['然而,没有显著的相互作用被观察到在存在或缺乏心脏病的可行性和有益的效果CABG加上医疗治疗在医疗治疗单独(P = 0.34相互作用)之间。']",0.4666666666666667,"['presence', 'plus', 'viability', 'medical', 'therapy', 'CABG', 'absence', 'no', 'interaction', 'effect', 'myocardial', 'P', 'over', 'and', 'alone']","['presence', 'plus', 'therapy', 'absence', 'effect', 'and', 'alone']",,
1648,1635,"an increase in left ventricular ejection fraction was observed only among patients with myocardial viability , irrespective of treatment assignment .",左心室射血分数增加仅在有心肌活力的患者中观察到，与治疗分配无关。,0.1818181818181818,"['ejection', 'viability', 'treatment', 'ventricular', 'fraction', 'myocardial', 'irrespective', 'increase', 'assignment', 'with', 'ejection fraction']","['treatment', 'ejection fraction']",1635,"['左<unk>排泄分裂的增加仅在患有心血管可行性患者中被观察到,无论治疗任务如何。']",0.0909090909090909,"['ejection', 'viability', 'treatment', 'ventricular', 'fraction', 'myocardial', 'irrespective', 'increase', 'assignment', 'with', 'ejection fraction']",['treatment'],,
1649,1636,there was no association between changes in left ventricular ejection fraction and subsequent death .,左心室射血分数的变化与随后的死亡之间没有关联。,0.3,"['ejection', 'death', 'association', 'no', 'ventricular', 'fraction', 'subsequent', 'ejection fraction', 'in', 'and']","['death', 'association', 'ejection fraction']",1636,['左腹部排泄分裂和随后的死亡之间没有任何联系。'],0.2,"['ejection', 'death', 'association', 'no', 'ventricular', 'fraction', 'subsequent', 'ejection fraction', 'in', 'and']","['death', 'association']",,
1650,1637,"ischemic heart disease is the most common and most lethal cause of heart failure.1,2","缺血性心脏病是心力衰竭最常见和最致命的原因。 1,2",0.75,"['heart', 'disease', 'heart disease', 'lethal', 'ischemic heart disease', 'common', 'cause', 'and']","['heart', 'disease', 'heart disease', 'lethal', 'ischemic heart disease', 'cause']",1637,['心脏病是最常见和最致命的心脏衰竭的原因。'],0.625,"['heart', 'disease', 'heart disease', 'lethal', 'ischemic heart disease', 'common', 'cause', 'and']","['heart', 'disease', 'heart disease', 'lethal', 'cause']",,
1651,1638,it is also the only cause of left ventricular dysfunction that is amenable to the benefit of surgical revascularization .,它也是左心室功能障碍的唯一原因，可以通过手术血运重建获益。,0.25,"['dysfunction', 'surgical', 'revascularization', 'cause', 'ventricular', 'benefit', 'that', 'to']","['revascularization', 'cause']",1638,"['它也是左<unk>功能障碍的唯一原因,可益于手术复发。']",0.25,"['dysfunction', 'surgical', 'revascularization', 'cause', 'ventricular', 'benefit', 'that', 'to']","['cause', 'to']",,
1652,1639,"the STICH trial was a prospective , multicenter , randomized , nonblinded trial sponsored by the National Heart , Lung , and Blood Institute ( NHLBI ) of the National Institutes of Health .",STICH 试验是一项前瞻性、多中心、随机、非盲试验，由美国国立卫生研究院下属的国家心肺血液研究所 (NHLBI) 赞助。,0.75,"['heart', 'lung', 'health', 'blood', 'institute', 'trial', 'by', 'and']","['heart', 'lung', 'health', 'blood', 'institute', 'by']",1639,['STICH审查是由国家卫生研究所国家心脏、肺和血液研究所(NHLBI)赞助的可见、多中心、随机、无盲的审查。'],0.75,"['heart', 'lung', 'health', 'blood', 'institute', 'trial', 'by', 'and']","['heart', 'lung', 'health', 'blood', 'institute', 'by']",,
1653,1640,"in this trial , 1212 patients with coronary artery disease who had a left ventricular ejection fraction of 35 % or lower were enrolled during the period from 2002 through 2007 .",在这项试验中，2002 年至 2007 年期间纳入了 1212 名左心室射血分数为 35% 或更低的冠状动脉疾病患者。,0.3571428571428571,"['period', 'disease', 'ejection', 'who', 'coronary', 'lower', 'ventricular', 'fraction', 'trial', 'with', 'coronary artery', 'ejection fraction', 'this', 'in']","['period', 'disease', 'coronary', 'coronary artery', 'ejection fraction']",1640,"['在这项研究中,1212名患有冠状动脉疾病的患者在2002年至2007年期间注册了35%或更低的左<unk>排泄分。']",0.2857142857142857,"['period', 'disease', 'ejection', 'who', 'coronary', 'lower', 'ventricular', 'fraction', 'trial', 'with', 'coronary artery', 'ejection fraction', 'this', 'in']","['period', 'disease', 'coronary', 'coronary artery']",,
1654,1641,the trial was performed to test the hypothesis that CABG in combination with appropriate medical therapy would result in better survival outcomes than appropriate medical therapy alone .,进行该试验是为了验证 CABG 联合适当的药物治疗会比单独使用适当的药物治疗带来更好的生存结果这一假设。,0.5,"['combination', 'hypothesis', 'survival', 'test', 'medical', 'therapy', 'CABG', 'trial', 'result', 'with', 'that', 'to', 'alone', 'appropriate']","['combination', 'hypothesis', 'survival', 'test', 'therapy', 'result', 'alone']",1641,['试验是为了测试假设CABG与适当的医疗治疗将导致比适当的医疗治疗单独更好的生存结果。'],0.4285714285714285,"['combination', 'hypothesis', 'survival', 'test', 'medical', 'therapy', 'CABG', 'trial', 'result', 'with', 'that', 'to', 'alone', 'appropriate']","['hypothesis', 'survival', 'test', 'therapy', 'result', 'alone']",,
1655,1642,"a complete list of inclusion and exclusion criteria is provided in Table S1 in the Supplementary Appendix , available with the full text of this article at NEJM.org .",补充附录表 S1 中提供了纳入和排除标准的完整列表，补充附录与本文全文可在 NEJM.org 获取。,0.1176470588235294,"['a', 'appendix', 'table', 'inclusion', 'article', 'supplementary', 'exclusion', 'complete', 'available', 'text', 'list', 'with', 'at', 'full', 'S1', 'this', 'and']","['table', 'full']",1642,"['包含和排除标准的完整列表在附件中的表 S1,可在NEJM.org上找到本文的完整文本。']",0.2352941176470588,"['a', 'appendix', 'table', 'inclusion', 'article', 'supplementary', 'exclusion', 'complete', 'available', 'text', 'list', 'with', 'at', 'full', 'S1', 'this', 'and']","['appendix', 'table', 'inclusion', 'full']",,
1656,1643,"the NHLBI and the ethics committee at each participating center approved the trial protocol , available at NEJM.org .",NHLBI 和每个参与中心的伦理委员会批准了试验方案，可在 NEJM.org 获取。,0.3333333333333333,"['center', 'protocol', 'ethics', 'available', 'committee', 'trial', 'at', 'each', 'and']","['center', 'protocol', 'committee']",1643,"['NHLBI 和各参与中心的伦理委员会批准了审判协议,可在 NEJM.org 上找到。']",0.5555555555555556,"['center', 'protocol', 'ethics', 'available', 'committee', 'trial', 'at', 'each', 'and']","['center', 'protocol', 'committee', 'trial', 'each']",,
1657,1644,"the design of the STICH trial and the results of the analysis of the primary hypothesis have been reported previously.3,4,13","STICH 试验的设计和主要假设的分析结果之前已有报道。 3,4,13",0.5714285714285714,"['analysis', 'hypothesis', 'primary', 'trial', 'design', 'have', 'and']","['analysis', 'hypothesis', 'design', 'have']",1644,['STICH试验的设计和初始假设的分析结果已提前报告。'],0.4285714285714285,"['analysis', 'hypothesis', 'primary', 'trial', 'design', 'have', 'and']","['analysis', 'hypothesis', 'design']",,
1658,1645,"although tests to assess myocardial viability were initially mandated as part of the STICH protocol , this requirement was discontinued because of difficulties in patient enrollment .",尽管评估心肌活力的测试最初是作为 STICH 协议的一部分强制执行的，但由于患者招募困难，这一要求已被中止。,0.625,"['part', 'requirement', 'protocol', 'viability', 'in patient', 'myocardial', 'assess', 'this']","['part', 'requirement', 'protocol', 'assess', 'this']",1645,"['雖然考試以評估心血管可行性最初被委託作為STICH議定書的一部分,但這項要求因病人登記的困難而被中止。']",0.25,"['part', 'requirement', 'protocol', 'viability', 'in patient', 'myocardial', 'assess', 'this']","['part', 'requirement']",,
1659,1646,"hence , only a proportion of patients enrolled in the STICH trial were included in the myocardial viability substudy .",因此，只有一部分参加 STICH 试验的患者被纳入心肌存活子研究。,0.1666666666666666,"['proportion', 'a', 'viability', 'trial', 'myocardial', 'in']",['proportion'],1646,"['因此,只有百分之百的病人被列入STICH试验被列入心血管可行性研究。']",0.0,"['proportion', 'a', 'viability', 'trial', 'myocardial', 'in']",[],,
1660,1647,the current study was designed by the first author and was approved by the policy and publications committee of the STICH trial .,本研究由第一作者设计，并获得 STICH 试验政策和出版委员会的批准。,0.375,"['author', 'study', 'committee', 'trial', 'current', 'by', 'and', 'first']","['committee', 'by', 'first']",1647,"['目前的研究是由第一位作者设计的,由STICH审判的政策和出版委员会批准。']",0.5,"['author', 'study', 'committee', 'trial', 'current', 'by', 'and', 'first']","['committee', 'trial', 'by', 'first']",,
1661,1648,the clinical and outcomes data were collected by personnel at the participating sites and were sent directly to the data coordinating center at the Duke Clinical Research Institute .,临床和结果数据由参与地点的人员收集，并直接发送到杜克临床研究所的数据协调中心。,0.7777777777777778,"['center', 'research', 'data', 'clinical', 'institute', 'personnel', 'by', 'to', 'and']","['center', 'research', 'data', 'clinical', 'institute', 'personnel', 'by']",1648,"['临床和结果数据由参与场所的员工收集,并直接发送到杜克临床研究所的数据协调中心。']",0.6666666666666666,"['center', 'research', 'data', 'clinical', 'institute', 'personnel', 'by', 'to', 'and']","['center', 'research', 'data', 'clinical', 'institute', 'by']",,
1662,1649,"the images obtained for myocardial viability and other noninvasive studies were sent from the participating sites to the respective independent core laboratories , where they were evaluated ; the resultant data were then sent to the data coordinating center .",为心肌活力和其他非侵入性研究获得的图像从参与地点发送到各自的独立核心实验室，在那里进行评估；然后将生成的数据发送到数据协调中心。,0.3,"['center', 'core', 'data', 'viability', 'independent', 'myocardial', 'resultant', 'to', 'and', 'noninvasive']","['center', 'core', 'data']",1649,"['为了心血管可行性和其他非侵略性研究而获得的图像,从参与场所发送到各自的核心实验室,在那里它们被评估;结果的数据随后发送到数据协调中心。']",0.5,"['center', 'core', 'data', 'viability', 'independent', 'myocardial', 'resultant', 'to', 'and', 'noninvasive']","['center', 'core', 'data', 'resultant', 'and']",,
1663,1650,"the data coordinating center stored the data , and the statisticians at the Duke Clinical Research Institute ( the second and third authors ) wrote the statistical analysis plan and conducted the data analyses .",数据协调中心存储数据，杜克临床研究所的统计学家（第二和第三作者）编写统计分析计划并进行数据分析。,0.8,"['center', 'research', 'data', 'analysis', 'clinical', 'institute', 'statistical analysis', 'second', 'and', 'third']","['center', 'research', 'data', 'analysis', 'clinical', 'institute', 'statistical analysis', 'third']",1650,"['数据协调中心存储了数据,杜克临床研究所的统计学家(第二和第三作者)写了统计分析计划,并进行了数据分析。']",0.8,"['center', 'research', 'data', 'analysis', 'clinical', 'institute', 'statistical analysis', 'second', 'and', 'third']","['center', 'research', 'data', 'analysis', 'clinical', 'institute', 'statistical analysis', 'third']",,
1664,1651,all the authors vouch for the accuracy and completeness of the data and for the fidelity of the study to the protocol .,所有作者保证数据的准确性和完整性以及研究对方案的忠实度。,0.375,"['fidelity', 'data', 'accuracy', 'protocol', 'study', 'completeness', 'all', 'and']","['data', 'accuracy', 'completeness']",1651,"['所有作者都赞扬数据的准确性和完整性,以及研究对议定书的忠诚性。']",0.5,"['fidelity', 'data', 'accuracy', 'protocol', 'study', 'completeness', 'all', 'and']","['data', 'accuracy', 'protocol', 'completeness']",,
1665,1652,"the first draft of the manuscript was written by the first author , and all the authors reviewed and revised subsequent drafts .",手稿的初稿由第一作者撰写，所有作者审阅并修改了后续草稿。,0.375,"['author', 'manuscript', 'subsequent', 'all', 'by', 'and', 'first', 'draft']","['manuscript', 'by', 'first']",1652,"['手稿的第一张草案是由第一位作者撰写的,所有作者都审查并审查了随后的草案。']",0.375,"['author', 'manuscript', 'subsequent', 'all', 'by', 'and', 'first', 'draft']","['manuscript', 'by', 'first']",,
1666,1653,the manuscript was reviewed and approved for submission by the policy and publications committee of the STICH trial and by the NHLBI .,STICH 试验的政策和出版委员会以及 NHLBI 审查并批准了手稿提交。,0.5,"['manuscript', 'committee', 'trial', 'submission', 'by', 'and']","['manuscript', 'committee', 'by']",1653,['手稿已被STICH审判的政策和出版委员会和NHLBI审查和批准提交。'],0.5,"['manuscript', 'committee', 'trial', 'submission', 'by', 'and']","['manuscript', 'committee', 'trial']",,
1667,1654,assessment OF MYOCARDIAL VIABILITY,心肌活力评估,1.0,['assessment'],['assessment'],1654,['心血管生存率评估'],1.0,['assessment'],['assessment'],,
1668,1655,data collection for and analysis of the SPECT and dobutamine echocardiographic studies were coordinated at independent core laboratories that were funded by the NHLBI ; investigators at each laboratory were unaware of the treatment assignments and the individual characteristics of the patients .,SPECT 和多巴酚丁胺超声心动图研究的数据收集和分析在 NHLBI 资助的独立核心实验室进行协调；每个实验室的研究人员都不知道治疗分配和患者的个体特征。,0.6470588235294118,"['SPECT', 'core', 'data', 'analysis', 'individual', 'collection', 'treatment', 'characteristics', 'laboratory', 'independent', 'unaware', 'data collection', 'that', 'each', 'by', 'and', 'echocardiographic']","['SPECT', 'core', 'data', 'analysis', 'individual', 'collection', 'treatment', 'characteristics', 'laboratory', 'data collection', 'echocardiographic']",1655,"['对SPECT和Dubutamine的数据收集和分析,在由NHLBI资助的独立核心实验室进行了协调;每个实验室的研究人员都不知道治疗任务和患者的个性特征。']",0.5882352941176471,"['SPECT', 'core', 'data', 'analysis', 'individual', 'collection', 'treatment', 'characteristics', 'laboratory', 'independent', 'unaware', 'data collection', 'that', 'each', 'by', 'and', 'echocardiographic']","['SPECT', 'core', 'data', 'analysis', 'collection', 'treatment', 'characteristics', 'laboratory', 'data collection', 'by']",,
1669,1656,"details of the imaging protocols used to identify and quantify viable myocardium have been published previously.5,14","用于识别和量化活心肌的成像协议的详细信息之前已发表。 5,14",0.4285714285714285,"['viable', 'myocardium', 'identify', 'imaging', 'have', 'to', 'and']","['myocardium', 'identify', 'to']",1656,['图像协议的详细信息用于识别和量化可行的心血管已经公布。'],0.2857142857142857,"['viable', 'myocardium', 'identify', 'imaging', 'have', 'to', 'and']","['identify', 'to']",,
1670,1657,"in brief , thresholds of the extent of viable myocardium were prespecified to classify patients in a binary fashion as either having or not having substantial myocardial viability .",简而言之，存活心肌范围的阈值被预先指定，以二元方式将患者分类为具有或不具有实质性心肌存活。,0.2,"['a', 'viable', 'myocardium', 'binary', 'viability', 'myocardial', 'extent', 'as', 'to', 'substantial']","['viable', 'myocardium']",1657,"['简而言之,可行的心脏病的范围的边界被预定为将病人以二进制方式分类为有或没有显著的心脏病的可行性。']",0.0,"['a', 'viable', 'myocardium', 'binary', 'viability', 'myocardial', 'extent', 'as', 'to', 'substantial']",[],,
1671,1658,"for SPECT , patients with viability were defined as those with 11 or more viable segments on the basis of relative tracer activity .",对于 SPECT，具有存活性的患者被定义为根据相对示踪剂活性具有 11 个或更多存活节段的患者。,0.3,"['SPECT', 'viable', 'defined', 'activity', 'viability', 'basis', 'tracer', 'relative', 'with', 'on']","['SPECT', 'viable', 'activity']",1658,"['对于SPECT,可行性患者被定义为基于相对跟踪活动的11个或多个可行性分区的患者。']",0.2,"['SPECT', 'viable', 'defined', 'activity', 'viability', 'basis', 'tracer', 'relative', 'with', 'on']","['SPECT', 'activity']",,
1672,1659,"for dobutamine echocardiography , patients with viability were defined as those with 5 or more segments with abnormal resting systolic function but manifesting contractile reserve during dobutamine administration .",对于多巴酚丁胺超声心动图，有活力的患者被定义为具有 5 个或更多节段且静息收缩功能异常但在多巴酚丁胺给药期间表现出收缩储备的患者。,0.3846153846153846,"['5', 'defined', 'reserve', 'administration', 'function', 'viability', 'abnormal', 'systolic', 'as', 'with', 'but', 'echocardiography', 'contractile']","['5', 'reserve', 'function', 'abnormal', 'but']",1659,"['对于Dubutamine echocardiography,可行性患者被定义为具有5个或多个分区的患者,在Dubutamine服用期间表现出异常的休息系统功能,但在服用期间表现出合并性储备。']",0.3846153846153846,"['5', 'defined', 'reserve', 'administration', 'function', 'viability', 'abnormal', 'systolic', 'as', 'with', 'but', 'echocardiography', 'contractile']","['5', 'reserve', 'function', 'abnormal', 'but']",,
1673,1660,"in addition , we analyzed myocardial viability as a continuous variable by computing the proportion of viable segments relative to the number of segments analyzed for each individual patient.5,14","此外，我们通过计算每个患者的存活节段相对于分析的节段数量的比例，将心肌活力作为连续变量进行分析。 5,14",0.4,"['proportion', 'variable', 'viable', 'individual', 'continuous', 'addition', 'viability', 'relative', 'number', 'myocardial', 'as', 'each', 'by', 'to', 'we']","['proportion', 'variable', 'viable', 'continuous', 'number', 'to']",1660,"['此外,我们分析了心脏病的可行性作为持续变量,计算了可行分区的比例,与每个患者分析的分区数量相比。']",0.2,"['proportion', 'variable', 'viable', 'individual', 'continuous', 'addition', 'viability', 'relative', 'number', 'myocardial', 'as', 'each', 'by', 'to', 'we']","['proportion', 'variable', 'number']",,
1674,1661,assessment OF LEFT VENTRICULAR FUNCTION,左心室功能评估,1.0,['assessment'],['assessment'],1661,['空气风力功能评估'],1.0,['assessment'],['assessment'],,
1675,1662,"the study protocol specified that patients had to undergo echocardiography , radionuclide scanning , or cardiac magnetic resonance imaging at baseline and at 4 months after randomization .",研究方案规定，患者必须在基线和随机分组后 4 个月时接受超声心动图、放射性核素扫描或心脏磁共振成像。,0.4285714285714285,"['resonance', 'cardiac', 'randomization', 'baseline', 'radionuclide', 'protocol', 'undergo', 'study', 'magnetic resonance imaging', 'scanning', 'after', '4', 'that', 'echocardiography']","['resonance', 'cardiac', 'randomization', 'baseline', 'radionuclide', 'after']",1662,"['研究协议规定,患者必须在基线上进行 echocardiography、 radionuclide 扫描或心脏磁响应图像,并在 randomization 后 4 个月进行。']",0.2857142857142857,"['resonance', 'cardiac', 'randomization', 'baseline', 'radionuclide', 'protocol', 'undergo', 'study', 'magnetic resonance imaging', 'scanning', 'after', '4', 'that', 'echocardiography']","['cardiac', 'baseline', 'protocol', 'after']",,
1676,1663,details of the methods of assessment of left ventricular volume at each independent core laboratory have been reported previously.15,每个独立核心实验室的左心室容积评估方法的细节以前都有报道。 15,0.75,"['volume', 'core', 'assessment', 'ventricular', 'laboratory', 'independent', 'have', 'each']","['volume', 'core', 'assessment', 'ventricular', 'laboratory', 'have']",1663,['每个独立核心实验室的左<unk>体积评估方法的详细信息已提前报告。'],0.625,"['volume', 'core', 'assessment', 'ventricular', 'laboratory', 'independent', 'have', 'each']","['volume', 'core', 'assessment', 'ventricular', 'laboratory']",,
1677,1664,"when more than one imaging method was used for a patient at a single time point , we used a prespecified hierarchical algorithm that was based on the quality of each of the imaging studies to determine the best available method for measurement of the left ventricular ejection fraction.15",当在单个时间点对患者使用多种成像方法时，我们使用基于每项成像研究质量的预先指定的分级算法来确定测量左心室射血分数的最佳可用方法。 15,0.4444444444444444,"['a', 'ejection', 'algorithm', 'quality', 'time', 'available', 'ventricular', 'measurement', 'patient', 'method', 'point', 'imaging', 'that', 'each', 'single', 'to', 'determine', 'we']","['algorithm', 'quality', 'time', 'measurement', 'patient', 'point', 'single', 'to']",1664,"['当一个患者在一个时间点使用超过一个图像方法时,我们使用了一个预定的序列算法,该算法是基于图像研究的质量,以确定测量左<unk>排泄分的最佳可用方法。']",0.3888888888888889,"['a', 'ejection', 'algorithm', 'quality', 'time', 'available', 'ventricular', 'measurement', 'patient', 'method', 'point', 'imaging', 'that', 'each', 'single', 'to', 'determine', 'we']","['algorithm', 'quality', 'time', 'measurement', 'patient', 'point', 'to']",,
1678,1665,"after enrollment , patients were followed every 4 months during the first year and every 6 months thereafter .",入组后，第一年每 4 个月对患者进行一次随访，此后每 6 个月随访一次。,0.6,"['year', 'after', '4', 'and', 'first']","['year', 'after', 'first']",1665,"['在注册后,患者在第一年每4个月,随后每6个月都被跟踪。']",0.6,"['year', 'after', '4', 'and', 'first']","['year', 'after', 'first']",,
1679,1666,the primary outcome was death from any cause .,主要结果是全因死亡。,0.5,"['outcome', 'death', 'primary', 'cause']","['outcome', 'death']",1666,['主要的结果是任何原因的死亡。'],1.0,"['outcome', 'death', 'primary', 'cause']","['outcome', 'death', 'primary', 'cause']",,
1680,1667,secondary end points were death from cardiovascular causes and a composite of death from any cause or hospitalization for cardiovascular causes .,次要终点是心血管原因死亡以及任何原因死亡或心血管原因住院的复合终点。,0.5555555555555556,"['composite', 'a', 'cardiovascular', 'death', 'hospitalization', 'end points', 'cause', 'secondary', 'and']","['cardiovascular', 'death', 'hospitalization', 'end points', 'cause']",1667,['二次终点是心血管原因死亡和任何原因或心血管原因的住院死亡的组成部分。'],0.5555555555555556,"['composite', 'a', 'cardiovascular', 'death', 'hospitalization', 'end points', 'cause', 'secondary', 'and']","['cardiovascular', 'death', 'hospitalization', 'end points', 'cause']",,
1681,1668,definitions of the trial end points have been reported previously.13,之前已经报告了试验终点的定义。 13,0.3333333333333333,"['end points', 'trial', 'have']",['end points'],1668,['审判终点的定义已被提交。13'],0.6666666666666666,"['end points', 'trial', 'have']","['end points', 'trial']",,
1682,1669,"other assessments included the difference between patients who had myocardial viability and those who did not with respect to the incidence of death from any cause and the incidence of death from cardiovascular causes ; the interaction between treatment assignment and myocardial viability status with respect to death from any cause , death from cardiovascular causes , and a composite of death from any cause or hospitalization for cardiovascular causes ; the difference between patients who had improvement in left ventricular ejection fraction and those who did not , among patients who were alive at 4 months , with respect to subsequent death from any cause and death from cardiovascular causes ; and the interaction between improvement in left ventricular ejection fraction and myocardial viability status with respect to death from any cause and death from cardiovascular causes .",其他评估包括在任何原因死亡发生率和心血管原因死亡发生率方面，具有心肌存活能力的患者与不具有心肌存活能力的患者之间的差异；关于任何原因死亡、心血管原因死亡以及任何原因死亡或因心血管原因住院的复合，治疗分配与心肌存活状态之间的相互作用；在存活 4 个月的患者中，左心室射血分数有改善的患者与没有改善的患者之间在随后的任何原因死亡和心血管原因死亡方面的差异；以及左心室射血分数改善与心肌活力状态之间的交互作用，与全因死亡和心血管原因死亡有关。,0.4230769230769231,"['composite', 'improvement', 'incidence', 'a', 'cardiovascular', 'ejection', 'who', 'death', 'viability', 'difference', 'status', 'hospitalization', 'treatment', 'cause', 'ventricular', 'fraction', 'interaction', 'subsequent', 'myocardial', '4', 'assignment', 'with', 'respect', 'ejection fraction', 'to', 'and']","['improvement', 'incidence', 'cardiovascular', 'death', 'difference', 'status', 'hospitalization', 'treatment', 'cause', 'ejection fraction', 'to']",1669,"['其他评估包括患有心血管生存率的患者和不因任何原因而死亡的患者之间的差异,以及因心血管原因而死亡的患者之间的差异,以及因心血管原因而死亡,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心血管原因而死亡的组成,以及因心']",0.1923076923076923,"['composite', 'improvement', 'incidence', 'a', 'cardiovascular', 'ejection', 'who', 'death', 'viability', 'difference', 'status', 'hospitalization', 'treatment', 'cause', 'ventricular', 'fraction', 'interaction', 'subsequent', 'myocardial', '4', 'assignment', 'with', 'respect', 'ejection fraction', 'to', 'and']","['cardiovascular', 'death', 'difference', 'cause', 'and']",,
1683,1670,a generalized linear model was used to assess differences in the change in left ventricular ejection fraction in various subgroups of patients .,广义线性模型用于评估不同患者亚组左心室射血分数变化的差异。,0.4615384615384615,"['a', 'ejection', 'model', 'various', 'linear', 'ventricular', 'fraction', 'generalized', 'linear model', 'assess', 'change', 'ejection fraction', 'to']","['model', 'linear model', 'assess', 'change', 'ejection fraction', 'to']",1670,['一般化线性模型被用来评估患者的不同子群中的左<unk>排泄分裂的变化差异。'],0.3076923076923077,"['a', 'ejection', 'model', 'various', 'linear', 'ventricular', 'fraction', 'generalized', 'linear model', 'assess', 'change', 'ejection fraction', 'to']","['model', 'linear model', 'assess', 'change']",,
1684,1671,all generalized linear models included the baseline value of left ventricular ejection fraction as a covariate .,所有广义线性模型都包括左心室射血分数的基线值作为协变量。,0.2,"['a', 'ejection', 'baseline', 'value', 'linear', 'ventricular', 'fraction', 'generalized', 'ejection fraction', 'all']","['baseline', 'ejection fraction']",1671,['所有通用的线性模型都包含了左<unk>排泄部分作为科瓦里亚特的基值。'],0.1,"['a', 'ejection', 'baseline', 'value', 'linear', 'ventricular', 'fraction', 'generalized', 'ejection fraction', 'all']",['fraction'],,
1685,1672,"because the study protocol did not include a method for adjusting for multiplicity in testing , summary statistics are limited to point estimates and 95 % confidence intervals .",因为研究方案不包括调整测试多重性的方法，所以汇总统计仅限于点估计和 95% 置信区间。,0.25,"['statistics', 'protocol', 'study', 'method', 'multiplicity', 'point', 'testing', 'confidence', 'limited', 'and', 'intervals', 'adjusting']","['statistics', 'multiplicity', 'point']",1672,"['由于研究协议不包含对测试中的多样性进行调整的方法,总结统计数据仅限于点估计和95%的信任间隔。']",0.25,"['statistics', 'protocol', 'study', 'method', 'multiplicity', 'point', 'testing', 'confidence', 'limited', 'and', 'intervals', 'adjusting']","['statistics', 'protocol', 'point']",,
1686,1673,"the widths of the intervals were not adjusted for multiplicity ; therefore , the intervals should not be viewed as evidence for significant associations or treatment effects .",间隔的宽度未针对多重性进行调整；因此，间隔不应被视为显着关联或治疗效果的证据。,0.4285714285714285,"['be', 'treatment', 'evidence', 'multiplicity', 'as', 'therefore', 'intervals']","['treatment', 'evidence', 'multiplicity']",1673,"['间隔的宽度不适用于多样性;因此,间隔不应视为显著的结合或治疗效果的证据。']",0.2857142857142857,"['be', 'treatment', 'evidence', 'multiplicity', 'as', 'therefore', 'intervals']","['treatment', 'evidence']",,
1687,1674,P values of less than 0.05 were considered to indicate statistical significance .,小于 0.05 的 P 值被认为表明具有统计学意义。,0.3333333333333333,"['indicate', 'significance', 'statistical significance', 'values', 'P', 'to']","['significance', 'to']",1674,['低于 0.05 的 P 值被认为表明统计意义。'],0.3333333333333333,"['indicate', 'significance', 'statistical significance', 'values', 'P', 'to']","['significance', 'to']",,
1688,1675,study POPULATION AND THE EFFECT OF CABG,研究人口和 CABG 的影响,0.0,"['study', 'CABG']",[],1675,['研究人口和CABG的影响'],0.0,"['study', 'CABG']",[],,
1689,1676,"of the 1212 patients enrolled in the STICH trial , 601 patients who underwent myocardial viability testing met the inclusion criteria for the substudy .",在参加 STICH 试验的 1212 名患者中，有 601 名接受过心肌活力测试的患者符合子研究的纳入标准。,0.0,"['who', 'inclusion', 'viability', 'trial', 'myocardial', 'testing', 'met']",[],1676,"['在 STICH 研究中注册的 1212 名患者中,601 名接受心血管可行性测试的患者满足了本科研究的包含标准。']",0.1428571428571428,"['who', 'inclusion', 'viability', 'trial', 'myocardial', 'testing', 'met']",['inclusion'],,
1690,1677,the baseline characteristics of the 1212 patients overall and according to whether they underwent viability testing are shown in Table S2 in the Supplementary Appendix .,补充附录表 S2 显示了 1212 名患者的总体基线特征以及他们是否接受了生存力测试。,0.3,"['appendix', 'table', 'baseline', 'viability', 'supplementary', 'characteristics', 'testing', 'S2', 'to', 'and']","['table', 'baseline', 'characteristics']",1677,"['根据1212名患者的基本特征,以及他们是否经过可行性测试,在附件中的表 S2 显示。']",0.3,"['appendix', 'table', 'baseline', 'viability', 'supplementary', 'characteristics', 'testing', 'S2', 'to', 'and']","['appendix', 'table', 'characteristics']",,
1691,1678,outcomes IN PATIENTS WITH AND THOSE WITHOUT MYOCARDIAL VIABILITY,具有和不具有心肌活力的患者的结果,,[],[],1678,['患有和没有心脏病的患者的结果'],,[],[],,
1692,1679,"among the 601 patients , 487 ( 81 % ) were considered to have myocardial viability , as defined in the protocol .",在 601 名患者中，487 名 (81%) 被认为具有方案中定义的心肌活力。,0.1666666666666666,"['defined', 'protocol', 'viability', 'myocardial', 'as', 'have']",['have'],1679,"['在601名患者中,487人(81%)被认为有心脏病的可行性,如议定书所定义。']",0.5,"['defined', 'protocol', 'viability', 'myocardial', 'as', 'have']","['protocol', 'as', 'have']",,
1693,1680,the remaining 114 patients ( 19 % ) were classified as not having viability .,其余 114 名患者 (19%) 被归类为没有生存能力。,0.0,"['viability', 'classified']",[],1680,['其余的114名患者(19%)被列为无可行性。'],0.0,"['viability', 'classified']",[],,
1694,1681,Table 1 lists the demographic and clinical characteristics of the patients overall and according to the presence or absence of myocardial viability .,表 1 列出了患者的总体人口统计学和临床特征，以及是否存在心肌活力。,0.5,"['presence', 'table', '1', 'viability', 'absence', 'clinical', 'characteristics', 'myocardial', 'to', 'and']","['presence', 'table', '1', 'clinical', 'characteristics']",1681,"['图1列出患者的人口和临床特征,并根据心血管可行性的存在或缺席。']",0.5,"['presence', 'table', '1', 'viability', 'absence', 'clinical', 'characteristics', 'myocardial', 'to', 'and']","['presence', '1', 'absence', 'clinical', 'characteristics']",,
1695,1682,"although CABG plus medical therapy was associated with a lower incidence of death from any cause than medical therapy alone ( Figure 1A ) , the interaction between the presence or absence of myocardial viability and the beneficial effect of CABG plus medical therapy over medical therapy alone was not significant ( P = 0.34 ) ( Figure 1B and 1C ) .",尽管 CABG 联合药物治疗与全因死亡发生率低于单独药物治疗相关（图 1A ），但心肌活力的存在与否与 CABG 联合药物治疗相对于单独药物治疗的有益效果之间的交互作用并不明显。显着 (P = 0.34)（图 1B 和 1C）。,0.2727272727272727,"['presence', 'incidence', 'a', 'death', 'figure', 'plus', 'viability', 'medical', 'lower', 'therapy', 'CABG', 'associated', 'absence', 'cause', 'interaction', 'effect', 'myocardial', 'with', 'P', 'over', 'and', 'alone']","['presence', 'incidence', 'death', 'therapy', 'effect', 'alone']",1682,"['雖然CABG加上醫療治療與任何原因死亡率低於醫療治療(圖1A)相結合,但心血管生存能力的存在或缺乏與CABG加上醫療治療對醫療治療的有益效應之間的相互作用並不顯著(圖1B和1C)。']",0.2727272727272727,"['presence', 'incidence', 'a', 'death', 'figure', 'plus', 'viability', 'medical', 'lower', 'therapy', 'CABG', 'associated', 'absence', 'cause', 'interaction', 'effect', 'myocardial', 'with', 'P', 'over', 'and', 'alone']","['presence', 'death', 'plus', 'absence', 'cause', 'effect']",,
1696,1683,left VENTRICULAR EJECTION FRACTION AND SUBSEQUENT OUTCOMES,左心室射血分数和后续结果,,[],[],1683,['左'],,[],[],,
1697,1684,"of the remaining 567 patients , 318 ( 56 % ) had paired imaging at baseline and at 4 months for measurement of left ventricular ejection fraction .",在其余 567 名患者中，318 名 (56%) 在基线和 4 个月时进行了配对成像测量左心室射血分数。,0.3,"['ejection', 'baseline', 'ventricular', 'measurement', 'fraction', '4', 'ejection fraction', 'at', 'imaging', 'and']","['baseline', 'measurement', 'ejection fraction']",1684,"['在剩余567名患者中,有318人(56%)在基线上和4个月内进行测量,以测量左<unk>排泄分。']",0.2,"['ejection', 'baseline', 'ventricular', 'measurement', 'fraction', '4', 'ejection fraction', 'at', 'imaging', 'and']","['baseline', 'measurement']",,
1698,1685,"in contrast , among patients without myocardial viability , there was no improvement in left ventricular ejection fraction in either treatment group ( Figure 3 ) .",相反，在没有心肌活力的患者中，两个治疗组的左心室射血分数都没有改善（图 3）。,0.3125,"['group', 'improvement', 'ejection', 'contrast', 'figure', 'viability', 'treatment', 'no', 'ventricular', 'fraction', 'myocardial', '3', 'treatment group', 'ejection fraction', 'in', 'without']","['group', 'improvement', 'treatment', 'treatment group', 'ejection fraction']",1685,"['相比之下,在没有心血管可行性患者中,在任何治疗组中,左<unk>排泄分子没有改善(图3)。']",0.25,"['group', 'improvement', 'ejection', 'contrast', 'figure', 'viability', 'treatment', 'no', 'ventricular', 'fraction', 'myocardial', '3', 'treatment group', 'ejection fraction', 'in', 'without']","['group', 'improvement', 'treatment', 'treatment group']",,
1699,1686,our study showed a lower incidence of death from any cause with CABG plus medical therapy than with medical therapy alone .,我们的研究表明，CABG 联合药物治疗的全因死亡发生率低于单独药物治疗。,0.3333333333333333,"['incidence', 'a', 'death', 'plus', 'study', 'medical', 'lower', 'therapy', 'CABG', 'cause', 'with', 'alone']","['incidence', 'death', 'therapy', 'alone']",1686,"['我们的研究表明,与CABG加医疗治疗的任何原因死亡的发病率低于单独医疗治疗的发病率。']",0.5,"['incidence', 'a', 'death', 'plus', 'study', 'medical', 'lower', 'therapy', 'CABG', 'cause', 'with', 'alone']","['incidence', 'death', 'plus', 'therapy', 'cause', 'alone']",,
1700,1687,"however , the tests of interaction between myocardial viability and treatment effect of CABG were not significant for any of the three end points .",然而，心肌活力与CABG治疗效果之间交互作用的检验对于三个终点中的任何一个都不显着。,0.5,"['viability', 'end points', 'CABG', 'treatment', 'interaction', 'effect', 'myocardial', 'treatment effect', 'three', 'and']","['end points', 'treatment', 'effect', 'treatment effect', 'and']",1687,"['然而,心血管可行性和CABG的治疗效应之间的相互作用测试在三个终点中都没有显著。']",0.4,"['viability', 'end points', 'CABG', 'treatment', 'interaction', 'effect', 'myocardial', 'treatment effect', 'three', 'and']","['end points', 'treatment', 'effect', 'and']",,
1701,1688,"therefore , we must conclude that there is no statistical evidence of association between myocardial viability and benefit from CABG .",因此，我们必须得出结论，没有统计证据表明心肌活力与 CABG 获益之间存在关联。,0.1538461538461538,"['must', 'association', 'viability', 'CABG', 'no', 'myocardial', 'evidence', 'benefit', 'conclude', 'therefore', 'that', 'and', 'we']","['association', 'evidence']",1688,"['因此,我们必须得出结论,心血管可行性与CABG的好处之间没有统计证据的联系。']",0.1538461538461538,"['must', 'association', 'viability', 'CABG', 'no', 'myocardial', 'evidence', 'benefit', 'conclude', 'therefore', 'that', 'and', 'we']","['association', 'evidence']",,
1702,1689,"a number of various possibilities , alone or in combination , may account for the negative results of our study .",许多不同的可能性，单独或组合，可能会导致我们研究的负面结果。,0.5,"['combination', 'study', 'negative', 'various', 'number', 'alone']","['combination', 'various', 'alone']",1689,"['多种不同的可能性,单独或结合,可能会对我们的研究的负面结果负责。']",0.5,"['combination', 'study', 'negative', 'various', 'number', 'alone']","['combination', 'various', 'alone']",,
1703,1690,"it is certainly possible that a true biologic interaction exists between myocardial viability and the benefit of revascularization and that we were unable to unveil it because of the relatively small number of patients , especially patients without myocardial viability , included in our study .",心肌活力和血运重建的益处之间存在真正的生物学相互作用当然是可能的，但由于纳入我们研究的患者数量相对较少，尤其是没有心肌活力的患者，我们无法揭示这一点。,0.25,"['a', 'true', 'biologic', 'viability', 'study', 'revascularization', 'number', 'interaction', 'myocardial', 'benefit', 'that', 'to', 'and', 'unable to', 'without', 'we']","['revascularization', 'number', 'to', 'without']",1690,"['毫无疑问,在心脏病的可行性和复发的好处之间存在真正的生物相互作用,并且由于我们研究中所涉及的患者,尤其是没有心脏病的可行性患者,相对较少的数量,我们无法揭示它。']",0.1875,"['a', 'true', 'biologic', 'viability', 'study', 'revascularization', 'number', 'interaction', 'myocardial', 'benefit', 'that', 'to', 'and', 'unable to', 'without', 'we']","['number', 'to', 'without']",,
1704,1691,"a complementary explanation is that the physiological complexity underpinning the potential therapeutic benefit of surgical revascularization cannot be surmised from the results of a single test of myocardial viability , particularly when those results are expressed in a dichotomous fashion ( i.e. , patients having or not having viability ) .",一个补充的解释是，不能从单一的心肌活力测试结果中推测支持手术血运重建潜在治疗益处的生理学复杂性，特别是当这些结果以二分法方式表示时（即，患者有或没有活力） .,0.1875,"['complementary', 'test', 'potential', 'complexity', 'viability', 'surgical', 'be', 'revascularization', 'therapeutic', 'myocardial', 'physiological', 'benefit', 'underpinning', 'explanation', 'that', 'single']","['be', 'revascularization', 'single']",1691,"['一个补充的解释是,基于外科复发的潜在治疗好处的生理复杂性不能从单一心脏可行性测试的结果中超越,特别是当这些结果以二元性方式表达(即有或没有可行性患者)。']",0.125,"['complementary', 'test', 'potential', 'complexity', 'viability', 'surgical', 'be', 'revascularization', 'therapeutic', 'myocardial', 'physiological', 'benefit', 'underpinning', 'explanation', 'that', 'single']","['be', 'single']",,
1705,1692,"in fact , previous results from the STICH trial showed that the degree of left ventricular systolic dysfunction and remodeling and the number of stenotic coronary arteries appear to be stronger determinants of the benefit of revascularization than myocardial viability.19",事实上，之前 STICH 试验的结果表明，左心室收缩功能障碍和重塑的程度以及狭窄冠状动脉的数量似乎是血运重建获益的比心肌活力更强的决定因素。 19,0.25,"['dysfunction', 'previous', 'coronary', 'degree', 'be', 'revascularization', 'stenotic', 'number', 'ventricular', 'systolic', 'trial', 'myocardial', 'benefit', 'that', 'in', 'and']","['coronary', 'degree', 'revascularization', 'number']",1692,"['事实上,STICH试验的先前结果表明,左腹部系统性功能障碍和修复的程度以及甲状腺甲状腺的数量似乎比心血管生存能力更为决定性。']",0.125,"['dysfunction', 'previous', 'coronary', 'degree', 'be', 'revascularization', 'stenotic', 'number', 'ventricular', 'systolic', 'trial', 'myocardial', 'benefit', 'that', 'in', 'and']","['degree', 'number']",,
1706,1693,patients with ischemic cardiomyopathy often present with complex and challenging clinical scenarios .,缺血性心肌病患者通常会出现复杂且具有挑战性的临床情况。,0.4285714285714285,"['complex', 'clinical', 'cardiomyopathy', 'present', 'with', 'and', 'ischemic']","['clinical', 'cardiomyopathy', 'present']",1693,['患有催化性心脏病的患者经常面临复杂和挑战性的临床场景。'],0.1428571428571428,"['complex', 'clinical', 'cardiomyopathy', 'present', 'with', 'and', 'ischemic']",['clinical'],,
1707,1694,"therefore , the results of tests for detection of viable myocardium must be interpreted within the context of the multiplicity of factors necessary to reach the best treatment decision for each patient .",因此，必须在为每位患者做出最佳治疗决策所需的多种因素的背景下解释活心肌检测试验的结果。,0.4,"['must', 'viable', 'detection', 'myocardium', 'context', 'be', 'treatment', 'necessary', 'patient', 'decision', 'multiplicity', 'therefore', 'each', 'to', 'reach']","['detection', 'myocardium', 'be', 'treatment', 'patient', 'decision']",1694,"['因此,可行的心脏病检测测试的结果必须在每个患者获得最佳治疗决策所需的因素多样性背景下进行解释。']",0.3333333333333333,"['must', 'viable', 'detection', 'myocardium', 'context', 'be', 'treatment', 'necessary', 'patient', 'decision', 'multiplicity', 'therefore', 'each', 'to', 'reach']","['detection', 'be', 'treatment', 'patient', 'decision']",,
1708,1695,"these factors include not only the results of functional tests but also the anatomical extent of coronary and myocardial disease , as well as the regional correspondence between segmental left ventricular dysfunction and the likelihood of successful revascularization of the corresponding coronary arteries .",这些因素不仅包括功能测试的结果，还包括冠状动脉和心肌疾病的解剖范围，以及节段性左心室功能障碍与相应冠状动脉成功血运重建的可能性之间的区域对应关系。,0.25,"['correspondence', 'corresponding', 'dysfunction', 'anatomical', 'disease', 'regional', 'functional', 'coronary', 'revascularization', 'well', 'ventricular', 'segmental', 'myocardial', 'extent', 'but', 'and']","['correspondence', 'disease', 'coronary', 'revascularization']",1695,"['这些因素不仅包括功能测试的结果,而且还包括冠状和心血管疾病的解剖学范围,以及分区左<unk>功能障碍和相关冠状动脉的成功复发的可能性之间的区域匹配。']",0.25,"['correspondence', 'corresponding', 'dysfunction', 'anatomical', 'disease', 'regional', 'functional', 'coronary', 'revascularization', 'well', 'ventricular', 'segmental', 'myocardial', 'extent', 'but', 'and']","['disease', 'coronary', 'but', 'and']",,
1709,1696,a putative mechanism that mediates the benefit of CABG among patients with myocardial viability is the improvement in left ventricular systolic function that results from revascularization .,在有心肌活力的患者中介导 CABG 获益的推定机制是血运重建导致左心室收缩功能的改善。,0.2857142857142857,"['improvement', 'a', 'mechanism', 'function', 'viability', 'revascularization', 'CABG', 'ventricular', 'systolic', 'myocardial', 'benefit', 'with', 'that', 'in']","['improvement', 'mechanism', 'function', 'revascularization']",1696,['在患有心血管可行性患者中介CABG的好处的突出机制是由于重复性而导致的左侧阴道系统功能的改善。'],0.2142857142857142,"['improvement', 'a', 'mechanism', 'function', 'viability', 'revascularization', 'CABG', 'ventricular', 'systolic', 'myocardial', 'benefit', 'with', 'that', 'in']","['improvement', 'mechanism', 'function']",,
1710,1697,"in our study , a modest but significant increase in left ventricular ejection fraction at 4 months was indeed observed among patients with viable myocardium .",在我们的研究中，确实在有存活心肌的患者中观察到 4 个月时左心室射血分数适度但显着的增加。,0.2857142857142857,"['a', 'ejection', 'viable', 'myocardium', 'study', 'ventricular', 'fraction', '4', 'increase', 'with', 'ejection fraction', 'at', 'indeed', 'but']","['viable', 'myocardium', 'ejection fraction', 'but']",1697,"['在我們的研究中,在4個月的左<unk>排泄分子中,實際上在患有生存性心臟病的患者中發現了一種微不足道但有意義的增加。']",0.0714285714285714,"['a', 'ejection', 'viable', 'myocardium', 'study', 'ventricular', 'fraction', '4', 'increase', 'with', 'ejection fraction', 'at', 'indeed', 'but']",['but'],,
1711,1698,"nevertheless , when the amount of viable myocardium was assessed as a continuous variable , no association was observed between the extent of viability and the magnitude of improvement in left ventricular function either with or without CABG , findings that indicate that the quantitative relationship between these variables is weak .",尽管如此，当存活心肌的数量被评估为一个连续变量时，无论有无 CABG，在存活程度和左心室功能改善程度之间均未观察到关联，这些发现表明这些变量之间的定量关系是虚弱的 。,0.4545454545454545,"['variable', 'improvement', 'relationship', 'viable', 'myocardium', 'association', 'continuous', 'function', 'viability', 'indicate', 'CABG', 'amount', 'no', 'ventricular', 'weak', 'magnitude', 'extent', 'with', 'that', 'and', 'without', 'assessed']","['variable', 'improvement', 'viable', 'myocardium', 'association', 'continuous', 'function', 'amount', 'magnitude', 'without']",1698,"['然而,当可行的心血管量被评为连续变量时,没有观察到可行的程度和左肢功能的改善程度之间的联系,无论是与或没有CABG,这些发现表明这些变量之间的定量关系很弱。']",0.4090909090909091,"['variable', 'improvement', 'relationship', 'viable', 'myocardium', 'association', 'continuous', 'function', 'viability', 'indicate', 'CABG', 'amount', 'no', 'ventricular', 'weak', 'magnitude', 'extent', 'with', 'that', 'and', 'without', 'assessed']","['variable', 'improvement', 'association', 'continuous', 'function', 'amount', 'magnitude', 'and', 'without']",,
1712,1699,"there was no association between improvement in left ventricular ejection fraction at 4 months and subsequent survival , nor was there a significant interaction between myocardial viability and changes in left ventricular ejection fraction with regard to death from any cause or death from cardiovascular causes .",4 个月时左心室射血分数的改善与随后的生存率之间没有关联，在任何原因死亡或心血管原因死亡方面，心肌活力和左心室射血分数变化之间也没有显着的相互作用。,0.35,"['improvement', 'a', 'cardiovascular', 'ejection', 'survival', 'death', 'association', 'viability', 'cause', 'no', 'ventricular', 'fraction', 'interaction', 'subsequent', 'myocardial', '4', 'with', 'ejection fraction', 'to', 'and']","['improvement', 'cardiovascular', 'survival', 'death', 'association', 'cause', 'ejection fraction']",1699,"['4个月的左<unk>排泄部分的改善和随后的生存之间没有任何联系,心血管生存和左<unk>排泄部分的变化与任何原因死亡或心血管原因死亡之间没有任何显著的相互作用。']",0.35,"['improvement', 'a', 'cardiovascular', 'ejection', 'survival', 'death', 'association', 'viability', 'cause', 'no', 'ventricular', 'fraction', 'interaction', 'subsequent', 'myocardial', '4', 'with', 'ejection fraction', 'to', 'and']","['improvement', 'cardiovascular', 'survival', 'death', 'association', 'cause', 'fraction']",,
1713,1700,"thus , our results suggest that abatement or reversal of left ventricular systolic dysfunction is not a critical mechanism involved in mediating the beneficial effect of CABG in these patients .",因此，我们的研究结果表明，减轻或逆转左心室收缩功能障碍并不是介导这些患者接受 CABG 有益效果的关键机制。,0.2307692307692307,"['dysfunction', 'a', 'mechanism', 'CABG', 'abatement', 'ventricular', 'thus', 'systolic', 'effect', 'critical', 'suggest', 'that', 'in']","['mechanism', 'thus', 'effect']",1700,"['因此,我們的結果表明,左<unk>系統功能障礙的下降或逆轉並不是對這些患者中介CABG的有益效果的關鍵機制。']",0.1538461538461538,"['dysfunction', 'a', 'mechanism', 'CABG', 'abatement', 'ventricular', 'thus', 'systolic', 'effect', 'critical', 'suggest', 'that', 'in']","['thus', 'effect']",,
1714,1701,certain limitations of this study must be acknowledged .,必须承认这项研究的某些局限性。,0.0,"['must', 'study', 'be', 'certain', 'this']",[],1701,['该研究的某些限制必须得到认可。'],0.0,"['must', 'study', 'be', 'certain', 'this']",[],,
1715,1702,"first , only half the patients enrolled in the STICH trial had an assessment of myocardial viability .",首先，参加 STICH 试验的患者中只有一半对心肌活力进行了评估。,0.4285714285714285,"['half', 'viability', 'assessment', 'trial', 'myocardial', 'in', 'first']","['half', 'assessment', 'first']",1702,"['首先,只有半数参加STICH试验的患者对心血管可行性进行了评估。']",0.4285714285714285,"['half', 'viability', 'assessment', 'trial', 'myocardial', 'in', 'first']","['half', 'assessment', 'first']",,
1716,1703,"consequently , the development and potential prognostic effect of changes in left ventricular function that might have occurred at a later time could not be assessed as part of this study .",因此，作为本研究的一部分，无法评估可能在稍后时间发生的左心室功能变化的发展和潜在的预后影响。,0.3684210526315789,"['part', 'potential', 'function', 'study', 'time', 'be', 'ventricular', 'prognostic', 'effect', 'development', 'as', 'at', 'have', 'this', 'that', 'later', 'in', 'and', 'assessed']","['part', 'potential', 'function', 'time', 'be', 'development', 'later']",1703,"['因此,在后期可能发生的左<unk>功能的变化的发展和潜在的预测效果不能作为这项研究的一部分进行评估。']",0.4210526315789473,"['part', 'potential', 'function', 'study', 'time', 'be', 'ventricular', 'prognostic', 'effect', 'development', 'as', 'at', 'have', 'this', 'that', 'later', 'in', 'and', 'assessed']","['part', 'potential', 'function', 'be', 'prognostic', 'effect', 'development', 'later']",,
1717,1704,"it must also be noted that the assessment of changes in left ventricular ejection fraction was performed only among patients with paired studies at baseline and 4 months , with the resultant reduction in the number of observations .",还必须指出的是，左心室射血分数变化的评估仅在基线和 4 个月时进行配对研究的患者中进行，结果导致观察次数减少。,0.4375,"['must', 'ejection', 'baseline', 'reduction', 'be', 'assessment', 'number', 'ventricular', 'fraction', 'resultant', '4', 'with', 'ejection fraction', 'at', 'that', 'and']","['baseline', 'reduction', 'be', 'assessment', 'number', 'resultant', 'ejection fraction']",1704,"['值得注意的是,左腹部排泄部分的变化评估仅在基线和4个月的患者中进行,结果观测数量减少。']",0.4375,"['must', 'ejection', 'baseline', 'reduction', 'be', 'assessment', 'number', 'ventricular', 'fraction', 'resultant', '4', 'with', 'ejection fraction', 'at', 'that', 'and']","['baseline', 'reduction', 'be', 'assessment', 'number', 'fraction', 'resultant']",,
1718,1705,"finally , our findings are based on the assessment of myocardial viability with either SPECT or dobutamine echocardiography .",最后，我们的研究结果基于使用 SPECT 或多巴酚丁胺超声心动图评估心肌活力。,0.2857142857142857,"['SPECT', 'viability', 'assessment', 'myocardial', 'with', 'on', 'echocardiography']","['SPECT', 'assessment']",1705,"['最后,我们的发现是基于对心脏病的可行性评估,无论是SPECT还是Dubutamine echocardiography。']",0.2857142857142857,"['SPECT', 'viability', 'assessment', 'myocardial', 'with', 'on', 'echocardiography']","['SPECT', 'assessment']",,
1719,1706,"the study did not include the routine performance of cardiac magnetic resonance imaging , which has become an accepted technique for the assessment of myocardial scarring .",该研究不包括心脏磁共振成像的常规表现，这已成为评估心肌瘢痕形成的公认技术。,0.5833333333333334,"['resonance', 'cardiac', 'routine', 'study', 'magnetic resonance imaging', 'assessment', 'scarring', 'technique', 'myocardial', 'performance', 'accepted', 'become']","['resonance', 'cardiac', 'routine', 'assessment', 'scarring', 'technique', 'become']",1706,"['该研究不包括心脏磁响图像的日常性能,这已成为评估心脏刺激的接受技术。']",0.4166666666666667,"['resonance', 'cardiac', 'routine', 'study', 'magnetic resonance imaging', 'assessment', 'scarring', 'technique', 'myocardial', 'performance', 'accepted', 'become']","['cardiac', 'assessment', 'technique', 'performance', 'become']",,
1720,1707,"for neonatal as well as maternal outcomes , the 39th week of gestation appears to be the sweet spot .",对于新生儿和产妇的结局，妊娠第 39 周似乎是最佳时期。,0.3,"['neonatal', 'maternal', 'gestation', 'be', 'well', 'week', 'spot', 'as', 'sweet', 'to']","['gestation', 'week', 'to']",1707,"['对于新生儿和母亲的结果,第39周的怀孕似乎是甜点。']",0.5,"['neonatal', 'maternal', 'gestation', 'be', 'well', 'week', 'spot', 'as', 'sweet', 'to']","['maternal', 'gestation', 'week', 'spot', 'to']",,
1721,1708,"the composite adverse maternal outcome ( ICU admission , blood transfusion , uterine rupture , unplanned hysterectomy ) occurred in 0.21 % , 0.24 % , and 0.31 % of births ( aOR for 41 vs. 39 weeks , 1.50 ) .",复合不良母体结局（入住 ICU、输血、子宫破裂、计划外子宫切除术）分别发生在 0.21%、0.24% 和 0.31% 的分娩中（41 周对 39 周的 aOR 为 1.50）。,0.4166666666666667,"['composite', 'transfusion', 'maternal', 'hysterectomy', 'rupture', 'outcome', 'blood', 'uterine', 'admission', 'adverse', 'blood transfusion', 'and']","['transfusion', 'maternal', 'hysterectomy', 'rupture', 'blood transfusion']",1708,['合成不良母性结果(ICU接收、血液转移、子宫骨折、未计划的歇斯底里)发生在0.21%、0.24%和0.31%的出生(AOR为41对39周、1.50)。'],0.3333333333333333,"['composite', 'transfusion', 'maternal', 'hysterectomy', 'rupture', 'outcome', 'blood', 'uterine', 'admission', 'adverse', 'blood transfusion', 'and']","['maternal', 'outcome', 'blood', 'admission']",,
1722,1709,both these studies are limited by their retrospective design .,这两项研究都受到回顾性设计的限制。,0.3333333333333333,"['design', 'limited', 'by']",['design'],1709,['这两项研究都受到其逆向设计的限制。'],0.3333333333333333,"['design', 'limited', 'by']",['design'],,
1723,1710,decisions about induction or expectant management are jointly made by clinicians and patients .,关于诱导或期待治疗的决定由临床医生和患者共同做出。,0.5,"['induction', 'management', 'by', 'and']","['induction', 'by']",1710,['关于引发或预期管理的决定由临床医生和患者共同做出。'],0.5,"['induction', 'management', 'by', 'and']","['management', 'by']",,
1724,1711,"in our practice , such decisions reflect national guidelines to avoid elective induction before 39 weeks and 0 days gestation ; also , we recommend against continuing pregnancy beyond 41 weeks and 0 days gestation .",在我们的实践中，此类决定反映了避免在妊娠 39 周和 0 天前进行选择性引产的国家指南；此外，我们建议不要继续怀孕超过 41 周和 0 天妊娠。,0.5833333333333334,"['pregnancy', 'induction', 'gestation', 'recommend', 'reflect', 'elective', 'practice', 'before', 'to', 'and', 'avoid', 'we']","['pregnancy', 'gestation', 'recommend', 'reflect', 'practice', 'before', 'avoid']",1711,"['在我们的实践中,这些决定反映了国家指南,以避免在39周和0天怀孕前选择性引发;此外,我们建议在41周和0天怀孕后继续怀孕。']",0.5833333333333334,"['pregnancy', 'induction', 'gestation', 'recommend', 'reflect', 'elective', 'practice', 'before', 'to', 'and', 'avoid', 'we']","['pregnancy', 'gestation', 'recommend', 'reflect', 'practice', 'before', 'avoid']",,
1725,1712,"limited data document the benefits and safety of intensive lipid lowering in adults aged ≥ 75 , who are often underrepresented in clinical trials .",有限的数据记录了强化降脂对 75 岁以上成年人的益处和安全性，这些人在临床试验中的代表性往往不足。,0.4545454545454545,"['safety', 'lipid', 'data', 'who', 'document', 'intensive', 'clinical', 'aged', 'lowering', 'limited', 'and']","['safety', 'data', 'document', 'clinical', 'limited']",1712,"['有限的数据证明了75岁以上的成年人强烈脂肪降低的好处和安全性,他们在临床试验中经常被低估。']",0.3636363636363636,"['safety', 'lipid', 'data', 'who', 'document', 'intensive', 'clinical', 'aged', 'lowering', 'limited', 'and']","['safety', 'data', 'clinical', 'limited']",,
1726,1713,no group had an increase in adverse events .,没有任何一组的不良事件增加。,0.25,"['group', 'adverse', 'no', 'increase']",['group'],1713,['没有一个群体出现了不良事件的增加。'],0.25,"['group', 'adverse', 'no', 'increase']",['group'],,
1727,1714,"every additional hour engaged in social media , computer use , or television viewing was associated with increased severity of depressive symptoms .",参与社交媒体、使用电脑或看电视的时间每增加一小时，抑郁症状的严重程度就会增加。,0.4,"['computer', 'symptoms', 'media', 'associated', 'additional', 'depressive', 'with', 'television', 'hour', 'in']","['computer', 'depressive', 'television', 'hour']",1714,['社交媒体、计算机使用或电视观看的每一个额外的小时都与抑郁症状的严重性增加有关。'],0.5,"['computer', 'symptoms', 'media', 'associated', 'additional', 'depressive', 'with', 'television', 'hour', 'in']","['computer', 'additional', 'depressive', 'television', 'hour']",,
1728,1715,whether increased screen time contributes to the rise in depression among adolescents is unclear .,屏幕时间的增加是否会导致青少年抑郁症的增加尚不清楚。,0.5,"['depression', 'time', 'rise', 'screen', 'in', 'to']","['depression', 'time', 'screen']",1715,['是否增加屏幕时间有助于青少年抑郁症的上升是不清楚的。'],0.8333333333333334,"['depression', 'time', 'rise', 'screen', 'in', 'to']","['depression', 'time', 'rise', 'screen', 'to']",,
1729,1716,researchers conducted a secondary analysis of survey data for 3826 adolescents in Montreal followed over 4 years .,研究人员对蒙特利尔 3826 名青少年跟踪调查 4 年的调查数据进行了二次分析。,0.4444444444444444,"['a', 'data', 'analysis', 'survey', 'secondary', '4', 'survey data', 'in', 'over']","['data', 'analysis', 'survey', 'survey data']",1716,"['研究人员对蒙特利尔的3826名青少年进行了次要分析,其次是4年。']",0.1111111111111111,"['a', 'data', 'analysis', 'survey', 'secondary', '4', 'survey data', 'in', 'over']",['analysis'],,
1730,1717,increased time engaged in video games was not associated with increased depressive symptoms in either analysis .,在任何一项分析中，增加玩电子游戏的时间都与抑郁症状增加无关。,0.375,"['analysis', 'symptoms', 'time', 'associated', 'depressive', 'video', 'with', 'in']","['analysis', 'time', 'depressive']",1717,['在视频游戏中花费的时间增加与任何分析中增加的抑郁症状无关。'],0.375,"['analysis', 'symptoms', 'time', 'associated', 'depressive', 'video', 'with', 'in']","['analysis', 'time', 'depressive']",,
1731,1718,these findings confirm that increased screen time is associated with adverse mental health outcomes for teens .,这些发现证实，屏幕时间增加与青少年的不良心理健康结果有关。,0.5,"['health', 'mental', 'mental health', 'time', 'adverse', 'associated', 'screen', 'with', 'teens', 'that']","['health', 'mental health', 'time', 'screen', 'teens']",1718,"['这些发现证实,增加屏幕时间与青少年精神健康的负面结果有关。']",0.6,"['health', 'mental', 'mental health', 'time', 'adverse', 'associated', 'screen', 'with', 'teens', 'that']","['health', 'mental', 'mental health', 'time', 'screen', 'teens']",,
1732,1719,ischemic stroke risk was associated with Lp ( a ) levels and LPA gene variants in a contemporary Danish population study .,在当代丹麦人口研究中，缺血性中风风险与 Lp (a) 水平和 LPA 基因变异有关。,0.5833333333333334,"['gene', 'population', 'lp', 'stroke', 'study', 'associated', 'risk', 'with', 'population study', 'in', 'and', 'ischemic']","['gene', 'population', 'lp', 'stroke', 'risk', 'population study', 'in']",1719,"['在当代丹麦人口研究中,伊斯基米性中风风险与Lp(a)水平和LPA基因变异有关。']",0.5833333333333334,"['gene', 'population', 'lp', 'stroke', 'study', 'associated', 'risk', 'with', 'population study', 'in', 'and', 'ischemic']","['gene', 'population', 'lp', 'stroke', 'risk', 'population study', 'in']",,
1733,1720,Lp ( a ) levels are primarily genetically determined and remain stable over time .,Lp(a) 水平主要由基因决定，并随时间保持稳定。,0.2,"['lp', 'a', 'time', 'over', 'and']",['time'],1720,"['Lp(a)水平主要是基因定义的,并且随着时间的推移保持稳定。']",0.2,"['lp', 'a', 'time', 'over', 'and']",['time'],,
1734,1721,"using data from the contemporary Copenhagen General Population Study ( n = 49,699 ) and the historical Copenhagen City Heart Study ( n = 10,813 ) , investigators explored whether elevated Lp ( a ) is associated with increased risk for ischemic stroke .","使用当代哥本哈根一般人口研究 (n = 49,699) 和历史哥本哈根城市心脏研究 (n = 10,813) 的数据，研究人员探讨了升高的 Lp (a) 是否与缺血性中风的风险增加有关。",0.4615384615384615,"['heart', 'population', 'lp', 'stroke', 'data', 'general', 'study', 'associated', 'risk', 'with', 'population study', 'and', 'ischemic']","['heart', 'population', 'stroke', 'data', 'risk', 'population study']",1721,"['使用现代哥本哈根一般人口研究(n = 49,699 )和历史哥本哈根市心脏研究(n = 10,813 )的数据,研究人员研究了高Lp(a)是否与增加的伊斯基米性中风风险有关。']",0.4615384615384615,"['heart', 'population', 'lp', 'stroke', 'data', 'general', 'study', 'associated', 'risk', 'with', 'population study', 'and', 'ischemic']","['heart', 'population', 'stroke', 'data', 'risk', 'population study']",,
1735,1722,each 50 mg / dL increase in Lp ( a ) level corresponded to a hazard ratio for ischemic stroke of 1.20 in observational analyses and 1.20 and 1.27 in the two genetic analyses .,Lp(a) 水平每增加 50 mg/dL，在观察分析中对应的缺血性中风风险比为 1.20，在两个遗传分析中分别为 1.20 和 1.27。,0.3571428571428571,"['lp', 'a', 'stroke', 'ratio', 'hazard ratio', '/', 'genetic', 'level', 'increase', 'each', 'to', 'and', 'two', 'ischemic']","['stroke', 'ratio', 'hazard ratio', 'level', 'two']",1722,"['每 50 mg / dL 的 Lp (a ) 水平增加,相当于在观测分析中患有 1.20 和在两种基因分析中患有 1.20 和 1.27 的风险比例。']",0.4285714285714285,"['lp', 'a', 'stroke', 'ratio', 'hazard ratio', '/', 'genetic', 'level', 'increase', 'each', 'to', 'and', 'two', 'ischemic']","['stroke', 'ratio', 'hazard ratio', 'level', 'to', 'two']",,
1736,1723,the highest absolute risk for stroke was found in individuals older than 70 who were active smokers and had hypertension .,中风绝对风险最高的人群是 70 岁以上的活跃吸烟者和高血压患者。,0.5,"['stroke', 'hypertension', 'who', 'absolute', 'active', 'risk', 'in', 'and']","['stroke', 'hypertension', 'absolute', 'risk']",1723,"['发作的最高绝对风险是在70岁以上的人中发现的,他们是活跃的吸烟者,并且患有高血压。']",0.5,"['stroke', 'hypertension', 'who', 'absolute', 'active', 'risk', 'in', 'and']","['stroke', 'hypertension', 'absolute', 'risk']",,
1737,1724,"in the historical cohort , the results were directionally similar but did not reach statistical significance .",在历史队列中，结果在方向上相似，但未达到统计学意义。,0.2857142857142857,"['significance', 'statistical significance', 'cohort', 'in', 'but', 'reach', 'similar']","['significance', 'but']",1724,"['在历史联盟中,结果是方向上相似的,但没有达到统计意义。']",0.4285714285714285,"['significance', 'statistical significance', 'cohort', 'in', 'but', 'reach', 'similar']","['significance', 'but', 'similar']",,
1738,1725,the independent association of Lp ( a ) with ischemic stroke risk is unsurprising and adds to the growing body of evidence supporting a causal link between Lp ( a ) and cardiovascular disease .,Lp(a) 与缺血性中风风险的独立关联不足为奇，并且增加了支持 Lp(a) 与心血管疾病之间因果关系的越来越多的证据。,0.5,"['disease', 'lp', 'cardiovascular', 'stroke', 'association', 'cardiovascular disease', 'link', 'risk', 'causal', 'independent', 'evidence', 'body', 'with', 'to', 'and', 'ischemic']","['disease', 'cardiovascular', 'stroke', 'association', 'cardiovascular disease', 'risk', 'causal', 'evidence']",1725,"['Lp(a)与心血管中风风险的独立联系是令人惊讶的,并为成长的身体添加了支持Lp(a)与心血管疾病之间的因果联系的证据。']",0.5,"['disease', 'lp', 'cardiovascular', 'stroke', 'association', 'cardiovascular disease', 'link', 'risk', 'causal', 'independent', 'evidence', 'body', 'with', 'to', 'and', 'ischemic']","['disease', 'cardiovascular', 'stroke', 'association', 'cardiovascular disease', 'risk', 'evidence', 'body']",,
1739,1726,nutritional supplements are used widely despite minimal or no evidence of value for many of them .,营养补充剂被广泛使用，尽管其中许多补充剂的价值证据很少或没有证据。,0.3333333333333333,"['value', 'no', 'nutritional', 'minimal', 'evidence', 'despite']","['value', 'evidence']",1726,"['营养补充剂广泛使用,尽管对许多人来说是最小的或没有证据的价值。']",0.5,"['value', 'no', 'nutritional', 'minimal', 'evidence', 'despite']","['value', 'minimal', 'evidence']",,
1740,1727,significant results were found for the following supplements and interventions :,发现以下补充剂和干预措施的显着结果：,0.0,"['and', 'following']",[],1727,['在以下补充剂和干预中发现了显著的结果:'],0.0,"['and', 'following']",[],,
1741,1728,"folic acid supplementation was associated with 20 % lower risk for stroke ( low certainty ) , but supplementation with calcium plus vitamin D was associated with 17 % higher risk ( moderate certainty ) .",补充叶酸与降低 20% 的中风风险相关（低确定性），但补充钙和维生素 D 与高 17% 的风险相关（中等确定性）。,0.4285714285714285,"['calcium', 'stroke', 'vitamin', 'plus', 'moderate', 'lower', 'folic acid', 'associated', 'risk', 'D', 'certainty', 'with', 'vitamin D', 'but']","['calcium', 'stroke', 'vitamin', 'folic acid', 'risk', 'but']",1728,"['叶酸补充与中风风险(低确定性)降低20%,但加钙和维生素D补充与17%高的风险(适度确定性)相关。']",0.5714285714285714,"['calcium', 'stroke', 'vitamin', 'plus', 'moderate', 'lower', 'folic acid', 'associated', 'risk', 'D', 'certainty', 'with', 'vitamin D', 'but']","['calcium', 'stroke', 'vitamin', 'plus', 'folic acid', 'risk', 'vitamin D', 'but']",,
1742,1729,outcomes were not statistically significant for any other supplement or intervention .,任何其他补充剂或干预的结果均无统计学意义。,0.5,"['supplement', 'intervention']",['supplement'],1729,['结果对任何其他补充或干预都没有统计意义。'],0.5,"['supplement', 'intervention']",['supplement'],,
1743,1730,"all in all , these results do not change the current recommendation that nutritional supplements generally have little or no value in preventing adverse cardiovascular events .",总而言之，这些结果并未改变目前的建议，即营养补充剂在预防不良心血管事件方面通常价值很小或没有价值。,0.2727272727272727,"['cardiovascular', 'value', 'adverse', 'no', 'nutritional', 'current', 'change', 'have', 'all', 'that', 'in']","['cardiovascular', 'value', 'have']",1730,"['总的来说,这些结果不会改变目前的建议,营养补充剂通常在预防不良心血管事件方面有很少或没有价值。']",0.2727272727272727,"['cardiovascular', 'value', 'adverse', 'no', 'nutritional', 'current', 'change', 'have', 'all', 'that', 'in']","['cardiovascular', 'value', 'have']",,
1744,1731,early involvement by an endocrinologist and diabetes nurse improved glycemic control but not most clinical outcomes .,内分泌学家和糖尿病护士的早期参与改善了血糖控制，但并未改善大多数临床结果。,0.7,"['diabetes', 'nurse', 'control', 'early', 'clinical', 'endocrinologist', 'involvement', 'by', 'but', 'and']","['diabetes', 'nurse', 'control', 'early', 'clinical', 'endocrinologist', 'but']",1731,"['内分泌学家和糖尿病护士的早期参与改善了血糖控制,但没有大多数临床结果。']",0.7,"['diabetes', 'nurse', 'control', 'early', 'clinical', 'endocrinologist', 'involvement', 'by', 'but', 'and']","['diabetes', 'nurse', 'control', 'early', 'clinical', 'endocrinologist', 'but']",,
1745,1732,hypoglycemia and hyperglycemia in hospitalized patients are associated with worse patient outcomes .,住院患者的低血糖和高血糖与较差的患者预后相关。,0.25,"['hypoglycemia', 'associated', 'hyperglycemia', 'patient', 'with', 'worse', 'in', 'and']","['hyperglycemia', 'patient']",1732,['住院患者的低血糖和高血糖与病人结果恶化有关。'],0.25,"['hypoglycemia', 'associated', 'hyperglycemia', 'patient', 'with', 'worse', 'in', 'and']","['hyperglycemia', 'patient']",,
1746,1733,"to improve glycemic control , many hospitals have implemented inpatient diabetes teams .",为改善血糖控制，许多医院都实施了住院糖尿病小组。,0.4,"['diabetes', 'control', 'inpatient', 'have', 'to']","['diabetes', 'control']",1733,"['为了改善血糖控制,许多医院已经实施了患有糖尿病的团队。']",0.6,"['diabetes', 'control', 'inpatient', 'have', 'to']","['diabetes', 'control', 'have']",,
1747,1734,"the intervention involved electronic identification of patients with preexisting diabetes or hyperglycemia , with the goal of management within 24 hours by an inpatient team consisting of a diabetes nurse and an endocrinologist .",干预涉及对先前患有糖尿病或高血糖症的患者进行电子识别，目标是在 24 小时内由由一名糖尿病护士和一名内分泌学家组成的住院团队进行管理。,0.6428571428571429,"['diabetes', 'nurse', 'identification', 'team', 'hyperglycemia', 'intervention', 'endocrinologist', 'management', 'goal', 'electronic', 'with', 'inpatient', 'by', 'and']","['diabetes', 'nurse', 'identification', 'team', 'hyperglycemia', 'endocrinologist', 'management', 'goal', 'by']",1734,"['干预涉及现有糖尿病或高血糖病患者的电子识别,目的是由由糖尿病护士和内分泌学家组成的患者团队在24小时内进行管理。']",0.5714285714285714,"['diabetes', 'nurse', 'identification', 'team', 'hyperglycemia', 'intervention', 'endocrinologist', 'management', 'goal', 'electronic', 'with', 'inpatient', 'by', 'and']","['diabetes', 'nurse', 'identification', 'team', 'hyperglycemia', 'endocrinologist', 'management', 'by']",,
1748,1735,about 1000 patients were admitted during the study period .,研究期间约有 1000 名患者入院。,0.5,"['period', 'study']",['period'],1735,"['在研究期间,约有1000名患者被接受。']",0.5,"['period', 'study']",['period'],,
1749,1736,"in the intervention arm , the proportion of patients who received new insulin treatment rose from 34 % at baseline to 57 % during the intervention .",在干预组中，接受新胰岛素治疗的患者比例从基线时的 34% 上升到干预期间的 57%。,0.5,"['proportion', 'insulin', 'rose', 'arm', 'who', 'baseline', 'treatment', 'intervention', 'to', 'new']","['proportion', 'insulin', 'baseline', 'treatment', 'new']",1736,"['在干预手臂中,接受新胰岛素治疗的患者比例从基线34%上升到干预期间57%。']",0.6,"['proportion', 'insulin', 'rose', 'arm', 'who', 'baseline', 'treatment', 'intervention', 'to', 'new']","['proportion', 'insulin', 'arm', 'baseline', 'treatment', 'new']",,
1750,1737,"in the control arm , use of insulin and clinical outcomes did not change during the study period .",在对照组中，胰岛素的使用和临床结果在研究期间没有改变。,0.5,"['insulin', 'period', 'control', 'arm', 'study', 'clinical', 'change', 'and']","['insulin', 'period', 'control', 'clinical']",1737,"['在控制手臂中,胰岛素的使用和临床结果在研究期间没有变化。']",0.75,"['insulin', 'period', 'control', 'arm', 'study', 'clinical', 'change', 'and']","['insulin', 'period', 'control', 'arm', 'clinical', 'change']",,
1751,1738,"within 4.5 hours after ischemic stroke , endovascular therapy is more beneficial the sooner it is performed .",缺血性中风后 4.5 小时内，血管内治疗越早进行越有益。,0.75,"['stroke', 'therapy', 'after', 'ischemic']","['stroke', 'therapy', 'after']",1738,"['在伊斯坦布尔发作后4,5小时内,内分泌疗法越早就越有益。']",0.75,"['stroke', 'therapy', 'after', 'ischemic']","['stroke', 'therapy', 'after']",,
1752,1739,whether endovascular therapy ( EVT ) for patients with large vessel occlusion has the same dependence on time is less certain .,大血管闭塞患者的血管内治疗 (EVT) 是否具有相同的时间依赖性尚不确定。,0.25,"['vessel', 'occlusion', 'dependence', 'large', 'time', 'therapy', 'with', 'certain']","['time', 'therapy']",1739,"['对于患有大血管封闭的患者是否有相同的时间依赖,则不确定。']",0.125,"['vessel', 'occlusion', 'dependence', 'large', 'time', 'therapy', 'with', 'certain']",['time'],,
1753,1740,the authors analyzed two key variables : time from stroke onset to groin puncture ( onset to puncture ) and time from hospital arrival to groin puncture ( door to puncture ) .,作者分析了两个关键变量：从中风发作到腹股沟穿刺的时间（开始到穿刺）和从到达医院到腹股沟穿刺的时间（门到穿刺）。,0.8,"['key', 'stroke', 'groin', 'puncture', 'time', 'onset', 'hospital', 'to', 'and', 'two']","['key', 'stroke', 'groin', 'puncture', 'time', 'onset', 'hospital', 'two']",1740,['作者分析了两个关键变量:时间从中风开始到中风点(开始到中风点)和时间从医院到中风点(门到中风点)。'],0.6,"['key', 'stroke', 'groin', 'puncture', 'time', 'onset', 'hospital', 'to', 'and', 'two']","['key', 'stroke', 'time', 'onset', 'hospital', 'two']",,
1754,1741,"key study endpoints included independent ambulation at discharge , functional independence at discharge , and discharge to home .",主要研究终点包括出院时独立行走、出院时功能独立和出院回家。,0.1,"['discharge', 'key', 'functional', 'study', 'independent', 'independence', 'at', 'ambulation', 'to', 'and']",['independence'],1741,"['关键研究终点包括在排放时独立救护,在排放时功能独立,并在家中排放。']",0.2,"['discharge', 'key', 'functional', 'study', 'independent', 'independence', 'at', 'ambulation', 'to', 'and']","['key', 'independence']",,
1755,1742,safety endpoints evaluated were symptomatic intracerebral hemorrhage ( sICH ) and death / discharge to hospice .,评估的安全性终点是症状性脑出血 (sICH) 和死亡/出院到临终关怀中心。,0.4444444444444444,"['safety', 'discharge', 'death', 'hemorrhage', '/', 'intracerebral', 'symptomatic', 'and', 'hospice']","['safety', 'death', 'hemorrhage', 'hospice']",1742,['评估的安全终点是症状性脑内出血(sICH)和死亡 / 释放到医院。'],0.4444444444444444,"['safety', 'discharge', 'death', 'hemorrhage', '/', 'intracerebral', 'symptomatic', 'and', 'hospice']","['safety', 'death', 'hemorrhage', 'intracerebral']",,
1756,1743,"the median NIH Stroke Scale score was 17 , indicating severe strokes .",NIH 中风量表评分中位数为 17，表明中风严重。,0.4,"['median', 'stroke', 'scale', 'score', 'severe']","['stroke', 'scale']",1743,"['NIH Stroke Scale 平均分数为 17,表明严重的中风。']",0.6,"['median', 'stroke', 'scale', 'score', 'severe']","['stroke', 'scale', 'score']",,
1757,1744,"of the patients , 68 % received alteplase .",68% 的患者接受了阿替普酶治疗。,,[],[],1744,"['在患者中,68%接受了阿尔特普拉斯。']",,[],[],,
1758,1745,improved outcome with earlier treatment was more notable among patients treated within 270 minutes of stroke onset .,在卒中发作后 270 分钟内接受治疗的患者中，早期治疗改善的结果更为显着。,0.5,"['stroke', 'outcome', 'treatment', 'onset', 'with', 'earlier']","['stroke', 'outcome', 'treatment']",1745,['早期治疗的改善结果在发作开始后270分钟内治疗的患者中更为显著。'],0.6666666666666666,"['stroke', 'outcome', 'treatment', 'onset', 'with', 'earlier']","['stroke', 'outcome', 'treatment', 'onset']",,
1759,1746,"in this group , for every 1000 patients treated 15 minutes earlier , there were 11 more patients with independent ambulation at discharge , 12 more discharged to home , and 9 more with functional independence .",在该组中，每 1000 名患者提前 15 分钟接受治疗，出院时能够独立行走的患者就会多出 11 名，出院回家的患者会多出 12 名，功能独立的患者多出 9 名。,0.25,"['group', 'discharge', 'functional', 'independent', 'independence', 'with', 'at', 'ambulation', 'this', 'earlier', 'to', 'and']","['group', 'independent', 'independence']",1746,"['在这个群体中,每1000名患者15分钟提前接受治疗,有11名患者在排放时有独立救护车,12名患者在排放时有更多,9名患者在功能独立。']",0.1666666666666666,"['group', 'discharge', 'functional', 'independent', 'independence', 'with', 'at', 'ambulation', 'this', 'earlier', 'to', 'and']","['group', 'independence']",,
1760,1747,"this analysis shows that for patients who receive EVT within 4.5 hours of stroke onset , earlier treatment within that window has tangible benefits .",该分析表明，对于在中风发作后 4.5 小时内接受 EVT 的患者，在该窗口内进行早期治疗具有明显的好处。,0.4,"['stroke', 'who', 'analysis', 'window', 'treatment', 'onset', 'tangible', 'this', 'that', 'earlier']","['stroke', 'analysis', 'window', 'treatment']",1747,"['这项分析表明,在发作开始后4,5小时内接受EVT的患者,该窗口内的早期治疗有显而易见的好处。']",0.5,"['stroke', 'who', 'analysis', 'window', 'treatment', 'onset', 'tangible', 'this', 'that', 'earlier']","['stroke', 'analysis', 'window', 'treatment', 'onset']",,
1761,1748,hospitals should rigorously evaluate their work flow and identify bottlenecks that hinder rapid treatment .,医院应严格评估其工作流程，找出阻碍快速治疗的瓶颈。,0.375,"['flow', 'treatment', 'identify', 'that', 'and', 'hinder', 'work', 'rapid']","['flow', 'treatment', 'work']",1748,"['医院应严格评估其工作流,并确定阻碍快速治疗的瓶子。']",0.375,"['flow', 'treatment', 'identify', 'that', 'and', 'hinder', 'work', 'rapid']","['flow', 'treatment', 'work']",,
1762,1749,establishing cardiovascular safety of new therapies for type 2 diabetes is important .,确定 2 型糖尿病新疗法的心血管安全性很重要。,1.0,"['safety', 'diabetes', 'type', 'cardiovascular', '2', 'new']","['safety', 'diabetes', 'type', 'cardiovascular', '2', 'new']",1749,['建立二型糖尿病新治疗的心血管安全至关重要。'],0.8333333333333334,"['safety', 'diabetes', 'type', 'cardiovascular', '2', 'new']","['safety', 'diabetes', 'type', 'cardiovascular', 'new']",,
1763,1750,the trial was designed to rule out 80 % excess cardiovascular risk as compared with placebo ( noninferiority margin of 1.8 for the upper boundary of the 95 % confidence interval for the hazard ratio for the primary outcome ) .,与安慰剂相比，该试验旨在排除 80% 的额外心血管风险（主要结果的风险比的 95% 置信区间上限的非劣效性界限为 1.8）。,0.5882352941176471,"['boundary', 'placebo', 'excess', 'cardiovascular', 'margin', 'interval', 'rule', 'ratio', 'hazard ratio', 'outcome', 'upper', 'primary', 'risk', 'trial', 'confidence interval', 'with', 'to']","['boundary', 'placebo', 'cardiovascular', 'margin', 'interval', 'ratio', 'hazard ratio', 'outcome', 'risk', 'confidence interval']",1750,['该试验旨在排除与 placebo 相比80%的过度心血管风险(对初始结果的风险比例的95%信任间隔的上限为1.8的非低度边界)。'],0.4705882352941176,"['boundary', 'placebo', 'excess', 'cardiovascular', 'margin', 'interval', 'rule', 'ratio', 'hazard ratio', 'outcome', 'upper', 'primary', 'risk', 'trial', 'confidence interval', 'with', 'to']","['boundary', 'cardiovascular', 'margin', 'interval', 'ratio', 'hazard ratio', 'outcome', 'risk']",,
1764,1751,a total of 3183 patients were randomly assigned to receive oral semaglutide or placebo .,共有 3183 名患者被随机分配接受口服索马鲁肽或安慰剂。,0.5,"['placebo', 'oral', 'total', 'semaglutide']","['placebo', 'semaglutide']",1751,['总共有3183名患者随机服用口服半糖或 placebo。'],0.0,"['placebo', 'oral', 'total', 'semaglutide']",[],,
1765,1752,the mean age of the patients was 66 years ; 2695 patients ( 84.7 % ) were 50 years of age or older and had cardiovascular or chronic kidney disease .,患者的平均年龄为 66 岁； 2695 名患者 (84.7%) 年龄在 50 岁或以上，患有心血管疾病或慢性肾脏疾病。,0.8571428571428571,"['kidney', 'disease', 'cardiovascular', 'mean', 'chronic', 'age', 'and']","['kidney', 'disease', 'cardiovascular', 'mean', 'chronic', 'age']",1752,"['患者的平均年龄为66岁;2695名患者(84.7%)年龄为50岁或以上,患有心血管或慢性肾脏疾病。']",0.8571428571428571,"['kidney', 'disease', 'cardiovascular', 'mean', 'chronic', 'age', 'and']","['kidney', 'disease', 'cardiovascular', 'mean', 'chronic', 'age']",,
1766,1753,the median time in the trial was 15.9 months .,试验的中位时间为 15.9 个月。,0.25,"['median', 'time', 'trial', 'in']",['time'],1753,['审判的平均时间为159个月。'],0.5,"['median', 'time', 'trial', 'in']","['time', 'trial']",,
1767,1754,"results for components of the primary outcome were as follows : death from cardiovascular causes , 15 of 1591 patients ( 0.9 % ) in the oral semaglutide group and 30 of 1592 ( 1.9 % ) in the placebo group ( hazard ratio , 0.49 ; 95 % CI , 0.27 to 0.92 ) ; nonfatal myocardial infarction , 37 of 1591 patients ( 2.3 % ) and 31 of 1592 ( 1.9 % ) , respectively ( hazard ratio , 1.18 ; 95 % CI , 0.73 to 1.90 ) ; and nonfatal stroke , 12 of 1591 patients ( 0.8 % ) and 16 of 1592 ( 1.0 % ) , respectively ( hazard ratio , 0.74 ; 95 % CI , 0.35 to 1.57 ) .","主要结果的组成部分的结果如下：心血管原因死亡，口服索马鲁肽组 1591 名患者中的 15 名 ( 0.9 % ) 和安慰剂组 1592 名患者中的 30 名 ( 1.9 % )（风险比， 0.49 ； 95 % CI , 0.27 至 0.92 ) ;非致死性心肌梗死，分别为 1591 名患者中的 37 名 (2.3%) 和 1592 名患者中的 31 名 (1.9%)（风险比，1.18；95% CI，0.73 至 1.90）；和非致死性卒中，1591 名患者中有 12 名 (0.8%) 和 1592 名患者中有 16 名 (1.0%)（风险比，0.74；95% CI，0.35 至 1.57）。",0.6666666666666666,"['group', 'myocardial infarction', 'placebo', 'cardiovascular', 'stroke', 'ratio', 'hazard ratio', 'outcome', 'death', 'oral', 'primary', 'semaglutide', 'CI', 'to', 'and']","['group', 'myocardial infarction', 'placebo', 'cardiovascular', 'stroke', 'ratio', 'hazard ratio', 'outcome', 'death', 'semaglutide']",1754,"['初始结果的组成部分的结果如下:心血管原因死亡151名患者(0.9%)在口腔半糖群中和1592名患者(1.9%)在 placebo群中(危险比例,0.49;95%CI,0.27至0.92);非致命心脏病发作37名患者(2.3%)和31名患者(1.9%)分别(危险比例,1.18;95%CI,0.73至1.90);非致命中,1591名患者(0.8%)和1592名患者(1.0%)分别(危险比例,0.74;95%CI,0.35至1.57)。']",0.4,"['group', 'myocardial infarction', 'placebo', 'cardiovascular', 'stroke', 'ratio', 'hazard ratio', 'outcome', 'death', 'oral', 'primary', 'semaglutide', 'CI', 'to', 'and']","['group', 'cardiovascular', 'stroke', 'ratio', 'outcome', 'death']",,
1768,1755,"death from any cause occurred in 23 of 1591 patients ( 1.4 % ) in the oral semaglutide group and 45 of 1592 ( 2.8 % ) in the placebo group ( hazard ratio , 0.51 ; 95 % CI , 0.31 to 0.84 ) .",口服 semaglutide 组 1591 名患者中有 23 名 (1.4%) 和安慰剂组 1592 名患者中有 45 名 (2.8%) 发生全因死亡（风险比，0.51；95% CI，0.31 至 0.84）。,0.4166666666666667,"['group', 'placebo', 'ratio', 'hazard ratio', 'death', 'oral', 'cause', 'semaglutide', 'CI', 'in', 'to', 'and']","['group', 'placebo', 'ratio', 'hazard ratio', 'death']",1755,"['由任何原因导致的死亡发生在1591名患者中(1.4% )在口腔半糖群中和1592名患者中(2.8% )在 placebo群中(风险比例,0.51;95% CI,0.31至0.84 )。']",0.4166666666666667,"['group', 'placebo', 'ratio', 'hazard ratio', 'death', 'oral', 'cause', 'semaglutide', 'CI', 'in', 'to', 'and']","['group', 'ratio', 'hazard ratio', 'death', 'cause']",,
1769,1756,gastrointestinal adverse events leading to discontinuation of oral semaglutide or placebo were more common with oral semaglutide .,导致停用口服索马鲁肽或安慰剂的胃肠道不良事件在口服索马鲁肽中更为常见。,0.3333333333333333,"['placebo', 'gastrointestinal', 'oral', 'common', 'adverse', 'leading', 'with', 'semaglutide', 'to']","['placebo', 'gastrointestinal', 'semaglutide']",1756,['胃肠道不良事件导致口腔半糖或 placebo的停止更常见。'],0.1111111111111111,"['placebo', 'gastrointestinal', 'oral', 'common', 'adverse', 'leading', 'with', 'semaglutide', 'to']",['gastrointestinal'],,
1770,1757,"in this trial involving patients with type 2 diabetes , the cardiovascular risk profile of oral semaglutide was not inferior to that of placebo . ( Funded by Novo Nordisk ; PIONEER 6 ClinicalTrials.gov number , NCT02692716 . )",在这项涉及 2 型糖尿病患者的试验中，口服 semaglutide 的心血管风险特征并不劣于安慰剂。 （由 Novo Nordisk 资助；PIONEER 6 ClinicalTrials.gov 编号，NCT02692716。）,0.5294117647058824,"['diabetes', 'type', 'placebo', 'cardiovascular', '2', 'oral', 'number', 'risk', 'trial', 'profile', 'with', 'semaglutide', 'this', 'that', 'inferior', 'by', 'to']","['diabetes', 'type', 'placebo', 'cardiovascular', '2', 'number', 'risk', 'by', 'to']",1757,"['在这项涉及2型糖尿病患者的研究中,口腔半糖尿病的心血管风险资料不低于口腔半糖尿病(由Novo Nordisk资助;PIONEER 6 ClinicalTrials.gov号,NCT02692716 )。']",0.4705882352941176,"['diabetes', 'type', 'placebo', 'cardiovascular', '2', 'oral', 'number', 'risk', 'trial', 'profile', 'with', 'semaglutide', 'this', 'that', 'inferior', 'by', 'to']","['diabetes', 'type', 'cardiovascular', '2', 'number', 'risk', 'by', 'to']",,
1771,1758,"these agents have shown cardiovascular safety ( lixisenatide12 and exenatide13 ) and , in several cases , benefit ( liraglutide , 14 albiglutide , 15 semaglutide , 16 and , most recently , dulaglutide17 ) .",这些药物已显示出心血管安全性（lixisenatide12 和 exenatide13），并且在一些情况下有益（liraglutide、14 albiglutide、15 semaglutide、16 以及最近的 dulaglutide17）。,0.375,"['safety', 'cardiovascular', 'benefit', 'semaglutide', 'liraglutide', 'have', 'in', 'and']","['safety', 'cardiovascular', 'have']",1758,"['这些物质表明了心血管安全(Lixisenatide12和Exenatide13),并在几种情况下有益(Liraglutide,14 albiglutide,15 semaglutide,16和,最近,dulaglutide17)。']",0.375,"['safety', 'cardiovascular', 'benefit', 'semaglutide', 'liraglutide', 'have', 'in', 'and']","['safety', 'cardiovascular', 'have']",,
1772,1759,"however , once the drug is absorbed , the pharmacokinetic properties and effects of semaglutide are similar , regardless of the route of administration.21,22","然而，一旦药物被吸收，无论给药途径如何，索马鲁肽的药代动力学特性和作用都是相似的。 21,22",0.8333333333333334,"['properties', 'drug', 'semaglutide', 'pharmacokinetic', 'and', 'similar']","['drug', 'semaglutide', 'pharmacokinetic', 'and', 'similar']",1759,"['然而,一旦药物被吸收,Semaglutide的药物和药物的药物性能和效果是相似的,无论服用方式如何。']",0.5,"['properties', 'drug', 'semaglutide', 'pharmacokinetic', 'and', 'similar']","['drug', 'and', 'similar']",,
1773,1760,"detailed methods for this trial , which was conducted at 214 sites in 21 countries , have been published previously , 23 and the protocol is available with the full text of this article at NEJM.org .",该试验在 21 个国家的 214 个地点进行，其详细方法之前已发表，23 试验方案与本文全文可在 NEJM.org 上获取。,0.0833333333333333,"['protocol', 'article', 'available', 'trial', 'text', 'with', 'at', 'full', 'have', 'this', 'in', 'and']",['protocol'],1760,"['此案的详细方法,在21个国家的214个网站上进行,已公布,23个议定书与本文的完整文本在NEJM.org上可用。']",0.1666666666666666,"['protocol', 'article', 'available', 'trial', 'text', 'with', 'at', 'full', 'have', 'this', 'in', 'and']","['protocol', 'full']",,
1774,1761,"the sponsor ( Novo Nordisk ) designed the trial and was responsible for the trial conduct , data collection , and data analysis .",主办方（诺和诺德）设计了试验并负责试验实施、数据收集和数据分析。,0.5,"['data', 'analysis', 'sponsor', 'collection', 'trial', 'conduct', 'data collection', 'and']","['data', 'analysis', 'collection', 'data collection']",1761,"['赞助商(Novo Nordisk)设计了审判,负责审判行为、数据收集和数据分析。']",0.625,"['data', 'analysis', 'sponsor', 'collection', 'trial', 'conduct', 'data collection', 'and']","['data', 'analysis', 'collection', 'trial', 'data collection']",,
1775,1762,an independent data monitoring committee evaluated unblinded trial data .,一个独立的数据监测委员会评估了非盲试验数据。,0.8,"['monitoring', 'data', 'committee', 'trial', 'independent']","['monitoring', 'data', 'committee', 'independent']",1762,['一个独立的数据监测委员会评估了未透露的审查数据。'],0.8,"['monitoring', 'data', 'committee', 'trial', 'independent']","['monitoring', 'data', 'committee', 'independent']",,
1776,1763,"all the authors had full access to the data , participated in drafting or critical revision of the manuscript , made the decision to submit the manuscript for publication , and vouch for the accuracy and completeness of the data and for the adherence of the trial to the protocol .",所有作者都可以完全访问数据，参与了文稿的起草或重要修改，做出了投稿发表的决定，并保证数据的准确性和完整性以及试验对方案的依从性。 .,0.3529411764705882,"['data', 'accuracy', 'protocol', 'access', 'publication', 'manuscript', 'trial', 'critical', 'decision', 'completeness', 'revision', 'adherence', 'full', 'all', 'in', 'and', 'drafting']","['data', 'accuracy', 'publication', 'decision', 'completeness', 'full']",1763,"['所有作者都完全访问了数据,参与了手稿的编写或批判性修订,决定提交手稿出版,并为数据的准确性和完整性以及审判对议定书的遵守提供支持。']",0.5294117647058824,"['data', 'accuracy', 'protocol', 'access', 'publication', 'manuscript', 'trial', 'critical', 'decision', 'completeness', 'revision', 'adherence', 'full', 'all', 'in', 'and', 'drafting']","['data', 'accuracy', 'protocol', 'publication', 'manuscript', 'trial', 'decision', 'completeness', 'full']",,
1777,1764,"the manuscript was drafted with support from a medical writer ( funded by the sponsor ) , under the direction of the authors .",该手稿是在作者的指导下，在一位医学作家（由申办者资助）的支持下起草的。,0.6666666666666666,"['a', 'support', 'sponsor', 'medical', 'manuscript', 'writer', 'direction', 'with', 'by']","['support', 'sponsor', 'manuscript', 'writer', 'direction', 'by']",1764,"['手稿是由医学作家(由赞助商资助)的支持下,由作者指导。']",0.5555555555555556,"['a', 'support', 'sponsor', 'medical', 'manuscript', 'writer', 'direction', 'with', 'by']","['support', 'manuscript', 'writer', 'direction', 'by']",,
1778,1765,"patients were eligible to participate if they were 50 years of age or older and had established cardiovascular disease or chronic kidney disease , or if they were 60 years of age or older and had cardiovascular risk factors only .",如果患者年满 50 岁并患有心血管疾病或慢性肾病，或者年满 60 岁且仅具有心血管危险因素，则患者有资格参加。,0.5454545454545454,"['kidney', 'disease', 'cardiovascular', 'cardiovascular disease', 'chronic', 'age', 'risk', 'if', 'to', 'and', 'eligible']","['kidney', 'disease', 'cardiovascular', 'cardiovascular disease', 'chronic', 'risk']",1765,"['患者有资格参加,如果他们年龄为50岁或以上,并且发现了心血管疾病或慢性肾脏疾病,或者如果他们年龄为60岁或以上,并且只有心血管风险因素。']",0.6363636363636364,"['kidney', 'disease', 'cardiovascular', 'cardiovascular disease', 'chronic', 'age', 'risk', 'if', 'to', 'and', 'eligible']","['kidney', 'disease', 'cardiovascular', 'cardiovascular disease', 'chronic', 'age', 'risk']",,
1779,1766,"the full eligibility criteria are provided in the Supplementary Appendix , available at NEJM.org .",补充附录中提供了完整的资格标准，补充附录可在 NEJM.org 获取。,0.1666666666666666,"['appendix', 'supplementary', 'available', 'at', 'full', 'in']",['full'],1766,"['完整的可选性标准如附件中所述,可在NEJM.org上找到。']",0.3333333333333333,"['appendix', 'supplementary', 'available', 'at', 'full', 'in']","['appendix', 'full']",,
1780,1767,randomization was stratified according to evidence of established cardiovascular disease or chronic kidney disease or the presence of cardiovascular risk factors only .,根据确定的心血管疾病或慢性肾脏疾病的证据或仅存在心血管危险因素，对随机化进行分层。,0.9,"['presence', 'kidney', 'disease', 'cardiovascular', 'randomization', 'cardiovascular disease', 'chronic', 'risk', 'evidence', 'to']","['presence', 'kidney', 'disease', 'cardiovascular', 'randomization', 'cardiovascular disease', 'chronic', 'risk', 'evidence']",1767,['随机化是根据确定的心血管疾病或慢性肾脏疾病或只有心血管风险因素的存在的证据进行分类。'],0.9,"['presence', 'kidney', 'disease', 'cardiovascular', 'randomization', 'cardiovascular disease', 'chronic', 'risk', 'evidence', 'to']","['presence', 'kidney', 'disease', 'cardiovascular', 'randomization', 'cardiovascular disease', 'chronic', 'risk', 'evidence']",,
1781,1768,"patients were instructed to take oral semaglutide or placebo in the morning , with up to 120 ml of water , in a fasting state , and at least 30 minutes before eating , drinking , or taking any other oral medication .",患者被指示在早上服用 semaglutide 或安慰剂，在空腹状态下用最多 120 毫升的水服用，并且在进食、饮水或服用任何其他口服药物前至少 30 分钟服用。,0.375,"['placebo', 'state', 'taking', 'oral', 'oral medication', 'water', 'drinking', 'fasting', 'ml', 'up', 'with', 'semaglutide', 'before', 'to', 'and', 'morning']","['placebo', 'state', 'water', 'drinking', 'before', 'morning']",1768,"['患者被指示在早上服用口服半糖或 placebo,在禁食状态下服用高达120毫升的水,并且至少在吃饭、喝酒或服用任何其他口服药物前30分钟。']",0.25,"['placebo', 'state', 'taking', 'oral', 'oral medication', 'water', 'drinking', 'fasting', 'ml', 'up', 'with', 'semaglutide', 'before', 'to', 'and', 'morning']","['state', 'water', 'before', 'morning']",,
1782,1769,"in such cases , investigators were encouraged to consider reescalating the dose once the symptoms had resolved or diminished .",在这种情况下，鼓励研究人员在症状消失或减轻后考虑重新增加剂量。,0.3333333333333333,"['symptoms', 'dose', 'in']",['dose'],1769,"['在这种情况下,研究人员被鼓励考虑重新升级剂量,一旦症状已解决或减少。']",0.3333333333333333,"['symptoms', 'dose', 'in']",['dose'],,
1783,1770,a full schedule of assessments is provided in the Supplementary Appendix .,补充附录中提供了完整的评估时间表。,0.1666666666666666,"['a', 'appendix', 'supplementary', 'schedule', 'full', 'in']",['full'],1770,['完整的评估时间表在附件中提供。'],0.3333333333333333,"['a', 'appendix', 'supplementary', 'schedule', 'full', 'in']","['appendix', 'full']",,
1784,1771,"the primary outcome was the time from randomization to the first occurrence of a major adverse cardiovascular event , a composite of death from cardiovascular causes ( including undetermined causes of death ) , nonfatal myocardial infarction , or nonfatal stroke .",主要结果是从随机化到第一次发生主要不良心血管事件、心血管原因死亡（包括未确定的死亡原因）、非致死性心肌梗死或非致死性中风的复合事件的时间。,0.6470588235294118,"['myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'randomization', 'outcome', 'death', 'occurrence', 'time', 'major', 'adverse', 'causes of death', 'primary', 'event', 'undetermined', 'to', 'first']","['myocardial infarction', 'cardiovascular', 'stroke', 'randomization', 'outcome', 'death', 'occurrence', 'time', 'event', 'undetermined', 'first']",1771,"['主要结果是从随机化到主要不良心血管事件的第一次出现,由心血管原因导致的死亡组合(包括不确定的死亡原因),非致命心脏病发作或非致命中风。']",0.4705882352941176,"['myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'randomization', 'outcome', 'death', 'occurrence', 'time', 'major', 'adverse', 'causes of death', 'primary', 'event', 'undetermined', 'to', 'first']","['cardiovascular', 'stroke', 'randomization', 'outcome', 'death', 'occurrence', 'event', 'first']",,
1785,1772,"secondary cardiovascular outcomes included the time from randomization to the first occurrence of the following : an expanded composite outcome consisting of the primary outcome plus unstable angina resulting in hospitalization or heart failure resulting in hospitalization ; a composite of death from any cause , nonfatal myocardial infarction , or nonfatal stroke ; and the individual components of these composite outcomes .",次要心血管结果包括从随机化到以下情况首次发生的时间：扩展复合结果，包括主要结果加上导致住院的不稳定型心绞痛或导致住院的心力衰竭；由全因死亡、非致死性心肌梗死或非致死性中风组成的复合死亡；以及这些复合结果的各个组成部分。,0.6521739130434783,"['heart', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'randomization', 'failure', 'outcome', 'individual', 'death', 'plus', 'occurrence', 'angina', 'time', 'hospitalization', 'heart failure', 'primary', 'cause', 'unstable', 'secondary', 'to', 'first', 'following']","['heart', 'myocardial infarction', 'cardiovascular', 'stroke', 'randomization', 'failure', 'outcome', 'death', 'plus', 'occurrence', 'angina', 'time', 'hospitalization', 'heart failure', 'unstable']",1772,"['二次心血管结果包括从随机化到第一次出现的时间:由初始结果组成的扩展化合物结果,加上导致入院或导致入院心脏衰竭的不稳定的腹泻;由任何原因导致死亡的组合,非致命心脏病发作或非致命中风;以及这些组合结果的个人组成部分。']",0.6086956521739131,"['heart', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'randomization', 'failure', 'outcome', 'individual', 'death', 'plus', 'occurrence', 'angina', 'time', 'hospitalization', 'heart failure', 'primary', 'cause', 'unstable', 'secondary', 'to', 'first', 'following']","['heart', 'cardiovascular', 'stroke', 'randomization', 'failure', 'outcome', 'individual', 'death', 'plus', 'occurrence', 'time', 'cause', 'unstable', 'first']",,
1786,1773,"additional efficacy outcomes included the change from baseline to the end of the treatment period in the glycated hemoglobin level , body weight , and lipid levels .",其他疗效结果包括糖化血红蛋白水平、体重和血脂水平从基线到治疗期结束的变化。,0.4615384615384615,"['body weight', 'period', 'lipid', 'baseline', 'hemoglobin', 'hemoglobin level', 'treatment', 'additional', 'efficacy', 'end', 'change', 'to', 'and']","['body weight', 'period', 'baseline', 'hemoglobin', 'treatment', 'change']",1773,"['额外的有效性结果包括从基线到治疗期结束的变化在血糖血糖水平,体重和脂肪水平。']",0.5384615384615384,"['body weight', 'period', 'lipid', 'baseline', 'hemoglobin', 'hemoglobin level', 'treatment', 'additional', 'efficacy', 'end', 'change', 'to', 'and']","['body weight', 'period', 'baseline', 'treatment', 'additional', 'efficacy', 'change']",,
1787,1774,"a select set of safety outcomes was investigated , encompassing adverse events leading to discontinuation of semaglutide or placebo , serious adverse events , and adverse events of special interest ( including diabetic retinopathy assessed by scheduled eye examinations , and severe hypoglycemic episodes ) .",研究了一组选定的安全性结果，包括导致停用 semaglutide 或安慰剂的不良事件、严重不良事件和特别关注的不良事件（包括通过定期眼科检查评估的糖尿病性视网膜病变和严重低血糖事件）。,0.2631578947368421,"['safety', 'placebo', 'diabetic', 'adverse', 'examinations', 'episodes', 'set', 'leading', 'eye', 'severe', 'semaglutide', 'diabetic retinopathy', 'hypoglycemic', 'serious', 'by', 'to', 'and', 'special', 'assessed']","['safety', 'placebo', 'eye', 'diabetic retinopathy', 'special']",1774,"['调查了一系列安全结果,包括导致半糖或 placebo 停止的不良事件,严重的不良事件,以及特殊兴趣的不良事件(包括糖尿病 retinopathy 通过计划的眼科检查评估,以及严重的催眠性事件)。']",0.2105263157894736,"['safety', 'placebo', 'diabetic', 'adverse', 'examinations', 'episodes', 'set', 'leading', 'eye', 'severe', 'semaglutide', 'diabetic retinopathy', 'hypoglycemic', 'serious', 'by', 'to', 'and', 'special', 'assessed']","['safety', 'eye', 'by', 'special']",,
1788,1775,"the statistical methods have been reported previously , 23 and further information is provided in the Supplementary Appendix and below .",统计方法之前已有报道，23 补充附录和下文中提供了更多信息。,0.4,"['appendix', 'supplementary', 'information', 'have', 'and']","['information', 'have']",1775,"['统计方法已提前报告,23和更多信息在附件和下方提供。']",0.4,"['appendix', 'supplementary', 'information', 'have', 'and']","['appendix', 'information']",,
1789,1776,"the trial continued until accrual of at least 122 events , with no predefined minimum duration .",试验一直持续到至少发生 122 起事件，没有预先确定的最短持续时间。,0.2,"['minimum', 'no', 'trial', 'duration', 'with']",['duration'],1776,"['审判持续到至少122起事件的积累,没有预定最低期限。']",0.6,"['minimum', 'no', 'trial', 'duration', 'with']","['minimum', 'trial', 'duration']",,
1790,1777,"all analyses involved the full analysis set , which included all randomly assigned patients .",所有分析均涉及完整的分析集，其中包括所有随机分配的患者。,0.5,"['analysis', 'set', 'full', 'all']","['analysis', 'full']",1777,"['所有分析都包含了完整的分析组,其中包括所有随机分配的患者。']",0.5,"['analysis', 'set', 'full', 'all']","['analysis', 'full']",,
1791,1778,"conditional to confirmation of noninferiority , superiority testing was performed on the primary outcome .",以确认非劣效性为条件，对主要结果进行优效性测试。,0.2857142857142857,"['outcome', 'confirmation', 'conditional', 'primary', 'superiority', 'testing', 'to']","['outcome', 'confirmation']",1778,"['在确认不低的条件下,优越性测试在初始结果上进行。']",0.4285714285714285,"['outcome', 'confirmation', 'conditional', 'primary', 'superiority', 'testing', 'to']","['outcome', 'confirmation', 'superiority']",,
1792,1779,analyses of all other outcomes were not controlled for multiple comparisons and should be interpreted as exploratory .,对所有其他结果的分析未针对多重比较进行控制，应被解释为探索性的。,0.1428571428571428,"['multiple', 'controlled', 'be', 'exploratory', 'as', 'all', 'and']",['controlled'],1779,"['所有其他结果的分析不被控制为多种比较,应该被解释为探索性。']",0.1428571428571428,"['multiple', 'controlled', 'be', 'exploratory', 'as', 'all', 'and']",['controlled'],,
1793,1780,prespecified sensitivity and subgroup analyses explored the robustness of the primary outcome analysis .,预先指定的敏感性和亚组分析探索了主要结果分析的稳健性。,0.4285714285714285,"['analysis', 'outcome', 'primary', 'subgroup', 'sensitivity', 'robustness', 'and']","['analysis', 'outcome', 'robustness']",1780,['预定敏感性和子组分析探讨了主要结果分析的强度。'],0.2857142857142857,"['analysis', 'outcome', 'primary', 'subgroup', 'sensitivity', 'robustness', 'and']","['analysis', 'outcome']",,
1794,1781,secondary efficacy outcomes and adverse events were assessed by means of descriptive statistics .,次要疗效结果和不良事件通过描述性统计方法进行评估。,0.2,"['statistics', 'descriptive', 'adverse', 'secondary', 'efficacy', 'means', 'descriptive statistics', 'by', 'and', 'assessed']","['statistics', 'descriptive']",1781,['二次效益结果和不良事件通过描述统计数据进行评估。'],0.1,"['statistics', 'descriptive', 'adverse', 'secondary', 'efficacy', 'means', 'descriptive statistics', 'by', 'and', 'assessed']",['statistics'],,
1795,1782,"between January and August 2017 , a total of 3183 patients were randomly assigned to oral semaglutide ( 1591 patients ) or placebo ( 1592 patients ) .",2017 年 1 月至 2017 年 8 月期间，共有 3183 名患者被随机分配接受口服索马鲁肽（1591 名患者）或安慰剂（1592 名患者）。,0.4,"['placebo', 'oral', 'total', 'semaglutide', 'and']","['placebo', 'semaglutide']",1782,"['2017 年 1 月至 8 月,共 3183 名患者随机分配到口服半糖(1591 名患者)或 placebo(1592 名患者)。']",0.0,"['placebo', 'oral', 'total', 'semaglutide', 'and']",[],,
1796,1783,baseline characteristics were similar in the two groups .,两组的基线特征相似。,0.75,"['baseline', 'characteristics', 'two', 'similar']","['baseline', 'characteristics', 'two']",1783,['基层特征在两组中相似。'],0.5,"['baseline', 'characteristics', 'two', 'similar']","['characteristics', 'two']",,
1797,1784,"patients were predominantly male ( 2176 patients , 68.4 % ) , and 2695 patients ( 84.7 % ) were 50 years of age or older and had established cardiovascular disease or chronic kidney disease ( Table 1 , and Tables S1 and S2 in the Supplementary Appendix ) .",患者主要为男性（2176 名患者，68.4%），2695 名患者（84.7%）年龄在 50 岁或以上，并且患有心血管疾病或慢性肾病（表 1 以及补充附录中的表 S1 和表 S2）。,0.6,"['kidney', 'disease', 'cardiovascular', 'appendix', 'table', '1', 'male', 'supplementary', 'cardiovascular disease', 'chronic', 'age', 'S1', 'S2', 'in', 'and']","['kidney', 'disease', 'cardiovascular', 'table', '1', 'male', 'cardiovascular disease', 'chronic', 'age']",1784,"['患者主要是男性(2176名患者,68.4%)和2695名患者(84.7%)年龄为50岁或以上,并且发现了心血管疾病或慢性肾脏疾病(图1和附件中的S1和S2表)。']",0.6666666666666666,"['kidney', 'disease', 'cardiovascular', 'appendix', 'table', '1', 'male', 'supplementary', 'cardiovascular disease', 'chronic', 'age', 'S1', 'S2', 'in', 'and']","['kidney', 'disease', 'cardiovascular', 'appendix', 'table', '1', 'male', 'cardiovascular disease', 'chronic', 'age']",,
1798,1785,the mean estimated GFR at baseline was 74 ± 21 ml per minute per 1.73 m2 .,基线时的平均估计 GFR 为每分钟每 1.73 平方米 74 ± 21 毫升。,0.5,"['mean', 'baseline', 'minute', 'ml', 'at', 'GFR']","['mean', 'baseline', 'minute']",1785,"['基线的平均估计GFR为74 ± 21 毫升每分钟,每 1.73 平方米。']",0.5,"['mean', 'baseline', 'minute', 'ml', 'at', 'GFR']","['mean', 'baseline', 'minute']",,
1799,1786,the primary outcome occurred in 61 of 1591 patients ( 3.8 % ) receiving oral semaglutide and 76 of 1592 ( 4.8 % ) receiving placebo .,主要结果发生在接受口服索马鲁肽的 1591 名患者中的 61 名 (3.8%) 和接受安慰剂的 1592 名患者中的 76 名 (4.8%)。,0.4285714285714285,"['placebo', 'outcome', 'oral', 'primary', 'semaglutide', 'in', 'and']","['placebo', 'outcome', 'semaglutide']",1786,['初始结果发生在1591名患者中(3.8%)接受口服半<unk>和1592名患者中(4.8%)接受 placebo。'],0.1428571428571428,"['placebo', 'outcome', 'oral', 'primary', 'semaglutide', 'in', 'and']",['outcome'],,
1800,1787,"among the individual components of the primary outcome , death from cardiovascular causes occurred in 15 of 1591 patients ( 0.9 % ) in the oral semaglutide group and 30 of 1592 ( 1.9 % ) in the placebo group ( hazard ratio , 0.49 ; 95 % CI , 0.27 to 0.92 ) ( Figure 1 and Table 2 ) .",在主要结局的各个组成部分中，口服索马鲁肽组 1591 名患者中有 15 名 ( 0.9 % ) 和安慰剂组 1592 名患者中有 30 名 ( 1.9 % ) 死于心血管原因（风险比， 0.49 ； 95 % CI ， 0.27 至 0.92)（图 1 和表 2）。,0.6111111111111112,"['group', 'placebo', 'cardiovascular', 'table', '1', '2', 'ratio', 'hazard ratio', 'outcome', 'individual', 'death', 'figure', 'oral', 'primary', 'semaglutide', 'CI', 'to', 'and']","['group', 'placebo', 'cardiovascular', 'table', '1', '2', 'ratio', 'hazard ratio', 'death', 'semaglutide', 'to']",1787,"['在初始结果的个体组成部分中,心血管导致的死亡发生在151名患者中(0.9%)在口腔半糖群中和1592名患者中(1.9%)在 placebo群中(风险比例,0.49;95% CI,0.27至0.92 )(图1和图2)。']",0.5,"['group', 'placebo', 'cardiovascular', 'table', '1', '2', 'ratio', 'hazard ratio', 'outcome', 'individual', 'death', 'figure', 'oral', 'primary', 'semaglutide', 'CI', 'to', 'and']","['group', 'cardiovascular', '1', '2', 'ratio', 'hazard ratio', 'outcome', 'individual', 'death']",,
1801,1788,"first events of nonfatal myocardial infarction occurred in 37 of 1591 patients ( 2.3 % ) and 31 of 1592 ( 1.9 % ) , respectively ( hazard ratio , 1.18 ; 95 % CI , 0.73 to 1.90 ) .",非致死性心肌梗死的首发事件分别发生在 1591 名患者中的 37 名 (2.3%) 和 1592 名患者中的 31 名 (1.9%)（风险比，1.18；95% CI，0.73 至 1.90）。,0.5714285714285714,"['myocardial infarction', 'ratio', 'hazard ratio', 'CI', 'to', 'and', 'first']","['myocardial infarction', 'ratio', 'hazard ratio', 'first']",1788,"['第一次非致命心脏病发作发生在1591名患者中37人(2.3%)和1592名患者中31人(1.9%),分别(风险比率,1.18;95%CI,0.73至1.90)。']",0.4285714285714285,"['myocardial infarction', 'ratio', 'hazard ratio', 'CI', 'to', 'and', 'first']","['ratio', 'hazard ratio', 'first']",,
1802,1789,"first events of nonfatal stroke occurred in 12 of 1591 patients ( 0.8 % ) and 16 of 1592 ( 1.0 % ) , respectively ( hazard ratio , 0.74 ; 95 % CI , 0.35 to 1.57 ) .",首次非致死性卒中事件分别发生在 1591 名患者中的 12 名 (0.8%) 和 1592 名患者中的 16 名 (1.0%)（风险比，0.74；95% CI，0.35 至 1.57）。,0.375,"['stroke', 'ratio', 'hazard ratio', 'CI', 'in', 'to', 'and', 'first']","['stroke', 'ratio', 'hazard ratio']",1789,"['在1591名患者(0.8%)和1592名患者(1.0%)中发生了12次非致命发作,分别发生了16次(风险比率,0.74;95%CI,0.35至1.57)。']",0.375,"['stroke', 'ratio', 'hazard ratio', 'CI', 'in', 'to', 'and', 'first']","['stroke', 'ratio', 'hazard ratio']",,
1803,1790,"death from any cause occurred in 23 of 1591 patients ( 1.4 % ) in the oral semaglutide group and 45 of 1592 ( 2.8 % ) in the placebo group ( hazard ratio , 0.51 ; 95 % CI , 0.31 to 0.84 ) ( Table 2 ) .",口服 semaglutide 组 1591 名患者中有 23 名 (1.4%) 和安慰剂组 1592 名患者中有 45 名 (2.8%) 发生全因死亡（风险比，0.51；95% CI，0.31 至 0.84）（表 2）。,0.5,"['group', 'placebo', 'table', '2', 'ratio', 'hazard ratio', 'death', 'oral', 'cause', 'semaglutide', 'CI', 'in', 'to', 'and']","['group', 'placebo', 'table', '2', 'ratio', 'hazard ratio', 'death']",1790,"['由任何原因导致的死亡发生在1591名患者中(1.4% )在口腔半糖群中和1592名患者中(2.8% )在血浆群中(风险比例,0.51;95% CI,0.31至0.84 )(图2 )。']",0.4285714285714285,"['group', 'placebo', 'table', '2', 'ratio', 'hazard ratio', 'death', 'oral', 'cause', 'semaglutide', 'CI', 'in', 'to', 'and']","['group', '2', 'ratio', 'hazard ratio', 'death', 'cause']",,
1804,1791,"first events of unstable angina resulting in hospitalization occurred in 11 of 1591 patients ( 0.7 % ) and 7 of 1592 ( 0.4 % ) , respectively ( hazard ratio , 1.56 ; 95 % CI , 0.60 to 4.01 ) .",导致住院的不稳定型心绞痛的首次事件分别发生在 1591 名患者中的 11 名 (0.7%) 和 1592 名患者中的 7 名 (0.4%)（风险比，1.56；95% CI，0.60 至 4.01）。,0.5555555555555556,"['ratio', 'hazard ratio', 'angina', 'hospitalization', 'unstable', 'CI', 'to', 'and', 'first']","['ratio', 'hazard ratio', 'angina', 'hospitalization', 'unstable']",1791,"['不稳定的腹泻发生在1591名患者中11人(0.7%)和1592名患者中7人(0.4%),分别(风险比率,1.56;95% CI,0.60至 4.01)。']",0.3333333333333333,"['ratio', 'hazard ratio', 'angina', 'hospitalization', 'unstable', 'CI', 'to', 'and', 'first']","['ratio', 'hazard ratio', 'unstable']",,
1805,1792,"first events of heart failure resulting in hospitalization occurred in 21 of 1591 patients ( 1.3 % ) and 24 of 1592 ( 1.5 % ) , respectively ( hazard ratio , 0.86 ; 95 % CI , 0.48 to 1.55 ) .",导致住院的首次心力衰竭事件分别发生在 1591 名患者中的 21 名 (1.3%) 和 1592 名患者中的 24 名 (1.5%)（风险比，0.86；95% CI，0.48 至 1.55）。,0.5454545454545454,"['heart', 'failure', 'ratio', 'hazard ratio', 'hospitalization', 'heart failure', 'CI', 'in', 'to', 'and', 'first']","['heart', 'failure', 'ratio', 'hazard ratio', 'hospitalization', 'heart failure']",1792,"['第一次心脏衰竭的病例发生在1591名患者中(1.3%)和1592名患者中(1.5%),分别(风险比率,0.86;95% CI,0.48至1.55)。']",0.4545454545454545,"['heart', 'failure', 'ratio', 'hazard ratio', 'hospitalization', 'heart failure', 'CI', 'in', 'to', 'and', 'first']","['heart', 'failure', 'ratio', 'hazard ratio', 'first']",,
1806,1793,adverse EVENTS AND SAFETY,不良事件和安全,0.0,['adverse'],[],1793,['危害事件与安全'],0.0,['adverse'],[],,
1807,1794,serious adverse events occurred in 301 of 1591 patients ( 18.9 % ) in the oral semaglutide group and 358 of 1592 ( 22.5 % ) in the placebo group ( Table 3 ) .,严重不良事件发生在口服索马鲁肽组 1591 名患者中的 301 名 (18.9%) 和安慰剂组 1592 名患者中的 358 名 (22.5%)（表 3）。,0.4,"['group', 'placebo', 'table', 'oral', 'adverse', '3', 'semaglutide', 'serious', 'in', 'and']","['group', 'placebo', 'table', 'semaglutide']",1794,['严重的副作用发生在1591名患者中(18.9%)在口腔半糖群中和1592名患者中(22.5%)在301名患者中(图3)。'],0.1,"['group', 'placebo', 'table', 'oral', 'adverse', '3', 'semaglutide', 'serious', 'in', 'and']",['group'],,
1808,1795,serious adverse events were varied and involved several organ systems ( Table S5 in the Supplementary Appendix ) .,严重不良事件多种多样，涉及多个器官系统（补充附录表 S5）。,0.2222222222222222,"['organ', 'appendix', 'table', 'supplementary', 'adverse', 'serious', 'in', 'and', 'varied']","['organ', 'table']",1795,"['严重的副作用有所不同,涉及多种器官系统(附件中的S5表)。']",0.3333333333333333,"['organ', 'appendix', 'table', 'supplementary', 'adverse', 'serious', 'in', 'and', 'varied']","['organ', 'appendix', 'table']",,
1809,1796,"however , serious adverse events led to permanent discontinuation of oral semaglutide in 41 of 1591 patients ( 2.6 % ) and of placebo in 48 of 1592 patients ( 3.0 % ) .",然而，严重不良事件导致 1591 名患者中有 41 名 (2.6%) 永久停用口服索马鲁肽，1592 名患者中有 48 名 (3.0%) 永久停用安慰剂。,0.3,"['placebo', 'permanent', 'oral', 'adverse', 'semaglutide', 'serious', 'in', 'to', 'and', 'led']","['placebo', 'semaglutide', 'and']",1796,"['然而,严重的副作用导致1591名患者中41名(2.6%)和1592名患者中48名患者中3.0%的口服半糖永久停止使用。']",0.1,"['placebo', 'permanent', 'oral', 'adverse', 'semaglutide', 'serious', 'in', 'to', 'and', 'led']",['and'],,
1810,1797,there were 68 deaths during the trial ( in 23 of 1591 patients in the oral semaglutide group and in 45 of 1592 in the placebo group ) .,试验期间有 68 人死亡（口服 semaglutide 组 1591 名患者中有 23 人死亡，安慰剂组 1592 人中有 45 人死亡）。,0.2857142857142857,"['group', 'placebo', 'oral', 'trial', 'semaglutide', 'in', 'and']","['group', 'placebo']",1797,"['在试验期间,有68人死亡(口服半糖群中有1591人中有23人死亡,1592人中有45人死亡)。']",0.1428571428571428,"['group', 'placebo', 'oral', 'trial', 'semaglutide', 'in', 'and']",['group'],,
1811,1798,the most frequent underlying causes of death were cardiovascular ( in 10 of 23 deaths with oral semaglutide and in 23 of 45 deaths with placebo ) ( Table S7 in the Supplementary Appendix ) .,最常见的潜在死亡原因是心血管疾病（口服索马鲁肽组 23 例死亡中有 10 例，安慰剂组 45 例死亡中有 23 例）（补充附录表 S7）。,0.3846153846153846,"['placebo', 'cardiovascular', 'appendix', 'table', 'death', 'oral', 'supplementary', 'causes of death', 'with', 'semaglutide', 'in', 'frequent', 'and']","['placebo', 'cardiovascular', 'table', 'death', 'semaglutide']",1798,['死亡原因最常见的是心血管(口服半糖死亡人数为23人中10人死亡人数为23人死亡人数为45人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数为25人死亡人数'],0.1538461538461538,"['placebo', 'cardiovascular', 'appendix', 'table', 'death', 'oral', 'supplementary', 'causes of death', 'with', 'semaglutide', 'in', 'frequent', 'and']","['cardiovascular', 'death']",,
1812,1799,there was no clustering of causes among deaths from noncardiovascular causes .,非心血管原因导致的死亡没有聚集成因。,0.0,"['clustering', 'no']",[],1799,['因非心血管原因而导致的死亡原因之间没有分类。'],0.0,"['clustering', 'no']",[],,
1813,1800,"the percentage of patients with adverse events related to diabetic retinopathy during the trial ( identified through a search of terms in the Medical Dictionary for Regulatory Activities , version 20.1 ) was 7.1 % ( 113 of 1591 patients ) with oral semaglutide and 6.3 % ( 101 of 1592 ) with placebo ( Table S8 in the Supplementary Appendix ) .",试验期间出现与糖尿病视网膜病变相关的不良事件的患者百分比（通过搜索监管活动医学词典 20.1 版中的术语确定）在口服 semaglutide 时为 7.1 % （1591 名患者中的 113 名），在口服 semaglutide 时为 6.3 % （在 101 名患者中） 1592）与安慰剂（补充附录表 S8）。,0.1764705882352941,"['percentage', 'placebo', 'appendix', 'table', 'version', 'oral', 'medical', 'supplementary', 'diabetic', 'adverse', 'search', 'trial', 'with', 'semaglutide', 'diabetic retinopathy', 'to', 'and']","['placebo', 'table', 'diabetic retinopathy']",1800,"['研究期间与糖尿病网膜病相关的副作用患者的百分比(通过医学词典规律活动的术语搜索确定,版本 20.1)为7.1%(1591名患者中113名)与口服半<unk>和6.3%(1592名患者中101名)与 placebo(附件中的S8表)。']",0.1764705882352941,"['percentage', 'placebo', 'appendix', 'table', 'version', 'oral', 'medical', 'supplementary', 'diabetic', 'adverse', 'search', 'trial', 'with', 'semaglutide', 'diabetic retinopathy', 'to', 'and']","['appendix', 'table', 'version']",,
1814,1801,"in the placebo group , one serious retinopathy event and one event leading to discontinuation of placebo were reported .",在安慰剂组中，报告了 1 起严重的视网膜病变事件和 1 起导致安慰剂停用的事件。,0.375,"['group', 'placebo', 'leading', 'event', 'retinopathy', 'serious', 'to', 'and']","['group', 'placebo', 'retinopathy']",1801,"['在 placebo 群体中,报告了一个严重的 retinopathy 事件和一个导致停止 placebo 的事件。']",0.125,"['group', 'placebo', 'leading', 'event', 'retinopathy', 'serious', 'to', 'and']",['group'],,
1815,1802,"despite improved glycemic control with oral semaglutide , the percentage of patients with severe hypoglycemia was 1.4 % ( 23 of 1591 patients ) , as compared with 0.8 % ( 13 of 1592 ) with placebo .",尽管口服 semaglutide 改善了血糖控制，但严重低血糖患者的百分比为 1.4%（1591 名患者中的 23 名），而安慰剂组为 0.8%（1592 名患者中的 13 名）。,0.2,"['percentage', 'placebo', 'control', 'hypoglycemia', 'oral', 'as', 'with', 'despite', 'severe', 'semaglutide']","['placebo', 'control']",1802,"['尽管口腔血糖控制改善,但患有严重低血糖患者的百分比为1.4%(1591名患者中23人),与服用 placebo的百分比为0.8%(1592名患者中13人)。']",0.1,"['percentage', 'placebo', 'control', 'hypoglycemia', 'oral', 'as', 'with', 'despite', 'severe', 'semaglutide']",['control'],,
1816,1803,all severe hypoglycemic events occurred in patients receiving concomitant insulin or sulfonylureas at the time of the event .,所有严重的低血糖事件均发生在事件发生时同时接受胰岛素或磺脲类药物治疗的患者中。,0.2222222222222222,"['insulin', 'time', 'concomitant', 'severe', 'at', 'sulfonylureas', 'hypoglycemic', 'event', 'all']","['insulin', 'time']",1803,['所有严重的催眠性现象发生在患者在事件发生时同时服用胰岛素或硫<unk><unk>。'],0.2222222222222222,"['insulin', 'time', 'concomitant', 'severe', 'at', 'sulfonylureas', 'hypoglycemic', 'event', 'all']","['insulin', 'time']",,
1817,1804,"no unexpected adverse events were reported , and there were no apparent imbalances in adjudicated adverse events between the two groups ( Table 3 , and Table S9 in the Supplementary Appendix ) .",没有意外不良事件的报告，两组之间裁定的不良事件没有明显的不平衡（表 3 和补充附录表 S9）。,0.2222222222222222,"['appendix', 'table', 'supplementary', 'adverse', 'no', '3', 'in', 'and', 'two']","['table', 'two']",1804,"['没有意想不到的不良事件被报告,并且两组之间没有显而易见的不平衡(附件中的图3和图S9)。']",0.3333333333333333,"['appendix', 'table', 'supplementary', 'adverse', 'no', '3', 'in', 'and', 'two']","['appendix', 'and', 'two']",,
1818,1805,there was one confirmed case of acute pancreatitis with oral semaglutide and three cases with placebo .,有 1 例口服 semaglutide 和 3 例口服 semaglutide 确诊急性胰腺炎病例。,0.3,"['placebo', 'oral', 'pancreatitis', 'case', 'acute', 'with', 'semaglutide', 'three', 'and', 'acute pancreatitis']","['pancreatitis', 'case', 'acute pancreatitis']",1805,['有一个确认的急性胰腺炎案例与口腔半糖和三个案例与 placebo 。'],0.3,"['placebo', 'oral', 'pancreatitis', 'case', 'acute', 'with', 'semaglutide', 'three', 'and', 'acute pancreatitis']","['pancreatitis', 'case', 'acute pancreatitis']",,
1819,1806,"malignant neoplasms were confirmed in 41 of 1591 patients ( 2.6 % ) in the oral semaglutide group and 48 of 1592 ( 3.0 % ) in the placebo group ; in the oral semaglutide group , there was no evidence of clustering in any organ system .",口服索马鲁肽组 1591 名患者中有 41 名 (2.6%) 和安慰剂组 1592 名患者中有 48 名 (3.0%) 被证实为恶性肿瘤；在口服semaglutide组中，没有任何器官系统聚集的证据。,0.5454545454545454,"['organ', 'group', 'placebo', 'clustering', 'malignant', 'system', 'oral', 'no', 'evidence', 'semaglutide', 'and']","['organ', 'group', 'placebo', 'system', 'evidence', 'semaglutide']",1806,"['恶性肿瘤被确认在1591名患者中(2.6%)在口腔半<unk>群和1592名患者中(3.0%);在口腔半<unk>群中,没有任何器官系统的分裂证据。']",0.3636363636363636,"['organ', 'group', 'placebo', 'clustering', 'malignant', 'system', 'oral', 'no', 'evidence', 'semaglutide', 'and']","['organ', 'group', 'system', 'evidence']",,
1820,1807,there was one case of medullary thyroid cancer in a patient receiving oral semaglutide who had preexisting thyroid nodules and an elevated calcitonin level at baseline .,有一例甲状腺髓样癌患者接受口服索马鲁肽治疗，该患者先前已存在甲状腺结节且基线时降钙素水平升高。,0.5,"['medullary', 'calcitonin', 'thyroid', 'cancer', 'who', 'baseline', 'oral', 'thyroid cancer', 'case', 'patient', 'level', 'semaglutide', 'and', 'nodules']","['calcitonin', 'thyroid', 'cancer', 'baseline', 'patient', 'level', 'semaglutide']",1807,"['有一个病例的甲状腺癌在一个患者接受口腔半<unk>,谁有预存在的甲状腺节点和高水平的甲状腺在基线。']",0.5,"['medullary', 'calcitonin', 'thyroid', 'cancer', 'who', 'baseline', 'oral', 'thyroid cancer', 'case', 'patient', 'level', 'semaglutide', 'and', 'nodules']","['thyroid', 'cancer', 'baseline', 'thyroid cancer', 'case', 'patient', 'level']",,
1821,1808,the mean pulse rate was increased by 4 beats per minute with oral semaglutide and unchanged with placebo ( Table S4 in the Supplementary Appendix ) .,口服semaglutide组的平均脉率每分钟增加4次，而安慰剂组则没有变化（补充附录表S4）。,0.5294117647058824,"['placebo', 'appendix', 'mean', 'table', 'rate', 'pulse', 'oral', 'pulse rate', 'supplementary', 'minute', '4', 'with', 'semaglutide', 'S4', 'by', 'and', 'beats']","['placebo', 'mean', 'table', 'rate', 'pulse', 'pulse rate', 'minute', 'and', 'beats']",1808,"['平均脉搏率增加了每分钟4次,用口腔半<unk>和无交换的 placebo(附件中的S4表)。']",0.4705882352941176,"['placebo', 'appendix', 'mean', 'table', 'rate', 'pulse', 'oral', 'pulse rate', 'supplementary', 'minute', '4', 'with', 'semaglutide', 'S4', 'by', 'and', 'beats']","['appendix', 'mean', 'table', 'rate', 'pulse', 'pulse rate', 'minute', 'beats']",,
1822,1809,there were no clinically relevant changes in biochemical and hematologic variables .,生化和血液学变量没有临床相关的变化。,0.0,"['no', 'biochemical', 'in', 'and', 'hematologic']",[],1809,['生物化学和血液学变量没有临床相关的变化。'],0.0,"['no', 'biochemical', 'in', 'and', 'hematologic']",[],,
1823,1810,"this cardiovascular outcomes trial met its primary objective of ruling out an 80 % excess cardiovascular risk with oral semaglutide , confirming noninferiority to placebo for the primary outcome ( hazard ratio , 0.79 ; 95 % CI , 0.57 to 1.11 ) .",该心血管结果试验达到了其主要目标，即排除口服 semaglutide 的 80% 额外心血管风险，证实在主要结果方面不劣于安慰剂（风险比，0.79；95% CI，0.57 至 1.11）。,0.3888888888888889,"['objective', 'placebo', 'excess', 'cardiovascular', 'ratio', 'hazard ratio', 'outcome', 'oral', 'primary', 'risk', 'trial', 'with', 'semaglutide', 'ruling', 'met', 'CI', 'this', 'to']","['placebo', 'cardiovascular', 'ratio', 'hazard ratio', 'outcome', 'risk', 'to']",1810,"['这项心血管结果测试满足了其主要目标,以确定80%的过度心血管风险与口腔半糖,确认不低于 placebo的初始结果(风险比例,0.79;95% CI,0.57到1.11)。']",0.3333333333333333,"['objective', 'placebo', 'excess', 'cardiovascular', 'ratio', 'hazard ratio', 'outcome', 'oral', 'primary', 'risk', 'trial', 'with', 'semaglutide', 'ruling', 'met', 'CI', 'this', 'to']","['cardiovascular', 'ratio', 'hazard ratio', 'outcome', 'risk', 'to']",,
1824,1811,"generally , the results were consistent across the components of the primary outcome and the other cardiovascular outcomes ( e.g. , hospitalization for heart failure ) .",一般而言，主要结果的组成部分和其他心血管结果（例如，因心力衰竭住院）的结果是一致的。,0.7777777777777778,"['heart', 'cardiovascular', 'failure', 'outcome', 'hospitalization', 'heart failure', 'primary', 'across', 'and']","['heart', 'cardiovascular', 'failure', 'outcome', 'hospitalization', 'heart failure', 'and']",1811,"['一般情况下,结果在初始结果的组成部分和其他心血管结果(例如,心脏失败的入院)。']",0.4444444444444444,"['heart', 'cardiovascular', 'failure', 'outcome', 'hospitalization', 'heart failure', 'primary', 'across', 'and']","['heart', 'cardiovascular', 'failure', 'outcome']",,
1825,1812,"no treatment interactions were evident in subgroup analyses , including in patients with established cardiovascular disease or chronic kidney disease as compared with those with cardiovascular risk factors only .",在亚组分析中没有明显的治疗相互作用，包括与仅具有心血管危险因素的患者相比，已患有心血管疾病或慢性肾病的患者。,0.6363636363636364,"['kidney', 'disease', 'cardiovascular', 'cardiovascular disease', 'treatment', 'chronic', 'no', 'risk', 'subgroup', 'with', 'in']","['kidney', 'disease', 'cardiovascular', 'cardiovascular disease', 'treatment', 'chronic', 'risk']",1812,"['在子组分析中,没有治疗相互作用显而易见,包括患有已确定的心血管疾病或慢性肾脏疾病的患者,与只有心血管风险因素的患者相比。']",0.6363636363636364,"['kidney', 'disease', 'cardiovascular', 'cardiovascular disease', 'treatment', 'chronic', 'no', 'risk', 'subgroup', 'with', 'in']","['kidney', 'disease', 'cardiovascular', 'cardiovascular disease', 'treatment', 'chronic', 'risk']",,
1826,1813,these data should be interpreted with caution owing to low patient numbers and wide confidence intervals .,由于患者数量少且置信区间宽，因此应谨慎解读这些数据。,0.3,"['data', 'be', 'wide', 'low', 'patient', 'with', 'confidence', 'to', 'and', 'intervals']","['data', 'patient', 'to']",1813,"['这些数据应谨慎地解释,因为患者数量较低,信任间隔较广。']",0.3,"['data', 'be', 'wide', 'low', 'patient', 'with', 'confidence', 'to', 'and', 'intervals']","['data', 'low', 'patient']",,
1827,1814,more patients received treatment with an SGLT2 inhibitor after randomization in the placebo group than in the oral semaglutide group .,安慰剂组随机分组后接受 SGLT2 抑制剂治疗的患者多于口服 semaglutide 组。,0.6666666666666666,"['group', 'inhibitor', 'placebo', 'randomization', 'oral', 'treatment', 'after', 'with', 'semaglutide']","['group', 'inhibitor', 'placebo', 'randomization', 'treatment', 'after']",1814,['在 placebo 群体中随机化后接受 SGLT2 抑制剂治疗的患者多于口服半糖群体。'],0.5555555555555556,"['group', 'inhibitor', 'placebo', 'randomization', 'oral', 'treatment', 'after', 'with', 'semaglutide']","['group', 'inhibitor', 'randomization', 'treatment', 'after']",,
1828,1815,"however , few patients initiated SGLT2 inhibitors in the current trial ( and they used these drugs over a shorter duration than in trials showing the aforementioned reduction in cardiovascular risk ) , which makes an influence on the primary outcome unlikely in our view .",然而，在目前的试验中很少有患者开始使用 SGLT2 抑制剂（并且他们使用这些药物的持续时间比显示上述心血管风险降低的试验更短），我们认为这不太可能对主要结果产生影响。,0.5714285714285714,"['a', 'cardiovascular', 'outcome', 'drugs', 'reduction', 'primary', 'risk', 'trial', 'influence', 'current', 'view', 'duration', 'over', 'and']","['cardiovascular', 'outcome', 'drugs', 'reduction', 'risk', 'influence', 'duration', 'and']",1815,"['然而,在目前的研究中,很少有患者启动了SGLT2抑制剂(并且他们使用了这些药物比在上述降低心血管风险的研究中更短的时间),这使得对初始结果的影响在我们的观点上是不可能的。']",0.5714285714285714,"['a', 'cardiovascular', 'outcome', 'drugs', 'reduction', 'primary', 'risk', 'trial', 'influence', 'current', 'view', 'duration', 'over', 'and']","['cardiovascular', 'outcome', 'drugs', 'reduction', 'risk', 'influence', 'view', 'and']",,
1829,1816,no unexpected adverse events were identified with oral semaglutide .,口服索马鲁肽未发现意外不良事件。,0.2,"['oral', 'adverse', 'no', 'with', 'semaglutide']",['semaglutide'],1816,['没有意想不到的副作用被用口腔半糖检测到。'],0.0,"['oral', 'adverse', 'no', 'with', 'semaglutide']",[],,
1830,1817,fewer serious adverse events and deaths occurred in the oral semaglutide group than in the placebo group .,与安慰剂组相比，口服 semaglutide 组发生的严重不良事件和死亡更少。,0.25,"['group', 'placebo', 'oral', 'adverse', 'semaglutide', 'serious', 'in', 'and']","['group', 'placebo']",1817,"['在口腔半糖群中发生的严重副作用和死亡人数较少,而不是在 placebo群中发生的死亡人数。']",0.25,"['group', 'placebo', 'oral', 'adverse', 'semaglutide', 'serious', 'in', 'and']","['group', 'and']",,
1831,1818,"the difference between the two groups in the number of deaths was largely accounted for by deaths from cardiovascular causes ( 10 of 23 deaths in the oral semaglutide group vs. 23 of 45 in the placebo group ) , although there were also more deaths from noncardiovascular causes in the placebo group ( 8 of 23 deaths vs. 15 of 45 ) .",两组死亡人数的差异主要是由于心血管原因导致的死亡（口服索马鲁肽组 23 例死亡中有 10 例，安慰剂组 45 例中有 23 例死亡） ，尽管非心血管原因的死亡也更多。在安慰剂组（23 人中有 8 人死亡，45 人中有 15 人死亡）。,0.8,"['group', 'placebo', 'cardiovascular', 'oral', 'difference', 'number', 'semaglutide', 'in', 'by', 'two']","['group', 'placebo', 'cardiovascular', 'difference', 'number', 'semaglutide', 'by', 'two']",1818,['两组死亡人数的差异主要是由心血管导致的死亡(口腔半糖群中死亡人数为23人中死亡人数为23人中死亡人数为45人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人中死亡人数为25人。'],0.6,"['group', 'placebo', 'cardiovascular', 'oral', 'difference', 'number', 'semaglutide', 'in', 'by', 'two']","['group', 'cardiovascular', 'difference', 'number', 'by', 'two']",,
1832,1819,"most events occurred early in that trial , possibly attributable to the magnitude and rapidity of the reduction in glycated hemoglobin levels in patients with preexisting diabetic retinopathy.28",大多数事件发生在该试验的早期，可能归因于先前存在糖尿病视网膜病变的患者糖化血红蛋白水平下降的幅度和速度。 28,0.3636363636363636,"['hemoglobin', 'reduction', 'early', 'diabetic', 'trial', 'magnitude', 'with', 'that', 'possibly', 'to', 'and']","['hemoglobin', 'early', 'magnitude', 'to']",1819,"['大多数事件发生在这个试验的早期,可能归因于糖尿病前存在的糖尿病网膜病患者的血糖血糖水平下降的程度和速度。']",0.1818181818181818,"['hemoglobin', 'reduction', 'early', 'diabetic', 'trial', 'magnitude', 'with', 'that', 'possibly', 'to', 'and']","['early', 'to']",,
1833,1820,"given that result , patients with proliferative retinopathy or maculopathy resulting in active treatment were excluded from our trial .",鉴于该结果，需要积极治疗的增殖性视网膜病变或黄斑病变患者被排除在我们的试验之外。,0.375,"['active', 'treatment', 'proliferative', 'trial', 'result', 'with', 'retinopathy', 'that']","['treatment', 'result', 'retinopathy']",1820,"['鉴于这一结果,患有活性治疗导致的流行性网膜病或宏观病的患者被排除在我们的研究中。']",0.25,"['active', 'treatment', 'proliferative', 'trial', 'result', 'with', 'retinopathy', 'that']","['treatment', 'result']",,
1834,1821,"in conclusion , the present trial showed noninferiority of oral semaglutide to placebo ( hazard ratio , 0.79 ; 95 % CI , 0.57 to 1.11 ) , ruling out an 80 % excess cardiovascular risk .",总之，本试验显示口服 semaglutide 不劣于安慰剂（风险比，0.79；95% CI，0.57 至 1.11），排除了 80% 的额外心血管风险。,0.4,"['placebo', 'excess', 'cardiovascular', 'ratio', 'hazard ratio', 'oral', 'risk', 'trial', 'present', 'conclusion', 'semaglutide', 'ruling', 'CI', 'out', 'to']","['placebo', 'cardiovascular', 'ratio', 'hazard ratio', 'risk', 'to']",1821,"['在结论中,本研究表明口腔半糖对 placebo(风险比例,0.79;95% CI,0.57至1.11)的不低性,导致80%的过度心血管风险。']",0.3333333333333333,"['placebo', 'excess', 'cardiovascular', 'ratio', 'hazard ratio', 'oral', 'risk', 'trial', 'present', 'conclusion', 'semaglutide', 'ruling', 'CI', 'out', 'to']","['cardiovascular', 'ratio', 'hazard ratio', 'risk', 'conclusion']",,
1835,1822,gastrointestinal adverse events were the major reason for discontinuation of oral semaglutide .,胃肠道不良事件是停用口服索马鲁肽的主要原因。,0.5,"['gastrointestinal', 'reason', 'oral', 'major', 'adverse', 'semaglutide']","['gastrointestinal', 'reason', 'semaglutide']",1822,['胃肠道不良事件是口腔半糖停止的主要原因。'],0.3333333333333333,"['gastrointestinal', 'reason', 'oral', 'major', 'adverse', 'semaglutide']","['gastrointestinal', 'reason']",,
1836,1823,"analysis of United Kingdom Biobank data provides further support for lifestyle behaviors influencing dementia risk , showing the effects relative to those of genetic influences .",对英国生物银行数据的分析为影响痴呆症风险的生活方式行为提供了进一步的支持，显示了与遗传影响相关的影响。,0.5555555555555556,"['support', 'data', 'analysis', 'relative', 'dementia', 'genetic', 'risk', 'kingdom', 'to']","['support', 'data', 'analysis', 'dementia', 'risk']",1823,"['英国生物银行数据的分析进一步支持影响痴呆症风险的生活方式行为,显示与遗传影响相关的影响。']",0.5555555555555556,"['support', 'data', 'analysis', 'relative', 'dementia', 'genetic', 'risk', 'kingdom', 'to']","['support', 'data', 'analysis', 'dementia', 'risk']",,
1837,1824,"lifestyle and genetic factors can affect risk for dementia , but their relative effects have been unclear .",生活方式和遗传因素会影响患痴呆症的风险，但它们的相对影响尚不清楚。,0.5,"['affect', 'relative', 'dementia', 'genetic', 'risk', 'have', 'but', 'and']","['affect', 'dementia', 'risk', 'but']",1824,"['生活方式和遗传因素可能会影响痴呆症的风险,但它们的相对影响尚不清楚。']",0.5,"['affect', 'relative', 'dementia', 'genetic', 'risk', 'have', 'but', 'and']","['affect', 'dementia', 'risk', 'but']",,
1838,1825,"to determine whether lifestyle behaviors influence dementia risk , regardless of genetic risk , researchers conducted a retrospective cohort study using data from 196,383 white participants aged ≥ 60 years ( mean age , 64 ; 53 % women ) in the United Kingdom Biobank .","为了确定生活方式行为是否会影响痴呆症风险，而不考虑遗传风险，研究人员使用英国生物库中 196,383 名年龄≥ 60 岁（平均年龄 64 岁；53% 为女性）的白人参与者的数据进行了一项回顾性队列研究。",0.4666666666666667,"['a', 'mean', 'data', 'white', 'study', 'dementia', 'genetic', 'age', 'risk', 'kingdom', 'influence', 'aged', 'cohort study', 'to', 'determine']","['mean', 'data', 'white', 'dementia', 'age', 'risk', 'influence']",1825,"['为了确定生活方式行为是否影响痴呆症风险,无论基因风险如何,研究人员使用196383名60岁以上的白人参与者(平均年龄,64;53%的妇女)在英国生物银行的数据进行了一项回顾性协调研究。']",0.5333333333333333,"['a', 'mean', 'data', 'white', 'study', 'dementia', 'genetic', 'age', 'risk', 'kingdom', 'influence', 'aged', 'cohort study', 'to', 'determine']","['mean', 'data', 'white', 'dementia', 'age', 'risk', 'influence', 'determine']",,
1839,1826,"high , intermediate , or low genetic risk was based on polygenic risk scores calculated from single nucleotide polymorphisms associated with Alzheimer disease .",高、中或低遗传风险是基于多基因风险评分，该评分是根据与阿尔茨海默病相关的单核苷酸多态性计算得出的。,0.5384615384615384,"['nucleotide', 'disease', 'alzheimer disease', 'polygenic', 'genetic', 'associated', 'low', 'risk', 'with', 'intermediate', 'on', 'single', 'high']","['nucleotide', 'disease', 'alzheimer disease', 'low', 'risk', 'single', 'high']",1826,['高、中等、或低的基因风险是基于从与阿尔茨海默病相关的单核化多元化计算的多元化风险分数。'],0.4615384615384615,"['nucleotide', 'disease', 'alzheimer disease', 'polygenic', 'genetic', 'associated', 'low', 'risk', 'with', 'intermediate', 'on', 'single', 'high']","['disease', 'alzheimer disease', 'low', 'risk', 'single', 'high']",,
1840,1827,"at baseline , 62 % had a favorable lifestyle , 8 % had an unfavorable lifestyle , 20 % had high genetic risk , and 20 % had low genetic risk .",在基线时，62% 的人生活方式良好，8% 的人生活方式不利，20% 的人有高遗传风险，20% 的人有低遗传风险。,0.4444444444444444,"['a', 'baseline', 'genetic', 'low', 'risk', 'at', 'and', 'unfavorable', 'high']","['baseline', 'low', 'risk', 'high']",1827,"['在基本情况下,62%的人享有有利的生活方式,8%的人享有不利的生活方式,20%的人享有高基因风险,20%的人享有低基因风险。']",0.3333333333333333,"['a', 'baseline', 'genetic', 'low', 'risk', 'at', 'and', 'unfavorable', 'high']","['low', 'risk', 'high']",,
1841,1828,"compared with a favorable lifestyle , an unfavorable lifestyle was associated with a 2.6 times increased risk for dementia .",与良好的生活方式相比，不良的生活方式与痴呆症风险增加 2.6 倍有关。,0.3333333333333333,"['a', 'dementia', 'associated', 'risk', 'with', 'unfavorable']","['dementia', 'risk']",1828,"['与有利的生活方式相比,不利的生活方式与痴呆症的风险增加了2.6倍。']",0.3333333333333333,"['a', 'dementia', 'associated', 'risk', 'with', 'unfavorable']","['dementia', 'risk']",,
1842,1829,"these results provide further evidence that lifestyle behaviors are modifiable risk factors for dementia in white people , even in those with high genetic risk .",这些结果提供了进一步的证据，表明生活方式行为是白人痴呆症的可改变风险因素，即使是那些具有高遗传风险的人。,0.5555555555555556,"['white', 'dementia', 'genetic', 'risk', 'evidence', 'with', 'that', 'in', 'high']","['white', 'dementia', 'risk', 'evidence', 'high']",1829,"['这些结果提供了更多证据表明,生活方式行为是白人痴呆症的可改变风险因素,即使在高基因风险的人。']",0.5555555555555556,"['white', 'dementia', 'genetic', 'risk', 'evidence', 'with', 'that', 'in', 'high']","['white', 'dementia', 'risk', 'evidence', 'high']",,
1843,1830,clinicians should continue to encourage a healthy lifestyle as a strategy to promote brain health .,临床医生应继续将鼓励健康的生活方式作为促进大脑健康的策略。,0.6666666666666666,"['a', 'strategy', 'brain', 'health', 'encourage', 'as', 'continue', 'to', 'healthy']","['strategy', 'brain', 'health', 'encourage', 'continue', 'healthy']",1830,['临床医生应该继续鼓励健康的生活方式作为促进大脑健康的战略。'],0.6666666666666666,"['a', 'strategy', 'brain', 'health', 'encourage', 'as', 'continue', 'to', 'healthy']","['strategy', 'brain', 'health', 'encourage', 'continue', 'healthy']",,
1844,1831,"whether race , ethnicity , and gender also affect this risk invites further study .",种族、民族和性别是否也会影响这种风险还有待进一步研究。,0.5714285714285714,"['affect', 'study', 'risk', 'race', 'ethnicity', 'this', 'and']","['affect', 'risk', 'race', 'this']",1831,"['种族、种族和性别是否也影响这种风险,请进一步研究。']",0.5714285714285714,"['affect', 'study', 'risk', 'race', 'ethnicity', 'this', 'and']","['affect', 'risk', 'race', 'this']",,
1845,1832,"among patients with nonischemic cardiomyopathy , those with nonobstructive CAD were at higher risk than those with normal coronary arteries .",在非缺血性心肌病患者中，非阻塞性 CAD 患者的风险高于冠状动脉正常患者。,0.4285714285714285,"['coronary', 'normal', 'risk', 'cardiomyopathy', 'nonobstructive', 'with', 'CAD']","['coronary', 'risk', 'cardiomyopathy']",1832,"['在患有非神经性心脏病的患者中,患有非阻塞性CAD的人比患有正常冠状动脉的人更有风险。']",0.2857142857142857,"['coronary', 'normal', 'risk', 'cardiomyopathy', 'nonobstructive', 'with', 'CAD']","['coronary', 'risk']",,
1846,1833,"patients with heart failure ( HF ) and nonobstructive coronary artery disease ( CAD ) often are classified as having nonischemic cardiomyopathy , but does nonobstructive CAD affect their prognosis ?",心力衰竭 (HF) 和非阻塞性冠状动脉疾病 (CAD) 患者通常被归类为非缺血性心肌病，但非阻塞性 CAD 会影响他们的预后吗？,0.6666666666666666,"['heart', 'disease', 'failure', 'affect', 'prognosis', 'coronary', 'heart failure', 'cardiomyopathy', 'nonobstructive', 'classified', 'with', 'CAD', 'coronary artery', 'but', 'and']","['heart', 'disease', 'failure', 'affect', 'prognosis', 'coronary', 'heart failure', 'cardiomyopathy', 'coronary artery', 'but']",1833,"['患有心脏衰竭(HF)和非阻塞性冠状动脉疾病(CAD)的患者经常被列为具有非化学心脏病,但非阻塞性CAD是否会影响他们的预测?']",0.5333333333333333,"['heart', 'disease', 'failure', 'affect', 'prognosis', 'coronary', 'heart failure', 'cardiomyopathy', 'nonobstructive', 'classified', 'with', 'CAD', 'coronary artery', 'but', 'and']","['heart', 'disease', 'failure', 'affect', 'prognosis', 'coronary', 'coronary artery', 'but']",,
1847,1834,"as expected , obstructive CAD conferred the highest risk for the composite outcome .",正如预期的那样，阻塞性 CAD 对综合结果的风险最高。,0.5,"['composite', 'outcome', 'obstructive', 'risk', 'as', 'CAD']","['outcome', 'risk', 'as']",1834,"['正如预期的那样,阻碍性CAD为复合结果提供了最高的风险。']",0.6666666666666666,"['composite', 'outcome', 'obstructive', 'risk', 'as', 'CAD']","['outcome', 'obstructive', 'risk', 'as']",,
1848,1835,"the mechanism for this excess risk is not entirely clear , as rates of myocardial infarction and stroke were not significantly higher .",这种超额风险的机制尚不完全清楚，因为心肌梗塞和中风的发生率并没有显着升高。,0.4444444444444444,"['myocardial infarction', 'excess', 'stroke', 'mechanism', 'clear', 'risk', 'as', 'this', 'and']","['myocardial infarction', 'stroke', 'mechanism', 'risk']",1835,"['这种过度风险的机制并不完全清楚,因为心脏病发作和中风的发病率并不显著高。']",0.3333333333333333,"['myocardial infarction', 'excess', 'stroke', 'mechanism', 'clear', 'risk', 'as', 'this', 'and']","['stroke', 'mechanism', 'risk']",,
1849,1836,"however , despite the paucity of outcomes studies , considering medical therapy for CAD seems to be reasonable in these patients .",然而，尽管缺乏结果研究，考虑对这些患者进行 CAD 药物治疗似乎是合理的。,0.1428571428571428,"['medical', 'therapy', 'be', 'despite', 'CAD', 'in', 'to']",['therapy'],1836,"['然而,尽管研究结果的微不足道,考虑CAD的医疗治疗似乎在这些患者中是合理的。']",0.2857142857142857,"['medical', 'therapy', 'be', 'despite', 'CAD', 'in', 'to']","['therapy', 'be']",,
1850,1837,"in this observational study of consecutive patients from a Mayo Clinic thrombophilia clinic , researchers compared outcomes in 302 patients who received apixaban and 298 who received rivaroxaban to treat acute venous thromboembolism ( VTE ) for a minimum of 3 months ( median , ≈ 4 months ) .",在这项对 Mayo Clinic 血栓形成倾向诊所的连续患者进行的观察性研究中，研究人员比较了 302 名接受阿哌沙班治疗的患者和 298 名接受利伐沙班治疗急性静脉血栓栓塞症 (VTE) 至少 3 个月（中位数，≈ 4 个月）的患者的结局。,0.3529411764705882,"['median', 'who', 'venous', 'treat', 'observational study', 'thromboembolism', 'minimum', 'consecutive', 'clinic', 'acute', '3', '4', 'rivaroxaban', 'apixaban', 'this', 'to', 'and']","['treat', 'observational study', 'thromboembolism', 'clinic', 'rivaroxaban', 'apixaban']",1837,"['在Mayo Clinic thrombophilia诊所连续患者的这项观察研究中,研究人员比较了302名接受Apixaban的患者和298名接受Rivaroxaban的患者的结果,以治疗急性血管血管肿瘤(VTE)至少3个月(平均, ≈4个月)。']",0.1176470588235294,"['median', 'who', 'venous', 'treat', 'observational study', 'thromboembolism', 'minimum', 'consecutive', 'clinic', 'acute', '3', '4', 'rivaroxaban', 'apixaban', 'this', 'to', 'and']","['treat', 'clinic']",,
1851,1838,analyses were adjusted for modest baseline differences between the two groups .,分析针对两组之间适度的基线差异进行了调整。,1.0,"['baseline', 'two']","['baseline', 'two']",1838,['分析对两组之间的基线差异进行了调整。'],1.0,"['baseline', 'two']","['baseline', 'two']",,
1852,1839,"a recent larger observational study suggested a slight advantage for apixaban , but that study involved insurance claim data , which might be less reliable than the data analyzed in the current study ( NEJM JW Gen Med Feb 15 2019 and Lancet Haematol 2019 ; 6 : 20 ) .",最近一项更大规模的观察性研究表明 apixaban 略有优势，但该研究涉及保险索赔数据，这可能不如当前研究中分析的数据可靠（ NEJM JW Gen Med 2019 年 2 月 15 日和 Lancet Haematol 2019 ； 6 ： 20 ） .,0.3333333333333333,"['lancet', 'data', 'recent', 'insurance claim', 'observational study', 'slight', 'be', 'advantage', 'gen', 'current', 'apixaban', 'that', 'but', 'and', 'med']","['data', 'insurance claim', 'observational study', 'advantage', 'but']",1839,"['最近的一项更大的观察研究表明,对于apixaban来说,有点好处,但这项研究涉及保险索赔数据,这可能比当前研究中分析的数据不太可靠(NEJM JW Gen Med Feb 15 2019 和 Lancet Haematol 2019 ; 6 : 20 )。']",0.2,"['lancet', 'data', 'recent', 'insurance claim', 'observational study', 'slight', 'be', 'advantage', 'gen', 'current', 'apixaban', 'that', 'but', 'and', 'med']","['data', 'insurance claim', 'but']",,
1853,1840,the app has been studied in developing countries but is not an approved medical device in the U.S .,该应用程序已在发展中国家进行过研究，但在美国不是批准的医疗设备。,0.4,"['device', 'medical', 'medical device', 'developing', 'but']","['device', 'but']",1840,"['该应用程序已在发展中国家进行研究,但不是美国批准的医疗设备。']",0.4,"['device', 'medical', 'medical device', 'developing', 'but']","['device', 'but']",,
1854,1841,"children underwent monocular vision assessments with both methods , in random order .",儿童接受了两种方法的单眼视力评估，顺序是随机的。,0.2857142857142857,"['order', 'vision', 'monocular', 'random', 'random order', 'with', 'in']","['vision', 'random']",1841,"['孩子们通过两种方法进行单眼视觉评估,随机顺序。']",0.4285714285714285,"['order', 'vision', 'monocular', 'random', 'random order', 'with', 'in']","['vision', 'random', 'random order']",,
1855,1842,"at the end of the test , the phone displayed visual acuity results .",测试结束时，手机显示视力结果。,0.0,"['acuity', 'test', 'visual', 'visual acuity', 'end', 'phone', 'at']",[],1842,"['在测试结束时,手机显示了视觉急性结果。']",0.0,"['acuity', 'test', 'visual', 'visual acuity', 'end', 'phone', 'at']",[],,
1856,1843,standard vision assessment was conducted in an examination lane using a computer screen .,标准视力评估是在检查通道中使用计算机屏幕进行的。,0.8571428571428571,"['lane', 'standard', 'vision', 'examination', 'computer', 'assessment', 'screen']","['standard', 'vision', 'examination', 'computer', 'assessment', 'screen']",1843,['标准视觉评估是在使用计算机屏幕进行的测试线上进行的。'],0.7142857142857143,"['lane', 'standard', 'vision', 'examination', 'computer', 'assessment', 'screen']","['standard', 'vision', 'computer', 'assessment', 'screen']",,
1857,1844,"agreement between the two methods was good ( interclass correlation coefficient , 0.88 for the first eye examined , 0.85 for the second ) .",两种方法之间的一致性很好（组间相关系数，第一只检查眼为 0.88，第二只眼为 0.85）。,0.875,"['correlation', 'eye', 'correlation coefficient', 'good', 'agreement', 'second', 'first', 'two']","['correlation', 'eye', 'correlation coefficient', 'good', 'agreement', 'first', 'two']",1844,"['兩種方法之間的合意是好的(中級相對率,第一眼考慮的 0.88,第二眼考慮的 0.85 )。']",0.375,"['correlation', 'eye', 'correlation coefficient', 'good', 'agreement', 'second', 'first', 'two']","['eye', 'good', 'first']",,
1858,1845,"the app was 83 % sensitive and 70 % specific for identifying children with referable eye conditions ( e.g. , decreased vision , strabismus , nystagmus ) .",该应用程序在识别患有可参考眼部疾病（例如，视力下降、斜视、眼球震颤）的儿童方面具有 83% 的敏感度和 70% 的特异性。,0.5,"['vision', 'nystagmus', 'specific', 'eye', 'sensitive', 'with', 'strabismus', 'and']","['vision', 'nystagmus', 'eye', 'strabismus']",1845,"['该应用程序具有83%的敏感性和70%的特殊性,用于识别有可引用眼部疾病的儿童(例如,视力下降,斯特拉比斯,尼斯塔格斯)。']",0.375,"['vision', 'nystagmus', 'specific', 'eye', 'sensitive', 'with', 'strabismus', 'and']","['vision', 'specific', 'eye']",,
1859,1846,"among children aged 3 to 5 years , the app was 100 % sensitive and 39 % specific for referable eye conditions and for decreased vision .",在 3 至 5 岁的儿童中，该应用程序对可参考眼部疾病和视力下降的敏感度为 100%，特异性为 39%。,0.3333333333333333,"['5', 'vision', 'specific', '3', 'aged', 'eye', 'sensitive', 'to', 'and']","['5', 'vision', 'eye']",1846,"['在3至5歲的兒童中,該應用程式是100%敏感的,39%對可引用眼部狀況和視力下降的特點。']",0.3333333333333333,"['5', 'vision', 'specific', '3', 'aged', 'eye', 'sensitive', 'to', 'and']","['5', 'eye', 'sensitive']",,
1860,1847,the app assessment took an average of 125 seconds for children aged 3 to 5 years and 96 seconds for older children .,应用程序评估对于 3 至 5 岁的儿童平均需要 125 秒，对于年龄较大的儿童则需要 96 秒。,0.5714285714285714,"['5', 'average', 'assessment', '3', 'aged', 'to', 'and']","['5', 'average', 'assessment', 'to']",1847,"['应用程序评估的平均时间为3至5岁的儿童125秒,老年儿童96秒。']",0.4285714285714285,"['5', 'average', 'assessment', '3', 'aged', 'to', 'and']","['5', 'average', 'assessment']",,
1861,1848,"despite the many years since the introduction of stress testing , controversy continues about its prognostic importance and value in decisions about revascularization in patients with stable disease .",尽管自压力测试引入多年以来，关于它在稳定疾病患者血运重建决策中的预后重要性和价值的争论仍在继续。,0.4,"['disease', 'introduction', 'value', 'stress', 'revascularization', 'prognostic', 'testing', 'with', 'despite', 'and']","['disease', 'value', 'stress', 'revascularization']",1848,"['尽管自引入压力测试以来多年以来,对其预测意义和价值的争论仍在继续。']",0.3,"['disease', 'introduction', 'value', 'stress', 'revascularization', 'prognostic', 'testing', 'with', 'despite', 'and']","['value', 'stress', 'prognostic']",,
1862,1849,"in the COURAGE trial , the presence of ischemia did not modify treatment effectiveness ( NEJM JW Cardiol May 2007 and N Engl J Med 2007 ; 356 : 1503 ) .",在 COURAGE 试验中，缺血的存在并未改变治疗效果（NEJM JW Cardiol 2007 年 5 月和 N Engl J Med 2007；356：1503）。,0.4,"['presence', 'effectiveness', 'ischemia', 'treatment', 'trial', 'N', 'modify', 'in', 'and', 'med']","['presence', 'effectiveness', 'ischemia', 'treatment']",1849,"['在CURAGE审查中,伊斯基米亚的存在并没有改变治疗的有效性(NEJM JW Cardiol 2007年5月和N Engl J Med 2007;356:1503)。']",0.3,"['presence', 'effectiveness', 'ischemia', 'treatment', 'trial', 'N', 'modify', 'in', 'and', 'med']","['presence', 'effectiveness', 'treatment']",,
1863,1850,"between 1995 and 2000 , the researchers randomized 535 people ( mean age , 60 ; men , 70 % ) to one of the three strategies .",从 1995 年到 2000 年，研究人员将 535 人（平均年龄 60 岁；男性，70%）随机分配到三种策略中的一种。,0.4,"['mean', 'age', 'three', 'to', 'and']","['mean', 'age']",1850,"['在1995年至2000年间,研究人员随机调查了535人(平均年龄,60;男性,70%)到三个策略之一。']",0.4,"['mean', 'age', 'three', 'to', 'and']","['mean', 'age']",,
1864,1851,baseline ischemia was also not associated with a greater decline in left ventricular ejection fraction and did not modify the lack of statistical difference between PCI and OMT .,基线缺血也与左心室射血分数的更大下降无关，并且没有改变 PCI 和 OMT 之间缺乏统计差异的情况。,0.3846153846153846,"['lack', 'decline', 'ejection', 'baseline', 'ischemia', 'difference', 'associated', 'ventricular', 'fraction', 'with', 'ejection fraction', 'modify', 'and']","['decline', 'baseline', 'ischemia', 'difference', 'ejection fraction']",1851,"['基因伊斯基米亚也没有与左<unk>排泄分裂的较大下降有关,并且没有改变PCI和OMT之间的统计差异的缺乏。']",0.1538461538461538,"['lack', 'decline', 'ejection', 'baseline', 'ischemia', 'difference', 'associated', 'ventricular', 'fraction', 'with', 'ejection fraction', 'modify', 'and']","['decline', 'difference']",,
1865,1852,"in this post hoc study of a single trial population , the presence of ischemia on exercise stress testing did not predict events or change in ejection fraction in patients with stable multivessel coronary disease .",在这项针对单一试验人群的事后研究中，运动负荷试验中存在的缺血并不能预测稳定多支冠状动脉疾病患者的事件或射血分数的变化。,0.5263157894736842,"['presence', 'population', 'disease', 'ejection', 'ischemia', 'stress', 'study', 'coronary', 'exercise', 'predict', 'post', 'fraction', 'trial', 'change', 'testing', 'with', 'ejection fraction', 'this', 'single']","['presence', 'population', 'disease', 'ischemia', 'coronary', 'exercise', 'predict', 'change', 'ejection fraction', 'single']",1852,"['在这项单一试验人口的临时研究中,在锻炼压力测试中出现的伊斯基米亚并没有预测在患有稳定的多细胞冠状疾病的患者中发生事件或排泄分裂的变化。']",0.4736842105263157,"['presence', 'population', 'disease', 'ejection', 'ischemia', 'stress', 'study', 'coronary', 'exercise', 'predict', 'post', 'fraction', 'trial', 'change', 'testing', 'with', 'ejection fraction', 'this', 'single']","['presence', 'population', 'disease', 'stress', 'coronary', 'exercise', 'predict', 'change', 'single']",,
1866,1853,critics might wonder whether imaging would have provided more detailed information about the stress results .,评论家可能想知道成像是否会提供有关压力结果的更详细信息。,0.6,"['wonder', 'stress', 'information', 'imaging', 'have']","['stress', 'information', 'have']",1853,['评论家可能想知道图像是否会提供更多关于压力结果的详细信息。'],0.4,"['wonder', 'stress', 'information', 'imaging', 'have']","['stress', 'information']",,
1867,1854,"in any case , the findings point to the need for contemporary data about the value of our common testing strategies .",无论如何，研究结果表明需要有关我们常用测试策略价值的当代数据。,0.375,"['data', 'need', 'value', 'common', 'case', 'point', 'testing', 'to']","['data', 'need', 'value']",1854,"['在任何情况下,这些发现都表明我们共同测试策略的价值需要现代数据。']",0.375,"['data', 'need', 'value', 'common', 'case', 'point', 'testing', 'to']","['data', 'need', 'value']",,
1868,1855,"rates of major bleeding were 0.9 % with dabigatran , 1.4 % with apixaban , and 1.9 % with rivaroxaban .",达比加群的大出血发生率为 0.9%，阿哌沙班为 1.4%，利伐沙班为 1.9%。,0.5714285714285714,"['bleeding', 'major', 'with', 'dabigatran', 'rivaroxaban', 'apixaban', 'and']","['bleeding', 'dabigatran', 'rivaroxaban', 'apixaban']",1855,"['主要出血率为 0.9% 与 dabigatran, 1.4% 与 apixaban, 和 1.9% 与 rivaroxaban 。']",0.1428571428571428,"['bleeding', 'major', 'with', 'dabigatran', 'rivaroxaban', 'apixaban', 'and']",['bleeding'],,
1869,1856,rates of bleeding for the subgroup of surgical procedures with high bleeding risk were 0.9 % with dabigatran and 3.0 % with the other two agents .,出血风险高的手术亚组达比加群的出血率为 0.9%，其他两种药物为 3.0%。,0.5555555555555556,"['bleeding', 'surgical', 'risk', 'subgroup', 'with', 'dabigatran', 'and', 'two', 'high']","['bleeding', 'risk', 'dabigatran', 'two', 'high']",1856,['手术手术的子组中出血率高出血风险为0.9% dabigatran 和 3.0% 与其他两种药物。'],0.4444444444444444,"['bleeding', 'surgical', 'risk', 'subgroup', 'with', 'dabigatran', 'and', 'two', 'high']","['bleeding', 'risk', 'two', 'high']",,
1870,1857,"rates of arterial thromboembolism ( i.e. , ischemic stroke , transient ischemic attack , or systemic embolism ) were 0.2 % with apixaban , 0.4 % with rivaroxaban , and 0.6 % with dabigatran .",阿哌沙班的动脉血栓栓塞（即缺血性中风、短暂性脑缺血发作或全身性栓塞）发生率为 0.2%，利伐沙班为 0.4%，达比加群为 0.6%。,0.7272727272727273,"['attack', 'transient', 'stroke', 'thromboembolism', 'systemic', 'with', 'dabigatran', 'rivaroxaban', 'transient ischemic attack', 'apixaban', 'and']","['attack', 'transient', 'stroke', 'thromboembolism', 'dabigatran', 'rivaroxaban', 'transient ischemic attack', 'apixaban']",1857,"['血管血管肿瘤的发病率(即血管中风、过渡性血管肿瘤或系统性血管肿瘤)为 apixaban 的 0.2%, rivaroxaban 的 0.4%, dabigatran 的 0.6% 。']",0.0909090909090909,"['attack', 'transient', 'stroke', 'thromboembolism', 'systemic', 'with', 'dabigatran', 'rivaroxaban', 'transient ischemic attack', 'apixaban', 'and']",['stroke'],,
1871,1858,"no accepted standardized protocols exist with which to compare these results ; however , they provide a solid start toward developing a simple protocol with acceptable postoperative risks for bleeding or thromboembolism in AF patients .",不存在可以用来比较这些结果的公认的标准化协议；然而，它们为开发一个简单的方案提供了坚实的开端，该方案具有可接受的 AF 患者术后出血或血栓栓塞风险。,0.4375,"['bleeding', 'a', 'protocol', 'simple', 'thromboembolism', 'solid', 'postoperative', 'developing', 'no', 'compare', 'accepted', 'acceptable', 'exist', 'with', 'start', 'toward']","['bleeding', 'protocol', 'simple', 'thromboembolism', 'compare', 'acceptable', 'exist']",1858,"['没有接受的标准化协议与这些结果进行比较;但是,它们提供了一个坚实的开始,以开发一个简单的协议,手术后可接受的出血或血管肿瘤的风险在AF患者。']",0.3125,"['bleeding', 'a', 'protocol', 'simple', 'thromboembolism', 'solid', 'postoperative', 'developing', 'no', 'compare', 'accepted', 'acceptable', 'exist', 'with', 'start', 'toward']","['bleeding', 'protocol', 'simple', 'compare', 'acceptable']",,
1872,1859,OS was similar between the groups .,各组之间的 OS 相似。,0.0,['similar'],[],1859,['他们在团体之间是相似的。'],1.0,['similar'],['similar'],,
1873,1860,"in a phase 3 trial , we randomly assigned ( in a 2 : 1 ratio ) patients 70 years of age or younger with previously untreated CLL to receive either ibrutinib and rituximab for six cycles ( after a single cycle of ibrutinib alone ) , followed by ibrutinib until disease progression , or six cycles of chemoimmunotherapy with fludarabine , cyclophosphamide , and rituximab .",在一项 3 期试验中，我们随机分配（以 2 : 1 的比例）年龄在 70 岁或以下的既往未接受过治疗的 CLL 患者接受依鲁替尼和利妥昔单抗治疗六个周期（单独依鲁替尼治疗一个周期后） ，随后接受依鲁替尼治疗。直至疾病进展，或使用氟达拉滨、环磷酰胺和利妥昔单抗进行六个周期的化学免疫疗法。,0.6521739130434783,"['cyclophosphamide', 'disease', 'phase', '1', '2', 'ratio', 'untreated', 'cycle', 'progression', 'age', 'after', 'trial', '3', 'with', 'ibrutinib', 'fludarabine', 'CLL', 'single', 'by', 'to', 'and', 'alone', 'we']","['cyclophosphamide', 'disease', 'phase', '1', '2', 'ratio', 'cycle', 'progression', 'age', 'after', 'ibrutinib', 'fludarabine', 'single', 'by', 'alone']",1860,"['在一个阶段3试验中,我们随机分配(在2:1的比例)70岁或更年轻的患者,以前未经治疗的CLL接受ibrutinib和rituximab为六个周期(仅仅一个周期的ibrutinib),随之为ibrutinib直到疾病进展,或六个周期的化学免疫治疗与fludarabine,cyclophosphamide,和rituximab。']",0.3478260869565217,"['cyclophosphamide', 'disease', 'phase', '1', '2', 'ratio', 'untreated', 'cycle', 'progression', 'age', 'after', 'trial', '3', 'with', 'ibrutinib', 'fludarabine', 'CLL', 'single', 'by', 'to', 'and', 'alone', 'we']","['disease', 'phase', '1', '2', 'ratio', 'cycle', 'progression', 'by']",,
1874,1861,we report the results of a planned interim analysis .,我们报告了计划中的中期分析结果。,0.5,"['a', 'analysis', 'report', 'we']","['analysis', 'report']",1861,['我们报告计划的临时分析的结果。'],0.5,"['a', 'analysis', 'report', 'we']","['analysis', 'report']",,
1875,1862,"chronic lymphocytic leukemia ( CLL ) is one of the most common lymphoid cancers , accounting for approximately 11 % of hematologic neoplasms .",慢性淋巴细胞白血病(CLL)是最常见的淋巴癌之一，约占血液肿瘤的11%。,0.375,"['lymphoid', 'leukemia', 'lymphocytic', 'common', 'chronic', 'CLL', 'approximately', 'hematologic']","['lymphoid', 'leukemia', 'chronic']",1862,"['慢性淋巴细胞白血病(CLL)是最常见的淋巴癌症之一,占血液肿瘤的约11%。']",0.375,"['lymphoid', 'leukemia', 'lymphocytic', 'common', 'chronic', 'CLL', 'approximately', 'hematologic']","['lymphoid', 'leukemia', 'chronic']",,
1876,1863,"ibrutinib was initially found to have durable efficacy in patients who had relapsed or refractory CLL.13,14","伊布替尼最初被发现对复发或难治性 CLL 患者具有持久疗效。 13,14",0.2,"['who', 'refractory', 'efficacy', 'ibrutinib', 'have']",['have'],1863,"['ibrutinib 最初被发现具有持久有效性,在患有复发或复发性 CLL 的患者中。']",0.4,"['who', 'refractory', 'efficacy', 'ibrutinib', 'have']","['efficacy', 'have']",,
1877,1864,"eligible participants were previously untreated patients with CLL or the small lymphocytic lymphoma ( SLL ) subtype of CLL who were 70 years of age or younger and who would be appropriate candidates for treatment according to the International Workshop on Chronic Lymphocytic Leukemia ( IWCLL ) Working Group criteria ( see the Supplementary Appendix , available with the full text of this article at NEJM.org ) .16",符合条件的参与者是以前未经治疗的 CLL 或小淋巴细胞淋巴瘤 ( SLL ) 亚型 CLL 患者，年龄不超过 70 岁，并且根据国际慢性淋巴细胞白血病研讨会 ( IWCLL ) 工作组标准，他们是合适的治疗候选人（见补充附录，与本文全文可在 NEJM.org 获取）.16,0.2916666666666667,"['group', 'appendix', 'who', 'leukemia', 'article', 'supplementary', 'untreated', 'lymphocytic', 'be', 'treatment', 'chronic', 'available', 'age', 'lymphoma', 'text', 'with', 'CLL', 'full', 'this', 'to', 'and', 'appropriate', 'eligible', 'workshop']","['group', 'leukemia', 'be', 'treatment', 'chronic', 'age', 'this']",1864,"['合格的参与者是以前未经治疗的患有CLL或小淋巴细胞淋巴(SLL)子类的患者,他们年龄为70岁或年轻,并根据国际慢性淋巴细胞淋巴病研讨会(IWCLL)工作组标准(参见附加附件,可在NEJM.org上找到本文的完整文本)。']",0.4166666666666667,"['group', 'appendix', 'who', 'leukemia', 'article', 'supplementary', 'untreated', 'lymphocytic', 'be', 'treatment', 'chronic', 'available', 'age', 'lymphoma', 'text', 'with', 'CLL', 'full', 'this', 'to', 'and', 'appropriate', 'eligible', 'workshop']","['group', 'appendix', 'be', 'treatment', 'chronic', 'age', 'lymphoma', 'full', 'this', 'eligible']",,
1878,1865,comprehensive eligibility criteria are listed in the Supplementary Appendix .,补充附录中列出了全面的资格标准。,0.0,"['appendix', 'comprehensive', 'supplementary', 'in']",[],1865,['全面可选性标准在附件中列出。'],0.25,"['appendix', 'comprehensive', 'supplementary', 'in']",['appendix'],,
1879,1866,the trial protocol ( available at NEJM.org ) was approved by the National Cancer Institute ( NCI ) central institutional review board and local institutional review boards as required by participating institutions .,试验方案（可在 NEJM.org 获取）根据参与机构的要求获得国家癌症研究所 (NCI) 中央机构审查委员会和地方机构审查委员会的批准。,0.3076923076923077,"['cancer', 'review', 'protocol', 'local', 'central', 'available', 'board', 'institute', 'trial', 'as', 'at', 'by', 'and']","['cancer', 'review', 'protocol', 'institute']",1866,['试验协议(在NEJM.org上可用)由国家癌症研究所(NCI)中央机构审查委员会和当地机构审查委员会根据参与机构的要求批准。'],0.4615384615384615,"['cancer', 'review', 'protocol', 'local', 'central', 'available', 'board', 'institute', 'trial', 'as', 'at', 'by', 'and']","['cancer', 'review', 'protocol', 'institute', 'at', 'by']",,
1880,1867,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],1867,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1881,1867,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],1867,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1882,1867,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],1867,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1883,1867,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],1867,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1884,1867,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],2644,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1885,1867,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],2644,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1886,1867,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],2644,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1887,1867,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],2644,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1888,2644,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],1867,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1889,2644,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],1867,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1890,2644,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],1867,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1891,2644,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],1867,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1892,2644,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],2644,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1893,2644,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],2644,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1894,2644,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],2644,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1895,2644,the trial was conducted in accordance with the principles of the Declaration of Helsinki .,审判是按照赫尔辛基宣言的原则进行的。,0.3333333333333333,"['trial', 'with', 'in']",['trial'],2644,['审判按照赫尔辛基宣言的原则进行。'],0.3333333333333333,"['trial', 'with', 'in']",['trial'],,
1896,1868,the authors reviewed and approved the manuscript for submission for publication and vouch for the accuracy and completeness of the data and for the adherence of the trial to the protocol .,作者审阅并批准投稿发表，并保证数据的准确性和完整性以及试验对方案的依从性。,0.4,"['data', 'accuracy', 'protocol', 'publication', 'manuscript', 'trial', 'completeness', 'submission', 'adherence', 'and']","['data', 'accuracy', 'publication', 'completeness']",1868,"['作者审查并批准了手稿提交出版,并为数据的准确性和完整性以及审判对议定书的遵守。']",0.7,"['data', 'accuracy', 'protocol', 'publication', 'manuscript', 'trial', 'completeness', 'submission', 'adherence', 'and']","['data', 'accuracy', 'protocol', 'publication', 'manuscript', 'trial', 'completeness']",,
1897,1869,ibrutinib was provided by Pharmacyclics ( a subsidiary of AbbVie ) under a cooperative research and development agreement with the NCI .,ibrutinib 由 Pharmacyclics（AbbVie 的子公司）根据与 NCI 的合作研发协议提供。,0.2857142857142857,"['research and development', 'cooperative', 'subsidiary', 'with', 'ibrutinib', 'agreement', 'by']","['research and development', 'by']",1869,['ibrutinib 由 Pharmacyclics ( AbbVie 的子公司 ) 在与 NCI 的合作研究和开发协议下提供。'],0.2857142857142857,"['research and development', 'cooperative', 'subsidiary', 'with', 'ibrutinib', 'agreement', 'by']","['research and development', 'by']",,
1898,1870,patients who were randomly assigned to the chemoimmunotherapy group received six cycles of intravenous fludarabine ( at a dose of 25 mg per square meter ) and cyclophosphamide ( 250 mg per square meter ) on days 1 through 3 with rituximab ( 50 mg per square meter on day 1 of cycle 1 ; 325 mg per square meter on day 2 of cycle 1 ; and 500 mg per square meter on day 1 of cycles 2 through 6 ) every 28 days .,被随机分配到化学免疫治疗组的患者在第 1 天到第 3 天接受了六个周期的静脉注射氟达拉滨（剂量为每平方米 25 毫克）和环磷酰胺（每平方米 250 毫克）和利妥昔单抗（第 5 天每平方米 50 毫克）第 1 周期第 1 次；第 1 周期第 2 天每平方米 325 毫克；第 2 至第 6 周期第 1 天每平方米 500 毫克）每 28 天一次。,0.5294117647058824,"['group', 'cyclophosphamide', 'who', '1', '2', 'meter', 'cycle', 'intravenous', '3', 'with', 'fludarabine', 'at', 'dose', 'on', 'to', 'and', 'square']","['group', 'cyclophosphamide', '1', '2', 'meter', 'cycle', 'fludarabine', 'dose', 'square']",1870,['随机分配给化免疫治疗组的患者在1至3天内接受了6个 intravenous fludarabine(每平方米25毫克的剂量)和cyclophosphamide(每平方米250毫克)的周期(每周1周1周50毫克每平方米325毫克每平方米1周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周2周'],0.4117647058823529,"['group', 'cyclophosphamide', 'who', '1', '2', 'meter', 'cycle', 'intravenous', '3', 'with', 'fludarabine', 'at', 'dose', 'on', 'to', 'and', 'square']","['group', '1', '2', 'meter', 'cycle', 'dose', 'square']",,
1899,1871,"full treatment information , including instructions regarding dose delays and modifications , is provided in the Supplementary Appendix .",补充附录中提供了完整的治疗信息，包括有关剂量延迟和修改的说明。,0.5555555555555556,"['appendix', 'supplementary', 'regarding', 'information', 'treatment', 'dose', 'full', 'and', 'instructions']","['regarding', 'information', 'treatment', 'dose', 'full']",1871,"['完整的治疗信息,包括关于剂量延迟和修改的指示,在附件中提供。']",0.6666666666666666,"['appendix', 'supplementary', 'regarding', 'information', 'treatment', 'dose', 'full', 'and', 'instructions']","['appendix', 'regarding', 'information', 'treatment', 'dose', 'full']",,
1900,1872,all patients received allopurinol ( 300 mg orally once daily ) on days 1 through 14 of cycle 1 .,所有患者在第 1 周期的第 1 天到第 14 天接受别嘌醇（300 毫克，每天口服一次）。,0.5,"['1', 'cycle', 'on', 'all']","['1', 'cycle']",1872,['所有患者在周期1日至14日服用阿洛普林(每日一次口服服300毫克)。'],0.5,"['1', 'cycle', 'on', 'all']","['1', 'cycle']",,
1901,1873,growth factor support was permitted per guidelines of the American Society of Clinical Oncology ( see the Supplementary Appendix ) .18,美国临床肿瘤学会指南允许生长因子支持（见补充附录）.18,0.6666666666666666,"['growth factor', 'support', 'appendix', 'supplementary', 'society', 'clinical']","['growth factor', 'support', 'society', 'clinical']",1873,"['根据美国临床肿瘤学会(参见补充附件)的指导方针,增长因素支持被允许。']",0.6666666666666666,"['growth factor', 'support', 'appendix', 'supplementary', 'society', 'clinical']","['support', 'appendix', 'society', 'clinical']",,
1902,1874,assessments OF SAFETY AND RESPONSE,安全和响应评估,,[],[],1874,['安全与响应评估'],,[],[],,
1903,1875,"all adverse events were graded according to the NCI Common Toxicity Criteria , version 4 .",所有不良事件均根据 NCI 通用毒性标准第 4 版进行分级。,0.1666666666666666,"['toxicity', 'version', 'common', 'adverse', '4', 'all']",['toxicity'],1875,"['所有不良事件都按 NCI 常见毒性标准,版本 4 进行分类。']",0.3333333333333333,"['toxicity', 'version', 'common', 'adverse', '4', 'all']","['toxicity', 'version']",,
1904,1876,"for the purposes of dose modification , adverse events involving platelet count and hemoglobin level were graded according to the IWCLL CLL Working Group grading scale ( see the Supplementary Appendix ) .16",为了调整剂量，涉及血小板计数和血红蛋白水平的不良事件根据 IWCLL CLL 工作组分级量表（见补充附录）进行分级。16,0.4,"['count', 'group', 'modification', 'appendix', 'hemoglobin', 'scale', 'supplementary', 'hemoglobin level', 'adverse', 'platelet', 'CLL', 'dose', 'to', 'and', 'grading']","['count', 'group', 'hemoglobin', 'scale', 'platelet', 'dose']",1876,"['对于剂量调整的目的,包括平板细胞计算和血球水平的副作用根据 IWCLL CLL 工作组评级规模进行评级(参见附件)。']",0.2666666666666666,"['count', 'group', 'modification', 'appendix', 'hemoglobin', 'scale', 'supplementary', 'hemoglobin level', 'adverse', 'platelet', 'CLL', 'dose', 'to', 'and', 'grading']","['group', 'appendix', 'dose', 'to']",,
1905,1877,responses were graded according to the 2008 IWCLL Working Group criteria that were in effect at the start of the trial16 along with the 2018 modification that included the category of complete response with incomplete bone marrow recovery19 ( see the Supplementary Appendix ) .,根据 2008 年 IWCLL 工作组标准对反应进行分级，该标准在试验开始时生效 16 以及 2018 年的修改，其中包括完全反应和不完全骨髓恢复的类别 19（见补充附录）。,0.25,"['group', 'bone', 'modification', 'bone marrow', 'appendix', 'supplementary', 'complete', 'along', 'response', 'incomplete', 'effect', 'with', 'category', 'start', 'that', 'to']","['group', 'bone', 'bone marrow', 'response']",1877,"['答案根据2008 IWCLL 工作组的标准进行评级,该标准在审查开始时有效16 以及2018 年修正案,该修正案包括未完成骨髓恢复的完整答案类别19(参见附件)。']",0.25,"['group', 'bone', 'modification', 'bone marrow', 'appendix', 'supplementary', 'complete', 'along', 'response', 'incomplete', 'effect', 'with', 'category', 'start', 'that', 'to']","['group', 'bone', 'bone marrow', 'appendix']",,
1906,1878,"bone marrow biopsies were performed at enrollment and at 12 months to assess response , with central review by an expert hematopathologist ( see the Supplementary Appendix ) .",骨髓活检在入组时和 12 个月时进行，以评估反应，并由血液病理学家专家进行集中审查（见补充附录）。,0.4615384615384615,"['bone', 'bone marrow', 'appendix', 'review', 'supplementary', 'central', 'response', 'assess', 'with', 'at', 'by', 'to', 'and']","['bone', 'bone marrow', 'review', 'response', 'assess', 'by']",1878,"['骨<unk>生物检测是在注册和12个月进行,以评估反应,由专家血病学家进行中心审查(参见补充附件)。']",0.4615384615384615,"['bone', 'bone marrow', 'appendix', 'review', 'supplementary', 'central', 'response', 'assess', 'with', 'at', 'by', 'to', 'and']","['bone', 'appendix', 'review', 'response', 'assess', 'by']",,
1907,1879,"computed tomographic ( CT ) scans of the chest , abdomen , and pelvis were performed in all patients at enrollment and at the evaluation for response at 12 months .",在入组时和 12 个月时的反应评估时，对所有患者进行了胸部、腹部和骨盆的计算机断层扫描 (CT)。,0.5,"['abdomen', 'pelvis', 'chest', 'evaluation', 'response', 'CT', 'all', 'in', 'and', 'tomographic']","['abdomen', 'pelvis', 'chest', 'response', 'tomographic']",1879,['乳房、腹部和阴道的计算 tomographic (CT ) 扫描在所有患者在注册和评估时进行12个月的回应。'],0.1,"['abdomen', 'pelvis', 'chest', 'evaluation', 'response', 'CT', 'all', 'in', 'and', 'tomographic']",['abdomen'],,
1908,1880,patients alive without documented progression had their data censored at the last disease assessment .,没有记录到进展的存活患者在最后一次疾病评估时对他们的数据进行了审查。,0.8,"['disease', 'data', 'assessment', 'progression', 'without']","['disease', 'data', 'assessment', 'progression']",1880,['未经记录进展的患者在最后一次疾病评估中审查了他们的数据。'],0.8,"['disease', 'data', 'assessment', 'progression', 'without']","['disease', 'data', 'assessment', 'progression']",,
1909,1881,futility rules for harm and inefficacy were included ( see the Supplementary Appendix ) .,伤害和无效的无效规则也包括在内（见补充附录）。,0.25,"['appendix', 'supplementary', 'and', 'futility']",['futility'],1881,['对损害和无效的无效性规则被列入(参见附件)。'],0.5,"['appendix', 'supplementary', 'and', 'futility']","['appendix', 'futility']",,
1910,1882,patients who were alive had their data censored at the last date of contact .,活着的患者在最后一次联系时的数据会被删减。,0.3333333333333333,"['data', 'who', 'date']",['data'],1882,['活着的病人在接触的最后一天被审查了他们的数据。'],0.3333333333333333,"['data', 'who', 'date']",['data'],,
1911,1883,descriptive statistics were used to summarize the characteristics of the patients .,描述性统计用于总结患者的特征。,0.8,"['statistics', 'descriptive', 'characteristics', 'descriptive statistics', 'to']","['statistics', 'descriptive', 'characteristics', 'to']",1883,['描述性统计被用来总结患者的特点。'],0.4,"['statistics', 'descriptive', 'characteristics', 'descriptive statistics', 'to']","['statistics', 'descriptive']",,
1912,1884,"from March 2014 through June 2016 , the trial enrolled 529 patients ( Table 1 ) .",从 2014 年 3 月到 2016 年 6 月，该试验招募了 529 名患者（表 1）。,0.5,"['table', '1', 'march', 'trial']","['table', '1']",1884,"['截至2014年3月至2016年6月,该研究注册了529名患者(表1)。']",0.5,"['table', '1', 'march', 'trial']","['table', '1']",,
1913,1885,the mean number of treatment cycles among all the patients in the chemoimmunotherapy group who started therapy was five ; 67.1 % of these patients ( 106 of 158 patients ) received six cycles .,化学免疫治疗组开始治疗的所有患者的平均治疗周期数为五个；这些患者中有 67.1%（158 名患者中的 106 名）接受了六个周期。,0.5555555555555556,"['group', 'mean', 'who', 'therapy', 'treatment', 'number', 'all', 'five', 'in']","['group', 'mean', 'therapy', 'treatment', 'number']",1885,"['開始治療的化免疫療法群體的所有患者中,治療周期的平均數量為五個;這些患者中有67.1%(106人中有158人)接受了六個周期。']",0.2222222222222222,"['group', 'mean', 'who', 'therapy', 'treatment', 'number', 'all', 'five', 'in']","['group', 'mean']",,
1914,1886,all adverse events of grade 3 or higher that were reported in more than 2 % of the patients in either group are summarized in Table 2 .,表 2 总结了两组中超过 2% 的患者报告的所有 3 级或更高级别的不良事件。,0.3333333333333333,"['group', 'table', '2', 'grade', 'adverse', '3', 'all', 'that', 'in']","['group', 'table', '2']",1886,['任何在任何群体中的患者中报告的3级或更高级别的任何不良事件都被总结在表2中。'],0.3333333333333333,"['group', 'table', '2', 'grade', 'adverse', '3', 'all', 'that', 'in']","['group', 'table', '2']",,
1915,1887,a detailed summary of all adverse events of grade 3 or higher that were attributed by the treating physician to trial treatment is provided in Table S7 in the Supplementary Appendix .,补充附录表 S7 提供了治疗医师归因于试验治疗的所有 3 级或更高级别不良事件的详细总结。,0.2666666666666666,"['a', 'appendix', 'table', 'grade', 'physician', 'supplementary', 'adverse', 'treatment', 'trial', '3', 'all', 'that', 'in', 'by', 'to']","['table', 'physician', 'treatment', 'to']",1887,['3级或更高的所有被治疗医生归因于试验治疗的不良事件的详细概述在附加附件的S7表中提供。'],0.3333333333333333,"['a', 'appendix', 'table', 'grade', 'physician', 'supplementary', 'adverse', 'treatment', 'trial', '3', 'all', 'that', 'in', 'by', 'to']","['appendix', 'table', 'physician', 'treatment', 'to']",,
1916,1888,causes of death are listed in Table S6 in the Supplementary Appendix .,死因列于补充附录表 S6。,0.5,"['appendix', 'table', 'death', 'supplementary', 'causes of death', 'in']","['table', 'death', 'causes of death']",1888,['死亡原因在附件中的S6表中列出。'],0.5,"['appendix', 'table', 'death', 'supplementary', 'causes of death', 'in']","['appendix', 'table', 'death']",,
1917,1889,the proportion of patients who had an adverse event of grade 3 or higher was similar in the two groups .,两组发生 3 级或更高级别不良事件的患者比例相似。,0.3333333333333333,"['proportion', 'who', 'grade', 'adverse', 'adverse event', '3', 'in', 'two', 'similar']","['proportion', 'adverse event', 'two']",1889,['患有3级或更高的副作用的患者比例在两组中相似。'],0.2222222222222222,"['proportion', 'who', 'grade', 'adverse', 'adverse event', '3', 'in', 'two', 'similar']","['proportion', 'two']",,
1918,1890,"three previous trials have shown a survival advantage with one therapy over another among patients with previously untreated CLL.1,2,15","之前的三项试验表明，在先前未治疗的 CLL 患者中，一种疗法比另一种疗法具有生存优势。 1,2,15",0.4,"['a', 'survival', 'previous', 'untreated', 'therapy', 'advantage', 'with', 'have', 'three', 'over']","['survival', 'therapy', 'advantage', 'have']",1890,"['三项以前的研究表明,在未经治疗的CLL患者中,一项治疗对另一项治疗有生存优势。']",0.5,"['a', 'survival', 'previous', 'untreated', 'therapy', 'advantage', 'with', 'have', 'three', 'over']","['survival', 'previous', 'therapy', 'advantage', 'have']",,
1919,1891,"an age of 65 years or older , history of hypertension , and history of atrial fibrillation are risk factors for the development of atrial fibrillation during ibrutinib treatment , 25 which suggests that the lower incidence of cardiac complications in the E1912 trial may be due to the younger patient population ( median age , 58 years ) relative to a pooled analysis of patients participating in other trials ( median age , 67 years ) .25",年龄在 65 岁或以上、高血压病史和房颤病史是依鲁替尼治疗期间发生房颤的危险因素 25 ，这表明 E1912 试验中心脏并发症发生率较低可能是由于年龄较小患者人群（中位年龄，58 岁）相对于参与其他试验的患者（中位年龄，67 岁）的汇总分析 .25,0.5217391304347826,"['atrial', 'cardiac', 'population', 'median', 'incidence', 'hypertension', 'analysis', 'fibrillation', 'relative', 'history', 'lower', 'be', 'atrial fibrillation', 'treatment', 'age', 'risk', 'patient', 'development', 'due', 'ibrutinib', 'median age', 'that', 'and']","['cardiac', 'population', 'incidence', 'hypertension', 'analysis', 'fibrillation', 'be', 'treatment', 'age', 'risk', 'patient', 'ibrutinib']",1891,"['65岁及以上的年龄,高血压史和甲状腺纤维史是甲状腺纤维治疗期间甲状腺纤维发育的风险因素,这表明,在E1912试验中,心脏并发症的发病率较低可能是由于患者人口较年轻(平均年龄,58岁)与其他试验中参与患者的集成分析(平均年龄,67岁)。']",0.4782608695652174,"['atrial', 'cardiac', 'population', 'median', 'incidence', 'hypertension', 'analysis', 'fibrillation', 'relative', 'history', 'lower', 'be', 'atrial fibrillation', 'treatment', 'age', 'risk', 'patient', 'development', 'due', 'ibrutinib', 'median age', 'that', 'and']","['cardiac', 'population', 'incidence', 'hypertension', 'analysis', 'be', 'treatment', 'age', 'risk', 'patient', 'development']",,
1920,1892,"unexplained or unwitnessed death , which can be due to cardiac arrhythmias , was observed in only 1 patient in the E1912 trial , as compared with 11 of 361 patients ( 3 % ) treated with ibrutinib in the Alliance 041202 trial.24",在 E1912 试验中仅观察到 1 例患者因心律失常导致不明原因或无人目击的死亡，而在 Alliance 041202 试验中接受依鲁替尼治疗的 361 例患者中有 11 例 ( 3 % )。 24,0.4285714285714285,"['cardiac', 'alliance', '1', 'death', 'be', 'arrhythmias', 'patient', 'trial', '3', 'unexplained', 'due', 'with', 'ibrutinib', 'to']","['cardiac', '1', 'death', 'be', 'patient', 'ibrutinib']",1892,"['在E1912试验中,只有1名患者死亡,而在联盟 041202试验中,有11名361名患者(3%)接受ibrutinib治疗。']",0.2857142857142857,"['cardiac', 'alliance', '1', 'death', 'be', 'arrhythmias', 'patient', 'trial', '3', 'unexplained', 'due', 'with', 'ibrutinib', 'to']","['1', 'death', 'be', 'patient']",,
1921,1893,"as of the interim analysis , one case of nonfatal cardiac arrest has been observed in the E1912 trial .",截至中期分析，在 E1912 试验中观察到一例非致命性心脏骤停。,0.2857142857142857,"['cardiac', 'arrest', 'analysis', 'cardiac arrest', 'case', 'trial', 'in']","['cardiac', 'analysis']",1893,"['在临时分析中,在E1912审查中发现了一例非致命心脏停滞。']",0.4285714285714285,"['cardiac', 'arrest', 'analysis', 'cardiac arrest', 'case', 'trial', 'in']","['cardiac', 'arrest', 'analysis']",,
1922,1894,several possible factors may contribute to these findings .,几个可能的因素可能促成这些发现。,0.0,['to'],[],1894,['有几个可能的因素可以为这些发现做出贡献。'],0.0,['to'],[],,
1923,1895,"first , more efficacious therapy may contribute more to survival prospects in younger patients with CLL with fewer coexisting conditions , who are less likely than older patients to die from unrelated causes .",首先，更有效的治疗可能对伴有较少合并症的年轻 CLL 患者的生存前景有更大贡献，与老年患者相比，他们死于无关原因的可能性更小。,0.4444444444444444,"['who', 'survival', 'therapy', 'die', 'with', 'CLL', 'in', 'to', 'first']","['survival', 'therapy', 'to', 'first']",1895,"['首先,更有效的治疗可能有助于更年轻的患有CLL的患者的生存前景,这些患者比老年患者更少可能死于不相关原因。']",0.4444444444444444,"['who', 'survival', 'therapy', 'die', 'with', 'CLL', 'in', 'to', 'first']","['survival', 'therapy', 'to', 'first']",,
1924,1896,it is unclear whether these findings can be extrapolated to patients 70 years of age or younger with previously untreated CLL .,目前尚不清楚这些发现是否可以外推至 70 岁或以下的既往未治疗 CLL 患者。,0.0,"['untreated', 'be', 'age', 'with', 'CLL', 'to']",[],1896,['目前尚不清楚这些发现是否可以向70岁以上或未经治疗的CLL患者提取。'],0.0,"['untreated', 'be', 'age', 'with', 'CLL', 'to']",[],,
1925,1897,clinicians often prescribe antibiotics to patients with exacerbations of chronic obstructive pulmonary disease ( COPD ) - especially those with increased sputum volume and discoloration .,临床医生经常给慢性阻塞性肺疾病 (COPD) 恶化的患者开抗生素处方，尤其是那些痰量增加和变色的患者。,0.3846153846153846,"['COPD', 'volume', 'disease', 'sputum', 'obstructive', 'pulmonary', 'chronic', 'prescribe', 'antibiotics', 'with', '-', 'to', 'and']","['COPD', 'disease', 'sputum', 'chronic', 'antibiotics']",1897,['临床医生经常给患有慢性阻塞性肺疾病(COPD)的患者处方抗生素 - 特别是患有肿瘤数量增加和分色。'],0.3076923076923077,"['COPD', 'volume', 'disease', 'sputum', 'obstructive', 'pulmonary', 'chronic', 'prescribe', 'antibiotics', 'with', '-', 'to', 'and']","['COPD', 'disease', 'chronic', 'antibiotics']",,
1926,1898,"however , the evidence supporting antibiotic therapy is mixed .",然而，支持抗生素治疗的证据不一。,0.5,"['antibiotic', 'antibiotic therapy', 'mixed', 'evidence']","['antibiotic', 'evidence']",1898,"['然而,支持抗生素治疗的证据是混合的。']",0.75,"['antibiotic', 'antibiotic therapy', 'mixed', 'evidence']","['antibiotic', 'mixed', 'evidence']",,
1927,1899,clinical outcomes such as general health status and eventual need for hospitalization were similar in the two groups .,两组的一般健康状况和最终住院需要等临床结果相似。,0.5454545454545454,"['need', 'health', 'general', 'status', 'hospitalization', 'clinical', 'as', 'eventual', 'and', 'two', 'similar']","['need', 'health', 'status', 'hospitalization', 'clinical', 'two']",1899,"['临床结果,如整体健康状况和可能需要入院等,在两组中相似。']",0.5454545454545454,"['need', 'health', 'general', 'status', 'hospitalization', 'clinical', 'as', 'eventual', 'and', 'two', 'similar']","['need', 'health', 'status', 'clinical', 'as', 'two']",,
1928,1900,formal weight loss programs were associated with improved biomarkers for liver disease in patients with NAFLD .,正式的减肥计划与 NAFLD 患者肝病生物标志物的改善有关。,0.4,"['liver', 'disease', 'weight', 'liver disease', 'formal', 'associated', 'loss', 'with', 'weight loss', 'in']","['liver', 'disease', 'liver disease', 'formal']",1900,['正式的减肥计划与纳菲尔德患者的肝脏疾病的改善生物标志相结合。'],0.3,"['liver', 'disease', 'weight', 'liver disease', 'formal', 'associated', 'loss', 'with', 'weight loss', 'in']","['liver', 'disease', 'formal']",,
1929,1901,"as there is no licensed pharmacologic therapy for the treatment of nonalcoholic fatty liver disease ( NAFLD ) , clinical guidelines recommend counseling patients to lose weight through modifying diet and exercise .",由于尚无治疗非酒精性脂肪性肝病 (NAFLD) 的许可药物疗法，临床指南建议建议患者通过调整饮食和锻炼来减轻体重。,0.6470588235294118,"['liver', 'disease', 'weight', 'fatty liver', 'diet', 'exercise', 'liver disease', 'recommend', 'therapy', 'lose', 'treatment', 'no', 'clinical', 'counseling', 'pharmacologic', 'to', 'and']","['liver', 'disease', 'weight', 'diet', 'exercise', 'liver disease', 'recommend', 'therapy', 'treatment', 'clinical', 'to']",1901,"['由于没有许可的药物治疗,以治疗非酒精脂肪肝疾病(NAFLD),临床指南建议建议患者通过改变饮食和锻炼来减肥。']",0.5882352941176471,"['liver', 'disease', 'weight', 'fatty liver', 'diet', 'exercise', 'liver disease', 'recommend', 'therapy', 'lose', 'treatment', 'no', 'clinical', 'counseling', 'pharmacologic', 'to', 'and']","['liver', 'disease', 'fatty liver', 'diet', 'exercise', 'recommend', 'therapy', 'treatment', 'clinical', 'to']",,
1930,1902,"however , guidelines fall short of recommending any specific weight loss intervention .",然而，指南并未推荐任何具体的减肥干预措施。,0.0,"['weight', 'short', 'fall', 'loss', 'intervention', 'specific', 'fall short', 'weight loss', 'specific weight']",[],1902,"['然而,指令缺乏推荐任何具体的减肥干预。']",0.0,"['weight', 'short', 'fall', 'loss', 'intervention', 'specific', 'fall short', 'weight loss', 'specific weight']",[],,
1931,1903,the median treatment duration was 6 months .,中位治疗持续时间为 6 个月。,0.6666666666666666,"['median', 'treatment', 'duration']","['treatment', 'duration']",1903,['平均治疗时间为6个月。'],0.3333333333333333,"['median', 'treatment', 'duration']",['treatment'],,
1932,1904,"researchers assessed the intensity of interventions based on the degree of behavioral support , prescribed energy deficit , or pharmacologic dose .",研究人员根据行为支持的程度、规定的能量不足或药物剂量来评估干预的强度。,0.5555555555555556,"['energy', 'support', 'deficit', 'degree', 'intensity', 'dose', 'on', 'pharmacologic', 'assessed']","['energy', 'support', 'deficit', 'degree', 'dose']",1904,"['研究人员评估了干预的强度,基于行为支持程度、处方能量短缺或药物剂量。']",0.4444444444444444,"['energy', 'support', 'deficit', 'degree', 'intensity', 'dose', 'on', 'pharmacologic', 'assessed']","['energy', 'support', 'degree', 'dose']",,
1933,1905,"however , weight loss interventions did not improve liver fibrosis .",然而，减肥干预并没有改善肝纤维化。,0.3333333333333333,"['liver', 'weight', 'fibrosis', 'loss', 'liver fibrosis', 'weight loss']","['liver', 'fibrosis']",1905,"['然而,减肥干预并没有改善肝纤维。']",0.1666666666666666,"['liver', 'weight', 'fibrosis', 'loss', 'liver fibrosis', 'weight loss']",['liver'],,
1934,1906,"in subgroup analysis , behavioral interventions improved liver steatosis , but pharmacotherapy did not .",在亚组分析中，行为干预改善了肝脂肪变性，但药物治疗没有。,0.5714285714285714,"['liver', 'analysis', 'steatosis', 'pharmacotherapy', 'subgroup', 'in', 'but']","['liver', 'analysis', 'steatosis', 'but']",1906,"['在子组分析中,行为干预改善了肝静化,但药物治疗没有。']",0.4285714285714285,"['liver', 'analysis', 'steatosis', 'pharmacotherapy', 'subgroup', 'in', 'but']","['liver', 'analysis', 'but']",,
1935,1907,estimates were largely unaffected when excluding 12 studies at high risk for bias and 7 at unclear risk .,当排除 12 项高偏倚风险研究和 7 项风险不明研究时，估计值基本未受影响。,0.5,"['bias', 'high risk', 'at', 'and']","['bias', 'at']",1907,['估计在排除12项高风险的研究和7项不明确风险的研究时大多没有影响。'],0.0,"['bias', 'high risk', 'at', 'and']",[],,
1936,1908,formal weight loss interventions appear to improve biomarkers for liver disease in patients with NAFLD .,正式的减肥干预措施似乎可以改善 NAFLD 患者肝病的生物标志物。,0.4,"['liver', 'disease', 'weight', 'liver disease', 'formal', 'loss', 'with', 'weight loss', 'in', 'to']","['liver', 'disease', 'liver disease', 'formal']",1908,['正式的减肥干预似乎在患有NAFLD的患者中改善了肝脏疾病的生物标志。'],0.3,"['liver', 'disease', 'weight', 'liver disease', 'formal', 'loss', 'with', 'weight loss', 'in', 'to']","['liver', 'disease', 'formal']",,
1937,1909,"pharmacotherapy alone did not impact liver steatosis , which is in line with current evidence indicating that no pharmacologic therapy appears to be effective in NAFLD .",单独的药物治疗不会影响肝脂肪变性，这与目前的证据一致，表明没有药物治疗似乎对 NAFLD 有效。,0.4285714285714285,"['liver', 'in line', 'therapy', 'be', 'impact', 'no', 'steatosis', 'current', 'evidence', 'pharmacotherapy', 'with', 'pharmacologic', 'that', 'alone']","['liver', 'therapy', 'impact', 'steatosis', 'evidence', 'alone']",1909,"['单独的药物治疗没有影响肝固化,这与目前的证据一致,表明没有药物治疗似乎在NAFLD中有效。']",0.4285714285714285,"['liver', 'in line', 'therapy', 'be', 'impact', 'no', 'steatosis', 'current', 'evidence', 'pharmacotherapy', 'with', 'pharmacologic', 'that', 'alone']","['liver', 'therapy', 'be', 'impact', 'evidence', 'alone']",,
1938,1910,"unfortunately , liver fibrosis did not improve , but this is not surprising given the short treatment duration .",不幸的是，肝纤维化没有改善，但考虑到治疗持续时间短，这并不奇怪。,0.75,"['liver', 'fibrosis', 'short', 'treatment', 'liver fibrosis', 'duration', 'this', 'but']","['liver', 'fibrosis', 'treatment', 'duration', 'this', 'but']",1910,"['不幸的是,肝炎并没有改善,但这并不奇怪,因为治疗时间很短。']",0.5,"['liver', 'fibrosis', 'short', 'treatment', 'liver fibrosis', 'duration', 'this', 'but']","['liver', 'treatment', 'this', 'but']",,
1939,1911,I agree with authors of an accompanying editorial that these results should encourage all clinicians to incorporate formal weight loss programs into their treatment of NAFLD .,我同意随附社论的作者的观点，即这些结果应该鼓励所有临床医生将正式的减肥计划纳入他们对 NAFLD 的治疗。,0.3076923076923077,"['weight', 'formal', 'loss', 'treatment', 'incorporate', 'agree', 'encourage', 'with', 'weight loss', 'I', 'all', 'that', 'to']","['formal', 'treatment', 'agree', 'encourage']",1911,"['我同意附属编辑的作者,这些结果应该鼓励所有诊所医生将正式的减肥计划纳入他们的治疗NAFLD。']",0.3076923076923077,"['weight', 'formal', 'loss', 'treatment', 'incorporate', 'agree', 'encourage', 'with', 'weight loss', 'I', 'all', 'that', 'to']","['formal', 'treatment', 'agree', 'encourage']",,
1940,1912,a total of 653 patients underwent randomization .,共有 653 名患者接受了随机分组。,0.3333333333333333,"['a', 'randomization', 'total']",['randomization'],1912,['总共有653名患者遭到随机化。'],0.3333333333333333,"['a', 'randomization', 'total']",['randomization'],,
1941,1913,"primary care providers are responsible for the majority of antibiotic prescriptions , and the highest overall number of such prescriptions are issued by family physicians.1",初级保健提供者负责大部分抗生素处方，而此类处方的总数最多是由家庭医生开出的。 1,0.5555555555555556,"['family', 'antibiotic', 'primary', 'number', 'care', 'majority', 'prescriptions', 'issued by', 'and']","['family', 'antibiotic', 'number', 'prescriptions', 'and']",1913,"['初级护理提供商对抗生素处方的多数负责,这些处方的总数最高由家庭医生发出。']",0.4444444444444444,"['family', 'antibiotic', 'primary', 'number', 'care', 'majority', 'prescriptions', 'issued by', 'and']","['family', 'antibiotic', 'number', 'prescriptions']",,
1942,1914,"there is reason to believe that many of these prescriptions could be avoided.2,3","有理由相信其中许多处方是可以避免的。 2,3",0.3333333333333333,"['reason', 'be', 'believe', 'prescriptions', 'that', 'to']","['reason', 'prescriptions']",1914,"['有理由相信,许多这些处方可以避免。']",0.3333333333333333,"['reason', 'be', 'believe', 'prescriptions', 'that', 'to']","['reason', 'prescriptions']",,
1943,1915,"chronic obstructive pulmonary disease ( COPD ) was the third leading cause of death in the United States in 2014,15 and 6.4 % of Americans reported receiving a diagnosis of the condition.16",慢性阻塞性肺病 (COPD) 是 2014 年美国第三大死亡原因，15 6.4% 的美国人报告被诊断患有此病。 16,0.5833333333333334,"['COPD', 'disease', 'death', 'obstructive', 'pulmonary', 'diagnosis', 'chronic', 'cause', 'cause of death', 'leading', 'and', 'third']","['COPD', 'disease', 'death', 'diagnosis', 'chronic', 'cause', 'third']",1915,"['慢性抑制性肺疾病(COPD)是美国2014年第三大死亡原因,15%和6.4%的美国人报告得出这种疾病的诊断。']",0.5833333333333334,"['COPD', 'disease', 'death', 'obstructive', 'pulmonary', 'diagnosis', 'chronic', 'cause', 'cause of death', 'leading', 'and', 'third']","['COPD', 'disease', 'death', 'diagnosis', 'chronic', 'cause', 'third']",,
1944,1916,"about 2 % of the adult population in the United Kingdom have a diagnosis of COPD in their primary care medical record.17,18","在英国，大约 2% 的成年人口在他们的初级保健医疗记录中被诊断为 COPD。 17,18",0.5,"['population', 'COPD', '2', 'medical', 'diagnosis', 'primary', 'adult', 'kingdom', 'care', 'have']","['population', 'COPD', '2', 'diagnosis', 'adult']",1916,['大约有2%的英国成年人口在他们的初级医疗记录中被诊断为COPD。'],0.6,"['population', 'COPD', '2', 'medical', 'diagnosis', 'primary', 'adult', 'kingdom', 'care', 'have']","['population', 'COPD', '2', 'diagnosis', 'adult', 'have']",,
1945,1917,"each year , approximately half the patients living with COPD have one or more acute exacerbations of the disease that leads to treatment with oral glucocorticoids , antibiotics , or both or hospitalization , and a quarter have two or more acute exacerbations per year.19,20","每年，大约一半的 COPD 患者有一次或多次疾病急性加重，导致口服糖皮质激素、抗生素或两者兼用治疗或住院治疗，四分之一的患者每年有两次或两次以上急性加重。 19,20",0.4285714285714285,"['COPD', 'disease', 'year', 'half', 'oral', 'quarter', 'hospitalization', 'treatment', 'acute', 'living', 'antibiotics', 'with', 'glucocorticoids', 'have', 'approximately', 'that', 'each', 'to', 'and', 'two', 'leads']","['COPD', 'disease', 'year', 'half', 'hospitalization', 'treatment', 'antibiotics', 'have', 'two']",1917,"['每年,大约一半患有COPD的患者患有一种或多种急性疾病恶化,导致口服糖尿病、抗生素或两种治疗或入院,四分之一每年有两种或多种急性恶化。']",0.4285714285714285,"['COPD', 'disease', 'year', 'half', 'oral', 'quarter', 'hospitalization', 'treatment', 'acute', 'living', 'antibiotics', 'with', 'glucocorticoids', 'have', 'approximately', 'that', 'each', 'to', 'and', 'two', 'leads']","['COPD', 'disease', 'year', 'half', 'quarter', 'treatment', 'antibiotics', 'have', 'two']",,
1946,1918,"more than 80 % of these patients receive antibiotic prescriptions in the United States21,22 and in Europe.23",在美国 21、22 和欧洲，超过 80% 的这些患者接受了抗生素处方。 23,0.5,"['antibiotic', 'prescriptions', 'in', 'and']","['antibiotic', 'prescriptions']",1918,"['超过80%的这些患者在美国接受抗生素处方21,22和欧洲。']",0.5,"['antibiotic', 'prescriptions', 'in', 'and']","['antibiotic', 'prescriptions']",,
1947,1919,noninfectious factors were thought to cause approximately 20 % of acute exacerbations of COPD in a hospital study.27,在一项医院研究中，非感染性因素被认为导致了大约 20% 的 COPD 急性加重。 27,0.2222222222222222,"['COPD', 'a', 'thought', 'cause', 'acute', 'hospital', 'approximately', 'in', 'to']","['COPD', 'hospital']",1919,['非感染因素被认为在医院研究中导致大约20%的COPD急剧加剧。'],0.2222222222222222,"['COPD', 'a', 'thought', 'cause', 'acute', 'hospital', 'approximately', 'in', 'to']","['COPD', 'hospital']",,
1948,1920,the guidelines of the Global Initiative for Chronic Obstructive Lung Disease recommend the use of antibiotics in moderately or severely ill patients with acute exacerbations of COPD who have increased cough and sputum purulence.28,慢性阻塞性肺病全球倡议的指南建议对咳嗽和脓痰加重的中度或重度慢性阻塞性肺病急性加重患者使用抗生素。 28,0.4444444444444444,"['lung', 'COPD', 'disease', 'sputum', 'who', 'global', 'obstructive', 'recommend', 'moderately', 'cough', 'chronic', 'ill', 'acute', 'antibiotics', 'initiative', 'with', 'have', 'and']","['lung', 'disease', 'sputum', 'global', 'recommend', 'cough', 'chronic', 'antibiotics']",1920,"['全球慢性阻塞性肺病倡议的指导方针建议在患有急性COPD加剧的患者中使用抗生素,并增加了咳嗽和肿瘤发烧。']",0.5,"['lung', 'COPD', 'disease', 'sputum', 'who', 'global', 'obstructive', 'recommend', 'moderately', 'cough', 'chronic', 'ill', 'acute', 'antibiotics', 'initiative', 'with', 'have', 'and']","['lung', 'COPD', 'disease', 'global', 'recommend', 'cough', 'chronic', 'antibiotics', 'have']",,
1949,1921,"recommendations for antibiotic prescribing in primary care practice are generally based on clinical features alone ( e.g. , the Anthonisen criteria , 29 which include increased dyspnea , increased sputum volume , and increased sputum purulence ) , but these features are subjective and insufficiently accurate in predicting which patients can be treated safely without antibiotics.24",初级保健实践中抗生素处方的建议通常仅基于临床特征（例如 Anthonisen 标准， 29 其中包括呼吸困难增加、痰量增加和痰液化脓增加） ，但这些特征是主观的并且在预测哪些患者时不够准确。无需抗生素即可安全治疗。 24,0.5625,"['antibiotic', 'volume', 'sputum', 'dyspnea', 'subjective', 'accurate', 'be', 'primary', 'clinical', 'practice', 'care', 'on', 'but', 'and', 'alone', 'without']","['antibiotic', 'sputum', 'dyspnea', 'subjective', 'be', 'clinical', 'practice', 'but', 'without']",1921,"['在初级护理实践中处方抗生素的建议通常仅基于临床特征(例如,安东尼森标准,29包括增加<unk>疹、增加<unk>丸容量和增加<unk>丸发烧),但这些特征是主观的,并且在预测哪些患者可以安全地治疗没有抗生素时不够准确。']",0.375,"['antibiotic', 'volume', 'sputum', 'dyspnea', 'subjective', 'accurate', 'be', 'primary', 'clinical', 'practice', 'care', 'on', 'but', 'and', 'alone', 'without']","['antibiotic', 'subjective', 'be', 'clinical', 'practice', 'but']",,
1950,1922,"a randomized , controlled trial involving patients with acute exacerbations of COPD recruited from primary care practices showed little difference in the rate of clinical cure with either antibiotics or placebo among those who had a CRP level of less than 40 mg per liter.32",一项涉及从初级保健机构招募的慢性阻塞性肺病急性加重患者的随机对照试验显示，在 CRP 水平低于 40 毫克/升的患者中，使用抗生素或安慰剂的临床治愈率几乎没有差异。 32,0.5,"['COPD', 'placebo', 'cure', 'who', 'rate', 'difference', 'controlled', 'primary', 'clinical', 'trial', 'acute', 'antibiotics', 'level', 'care', 'with', 'controlled trial']","['placebo', 'cure', 'rate', 'difference', 'clinical', 'antibiotics', 'level', 'controlled trial']",1922,"['一项随机控制的研究,涉及从初级护理实践中招聘的急性COPD恶化患者,在那些患有CRP水平低于每升40毫克的人中,对抗生素或 placebo的临床治疗率的差异很小。']",0.5,"['COPD', 'placebo', 'cure', 'who', 'rate', 'difference', 'controlled', 'primary', 'clinical', 'trial', 'acute', 'antibiotics', 'level', 'care', 'with', 'controlled trial']","['COPD', 'cure', 'rate', 'difference', 'controlled', 'clinical', 'antibiotics', 'level']",,
1951,1923,the trial involved patients recruited from 86 general medical practices in the United Kingdom .,该试验涉及从英国 86 家普通医疗机构招募的患者。,0.0,"['general', 'medical', 'kingdom', 'trial']",[],1923,['该研究涉及来自英国86个一般医学实践的患者。'],0.0,"['general', 'medical', 'kingdom', 'trial']",[],,
1952,1924,"the Research Ethics Committee for Wales , recognized by the United Kingdom Ethics Committee Authority , approved the trial protocol on September 15 , 2014 , as well as the inclusion of all the recruitment sites in the trial .",由英国伦理委员会管理局认可的威尔士研究伦理委员会于 2014 年 9 月 15 日批准了试验方案，并将所有招募地点纳入试验。,0.3333333333333333,"['research', 'inclusion', 'protocol', 'ethics', 'recruitment', 'well', 'kingdom', 'committee', 'trial', 'as', 'all', 'by']","['research', 'protocol', 'committee', 'by']",1924,"['2014年9月15日,英国伦理委员会认可的威尔士研究伦理委员会批准了审判议定书,并将所有招聘网站纳入审判。']",0.3333333333333333,"['research', 'inclusion', 'protocol', 'ethics', 'recruitment', 'well', 'kingdom', 'committee', 'trial', 'as', 'all', 'by']","['research', 'protocol', 'committee', 'trial']",,
1953,1925,health boards and clinical commissioning groups of the National Health Service gave research and development approval to participating sites .,国家卫生服务局的卫生委员会和临床委托小组批准了参与地点的研发。,0.5714285714285714,"['research and development', 'approval', 'health', 'service', 'clinical', 'commissioning', 'to']","['research and development', 'approval', 'health', 'clinical']",1925,['国家卫生服务的卫生委员会和临床委托小组给了参与网站的研究和开发批准。'],0.5714285714285714,"['research and development', 'approval', 'health', 'service', 'clinical', 'commissioning', 'to']","['research and development', 'approval', 'health', 'clinical']",,
1954,1926,written informed consent was obtained from all the patients by the responsible primary care physician or an appropriately trained staff member .,负责的初级保健医生或经过适当培训的工作人员从所有患者处获得了书面知情同意书。,0.3333333333333333,"['staff', 'physician', 'primary', 'member', 'consent', 'informed consent', 'care', 'all', 'by']","['physician', 'consent', 'by']",1926,"['从所有患者获得书面信息的同意,由负责的初级护理医生或适当训练有素的员工。']",0.3333333333333333,"['staff', 'physician', 'primary', 'member', 'consent', 'informed consent', 'care', 'all', 'by']","['physician', 'consent', 'by']",,
1955,1927,the authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol .,作者保证数据的准确性和完整性以及试验对方案的忠实度。,0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'completeness']",1927,['作者保证数据的准确性和完整性以及审判对议定书的忠诚性。'],0.7142857142857143,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
1956,1927,the authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol .,作者保证数据的准确性和完整性以及试验对方案的忠实度。,0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'completeness']",1927,['作者保证数据的准确性和完整性以及审判对议定书的忠诚性。'],0.7142857142857143,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
1957,1927,the authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol .,作者保证数据的准确性和完整性以及试验对方案的忠实度。,0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'completeness']",1927,['作者保证数据的准确性和完整性以及审判对议定书的忠诚性。'],0.7142857142857143,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
1958,1927,the authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol .,作者保证数据的准确性和完整性以及试验对方案的忠实度。,0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'completeness']",1927,['作者保证数据的准确性和完整性以及审判对议定书的忠诚性。'],0.7142857142857143,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
1959,1928,an independent trial steering committee and a data monitoring and ethics committee provided trial oversight .,一个独立的试验指导委员会和一个数据监测和伦理委员会提供试验监督。,0.4444444444444444,"['monitoring', 'a', 'data', 'steering', 'ethics', 'committee', 'trial', 'independent', 'and']","['monitoring', 'data', 'committee', 'independent']",1928,['一个独立的审判管理委员会和一个数据监测和伦理委员会提供审判监督。'],0.5555555555555556,"['monitoring', 'a', 'data', 'steering', 'ethics', 'committee', 'trial', 'independent', 'and']","['monitoring', 'data', 'committee', 'trial', 'independent']",,
1960,1929,"the staff members at the general medical practices were trained in the use , care , and calibration of the devices by representatives of Alere ( at no cost to the trial or to the practices ) or by members of the trial team .",一般医疗机构的工作人员接受了 Alere 代表或试验团队成员的设备使用、保养和校准方面的培训（试验或医疗机构无需支付任何费用）。,0.1333333333333333,"['calibration', 'members', 'staff', 'general', 'medical', 'team', 'no', 'trial', 'cost', 'at no', 'care', 'in', 'by', 'to', 'and']","['calibration', 'team']",1929,['一般医学实践的员工在使用、照顾和调节设备方面由Aleer的代表(没有考验或实践的代价)或考验团队的成员进行培训。'],0.2,"['calibration', 'members', 'staff', 'general', 'medical', 'team', 'no', 'trial', 'cost', 'at no', 'care', 'in', 'by', 'to', 'and']","['team', 'cost', 'by']",,
1961,1930,"the company had no role in the design of the trial ; in the accrual , analysis , or interpretation of the data ; or in the preparation of the manuscript .",公司未参与试验设计；在数据的累积、分析或解释中；或在准备手稿。,0.6666666666666666,"['data', 'analysis', 'preparation', 'interpretation', 'role', 'no', 'manuscript', 'trial', 'design']","['data', 'analysis', 'preparation', 'interpretation', 'manuscript', 'design']",1930,['公司在审判的设计中没有任何作用;在数据的收集、分析或解释中;或在手稿的编制中。'],0.7777777777777778,"['data', 'analysis', 'preparation', 'interpretation', 'role', 'no', 'manuscript', 'trial', 'design']","['data', 'analysis', 'interpretation', 'role', 'manuscript', 'trial', 'design']",,
1962,1931,two participating practices used their own CRP test device .,两个参与实践使用了他们自己的 CRP 测试设备。,0.6666666666666666,"['device', 'test', 'two']","['device', 'two']",1931,['兩個參與實踐使用自己的CRP測試裝置。'],0.0,"['device', 'test', 'two']",[],,
1963,1932,patients who were 40 years of age or older were eligible for inclusion if they had a diagnosis of COPD in their primary care clinical record and were presenting with an acute exacerbation of COPD with at least one of the Anthonisen criteria .,年龄在 40 岁或以上的患者如果在其初级保健临床记录中诊断为 COPD 并且出现 COPD 急性加重并至少符合 Anthonisen 标准之一，则符合入选条件。,0.3125,"['record', 'COPD', 'a', 'who', 'inclusion', 'exacerbation', 'diagnosis', 'primary', 'clinical', 'age', 'acute', 'care', 'with', 'if', 'and', 'eligible']","['record', 'COPD', 'diagnosis', 'clinical', 'age']",1932,"['40岁及以上的患者,如果他们在他们的初级护理临床记录中被诊断为COPD,并且具有至少一个Anthonisen标准的COPD急剧加剧。']",0.25,"['record', 'COPD', 'a', 'who', 'inclusion', 'exacerbation', 'diagnosis', 'primary', 'clinical', 'age', 'acute', 'care', 'with', 'if', 'and', 'eligible']","['record', 'COPD', 'diagnosis', 'clinical']",,
1964,1933,"a full list of inclusion and exclusion criteria is provided in Section 1 in the Supplementary Appendix , available at NEJM.org .",补充附录第 1 部分提供了纳入和排除标准的完整列表，补充附录可在 NEJM.org 获取。,0.1666666666666666,"['a', 'appendix', 'inclusion', '1', 'section', 'supplementary', 'exclusion', 'available', 'list', 'at', 'full', 'and']","['1', 'full']",1933,"['包含和排除标准的完整列表在附加附件第1节中提供,可在NEJM.org上找到。']",0.3333333333333333,"['a', 'appendix', 'inclusion', '1', 'section', 'supplementary', 'exclusion', 'available', 'list', 'at', 'full', 'and']","['appendix', 'inclusion', '1', 'full']",,
1965,1934,clinicians recorded their antibiotic prescribing and other management decisions after randomization on a case report form .,临床医生在病例报告表上记录了随机分组后他们的抗生素处方和其他管理决定。,0.75,"['antibiotic', 'form', 'randomization', 'report', 'case', 'after', 'case report', 'management']","['antibiotic', 'randomization', 'report', 'case', 'after', 'management']",1934,['临床医生记录了他们的抗生素处方和其他管理决策后随机化案例报告表格。'],0.75,"['antibiotic', 'form', 'randomization', 'report', 'case', 'after', 'case report', 'management']","['antibiotic', 'randomization', 'report', 'case', 'after', 'management']",,
1966,1935,additional details regarding trial procedures are provided in Section 2 in the Supplementary Appendix .,补充附录第 2 部分提供了有关试验程序的更多详细信息。,0.2857142857142857,"['appendix', '2', 'section', 'supplementary', 'regarding', 'additional', 'trial']","['2', 'regarding']",1935,['有关审判程序的详细信息如附件第2节所示。'],0.5714285714285714,"['appendix', '2', 'section', 'supplementary', 'regarding', 'additional', 'trial']","['appendix', '2', 'regarding', 'trial']",,
1967,1936,all the participating sites were provided with a summary of guidance from the National Institute for Health and Care Excellence and the Global Initiative for Chronic Obstructive Lung Disease .,所有参与地点都收到了国家健康与护理卓越研究所和慢性阻塞性肺病全球倡议的指导摘要。,0.4285714285714285,"['lung', 'disease', 'global', 'obstructive', 'health', 'chronic', 'institute', 'care', 'excellence', 'initiative', 'with', 'all', 'and', 'guidance']","['lung', 'disease', 'global', 'health', 'chronic', 'institute']",1936,['所有参与的网站都提供了国家卫生和护理卓越研究所和慢性阻塞性肺疾病全球倡议的指导总结。'],0.4285714285714285,"['lung', 'disease', 'global', 'obstructive', 'health', 'chronic', 'institute', 'care', 'excellence', 'initiative', 'with', 'all', 'and', 'guidance']","['lung', 'disease', 'global', 'health', 'chronic', 'institute']",,
1968,1937,"the guidance noted that for patients with a CRP level lower than 20 mg per liter , antibiotics are unlikely to be beneficial and usually should not be prescribed ; for those with a CRP level from 20 to 40 mg per liter , antibiotics may be beneficial , mainly if purulent sputum is present ; and for those with a CRP level higher than 40 mg per liter , antibiotics are likely to be beneficial.24",该指南指出，对于 CRP 水平低于 20 毫克/升的患者，抗生素不太可能有益，通常不应开处方；对于 CRP 水平为 20 至 40 毫克/升的患者，抗生素可能有益，主要是在出现脓性痰时；对于 CRP 水平高于每升 40 毫克的人，抗生素可能是有益的。 24,0.5,"['a', 'liter', 'sputum', 'lower', 'be', 'present', 'antibiotics', 'level', 'with', 'that', 'if', 'to', 'and', 'guidance']","['liter', 'sputum', 'be', 'present', 'antibiotics', 'level', 'to']",1937,"['指南指出,对于患有CRP水平低于每升20毫克的患者,抗生素是不可能有益的,通常不应处方;对于患有CRP水平从每升20至40毫克的人,抗生素可能有益,主要是如果有发烧性斑点;对于患有CRP水平高于每升40毫克的人,抗生素可能有益。']",0.2857142857142857,"['a', 'liter', 'sputum', 'lower', 'be', 'present', 'antibiotics', 'level', 'with', 'that', 'if', 'to', 'and', 'guidance']","['liter', 'antibiotics', 'level', 'to']",,
1969,1938,"given the noninferiority research question , we were interested in the upper limit of the confidence interval of the adjusted mean difference .",考虑到非劣效性研究问题，我们对调整均值差的置信区间上限感兴趣。,0.5,"['interval', 'mean', 'research', 'question', 'upper', 'difference', 'confidence interval', 'limit', 'upper limit', 'we']","['interval', 'research', 'question', 'confidence interval', 'upper limit']",1938,"['考虑到非较低的研究问题,我们对调整的平均差异的信任间隔的上限感兴趣。']",0.6,"['interval', 'mean', 'research', 'question', 'upper', 'difference', 'confidence interval', 'limit', 'upper limit', 'we']","['interval', 'mean', 'research', 'question', 'difference', 'upper limit']",,
1970,1939,additional details on the sample size justification are provided in Section 3 in the Supplementary Appendix .,补充附录第 3 部分提供了关于样本量合理性的更多详细信息。,0.1,"['sample', 'appendix', 'section', 'supplementary', 'justification', 'size', 'additional', '3', 'sample size', 'in']",['sample'],1939,['关于样品尺寸证明的额外细节如附件第3节所示。'],0.3,"['sample', 'appendix', 'section', 'supplementary', 'justification', 'size', 'additional', '3', 'sample size', 'in']","['sample', 'appendix', 'size']",,
1971,1940,the model was adjusted for the number of Anthonisen criteria present before randomization .,该模型根据随机化前存在的 Anthonisen 标准数量进行了调整。,0.8,"['model', 'randomization', 'number', 'present', 'before']","['model', 'randomization', 'number', 'before']",1940,['该模型适用于在随机化之前存在的Anthonisen标准的数量。'],0.8,"['model', 'randomization', 'number', 'present', 'before']","['model', 'randomization', 'number', 'before']",,
1972,1941,full details of the subgroup analyses are provided in Section 9 in the Supplementary Appendix .,补充附录第 9 部分提供了亚组分析的全部细节。,0.1666666666666666,"['appendix', 'section', 'supplementary', 'subgroup', 'full', 'in']",['full'],1941,['对子组分析的完整细节如附件第9节所示。'],0.3333333333333333,"['appendix', 'section', 'supplementary', 'subgroup', 'full', 'in']","['appendix', 'full']",,
1973,1942,"between January 2015 and February 2017 , a total of 653 patients from 86 general medical practices underwent randomization ( Figure 1 ) .",2015 年 1 月至 2017 年 2 月期间，共有来自 86 家普通医疗机构的 653 名患者接受了随机分组（图 1）。,0.2857142857142857,"['a', 'randomization', '1', 'figure', 'general', 'medical', 'total']","['randomization', '1']",1942,"['2015 年 1 月至 2017 年 2 月之間,共有 653 人從 86 個一般醫療實踐中經歷過 randomization ( 圖 1 ) 。']",0.1428571428571428,"['a', 'randomization', '1', 'figure', 'general', 'medical', 'total']",['1'],,
1974,1943,the trial groups were well matched at baseline ( Table 1 ) .,试验组在基线时匹配良好（表 1）。,0.5,"['table', 'baseline', '1', 'well', 'trial', 'at']","['table', 'baseline', '1']",1943,['试验小组在基线上很好地匹配(图1)。'],0.3333333333333333,"['table', 'baseline', '1', 'well', 'trial', 'at']","['baseline', '1']",,
1975,1944,the microbiologic features of the sputum samples obtained at baseline are provided in Figure S1 and Table S1 in the Supplementary Appendix .,补充附录图 S1 和表 S1 提供了基线时获得的痰样本的微生物学特征。,0.3333333333333333,"['appendix', 'sputum', 'table', 'baseline', 'figure', 'supplementary', 'at', 'S1', 'and']","['sputum', 'table', 'baseline']",1944,['基线上获取的精子样本的微生物特征在附件中的图 S1 和图 S1 中提供。'],0.2222222222222222,"['appendix', 'sputum', 'table', 'baseline', 'figure', 'supplementary', 'at', 'S1', 'and']","['appendix', 'baseline']",,
1976,1945,"among these 317 patients , 241 ( 76.0 % ) had CRP values lower than 20 mg per liter ; 38 ( 12.0 % ) had CRP values between 20 and 40 mg per liter , and 38 ( 12.0 % ) had CRP values higher than 40 mg per liter .",在这 317 名患者中，241 名 (76.0%) 的 CRP 值低于 20 mg/L； 38 人 (12.0%) 的 CRP 值在 20 到 40 毫克/升之间，38 人 (12.0%) 的 CRP 值高于 40 毫克/升。,0.25,"['liter', 'lower', 'values', 'and']",['liter'],1945,"['在这些317名患者中,241人(76.0%)的CRP值低于每升20毫克;38人(12.0%)的CRP值在每升20至40毫克之间;38人(12.0%)的CRP值高于每升40毫克。']",0.25,"['liter', 'lower', 'values', 'and']",['liter'],,
1977,1946,the upper limit of the confidence interval for both analyses did not contain the prespecified noninferiority margin of 0.3 .,两项分析的置信区间上限不包含预设的非劣效性界值 0.3。,0.5,"['margin', 'interval', 'upper', 'confidence interval', 'limit', 'upper limit']","['interval', 'confidence interval', 'upper limit']",1946,['对两项分析的信任间隔的上限不包含预定不低于 0.3 的边界。'],0.6666666666666666,"['margin', 'interval', 'upper', 'confidence interval', 'limit', 'upper limit']","['margin', 'interval', 'limit', 'upper limit']",,
1978,1947,differences in reported antibiotic use were only observed for the patients who had at last two of the Anthonisen criteria ( Figure 2 ) .,仅在至少满足两项 Anthonisen 标准的患者中观察到报告的抗生素使用差异（图 2）。,0.4285714285714285,"['antibiotic', 'who', '2', 'figure', 'at', 'in', 'two']","['antibiotic', '2', 'two']",1947,['对抗生素使用的差异仅在最后两项安东尼森标准的患者中被观察到(图2)。'],0.4285714285714285,"['antibiotic', 'who', '2', 'figure', 'at', 'in', 'two']","['antibiotic', '2', 'two']",,
1979,1948,other differential effects of the assigned interventions are described in Section 9 in the Supplementary Appendix .,补充附录第 9 部分描述了指定干预措施的其他不同影响。,0.0,"['differential', 'appendix', 'section', 'supplementary', 'in']",[],1948,['授予的干预的其他差异效应如附件第9节所描述。'],0.2,"['differential', 'appendix', 'section', 'supplementary', 'in']",['appendix'],,
1980,1949,the prescribed antibiotics are listed in Table S10 in the Supplementary Appendix .,处方抗生素列于补充附录表 S10 中。,0.3333333333333333,"['appendix', 'table', 'supplementary', 'antibiotics', 'S10', 'in']","['table', 'antibiotics']",1949,['处方的抗生素在附件中的表 S10 列出。'],0.5,"['appendix', 'table', 'supplementary', 'antibiotics', 'S10', 'in']","['appendix', 'table', 'antibiotics']",,
1981,1950,"we captured data regarding antibiotic prescribing , antibiotic use , and health care utilization to determine whether fewer initial prescriptions might have increased subsequent consulting and antibiotic prescribing and found that it did not .",我们收集了有关抗生素处方、抗生素使用和医疗保健利用的数据，以确定较少的初始处方是否会增加后续咨询和抗生素处方，并发现事实并非如此。,0.5333333333333333,"['antibiotic', 'data', 'utilization', 'health', 'regarding', 'initial', 'health care', 'subsequent', 'prescriptions', 'have', 'that', 'to', 'and', 'determine', 'we']","['antibiotic', 'data', 'utilization', 'regarding', 'initial', 'health care', 'prescriptions', 'have']",1950,"['我们收集了关于抗生素处方、抗生素使用和医疗保健使用的数据,以确定是否较少的初始处方可能增加了随后的咨询和抗生素处方,并发现没有。']",0.5333333333333333,"['antibiotic', 'data', 'utilization', 'health', 'regarding', 'initial', 'health care', 'subsequent', 'prescriptions', 'have', 'that', 'to', 'and', 'determine', 'we']","['antibiotic', 'data', 'regarding', 'initial', 'health care', 'prescriptions', 'have', 'to']",,
1982,1951,a nonrandomized Spanish study showed that the rate of antibiotic overprescribing for acute exacerbations of COPD was lower among primary care clinicians who received training in CRP testing than among those who did not.48,西班牙的一项非随机研究表明，接受过 CRP 检测培训的初级保健临床医生因 COPD 急性加重过度使用抗生素的比例低于未接受培训的初级保健临床医生。 48,0.2307692307692307,"['COPD', 'antibiotic', 'who', 'rate', 'training', 'study', 'lower', 'primary', 'acute', 'care', 'testing', 'that', 'nonrandomized']","['COPD', 'antibiotic', 'nonrandomized']",1951,"['一项非随机的西班牙研究表明,在接受CRP测试培训的初级护理诊所患者中,对COPD急剧加剧的抗生素过度处方率低于那些没有接受CRP测试的诊所患者中。']",0.3076923076923077,"['COPD', 'antibiotic', 'who', 'rate', 'training', 'study', 'lower', 'primary', 'acute', 'care', 'testing', 'that', 'nonrandomized']","['COPD', 'antibiotic', 'rate', 'nonrandomized']",,
1983,1952,a recent post hoc comparison indicated that men who were given abiraterone or docetaxel early in the course of treatment had similar outcomes with respect to overall survival.14,最近的一项事后比较表明，在治疗过程早期接受阿比特龙或多西紫杉醇治疗的男性在总生存期方面具有相似的结果。 14,0.4,"['a', 'who', 'recent', 'comparison', 'early', 'post', 'treatment', 'course', 'with', 'respect', 'docetaxel', 'that', 'in', 'to', 'similar']","['comparison', 'early', 'treatment', 'course', 'docetaxel', 'similar']",1952,"['最近的一项临床后比较表明,在治疗过程中早期服用阿比拉特伦或多克萨克尔的男性对整体生存产生了类似的结果。']",0.3333333333333333,"['a', 'who', 'recent', 'comparison', 'early', 'post', 'treatment', 'course', 'with', 'respect', 'docetaxel', 'that', 'in', 'to', 'similar']","['comparison', 'early', 'treatment', 'course', 'that']",,
1984,1953,testosterone suppression was initiated up to 12 weeks before randomization .,睾酮抑制在随机分组前 12 周开始。,1.0,"['suppression', 'testosterone', 'randomization', 'before']","['suppression', 'testosterone', 'randomization', 'before']",1953,['抑制<unk>丸激素在随机化前12周开始。'],0.75,"['suppression', 'testosterone', 'randomization', 'before']","['suppression', 'randomization', 'before']",,
1985,1954,previous adjuvant testosterone suppression for up to 24 months was allowed if the treatment had been completed at least 12 months earlier .,如果至少在 12 个月前完成治疗，则允许先前辅助性睾酮抑制长达 24 个月。,0.5714285714285714,"['suppression', 'testosterone', 'adjuvant', 'previous', 'treatment', 'earlier', 'if']","['suppression', 'testosterone', 'treatment', 'earlier']",1954,"['以前的补充性<unk>丸激素抑制最多24个月被允许,如果治疗已经完成至少12个月之前。']",0.4285714285714285,"['suppression', 'testosterone', 'adjuvant', 'previous', 'treatment', 'earlier', 'if']","['suppression', 'previous', 'treatment']",,
1986,1955,the trial protocol and Supplementary Appendix are available with the full text of this article at NEJM.org .,试验方案和补充附录与本文全文可在 NEJM.org 获取。,0.0833333333333333,"['appendix', 'protocol', 'article', 'supplementary', 'available', 'trial', 'text', 'with', 'at', 'full', 'this', 'and']",['protocol'],1955,['试验协议和补充附件可在NEJM.org上找到本文的完整文本。'],0.25,"['appendix', 'protocol', 'article', 'supplementary', 'available', 'trial', 'text', 'with', 'at', 'full', 'this', 'and']","['appendix', 'protocol', 'full']",,
1987,1956,"in the two groups , background therapy included continuous testosterone suppression .",在两组中，背景治疗包括持续抑制睾酮。,0.8333333333333334,"['background', 'suppression', 'testosterone', 'continuous', 'therapy', 'two']","['background', 'suppression', 'testosterone', 'therapy', 'two']",1956,"['在两组中,背景治疗包括持续的<unk>丸激素抑制。']",0.6666666666666666,"['background', 'suppression', 'testosterone', 'continuous', 'therapy', 'two']","['background', 'suppression', 'therapy', 'two']",,
1988,1957,"after the enrollment of 88 patients ( mainly from Australia and New Zealand ) , the early administration of docetaxel with testosterone suppression was permitted in protocol version 2 ( as revised on November 2014 ) as a stratification factor before randomization , according to evidence showing improved survival with this approach.1",在纳入 88 名患者（主要来自澳大利亚和新西兰）之后，方案版本 2（2014 年 11 月修订）允许早期给予多西他赛和睾酮抑制作为随机化前的分层因素，证据表明这种方法.1,0.6666666666666666,"['suppression', 'stratification', 'testosterone', 'australia', 'randomization', 'factor', '2', 'survival', 'protocol', 'version', 'administration', 'early', 'november', 'after', 'evidence', 'as', 'with', 'docetaxel', 'this', 'before', 'new']","['suppression', 'stratification', 'testosterone', 'australia', 'randomization', 'factor', '2', 'version', 'early', 'after', 'evidence', 'docetaxel', 'before', 'new']",1957,"['在88名患者(主要来自澳大利亚和新西兰)的注册后,早期服用Docetaxel与<unk>丸激素抑制被允许在协议版本2(修订于2014年11月)作为分裂因素之前的随机化,根据证据表明通过这种方法改善生存。']",0.6190476190476191,"['suppression', 'stratification', 'testosterone', 'australia', 'randomization', 'factor', '2', 'survival', 'protocol', 'version', 'administration', 'early', 'november', 'after', 'evidence', 'as', 'with', 'docetaxel', 'this', 'before', 'new']","['suppression', 'australia', 'randomization', 'factor', '2', 'survival', 'protocol', 'version', 'early', 'after', 'evidence', 'before', 'new']",,
1989,1958,the decision to initiate early treatment with docetaxel was left up to the individual patients and their physicians .,开始使用多西紫杉醇进行早期治疗的决定由患者及其医生决定。,0.4545454545454545,"['individual', 'early', 'treatment', 'early treatment', 'decision', 'up', 'with', 'docetaxel', 'to', 'and', 'physicians']","['early', 'treatment', 'early treatment', 'decision', 'docetaxel']",1958,['早期启动Docetaxel治疗的决定留给了个人病人和他们的医生。'],0.3636363636363636,"['individual', 'early', 'treatment', 'early treatment', 'decision', 'up', 'with', 'docetaxel', 'to', 'and', 'physicians']","['individual', 'early', 'treatment', 'decision']",,
1990,1959,up to two cycles of docetaxel were permitted before randomization .,在随机化之前允许最多两个周期的多西紫杉醇。,0.6666666666666666,"['randomization', 'up', 'docetaxel', 'before', 'to', 'two']","['randomization', 'docetaxel', 'before', 'two']",1959,"['在随机化之前,允许多达两个Docetaxel周期。']",0.5,"['randomization', 'up', 'docetaxel', 'before', 'to', 'two']","['randomization', 'before', 'two']",,
1991,1960,the central randomization system implemented minimization with a random component .,中央随机化系统使用随机成分实现了最小化。,0.4285714285714285,"['component', 'a', 'randomization', 'system', 'central', 'with', 'minimization']","['component', 'randomization', 'system']",1960,['中央随机化系统实施了随机组件的最小化。'],0.4285714285714285,"['component', 'a', 'randomization', 'system', 'central', 'with', 'minimization']","['component', 'randomization', 'system']",,
1992,1961,"the trial was led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group ( ANZUP ) and the National Health and Medical Research Council ( NHMRC ) Clinical Trials Centre , University of Sydney .",该试验由澳大利亚和新西兰泌尿生殖系统和前列腺癌试验小组 (ANZUP) 以及悉尼大学国家卫生和医学研究委员会 (NHMRC) 临床试验中心牵头。,0.7333333333333333,"['group', 'cancer', 'research', 'prostate cancer', 'health', 'university', 'centre', 'medical', 'urogenital', 'clinical', 'trial', 'by', 'and', 'new', 'led']","['group', 'cancer', 'research', 'prostate cancer', 'health', 'university', 'centre', 'urogenital', 'clinical', 'by', 'new']",1961,"['该研究由澳大利亚和新西兰尿道和前列腺癌试验集团(ANZUP)和国家卫生和医学研究委员会(NHMRC)临床试验中心,悉尼大学领导。']",0.6666666666666666,"['group', 'cancer', 'research', 'prostate cancer', 'health', 'university', 'centre', 'medical', 'urogenital', 'clinical', 'trial', 'by', 'and', 'new', 'led']","['group', 'cancer', 'research', 'prostate cancer', 'health', 'university', 'centre', 'clinical', 'by', 'new']",,
1993,1962,the trial was designed by the ANZUP investigators .,该试验由 ANZUP 研究人员设计。,0.5,"['trial', 'by']",['by'],1962,['审判是由ANZUP调查人员设计的。'],1.0,"['trial', 'by']","['trial', 'by']",,
1994,1963,data were collected and analyzed by the NHMRC Clinical Trials Centre .,数据由 NHMRC 临床试验中心收集和分析。,0.8,"['data', 'centre', 'clinical', 'by', 'and']","['data', 'centre', 'clinical', 'by']",1963,['数据由NHMRC临床试验中心收集和分析。'],0.8,"['data', 'centre', 'clinical', 'by', 'and']","['data', 'centre', 'clinical', 'by']",,
1995,1964,the authors were solely responsible for the writing of the manuscript .,作者全权负责手稿的撰写。,0.5,"['manuscript', 'writing']",['manuscript'],1964,['作者仅负责手稿的写作。'],1.0,"['manuscript', 'writing']","['manuscript', 'writing']",,
1996,1965,"Astellas Pharma provided enzalutamide and financial support for trial conduct ; representatives of the company reviewed drafts of the protocol and trial report but were not otherwise involved in any aspects of the trial design , data accrual , data analysis , or manuscript preparation .",安斯泰来制药为试验进行提供了恩杂鲁胺和资金支持；公司代表审阅了试验方案和试验报告的草稿，但不参与试验设计、数据收集、数据分析或手稿准备的任何方面。,0.7142857142857143,"['support', 'data', 'analysis', 'preparation', 'report', 'protocol', 'manuscript', 'trial', 'conduct', 'design', 'enzalutamide', 'in', 'but', 'and']","['support', 'data', 'analysis', 'preparation', 'report', 'protocol', 'manuscript', 'design', 'enzalutamide', 'but']",1965,"['Astellas Pharma为审判行为提供了 enzalutamide 和财务支持;公司代表审查了议定书和审判报告的草案,但没有其他参与审判设计、数据积累、数据分析或手稿编制的任何方面。']",0.6428571428571429,"['support', 'data', 'analysis', 'preparation', 'report', 'protocol', 'manuscript', 'trial', 'conduct', 'design', 'enzalutamide', 'in', 'but', 'and']","['support', 'data', 'analysis', 'report', 'protocol', 'manuscript', 'trial', 'design', 'but']",,
1997,1966,"testosterone suppression , standard antiandrogen drugs , docetaxel , and all subsequent treatments were accessed according to local standard practice .",睾酮抑制、标准抗雄激素药物、多西紫杉醇和所有后续治疗均根据当地标准实践进行。,0.6,"['standard', 'suppression', 'testosterone', 'drugs', 'local', 'practice', 'subsequent', 'docetaxel', 'standard practice', 'all']","['standard', 'suppression', 'testosterone', 'drugs', 'practice', 'docetaxel']",1966,['抑制<unk>丸激素、标准抗 androgen 药物、docetaxel 和所有随后的治疗都按照当地标准实践获得。'],0.4,"['standard', 'suppression', 'testosterone', 'drugs', 'local', 'practice', 'subsequent', 'docetaxel', 'standard practice', 'all']","['standard', 'suppression', 'drugs', 'practice']",,
1998,1967,the authors vouch for the accuracy and completeness of the reported data and for the fidelity of the trial to the protocol .,作者保证所报告数据的准确性和完整性，以及试验对方案的忠实度。,0.4285714285714285,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'completeness']",1967,"['作者保证报告数据的准确性和完整性,以及审判对议定书的忠诚性。']",0.7142857142857143,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
1999,1968,an independent data and safety monitoring committee reviewed the progress and results of the trial .,一个独立的数据和安全监督委员会审查了试验的进展和结果。,0.5,"['safety', 'monitoring', 'data', 'committee', 'trial', 'independent', 'progress', 'and']","['safety', 'data', 'committee', 'independent']",1968,['一个独立的数据和安全监测委员会审查了审查进展和结果。'],0.625,"['safety', 'monitoring', 'data', 'committee', 'trial', 'independent', 'progress', 'and']","['safety', 'monitoring', 'data', 'committee', 'independent']",,
2000,1969,the trial was conducted in accordance with the principles of Good Clinical Practice guidelines and the Declaration of Helsinki .,该试验是根据良好临床实践指南和赫尔辛基宣言的原则进行的。,0.0,"['good clinical practice', 'trial', 'with', 'and']",[],1969,['根据《好临床实践指南》和《赫尔辛基宣言》的原则进行审查。'],0.0,"['good clinical practice', 'trial', 'with', 'and']",[],,
2001,1970,the protocol was independently reviewed and approved as required at each participating institution .,每个参与机构都根据需要独立审查和批准了该协议。,0.3333333333333333,"['protocol', 'institution', 'as', 'at', 'each', 'and']","['protocol', 'institution']",1970,['该议定书根据每个参与机构的要求独立审查和批准。'],0.3333333333333333,"['protocol', 'institution', 'as', 'at', 'each', 'and']","['protocol', 'institution']",,
2002,1971,the primary end point of overall survival was measured as the interval from randomization to death from any cause or to the date at which the patient was last known to be alive .,总生存期的主要终点是从随机分组到任何原因死亡或到最后一次知道患者还活着的日期的间隔。,0.6153846153846154,"['interval', 'randomization', 'survival', 'death', 'date', 'be', 'primary', 'cause', 'patient', 'end', 'point', 'as', 'to']","['interval', 'randomization', 'survival', 'death', 'date', 'cause', 'patient', 'point']",1971,"['总生存的初始终点被测量为从随机化到任何原因死亡的间隔,或到患者最后知道活着的日期。']",0.6153846153846154,"['interval', 'randomization', 'survival', 'death', 'date', 'be', 'primary', 'cause', 'patient', 'end', 'point', 'as', 'to']","['interval', 'randomization', 'survival', 'death', 'date', 'cause', 'patient', 'point']",,
2003,1972,imaging by means of CT and bone scanning was recommended to confirm clinical suspicion of progressive disease .,建议通过 CT 和骨扫描进行成像，以确认临床对进展性疾病的怀疑。,0.5,"['bone', 'disease', 'progressive', 'clinical', 'scanning', 'CT', 'means', 'suspicion', 'imaging', 'by', 'to', 'and']","['bone', 'disease', 'progressive', 'clinical', 'suspicion', 'by']",1972,"['通过CT和骨骼扫描进行图像,建议确认临床怀疑进展性疾病。']",0.4166666666666667,"['bone', 'disease', 'progressive', 'clinical', 'scanning', 'CT', 'means', 'suspicion', 'imaging', 'by', 'to', 'and']","['bone', 'disease', 'progressive', 'clinical', 'suspicion']",,
2004,1973,imaging reports ( but not the images themselves ) were reviewed centrally .,成像报告（但不是图像本身）被集中审查。,0.5,"['imaging', 'but']",['but'],1973,['图像报告(但不是图像本身)被集中审查。'],0.5,"['imaging', 'but']",['but'],,
2005,1974,"adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events , version 4.02 .",不良事件根据美国国家癌症研究所不良事件通用术语标准 4.02 版进行分级。,0.4285714285714285,"['cancer', 'version', 'common', 'adverse', 'terminology', 'institute', 'to']","['cancer', 'terminology', 'institute']",1974,"['根据国家癌症研究所(National Cancer Institute Common Terminology Criteria for Adverse Events)的评分,版本 4.02。']",0.4285714285714285,"['cancer', 'version', 'common', 'adverse', 'terminology', 'institute', 'to']","['cancer', 'version', 'institute']",,
2006,1975,"protocol version 3 , which was written after external evidence became available for improved overall survival with early abiraterone treatment , 8,9 added interim analyses of overall survival after the occurrence of 50 % and 80 % of the prespecified 470 deaths .","第 3 版方案是在早期阿比特龙治疗改善总生存期的外部证据可用后编写的，8,9 在预先指定的 470 例死亡发生 50% 和 80% 后增加了对总生存期的中期分析。",0.4615384615384615,"['external', 'survival', 'protocol', 'version', 'occurrence', 'early', 'treatment', 'available', 'after', '3', 'evidence', 'with', 'and']","['survival', 'occurrence', 'early', 'treatment', 'after', 'evidence']",1975,"['该议定书版本3,在外部证据通过早期阿比拉特隆治疗获得改善总生存后编写,8、9 补充了总生存的临时分析,在预定死亡人数的50%和80%发生后。']",0.6153846153846154,"['external', 'survival', 'protocol', 'version', 'occurrence', 'early', 'treatment', 'available', 'after', '3', 'evidence', 'with', 'and']","['survival', 'protocol', 'version', 'occurrence', 'early', 'treatment', 'after', 'evidence']",,
2007,1976,the trial executive committee made these decisions without any knowledge of outcomes in each treatment group .,试验执行委员会在对每个治疗组的结果一无所知的情况下做出了这些决定。,0.5555555555555556,"['group', 'knowledge', 'treatment', 'committee', 'trial', 'treatment group', 'each', 'in', 'without']","['group', 'treatment', 'committee', 'treatment group', 'without']",1976,['审判执行委员会在每个处理组中未了解结果的情况下作出这些决定。'],0.4444444444444444,"['group', 'knowledge', 'treatment', 'committee', 'trial', 'treatment group', 'each', 'in', 'without']","['group', 'treatment', 'committee', 'trial']",,
2008,1977,patients who had undergone randomization and received a dose of any trial drug were included in analyses of drug exposure and safety .,接受随机分组并接受任何试验药物剂量的患者被纳入药物暴露和安全性分析。,0.625,"['safety', 'randomization', 'who', 'exposure', 'trial', 'drug', 'dose', 'in']","['safety', 'randomization', 'exposure', 'drug', 'dose']",1977,['患有随机化并接受任何试用药物的患者被列入药物暴露和安全性分析。'],0.5,"['safety', 'randomization', 'who', 'exposure', 'trial', 'drug', 'dose', 'in']","['safety', 'randomization', 'exposure', 'drug']",,
2009,1978,we prespecified that the effects of enzalutamide according to the volume of disease and the use of early docetaxel treatment were of particular interest .,我们预先指定，根据疾病的体积和早期多西他赛治疗的使用，恩杂鲁胺的作用特别令人感兴趣。,0.5,"['volume', 'disease', 'early', 'particular', 'treatment', 'of disease', 'docetaxel', 'enzalutamide', 'that', 'to', 'and', 'we']","['volume', 'disease', 'early', 'treatment', 'docetaxel', 'enzalutamide']",1978,"['我们预测,根据疾病的范围和早期Docetaxel治疗的使用,Enzalutamide的作用特别有兴趣。']",0.25,"['volume', 'disease', 'early', 'particular', 'treatment', 'of disease', 'docetaxel', 'enzalutamide', 'that', 'to', 'and', 'we']","['disease', 'early', 'treatment']",,
2010,1979,the baseline characteristics of all the patients are summarized in Table 1 and detailed in the Supplementary Appendix .,表 1 总结了所有患者的基线特征，并在补充附录中进行了详细说明。,0.5,"['appendix', 'table', 'baseline', '1', 'supplementary', 'characteristics', 'all', 'and']","['table', 'baseline', '1', 'characteristics']",1979,"['所有患者的基本特征在表1中总结,并在补充附件中详细说明。']",0.5,"['appendix', 'table', 'baseline', '1', 'supplementary', 'characteristics', 'all', 'and']","['appendix', 'table', '1', 'characteristics']",,
2011,1980,overall SURVIVAL,总体生存,,[],[],1980,['总体生存'],,[],[],,
2012,1981,"the first interim analysis of the primary end point occurred on February 28 , 2019 , after the occurrence of 235 deaths .",主要终点的第一次中期分析发生在 2019 年 2 月 28 日，当时发生了 235 例死亡事件。,0.5,"['analysis', 'occurrence', 'primary', 'after', 'end', 'point', 'on', 'first']","['analysis', 'occurrence', 'point', 'first']",1981,"['初级终点的第一次临时分析发生于2019年2月28日,发生了235人死亡。']",0.5,"['analysis', 'occurrence', 'primary', 'after', 'end', 'point', 'on', 'first']","['analysis', 'occurrence', 'point', 'first']",,
2013,1982,"on March 7 , 2019 , the independent data and safety monitoring committee recommended that the unblinded results be provided to the trial executive committee so that plans for definitive analyses could be implemented .",2019 年 3 月 7 日，独立数据和安全监察委员会建议将非盲化结果提供给试验执行委员会，以便实施最终分析计划。,0.25,"['safety', 'monitoring', 'data', 'definitive', 'march', 'be', 'committee', 'trial', 'independent', 'that', 'so', 'and']","['safety', 'data', 'committee']",1982,"['2019年3月7日,独立数据和安全监测委员会建议将未透露的结果交给审判执行委员会,以便实施最终分析计划。']",0.4166666666666667,"['safety', 'monitoring', 'data', 'definitive', 'march', 'be', 'committee', 'trial', 'independent', 'that', 'so', 'and']","['safety', 'monitoring', 'data', 'committee', 'trial']",,
2014,1983,the observed P value of 0.0016 met the rejection boundary of 0.0031 for the null hypothesis that was specified for this interim analysis .,观察到的 P 值 0.0016 符合为该中期分析指定的原假设的拒绝边界 0.0031。,0.2727272727272727,"['boundary', 'analysis', 'hypothesis', 'value', 'rejection', 'null', 'null hypothesis', 'P', 'met', 'this', 'that']","['boundary', 'analysis', 'hypothesis']",1983,['观察到的 P 值为 0.0016 与此临时分析所规定的零假设为 0.0031 的拒绝限制相匹配。'],0.2727272727272727,"['boundary', 'analysis', 'hypothesis', 'value', 'rejection', 'null', 'null hypothesis', 'P', 'met', 'this', 'that']","['analysis', 'hypothesis', 'null']",,
2015,1984,"the results were unaffected by adjustments for geographical region , volume of disease , use of early docetaxel treatment , bone antiresorptive therapy , and coexisting conditions .",结果不受地理区域、疾病体积、早期多西紫杉醇治疗的使用、骨抗吸收治疗和合并症的调整的影响。,0.7272727272727273,"['bone', 'volume', 'disease', 'early', 'region', 'therapy', 'treatment', 'of disease', 'docetaxel', 'by', 'and']","['bone', 'volume', 'disease', 'early', 'region', 'therapy', 'treatment', 'docetaxel']",1984,['结果没有受到地理区域调整、疾病量、早期多塞克斯治疗、骨质抗放松治疗和共同存在条件的影响。'],0.5454545454545454,"['bone', 'volume', 'disease', 'early', 'region', 'therapy', 'treatment', 'of disease', 'docetaxel', 'by', 'and']","['bone', 'disease', 'early', 'region', 'therapy', 'treatment']",,
2016,1985,the median survival time was not yet estimable in either trial group .,两个试验组的中位生存时间均无法估计。,0.5,"['group', 'median', 'survival', 'time', 'trial', 'in']","['group', 'survival', 'time']",1985,"['在任何审判组中,平均生存时间尚未可估计。']",0.6666666666666666,"['group', 'median', 'survival', 'time', 'trial', 'in']","['group', 'survival', 'time', 'trial']",,
2017,1986,"after adjustment for multiple comparisons , P values for heterogeneity of the treatment effect of enzalutamide were 0.14 for volume of disease , 0.14 for early docetaxel treatment , and 0.06 for the use of bone antiresorptive therapy .",调整多重比较后，恩杂鲁胺治疗效果的异质性 P 值对于疾病体积为 0.14，对于早期多西他赛治疗为 0.14，对于骨抗吸收治疗的使用为 0.06。,0.6666666666666666,"['bone', 'volume', 'disease', 'heterogeneity', 'multiple', 'adjustment', 'early', 'therapy', 'treatment', 'after', 'of disease', 'effect', 'values', 'treatment effect', 'docetaxel', 'P', 'enzalutamide', 'and']","['bone', 'volume', 'disease', 'heterogeneity', 'early', 'therapy', 'treatment', 'after', 'effect', 'treatment effect', 'docetaxel', 'enzalutamide']",1986,"['经过多次比较调整后,P值对治疗效应的异常性为0.14为疾病量、0.14为早期Docetaxel治疗和0.06为骨质反复治疗。']",0.3888888888888889,"['bone', 'volume', 'disease', 'heterogeneity', 'multiple', 'adjustment', 'early', 'therapy', 'treatment', 'after', 'of disease', 'effect', 'values', 'treatment effect', 'docetaxel', 'P', 'enzalutamide', 'and']","['bone', 'disease', 'early', 'therapy', 'treatment', 'after', 'effect']",,
2018,1987,we anticipated that the smaller number of deaths would limit the reliability of subgroup analyses of overall survival .,我们预计较小的死亡人数会限制总生存期亚组分析的可靠性。,0.5714285714285714,"['survival', 'reliability', 'number', 'limit', 'subgroup', 'that', 'we']","['survival', 'reliability', 'number', 'limit']",1987,['我们预测死亡人数较少会限制子组对整体生存分析的可靠性。'],0.5714285714285714,"['survival', 'reliability', 'number', 'limit', 'subgroup', 'that', 'we']","['survival', 'reliability', 'number', 'limit']",,
2019,1988,subsequent ANTICANCER THERAPIES,随后的抗癌治疗,0.0,['subsequent'],[],1988,['接下来的抗癌治疗'],0.0,['subsequent'],[],,
2020,1989,treatment after progression was initiated at the discretion of the patients and their physicians .,进展后的治疗由患者及其医生决定。,0.6,"['treatment', 'progression', 'after', 'and', 'physicians']","['treatment', 'progression', 'after']",1989,['进展后的治疗是在患者和他们的医生的判断下开始的。'],0.6,"['treatment', 'progression', 'after', 'and', 'physicians']","['treatment', 'progression', 'after']",,
2021,1990,treatment DURATION,治疗持续时间,1.0,['treatment'],['treatment'],1990,['治疗时间'],1.0,['treatment'],['treatment'],,
2022,1991,discontinuation for reasons other than disease progression occurred in 68 of 563 patients ( 12 % ) and 105 of 558 patients ( 19 % ) in the respective groups .,各组 563 名患者中有 68 名 (12%) 和 558 名患者中有 105 名 (19%) 因疾病进展以外的原因停药。,0.5,"['disease', 'progression', 'in', 'and']","['disease', 'progression']",1991,['因疾病进展以外的原因中断发生在各个群体中有563名患者(12%)和558名患者(19%)中有68人。'],0.5,"['disease', 'progression', 'in', 'and']","['disease', 'progression']",,
2023,1992,early docetaxel treatment was administered in 227 of 487 patients ( 47 % ) who subsequently had clinical progression and in 91 of 203 ( 45 % ) who died from prostate cancer .,487 名随后出现临床进展的患者中有 227 名 (47%) 接受了早期多西紫杉醇治疗，203 名死于前列腺癌的患者中有 91 名 (45%) 接受了早期多西紫杉醇治疗。,0.7777777777777778,"['cancer', 'who', 'prostate cancer', 'early', 'treatment', 'progression', 'clinical', 'docetaxel', 'and']","['cancer', 'prostate cancer', 'early', 'treatment', 'progression', 'clinical', 'docetaxel']",1992,"['早期Docetaxel治疗在487名患者(47%)中进行了227次,随后有临床进展,并在203名患者(45%)中死于前列腺癌。']",0.6666666666666666,"['cancer', 'who', 'prostate cancer', 'early', 'treatment', 'progression', 'clinical', 'docetaxel', 'and']","['cancer', 'prostate cancer', 'early', 'treatment', 'progression', 'clinical']",,
2024,1993,"the number of patients with febrile neutropenia was similar in the two treatment groups ( 37 with enzalutamide and 32 with standard care ) , and all but 2 of these events ( 67 of 69 ) occurred during early docetaxel treatment .",两个治疗组中出现发热性中性粒细胞减少症的患者人数相似（恩杂鲁胺组 37 人，标准治疗组 32 人），除 2 例（69 例中的 67 例）外，所有这些事件都发生在早期多西他赛治疗期间。,0.5625,"['standard', 'febrile', '2', 'neutropenia', 'early', 'treatment', 'number', 'care', 'with', 'docetaxel', 'enzalutamide', 'all', 'in', 'but', 'two', 'similar']","['standard', '2', 'neutropenia', 'early', 'treatment', 'number', 'docetaxel', 'enzalutamide', 'two']",1993,"['患有发烧性内分泌症的患者数量在两组治疗中是相似的(37与酶和32与标准护理),而所有这些事件中只有2个(67的69),在早期治疗中发生。']",0.5,"['standard', 'febrile', '2', 'neutropenia', 'early', 'treatment', 'number', 'care', 'with', 'docetaxel', 'enzalutamide', 'all', 'in', 'but', 'two', 'similar']","['standard', '2', 'early', 'treatment', 'number', 'but', 'two', 'similar']",,
2025,1994,seizures occurred more frequently in patients in the enzalutamide group ( 7 vs. 0 ) .,enzalutamide 组患者的癫痫发作更频繁（7 次对 0 次）。,0.4,"['group', 'frequently', 'enzalutamide', 'in', 'seizures']","['group', 'seizures']",1994,['受伤发生在 enzalutamide 群体(7 vs. 0 )的患者中更频繁。'],0.2,"['group', 'frequently', 'enzalutamide', 'in', 'seizures']",['group'],,
2026,1995,six patients discontinued enzalutamide because of seizure ; 1 discontinued enzalutamide because of clinical progression before the seizure event .,六名患者因癫痫发作而停用恩杂鲁胺； 1 因癫痫发作前的临床进展而停用恩杂鲁胺。,0.8571428571428571,"['1', 'seizure', 'progression', 'clinical', 'enzalutamide', 'event', 'before']","['1', 'seizure', 'progression', 'clinical', 'enzalutamide', 'before']",1995,['六名患者因收获而中断了酵素;1因临床进展而中断了酵素。'],0.4285714285714285,"['1', 'seizure', 'progression', 'clinical', 'enzalutamide', 'event', 'before']","['1', 'progression', 'clinical']",,
2027,1996,"fatigue of any grade was more common with enzalutamide than with standard care ( 465 patients and 363 patients , respectively ) .",enzalutamide 组出现任何级别的疲劳比标准治疗组更常见（分别为 465 名患者和 363 名患者）。,0.2857142857142857,"['standard', 'fatigue', 'grade', 'common', 'care', 'with', 'enzalutamide']","['standard', 'fatigue']",1996,['任何程度的疲劳比标准护理(465名患者和363名患者相应)更常见。'],0.4285714285714285,"['standard', 'fatigue', 'grade', 'common', 'care', 'with', 'enzalutamide']","['standard', 'fatigue', 'grade']",,
2028,1997,adverse events that occurred during the first 6 months among the patients who received early docetaxel treatment are shown in Table S8 in the Supplementary Appendix .,接受早期多西他赛治疗的患者在前 6 个月内发生的不良事件见补充附录表 S8。,0.3636363636363636,"['appendix', 'table', 'who', 'supplementary', 'early', 'adverse', 'treatment', 'docetaxel', 'that', 'in', 'first']","['table', 'early', 'treatment', 'docetaxel']",1997,"['在接受早期Docetaxel治疗的患者中,在第一个6个月内发生的副作用在附件中的S8表中显示。']",0.4545454545454545,"['appendix', 'table', 'who', 'supplementary', 'early', 'adverse', 'treatment', 'docetaxel', 'that', 'in', 'first']","['appendix', 'table', 'early', 'treatment', 'first']",,
2029,1998,the larger number of serious adverse events associated with enzalutamide was commensurate with the longer duration of trial treatment .,与恩杂鲁胺相关的大量严重不良事件与较长的试验治疗持续时间相称。,0.3333333333333333,"['adverse', 'associated', 'treatment', 'number', 'trial', 'duration', 'with', 'enzalutamide', 'serious']","['treatment', 'duration', 'enzalutamide']",1998,"['与Enzalutamide相关的严重副作用的数量较大,与试验治疗的长时间相匹配。']",0.2222222222222222,"['adverse', 'associated', 'treatment', 'number', 'trial', 'duration', 'with', 'enzalutamide', 'serious']","['treatment', 'number']",,
2030,1999,"all the patients received testosterone suppression , plus the addition of docetaxel when appropriate .",所有患者均接受睾酮抑制，并在适当时加用多西紫杉醇。,0.7142857142857143,"['suppression', 'testosterone', 'plus', 'addition', 'docetaxel', 'all', 'appropriate']","['suppression', 'testosterone', 'plus', 'addition', 'docetaxel']",1999,"['所有患者都接受了<unk>丸激素抑制,并在适当情况下添加Docetaxel。']",0.4285714285714285,"['suppression', 'testosterone', 'plus', 'addition', 'docetaxel', 'all', 'appropriate']","['suppression', 'plus', 'addition']",,
2031,2000,the control group in this trial was treated with standard antiandrogen therapy to provide a stringent comparator .,该试验中的对照组接受标准抗雄激素治疗以提供严格的比较。,0.5,"['group', 'standard', 'control', 'control group', 'therapy', 'stringent', 'trial', 'with', 'comparator', 'this']","['group', 'standard', 'control', 'control group', 'therapy']",2000,"['在此试验中,控制组用标准抗安德鲁素疗法进行治疗,以提供严格的比较。']",0.4,"['group', 'standard', 'control', 'control group', 'therapy', 'stringent', 'trial', 'with', 'comparator', 'this']","['group', 'standard', 'control', 'therapy']",,
2032,2001,the frequency of early docetaxel treatment was similar in the two groups .,两组早期多西他赛治疗的频率相似。,0.7142857142857143,"['frequency', 'early', 'treatment', 'docetaxel', 'in', 'two', 'similar']","['frequency', 'early', 'treatment', 'docetaxel', 'two']",2001,['早期Docetaxel治疗的频率在两组中是相似的。'],0.7142857142857143,"['frequency', 'early', 'treatment', 'docetaxel', 'in', 'two', 'similar']","['frequency', 'early', 'treatment', 'two', 'similar']",,
2033,2002,"thus , the observed benefits of early enzalutamide therapy are not explained by differences in access to or use of subsequent therapies .",因此，观察到的早期恩杂鲁胺治疗的益处不能用获得或使用后续治疗的差异来解释。,0.5555555555555556,"['access', 'early', 'therapy', 'thus', 'subsequent', 'enzalutamide', 'in', 'by', 'to']","['access', 'early', 'therapy', 'thus', 'enzalutamide']",2002,"['因此,早期内萨拉塔米德治疗的可观察的好处不被接入或使用后续治疗的差异解释。']",0.4444444444444444,"['access', 'early', 'therapy', 'thus', 'subsequent', 'enzalutamide', 'in', 'by', 'to']","['access', 'early', 'therapy', 'thus']",,
2034,2003,"we found that adding early enzalutamide to testosterone suppression was associated with a higher frequency of toxic effects , especially peripheral neuropathy associated with the concomitant use of docetaxel .",我们发现，在睾酮抑制的基础上早期加入恩杂鲁胺与更高频率的毒性作用相关，尤其是与同时使用多西紫杉醇相关的周围神经病变。,0.4666666666666667,"['suppression', 'testosterone', 'frequency', 'a', 'peripheral', 'toxic', 'neuropathy', 'early', 'concomitant', 'associated', 'with', 'docetaxel', 'enzalutamide', 'that', 'we']","['suppression', 'testosterone', 'frequency', 'neuropathy', 'early', 'docetaxel', 'enzalutamide']",2003,"['我们发现,早期添加<unk>素到<unk>丸激素抑制与毒性作用的频率较高有关,尤其是与同步使用Docetaxel相关的周边神经病。']",0.2666666666666666,"['suppression', 'testosterone', 'frequency', 'a', 'peripheral', 'toxic', 'neuropathy', 'early', 'concomitant', 'associated', 'with', 'docetaxel', 'enzalutamide', 'that', 'we']","['suppression', 'frequency', 'neuropathy', 'early']",,
2035,2004,patients who were treated with enzalutamide reported more fatigue and more often discontinued therapy before disease progression .,接受恩杂鲁胺治疗的患者报告更容易疲劳，并且更常在疾病进展前停止治疗。,0.6666666666666666,"['disease', 'who', 'fatigue', 'therapy', 'progression', 'with', 'enzalutamide', 'before', 'and']","['disease', 'fatigue', 'therapy', 'progression', 'enzalutamide', 'before']",2004,['接受Enzalutamide治疗的患者在疾病进展前得到了更多的疲劳和更频繁的停止治疗。'],0.5555555555555556,"['disease', 'who', 'fatigue', 'therapy', 'progression', 'with', 'enzalutamide', 'before', 'and']","['disease', 'fatigue', 'therapy', 'progression', 'before']",,
2036,2005,"seven patients ( 1 % ) in this group had seizures , a known potential side effect of enzalutamide .",该组中有 7 名患者 (1%) 出现癫痫发作，这是 enzalutamide 已知的潜在副作用。,0.5555555555555556,"['group', 'side effect', 'a', '1', 'potential', 'enzalutamide', 'this', 'in', 'seizures']","['group', 'side effect', '1', 'this', 'seizures']",2005,"['七名患者(1%)在这个群体中患有麻疹,已知的潜在副作用Enzalutamide。']",0.3333333333333333,"['group', 'side effect', 'a', '1', 'potential', 'enzalutamide', 'this', 'in', 'seizures']","['group', 'side effect', '1']",,
2037,2006,the effect of enzalutamide on overall survival appeared to be smaller in the subgroup with early docetaxel treatment .,在接受早期多西他赛治疗的亚组中，恩杂鲁胺对总生存期的影响似乎较小。,0.5,"['survival', 'early', 'be', 'treatment', 'effect', 'subgroup', 'with', 'docetaxel', 'enzalutamide', 'on', 'in', 'to']","['survival', 'early', 'be', 'treatment', 'docetaxel', 'enzalutamide']",2006,['Enzalutamide 对整体生存的影响似乎在早期 docetaxel 治疗的子群中较小。'],0.4166666666666667,"['survival', 'early', 'be', 'treatment', 'effect', 'subgroup', 'with', 'docetaxel', 'enzalutamide', 'on', 'in', 'to']","['survival', 'early', 'be', 'treatment', 'subgroup']",,
2038,2007,"however , this trial was neither designed nor powered to reliably analyze the results in this subgroup .",然而，该试验既没有设计也没有动力可靠地分析该亚组的结果。,0.1666666666666666,"['trial', 'subgroup', 'analyze', 'this', 'in', 'to']",['analyze'],2007,"['然而,这项试验并未被设计或授权可靠地分析该子组的结果。']",0.1666666666666666,"['trial', 'subgroup', 'analyze', 'this', 'in', 'to']",['analyze'],,
2039,2008,our current data support the claim that early enzalutamide prolongs survival within 3 years in the entire trial population but provide limited support that it prolongs overall survival within 3 years in patients who received early docetaxel treatment .,我们目前的数据支持早期恩杂鲁胺可在整个试验人群中延长 3 年内生存期的说法，但对接受早期多西他赛治疗的患者在 3 年内延长总生存期提供的支持有限。,0.5294117647058824,"['population', 'support', 'data', 'who', 'survival', 'early', 'treatment', 'trial', 'claim', '3', 'current', 'docetaxel', 'enzalutamide', 'limited', 'that', 'in', 'but']","['population', 'support', 'data', 'survival', 'early', 'treatment', 'docetaxel', 'enzalutamide', 'but']",2008,"['目前的数据支持早期酵素在整个试验人口中延长生存3年,但提供有限的支持,在接受早期Docetaxel治疗的患者中延长总生存3年。']",0.4705882352941176,"['population', 'support', 'data', 'who', 'survival', 'early', 'treatment', 'trial', 'claim', '3', 'current', 'docetaxel', 'enzalutamide', 'limited', 'that', 'in', 'but']","['population', 'support', 'data', 'survival', 'early', 'treatment', 'limited', 'but']",,
2040,2009,the main limitations of this trial are consequences of the detection of evidence of benefit at the first planned interim analysis .,该试验的主要局限性是在第一次计划的中期分析中检测获益证据的结果。,0.625,"['detection', 'analysis', 'trial', 'evidence', 'benefit', 'at', 'this', 'first']","['detection', 'analysis', 'evidence', 'this', 'first']",2009,['本审查的主要限制是第一次计划的临时分析中发现利润证据的后果。'],0.625,"['detection', 'analysis', 'trial', 'evidence', 'benefit', 'at', 'this', 'first']","['analysis', 'evidence', 'benefit', 'this', 'first']",,
2041,2010,this early analysis may have overestimated the eventual treatment benefit.20,这种早期分析可能高估了最终的治疗益处。 20,0.5,"['analysis', 'early', 'treatment', 'eventual', 'have', 'this']","['analysis', 'early', 'treatment']",2010,['这种早期分析可能过度估计了可能的治疗好处。'],0.5,"['analysis', 'early', 'treatment', 'eventual', 'have', 'this']","['analysis', 'early', 'treatment']",,
2042,2011,"there was no central review of actual imaging , but this factor would have no effect on the rate of death , the primary end point .",没有对实际成像进行集中审查，但这个因素对主要终点死亡率没有影响。,0.4375,"['factor', 'rate', 'review', 'death', 'actual', 'central', 'primary', 'no', 'effect', 'end', 'point', 'on', 'imaging', 'have', 'this', 'but']","['factor', 'rate', 'review', 'death', 'point', 'have', 'but']",2011,"['没有真正的图像的中央审查,但这个因素不会影响死亡率,主要的终点。']",0.5,"['factor', 'rate', 'review', 'death', 'actual', 'central', 'primary', 'no', 'effect', 'end', 'point', 'on', 'imaging', 'have', 'this', 'but']","['factor', 'rate', 'review', 'death', 'primary', 'point', 'have', 'but']",,
2043,2012,"however , enzalutamide was associated with some additional toxic effects , including fatigue and a small risk of seizures .",然而，enzalutamide 与一些额外的毒性作用有关，包括疲劳和癫痫发作的小风险。,0.5,"['a', 'fatigue', 'toxic', 'associated', 'risk', 'additional', 'with', 'enzalutamide', 'and', 'seizures']","['fatigue', 'risk', 'additional', 'and', 'seizures']",2012,"['然而,Enzalutamide与一些额外的毒性作用有关,包括疲劳和小损伤的风险。']",0.4,"['a', 'fatigue', 'toxic', 'associated', 'risk', 'additional', 'with', 'enzalutamide', 'and', 'seizures']","['fatigue', 'risk', 'additional', 'and']",,
2044,2013,"supported by Astellas Scientific and Medical Affairs , a grant ( 704970 ) from the Canadian Cancer Society , the Support for Cancer Clinical Trials Program of Cancer Australia , and a practitioner fellowship ( APP1102604 ) and program grants ( 1037786 and 1150467 ) from the National Health and Medical Research Council of the Australian Government Department of Health .",由 Astellas 科学和医疗事务部、加拿大癌症协会的赠款 ( 704970 ) 、澳大利亚癌症协会的癌症临床试验支持项目以及国家卫生和健康中心的从业者奖学金 ( APP1102604 ) 和项目赠款 ( 1037786 和 1150467 ) 支持澳大利亚政府卫生部医学研究委员会。,0.5294117647058824,"['a', 'cancer', 'support', 'australia', 'research', 'program', 'health', 'department', 'medical', 'scientific', 'society', 'clinical', 'grant', 'government', 'practitioner', 'by', 'and']","['cancer', 'support', 'australia', 'research', 'health', 'department', 'society', 'clinical', 'by']",2013,"['由Astellas科学和医疗事务支持,加拿大癌症协会的奖学金(704970),澳大利亚癌症临床试验计划的支持,以及澳大利亚政府卫生部国家卫生和医学研究委员会的实习生协会(APP1102604)和计划奖学金(1037786和1150467)。']",0.5882352941176471,"['a', 'cancer', 'support', 'australia', 'research', 'program', 'health', 'department', 'medical', 'scientific', 'society', 'clinical', 'grant', 'government', 'practitioner', 'by', 'and']","['cancer', 'support', 'australia', 'research', 'program', 'health', 'department', 'society', 'clinical', 'by']",,
2045,2014,"the primary end points were freedom from pain and freedom from the most bothersome symptom ( other than pain ) identified by the patient , both of which were assessed 2 hours after the dose of rimegepant or placebo was administered .",主要终点是无疼痛和无患者确定的最烦人的症状（疼痛除外），这两项都是在服用 rimegepant 或安慰剂后 2 小时进行评估。,0.5,"['placebo', 'symptom', '2', 'end points', 'pain', 'primary', 'freedom', 'patient', 'after', 'rimegepant', 'dose', 'by', 'and', 'assessed']","['placebo', 'symptom', '2', 'end points', 'pain', 'patient', 'after']",2014,"['初级终点是患者识别的最可怕的症状(除了疼痛)的免疫和免疫,其中两者在服用Rimegepant或 placebo后2小时进行评估。']",0.4285714285714285,"['placebo', 'symptom', '2', 'end points', 'pain', 'primary', 'freedom', 'patient', 'after', 'rimegepant', 'dose', 'by', 'and', 'assessed']","['symptom', '2', 'end points', 'pain', 'patient', 'after']",,
2046,2015,"a total of 1186 patients were randomly assigned to receive rimegepant ( 594 patients ) or placebo ( 592 patients ) ; of these , 537 patients in the rimegepant group and 535 patients in the placebo group could be evaluated for efficacy .",共有 1186 名患者被随机分配接受 rimegepant（594 名患者）或安慰剂（592 名患者）；其中，rimegepant 组的 537 名患者和安慰剂组的 535 名患者可以评估疗效。,0.25,"['group', 'placebo', 'total', 'be', 'efficacy', 'rimegepant', 'in', 'and']","['group', 'placebo']",2015,"['总共1186名患者被随机分配接受Rimegepant(594名患者)或Placebo(592名患者),其中537名患者在Rimegepant群体和535名患者在Placebo群体可以评估其有效性。']",0.375,"['group', 'placebo', 'total', 'be', 'efficacy', 'rimegepant', 'in', 'and']","['group', 'be', 'efficacy']",,
2047,2016,"the overall mean age of the patients evaluated for efficacy was 40.6 years , and 88.7 % were women .",评估疗效的患者的总体平均年龄为 40.6 岁，88.7% 为女性。,0.5,"['mean', 'age', 'efficacy', 'and']","['mean', 'age']",2016,"['对有效性进行评估的患者的平均年龄为40.6年,88.7%是女性。']",0.75,"['mean', 'age', 'efficacy', 'and']","['mean', 'age', 'efficacy']",,
2048,2017,the most common adverse events were nausea and urinary tract infection .,最常见的不良事件是恶心和尿路感染。,0.4285714285714285,"['infection', 'tract', 'urinary tract infection', 'nausea', 'common', 'adverse', 'and']","['infection', 'urinary tract infection', 'nausea']",2017,['最常见的副作用是恶心和尿道感染。'],0.4285714285714285,"['infection', 'tract', 'urinary tract infection', 'nausea', 'common', 'adverse', 'and']","['infection', 'tract', 'nausea']",,
2049,2018,migraine is a common chronic neurologic disease that may affect nearly 1 billion people worldwide.1,偏头痛是一种常见的慢性神经系统疾病，可能影响全球近 10 亿人。 1,0.75,"['disease', '1', 'affect', 'common', 'chronic', 'migraine', 'that', 'neurologic']","['disease', '1', 'affect', 'chronic', 'migraine', 'neurologic']",2018,"['甲状腺炎是一种常见的慢性神经疾病,可能影响全球近10亿人。']",0.625,"['disease', '1', 'affect', 'common', 'chronic', 'migraine', 'that', 'neurologic']","['disease', '1', 'affect', 'chronic', 'neurologic']",,
2050,2019,"triptans also are either contraindicated or must be used with caution in an estimated 3.5 million of the 40 million Americans with migraine because of concerns about cardiovascular effects.8,9","由于担心心血管影响，在 4000 万患有偏头痛的美国人中，估计有 350 万人禁忌或必须谨慎使用曲坦类药物。 8,9",0.5714285714285714,"['must', 'cardiovascular', 'contraindicated', 'be', 'with', 'migraine', 'million']","['cardiovascular', 'contraindicated', 'be', 'migraine']",2019,"['由于心血管影响的担忧,在40万美国人中估计有350万人患有 migraine 或应谨慎使用。']",0.2857142857142857,"['must', 'cardiovascular', 'contraindicated', 'be', 'with', 'migraine', 'million']","['cardiovascular', 'be']",,
2051,2020,"gepants may be effective in patients whose symptoms do not respond to triptans , owing to their different mechanisms of action .",gepants 可能对症状对曲坦类药物无反应的患者有效，因为它们的作用机制不同。,0.4,"['action', 'symptoms', 'be', 'in', 'respond to']","['action', 'respond to']",2020,"['<unk>子可能有效于患者,其症状因其不同的作用机制而不响应<unk>子。']",0.4,"['action', 'symptoms', 'be', 'in', 'respond to']","['action', 'respond to']",,
2052,2021,"unlike triptans , which are contraindicated in patients with cardiovascular disease because of the possibility of vasoconstriction , rimegepant does not have vasoconstrictive effects.16",与曲普坦类药物不同，曲普坦类药物因血管收缩的可能性而禁用于心血管疾病患者，而 rimegepant 不具有血管收缩作用。 16,0.5555555555555556,"['disease', 'cardiovascular', 'vasoconstriction', 'contraindicated', 'cardiovascular disease', 'with', 'rimegepant', 'have', 'unlike']","['disease', 'cardiovascular', 'vasoconstriction', 'cardiovascular disease', 'have']",2021,"['与心血管疾病患者因血管抑制的可能性而对抗的特里普坦不同,Rimegepant没有血管抑制作用。']",0.4444444444444444,"['disease', 'cardiovascular', 'vasoconstriction', 'contraindicated', 'cardiovascular disease', 'with', 'rimegepant', 'have', 'unlike']","['disease', 'cardiovascular', 'cardiovascular disease', 'have']",,
2053,2022,"the current phase 3 trial was conducted to evaluate the efficacy and safety of rimegepant ( at an oral dose of 75 mg ) , as compared with placebo , in acute migraine treatment .",目前的 3 期试验旨在评估 rimegepant（口服剂量为 75 毫克）与安慰剂相比在急性偏头痛治疗中的疗效和安全性。,0.375,"['safety', 'placebo', 'phase', 'oral', 'treatment', 'trial', 'acute', 'efficacy', '3', 'current', 'with', 'migraine', 'rimegepant', 'dose', 'to', 'and']","['safety', 'placebo', 'phase', 'treatment', 'migraine', 'dose']",2022,"['目前的第三阶段试验进行,以评估Rimegepant的有效性和安全性(口服剂量为75毫克),与 placebo相比,在急性 migraine 治疗中。']",0.3125,"['safety', 'placebo', 'phase', 'oral', 'treatment', 'trial', 'acute', 'efficacy', '3', 'current', 'with', 'migraine', 'rimegepant', 'dose', 'to', 'and']","['safety', 'phase', 'treatment', 'efficacy', 'dose']",,
2054,2023,"men and women 18 years of age or older were recruited by referral from physicians and other health care professionals and by standard methods of recruitment , including enrollment from clinical practices and through advertising .",18 岁或 18 岁以上的男性和女性是通过医生和其他医疗保健专业人员的推荐以及标准招募方法招募的，包括临床实践和广告招募。,0.4,"['standard', 'health', 'recruitment', 'clinical', 'age', 'health care', 'referral', 'advertising', 'by standard', 'physicians']","['standard', 'clinical', 'health care', 'advertising']",2023,"['18岁及以上的男性和女性通过医生和其他医疗保健专业人士的参考和标准招聘方法,包括从临床实践中注册和通过广告进行招聘。']",0.4,"['standard', 'health', 'recruitment', 'clinical', 'age', 'health care', 'referral', 'advertising', 'by standard', 'physicians']","['standard', 'clinical', 'health care', 'advertising']",,
2055,2024,"treatment settings included clinics , institutions , and private office practices .",治疗场所包括诊所、机构和私人诊所。,0.25,"['office', 'private', 'treatment', 'and']",['treatment'],2024,['治疗设置包括诊所、机构和私人办公室实践。'],0.25,"['office', 'private', 'treatment', 'and']",['treatment'],,
2056,2025,persons who were receiving preventive migraine medication had to be receiving a stable dose for at least 3 months before trial entry .,接受预防性偏头痛药物治疗的人在进入试验前必须接受至少 3 个月的稳定剂量。,0.3333333333333333,"['a', 'who', 'preventive', 'be', 'medication', 'trial', '3', 'entry', 'migraine', 'dose', 'before', 'to']","['be', 'migraine', 'dose', 'before']",2025,['接受预防性 migraine 药物的人必须在试验进入前至少3个月接受稳定的剂量。'],0.25,"['a', 'who', 'preventive', 'be', 'medication', 'trial', '3', 'entry', 'migraine', 'dose', 'before', 'to']","['be', 'dose', 'before']",,
2057,2026,patients were also excluded if they had received nonbiologic investigational agents within 30 days before the baseline visit or if they had received biologic investigational agents within 90 days before the baseline visit .,如果患者在基线访视前 30 天内接受过非生物研究药物，或者如果他们在基线访视前 90 天内接受过生物研究药物，也被排除在外。,0.4,"['baseline', 'biologic', 'before', 'if', 'visit']","['baseline', 'before']",2026,"['患者也被排除,如果他们在基线访问前30天内接收非生物学调查代理,或者如果他们在基线访问前90天内接收生物学调查代理。']",0.4,"['baseline', 'biologic', 'before', 'if', 'visit']","['baseline', 'before']",,
2058,2027,"complete criteria for participation are listed in the protocol , available with the full text of this article at NEJM.org .",完整的参与标准列在方案中，方案与本文全文可在 NEJM.org 获取。,0.3,"['protocol', 'article', 'complete', 'available', 'text', 'with', 'participation', 'full', 'this', 'in']","['complete', 'participation', 'full']",2027,"['参与的完整标准列入协议中,可在NEJM.org上找到本文的完整文本。']",0.3,"['protocol', 'article', 'complete', 'available', 'text', 'with', 'participation', 'full', 'this', 'in']","['protocol', 'participation', 'full']",,
2059,2028,"the trial was conducted in accordance with International Conference on Harmonisation Good Clinical Practice guidelines , the principles of the Declaration of Helsinki , and all applicable local regulations .",该试验是根据国际协调会议良好临床实践指南、赫尔辛基宣言的原则以及所有适用的地方法规进行的。,0.0,"['good clinical practice', 'local', 'trial', 'with', 'on', 'all', 'and']",[],2028,['审查按照《国际临床良好实践指导方针》和《赫尔辛基宣言》的原则和所有适用的地方法规进行。'],0.0,"['good clinical practice', 'local', 'trial', 'with', 'on', 'all', 'and']",[],,
2060,2029,the protocol was approved by an independent ethics committee or institutional review board at each trial center .,该方案由每个试验中心的独立伦理委员会或机构审查委员会批准。,0.3636363636363636,"['center', 'review', 'protocol', 'ethics', 'board', 'committee', 'trial', 'independent', 'at', 'each', 'by']","['center', 'review', 'committee', 'by']",2029,['该议定书由一个独立的伦理委员会或每个审查中心的机构审查委员会批准。'],0.5454545454545454,"['center', 'review', 'protocol', 'ethics', 'board', 'committee', 'trial', 'independent', 'at', 'each', 'by']","['center', 'review', 'protocol', 'committee', 'independent', 'by']",,
2061,2030,all patients provided written informed consent .,所有患者都提供了书面知情同意书。,0.3333333333333333,"['consent', 'informed consent', 'all']",['consent'],2030,['所有患者提供书面通知的同意。'],0.3333333333333333,"['consent', 'informed consent', 'all']",['consent'],,
2062,2030,all patients provided written informed consent .,所有患者都提供了书面知情同意书。,0.3333333333333333,"['consent', 'informed consent', 'all']",['consent'],2030,['所有患者提供书面通知的同意。'],0.3333333333333333,"['consent', 'informed consent', 'all']",['consent'],,
2063,2031,"Biohaven Pharmaceuticals sponsored the trial , supplied the trial agents , reviewed the trial design , collected the data , and performed data management and analysis .",Biohaven Pharmaceuticals 赞助了该试验，提供了试验药物，审查了试验设计，收集了数据，并进行了数据管理和分析。,0.6666666666666666,"['data', 'analysis', 'trial', 'management', 'design', 'and']","['data', 'analysis', 'management', 'design']",2031,"['Biohaven Pharmaceuticals 赞助了审查,供应了审查代理,审查了审查设计,收集了数据,并进行了数据管理和分析。']",0.6666666666666666,"['data', 'analysis', 'trial', 'management', 'design', 'and']","['data', 'analysis', 'management', 'design']",,
2064,2032,the manuscript was written with the assistance of a medical writer funded by Biohaven Pharmaceuticals .,该手稿是在一位由 Biohaven Pharmaceuticals 资助的医学作家的协助下撰写的。,0.2857142857142857,"['a', 'medical', 'manuscript', 'writer', 'assistance', 'with', 'by']","['manuscript', 'by']",2032,['手稿是由Biohaven Pharmaceuticals资助的医学作家的帮助下写的。'],0.2857142857142857,"['a', 'medical', 'manuscript', 'writer', 'assistance', 'with', 'by']","['manuscript', 'by']",,
2065,2033,"all the authors have confidentiality agreements with Biohaven Pharmaceuticals , either as a condition of employment or in their role as consultants .",所有作者都与 Biohaven Pharmaceuticals 签订了保密协议，无论是作为雇佣条件还是作为顾问。,0.3,"['confidentiality', 'condition', 'role', 'agreements', 'employment', 'as', 'with', 'have', 'all', 'in']","['confidentiality', 'condition', 'have']",2033,"['所有作者都有与Biohaven Pharmaceuticals的隐私协议,无论是作为就业条件还是作为顾问的角色。']",0.4,"['confidentiality', 'condition', 'role', 'agreements', 'employment', 'as', 'with', 'have', 'all', 'in']","['condition', 'role', 'employment', 'have']",,
2066,2034,"after providing written informed consent , patients underwent screening procedures as specified in the protocol .",在提供书面知情同意书后，患者按照方案中的规定接受筛查程序。,0.5,"['protocol', 'screening', 'after', 'consent', 'informed consent', 'as']","['screening', 'after', 'consent']",2034,"['经过书面通知的同意后,患者按照议定书规定的检查程序进行检查。']",0.5,"['protocol', 'screening', 'after', 'consent', 'informed consent', 'as']","['protocol', 'after', 'consent']",,
2067,2035,they were given an electronic diary and were instructed on the proper use of the diary before they left the trial center .,他们得到了一本电子日记，并在他们离开试验中心之前得到了正确使用日记的指导。,0.4,"['center', 'trial', 'electronic', 'before', 'and']","['center', 'before']",2035,"['他们被授予电子日记,并被指示在他们离开审查中心之前正确使用日记。']",0.4,"['center', 'trial', 'electronic', 'before', 'and']","['center', 'before']",,
2068,2036,patients completed the electronic diary for up to 48 hours after taking the trial agent .,患者在服用试验药物后最多可在 48 小时内完成电子日记。,0.1428571428571428,"['taking', 'after', 'trial', 'up', 'electronic', 'agent', 'to']",['after'],2036,['患者在服用试用剂后完成电子日记最多48小时。'],0.1428571428571428,"['taking', 'after', 'trial', 'up', 'electronic', 'agent', 'to']",['after'],,
2069,2037,"pain intensity , the presence or absence of associated symptoms , and ratings of functional disability were assessed at the onset of the treated attack ; at 15 , 30 , 45 , 60 , and 90 minutes after the dose ; and at 2 , 3 , 4 , 6 , 8 , 24 , and 48 hours after the dose .",在接受治疗的发作开始时评估疼痛强度、是否存在相关症状以及功能障碍等级；给药后 15、30、45、60 和 90 分钟；以及给药后 2、3、4、6、8、24 和 48 小时。,0.3529411764705882,"['presence', 'attack', '2', 'functional', 'disability', 'symptoms', 'pain', 'associated', 'onset', 'absence', 'intensity', 'after', '3', '4', 'dose', 'and', 'assessed']","['presence', 'attack', '2', 'pain', 'onset', 'after']",2037,['疼痛强度、相关症状的存在或缺席以及功能障碍的评估在治疗的发作开始时;在剂量后15、30、45、60和90分钟;在剂量后2、3、4、6、8、24和48小时进行评估。'],0.4705882352941176,"['presence', 'attack', '2', 'functional', 'disability', 'symptoms', 'pain', 'associated', 'onset', 'absence', 'intensity', 'after', '3', '4', 'dose', 'and', 'assessed']","['presence', 'attack', '2', 'pain', 'onset', 'absence', 'after', 'dose']",,
2070,2038,patients were asked to return to the trial center within 7 days after taking the dose of rimegepant or placebo .,要求患者在服用 rimegepant 或安慰剂后 7 天内返回试验中心。,0.3333333333333333,"['center', 'placebo', 'taking', 'after', 'trial', 'rimegepant', 'dose', 'return', 'to']","['center', 'placebo', 'after']",2038,['患者被要求在服用Rimegepant或Placebo后7天内返回试验中心。'],0.2222222222222222,"['center', 'placebo', 'taking', 'after', 'trial', 'rimegepant', 'dose', 'return', 'to']","['center', 'after']",,
2071,2039,"at that visit , trial personnel reviewed adherence to the electronic diary assessments , confirmed that the patient had taken the dose , and monitored safety variables .",在那次访问中，试验人员审查了对电子日记评估的依从性，确认患者服用了剂量，并监测了安全变量。,0.3636363636363636,"['safety', 'patient', 'trial', 'personnel', 'electronic', 'dose', 'adherence', 'that', 'to', 'and', 'visit']","['safety', 'patient', 'personnel', 'dose']",2039,"['在访问期间,试验人员审查了对电子日记评估的遵守,确认患者服用了剂量,并监测了安全变量。']",0.3636363636363636,"['safety', 'patient', 'trial', 'personnel', 'electronic', 'dose', 'adherence', 'that', 'to', 'and', 'visit']","['safety', 'patient', 'personnel', 'dose']",,
2072,2040,patients who had not had an attack of sufficient severity within 45 days after randomization were withdrawn and were instructed to return the unused trial agent and the electronic diary .,随机分组后 45 天内未发生足够严重程度发作的患者被退出，并被要求归还未使用的试验药物和电子日记。,0.3333333333333333,"['attack', 'randomization', 'who', 'after', 'trial', 'electronic', 'agent', 'return', 'to']","['attack', 'randomization', 'after']",2040,['在随机化后45天内未经历过足够严重的攻击的患者被撤回并被命令返回未使用的试用剂和电子日记。'],0.3333333333333333,"['attack', 'randomization', 'who', 'after', 'trial', 'electronic', 'agent', 'return', 'to']","['attack', 'randomization', 'after']",,
2073,2041,"the methods used to measure efficacy end points are described in the Supplementary Appendix , available at NEJM.org .",用于衡量疗效终点的方法在补充附录中进行了描述，补充附录可在 NEJM.org 获取。,0.375,"['appendix', 'supplementary', 'end points', 'available', 'efficacy', 'measure', 'at', 'to']","['end points', 'at', 'to']",2041,"['用于测量效率终点的方法在附件中描述,可在NEJM.org上找到。']",0.625,"['appendix', 'supplementary', 'end points', 'available', 'efficacy', 'measure', 'at', 'to']","['appendix', 'end points', 'measure', 'at', 'to']",,
2074,2042,"safety and other assessments included evaluation of adverse events , electrocardiography , vital signs , measurements of height and weight , routine laboratory testing and the Sheehan Suicidality Tracking Scale.19",安全和其他评估包括不良事件评估、心电图、生命体征、身高和体重测量、常规实验室测试和 Sheehan 自杀追踪量表。 19,0.5454545454545454,"['safety', 'vital signs', 'height', 'weight', 'evaluation', 'routine', 'electrocardiography', 'adverse', 'laboratory', 'testing', 'and']","['safety', 'vital signs', 'weight', 'routine', 'electrocardiography', 'laboratory']",2042,['安全和其他评估包括对不良事件的评估、电心图、重要迹象、高度和体重的测量、常规实验室测试和Sheehan自杀跟踪规模。'],0.4545454545454545,"['safety', 'vital signs', 'height', 'weight', 'evaluation', 'routine', 'electrocardiography', 'adverse', 'laboratory', 'testing', 'and']","['safety', 'height', 'weight', 'routine', 'laboratory']",,
2075,2043,"on the basis of the results of the previous phase 2b trial , 16 we estimated that a sample of 550 patients in each group would provide the trial with more than 95 % power to detect a significant difference between the rimegepant group and the placebo group in each of the two primary end points and hence at least 90 % power to detect a significant difference between the groups in both end points jointly .",根据先前 2b 期试验的结果 16 ，我们估计每组 550 名患者的样本将为该试验提供超过 95 % 的功效来检测每组中 rimegepant 组和安慰剂组之间的显着差异。的两个主要终点，因此至少有 90% 的功效可以共同检测两个终点中各组之间的显着差异。,0.4090909090909091,"['sample', 'group', 'placebo', 'phase', 'power', 'previous', 'basis', 'difference', 'end points', 'primary', 'detect', 'trial', 'with', 'rimegepant', 'at', 'significant difference', 'on', 'that', 'each', 'to', 'and', 'two']","['sample', 'group', 'placebo', 'phase', 'difference', 'end points', 'detect', 'each', 'two']",2043,"['基于前一阶段2b试验的结果,16我们估计,每个群体550名患者的样本将为试验提供超过95%的能力,以便在两个主要终点中发现回应群体和 placebo群体之间的显著差异,因此至少90%的能力,以便在两个终点中共同发现群体之间的显著差异。']",0.4545454545454545,"['sample', 'group', 'placebo', 'phase', 'power', 'previous', 'basis', 'difference', 'end points', 'primary', 'detect', 'trial', 'with', 'rimegepant', 'at', 'significant difference', 'on', 'that', 'each', 'to', 'and', 'two']","['sample', 'group', 'phase', 'power', 'difference', 'end points', 'detect', 'at', 'to', 'two']",,
2076,2044,"the safety analyses were conducted in the safety population , which included all patients who underwent randomization and took a dose of rimegepant or placebo .",安全性分析是在安全性人群中进行的，其中包括接受随机分组并服用了 rimegepant 或安慰剂剂量的所有患者。,0.5555555555555556,"['safety', 'population', 'placebo', 'randomization', 'who', 'rimegepant', 'dose', 'all', 'in']","['safety', 'population', 'placebo', 'randomization', 'dose']",2044,"['安全分析是在安全人口中进行的,其中包括所有经历过随机化并服用Rimegepant或Placebo的患者。']",0.3333333333333333,"['safety', 'population', 'placebo', 'randomization', 'who', 'rimegepant', 'dose', 'all', 'in']","['safety', 'population', 'randomization']",,
2077,2045,we specified that rimegepant would be considered to be superior to placebo with respect to the two primary end points ( freedom from pain 2 hours after the dose and freedom from the most bothersome symptom 2 hours after the dose ) if the P value for both comparisons was less than 0.05 .,我们指定，如果两个比较的 P 值为小于 0.05 。,0.0476190476190476,"['placebo', 'symptom', '2', 'value', 'superior', 'end points', 'be', 'pain', 'primary', 'freedom', 'after', 'with', 'respect', 'rimegepant', 'dose', 'P', 'that', 'if', 'and', 'two', 'we']",['two'],2045,"['我们指出,如果两次比较的P值低于0.05的情况下,Remegepant将被认为是比 placebo优越的两个主要终点(剂量后2小时免于疼痛和最令人不安的症状免于2小时免于剂量后2小时),如果两次比较的P值低于0.05。']",0.3809523809523809,"['placebo', 'symptom', '2', 'value', 'superior', 'end points', 'be', 'pain', 'primary', 'freedom', 'after', 'with', 'respect', 'rimegepant', 'dose', 'P', 'that', 'if', 'and', 'two', 'we']","['symptom', '2', 'superior', 'end points', 'pain', 'after', 'dose', 'two']",,
2078,2046,patients who used rescue medication were considered to have treatment failure as of the time the medications were used .,使用急救药物的患者被认为在使用药物时治疗失败。,0.3333333333333333,"['failure', 'who', 'time', 'medication', 'treatment', 'as', 'have', 'to', 'rescue']","['failure', 'time', 'treatment']",2046,['使用救援药物的患者被认为是从药物被使用时开始治疗失败的。'],0.4444444444444444,"['failure', 'who', 'time', 'medication', 'treatment', 'as', 'have', 'to', 'rescue']","['failure', 'time', 'treatment', 'rescue']",,
2079,2047,we performed sensitivity analyses that took missing data into account ; the results are shown in the Supplementary Appendix .,我们进行了考虑缺失数据的敏感性分析；结果见补充附录。,0.25,"['appendix', 'data', 'supplementary', 'sensitivity', 'that', 'in', 'missing', 'we']","['data', 'missing']",2047,"['我们进行了敏感性分析,考虑到缺乏数据;结果显示在附件中。']",0.375,"['appendix', 'data', 'supplementary', 'sensitivity', 'that', 'in', 'missing', 'we']","['appendix', 'data', 'missing']",,
2080,2048,"to maintain the type I error rate at 0.05 , a prespecified hierarchical gatekeeping procedure was applied in which the secondary end points were tested in the order indicated above and in the protocol .",为了将 I 类错误率保持在 0.05，应用了预先指定的分级把关程序，其中次要终点按照上述和方案中指定的顺序进行测试。,0.4285714285714285,"['type', 'a', 'procedure', 'rate', 'order', 'protocol', 'maintain', 'end points', 'secondary', 'error', 'applied', 'I', 'and', 'error rate']","['procedure', 'rate', 'order', 'end points', 'error', 'error rate']",2048,"['为了保持 I 型错误率为 0.05,实施了预先规定的序列关闭程序,其次端点在上述顺序和议定书中进行测试。']",0.5,"['type', 'a', 'procedure', 'rate', 'order', 'protocol', 'maintain', 'end points', 'secondary', 'error', 'applied', 'I', 'and', 'error rate']","['type', 'procedure', 'rate', 'order', 'protocol', 'error', 'error rate']",,
2081,2049,a comparison was considered to be significant if that comparison and each of the preceding comparisons showed a significant difference between the treatment groups .,如果该比较和之前的每个比较显示治疗组之间存在显着差异，则该比较被认为是显着的。,0.3636363636363636,"['a', 'comparison', 'difference', 'be', 'treatment', 'preceding', 'significant difference', 'that', 'each', 'to', 'and']","['comparison', 'difference', 'be', 'treatment']",2049,"['一种比较被认为是显著的,如果这种比较和每个以前的比较都表明了治疗组之间的显著差异。']",0.2727272727272727,"['a', 'comparison', 'difference', 'be', 'treatment', 'preceding', 'significant difference', 'that', 'each', 'to', 'and']","['comparison', 'difference', 'treatment']",,
2082,2050,"if a significant difference was not observed for an end point , any subsequent comparisons were reported without P values .",如果在终点没有观察到显着差异，则报告任何后续比较时不包含 P 值。,0.2222222222222222,"['a', 'difference', 'subsequent', 'values', 'end', 'point', 'P', 'significant difference', 'without']","['difference', 'point']",2050,"['如果在终点上没有显著的差异,则没有 P 值的后续比较报告。']",0.2222222222222222,"['a', 'difference', 'subsequent', 'values', 'end', 'point', 'P', 'significant difference', 'without']","['difference', 'point']",,
2083,2051,"for each time point , the number of patients eligible to become free from pain or free from their most bothersome symptom and the number of patients who reported the first occurrence of the event were used to calculate the probability estimate ( with 95 % confidence intervals ) .",对于每个时间点，有资格摆脱疼痛或摆脱最烦人症状的患者人数以及报告首次发生该事件的患者人数用于计算概率估计值（95% 置信区间）。,0.45,"['symptom', 'who', 'probability', 'occurrence', 'time', 'free', 'pain', 'number', 'estimate', 'point', 'with', 'confidence', 'event', 'each', 'calculate', 'become', 'and', 'first', 'intervals', 'eligible']","['symptom', 'probability', 'occurrence', 'time', 'pain', 'number', 'estimate', 'point', 'calculate']",2051,"['对于每个时间点,有资格免受疼痛或免受最令人不安的症状的患者数量以及报告事件发生的患者数量,用于计算概率估计(有95%的信心间隔)。']",0.45,"['symptom', 'who', 'probability', 'occurrence', 'time', 'free', 'pain', 'number', 'estimate', 'point', 'with', 'confidence', 'event', 'each', 'calculate', 'become', 'and', 'first', 'intervals', 'eligible']","['symptom', 'probability', 'occurrence', 'time', 'pain', 'number', 'point', 'confidence', 'calculate']",,
2084,2052,"from July 2017 through January 2018 , a total of 1186 patients participated in the trial at 49 centers in the United States .",从 2017 年 7 月到 2018 年 1 月，共有 1186 名患者在美国的 49 个中心参与了试验。,0.0,"['a', 'total', 'trial', 'at', 'in']",[],2052,"['从2017年7月到2018年1月,共有1186名患者在美国49个中心参加了试验。']",0.0,"['a', 'total', 'trial', 'at', 'in']",[],,
2085,2053,patients were randomly assigned to receive rimegepant ( 594 patients ) or placebo ( 592 patients ) .,患者被随机分配接受 rimegepant（594 名患者）或安慰剂（592 名患者）。,0.3333333333333333,"['placebo', 'rimegepant', 'to']",['placebo'],2053,['病人随机被授予接受Rimegepant(594名患者)或 placebo(592名患者)。'],0.0,"['placebo', 'rimegepant', 'to']",[],,
2086,2054,"a total of 1086 patients received the assigned dose of rimegepant or placebo , and 1080 of these patients ( 99.4 % ) completed the trial ( 538 in the rimegepant group and 542 in the placebo group ) ( Figure 1 ) .",共有 1086 名患者接受了指定剂量的 rimegepant 或安慰剂，其中 1080 名 (99.4%) 完成了试验（rimegepant 组 538 名，安慰剂组 542 名）（图 1）。,0.4,"['group', 'placebo', '1', 'figure', 'total', 'trial', 'rimegepant', 'dose', 'in', 'and']","['group', 'placebo', '1', 'dose']",2054,"['共1086名患者接受了授予的 rimegepant 或 placebo 剂量,其中1080名患者(99.4%)完成了试验(538名患者在 rimegepant 群体和 542名患者在 placebo 群体)。']",0.3,"['group', 'placebo', '1', 'figure', 'total', 'trial', 'rimegepant', 'dose', 'in', 'and']","['group', '1', 'dose']",,
2087,2055,the demographic and clinical characteristics of the two treatment groups were similar ( Table 1 ) .,两个治疗组的人口统计学和临床特征相似（表 1）。,0.75,"['table', '1', 'treatment', 'clinical', 'characteristics', 'and', 'two', 'similar']","['table', '1', 'treatment', 'clinical', 'characteristics', 'two']",2055,['两组治疗的人口和临床特征是相似的(图1)。'],0.75,"['table', '1', 'treatment', 'clinical', 'characteristics', 'and', 'two', 'similar']","['1', 'treatment', 'clinical', 'characteristics', 'two', 'similar']",,
2088,2056,"most of the patients ( 88.7 % ) were women , and the mean age of the overall population was 40.6 years .",大多数患者 (88.7%) 为女性，总人口的平均年龄为 40.6 岁。,0.75,"['population', 'mean', 'age', 'and']","['population', 'mean', 'age']",2056,"['大多数患者(88.7%)是女性,总人口的平均年龄为40.6年。']",0.75,"['population', 'mean', 'age', 'and']","['population', 'mean', 'age']",,
2089,2057,"the patients reported a history of 4.6 migraine attacks per month , each of which lasted an average of 32.5 hours if left untreated .",患者报告每月有 4.6 次偏头痛发作，如果不及时治疗，每次平均持续 32.5 小时。,0.375,"['a', 'average', 'month', 'history', 'untreated', 'migraine', 'each', 'if']","['average', 'month', 'migraine']",2057,"['患者每月报告了 4.6 次 migraine 发作的历史,如果没有治疗,每次平均持续 32.5 小时。']",0.375,"['a', 'average', 'month', 'history', 'untreated', 'migraine', 'each', 'if']","['average', 'month', 'history']",,
2090,2058,the groups were balanced with respect to the distribution of the most bothersome symptom ( Table 1 ) .,这些组在最烦人的症状分布方面是平衡的（表 1）。,0.6666666666666666,"['symptom', 'table', '1', 'distribution', 'with', 'respect']","['symptom', 'table', '1', 'distribution']",2058,['群体均衡于最可怕的症状的分布(图1)。'],0.5,"['symptom', 'table', '1', 'distribution', 'with', 'respect']","['symptom', '1', 'distribution']",,
2091,2059,exploratory analyses of freedom from pain and freedom from the most bothersome symptom during the first 8 hours after the dose of rimegepant or placebo are shown in Figure 2 .,图 2 显示了在服用 rimegepant 或安慰剂后最初 8 小时内没有疼痛和没有最烦人症状的探索性分析。,0.4166666666666667,"['placebo', 'symptom', '2', 'figure', 'pain', 'exploratory', 'freedom', 'after', 'rimegepant', 'dose', 'and', 'first']","['placebo', 'symptom', '2', 'pain', 'after']",2059,['在 rimegepant 或 placebo 剂量后的第 1 8 小时内发现免受疼痛和免受最令人不安的症状的研究分析显示在图 2 。'],0.4166666666666667,"['placebo', 'symptom', '2', 'figure', 'pain', 'exploratory', 'freedom', 'after', 'rimegepant', 'dose', 'and', 'first']","['symptom', '2', 'pain', 'after', 'dose']",,
2092,2060,"the most common adverse events were nausea ( 1.8 % in the rimegepant group and 1.1 % in the placebo group ) and urinary tract infection ( 1.5 % and 1.1 % , respectively ) .",最常见的不良事件是恶心（rimegepant 组为 1.8%，安慰剂组为 1.1%）和尿路感染（分别为 1.5% 和 1.1%）。,0.5,"['infection', 'group', 'tract', 'placebo', 'urinary tract infection', 'nausea', 'common', 'adverse', 'rimegepant', 'and']","['infection', 'group', 'placebo', 'urinary tract infection', 'nausea']",2060,['最常见的副作用是恶心(Rimegepant群体的1.8%和 placebo群体的1.1%)和尿道感染(尿道感染的1.5%和1.1%相应)。'],0.4,"['infection', 'group', 'tract', 'placebo', 'urinary tract infection', 'nausea', 'common', 'adverse', 'rimegepant', 'and']","['infection', 'group', 'tract', 'nausea']",,
2093,2061,serious adverse events were reported in one patient in the rimegepant group ( back pain ) and in two patients in the placebo group ( Table 3 ) .,rimegepant 组的一名患者（背痛）和安慰剂组的两名患者报告了严重不良事件（表 3）。,0.6153846153846154,"['group', 'placebo', 'table', 'back', 'adverse', 'pain', 'patient', '3', 'rimegepant', 'serious', 'back pain', 'and', 'two']","['group', 'placebo', 'table', 'back', 'pain', 'patient', 'back pain', 'two']",2061,['严重的副作用发生在一个患者在Rimegepant组(背痛)和两个患者在 placebo组(图3)中报告。'],0.4615384615384615,"['group', 'placebo', 'table', 'back', 'adverse', 'pain', 'patient', '3', 'rimegepant', 'serious', 'back pain', 'and', 'two']","['group', 'back', 'pain', 'patient', 'back pain', 'two']",,
2094,2062,"no patient in either treatment group had an alanine aminotransferase level or an aspartate aminotransferase level of more than three times the upper limit of the normal range , and no total bilirubin level of more than two times the upper limit of the normal range was observed .",两个治疗组中没有患者的谷丙转氨酶水平或天冬氨酸转氨酶水平超过正常范围上限的三倍，也没有观察到总胆红素水平超过正常范围上限的两倍。,0.5789473684210527,"['group', 'alanine', 'range', 'bilirubin', 'alanine aminotransferase', 'upper', 'total', 'normal', 'aspartate aminotransferase', 'treatment', 'patient', 'limit', 'level', 'normal range', 'upper limit', 'treatment group', 'three', 'and', 'two']","['group', 'range', 'bilirubin', 'aspartate aminotransferase', 'treatment', 'patient', 'level', 'normal range', 'upper limit', 'treatment group', 'two']",2062,"['在任何治疗组中,没有患者患有过三倍以上的阿拉丁氨基转移剂或阿斯帕特氨基转移剂水平,并且没有观察到超过正常范围的两倍以上的总比利比鲁宾水平。']",0.4210526315789473,"['group', 'alanine', 'range', 'bilirubin', 'alanine aminotransferase', 'upper', 'total', 'normal', 'aspartate aminotransferase', 'treatment', 'patient', 'limit', 'level', 'normal range', 'upper limit', 'treatment group', 'three', 'and', 'two']","['group', 'range', 'treatment', 'patient', 'level', 'normal range', 'treatment group', 'two']",,
2095,2063,"the results of the analyses of the secondary end points of freedom from photophobia , freedom from phonophobia , and pain relief , each assessed 2 hours after the dose of rimegepant or placebo , showed the superiority of rimegepant over placebo ; however , rimegepant was not found to be superior to placebo with respect to freedom from nausea .",在 rimegepant 或安慰剂给药后 2 小时评估的次要终点（无畏光、无声音恐惧症和疼痛缓解）的分析结果显示 rimegepant 优于安慰剂；然而，在消除恶心方面，并未发现 rimegepant 优于安慰剂。,0.4761904761904761,"['placebo', '2', 'relief', 'superior', 'end points', 'be', 'nausea', 'pain', 'freedom', 'secondary', 'after', 'photophobia', 'superiority', 'with', 'respect', 'rimegepant', 'dose', 'each', 'over', 'and', 'assessed']","['placebo', '2', 'relief', 'end points', 'be', 'nausea', 'pain', 'after', 'photophobia', 'and']",2063,"['对二级终结点的分析结果,即免于光波比、免于光波比和疼痛缓解,每个评估后2小时的 rimegepant 或 placebo 剂量,显示了 rimegepant 对 placebo 的优越性;然而, rimegepant 没有发现比 placebo 的优越性。']",0.2857142857142857,"['placebo', '2', 'relief', 'superior', 'end points', 'be', 'nausea', 'pain', 'freedom', 'secondary', 'after', 'photophobia', 'superiority', 'with', 'respect', 'rimegepant', 'dose', 'each', 'over', 'and', 'assessed']","['2', 'pain', 'after', 'superiority', 'dose', 'and']",,
2096,2064,nausea and urinary tract infection were the only adverse events reported in more than 1 % of the patients in each group .,恶心和尿路感染是在每组中超过 1% 的患者中报告的唯一不良事件。,0.5555555555555556,"['infection', 'group', 'tract', '1', 'urinary tract infection', 'nausea', 'adverse', 'each', 'and']","['infection', 'group', '1', 'urinary tract infection', 'nausea']",2064,['恶心和尿道感染是每组患者中超过1%的患者中唯一报告的副作用。'],0.5555555555555556,"['infection', 'group', 'tract', '1', 'urinary tract infection', 'nausea', 'adverse', 'each', 'and']","['infection', 'group', 'tract', '1', 'nausea']",,
2097,2065,our trial had several limitations .,我们的试验有几个局限性。,0.0,['trial'],[],2065,['我们的审判有几个限制。'],1.0,['trial'],['trial'],,
2098,2066,"first , the trial did not include an active comparator to rimegepant .",首先，该试验不包括 rimegepant 的活性对照药。,0.2,"['active', 'trial', 'rimegepant', 'comparator', 'first']",['first'],2066,"['首先,审判不包括一个活跃的比较者与反对者。']",0.4,"['active', 'trial', 'rimegepant', 'comparator', 'first']","['trial', 'first']",,
2099,2067,"third , although no evidence of adverse cardiac effects was observed , the trial population was not enriched for patients with cardiovascular disease .",第三，虽然没有观察到不良心脏影响的证据，但试验人群并未针对心血管疾病患者进行扩充。,0.6363636363636364,"['cardiac', 'population', 'disease', 'cardiovascular', 'cardiovascular disease', 'adverse', 'no', 'trial', 'evidence', 'with', 'third']","['cardiac', 'population', 'disease', 'cardiovascular', 'cardiovascular disease', 'evidence', 'third']",2067,"['第三,虽然没有发现心脏不良影响的证据,但在心血管疾病患者中,试验人口并没有得到丰富。']",0.6363636363636364,"['cardiac', 'population', 'disease', 'cardiovascular', 'cardiovascular disease', 'adverse', 'no', 'trial', 'evidence', 'with', 'third']","['cardiac', 'population', 'disease', 'cardiovascular', 'cardiovascular disease', 'evidence', 'third']",,
2100,2068,"this trial showed that among patients with migraine , treatment of an attack with rimegepant , which acts through inhibition of the CGRP receptor , resulted in a moderately higher percentage of patients who were free from pain and free from their most bothersome symptom 2 hours after the dose than placebo .",该试验表明，在偏头痛患者中，使用通过抑制 CGRP 受体起作用的 rimegepant 治疗偏头痛发作，导致在给药后 2 小时没有疼痛和最烦人的症状的患者百分比适度升高。比安慰剂。,0.4545454545454545,"['CGRP', 'attack', 'receptor', 'percentage', 'inhibition', 'placebo', 'symptom', 'who', '2', 'moderately', 'free', 'pain', 'treatment', 'after', 'trial', 'with', 'migraine', 'rimegepant', 'dose', 'this', 'that', 'and']","['attack', 'receptor', 'inhibition', 'placebo', 'symptom', '2', 'pain', 'treatment', 'after', 'migraine']",2068,"['这项研究表明,在患有 migraine 的患者中,使用 rimegepant 攻击的治疗,通过 CGRP 受体的抑制作用,导致患有疼痛和免于其最令人不安的症状的患者的比例相对较高,比 placebo 剂量后 2 小时。']",0.4090909090909091,"['CGRP', 'attack', 'receptor', 'percentage', 'inhibition', 'placebo', 'symptom', 'who', '2', 'moderately', 'free', 'pain', 'treatment', 'after', 'trial', 'with', 'migraine', 'rimegepant', 'dose', 'this', 'that', 'and']","['attack', 'receptor', 'inhibition', 'symptom', '2', 'pain', 'treatment', 'after', 'dose']",,
2101,2069,larger and longer trials are needed to determine the consistency of response and the safety and effectiveness of the drug as compared with other migraine treatments .,与其他偏头痛治疗相比，需要更大规模和更长时间的试验来确定反应的一致性以及该药物的安全性和有效性。,0.5454545454545454,"['safety', 'effectiveness', 'consistency', 'response', 'as', 'with', 'migraine', 'drug', 'to', 'and', 'determine']","['safety', 'effectiveness', 'consistency', 'response', 'migraine', 'drug']",2069,"['需要更大、更长的试验来确定反应的一致性和药物的安全性和有效性,与其他 migraine 治疗方法相比。']",0.4545454545454545,"['safety', 'effectiveness', 'consistency', 'response', 'as', 'with', 'migraine', 'drug', 'to', 'and', 'determine']","['safety', 'effectiveness', 'consistency', 'response', 'drug']",,
2102,2070,highlights of new treatments for myeloma and lymphoma,骨髓瘤和淋巴瘤新疗法的亮点,0.5,"['myeloma', 'lymphoma', 'and', 'new']","['myeloma', 'new']",2070,['下一篇:新治疗甲状腺和淋巴瘤'],0.25,"['myeloma', 'lymphoma', 'and', 'new']",['new'],,
2103,2071,patients were randomized to lenalidomide or observation .,患者被随机分配到来那度胺组或观察组。,0.5,"['observation', 'to']",['observation'],2071,['病人被随机转移到Lenalidomide或观察。'],0.5,"['observation', 'to']",['observation'],,
2104,2072,toxicities were as expected ; 80 % of phase II and 51 % of phase III patients discontinued lenalidomide due to adverse events or patient withdrawal .,毒性符合预期； 80% 的 II 期患者和 51% 的 III 期患者因不良事件或患者退出而停用来那度胺。,0.4285714285714285,"['phase', 'withdrawal', 'adverse', 'patient', 'due', 'to', 'and']","['phase', 'patient', 'and']",2072,['毒性如预期;80%的II阶段和51%的III阶段患者因不良事件或患者退出而中断列纳利多米德。'],0.4285714285714285,"['phase', 'withdrawal', 'adverse', 'patient', 'due', 'to', 'and']","['phase', 'patient', 'and']",,
2105,2073,rates of second primary malignancies with lenalidomide and placebo were 5.2 % and 3.5 % .,来那度胺和安慰剂组的第二原发性恶性肿瘤发生率分别为 5.2% 和 3.5%。,0.2,"['placebo', 'primary', 'with', 'second', 'and']",['placebo'],2073,['与Lenalidomide和Placebo的第二主要恶性疾病的发病率为5.2%和3.5%。'],0.0,"['placebo', 'primary', 'with', 'second', 'and']",[],,
2106,2074,"however , the relapse rate remains high after autologous SCT .",然而，自体干细胞移植后的复发率仍然很高。,0.7142857142857143,"['relapse', 'rate', 'autologous', 'after', 'relapse rate', 'SCT', 'high']","['relapse', 'rate', 'after', 'relapse rate', 'high']",2074,"['然而,在自动 SCT 之后,逆转率仍然很高。']",0.4285714285714285,"['relapse', 'rate', 'autologous', 'after', 'relapse rate', 'SCT', 'high']","['rate', 'after', 'high']",,
2107,2075,"autologous SCT remains a standard for PTCL in first remission , thus reserving allogeneic STC for relapsing patients .",自体 SCT 仍然是首次缓解期 PTCL 的标准，因此为复发患者保留同种异体 STC。,0.375,"['standard', 'relapsing', 'autologous', 'thus', 'remission', 'allogeneic', 'SCT', 'first']","['standard', 'thus', 'remission']",2075,"['autologous SCT 仍然是 PTCL 的标准,因此保留 Allogenic STC 为患者复发。']",0.25,"['standard', 'relapsing', 'autologous', 'thus', 'remission', 'allogeneic', 'SCT', 'first']","['standard', 'thus']",,
2108,2076,a second component of the trial randomized 398 patients who achieved complete remission from induction therapy to receive maintenance rituximab or observation .,该试验的第二部分随机分配了 398 名从诱导治疗中获得完全缓解的患者，以接受利妥昔单抗维持治疗或观察治疗。,0.3846153846153846,"['component', 'induction', 'a', 'who', 'therapy', 'complete', 'trial', 'maintenance', 'remission', 'observation', 'achieved', 'second', 'to']","['induction', 'therapy', 'maintenance', 'remission', 'observation']",2076,"['试验的第二组成部分随机398名患者从引导治疗中获得完整的恢复,以获得维持 rituximab 或观察。']",0.3846153846153846,"['component', 'induction', 'a', 'who', 'therapy', 'complete', 'trial', 'maintenance', 'remission', 'observation', 'achieved', 'second', 'to']","['induction', 'therapy', 'complete', 'maintenance', 'observation']",,
2109,2077,no clinical DLBCL subgroup showed a benefit from maintenance rituximab .,没有临床 DLBCL 亚组显示利妥昔单抗维持治疗有益。,0.5,"['a', 'no', 'clinical', 'maintenance', 'subgroup', 'benefit']","['clinical', 'maintenance', 'benefit']",2077,['没有临床DLBCL子组显示了维持Rituximab的好处。'],0.3333333333333333,"['a', 'no', 'clinical', 'maintenance', 'subgroup', 'benefit']","['clinical', 'maintenance']",,
2110,2078,WCH and WCE were confirmed by either ambulatory BP monitoring or home BP monitoring .,WCH 和 WCE 通过动态血压监测或家庭血压监测确认。,0.25,"['monitoring', 'ambulatory', 'by', 'and']",['monitoring'],2078,['WCH 和 WCE 是通过外科 BP 监测或家庭 BP 监测确认的。'],0.25,"['monitoring', 'ambulatory', 'by', 'and']",['monitoring'],,
2111,2079,"WCE did not confer excess risk for adverse CV events , stroke , or early mortality .",WCE 不会增加不良 CV 事件、中风或早期死亡的风险。,0.5,"['excess', 'stroke', 'early', 'adverse', 'mortality', 'risk']","['stroke', 'early', 'risk']",2079,"['WCE没有给予过度风险的负面CV事件,中风,或早期死亡。']",0.5,"['excess', 'stroke', 'early', 'adverse', 'mortality', 'risk']","['stroke', 'early', 'risk']",,
2112,2080,"based on data in this analysis , editorialists note that excess risk associated with WCH usually is seen in older patients with high CV risk .",根据该分析中的数据，编辑指出，与 WCH 相关的额外风险通常见于具有高 CV 风险的老年患者。,0.3333333333333333,"['excess', 'data', 'analysis', 'associated', 'risk', 'note', 'with', 'on', 'this', 'that', 'in', 'high']","['data', 'analysis', 'risk', 'high']",2080,"['基于此分析中的数据,编辑学家指出,与WCH相关的过度风险通常在患有高CV风险的老年患者中出现。']",0.3333333333333333,"['excess', 'data', 'analysis', 'associated', 'risk', 'note', 'with', 'on', 'this', 'that', 'in', 'high']","['data', 'analysis', 'risk', 'high']",,
2113,2081,"if WCH is suspected in older patients with high risk for adverse CV events , empirical treatment of WCH might be reasonable - but randomized trials to validate this approach would be desirable .",如果疑似 WCH 存在于心血管不良事件高风险的老年患者中，WCH 的经验性治疗可能是合理的，但需要随机试验来验证这种方法。,0.3846153846153846,"['approach', 'high risk', 'be', 'adverse', 'treatment', 'empirical', 'with', '-', 'this', 'if', 'in', 'but', 'to']","['be', 'treatment', 'this', 'but', 'to']",2081,"['如果WCH在患有高风险的老年患者中被怀疑,则实验性治疗WCH可能是合理的,但随机试验来验证这种方法是可取的。']",0.3076923076923077,"['approach', 'high risk', 'be', 'adverse', 'treatment', 'empirical', 'with', '-', 'this', 'if', 'in', 'but', 'to']","['be', 'treatment', 'this', 'but']",,
2114,2082,the editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference .,NEJM Journal Watch Oncology and Hematology 的编辑们在现场报告了会议的亮点。,0.1666666666666666,"['report', 'hematology', 'watch', 'journal', 'hand', 'on']",['report'],2082,['NEJM Journal Watch Oncology and Hematology的编辑们正在报告会议的突出点。'],0.1666666666666666,"['report', 'hematology', 'watch', 'journal', 'hand', 'on']",['report'],,
2115,2082,the editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference .,NEJM Journal Watch Oncology and Hematology 的编辑们在现场报告了会议的亮点。,0.1666666666666666,"['report', 'hematology', 'watch', 'journal', 'hand', 'on']",['report'],2082,['NEJM Journal Watch Oncology and Hematology的编辑们正在报告会议的突出点。'],0.1666666666666666,"['report', 'hematology', 'watch', 'journal', 'hand', 'on']",['report'],,
2116,2083,all meeting abstracts can be viewed in the ASCO meeting library .,所有会议摘要都可以在 ASCO 会议图书馆中查看。,0.5,"['library', 'be', 'all', 'in']","['library', 'be']",2083,['所有会议抽象都可以在ASCO会议图书馆中查看。'],0.5,"['library', 'be', 'all', 'in']","['library', 'be']",,
2117,2083,all meeting abstracts can be viewed in the ASCO meeting library .,所有会议摘要都可以在 ASCO 会议图书馆中查看。,0.5,"['library', 'be', 'all', 'in']","['library', 'be']",2083,['所有会议抽象都可以在ASCO会议图书馆中查看。'],0.5,"['library', 'be', 'all', 'in']","['library', 'be']",,
2118,2084,but whether to give monotherapy or doublet maintenance therapy to patients receiving a triplet combination is unknown .,但对于接受三药联合治疗的患者是给予单药治疗还是双药维持治疗尚不清楚。,0.625,"['triplet', 'combination', 'doublet', 'therapy', 'maintenance', 'give', 'but', 'to']","['combination', 'therapy', 'maintenance', 'but', 'to']",2084,['但是否给予单治疗或双维治疗给接受三重组合的患者是不清楚的。'],0.375,"['triplet', 'combination', 'doublet', 'therapy', 'maintenance', 'give', 'but', 'to']","['combination', 'therapy', 'but']",,
2119,2085,"patients who did not progress were then randomized 1 : 1 : 1 to maintenance therapy with bevacizumab , pemetrexed , or a combination of the two agents .",没有进展的患者随后以 1:1:1 的比例被随机分配到使用贝伐单抗、培美曲塞或两种药物的组合进行维持治疗。,0.5555555555555556,"['combination', 'who', '1', 'therapy', 'progress', 'maintenance', 'with', 'to', 'two']","['combination', '1', 'therapy', 'maintenance', 'two']",2085,"['未取得进展的患者随机1:1:1进行维持治疗,使用bevacizumab、pemetrexed或两种药物的组合。']",0.5555555555555556,"['combination', 'who', '1', 'therapy', 'progress', 'maintenance', 'with', 'to', 'two']","['combination', '1', 'therapy', 'maintenance', 'two']",,
2120,2086,"however , overall survival ( OS ; the primary endpoint ) was similar between combination maintenance and bevacizumab ( 16.4 and 14.4 months , respectively ) and between combination maintenance and pemetrexed ( 16.4 and 15.9 months ) .",然而，总生存期（OS；主要终点）在联合维持和贝伐单抗之间（分别为 16.4 和 14.4 个月）以及联合维持和培美曲塞之间（16.4 和 15.9 个月）相似。,0.5714285714285714,"['combination', 'survival', 'primary', 'maintenance', 'endpoint', 'and', 'similar']","['combination', 'survival', 'maintenance', 'and']",2086,"['然而,整体生存(OS;主要终点)是相似的组合维修和bevacizumab( 16.4 和 14.4 个月,分别)和组合维修和 pemetrexed( 16.4 和 15.9 个月)之间。']",0.5714285714285714,"['combination', 'survival', 'primary', 'maintenance', 'endpoint', 'and', 'similar']","['combination', 'survival', 'and', 'similar']",,
2121,2087,"in these patients who are eligible for maintenance therapy , it would be recommended to give them continuation bevacizumab or switch them to pemetrexed maintenance .",在这些符合维持治疗条件的患者中，建议继续给予贝伐珠单抗或换用培美曲塞维持治疗。,0.375,"['who', 'switch', 'therapy', 'be', 'maintenance', 'give', 'to', 'eligible']","['therapy', 'be', 'maintenance']",2087,"['在这些患者谁是合格的维护治疗, 建议给他们继续 bevacizumab 或将他们转换为 pemetrexed 维护。']",0.375,"['who', 'switch', 'therapy', 'be', 'maintenance', 'give', 'to', 'eligible']","['therapy', 'be', 'eligible']",,
2122,2088,current trials are ongoing to explore the use of checkpoint inhibitors for various durations of therapy in the metastatic setting .,目前正在进行的试验旨在探索检查点抑制剂在转移性治疗中的不同疗程。,0.2857142857142857,"['setting', 'various', 'therapy', 'metastatic', 'current', 'explore', 'to']","['therapy', 'explore']",2088,"['目前正在进行试验,以探讨检查点抑制剂在不同治疗时间的使用。']",0.1428571428571428,"['setting', 'various', 'therapy', 'metastatic', 'current', 'explore', 'to']",['therapy'],,
2123,2089,"Provencio and colleagues report the results of the phase II NADIM trial ( abstract 8509 ) involving 41 patients with resectable stage IIIA NSCLC treated with neoadjuvant nivolumab , paclitaxel , and carboplatin .",Provencio 及其同事报告了 II 期 NADIM 试验（摘要 8509）的结果，该试验涉及 41 名可切除的 IIIA 期 NSCLC 患者，这些患者接受了新辅助纳武单抗、紫杉醇和卡铂治疗。,0.5555555555555556,"['stage', 'phase', 'report', 'trial', 'with', 'carboplatin', 'nivolumab', 'paclitaxel', 'and']","['stage', 'phase', 'report', 'carboplatin', 'paclitaxel']",2089,"['普朗西奥和同事报告了第二阶段NADIM试验(抽象8509)的结果,其中41名患有可恢复阶段IIIANSCLC的患者接受了新增Nivolumab、Paclitaxel和Carboplatin的治疗。']",0.2222222222222222,"['stage', 'phase', 'report', 'trial', 'with', 'carboplatin', 'nivolumab', 'paclitaxel', 'and']","['phase', 'report']",,
2124,2090,"after resection ( 90 % lobectomy , 10 % pneumonectomy ) , patients were given adjuvant nivolumab for 1 year .",切除后（90% 肺叶切除术，10% 全肺切除术），患者接受 nivolumab 辅助治疗 1 年。,0.75,"['year', '1', 'adjuvant', 'pneumonectomy', 'lobectomy', 'resection', 'after', 'nivolumab']","['year', '1', 'pneumonectomy', 'lobectomy', 'resection', 'after']",2090,['恢复后(90% lobectomy、10% pneumonectomy)患者服用补充Nivolumab1年。'],0.375,"['year', '1', 'adjuvant', 'pneumonectomy', 'lobectomy', 'resection', 'after', 'nivolumab']","['year', '1', 'after']",,
2125,2091,"a major pathologic response was seen in 83 % of patients , and a complete pathologic response was see in 71 % .",83%的患者出现主要病理反应，71%的患者出现完全病理反应。,0.1428571428571428,"['a', 'major', 'complete', 'pathologic', 'response', 'in', 'and']",['response'],2091,"['在83%的患者中,主要的病理反应被观察到,71%的患者中,完全的病理反应被观察到。']",0.2857142857142857,"['a', 'major', 'complete', 'pathologic', 'response', 'in', 'and']","['complete', 'response']",,
2126,2092,downstaging was seen in 90 % of cases .,90% 的病例出现降期。,0.0,['in'],[],2092,"['在90%的案例中,出现了下降。']",0.0,['in'],[],,
2127,2093,radiographic evaluation by RECIST showed a 71 % partial response and 7 % complete response .,RECIST 的影像学评估显示 71% 的部分反应和 7% 的完全反应。,0.125,"['a', 'evaluation', 'radiographic', 'complete', 'response', 'partial', 'by', 'and']",['response'],2093,['RECIST的放射评估显示了71%的部分回应和7%的完整回应。'],0.0,"['a', 'evaluation', 'radiographic', 'complete', 'response', 'partial', 'by', 'and']",[],,
2128,2094,this study was important for three main reasons .,这项研究之所以重要，主要有以下三个原因。,0.0,"['study', 'three', 'this']",[],2094,['这项研究因三个主要原因至关重要。'],0.0,"['study', 'three', 'this']",[],,
2129,2095,"second , the trial showed that neoadjuvant chemoimmunotherapy did not induce adverse toxicity and did not prevent surgical resections .",其次，该试验表明，新辅助化学免疫疗法不会引起不良毒性，也不会阻止手术切除。,0.3333333333333333,"['toxicity', 'surgical', 'induce', 'adverse', 'trial', 'prevent', 'second', 'that', 'and']","['toxicity', 'induce', 'second']",2095,"['第二,研究表明,新增化免疫疗法没有引发不良毒性,也没有预防手术复发。']",0.2222222222222222,"['toxicity', 'surgical', 'induce', 'adverse', 'trial', 'prevent', 'second', 'that', 'and']","['toxicity', 'prevent']",,
2130,2096,"third , because this was a multicenter study that was conducted throughout Spain , it showed that this treatment strategy is feasible and can be performed in the community .",第三，因为这是一项在整个西班牙进行的多中心研究，表明这种治疗策略是可行的，可以在社区进行。,0.5454545454545454,"['a', 'strategy', 'community', 'study', 'be', 'treatment', 'this', 'that', 'in', 'and', 'third']","['strategy', 'community', 'be', 'treatment', 'this', 'third']",2096,"['第三,因为这是整个西班牙进行的多中心研究,它表明这种治疗策略是可行的,可以在社区中进行。']",0.5454545454545454,"['a', 'strategy', 'community', 'study', 'be', 'treatment', 'this', 'that', 'in', 'and', 'third']","['strategy', 'community', 'be', 'treatment', 'this', 'third']",,
2131,2097,"however , it remains to be seen if these early markers of response will translate into a survival benefit .",然而，这些早期反应标志物是否会转化为生存获益还有待观察。,0.3,"['a', 'survival', 'early', 'be', 'response', 'benefit', 'translate', 'will', 'if', 'to']","['survival', 'early', 'response']",2097,"['然而,仍然可以看到这些早期反应标记是否会转化为生存效益。']",0.3,"['a', 'survival', 'early', 'be', 'response', 'benefit', 'translate', 'will', 'if', 'to']","['survival', 'early', 'response']",,
2132,2098,additional survival outcomes should be reported within the next year .,明年应报告更多的生存结果。,0.4,"['year', 'survival', 'be', 'additional', 'next']","['year', 'survival']",2098,['预计在明年内将公布额外的生存成果。'],0.8,"['year', 'survival', 'be', 'additional', 'next']","['year', 'survival', 'be', 'additional']",,
2133,2099,we hope they will show that the high responses translate into higher cure rates .,我们希望他们将证明高反应转化为更高的治愈率。,0.4285714285714285,"['cure', 'hope', 'translate', 'will', 'that', 'high', 'we']","['cure', 'hope', 'high']",2099,"['我们希望他们会证明,高反应将转化为更高的治疗率。']",0.4285714285714285,"['cure', 'hope', 'translate', 'will', 'that', 'high', 'we']","['cure', 'hope', 'high']",,
2134,2100,"in NSCLC , RET fusions are identified in 2 % of NSCLC patients .",在 NSCLC 中，RET 融合在 2% 的 NSCLC 患者中被发现。,0.5,"['2', 'in']",['2'],2100,"['在NSCLC中,RET合并在NSCLC患者的2%中被确定。']",0.5,"['2', 'in']",['2'],,
2135,2101,"the RET alterations included 44 KIF5B , 16 CCDC6 , and 19 others ; 39 % of patients had baseline brain metastases , and the median number of prior therapies was 2 .",RET 改变包括 44 个 KIF5B、16 个 CCDC6 和 19 个其他； 39 % 的患者有基线脑转移，先前治疗的中位数为 2 .,0.7142857142857143,"['median', 'baseline', '2', 'brain', 'number', 'prior', 'and']","['baseline', '2', 'brain', 'number', 'prior']",2101,"['RET 变化包括 44 KIF5B, 16 CCDC6, 和 19 其他 ; 39% 的患者患有基因脑转移, 预先治疗的平均数量为 2 。']",0.4285714285714285,"['median', 'baseline', '2', 'brain', 'number', 'prior', 'and']","['2', 'brain', 'number']",,
2136,2102,"in 30 patients who received the recommended phase II dose of 400 mg daily and who had prior platinum chemotherapy , the response rate was 60 % .",在 30 名接受推荐 II 期剂量 400 mg/d 且之前接受过铂类化疗的患者中，反应率为 60%。,0.7,"['chemotherapy', 'phase', 'who', 'rate', 'platinum', 'response', 'prior', 'response rate', 'dose', 'and']","['chemotherapy', 'phase', 'rate', 'platinum', 'response', 'response rate', 'dose']",2102,"['在30名患者中,每日服用第2阶段推荐剂量为400毫克,并接受了先前的柏拉丁化疗,反应率为60%。']",0.7,"['chemotherapy', 'phase', 'who', 'rate', 'platinum', 'response', 'prior', 'response rate', 'dose', 'and']","['chemotherapy', 'phase', 'rate', 'response', 'prior', 'response rate', 'dose']",,
2137,2103,"grade ≥ 3 toxicity ( increased liver function tests , hypertension , fatigue , decreased neutrophils , and constipation ) was seen in 28 % of patients , and 3 % discontinued treatment due to toxicity .",28% 的患者出现 ≥ 3 级毒性（肝功能测试增加、高血压、疲劳、中性粒细胞减少和便秘），3% 的患者因毒性而停止治疗。,0.6923076923076923,"['constipation', 'liver', 'toxicity', 'hypertension', 'fatigue', 'grade', 'function', 'treatment', '3', 'due', 'liver function', 'in', 'and']","['constipation', 'liver', 'toxicity', 'hypertension', 'fatigue', 'function', 'treatment', 'liver function', 'and']",2103,"['度 ≥ 3 的毒性(增加肝功能测试、高血压、疲劳、减少中性素和堵塞)在28%的患者中被观察到,因毒性而停止治疗的3%。']",0.6923076923076923,"['constipation', 'liver', 'toxicity', 'hypertension', 'fatigue', 'grade', 'function', 'treatment', '3', 'due', 'liver function', 'in', 'and']","['liver', 'toxicity', 'hypertension', 'fatigue', 'grade', 'function', 'treatment', 'liver function', 'and']",,
2138,2104,"the toxicity profile is reasonable and manageable , and it is anticipated that once expansion cohort data are complete , registration approval will occur if the response rate holds .",毒性特征是合理且可控的，预计一旦扩展队列数据完成，如果反应率保持不变，就会批准注册。,0.4375,"['toxicity', 'data', 'rate', 'approval', 'registration', 'complete', 'response', 'expansion', 'profile', 'cohort', 'will', 'response rate', 'occur', 'that', 'if', 'and']","['toxicity', 'data', 'rate', 'approval', 'registration', 'response', 'response rate']",2104,"['毒性资料是合理的和可管理的,并预计一旦扩展量数据完成,注册批准将发生,如果响应率保持。']",0.4375,"['toxicity', 'data', 'rate', 'approval', 'registration', 'complete', 'response', 'expansion', 'profile', 'cohort', 'will', 'response rate', 'occur', 'that', 'if', 'and']","['toxicity', 'data', 'rate', 'approval', 'registration', 'response', 'occur']",,
2139,2105,five of 8 patients who had prior immunotherapy had a confirmed response .,先前接受过免疫治疗的 8 名患者中有 5 名确认有反应。,0.5,"['a', 'who', 'immunotherapy', 'response', 'prior', 'five']","['immunotherapy', 'response', 'prior']",2105,['接受前免疫治疗的8名患者中有5人获得了确认的回应。'],0.1666666666666666,"['a', 'who', 'immunotherapy', 'response', 'prior', 'five']",['immunotherapy'],,
2140,2106,"the most common adverse effect was myelosuppression ( 22.0 % grade 3 , 23.8 % grade 4 ) ; 3.8 % had grade 3 or 4 febrile neutropenia , and 6.6 % had grade 3 or 4 thrombocytopenia .",最常见的不良反应是骨髓抑制（22.0% 3 级，23.8% 4 级）； 3.8% 有 3 级或 4 级发热性中性粒细胞减少症，6.6% 有 3 级或 4 级血小板减少症。,0.2,"['febrile', 'grade', 'neutropenia', 'thrombocytopenia', 'common', 'adverse', 'adverse effect', '3', '4', 'and']","['neutropenia', 'thrombocytopenia']",2106,"['最常见的副作用是甲状腺抑郁症(3级22.0%,4级23.8%);3级或4级热性中性中性中性中性中性中性中性中性中性中性中性中性中性中性中性中性中性中性中性中性中性。']",0.0,"['febrile', 'grade', 'neutropenia', 'thrombocytopenia', 'common', 'adverse', 'adverse effect', '3', '4', 'and']",[],,
2141,2107,only 3.8 % of patients required treatment discontinuation .,只有 3.8% 的患者需要停止治疗。,1.0,['treatment'],['treatment'],2107,['只有3.8%的患者需要停止治疗。'],1.0,['treatment'],['treatment'],,
2142,2108,"however , additional studies are needed to better identify which patients would benefit from this agent ; those with sensitive disease appear to have the greatest survival benefit .",然而，需要更多的研究来更好地确定哪些患者会从该药物中获益；那些患有敏感疾病的人似乎有最大的生存益处。,0.2727272727272727,"['disease', 'survival', 'additional', 'identify', 'benefit', 'sensitive', 'with', 'agent', 'have', 'this', 'to']","['disease', 'survival', 'have']",2108,"['然而,需要进一步的研究,以更好地确定哪些患者会从这种药物中受益;患有敏感疾病的人似乎有最大的生存好处。']",0.2727272727272727,"['disease', 'survival', 'additional', 'identify', 'benefit', 'sensitive', 'with', 'agent', 'have', 'this', 'to']","['disease', 'survival', 'have']",,
2143,2109,what was interesting in this trial was that the cohort of patients who had prior immunotherapy appeared to respond well to lurbinectedin .,该试验的有趣之处在于，先前接受过免疫治疗的患者队列似乎对 lurbinectedin 反应良好。,0.2727272727272727,"['who', 'immunotherapy', 'well', 'interesting', 'prior', 'trial', 'cohort', 'lurbinectedin', 'this', 'that', 'to']","['immunotherapy', 'prior', 'to']",2109,"['在这项研究中,有趣的是,先前免疫治疗的患者的团体似乎对 lurbinectedin 很好地响应。']",0.3636363636363636,"['who', 'immunotherapy', 'well', 'interesting', 'prior', 'trial', 'cohort', 'lurbinectedin', 'this', 'that', 'to']","['immunotherapy', 'interesting', 'prior', 'this']",,
2144,2110,additional studies are ongoing .,更多的研究正在进行中。,0.0,['additional'],[],2110,['进一步的研究正在进行中。'],0.0,['additional'],[],,
2145,2111,"after adjustment for multiple variables , people in the highest quartile had 25 % , 22 % , and 25 % higher risks for overall CVD , coronary heart disease , and cerebrovascular disease , respectively , than did people in the lowest quartile during a median of 5 years .",对多个变量进行调整后，在中位数 5 年中，处于最高四分位数的人患心血管疾病、冠心病和脑血管疾病的风险分别比处于最低四分位数的人高 25 % 、 22 % 和 25 % 。 .,0.5625,"['heart', 'median', '5', 'disease', 'heart disease', 'cerebrovascular', 'coronary', 'multiple', 'adjustment', 'cerebrovascular disease', 'after', 'quartile', 'CVD', 'in', 'coronary heart disease', 'and']","['heart', '5', 'disease', 'heart disease', 'cerebrovascular', 'coronary', 'after', 'quartile', 'coronary heart disease']",2111,"['在多变量调整后,最高四分之一的人有25%、22%和25%的总体CVD、冠状心脏病和脑血管疾病的风险,相应地比在5年中最低四分之一的人更高。']",0.4375,"['heart', 'median', '5', 'disease', 'heart disease', 'cerebrovascular', 'coronary', 'multiple', 'adjustment', 'cerebrovascular disease', 'after', 'quartile', 'CVD', 'in', 'coronary heart disease', 'and']","['heart', '5', 'disease', 'heart disease', 'cerebrovascular', 'coronary', 'after']",,
2146,2112,"in addition , in a prospective Spanish study , researchers examined 20,000 university graduates ( mean age , 38 ) .","此外，在一项前瞻性西班牙研究中，研究人员对 20,000 名大学毕业生（平均年龄 38 岁）进行了检查。",0.4285714285714285,"['a', 'mean', 'university', 'addition', 'study', 'age', 'in']","['mean', 'university', 'age']",2112,"['此外,在一个有前途的西班牙研究中,研究人员审查了2万名大学毕业生(平均年龄,38岁)。']",0.4285714285714285,"['a', 'mean', 'university', 'addition', 'study', 'age', 'in']","['mean', 'university', 'age']",,
2147,2113,"intravenous thrombolysis and mechanical thrombectomy for acute ischemic stroke are largely focused on recanalization , but enhancing collateral blood flow could also improve perfusion and limit infarction .",急性缺血性卒中的静脉溶栓和机械血栓切除术主要集中在再通，但增强侧支血流也可以改善灌注和限制梗死。,0.6,"['perfusion', 'blood flow', 'stroke', 'mechanical', 'recanalization', 'infarction', 'thrombolysis', 'collateral', 'thrombectomy', 'acute', 'intravenous', 'limit', 'but', 'and', 'ischemic']","['perfusion', 'blood flow', 'stroke', 'recanalization', 'infarction', 'thrombolysis', 'thrombectomy', 'limit', 'but']",2113,"['急性腹泻的内血血管和机械腹泻主要集中在重新诊断,但增强副血流也可能改善注射和限制心脏病发作。']",0.2666666666666666,"['perfusion', 'blood flow', 'stroke', 'mechanical', 'recanalization', 'infarction', 'thrombolysis', 'collateral', 'thrombectomy', 'acute', 'intravenous', 'limit', 'but', 'and', 'ischemic']","['blood flow', 'stroke', 'limit', 'but']",,
2148,2114,"stimulation of the sphenopalatine ganglion , which is accessible through the nasal mucosa , is thought to increase collateral cerebral blood flow through parasympathetic effects on anterior circulation vasculature and has been proposed as a potential intervention for stroke .",刺激可通过鼻粘膜进入的蝶腭神经节，被认为可通过对前循环血管系统的副交感神经作用增加侧支脑血流量，并已被提议作为中风的潜在干预措施。,0.4,"['ganglion', 'mucosa', 'blood flow', 'stroke', 'circulation', 'stimulation', 'potential', 'cerebral', 'anterior', 'parasympathetic', 'nasal', 'thought', 'collateral', 'intervention', 'sphenopalatine', 'accessible', 'increase', 'nasal mucosa', 'to', 'and']","['ganglion', 'mucosa', 'blood flow', 'stroke', 'circulation', 'stimulation', 'anterior', 'nasal mucosa']",2114,"['通过鼻膜可访问的Sfenopalatine ganglion的刺激,被认为通过对前循环血管的 parasympathetic 影响增加胆固醇脑血流,并被建议作为可能的中风干预。']",0.25,"['ganglion', 'mucosa', 'blood flow', 'stroke', 'circulation', 'stimulation', 'potential', 'cerebral', 'anterior', 'parasympathetic', 'nasal', 'thought', 'collateral', 'intervention', 'sphenopalatine', 'accessible', 'increase', 'nasal mucosa', 'to', 'and']","['blood flow', 'stroke', 'circulation', 'stimulation', 'anterior']",,
2149,2115,patients eligible for reperfusion therapy were excluded .,符合再灌注治疗条件的患者被排除在外。,0.3333333333333333,"['therapy', 'reperfusion', 'eligible']",['therapy'],2115,['被排除接受反射治疗的患者。'],0.3333333333333333,"['therapy', 'reperfusion', 'eligible']",['therapy'],,
2150,2116,"at 90 days , the proportion of patients with a lower level of disability than expected was similar in the two groups ( 49 % active vs. 45 % sham ; P = 0.31 ) .",在 90 天时，两组中残疾水平低于预期的患者比例相似（49% 活动组 45% 假组；P = 0.31）。,0.3846153846153846,"['proportion', 'a', 'disability', 'active', 'lower', 'level', 'with', 'sham', 'at', 'P', 'in', 'two', 'similar']","['proportion', 'disability', 'level', 'at', 'two']",2116,"['在90天,患有低于预期的残疾患者的比例在两组中相似(49%活性与45%羞耻;P = 0.31)。']",0.3076923076923077,"['proportion', 'a', 'disability', 'active', 'lower', 'level', 'with', 'sham', 'at', 'P', 'in', 'two', 'similar']","['proportion', 'disability', 'at', 'two']",,
2151,2117,"however , among the subset of 520 patients with confirmed cortical involvement and an NIHSS score ≥ 10 , 50 % of the active intervention group had improvement beyond expectation vs. 40 % of sham group ( P = 0.026 ) .",然而，在 520 名确诊皮质受累且 NIHSS 评分≥ 10 的患者子集中，50% 的积极干预组的改善超出预期，而假手术组为 40% (P = 0.026)。,0.3076923076923077,"['group', 'improvement', 'subset', 'active', 'intervention', 'cortical', 'expectation', 'score', 'involvement', 'with', 'sham', 'P', 'and']","['group', 'improvement', 'expectation', 'and']",2117,"['然而,在520名患有确认的皮质参与和NIHSS分数 ≥10的患者中,50%的活跃干预群体比40%的羞耻群体(P = 0.026 )有所改善。']",0.3076923076923077,"['group', 'improvement', 'subset', 'active', 'intervention', 'cortical', 'expectation', 'score', 'involvement', 'with', 'sham', 'P', 'and']","['group', 'improvement', 'score', 'and']",,
2152,2118,serious adverse events and mortality were similar in the two groups .,两组的严重不良事件和死亡率相似。,0.2857142857142857,"['adverse', 'mortality', 'serious', 'in', 'and', 'two', 'similar']","['mortality', 'two']",2118,['严重的不良事件和死亡率在两组中是相似的。'],0.4285714285714285,"['adverse', 'mortality', 'serious', 'in', 'and', 'two', 'similar']","['mortality', 'two', 'similar']",,
2153,2119,sphenopalatine ganglion stimulation appears to be safe .,刺激蝶腭神经节似乎是安全的。,0.4,"['ganglion', 'stimulation', 'be', 'sphenopalatine', 'to']","['ganglion', 'stimulation']",2119,['Sphenopalatine ganglion 刺激似乎是安全的。'],0.2,"['ganglion', 'stimulation', 'be', 'sphenopalatine', 'to']",['stimulation'],,
2154,2120,the relationship between outpatient systolic and diastolic blood pressure and cardiovascular outcomes remains unclear and has been complicated by recently revised guidelines with two different thresholds ( ≥ 140 / 90 mm Hg and ≥ 130 / 80 mm Hg ) for treating hypertension .,门诊收缩压和舒张压与心血管结局之间的关系仍不清楚，最近修订的指南中有两个不同的高血压治疗阈值（≥ 140 / 90 毫米汞柱和≥ 130 / 80 毫米汞柱），这一关系变得复杂。,0.2666666666666666,"['relationship', 'pressure', 'cardiovascular', 'hypertension', '/', 'blood', 'blood pressure', 'complicated', 'diastolic', 'systolic', 'with', 'by', 'and', 'two', 'complicated by']","['cardiovascular', 'hypertension', 'blood pressure', 'two']",2120,"['患上血压和心血管血压之间的关系仍然不清楚,并且由于最近修订的指令,两种不同的边界( ≥ 140 / 90 毫米 Hg 和 ≥ 130 / 80 毫米 Hg )对高血压的治疗有所复杂。']",0.3333333333333333,"['relationship', 'pressure', 'cardiovascular', 'hypertension', '/', 'blood', 'blood pressure', 'complicated', 'diastolic', 'systolic', 'with', 'by', 'and', 'two', 'complicated by']","['cardiovascular', 'hypertension', 'blood pressure', 'by', 'two']",,
2155,2121,"using data from 1.3 million adults in a general outpatient population , we performed a multivariable Cox survival analysis to determine the effect of the burden of systolic and diastolic hypertension on a composite outcome of myocardial infarction , ischemic stroke , or hemorrhagic stroke over a period of 8 years .",使用普通门诊患者中 130 万成年人的数据，我们进行了多变量 Cox 生存分析，以确定收缩压和舒张压高血压的负担对心肌梗死、缺血性中风或出血性中风的复合结果的影响，持续时间为 8 年。年 。,0.3181818181818182,"['myocardial infarction', 'composite', 'population', 'period', 'stroke', 'data', 'hypertension', 'analysis', 'survival', 'outcome', 'general', 'diastolic', 'hemorrhagic', 'systolic', 'effect', 'over', 'and', 'determine', 'ischemic', 'burden', 'million', 'we']","['myocardial infarction', 'stroke', 'data', 'hypertension', 'analysis', 'survival', 'outcome']",2121,"['使用1300万成年人的数据,我们进行了多变的Cox生存分析,以确定系统和甲状腺高血压的负担在8年内对心脏病发作、骨质中风或血管中风的合成结果的影响。']",0.2727272727272727,"['myocardial infarction', 'composite', 'population', 'period', 'stroke', 'data', 'hypertension', 'analysis', 'survival', 'outcome', 'general', 'diastolic', 'hemorrhagic', 'systolic', 'effect', 'over', 'and', 'determine', 'ischemic', 'burden', 'million', 'we']","['stroke', 'data', 'hypertension', 'analysis', 'survival', 'outcome']",,
2156,2122,the analysis controlled for demographic characteristics and coexisting conditions .,该分析控制了人口特征和合并症。,0.5,"['analysis', 'controlled', 'demographic characteristics', 'and']","['analysis', 'controlled']",2122,['对人口特征和共同存在条件进行控制的分析。'],0.5,"['analysis', 'controlled', 'demographic characteristics', 'and']","['analysis', 'controlled']",,
2157,2123,the burdens of systolic and diastolic hypertension each independently predicted adverse outcomes .,收缩压和舒张压高血压的负担各自独立预测不良后果。,0.3333333333333333,"['hypertension', 'diastolic', 'adverse', 'systolic', 'each', 'and']","['hypertension', 'each']",2123,"['系统和催眠高血压的负担,每个独立预测的负面结果。']",0.1666666666666666,"['hypertension', 'diastolic', 'adverse', 'systolic', 'each', 'and']",['hypertension'],,
2158,2124,similar results were observed with the lower threshold of hypertension ( ≥ 130 / 80 mm Hg ) and with systolic and diastolic blood pressures used as predictors without hypertension thresholds .,在较低的高血压阈值 (≥ 130 / 80 mm Hg) 以及在没有高血压阈值的情况下将收缩压和舒张压用作预测指标时观察到类似的结果。,0.2727272727272727,"['threshold', 'hypertension', '/', 'blood', 'lower', 'diastolic', 'systolic', 'with', 'and', 'without', 'similar']","['threshold', 'hypertension', 'lower']",2124,['类似的结果被观察到低血压边界( ≥ 130 / 80 mm Hg )和系统和神经血压用作预测器没有高血压边界。'],0.0909090909090909,"['threshold', 'hypertension', '/', 'blood', 'lower', 'diastolic', 'systolic', 'with', 'and', 'without', 'similar']",['hypertension'],,
2159,2125,thresholds for hypertension and prevailing concepts about hypertension have shifted over time .,随着时间的推移，高血压的阈值和关于高血压的流行观念发生了变化。,0.4,"['hypertension', 'time', 'have', 'over', 'and']","['hypertension', 'time']",2125,['高血压的边界和关于高血压的主导概念随着时间的推移而变化。'],0.6,"['hypertension', 'time', 'have', 'over', 'and']","['hypertension', 'time', 'and']",,
2160,2126,"constructs about the consequences of isolated diastolic , isolated systolic , and combined systolic and diastolic hypertension1 evolved in the 1960s , with a prevailing notion that only diastolic hypertension affected outcomes .",关于单纯舒张期高血压、单纯收缩期高血压以及收缩压和舒张期合并高血压 1 的后果的构想在 1960 年代形成，普遍认为只有舒张期高血压会影响结局。,0.3333333333333333,"['a', 'hypertension', 'diastolic', 'systolic', 'notion', 'with', 'that', 'in', 'and']","['hypertension', 'diastolic', 'systolic']",2126,"['关于孤立的催眠性、孤立的催眠性、结合的催眠性和催眠性高血压的后果,在1960年代发展,只有催眠性高血压影响了结果。']",0.1111111111111111,"['a', 'hypertension', 'diastolic', 'systolic', 'notion', 'with', 'that', 'in', 'and']",['hypertension'],,
2161,2127,"despite often assigning little importance to diastolic blood pressure in the management of hypertension , clinicians still record and target values for both systolic and diastolic blood pressures .",尽管在高血压的管理中通常不太重视舒张压，临床医生仍然记录收缩压和舒张压的目标值。,0.3571428571428571,"['record', 'pressure', 'hypertension', 'blood', 'blood pressure', 'still', 'diastolic', 'target', 'systolic', 'values', 'management', 'despite', 'in', 'and']","['record', 'hypertension', 'blood pressure', 'target', 'management']",2127,"['尽管在高血压管理中经常对血压给予微小重视,但临床医生仍然记录并对血压和血压的目标值。']",0.3571428571428571,"['record', 'pressure', 'hypertension', 'blood', 'blood pressure', 'still', 'diastolic', 'target', 'systolic', 'values', 'management', 'despite', 'in', 'and']","['record', 'hypertension', 'blood pressure', 'target', 'management']",,
2162,2128,we sought to determine whether the burdens of systolic and diastolic hypertension each independently predict the risk of adverse cardiovascular outcomes .,我们试图确定收缩压和舒张压高血压的负担是否各自独立预测不良心血管结局的风险。,0.4545454545454545,"['cardiovascular', 'hypertension', 'diastolic', 'predict', 'adverse', 'risk', 'systolic', 'each', 'and', 'determine', 'we']","['cardiovascular', 'hypertension', 'predict', 'risk', 'each']",2128,['我们试图确定是否系统和二进制高血压的负担独立预测不良心血管结果的风险。'],0.3636363636363636,"['cardiovascular', 'hypertension', 'diastolic', 'predict', 'adverse', 'risk', 'systolic', 'each', 'and', 'determine', 'we']","['cardiovascular', 'hypertension', 'predict', 'risk']",,
2163,2129,"we performed a retrospective cohort study involving outpatients from Kaiser Permanente Northern California ( KPNC ) , a large integrated health care delivery system with more than 4 million members that reflects the diverse population of Northern California.13",我们进行了一项回顾性队列研究，涉及来自 Kaiser Permanente Northern California (KPNC) 的门诊患者，这是一个大型综合医疗保健服务系统，拥有超过 400 万名成员，反映了北加州多样化的人口。 13,0.2,"['population', 'members', 'system', 'health', 'study', 'delivery', 'large', 'health care', '4', 'cohort study', 'with', 'that', 'delivery system', 'million', 'we']","['population', 'system', 'health care']",2129,"['我们进行了一项回顾性协调研究,涉及来自加利福尼亚北部Kaiser Permanente(KPNC)的外科患者,一个大型综合医疗保健提供系统,拥有超过4百万成员,反映了加利福尼亚北部的多样人口。']",0.2,"['population', 'members', 'system', 'health', 'study', 'delivery', 'large', 'health care', '4', 'cohort study', 'with', 'that', 'delivery system', 'million', 'we']","['population', 'system', 'health care']",,
2164,2130,"KPNC integrates data on outpatient encounters , inpatient care , pharmacy services , and laboratory services into a single electronic medical record.14",KPNC 将门诊、住院护理、药房服务和实验室服务的数据整合到一个电子病历中。 14,0.3,"['a', 'data', 'medical', 'laboratory', 'pharmacy', 'care', 'electronic', 'inpatient', 'single', 'and']","['data', 'laboratory', 'pharmacy']",2130,['KPNC将外病人会面、病人护理、药店服务和实验室服务的数据集成到一个单一的电子医疗记录中。'],0.3,"['a', 'data', 'medical', 'laboratory', 'pharmacy', 'care', 'electronic', 'inpatient', 'single', 'and']","['data', 'laboratory', 'single']",,
2165,2131,"participants were enrolled in KPNC from January 1 , 2007 , through December 31 , 2016 , or until death , with no more than a mean of 31 days of disenrollment per year in the study .",参与者从 2007 年 1 月 1 日到 2016 年 12 月 31 日，或直到死亡，在该研究中每年平均退出时间不超过 31 天。,0.4444444444444444,"['a', 'mean', 'year', '1', 'death', 'study', 'no', 'with', 'in']","['mean', 'year', '1', 'death']",2131,"['參與者從 2007 年 1 月 1 日至 2016 年 12 月 31 日,或直到死亡,每年在研究中不超過平均 31 天的退學日期。']",0.4444444444444444,"['a', 'mean', 'year', '1', 'death', 'study', 'no', 'with', 'in']","['mean', 'year', '1', 'death']",,
2166,2132,primary PREDICTORS,主要预测因素,0.0,['primary'],[],2132,['主要预言者'],0.0,['primary'],[],,
2167,2133,"the primary predictors in our study were the burdens of systolic and diastolic hypertension , which are continuous measures of the degree of hypertension , calculated as follows .",我们研究中的主要预测因子是收缩压和舒张压高血压的负担，它们是高血压程度的连续测量值，计算如下。,0.375,"['hypertension', 'continuous', 'study', 'degree', 'diastolic', 'primary', 'systolic', 'and']","['hypertension', 'continuous', 'degree']",2133,"['在我们的研究中,主要预测器是系统性高血压和高血压的负担,这些负担是高血压程度的持续测量,如下计算。']",0.25,"['hypertension', 'continuous', 'study', 'degree', 'diastolic', 'primary', 'systolic', 'and']","['hypertension', 'degree']",,
2168,2134,"the weighted average blood pressure was first determined by performing linear interpolation over the days between measurements , including data from both the baseline and observation periods , up to an outcome event , if one occurred .",加权平均血压首先是通过在测量之间的几天内进行线性插值来确定的，包括来自基线和观察期的数据，直到出现结果事件（如果发生的话）。,0.4090909090909091,"['pressure', 'average', 'data', 'baseline', 'outcome', 'blood', 'blood pressure', 'linear', 'weighted average', 'up', 'observation', 'performing', 'interpolation', 'periods', 'event', 'if', 'by', 'over', 'to', 'and', 'first', 'linear interpolation']","['average', 'data', 'baseline', 'outcome', 'blood pressure', 'observation', 'event', 'over', 'first']",2134,"['重量的平均血压首先是通过在测量之间的日期进行线性间隔,包括从基线和观测期间的数据,到一个结果事件,如果发生。']",0.4545454545454545,"['pressure', 'average', 'data', 'baseline', 'outcome', 'blood', 'blood pressure', 'linear', 'weighted average', 'up', 'observation', 'performing', 'interpolation', 'periods', 'event', 'if', 'by', 'over', 'to', 'and', 'first', 'linear interpolation']","['average', 'data', 'baseline', 'outcome', 'blood pressure', 'observation', 'event', 'by', 'over', 'first']",,
2169,2135,measured values and the interpolated daily values between measurements were then averaged .,然后对测量值和测量之间的内插日值进行平均。,0.0,"['values', 'and']",[],2135,['然后测量值和测量之间的每日值中间值被测量。'],0.0,"['values', 'and']",[],,
2170,2136,all multivariable models ( see below ) controlled for all covariates unless stated otherwise .,除非另有说明，否则所有多变量模型（见下文）均针对所有协变量进行控制。,0.5,"['controlled', 'all']",['controlled'],2136,"['所有多变型模型(参见下方)对所有可变型进行控制,除非另有说明。']",0.5,"['controlled', 'all']",['controlled'],,
2171,2137,"the primary outcome in our study was a composite of the first episode of myocardial infarction , ischemic stroke , or hemorrhagic stroke during the observation period , with an event defined as hospitalization with a discharge diagnosis matching one of the components of the composite primary outcome , as previously validated for this population.15,16","我们研究中的主要结果是观察期间首次心肌梗死、缺血性卒中或出血性卒中的复合事件，事件定义为住院，出院诊断与复合主要结果的一个组成部分相匹配，如之前已针对该人群进行过验证。 15,16",0.5238095238095238,"['myocardial infarction', 'discharge', 'composite', 'period', 'stroke', 'defined', 'outcome', 'study', 'episode', 'hospitalization', 'diagnosis', 'primary', 'hemorrhagic', 'matching', 'observation', 'as', 'with', 'event', 'this', 'first', 'ischemic']","['myocardial infarction', 'period', 'stroke', 'outcome', 'hospitalization', 'diagnosis', 'matching', 'observation', 'as', 'event', 'this']",2137,"['我们的研究中的主要结果是观察期内心脏病发作、骨头发作或血管发作的第一个阶段的组成部分,其中一个事件被定义为医院诊断,排泄诊断与组成部分的组成部分相匹配,如此前对该人口确认。']",0.5238095238095238,"['myocardial infarction', 'discharge', 'composite', 'period', 'stroke', 'defined', 'outcome', 'study', 'episode', 'hospitalization', 'diagnosis', 'primary', 'hemorrhagic', 'matching', 'observation', 'as', 'with', 'event', 'this', 'first', 'ischemic']","['period', 'stroke', 'outcome', 'episode', 'diagnosis', 'matching', 'observation', 'as', 'event', 'this', 'first']",,
2172,2138,death was not part of the primary outcome .,死亡不是主要结果的一部分。,0.75,"['part', 'outcome', 'death', 'primary']","['part', 'outcome', 'death']",2138,['死亡并不是主要结果的一部分。'],0.75,"['part', 'outcome', 'death', 'primary']","['part', 'outcome', 'death']",,
2173,2139,"all multivariable models in the study controlled for the full set of covariates ( see above ) , with the exception of models specifically addressing the role of confounding by age in producing a J curve in bivariate analysis ( see below ) .",研究中的所有多变量模型都控制了整套协变量（见上文），但在双变量分析中专门解决年龄混淆在产生 J 曲线中的作用的模型除外（见下文）。,0.4,"['a', 'analysis', 'study', 'controlled', 'role', 'curve', 'bivariate', 'age', 'set', 'exception', 'with', 'full', 'all', 'in', 'by']","['analysis', 'controlled', 'role', 'curve', 'age', 'set']",2139,"['研究中的所有多变型模型都被控制为整个集合的科瓦里亚特(参见上),除非模型具体讨论了根据年龄在产生J曲线在比瓦里亚特分析中的混合作用(参见下)。']",0.3333333333333333,"['a', 'analysis', 'study', 'controlled', 'role', 'curve', 'bivariate', 'age', 'set', 'exception', 'with', 'full', 'all', 'in', 'by']","['analysis', 'controlled', 'role', 'curve', 'age']",,
2174,2140,bivariate analyses were also performed to explore the tabular relationship between quantiles ( cutoff points ) of blood pressures and the risk of a composite outcome event at each quantile .,还进行了双变量分析，以探索血压分位数（截止点）与每个分位数的复合结果事件风险之间的表格关系。,0.3333333333333333,"['composite', 'cutoff', 'relationship', 'outcome', 'blood', 'tabular', 'bivariate', 'risk', 'explore', 'event', 'each', 'and']","['outcome', 'risk', 'explore', 'event']",2140,"['此外,Bivariate分析也进行,以探讨血压量的量子(切割点)和每量子中的合成结果事件的风险之间的表面关系。']",0.25,"['composite', 'cutoff', 'relationship', 'outcome', 'blood', 'tabular', 'bivariate', 'risk', 'explore', 'event', 'each', 'and']","['outcome', 'risk', 'event']",,
2175,2141,"to perform similar analyses , but with control for the full list of covariates above , multivariable logistic regression was used to generate a model estimation of event risk , with controls held at means .",为了执行类似的分析，但控制了上述协变量的完整列表，使用多变量逻辑回归来生成事件风险的模型估计，控制保持在均值。,0.375,"['a', 'logistic regression', 'estimation', 'control', 'model', 'risk', 'list', 'generate', 'means', 'controls', 'with', 'event', 'full', 'but', 'to', 'similar']","['estimation', 'control', 'model', 'risk', 'full', 'but']",2141,"['为了进行类似的分析,但在上面的科瓦里亚特的完整列表的控制下,多变的物流回归被用来产生事件风险的模型估计,并在中间进行控制。']",0.375,"['a', 'logistic regression', 'estimation', 'control', 'model', 'risk', 'list', 'generate', 'means', 'controls', 'with', 'event', 'full', 'but', 'to', 'similar']","['estimation', 'control', 'model', 'risk', 'full', 'but']",,
2176,2142,"the same structure of predictors ( including blood pressures recorded up to the point of an event , if one occurred ) , covariates , and outcomes that were used in Cox regression was used in logistic regression but without the time coding of outcome that was used in the Cox models .",Cox 回归中使用的相同预测变量结构（包括事件发生时的血压记录，如果发生的话） 、协变量和结果用于逻辑回归，但没有用于结果的时间编码考克斯模型。,0.4666666666666667,"['coding', 'logistic regression', 'outcome', 'blood', 'time', 'structure', 'point', 'up', 'event', 'that', 'if', 'but', 'to', 'and', 'without']","['coding', 'outcome', 'time', 'structure', 'event', 'but', 'to']",2142,"['相同的预测器结构(包括血压记录到事件发生时),科瓦里亚特和在科克斯回归中使用的结果在物流回归中使用,但没有在科克斯模型中使用的结果的时间编码。']",0.4,"['coding', 'logistic regression', 'outcome', 'blood', 'time', 'structure', 'point', 'up', 'event', 'that', 'if', 'but', 'to', 'and', 'without']","['coding', 'outcome', 'time', 'structure', 'event', 'but']",,
2177,2143,"study POPULATION , MEASUREMENTS , AND OUTCOMES",研究人口、测量和结果,0.0,['study'],[],2143,['研究人口、测量和外观'],0.0,['study'],[],,
2178,2144,the baseline characteristics of the participants are shown in Table 1 .,参与者的基线特征如表1所示。,1.0,"['table', 'baseline', '1', 'characteristics']","['table', 'baseline', '1', 'characteristics']",2144,['參與者的基本特點在表1中顯示。'],0.5,"['table', 'baseline', '1', 'characteristics']","['table', '1']",,
2179,2144,the baseline characteristics of the participants are shown in Table 1 .,参与者的基线特征如表1所示。,1.0,"['table', 'baseline', '1', 'characteristics']","['table', 'baseline', '1', 'characteristics']",2144,['參與者的基本特點在表1中顯示。'],0.5,"['table', 'baseline', '1', 'characteristics']","['table', '1']",,
2180,2145,prevalence OF MEASUREMENTS INDICATING HYPERTENSION,指示高血压的测量值的患病率,0.0,['prevalence'],[],2145,['指示高压的测量率'],0.0,['prevalence'],[],,
2181,2146,"for the threshold of 140 / 90 mm Hg , 18.9 % of the measurements showed hypertension , whereas for the threshold of 130 / 80 mm Hg , 43.5 % of the measurements showed hypertension .",对于140 / 90 mm Hg 的阈值，18.9% 的测量值显示高血压，而对于130 / 80 mm Hg 的阈值，43.5% 的测量值显示高血压。,0.6666666666666666,"['threshold', 'hypertension', '/']","['threshold', 'hypertension']",2146,"['对于 140 / 90 mm Hg 的边界, 18.9% 的测量显示高血压,而对于 130 / 80 mm Hg 的边界, 43.5% 的测量显示高血压。']",0.3333333333333333,"['threshold', 'hypertension', '/']",['hypertension'],,
2182,2147,relationship BETWEEN BLOOD PRESSURE AND CARDIOVASCULAR OUTCOMES,血压与心血管结果之间的关系,0.0,['relationship'],[],2147,['BETWEEN 血压与心血管外科'],0.0,['relationship'],[],,
2183,2148,quantiles of increasing systolic blood pressure were associated with an increased risk of an adverse outcome ( Figure 3A and 3B ) .,收缩压升高的分位数与不良后果风险增加相关（图 3A 和 3B）。,0.0909090909090909,"['pressure', 'outcome', 'figure', 'blood', 'blood pressure', 'adverse', 'associated', 'risk', 'systolic', 'with', 'and']",['risk'],2148,['增加血压的量与不良结果的风险增加有关(图3A和3B)。'],0.2727272727272727,"['pressure', 'outcome', 'figure', 'blood', 'blood pressure', 'adverse', 'associated', 'risk', 'systolic', 'with', 'and']","['outcome', 'blood pressure', 'risk']",,
2184,2149,age and other covariates appeared to explain at least part of this relationship ( Figure 3D ) .,年龄和其他协变量似乎至少可以部分解释这种关系（图 3D）。,0.1428571428571428,"['part', 'relationship', 'figure', 'age', 'this', 'to', 'and']",['age'],2149,['年龄和其他偏见似乎解释至少这一关系的一部分(图3D)。'],0.2857142857142857,"['part', 'relationship', 'figure', 'age', 'this', 'to', 'and']","['part', 'age']",,
2185,2150,stratification of these models according to race or ethnic group or to sex showed similar results across these categories .,根据种族或族裔群体或性别对这些模型进行分层显示，这些类别的结果相似。,0.4444444444444444,"['group', 'stratification', 'sex', 'categories', 'across', 'ethnic group', 'race', 'to', 'similar']","['group', 'stratification', 'sex', 'race']",2150,"['根据种族或种族群体或性别,这些模型的分类在这些类别中表现出类似的结果。']",0.4444444444444444,"['group', 'stratification', 'sex', 'categories', 'across', 'ethnic group', 'race', 'to', 'similar']","['group', 'sex', 'ethnic group', 'race']",,
2186,2151,"when we used blood pressures from only the baseline period , similar results were seen for both hypertension thresholds .",当我们仅使用基线期的血压时，两个高血压阈值的结果相似。,0.5,"['period', 'hypertension', 'baseline', 'blood', 'similar', 'we']","['period', 'hypertension', 'baseline']",2151,"['当我们使用血压仅从基层期,相似的结果被视为两种高血压边界。']",0.5,"['period', 'hypertension', 'baseline', 'blood', 'similar', 'we']","['period', 'hypertension', 'similar']",,
2187,2152,we also constructed models in which continuous blood pressures were used without the introduction of thresholds .,我们还构建了在不引入阈值的情况下使用连续血压的模型。,0.2,"['introduction', 'continuous', 'blood', 'without', 'we']",['continuous'],2152,"['我们还建造了模型,在这些模型中,持续的血压被使用,没有引入边界。']",0.0,"['introduction', 'continuous', 'blood', 'without', 'we']",[],,
2188,2153,these relationships also did not differ when we compared participants taking antihypertensive medications throughout the observation period with participants who were not taking antihypertensive medications at any point .,当我们将在整个观察期间服用抗高血压药物的参与者与在任何时候都没有服用抗高血压药物的参与者进行比较时，这些关系也没有差异。,0.3333333333333333,"['antihypertensive', 'period', 'who', 'taking', 'differ', 'point', 'observation', 'with', 'we']","['antihypertensive', 'period', 'observation']",2153,"['这些关系也没有差异,当我们比较参与者在观察期间服用抗高血压药物时,与没有在任何时候服用抗高血压药物的参与者。']",0.3333333333333333,"['antihypertensive', 'period', 'who', 'taking', 'differ', 'point', 'observation', 'with', 'we']","['antihypertensive', 'period', 'observation']",,
2189,2154,"the overall pattern of a greater effect of systolic blood pressure on outcomes was observed across age groups , with lower hazard ratios for both systolic and diastolic hypertension burden observed at older ages .",在不同年龄组观察到收缩压对结果影响更大的总体模式，在年龄较大的人群中观察到收缩压和舒张压高血压负担的风险比较低。,0.25,"['a', 'pressure', 'pattern', 'hypertension', 'blood', 'blood pressure', 'lower', 'diastolic', 'across', 'hazard', 'age', 'systolic', 'effect', 'with', 'and', 'burden']","['pattern', 'hypertension', 'blood pressure', 'age']",2154,"['基因血压对结果的影响的总体模式在年龄组中被观察到,在老年时观察到基因血压负担和基因血压负担的风险比率较低。']",0.1875,"['a', 'pressure', 'pattern', 'hypertension', 'blood', 'blood pressure', 'lower', 'diastolic', 'across', 'hazard', 'age', 'systolic', 'effect', 'with', 'and', 'burden']","['pattern', 'blood pressure', 'age']",,
2190,2155,details are provided in Figure S9 and Tables S4 through S7 in the Supplementary Appendix .,补充附录中的图 S9 和表 S4 至表 S7 提供了详细信息。,0.0,"['appendix', 'figure', 'supplementary', 'S4', 'in', 'and']",[],2155,['详细信息在图 S9 和图 S4 到 S7 在附件中提供。'],0.1666666666666666,"['appendix', 'figure', 'supplementary', 'S4', 'in', 'and']",['appendix'],,
2191,2156,"at both thresholds , the burden of isolated diastolic hypertension was also associated with the composite outcome among participants who did not have a burden of systolic hypertension .",在这两个阈值下，单纯舒张期高血压的负担也与没有收缩期高血压负担的参与者的综合结果相关。,0.4545454545454545,"['composite', 'a', 'hypertension', 'who', 'outcome', 'systolic hypertension', 'diastolic', 'associated', 'with', 'have', 'burden']","['hypertension', 'outcome', 'systolic hypertension', 'diastolic', 'have']",2156,"['在两边,孤立的甲状腺高血压的负担也与没有甲状腺高血压负担的参与者的组合结果有关。']",0.2727272727272727,"['composite', 'a', 'hypertension', 'who', 'outcome', 'systolic hypertension', 'diastolic', 'associated', 'with', 'have', 'burden']","['hypertension', 'outcome', 'have']",,
2192,2157,systolic hypertension had a greater effect at lower diastolic blood pressures .,收缩压升高在舒张压降低时影响更大。,0.0,"['a', 'hypertension', 'blood', 'systolic hypertension', 'lower', 'diastolic', 'effect', 'at']",[],2157,['系统性高血压对低血压产生了更大的影响。'],0.125,"['a', 'hypertension', 'blood', 'systolic hypertension', 'lower', 'diastolic', 'effect', 'at']",['hypertension'],,
2193,2158,"participants with a weighted average systolic blood pressure of approximately 160 mm Hg ( z score , + 3 ) had a predicted risk of a composite outcome event at 8 years of 4.8 % , whereas those with a systolic blood pressure of approximately 136 mm Hg ( z score , + 1 ) had a predicted risk of 1.9 % .","加权平均收缩压约为 160 毫米汞柱（ z 评分， + 3 ）的参与者在 8 年时发生复合结果事件的预测风险为 4.8 % ，而那些收缩压约为 136 毫米汞柱（ z分数, + 1) 的预测风险为 1.9%。",0.3529411764705882,"['composite', 'a', 'pressure', 'average', '1', 'outcome', 'blood', 'blood pressure', 'risk', 'systolic', '3', 'score', 'weighted average', 'with', 'at', 'event', 'approximately']","['average', '1', 'outcome', 'risk', 'score', 'event']",2158,"['体重平均血压约为160毫米Hg(z分数 +3)的参与者在8年间有4.8%的合成结果发生的预测风险,而体重约为136毫米Hg(z分数 +1)的参与者则有1.9%的预测风险。']",0.4117647058823529,"['composite', 'a', 'pressure', 'average', '1', 'outcome', 'blood', 'blood pressure', 'risk', 'systolic', '3', 'score', 'weighted average', 'with', 'at', 'event', 'approximately']","['average', '1', 'outcome', 'blood pressure', 'risk', 'score', 'event']",,
2194,2159,"participants with a diastolic blood pressure of approximately 96 mm Hg ( z score , + 3 ) had a predicted risk of the composite outcome of 3.6 % , whereas those with a diastolic blood pressure of approximately 81 mm Hg ( z score , + 1 ) had a predicted risk of 1.9 % .",舒张压约为 96 毫米汞柱（ z 分数， + 3 ）的参与者的复合结果的预测风险为 3.6 % ，而舒张压约为 81 毫米汞柱（ z 分数， + 1 ）的参与者有预测风险为 1.9%。,0.3076923076923077,"['composite', 'a', 'pressure', '1', 'outcome', 'blood', 'blood pressure', 'diastolic', 'risk', '3', 'score', 'with', 'approximately']","['1', 'outcome', 'risk', 'score']",2159,"['患有大约96毫米Hg的血压(z分数 +3)的参与者预测合成结果的风险为3.6%,而患有大约81毫米Hg的血压(z分数 +1)的参与者预测的风险为1.9%。']",0.3846153846153846,"['composite', 'a', 'pressure', '1', 'outcome', 'blood', 'blood pressure', 'diastolic', 'risk', '3', 'score', 'with', 'approximately']","['1', 'outcome', 'blood pressure', 'risk', 'score']",,
2195,2160,"we found that systolic and diastolic hypertension independently predicted adverse outcomes , despite a greater effect of systolic hypertension .",我们发现收缩压和舒张压高血压可独立预测不良后果，尽管收缩压高血压的影响更大。,0.1,"['a', 'hypertension', 'systolic hypertension', 'diastolic', 'adverse', 'effect', 'despite', 'that', 'and', 'we']",['hypertension'],2160,"['我们发现,系统性高血压和神经性高血压独立预测不良结果,尽管系统性高血压的影响更大。']",0.1,"['a', 'hypertension', 'systolic hypertension', 'diastolic', 'adverse', 'effect', 'despite', 'that', 'and', 'we']",['hypertension'],,
2196,2161,"we found that the J curve was explained at least in part by the relationship to age and other covariates ; in addition , we found that systolic hypertension had a greater effect in the group of participants with lower diastolic blood pressures , an observation that had been previously reported to explain the J curve.18",我们发现 J 曲线至少部分可以通过与年龄和其他协变量的关系来解释；此外，我们发现收缩压高血压对舒张压较低的参与者组的影响更大，这一观察结果曾被报道用于解释 J 曲线。 18,0.3888888888888889,"['group', 'part', 'relationship', 'hypertension', 'blood', 'addition', 'systolic hypertension', 'lower', 'diastolic', 'curve', 'age', 'effect', 'observation', 'with', 'that', 'in', 'by', 'and']","['group', 'hypertension', 'lower', 'curve', 'age', 'observation', 'by']",2161,"['我们发现,J曲线至少部分由与年龄和其他曲线的关系解释;此外,我们发现,系统性高血压在低血压的参与者群体中具有更大的影响,这是一个预先报告的观察,以解释J曲线。']",0.3333333333333333,"['group', 'part', 'relationship', 'hypertension', 'blood', 'addition', 'systolic hypertension', 'lower', 'diastolic', 'curve', 'age', 'effect', 'observation', 'with', 'that', 'in', 'by', 'and']","['group', 'hypertension', 'curve', 'age', 'observation', 'by']",,
2197,2162,"despite this , it has been argued , on the basis of data from the Framingham Heart Study , 2 that treatment for hypertension could improve with measurement of only systolic blood pressure.3",尽管如此，根据 Framingham 心脏研究 2 的数据，有人认为仅通过测量收缩压可以改善高血压的治疗。 3,0.4285714285714285,"['heart', 'data', 'hypertension', '2', 'blood', 'study', 'basis', 'treatment', 'measurement', 'systolic', 'with', 'despite', 'this', 'that']","['heart', 'data', 'hypertension', '2', 'treatment', 'measurement']",2162,"['尽管如此,根据Framingham心脏研究的数据,2认为高血压治疗只能通过测量系统血压来改善。']",0.4285714285714285,"['heart', 'data', 'hypertension', '2', 'blood', 'study', 'basis', 'treatment', 'measurement', 'systolic', 'with', 'despite', 'this', 'that']","['heart', 'data', 'hypertension', '2', 'treatment', 'measurement']",,
2198,2163,"our results show that this would be inappropriate : although systolic blood pressure indeed had a greater effect , systolic and diastolic blood pressures each independently influenced cardiovascular outcomes , and therefore diastolic blood pressure ought not to be ignored .",我们的结果表明这是不恰当的：虽然收缩压确实有更大的影响，但收缩压和舒张压各自独立地影响心血管结果，因此不应忽视舒张压。,0.2,"['a', 'pressure', 'cardiovascular', 'blood', 'blood pressure', 'be', 'diastolic', 'systolic', 'effect', 'therefore', 'this', 'that', 'indeed', 'each', 'and']","['cardiovascular', 'this', 'each']",2163,"['我们的结果表明,这将是不合适的:虽然系统性血压实际上具有更大的效果,但系统性和神经性血压每一个独立影响心血管结果,因此神经性血压不应该被忽视。']",0.2666666666666666,"['a', 'pressure', 'cardiovascular', 'blood', 'blood pressure', 'be', 'diastolic', 'systolic', 'effect', 'therefore', 'this', 'that', 'indeed', 'each', 'and']","['cardiovascular', 'blood pressure', 'effect', 'this']",,
2199,2164,data were obtained retrospectively from prospectively populated clinical databases .,数据是从前瞻性填充的临床数据库中回顾性获得的。,1.0,"['data', 'clinical']","['data', 'clinical']",2164,['数据是从前瞻性人口的临床数据库中获取的。'],1.0,"['data', 'clinical']","['data', 'clinical']",,
2200,2165,"although we included data on antihypertensive treatment , we did not include data on measures such as diet modification .",尽管我们纳入了抗高血压治疗的数据，但并未纳入饮食调整等措施的数据。,0.5714285714285714,"['modification', 'antihypertensive', 'data', 'diet', 'treatment', 'as', 'we']","['antihypertensive', 'data', 'diet', 'treatment']",2165,"['虽然我们包含了对抗高血压治疗的数据,但我们并没有包含对饮食修改等措施的数据。']",0.5714285714285714,"['modification', 'antihypertensive', 'data', 'diet', 'treatment', 'as', 'we']","['antihypertensive', 'data', 'diet', 'treatment']",,
2201,2166,"death was used for censoring purposes , but it was not part of the primary outcome .",死亡被用于审查目的，但它不是主要结果的一部分。,0.8,"['part', 'outcome', 'death', 'primary', 'but']","['part', 'outcome', 'death', 'but']",2166,"['死亡是用来审查的目的,但它不是主要结果的一部分。']",0.8,"['part', 'outcome', 'death', 'primary', 'but']","['part', 'outcome', 'death', 'but']",,
2202,2167,"we controlled for hypercholesterolemia as part of the medical history , but we did not include measured cholesterol values .",我们控制了作为病史一部分的高胆固醇血症，但我们没有包括测得的胆固醇值。,0.625,"['cholesterol', 'part', 'medical history', 'controlled', 'values', 'as', 'but', 'we']","['cholesterol', 'part', 'medical history', 'controlled', 'but']",2167,"['我们在医学史的一部分检查过高胆固醇,但我们没有包含测量胆固醇值。']",0.375,"['cholesterol', 'part', 'medical history', 'controlled', 'values', 'as', 'but', 'we']","['cholesterol', 'part', 'but']",,
2203,2168,"finally , our results from a large , multiethnic , and generally healthy population , across a wide range of ages , may not apply to specific subpopulations .",最后，我们的结果来自大量的、多种族的、普遍健康的人群，跨越广泛的年龄范围，可能不适用于特定的亚人群。,0.6,"['population', 'range', 'large', 'wide', 'across', 'apply', 'specific', 'to', 'and', 'healthy']","['population', 'range', 'wide', 'apply', 'to', 'healthy']",2168,"['最后,我们从一个大、多种族、一般健康的人口的结果,在一个广泛的年龄范围内,可能不适用于特定的子群。']",0.6,"['population', 'range', 'large', 'wide', 'across', 'apply', 'specific', 'to', 'and', 'healthy']","['population', 'range', 'wide', 'apply', 'to', 'healthy']",,
2204,2169,our study also has certain strengths .,我们的学习也有一定的优势。,0.5,"['study', 'certain']",['study'],2169,['我们的研究也有一定的力量。'],0.0,"['study', 'certain']",[],,
2205,2170,"because our data came from a comprehensive electronic medical record , 13,14 rather than a billing and administrative database , we used rigorously identified covariates and outcomes .","因为我们的数据来自全面的电子病历 13,14 而不是计费和管理数据库，所以我们使用了严格确定的协变量和结果。",0.1111111111111111,"['record', 'a', 'database', 'comprehensive', 'medical', 'medical record', 'electronic', 'and', 'we']",['and'],2170,"['因为我们的数据来自一个全面的电子医疗记录,1314而不是计算和行政数据库,我们使用了严格确认的科瓦里亚特和结果。']",0.2222222222222222,"['record', 'a', 'database', 'comprehensive', 'medical', 'medical record', 'electronic', 'and', 'we']","['record', 'and']",,
2206,2171,"in conclusion , both systolic and diastolic hypertension contribute significantly to cardiovascular risk , regardless of the threshold used for hypertension ( ≥ 140 / 90 mm Hg or ≥ 130 / 80 mm Hg ) .",总之，无论用于高血压的阈值（≥ 140 / 90 mm Hg 或≥ 130 / 80 mm Hg）如何，收缩压和舒张压高血压都会显着增加心血管风险。,0.4,"['threshold', 'cardiovascular', 'hypertension', '/', 'diastolic', 'risk', 'systolic', 'conclusion', 'in', 'and']","['threshold', 'cardiovascular', 'hypertension', 'risk']",2171,"['在结论中,系统性高血压和中性高血压都对心血管风险有显著贡献,无论用于高血压的边界( ≥ 140 / 90 mm Hg 或 ≥ 130 / 80 mm Hg )。']",0.4,"['threshold', 'cardiovascular', 'hypertension', '/', 'diastolic', 'risk', 'systolic', 'conclusion', 'in', 'and']","['cardiovascular', 'hypertension', 'risk', 'conclusion']",,
2207,2172,"exposure to light affects circadian rhythm by altering melatonin activity and can influence seasonal affective disorder , bipolar depression , and mania .",暴露在光线下会通过改变褪黑激素的活性来影响昼夜节律，并且会影响季节性情感障碍、双相抑郁症和躁狂症。,0.6470588235294118,"['depression', 'bipolar', 'rhythm', 'melatonin', 'circadian', 'disorder', 'circadian rhythm', 'exposure', 'affective', 'affective disorder', 'mania', 'activity', 'light', 'seasonal', 'influence', 'by', 'and']","['depression', 'rhythm', 'circadian', 'disorder', 'circadian rhythm', 'exposure', 'affective disorder', 'mania', 'activity', 'light', 'influence']",2172,"['对光的曝光会影响循环节奏,通过改变<unk>素的活动,并可能影响季节性情感障碍、双极抑郁症和精神病。']",0.4705882352941176,"['depression', 'bipolar', 'rhythm', 'melatonin', 'circadian', 'disorder', 'circadian rhythm', 'exposure', 'affective', 'affective disorder', 'mania', 'activity', 'light', 'seasonal', 'influence', 'by', 'and']","['depression', 'rhythm', 'disorder', 'exposure', 'affective disorder', 'activity', 'light', 'influence']",,
2208,2173,"however , do individuals vary in the intensity of light that would suppress melatonin secretion ?",然而，抑制褪黑激素分泌的光照强度是否因人而异？,0.4285714285714285,"['secretion', 'melatonin', 'suppress', 'light', 'intensity', 'intensity of light', 'that']","['secretion', 'suppress', 'light']",2173,"['然而,个人在光的强度有所不同,这会抑制<unk>素分泌吗?']",0.4285714285714285,"['secretion', 'melatonin', 'suppress', 'light', 'intensity', 'intensity of light', 'that']","['secretion', 'suppress', 'light']",,
2209,2174,"overall , the mean effective dose for 50 % suppression of melatonin ( ED50 ) was 24.6 lux .",总体而言，抑制 50% 褪黑激素 (ED50) 的平均有效剂量为 24.6 lux。,0.3333333333333333,"['suppression', 'melatonin', 'mean', 'ED50', 'effective dose', 'lux']","['suppression', 'mean']",2174,"['总体而言,50%抑制梅拉顿(ED50)的平均有效剂量为24.6卢克。']",0.3333333333333333,"['suppression', 'melatonin', 'mean', 'ED50', 'effective dose', 'lux']","['suppression', 'mean']",,
2210,2175,greater light intensity was related to delayed melatonin onset .,更强的光照强度与延迟的褪黑激素作用有关。,0.25,"['light intensity', 'melatonin', 'onset', 'delayed']",['delayed'],2175,['更大的光强度与延迟的梅拉顿因发起有关。'],0.5,"['light intensity', 'melatonin', 'onset', 'delayed']","['light intensity', 'delayed']",,
2211,2176,varying light intensity from 10 to 50 lux delayed melatonin onset from 22 to 109 minutes .,从 10 勒克斯到 50 勒克斯不等的光照强度可将褪黑激素的作用延迟 22 到 109 分钟。,0.4,"['light intensity', 'melatonin', 'onset', 'lux', 'delayed']","['lux', 'delayed']",2176,['光强度从 10 到 50 卢克延迟出发 梅拉顿因 22 到 109 分钟。'],0.4,"['light intensity', 'melatonin', 'onset', 'lux', 'delayed']","['light intensity', 'delayed']",,
2212,2177,"great interindividual differences were seen , from 6 to 350 lux .",从 6 勒克斯到 350 勒克斯可见很大的个体差异。,0.6666666666666666,"['lux', 'great', 'to']","['lux', 'great']",2177,"['显著的间人差异,从6到350卢克。']",0.0,"['lux', 'great', 'to']",[],,
2213,2178,this variability could affect many neuropsychiatric disorders .,这种变异性可能会影响许多神经精神疾病。,0.5,"['variability', 'affect', 'disorders', 'this']","['variability', 'affect']",2178,['这种变化可能会影响许多神经精神疾病。'],0.25,"['variability', 'affect', 'disorders', 'this']",['affect'],,
2214,2179,"for example , our instructions for sleep hygiene often include a directive to avoid bright screens in the evening , but the range of responsivity to dim indoor light ( 50 lux ) is large .",例如，我们的睡眠卫生说明通常包括避免在晚上使用明亮屏幕的指令，但对昏暗室内光线 (50 lux) 的响应范围很大。,0.5714285714285714,"['hygiene', 'a', 'range', 'large', 'light', 'sleep hygiene', 'indoor', 'lux', 'evening', 'example', 'but', 'to', 'avoid', 'instructions']","['hygiene', 'range', 'light', 'sleep hygiene', 'evening', 'example', 'but', 'avoid']",2179,"['例如,我们的睡眠卫生指南往往包含一个指令,以避免夜间亮屏,但对干净室内光(50卢克)的响应范围很大。']",0.5,"['hygiene', 'a', 'range', 'large', 'light', 'sleep hygiene', 'indoor', 'lux', 'evening', 'example', 'but', 'to', 'avoid', 'instructions']","['hygiene', 'range', 'light', 'sleep hygiene', 'example', 'but', 'avoid']",,
2215,2180,"disorders like circadian rhythm disturbances , daytime fatigue , and mood disorders might involve large interindividual differences for response to light .",昼夜节律紊乱、白天疲劳和情绪障碍等疾病可能涉及对光反应的巨大个体差异。,0.5714285714285714,"['mood', 'rhythm', 'circadian', 'circadian rhythm', 'fatigue', 'large', 'involve', 'response', 'light', 'disorders', 'daytime', 'like', 'to', 'and']","['rhythm', 'circadian', 'circadian rhythm', 'fatigue', 'response', 'light', 'disorders', 'daytime']",2180,['如循环节奏障碍、白天疲劳和情绪障碍可能会导致对光的反应有很大的差异。'],0.3571428571428571,"['mood', 'rhythm', 'circadian', 'circadian rhythm', 'fatigue', 'large', 'involve', 'response', 'light', 'disorders', 'daytime', 'like', 'to', 'and']","['rhythm', 'fatigue', 'response', 'light', 'disorders']",,
2216,2181,"high consumption of red meat is associated with excess risks for cardiovascular disease ( CVD ) , cancer , and death .",大量食用红肉会增加心血管疾病 (CVD)、癌症和死亡的风险。,0.3846153846153846,"['excess', 'disease', 'cancer', 'cardiovascular', 'consumption', 'death', 'cardiovascular disease', 'red', 'associated', 'with', 'CVD', 'and', 'high']","['disease', 'cancer', 'cardiovascular', 'death', 'cardiovascular disease']",2181,['红肉的高消耗与心血管疾病(CVD)、癌症和死亡的过度风险有关。'],0.5384615384615384,"['excess', 'disease', 'cancer', 'cardiovascular', 'consumption', 'death', 'cardiovascular disease', 'red', 'associated', 'with', 'CVD', 'and', 'high']","['disease', 'cancer', 'cardiovascular', 'consumption', 'death', 'cardiovascular disease', 'high']",,
2217,2182,participants were free of CVD and cancer at baseline .,参与者在基线时没有 CVD 和癌症。,0.3333333333333333,"['cancer', 'baseline', 'free', 'at', 'CVD', 'and']","['cancer', 'baseline']",2182,['參與者在基線上免受CVD和癌症。'],0.1666666666666666,"['cancer', 'baseline', 'free', 'at', 'CVD', 'and']",['cancer'],,
2218,2183,data were collected from 1986 through 2010 ; diet and lifestyle factors were measured every 4 years .,数据收集自 1986 年至 2010 年；每 4 年测量一次饮食和生活方式因素。,0.5,"['data', 'diet', '4', 'and']","['data', 'diet']",2183,['数据从1986年到2010年收集;饮食和生活方式因素每4年进行测量。'],0.5,"['data', 'diet', '4', 'and']","['data', 'diet']",,
2219,2184,"more than 14,000 deaths occurred during the studies .","超过 14,000 人在研究期间死亡。",,[],[],2184,"['在研究期间,有14000多人死亡。']",,[],[],,
2220,2185,"reducing red meat intake and replacing it with other sources of protein , whole grains , or vegetables was associated with significantly lower relative risks ( range , 5 % to 26 % lower ) .",减少红肉摄入量并用其他来源的蛋白质、全谷物或蔬菜取而代之与显着降低的相对风险相关（范围，降低 5% 至 26%）。,0.2857142857142857,"['intake', '5', 'grains', 'range', 'protein', 'relative', 'lower', 'red', 'associated', 'with', 'whole', 'to', 'and', 'vegetables']","['5', 'range', 'protein', 'and']",2185,"['减少红肉的摄入量,并将其替换为其他蛋白质、全谷物或蔬菜来源,与相对风险显著降低(范围为5%至26%低)。']",0.2142857142857142,"['intake', '5', 'grains', 'range', 'protein', 'relative', 'lower', 'red', 'associated', 'with', 'whole', 'to', 'and', 'vegetables']","['5', 'range', 'protein']",,
2221,2186,elevated expression of FKBP5 protein promotes inflammation .,FKBP5 蛋白表达升高促进炎症。,1.0,"['protein', 'expression', 'inflammation']","['protein', 'expression', 'inflammation']",2186,['FKBP5 蛋白质的高表达促进炎症。'],1.0,"['protein', 'expression', 'inflammation']","['protein', 'expression', 'inflammation']",,
2222,2187,"aging , stress ( particularly childhood trauma ) , and depression are associated with elevated risk for cardiovascular disease , but how ?",衰老、压力（尤其是童年创伤）和抑郁与心血管疾病风险增加有关，但如何关联呢？,0.6923076923076923,"['childhood', 'depression', 'trauma', 'aging', 'disease', 'cardiovascular', 'stress', 'cardiovascular disease', 'associated', 'risk', 'with', 'but', 'and']","['depression', 'trauma', 'aging', 'disease', 'cardiovascular', 'stress', 'cardiovascular disease', 'risk', 'but']",2187,"['老化、压力(尤其是童年创伤)和抑郁症与心血管疾病的风险增加有关,但如何?']",0.6923076923076923,"['childhood', 'depression', 'trauma', 'aging', 'disease', 'cardiovascular', 'stress', 'cardiovascular disease', 'associated', 'risk', 'with', 'but', 'and']","['depression', 'trauma', 'aging', 'disease', 'cardiovascular', 'stress', 'cardiovascular disease', 'risk', 'but']",,
2223,2188,an international consortium studied four large cohorts that involved more than 3000 people and identified one potentially important mechanism .,一个国际财团研究了四个涉及 3000 多人的大型队列，并确定了一个潜在的重要机制。,0.1666666666666666,"['consortium', 'mechanism', 'large', 'cohorts', 'that', 'and']",['mechanism'],2188,"['一个国际联盟研究了四个大联盟,其中有超过3000人,并确定了一个潜在重要机制。']",0.1666666666666666,"['consortium', 'mechanism', 'large', 'cohorts', 'that', 'and']",['mechanism'],,
2224,2189,"aging , stress , and depression all were correlated not only with the incidence of cardiovascular disease but also with increased production ( expression ) of a protein called FKBP5 .",衰老、压力和抑郁不仅与心血管疾病的发病率有关，而且与一种叫做 FKBP5 的蛋白质的产生（表达）增加有关。,0.7857142857142857,"['production', 'depression', 'aging', 'incidence', 'disease', 'cardiovascular', 'protein', 'expression', 'stress', 'cardiovascular disease', 'with', 'all', 'but', 'and']","['depression', 'aging', 'incidence', 'disease', 'cardiovascular', 'protein', 'expression', 'stress', 'cardiovascular disease', 'but', 'and']",2189,"['老化、压力和抑郁症都与心血管疾病的发病率有关,而且与一种称为FKBP5的蛋白质的产量增加有关。']",0.7142857142857143,"['production', 'depression', 'aging', 'incidence', 'disease', 'cardiovascular', 'protein', 'expression', 'stress', 'cardiovascular disease', 'with', 'all', 'but', 'and']","['depression', 'aging', 'incidence', 'disease', 'cardiovascular', 'protein', 'stress', 'cardiovascular disease', 'but', 'and']",,
2225,2190,"diminishing the production of FKBP5 by gene editing , and blocking the action of FKBP5 by pharmacological inhibitors , both greatly diminished the inflammatory response .",通过基因编辑减少 FKBP5 的产生，以及通过药理学抑制剂阻断 FKBP5 的作用，都大大减少了炎症反应。,0.6,"['production', 'gene', 'inflammatory response', 'blocking', 'editing', 'gene editing', 'pharmacological', 'action', 'by', 'and']","['gene', 'blocking', 'gene editing', 'pharmacological', 'action', 'by']",2190,"['通过基因编辑减少FKBP5的产量,并通过药物抑制剂阻止FKBP5的作用,两者都显著减少了炎症反应。']",0.3,"['production', 'gene', 'inflammatory response', 'blocking', 'editing', 'gene editing', 'pharmacological', 'action', 'by', 'and']","['gene', 'gene editing', 'action']",,
2226,2191,"certain inherited alterations in gene structure ( e.g. , mutations in the gene for the LDL cholesterol receptor ) affect cardiovascular risk .",基因结构的某些遗传改变（例如 LDL 胆固醇受体基因突变）会影响心血管风险。,0.7,"['cholesterol', 'gene', 'receptor', 'LDL cholesterol', 'cardiovascular', 'inherited', 'affect', 'risk', 'structure', 'certain']","['cholesterol', 'gene', 'receptor', 'cardiovascular', 'affect', 'risk', 'structure']",2191,"['某些遗传基因结构的变化(例如,LDL胆固醇受体基因中的突变)影响心血管风险。']",0.8,"['cholesterol', 'gene', 'receptor', 'LDL cholesterol', 'cardiovascular', 'inherited', 'affect', 'risk', 'structure', 'certain']","['cholesterol', 'gene', 'receptor', 'LDL cholesterol', 'cardiovascular', 'affect', 'risk', 'structure']",,
2227,2192,"however , this study suggests that changing the expression ( not the structure ) of genes is one way that aging , lifestyle , and life events might affect risk .",然而，这项研究表明，改变基因的表达（而不是结构）是衰老、生活方式和生活事件可能影响风险的一种方式。,0.75,"['life', 'aging', 'way', 'expression', 'affect', 'study', 'risk', 'structure', 'life events', 'this', 'that', 'and']","['life', 'aging', 'expression', 'affect', 'risk', 'structure', 'life events', 'this', 'and']",2192,"['然而,这项研究表明,改变基因的表达(而不是结构)是老龄化、生活方式和生活事件可能影响风险的一种方式。']",0.6666666666666666,"['life', 'aging', 'way', 'expression', 'affect', 'study', 'risk', 'structure', 'life events', 'this', 'that', 'and']","['life', 'expression', 'affect', 'risk', 'structure', 'life events', 'this', 'and']",,
2228,2193,"in showing that increased expression of the FKBP5 gene promotes inflammation , which confers vascular disease risk , the investigators also have identified the FKBP5 protein as a potential target for therapeutic intervention .",为了表明 FKBP5 基因表达的增加会促进炎症，从而增加血管疾病的风险，研究人员还将 FKBP5 蛋白确定为治疗干预的潜在目标。,0.5714285714285714,"['gene', 'disease', 'protein', 'potential', 'expression', 'inflammation', 'vascular', 'vascular disease', 'target', 'therapeutic', 'intervention', 'risk', 'have', 'that']","['gene', 'disease', 'protein', 'expression', 'inflammation', 'vascular disease', 'target', 'risk']",2193,"['在表明FKBP5基因的增加表达促进炎症,这导致血管疾病的风险,研究人员也确定了FKBP5蛋白作为治疗干预的潜在目标。']",0.5714285714285714,"['gene', 'disease', 'protein', 'potential', 'expression', 'inflammation', 'vascular', 'vascular disease', 'target', 'therapeutic', 'intervention', 'risk', 'have', 'that']","['gene', 'disease', 'protein', 'expression', 'inflammation', 'vascular disease', 'target', 'risk']",,
2229,2194,a new online tool could allow assessment of risk for myocardial infarction during the ED visit .,一种新的在线工具可以在急诊就诊期间评估心肌梗塞的风险。,0.7142857142857143,"['myocardial infarction', 'allow', 'assessment', 'risk', 'tool', 'new', 'visit']","['myocardial infarction', 'assessment', 'risk', 'tool', 'new']",2194,['一个新的在线工具可以允许在ED访问期间评估心脏病发作的风险。'],0.7142857142857143,"['myocardial infarction', 'allow', 'assessment', 'risk', 'tool', 'new', 'visit']","['allow', 'assessment', 'risk', 'tool', 'new']",,
2230,2195,"unfortunately , most prior studies evaluated a specific test ( troponin I or troponin T ) and a specific strategy ( single , early repeated , or delayed repeated measurements ) and are not applicable across all practice environments .",不幸的是，大多数先前的研究评估了特定测试（肌钙蛋白 I 或肌钙蛋白 T）和特定策略（单次、早期重复或延迟重复测量）并且不适用于所有实践环境。,0.4375,"['a', 'strategy', 'test', 'early', 'across', 'prior', 'practice', 'specific', 'T', 'troponin', 'I', 'delayed', 'repeated', 'all', 'single', 'and']","['strategy', 'early', 'prior', 'practice', 'troponin', 'delayed', 'single']",2195,"['不幸的是,大多数以前的研究评估了一个特定的测试(特洛波因I或特洛波因T)和一个特定的策略(单一,早期重复或延迟重复测量),并且不适用于所有实践环境。']",0.3125,"['a', 'strategy', 'test', 'early', 'across', 'prior', 'practice', 'specific', 'T', 'troponin', 'I', 'delayed', 'repeated', 'all', 'single', 'and']","['strategy', 'early', 'practice', 'delayed', 'single']",,
2231,2196,"among 22,651 patients , MI was diagnosed in 15 % .","在 22,651 名患者中，有 15% 的患者被诊断出心梗。",0.5,"['MI', 'in']",['MI'],2196,"['在22651名患者中,MI被诊断为15%。']",0.0,"['MI', 'in']",[],,
2232,2197,risk for MI increased with higher initial troponin level and with increases on remeasurement .,心肌梗死的风险随着初始肌钙蛋白水平的升高和重新测量的增加而增加。,0.6666666666666666,"['MI', 'initial', 'risk', 'increases', 'level', 'with', 'on', 'troponin', 'and']","['MI', 'initial', 'risk', 'level', 'troponin', 'and']",2197,['MI的风险增加了较高的初始特洛波尼素水平和重新测量的增加。'],0.3333333333333333,"['MI', 'initial', 'risk', 'increases', 'level', 'with', 'on', 'troponin', 'and']","['initial', 'risk', 'level']",,
2233,2198,"by now , associations between elevated troponins and poor outcomes are not novel ( NEJM JW Emerg Med May 2019 and BMJ 2019 ; 364 : 1729 ) .",到目前为止，肌钙蛋白升高与不良结果之间的关联并不新鲜（NEJM JW Emerg Med 2019 年 5 月和 BMJ 2019；364：1729）。,0.0,"['novel', 'poor', 'by', 'and', 'med']",[],2198,"['到目前为止,高峰和不良结果之间的联系并不新鲜(NEJM JW Emerg Med May 2019 和 BMJ 2019 ; 364 : 1729 )。']",0.0,"['novel', 'poor', 'by', 'and', 'med']",[],,
2234,2199,"expanding blood pressure treatment , reducing dietary sodium , and eliminating trans fats could dramatically decrease mortality .",扩大血压治疗、减少饮食中的钠含量和消除反式脂肪可以显着降低死亡率。,0.5555555555555556,"['pressure', 'decrease', 'sodium', 'blood', 'blood pressure', 'treatment', 'mortality', 'dietary', 'and']","['decrease', 'sodium', 'blood pressure', 'treatment', 'mortality']",2199,['扩大血压治疗、减少饮食<unk>和消除过渡脂肪可以显著降低死亡率。'],0.4444444444444444,"['pressure', 'decrease', 'sodium', 'blood', 'blood pressure', 'treatment', 'mortality', 'dietary', 'and']","['decrease', 'blood pressure', 'treatment', 'mortality']",,
2235,2200,noncommunicable diseases ( NCDs ) are the leading cause of death worldwide and are largely preventable through changes in modifiable risk factors .,非传染性疾病 (NCD) 是全世界死亡的主要原因，并且在很大程度上可以通过改变可改变的风险因素来预防。,0.5,"['death', 'cause', 'risk', 'cause of death', 'leading', 'and']","['death', 'cause', 'risk']",2200,"['非传染性疾病(非传染性疾病)是全球死亡的主要原因,主要是通过可改变风险因素的变化来预防的。']",0.5,"['death', 'cause', 'risk', 'cause of death', 'leading', 'and']","['death', 'cause', 'risk']",,
2236,2201,"researchers quantified the global impact of three public health interventions on NCD mortality : increasing the coverage of hypertension treatment to 70 % , reducing dietary sodium by 30 % , and eliminating trans fats .",研究人员量化了三种公共卫生干预措施对非传染性疾病死亡率的全球影响：将高血压治疗的覆盖率提高到 70%，将饮食中的钠含量减少 30%，以及消除反式脂肪。,0.5714285714285714,"['hypertension', 'global', 'sodium', 'coverage', 'health', 'public', 'impact', 'treatment', 'mortality', 'dietary', 'three', 'by', 'to', 'and']","['hypertension', 'global', 'sodium', 'health', 'impact', 'treatment', 'mortality', 'by']",2201,"['研究人员衡量了三项公共卫生干预对NCD死亡率的全球影响:增加高血压治疗的覆盖范围到70%,减少30%的饮食<unk>,并消除跨脂肪。']",0.4285714285714285,"['hypertension', 'global', 'sodium', 'coverage', 'health', 'public', 'impact', 'treatment', 'mortality', 'dietary', 'three', 'by', 'to', 'and']","['hypertension', 'global', 'health', 'impact', 'treatment', 'mortality']",,
2237,2202,"using data from a myriad of sources , including population health surveys and WHO Global Health Estimates , the investigators predicted changes in mortality between 2015 and 2040 .",研究人员使用多种来源的数据，包括人口健康调查和 WHO 全球健康估计，预测了 2015 年至 2040 年间死亡率的变化。,0.625,"['population', 'data', 'global', 'health', 'WHO', 'mortality', 'in', 'and']","['population', 'data', 'global', 'health', 'mortality']",2202,"['使用来自数千个来源的数据,包括人口健康调查和世界卫生组织全球健康估计,调查人员预测了2015年至2040年间的死亡率变化。']",0.75,"['population', 'data', 'global', 'health', 'WHO', 'mortality', 'in', 'and']","['population', 'data', 'global', 'health', 'WHO', 'mortality']",,
2238,2203,"according to the analysis , the three interventions could delay 94.3 million deaths during 25 years ( 39.4 million from boosting hypertension treatment , 40.0 million from reducing sodium intake , and 14.8 million from eliminating trans fats ) .",根据分析，这三项干预措施可以在 25 年内延迟 9430 万人的死亡（3940 万人来自加强高血压治疗，4000 万人来自减少钠摄入量，1480 万人来自消除反式脂肪）。,0.4545454545454545,"['intake', 'delay', 'hypertension', 'analysis', 'sodium', 'sodium intake', 'treatment', 'three', 'to', 'and', 'million']","['delay', 'hypertension', 'analysis', 'sodium', 'treatment']",2203,"['根据分析,这三次干预可能在25年内延迟94.3百万死亡(增加高血压治疗的39.4百万,减少<unk>摄入量的40.0百万,消除过渡脂肪的14.8百万)。']",0.3636363636363636,"['intake', 'delay', 'hypertension', 'analysis', 'sodium', 'sodium intake', 'treatment', 'three', 'to', 'and', 'million']","['delay', 'hypertension', 'analysis', 'treatment']",,
2239,2204,the effects were greater for men than women and for older ( age ≥ 70 ) than younger people .,男性的影响大于女性，老年人（≥ 70 岁）的影响大于年轻人。,0.0,"['age', 'and']",[],2204,"['對男性比女性的影響更大,對老年人(70歲以上)比年輕人更大。']",0.0,"['age', 'and']",[],,
2240,2205,two randomized studies challenge the need for prolonged DAPT .,两项随机研究质疑延长 DAPT 的必要性。,0.25,"['need', 'challenge', 'prolonged', 'two']",['two'],2205,['两项随机研究挑战了延长DAPT的需要。'],0.75,"['need', 'challenge', 'prolonged', 'two']","['need', 'challenge', 'two']",,
2241,2206,two research groups have now examined this recommendation .,两个研究小组现在已经研究了这个建议。,0.5,"['research', 'have', 'this', 'two']","['research', 'two']",2206,"['目前,两个研究小组已经审查了这一建议。']",0.5,"['research', 'have', 'this', 'two']","['research', 'two']",,
2242,2207,the first month in both groups could be prasugrel ( 38 % of patients ) or clopidogrel .,两组的第一个月都可以使用普拉格雷（38% 的患者）或氯吡格雷。,0.6666666666666666,"['month', 'clopidogrel', 'be', 'prasugrel', 'in', 'first']","['month', 'clopidogrel', 'prasugrel', 'first']",2207,['第一個月在兩個群體可能是 prasugrel(38%的患者)或clopidogrel。'],0.5,"['month', 'clopidogrel', 'be', 'prasugrel', 'in', 'first']","['month', 'be', 'first']",,
2243,2208,"this study allowed multiple DES types and other potent thienopyridines ( 23 % ) , not only clopidogrel .",这项研究允许使用多种 DES 类型和其他有效的噻吩并吡啶 (23%)，而不仅仅是氯吡格雷。,0.5,"['study', 'multiple', 'clopidogrel', 'potent', 'this', 'and']","['clopidogrel', 'this', 'and']",2208,"['这项研究允许多种DES类型和其他强大的蒂诺皮里丁(23%),而不仅仅是克洛皮多格勒。']",0.3333333333333333,"['study', 'multiple', 'clopidogrel', 'potent', 'this', 'and']","['this', 'and']",,
2244,2209,the rate of all ( but not major ) bleeding was lower with short DAPT .,短期 DAPT 的所有（但不是主要）出血率较低。,0.375,"['bleeding', 'rate', 'short', 'lower', 'major', 'with', 'all', 'but']","['bleeding', 'rate', 'but']",2209,['所有的(但不是主要的)出血率低于短DAPT。'],0.375,"['bleeding', 'rate', 'short', 'lower', 'major', 'with', 'all', 'but']","['bleeding', 'rate', 'but']",,
2245,2210,the findings were similar in ACS and stable CAD subgroups and across types of thienopyridine .,研究结果在 ACS 和稳定的 CAD 亚组以及噻吩并吡啶的不同类型中是相似的。,0.1666666666666666,"['across', 'ACS', 'CAD', 'in', 'and', 'similar']",['similar'],2210,"['这些发现类似于ACS和稳定的CAD子组,以及各式各样的蒂诺皮里丁。']",0.0,"['across', 'ACS', 'CAD', 'in', 'and', 'similar']",[],,
2246,2211,"because many monotherapy patients continued aspirin beyond 3 months , study protocol adherence was 79 % in that arm .",由于许多单药治疗患者继续服用阿司匹林超过 3 个月，该组的研究方案依从性为 79%。,0.1428571428571428,"['aspirin', 'arm', 'protocol', 'study', '3', 'adherence', 'that']",['aspirin'],2211,"['由于许多单治疗患者在3个月以上继续服用阿司匹林,该研究协议的遵守率在该手中为79%。']",0.4285714285714285,"['aspirin', 'arm', 'protocol', 'study', '3', 'adherence', 'that']","['aspirin', 'arm', 'protocol']",,
2247,2212,"these trials highlight the bleeding risks associated with DAPT and the low risk of ischemic events , including stent thrombosis , with current DES .",这些试验强调了与 DAPT 相关的出血风险和低风险的缺血事件，包括支架内血栓形成，目前的 DES。,0.4,"['bleeding', 'thrombosis', 'associated', 'low', 'stent', 'risk', 'current', 'with', 'and', 'ischemic']","['bleeding', 'thrombosis', 'low', 'risk']",2212,"['这些研究强调了与DAPT相关的出血风险,以及与当前DES相关的伊斯克米事件的低风险,包括<unk>血病。']",0.3,"['bleeding', 'thrombosis', 'associated', 'low', 'stent', 'risk', 'current', 'with', 'and', 'ischemic']","['bleeding', 'low', 'risk']",,
2248,2213,"however , the current findings suggest that our guidelines should be updated to include shorter duration of DAPT via early discontinuation of aspirin in selected patients .",然而，目前的研究结果表明，我们的指南应该更新，以包括通过在选定患者中提前停用阿司匹林来缩短 DAPT 的持续时间。,0.3333333333333333,"['aspirin', 'via', 'early', 'be', 'current', 'duration', 'suggest', 'that', 'to']","['aspirin', 'be', 'duration']",2213,"['然而,目前的发现表明,我们的指导方针应该更新,包括通过早期停止阿司匹林在选择的患者中更短的DAPT寿命。']",0.3333333333333333,"['aspirin', 'via', 'early', 'be', 'current', 'duration', 'suggest', 'that', 'to']","['aspirin', 'early', 'be']",,
2249,2214,"because type 1 diabetes mellitus ( DM ) is the result of immune destruction of pancreatic islet cells , immunologic interventions have shown promise in delaying its onset .",由于 1 型糖尿病 (DM) 是胰岛细胞免疫破坏的结果，免疫干预已显示出延缓其发病的希望。,0.5333333333333333,"['islet', 'diabetes', 'type', '1', 'pancreatic', 'diabetes mellitus', 'onset', 'immune', 'DM', 'islet cells', 'immunologic', 'result', 'destruction', 'have', 'in']","['islet', 'diabetes', 'type', '1', 'diabetes mellitus', 'islet cells', 'result', 'destruction']",2214,"['由于1型糖尿病(DM)是胰岛素细胞免疫破坏的结果,免疫干预已表明延迟其起源的承诺。']",0.4666666666666667,"['islet', 'diabetes', 'type', '1', 'pancreatic', 'diabetes mellitus', 'onset', 'immune', 'DM', 'islet cells', 'immunologic', 'result', 'destruction', 'have', 'in']","['islet', 'diabetes', 'type', '1', 'diabetes mellitus', 'result', 'destruction']",,
2250,2215,the median time to diagnosis of clinical DM was 48 months in the teplizumab group compared with 24 months in the placebo group ( P = 0.006 ) .,teplizumab 组诊断临床 DM 的中位时间为 48 个月，而安慰剂组为 24 个月 (P = 0.006)。,0.5,"['group', 'median', 'placebo', 'time', 'diagnosis', 'clinical', 'DM', 'with', 'P', 'to']","['group', 'placebo', 'time', 'diagnosis', 'clinical']",2215,"['诊断临床DM的平均时间在Termizumab群体中为48个月,而在 placebo群体中为24个月(P=0.006)。']",0.4,"['group', 'median', 'placebo', 'time', 'diagnosis', 'clinical', 'DM', 'with', 'P', 'to']","['group', 'time', 'diagnosis', 'clinical']",,
2251,2216,five times more adverse events were reported in the teplizumab group than in the placebo group ( 112 vs. 32 ) ; the most frequent adverse events among teplizumab recipients were transient lymphopenia ( 75 % ) and rash ( 36 % ) .,teplizumab 组报告的不良事件是安慰剂组的五倍（112 对 32）； teplizumab 接受者中最常见的不良事件是短暂性淋巴细胞减少 (75%) 和皮疹 (36%)。,0.3333333333333333,"['transient', 'group', 'placebo', 'rash', 'adverse', 'five', 'in', 'frequent', 'and']","['transient', 'group', 'placebo']",2216,"['在 teplizumab 群体中报告了五倍的副作用,而在 placebo 群体中( 112 与 32 );在 teplizumab 受体中,最常见的副作用是过渡性淋巴<unk>( 75 % )和发作( 36 % )。']",0.2222222222222222,"['transient', 'group', 'placebo', 'rash', 'adverse', 'five', 'in', 'frequent', 'and']","['group', 'and']",,
2252,2217,immune therapy can delay onset of clinical DM in those already in early stages of its natural history .,免疫治疗可以延迟那些已经处于其自然病程早期阶段的临床 DM 的发作。,0.5,"['delay', 'natural history', 'early', 'therapy', 'onset', 'clinical', 'immune', 'DM']","['delay', 'early', 'therapy', 'clinical']",2217,"['免疫疗法可以延迟临床DM的出现,在其自然历史的早期阶段。']",0.5,"['delay', 'natural history', 'early', 'therapy', 'onset', 'clinical', 'immune', 'DM']","['delay', 'early', 'therapy', 'clinical']",,
2253,2218,"while this is a significant advance , as editorialists state , it is not yet a cure .",虽然这是一个重大进步，正如社论所说，但它还不能治愈。,0.6666666666666666,"['a', 'state', 'cure', 'advance', 'as', 'this']","['cure', 'advance', 'as', 'this']",2218,"['虽然这是一个显著的进步,正如编辑家所说,它还不是治疗。']",0.6666666666666666,"['a', 'state', 'cure', 'advance', 'as', 'this']","['cure', 'advance', 'as', 'this']",,
2254,2219,yet these impressive results hold promise for the future .,然而，这些令人印象深刻的结果为未来带来了希望。,0.0,"['impressive', 'hold']",[],2219,"['然而,这些令人印象深刻的结果仍然对未来有承诺。']",0.0,"['impressive', 'hold']",[],,
2255,2220,recombinant human soluble thrombomodulin caused excess bleeding .,重组人可溶性血栓调节蛋白引起出血过多。,0.3333333333333333,"['bleeding', 'thrombomodulin', 'excess', 'recombinant', 'soluble', 'human']","['bleeding', 'human']",2220,['人类可溶性 recombinant thrombomodulin 导致过量出血。'],0.5,"['bleeding', 'thrombomodulin', 'excess', 'recombinant', 'soluble', 'human']","['bleeding', 'excess', 'human']",,
2256,2221,"based on a single 2001 study , the U.S. FDA approved recombinant activated protein C ( drotrecogin alfa ; Xigris ) for patients with severe sepsis ( NEJM JW Gen Med Apr 15 2001 and N Engl J Med 2001 ; 344 : 699 ) .",基于 2001 年的一项研究，美国 FDA 批准重组活化蛋白 C（drotrecogin alfa；Xigris）用于严重败血症患者（NEJM JW Gen Med 2001 年 4 月 15 日和 N Engl J Med 2001；344：699）。,0.125,"['a', 'recombinant', 'protein', 'study', 'sepsis', 'FDA', 'gen', 'N', 'with', 'severe', 'C', 'activated', 'on', 'single', 'and', 'med']","['protein', 'sepsis']",2221,"['基于一个单一的2001研究,美国FDA批准 recombinant C 激活蛋白( drotrecogin alfa ; Xigris )为患有严重的塞普西斯的患者(NEJM JW Gen Med Apr 15 2001 和 N Engl J Med 2001 ; 344 : 699 )。']",0.125,"['a', 'recombinant', 'protein', 'study', 'sepsis', 'FDA', 'gen', 'N', 'with', 'severe', 'C', 'activated', 'on', 'single', 'and', 'med']","['protein', 'single']",,
2257,2222,investigators randomized 800 patients with sepsis and coagulopathy to receive rhsTM or placebo .,研究人员将 800 名患有脓毒症和凝血病的患者随机分配接受 rhsTM 或安慰剂。,0.3333333333333333,"['placebo', 'sepsis', 'coagulopathy', 'with', 'to', 'and']","['placebo', 'sepsis']",2222,['研究人员随机调查了800名患有塞普西斯和科古洛帕蒂的患者接受RHSTM或 placebo。'],0.0,"['placebo', 'sepsis', 'coagulopathy', 'with', 'to', 'and']",[],,
2258,2223,"three quarters of patients had multiple organ dysfunction , most commonly cardiovascular and respiratory .",四分之三的患者有多器官功能障碍，最常见的是心血管和呼吸系统。,0.2857142857142857,"['organ', 'dysfunction', 'cardiovascular', 'respiratory', 'multiple', 'three', 'and']","['organ', 'cardiovascular']",2223,"['三分之四的患者患有多器官功能障碍,最常见的是心血管和呼吸系统。']",0.2857142857142857,"['organ', 'dysfunction', 'cardiovascular', 'respiratory', 'multiple', 'three', 'and']","['organ', 'cardiovascular']",,
2259,2224,patients with sepsis and coagulopathy should not be treated with rhsTM ( which is not available in the U.S. ) .,脓毒症和凝血病患者不应接受 rhsTM（在美国不可用）治疗。,0.2857142857142857,"['sepsis', 'be', 'available', 'coagulopathy', 'with', 'in', 'and']","['sepsis', 'be']",2224,['患有<unk>疹和<unk>疹的患者不应使用rhsTM(在美国不适用)。'],0.1428571428571428,"['sepsis', 'be', 'available', 'coagulopathy', 'with', 'in', 'and']",['be'],,
2260,2225,we randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy ( goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen ) .,除了内分泌治疗（戈舍瑞林和非甾体芳香化酶抑制剂或他莫昔芬）外，我们随机分配患者接受瑞博西尼或安慰剂。,0.5,"['inhibitor', 'placebo', 'aromatase', 'endocrine', 'addition', 'therapy', 'endocrine therapy', 'ribociclib', 'tamoxifen', 'aromatase inhibitor', 'and', 'we']","['inhibitor', 'placebo', 'endocrine', 'therapy', 'ribociclib', 'tamoxifen']",2225,['我们随机命令患者接受Ribociclib或Placebo除了内分泌疗法(Goserelin和非类固醇 aromatase抑制剂或Tamoxifen)。'],0.3333333333333333,"['inhibitor', 'placebo', 'aromatase', 'endocrine', 'addition', 'therapy', 'endocrine therapy', 'ribociclib', 'tamoxifen', 'aromatase inhibitor', 'and', 'we']","['inhibitor', 'endocrine', 'therapy', 'endocrine therapy']",,
2261,2226,there were 83 deaths among 335 patients ( 24.8 % ) in the ribociclib group and 109 deaths among 337 patients ( 32.3 % ) in the placebo group .,瑞博西尼组 335 名患者 (24.8%) 中有 83 人死亡，安慰剂组 337 名患者 (32.3%) 中有 109 人死亡。,0.6,"['group', 'placebo', 'ribociclib', 'in', 'and']","['group', 'placebo', 'ribociclib']",2226,"['在Ribociclib群体中有335名患者(24.8%)中有83人死亡,在337名患者(32.3%)中有109人死亡。']",0.2,"['group', 'placebo', 'ribociclib', 'in', 'and']",['group'],,
2262,2227,the addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone .,在内分泌治疗中加入瑞博西尼比单独使用内分泌治疗可显着延长总生存期。,0.75,"['survival', 'endocrine', 'addition', 'therapy', 'endocrine therapy', 'ribociclib', 'to', 'alone']","['survival', 'endocrine', 'addition', 'therapy', 'ribociclib', 'alone']",2227,['添加Ribociclib到内分泌疗法导致比内分泌疗法单独更长的整体生存。'],0.75,"['survival', 'endocrine', 'addition', 'therapy', 'endocrine therapy', 'ribociclib', 'to', 'alone']","['survival', 'endocrine', 'addition', 'therapy', 'endocrine therapy', 'alone']",,
2263,2228,the percentage of patients who received subsequent antineoplastic therapy was balanced between the groups ( 68.9 % in the ribociclib group and 73.2 % in the placebo group ) .,接受后续抗肿瘤治疗的患者百分比在各组之间保持平衡（ribociclib 组为 68.9%，安慰剂组为 73.2%）。,0.3333333333333333,"['group', 'percentage', 'placebo', 'who', 'antineoplastic', 'therapy', 'subsequent', 'ribociclib', 'and']","['group', 'placebo', 'therapy']",2228,['接下来的抗生素治疗患者的比例在群体之间均衡(Ribociclib群体的68.9%和 placebo群体的73.2%)。'],0.2222222222222222,"['group', 'percentage', 'placebo', 'who', 'antineoplastic', 'therapy', 'subsequent', 'ribociclib', 'and']","['group', 'therapy']",,
2264,2229,"ovarian suppression induces menopause in premenopausal patients ; however , suppression may not be complete , 7 and breast cancer that develops in premenopausal women may have biologic differences from that which develops in postmenopausal women .",卵巢抑制导致绝经前患者更年期；然而，抑制可能并不完全， 7 绝经前妇女患上的乳腺癌可能与绝经后妇女患上的乳腺癌有生物学上的差异。,0.4615384615384615,"['suppression', 'cancer', 'postmenopausal', 'biologic', 'menopause', 'breast cancer', 'complete', 'be', 'premenopausal', 'have', 'that', 'in', 'and']","['suppression', 'cancer', 'menopause', 'breast cancer', 'have', 'and']",2229,"['卵巢抑制导致更年期;然而,抑制可能不是完整的,7和乳腺癌发生在更年期妇女可能有生物差异与发生在更年期妇女。']",0.6153846153846154,"['suppression', 'cancer', 'postmenopausal', 'biologic', 'menopause', 'breast cancer', 'complete', 'be', 'premenopausal', 'have', 'that', 'in', 'and']","['suppression', 'cancer', 'menopause', 'breast cancer', 'complete', 'be', 'have', 'and']",,
2265,2230,premenopausal patients tend to be underrepresented in clinical trials of breast cancer .,绝经前患者在乳腺癌临床试验中的代表性往往不足。,0.5714285714285714,"['cancer', 'breast cancer', 'be', 'premenopausal', 'clinical', 'tend', 'to']","['cancer', 'breast cancer', 'be', 'clinical']",2230,"['在临床试验中,乳腺癌患者往往被低估。']",0.5714285714285714,"['cancer', 'breast cancer', 'be', 'premenopausal', 'clinical', 'tend', 'to']","['cancer', 'breast cancer', 'be', 'clinical']",,
2266,2231,"it has been acknowledged that showing improvements in overall survival in trials involving patients with metastatic breast cancer may be challenging because of potential crossover between treatment groups and subsequent receipt of active treatments , as well as variability in previous treatment exposures between the groups.23,24","人们已经认识到，在涉及转移性乳腺癌患者的试验中显示总生存期的改善可能具有挑战性，因为治疗组之间可能存在交叉，随后接受积极治疗，以及各组之间先前治疗暴露的差异。 23,24",0.3125,"['cancer', 'survival', 'variability', 'potential', 'previous', 'active', 'breast cancer', 'be', 'metastatic', 'treatment', 'well', 'subsequent', 'with', 'that', 'in', 'and']","['cancer', 'survival', 'breast cancer', 'be', 'treatment']",2231,"['已被认可,在涉及转移性乳腺癌患者的研究中表现出整体生存的改善可能因治疗群体之间的潜在交叉和随后接受活性治疗以及以前治疗群体之间的曝光的变化而具有挑战性。']",0.375,"['cancer', 'survival', 'variability', 'potential', 'previous', 'active', 'breast cancer', 'be', 'metastatic', 'treatment', 'well', 'subsequent', 'with', 'that', 'in', 'and']","['cancer', 'survival', 'breast cancer', 'be', 'treatment', 'and']",,
2267,2232,"patients were randomly assigned , in a 1 : 1 ratio , to receive ribociclib ( at a dose of 600 mg , administered orally once daily for 21 consecutive days , followed by 7 days off , for a complete cycle of 28 days ) or matching placebo .",患者以 1:1 的比例被随机分配接受瑞博西尼（剂量为 600 毫克，每天口服一次，连续 21 天，然后停药 7 天，一个完整的 28 天周期）或匹配的安慰剂。,0.8181818181818182,"['placebo', '1', 'ratio', 'cycle', 'complete', 'consecutive', 'matching', 'ribociclib', 'dose', 'by', 'to']","['placebo', '1', 'ratio', 'cycle', 'complete', 'matching', 'ribociclib', 'dose', 'by']",2232,"['病人随机分配,在1:1的比例,接受Ribociclib(在600毫克的剂量,口服每天一次21天连续,随后7天休息,一个完整的周期为28天)或相匹配的 placebo。']",0.5454545454545454,"['placebo', '1', 'ratio', 'cycle', 'complete', 'consecutive', 'matching', 'ribociclib', 'dose', 'by', 'to']","['1', 'ratio', 'cycle', 'complete', 'matching', 'dose']",,
2268,2233,"patients also received either a nonsteroidal aromatase inhibitor ( letrozole at a dose of 2.5 mg or anastrozole at a dose of 1 mg ) or tamoxifen ( at a dose of 20 mg ) , administered orally once daily continuously .",患者还接受了非甾体芳香化酶抑制剂（来曲唑剂量为 2.5 毫克或阿那曲唑剂量为 1 毫克）或他莫昔芬（剂量为 20 毫克），每天连续口服一次。,0.625,"['inhibitor', 'a', 'aromatase', '1', 'tamoxifen', 'letrozole', 'dose', 'aromatase inhibitor']","['inhibitor', '1', 'tamoxifen', 'letrozole', 'dose']",2233,"['患者也接受了非类固醇 aromatase 抑制剂( 2.5 毫克的 letrozole 或 1 毫克的 anastrozole )或 tamoxifen( 20 毫克的剂量 ),每天一次连续服用口服。']",0.375,"['inhibitor', 'a', 'aromatase', '1', 'tamoxifen', 'letrozole', 'dose', 'aromatase inhibitor']","['inhibitor', '1', 'dose']",,
2269,2234,crossover between the two groups was not permitted .,两组之间的交叉是不允许的。,1.0,['two'],['two'],2234,['两组之间的交叉不允许。'],1.0,['two'],['two'],,
2270,2235,patients who had received adjuvant or neoadjuvant endocrine therapy were permitted to enroll .,允许接受辅助或新辅助内分泌治疗的患者入组。,0.3333333333333333,"['who', 'adjuvant', 'endocrine', 'therapy', 'endocrine therapy', 'to']","['endocrine', 'therapy']",2235,['接受补充或新补充内分泌治疗的患者被允许注册。'],0.3333333333333333,"['who', 'adjuvant', 'endocrine', 'therapy', 'endocrine therapy', 'to']","['endocrine', 'therapy']",,
2271,2236,"previous endocrine therapy in the context of advanced disease was not permitted , but patients could have received tamoxifen or an aromatase inhibitor within 14 days before randomization or goserelin within 28 days before randomization for advanced breast cancer ; these patients continued treatment with goserelin plus the same hormone agent .",不允许既往在晚期疾病背景下接受过内分泌治疗，但患者可能在随机分组前 14 天内接受过他莫昔芬或芳香化酶抑制剂治疗，或在随机分组前 28 天内接受过戈舍瑞林治疗晚期乳腺癌；这些患者继续接受戈舍瑞林加同种激素药物的治疗。,0.5909090909090909,"['inhibitor', 'disease', 'cancer', 'aromatase', 'hormone', 'randomization', 'context', 'endocrine', 'plus', 'previous', 'breast cancer', 'therapy', 'endocrine therapy', 'treatment', 'advanced', 'with', 'tamoxifen', 'agent', 'aromatase inhibitor', 'have', 'before', 'but']","['inhibitor', 'disease', 'cancer', 'hormone', 'randomization', 'endocrine', 'plus', 'breast cancer', 'therapy', 'treatment', 'tamoxifen', 'before', 'but']",2236,"['以前的内分泌治疗在先进疾病的背景下是不允许的,但患者可能在随机化或Goserelin前14天内接受了Tamoxifen或Aomatase抑制剂;这些患者继续使用Goserelin加上相同的荷尔蒙物质治疗。']",0.4545454545454545,"['inhibitor', 'disease', 'cancer', 'aromatase', 'hormone', 'randomization', 'context', 'endocrine', 'plus', 'previous', 'breast cancer', 'therapy', 'endocrine therapy', 'treatment', 'advanced', 'with', 'tamoxifen', 'agent', 'aromatase inhibitor', 'have', 'before', 'but']","['inhibitor', 'disease', 'randomization', 'endocrine', 'plus', 'previous', 'therapy', 'treatment', 'before', 'but']",,
2272,2237,patients who had received no more than one previous line of chemotherapy for advanced disease were also eligible .,先前因晚期疾病接受过不超过一种化疗的患者也符合条件。,0.25,"['chemotherapy', 'disease', 'who', 'line', 'previous', 'no', 'advanced', 'eligible']","['chemotherapy', 'disease']",2237,['未接受过先前一行化疗先进疾病的患者也可接受。'],0.25,"['chemotherapy', 'disease', 'who', 'line', 'previous', 'no', 'advanced', 'eligible']","['chemotherapy', 'disease']",,
2273,2238,previous treatment with a CDK4 / 6 inhibitor was not permitted .,不允许先前使用 CDK4/6 抑制剂进行治疗。,0.3333333333333333,"['inhibitor', 'a', '/', 'previous', 'treatment', 'with']","['inhibitor', 'treatment']",2238,['以前使用 CDK4 / 6 抑制剂的治疗是不允许的。'],0.3333333333333333,"['inhibitor', 'a', '/', 'previous', 'treatment', 'with']","['inhibitor', 'treatment']",,
2274,2239,"randomization was stratified according to the presence or absence of liver or lung metastases , previous chemotherapy for advanced disease ( yes or no ) , and endocrine therapy ( tamoxifen plus goserelin or an aromatase inhibitor plus goserelin ) .",根据是否存在肝或肺转移、既往晚期疾病化疗（是或否）和内分泌治疗（他莫昔芬加戈舍瑞林或芳香化酶抑制剂加戈舍瑞林）对随机化进行分层。,0.5882352941176471,"['presence', 'inhibitor', 'chemotherapy', 'liver', 'lung', 'disease', 'aromatase', 'randomization', 'endocrine', 'plus', 'previous', 'endocrine therapy', 'absence', 'no', 'advanced', 'tamoxifen', 'aromatase inhibitor']","['presence', 'inhibitor', 'chemotherapy', 'liver', 'lung', 'disease', 'randomization', 'endocrine', 'plus', 'tamoxifen']",2239,"['随机化根据肝脏或肺转移的存在或缺席,先进疾病(是或没有)的先前化疗和内分泌疗法(塔米克西芬加戈塞林或香水抑制剂加戈塞林)。']",0.6470588235294118,"['presence', 'inhibitor', 'chemotherapy', 'liver', 'lung', 'disease', 'aromatase', 'randomization', 'endocrine', 'plus', 'previous', 'endocrine therapy', 'absence', 'no', 'advanced', 'tamoxifen', 'aromatase inhibitor']","['presence', 'inhibitor', 'chemotherapy', 'liver', 'lung', 'disease', 'randomization', 'endocrine', 'plus', 'endocrine therapy', 'absence']",,
2275,2240,"all patients as well as all investigators who administered treatment , assessed outcomes , and analyzed data were unaware of the group assignments .",所有患者以及实施治疗、评估结果和分析数据的所有研究人员都不知道分组情况。,0.3,"['group', 'data', 'who', 'treatment', 'well', 'unaware', 'as', 'all', 'and', 'assessed']","['group', 'data', 'treatment']",2240,['所有患者以及所有接受治疗、评估结果和分析数据的研究人员都不知道组任务。'],0.3,"['group', 'data', 'who', 'treatment', 'well', 'unaware', 'as', 'all', 'and', 'assessed']","['group', 'data', 'treatment']",,
2276,2241,detailed methods of this trial have been reported previously.17,该试验的详细方法之前已有报道。 17,0.3333333333333333,"['trial', 'have', 'this']",['have'],2241,['此前已有详细的审判方法。17'],0.6666666666666666,"['trial', 'have', 'this']","['trial', 'have']",,
2277,2242,"the protocol , along with the statistical analysis plan , is available with the full text of this article at NEJM.org .",该方案和统计分析计划可与本文全文一起在 NEJM.org 获取。,0.2,"['analysis', 'protocol', 'article', 'available', 'along', 'text', 'statistical analysis', 'with', 'full', 'this']","['analysis', 'statistical analysis']",2242,"['该协议,以及统计分析计划,与本文的完整文本在NEJM.org上可用。']",0.4,"['analysis', 'protocol', 'article', 'available', 'along', 'text', 'statistical analysis', 'with', 'full', 'this']","['analysis', 'protocol', 'statistical analysis', 'full']",,
2278,2242,"the protocol , along with the statistical analysis plan , is available with the full text of this article at NEJM.org .",该方案和统计分析计划可与本文全文一起在 NEJM.org 获取。,0.2,"['analysis', 'protocol', 'article', 'available', 'along', 'text', 'statistical analysis', 'with', 'full', 'this']","['analysis', 'statistical analysis']",2242,"['该协议,以及统计分析计划,与本文的完整文本在NEJM.org上可用。']",0.4,"['analysis', 'protocol', 'article', 'available', 'along', 'text', 'statistical analysis', 'with', 'full', 'this']","['analysis', 'protocol', 'statistical analysis', 'full']",,
2279,2243,the time to subsequent chemotherapy was defined as the time from randomization to the beginning of the first chemotherapy after discontinuation of the trial regimen .,至后续化疗的时间定义为从随机化至停用试验方案后开始首次化疗的时间。,0.4,"['chemotherapy', 'defined', 'randomization', 'time', 'after', 'trial', 'subsequent', 'as', 'to', 'first']","['chemotherapy', 'randomization', 'time', 'after']",2243,"['接下来的化疗时间被定义为从随机化学到第一次化疗的开始,试验制度停止后的时间。']",0.5,"['chemotherapy', 'defined', 'randomization', 'time', 'after', 'trial', 'subsequent', 'as', 'to', 'first']","['chemotherapy', 'randomization', 'time', 'after', 'first']",,
2280,2244,"adverse events were monitored throughout the trial and were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events , version 4.03 .",在整个试验过程中监测不良事件，并根据美国国家癌症研究所不良事件通用术语标准 4.03 版进行分级。,0.3333333333333333,"['cancer', 'version', 'common', 'adverse', 'terminology', 'institute', 'trial', 'to', 'and']","['cancer', 'terminology', 'institute']",2244,"['对不良事件进行了整个试验的监测,并根据国家癌症研究所(National Cancer Institute Common Terminology Criteria for Adverse Events)的评级,版本 4.03。']",0.3333333333333333,"['cancer', 'version', 'common', 'adverse', 'terminology', 'institute', 'trial', 'to', 'and']","['cancer', 'version', 'institute']",,
2281,2245,the trial was funded by Novartis and was conducted in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines .,该试验由诺华公司资助，并根据赫尔辛基宣言和良好临床实践指南的规定进行。,0.2,"['good clinical practice', 'trial', 'with', 'by', 'and']",['by'],2245,"['该调查由诺瓦蒂斯资助,并按照赫尔辛基宣言和良好临床实践指南的规定进行。']",0.2,"['good clinical practice', 'trial', 'with', 'by', 'and']",['by'],,
2282,2246,the trial protocol and all amendments were approved by an independent ethics committee or the institutional review board at each site .,试验方案和所有修正案均由每个研究中心的独立伦理委员会或机构审查委员会批准。,0.3076923076923077,"['site', 'review', 'protocol', 'ethics', 'board', 'committee', 'trial', 'independent', 'at', 'all', 'each', 'by', 'and']","['review', 'protocol', 'committee', 'by']",2246,['审判议定书和所有修正案都是由一个独立的伦理委员会或每个网站的机构审查委员会批准的。'],0.4615384615384615,"['site', 'review', 'protocol', 'ethics', 'board', 'committee', 'trial', 'independent', 'at', 'all', 'each', 'by', 'and']","['review', 'protocol', 'committee', 'trial', 'independent', 'by']",,
2283,2247,a trial steering committee composed of participating international investigators and representatives of the sponsor oversaw the conduct of the trial .,由参与的国际研究人员和申办方代表组成的试验指导委员会监督试验的进行。,0.1428571428571428,"['a', 'sponsor', 'steering', 'committee', 'trial', 'conduct', 'and']",['committee'],2247,['由参与的国际调查人员和赞助商的代表组成的审判管理委员会监督审判的进展。'],0.2857142857142857,"['a', 'sponsor', 'steering', 'committee', 'trial', 'conduct', 'and']","['committee', 'trial']",,
2284,2248,safety data were assessed by an independent data monitoring committee .,安全数据由一个独立的数据监测委员会评估。,0.8571428571428571,"['safety', 'monitoring', 'data', 'committee', 'independent', 'by', 'assessed']","['safety', 'monitoring', 'data', 'committee', 'independent', 'by']",2248,['安全数据由独立数据监测委员会评估。'],0.7142857142857143,"['safety', 'monitoring', 'data', 'committee', 'independent', 'by', 'assessed']","['safety', 'monitoring', 'data', 'committee', 'by']",,
2285,2249,all patients provided written informed consent before enrollment .,所有患者在入组前均提供了书面知情同意书。,0.5,"['consent', 'informed consent', 'all', 'before']","['consent', 'before']",2249,['所有患者在登记前提供书面通知同意。'],0.5,"['consent', 'informed consent', 'all', 'before']","['consent', 'before']",,
2286,2249,all patients provided written informed consent before enrollment .,所有患者在入组前均提供了书面知情同意书。,0.5,"['consent', 'informed consent', 'all', 'before']","['consent', 'before']",2249,['所有患者在登记前提供书面通知同意。'],0.5,"['consent', 'informed consent', 'all', 'before']","['consent', 'before']",,
2287,2249,all patients provided written informed consent before enrollment .,所有患者在入组前均提供了书面知情同意书。,0.5,"['consent', 'informed consent', 'all', 'before']","['consent', 'before']",2249,['所有患者在登记前提供书面通知同意。'],0.5,"['consent', 'informed consent', 'all', 'before']","['consent', 'before']",,
2288,2250,"representatives of the sponsor designed the trial , compiled the data , and vouch for the accuracy of the analyses .",申办者的代表设计了试验，整理了数据，并保证分析的准确性。,0.6,"['data', 'accuracy', 'sponsor', 'trial', 'and']","['data', 'accuracy', 'sponsor']",2250,"['赞助商的代表设计了审判,编制了数据,并为分析的准确性提供支票。']",0.6,"['data', 'accuracy', 'sponsor', 'trial', 'and']","['data', 'accuracy', 'trial']",,
2289,2251,all authors had access to the data and vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol .,所有作者都可以访问数据并保证数据的准确性和完整性以及试验对方案的忠实度。,0.3333333333333333,"['fidelity', 'data', 'accuracy', 'protocol', 'access', 'trial', 'completeness', 'all', 'and']","['data', 'accuracy', 'completeness']",2251,"['所有作者都可以访问数据,并为数据的准确性和完整性以及审判对议定书的忠诚度提供服务。']",0.5555555555555556,"['fidelity', 'data', 'accuracy', 'protocol', 'access', 'trial', 'completeness', 'all', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
2290,2252,"all authors were involved in the interpretation of the data , contributed to the writing and review of all drafts of the manuscript , and made the decision to submit the manuscript for publication .",所有作者都参与了数据的解释，参与了所有手稿草稿的撰写和审阅，并做出了投稿发表的决定。,0.6,"['data', 'review', 'interpretation', 'publication', 'manuscript', 'writing', 'decision', 'all', 'to', 'and']","['data', 'review', 'interpretation', 'publication', 'manuscript', 'decision']",2252,"['所有作者都参与了数据的解释,参与了手稿的所有草案的写作和审查,并决定提交手稿出版。']",0.7,"['data', 'review', 'interpretation', 'publication', 'manuscript', 'writing', 'decision', 'all', 'to', 'and']","['data', 'review', 'interpretation', 'publication', 'manuscript', 'writing', 'decision']",,
2291,2253,two professional medical writers provided editorial support and were paid by the sponsor .,两名专业医学作家提供编辑支持，费用由申办方支付。,0.4285714285714285,"['support', 'sponsor', 'medical', 'professional', 'by', 'and', 'two']","['support', 'by', 'two']",2253,"['两名专业的医学作家提供编辑支持,并由赞助商支付。']",0.4285714285714285,"['support', 'sponsor', 'medical', 'professional', 'by', 'and', 'two']","['support', 'by', 'two']",,
2292,2254,"for the analysis of overall survival , data for patients were censored at the date the patient was last known to be alive .",为了分析总生存期，患者的数据在最后一次知道患者还活着的日期进行了截尾。,0.8571428571428571,"['data', 'analysis', 'survival', 'date', 'be', 'patient', 'to']","['data', 'analysis', 'survival', 'date', 'be', 'patient']",2254,"['对于整体生存的分析,患者的数据被审查到病人最后知道活着的日期。']",0.8571428571428571,"['data', 'analysis', 'survival', 'date', 'be', 'patient', 'to']","['data', 'analysis', 'survival', 'date', 'patient', 'to']",,
2293,2255,"from December 17 , 2014 , to August 1 , 2016 , a total of 335 patients were randomly assigned to the ribociclib group , and 337 to the placebo group ( Table S1 in the Supplementary Appendix , available at NEJM.org ) .",从 2014 年 12 月 17 日到 2016 年 8 月 1 日，共有 335 名患者被随机分配到瑞博西尼组，337 名患者分配到安慰剂组（补充附录表 S1，可在 NEJM.org 获取）。,0.3846153846153846,"['group', 'placebo', 'appendix', 'table', '1', 'supplementary', 'total', 'available', 'ribociclib', 'at', 'S1', 'in', 'and']","['group', 'placebo', 'table', '1', 'ribociclib']",2255,"['2014 年 12 月 17 日至 2016 年 8 月 1 日,共有 335 名患者随机分配给 Ribociclib 组,以及 337 名患者分配给 placebo 组(附件中的 S1 表,可在 NEJM.org 上找到)。']",0.3076923076923077,"['group', 'placebo', 'appendix', 'table', '1', 'supplementary', 'total', 'available', 'ribociclib', 'at', 'S1', 'in', 'and']","['group', 'appendix', 'table', '1']",,
2294,2256,details regarding patient screening and the population included in the efficacy analysis have been published previously.17,有关患者筛查和功效分析中包含的人群的详细信息先前已发表。 17,0.875,"['population', 'analysis', 'screening', 'regarding', 'patient', 'efficacy', 'have', 'and']","['population', 'analysis', 'screening', 'regarding', 'patient', 'efficacy', 'have']",2256,['有关患者筛查的详细信息以及在有效性分析中包含的人口已被公布。'],0.875,"['population', 'analysis', 'screening', 'regarding', 'patient', 'efficacy', 'have', 'and']","['population', 'analysis', 'screening', 'regarding', 'patient', 'efficacy', 'have']",,
2295,2257,"at the cutoff date for this analysis of overall survival , 173 patients were still receiving trial treatment : 116 of 335 patients ( 34.6 % ) in the ribociclib group and 57 of 337 ( 16.9 % ) in the placebo group .",在该总生存期分析的截止日期，173 名患者仍在接受试验治疗：ribociclib 组 335 名患者中的 116 名 (34.6%) 和安慰剂组 337 名患者中的 57 名 (16.9%)。,0.4615384615384615,"['group', 'cutoff', 'placebo', 'analysis', 'survival', 'date', 'still', 'treatment', 'trial', 'ribociclib', 'this', 'in', 'and']","['group', 'placebo', 'analysis', 'survival', 'date', 'treatment']",2257,"['在这一整体生存分析的截止日期,173名患者仍在接受试验治疗:Ribociclib群体的335名患者中有116人(34.6%)和 placebo群体的337人中有57人(16.9%)。']",0.3846153846153846,"['group', 'cutoff', 'placebo', 'analysis', 'survival', 'date', 'still', 'treatment', 'trial', 'ribociclib', 'this', 'in', 'and']","['group', 'analysis', 'survival', 'date', 'treatment']",,
2296,2258,the median duration of exposure to placebo was approximately 1 year .,接触安慰剂的中位持续时间约为 1 年。,0.5,"['median', 'placebo', 'year', 'exposure', '1', 'duration', 'approximately', 'to']","['placebo', 'year', '1', 'duration']",2258,['对 placebo 的平均曝光时间大约为1年。'],0.375,"['median', 'placebo', 'year', 'exposure', '1', 'duration', 'approximately', 'to']","['year', 'exposure', '1']",,
2297,2259,"overall survival was significantly longer in the ribociclib group than in the placebo group , with a 29 % lower risk of death ( hazard ratio for death , 0.71 ; 95 % CI , 0.54 to 0.95 ) ( Figure 1A ) .",ribociclib 组的总生存期明显长于安慰剂组，死亡风险降低 29%（死亡风险比，0.71；95% CI，0.54 至 0.95）（图 1A）。,0.5714285714285714,"['group', 'placebo', 'survival', 'ratio', 'hazard ratio', 'death', 'figure', 'lower', 'risk', 'with', 'ribociclib', 'CI', 'in', 'to']","['group', 'placebo', 'survival', 'ratio', 'hazard ratio', 'death', 'risk', 'to']",2259,"['在Ribociclib群体中,总生存比 placebo群体更长,死亡风险低于29%(死亡风险比例为0.71;95%的CI,0.54至0.95)。']",0.5,"['group', 'placebo', 'survival', 'ratio', 'hazard ratio', 'death', 'figure', 'lower', 'risk', 'with', 'ribociclib', 'CI', 'in', 'to']","['group', 'survival', 'ratio', 'hazard ratio', 'death', 'risk', 'to']",,
2298,2260,"the median overall survival could not be estimated in the ribociclib group and was 40.9 months in the placebo group ( 95 % CI , 37.8 to could not be estimated ) ( Figure 1A ) .",ribociclib 组的中位总生存期无法估计，安慰剂组为 40.9 个月（95% CI，37.8 至无法估计）（图 1A）。,0.3636363636363636,"['group', 'median', 'placebo', 'survival', 'figure', 'be', 'ribociclib', 'CI', 'in', 'to', 'and']","['group', 'placebo', 'survival', 'figure']",2260,"['平均总生存率在Ribociclib群体中无法估计,并且在 placebo群体中为40.9个月(95% CI,37.8 无法估计)(图1A)。']",0.3636363636363636,"['group', 'median', 'placebo', 'survival', 'figure', 'be', 'ribociclib', 'CI', 'in', 'to', 'and']","['group', 'survival', 'figure', 'be']",,
2299,2261,"because the efficacy stopping boundary was crossed , the results reported here showed the superiority of ribociclib to placebo with respect to the key secondary end point of overall survival , and , according to the protocol , are considered final .",由于跨越了疗效终止边界，此处报告的结果表明，在关键的次要终点总生存期方面，ribociclib 优于安慰剂，并且根据方案，该结果被认为是最终结果。,0.3125,"['boundary', 'placebo', 'key', 'survival', 'protocol', 'crossed', 'secondary', 'efficacy', 'superiority', 'end', 'point', 'with', 'respect', 'ribociclib', 'stopping', 'and']","['boundary', 'placebo', 'key', 'survival', 'point']",2261,"['由于有效性停止边界被克服,这里报告的结果显示了Ribociclib对 placebo的优越性,与总生存的关键二级终点相比,并根据协议被认为是最终的。']",0.4375,"['boundary', 'placebo', 'key', 'survival', 'protocol', 'crossed', 'secondary', 'efficacy', 'superiority', 'end', 'point', 'with', 'respect', 'ribociclib', 'stopping', 'and']","['boundary', 'key', 'survival', 'protocol', 'efficacy', 'superiority', 'point']",,
2300,2262,prespecified analyses of overall survival were performed in subgroups defined according to the endocrine therapy received .,在根据接受的内分泌治疗定义的亚组中进行了预先指定的总生存期分析。,0.5,"['defined', 'survival', 'endocrine', 'therapy', 'endocrine therapy', 'to']","['survival', 'endocrine', 'therapy']",2262,['预定的整体生存分析是在根据接受的内分泌疗法定义的子组进行的。'],0.6666666666666666,"['defined', 'survival', 'endocrine', 'therapy', 'endocrine therapy', 'to']","['survival', 'endocrine', 'therapy', 'endocrine therapy']",,
2301,2263,"among the 495 patients who received an aromatase inhibitor , 61 of 248 patients ( 24.6 % ) in the ribociclib group and 80 of 247 ( 32.4 % ) in the placebo group died .",在接受芳香化酶抑制剂治疗的 495 名患者中，ribociclib 组 248 名患者中的 61 名 (24.6%) 和安慰剂组 247 名患者中的 80 名 (32.4%) 死亡。,0.375,"['group', 'inhibitor', 'placebo', 'aromatase', 'who', 'ribociclib', 'aromatase inhibitor', 'and']","['group', 'inhibitor', 'placebo']",2263,"['在接受香水抑制剂的495名患者中,Ribociclib群体的248名患者中有61人(246%)和 placebo群体的247名患者中有80人(32%)死亡。']",0.25,"['group', 'inhibitor', 'placebo', 'aromatase', 'who', 'ribociclib', 'aromatase inhibitor', 'and']","['group', 'inhibitor']",,
2302,2264,"estimated overall survival at 42 months among patients who received an aromatase inhibitor was 69.7 % ( 95 % CI , 61.3 to 76.7 ) in the ribociclib group and 43.0 % ( 95 % CI , 25.9 to 59.0 ) in the placebo group , and the hazard ratio for death was 0.70 ( 95 % CI , 0.50 to 0.98 ) ( Figure 1B ) .",瑞博西尼组接受芳香酶抑制剂治疗的患者在 42 个月时的估计总生存率为 69.7 % ( 95 % CI 61.3 至 76.7 ) ，安慰剂组为 43.0 % ( 95 % CI 25.9 至 59.0 ) ，风险比死亡率为 0.70（95% CI，0.50 至 0.98）（图 1B）。,0.7142857142857143,"['group', 'inhibitor', 'placebo', 'aromatase', 'who', 'survival', 'ratio', 'hazard ratio', 'death', 'figure', 'ribociclib', 'aromatase inhibitor', 'CI', 'and']","['group', 'inhibitor', 'placebo', 'aromatase', 'survival', 'ratio', 'hazard ratio', 'death', 'figure', 'ribociclib']",2264,"['在接受香水抑制剂的患者中,估计42个月的总生存率为Ribociclib群体的69.7%(95%CI,61.3至76.7)和Placebo群体的43.0%(95%CI,259.9至59.0),死亡风险比例为0.70(95%CI,0.50至0.98)。']",0.5,"['group', 'inhibitor', 'placebo', 'aromatase', 'who', 'survival', 'ratio', 'hazard ratio', 'death', 'figure', 'ribociclib', 'aromatase inhibitor', 'CI', 'and']","['group', 'inhibitor', 'survival', 'ratio', 'hazard ratio', 'death', 'figure']",,
2303,2265,"among the 177 patients who received tamoxifen , 22 of 87 patients ( 25.3 % ) in the ribociclib group and 29 of 90 ( 32.2 % ) in the placebo group died .",在接受他莫昔芬治疗的 177 名患者中，ribociclib 组 87 名患者中的 22 名 (25.3%) 和安慰剂组 90 名患者中的 29 名 (32.2%) 死亡。,0.4285714285714285,"['group', 'placebo', 'who', 'ribociclib', 'tamoxifen', 'in', 'and']","['group', 'placebo', 'tamoxifen']",2265,"['在接受Tamoxifen的177名患者中,Ribociclib群体的87名患者中有22名(25,3%)和 placebo群体的90名患者中有29名(32.2%)死亡。']",0.1428571428571428,"['group', 'placebo', 'who', 'ribociclib', 'tamoxifen', 'in', 'and']",['group'],,
2304,2266,"estimated overall survival at 42 months among patients who received tamoxifen was 71.2 % ( 95 % CI , 58.0 to 80.9 ) in the ribociclib group and 54.5 % ( 95 % CI , 36.0 to 69.7 ) in the placebo group , and the hazard ratio for death was 0.79 ( 95 % CI , 0.45 to 1.38 ) ( Figure 1C ) .",瑞博西尼组接受他莫昔芬治疗的患者在 42 个月时的总生存率估计为 71.2 % （ 95 % CI 58.0 至 80.9 ） ，安慰剂组为 54.5 % （ 95 % CI 36.0 至 69.7 ） ，死亡风险比为 0.79（95% CI，0.45 至 1.38）（图 1C）。,0.6428571428571429,"['group', 'placebo', 'who', 'survival', 'ratio', 'hazard ratio', 'death', 'figure', 'ribociclib', 'tamoxifen', 'CI', 'in', 'to', 'and']","['group', 'placebo', 'survival', 'ratio', 'hazard ratio', 'death', 'figure', 'ribociclib', 'tamoxifen']",2266,"['在接受tamoxifen的患者中,估计在42个月的总生存率为71.2%(95%CI,58.0至80.9)在Ribociclib群体和54.5%(95%CI,36.0至69.7)在 placebo群体,死亡风险比例为0.79(95%CI,0.45至1.38)。']",0.4285714285714285,"['group', 'placebo', 'who', 'survival', 'ratio', 'hazard ratio', 'death', 'figure', 'ribociclib', 'tamoxifen', 'CI', 'in', 'to', 'and']","['group', 'survival', 'ratio', 'hazard ratio', 'death', 'figure']",,
2305,2267,"overall survival was also assessed in exploratory subgroups defined according to patient and disease characteristics , previous therapies , and geographic region ( Figure 2 ) .",总生存期也在根据患者和疾病特征、既往治疗和地理区域定义的探索性亚组中进行评估（图 2）。,0.4615384615384615,"['disease', 'defined', '2', 'survival', 'figure', 'previous', 'region', 'exploratory', 'characteristics', 'patient', 'geographic', 'and', 'assessed']","['disease', '2', 'survival', 'region', 'characteristics', 'patient']",2267,['总生存也被评估在根据患者和疾病特征、以前的治疗和地理区域定义的探险子组(图2)。'],0.6153846153846154,"['disease', 'defined', '2', 'survival', 'figure', 'previous', 'region', 'exploratory', 'characteristics', 'patient', 'geographic', 'and', 'assessed']","['disease', '2', 'survival', 'previous', 'region', 'exploratory', 'characteristics', 'patient']",,
2306,2268,"in general , the overall survival benefit with ribociclib in these subgroups was consistent with that in the overall population ; however , the small numbers of patients in some of these subgroups resulted in wide confidence intervals .",总的来说，ribociclib 在这些亚组中的总体生存获益与在总体人群中的获益一致；然而，其中一些亚组中的少数患者导致置信区间较宽。,0.2727272727272727,"['population', 'survival', 'general', 'wide', 'benefit', 'with', 'confidence', 'ribociclib', 'that', 'in', 'intervals']","['population', 'survival', 'general']",2268,"['总体而言,这些子群中Ribociclib的总生存益与总人口的相一致;然而,这些子群中的一些小患者的数量导致了广泛的信任间隔。']",0.2727272727272727,"['population', 'survival', 'general', 'wide', 'benefit', 'with', 'confidence', 'ribociclib', 'that', 'in', 'intervals']","['population', 'survival', 'wide']",,
2307,2269,a total of 219 patients in the ribociclib group and 280 patients in the placebo group discontinued the trial regimen .,ribociclib 组中共有 219 名患者和安慰剂组中有 280 名患者停止了试验治疗。,0.2857142857142857,"['group', 'placebo', 'total', 'trial', 'ribociclib', 'in', 'and']","['group', 'placebo']",2269,['总共有219名Ribociclib患者和280名 placebo患者中断了试验计划。'],0.0,"['group', 'placebo', 'total', 'trial', 'ribociclib', 'in', 'and']",[],,
2308,2270,the percentage of these patients who received subsequent antineoplastic therapies was similar in the two groups : 151 patients ( 68.9 % ) in the ribociclib group and 205 ( 73.2 % ) in the placebo group ( Table 2 ) .,这些患者接受后续抗肿瘤治疗的百分比在两组中相似：ribociclib 组 151 名患者 (68.9%) 和安慰剂组 205 名 (73.2%)（表 2）。,0.4166666666666667,"['group', 'percentage', 'placebo', 'table', 'who', '2', 'antineoplastic', 'subsequent', 'ribociclib', 'and', 'two', 'similar']","['group', 'placebo', 'table', '2', 'two']",2270,['接下来的抗生素治疗患者的比例在两个群体中相似:Ribociclib群体的151名患者(68.9%)和 placebo群体的205名患者(73.2%)。'],0.25,"['group', 'percentage', 'placebo', 'table', 'who', '2', 'antineoplastic', 'subsequent', 'ribociclib', 'and', 'two', 'similar']","['group', '2', 'two']",,
2309,2271,"chemotherapy alone ( 22.4 % in the ribociclib group and 28.6 % in the placebo group ) and hormone therapy alone ( 22.4 % and 20.4 % , respectively ) were the most common first subsequent antineoplastic therapies .",单纯化疗（ribociclib 组为 22.4%，安慰剂组为 28.6%）和单纯激素治疗（分别为 22.4% 和 20.4%）是最常见的后续抗肿瘤治疗。,0.3636363636363636,"['group', 'chemotherapy', 'placebo', 'hormone', 'antineoplastic', 'common', 'subsequent', 'ribociclib', 'and', 'alone', 'first']","['group', 'chemotherapy', 'placebo', 'hormone']",2271,['只有化疗(Ribociclib群体的22.4%和 placebo群体的28.6%)和荷尔蒙治疗(相应的22.4%和20.4%)是最常见的第一次随后的抗生素治疗。'],0.2727272727272727,"['group', 'chemotherapy', 'placebo', 'hormone', 'antineoplastic', 'common', 'subsequent', 'ribociclib', 'and', 'alone', 'first']","['group', 'chemotherapy', 'first']",,
2310,2272,"pyrimidine analogues ( 29.7 % in the ribociclib group and 33.6 % in the placebo group ) and taxanes ( 24.2 % and 26.8 % , respectively ) were the most common chemotherapies in all subsequent lines of therapy .",嘧啶类似物（ribociclib 组为 29.7%，安慰剂组为 33.6%）和紫杉烷类（分别为 24.2% 和 26.8%）是所有后续治疗中最常用的化疗药物。,0.4,"['pyrimidine', 'group', 'placebo', 'lines', 'therapy', 'common', 'subsequent', 'ribociclib', 'all', 'and']","['pyrimidine', 'group', 'placebo', 'therapy']",2272,['皮里米丁类似物(Ribociclib群体的29.7%和 placebo群体的33.6%)和Taxanes(相应的24.2%和26.8%)是所有随后的治疗线中最常见的化疗。'],0.2,"['pyrimidine', 'group', 'placebo', 'lines', 'therapy', 'common', 'subsequent', 'ribociclib', 'all', 'and']","['group', 'therapy']",,
2311,2273,"aromatase inhibitors ( 29.2 % in the ribociclib group and 27.5 % in the placebo group ) and antiestrogens ( 23.3 % and 25.4 % , respectively ) were the most common hormone therapies .",芳香化酶抑制剂（ribociclib 组为 29.2%，安慰剂组为 27.5%）和抗雌激素（分别为 23.3% 和 25.4%）是最常见的激素疗法。,0.375,"['group', 'placebo', 'aromatase', 'hormone', 'common', 'ribociclib', 'in', 'and']","['group', 'placebo', 'hormone']",2273,['香水抑制剂(Ribociclib群体的29.2%和 placebo群体的27.5%)和抗雌激素(相应的23.3%和25.4%)是最常见的荷尔蒙治疗。'],0.25,"['group', 'placebo', 'aromatase', 'hormone', 'common', 'ribociclib', 'in', 'and']","['group', 'hormone']",,
2312,2274,adverse events in the two groups remained consistent with those in the primary analysis ( Table S3 in the Supplementary Appendix ) .,两组的不良事件与主要分析中的一致（补充附录表S3）。,0.3,"['appendix', 'table', 'analysis', 'supplementary', 'adverse', 'primary', 'with', 'S3', 'in', 'two']","['table', 'analysis', 'two']",2274,['两组的副作用仍然与初级分析中的副作用一致(附件中的S3表)。'],0.4,"['appendix', 'table', 'analysis', 'supplementary', 'adverse', 'primary', 'with', 'S3', 'in', 'two']","['appendix', 'table', 'analysis', 'two']",,
2313,2275,"key grade 3 or 4 adverse events of special interest were neutropenia ( in 63.5 % of patients in the ribociclib group and 4.5 % in the placebo group ) , hepatobiliary toxic effects ( in 11 % and 6.8 % , respectively ) , and prolonged QT interval ( in 1.8 % and 1.2 % , respectively ) .",特别关注的关键 3 级或 4 级不良事件是中性粒细胞减少症（瑞博西尼组 63.5 % 的患者和安慰剂组 4.5 % 的患者） 、肝胆毒性作用（分别为 11 % 和 6.8 % ）和 QT 间期延长（分别为 1.8% 和 1.2%）。,0.5,"['group', 'placebo', 'key', 'interval', 'toxic', 'grade', 'neutropenia', 'adverse', '3', '4', 'ribociclib', 'prolonged', 'and', 'special']","['group', 'placebo', 'key', 'interval', 'neutropenia', 'ribociclib', 'special']",2275,"['主要类别3或4的特殊兴趣的副作用是中性<unk>(在Ribociclib群体患者的63.5%和Placebo群体患者的4.5%),肝脏毒性影响(相应11%和6.8%),以及延长QT间隔(相应1.8%和1.2%)。']",0.2142857142857142,"['group', 'placebo', 'key', 'interval', 'toxic', 'grade', 'neutropenia', 'adverse', '3', '4', 'ribociclib', 'prolonged', 'and', 'special']","['group', 'interval', 'special']",,
2314,2276,"because overall survival and postprogression outcomes are key factors in clinical decision making , the results of adding biologic treatments to endocrine therapies in early lines of therapy are highly relevant in this patient population .",由于总生存期和进展后结果是临床决策制定的关键因素，因此在早期治疗中将生物治疗加入内分泌治疗的结果与该患者群体高度相关。,0.8,"['population', 'lines', 'key', 'survival', 'endocrine', 'biologic', 'early', 'therapy', 'clinical', 'patient', 'decision', 'decision making', 'this', 'to', 'and']","['population', 'key', 'survival', 'endocrine', 'early', 'therapy', 'clinical', 'patient', 'decision', 'decision making', 'this', 'to']",2276,"['由于整体生存和后进化结果是临床决策的关键因素,因此在治疗的早期线内添加生物治疗的结果在这种患者群体中非常重要。']",0.7333333333333333,"['population', 'lines', 'key', 'survival', 'endocrine', 'biologic', 'early', 'therapy', 'clinical', 'patient', 'decision', 'decision making', 'this', 'to', 'and']","['population', 'key', 'survival', 'early', 'therapy', 'clinical', 'patient', 'decision', 'decision making', 'this', 'to']",,
2315,2277,"after a median of 2 years of treatment exposure in the ribociclib group , no new safety signals were observed.17",ribociclib 组接受治疗的中位数为 2 年之后，没有观察到新的安全信号。 17,0.5454545454545454,"['safety', 'group', 'median', 'exposure', '2', 'treatment', 'no', 'after', 'ribociclib', 'in', 'new']","['safety', 'group', '2', 'treatment', 'after', 'new']",2277,"['在Ribociclib群体中中间2年的治疗暴露后,没有发现新的安全信号。']",0.6363636363636364,"['safety', 'group', 'median', 'exposure', '2', 'treatment', 'no', 'after', 'ribociclib', 'in', 'new']","['safety', 'group', 'exposure', '2', 'treatment', 'after', 'new']",,
2316,2278,no instances of symptomatic arrhythmias or torsades de pointes have been observed in this trial .,在该试验中没有观察到有症状的心律失常或尖端扭转型室性心动过速的实例。,0.25,"['no', 'symptomatic', 'arrhythmias', 'trial', 'de', 'have', 'this', 'in']","['symptomatic', 'have']",2278,['在此研究中没有观察到任何症状性甲状腺炎或甲状腺炎的例子。'],0.125,"['no', 'symptomatic', 'arrhythmias', 'trial', 'de', 'have', 'this', 'in']",['have'],,
2317,2279,one possible explanation for this treatment effect of ribociclib could be the premenopausal patient population .,对 ribociclib 的这种治疗效果的一种可能解释可能是绝经前患者群体。,0.6,"['population', 'be', 'treatment', 'premenopausal', 'patient', 'effect', 'treatment effect', 'explanation', 'ribociclib', 'this']","['population', 'treatment', 'patient', 'effect', 'treatment effect', 'this']",2279,['一个可能的解释这个治疗效果的Ribociclib可能是前更年期患者人口。'],0.6,"['population', 'be', 'treatment', 'premenopausal', 'patient', 'effect', 'treatment effect', 'explanation', 'ribociclib', 'this']","['population', 'treatment', 'patient', 'effect', 'treatment effect', 'this']",,
2318,2280,alterations in the gene encoding fibroblast growth factor receptor ( FGFR ) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions .,编码成纤维细胞生长因子受体 (FGFR) 的基因的改变在尿路上皮癌中很常见，并且可能与免疫干预的敏感性降低有关。,0.5333333333333333,"['growth factor', 'gene', 'receptor', 'carcinoma', 'fibroblast', 'fibroblast growth factor', 'encoding', 'lower', 'be', 'common', 'associated', 'immune', 'with', 'sensitivity', 'and']","['growth factor', 'gene', 'receptor', 'carcinoma', 'fibroblast', 'fibroblast growth factor', 'encoding', 'be']",2280,"['FGFR(Fibroblast Growth Factor Receptor)代码基因的变化在尿道癌症中常见,可能与免疫干预的敏感度较低有关。']",0.2,"['growth factor', 'gene', 'receptor', 'carcinoma', 'fibroblast', 'fibroblast growth factor', 'encoding', 'lower', 'be', 'common', 'associated', 'immune', 'with', 'sensitivity', 'and']","['gene', 'carcinoma', 'be']",,
2319,2281,all the patients had a history of disease progression during or after at least one course of chemotherapy or within 12 months after neoadjuvant or adjuvant chemotherapy .,所有患者在至少一个疗程的化疗期间或之后或在新辅助或辅助化疗后12个月内均有疾病进展史。,0.4,"['chemotherapy', 'disease', 'adjuvant', 'history', 'progression', 'after', 'of disease', 'course', 'at', 'all']","['chemotherapy', 'disease', 'progression', 'after']",2281,"['所有患者在至少一次化疗期间或之后,或在新辅助或辅助化疗后12个月内患有疾病进展史。']",0.4,"['chemotherapy', 'disease', 'adjuvant', 'history', 'progression', 'after', 'of disease', 'course', 'at', 'all']","['chemotherapy', 'disease', 'progression', 'after']",,
2320,2282,prior immunotherapy was allowed .,之前的免疫治疗是允许的。,0.5,"['immunotherapy', 'prior']",['immunotherapy'],2282,['以前的免疫疗法是允许的。'],0.5,"['immunotherapy', 'prior']",['immunotherapy'],,
2321,2283,the primary end point was the objective response rate .,主要终点是客观反应率。,0.5714285714285714,"['objective', 'rate', 'primary', 'response', 'end', 'point', 'response rate']","['rate', 'response', 'point', 'response rate']",2283,['主要的终点是客观反应率。'],0.7142857142857143,"['objective', 'rate', 'primary', 'response', 'end', 'point', 'response rate']","['rate', 'primary', 'response', 'point', 'response rate']",,
2322,2284,"of these patients , 43 % had received at least two previous courses of treatment , 79 % had visceral metastases , and 53 % had a creatinine clearance of less than 60 ml per minute .",在这些患者中，43% 之前至少接受过两个疗程，79% 有内脏转移，53% 的肌酐清除率低于每分钟 60 毫升。,0.3,"['creatinine', 'previous', 'courses', 'minute', 'visceral', 'treatment', 'clearance', 'ml', 'and', 'two']","['minute', 'clearance', 'two']",2284,"['在这些患者中,43%至少接受了前两次治疗,79%患有阴道转移,53%患有每分钟60毫升以下的克里亚丁清洁剂。']",0.3,"['creatinine', 'previous', 'courses', 'minute', 'visceral', 'treatment', 'clearance', 'ml', 'and', 'two']","['minute', 'treatment', 'two']",,
2323,2285,the rate of confirmed response to erdafitinib therapy was 40 % ( 3 % with a complete response and 37 % with a partial response ) .,对厄达替尼治疗的确认反应率为 40%（3% 完全反应，37% 部分反应）。,0.3,"['a', 'rate', 'therapy', 'complete', 'response', 'partial', '3', 'with', 'to', 'and']","['rate', 'therapy', 'response']",2285,['对埃尔达菲蒂尼布治疗的确认反应率为40%(全反应率为3%、部分反应率为37%)。'],0.3,"['a', 'rate', 'therapy', 'complete', 'response', 'partial', '3', 'with', 'to', 'and']","['rate', 'therapy', 'response']",,
2324,2286,"among the 22 patients who had undergone previous immunotherapy , the confirmed response rate was 59 % .",在既往接受过免疫治疗的 22 名患者中，确诊反应率为 59%。,0.6666666666666666,"['who', 'rate', 'immunotherapy', 'previous', 'response', 'response rate']","['rate', 'immunotherapy', 'response', 'response rate']",2286,"['在过去接受免疫治疗的22名患者中,确认的反应率为59%。']",0.6666666666666666,"['who', 'rate', 'immunotherapy', 'previous', 'response', 'response rate']","['rate', 'immunotherapy', 'response', 'response rate']",,
2325,2287,the use of erdafitinib was associated with an objective tumor response in 40 % of previously treated patients who had locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations .,erdafitinib 的使用与 40% 的先前接受过治疗的局部晚期和不可切除或转移性尿路上皮癌伴 FGFR 改变的患者的客观肿瘤反应相关。,0.2727272727272727,"['objective', 'carcinoma', 'who', 'tumor', 'metastatic', 'associated', 'response', 'advanced', 'unresectable', 'with', 'and']","['carcinoma', 'tumor', 'response']",2287,"['埃尔达菲蒂尼布的使用与预先治疗的40%患者的客观肿瘤反应有关,这些患者患有本地发达、不可恢复或转化性甲状腺癌,并患有FGFR变异。']",0.2727272727272727,"['objective', 'carcinoma', 'who', 'tumor', 'metastatic', 'associated', 'response', 'advanced', 'unresectable', 'with', 'and']","['carcinoma', 'tumor', 'response']",,
2326,2288,"FGFRs induce signaling through networks that regulate cell proliferation , survival , migration , and differentiation.15",FGFRs 通过调节细胞增殖、存活、迁移和分化的网络诱导信号传导。 15,0.75,"['cell', 'migration', 'survival', 'proliferation', 'induce', 'cell proliferation', 'that', 'and']","['cell', 'migration', 'survival', 'proliferation', 'induce', 'cell proliferation']",2288,['FGFR 引发通过调节细胞繁殖、生存、迁移和差异化网络的信号。'],0.375,"['cell', 'migration', 'survival', 'proliferation', 'induce', 'cell proliferation', 'that', 'and']","['cell', 'migration', 'survival']",,
2327,2289,"mutations and fusions in FGFR2 / 3 are common in patients with urothelial carcinoma , particularly in the luminal I subtype , and can cause constitutive FGFR signaling that may contribute to carcinogenesis.15",FGFR2 / 3 的突变和融合在尿路上皮癌患者中很常见，特别是在 luminal I 亚型中，并且可以引起可能导致癌变的组成型 FGFR 信号。 15,0.0909090909090909,"['carcinoma', 'luminal', '/', 'common', 'cause', '3', 'with', 'I', 'that', 'to', 'and']",['carcinoma'],2289,"['FGFR2/3的突变和合并在患有尿道癌症的患者中常见,特别是在光 I 子类型,并且可能导致形成的 FGFR 信号,这可能有助于癌症产生。']",0.1818181818181818,"['carcinoma', 'luminal', '/', 'common', 'cause', '3', 'with', 'I', 'that', 'to', 'and']","['carcinoma', 'to']",,
2328,2290,"as many as 20 % of patients with advanced urothelial carcinoma have FGFR alterations , 16 and such mutations are even more frequent ( 37 % ) in patients with upper tract urothelial carcinoma.17",多达 20 % 的晚期尿路上皮癌患者有 FGFR 改变 16 ，这种突变在上尿路尿路上皮癌患者中更为常见 ( 37 % ) 17,0.2222222222222222,"['tract', 'carcinoma', 'upper', 'advanced', 'as', 'with', 'have', 'frequent', 'and']","['carcinoma', 'have']",2290,"['大约有20%患有先进的尿道癌的患者患有FGFR变异,16和这些变异在患上高管尿道癌的患者中更为常见(37%)。']",0.3333333333333333,"['tract', 'carcinoma', 'upper', 'advanced', 'as', 'with', 'have', 'frequent', 'and']","['tract', 'carcinoma', 'have']",,
2329,2291,"thus , FGFR inhibition may be particularly appropriate in patients with luminal I subtype disease , in which immunotherapeutic approaches may be less effective .",因此，FGFR 抑制可能特别适用于 luminal I 亚型疾病患者，在这些患者中免疫治疗方法可能效果较差。,0.5,"['inhibition', 'disease', 'luminal', 'be', 'thus', 'with', 'I', 'appropriate']","['inhibition', 'disease', 'be', 'thus']",2291,"['因此,FGFR抑制可能特别适用于患有光 I子型疾病的患者,免疫治疗方法可能不太有效。']",0.375,"['inhibition', 'disease', 'luminal', 'be', 'thus', 'with', 'I', 'appropriate']","['inhibition', 'disease', 'thus']",,
2330,2292,"this ongoing study that included 126 sites in 14 countries was designed by the sponsor , Janssen Research and Development , with input from the first and last authors .",这项正在进行的研究包括 14 个国家的 126 个地点，由赞助商 Janssen Research and Development 设计，第一作者和最后一位作者提供了意见。,0.2222222222222222,"['research and development', 'sponsor', 'study', 'input', 'with', 'this', 'that', 'by', 'first']","['by', 'first']",2292,"['这项正在进行的研究,其中包括14个国家的126个网站,由赞助商Janssen Research and Development设计,其中包括第一和最后的作者。']",0.2222222222222222,"['research and development', 'sponsor', 'study', 'input', 'with', 'this', 'that', 'by', 'first']","['by', 'first']",,
2331,2293,all the patients have provided written informed consent .,所有患者均提供了书面知情同意书。,0.5,"['consent', 'informed consent', 'have', 'all']","['consent', 'have']",2293,['所有患者已提供书面信息的同意。'],0.5,"['consent', 'informed consent', 'have', 'all']","['consent', 'have']",,
2332,2294,"a data review committee was commissioned by the sponsor to conduct interim analyses , monitor safety , review efficacy , and make recommendations regarding study conduct .",赞助商委托数据审查委员会进行中期分析、监测安全性、审查疗效并就研究实施提出建议。,0.3076923076923077,"['safety', 'monitor', 'data', 'review', 'sponsor', 'study', 'regarding', 'committee', 'efficacy', 'conduct', 'by', 'and', 'make']","['safety', 'data', 'review', 'committee']",2294,['赞助商委托一个数据审查委员会进行临时分析、监测安全、审查效率以及对研究行为提出建议。'],0.3846153846153846,"['safety', 'monitor', 'data', 'review', 'sponsor', 'study', 'regarding', 'committee', 'efficacy', 'conduct', 'by', 'and', 'make']","['safety', 'data', 'review', 'committee', 'by']",,
2333,2295,all the authors assume responsibility for the completeness and accuracy of the data and for the fidelity of the study to the protocol ( available with the full text of this article at NEJM.org ) .,所有作者均对数据的完整性和准确性以及研究对方案（与本文全文可在 NEJM.org 获取）的忠实度负责。,0.2666666666666666,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'responsibility', 'study', 'available', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",2295,['所有作者对数据的完整性和准确性以及研究对协议的忠诚性负责(可在NEJM.org上提供本文的完整文本)。'],0.3333333333333333,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'responsibility', 'study', 'available', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'protocol', 'completeness', 'full']",,
2334,2296,the first and last authors developed the first draft of the manuscript with editorial assistance funded by the sponsor .,第一作者和最后一位作者在赞助商资助的编辑协助下起草了手稿的初稿。,0.25,"['sponsor', 'manuscript', 'assistance', 'with', 'by', 'and', 'first', 'draft']","['manuscript', 'first']",2296,"['第一和最后的作者开发了手稿的第一个草案,由赞助商资助的编辑援助。']",0.5,"['sponsor', 'manuscript', 'assistance', 'with', 'by', 'and', 'first', 'draft']","['manuscript', 'assistance', 'by', 'first']",,
2335,2297,all the authors had full access to and participated in the interpretation of the data and reviewed and approved the manuscript before submission for publication .,所有作者都可以完全访问并参与数据的解释，并在投稿前审阅并批准了手稿。,0.3636363636363636,"['data', 'access', 'interpretation', 'publication', 'manuscript', 'submission', 'full', 'all', 'before', 'to', 'and']","['data', 'interpretation', 'manuscript', 'before']",2297,"['所有作者都有充分的访问和参与了数据的解释,并在提交出版之前审查和批准了手稿。']",0.4545454545454545,"['data', 'access', 'interpretation', 'publication', 'manuscript', 'submission', 'full', 'all', 'before', 'to', 'and']","['data', 'interpretation', 'publication', 'manuscript', 'before']",,
2336,2298,there was no specific selection of patients with any particular fusion or mutation on the list .,没有具体选择名单上有任何特定融合或突变的患者。,0.2857142857142857,"['fusion', 'mutation', 'particular', 'no', 'specific', 'list', 'with']","['fusion', 'mutation']",2298,['列表中没有任何特定合并或突变的患者的具体选择。'],0.1428571428571428,"['fusion', 'mutation', 'particular', 'no', 'specific', 'list', 'with']",['mutation'],,
2337,2299,patients were also required to have a history of disease progression during or after at least one course of previous systemic chemotherapy or within 12 months after receiving neoadjuvant or adjuvant chemotherapy .,还要求患者在先前至少一个全身化疗期间或之后，或在接受新辅助或辅助化疗后 12 个月内有疾病进展史。,0.4166666666666667,"['chemotherapy', 'disease', 'adjuvant', 'previous', 'history', 'progression', 'systemic', 'after', 'of disease', 'course', 'at', 'have']","['chemotherapy', 'disease', 'progression', 'after', 'have']",2299,['患者还需要在至少一个系统化疗前期或12个月内接受新补充或补充化疗期间或之后进行疾病进展史。'],0.3333333333333333,"['chemotherapy', 'disease', 'adjuvant', 'previous', 'history', 'progression', 'systemic', 'after', 'of disease', 'course', 'at', 'have']","['chemotherapy', 'disease', 'progression', 'after']",,
2338,2300,"there was no limit on the number of previous courses of treatment or on the previous receipt of immunotherapy ( e.g. , treatment with an immune checkpoint inhibitor ) .",对既往疗程或既往接受免疫治疗（例如，免疫检查点抑制剂治疗）的次数没有限制。,0.5,"['inhibitor', 'immunotherapy', 'previous', 'courses', 'treatment', 'number', 'immune', 'limit', 'with', 'on']","['inhibitor', 'immunotherapy', 'treatment', 'number', 'limit']",2300,"['没有对以前的治疗课程或接收免疫治疗的数量的限制(例如,用免疫检查点抑制剂进行治疗)。']",0.6,"['inhibitor', 'immunotherapy', 'previous', 'courses', 'treatment', 'number', 'immune', 'limit', 'with', 'on']","['inhibitor', 'immunotherapy', 'previous', 'treatment', 'number', 'limit']",,
2339,2301,"patients were required to have adequate bone marrow , liver , and kidney function ( creatinine clearance , ≥ 40 ml per minute ) .",要求患者具有足够的骨髓、肝和肾功能（肌酐清除率，≥ 40 毫升/分钟）。,0.6923076923076923,"['bone', 'creatinine', 'liver', 'bone marrow', 'kidney', 'function', 'minute', 'clearance', 'adequate', 'ml', 'have', 'to', 'and']","['bone', 'liver', 'bone marrow', 'kidney', 'function', 'minute', 'clearance', 'adequate', 'have']",2301,"['患者需要有足够的骨髓、肝脏和肾功能(克里亚丁清洁剂,每分钟 ≥40毫升)。']",0.6153846153846154,"['bone', 'creatinine', 'liver', 'bone marrow', 'kidney', 'function', 'minute', 'clearance', 'adequate', 'ml', 'have', 'to', 'and']","['bone', 'liver', 'bone marrow', 'kidney', 'function', 'minute', 'adequate', 'have']",,
2340,2302,"patients with phosphate levels persistently above the upper limit of the normal range despite medical management , uncontrolled cardiovascular disease , brain metastases , known hepatitis B or C infection , or known infection with the human immunodeficiency virus were excluded .",尽管进行了医疗管理，但磷酸盐水平持续高于正常范围上限的患者、未控制的心血管疾病、脑转移、已知的乙型或丙型肝炎感染或已知的人类免疫缺陷病毒感染被排除在外。,0.5714285714285714,"['human immunodeficiency virus', 'infection', 'disease', 'cardiovascular', 'range', 'phosphate', 'brain', 'upper', 'B', 'medical', 'normal', 'hepatitis', 'cardiovascular disease', 'limit', 'uncontrolled', 'management', 'normal range', 'upper limit', 'with', 'despite', 'C']","['human immunodeficiency virus', 'infection', 'disease', 'cardiovascular', 'range', 'phosphate', 'brain', 'hepatitis', 'cardiovascular disease', 'management', 'normal range', 'upper limit']",2302,['尽管医学管理、未经控制的心血管疾病、脑转移、已知的肝炎B或C感染或已知的人类免疫缺陷病毒感染被排除。'],0.3809523809523809,"['human immunodeficiency virus', 'infection', 'disease', 'cardiovascular', 'range', 'phosphate', 'brain', 'upper', 'B', 'medical', 'normal', 'hepatitis', 'cardiovascular disease', 'limit', 'uncontrolled', 'management', 'normal range', 'upper limit', 'with', 'despite', 'C']","['human immunodeficiency virus', 'infection', 'disease', 'cardiovascular', 'brain', 'hepatitis', 'cardiovascular disease', 'management']",,
2341,2303,a planned interim analysis of safety and efficacy was performed in June and July 2016 .,计划于 2016 年 6 月和 2016 年 7 月进行安全性和有效性中期分析。,0.6,"['safety', 'analysis', 'efficacy', 'in', 'and']","['safety', 'analysis', 'efficacy']",2303,['计划的安全和效率临时分析是在2016年6月和7月进行的。'],0.4,"['safety', 'analysis', 'efficacy', 'in', 'and']","['safety', 'analysis']",,
2342,2304,"the amendment further specified that on day 14 , in patients with no adverse events that were considered by the investigator to be related to treatment , the daily dose of erdafitinib could be escalated to 9 mg with the use of a pharmacodynamically guided approach if the patients had not reached the target phosphate level of 5.5 mg per deciliter ( 1.8 mmol per liter ) , a level that had been associated with an improved response rate in the phase 1 study ( see the Background section in the Supplementary Appendix ) .",该修正案进一步规定，在第14天，如果患者没有发生研究者认为与治疗相关的不良事件，则可以使用药效学指导方法将厄达替尼的日剂量增加至9 mg ，如果患者有未达到 5.5 毫克/分升（1.8 毫摩尔/升）的目标磷酸盐水平，该水平在 1 期研究中与改善的反应率相关（见补充附录的背景部分）。,0.5714285714285714,"['approach', 'background', 'appendix', 'liter', 'phase', 'rate', '1', 'section', 'investigator', 'phosphate', 'deciliter', 'study', 'supplementary', 'be', 'adverse', 'associated', 'treatment', 'no', 'target', 'response', 'daily dose', 'level', 'response rate', 'with', 'that', 'if', 'by', 'amendment']","['background', 'liter', 'phase', 'rate', '1', 'investigator', 'phosphate', 'be', 'treatment', 'target', 'response', 'level', 'response rate', 'that', 'by', 'amendment']",2304,"['修正案进一步指出,在第十四天,在没有与治疗有关的研究人员所考虑的副作用的患者中,如果患者未达到目标磷酸盐水平为每分升5,5 mg(每升1.8 mmol),则可以通过药物导向方法将每日剂量增加到9 mg(参见补充附件的背景部分)。']",0.3928571428571428,"['approach', 'background', 'appendix', 'liter', 'phase', 'rate', '1', 'section', 'investigator', 'phosphate', 'deciliter', 'study', 'supplementary', 'be', 'adverse', 'associated', 'treatment', 'no', 'target', 'response', 'daily dose', 'level', 'response rate', 'with', 'that', 'if', 'by', 'amendment']","['background', 'appendix', 'liter', '1', 'phosphate', 'be', 'treatment', 'target', 'level', 'by', 'amendment']",,
2343,2305,the patients continued to receive 8 mg once daily if their serum phosphate levels on day 14 were within the target range of 5.5 to less than 7.0 mg per deciliter ( 2.3 mmol per liter ) .,如果患者在第 14 天的血清磷酸盐水平在 5.5 至低于 7.0 毫克/分升（2.3 毫摩尔/升）的目标范围内，则他们继续接受 8 毫克每天一次的治疗。,0.6666666666666666,"['liter', 'range', 'phosphate', 'deciliter', 'serum', 'target', 'on', 'if', 'to']","['liter', 'range', 'phosphate', 'serum', 'target', 'to']",2305,"['患者每天服用8毫克,如果他们的血清磷酸水平在14日的目标范围内为5.5至低于7.0毫克每分升(每升2.3毫莫尔)。']",0.6666666666666666,"['liter', 'range', 'phosphate', 'deciliter', 'serum', 'target', 'on', 'if', 'to']","['liter', 'range', 'phosphate', 'serum', 'target', 'to']",,
2344,2306,"the treatment with erdafitinib continued until disease progression or unacceptable adverse events , as determined by the investigator .",erdafitinib 治疗一直持续到研究者确定出现疾病进展或不可接受的不良事件。,0.625,"['disease', 'investigator', 'adverse', 'treatment', 'progression', 'unacceptable', 'with', 'by']","['disease', 'investigator', 'treatment', 'progression', 'unacceptable']",2306,"['使用甲状腺素的治疗一直持续到疾病进展或不接受的副作用,根据研究人员的确定。']",0.375,"['disease', 'investigator', 'adverse', 'treatment', 'progression', 'unacceptable', 'with', 'by']","['disease', 'treatment', 'progression']",,
2345,2307,prophylactic measures to prevent adverse events are described in the Methods section in the Supplementary Appendix .,补充附录的方法部分描述了预防不良事件的预防措施。,0.125,"['appendix', 'section', 'supplementary', 'adverse', 'prevent', 'prophylactic', 'in', 'to']",['prevent'],2307,['防止不良事件的预防措施在补充附件中的方法部分中描述。'],0.25,"['appendix', 'section', 'supplementary', 'adverse', 'prevent', 'prophylactic', 'in', 'to']","['appendix', 'prevent']",,
2346,2308,"we used RECIST to assess patients for efficacy using computed tomography or magnetic resonance imaging of the chest , abdomen , and pelvis once every 6 weeks for the first 3 months , once every 12 weeks for the next 9 months , and then once every 4 to 6 months until disease progression .",我们使用 RECIST 评估患者的疗效，使用胸部、腹部和骨盆的计算机断层扫描或磁共振成像，前 3 个月每 6 周一次，接下来的 9 个月每 12 周一次，然后每 4 至 6 个月一次月直至病情进展。,0.5294117647058824,"['resonance', 'abdomen', 'pelvis', 'tomography', 'disease', 'chest', 'magnetic resonance imaging', 'progression', 'efficacy', '3', '4', 'assess', 'computed tomography', 'and', 'first', 'next', 'we']","['resonance', 'abdomen', 'pelvis', 'tomography', 'disease', 'chest', 'progression', 'assess', 'next']",2308,"['我们使用RECIST来评估患者的有效性,使用计算 tomography或磁响图像的乳房,腹部和阴道每6周一次,在前3个月,每12周一次,在接下来的9个月,然后每4到6个月一次,直到疾病进展。']",0.3529411764705882,"['resonance', 'abdomen', 'pelvis', 'tomography', 'disease', 'chest', 'magnetic resonance imaging', 'progression', 'efficacy', '3', '4', 'assess', 'computed tomography', 'and', 'first', 'next', 'we']","['abdomen', 'disease', 'progression', 'efficacy', 'assess', 'next']",,
2347,2309,all objective responses required confirmation by an additional scan within 4 to 6 weeks after the first assessment .,所有客观反应都需要在第一次评估后 4 至 6 周内通过额外扫描进行确认。,0.4,"['objective', 'confirmation', 'assessment', 'additional', 'after', '4', 'all', 'by', 'to', 'first']","['confirmation', 'assessment', 'after', 'first']",2309,['所有客观答案需要在第一次评估后4至6周内通过额外扫描确认。'],0.4,"['objective', 'confirmation', 'assessment', 'additional', 'after', '4', 'all', 'by', 'to', 'first']","['confirmation', 'assessment', 'after', 'first']",,
2348,2310,patients were contacted every 12 weeks for survival assessment .,每 12 周联系患者进行生存评估。,1.0,"['survival', 'assessment']","['survival', 'assessment']",2310,['患者每12周进行生存评估。'],1.0,"['survival', 'assessment']","['survival', 'assessment']",,
2349,2311,"we evaluated safety using the results of clinical laboratory testing , physical examination , electrocardiography , and ophthalmologic examination .",我们使用临床实验室测试、身体检查、心电图和眼科检查的结果评估了安全性。,0.5454545454545454,"['safety', 'electrocardiography', 'physical', 'examination', 'physical examination', 'ophthalmologic', 'clinical', 'laboratory', 'testing', 'and', 'we']","['safety', 'electrocardiography', 'examination', 'physical examination', 'clinical', 'laboratory']",2311,['我们使用临床实验室测试、物理检查、电心图和眼科检查的结果来评估安全性。'],0.3636363636363636,"['safety', 'electrocardiography', 'physical', 'examination', 'physical examination', 'ophthalmologic', 'clinical', 'laboratory', 'testing', 'and', 'we']","['safety', 'examination', 'clinical', 'laboratory']",,
2350,2312,adverse events and abnormalities were assessed by the investigators and graded according to the National Cancer Institute criteria .,不良事件和异常由研究者评估，并根据美国国家癌症研究所的标准进行分级。,0.4285714285714285,"['cancer', 'adverse', 'institute', 'by', 'to', 'and', 'assessed']","['cancer', 'institute', 'by']",2312,"['副作用和异常被调查人员评估,并根据国家癌症研究所的标准进行评估。']",0.2857142857142857,"['cancer', 'adverse', 'institute', 'by', 'to', 'and', 'assessed']","['cancer', 'institute']",,
2351,2313,the primary end point was the confirmed response rate among patients treated with the selected regimen .,主要终点是接受所选方案治疗的患者中确认的反应率。,0.5714285714285714,"['rate', 'primary', 'response', 'end', 'point', 'response rate', 'with']","['rate', 'response', 'point', 'response rate']",2313,['主要的终点是根据所选择的治疗方案治疗的患者中确认的反应率。'],0.7142857142857143,"['rate', 'primary', 'response', 'end', 'point', 'response rate', 'with']","['rate', 'primary', 'response', 'point', 'response rate']",,
2352,2314,the primary hypothesis was that the objective response rate to a daily regimen of 8 mg or 9 mg of erdafitinib would be more than 25 % .,主要假设是，每天服用 8 毫克或 9 毫克厄达替尼的客观反应率将超过 25%。,0.4,"['objective', 'a', 'hypothesis', 'rate', 'be', 'primary', 'response', 'response rate', 'that', 'to']","['hypothesis', 'rate', 'response', 'response rate']",2314,"['原始假设是,对8毫克或9毫克的日常饮食的客观反应率将超过25%。']",0.4,"['objective', 'a', 'hypothesis', 'rate', 'be', 'primary', 'response', 'response rate', 'that', 'to']","['hypothesis', 'rate', 'response', 'response rate']",,
2353,2315,efficacy end points were analyzed at the cutoff date for the primary analysis .,在主要分析的截止日期分析疗效终点。,0.5,"['cutoff', 'analysis', 'date', 'end points', 'primary', 'efficacy']","['analysis', 'date', 'end points']",2315,['有效性终点在初始分析的截止日期被分析。'],0.6666666666666666,"['cutoff', 'analysis', 'date', 'end points', 'primary', 'efficacy']","['analysis', 'date', 'end points', 'efficacy']",,
2354,2316,"of 210 eligible patients , 33 were randomly assigned to the intermittent regimen and 78 to the continuous regimen .",在 210 名符合条件的患者中，33 名被随机分配到间歇性治疗方案，78 名患者被随机分配到连续性治疗方案。,0.4,"['continuous', 'intermittent', 'to', 'and', 'eligible']","['continuous', 'intermittent']",2316,"['其中有210名有资格的病人,33人随机被分配到中间制度,78人被分配到连续制度。']",0.2,"['continuous', 'intermittent', 'to', 'and', 'eligible']",['continuous'],,
2355,2317,"the median number of monthly cycles of erdafitinib was 5 ( range , 1 to 18 ) ; the median treatment duration was 5.3 months .",erdafitinib 的月周期中位数为 5（范围，1 至 18）；中位治疗持续时间为 5.3 个月。,0.6666666666666666,"['median', '5', 'range', '1', 'monthly', 'treatment', 'number', 'duration', 'to']","['5', 'range', '1', 'treatment', 'number', 'duration']",2317,"['月经周期的平均数量为5(范围为1至18),平均治疗时间为5.3个月。']",0.5555555555555556,"['median', '5', 'range', '1', 'monthly', 'treatment', 'number', 'duration', 'to']","['5', 'range', '1', 'treatment', 'number']",,
2356,2318,"of the 99 patients , 41 had an escalation in the daily dose of erdafitinib to 9 mg ; 13 patients continued treatment for at least 4 weeks after disease progression , according to the protocol .",在 99 名患者中，41 名将厄达替尼的日剂量增加至 9 毫克；根据方案，13 名患者在疾病进展后继续治疗至少 4 周。,0.5,"['disease', 'protocol', 'treatment', 'progression', 'after', 'daily dose', '4', 'in']","['disease', 'treatment', 'progression', 'after']",2318,"['在99名患者中,41名患者每天服用埃尔达菲蒂尼布的剂量上升至9毫克,13名患者在疾病进展后至少持续了4周,根据该协议。']",0.5,"['disease', 'protocol', 'treatment', 'progression', 'after', 'daily dose', '4', 'in']","['disease', 'protocol', 'progression', 'after']",,
2357,2319,the baseline characteristics of the patients who were treated during the randomized phase of the study are listed in Table S2 and the Results section in the Supplementary Appendix .,在研究的随机阶段接受治疗的患者的基线特征列于表 S2 和补充附录的结果部分。,0.4545454545454545,"['appendix', 'table', 'phase', 'who', 'baseline', 'section', 'study', 'supplementary', 'characteristics', 'S2', 'and']","['table', 'phase', 'baseline', 'section', 'characteristics']",2319,['研究随机阶段接受治疗的患者的基本特征列入S2表和附件中的结果部分。'],0.4545454545454545,"['appendix', 'table', 'phase', 'who', 'baseline', 'section', 'study', 'supplementary', 'characteristics', 'S2', 'and']","['appendix', 'table', 'phase', 'section', 'characteristics']",,
2358,2320,"because the lower boundary of the confidence interval was more than 25 % , the primary end point was achieved .",因为置信区间的下限超过 25%，所以达到了主要终点。,0.375,"['boundary', 'interval', 'lower', 'primary', 'confidence interval', 'end', 'point', 'achieved']","['interval', 'confidence interval', 'point']",2320,"['由于信任间隔的低限度超过25%,因此实现了初级终点。']",0.25,"['boundary', 'interval', 'lower', 'primary', 'confidence interval', 'end', 'point', 'achieved']","['interval', 'point']",,
2359,2321,two patients did not undergo any disease evaluation after baseline .,两名患者在基线后未进行任何疾病评估。,0.6666666666666666,"['disease', 'baseline', 'undergo', 'evaluation', 'after', 'two']","['disease', 'baseline', 'after', 'two']",2321,['两名患者在基线后没有接受任何疾病评估。'],0.6666666666666666,"['disease', 'baseline', 'undergo', 'evaluation', 'after', 'two']","['disease', 'baseline', 'after', 'two']",,
2360,2322,"response rates were similar regardless of previous chemotherapy , the number of previous courses of treatment , the presence of visceral metastasis , or baseline characteristics such as age , sex , hemoglobin level , or renal function ( Table 2 and Figure 1A ) .",无论既往化疗、既往疗程数、是否存在内脏转移或年龄、性别、血红蛋白水平或肾功能等基线特征如何，反应率都相似（表 2 和图 1A）。,0.6086956521739131,"['presence', 'chemotherapy', 'metastasis', 'table', 'baseline', '2', 'sex', 'hemoglobin', 'figure', 'function', 'previous', 'courses', 'hemoglobin level', 'visceral', 'treatment', 'number', 'renal', 'age', 'response', 'characteristics', 'and', 'renal function', 'similar']","['presence', 'chemotherapy', 'metastasis', 'table', 'baseline', '2', 'sex', 'hemoglobin', 'function', 'number', 'age', 'response', 'characteristics', 'renal function']",2322,"['反应率是相似的,无论以前的化疗,前治疗的数量,阴道转移的存在,或基因特征,如年龄,性别,血球水平,或肾功能(图2和图1A)。']",0.6086956521739131,"['presence', 'chemotherapy', 'metastasis', 'table', 'baseline', '2', 'sex', 'hemoglobin', 'figure', 'function', 'previous', 'courses', 'hemoglobin level', 'visceral', 'treatment', 'number', 'renal', 'age', 'response', 'characteristics', 'and', 'renal function', 'similar']","['presence', 'chemotherapy', 'metastasis', '2', 'sex', 'function', 'previous', 'treatment', 'number', 'age', 'response', 'characteristics', 'renal function', 'similar']",,
2361,2323,"the response rate according to independent radiologic review was 34 % ( 95 % CI , 25 to 44 ) , which resulted in a relative discordance rate of 16 % in the primary efficacy population .",根据独立放射学审查的反应率为 34%（95% CI，25 至 44），这导致主要疗效人群的相对不一致率为 16%。,0.3846153846153846,"['population', 'rate', 'review', 'discordance', 'radiologic', 'relative', 'primary', 'response', 'independent', 'efficacy', 'response rate', 'CI', 'to']","['population', 'rate', 'review', 'response', 'response rate']",2323,"['根据独立的放射性审查,反应率为34%(95% CI,25至44),导致初级效率人口中相对差异率为16%。']",0.4615384615384615,"['population', 'rate', 'review', 'discordance', 'radiologic', 'relative', 'primary', 'response', 'independent', 'efficacy', 'response rate', 'CI', 'to']","['population', 'rate', 'review', 'response', 'independent', 'response rate']",,
2362,2324,response rates among the patients who received the randomized intermittent and continuous regimens are listed in Table S3 in the Supplementary Appendix .,补充附录表 S3 列出了接受随机间歇和连续治疗方案的患者的缓解率。,0.3333333333333333,"['appendix', 'table', 'who', 'continuous', 'supplementary', 'intermittent', 'response', 'S3', 'and']","['table', 'continuous', 'intermittent']",2324,['接受随机中断和持续饮食的患者的反应率在附件中的S3表中列出。'],0.3333333333333333,"['appendix', 'table', 'who', 'continuous', 'supplementary', 'intermittent', 'response', 'S3', 'and']","['appendix', 'table', 'response']",,
2363,2325,"an additional 26 patients with FGFR mutations had stable disease for a median of 3.7 months ( range , 0 to 13.6 ) .",另外 26 名 FGFR 突变患者的疾病稳定期中位数为 3.7 个月（范围，0 至 13.6）。,0.3333333333333333,"['median', 'disease', 'range', 'additional', 'with', 'to']","['disease', 'range']",2325,['另有26名患有FGFR突变的患者平均为3.7个月(范围为0至13.6)的稳定疾病。'],0.3333333333333333,"['median', 'disease', 'range', 'additional', 'with', 'to']","['disease', 'range']",,
2364,2326,responses were not affected by the presence of a particular mutation .,反应不受特定突变的影响。,0.25,"['presence', 'mutation', 'particular', 'by']",['mutation'],2326,['答案没有受到某个特定的突变的存在的影响。'],0.5,"['presence', 'mutation', 'particular', 'by']","['presence', 'mutation']",,
2365,2327,"among the 25 patients with FGFR fusions , the response rate was 16 % .",在 25 名 FGFR 融合患者中，缓解率为 16%。,0.25,"['rate', 'response', 'response rate', 'with']",['rate'],2327,"['在25名患有FGFR合并的患者中,反应率为16%。']",0.75,"['rate', 'response', 'response rate', 'with']","['rate', 'response', 'response rate']",,
2366,2328,"the most common fusion was FGFR3 : TACC3v1 , which was found in 11 patients ( Table S1 in the Supplementary Appendix ) ; of these patients , 4 ( 36 % ) had a response to treatment .",最常见的融合是 FGFR3:TACC3v1，在 11 名患者中发现（补充附录表 S1）；在这些患者中，有 4 名 (36%) 对治疗有反应。,0.3333333333333333,"['fusion', 'a', 'appendix', 'table', 'supplementary', 'common', 'treatment', 'response', '4', 'S1', 'in', 'to']","['fusion', 'table', 'treatment', 'response']",2328,"['最常见的合并是FGFR3 : TACC3v1,在11名患者中发现(附件中的S1表),其中4名患者(36%)对治疗有反应。']",0.3333333333333333,"['fusion', 'a', 'appendix', 'table', 'supplementary', 'common', 'treatment', 'response', '4', 'S1', 'in', 'to']","['appendix', 'table', 'treatment', 'response']",,
2367,2329,approximately 30 % of these responses were maintained for more than 12 months ( Figure 1B ) .,这些反应中约有 30% 维持了 12 个月以上（图 1B）。,0.0,"['figure', 'approximately']",[],2329,['大约30%的这些回复保持了超过12个月(图1B)。'],0.0,"['figure', 'approximately']",[],,
2368,2330,"at the time of data cutoff , 21 % of the patients were continuing to receive erdafitinib .",在数据截止时，21% 的患者继续接受厄达替尼治疗。,0.6666666666666666,"['cutoff', 'data', 'time']","['data', 'time']",2330,"['在数据中断时,21%的患者继续服用Erdafitinib。']",0.6666666666666666,"['cutoff', 'data', 'time']","['data', 'time']",,
2369,2331,"at 12 months , the rate of overall survival was 55 % ( 95 % CI , 43 to 66 ) .",12 个月时，总生存率为 55%（95% CI，43 至 66）。,0.5,"['rate', 'survival', 'CI', 'to']","['rate', 'survival']",2331,"['在12個月內,總生存率為55%(95% CI,43至66%)。']",0.5,"['rate', 'survival', 'CI', 'to']","['rate', 'survival']",,
2370,2332,"subsequent therapy was administered to 34 patients , of whom 25 % received one subsequent course of treatment and 9 % received two subsequent courses ; 19 patients received chemotherapy , and 15 received immunotherapy as a first subsequent therapy .",34例患者接受了后续治疗，其中25%接受了1个后续疗程，9%接受了2个后续疗程。 19 名患者接受了化疗，15 名患者接受了免疫治疗作为第一种后续治疗。,0.4,"['chemotherapy', 'immunotherapy', 'courses', 'treatment', 'subsequent', 'as', 'to', 'and', 'first', 'two']","['chemotherapy', 'immunotherapy', 'treatment', 'first']",2332,"['接下来的治疗给了34名患者,其中25%接受了一个接下来的治疗,9%接受了两个接下来的治疗;19名患者接受了化疗,15名患者接受了免疫治疗作为第一次接下来的治疗。']",0.5,"['chemotherapy', 'immunotherapy', 'courses', 'treatment', 'subsequent', 'as', 'to', 'and', 'first', 'two']","['chemotherapy', 'immunotherapy', 'treatment', 'first', 'two']",,
2371,2333,no patient had an objective response to the first subsequent course of chemotherapy ; 1 patient had a partial response to the first subsequent course of immunotherapy .,没有患者对第一个后续化疗疗程有客观反应； 1 名患者对随后的第一个免疫治疗疗程有部分反应。,0.5454545454545454,"['chemotherapy', 'objective', '1', 'immunotherapy', 'response', 'partial', 'patient', 'subsequent', 'course', 'to', 'first']","['chemotherapy', '1', 'immunotherapy', 'response', 'patient', 'first']",2333,['没有患者对第一次接下来的化疗进行客观反应;1名患者对第一次接下来的免疫疗法进行部分反应。'],0.5454545454545454,"['chemotherapy', 'objective', '1', 'immunotherapy', 'response', 'partial', 'patient', 'subsequent', 'course', 'to', 'first']","['chemotherapy', '1', 'immunotherapy', 'response', 'patient', 'first']",,
2372,2334,a total of 67 % of such events were of grade 3 or 4 ; 46 % of the patients reported having an adverse event of grade 3 or higher that was considered by investigators to be related to treatment ( Table S6 in the Supplementary Appendix ) .,总共 67% 的此类事件属于 3 级或 4 级； 46% 的患者报告有 3 级或更高级别的不良事件，研究人员认为这些不良事件与治疗相关（补充附录表 S6）。,0.2,"['a', 'appendix', 'table', 'grade', 'supplementary', 'total', 'be', 'adverse', 'treatment', 'adverse event', '3', '4', 'that', 'in', 'by']","['table', 'treatment', 'adverse event']",2334,"['总共有67%的病例是3级或4级;46%的病人报告患有3级或更高的不良病例,研究人员认为与治疗有关(附件中的S6表)。']",0.2,"['a', 'appendix', 'table', 'grade', 'supplementary', 'total', 'be', 'adverse', 'treatment', 'adverse event', '3', '4', 'that', 'in', 'by']","['appendix', 'table', 'treatment']",,
2373,2335,"common adverse events of grade 3 or higher were hyponatremia ( 11 % ) , stomatitis ( 10 % ) , and asthenia ( 7 % ) .",3 级或更高级别的常见不良事件是低钠血症 (11%)、口腔炎 (10%) 和乏力 (7%)。,0.25,"['asthenia', 'grade', 'hyponatremia', 'common', 'adverse', 'stomatitis', '3', 'and']","['hyponatremia', 'stomatitis']",2335,['3级或更高的常见副作用是甲状腺炎(11%)、骨质炎(10%)和哮喘(7%)。'],0.0,"['asthenia', 'grade', 'hyponatremia', 'common', 'adverse', 'stomatitis', '3', 'and']",[],,
2374,2336,serious adverse events were reported in 39 patients ( Table S4 in the Supplementary Appendix ) .,39 名患者报告了严重不良事件（补充附录表 S4）。,0.1428571428571428,"['appendix', 'table', 'supplementary', 'adverse', 'S4', 'serious', 'in']",['table'],2336,['在39名患者中报告了严重的副作用(附件中的S4表)。'],0.2857142857142857,"['appendix', 'table', 'supplementary', 'adverse', 'S4', 'serious', 'in']","['appendix', 'table']",,
2375,2337,a dose reduction was required in 55 patients .,55 名患者需要减少剂量。,0.5,"['a', 'reduction', 'dose', 'in']","['reduction', 'dose']",2337,"['在55名患者中,需要减少剂量。']",0.5,"['a', 'reduction', 'dose', 'in']","['reduction', 'dose']",,
2376,2338,the most common adverse events leading to a dose reduction were stomatitis in 16 patients and hyperphosphatemia in 9 patients .,导致剂量减少的最常见不良事件是 16 名患者的口腔炎和 9 名患者的高磷血症。,0.4444444444444444,"['a', 'reduction', 'common', 'adverse', 'hyperphosphatemia', 'stomatitis', 'leading', 'dose', 'and']","['reduction', 'hyperphosphatemia', 'stomatitis', 'dose']",2338,['导致剂量减少的最常见的副作用是16名患者的骨质炎和9名患者的甲状腺炎。'],0.2222222222222222,"['a', 'reduction', 'common', 'adverse', 'hyperphosphatemia', 'stomatitis', 'leading', 'dose', 'and']","['reduction', 'dose']",,
2377,2339,"among the 41 patients who had a dose escalation to 9 mg of erdafitinib per day , 24 ( 59 % ) required at least one dose reduction .",在剂量增加到每天 9 mg erdafitinib 的 41 名患者中，24 名 (59%) 需要至少减少一次剂量。,0.3333333333333333,"['a', 'who', 'reduction', 'at', 'dose', 'to']","['reduction', 'dose']",2339,"['在41名患者中,每日增加到9毫克埃尔达菲蒂尼布的剂量,24(59%)需要至少减少1剂量。']",0.3333333333333333,"['a', 'who', 'reduction', 'at', 'dose', 'to']","['reduction', 'dose']",,
2378,2340,"common adverse events were similar among all the regimens ( Tables S5 , S6 , and S7 in the Supplementary Appendix ) .",所有方案的常见不良事件相似（补充附录表 S5、S6 和 S7）。,0.0,"['appendix', 'supplementary', 'common', 'adverse', 'all', 'in', 'and', 'similar']",[],2340,['一般的副作用在所有模式中都是相似的(附件中的表 S5、S6 和 S7 )。'],0.25,"['appendix', 'supplementary', 'common', 'adverse', 'all', 'in', 'and', 'similar']","['appendix', 'similar']",,
2379,2341,one patient died from a myocardial infarction that was considered to be unrelated to treatment .,一名患者死于被认为与治疗无关的心肌梗塞。,0.6666666666666666,"['myocardial infarction', 'be', 'treatment', 'patient', 'that', 'to']","['myocardial infarction', 'treatment', 'patient', 'to']",2341,"['一名病人死于心脏病发作,被认为与治疗无关。']",0.5,"['myocardial infarction', 'be', 'treatment', 'patient', 'that', 'to']","['treatment', 'patient', 'to']",,
2380,2342,adverse events of special interest or clinical importance and their management are presented in Table S8 and the Results section in the Supplementary Appendix .,具有特殊意义或临床重要性的不良事件及其处理见表 S8 和补充附录的结果部分。,0.3333333333333333,"['appendix', 'table', 'section', 'supplementary', 'adverse', 'clinical', 'management', 'and', 'special']","['table', 'clinical', 'special']",2342,['具有特殊兴趣或临床意义的不良事件及其管理在表 S8 和附件中的结果部分中呈现。'],0.5555555555555556,"['appendix', 'table', 'section', 'supplementary', 'adverse', 'clinical', 'management', 'and', 'special']","['appendix', 'table', 'clinical', 'management', 'special']",,
2381,2343,"among the patients with central serous retinopathy events , 76 % of the events resolved with a dose interruption or reduction or with the administration of a concomitant medication ; all unresolved events were of grade 1 or 2 .",在发生中心性浆液性视网膜病变事件的患者中，76% 的事件通过中断或减少剂量或同时服用药物而得到解决；所有未解决的事件均为 1 级或 2 级。,0.4,"['a', '1', '2', 'grade', 'administration', 'interruption', 'reduction', 'serous', 'medication', 'concomitant', 'central', 'with', 'dose', 'retinopathy', 'all']","['1', '2', 'interruption', 'reduction', 'dose', 'retinopathy']",2343,"['在患有中央血清网膜病的患者中,76%的病例通过剂量中断或减少或同时服用药物解决;所有未解决的病例均为1级或2级。']",0.3333333333333333,"['a', '1', '2', 'grade', 'administration', 'interruption', 'reduction', 'serous', 'medication', 'concomitant', 'central', 'with', 'dose', 'retinopathy', 'all']","['1', '2', 'interruption', 'reduction', 'dose']",,
2382,2344,"this study met its primary objective , with a 40 % confirmed response rate after continuous daily treatment with 8 mg or 9 mg of oral erdafitinib .",这项研究达到了其主要目标，在连续每天口服 8 毫克或 9 毫克厄达替尼治疗后，确认的缓解率为 40%。,0.2857142857142857,"['objective', 'a', 'rate', 'continuous', 'oral', 'study', 'treatment', 'primary', 'response', 'after', 'response rate', 'with', 'met', 'this']","['rate', 'continuous', 'treatment', 'after']",2344,"['这项研究满足了其主要目标,在持续的每日治疗后,40%确认的反应率为8mg或9mg的口服埃尔达菲蒂尼布。']",0.3571428571428571,"['objective', 'a', 'rate', 'continuous', 'oral', 'study', 'treatment', 'primary', 'response', 'after', 'response rate', 'with', 'met', 'this']","['rate', 'treatment', 'response', 'after', 'response rate']",,
2383,2345,"these findings showed that among patients with locally advanced and unresectable or metastatic urothelial carcinoma with certain FGFR alterations , erdafitinib had promising antitumor activity .",这些发现表明，在具有某些 FGFR 改变的局部晚期和不可切除或转移性尿路上皮癌患者中，erdafitinib 具有令人鼓舞的抗肿瘤活性。,0.2222222222222222,"['carcinoma', 'activity', 'metastatic', 'advanced', 'unresectable', 'with', 'certain', 'that', 'and']","['carcinoma', 'activity']",2345,"['这些发现表明,在患有某些FGFR变异的本地先进和不可恢复或转移性尿道癌症的患者中,Erdafitinib具有有前途的抗肿瘤活动。']",0.2222222222222222,"['carcinoma', 'activity', 'metastatic', 'advanced', 'unresectable', 'with', 'certain', 'that', 'and']","['carcinoma', 'activity']",,
2384,2346,"the response to erdafitinib was rapid and independent of the number of previous courses and types of therapy , the presence of visceral metastasis , or tumor location .",对 erdafitinib 的反应非常迅速，并且与之前的疗程数和治疗类型、是否存在内脏转移或肿瘤位置无关。,0.5,"['presence', 'metastasis', 'tumor', 'previous', 'courses', 'location', 'therapy', 'visceral', 'number', 'response', 'independent', 'to', 'and', 'rapid']","['presence', 'metastasis', 'tumor', 'location', 'therapy', 'number', 'response']",2346,"['对埃尔达菲蒂尼布的反应是快速的,独立于以前的治疗课程和类型的数量,阴道转移的存在,或肿瘤的位置。']",0.6428571428571429,"['presence', 'metastasis', 'tumor', 'previous', 'courses', 'location', 'therapy', 'visceral', 'number', 'response', 'independent', 'to', 'and', 'rapid']","['presence', 'metastasis', 'tumor', 'previous', 'location', 'therapy', 'number', 'response', 'to']",,
2385,2347,included in this analysis were patients with visceral metastasis and poor kidney function in whom multiple courses of therapy had failed .,纳入该分析的是患有内脏转移和肾功能不佳且多个疗程均失败的患者。,0.3846153846153846,"['kidney', 'metastasis', 'analysis', 'function', 'courses', 'multiple', 'therapy', 'visceral', 'with', 'poor', 'this', 'in', 'and']","['kidney', 'metastasis', 'analysis', 'function', 'this']",2347,"['在此分析中,包括患有粘膜转移和肾功能不佳的患者,其中多次治疗失败。']",0.3846153846153846,"['kidney', 'metastasis', 'analysis', 'function', 'courses', 'multiple', 'therapy', 'visceral', 'with', 'poor', 'this', 'in', 'and']","['kidney', 'metastasis', 'analysis', 'function', 'therapy']",,
2386,2348,"as allowed in the protocol , 13 patients continued to receive treatment after disease progression , which included limited progression in a target lesion or the appearance of a small new lesion while the patient was assessed as having ongoing clinical benefit .",按照方案的规定，13 名患者在疾病进展后继续接受治疗，包括目标病灶进展有限或出现新的小病灶，同时患者被评估为具有持续的临床获益。,0.6428571428571429,"['lesion', 'disease', 'protocol', 'treatment', 'target', 'progression', 'clinical', 'patient', 'after', 'appearance', 'benefit', 'limited', 'new', 'assessed']","['lesion', 'disease', 'treatment', 'target', 'progression', 'clinical', 'patient', 'after', 'new']",2348,"['根据该协议允许,13名患者在疾病进展后继续接受治疗,其中包括目标损伤的有限进展或新小损伤的出现,而患者被评为持久的临床益处。']",0.7142857142857143,"['lesion', 'disease', 'protocol', 'treatment', 'target', 'progression', 'clinical', 'patient', 'after', 'appearance', 'benefit', 'limited', 'new', 'assessed']","['lesion', 'disease', 'protocol', 'treatment', 'target', 'progression', 'clinical', 'patient', 'after', 'new']",,
2387,2349,"the safety profile allowed for the continuous daily administration of 8 mg of erdafitinib , with a dose escalation to 9 mg daily guided by the serum phosphate level .",安全性允许每天连续服用 8 mg erdafitinib，并根据血清磷酸盐水平将剂量增加到每天 9 mg。,0.5454545454545454,"['safety', 'phosphate', 'continuous', 'administration', 'serum', 'profile', 'level', 'with', 'dose', 'by', 'to']","['safety', 'phosphate', 'continuous', 'serum', 'level', 'dose']",2349,"['安全预测允许持续每日服用8毫克埃尔达菲蒂尼布,剂量升级至9毫克每日,由血清磷酸素水平指导。']",0.5454545454545454,"['safety', 'phosphate', 'continuous', 'administration', 'serum', 'profile', 'level', 'with', 'dose', 'by', 'to']","['safety', 'phosphate', 'serum', 'level', 'dose', 'by']",,
2388,2350,"such dose escalation did not increase the severity of adverse events , with a similar percentage of events of grade 3 or higher in the two dose groups .",这种剂量增加并没有增加不良事件的严重程度，两个剂量组中 3 级或更高级别事件的百分比相似。,0.3333333333333333,"['percentage', 'grade', 'adverse', '3', 'increase', 'with', 'dose', 'two', 'similar']","['grade', 'dose', 'two']",2350,"['这种剂量升级并没有增加不良事件的严重性,在两组剂量中,类似的3级或更高的事件比例。']",0.2222222222222222,"['percentage', 'grade', 'adverse', '3', 'increase', 'with', 'dose', 'two', 'similar']","['dose', 'two']",,
2389,2351,"hyperphosphatemia , a known class effect of FGFR inhibitors , 24 was reported in 77 % of the patients .",高磷酸盐血症是 FGFR 抑制剂的一种已知类效应，24 据报道 77% 的患者发生。,0.4,"['a', 'class', 'hyperphosphatemia', 'effect', 'in']","['hyperphosphatemia', 'effect']",2351,"['FGFR 抑制剂的已知类效应,24 已在 77% 的患者中报告。']",0.2,"['a', 'class', 'hyperphosphatemia', 'effect', 'in']",['effect'],,
2390,2352,"although ocular adverse events were common with erdafitinib treatment , the events were mostly mild to moderate and resolved with dose interruption or reduction .",尽管眼部不良事件在厄达替尼治疗中很常见，但这些事件大多为轻度至中度，并可通过中断或减少剂量来解决。,0.4166666666666667,"['ocular', 'interruption', 'reduction', 'moderate', 'common', 'adverse', 'treatment', 'with', 'mild', 'dose', 'to', 'and']","['interruption', 'reduction', 'treatment', 'mild', 'dose']",2352,"['虽然眼部不良事件是常见的埃尔达菲蒂尼布治疗,但这些事件大多是轻到温和的,并通过剂量中断或减少解决。']",0.3333333333333333,"['ocular', 'interruption', 'reduction', 'moderate', 'common', 'adverse', 'treatment', 'with', 'mild', 'dose', 'to', 'and']","['interruption', 'reduction', 'treatment', 'dose']",,
2391,2353,patients with FGFR mutations or fusions may be less likely to have a response to immunotherapy than are those without such alterations .,与没有此类改变的患者相比，具有 FGFR 突变或融合的患者对免疫疗法产生反应的可能性更小。,0.375,"['a', 'immunotherapy', 'be', 'response', 'with', 'have', 'to', 'without']","['immunotherapy', 'response', 'have']",2353,['患有FGFR突变或合并的患者可能比没有这种变化的人更少对免疫疗法作出反应。'],0.375,"['a', 'immunotherapy', 'be', 'response', 'with', 'have', 'to', 'without']","['immunotherapy', 'response', 'have']",,
2392,2354,"in our study , only 1 of 22 patients ( 5 % ) had a history of response to previous immunotherapy ; of these patients , 59 % had a response to erdafitinib after failure of immunotherapy .",在我们的研究中，22 名患者中只有 1 名 (5%) 对既往免疫疗法有反应；在这些患者中，59% 在免疫治疗失败后对 erdafitinib 有反应。,0.5454545454545454,"['5', 'a', 'failure', '1', 'immunotherapy', 'previous', 'study', 'history', 'response', 'after', 'in']","['5', 'failure', '1', 'immunotherapy', 'response', 'after']",2354,"['在我们的研究中,只有22名患者中有1人(5%)对以前的免疫疗法有回应史;这些患者中有59%在免疫疗法失败后对埃尔达菲蒂尼布有回应。']",0.5454545454545454,"['5', 'a', 'failure', '1', 'immunotherapy', 'previous', 'study', 'history', 'response', 'after', 'in']","['5', 'failure', '1', 'immunotherapy', 'previous', 'after']",,
2393,2355,"this observation was also noted in a study of rogaratinib involving 10 patients , in whom 90 % had a history of disease progression while receiving immunotherapy , whereas 30 % had a response to rogaratinib.27",一项涉及 10 名患者的 rogaratinib 研究也注意到了这一观察结果，其中 90 % 在接受免疫治疗时有疾病进展史，而 30 % 对 rogaratinib 有反应。 27,0.5,"['disease', 'immunotherapy', 'study', 'history', 'progression', 'response', 'of disease', 'observation', 'this', 'in']","['disease', 'immunotherapy', 'progression', 'response', 'observation']",2355,"['这种观察也被注意到在10名患者的罗加蒂尼布研究中,其中90%在接受免疫治疗时有疾病进展史,而30%对罗加蒂尼布有反应。']",0.5,"['disease', 'immunotherapy', 'study', 'history', 'progression', 'response', 'of disease', 'observation', 'this', 'in']","['disease', 'immunotherapy', 'progression', 'response', 'observation']",,
2394,2356,patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer .,具有种系 BRCA1 或 BRCA2 突变的患者构成了转移性胰腺癌患者的一小部分。,0.2,"['mutation', 'cancer', 'germline', 'pancreatic', 'metastatic', 'up', 'subgroup', 'with', 'pancreatic cancer', 'make']","['mutation', 'cancer']",2356,['患有基因 BRCA1 或 BRCA2 突变的患者组成一个小组患有甲状腺癌的人。'],0.2,"['mutation', 'cancer', 'germline', 'pancreatic', 'metastatic', 'up', 'subgroup', 'with', 'pancreatic cancer', 'make']","['mutation', 'cancer']",,
2395,2357,"patients were randomly assigned , in a 3 : 2 ratio , to receive maintenance olaparib tablets ( 300 mg twice daily ) or placebo .",患者以 3:2 的比例被随机分配接受奥拉帕尼维持药片（300 毫克，每天两次）或安慰剂。,0.5714285714285714,"['placebo', '2', 'ratio', '3', 'maintenance', 'to', 'twice']","['placebo', '2', 'ratio', 'maintenance']",2357,"['病人随机分配,在3:2的比例,接受维持Oaparib药片(每日两次300毫克)或 placebo。']",0.4285714285714285,"['placebo', '2', 'ratio', '3', 'maintenance', 'to', 'twice']","['2', 'ratio', 'maintenance']",,
2396,2358,"of the 3315 patients who underwent screening , 154 underwent randomization and were assigned to a trial intervention ( 92 to receive olaparib and 62 to receive placebo ) .",在接受筛查的 3315 名患者中，有 154 名接受了随机分组并被分配到试验干预组（92 名接受奥拉帕尼，62 名接受安慰剂）。,0.4285714285714285,"['placebo', 'randomization', 'who', 'screening', 'intervention', 'trial', 'to']","['placebo', 'randomization', 'screening']",2358,"['在接受筛查的315名患者中,有154人接受了随机化,并被分配给试验干预(92人接受了olaparib,62人接受了 placebo)。']",0.2857142857142857,"['placebo', 'randomization', 'who', 'screening', 'intervention', 'trial', 'to']","['randomization', 'screening']",,
2397,2359,"an interim analysis of overall survival , at a data maturity of 46 % , showed no difference between the olaparib and placebo groups ( median , 18.9 months vs. 18.1 months ; hazard ratio for death , 0.91 ; 95 % CI , 0.56 to 1.46 ; P = 0.68 ) .",在数据成熟度为 46 % 时对总生存期进行的中期分析显示，奥拉帕尼组和安慰剂组之间没有差异（中位数，18.9 个月对 18.1 个月；死亡风险比，0.91；95 % CI，0.56 至 1.46；P = 0.68）。,0.6,"['median', 'placebo', 'data', 'analysis', 'maturity', 'survival', 'ratio', 'hazard ratio', 'death', 'difference', 'no', 'P', 'CI', 'to', 'and']","['placebo', 'data', 'analysis', 'maturity', 'survival', 'ratio', 'hazard ratio', 'death', 'difference']",2359,"['总生存的临时分析,数据成熟度为46%,没有显示Olaparib和Placebo群体之间的差异(平均,18.9个月与18.1个月;死亡风险比例,0.91;95% CI,0.56到1.46;P=0.68)。']",0.5333333333333333,"['median', 'placebo', 'data', 'analysis', 'maturity', 'survival', 'ratio', 'hazard ratio', 'death', 'difference', 'no', 'P', 'CI', 'to', 'and']","['data', 'analysis', 'maturity', 'survival', 'ratio', 'hazard ratio', 'death', 'difference']",,
2398,2360,metastatic pancreatic cancer is particularly refractory to treatment.1,转移性胰腺癌尤其难治。 1,0.2,"['cancer', 'refractory', 'pancreatic', 'metastatic', 'pancreatic cancer']",['cancer'],2360,['甲状腺癌对治疗特别有反应1'],0.2,"['cancer', 'refractory', 'pancreatic', 'metastatic', 'pancreatic cancer']",['cancer'],,
2399,2361,"the PARP inhibitor olaparib has been shown to have clinical efficacy in patients with a germline BRCA mutation and ovarian or breast cancer , 11,12 and in a phase 2 trial , olaparib had antitumor activity in heavily pretreated patients with a germline BRCA mutation and metastatic pancreatic cancer.13","PARP 抑制剂奥拉帕尼已被证明对患有胚系 BRCA 突变和卵巢癌或乳腺癌的患者具有临床疗效， 11,12 并且在一项 2 期试验中，奥拉帕尼在经过大量预处理的患有胚系 BRCA 突变和转移性胰腺癌的患者中具有抗肿瘤活性。癌症.13",0.5625,"['inhibitor', 'mutation', 'cancer', 'phase', 'germline', '2', 'activity', 'pancreatic', 'breast cancer', 'metastatic', 'clinical', 'trial', 'efficacy', 'with', 'have', 'and']","['inhibitor', 'mutation', 'cancer', 'phase', '2', 'activity', 'breast cancer', 'clinical', 'have']",2361,"['PARP 抑制剂 olaparib 已被证明在患有基因 BRCA 突变和卵巢或乳腺癌的患者中具有临床有效性,11,12 并且在 2 阶段的研究中, olaparib 在患有基因 BRCA 突变和甲状腺癌的患者中具有抗肿瘤活动。']",0.625,"['inhibitor', 'mutation', 'cancer', 'phase', 'germline', '2', 'activity', 'pancreatic', 'breast cancer', 'metastatic', 'clinical', 'trial', 'efficacy', 'with', 'have', 'and']","['inhibitor', 'mutation', 'cancer', 'phase', '2', 'activity', 'breast cancer', 'clinical', 'efficacy', 'have']",,
2400,2362,"maintenance treatment is a new concept in pancreatic cancer , although early studies of maintenance sunitinib and fluorouracil have shown promising results.18,19","维持治疗是胰腺癌的一个新概念，尽管舒尼替尼和氟尿嘧啶维持治疗的早期研究已经显示出可喜的结果。 18,19",0.5833333333333334,"['a', 'cancer', 'pancreatic', 'early', 'treatment', 'concept', 'maintenance', 'fluorouracil', 'pancreatic cancer', 'have', 'and', 'new']","['cancer', 'early', 'treatment', 'concept', 'maintenance', 'fluorouracil', 'new']",2362,"['维护治疗是胰腺癌的新概念,尽管早期维护 sunitinib 和 fluorouracil 的研究表明有前途的结果。']",0.5,"['a', 'cancer', 'pancreatic', 'early', 'treatment', 'concept', 'maintenance', 'fluorouracil', 'pancreatic cancer', 'have', 'and', 'new']","['cancer', 'early', 'treatment', 'concept', 'have', 'new']",,
2401,2363,patients were eligible if they were 18 years of age or older and had histologically or cytologically confirmed pancreatic adenocarcinoma and a documented deleterious or suspected deleterious germline mutation in BRCA1 or BRCA2 .,如果患者年满 18 岁，并且经组织学或细胞学证实为胰腺癌，并且有记录的 BRCA1 或 BRCA2 有害或疑似有害种系突变，则患者符合条件。,0.2,"['mutation', 'germline', 'histologically', 'adenocarcinoma', 'deleterious', 'pancreatic', 'age', 'if', 'and', 'eligible']","['mutation', 'adenocarcinoma']",2363,"['患者有资格,如果他们18岁或以上,并且有历史学或细胞学证实的胰腺肾癌和记录的恶性或怀疑恶性基因变异在BRCA1或BRCA2。']",0.0,"['mutation', 'germline', 'histologically', 'adenocarcinoma', 'deleterious', 'pancreatic', 'age', 'if', 'and', 'eligible']",[],,
2402,2364,eligibility was based on detection of a germline BRCA mutation by central testing with the use of the BRACAnalysis CDx test ( Myriad Genetic Laboratories ) or by local testing with subsequent confirmation with the use of the BRACAnalysis CDx test after randomization .,合格性基于通过使用 BRACAnalysis CDx 测试（Myriad Genetic Laboratories）进行中央测试或通过在随机化后使用 BRACAnalysis CDx 测试进行后续确认的本地测试来检测种系 BRCA 突变。,0.4285714285714285,"['mutation', 'detection', 'randomization', 'germline', 'test', 'genetic', 'local', 'confirmation', 'central', 'after', 'subsequent', 'testing', 'with', 'by']","['mutation', 'detection', 'randomization', 'test', 'confirmation', 'after']",2364,['合格性是基于检测基因 BRCA 突变的中央测试使用 BRACAnalysis CDx 测试( Myriad Genetic Laboratories )或通过本地测试与随后的确认使用 BRACAnalysis CDx 测试随机测试。'],0.3571428571428571,"['mutation', 'detection', 'randomization', 'germline', 'test', 'genetic', 'local', 'confirmation', 'central', 'after', 'subsequent', 'testing', 'with', 'by']","['mutation', 'detection', 'randomization', 'confirmation', 'after']",,
2403,2365,the platinum component of chemotherapy could have been discontinued because of toxic effects at any time after 16 weeks .,由于 16 周后的任何时间的毒性作用，化疗的铂成分可能已经停止。,0.7142857142857143,"['component', 'chemotherapy', 'toxic', 'time', 'platinum', 'after', 'have']","['component', 'chemotherapy', 'time', 'platinum', 'after']",2365,['塑料化疗的组成部分可能在16周后任何时候因有毒作用而被中断。'],0.5714285714285714,"['component', 'chemotherapy', 'toxic', 'time', 'platinum', 'after', 'have']","['chemotherapy', 'time', 'after', 'have']",,
2404,2366,eligible patients had normal organ and acceptable bone marrow function .,符合条件的患者具有正常的器官和可接受的骨髓功能。,0.75,"['organ', 'bone', 'bone marrow', 'function', 'normal', 'acceptable', 'and', 'eligible']","['organ', 'bone', 'bone marrow', 'function', 'normal', 'acceptable']",2366,['合格的患者有正常的器官和可接受的骨髓功能。'],0.875,"['organ', 'bone', 'bone marrow', 'function', 'normal', 'acceptable', 'and', 'eligible']","['organ', 'bone', 'bone marrow', 'function', 'normal', 'acceptable', 'eligible']",,
2405,2367,"full eligibility criteria are provided in the trial protocol , available with the full text of this article at NEJM.org .",试验方案中提供了完整的资格标准，试验方案与本文全文可在 NEJM.org 上获取。,0.2,"['protocol', 'article', 'available', 'trial', 'text', 'with', 'at', 'full', 'this', 'in']","['protocol', 'full']",2367,"['完整的可选性标准在试验协议中提供,可在NEJM.org上找到本文的完整文本。']",0.2,"['protocol', 'article', 'available', 'trial', 'text', 'with', 'at', 'full', 'this', 'in']","['protocol', 'full']",,
2406,2368,"with the use of a central interactive voice or Web response system that incorporated a block randomization scheme , patients were randomly assigned , in a 3 : 2 ratio , to receive maintenance olaparib tablets ( 300 mg twice daily ) or matching placebo .",通过使用包含块随机化方案的中央交互式语音或网络响应系统，患者被随机分配，以 3:2 的比例接受奥拉帕尼维持药片（300 毫克，每天两次）或匹配的安慰剂。,0.5263157894736842,"['placebo', 'web', 'randomization', 'voice', 'system', '2', 'block', 'ratio', 'central', 'scheme', 'response', 'matching', '3', 'maintenance', 'with', 'response system', 'that', 'to', 'twice']","['placebo', 'randomization', 'voice', 'system', '2', 'block', 'ratio', 'response', 'matching', 'maintenance']",2368,"['使用中央互动语音或网络响应系统,其中包含了区块随机化计划,患者随机分配,在3:2的比例,接受维持Oaparib药片(每日300毫克两次)或匹配 placebo。']",0.4736842105263157,"['placebo', 'web', 'randomization', 'voice', 'system', '2', 'block', 'ratio', 'central', 'scheme', 'response', 'matching', '3', 'maintenance', 'with', 'response system', 'that', 'to', 'twice']","['randomization', 'voice', 'system', '2', 'block', 'ratio', 'response', 'matching', 'maintenance']",,
2407,2369,no stratification factors were used .,没有使用分层因素。,0.5,"['stratification', 'no']",['stratification'],2369,['没有使用的分裂因素。'],0.0,"['stratification', 'no']",[],,
2408,2370,crossover to olaparib was not permitted during this trial .,在此试验期间不允许交叉使用奥拉帕尼。,0.0,"['trial', 'this', 'to']",[],2370,"['在此审判期间,不允许跨越到olaparib。']",0.3333333333333333,"['trial', 'this', 'to']",['trial'],,
2409,2371,"computed tomography or magnetic resonance imaging of the chest , abdomen , and pelvis were performed at baseline , every 8 weeks for 40 weeks , and then every 12 weeks until disease progression .",胸部、腹部和骨盆的计算机断层扫描或磁共振成像在基线时进行，每 8 周一次，持续 40 周，然后每 12 周一次，直至疾病进展。,0.6666666666666666,"['resonance', 'abdomen', 'pelvis', 'tomography', 'disease', 'chest', 'baseline', 'magnetic resonance imaging', 'progression', 'at', 'computed tomography', 'and']","['resonance', 'abdomen', 'pelvis', 'tomography', 'disease', 'chest', 'baseline', 'progression']",2371,"['胸部、腹部和阴道的计算图像或磁响图像在基线上进行,每8周进行40周,然后每12周进行,直到疾病进展。']",0.4166666666666667,"['resonance', 'abdomen', 'pelvis', 'tomography', 'disease', 'chest', 'baseline', 'magnetic resonance imaging', 'progression', 'at', 'computed tomography', 'and']","['abdomen', 'disease', 'chest', 'baseline', 'progression']",,
2410,2372,"survival , second progression , and subsequent treatments for cancer were assessed every 8 weeks after progression .",在进展后每 8 周评估一次生存、二次进展和随后的癌症治疗。,0.625,"['cancer', 'survival', 'progression', 'after', 'subsequent', 'second', 'and', 'assessed']","['cancer', 'survival', 'progression', 'after', 'second']",2372,"['生存、第二进展和随后的癌症治疗,在进展后每8周进行评估。']",0.5,"['cancer', 'survival', 'progression', 'after', 'subsequent', 'second', 'and', 'assessed']","['cancer', 'survival', 'progression', 'after']",,
2411,2373,"adverse events were graded according to the NCI CTCAE , version 4.0 .",不良事件根据 NCI CTCAE 4.0 版进行分级。,0.0,"['version', 'adverse', 'to']",[],2373,"['根据 NCI CTCAE, 版本 4.0 等级不良事件。']",0.3333333333333333,"['version', 'adverse', 'to']",['version'],,
2412,2374,"this trial was performed in accordance with the principles of the Declaration of Helsinki , Good Clinical Practice guidelines , and the AstraZeneca policy of bioethics.22",该试验是根据赫尔辛基宣言、良好临床实践指南和阿斯利康生物伦理学政策的原则进行的。 22,0.2,"['good clinical practice', 'trial', 'with', 'this', 'and']",['this'],2374,['本审查按照赫尔辛基宣言、良好临床实践指南和AstraZeneca生物伦理政策的原则进行。'],0.0,"['good clinical practice', 'trial', 'with', 'this', 'and']",[],,
2413,2375,the trial was designed by the first and last authors in collaboration with AstraZeneca .,该试验由第一作者和最后一名作者与阿斯利康合作设计。,0.4285714285714285,"['trial', 'collaboration', 'with', 'in', 'by', 'and', 'first']","['collaboration', 'by', 'first']",2375,['审判由第一和最后的作者与AstraZeneca合作设计。'],0.5714285714285714,"['trial', 'collaboration', 'with', 'in', 'by', 'and', 'first']","['trial', 'collaboration', 'by', 'first']",,
2414,2376,"AstraZeneca was responsible for overseeing the collection , analysis , and interpretation of the data .",阿斯利康负责监督数据的收集、分析和解释。,0.8,"['data', 'analysis', 'collection', 'interpretation', 'and']","['data', 'analysis', 'collection', 'interpretation']",2376,['AstraZeneca负责监督数据收集、分析和解释。'],0.8,"['data', 'analysis', 'collection', 'interpretation', 'and']","['data', 'analysis', 'collection', 'interpretation']",,
2415,2376,"AstraZeneca was responsible for overseeing the collection , analysis , and interpretation of the data .",阿斯利康负责监督数据的收集、分析和解释。,0.8,"['data', 'analysis', 'collection', 'interpretation', 'and']","['data', 'analysis', 'collection', 'interpretation']",2376,['AstraZeneca负责监督数据收集、分析和解释。'],0.8,"['data', 'analysis', 'collection', 'interpretation', 'and']","['data', 'analysis', 'collection', 'interpretation']",,
2416,2377,"the manuscript was written with medical writing assistance funded by AstraZeneca and MSD , with critical review and input by the authors .",该手稿是在阿斯利康和默沙东资助的医学写作协助下撰写的，作者进行了严格的审查和输入。,0.4,"['review', 'medical', 'manuscript', 'writing', 'input', 'critical', 'assistance', 'with', 'by', 'and']","['review', 'manuscript', 'writing', 'input']",2377,"['手稿是由AstraZeneca和MSD资助的医学写作协助写的,作者批判性审查和引用。']",0.4,"['review', 'medical', 'manuscript', 'writing', 'input', 'critical', 'assistance', 'with', 'by', 'and']","['review', 'manuscript', 'writing', 'by']",,
2417,2378,the authors attest to the accuracy and completeness of the data and the fidelity of the trial to the protocol .,作者证明数据的准确性和完整性以及试验对方案的忠实度。,0.375,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'attest', 'completeness', 'and']","['data', 'accuracy', 'completeness']",2378,['作者证明数据的准确性和完整性以及审判对议定书的忠诚性。'],0.625,"['fidelity', 'data', 'accuracy', 'protocol', 'trial', 'attest', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
2418,2379,"data on patients who had not had disease progression and who had not died at the time of the primary analysis , or who had progression or had died after two or more missed visits , were censored at the date of the last tumor assessment for which data could be evaluated .",未出现疾病进展且在主要分析时未死亡，或出现疾病进展或在两次或两次以上错过就诊后死亡的患者的数据在最后一次肿瘤评估日期截尾，其数据可能得到评价。,0.7857142857142857,"['disease', 'data', 'who', 'analysis', 'tumor', 'date', 'time', 'be', 'assessment', 'primary', 'progression', 'after', 'and', 'two']","['disease', 'data', 'analysis', 'tumor', 'date', 'time', 'be', 'assessment', 'progression', 'after', 'two']",2379,"['没有疾病进展的病人,并且在初步分析时没有死亡的病人,或者在两次或多次失踪访问后出现进展或死亡的病人,在最后一次肿瘤评估的日期被审查,这些病人可以评估。']",0.7142857142857143,"['disease', 'data', 'who', 'analysis', 'tumor', 'date', 'time', 'be', 'assessment', 'primary', 'progression', 'after', 'and', 'two']","['disease', 'analysis', 'tumor', 'date', 'time', 'be', 'assessment', 'progression', 'after', 'two']",,
2419,2380,a change of 10 points in either direction was considered to be a clinically significant difference .,任一方向 10 个点的变化被认为是临床显着差异。,0.375,"['a', 'difference', 'be', 'change', 'direction', 'significant difference', 'in', 'to']","['difference', 'change', 'direction']",2380,['每个方向的10点的变化被认为是临床上显著的差异。'],0.375,"['a', 'difference', 'be', 'change', 'direction', 'significant difference', 'in', 'to']","['difference', 'change', 'direction']",,
2420,2381,the final overall survival analysis is planned after 106 deaths .,最终的总体生存分析计划在 106 人死亡后进行。,1.0,"['analysis', 'survival', 'after']","['analysis', 'survival', 'after']",2381,['最终的总生存分析计划在106人死亡后进行。'],1.0,"['analysis', 'survival', 'after']","['analysis', 'survival', 'after']",,
2421,2382,the statistical analysis plan is available with the protocol at NEJM.org .,统计分析计划可与方案一起在 NEJM.org 上获得。,0.4,"['analysis', 'protocol', 'available', 'statistical analysis', 'with']","['analysis', 'statistical analysis']",2382,['统计分析计划与协议在NEJM.org上可用。'],0.6,"['analysis', 'protocol', 'available', 'statistical analysis', 'with']","['analysis', 'protocol', 'statistical analysis']",,
2422,2382,the statistical analysis plan is available with the protocol at NEJM.org .,统计分析计划可与方案一起在 NEJM.org 上获得。,0.4,"['analysis', 'protocol', 'available', 'statistical analysis', 'with']","['analysis', 'statistical analysis']",2382,['统计分析计划与协议在NEJM.org上可用。'],0.6,"['analysis', 'protocol', 'available', 'statistical analysis', 'with']","['analysis', 'protocol', 'statistical analysis']",,
2423,2382,the statistical analysis plan is available with the protocol at NEJM.org .,统计分析计划可与方案一起在 NEJM.org 上获得。,0.4,"['analysis', 'protocol', 'available', 'statistical analysis', 'with']","['analysis', 'statistical analysis']",2382,['统计分析计划与协议在NEJM.org上可用。'],0.6,"['analysis', 'protocol', 'available', 'statistical analysis', 'with']","['analysis', 'protocol', 'statistical analysis']",,
2424,2383,a total of 3315 patients were screened for trial entry ; 247 ( 7.5 % ) of these patients had a germline BRCA mutation .,共有 3315 名患者接受了试验筛选；这些患者中有 247 名 (7.5%) 有种系 BRCA 突变。,0.2,"['mutation', 'germline', 'total', 'trial', 'entry']",['mutation'],2383,"['总共有3315名患者接受试验,其中247(7.5%)患有基因BRCA突变。']",0.2,"['mutation', 'germline', 'total', 'trial', 'entry']",['mutation'],,
2425,2384,"between January 2015 and January 2019 , a total of 154 patients underwent randomization ( Table S1 in the Supplementary Appendix ) , and 90 of 92 patients who were assigned to olaparib and 61 of 62 patients who were assigned to placebo received the trial intervention ( Figure 1 ) .",2015 年 1 月至 2019 年 1 月期间，共有 154 名患者接受了随机分组（补充附录表 S1） ，分配至奥拉帕尼组的 92 名患者中有 90 名和分配至安慰剂组的 62 名患者中有 61 名接受了试验干预（图 1 ) 。,0.3333333333333333,"['placebo', 'appendix', 'randomization', 'table', 'who', '1', 'figure', 'supplementary', 'total', 'intervention', 'trial', 'S1']","['placebo', 'randomization', 'table', '1']",2384,"['在2015年1月至2019年1月之间,共有154名患者遭到随机化(附件中的S1表),90名被分配给olaparib的92名患者和61名被分配给 placebo的62名患者接受了试验干预(图1)。']",0.3333333333333333,"['placebo', 'appendix', 'randomization', 'table', 'who', '1', 'figure', 'supplementary', 'total', 'intervention', 'trial', 'S1']","['appendix', 'randomization', 'table', '1']",,
2426,2385,"at the time of data cutoff for this analysis ( January 15 , 2019 ) , 30 patients were still receiving olaparib and 8 were still receiving placebo .",在该分析的数据截止时（2019 年 1 月 15 日），30 名患者仍在接受奥拉帕尼治疗，8 名患者仍在接受安慰剂治疗。,0.5,"['cutoff', 'placebo', 'data', 'analysis', 'time', 'still', 'this', 'and']","['placebo', 'data', 'analysis', 'time']",2385,"['在此分析数据收集(2019年1月15日)时,30名患者仍在接受Oaparib,8名患者仍在接受 placebo。']",0.375,"['cutoff', 'placebo', 'data', 'analysis', 'time', 'still', 'this', 'and']","['data', 'analysis', 'time']",,
2427,2386,"the baseline characteristics of the patients are listed in Table 1 , and in Table S2 in the Supplementary Appendix .",表 1 和补充附录表 S2 列出了患者的基线特征。,0.5,"['appendix', 'table', 'baseline', '1', 'supplementary', 'characteristics', 'S2', 'and']","['table', 'baseline', '1', 'characteristics']",2386,['患者的基本特征在表1和附件S2中列出。'],0.5,"['appendix', 'table', 'baseline', '1', 'supplementary', 'characteristics', 'S2', 'and']","['appendix', 'table', '1', 'characteristics']",,
2428,2387,"the analysis of the primary end point was performed after 104 of 154 patients had had disease progression ( assessed by blinded independent central review ) or had died ( data maturity , 68 % ) .",主要终点分析是在 154 名患者中有 104 名出现疾病进展（通过盲法独立中央审查评估）或死亡（数据成熟度为 68%）后进行的。,0.6153846153846154,"['disease', 'data', 'analysis', 'maturity', 'review', 'central', 'primary', 'progression', 'after', 'independent', 'point', 'by', 'assessed']","['disease', 'data', 'analysis', 'maturity', 'review', 'progression', 'after', 'point']",2387,"['初级终点分析是在154名患者中有104人患有疾病进展(由盲目独立中心审查评估)或死亡(数据成熟度,68%)之后进行的。']",0.6923076923076923,"['disease', 'data', 'analysis', 'maturity', 'review', 'central', 'primary', 'progression', 'after', 'independent', 'point', 'by', 'assessed']","['disease', 'data', 'analysis', 'maturity', 'review', 'progression', 'after', 'point', 'by']",,
2429,2388,a multivariate Cox regression analysis showed that the treatment effect was not affected by imbalances in baseline factors between the trial groups ( Table S6 in the Supplementary Appendix ) .,多变量 Cox 回归分析表明，治疗效果不受试验组之间基线因素不平衡的影响（补充附录表 S6）。,0.6,"['a', 'appendix', 'table', 'analysis', 'baseline', 'supplementary', 'regression', 'treatment', 'trial', 'effect', 'treatment effect', 'multivariate', 'regression analysis', 'that', 'by']","['table', 'analysis', 'baseline', 'regression', 'treatment', 'effect', 'treatment effect', 'multivariate', 'regression analysis']",2388,"['多元化 Cox 回归分析表明,治疗效果不受测试组之间的基因因素的不平衡影响(附件中的 S6 表)。']",0.5333333333333333,"['a', 'appendix', 'table', 'analysis', 'baseline', 'supplementary', 'regression', 'treatment', 'trial', 'effect', 'treatment effect', 'multivariate', 'regression analysis', 'that', 'by']","['appendix', 'table', 'analysis', 'regression', 'treatment', 'effect', 'treatment effect', 'regression analysis']",,
2430,2389,"at the primary data cutoff date , 41 patients in the olaparib group and 30 patients in the placebo group had died .",在主要数据截止日期，奥拉帕尼组中有 41 名患者死亡，安慰剂组中有 30 名患者死亡。,0.4444444444444444,"['group', 'cutoff', 'placebo', 'data', 'date', 'primary', 'primary data', 'in', 'and']","['group', 'placebo', 'data', 'date']",2389,"['截至初步数据截止日期,Oaparib群体的41名患者和 placebo群体的30名患者死亡。']",0.3333333333333333,"['group', 'cutoff', 'placebo', 'data', 'date', 'primary', 'primary data', 'in', 'and']","['group', 'data', 'date']",,
2431,2390,"a planned interim analysis of overall survival that took place at a data maturity of 46 % showed no evidence of a difference in overall survival between the groups ( median , 18.9 months in the olaparib group and 18.1 months in the placebo group ; hazard ratio for death , 0.91 ; 95 % CI , 0.56 to 1.46 ; P = 0.68 ) ( Figure 2B ) .","计划在数据成熟度为 46 % 时进行的总生存期中期分析显示，没有证据表明两组之间的总生存期存在差异（奥拉帕利组中位数为 18.9 个月，安慰剂组为 18.1 个月；死亡风险比, 0.91；95% CI，0.56 至 1.46；P = 0.68)（图 2B）。",0.55,"['group', 'median', 'placebo', 'data', 'analysis', 'maturity', 'survival', 'ratio', 'hazard ratio', 'death', 'figure', 'difference', 'no', 'evidence', 'P', 'CI', 'that', 'in', 'to', 'and']","['group', 'placebo', 'data', 'analysis', 'maturity', 'survival', 'ratio', 'hazard ratio', 'death', 'difference', 'evidence']",2390,"['在46%的数据成熟时进行的总生存的计划临时分析中,没有证据表明群体之间的总生存差异(平均,在Oaparib群体中有18.9个月,在 placebo群体中有18.1个月;死亡风险比例,0.91;95% CI,0.56到1.46;P=0.68)。']",0.5,"['group', 'median', 'placebo', 'data', 'analysis', 'maturity', 'survival', 'ratio', 'hazard ratio', 'death', 'figure', 'difference', 'no', 'evidence', 'P', 'CI', 'that', 'in', 'to', 'and']","['group', 'data', 'analysis', 'maturity', 'survival', 'ratio', 'hazard ratio', 'death', 'difference', 'evidence']",,
2432,2391,"a primary analysis of overall survival was planned after 106 events ( data maturity , 69 % ) .",计划在发生 106 次事件（数据成熟度为 69%）后对总生存期进行初步分析。,0.7142857142857143,"['a', 'data', 'analysis', 'maturity', 'survival', 'primary', 'after']","['data', 'analysis', 'maturity', 'survival', 'after']",2391,"['总生存的初步分析是在106个事件(数据成熟度,69%)之后进行的。']",0.7142857142857143,"['a', 'data', 'analysis', 'maturity', 'survival', 'primary', 'after']","['data', 'analysis', 'maturity', 'survival', 'after']",,
2433,2392,one patient in the olaparib group and 9 patients in the placebo group received treatment with a PARP inhibitor after discontinuation of the trial intervention ( Table S7 in the Supplementary Appendix ) .,奥拉帕利组的 1 名患者和安慰剂组的 9 名患者在试验干预停止后接受了 PARP 抑制剂治疗（补充附录表 S7）。,0.5384615384615384,"['group', 'inhibitor', 'placebo', 'appendix', 'table', 'supplementary', 'treatment', 'intervention', 'patient', 'after', 'trial', 'with', 'and']","['group', 'inhibitor', 'placebo', 'table', 'treatment', 'patient', 'after']",2392,"['在试验中断后,1名患者和9名 placebo 患者接受了 PARP 抑制剂的治疗(附件中的 S7 表)。']",0.4615384615384615,"['group', 'inhibitor', 'placebo', 'appendix', 'table', 'supplementary', 'treatment', 'intervention', 'patient', 'after', 'trial', 'with', 'and']","['inhibitor', 'appendix', 'table', 'treatment', 'patient', 'after']",,
2434,2393,"overall , 18 patients in the olaparib group ( 20 % ) and 6 patients in the placebo group ( 10 % ) had a response .",总的来说，奥拉帕尼组有 18 名患者 (20%) 和安慰剂组有 6 名患者 (10%) 有反应。,0.6,"['group', 'placebo', 'response', 'in', 'and']","['group', 'placebo', 'response']",2393,"['总体而言,奥拉帕里布群体的18名患者(20%)和 placebo群体的6名患者(10%)得到了回应。']",0.4,"['group', 'placebo', 'response', 'in', 'and']","['group', 'and']",,
2435,2394,"among patients with measurable disease at baseline , the response rate as assessed by blinded independent central review was 23 % in the olaparib group ( 18 of 78 patients ) and 12 % in the placebo group ( 6 of 52 patients ) ( odds ratio , 2.30 ; 95 % CI , 0.89 to 6.76 ) .",在基线时患有可测量疾病的患者中，奥拉帕利组（78 名患者中的 18 名）和安慰剂组（52 名患者中的 6 名）的反应率为 23%（优势比 2.30； 95% CI，0.89 至 6.76）。,0.4444444444444444,"['group', 'placebo', 'disease', 'baseline', 'rate', 'review', 'ratio', 'central', 'response', 'independent', 'response rate', 'with', 'CI', 'by', 'to', 'and', 'assessed', 'odds']","['group', 'placebo', 'disease', 'baseline', 'rate', 'ratio', 'response', 'response rate']",2394,"['在基层可测量的疾病患者中,由盲目独立中心审查评估的反应率为23%的Olaparib群体(78名患者中18人)和12%的Placebo群体(52名患者中6人)(概率比率,2.30;95%的CI,0.89至6.76)。']",0.4444444444444444,"['group', 'placebo', 'disease', 'baseline', 'rate', 'review', 'ratio', 'central', 'response', 'independent', 'response rate', 'with', 'CI', 'by', 'to', 'and', 'assessed', 'odds']","['group', 'disease', 'rate', 'review', 'ratio', 'response', 'response rate', 'by']",,
2436,2395,"two patients , both in the olaparib group , had a complete response ; both complete responses were ongoing at the time of data cutoff .",奥拉帕尼组中的两名患者获得了完全缓解；在数据截止时，两种完整的反应都在进行中。,0.6666666666666666,"['group', 'cutoff', 'a', 'data', 'time', 'complete', 'response', 'in', 'two']","['group', 'data', 'time', 'complete', 'response', 'two']",2395,"['兩個病人,兩個在 olaparib 群體中,有完整的回應;兩個完整的回應在數據收集時進行。']",0.3333333333333333,"['group', 'cutoff', 'a', 'data', 'time', 'complete', 'response', 'in', 'two']","['group', 'time', 'complete']",,
2437,2396,"the median duration of response was 24.9 months ( 95 % CI , 14.8 to could not be calculated ) and 3.7 months ( 95 % CI , 2.1 to could not be calculated ) and the median time to response was 5.4 months and 3.6 months in the olaparib and placebo groups , respectively .",中位反应持续时间为 24.9 个月（ 95 % CI ， 14.8 至无法计算）和 3.7 个月（ 95 % CI ， 2.1 至无法计算），中位反应时间在奥拉帕尼组中分别为 5.4 个月和 3.6 个月和安慰剂组，分别。,0.5,"['median', 'placebo', 'time', 'be', 'response', 'duration', 'CI', 'in', 'to', 'and']","['placebo', 'time', 'be', 'response', 'duration']",2396,"['答案的平均时间为 24.9 个月(95% CI, 14.8 无法计算 )和 3.7 个月(95% CI, 2.1 无法计算 )和答案的平均时间为 5.4 个月和 3.6 个月在 olaparib 和 placebo 群体, 相应。']",0.2,"['median', 'placebo', 'time', 'be', 'response', 'duration', 'CI', 'in', 'to', 'and']","['time', 'be']",,
2438,2397,"in the 151 patients who received a trial agent , the total median duration of treatment was 6.0 months ( range , 0.8 to 45.3 ) in the olaparib group and 3.7 months ( range , 0.1 to 30.1 ) in the placebo group ( related data on dose intensity are provided in the Results section in the Supplementary Appendix ) .",在接受试验药物治疗的 151 名患者中，奥拉帕利组的总中位治疗持续时间为 6.0 个月（范围 0.8 至 45.3 ） ，安慰剂组为 3.7 个月（范围 0.1 至 30.1 ）（有关剂量强度的相关数据）补充附录的结果部分提供）。,0.4444444444444444,"['group', 'median', 'placebo', 'appendix', 'range', 'data', 'who', 'section', 'supplementary', 'total', 'treatment', 'intensity', 'trial', 'related data', 'duration', 'agent', 'dose', 'and']","['group', 'placebo', 'range', 'data', 'treatment', 'related data', 'duration', 'dose']",2397,"['在接受试用剂的151名患者中,治疗的总平均时间为6.0个月(范围为0.8至45.3)在Olaparib组和3.7个月(范围为0.1至30.1)在 placebo组(相关的剂量强度数据在附件中的结果部分中提供)。']",0.3333333333333333,"['group', 'median', 'placebo', 'appendix', 'range', 'data', 'who', 'section', 'supplementary', 'total', 'treatment', 'intensity', 'trial', 'related data', 'duration', 'agent', 'dose', 'and']","['group', 'appendix', 'range', 'data', 'treatment', 'dose']",,
2439,2398,Table 2 shows the most common adverse events in the trial groups .,表 2 显示了试验组中最常见的不良事件。,0.3333333333333333,"['table', '2', 'common', 'adverse', 'trial', 'in']","['table', '2']",2398,['图2显示试验组中最常见的不良事件。'],0.1666666666666666,"['table', '2', 'common', 'adverse', 'trial', 'in']",['2'],,
2440,2399,serious adverse events occurred in 24 % of the patients who received olaparib and in 15 % of the patients who received placebo .,严重不良事件发生在 24% 接受奥拉帕尼的患者和 15% 接受安慰剂的患者中。,0.1666666666666666,"['placebo', 'who', 'adverse', 'serious', 'in', 'and']",['placebo'],2399,['严重的副作用发生在24%的患者接受了olaparib和15%的患者接受了 placebo。'],0.0,"['placebo', 'who', 'adverse', 'serious', 'in', 'and']",[],,
2441,2400,no adverse events that occurred during the trial intervention resulted in death .,试验干预期间没有发生导致死亡的不良事件。,0.1666666666666666,"['death', 'adverse', 'no', 'intervention', 'trial', 'that']",['death'],2400,['在审判中发生的任何不良事件都导致死亡。'],0.3333333333333333,"['death', 'adverse', 'no', 'intervention', 'trial', 'that']","['death', 'trial']",,
2442,2401,no cases of myelodysplastic syndrome or acute myeloid leukemia were reported in either group .,两组均未报告骨髓增生异常综合征或急性髓性白血病病例。,0.5,"['group', 'leukemia', 'syndrome', 'myelodysplastic syndrome', 'no', 'acute', 'in', 'myeloid']","['group', 'leukemia', 'syndrome', 'myeloid']",2401,['在任何群体中都没有报告过甲状腺炎症或急性甲状腺白血病的病例。'],0.25,"['group', 'leukemia', 'syndrome', 'myelodysplastic syndrome', 'no', 'acute', 'in', 'myeloid']","['group', 'leukemia']",,
2443,2402,"in two patients who received placebo , new primary cancers developed more than 30 days after the end of the trial intervention ( one patient had rectal cancer , and the other had a possible ovarian cancer , which resulted in death ) .",在接受安慰剂的两名患者中，试验干预结束后 30 多天后出现了新的原发性癌症（一名患者患有直肠癌，另一名患者可能患有卵巢癌，最终导致死亡）。,0.6,"['placebo', 'cancer', 'who', 'death', 'rectal cancer', 'ovarian cancer', 'primary', 'intervention', 'patient', 'after', 'trial', 'end', 'and', 'two', 'new']","['placebo', 'cancer', 'death', 'rectal cancer', 'ovarian cancer', 'patient', 'after', 'two', 'new']",2402,"['在接受 placebo 的 2 名患者中,试验干预结束后 30 天以上的新初级癌症出现(一个患者患有直肠癌,另一个患者患有可能的卵巢癌,导致死亡)。']",0.4666666666666667,"['placebo', 'cancer', 'who', 'death', 'rectal cancer', 'ovarian cancer', 'primary', 'intervention', 'patient', 'after', 'trial', 'end', 'and', 'two', 'new']","['cancer', 'death', 'rectal cancer', 'ovarian cancer', 'patient', 'after', 'new']",,
2444,2403,one diagnosis of grade 1 pneumonitis in a patient in the olaparib group was not considered by the investigators to be causally related to the trial intervention ( see the Results section in the Supplementary Appendix ) .,研究人员认为，奥拉帕利组患者的 1 级肺炎诊断与试验干预没有因果关系（见补充附录中的结果部分）。,0.3333333333333333,"['group', 'a', 'appendix', '1', 'section', 'grade', 'pneumonitis', 'supplementary', 'be', 'diagnosis', 'intervention', 'patient', 'trial', 'by', 'to']","['group', '1', 'pneumonitis', 'diagnosis', 'patient']",2403,['研究人员对1级肺炎患者的诊断没有被认为与试验干预有因果相关(参见附件中的结果部分)。'],0.3333333333333333,"['group', 'a', 'appendix', '1', 'section', 'grade', 'pneumonitis', 'supplementary', 'be', 'diagnosis', 'intervention', 'patient', 'trial', 'by', 'to']","['appendix', '1', 'pneumonitis', 'diagnosis', 'patient']",,
2445,2404,"the adjusted mean ( ± SE ) change from baseline across all time points was − 1.20 ± 1.42 ( 95 % CI , − 4.01 to 1.62 ) in 84 patients in the olaparib group and 1.27 ± 1.95 ( 95 % CI , − 2.58 to 5.12 ) in 54 patients in the placebo group .",在奥拉帕利组的 84 名患者中，所有时间点相对于基线的调整平均 (± SE) 变化为 − 1.20 ± 1.42（ 95 % CI ， − 4.01 至 1.62）和 1.27 ± 1.95 （ 95 % CI ， − 2.58 至 5.12）在安慰剂组的 54 名患者中。,0.5833333333333334,"['group', 'placebo', 'mean', 'baseline', 'time', 'across', 'change', 'SE', 'CI', 'all', 'to', 'and']","['group', 'placebo', 'mean', 'baseline', 'time', 'change', 'to']",2404,"['在所有时间点中,从基线调整的平均(±SE)变化为 − 1.20 ± 1.42 (95 % CI 、 − 4.01 至 1.62 ) 在 84 名患者的 olaparib 组和 1.27 ± 1.95 (95 % CI 、 − 2.58 至 5.12) 在 54 名患者的 placebo 组。']",0.4166666666666667,"['group', 'placebo', 'mean', 'baseline', 'time', 'across', 'change', 'SE', 'CI', 'all', 'to', 'and']","['group', 'mean', 'baseline', 'time', 'change']",,
2446,2405,overall survival data from an interim analysis at a data maturity of 46 % ( the final analysis was planned at a data maturity of 69 % ) show no significant difference in survival between the trial groups .,在数据成熟度为 46% 时（最终分析计划在数据成熟度为 69% 时）来自中期分析的总生存数据显示试验组之间的生存率没有显着差异。,0.5,"['a', 'data', 'analysis', 'maturity', 'survival', 'difference', 'no', 'trial', 'significant difference', 'in']","['data', 'analysis', 'maturity', 'survival', 'difference']",2405,"['数据成熟度为46%的临时分析(最终分析为69%的数据成熟度)的总生存数据显示,试验组之间的生存差异没有显著。']",0.5,"['a', 'data', 'analysis', 'maturity', 'survival', 'difference', 'no', 'trial', 'significant difference', 'in']","['data', 'analysis', 'maturity', 'survival', 'difference']",,
2447,2406,"overall survival may be confounded by subsequent therapies , including that of nine patients in the placebo group ( 15 % ) who went on to receive a PARP inhibitor after disease progression during the trial intervention ( Table S7 in the Supplementary Appendix ) .13",总生存期可能会受到后续治疗的影响，包括安慰剂组中的 9 名患者 (15%)，他们在试验干预期间疾病进展后继续接受 PARP 抑制剂治疗（补充附录表 S7）。13,0.5294117647058824,"['group', 'inhibitor', 'placebo', 'disease', 'appendix', 'table', 'who', 'survival', 'supplementary', 'be', 'progression', 'intervention', 'after', 'trial', 'subsequent', 'that', 'by']","['group', 'inhibitor', 'placebo', 'disease', 'table', 'survival', 'be', 'progression', 'after']",2406,"['总生存可能被随后的治疗所困扰,其中包括在试验中经历疾病进展后接受PARP抑制剂的9名 placebo群体患者(15%)的治疗(补充附件中的S7表)。']",0.5294117647058824,"['group', 'inhibitor', 'placebo', 'disease', 'appendix', 'table', 'who', 'survival', 'supplementary', 'be', 'progression', 'intervention', 'after', 'trial', 'subsequent', 'that', 'by']","['group', 'inhibitor', 'disease', 'appendix', 'table', 'survival', 'be', 'progression', 'after']",,
2448,2407,an analysis of the time to second disease progression suggested a trend toward benefit from maintenance olaparib through the next treatment .,对第二次疾病进展时间的分析表明，在下一次治疗中有从维持奥拉帕尼获益的趋势。,0.75,"['trend', 'disease', 'analysis', 'time', 'treatment', 'progression', 'maintenance', 'benefit', 'second', 'to', 'toward', 'next']","['trend', 'disease', 'analysis', 'time', 'treatment', 'progression', 'maintenance', 'second', 'next']",2407,"['一项时间到第二次疾病进展的分析表明,在接下来的治疗中,奥拉帕里布的维持受益的趋势。']",0.75,"['trend', 'disease', 'analysis', 'time', 'treatment', 'progression', 'maintenance', 'benefit', 'second', 'to', 'toward', 'next']","['trend', 'disease', 'analysis', 'time', 'treatment', 'progression', 'maintenance', 'second', 'next']",,
2449,2408,"although there is no precedent in pancreatic cancer , this end point has been assessed in studies of other tumor types and has been interpreted as a possible indicator of treatment benefit beyond disease progression.12",尽管在胰腺癌中没有先例，但这一终点已在其他肿瘤类型的研究中得到评估，并被解释为超越疾病进展的治疗获益的可能指标。 12,0.4285714285714285,"['disease', 'cancer', 'indicator', 'tumor', 'pancreatic', 'treatment', 'no', 'end', 'point', 'benefit', 'pancreatic cancer', 'this', 'and', 'assessed']","['disease', 'cancer', 'indicator', 'tumor', 'treatment', 'point']",2408,"['虽然胰腺癌没有先例,但这种终点在其他肿瘤类型的研究中被评估,并被解释为治疗益处超越疾病进展的可能指标。']",0.4285714285714285,"['disease', 'cancer', 'indicator', 'tumor', 'pancreatic', 'treatment', 'no', 'end', 'point', 'benefit', 'pancreatic cancer', 'this', 'and', 'assessed']","['disease', 'cancer', 'indicator', 'tumor', 'treatment', 'point']",,
2450,2409,"of 3315 patients screened for entry in the POLO trial , 7.5 % had a germline BRCA mutation .",在接受 POLO 试验筛选的 3315 名患者中，7.5% 的患者有种系 BRCA 突变。,0.25,"['mutation', 'germline', 'trial', 'entry']",['mutation'],2409,"['在3315名受试者中,有7,5%的患者患有基因BRCA突变。']",0.25,"['mutation', 'germline', 'trial', 'entry']",['mutation'],,
2451,2410,"in this trial , dual selection criteria were used to identify patients who would be likely to benefit from PARP inhibition .",在该试验中，使用双重选择标准来确定可能受益于 PARP 抑制的患者。,0.3333333333333333,"['inhibition', 'who', 'be', 'trial', 'identify', 'benefit', 'dual', 'this', 'to']","['inhibition', 'be', 'to']",2410,"['在这项研究中,使用了双选择标准来确定谁可能会受益于PARP抑制的患者。']",0.3333333333333333,"['inhibition', 'who', 'be', 'trial', 'identify', 'benefit', 'dual', 'this', 'to']","['inhibition', 'be', 'to']",,
2452,2411,"in an unselected population with metastatic pancreatic cancer , it is expected that approximately 30 % of patients will have disease progression during their first 4 months of treatment with FOLFIRINOX.2",在未经选择的转移性胰腺癌人群中，预计大约 30 % 的患者在接受 FOLFIRINOX 治疗的前 4 个月内会出现疾病进展。2,0.3125,"['population', 'disease', 'cancer', 'pancreatic', 'metastatic', 'treatment', 'progression', '4', 'will', 'with', 'pancreatic cancer', 'have', 'approximately', 'that', 'in', 'first']","['population', 'disease', 'cancer', 'treatment', 'progression']",2411,"['在未选择的甲状腺癌患者中,预计大约30%的患者在FOLFIRINOX治疗的前4个月内会出现疾病进展。']",0.25,"['population', 'disease', 'cancer', 'pancreatic', 'metastatic', 'treatment', 'progression', '4', 'will', 'with', 'pancreatic cancer', 'have', 'approximately', 'that', 'in', 'first']","['disease', 'cancer', 'treatment', 'progression']",,
2453,2412,British analysis suggests a preference for mornings can lower risk for breast cancer .,英国的分析表明，偏爱早晨可以降低患乳腺癌的风险。,0.5714285714285714,"['a', 'cancer', 'analysis', 'breast cancer', 'lower', 'risk', 'preference']","['cancer', 'analysis', 'breast cancer', 'risk']",2412,"['英国分析表明,早餐的偏好可以降低乳腺癌的风险。']",0.5714285714285714,"['a', 'cancer', 'analysis', 'breast cancer', 'lower', 'risk', 'preference']","['cancer', 'analysis', 'breast cancer', 'risk']",,
2454,2413,"mendelian randomization uses genetic variants highly associated with chronotype , sleep duration , and insomnia symptoms to help clarify this association .",孟德尔随机化使用与时间型、睡眠持续时间和失眠症状高度相关的遗传变异来帮助阐明这种关联。,0.5,"['randomization', 'association', 'genetic', 'symptoms', 'associated', 'sleep', 'duration', 'insomnia', 'with', 'this']","['randomization', 'association', 'sleep', 'duration', 'insomnia']",2413,['mendelian randomization 使用与时间典型、睡眠时间和失眠症状密切相关的遗传变量来帮助澄清这种联系。'],0.3,"['randomization', 'association', 'genetic', 'symptoms', 'associated', 'sleep', 'duration', 'insomnia', 'with', 'this']","['association', 'sleep', 'insomnia']",,
2455,2414,"among women with a preference for morning compared with evening , fully adjusted regression analysis showed a hazard ratio of 0.95 ( P = 0.002 ) for breast cancer .",在与晚上相比更喜欢早上的女性中，完全调整的回归分析显示乳腺癌的风险比为 0.95 (P = 0.002)。,0.6923076923076923,"['a', 'cancer', 'analysis', 'ratio', 'hazard ratio', 'breast cancer', 'regression', 'evening', 'preference', 'with', 'regression analysis', 'P', 'morning']","['cancer', 'analysis', 'ratio', 'hazard ratio', 'breast cancer', 'regression', 'evening', 'regression analysis', 'morning']",2414,"['在女性中,早上比晚上更有偏好,完全调整的回归分析显示了乳腺癌的风险比例为0.95(P=0.002)。']",0.6923076923076923,"['a', 'cancer', 'analysis', 'ratio', 'hazard ratio', 'breast cancer', 'regression', 'evening', 'preference', 'with', 'regression analysis', 'P', 'morning']","['cancer', 'analysis', 'ratio', 'hazard ratio', 'breast cancer', 'regression', 'evening', 'regression analysis', 'morning']",,
2456,2415,"mendelian analysis also found that morning preference was associated with lower risk for breast cancer ( HR , 0.85 ) ; however , this association did not achieve statistical significance .",孟德尔分析还发现，早起偏好与较低的乳腺癌风险相关（HR，0.85）；然而，这种关联并没有达到统计显着性。,0.5714285714285714,"['cancer', 'analysis', 'association', 'breast cancer', 'lower', 'associated', 'risk', 'significance', 'statistical significance', 'preference', 'with', 'this', 'that', 'morning']","['cancer', 'analysis', 'association', 'breast cancer', 'lower', 'risk', 'that', 'morning']",2415,"['梅德里安分析还发现,早晨偏好与乳腺癌的风险较低(HR,0.85 )有关;然而,这种协会没有报告统计意义。']",0.4285714285714285,"['cancer', 'analysis', 'association', 'breast cancer', 'lower', 'associated', 'risk', 'significance', 'statistical significance', 'preference', 'with', 'this', 'that', 'morning']","['cancer', 'analysis', 'breast cancer', 'risk', 'significance', 'morning']",,
2457,2416,neither analysis showed significant associations between breast cancer risk and sleep duration or insomnia .,两项分析均未显示乳腺癌风险与睡眠时间或失眠之间存在显着关联。,0.75,"['cancer', 'analysis', 'breast cancer', 'risk', 'sleep', 'duration', 'insomnia', 'and']","['cancer', 'analysis', 'breast cancer', 'risk', 'sleep', 'insomnia']",2416,['没有分析表明乳腺癌风险与睡眠时间或失眠之间存在明显的联系。'],0.75,"['cancer', 'analysis', 'breast cancer', 'risk', 'sleep', 'duration', 'insomnia', 'and']","['cancer', 'analysis', 'breast cancer', 'risk', 'sleep', 'insomnia']",,
2458,2417,six behaviors in kindergarten are linked to annual income 30 years later .,幼儿园的六种行为与30年后的年收入挂钩。,0.5,"['annual', 'income', 'later', 'to']","['income', 'later']",2417,['幼儿园的六种行为与30年后的年度收入有关。'],0.5,"['annual', 'income', 'later', 'to']","['income', 'later']",,
2459,2418,"it seems obvious that childhood behaviors predict adult outcomes , but demonstrating how this occurs is not easy .",童年行为预示着成年后的结果似乎很明显，但要证明这是如何发生的并不容易。,0.5714285714285714,"['childhood', 'predict', 'adult', 'easy', 'this', 'that', 'but']","['adult', 'easy', 'this', 'but']",2418,"['看起来很明显,童年行为预测成年人的结果,但证明这种情况是如何发生的并不容易。']",0.7142857142857143,"['childhood', 'predict', 'adult', 'easy', 'this', 'that', 'but']","['predict', 'adult', 'easy', 'this', 'but']",,
2460,2419,"inattention , hyperactivity , physical aggression , oppositional behavior , and anxiety , as well as family adversity , were significantly correlated negatively with earnings in adulthood , whereas prosocial behavior and higher IQ were correlated positively with earnings .",注意力不集中、多动、身体攻击、对立行为、焦虑以及家庭逆境与成年后的收入呈显着负相关，而亲社会行为和较高的智商与收入呈正相关。,0.5714285714285714,"['behavior', 'adulthood', 'family', 'anxiety', 'physical', 'hyperactivity', 'well', 'aggression', 'adversity', 'IQ', 'as', 'with', 'in', 'and']","['behavior', 'family', 'anxiety', 'hyperactivity', 'aggression', 'adversity', 'IQ', 'and']",2419,"['不注意、超活性、身体侵略、反对行为和焦虑以及家庭不良,与成年收入有显著的负面关系,而社会行为和更高的IQ与收入有积极的关系。']",0.2857142857142857,"['behavior', 'adulthood', 'family', 'anxiety', 'physical', 'hyperactivity', 'well', 'aggression', 'adversity', 'IQ', 'as', 'with', 'in', 'and']","['behavior', 'family', 'anxiety', 'and']",,
2461,2420,"although theoretically desirable , eliminating adversity and improving IQ are not practical goals , but increasing resilience is - if interventions occur early in life .",尽管从理论上讲是可取的，但消除逆境和提高智商并不是切实可行的目标，但如果在生命早期进行干预，则提高复原力是可行的。,0.4545454545454545,"['life', 'early', 'resilience', 'practical', 'adversity', 'IQ', 'occur', '-', 'in', 'but', 'and']","['life', 'early', 'adversity', 'IQ', 'but']",2420,"['雖然理論上是可取的,消除不良和改善IQ不是實際的目標,但增強耐力是 - 如果介入發生在早期的生活。']",0.2727272727272727,"['life', 'early', 'resilience', 'practical', 'adversity', 'IQ', 'occur', '-', 'in', 'but', 'and']","['life', 'early', 'but']",,
2462,2421,such interventions could mitigate the adverse impacts of economic and social deprivation and enhance later adjustment and productivity .,这种干预措施可以减轻经济和社会剥夺的不利影响，并加强后期调整和生产力。,0.4285714285714285,"['productivity', 'deprivation', 'adjustment', 'adverse', 'enhance', 'later', 'and']","['productivity', 'deprivation', 'later']",2421,"['这种干预可以缓解经济和社会剥夺的负面影响,并提高后来的调整和生产力。']",0.4285714285714285,"['productivity', 'deprivation', 'adjustment', 'adverse', 'enhance', 'later', 'and']","['productivity', 'deprivation', 'later']",,
2463,2422,the answer : worrisome .,答案：令人担忧。,,[],[],2422,['答案:令人担忧。'],,[],[],,
2464,2423,perioperative atrial fibrillation ( AF ) occurs in 15 % to 40 % of patients undergoing cardiac surgery and a smaller proportion of patients with noncardiac surgery .,围手术期心房颤动 (AF) 发生在 15% 到 40% 的心脏手术患者和较小比例的非心脏手术患者中。,0.4545454545454545,"['atrial', 'proportion', 'cardiac', 'surgery', 'fibrillation', 'atrial fibrillation', 'with', 'perioperative', 'in', 'to', 'and']","['proportion', 'cardiac', 'surgery', 'fibrillation', 'atrial fibrillation']",2423,['周期手术甲状腺纤维化(AF)发生在15%至40%的心脏手术患者和较少的非心脏手术患者中。'],0.1818181818181818,"['atrial', 'proportion', 'cardiac', 'surgery', 'fibrillation', 'atrial fibrillation', 'with', 'perioperative', 'in', 'to', 'and']","['cardiac', 'surgery']",,
2465,2424,studies that included patients with prior AF were excluded .,包括既往房颤患者的研究被排除在外。,0.0,"['prior', 'with', 'that']",[],2424,['包括以前 AF 患者的研究被排除。'],0.0,"['prior', 'with', 'that']",[],,
2466,2425,"the authors found 35 studies for inclusion with a total of 2,458,000 patients .","作者找到了 35 项研究，共纳入 2,458,000 名患者。",0.0,"['a', 'inclusion', 'total', 'with']",[],2425,"['作者发现了35项参与研究,总共有2458000名患者。']",0.0,"['a', 'inclusion', 'total', 'with']",[],,
2467,2426,"all but 3 of the studies had a preponderance of men , and 29 studies centered on patients undergoing cardiac surgery .",除 3 项研究外，所有研究均以男性为主，29 项研究以接受心脏手术的患者为中心。,0.2857142857142857,"['cardiac', 'surgery', 'preponderance', '3', 'all', 'but', 'and']","['cardiac', 'surgery']",2426,"['所有但3项研究中有男性的偏见,29项研究专注于心脏手术的患者。']",0.4285714285714285,"['cardiac', 'surgery', 'preponderance', '3', 'all', 'but', 'and']","['cardiac', 'surgery', 'but']",,
2468,2427,"the magnitude of the increased stroke risk was higher with noncardiac surgery ( hazard ratio , 2.0 ) than with cardiac surgery ( HR , 1.20 ) .",非心脏手术（风险比，2.0）的卒中风险增加幅度高于心脏手术（HR，1.20）。,0.875,"['cardiac', 'stroke', 'ratio', 'hazard ratio', 'surgery', 'risk', 'magnitude', 'with']","['cardiac', 'stroke', 'ratio', 'hazard ratio', 'surgery', 'risk', 'magnitude']",2427,"['与非心脏手术(风险比例,2.0)相比,心脏手术(HR,1.20)的风险增加的程度更高。']",0.625,"['cardiac', 'stroke', 'ratio', 'hazard ratio', 'surgery', 'risk', 'magnitude', 'with']","['cardiac', 'ratio', 'hazard ratio', 'surgery', 'risk']",,
2469,2428,these findings highlight that perioperative AF is not benign .,这些发现强调围手术期 AF 不是良性的。,0.3333333333333333,"['benign', 'perioperative', 'that']",['benign'],2428,"['这些发现表明, perioperative AF 不是善良的。']",0.0,"['benign', 'perioperative', 'that']",[],,
2470,2429,surgical procedures probably serve as a stress test for individuals who are sicker and more vulnerable to AF development .,外科手术可能是对病情较重和更易患 AF 的人的压力测试。,0.1666666666666666,"['a', 'who', 'test', 'stress', 'surgical', 'serve', 'stress test', 'vulnerable', 'development', 'as', 'to', 'and']","['stress', 'stress test']",2429,"['外科手术可能作为一个压力测试的个人,谁是麻烦和更脆弱的AF发展。']",0.3333333333333333,"['a', 'who', 'test', 'stress', 'surgical', 'serve', 'stress test', 'vulnerable', 'development', 'as', 'to', 'and']","['stress', 'stress test', 'vulnerable', 'development']",,
2471,2430,"of the 741 patients treated , the median age was 65 , most had undifferentiated tumors ( 65 % ) and two or more sites of metastasis ( 58 % ) , and a minority had prior gastrectomy ( 21 % ) or had received prior adjuvant chemotherapy ( about 10 % ) .",在接受治疗的 741 名患者中，中位年龄为 65 岁，大多数患有未分化肿瘤 ( 65 % ) 和两个或多个转移部位 ( 58 % ) ，少数曾接受过胃切除术 ( 21 % ) 或接受过辅助化疗 ( 约10%）。,0.4,"['chemotherapy', 'median', 'metastasis', 'adjuvant', 'undifferentiated', 'age', 'prior', 'median age', 'and', 'two']","['chemotherapy', 'metastasis', 'age', 'two']",2430,"['受治疗的741名患者中,平均年龄为65岁,大多数患有不差异的肿瘤(65%)和两个或多个转移地点(58%)和少数患有早期腹泻(21%)或接受早期补充化疗(约10%)。']",0.4,"['chemotherapy', 'median', 'metastasis', 'adjuvant', 'undifferentiated', 'age', 'prior', 'median age', 'and', 'two']","['chemotherapy', 'metastasis', 'age', 'two']",,
2472,2431,patients were randomized to oral semaglutide or placebo .,患者被随机分配至口服 semaglutide 或安慰剂组。,0.25,"['placebo', 'oral', 'semaglutide', 'to']",['placebo'],2431,['病人随机服用口服半糖或 placebo。'],0.0,"['placebo', 'oral', 'semaglutide', 'to']",[],,
2473,2432,"HbA1c fell by 1.0 and 0.3 percentage points in the semaglutide and placebo groups , respectively ; weight reduction was also greater with semaglutide ( 4.2 vs. 0.8 kg ) .",semaglutide 组和安慰剂组的 HbA1c 分别下降了 1.0 和 0.3 个百分点； semaglutide 的体重减轻也更大（4.2 公斤与 0.8 公斤）。,0.3333333333333333,"['percentage', 'placebo', 'weight', 'reduction', 'weight reduction', 'kg', 'fell', 'with', 'semaglutide', 'in', 'by', 'and']","['placebo', 'weight', 'weight reduction', 'kg']",2432,['HbA1c在半<unk>和 placebo 群体中分别下降了 1.0 和 0.3 个百分点;体重减少也比半<unk>更大( 4.2 比 0.8 公斤)。'],0.25,"['percentage', 'placebo', 'weight', 'reduction', 'weight reduction', 'kg', 'fell', 'with', 'semaglutide', 'in', 'by', 'and']","['weight', 'reduction', 'kg']",,
2474,2433,patients were more likely to stop semaglutide than placebo because of gastrointestinal side effects .,由于胃肠道副作用，患者比安慰剂更有可能停用 semaglutide。,0.6,"['placebo', 'gastrointestinal', 'side effects', 'semaglutide', 'stop']","['placebo', 'gastrointestinal', 'side effects']",2433,"['患者更有可能因胃肠道副作用而停止半糖化物,而不是 placebo。']",0.4,"['placebo', 'gastrointestinal', 'side effects', 'semaglutide', 'stop']","['gastrointestinal', 'side effects']",,
2475,2434,men who consumed at least two servings per week had decreased risk for adenomas .,每周至少食用两份的男性患腺瘤的风险降低。,0.6,"['who', 'risk', 'week', 'at', 'two']","['risk', 'week', 'two']",2434,['每周至少服用两份食物的男性患有肾上腺炎的风险较低。'],0.6,"['who', 'risk', 'week', 'at', 'two']","['risk', 'week', 'two']",,
2476,2435,"yogurt consumption has been associated with lower colorectal cancer ( CRC ) risk , but its relation to polyp risk is unknown .",酸奶消费与较低的结直肠癌 (CRC) 风险有关，但它与息肉风险的关系尚不清楚。,0.5833333333333334,"['polyp', 'cancer', 'consumption', 'relation', 'colorectal cancer', 'lower', 'associated', 'risk', 'yogurt', 'with', 'but', 'to']","['polyp', 'cancer', 'consumption', 'relation', 'lower', 'risk', 'but']",2435,"['食用酸奶已与较低的染色性癌症(CRC)风险有关,但其与聚合物风险的关系尚不清楚。']",0.4166666666666667,"['polyp', 'cancer', 'consumption', 'relation', 'colorectal cancer', 'lower', 'associated', 'risk', 'yogurt', 'with', 'but', 'to']","['cancer', 'relation', 'lower', 'risk', 'but']",,
2477,2436,"the analyses were adjusted for demographic and lifestyle factors , and dietary information was updated every 4 years .",这些分析根据人口统计和生活方式因素进行了调整，并且每 4 年更新一次饮食信息。,0.25,"['information', 'dietary', '4', 'and']",['information'],2436,"['分析对人口和生活方式因素进行了调整,饮食信息每4年更新。']",0.25,"['information', 'dietary', '4', 'and']",['information'],,
2478,2437,"men who consumed ≥ 2 yogurt servings / week had significantly lower risk for conventional adenomas compared with nonconsumers ( adjusted odds ratio , 0.81 ) .",与不喝酸奶的人相比，每周喝 ≥ 2 份酸奶的男性患传统腺瘤的风险显着降低（调整后的比值比为 0.81）。,0.4,"['who', '2', 'ratio', '/', 'lower', 'risk', 'week', 'yogurt', 'with', 'odds']","['2', 'ratio', 'risk', 'week']",2437,"['男性每周服用 ≥ 2 份酸奶的食物,与非消费者相比,常规肾上腺炎的风险显著低(调整率比例为 0.81 )。']",0.4,"['who', '2', 'ratio', '/', 'lower', 'risk', 'week', 'yogurt', 'with', 'odds']","['2', 'ratio', 'risk', 'week']",,
2479,2438,"no association was seen for serrated lesions , except for large ( ≥ 1 cm ) lesions ( aOR , 0.48 ) .",除了大的（≥ 1 厘米）病变 (aOR，0.48) 外，锯齿状病变没有相关性。,0.1666666666666666,"['1', 'association', 'cm', 'large', 'serrated', 'no']",['1'],2438,"['除大( ≥ 1 厘米)的受伤外,没有见证的合并( aOR, 0.48 )。']",0.1666666666666666,"['1', 'association', 'cm', 'large', 'serrated', 'no']",['1'],,
2480,2439,"in women , there were no associations between yogurt consumption and either conventional adenomas or serrated lesions .",在女性中，酸奶消费与传统腺瘤或锯齿状病变之间没有关联。,0.1666666666666666,"['consumption', 'serrated', 'no', 'yogurt', 'in', 'and']",['consumption'],2439,"['在女性中,酸奶摄入和常规肾上腺炎或粘膜损伤之间没有任何联系。']",0.0,"['consumption', 'serrated', 'no', 'yogurt', 'in', 'and']",[],,
2481,2440,"yogurt may exert its beneficial effects in CRC prevention by a variety of mechanisms , including favorable microbiome alterations .",酸奶可以通过多种机制发挥其预防 CRC 的有益作用，包括有益的微生物组改变。,0.5,"['microbiome', 'a', 'variety', 'prevention', 'yogurt', 'in', 'by', 'exert']","['microbiome', 'prevention', 'by', 'exert']",2440,"['酸奶可以通过各种机制,包括有益的微生物变化,对CRC的预防产生有益的影响。']",0.25,"['microbiome', 'a', 'variety', 'prevention', 'yogurt', 'in', 'by', 'exert']","['prevention', 'by']",,
2482,2441,regular consumption of yogurt may be a marker of other healthy lifestyle factors that decrease the risk for CRC and its precursor lesions .,经常饮用酸奶可能是其他健康生活方式因素的标志，这些因素可降低 CRC 及其前期病变的风险。,0.1666666666666666,"['precursor', 'a', 'decrease', 'consumption', 'marker', 'be', 'regular', 'risk', 'yogurt', 'that', 'and', 'healthy']","['risk', 'healthy']",2441,"['定期食用酸奶可能是其他健康生活方式因素的标志,降低CRC和其先驱损伤的风险。']",0.1666666666666666,"['precursor', 'a', 'decrease', 'consumption', 'marker', 'be', 'regular', 'risk', 'yogurt', 'that', 'and', 'healthy']","['risk', 'healthy']",,
2483,2442,"the lack of benefits observed in women , however , is not clear .",然而，在女性身上观察到的益处不足尚不清楚。,0.0,"['lack', 'clear', 'in']",[],2442,"['然而,女性所看到的缺点并不明显。']",0.0,"['lack', 'clear', 'in']",[],,
2484,2443,"in any case , the regular consumption of yogurt is a reasonable recommendation to help decrease CRC risk , in addition to healthy eating habits , exercise , and avoidance of smoking .",无论如何，除了健康的饮食习惯、锻炼和避免吸烟之外，定期饮用酸奶是有助于降低 CRC 风险的合理建议。,0.2857142857142857,"['a', 'decrease', 'consumption', 'addition', 'exercise', 'regular', 'case', 'risk', 'yogurt', 'avoidance', 'eating habits', 'to', 'and', 'healthy']","['exercise', 'risk', 'to', 'healthy']",2443,"['在任何情况下,定期摄入酸奶是一种合理的建议,有助于降低CRC风险,除了健康的饮食习惯,锻炼,避免吸烟。']",0.2857142857142857,"['a', 'decrease', 'consumption', 'addition', 'exercise', 'regular', 'case', 'risk', 'yogurt', 'avoidance', 'eating habits', 'to', 'and', 'healthy']","['exercise', 'risk', 'to', 'healthy']",,
2485,2444,a new scoring system uses readily available demographic and laboratory data to identify patients with higher risk for advanced fibrosis .,一个新的评分系统使用现成的人口统计和实验室数据来识别晚期纤维化风险较高的患者。,0.5384615384615384,"['a', 'data', 'system', 'fibrosis', 'available', 'risk', 'advanced', 'laboratory', 'identify', 'scoring', 'with', 'and', 'new']","['data', 'system', 'fibrosis', 'risk', 'laboratory', 'identify', 'new']",2444,['一个新的分数系统使用易于使用的人口和实验室数据来识别患有较高的发病风险的患者。'],0.4615384615384615,"['a', 'data', 'system', 'fibrosis', 'available', 'risk', 'advanced', 'laboratory', 'identify', 'scoring', 'with', 'and', 'new']","['data', 'system', 'risk', 'laboratory', 'identify', 'new']",,
2486,2445,"these authors devised the Hepamet Fibrosis scoring system , a noninvasive system using readily available standard variables .",这些作者设计了 Hepamet Fibrosis 评分系统，这是一种使用现成标准变量的无创系统。,0.3333333333333333,"['standard', 'system', 'fibrosis', 'available', 'scoring', 'noninvasive']","['standard', 'system']",2445,"['这些作家设计了Hepamet Fibrosis评分系统,一个不侵入的系统,使用易于使用的标准变量。']",0.3333333333333333,"['standard', 'system', 'fibrosis', 'available', 'scoring', 'noninvasive']","['standard', 'system']",,
2487,2446,"in univariate analysis , they identified variables independently associated with advanced fibrosis and then employed multivariate analysis to develop their system that includes gender , age , homeostatic model assessment score , presence of diabetes , AST , albumin , and platelet count .",在单变量分析中，他们确定了与晚期纤维化独立相关的变量，然后采用多变量分析来开发他们的系统，其中包括性别、年龄、稳态模型评估分数、是否患有糖尿病、AST、白蛋白和血小板计数。,0.5416666666666666,"['presence', 'count', 'diabetes', 'albumin', 'model', 'analysis', 'system', 'fibrosis', 'AST', 'develop', 'associated', 'assessment', 'age', 'advanced', 'univariate', 'score', 'univariate analysis', 'multivariate analysis', 'with', 'platelet', 'that', 'to', 'and', 'employed']","['count', 'diabetes', 'albumin', 'model', 'analysis', 'system', 'fibrosis', 'assessment', 'age', 'score', 'univariate analysis', 'multivariate analysis', 'platelet']",2446,"['在单元分析中,他们确定了与先进纤维炎独立相关的变量,然后使用多元分析来开发他们的系统,其中包括性别、年龄、同性化模型评估分数、糖尿病的存在、AST、阿尔博丁和板块数。']",0.4166666666666667,"['presence', 'count', 'diabetes', 'albumin', 'model', 'analysis', 'system', 'fibrosis', 'AST', 'develop', 'associated', 'assessment', 'age', 'advanced', 'univariate', 'score', 'univariate analysis', 'multivariate analysis', 'with', 'platelet', 'that', 'to', 'and', 'employed']","['presence', 'diabetes', 'model', 'analysis', 'system', 'assessment', 'age', 'score', 'multivariate analysis', 'that']",,
2488,2447,this large study identified readily available demographic and laboratory data that allow primary care clinicians to identify patients with higher risk for advanced fibrosis .,这项大型研究确定了现成的人口统计和实验室数据，使初级保健临床医生能够识别晚期纤维化风险较高的患者。,0.3125,"['data', 'fibrosis', 'study', 'allow', 'large', 'primary', 'available', 'risk', 'advanced', 'laboratory', 'identify', 'care', 'with', 'this', 'that', 'and']","['data', 'fibrosis', 'risk', 'laboratory', 'identify']",2447,"['这项大型研究确定了易于可用的人口和实验室数据,使初级护理诊所能够识别患有较高的发病风险的患者。']",0.3125,"['data', 'fibrosis', 'study', 'allow', 'large', 'primary', 'available', 'risk', 'advanced', 'laboratory', 'identify', 'care', 'with', 'this', 'that', 'and']","['data', 'available', 'risk', 'laboratory', 'identify']",,
2489,2448,previous treatment for localized disease and previous docetaxel therapy were allowed .,允许既往接受过局部疾病治疗和既往接受过多西紫杉醇治疗。,0.5714285714285714,"['disease', 'previous', 'localized', 'therapy', 'treatment', 'docetaxel', 'and']","['disease', 'therapy', 'treatment', 'docetaxel']",2448,['已被允许对本地疾病的先前治疗和先前Docetaxel治疗。'],0.4285714285714285,"['disease', 'previous', 'localized', 'therapy', 'treatment', 'docetaxel', 'and']","['disease', 'therapy', 'treatment']",,
2490,2449,a total of 525 patients were assigned to receive apalutamide plus ADT and 527 to receive placebo plus ADT .,共有 525 名患者被分配接受阿帕他胺加 ADT，527 名患者接受安慰剂加 ADT。,0.5,"['placebo', 'plus', 'total', 'and']","['placebo', 'plus']",2449,"['共有525名患者被分配接受阿帕卢塔米德加上ADT,527人接受 placebo加上ADT。']",0.25,"['placebo', 'plus', 'total', 'and']",['plus'],,
2491,2450,the median age was 68 years .,中位年龄为 68 岁。,0.3333333333333333,"['median', 'age', 'median age']",['age'],2450,['平均年龄为68岁。'],0.3333333333333333,"['median', 'age', 'median age']",['age'],,
2492,2451,"overall survival at 24 months was also greater with apalutamide than with placebo ( 82.4 % in the apalutamide group vs. 73.5 % in the placebo group ; hazard ratio for death , 0.67 ; 95 % CI , 0.51 to 0.89 ; P = 0.005 ) .",24 个月时，apalutamide 的总生存率也高于安慰剂组（apalutamide 组为 82.4% vs. 安慰剂组为 73.5%；死亡风险比为 0.67；95% CI，0.51 至 0.89；P = 0.005）。,0.6363636363636364,"['group', 'placebo', 'survival', 'ratio', 'hazard ratio', 'death', 'with', 'P', 'CI', 'in', 'to']","['group', 'placebo', 'survival', 'ratio', 'hazard ratio', 'death', 'to']",2451,"['24个月的总生存率也比平板药物更高(平板药物群体的82.4%与平板药物群体的73.5%;死亡风险比例,0.67;95% CI,0.51到0.89;P=0.005)。']",0.4545454545454545,"['group', 'placebo', 'survival', 'ratio', 'hazard ratio', 'death', 'with', 'P', 'CI', 'in', 'to']","['group', 'survival', 'ratio', 'hazard ratio', 'death']",,
2493,2452,the frequency of grade 3 or 4 adverse events was 42.2 % in the apalutamide group and 40.8 % in the placebo group ; rash was more common in the apalutamide group .,3 级或 4 级不良事件的频率在阿帕鲁胺组为 42.2%，在安慰剂组为 40.8%；皮疹在阿帕他胺组更常见。,0.2727272727272727,"['group', 'frequency', 'placebo', 'grade', 'rash', 'common', 'adverse', '3', '4', 'in', 'and']","['group', 'frequency', 'placebo']",2452,['3级或4级不良事件的发病率在 apalutamide 群体中为 42.2% 和 placebo 群体中为 40.8%;在 apalutamide 群体中发病率更为常见。'],0.0909090909090909,"['group', 'frequency', 'placebo', 'grade', 'rash', 'common', 'adverse', '3', '4', 'in', 'and']",['group'],,
2494,2453,"however , patient age , coexisting conditions , extent of disease , and preferences may affect decisions to initiate chemotherapy such as docetaxel.8,9","然而，患者年龄、合并症、疾病程度和偏好可能会影响开始化疗（如多西紫杉醇）的决定。 8,9",0.6666666666666666,"['chemotherapy', 'disease', 'affect', 'age', 'patient', 'of disease', 'extent', 'to', 'and']","['chemotherapy', 'disease', 'affect', 'age', 'patient', 'and']",2453,"['然而,患者的年龄、共同存在条件、疾病程度和偏好可能会影响开始化疗的决定,如docetaxel。']",0.6666666666666666,"['chemotherapy', 'disease', 'affect', 'age', 'patient', 'of disease', 'extent', 'to', 'and']","['chemotherapy', 'disease', 'affect', 'age', 'patient', 'and']",,
2495,2454,treatment with abiraterone acetate requires coadministration of prednisone to prevent increases in corticotropin and may cause adverse events related to mineralocorticoid excess and liver toxicity .,用醋酸阿比特龙治疗需要同时给予泼尼松以防止促肾上腺皮质激素增加，并可能导致与盐皮质激素过量和肝毒性相关的不良事件。,0.5384615384615384,"['liver', 'excess', 'toxicity', 'acetate', 'corticotropin', 'prednisone', 'adverse', 'treatment', 'cause', 'increases', 'with', 'prevent', 'and']","['liver', 'excess', 'toxicity', 'acetate', 'corticotropin', 'prednisone', 'treatment']",2454,"['使用阿比拉特龙酸素的治疗需要与<unk>剂一起服用,以防止<unk>素的增加,并可能导致与矿物质<unk>素过剩和肝脏毒性相关的不良事件。']",0.3076923076923077,"['liver', 'excess', 'toxicity', 'acetate', 'corticotropin', 'prednisone', 'adverse', 'treatment', 'cause', 'increases', 'with', 'prevent', 'and']","['liver', 'excess', 'toxicity', 'treatment']",,
2496,2455,"direct inhibition of the androgen receptor in addition to ADT may provide more a complete blockade of androgen signaling than ADT alone , leading to improved patient outcomes .",除了 ADT 外，直接抑制雄激素受体可能比单独使用 ADT 更能完全阻断雄激素信号，从而改善患者的预后。,0.4545454545454545,"['receptor', 'inhibition', 'a', 'addition', 'complete', 'patient', 'blockade', 'leading', 'direct', 'androgen', 'alone']","['receptor', 'inhibition', 'patient', 'direct', 'alone']",2455,"['除了ADT之外,直接抑制 androgen receptor 还可以提供更全面的 androgen 信号封锁,而不是单独的ADT,导致患者的结果得到改善。']",0.3636363636363636,"['receptor', 'inhibition', 'a', 'addition', 'complete', 'patient', 'blockade', 'leading', 'direct', 'androgen', 'alone']","['inhibition', 'patient', 'direct', 'alone']",,
2497,2456,trial DESIGN AND CONDUCT,试验设计和实施,0.0,['trial'],[],2456,['审判设计与驾驶'],1.0,['trial'],['trial'],,
2498,2457,the protocol and the statistical analysis plan are available with the full text of this article at NEJM.org .,该方案和统计分析计划与本文全文可在 NEJM.org 上获取。,0.2,"['analysis', 'protocol', 'article', 'available', 'text', 'statistical analysis', 'with', 'full', 'this', 'and']","['analysis', 'statistical analysis']",2457,['该协议和统计分析计划与本文的完整文本在NEJM.org上可用。'],0.4,"['analysis', 'protocol', 'article', 'available', 'text', 'statistical analysis', 'with', 'full', 'this', 'and']","['analysis', 'protocol', 'statistical analysis', 'full']",,
2499,2458,"review boards at all participating institutions approved the trial , which was conducted in accordance with current International Conference on Harmonisation guidelines for Good Clinical Practice and according to Declaration of Helsinki principles .",所有参与机构的审查委员会都批准了该试验，该试验是根据当前国际协调会议良好临床实践指南和赫尔辛基宣言原则进行的。,0.2,"['review', 'good clinical practice', 'trial', 'current', 'with', 'at', 'on', 'all', 'to', 'and']","['review', 'at']",2458,"['所有参与机构的审查委员会批准了这项试验,该试验按照当前国际临床实践协调指导方针会议和赫尔辛基原则宣言进行。']",0.2,"['review', 'good clinical practice', 'trial', 'current', 'with', 'at', 'on', 'all', 'to', 'and']","['review', 'at']",,
2500,2459,"patients underwent randomization between December 15 , 2015 , and July 25 , 2017 .",患者在 2015 年 12 月 15 日至 2017 年 7 月 25 日期间被随机分组。,1.0,['randomization'],['randomization'],2459,['患者在2015年12月15日至2017年7月25日之间经历了随机化。'],1.0,['randomization'],['randomization'],,
2501,2460,all the authors assume responsibility for the completeness and accuracy of the data and analyses and for the fidelity of the trial to the protocol .,所有作者均对数据和分析的完整性和准确性以及试验对方案的忠实度负责。,0.3333333333333333,"['fidelity', 'data', 'accuracy', 'protocol', 'responsibility', 'trial', 'completeness', 'all', 'and']","['data', 'accuracy', 'completeness']",2460,['所有作者对数据和分析的完整性和准确性以及审判对议定书的忠诚性承担责任。'],0.6666666666666666,"['fidelity', 'data', 'accuracy', 'protocol', 'responsibility', 'trial', 'completeness', 'all', 'and']","['data', 'accuracy', 'protocol', 'responsibility', 'trial', 'completeness']",,
2502,2461,the first author developed the first draft of the manuscript with editorial assistance funded by Janssen Research and Development .,第一作者在 Janssen Research and Development 资助的编辑协助下起草了手稿的初稿。,0.25,"['research and development', 'author', 'manuscript', 'assistance', 'with', 'by', 'first', 'draft']","['manuscript', 'first']",2461,"['第一位作者开发了手稿的第一个草案,由Janssen Research and Development资助的编辑援助。']",0.5,"['research and development', 'author', 'manuscript', 'assistance', 'with', 'by', 'first', 'draft']","['manuscript', 'assistance', 'by', 'first']",,
2503,2462,"all the authors had full access to the data , participated in data interpretation , and reviewed and approved the manuscript before submission .",所有作者都可以完全访问数据，参与数据解释，并在投稿前审阅并批准了手稿。,0.4,"['data', 'access', 'interpretation', 'manuscript', 'submission', 'full', 'all', 'before', 'to', 'and']","['data', 'interpretation', 'manuscript', 'before']",2462,"['所有作者都完全访问了数据,参与了数据的解释,并在提交之前审查并批准了手稿。']",0.4,"['data', 'access', 'interpretation', 'manuscript', 'submission', 'full', 'all', 'before', 'to', 'and']","['data', 'interpretation', 'manuscript', 'before']",,
2504,2463,"patients were castration sensitive ( i.e. , patients were not receiving ADT at the time of disease progression11,12 ) .","患者对去势敏感（即患者在疾病进展时未接受 ADT11,12）。",0.6,"['castration', 'disease', 'time', 'of disease', 'sensitive']","['castration', 'disease', 'time']",2463,['病人对催化敏感(即病人在疾病进展时不接受ADT11、12)。'],0.4,"['castration', 'disease', 'time', 'of disease', 'sensitive']","['disease', 'time']",,
2505,2464,antiandrogen therapy must have been discontinued before randomization .,随机分组前必须停止抗雄激素治疗。,0.6,"['must', 'randomization', 'therapy', 'have', 'before']","['randomization', 'therapy', 'before']",2464,['抗 androgen 治疗必须在随机化之前停止。'],0.6,"['must', 'randomization', 'therapy', 'have', 'before']","['randomization', 'therapy', 'before']",,
2506,2465,"patients with severe angina , myocardial infarction , congestive heart failure , arterial or venous thromboembolic events , a history of or predisposition to seizure , or recent ventricular arrhythmias were excluded .",患有严重心绞痛、心肌梗塞、充血性心力衰竭、动脉或静脉血栓栓塞事件、癫痫病史或癫痫倾向或近期室性心律失常的患者被排除在外。,0.5294117647058824,"['heart', 'myocardial infarction', 'predisposition', 'failure', 'recent', 'venous', 'angina', 'history', 'thromboembolic', 'heart failure', 'seizure', 'ventricular', 'congestive', 'arrhythmias', 'with', 'severe', 'congestive heart failure']","['heart', 'myocardial infarction', 'predisposition', 'failure', 'angina', 'heart failure', 'seizure', 'arrhythmias', 'congestive heart failure']",2465,['患有严重的腹泻、心脏病发作、心脏衰竭、血管或血管血管肿瘤事件、历史或倾向于入侵或最近的阴道动脉炎的患者被排除。'],0.2941176470588235,"['heart', 'myocardial infarction', 'predisposition', 'failure', 'recent', 'venous', 'angina', 'history', 'thromboembolic', 'heart failure', 'seizure', 'ventricular', 'congestive', 'arrhythmias', 'with', 'severe', 'congestive heart failure']","['heart', 'predisposition', 'failure', 'history', 'seizure']",,
2507,2466,"patients were randomly assigned in a 1 : 1 ratio to receive apalutamide ( 240 mg ) or matched placebo administered orally once daily , in addition to continuous ADT .",患者以 1:1 的比例被随机分配，除连续 ADT 外，每天口服一次阿帕他胺 (240 mg) 或匹配的安慰剂。,0.6666666666666666,"['placebo', '1', 'ratio', 'continuous', 'addition', 'to']","['placebo', '1', 'ratio', 'continuous']",2466,"['病人随机分配在1:1的比例接受阿帕卢塔米德(240毫克)或相匹配的 placebo 口服服一次,除了持续的ADT。']",0.3333333333333333,"['placebo', '1', 'ratio', 'continuous', 'addition', 'to']","['1', 'ratio']",,
2508,2467,overall survival was defined as the time from randomization to the date of death from any cause .,总生存期定义为从随机分组到因任何原因死亡的时间。,0.5555555555555556,"['defined', 'randomization', 'survival', 'death', 'date', 'time', 'cause', 'as', 'to']","['randomization', 'survival', 'death', 'time', 'cause']",2467,['总生存被定义为从随机化到任何原因死亡的日期。'],0.5555555555555556,"['defined', 'randomization', 'survival', 'death', 'date', 'time', 'cause', 'as', 'to']","['randomization', 'survival', 'death', 'date', 'cause']",,
2509,2468,"definitions of secondary and exploratory end points are provided in the Methods section in the Supplementary Appendix , available at NEJM.org .",补充附录的方法部分提供了次要终点和探索性终点的定义，补充附录可在 NEJM.org 获取。,0.125,"['appendix', 'section', 'supplementary', 'end points', 'exploratory', 'available', 'secondary', 'and']",['end points'],2468,"['二级和探险终点的定义在补充附件中的方法部分中提供,可在NEJM.org上找到。']",0.375,"['appendix', 'section', 'supplementary', 'end points', 'exploratory', 'available', 'secondary', 'and']","['appendix', 'end points', 'exploratory']",,
2510,2469,"patients were assessed for efficacy according to modified Response Evaluation Criteria in Solid Tumors , version 1.1 , with the use of CT or MRI of the chest , abdomen , and pelvis during screening ( ≤ 6 weeks before randomization ) and according to Prostate Cancer Working Group 2 criteria18 ( see the Methods section in the Supplementary Appendix ) with the use of bone scanning during cycles 3 and 5 and every fourth cycle thereafter .",根据修改后的实体瘤反应评估标准 1.1 版，在筛查期间（随机分组前 ≤ 6 周）使用胸部、腹部和骨盆的 CT 或 MRI 并根据前列腺癌工作组 2 评估患者的疗效标准 18（见补充附录中的方法部分）在第 3 和第 5 周期以及此后每四个周期使用骨扫描。,0.4827586206896552,"['group', 'bone', 'abdomen', 'pelvis', '5', 'cancer', 'appendix', 'randomization', 'chest', '2', 'section', 'prostate cancer', 'screening', 'evaluation', 'version', 'supplementary', 'cycle', 'solid', 'MRI', 'response', 'scanning', 'efficacy', '3', 'CT', 'with', 'evaluation criteria', 'before', 'to', 'assessed']","['group', 'bone', 'abdomen', 'pelvis', '5', 'cancer', 'randomization', 'chest', '2', 'prostate cancer', 'screening', 'cycle', 'response', 'before']",2469,"['患者根据修正的反应评估标准在固体肿瘤,版本 1.1,使用CT或MRI的乳房,腹部和阴道在筛查期间( ≤ 6 周之前的随机化 )和根据前列腺癌工作组 2 标准18(参见补充附件中的方法部分 )使用骨扫描在周期 3 和 5 和每个周期之后。']",0.5172413793103449,"['group', 'bone', 'abdomen', 'pelvis', '5', 'cancer', 'appendix', 'randomization', 'chest', '2', 'section', 'prostate cancer', 'screening', 'evaluation', 'version', 'supplementary', 'cycle', 'solid', 'MRI', 'response', 'scanning', 'efficacy', '3', 'CT', 'with', 'evaluation criteria', 'before', 'to', 'assessed']","['group', 'bone', 'abdomen', '5', 'cancer', 'appendix', 'randomization', '2', 'prostate cancer', 'screening', 'version', 'cycle', 'solid', 'response', 'before']",,
2511,2470,events of progression were assessed by the investigator .,进展事件由研究者评估。,0.75,"['investigator', 'progression', 'by', 'assessed']","['investigator', 'progression', 'by']",2470,['进展事件由调查人员评估。'],0.5,"['investigator', 'progression', 'by', 'assessed']","['progression', 'by']",,
2512,2471,scans from approximately 60 % of the patients were randomly selected for independent central review .,随机选择大约 60% 患者的扫描进行独立集中审查。,0.25,"['review', 'central', 'independent', 'approximately']",['review'],2471,['大约60%的病人随机被选为独立的中心审查。'],0.5,"['review', 'central', 'independent', 'approximately']","['review', 'independent']",,
2513,2472,"adverse events were assessed monthly and graded according to National Cancer Institute Common Terminology Criteria for Adverse Events , version 4.0.3 .",不良事件每月评估一次，并根据美国国家癌症研究所不良事件通用术语标准 4.0.3 版进行分级。,0.3,"['cancer', 'version', 'monthly', 'common', 'adverse', 'terminology', 'institute', 'to', 'and', 'assessed']","['cancer', 'terminology', 'institute']",2472,"['每月对不良事件进行评估,并根据国家癌症研究所(National Cancer Institute)对不良事件的常用术语标准,版本 4.0.3 进行评估。']",0.4,"['cancer', 'version', 'monthly', 'common', 'adverse', 'terminology', 'institute', 'to', 'and', 'assessed']","['cancer', 'version', 'terminology', 'institute']",,
2514,2473,the TITAN trial was designed to enroll approximately 1000 patients .,TITAN 试验旨在招募大约 1000 名患者。,0.0,"['trial', 'approximately', 'to']",[],2473,['该TITAN试验旨在招生大约1000名患者。'],0.0,"['trial', 'approximately', 'to']",[],,
2515,2474,"if the difference between the apalutamide group and the placebo group was considered to be statistically significant , the alpha was recycled to overall survival on the basis of the fallback method.19",如果apalutamide组和安慰剂组之间的差异被认为具有统计学显着性，则在回退方法的基础上将alpha循环到总生存期。 19,0.5,"['group', 'placebo', 'survival', 'basis', 'alpha', 'difference', 'be', 'on', 'to', 'and']","['group', 'placebo', 'survival', 'difference', 'be']",2474,"['如果 apalutamide 和 placebo 组之间的差异被认为是统计上显著的,则根据下跌方法将 alpha 重新回收到整体生存。']",0.3,"['group', 'placebo', 'survival', 'basis', 'alpha', 'difference', 'be', 'on', 'to', 'and']","['group', 'survival', 'difference']",,
2516,2475,an overall type I error of 5 % was planned .,计划的总体 I 类错误为 5%。,0.5,"['type', '5', 'error', 'I']","['5', 'error']",2475,['总体类型 I 错误为 5% 已计划。'],0.75,"['type', '5', 'error', 'I']","['type', '5', 'error']",,
2517,2476,two interim analyses were planned for overall survival .,计划对总生存期进行两项中期分析。,1.0,"['survival', 'two']","['survival', 'two']",2476,['兩個暫時分析為整體生存計劃。'],0.5,"['survival', 'two']",['survival'],,
2518,2477,subgroup analyses were prespecified to assess consistency of treatment effect .,预先指定亚组分析以评估治疗效果的一致性。,0.7142857142857143,"['consistency', 'treatment', 'effect', 'assess', 'treatment effect', 'subgroup', 'to']","['consistency', 'treatment', 'effect', 'assess', 'treatment effect']",2477,['子组分析被预定以评估治疗效果的一致性。'],0.7142857142857143,"['consistency', 'treatment', 'effect', 'assess', 'treatment effect', 'subgroup', 'to']","['consistency', 'treatment', 'effect', 'assess', 'treatment effect']",,
2519,2478,demographic and clinical characteristics at baseline were summarized with the use of descriptive statistics .,使用描述性统计总结了基线时的人口统计学和临床特征。,0.625,"['statistics', 'descriptive', 'baseline', 'clinical', 'characteristics', 'descriptive statistics', 'with', 'and']","['statistics', 'descriptive', 'baseline', 'clinical', 'characteristics']",2478,['基线上的人口和临床特征是用描述统计来总结的。'],0.5,"['statistics', 'descriptive', 'baseline', 'clinical', 'characteristics', 'descriptive statistics', 'with', 'and']","['statistics', 'baseline', 'clinical', 'characteristics']",,
2520,2479,"the median number of cycles received was 23 for apalutamide and 19 for placebo ( range , 1 to 37 in each group ) .",apalutamide 接受的周期中位数为 23，安慰剂为 19（范围，每组 1 至 37）。,0.5,"['group', 'median', 'placebo', 'range', '1', 'number', 'each', 'in', 'to', 'and']","['group', 'placebo', 'range', '1', 'number']",2479,['接收的平均周期为23个为apalutamide和19个为 placebo(范围为1至37个每个组)。'],0.3,"['group', 'median', 'placebo', 'range', '1', 'number', 'each', 'in', 'to', 'and']","['group', 'range', '1']",,
2521,2480,the median duration of the trial intervention was 20.5 months for apalutamide and 18.3 months for placebo .,试验干预的中位持续时间对于 apalutamide 为 20.5 个月，对于安慰剂为 18.3 个月。,0.3333333333333333,"['median', 'placebo', 'intervention', 'trial', 'duration', 'and']","['placebo', 'duration']",2480,"['试验干预的平均持续时间为20,5个月,阿帕卢塔米德的平均时间为183个月。']",0.1666666666666666,"['median', 'placebo', 'intervention', 'trial', 'duration', 'and']",['duration'],,
2522,2481,a total of 66.2 % of the patients in the apalutamide group and 46.1 % of those in the placebo group were receiving the trial intervention at the clinical cutoff date .,共有 66.2% 的阿帕他胺组患者和 46.1% 的安慰剂组患者在临床截止日期接受了试验干预。,0.4444444444444444,"['group', 'cutoff', 'placebo', 'date', 'total', 'clinical', 'intervention', 'trial', 'and']","['group', 'placebo', 'date', 'clinical']",2481,['总共66.2%的阿帕卢塔米德群体患者和46.1%的 placebo群体患者在临床截止日期接受了试验干预。'],0.3333333333333333,"['group', 'cutoff', 'placebo', 'date', 'total', 'clinical', 'intervention', 'trial', 'and']","['group', 'date', 'clinical']",,
2523,2482,"these patients were followed for survival and secondary end points , so their data were not missing .",对这些患者的生存期和次要终点进行了随访，因此他们的数据没有丢失。,0.4285714285714285,"['data', 'survival', 'end points', 'secondary', 'so', 'and', 'missing']","['data', 'survival', 'end points']",2482,"['这些病人被追踪为生存和次要终点,所以他们的数据没有错过。']",0.4285714285714285,"['data', 'survival', 'end points', 'secondary', 'so', 'and', 'missing']","['data', 'survival', 'end points']",,
2524,2483,"demographic and clinical characteristics at baseline were well balanced ( Table 1 , and Table S1 in the Supplementary Appendix ) .",基线时的人口统计学和临床特征得到很好的平衡（表 1 和补充附录中的表 S1）。,0.4545454545454545,"['appendix', 'table', 'baseline', '1', 'supplementary', 'well', 'clinical', 'characteristics', 'at', 'S1', 'and']","['table', 'baseline', '1', 'clinical', 'characteristics']",2483,['基层的人口和临床特征均衡良好(附件中的表1和表S1)。'],0.4545454545454545,"['appendix', 'table', 'baseline', '1', 'supplementary', 'well', 'clinical', 'characteristics', 'at', 'S1', 'and']","['appendix', 'table', '1', 'clinical', 'characteristics']",,
2525,2484,the median age of the patients across both groups was 68 years .,两组患者的中位年龄为 68 岁。,0.25,"['median', 'across', 'age', 'median age']",['age'],2484,['两组患者的平均年龄为68岁。'],0.25,"['median', 'across', 'age', 'median age']",['age'],,
2526,2485,previous therapies for prostate cancer are listed in Table S2 in the Supplementary Appendix .,既往的前列腺癌治疗见补充附录表 S2。,0.375,"['cancer', 'appendix', 'table', 'prostate cancer', 'previous', 'supplementary', 'S2', 'in']","['cancer', 'table', 'prostate cancer']",2485,['前列前列前列前列前列前列前列前列前列前列前列前列前列前列前列前列前列前列前列前列前列前列前列'],0.0,"['cancer', 'appendix', 'table', 'prostate cancer', 'previous', 'supplementary', 'S2', 'in']",[],,
2527,2486,a total of 365 events of radiographic progression were observed ( 134 in the apalutamide group and 231 in the placebo group ) .,总共观察到 365 起影像学进展事件（apalutamide 组 134 起，安慰剂组 231 起）。,0.4285714285714285,"['group', 'placebo', 'radiographic', 'total', 'progression', 'in', 'and']","['group', 'placebo', 'progression']",2486,['共观察到365个放射性进展事件(134个在阿帕卢塔米德群体和231个在 placebo群体)。'],0.2857142857142857,"['group', 'placebo', 'radiographic', 'total', 'progression', 'in', 'and']","['group', 'progression']",,
2528,2487,"blinded independent central imaging review confirmed investigator assessment of radiographic progression ( concordance , 84.5 % ) .",盲法独立中央影像审查证实了研究者对影像学进展的评估（一致性，84.5%）。,0.5555555555555556,"['review', 'investigator', 'concordance', 'radiographic', 'central', 'assessment', 'progression', 'independent', 'imaging']","['review', 'investigator', 'concordance', 'assessment', 'progression']",2487,"['盲目独立的中央图像审查证实了研究人员对放射进展的评估(一致性,84.5%)。']",0.5555555555555556,"['review', 'investigator', 'concordance', 'radiographic', 'central', 'assessment', 'progression', 'independent', 'imaging']","['review', 'concordance', 'assessment', 'progression', 'independent']",,
2529,2488,overall Survival,总生存期,1.0,['survival'],['survival'],2488,['总体生存'],1.0,['survival'],['survival'],,
2530,2489,the first interim analysis for overall survival occurred after 200 deaths were observed ( 83 in the apalutamide group and 117 in the placebo group ) .,在观察到 200 例死亡（apalutamide 组 83 例，安慰剂组 117 例）后，对总生存期进行了首次中期分析。,0.625,"['group', 'placebo', 'analysis', 'survival', 'after', 'in', 'and', 'first']","['group', 'placebo', 'analysis', 'survival', 'after']",2489,"['总生存的第一次临时分析发生在200人死亡(阿帕卢塔米德群体83人, placebo群体117人)之后。']",0.625,"['group', 'placebo', 'analysis', 'survival', 'after', 'in', 'and', 'first']","['group', 'analysis', 'survival', 'after', 'first']",,
2531,2490,"the overall survival percentage at 24 months was 82.4 % in the apalutamide group and 73.5 % in the placebo group ( hazard ratio for death , 0.67 ; 95 % CI , 0.51 to 0.89 ; P = 0.005 ) , and there was a 33 % lower risk of death in the apalutamide group ( Figure 2A ) .",24个月的总生存率在apalutamide组和安慰剂组分别为82.4 %和73.5 %（死亡风险比，0.67；95 % CI，0.51至0.89；P = 0.005），风险降低33 %阿帕他胺组的死亡人数（图 2A）。,0.4666666666666667,"['group', 'percentage', 'placebo', 'survival', 'ratio', 'hazard ratio', 'death', 'figure', 'lower', 'risk', 'P', 'CI', 'in', 'to', 'and']","['group', 'placebo', 'survival', 'ratio', 'hazard ratio', 'death', 'risk']",2490,"['24个月的总生存率为 apalutamide 群体的 82.4% 和 placebo 群体的 73.5% (死亡风险比例, 0.67 ; 95 % CI, 0.51 至 0.89 ; P = 0.005 ),并且在 apalutamide 群体中死亡风险低于 33% ( 图 2A ) 。']",0.4666666666666667,"['group', 'percentage', 'placebo', 'survival', 'ratio', 'hazard ratio', 'death', 'figure', 'lower', 'risk', 'P', 'CI', 'in', 'to', 'and']","['group', 'survival', 'ratio', 'hazard ratio', 'death', 'risk', 'to']",,
2532,2491,"the treatment effect on overall survival consistently favored apalutamide over placebo , with no significant difference in the effect of apalutamide according to disease volume ( Figure 2B ) .",对总生存期的治疗效果始终优于安慰剂，阿帕他胺的效果根据疾病体积没有显着差异（图 2B）。,0.5625,"['volume', 'placebo', 'disease', 'survival', 'figure', 'difference', 'treatment', 'no', 'effect', 'treatment effect', 'with', 'significant difference', 'on', 'in', 'over', 'to']","['volume', 'placebo', 'disease', 'survival', 'difference', 'treatment', 'effect', 'treatment effect', 'to']",2491,"['治疗对总体生存的影响,阿帕卢塔米德连续受益于 placebo,根据疾病量,阿帕卢塔米德的影响没有显著差异(图2B)。']",0.3125,"['volume', 'placebo', 'disease', 'survival', 'figure', 'difference', 'treatment', 'no', 'effect', 'treatment effect', 'with', 'significant difference', 'on', 'in', 'over', 'to']","['disease', 'survival', 'difference', 'treatment', 'to']",,
2533,2492,other CLINICALLY RELEVANT END POINTS,其他临床相关终点,,[],[],2492,['其他临床相关终点'],,[],[],,
2534,2493,a total of 87 patients in the apalutamide group and 190 in the placebo group received subsequent treatment for prostate cancer ( first subsequent therapies are shown in Table S3 in the Supplementary Appendix ) .,共有 87 名阿帕他胺组患者和 190 名安慰剂组患者接受了前列腺癌的后续治疗（首次后续治疗见补充附录表 S3）。,0.4285714285714285,"['group', 'placebo', 'cancer', 'appendix', 'table', 'prostate cancer', 'supplementary', 'total', 'treatment', 'subsequent', 'S3', 'in', 'and', 'first']","['group', 'placebo', 'cancer', 'table', 'prostate cancer', 'treatment']",2493,['总共有87名阿帕洛塔米德病人和190名 placebo病人接受了前列腺癌的后续治疗(第一次后续治疗在附件中的S3表中显示)。'],0.4285714285714285,"['group', 'placebo', 'cancer', 'appendix', 'table', 'prostate cancer', 'supplementary', 'total', 'treatment', 'subsequent', 'S3', 'in', 'and', 'first']","['cancer', 'appendix', 'table', 'prostate cancer', 'treatment', 'first']",,
2535,2494,there were few events of symptomatic local progression and no substantial difference between the two groups in the time to symptomatic local progression ( Table 2 ) .,有症状的局部进展事件很少，两组之间在有症状的局部进展的时间上没有实质性差异（表 2）。,0.6666666666666666,"['table', '2', 'difference', 'time', 'local', 'no', 'progression', 'symptomatic', 'in', 'and', 'substantial', 'two']","['table', '2', 'difference', 'time', 'local', 'progression', 'symptomatic', 'two']",2494,"['有很少的症状局部进展事件,并且在症状局部进展时,两组之间没有显著的差异(图2)。']",0.5,"['table', '2', 'difference', 'time', 'local', 'no', 'progression', 'symptomatic', 'in', 'and', 'substantial', 'two']","['2', 'difference', 'time', 'local', 'progression', 'two']",,
2536,2495,"Table 3 presents a summary of adverse events , and Table 4 shows the most common adverse events of any cause that occurred from the time of the first dose of the trial intervention through 30 days after the last dose .",表 3 总结了不良事件，表 4 显示了从第一次试验干预开始到最后一次给药后 30 天发生的最常见的任何原因的不良事件。,0.2666666666666666,"['a', 'table', 'time', 'common', 'adverse', 'cause', 'intervention', 'after', 'trial', '3', '4', 'dose', 'that', 'and', 'first']","['table', 'cause', 'after', 'first']",2495,"['图3显示了副作用的概述,图4显示了从试验干预的第一次剂量到最后剂量后30天发生的任何原因最常见的副作用。']",0.2666666666666666,"['a', 'table', 'time', 'common', 'adverse', 'cause', 'intervention', 'after', 'trial', '3', '4', 'dose', 'that', 'and', 'first']","['cause', 'after', 'dose', 'first']",,
2537,2496,frequencies of grade 3 or 4 events ( 42.2 % in the apalutamide group and 40.8 % in the placebo group ) and of serious adverse events ( 19.8 % in the apalutamide group and 20.3 % in the placebo group ) did not differ substantially between the two groups .,3级或4级事件（apalutamide组为42.2 %，安慰剂组为40.8 %）和严重不良事件（apalutamide组为19.8 %，安慰剂组为20.3 %）的频率在两组之间没有显着差异。 .,0.2727272727272727,"['group', 'placebo', 'grade', 'adverse', 'differ', '3', '4', 'serious', 'in', 'and', 'two']","['group', 'placebo', 'two']",2496,['3级或4级事件的频率( apalutamide 组中的 42.2 % 和 placebo 组中的 40.8 % )以及严重的副作用( apalutamide 组中的 19.8 % 和 placebo 组中的 20.3 % )在两组之间没有显著的差异。'],0.1818181818181818,"['group', 'placebo', 'grade', 'adverse', 'differ', '3', '4', 'serious', 'in', 'and', 'two']","['group', 'two']",,
2538,2497,adverse events led to discontinuation in 42 patients ( 8.0 % ) in the apalutamide group and 28 ( 5.3 % ) in the placebo group ( Table S4 in the Supplementary Appendix ) .,不良事件导致阿帕他胺组 42 名患者 (8.0%) 和安慰剂组 28 名 (5.3%) 患者停药（补充附录表 S4）。,0.2727272727272727,"['group', 'placebo', 'appendix', 'table', 'supplementary', 'adverse', 'S4', 'in', 'to', 'and', 'led']","['group', 'placebo', 'table']",2497,['副作用导致42名患者(8.0%)在阿帕卢塔米德群体和28名患者(5.3%)在 placebo群体中停止(附件中的S4表)。'],0.2727272727272727,"['group', 'placebo', 'appendix', 'table', 'supplementary', 'adverse', 'S4', 'in', 'to', 'and', 'led']","['group', 'appendix', 'table']",,
2539,2498,a total of 10 patients ( 1.9 % ) in the apalutamide group and 16 ( 3.0 % ) in the placebo group died as the result of an adverse event ( Table S5 in the Supplementary Appendix ) .,阿帕他胺组共有 10 名患者 (1.9%) 和安慰剂组有 16 名 (3.0%) 患者死于不良事件（补充附录表 S5）。,0.3333333333333333,"['group', 'placebo', 'appendix', 'table', 'supplementary', 'total', 'adverse', 'adverse event', 'result', 'as', 'in', 'and']","['group', 'placebo', 'table', 'adverse event']",2498,['总共10名患者(1.9%)在阿帕卢塔米德群体和16名患者(3.0%)在 placebo群体死于副作用(附件中的S5表)。'],0.25,"['group', 'placebo', 'appendix', 'table', 'supplementary', 'total', 'adverse', 'adverse event', 'result', 'as', 'in', 'and']","['group', 'appendix', 'table']",,
2540,2499,"rash of any grade was more common among patients who received apalutamide than among those who received placebo ( 27.1 % vs. 8.5 % ) ( Table 4 ) , and the most common adverse event of grade 3 or higher that was considered by the investigator to be related to apalutamide was rash of any type ( 6.3 % ) .",任何级别的皮疹在接受阿帕他胺的患者中比接受安慰剂的患者更常见（ 27.1 % 对 8.5 % ）（表 4） ，并且研究者认为最常见的 3 级或更高级别的不良事件是与 apalutamide 相关的是任何类型的皮疹 (6.3%)。,0.375,"['type', 'placebo', 'table', 'who', 'investigator', 'grade', 'rash', 'be', 'common', 'adverse', 'adverse event', '3', '4', 'that', 'by', 'and']","['type', 'placebo', 'table', 'investigator', 'be', 'adverse event']",2499,"['任何程度的发作在接受阿帕卢塔米德的患者中更为常见,而在接受 placebo 的患者中( 27.1 % 与 8.5 % )(图 4 ),并且研究人员认为与阿帕卢塔米德相关的3级或更高的最常见的副作用是任何类型的发作( 6.3 % )。']",0.25,"['type', 'placebo', 'table', 'who', 'investigator', 'grade', 'rash', 'be', 'common', 'adverse', 'adverse event', '3', '4', 'that', 'by', 'and']","['type', 'grade', 'be', 'and']",,
2541,2500,hypothyroidism was reported by 6.5 % of the patients in the apalutamide group and 1.1 % of those in the placebo group ( Table 4 ) ; all events were grade 1 or 2 .,阿帕他胺组 6.5% 的患者和安慰剂组 1.1% 的患者报告了甲状腺功能减退症（表 4）；所有事件均为 1 级或 2 级。,0.5,"['group', 'placebo', 'table', '1', '2', 'grade', 'hypothyroidism', '4', 'all', 'in', 'by', 'and']","['group', 'placebo', 'table', '1', '2', 'hypothyroidism']",2500,['甲状腺甲状腺炎被报告为阿帕卢塔米德群体的患者的6.5%和 placebo群体的患者的1.1%(图4);所有事件都是1级或2级。'],0.25,"['group', 'placebo', 'table', '1', '2', 'grade', 'hypothyroidism', '4', 'all', 'in', 'by', 'and']","['group', '1', '2']",,
2542,2501,ischemic heart disease was reported in 4.4 % of the patients in the apalutamide group and 1.5 % of those in the placebo group ; ischemic events led to death in two patients in each group .,阿帕鲁胺组 4.4% 的患者和安慰剂组 1.5% 的患者报告了缺血性心脏病；每组中有两名患者因缺血事件而死亡。,0.6923076923076923,"['group', 'heart', 'placebo', 'disease', 'heart disease', 'death', 'ischemic heart disease', 'each', 'in', 'to', 'and', 'two', 'led']","['group', 'heart', 'placebo', 'disease', 'heart disease', 'death', 'ischemic heart disease', 'and', 'two']",2501,['伊斯基米心脏病被报告在 apalutamide 群体中的 4.4% 和 placebo 群体中的 1.5 % 患者中; 伊斯基米事件导致每个群体中的 2 名患者死亡。'],0.3846153846153846,"['group', 'heart', 'placebo', 'disease', 'heart disease', 'death', 'ischemic heart disease', 'each', 'in', 'to', 'and', 'two', 'led']","['group', 'heart', 'disease', 'heart disease', 'death']",,
2543,2502,a post hoc analysis that accounted for the competing risk of death further supported the preplanned analyses presented in this article ( Table S6 in the Supplementary Appendix ) .,考虑了死亡竞争风险的事后分析进一步支持了本文中提出的预先计划的分析（补充附录表 S6）。,0.3333333333333333,"['a', 'appendix', 'table', 'analysis', 'death', 'article', 'supplementary', 'post', 'risk', 'this', 'that', 'in']","['table', 'analysis', 'death', 'risk']",2502,['对竞争死亡风险的后期分析进一步支持本文提交的预先规划分析(附件中的表 S6 )。'],0.4166666666666667,"['a', 'appendix', 'table', 'analysis', 'death', 'article', 'supplementary', 'post', 'risk', 'this', 'that', 'in']","['appendix', 'table', 'analysis', 'death', 'risk']",,
2544,2503,apalutamide plus ADT also resulted in a higher percentage of patients in whom undetectable PSA levels were achieved and a longer time to PSA progression than placebo plus ADT .,与安慰剂加 ADT 相比，apalutamide 加 ADT 还导致更高百分比的患者达到无法检测的 PSA 水平和更长的 PSA 进展时间。,0.4,"['percentage', 'placebo', 'plus', 'time', 'PSA', 'progression', 'achieved', 'in', 'to', 'and']","['placebo', 'plus', 'time', 'progression']",2503,"['Apalutamide 加上 ADT 也导致患者的百分比较高,其中无法检测的 PSA 水平达到,并且比 placebo 加上 ADT 的 PSA 进展时间更长。']",0.3,"['percentage', 'placebo', 'plus', 'time', 'PSA', 'progression', 'achieved', 'in', 'to', 'and']","['plus', 'time', 'progression']",,
2545,2504,"for example , although all the patients acknowledged the survival benefit of docetaxel during informed consent , only 10.7 % had received previous docetaxel therapy before trial enrollment .",例如，尽管所有患者在知情同意期间都承认多西紫杉醇的生存获益，但只有 10.7% 的患者在入组试验前曾接受过多西紫杉醇治疗。,0.5454545454545454,"['survival', 'previous', 'therapy', 'trial', 'consent', 'informed consent', 'benefit', 'docetaxel', 'example', 'all', 'before']","['survival', 'therapy', 'consent', 'docetaxel', 'example', 'before']",2504,"['例如,虽然所有患者在已知同意期间都承认了Docetaxel的生存效益,但只有10.7%在试验登记前接受了以前的Docetaxel治疗。']",0.5454545454545454,"['survival', 'previous', 'therapy', 'trial', 'consent', 'informed consent', 'benefit', 'docetaxel', 'example', 'all', 'before']","['survival', 'previous', 'therapy', 'consent', 'example', 'before']",,
2546,2505,this probably reflects perceived patient fitness for docetaxel and differences in patient choice or care approaches .,这可能反映了患者对多西紫杉醇的适应度以及患者选择或护理方法的差异。,0.2857142857142857,"['fitness', 'in patient', 'care', 'choice', 'docetaxel', 'this', 'and']","['choice', 'docetaxel']",2505,['这可能反映了患者对docetaxel的感知健身和患者选择或护理方法的差异。'],0.1428571428571428,"['fitness', 'in patient', 'care', 'choice', 'docetaxel', 'this', 'and']",['choice'],,
2547,2506,"however , the consistency of clinical benefit of apalutamide across all subgroups is reassuring .",然而，apalutamide 在所有亚组中的临床获益的一致性令人安心。,0.4,"['consistency', 'across', 'clinical', 'benefit', 'all']","['consistency', 'clinical']",2506,"['然而,在所有子群中,阿帕卢塔米德的临床益处的一致性是令人安慰的。']",0.4,"['consistency', 'across', 'clinical', 'benefit', 'all']","['consistency', 'clinical']",,
2548,2507,adverse events were generally consistent with the known safety profile of apalutamide .,不良事件与阿帕鲁胺已知的安全性基本一致。,0.25,"['safety', 'adverse', 'profile', 'with']",['safety'],2507,"['一般情况下,不良事件与阿帕卢塔米德的已知安全资料一致。']",0.25,"['safety', 'adverse', 'profile', 'with']",['safety'],,
2549,2508,"rash that was related to treatment with apalutamide was common and was typically managed with antihistamines and topical glucocorticoids , dose interruption , and dose reduction ( see the Results section in the Supplementary Appendix ) .",与阿帕鲁胺治疗相关的皮疹很常见，通常使用抗组胺药和局部糖皮质激素、中断剂量和减少剂量来控制（见补充附录中的结果部分）。,0.3333333333333333,"['appendix', 'section', 'rash', 'interruption', 'supplementary', 'reduction', 'topical', 'common', 'treatment', 'antihistamines', 'with', 'glucocorticoids', 'dose', 'that', 'and']","['interruption', 'reduction', 'treatment', 'antihistamines', 'dose']",2508,"['与 apalutamide 治疗相关的发作是常见的,通常用抗histamines 和当地的 glucocorticoids, 剂量中断, 和 剂量减少 ( 参见补充附件的结果部分 ) 。']",0.3333333333333333,"['appendix', 'section', 'rash', 'interruption', 'supplementary', 'reduction', 'topical', 'common', 'treatment', 'antihistamines', 'with', 'glucocorticoids', 'dose', 'that', 'and']","['appendix', 'interruption', 'reduction', 'treatment', 'dose']",,
2550,2509,hypothyroidism was mild to moderate ; the condition was monitored according to thyrotropin level and managed with levothyroxine .,甲状腺功能减退症为轻度至中度；根据促甲状腺激素水平监测病情，并用左旋甲状腺素进行管理。,0.4444444444444444,"['thyrotropin', 'hypothyroidism', 'condition', 'moderate', 'level', 'with', 'mild', 'to', 'and']","['thyrotropin', 'hypothyroidism', 'level', 'mild']",2509,"['甲状腺炎是轻到温和的;根据甲状腺素水平进行监测,并用 levothyroxine 管理。']",0.1111111111111111,"['thyrotropin', 'hypothyroidism', 'condition', 'moderate', 'level', 'with', 'mild', 'to', 'and']",['level'],,
2551,2510,the differences in the incidence of falls and fractures between the apalutamide group and the placebo group were smaller in the TITAN trial than in the SPARTAN trial.20,在 TITAN 试验中，apalutamide 组和安慰剂组之间跌倒和骨折发生率的差异小于 SPARTAN 试验。 20,0.6666666666666666,"['group', 'placebo', 'incidence', 'trial', 'fractures', 'and']","['group', 'placebo', 'incidence', 'fractures']",2510,"['在TITAN试验中,阿帕卢塔米德群体和 placebo群体之间的跌倒和裂缝的发病率差异比在SPARTAN试验中较小。']",0.3333333333333333,"['group', 'placebo', 'incidence', 'trial', 'fractures', 'and']","['group', 'incidence']",,
2552,2511,"as brain stimulation devices and procedures proliferate on the market and enter popular discourse , patients are likely to ask clinicians about using these for clinical treatments and even cognitive enhancement .",随着大脑刺激设备和程序在市场上激增并进入流行话题，患者很可能会询问临床医生有关使用这些设备进行临床治疗甚至认知增强的信息。,0.6363636363636364,"['enhancement', 'stimulation', 'proliferate', 'brain', 'clinical', 'market', 'brain stimulation', 'as', 'cognitive', 'to', 'and']","['enhancement', 'stimulation', 'proliferate', 'brain', 'clinical', 'market', 'brain stimulation']",2511,"['由于大脑刺激设备和程序在市场上繁殖,并进入受欢迎的演讲,患者可能会问诊所医生如何使用这些用于临床治疗,甚至认知增强。']",0.7272727272727273,"['enhancement', 'stimulation', 'proliferate', 'brain', 'clinical', 'market', 'brain stimulation', 'as', 'cognitive', 'to', 'and']","['enhancement', 'stimulation', 'brain', 'clinical', 'market', 'brain stimulation', 'as', 'to']",,
2553,2512,how these procedures might increase creativity is uncertain .,这些程序如何提高创造力尚不确定。,0.3333333333333333,"['uncertain', 'creativity', 'increase']",['creativity'],2512,['这些程序如何提高创造力是不确定的。'],0.6666666666666666,"['uncertain', 'creativity', 'increase']","['uncertain', 'creativity']",,
2554,2513,competing hypotheses favor heightened activity in left prefrontal and anterior cingulate cortices .,相互竞争的假设支持左前额叶和前扣带皮层的活动增强。,0.6666666666666666,"['cortices', 'activity', 'anterior', 'prefrontal', 'in', 'and']","['cortices', 'activity', 'anterior', 'prefrontal']",2513,['竞争假设有利于在左前线和前线甲状腺中增加的活动。'],0.3333333333333333,"['cortices', 'activity', 'anterior', 'prefrontal', 'in', 'and']","['activity', 'anterior']",,
2555,2514,the reverse pattern of anodal vs. cathodal stimulation ( L + R- ),阳极与阴极刺激的相反模式 ( L + R- ),0.6666666666666666,"['stimulation', 'pattern', 'reverse']","['stimulation', 'pattern']",2514,['反向安道尔与天主教刺激的模式(L + R- )'],1.0,"['stimulation', 'pattern', 'reverse']","['stimulation', 'pattern', 'reverse']",,
2556,2515,sham stimulation,假刺激,0.5,"['stimulation', 'sham']",['stimulation'],2515,['Sham 刺激'],0.5,"['stimulation', 'sham']",['stimulation'],,
2557,2516,participants were unable to distinguish active from sham stimulation .,参与者无法区分主动刺激和假刺激。,0.1666666666666666,"['stimulation', 'active', 'distinguish', 'sham', 'to', 'unable to']",['stimulation'],2516,['参与者无法区分活跃与羞耻刺激。'],0.1666666666666666,"['stimulation', 'active', 'distinguish', 'sham', 'to', 'unable to']",['stimulation'],,
2558,2517,these intriguing findings bear replication .,这些有趣的发现值得重复。,0.5,"['replication', 'bear']",['replication'],2517,['這些令人興奮的發現帶來反應。'],0.0,"['replication', 'bear']",[],,
2559,2518,stay tuned .,敬请关注 。,0.0,['stay'],[],2518,['保持沉默。'],0.0,['stay'],[],,
2560,2519,a large observational study suggests exposure to artificial light at night while sleeping raises risk for obesity .,一项大型观察性研究表明，夜间睡觉时接触人造光会增加肥胖风险。,0.4545454545454545,"['a', 'exposure', 'observational study', 'obesity', 'sleeping', 'large', 'artificial', 'risk', 'light', 'to', 'night']","['observational study', 'obesity', 'risk', 'light', 'night']",2519,"['大型观测研究表明,夜间暴露于人工光,而睡眠会增加肥胖的风险。']",0.5454545454545454,"['a', 'exposure', 'observational study', 'obesity', 'sleeping', 'large', 'artificial', 'risk', 'light', 'to', 'night']","['exposure', 'obesity', 'risk', 'light', 'to', 'night']",,
2561,2520,animal and limited human data indicate that exposure to artificial light at night ( ALAN ) contributes to obesity .,动物和有限的人类数据表明，夜间暴露于人造光 (ALAN) 会导致肥胖。,0.6923076923076923,"['data', 'exposure', 'indicate', 'obesity', 'artificial', 'animal', 'light', 'human', 'limited', 'that', 'to', 'and', 'night']","['data', 'exposure', 'obesity', 'animal', 'light', 'human', 'limited', 'to', 'night']",2520,"['动物和有限的人类数据表明,夜间暴露于人工光(ALAN)有助于肥胖。']",0.6923076923076923,"['data', 'exposure', 'indicate', 'obesity', 'artificial', 'animal', 'light', 'human', 'limited', 'that', 'to', 'and', 'night']","['data', 'exposure', 'obesity', 'animal', 'light', 'human', 'limited', 'to', 'night']",,
2562,2521,"baseline mean BMI progressively increased with ALAN exposure , from 27.0 kg / m2 ( C1 and C2 ) to 29.2 ( C4 ) .",基线平均 BMI 随着 ALAN 暴露逐渐增加，从 27.0 kg/m2（C1 和 C2）到 29.2（C4）。,0.3333333333333333,"['mean', 'baseline', 'exposure', '/', 'BMI', 'kg', 'with', 'to', 'and']","['mean', 'baseline', 'exposure']",2521,"['基线平均BMI与ALAN曝光逐渐增加,从27.0kg/m2(C1和C2)到29.2(C4)。']",0.3333333333333333,"['mean', 'baseline', 'exposure', '/', 'BMI', 'kg', 'with', 'to', 'and']","['mean', 'baseline', 'exposure']",,
2563,2522,"in analysis adjusted for several covariables , having any ALAN exposure was associated with higher prevalence of obesity at baseline ( prevalence ratio , 1.03 ) .",在针对多个协变量进行调整后的分析中，任何 ALAN 暴露都与基线时较高的肥胖患病率相关（患病率 1.03）。,0.5,"['analysis', 'baseline', 'exposure', 'ratio', 'prevalence', 'obesity', 'associated', 'with']","['analysis', 'baseline', 'exposure', 'obesity']",2522,"['在分析中,适用于多种可变物,有任何ALAN曝光与基因肥胖率较高的发病率有关(发病率, 1.03)。']",0.375,"['analysis', 'baseline', 'exposure', 'ratio', 'prevalence', 'obesity', 'associated', 'with']","['analysis', 'exposure', 'obesity']",,
2564,2523,"exposure to ALAN may suppress melatonin production , disrupting circadian rhythms .",接触 ALAN 可能会抑制褪黑激素的产生，扰乱昼夜节律。,0.3333333333333333,"['production', 'melatonin', 'circadian', 'exposure', 'circadian rhythms', 'suppress']","['circadian', 'suppress']",2523,"['对ALAN的曝光可能会抑制<unk>素产量,干扰循环节奏。']",0.3333333333333333,"['production', 'melatonin', 'circadian', 'exposure', 'circadian rhythms', 'suppress']","['exposure', 'suppress']",,
2565,2524,"in prediabetic adults with mostly normal vitamin D levels , supplementation did not affect rates of progression to diabetes .",在大多数维生素 D 水平正常的糖尿病前期成人中，补充剂不会影响进展为糖尿病的速度。,0.5555555555555556,"['diabetes', 'vitamin', 'affect', 'normal', 'progression', 'D', 'with', 'vitamin D', 'to']","['diabetes', 'vitamin', 'affect', 'normal', 'progression']",2524,"['在大多数正常维生素D水平的糖尿病前成年人中,补充剂没有影响糖尿病进展率。']",0.5555555555555556,"['diabetes', 'vitamin', 'affect', 'normal', 'progression', 'D', 'with', 'vitamin D', 'to']","['diabetes', 'vitamin', 'affect', 'progression', 'vitamin D']",,
2566,2525,"low vitamin D levels have been associated with excess risk for developing type 2 diabetes , but proof of a causal relation is lacking .",低维生素 D 水平与患 2 型糖尿病的风险过高有关，但缺乏因果关系的证据。,0.5882352941176471,"['diabetes', 'type', 'excess', 'vitamin', '2', 'relation', 'developing', 'associated', 'low', 'proof', 'risk', 'causal', 'D', 'with', 'vitamin D', 'have', 'but']","['diabetes', 'type', 'vitamin', '2', 'relation', 'low', 'risk', 'causal', 'have', 'but']",2525,"['低维生素D水平已与患2型糖尿病的过度风险有关,但缺乏因果关系的证据。']",0.6470588235294118,"['diabetes', 'type', 'excess', 'vitamin', '2', 'relation', 'developing', 'associated', 'low', 'proof', 'risk', 'causal', 'D', 'with', 'vitamin D', 'have', 'but']","['diabetes', 'type', 'vitamin', '2', 'relation', 'low', 'risk', 'causal', 'vitamin D', 'have', 'but']",,
2567,2526,"now , in the largest randomized trial to date , about 2400 U.S. adults with prediabetes received 4000 IU of vitamin D3 or placebo daily .",现在，在迄今为止规模最大的随机试验中，大约 2400 名患有糖尿病前期的美国成年人每天接受 4000 IU 的维生素 D3 或安慰剂。,0.3333333333333333,"['placebo', 'vitamin', 'date', 'trial', 'with', 'to']","['placebo', 'vitamin']",2526,"['目前,在迄今为止最大的随机试验中,约有2400名患有糖尿病的美国成年人每天接收了4000 IU的维生素D3或 placebo。']",0.1666666666666666,"['placebo', 'vitamin', 'date', 'trial', 'with', 'to']",['vitamin'],,
2568,2527,mean 25 ( OH ) D level increased to ≈ 50 ng / mL in the supplemented group and was unchanged in the placebo group .,补充剂组的平均 25 (OH) D 水平增加至 ≈ 50 ng/mL，而安慰剂组则没有变化。,0.5,"['group', 'placebo', 'mean', '/', 'D', 'level', 'ml', 'in', 'to', 'and']","['group', 'placebo', 'mean', 'level', 'and']",2527,['平均 25 (OH ) D 水平在补充组中增加到 ≈ 50 ng / mL 并且在 placebo 组中不变。'],0.3,"['group', 'placebo', 'mean', '/', 'D', 'level', 'ml', 'in', 'to', 'and']","['group', 'mean', 'level']",,
2569,2528,"we still have no compelling evidence that vitamin D supplementation will prevent type 2 diabetes ; thus , supplements should not be recommended for this purpose in prediabetic patients with normal vitamin D levels .",我们仍然没有令人信服的证据表明补充维生素 D 可以预防 2 型糖尿病；因此，不应推荐维生素 D 水平正常的糖尿病前期患者为此目的服用补充剂。,0.5555555555555556,"['diabetes', 'type', 'vitamin', '2', 'normal', 'still', 'thus', 'D', 'evidence', 'purpose', 'will', 'with', 'prevent', 'vitamin D', 'have', 'this', 'that', 'we']","['diabetes', 'type', 'vitamin', '2', 'normal', 'thus', 'evidence', 'purpose', 'prevent', 'have']",2528,"['我们仍然没有强迫的证据,维生素D补充将防止2型糖尿病;因此,补充剂不应该在正常维生素D水平的糖尿病前患者推荐为此目的。']",0.5,"['diabetes', 'type', 'vitamin', '2', 'normal', 'still', 'thus', 'D', 'evidence', 'purpose', 'will', 'with', 'prevent', 'vitamin D', 'have', 'this', 'that', 'we']","['diabetes', 'type', 'vitamin', '2', 'thus', 'evidence', 'purpose', 'vitamin D', 'have']",,
2570,2529,the protocol was modified after enrollment of 88 patients to allow patients to have previously received docetaxel for HSMPC .,该方案在 88 名患者入组后进行了修改，以允许患者之前接受过用于 HSMPC 的多西紫杉醇。,0.6,"['protocol', 'allow', 'after', 'docetaxel', 'have']","['allow', 'after', 'docetaxel']",2529,"['该协议在88名患者注册后被修改,以便允许患者提前接受Docetaxel为HSMPC。']",0.6,"['protocol', 'allow', 'after', 'docetaxel', 'have']","['protocol', 'allow', 'after']",,
2571,2530,these results were not affected by volume of disease or prior use of docetaxel .,这些结果不受疾病体积或先前使用多西紫杉醇的影响。,0.6666666666666666,"['volume', 'disease', 'prior', 'of disease', 'docetaxel', 'by volume']","['volume', 'disease', 'prior', 'docetaxel']",2530,['这些结果没有受到疾病量或以前使用Docetaxel的影响。'],0.1666666666666666,"['volume', 'disease', 'prior', 'of disease', 'docetaxel', 'by volume']",['disease'],,
2572,2531,"at 3 years , the percentage of patients still receiving a trial regimen was 62 % in the enzalutamide group and 34 % in the control group .",3 年时，恩杂鲁胺组仍在接受试验治疗的患者百分比为 62%，对照组为 34%。,0.3636363636363636,"['group', 'percentage', 'control', 'control group', 'still', 'trial', '3', 'at', 'enzalutamide', 'in', 'and']","['group', 'control', 'control group', 'enzalutamide']",2531,"['3岁时,仍在接受试验计划的患者的百分比为Enzalutamide群体的62%,控制群体的34%。']",0.1818181818181818,"['group', 'percentage', 'control', 'control group', 'still', 'trial', '3', 'at', 'enzalutamide', 'in', 'and']","['group', 'control']",,
2573,2532,fatigue and seizures were more common with enzalutamide .,恩杂鲁胺导致疲劳和癫痫发作更常见。,0.5,"['fatigue', 'common', 'with', 'enzalutamide', 'and', 'seizures']","['fatigue', 'enzalutamide', 'seizures']",2532,['疲劳和麻烦更常见于Enzalutamide。'],0.1666666666666666,"['fatigue', 'common', 'with', 'enzalutamide', 'and', 'seizures']",['fatigue'],,
2574,2533,"the authors note that the effect of enzalutamide on OS appeared smaller in the subgroup receiving prior docetaxel , but that the study was not powered to address this issue .",作者指出，enzalutamide 对 OS 的影响在既往接受过多西紫杉醇的亚组中似乎较小，但该研究无法解决这个问题。,0.2142857142857142,"['issue', 'study', 'prior', 'note', 'effect', 'subgroup', 'docetaxel', 'enzalutamide', 'on', 'this', 'that', 'in', 'but', 'to']","['issue', 'docetaxel', 'but']",2533,"['作者指出,在接收前docetaxel的子组中,Enzalutamide对OS的影响显得较小,但这项研究无法解决这个问题。']",0.1428571428571428,"['issue', 'study', 'prior', 'note', 'effect', 'subgroup', 'docetaxel', 'enzalutamide', 'on', 'this', 'that', 'in', 'but', 'to']","['issue', 'but']",,
2575,2534,there is a therapy burden associated with enzalutamide that must be considered by clinicians and patients as they review the evolving treatment options in this clinical space .,临床医生和患者在审查该临床领域不断发展的治疗方案时必须考虑到与恩杂鲁胺相关的治疗负担。,0.3529411764705882,"['must', 'a', 'review', 'space', 'therapy', 'be', 'associated', 'treatment', 'clinical', 'options', 'with', 'enzalutamide', 'this', 'that', 'by', 'and', 'burden']","['review', 'therapy', 'be', 'treatment', 'clinical', 'enzalutamide']",2534,"['有一个与Enzalutamide相关的治疗负担,必须由诊所医生和患者考虑,因为他们正在审查这种临床空间的治疗选项的进展。']",0.4117647058823529,"['must', 'a', 'review', 'space', 'therapy', 'be', 'associated', 'treatment', 'clinical', 'options', 'with', 'enzalutamide', 'this', 'that', 'by', 'and', 'burden']","['review', 'space', 'therapy', 'be', 'treatment', 'clinical', 'by']",,
2576,2535,"among more than 20,000 patients with cerebral ischemic events , presence of microbleeds increased risks for both future ischemic events and intracerebral hemorrhages .","在超过 20,000 名患有脑缺血事件的患者中，微出血的存在增加了未来发生缺血事件和脑出血的风险。",0.3333333333333333,"['presence', 'cerebral', 'intracerebral', 'with', 'and', 'ischemic']","['presence', 'ischemic']",2535,"['在20,000多名患有大脑催化事件的患者中,微生物的存在增加了未来催化事件和内脑出血的风险。']",0.3333333333333333,"['presence', 'cerebral', 'intracerebral', 'with', 'and', 'ischemic']","['presence', 'cerebral']",,
2577,2536,should treatment change for these patients ?,这些患者的治疗应该改变吗？,0.5,"['treatment', 'change']",['treatment'],2536,['这些病人需要治疗吗?'],0.5,"['treatment', 'change']",['treatment'],,
2578,2537,subcortical CMs may be a marker of small vessel vasculopathy ; lobar CMs may indicate cerebral amyloid angiopathy ( CAA ) .,皮层下 CM 可能是小血管病变的标志；大叶 CM 可能表明脑淀粉样血管病 (CAA)。,0.2,"['vessel', 'a', 'subcortical', 'amyloid', 'marker', 'cerebral', 'indicate', 'lobar', 'be', 'angiopathy']","['subcortical', 'angiopathy']",2537,['subcortical CMs 可能是小血管 vasculopathy 的标志; lobar CMs 可能指示脑 amyloid angiopathy ( CAA ) 。'],0.1,"['vessel', 'a', 'subcortical', 'amyloid', 'marker', 'cerebral', 'indicate', 'lobar', 'be', 'angiopathy']",['indicate'],,
2579,2538,the primary outcome was any symptomatic ICH or ischemic stroke .,主要结果是任何有症状的 ICH 或缺血性卒中。,0.6,"['stroke', 'outcome', 'primary', 'symptomatic', 'ischemic']","['stroke', 'outcome', 'symptomatic']",2538,['主要的结果是任何症状的ICH或伊斯基米性中风。'],0.8,"['stroke', 'outcome', 'primary', 'symptomatic', 'ischemic']","['stroke', 'outcome', 'primary', 'symptomatic']",,
2580,2539,"of the full group , CMs were present in 28 % , close to half ( 43 % ) of whom had only one documented microbleed .",在整个组中，CM 占 28%，其中将近一半 (43%) 只有一次微出血记录。,0.2857142857142857,"['group', 'half', 'present', 'full', 'in', 'to', 'close to']","['group', 'half']",2539,"['在整个群体中,有28%的CM存在,其中近一半(43%)只有一个有文档的微白。']",0.2857142857142857,"['group', 'half', 'present', 'full', 'in', 'to', 'close to']","['group', 'half']",,
2581,2540,"the adjusted hazard ratio was higher for symptomatic hemorrhagic stroke than for symptomatic ischemic stroke ( 2.45 for ICH , 1.23 for ischemic stroke ) .",症状性出血性卒中的校正风险比高于症状性缺血性卒中（ICH 为 2.45，缺血性卒中为 1.23）。,0.5,"['stroke', 'ratio', 'hazard ratio', 'hemorrhagic', 'symptomatic', 'ischemic']","['stroke', 'ratio', 'hazard ratio']",2540,['调整的风险比例在症状性发作中高于症状性发作中发作中发作中发作中发作中发作中发作中发作中发作中发作中发作中发作。'],0.5,"['stroke', 'ratio', 'hazard ratio', 'hemorrhagic', 'symptomatic', 'ischemic']","['stroke', 'ratio', 'hazard ratio']",,
2582,2541,"risk for hemorrhagic stroke increased with a higher CM burden ( adjusted HR , 4.55 with five or more CMs vs. no COMs ) .",出血性中风的风险随着 CM 负担的增加而增加（调整后的 HR，5 个或更多 CM 为 4.55 与没有 COM 相比）。,0.2222222222222222,"['a', 'stroke', 'CM', 'no', 'risk', 'hemorrhagic', 'with', 'five', 'burden']","['stroke', 'risk']",2541,"['血管中风的风险增加了较高的CM负担(调整的HR,4.55与五或多个CM相比没有COM)。']",0.2222222222222222,"['a', 'stroke', 'CM', 'no', 'risk', 'hemorrhagic', 'with', 'five', 'burden']","['stroke', 'risk']",,
2583,2542,"however , regardless of CM location or burden , the absolute risk for ischemic stroke was higher than the risk for ICH .",然而，无论 CM 位置或负担如何，缺血性卒中的绝对风险高于 ICH 的风险。,0.5714285714285714,"['stroke', 'absolute', 'location', 'CM', 'risk', 'ischemic', 'burden']","['stroke', 'absolute', 'location', 'risk']",2542,"['然而,无论CM的位置或负担,伊斯基米发作的绝对风险高于ICH的风险。']",0.5714285714285714,"['stroke', 'absolute', 'location', 'CM', 'risk', 'ischemic', 'burden']","['stroke', 'absolute', 'location', 'risk']",,
2584,2543,"Impressively , the authors collected data on more than 20,000 patients from multiple cohorts .","令人印象深刻的是，作者收集了来自多个队列的 20,000 多名患者的数据。",0.25,"['data', 'multiple', 'cohorts', 'on']",['data'],2543,"['令人印象深刻的是,作者收集了来自多组的20000多名患者的数据。']",0.25,"['data', 'multiple', 'cohorts', 'on']",['data'],,
2585,2544,the results reveal that presence of cerebral microbleeds suggests an increased risk for future vascular events .,结果表明，脑微出血的存在表明未来血管事件的风险增加。,0.4,"['presence', 'vascular', 'cerebral', 'risk', 'that']","['presence', 'risk']",2544,"['结果表明,大脑微博的存在表明,未来血管事件的风险增加。']",0.6,"['presence', 'vascular', 'cerebral', 'risk', 'that']","['presence', 'cerebral', 'risk']",,
2586,2545,"although the presence of CMs affects prognosis , whether detection of CMs should alter treatment is unclear .",尽管 CM 的存在会影响预后，但尚不清楚 CM 的检测是否应改变治疗。,1.0,"['presence', 'detection', 'prognosis', 'treatment']","['presence', 'detection', 'prognosis', 'treatment']",2545,"['虽然CM的存在影响预测,但是否检测CM应该改变治疗是不清楚的。']",1.0,"['presence', 'detection', 'prognosis', 'treatment']","['presence', 'detection', 'prognosis', 'treatment']",,
2587,2546,"because the rate of ischemic stroke outweighs the rate of ICH in patients with CMs , antiplatelet therapy could have some benefit in these patients .",由于 CM 患者的缺血性卒中发生率超过 ICH 发生率，因此抗血小板治疗可能对这些患者有一定益处。,0.4444444444444444,"['stroke', 'rate', 'antiplatelet', 'therapy', 'benefit', 'with', 'have', 'in', 'ischemic']","['stroke', 'rate', 'therapy', 'have']",2546,"['由于甲状腺肿瘤的发病率超过患有甲状腺肿瘤的患者的甲状腺肿瘤的发病率,因此抗甲状腺治疗可能对这些患者有好处。']",0.3333333333333333,"['stroke', 'rate', 'antiplatelet', 'therapy', 'benefit', 'with', 'have', 'in', 'ischemic']","['rate', 'therapy', 'have']",,
2588,2547,a large randomized trial is needed to provide definitive guidance on this issue .,需要一项大型随机试验来为这个问题提供明确的指导。,0.0,"['a', 'definitive', 'issue', 'large', 'trial', 'on', 'this', 'to', 'guidance']",[],2547,"['需要一个大规模的随机审查,以提供关于这个问题的最终指导。']",0.1111111111111111,"['a', 'definitive', 'issue', 'large', 'trial', 'on', 'this', 'to', 'guidance']",['to'],,
2589,2548,additional sedative agents were required for most intensive care patients to achieve targeted sedation .,大多数重症监护患者需要额外的镇静剂才能达到有针对性的镇静效果。,0.5,"['targeted', 'intensive care', 'sedation', 'additional', 'sedative', 'to']","['sedation', 'additional', 'sedative']",2548,"['对于大多数强烈护理患者来说,需要额外的镇静剂来实现目标镇静。']",0.6666666666666666,"['targeted', 'intensive care', 'sedation', 'additional', 'sedative', 'to']","['sedation', 'additional', 'sedative', 'to']",,
2590,2549,"in previous trials , requisite doses of benzodiazepines and propofol were lower among patients who received dexmedetomidine , and it is associated with lower rates of delirium ( e.g. , NEJM JW Gen Med Oct 15 2016 and Lancet 2016 ; 388 : 1893 ) .",在之前的试验中，接受右美托咪定的患者所需的苯二氮卓类药物和异丙酚剂量较低，并且与较低的谵妄发生率相关（例如，NEJM JW Gen Med 2016 年 10 月 15 日和柳叶刀 2016 年；388：1893）。,0.3333333333333333,"['lancet', 'who', 'previous', 'delirium', 'lower', 'associated', 'gen', 'requisite', 'with', 'propofol', 'dexmedetomidine', 'and']","['delirium', 'lower', 'propofol', 'dexmedetomidine']",2549,"['在以前的研究中,在服用 dexmedetomidine 的患者中,需要的 benzodiazepines 和 propofol 剂量较低,并且与较低的 delirium 率有关(例如,NEJM JW Gen Med Oct 15 2016 和 Lancet 2016; 388 : 1893 )。']",0.25,"['lancet', 'who', 'previous', 'delirium', 'lower', 'associated', 'gen', 'requisite', 'with', 'propofol', 'dexmedetomidine', 'and']","['previous', 'lower', 'requisite']",,
2591,2550,"as use of dexmedetomidine has grown , clinicians have been wondering whether it could be used as the sole sedating agent for critically ill patients .",随着右美托咪定的使用越来越多，临床医生一直在想它是否可以用作危重病人的唯一镇静剂。,0.375,"['be', 'ill', 'sole', 'as', 'dexmedetomidine', 'agent', 'have', 'critically']","['be', 'dexmedetomidine', 'critically']",2550,"['由于Dexmedetomidine的使用已经增加,临床医生一直在想,它是否可以作为关键病患者的唯一放松剂。']",0.125,"['be', 'ill', 'sole', 'as', 'dexmedetomidine', 'agent', 'have', 'critically']",['be'],,
2592,2551,investigators in eight countries randomized 4000 patients who were receiving mechanical ventilation either to dexmedetomidine as primary sedation or to usual care .,八个国家的研究人员将 4000 名接受机械通气的患者随机分为右美托咪定作为主要镇静剂或常规护理。,0.4,"['ventilation', 'mechanical', 'who', 'usual', 'mechanical ventilation', 'primary', 'sedation', 'care', 'as', 'dexmedetomidine']","['ventilation', 'mechanical ventilation', 'sedation', 'dexmedetomidine']",2551,"['八个国家的研究人员随机调查了4000名患者,他们接受机械通风,无论是德克塞米多米丁作为初级通风,还是普通护理。']",0.2,"['ventilation', 'mechanical', 'who', 'usual', 'mechanical ventilation', 'primary', 'sedation', 'care', 'as', 'dexmedetomidine']","['ventilation', 'mechanical ventilation']",,
2593,2552,most enrolled patients were receiving ventilation for respiratory disorders ; a quarter were postoperative patients .,大多数入组患者因呼吸系统疾病接受通气；四分之一是术后患者。,0.2,"['ventilation', 'quarter', 'respiratory', 'postoperative', 'disorders']",['ventilation'],2552,['大多数注册的患者接受了呼吸障碍的通风;四分之一是手术后患者。'],0.6,"['ventilation', 'quarter', 'respiratory', 'postoperative', 'disorders']","['ventilation', 'quarter', 'disorders']",,
2594,2553,"although most patients were deeply sedated when they were enrolled in the trial , the goal was light sedation unless contraindicated .",尽管大多数患者在参加试验时都处于深度镇静状态，但目标是轻度镇静，除非有禁忌症。,0.6,"['contraindicated', 'sedation', 'light', 'trial', 'goal']","['contraindicated', 'sedation', 'goal']",2553,"['雖然大多數患者在考試中被註冊時被深度鎮静,但目標是輕度鎮静,除非有反應。']",0.0,"['contraindicated', 'sedation', 'light', 'trial', 'goal']",[],,
2595,2554,"light sedation was slightly more likely to be achieved with dexmedetomidine ; however , three quarters of dexmedetomidine patients required addition of propofol , midazolam , or both .",右美托咪定更可能实现轻度镇静；然而，四分之三的右美托咪定患者需要加用异丙酚、咪达唑仑或两者。,0.5,"['addition', 'be', 'sedation', 'light', 'with', 'achieved', 'propofol', 'midazolam', 'dexmedetomidine', 'three']","['addition', 'sedation', 'propofol', 'midazolam', 'dexmedetomidine']",2554,['轻静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静'],0.0,"['addition', 'be', 'sedation', 'light', 'with', 'achieved', 'propofol', 'midazolam', 'dexmedetomidine', 'three']",[],,
2596,2555,"adverse events , most commonly bradycardia and hypotension , were more common in the dexmedetomidine group .",不良事件，最常见的是心动过缓和低血压，在右美托咪定组中更为常见。,0.5714285714285714,"['group', 'bradycardia', 'hypotension', 'common', 'adverse', 'dexmedetomidine', 'and']","['group', 'bradycardia', 'hypotension', 'dexmedetomidine']",2555,"['副作用,最常见的布拉迪卡迪和低血压,在德克塞米多米丁群体中更常见。']",0.2857142857142857,"['group', 'bradycardia', 'hypotension', 'common', 'adverse', 'dexmedetomidine', 'and']","['group', 'hypotension']",,
2597,2556,"as seen in previous studies , it did spare use of other agents , which might help avoid deeper sedation and delirium .",正如在之前的研究中所看到的，它确实没有使用其他药物，这可能有助于避免更深的镇静和精神错乱。,0.375,"['spare', 'previous', 'delirium', 'sedation', 'as', 'in', 'and', 'avoid']","['sedation', 'as', 'avoid']",2556,"['正如以前的研究所看到的那样,它预备了其他药物的使用,这可能有助于避免更深的沉默和<unk>。']",0.375,"['spare', 'previous', 'delirium', 'sedation', 'as', 'in', 'and', 'avoid']","['previous', 'as', 'avoid']",,
2598,2557,"it makes sense to use dexmedetomidine as an adjunctive agent , but caution should be exercised in patients who already are hypotensive or bradycardic .",使用右美托咪定作为辅助药物是有意义的，但对于已经出现低血压或心动过缓的患者应谨慎使用。,0.25,"['who', 'sense', 'be', 'hypotensive', 'as', 'dexmedetomidine', 'agent', 'but']","['dexmedetomidine', 'but']",2557,"['使用 dexmedetomidine 作为补充剂是有意义的,但应谨慎的患者已经是催眠性或乳腺炎。']",0.125,"['who', 'sense', 'be', 'hypotensive', 'as', 'dexmedetomidine', 'agent', 'but']",['but'],,
2599,2558,recurrent ICH was less common with than without antiplatelet therapy .,与未进行抗血小板治疗相比，复发性脑出血较少见。,0.1666666666666666,"['antiplatelet', 'therapy', 'recurrent', 'common', 'with', 'without']",['therapy'],2558,['重复的 ICH 比没有抗膜治疗更少。'],0.1666666666666666,"['antiplatelet', 'therapy', 'recurrent', 'common', 'with', 'without']",['therapy'],,
2600,2559,intracerebral hemorrhage ( ICH ) is associated with high levels of morbidity and mortality .,脑出血 (ICH) 与高发病率和死亡率有关。,0.5,"['morbidity', 'hemorrhage', 'intracerebral', 'associated', 'mortality', 'with', 'and', 'high']","['morbidity', 'hemorrhage', 'mortality', 'high']",2559,['脑内出血(ICH)与患病和死亡率的高水平有关。'],0.5,"['morbidity', 'hemorrhage', 'intracerebral', 'associated', 'mortality', 'with', 'and', 'high']","['hemorrhage', 'intracerebral', 'mortality', 'high']",,
2601,2560,patients with a previous ICH are also sometimes advised to avoid antithrombotic therapy .,有时也建议既往有 ICH 史的患者避免抗血栓治疗。,0.2857142857142857,"['a', 'antithrombotic', 'previous', 'therapy', 'with', 'to', 'avoid']","['therapy', 'avoid']",2560,['患有以前的ICD的患者也有时建议避免抗血管治疗。'],0.4285714285714285,"['a', 'antithrombotic', 'previous', 'therapy', 'with', 'to', 'avoid']","['previous', 'therapy', 'avoid']",,
2602,2561,"the RESTART Collaboration studied the effect of starting antiplatelet therapy or avoiding antiplatelet therapy in 537 survivors of a recent ICH ( 68 % male ; median age , 77 years ; 62 % lobar ICH ) recruited from multiple centers in the United Kingdom .",RESTART 协作研究了从英国多个中心招募的 537 名近期 ICH 幸存者（68% 男性；中位年龄 77 岁；62% 脑叶 ICH）开始抗血小板治疗或避免抗血小板治疗的效果。,0.3333333333333333,"['median', 'recent', 'male', 'antiplatelet', 'multiple', 'lobar', 'therapy', 'age', 'kingdom', 'effect', 'collaboration', 'median age']","['male', 'therapy', 'age', 'effect']",2561,"['RESTART 合作研究了从英国多个中心招募的近期 ICH 的 537 名幸存者(68 % 男性;中年,77 年; 62 % 洛巴尔 ICH )开始抗板治疗或避免抗板治疗的效果。']",0.3333333333333333,"['median', 'recent', 'male', 'antiplatelet', 'multiple', 'lobar', 'therapy', 'age', 'kingdom', 'effect', 'collaboration', 'median age']","['male', 'therapy', 'effect', 'collaboration']",,
2603,2562,patients were randomly assigned to start antiplatelet therapy ( START group ) or avoid antiplatelet therapy ( AVOID group ) .,患者被随机分配到开始抗血小板治疗（START 组）或避免抗血小板治疗（AVOID 组）。,0.5,"['group', 'antiplatelet', 'therapy', 'start', 'to', 'avoid']","['group', 'therapy', 'avoid']",2562,['病人随机被指定开始抗板膜治疗(START组)或避免抗板膜治疗(AVOID组)。'],0.5,"['group', 'antiplatelet', 'therapy', 'start', 'to', 'avoid']","['group', 'therapy', 'avoid']",,
2604,2563,patients were enrolled a median of 76 days after the ICH .,患者在 ICH 后的中位时间为 76 天。,0.5,"['median', 'after']",['after'],2563,['患者在 ICH 后 76 天中期。'],0.5,"['median', 'after']",['after'],,
2605,2564,"the primary endpoint was recurrent , symptomatic ICH .",主要终点是复发性、有症状的 ICH。,0.25,"['recurrent', 'primary', 'symptomatic', 'endpoint']",['symptomatic'],2564,"['主要的终点是重复的,症状的我。']",0.5,"['recurrent', 'primary', 'symptomatic', 'endpoint']","['primary', 'symptomatic']",,
2606,2565,"secondary outcomes included all major hemorrhages ( both intracranial and extracranial ) and occlusive vascular events ( e.g. , ischemic stroke or myocardial infarction ) .",次要结果包括所有大出血（颅内和颅外）和闭塞性血管事件（例如，缺血性中风或心肌梗塞）。,0.2727272727272727,"['myocardial infarction', 'stroke', 'vascular', 'occlusive', 'intracranial', 'major', 'secondary', 'all', 'and', 'extracranial', 'ischemic']","['myocardial infarction', 'stroke', 'extracranial']",2565,"['其次的结果包括所有主要的出血(内膜和外膜)和周围的血管事件(例如,腹泻或心脏病发作)。']",0.0909090909090909,"['myocardial infarction', 'stroke', 'vascular', 'occlusive', 'intracranial', 'major', 'secondary', 'all', 'and', 'extracranial', 'ischemic']",['stroke'],,
2607,2566,"the authors do not provide data on other relevant variables , such as blood pressure control .",作者没有提供其他相关变量的数据，例如血压控制。,0.5714285714285714,"['pressure', 'control', 'data', 'blood', 'blood pressure', 'as', 'pressure control']","['control', 'data', 'blood pressure', 'as']",2566,"['作者不提供其他相关变量的数据,如血压控制。']",0.5714285714285714,"['pressure', 'control', 'data', 'blood', 'blood pressure', 'as', 'pressure control']","['control', 'data', 'blood pressure', 'as']",,
2608,2567,"nevertheless , if a clinician judges that a patient with a recent ICH needs antiplatelet therapy , these findings provide reassurance that the practice appears to be safe .",然而，如果临床医生判断近期发生 ICH 的患者需要抗血小板治疗，这些发现可以确保这种做法似乎是安全的。,0.1666666666666666,"['a', 'recent', 'antiplatelet', 'therapy', 'be', 'clinician', 'patient', 'practice', 'with', 'that', 'if', 'to']","['therapy', 'patient']",2567,"['然而,如果一个诊所医生认为患有最近的ICH患者需要抗膜治疗,这些发现确保实践似乎是安全的。']",0.25,"['a', 'recent', 'antiplatelet', 'therapy', 'be', 'clinician', 'patient', 'practice', 'with', 'that', 'if', 'to']","['therapy', 'patient', 'practice']",,
2609,2568,stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence .,III 期或 IVA 期子宫内膜癌具有显着的全身和局部复发风险。,0.4285714285714285,"['stage', 'cancer', 'endometrial', 'risk', 'systemic', 'recurrence', 'and']","['stage', 'cancer', 'risk']",2568,['阶段 III 或 IVA 内分泌癌具有显著的系统和区域重复风险。'],0.2857142857142857,"['stage', 'cancer', 'endometrial', 'risk', 'systemic', 'recurrence', 'and']","['cancer', 'risk']",,
2610,2569,"secondary end points included overall survival , acute and chronic toxic effects , and quality of life .",次要终点包括总生存期、急性和慢性毒性作用以及生活质量。,0.6,"['life', 'survival', 'toxic', 'quality', 'end points', 'chronic', 'secondary', 'acute', 'quality of life', 'and']","['life', 'survival', 'quality', 'end points', 'chronic', 'quality of life']",2569,['二级终点包括整体生存、急性和慢性毒性影响以及生活质量。'],0.6,"['life', 'survival', 'toxic', 'quality', 'end points', 'chronic', 'secondary', 'acute', 'quality of life', 'and']","['life', 'survival', 'quality', 'end points', 'chronic', 'quality of life']",,
2611,2570,"pelvic or whole abdominal radiotherapy has traditionally followed surgical resection.6,8","盆腔或全腹放疗传统上是在手术切除后进行的。6,8",0.0,"['surgical', 'radiotherapy', 'abdominal', 'whole']",[],2570,['腰部或整个腹部放射治疗传统上跟随了手术恢复。'],0.5,"['surgical', 'radiotherapy', 'abdominal', 'whole']","['radiotherapy', 'whole']",,
2612,2571,"in a randomized trial conducted by the Gynecologic Oncology Group ( GOG ) , GOG 122 , chemotherapy was found to be superior to radiotherapy in treating locally advanced disease , and it thus became part of the standard treatment.9",在妇科肿瘤组 ( GOG ) 进行的一项随机试验中， GOG 122 发现化疗在治疗局部晚期疾病方面优于放疗，因此成为标准治疗的一部分。 9,0.5333333333333333,"['group', 'part', 'chemotherapy', 'standard', 'disease', 'superior', 'radiotherapy', 'be', 'thus', 'advanced', 'trial', 'gynecologic', 'in', 'by', 'to']","['group', 'part', 'chemotherapy', 'standard', 'disease', 'be', 'thus', 'to']",2571,"['在由妇科肿瘤学集团(GOG)进行的随机试验中,GOG122发现化疗在治疗本地先进的疾病时比放射治疗优越,因此成为标准治疗的一部分。']",0.6,"['group', 'part', 'chemotherapy', 'standard', 'disease', 'superior', 'radiotherapy', 'be', 'thus', 'advanced', 'trial', 'gynecologic', 'in', 'by', 'to']","['group', 'part', 'chemotherapy', 'standard', 'disease', 'radiotherapy', 'be', 'thus', 'by']",,
2613,2572,"however , if chemotherapy is given alone , the incidence of locoregional recurrence approaches 20 % , 9 heralding subsequent distant metastasis and death .",然而，如果单独给予化疗，局部区域复发的发生率接近 20%，9 预示着随后的远处转移和死亡。,0.6,"['chemotherapy', 'incidence', 'metastasis', 'death', 'distant', 'subsequent', 'recurrence', 'if', 'and', 'alone']","['chemotherapy', 'incidence', 'metastasis', 'death', 'and', 'alone']",2572,"['然而,如果单独进行化疗,则区域重复的发病率接近20%,9是随后的遥远转移和死亡。']",0.6,"['chemotherapy', 'incidence', 'metastasis', 'death', 'distant', 'subsequent', 'recurrence', 'if', 'and', 'alone']","['chemotherapy', 'incidence', 'metastasis', 'death', 'and', 'alone']",,
2614,2573,"therefore , it was logical to hypothesize that an approach that combined the methods of treatment would improve outcomes by preventing local ( pelvic ) and distant recurrences .",因此，可以合理地假设一种结合治疗方法的方法将通过预防局部（骨盆）和远处复发来改善结果。,0.3333333333333333,"['approach', 'local', 'treatment', 'distant', 'therefore', 'that', 'by', 'to', 'and']","['local', 'treatment', 'by']",2573,"['因此,假设结合治疗方法的方法会通过防止本地(阴道)和遥远的复发来改善结果。']",0.2222222222222222,"['approach', 'local', 'treatment', 'distant', 'therefore', 'that', 'by', 'to', 'and']","['treatment', 'distant']",,
2615,2574,"this combined approach has been studied , but its efficacy relative to that of chemotherapy alone is not known .",这种联合治疗方法已经过研究，但其相对于单独化疗的疗效尚不清楚。,0.4444444444444444,"['approach', 'chemotherapy', 'relative', 'efficacy', 'this', 'that', 'but', 'to', 'alone']","['chemotherapy', 'but', 'to', 'alone']",2574,"['这种结合方法已被研究,但其与化疗本身的有效性尚不清楚。']",0.3333333333333333,"['approach', 'chemotherapy', 'relative', 'efficacy', 'this', 'that', 'but', 'to', 'alone']","['chemotherapy', 'efficacy', 'but']",,
2616,2575,these results supported the feasibility and efficacy of a combined treatment strategy .,这些结果支持了联合治疗策略的可行性和有效性。,0.5,"['a', 'strategy', 'treatment', 'efficacy', 'feasibility', 'and']","['strategy', 'treatment', 'efficacy']",2575,['这些结果支持了结合治疗策略的可行性和有效性。'],0.5,"['a', 'strategy', 'treatment', 'efficacy', 'feasibility', 'and']","['strategy', 'treatment', 'efficacy']",,
2617,2576,patients AND TRIAL OVERSIGHT,患者和试验监督,,[],[],2576,['病人和实验超越'],,[],[],,
2618,2577,no single residual tumor mass could be larger than 2 cm in greatest dimension .,单个残留肿瘤块的最大尺寸不能大于 2 厘米。,0.4,"['dimension', '2', 'cm', 'tumor', 'be', 'no', 'mass', 'residual', 'in', 'single']","['dimension', '2', 'tumor', 'single']",2577,['没有一个残留的肿瘤大小可能大于2厘米。'],0.3,"['dimension', '2', 'cm', 'tumor', 'be', 'no', 'mass', 'residual', 'in', 'single']","['dimension', '2', 'tumor']",,
2619,2578,"normal organ function and a GOG performance status score of 2 or lower were required ( scores range from 0 to 5 , with higher scores reflecting greater disability ) .",要求器官功能正常且 GOG 体能状态评分为 2 分或更低（评分范围为 0 至 5，评分越高表示残疾越严重）。,0.5,"['organ', '5', 'range', '2', 'function', 'disability', 'status', 'normal', 'lower', 'score', 'performance', 'with', 'to', 'and']","['organ', '5', 'range', '2', 'function', 'disability', 'status']",2578,"['正常的器官功能和GOG性能状态分数为2或低(分数从0到5的范围,较高的分数反映了较大的残疾)。']",0.7142857142857143,"['organ', '5', 'range', '2', 'function', 'disability', 'status', 'normal', 'lower', 'score', 'performance', 'with', 'to', 'and']","['organ', '5', 'range', '2', 'function', 'disability', 'status', 'normal', 'score', 'performance']",,
2620,2579,patients with carcinosarcoma or recurrent endometrial carcinoma were excluded .,排除癌肉瘤或复发性子宫内膜癌患者。,0.5,"['carcinosarcoma', 'carcinoma', 'endometrial', 'recurrent', 'with', 'endometrial carcinoma']","['carcinosarcoma', 'carcinoma', 'endometrial carcinoma']",2579,['患有癌症或重复性内分泌癌症的患者被排除。'],0.1666666666666666,"['carcinosarcoma', 'carcinoma', 'endometrial', 'recurrent', 'with', 'endometrial carcinoma']",['carcinoma'],,
2621,2580,the trial was conducted in accordance with applicable regulatory requirements and the principles of the Declaration of Helsinki .,该试验是根据适用的监管要求和赫尔辛基宣言的原则进行的。,0.0,"['trial', 'with', 'in', 'and']",[],2580,['审判按照适用的法规要求和赫尔辛基宣言的原则进行。'],0.25,"['trial', 'with', 'in', 'and']",['trial'],,
2622,2581,patients provided written informed consent before enrollment .,患者在入组前提供了书面知情同意书。,0.6666666666666666,"['consent', 'informed consent', 'before']","['consent', 'before']",2581,['患者在登记前提供书面通知同意。'],0.6666666666666666,"['consent', 'informed consent', 'before']","['consent', 'before']",,
2623,2582,trial DESIGN AND END POINTS,试验设计和终点,0.0,['trial'],[],2582,['试点设计与终点'],0.0,['trial'],[],,
2624,2583,"this randomized , multicenter , phase 3 trial was designed with input from the Gynecologic Oncology Group .",这项随机、多中心、3 期试验的设计参考了妇科肿瘤组的意见。,0.25,"['group', 'phase', 'input', 'trial', 'gynecologic', '3', 'with', 'this']","['group', 'phase']",2583,"['这个随机的,多中心的,阶段3试验是由妇科肿瘤学集团的输入设计的。']",0.5,"['group', 'phase', 'input', 'trial', 'gynecologic', '3', 'with', 'this']","['group', 'phase', 'input', 'this']",,
2625,2584,"the authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol , available with the full text of this article at NEJM.org .",作者保证数据的准确性和完整性以及试验对方案的忠实度，方案与本文全文可在 NEJM.org 获取。,0.3076923076923077,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",2584,"['作者保证数据的准确性和完整性以及审判对议定书的忠诚性,可在NEJM.org上提供本文的完整文本。']",0.4615384615384615,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'full']",,
2626,2584,"the authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol , available with the full text of this article at NEJM.org .",作者保证数据的准确性和完整性以及试验对方案的忠实度，方案与本文全文可在 NEJM.org 获取。,0.3076923076923077,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",2584,"['作者保证数据的准确性和完整性以及审判对议定书的忠诚性,可在NEJM.org上提供本文的完整文本。']",0.4615384615384615,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'this', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'full']",,
2627,2585,"the trial treatments were paid for by medical insurance , and the trial was supported by the National Cancer Institute .",试验治疗由医疗保险支付，试验得到美国国家癌症研究所的支持。,0.5,"['cancer', 'medical', 'insurance', 'institute', 'trial', 'medical insurance', 'by', 'and']","['cancer', 'insurance', 'institute', 'by']",2585,"['试验治疗是由医疗保险支付的,试验由国家癌症研究所支持。']",0.5,"['cancer', 'medical', 'insurance', 'institute', 'trial', 'medical insurance', 'by', 'and']","['cancer', 'insurance', 'institute', 'by']",,
2628,2586,all the patients were registered through the National Cancer Institute Oncology Patient Enrollment Network .,所有患者均通过国家癌症研究所肿瘤患者登记网络登记。,0.8,"['cancer', 'network', 'institute', 'patient', 'all']","['cancer', 'network', 'institute', 'patient']",2586,['所有患者都通过国立癌症研究所肿瘤病人登记网络注册。'],0.8,"['cancer', 'network', 'institute', 'patient', 'all']","['cancer', 'network', 'institute', 'patient']",,
2629,2587,treatment was randomly assigned at the GOG Statistical and Data Center and was concealed until registration with verification of eligibility .,治疗是在 GOG 统计和数据中心随机分配的，并且在通过资格验证进行注册之前是隐藏的。,0.75,"['verification', 'center', 'data', 'registration', 'concealed', 'treatment', 'with', 'and']","['verification', 'center', 'data', 'registration', 'concealed', 'treatment']",2587,"['处理随机在GOG统计和数据中心授予,并被隐藏到登记,并确认可用性。']",0.5,"['verification', 'center', 'data', 'registration', 'concealed', 'treatment', 'with', 'and']","['center', 'data', 'registration', 'treatment']",,
2630,2588,randomization was stratified according to age and the presence or absence of gross residual disease .,根据年龄和是否存在大体残留病灶对随机化进行分层。,0.5,"['presence', 'disease', 'randomization', 'absence', 'age', 'gross', 'residual', 'to']","['presence', 'disease', 'randomization', 'age']",2588,['随机化根据年龄和残疾的存在或缺席进行分类。'],0.5,"['presence', 'disease', 'randomization', 'absence', 'age', 'gross', 'residual', 'to']","['presence', 'randomization', 'absence', 'age']",,
2631,2589,treatment AND ASSESSMENTS,治疗和评估,1.0,['treatment'],['treatment'],2589,['治疗与辅助'],1.0,['treatment'],['treatment'],,
2632,2590,the two treatment regimens were randomly assigned in a 1 : 1 ratio within permuted blocks .,两种治疗方案在排列区内以 1:1 的比例随机分配。,0.6666666666666666,"['a', '1', 'ratio', 'treatment', 'in', 'two']","['1', 'ratio', 'treatment', 'two']",2590,"['两种治疗模式随机分为1:1的比例,在转型区块内。']",0.6666666666666666,"['a', '1', 'ratio', 'treatment', 'in', 'two']","['1', 'ratio', 'treatment', 'two']",,
2633,2591,the planned total dose was 4500 cGy in 25 fractions at 180 cGy per fraction .,计划总剂量为 4500 cGy，分 25 次，每次 180 cGy。,0.0,"['total', 'total dose', 'fraction', 'at', 'in']",[],2591,"['计划的总剂量为4500cGy在25分,每分180cGy。']",0.0,"['total', 'total dose', 'fraction', 'at', 'in']",[],,
2634,2592,"disease assessments included computed tomography ( CT ) of the abdomen and pelvis and chest radiography at baseline , the end of treatment , every 6 months for the first 2 years , and then annually up to 5 years .",疾病评估包括腹部和骨盆的计算机断层扫描 (CT)，以及基线时的胸片、治疗结束时、前 2 年每 6 个月一次，然后每年一次，最多 5 年。,0.5625,"['abdomen', 'pelvis', 'tomography', '5', 'disease', 'chest', 'baseline', 'radiography', '2', 'treatment', 'end', 'CT', 'up', 'computed tomography', 'and', 'first']","['abdomen', 'pelvis', 'tomography', '5', 'disease', 'chest', 'baseline', '2', 'treatment']",2592,"['疾病评估包括腹部和阴道和乳房的计算图(CT)在基线上,治疗结束,每6个月为前2年,然后每年高达5年。']",0.375,"['abdomen', 'pelvis', 'tomography', '5', 'disease', 'chest', 'baseline', 'radiography', '2', 'treatment', 'end', 'CT', 'up', 'computed tomography', 'and', 'first']","['abdomen', '5', 'disease', 'baseline', '2', 'treatment']",,
2635,2593,"safety assessments included recording of adverse events and concomitant medications , physical examination , and hematologic and chemical testing on the same schedule .",安全性评估包括记录不良事件和合并用药、体格检查以及按同一时间表进行的血液学和化学测试。,0.25,"['safety', 'recording', 'chemical', 'physical', 'examination', 'physical examination', 'concomitant', 'adverse', 'schedule', 'testing', 'and', 'hematologic']","['safety', 'recording', 'examination']",2593,['安全评估包括在同一时间表上记录不良事件和同步药物、物理检查以及血液和化学测试。'],0.25,"['safety', 'recording', 'chemical', 'physical', 'examination', 'physical examination', 'concomitant', 'adverse', 'schedule', 'testing', 'and', 'hematologic']","['safety', 'recording', 'examination']",,
2636,2594,"adverse events were graded with the use of the Common Terminology Criteria for Adverse Events ( CTCAE ) , version 3.0 .",使用不良事件通用术语标准 (CTCAE) 3.0 版对不良事件进行分级。,0.2,"['version', 'common', 'adverse', 'terminology', 'with']",['terminology'],2594,"['此分類上一篇: 常用語言標準(Common Terminology Criteria for Adverse Events, CTCAE)']",0.0,"['version', 'common', 'adverse', 'terminology', 'with']",[],,
2637,2595,"a higher Trial Outcome Index , NTX , or gastrointestinal score suggests better quality of life or fewer symptoms .",较高的试验结果指数、NTX 或胃肠道评分表明生活质量较好或症状较少。,0.6,"['life', 'a', 'outcome', 'gastrointestinal', 'quality', 'index', 'symptoms', 'trial', 'quality of life', 'score']","['life', 'outcome', 'gastrointestinal', 'quality', 'index', 'quality of life']",2595,"['一个更高的测试结果指数,NTX,或胃肠分数表明更好的生活质量或更少的症状。']",0.7,"['life', 'a', 'outcome', 'gastrointestinal', 'quality', 'index', 'symptoms', 'trial', 'quality of life', 'score']","['life', 'outcome', 'gastrointestinal', 'quality', 'index', 'quality of life', 'score']",,
2638,2596,"assessments were completed before treatment ( at baseline ) , 1 week after completing radiation therapy or before cycle 3 of chemotherapy , and 18 and 70 weeks after the start of treatment .",评估在治疗前（基线时）、完成放疗后 1 周或化疗第 3 周期前以及治疗开始后 18 周和 70 周完成。,0.6153846153846154,"['chemotherapy', 'radiation', 'baseline', '1', 'cycle', 'treatment', 'week', 'after', '3', 'radiation therapy', 'start', 'before', 'and']","['chemotherapy', 'baseline', '1', 'cycle', 'treatment', 'week', 'after', 'before']",2596,"['评估是在治疗前完成(基线),放射治疗完成后1周或化疗3周前,治疗开始后18周和70周。']",0.6153846153846154,"['chemotherapy', 'radiation', 'baseline', '1', 'cycle', 'treatment', 'week', 'after', '3', 'radiation therapy', 'start', 'before', 'and']","['chemotherapy', 'radiation', 'baseline', '1', 'treatment', 'week', 'after', 'before']",,
2639,2597,quality ASSURANCE,质量保证,1.0,['quality'],['quality'],2597,['质量保险'],1.0,['quality'],['quality'],,
2640,2598,"the trial was open to enrollment between June 29 , 2009 , and July 28 , 2014 , and the data cutoff for analysis was March 9 , 2017 .",该试验于 2009 年 6 月 29 日至 2014 年 7 月 28 日期间开放注册，分析的数据截止日期为 2017 年 3 月 9 日。,0.2857142857142857,"['cutoff', 'data', 'analysis', 'march', 'open', 'trial', 'and']","['data', 'analysis']",2598,"['审判于2009年6月29日至2014年7月28日之间开放登记,分析数据截图为2017年3月9日。']",0.4285714285714285,"['cutoff', 'data', 'analysis', 'march', 'open', 'trial', 'and']","['data', 'analysis', 'trial']",,
2641,2599,"the GOG Pathology Committee verified histologic subtypes , grades , and stages for all patients .",GOG 病理学委员会验证了所有患者的组织学亚型、等级和分期。,0.5,"['pathology', 'committee', 'all', 'and']","['pathology', 'committee']",2599,['GOG 病理委员会对所有患者进行了 histological 子类、等级和阶段的验证。'],0.5,"['pathology', 'committee', 'all', 'and']","['pathology', 'committee']",,
2642,2600,"eligibility , surgery , and radiation plans were reviewed centrally .",对资格、手术和放疗计划进行集中审查。,0.3333333333333333,"['radiation', 'surgery', 'and']",['surgery'],2600,['可选性、手术和辐射计划进行了中心审查。'],0.6666666666666666,"['radiation', 'surgery', 'and']","['radiation', 'surgery']",,
2643,2601,"the trial chairs monitored eligibility , chemotherapy delivery and modifications , adverse events , and radiographic assessments .",试验主席监测了资格、化疗的实施和修改、不良事件和影像学评估。,0.1666666666666666,"['chemotherapy', 'radiographic', 'delivery', 'adverse', 'trial', 'and']",['chemotherapy'],2601,['审判席监测资格、化疗交付和修改、不良事件和放射性评估。'],0.5,"['chemotherapy', 'radiographic', 'delivery', 'adverse', 'trial', 'and']","['chemotherapy', 'delivery', 'trial']",,
2644,2602,"under the assumption of a decrease in the hazard of recurrence or death over time , a sample size of 804 was targeted .",假设随着时间的推移复发或死亡的风险降低，目标样本量为 804。,0.2727272727272727,"['sample', 'decrease', 'targeted', 'death', 'time', 'size', 'hazard', 'sample size', 'recurrence', 'in', 'over']","['sample', 'death', 'time']",2602,"['假设随着时间的推移,重复或死亡的风险下降,样品大小为804。']",0.3636363636363636,"['sample', 'decrease', 'targeted', 'death', 'time', 'size', 'hazard', 'sample size', 'recurrence', 'in', 'over']","['sample', 'death', 'time', 'size']",,
2645,2603,two interim analyses were planned when 42 % ( 105 ) and 83 % ( 210 ) of the expected number of recurrences or deaths had been reported .,当报告的复发或死亡人数达到预期的 42% (105) 和 83% (210) 时，计划进行两次中期分析。,0.5,"['number', 'expected number', 'and', 'two']","['number', 'two']",2603,['两次临时分析是在预期重复或死亡人数的42%(105)和83%(210)被报告时进行的。'],0.5,"['number', 'expected number', 'and', 'two']","['number', 'two']",,
2646,2604,these were reported to the data and safety monitoring board in September 2013 and January 2016 .,这些已于 2013 年 9 月和 2016 年 1 月报告给数据和安全监测委员会。,0.6,"['safety', 'monitoring', 'data', 'board', 'and']","['safety', 'monitoring', 'data']",2604,['这些报告于2013年9月和2016年1月向数据和安全监测委员会报告。'],0.6,"['safety', 'monitoring', 'data', 'board', 'and']","['safety', 'monitoring', 'data']",,
2647,2605,no action was taken to alter the conduct of the trial on the basis of those interim analyses .,没有采取任何行动来根据这些临时分析改变试验的进行。,0.0,"['basis', 'action', 'no', 'trial', 'conduct', 'to']",[],2605,"['根据这些临时分析,没有采取任何措施改变审判的进程。']",0.1666666666666666,"['basis', 'action', 'no', 'trial', 'conduct', 'to']",['trial'],,
2648,2606,"enrollment concluded with 813 patients ; 77 were deemed ineligible , most commonly because of an inappropriate cancer stage or a lack of pathological documentation .",入组结束时有 813 名患者； 77 人被认为不合格，最常见的原因是癌症分期不当或缺乏病理文件。,0.3333333333333333,"['stage', 'lack', 'cancer', 'documentation', 'pathological', 'with']","['stage', 'cancer']",2606,"['注册结束了813名患者;77人被认为是不可接受的,最常因不适当的癌症阶段或缺乏病理文件。']",0.1666666666666666,"['stage', 'lack', 'cancer', 'documentation', 'pathological', 'with']",['cancer'],,
2649,2607,"in addition , 29 eligible patients were never treated , with 24 of those having been assigned to the chemoradiotherapy group .",此外，29 名符合条件的患者从未接受过治疗，其中 24 名患者被分配到放化疗组。,0.1666666666666666,"['group', 'addition', 'with', 'in', 'to', 'eligible']",['group'],2607,"['此外,29名有资格的患者从未接受过治疗,其中24名已被分配给化疗组。']",0.1666666666666666,"['group', 'addition', 'with', 'in', 'to', 'eligible']",['group'],,
2650,2608,"the safety analysis included all eligible and treated patients , whereas the efficacy analysis included all eligible patients , regardless of whether they received treatment .",安全性分析包括所有符合条件和接受治疗的患者，而疗效分析包括所有符合条件的患者，无论他们是否接受治疗。,0.5,"['safety', 'analysis', 'treatment', 'efficacy', 'safety analysis', 'all', 'and', 'eligible']","['safety', 'analysis', 'treatment', 'and']",2608,"['安全分析包括所有有资格和接受治疗的患者,而有效分析包括所有有资格的患者,无论他们是否接受治疗。']",0.625,"['safety', 'analysis', 'treatment', 'efficacy', 'safety analysis', 'all', 'and', 'eligible']","['safety', 'analysis', 'treatment', 'safety analysis', 'and']",,
2651,2609,characteristics of the patient and the tumors are shown in Table 1 .,患者和肿瘤的特征如表1所示。,0.6666666666666666,"['table', '1', 'characteristics', 'patient', 'in', 'and']","['table', '1', 'characteristics', 'patient']",2609,['病人和肿瘤的特征在表1中显示。'],0.6666666666666666,"['table', '1', 'characteristics', 'patient', 'in', 'and']","['table', '1', 'characteristics', 'patient']",,
2652,2610,"the performance status score was 0 for 74 % of enrolled patients , and the endometrioid histologic type was predominant .",74% 的登记患者的体能状态评分为 0，并且子宫内膜样组织学类型占主导地位。,0.4285714285714285,"['type', 'endometrioid', 'status', 'predominant', 'score', 'performance', 'and']","['type', 'endometrioid', 'status']",2610,"['性能状态分为74%的病人,而内分泌物的催眠类型占主导地位。']",0.5714285714285714,"['type', 'endometrioid', 'status', 'predominant', 'score', 'performance', 'and']","['type', 'status', 'performance', 'and']",,
2653,2611,"stratification factors were balanced between the treatment groups , with nearly 98 % of patients having no gross residual disease .",治疗组之间的分层因素是平衡的，近 98% 的患者没有大体残留病灶。,0.4285714285714285,"['stratification', 'disease', 'treatment', 'no', 'gross', 'residual', 'with']","['stratification', 'disease', 'treatment']",2611,"['治疗小组之间的分裂因素均衡,几乎98%的患者没有重残疾。']",0.1428571428571428,"['stratification', 'disease', 'treatment', 'no', 'gross', 'residual', 'with']",['treatment'],,
2654,2612,"surgery to remove lymph nodes was reported in more than 94 % of patients , with a median number of 13 pelvic nodes and 3 paraaortic nodes removed .",据报道，超过 94% 的患者接受了淋巴结切除手术，切除的中位数为 13 个盆腔淋巴结和 3 个主动脉旁淋巴结。,0.3636363636363636,"['median', 'lymph', 'lymph nodes', 'surgery', 'number', 'remove', '3', 'with', 'in', 'to', 'and']","['lymph', 'lymph nodes', 'surgery', 'number']",2612,"['在94%以上的患者中报告了移除淋巴节的手术,中间13个阴道节和3个阴道节被移除。']",0.1818181818181818,"['median', 'lymph', 'lymph nodes', 'surgery', 'number', 'remove', '3', 'with', 'in', 'to', 'and']","['lymph', 'surgery']",,
2655,2613,"overall , 75 % of patients completed all prescribed chemoradiotherapy in a median period of 21 weeks .",总体而言，75% 的患者在中位 21 周的时间内完成了所有规定的化放疗。,0.0,"['period', 'median', 'all', 'in']",[],2613,"['总体而言,75%的患者在21周的平均时间内完成了所有处方化疗。']",0.0,"['period', 'median', 'all', 'in']",[],,
2656,2614,"two cycles of cisplatin were coadministered with radiation to more than 85 % of patients in the chemoradiotherapy group , and 75 % of the patients in that group received all four planned cycles of carboplatin and paclitaxel .",放化疗组中超过 85% 的患者同时接受了两个周期的顺铂和放疗，并且该组中 75% 的患者接受了所有四个计划周期的卡铂和紫杉醇。,0.4545454545454545,"['group', 'radiation', 'cisplatin', 'with', 'carboplatin', 'paclitaxel', 'all', 'that', 'to', 'and', 'two']","['group', 'cisplatin', 'carboplatin', 'paclitaxel', 'two']",2614,"['两周的西斯普拉丁与辐射伴随了85%以上的化疗患者,75%的患者接受了四个计划的碳普拉丁和帕克利塔克萨尔周期。']",0.2727272727272727,"['group', 'radiation', 'cisplatin', 'with', 'carboplatin', 'paclitaxel', 'all', 'that', 'to', 'and', 'two']","['radiation', 'that', 'two']",,
2657,2615,between 8 and 10 % of patients discontinued treatment due to adverse events .,8% 到 10% 的患者因不良事件而停止治疗。,0.4,"['adverse', 'treatment', 'due', 'to', 'and']","['treatment', 'and']",2615,['8%至10%的患者因副作用而停止治疗。'],0.4,"['adverse', 'treatment', 'due', 'to', 'and']","['treatment', 'and']",,
2658,2616,toxicity,毒性,1.0,['toxicity'],['toxicity'],2616,['毒性'],1.0,['toxicity'],['toxicity'],,
2659,2617,"Table 2 shows acute adverse events , regardless of attribution to the trial intervention , in the 707 eligible participants who initiated treatment .",表 2 显示了 707 名开始治疗的合格参与者的急性不良事件，无论归因于试验干预。,0.5454545454545454,"['table', 'who', '2', 'adverse', 'treatment', 'intervention', 'trial', 'acute', 'attribution', 'to', 'eligible']","['table', '2', 'treatment', 'attribution', 'to', 'eligible']",2617,"['图2显示,无论涉及到审判干预的情况如何,在707名合格的参与者开始治疗的急性副作用。']",0.3636363636363636,"['table', 'who', '2', 'adverse', 'treatment', 'intervention', 'trial', 'acute', 'attribution', 'to', 'eligible']","['2', 'treatment', 'trial', 'eligible']",,
2660,2618,"constitutional symptoms , fatigue , gastrointestinal events , renal or genitourinary events , and musculoskeletal events were significantly more frequent per grade in the chemoradiotherapy group .",全身症状、疲劳、胃肠道事件、肾脏或泌尿生殖系统事件以及肌肉骨骼事件在化放疗组中每个年级的发生率明显更高。,0.3636363636363636,"['group', 'fatigue', 'grade', 'gastrointestinal', 'symptoms', 'musculoskeletal', 'constitutional', 'renal', 'genitourinary', 'frequent', 'and']","['group', 'fatigue', 'grade', 'gastrointestinal']",2618,['宪法症状、疲劳、肠道事件、肾脏或尿道事件和肌肉骨骼事件在化学放射治疗小组中显著频繁。'],0.1818181818181818,"['group', 'fatigue', 'grade', 'gastrointestinal', 'symptoms', 'musculoskeletal', 'constitutional', 'renal', 'genitourinary', 'frequent', 'and']","['group', 'fatigue']",,
2661,2619,late toxic effects are summarized in Table S2 in the Supplementary Appendix .,补充附录表 S2 总结了晚期毒性作用。,0.1428571428571428,"['appendix', 'table', 'toxic', 'supplementary', 'late', 'S2', 'in']",['table'],2619,['延迟的毒性效应在附件中的S2表中总结。'],0.2857142857142857,"['appendix', 'table', 'toxic', 'supplementary', 'late', 'S2', 'in']","['appendix', 'table']",,
2662,2620,the results with regard to the primary end point did not reach significance .,关于主要终点的结果没有达到显着性。,0.2857142857142857,"['primary', 'significance', 'end', 'point', 'with', 'to', 'reach']","['point', 'to']",2620,['与初级终点有关的结果没有达到意义。'],0.2857142857142857,"['primary', 'significance', 'end', 'point', 'with', 'to', 'reach']","['significance', 'point']",,
2663,2621,a sensitivity analysis indicated that the results observed in the eligible treated population were consistent with the results among all eligible patients .,敏感性分析表明，在符合条件的治疗人群中观察到的结果与在所有符合条件的患者中观察到的结果一致。,0.25,"['population', 'analysis', 'with', 'sensitivity', 'all', 'that', 'in', 'eligible']","['population', 'analysis']",2621,"['敏感性分析表明,接受治疗的人口所观察的结果与所有接受治疗的患者的结果一致。']",0.25,"['population', 'analysis', 'with', 'sensitivity', 'all', 'that', 'in', 'eligible']","['population', 'analysis']",,
2664,2622,"of those deaths , 73 % and 81 % , respectively , were due to endometrial cancer progression .",在这些死亡中，分别有 73% 和 81% 是由于子宫内膜癌的进展。,0.5,"['cancer', 'endometrial', 'progression', 'due', 'to', 'and']","['cancer', 'progression', 'to']",2622,['73%和81%的死亡是由于内分泌癌症的进展。'],0.5,"['cancer', 'endometrial', 'progression', 'due', 'to', 'and']","['cancer', 'progression', 'to']",,
2665,2623,the data on overall survival are not sufficiently mature to allow comparison between the groups .,总生存期的数据不够成熟，无法进行组间比较。,0.5,"['data', 'survival', 'comparison', 'allow', 'mature', 'to']","['data', 'survival', 'comparison']",2623,['总体生存数据不足以使群体进行比较。'],0.5,"['data', 'survival', 'comparison', 'allow', 'mature', 'to']","['data', 'survival', 'comparison']",,
2666,2624,"this was shown in both the Post Operative Radiation Therapy in Endometrial Carcinoma ( PORTEC ) 1 trial and the GOG 99 trial , 17,19 and its use in this context remains tailored to women who are considered to be at high risk for relapse.20","这在子宫内膜癌术后放射治疗 (PORTEC) 1 试验和 GOG 99 试验 17,19 中均有体现，其在这种情况下的使用仍然针对被认为具有高复发风险的女性。 20",0.4375,"['carcinoma', 'radiation', 'context', 'who', '1', 'high risk', 'endometrial', 'therapy', 'be', 'post', 'operative', 'radiation therapy', 'endometrial carcinoma', 'this', 'to', 'and']","['carcinoma', 'radiation', '1', 'therapy', 'be', 'operative', 'endometrial carcinoma']",2624,"['这一点在内分泌癌症(PORTEC)1试验和GOG99试验(17,19)中都被证明,其在这种情况下使用仍然适用于被认为患有复发风险高的妇女。']",0.3125,"['carcinoma', 'radiation', 'context', 'who', '1', 'high risk', 'endometrial', 'therapy', 'be', 'post', 'operative', 'radiation therapy', 'endometrial carcinoma', 'this', 'to', 'and']","['carcinoma', '1', 'be', 'operative', 'to']",,
2667,2625,"however , given the competing risk of distant metastasis , which has led to the implementation of chemotherapy as the standard of care , 9 the role of radiotherapy remains uncertain .",然而，考虑到远处转移的竞争风险，导致化疗成为标准治疗的实施，9 放疗的作用仍不确定。,0.4166666666666667,"['chemotherapy', 'standard', 'metastasis', 'uncertain', 'radiotherapy', 'implementation', 'role', 'risk', 'distant', 'care', 'to', 'led']","['chemotherapy', 'standard', 'metastasis', 'role', 'risk']",2625,"['然而,鉴于远程转移的竞争风险,导致化疗作为护理标准的实施,9放射治疗的作用仍然不确定。']",0.5833333333333334,"['chemotherapy', 'standard', 'metastasis', 'uncertain', 'radiotherapy', 'implementation', 'role', 'risk', 'distant', 'care', 'to', 'led']","['chemotherapy', 'standard', 'metastasis', 'radiotherapy', 'role', 'risk', 'to']",,
2668,2626,this trial prospectively evaluated the effect of combined chemotherapy plus radiotherapy in patients with stage III or IVA endometrial carcinoma as compared with the effect of chemotherapy alone .,该试验前瞻性地评估了联合化疗加放疗对 III 期或 IVA 期子宫内膜癌患者的疗效，并与单独化疗的疗效进行了比较。,0.5,"['stage', 'chemotherapy', 'carcinoma', 'plus', 'endometrial', 'radiotherapy', 'effect', 'as', 'with', 'endometrial carcinoma', 'this', 'alone']","['stage', 'chemotherapy', 'carcinoma', 'plus', 'endometrial carcinoma', 'alone']",2626,"['在此研究中,有前途评估了三阶段或IVA内分泌癌症患者的结合化疗以及放射治疗的效果,而仅与化疗的效果相比。']",0.3333333333333333,"['stage', 'chemotherapy', 'carcinoma', 'plus', 'endometrial', 'radiotherapy', 'effect', 'as', 'with', 'endometrial carcinoma', 'this', 'alone']","['chemotherapy', 'carcinoma', 'radiotherapy', 'effect']",,
2669,2627,"with the revision of the FIGO staging system in 2009,23 the trial was amended to exclude patients with peritoneal washings that were positive for cancer cells but with no evidence of extrauterine endometrioid tumor , because such patients have better outcomes than other patients with stage III disease.24,25","随着 2009 年 FIGO 分期系统的修订，23 对试验进行了修订，排除了腹膜冲洗液为癌细胞阳性但没有宫外子宫内膜样肿瘤证据的患者，因为这些患者的预后优于其他 III 期疾病患者.24,25",0.5,"['stage', 'cancer', 'endometrioid', 'system', 'tumor', 'extrauterine', 'no', 'trial', 'peritoneal', 'evidence', 'cancer cells', 'exclude', 'with', 'revision', 'positive', 'have', 'that', 'but']","['stage', 'cancer', 'endometrioid', 'system', 'tumor', 'evidence', 'cancer cells', 'have', 'but']",2627,"['通过2009年FIGO排行系统的修订,23该试验被修改,以排除对癌细胞有积极的周围洗<unk>的患者,但没有非子宫内分泌肿瘤的证据,因为这些患者比其他患有第三阶段疾病的患者有更好的结果。']",0.3888888888888889,"['stage', 'cancer', 'endometrioid', 'system', 'tumor', 'extrauterine', 'no', 'trial', 'peritoneal', 'evidence', 'cancer cells', 'exclude', 'with', 'revision', 'positive', 'have', 'that', 'but']","['cancer', 'system', 'tumor', 'evidence', 'cancer cells', 'have', 'but']",,
2670,2628,"although surgical staging was not mandated , the majority of patients underwent full staging procedures .",尽管未强制要求进行手术分期，但大多数患者都接受了完整的分期程序。,0.6666666666666666,"['surgical', 'majority', 'full']","['majority', 'full']",2628,"['虽然手术不被授权,但大多数患者都接受了完整的手术。']",0.6666666666666666,"['surgical', 'majority', 'full']","['majority', 'full']",,
2671,2629,"in the GOG 122 trial , overall survival at 60 months was 10 percentage points higher among patients who received doxorubicin and platinum than among those treated with whole abdominal radiotherapy.9",在 GOG 122 试验中，接受多柔比星和铂类治疗的患者的 60 个月总生存期比接受全腹部放疗的患者高 10 个百分点。 9,0.2,"['percentage', 'doxorubicin', 'who', 'survival', 'platinum', 'abdominal', 'trial', 'with', 'whole', 'and']","['survival', 'platinum']",2629,"['在GOG122试验中,60个月的总生存率在接受多克索鲁比素和柏拉丁的患者中比接受全腹部放射治疗的患者中高10个百分点。']",0.1,"['percentage', 'doxorubicin', 'who', 'survival', 'platinum', 'abdominal', 'trial', 'with', 'whole', 'and']",['survival'],,
2672,2630,"full delivery of chemotherapy was diminished by the addition of radiotherapy , with only 75 % of women completing the four planned courses in the chemoradiotherapy group .",放疗的加入减少了化疗的完全实施，放化疗组只有 75% 的女性完成了四个计划疗程。,0.3,"['group', 'chemotherapy', 'addition', 'courses', 'radiotherapy', 'delivery', 'with', 'full', 'in', 'by']","['group', 'chemotherapy', 'addition']",2630,"['由于放射治疗的补充,化疗的全部供应减少了,只有75%的妇女在化疗组完成了计划的四个课程。']",0.6,"['group', 'chemotherapy', 'addition', 'courses', 'radiotherapy', 'delivery', 'with', 'full', 'in', 'by']","['group', 'chemotherapy', 'addition', 'radiotherapy', 'full', 'by']",,
2673,2631,"because these results have not been validated prospectively , they should not be adopted without further study .",由于这些结果尚未得到前瞻性验证，因此不应在没有进一步研究的情况下采用。,0.25,"['study', 'be', 'have not', 'without']",['be'],2631,"['由于这些结果未经前瞻性验证,因此不应在未进行进一步研究的情况下接受。']",0.25,"['study', 'be', 'have not', 'without']",['be'],,
2674,2632,late second cancers are also a risk .,晚期第二种癌症也是一种风险。,0.25,"['a', 'late', 'risk', 'second']",['risk'],2632,['第二次癌症也是危险的。'],0.5,"['a', 'late', 'risk', 'second']","['risk', 'second']",,
2675,2633,our data are compatible with the hypothesis from previous studies that completion of chemotherapy is important for the prevention of distant relapse .,我们的数据与之前研究的假设相符，即完成化疗对于预防远处复发很重要。,0.5454545454545454,"['chemotherapy', 'relapse', 'compatible', 'data', 'hypothesis', 'previous', 'prevention', 'distant', 'completion', 'with', 'that']","['chemotherapy', 'relapse', 'data', 'hypothesis', 'prevention', 'completion']",2633,"['我们的数据与以前的研究的假设相匹配,即完成化疗对远程复发的预防至关重要。']",0.6363636363636364,"['chemotherapy', 'relapse', 'compatible', 'data', 'hypothesis', 'previous', 'prevention', 'distant', 'completion', 'with', 'that']","['chemotherapy', 'relapse', 'data', 'hypothesis', 'previous', 'prevention', 'completion']",,
2676,2634,patients were randomly assigned in a 3 : 1 ratio to receive HTTRx or placebo as a bolus intrathecal administration every 4 weeks for four doses .,患者以 3:1 的比例随机分配接受 HTTRx 或安慰剂作为鞘内推注给药，每 4 周一次，共 4 个剂量。,0.4444444444444444,"['placebo', '1', 'ratio', 'administration', '3', '4', 'as', 'bolus', 'to']","['placebo', '1', 'ratio', 'bolus']",2634,"['病人随机分配为3:1的比例,以接受HTTRx或 placebo作为每4周的Bolus intrathecal剂量,为期4剂量。']",0.2222222222222222,"['placebo', '1', 'ratio', 'administration', '3', '4', 'as', 'bolus', 'to']","['1', 'ratio']",,
2677,2635,dose selection was guided by a preclinical model in mice and nonhuman primates that related dose level to reduction in the concentration of huntingtin .,剂量选择由小鼠和非人灵长类动物的临床前模型指导，该模型将剂量水平与亨廷顿蛋白浓度的降低相关联。,0.7272727272727273,"['primates', 'concentration', 'model', 'reduction', 'preclinical', 'level', 'dose', 'that', 'by', 'to', 'and']","['primates', 'concentration', 'model', 'reduction', 'preclinical', 'level', 'dose', 'by']",2635,"['剂量选择是由一个临床模型在老鼠和非人类原体,与剂量水平相关的减少在浓度的<unk>丁。']",0.5454545454545454,"['primates', 'concentration', 'model', 'reduction', 'preclinical', 'level', 'dose', 'that', 'by', 'to', 'and']","['concentration', 'model', 'reduction', 'level', 'dose', 'by']",,
2678,2636,the primary end point was safety .,主要终点是安全性。,0.5,"['safety', 'primary', 'end', 'point']","['safety', 'point']",2636,['主要的终点是安全。'],0.75,"['safety', 'primary', 'end', 'point']","['safety', 'primary', 'point']",,
2679,2636,the primary end point was safety .,主要终点是安全性。,0.5,"['safety', 'primary', 'end', 'point']","['safety', 'point']",2636,['主要的终点是安全。'],0.75,"['safety', 'primary', 'end', 'point']","['safety', 'primary', 'point']",,
2680,2637,the secondary end point was HTTRx pharmacokinetics in cerebrospinal fluid ( CSF ) .,次要终点是 HTTRx 在脑脊液 (CSF) 中的药代动力学。,0.6666666666666666,"['cerebrospinal fluid', 'pharmacokinetics', 'secondary', 'end', 'point', 'CSF']","['cerebrospinal fluid', 'pharmacokinetics', 'point', 'CSF']",2637,['其次的终点是心血管液中的HTTRx药理学(CSF)。'],0.1666666666666666,"['cerebrospinal fluid', 'pharmacokinetics', 'secondary', 'end', 'point', 'CSF']",['point'],,
2681,2638,prespecified exploratory end points included the concentration of mutant huntingtin in CSF .,预先指定的探索性终点包括脑脊液中突变亨廷顿蛋白的浓度。,0.6,"['mutant', 'concentration', 'end points', 'exploratory', 'CSF']","['concentration', 'end points', 'CSF']",2638,['预定的探索终点包括在CSF中突变狩猎的浓度。'],0.4,"['mutant', 'concentration', 'end points', 'exploratory', 'CSF']","['concentration', 'end points']",,
2682,2639,"of the 46 patients who were enrolled in the trial , 34 were randomly assigned to receive HTTRx ( at ascending dose levels of 10 to 120 mg ) and 12 were randomly assigned to receive placebo .",在参加该试验的 46 名患者中，34 名被随机分配接受 HTTRx（递增剂量水平为 10 至 120 毫克），12 名被随机分配接受安慰剂。,0.25,"['ascending', 'placebo', 'who', 'trial', 'at', 'dose', 'to', 'and']","['placebo', 'dose']",2639,"['在46名受试者中,34人随机分配接受HTTRx(增加剂量为10至120毫克),12人随机分配接受 placebo。']",0.125,"['ascending', 'placebo', 'who', 'trial', 'at', 'dose', 'to', 'and']",['dose'],,
2683,2640,each patient received all four doses and completed the trial .,每位患者都接受了所有四种剂量并完成了试验。,0.2,"['patient', 'trial', 'all', 'each', 'and']",['patient'],2640,"['每个患者都接受了四个剂量,并完成了测试。']",0.2,"['patient', 'trial', 'all', 'each', 'and']",['patient'],,
2684,2641,"adverse events , all of grade 1 or 2 , were reported in 98 % of the patients .",98% 的患者报告了所有 1 级或 2 级的不良事件。,0.3333333333333333,"['1', '2', 'grade', 'adverse', 'all', 'in']","['1', '2']",2641,"['所有1级或2级的副作用,已在98%的患者中报告。']",0.3333333333333333,"['1', '2', 'grade', 'adverse', 'all', 'in']","['1', '2']",,
2685,2642,there were no clinically relevant adverse changes in laboratory variables .,实验室变量没有临床相关的不良变化。,0.25,"['adverse', 'no', 'laboratory', 'in']",['laboratory'],2642,['实验室变量中没有临床上相关的负面变化。'],0.25,"['adverse', 'no', 'laboratory', 'in']",['laboratory'],,
2686,2643,predose ( trough ) concentrations of HTTRx in CSF showed dose dependence up to doses of 60 mg .,CSF 中 HTTRx 的给药前（谷值）浓度在高达 60 mg 的剂量下表现出剂量依赖性。,0.125,"['dependence', 'trough', 'up', 'CSF', 'dose', 'concentrations', 'in', 'to']",['dose'],2643,"['在CSF中,HTTRx的预剂量(微量)浓度显示到60毫克的剂量依赖。']",0.125,"['dependence', 'trough', 'up', 'CSF', 'dose', 'concentrations', 'in', 'to']",['dose'],,
2687,2645,the trial protocol ( available with the full text of this article at NEJM.org ) and all documentation were approved by the institutional review board or independent ethics committee at each investigational site .,试验方案（与本文全文可在 NEJM.org 上获取）和所有文件均由每个研究中心的机构审查委员会或独立伦理委员会批准。,0.2105263157894736,"['site', 'documentation', 'review', 'protocol', 'article', 'ethics', 'available', 'board', 'committee', 'trial', 'independent', 'text', 'with', 'full', 'all', 'this', 'each', 'by', 'and']","['review', 'protocol', 'committee', 'by']",2645,['审判议定书(可在NEJM.org上找到本文的完整文本)和所有文件都由机构审查委员会或每个调查网站的独立伦理委员会批准。'],0.3157894736842105,"['site', 'documentation', 'review', 'protocol', 'article', 'ethics', 'available', 'board', 'committee', 'trial', 'independent', 'text', 'with', 'full', 'all', 'this', 'each', 'by', 'and']","['review', 'protocol', 'committee', 'trial', 'full', 'by']",,
2688,2646,"the trial was sponsored by Ionis Pharmaceuticals , which provided the trial agents ( HTTRx and placebo ) .",该试验由 Ionis Pharmaceuticals 赞助，该公司提供了试验药物（HTTRx 和安慰剂）。,0.5,"['placebo', 'trial', 'by', 'and']","['placebo', 'by']",2646,"['该试验是由Ionis Pharmaceuticals赞助的,该试验机构(HTTRx和 placebo)提供。']",0.25,"['placebo', 'trial', 'by', 'and']",['by'],,
2689,2647,"an independent data and safety monitoring board authorized each dose escalation after unblinded review of safety data and consultation with the sponsor , Ionis Pharmaceuticals .",一个独立的数据和安全监测委员会在对安全数据进行非盲审查并与赞助商 Ionis Pharmaceuticals 协商后批准了每次剂量升级。,0.5384615384615384,"['safety', 'monitoring', 'data', 'review', 'sponsor', 'consultation', 'board', 'after', 'independent', 'with', 'dose', 'each', 'and']","['safety', 'monitoring', 'data', 'review', 'after', 'independent', 'dose']",2647,"['一个独立的数据和安全监测委员会在安全数据的盲目审查和与赞助商Ionis Pharmaceuticals的协商后,授权了每个剂量升级。']",0.5384615384615384,"['safety', 'monitoring', 'data', 'review', 'sponsor', 'consultation', 'board', 'after', 'independent', 'with', 'dose', 'each', 'and']","['safety', 'monitoring', 'data', 'review', 'after', 'independent', 'dose']",,
2690,2648,"the investigators collected the data , which were held and maintained by the sponsor .",调查人员收集了数据，这些数据由申办方持有和维护。,0.5,"['data', 'sponsor', 'by', 'and']","['data', 'by']",2648,['调查人员收集了由赞助商保留和维护的数据。'],0.5,"['data', 'sponsor', 'by', 'and']","['data', 'by']",,
2691,2649,data were analyzed by personnel from the sponsor and were interpreted by all the authors .,数据由申办方的人员进行分析，并由所有作者进行解读。,0.5,"['data', 'sponsor', 'personnel', 'all', 'by', 'and']","['data', 'personnel', 'by']",2649,"['数据由赞助商的工作人员分析,并由所有作者解释。']",0.5,"['data', 'sponsor', 'personnel', 'all', 'by', 'and']","['data', 'personnel', 'by']",,
2692,2650,the investigators vouch for the fidelity of the trial to the protocol and protocol amendments .,研究者保证试验忠实于方案和方案修正案。,0.0,"['fidelity', 'protocol', 'trial', 'and']",[],2650,['调查人员保证审判对议定书和议定书修正案的忠诚。'],0.5,"['fidelity', 'protocol', 'trial', 'and']","['protocol', 'trial']",,
2693,2651,the authors vouch for the completeness and accuracy of the data .,作者保证数据的完整性和准确性。,0.75,"['data', 'accuracy', 'completeness', 'and']","['data', 'accuracy', 'completeness']",2651,['作者保证数据的完整性和准确性。'],0.75,"['data', 'accuracy', 'completeness', 'and']","['data', 'accuracy', 'completeness']",,
2694,2652,the authors and sponsor made the decision to submit the manuscript for publication .,作者和赞助商决定投稿发表。,0.3333333333333333,"['sponsor', 'publication', 'manuscript', 'decision', 'to', 'and']","['publication', 'decision']",2652,['作者和赞助商决定提交手稿出版。'],0.5,"['sponsor', 'publication', 'manuscript', 'decision', 'to', 'and']","['publication', 'manuscript', 'decision']",,
2695,2653,"further details of the inclusion and exclusion criteria are provided in the Supplementary Appendix , available at NEJM.org .",补充附录中提供了纳入和排除标准的更多详细信息，补充附录可在 NEJM.org 获取。,0.0,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'available', 'at', 'and']",[],2653,"['更多关于包含和排除标准的详细信息在附加附件中提供,可在NEJM.org上找到。']",0.4285714285714285,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'available', 'at', 'and']","['appendix', 'inclusion', 'at']",,
2696,2654,"the trial was performed at nine centers in the United Kingdom , Germany , and Canada from August 2015 through November 2017 .",该试验于 2015 年 8 月至 2017 年 11 月在英国、德国和加拿大的九个中心进行。,0.2,"['november', 'kingdom', 'trial', 'at', 'and']",['at'],2654,['审判是在2015年8月至2017年11月在英国、德国和加拿大9个中心进行的。'],0.2,"['november', 'kingdom', 'trial', 'at', 'and']",['trial'],,
2697,2655,a cerebrospinal fluid ( CSF ) sample was obtained before each administration of HTTRx or placebo and either 4 or 8 weeks after the last dose was administered ( Figure 1 ) .,在每次 HTTRx 或安慰剂给药前以及最后一次给药后 4 或 8 周采集脑脊液 (CSF) 样本（图 1）。,0.5384615384615384,"['sample', 'placebo', 'cerebrospinal fluid', '1', 'figure', 'administration', 'after', '4', 'CSF', 'dose', 'before', 'each', 'and']","['sample', 'placebo', 'cerebrospinal fluid', '1', 'after', 'CSF', 'before']",2655,"['心血管液(CSF)样本在每一次服用HTTRx或 placebo之前获得,并在最后剂量服用后4至8周(图1)。']",0.3846153846153846,"['sample', 'placebo', 'cerebrospinal fluid', '1', 'figure', 'administration', 'after', '4', 'CSF', 'dose', 'before', 'each', 'and']","['sample', '1', 'after', 'dose', 'before']",,
2698,2656,the primary end point was the safety of HTTRx treatment .,主要终点是 HTTRx 治疗的安全性。,0.6,"['safety', 'treatment', 'primary', 'end', 'point']","['safety', 'treatment', 'point']",2656,['主要的终点是HTTRx治疗的安全性。'],0.8,"['safety', 'treatment', 'primary', 'end', 'point']","['safety', 'treatment', 'primary', 'point']",,
2699,2657,"safety evaluations included physical examination , neurologic examination , the Columbia Suicide Severity Rating Scale , laboratory assessments , vital signs , electrocardiograms , and safety neuroimaging sequences .",安全评估包括身体检查、神经系统检查、哥伦比亚自杀严重程度评定量表、实验室评估、生命体征、心电图和安全神经影像序列。,0.8333333333333334,"['safety', 'vital signs', 'scale', 'physical', 'examination', 'physical examination', 'laboratory', 'suicide', 'rating scale', 'and', 'electrocardiograms', 'neurologic']","['safety', 'vital signs', 'scale', 'examination', 'physical examination', 'laboratory', 'suicide', 'rating scale', 'electrocardiograms', 'neurologic']",2657,['安全评估包括物理检查、神经学检查、哥伦比亚自杀频率评估规模、实验室评估、重要迹象、电心图和安全神经图像序列。'],0.4166666666666667,"['safety', 'vital signs', 'scale', 'physical', 'examination', 'physical examination', 'laboratory', 'suicide', 'rating scale', 'and', 'electrocardiograms', 'neurologic']","['safety', 'examination', 'laboratory', 'suicide', 'neurologic']",,
2700,2658,the secondary end point was the characterization of the pharmacokinetics of HTTRx in CSF .,次要终点是 HTTRx 在 CSF 中的药代动力学特征。,0.3333333333333333,"['characterization', 'pharmacokinetics', 'secondary', 'end', 'point', 'CSF']","['pharmacokinetics', 'point']",2658,['其次的终点是HTTRx在CSF中的药物化学的特征。'],0.1666666666666666,"['characterization', 'pharmacokinetics', 'secondary', 'end', 'point', 'CSF']",['point'],,
2701,2659,measurement OF CEREBRAL VOLUME,脑容量测量,1.0,['measurement'],['measurement'],2659,['脑体积测量'],1.0,['measurement'],['measurement'],,
2702,2660,the primary objective of the trial was the evaluation of the safety of HTTRx treatment ( primary end point ) .,该试验的主要目的是评估 HTTRx 治疗的安全性（主要终点）。,0.375,"['safety', 'objective', 'evaluation', 'treatment', 'primary', 'trial', 'end', 'point']","['safety', 'treatment', 'point']",2660,['试验的主要目标是评估HTTRx治疗的安全性(初级终点)。'],0.375,"['safety', 'objective', 'evaluation', 'treatment', 'primary', 'trial', 'end', 'point']","['safety', 'treatment', 'point']",,
2703,2661,"adverse events and serious adverse events during the trial , laboratory tests ( in blood and CSF ) , vital signs , electrocardiographic measures , and observations from the Columbia Suicide Severity Rating Scale were summarized according to trial group .",根据试验组对试验期间的不良事件和严重不良事件、实验室检查（血液和脑脊液）、生命体征、心电图测量和哥伦比亚自杀严重程度评定量表的观察结果进行了总结。,0.6923076923076923,"['group', 'vital signs', 'scale', 'blood', 'adverse', 'trial', 'laboratory', 'suicide', 'CSF', 'rating scale', 'serious', 'and', 'electrocardiographic']","['group', 'vital signs', 'scale', 'blood', 'laboratory', 'suicide', 'CSF', 'rating scale', 'electrocardiographic']",2661,"['试验期间的不良事件和严重不良事件,实验室测试(血液和CSF),生命迹象,电心测量,以及来自哥伦比亚自杀频率评级规模的观察,根据试验组总结。']",0.3076923076923077,"['group', 'vital signs', 'scale', 'blood', 'adverse', 'trial', 'laboratory', 'suicide', 'CSF', 'rating scale', 'serious', 'and', 'electrocardiographic']","['group', 'blood', 'laboratory', 'suicide']",,
2704,2662,"where possible , pharmacokinetic variables were assessed for HTTRx in CSF ( secondary end point ) and plasma ( exploratory end point ) .",在可能的情况下，评估 CSF（次要终点）和血浆（探索性终点）中 HTTRx 的药代动力学变量。,0.3333333333333333,"['plasma', 'exploratory', 'secondary', 'end', 'point', 'CSF', 'pharmacokinetic', 'and', 'assessed']","['plasma', 'point', 'pharmacokinetic']",2662,"['在可能的情况下,HTTRx的药物化变量在CSF(二级终点)和血浆(探测终点)中被评估。']",0.3333333333333333,"['plasma', 'exploratory', 'secondary', 'end', 'point', 'CSF', 'pharmacokinetic', 'and', 'assessed']","['plasma', 'exploratory', 'point']",,
2705,2663,"because of the exploratory nature of this trial , adjustments for multiplicity of testing were not used .",由于该试验的探索性，未使用多重测试调整。,0.0,"['nature', 'exploratory', 'trial', 'multiplicity', 'testing', 'this']",[],2663,"['由于这项试验的探索性质,对多重试验的调整并没有被使用。']",0.1666666666666666,"['nature', 'exploratory', 'trial', 'multiplicity', 'testing', 'this']",['nature'],,
2706,2664,"from August 2015 through April 2017 , a total of 52 patients were screened for eligibility , and 46 patients underwent randomization according to the protocol .",从 2015 年 8 月到 2017 年 4 月，共有 52 名患者接受了资格筛选，46 名患者根据方案进行了随机分组。,0.25,"['a', 'randomization', 'protocol', 'total']",['randomization'],2664,"['截至2015年8月至2017年4月,共有52名患者被审查资格,46名患者根据议定书进行随机诊断。']",0.5,"['a', 'randomization', 'protocol', 'total']","['randomization', 'protocol']",,
2707,2665,"all the patients received all scheduled doses of the assigned trial agent ( HTTRx or placebo ) , and all the patients who had undergone randomization completed the trial according to the protocol . ( a diagram of the flow of patients through the trial is provided in Fig .",所有患者均接受了所有预定剂量的指定试验药物（HTTRx 或安慰剂），所有接受随机分组的患者均根据方案完成了试验。 （图 1 中提供了患者通过试验的流程图。,0.2727272727272727,"['diagram', 'placebo', 'randomization', 'fig', 'who', 'protocol', 'flow', 'trial', 'agent', 'all', 'in']","['placebo', 'randomization', 'flow']",2665,"['所有患者都接受了授予的试用药物(HTTRx或 placebo)的所有预定剂量,并根据协议完成了试用药物的所有患者(试用药物通过试用药物的流动图表在图中提供。']",0.1818181818181818,"['diagram', 'placebo', 'randomization', 'fig', 'who', 'protocol', 'flow', 'trial', 'agent', 'all', 'in']","['protocol', 'flow']",,
2708,2666,primary END POINT OF SAFETY,主要安全终点,0.0,['primary'],[],2666,['首要安全终点'],0.0,['primary'],[],,
2709,2667,the incidence of adverse events was similar among patients receiving HTTRx and those receiving placebo ( Table 2 ) .,接受 HTTRx 的患者和接受安慰剂的患者的不良事件发生率相似（表 2）。,0.5714285714285714,"['placebo', 'incidence', 'table', '2', 'adverse', 'and', 'similar']","['placebo', 'incidence', 'table', '2']",2667,['副作用的发病率在接受HTTRx的患者和接受 placebo的患者中是相似的(图2)。'],0.4285714285714285,"['placebo', 'incidence', 'table', '2', 'adverse', 'and', 'similar']","['incidence', '2', 'similar']",,
2710,2668,adverse events were reported in 98 % of the patients ; all events were mild ( 83 % ) or moderate ( 17 % ) in severity .,98% 的患者报告了不良事件；所有事件的严重程度均为轻度 (83%) 或中度 (17%)。,0.2,"['moderate', 'adverse', 'mild', 'all', 'in']",['mild'],2668,['在98%的病人中报告了不良事件;所有事件都是轻(83%)或适度(17%)的严重性。'],0.0,"['moderate', 'adverse', 'mild', 'all', 'in']",[],,
2711,2669,neither suicidal behavior nor serious suicidal ideation emerged in any patient during the trial .,在试验期间，任何患者均未出现自杀行为或严重的自杀意念。,0.4285714285714285,"['behavior', 'suicidal', 'patient', 'trial', 'ideation', 'serious', 'in']","['behavior', 'suicidal', 'patient']",2669,"['在任何患者中,没有自杀行为或严重的自杀想法在审判期间出现。']",0.5714285714285714,"['behavior', 'suicidal', 'patient', 'trial', 'ideation', 'serious', 'in']","['behavior', 'suicidal', 'patient', 'trial']",,
2712,2670,secondary END POINT,次要终点,0.0,['secondary'],[],2670,['二级终点'],0.0,['secondary'],[],,
2713,2671,HTTRx was measurable in the CSF of most patients who received doses of 30 mg or more .,大多数接受 30 mg 或更多剂量的患者的 CSF 中可测量 HTTRx。,0.0,"['who', 'CSF', 'in']",[],2671,['HTTRx 可在大多数接受 30 mg 或以上剂量的患者的 CSF 中测量。'],0.0,"['who', 'CSF', 'in']",[],,
2714,2672,no accumulation of HTTRx in CSF was observed over time .,随着时间的推移，未观察到 CSF 中 HTTRx 的积累。,0.1666666666666666,"['time', 'no', 'CSF', 'accumulation', 'in', 'over']",['time'],2672,"['随着时间的推移,CSF中没有HTTRx的积累。']",0.1666666666666666,"['time', 'no', 'CSF', 'accumulation', 'in', 'over']",['time'],,
2715,2673,exploratory END POINTS,探索性终点,0.0,['exploratory'],[],2673,['探索的终点'],0.0,['exploratory'],[],,
2716,2674,plasma Concentrations of HTTRx,HTTRx 的血浆浓度,0.5,"['plasma', 'concentrations']",['plasma'],2674,['HTTRx的血浆浓度'],0.5,"['plasma', 'concentrations']",['plasma'],,
2717,2675,the median peak plasma concentrations of HTTRx were reached within 4 hours after the bolus intrathecal administration and declined to less than 30 % of the peak concentration by 24 hours after administration .,HTTRx 的中位血浆峰浓度在鞘内推注给药后 4 小时内达到，给药后 24 小时降至峰浓度的 30% 以下。,0.4166666666666667,"['median', 'concentration', 'plasma', 'administration', 'after', 'peak', '4', 'bolus', 'concentrations', 'by', 'to', 'and']","['concentration', 'plasma', 'after', 'bolus', 'by']",2675,"['HTTRx的平均血浆浓度在服用后4小时内达到,并在服用后24小时下降至低于30%的血浆浓度。']",0.3333333333333333,"['median', 'concentration', 'plasma', 'administration', 'after', 'peak', '4', 'bolus', 'concentrations', 'by', 'to', 'and']","['concentration', 'plasma', 'after', 'to']",,
2718,2676,the concentration of HTTRx in plasma increased approximately proportionally to the dose over the explored dose range ( Figure 2B ) .,在探索的剂量范围内，血浆中 HTTRx 的浓度与剂量大致成正比增加（图 2B）。,0.4444444444444444,"['concentration', 'plasma', 'range', 'figure', 'dose', 'approximately', 'in', 'over', 'to']","['concentration', 'plasma', 'range', 'dose']",2676,['血液中HTTRx的浓度在研究剂量范围内大约比例增加(图2B)。'],0.3333333333333333,"['concentration', 'plasma', 'range', 'figure', 'dose', 'approximately', 'in', 'over', 'to']","['concentration', 'range', 'dose']",,
2719,2677,concentrations of Mutant HTT in CSF,CSF中突变体HTT的浓度,0.25,"['mutant', 'CSF', 'concentrations', 'in']",['mutant'],2677,['突变HTT在CSF中的浓度'],0.0,"['mutant', 'CSF', 'concentrations', 'in']",[],,
2720,2678,"in patients who received placebo , the mean percentage change from baseline was an increase of 10 % in the concentration of mutant HTT in CSF ( Figure 3A and 3B , and Table S1 in the Supplementary Appendix ) .",在接受安慰剂的患者中，CSF 中突变 HTT 浓度相对于基线的平均百分比变化增加了 10%（图 3A 和 3B，以及补充附录中的表 S1）。,0.375,"['percentage', 'placebo', 'mutant', 'concentration', 'appendix', 'mean', 'table', 'who', 'baseline', 'figure', 'supplementary', 'change', 'CSF', 'increase', 'S1', 'and']","['placebo', 'concentration', 'mean', 'table', 'baseline', 'change']",2678,"['在接受 placebo 的患者中,从基线的平均百分比变化是 CSF 中的突变 HTT 浓度的 10% 增加(图 3A 和 3B 和 附件中的 S1 表)。']",0.375,"['percentage', 'placebo', 'mutant', 'concentration', 'appendix', 'mean', 'table', 'who', 'baseline', 'figure', 'supplementary', 'change', 'CSF', 'increase', 'S1', 'and']","['concentration', 'appendix', 'mean', 'table', 'baseline', 'change']",,
2721,2679,additional Exploratory Outcomes,额外的探索性结果,0.5,"['exploratory', 'additional']",['additional'],2679,['更多探索成果'],0.0,"['exploratory', 'additional']",[],,
2722,2680,"by the start of the extension study ( 7 to 27 months after the final doses were administered in this trial ) , the concentrations of neurofilament light protein in the CSF had generally returned to pretrial concentrations .",到扩展研究开始时（在该试验中最后一次给药后 7 至 27 个月），CSF 中神经丝轻链蛋白的浓度通常已恢复到试验前的浓度。,0.2307692307692307,"['extension', 'neurofilament', 'protein', 'study', 'light', 'after', 'trial', 'CSF', 'concentrations', 'start', 'this', 'by', 'to']","['neurofilament', 'protein', 'after']",2680,"['在延伸研究开始时(在最终剂量在本试验中服用后7至27个月),CSF中神经纤维光蛋白的浓度通常恢复到前列浓度。']",0.3076923076923077,"['extension', 'neurofilament', 'protein', 'study', 'light', 'after', 'trial', 'CSF', 'concentrations', 'start', 'this', 'by', 'to']","['extension', 'protein', 'light', 'after']",,
2723,2681,"during the extension study , the concentrations rose with a time course and magnitude that were similar to those observed in this trial and then decreased at later time points despite continued treatment ( unpublished data ) .",在扩展研究期间，浓度随着时间进程和幅度上升，与本试验中观察到的相似，然后尽管继续治疗（未发表的数据），但在后来的时间点下降。,0.25,"['a', 'extension', 'rose', 'data', 'study', 'time', 'treatment', 'trial', 'magnitude', 'course', 'with', 'despite', 'concentrations', 'this', 'that', 'later', 'in', 'to', 'and', 'similar']","['data', 'time', 'treatment', 'magnitude', 'later']",2681,"['在延伸研究期间,这些浓度随着时间的流程和大小而上升,与本试验中观察到的类似,随后随着持续的处理(未公布的数据)的时间点下降。']",0.3,"['a', 'extension', 'rose', 'data', 'study', 'time', 'treatment', 'trial', 'magnitude', 'course', 'with', 'despite', 'concentrations', 'this', 'that', 'later', 'in', 'to', 'and', 'similar']","['extension', 'data', 'time', 'treatment', 'later', 'and']",,
2724,2682,"these correlations should be interpreted with caution , because the tests were not prespecified and the coefficients of correlation were not adjusted for multiple testing .",应该谨慎解释这些相关性，因为测试没有预先指定，相关系数也没有针对多重测试进行调整。,0.1666666666666666,"['correlation', 'multiple', 'be', 'testing', 'with', 'and']",['correlation'],2682,"['这些相互关系应谨慎地解释,因为测试没有预定,并且对多重测试的相互关系率没有调整。']",0.0,"['correlation', 'multiple', 'be', 'testing', 'with', 'and']",[],,
2725,2683,"given the results of only this trial , we do not know whether this reduction reflects a reduction in the concentration of mutant HTT in the central nervous system , although preclinical studies support the hypothesis that concentrations of mutant HTT in the CSF reflect the concentrations of mutant HTT in central nervous system tissue ( see the Supplementary Appendix , as well as Southwell et al.15 ) .",鉴于仅此试验的结果，我们不知道这种减少是否反映了中枢神经系统中突变 HTT 浓度的降低，尽管临床前研究支持 CSF 中突变 HTT 浓度反映突变 HTT 浓度的假设。在中枢神经系统组织中（见补充附录，以及 Southwell 等人 15）。,0.5,"['a', 'nervous system', 'tissue', 'mutant', 'support', 'concentration', 'appendix', 'hypothesis', 'central nervous system', 'supplementary', 'reduction', 'reflect', 'preclinical', 'well', 'trial', 'CSF', 'as', 'concentrations', 'this', 'that']","['nervous system', 'tissue', 'support', 'concentration', 'hypothesis', 'central nervous system', 'reduction', 'reflect', 'preclinical', 'this']",2683,"['鉴于仅此试验的结果,我们不知道这种减少是否反映了中枢神经系统中突变HTT浓度的下降,尽管临床研究支持假设,中枢神经系统中突变HTT浓度反映了中枢神经系统组织中突变HTT浓度(参见补充附件,以及南威尔等)。']",0.55,"['a', 'nervous system', 'tissue', 'mutant', 'support', 'concentration', 'appendix', 'hypothesis', 'central nervous system', 'supplementary', 'reduction', 'reflect', 'preclinical', 'well', 'trial', 'CSF', 'as', 'concentrations', 'this', 'that']","['nervous system', 'tissue', 'support', 'concentration', 'appendix', 'hypothesis', 'central nervous system', 'reduction', 'reflect', 'this', 'that']",,
2726,2684,prespecified secondary outcomes were tested hierarchically .,预先指定的次要结果进行了分层测试。,0.0,['secondary'],[],2684,['预定的次要结果是以序列测试的。'],0.0,['secondary'],[],,
2727,2685,the trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee .,在根据数据和安全监测委员会的建议进行计划中的中期分析后，该试验提前终止。,0.6666666666666666,"['safety', 'monitoring', 'data', 'analysis', 'early', 'committee', 'after', 'trial', 'and']","['safety', 'monitoring', 'data', 'analysis', 'committee', 'after']",2685,['审判在计划的数据和安全监测委员会建议的临时分析后早些时候停止。'],0.8888888888888888,"['safety', 'monitoring', 'data', 'analysis', 'early', 'committee', 'after', 'trial', 'and']","['safety', 'monitoring', 'data', 'analysis', 'early', 'committee', 'after', 'trial']",,
2728,2686,there were no significant differences in rates of amputation or fracture .,截肢率或骨折率没有显着差异。,0.5,"['fracture', 'amputation', 'no', 'in']","['fracture', 'amputation']",2686,['没有显著的破裂率或破裂率差异。'],0.25,"['fracture', 'amputation', 'no', 'in']",['fracture'],,
2729,2687,we designed the CREDENCE ( Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation ) trial to assess the effects of the SGLT2 inhibitor canagliflozin on renal outcomes in patients with type 2 diabetes and albuminuric chronic kidney disease .,我们设计了 CREDENCE（Canagliflozin 和糖尿病肾病临床评估中的肾脏事件）试验，以评估 SGLT2 抑制剂 canagliflozin 对 2 型糖尿病和白蛋白尿慢性肾病患者肾脏结局的影响。,0.5882352941176471,"['inhibitor', 'diabetes', 'type', 'kidney', 'disease', '2', 'evaluation', 'chronic', 'renal', 'nephropathy', 'clinical', 'trial', 'assess', 'with', 'canagliflozin', 'and', 'we']","['inhibitor', 'diabetes', 'type', 'kidney', 'disease', '2', 'chronic', 'nephropathy', 'clinical', 'assess']",2687,"['我们设计了信任(Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation)试验,以评估SGLT2抑制剂Canagliflozin对患有2型糖尿病和阿尔博明鲁慢性肾疾病的患者的肾结果的影响。']",0.4705882352941176,"['inhibitor', 'diabetes', 'type', 'kidney', 'disease', '2', 'evaluation', 'chronic', 'renal', 'nephropathy', 'clinical', 'trial', 'assess', 'with', 'canagliflozin', 'and', 'we']","['inhibitor', 'diabetes', 'type', 'kidney', 'disease', '2', 'chronic', 'assess']",,
2730,2688,the protocol ( available with the full text of this article at NEJM.org ) was reviewed by relevant regulatory authorities and ethics committees responsible for each trial site .,该方案（与本文全文可在 NEJM.org 上获取）由负责每个试验中心的相关监管机构和伦理委员会审查。,0.1333333333333333,"['site', 'protocol', 'article', 'ethics', 'available', 'trial', 'text', 'committees', 'with', 'at', 'full', 'this', 'each', 'by', 'and']","['committees', 'by']",2688,['该议定书(可在NEJM.org上提供本文的完整文本)由有关监管机构和负责每个审判网站的伦理委员会审查。'],0.3333333333333333,"['site', 'protocol', 'article', 'ethics', 'available', 'trial', 'text', 'committees', 'with', 'at', 'full', 'this', 'each', 'by', 'and']","['protocol', 'trial', 'committees', 'full', 'by']",,
2731,2689,technical editorial assistance provided by MedErgy was funded by the sponsor .,MedErgy 提供的技术编辑协助由申办方资助。,0.25,"['sponsor', 'technical', 'assistance', 'by']",['by'],2689,['由MedErgy提供的技术编辑援助由赞助商资助。'],0.5,"['sponsor', 'technical', 'assistance', 'by']","['assistance', 'by']",,
2732,2690,"members of the steering committee designed the trial , supervised its conduct , and were responsible for reporting the results .",指导委员会成员设计了试验，监督其实施，并负责报告结果。,0.1666666666666666,"['members', 'steering', 'committee', 'trial', 'conduct', 'and']",['committee'],2690,"['管理委员会的成员设计了审判,监督了审判的行为,负责报告结果。']",0.3333333333333333,"['members', 'steering', 'committee', 'trial', 'conduct', 'and']","['committee', 'trial']",,
2733,2691,analyses were performed by the sponsor and independently confirmed at George Clinical with the use of original data .,分析由申办方进行，并由 George Clinical 使用原始数据独立确认。,0.25,"['data', 'sponsor', 'clinical', 'original', 'original data', 'with', 'by', 'and']","['data', 'by']",2691,"['分析由赞助商进行,并在乔治诊所独立确认,使用原始数据。']",0.25,"['data', 'sponsor', 'clinical', 'original', 'original data', 'with', 'by', 'and']","['data', 'by']",,
2734,2692,"the first and last authors drafted the first version of the manuscript , and all the authors contributed to revisions .",第一作者和最后作者起草了手稿的第一版，所有作者都参与了修订。,0.3333333333333333,"['version', 'manuscript', 'all', 'to', 'and', 'first']","['manuscript', 'first']",2692,"['第一位和最后一位作家编写了手稿的第一版,所有作家都参与了审查。']",0.3333333333333333,"['version', 'manuscript', 'all', 'to', 'and', 'first']","['manuscript', 'first']",,
2735,2693,"the decision to submit the manuscript for publication was made jointly by all the authors , who vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol .",投稿发表的决定由所有作者共同做出，他们保证数据的完整性和准确性以及试验对方案的忠实度。,0.4615384615384615,"['fidelity', 'data', 'who', 'accuracy', 'protocol', 'publication', 'manuscript', 'trial', 'decision', 'completeness', 'all', 'by', 'and']","['data', 'accuracy', 'publication', 'decision', 'completeness', 'by']",2693,"['将手稿提交出版的决定是由所有作者共同作出的,他们为数据的完整性和准确性以及审判对议定书的忠诚度保证。']",0.6923076923076923,"['fidelity', 'data', 'who', 'accuracy', 'protocol', 'publication', 'manuscript', 'trial', 'decision', 'completeness', 'all', 'by', 'and']","['data', 'accuracy', 'protocol', 'publication', 'manuscript', 'trial', 'decision', 'completeness', 'by']",,
2736,2694,"patients were eligible if they were at least 30 years of age and had type 2 diabetes , with a glycated hemoglobin level of 6.5 to 12.0 % ( 6.5 to 10.5 % in Germany , according to a country amendment ) .",符合条件的患者年龄至少为 30 岁，患有 2 型糖尿病，糖化血红蛋白水平为 6.5% 至 12.0%（根据国家修正案，德国为 6.5% 至 10.5%）。,0.5,"['diabetes', 'type', '2', 'hemoglobin', 'country', 'hemoglobin level', 'age', 'with', 'at', 'if', 'to', 'and', 'eligible', 'amendment']","['diabetes', 'type', '2', 'hemoglobin', 'country', 'age', 'amendment']",2694,"['如果他们至少30岁,并且患有2型糖尿病,血糖水平为6,5至12.0%(根据国家修正案,德国6,5至10,5%)。']",0.3571428571428571,"['diabetes', 'type', '2', 'hemoglobin', 'country', 'hemoglobin level', 'age', 'with', 'at', 'if', 'to', 'and', 'eligible', 'amendment']","['diabetes', 'type', '2', 'country', 'amendment']",,
2737,2695,"patients who had suspected nondiabetic kidney disease or type 1 diabetes , had been treated with immunosuppression for kidney disease , or had a history of dialysis or kidney transplantation were excluded .",疑似非糖尿病肾病或 1 型糖尿病、接受过肾病免疫抑制治疗或有透析或肾移植病史的患者被排除在外。,0.6666666666666666,"['immunosuppression', 'dialysis', 'diabetes', 'type', 'transplantation', 'kidney', 'disease', 'who', '1', 'history', 'with', 'nondiabetic']","['immunosuppression', 'dialysis', 'diabetes', 'type', 'transplantation', 'kidney', 'disease', '1']",2695,"['患有非糖尿病或1型糖尿病的患者,被免疫抑制为肾病,或有糖尿病或肾移植的历史被排除。']",0.6666666666666666,"['immunosuppression', 'dialysis', 'diabetes', 'type', 'transplantation', 'kidney', 'disease', 'who', '1', 'history', 'with', 'nondiabetic']","['immunosuppression', 'diabetes', 'type', 'transplantation', 'kidney', 'disease', '1', 'history']",,
2738,2696,"full inclusion and exclusion criteria are described in the Supplementary Appendix , available at NEJM.org .",补充附录中描述了完整的纳入和排除标准，补充附录可在 NEJM.org 获取。,0.125,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'available', 'at', 'full', 'and']",['full'],2696,"['完整的包含和排除标准在附加附件中描述,可在NEJM.org上找到。']",0.375,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'available', 'at', 'full', 'and']","['appendix', 'inclusion', 'full']",,
2739,2697,"the administration of canagliflozin or placebo was to be continued until trial completion , initiation of dialysis , kidney transplantation , occurrence of diabetic ketoacidosis , pregnancy , or receipt of a disallowed therapy .",canagliflozin 或安慰剂的给药将持续到试验完成、开始透析、肾移植、发生糖尿病酮症酸中毒、怀孕或接受不允许的治疗。,0.6,"['pregnancy', 'dialysis', 'transplantation', 'placebo', 'kidney', 'initiation', 'administration', 'occurrence', 'therapy', 'be', 'diabetic', 'trial', 'completion', 'canagliflozin', 'to']","['pregnancy', 'dialysis', 'transplantation', 'placebo', 'kidney', 'initiation', 'occurrence', 'therapy', 'completion']",2697,"['使用Canagliflozin或Placebo应继续,直到试验完成、启动腹泻、肾移植、糖尿病<<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化<unk>化。']",0.2666666666666666,"['pregnancy', 'dialysis', 'transplantation', 'placebo', 'kidney', 'initiation', 'administration', 'occurrence', 'therapy', 'be', 'diabetic', 'trial', 'completion', 'canagliflozin', 'to']","['transplantation', 'kidney', 'initiation', 'completion']",,
2740,2698,additional testing of blood at either the central or local laboratory and safety assessments were permitted at any time at the discretion of the investigators .,研究人员可随时酌情允许在中央或地方实验室进行额外的血液检测和安全性评估。,0.5555555555555556,"['safety', 'blood', 'time', 'local', 'central', 'additional', 'laboratory', 'testing', 'and']","['safety', 'blood', 'time', 'additional', 'laboratory']",2698,"['在中央或地方实验室的额外血液测试和安全评估,随时随地根据调查人员的判断被允许。']",0.4444444444444444,"['safety', 'blood', 'time', 'local', 'central', 'additional', 'laboratory', 'testing', 'and']","['safety', 'blood', 'time', 'laboratory']",,
2741,2699,the use of other background therapy for glycemic management and control of cardiovascular risk factors was recommended in accordance with local guidelines .,根据当地指南，建议使用其他背景疗法来管理血糖和控制心血管危险因素。,0.7,"['background', 'control', 'cardiovascular', 'local', 'therapy', 'risk', 'management', 'with', 'in', 'and']","['background', 'control', 'cardiovascular', 'therapy', 'risk', 'management', 'in']",2699,"['使用其他背景治疗用于心血管风险因素的血糖管理和控制,根据当地指南,建议。']",0.7,"['background', 'control', 'cardiovascular', 'local', 'therapy', 'risk', 'management', 'with', 'in', 'and']","['background', 'control', 'cardiovascular', 'therapy', 'risk', 'management', 'in']",,
2742,2700,"during the trial , an increased risk of lower limb amputation was identified in another trial of canagliflozin.5",在试验期间，另一项卡格列净试验发现下肢截肢风险增加。 5,0.6666666666666666,"['limb', 'amputation', 'lower limb', 'risk', 'trial', 'in']","['limb', 'amputation', 'lower limb', 'risk']",2700,"['在试验期间,在另一个试验中发现了较低肢体解剖的风险增加。']",0.3333333333333333,"['limb', 'amputation', 'lower limb', 'risk', 'trial', 'in']","['limb', 'risk']",,
2743,2701,all other efficacy outcomes were exploratory .,所有其他疗效结果都是探索性的。,0.0,"['exploratory', 'efficacy', 'all']",[],2701,['所有其他有效性结果都是探索性的。'],0.3333333333333333,"['exploratory', 'efficacy', 'all']",['efficacy'],,
2744,2702,safety evaluations included laboratory testing and assessments of adverse events .,安全评估包括实验室测试和不良事件评估。,0.4,"['safety', 'adverse', 'laboratory', 'testing', 'and']","['safety', 'laboratory']",2702,['安全评估包括实验室测试和不良事件评估。'],0.4,"['safety', 'adverse', 'laboratory', 'testing', 'and']","['safety', 'laboratory']",,
2745,2703,a single interim analysis was to be conducted by an independent data monitoring committee after the primary outcome had occurred in 405 patients .,在 405 名患者发生主要结果后，独立数据监测委员会将进行一次中期分析。,0.5833333333333334,"['monitoring', 'a', 'data', 'analysis', 'outcome', 'be', 'primary', 'committee', 'after', 'independent', 'single', 'by']","['monitoring', 'data', 'analysis', 'outcome', 'be', 'committee', 'after']",2703,"['一个单一的临时分析由一个独立的数据监测委员会进行后,初始结果发生在405名患者。']",0.8333333333333334,"['monitoring', 'a', 'data', 'analysis', 'outcome', 'be', 'primary', 'committee', 'after', 'independent', 'single', 'by']","['monitoring', 'data', 'analysis', 'outcome', 'be', 'committee', 'after', 'independent', 'single', 'by']",,
2746,2704,all available measurements were used with no distinction made for missing outcomes for patients who were alive and outcomes that were not observed because of death .,使用了所有可用的测量值，但未区分存活患者的缺失结果和因死亡而未观察到的结果。,0.4,"['who', 'death', 'available', 'no', 'distinction', 'with', 'all', 'that', 'and', 'missing']","['death', 'available', 'and', 'missing']",2704,"['所有可用的测量都被使用,没有任何区别,为活着的患者缺乏结果,以及由于死亡而未被观察到的结果。']",0.4,"['who', 'death', 'available', 'no', 'distinction', 'with', 'all', 'that', 'and', 'missing']","['death', 'available', 'and', 'missing']",,
2747,2705,"slope analyses regarding the estimated GFR for the acute phase ( baseline to week 3 ) , chronic phase ( week 3 to end of treatment ) , and total slope through week 130 are described in the Supplementary Appendix .",关于急性期（基线至第 3 周）、慢性期（第 3 周至治疗结束）的估计 GFR 的斜率分析，以及至第 130 周的总斜率在补充附录中进行了描述。,0.5714285714285714,"['appendix', 'phase', 'baseline', 'supplementary', 'total', 'regarding', 'slope', 'treatment', 'chronic', 'week', 'acute', '3', 'GFR', 'and']","['phase', 'baseline', 'regarding', 'slope', 'treatment', 'chronic', 'week', 'acute']",2705,"['关于急性阶段(基线至3周),慢性阶段(3周至治疗结束)和周130周的总急性分析,在补充附件中描述。']",0.5,"['appendix', 'phase', 'baseline', 'supplementary', 'total', 'regarding', 'slope', 'treatment', 'chronic', 'week', 'acute', '3', 'GFR', 'and']","['appendix', 'phase', 'baseline', 'regarding', 'treatment', 'chronic', 'week']",,
2748,2706,"the baseline characteristics of the patients were similar in the two groups ( Table 1 , and Tables S1 and S2 in the Supplementary Appendix ) .10",两组患者的基线特征相似（表 1 以及补充附录中的表 S1 和 S2）。10,0.4545454545454545,"['appendix', 'table', 'baseline', '1', 'supplementary', 'characteristics', 'S1', 'S2', 'and', 'two', 'similar']","['table', 'baseline', '1', 'characteristics', 'two']",2706,['患者的基本特征在两组中是相似的(表1和附件中的表S1和S2)。'],0.5454545454545454,"['appendix', 'table', 'baseline', '1', 'supplementary', 'characteristics', 'S1', 'S2', 'and', 'two', 'similar']","['appendix', 'table', '1', 'characteristics', 'two', 'similar']",,
2749,2707,"the mean age was 63 years , and 33.9 % of the patients were women .",平均年龄为 63 岁，33.9% 的患者为女性。,0.6666666666666666,"['mean', 'age', 'and']","['mean', 'age']",2707,"['平均年龄为63岁,其中33.9%的患者是女性。']",0.6666666666666666,"['mean', 'age', 'and']","['mean', 'age']",,
2750,2708,the requisite number of primary outcome events to trigger the interim analysis were accrued by July 2018 .,到 2018 年 7 月，已收集到触发中期分析所需的主要结果事件数量。,0.5,"['trigger', 'analysis', 'outcome', 'primary', 'number', 'requisite', 'by', 'to']","['trigger', 'analysis', 'outcome', 'number']",2708,"['在2018年7月之前,需要的初始结果事件数量增加,以启发临时分析。']",0.625,"['trigger', 'analysis', 'outcome', 'primary', 'number', 'requisite', 'by', 'to']","['analysis', 'outcome', 'number', 'requisite', 'by']",,
2751,2709,the data monitoring committee advised the steering committee members that the prespecified efficacy criteria for early cessation had been achieved and recommended that the trial be stopped .,数据监测委员会告知指导委员会成员，预先设定的提前停止疗效标准已经达到，并建议停止试验。,0.2727272727272727,"['monitoring', 'members', 'data', 'steering', 'early', 'committee', 'trial', 'efficacy', 'achieved', 'that', 'and']","['monitoring', 'data', 'committee']",2709,"['数据监测委员会向管理委员会成员表示,预先确定的早期终止有效性标准已实现,并建议审判停止。']",0.5454545454545454,"['monitoring', 'members', 'data', 'steering', 'early', 'committee', 'trial', 'efficacy', 'achieved', 'that', 'and']","['monitoring', 'data', 'early', 'committee', 'trial', 'efficacy']",,
2752,2710,"the trial leadership accepted this recommendation , the patients were recalled for final visits , and the trial was concluded .",试验领导层接受了这一建议，患者被召回进行最后一次就诊，试验结束。,0.2,"['trial', 'accepted', 'leadership', 'this', 'and']",['leadership'],2710,"['试验领导人接受了这项建议,患者被召回最终访问,试验结束。']",0.2,"['trial', 'accepted', 'leadership', 'this', 'and']",['leadership'],,
2753,2711,effect ON THE PRIMARY OUTCOME AND RENAL COMPONENTS,对主要结果和肾脏成分的影响,0.0,['effect'],[],2711,['对初级外科和肾组件的影响'],0.0,['effect'],[],,
2754,2712,"nearly identical results were shown in sensitivity analyses that included imputation of missing data ( hazard ratio , 0.69 ; 95 % CI , 0.59 to 0.82 ) or that were adjusted for competing risks ( hazard ratio , 0.70 ; 95 % CI , 0.59 to 0.82 ) .",敏感性分析显示几乎相同的结果，包括缺失数据的填补（风险比，0.69；95% CI，0.59 至 0.82）或针对竞争风险进行调整（风险比，0.70；95% CI，0.59 至 0.82）。,0.5,"['data', 'ratio', 'hazard ratio', 'identical', 'sensitivity', 'CI', 'that', 'in', 'to', 'missing']","['data', 'ratio', 'hazard ratio', 'identical', 'missing']",2712,"['报告相同的结果在敏感性分析中显示,其中包括缺乏数据(风险比例,0.69;95% CI,0.59至0.82),或对竞争风险进行调整(风险比例,0.70;95% CI,0.59至0.82)。']",0.5,"['data', 'ratio', 'hazard ratio', 'identical', 'sensitivity', 'CI', 'that', 'in', 'to', 'missing']","['data', 'ratio', 'hazard ratio', 'identical', 'missing']",,
2755,2713,"the hazard ratio for death from any cause was 0.83 ( 95 % CI , 0.68 to 1.02 ) ( Table 2 and Figure 1F ) ; for the composite of cardiovascular death , myocardial infarction , stroke , or hospitalization for heart failure or unstable angina , the hazard ratio was 0.74 ( 95 % CI , 0.63 to 0.86 ) ( Table 2 ) .",全因死亡的风险比为 0.83（95% CI，0.68 至 1.02）（表 2 和图 1F）；对于心血管死亡、心肌梗死、卒中或因心力衰竭或不稳定型心绞痛住院的复合事件，风险比为 0.74（95% CI，0.63 至 0.86）（表 2）。,0.75,"['heart', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'failure', 'table', '2', 'ratio', 'hazard ratio', 'death', 'figure', 'angina', 'hospitalization', 'heart failure', 'cause', 'unstable', 'CI', 'to', 'and']","['heart', 'myocardial infarction', 'cardiovascular', 'stroke', 'failure', 'table', '2', 'ratio', 'hazard ratio', 'death', 'angina', 'hospitalization', 'heart failure', 'unstable', 'to']",2713,"['因任何原因死亡的风险比例为 0.83 (95% CI, 0.68 至 1.02 ) ( 图 2 和 图 1F ) ; 因心血管死亡, 心脏病发作, 发作, 或 心脏病发作或 不稳定的腹泻, 风险比例为 0.74 ( 95% CI, 0.63 至 0.86 ) ( 图 2 ) 。']",0.45,"['heart', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'failure', 'table', '2', 'ratio', 'hazard ratio', 'death', 'figure', 'angina', 'hospitalization', 'heart failure', 'cause', 'unstable', 'CI', 'to', 'and']","['heart', 'cardiovascular', 'stroke', '2', 'ratio', 'hazard ratio', 'death', 'cause', 'unstable']",,
2756,2714,effects ON SAFETY OUTCOMES,对安全结果的影响,,[],[],2714,['对安全商店的影响'],,[],[],,
2757,2715,"rates of adverse events and serious adverse events were similar overall in the canagliflozin group and the placebo group ( Table 2 , and Tables S4 and S5 in the Supplementary Appendix ) .",总体而言，卡格列净组和安慰剂组的不良事件和严重不良事件发生率相似（表 2 以及补充附录表 S4 和表 S5）。,0.5,"['group', 'placebo', 'appendix', 'table', '2', 'supplementary', 'adverse', 'canagliflozin', 'S4', 'serious', 'and', 'similar']","['group', 'placebo', 'table', '2', 'canagliflozin', 'and']",2715,['副作用和严重副作用的率在Cannagliflozin群体和Placebo群体中总体上是相似的(图2和附件中的S4和S5表)。'],0.4166666666666667,"['group', 'placebo', 'appendix', 'table', '2', 'supplementary', 'adverse', 'canagliflozin', 'S4', 'serious', 'and', 'similar']","['group', 'appendix', 'table', '2', 'similar']",,
2758,2716,"rates of fracture were also similar in the two groups ( hazard ratio , 0.98 ; 95 % CI , 0.70 to 1.37 ) .",两组的骨折率也相似（风险比，0.98；95% CI，0.70 至 1.37）。,0.5,"['fracture', 'ratio', 'hazard ratio', 'CI', 'in', 'to', 'two', 'similar']","['fracture', 'ratio', 'hazard ratio', 'two']",2716,"['在两组中,分裂率也相似(危险比例,0.98;95% CI,0.70至1.37)。']",0.25,"['fracture', 'ratio', 'hazard ratio', 'CI', 'in', 'to', 'two', 'similar']","['ratio', 'two']",,
2759,2717,effect ON INTERMEDIATE OUTCOMES,对中期结果的影响,0.0,['effect'],[],2717,['对中间商店的影响'],0.0,['effect'],[],,
2760,2718,"on average , levels were lower in the canagliflozin group for systolic blood pressure ( by 3.30 mm Hg ; 95 % CI , 2.73 to 3.87 ) , diastolic blood pressure ( by 0.95 mm Hg ; 95 % CI , 0.61 to 1.28 ) , and body weight ( by 0.80 kg ; 95 % CI , 0.69 to 0.92 ) .",平均而言，卡格列净组的收缩压（降低 3.30 mm Hg ； 95 % CI ， 2.73 至 3.87 ） 、舒张压（降低 0.95 mm Hg ； 95 % CI ， 0.61 至 1.28 ）和体重水平较低（减少 0.80 公斤；95% CI，0.69 至 0.92）。,0.4,"['group', 'body weight', 'pressure', 'average', 'blood', 'blood pressure', 'lower', 'diastolic', 'systolic', 'kg', 'canagliflozin', 'CI', 'on', 'by', 'and']","['group', 'body weight', 'average', 'kg', 'canagliflozin', 'and']",2718,"['平均而言,血压水平低于血压(3.30 mm Hg、95% CI、2.73 至 3.87 )、血压(0.95 mm Hg、95% CI、0.61 至 1.28 )、体重(0.80 kg、95% CI、0.69 至 0.92 )。']",0.2666666666666666,"['group', 'body weight', 'pressure', 'average', 'blood', 'blood pressure', 'lower', 'diastolic', 'systolic', 'kg', 'canagliflozin', 'CI', 'on', 'by', 'and']","['body weight', 'average', 'blood pressure', 'and']",,
2761,2719,"thereafter , the decline in the estimated GFR was slower in the canagliflozin group than in the placebo group ( -1.85 ± 0.13 vs. -4.59 ± 0.14 ml per minute per 1.73 m2 per year ) , for a difference of 2.74 ml per minute per 1.73 m2 per year ( 95 % CI , 2.37 to 3.11 ) .",此后，卡格列净组估计的 GFR 下降速度比安慰剂组慢（-1.85 ± 0.13 vs. -4.59 ± 0.14 毫升每分钟每 1.73 平方米每年） ，差异为每分钟每 1.73 平方米 2.74 毫升每年平方米（95% CI，2.37 至 3.11）。,0.6363636363636364,"['group', 'placebo', 'decline', 'year', 'difference', 'minute', 'ml', 'GFR', 'canagliflozin', 'CI', 'to']","['group', 'placebo', 'decline', 'year', 'difference', 'minute', 'canagliflozin']",2719,"['随后,估计GFR的下降在Canagliflozin群体比 placebo群体( -1.85 ± 0.13 与 -4.59 ± 0.14 毫升每分钟为 1.73 m2 每年)较慢,差距为 2.74 毫升每分钟为 1.73 m2 每年( 95% CI, 2.37 至 3.11 )。']",0.3636363636363636,"['group', 'placebo', 'decline', 'year', 'difference', 'minute', 'ml', 'GFR', 'canagliflozin', 'CI', 'to']","['group', 'decline', 'year', 'minute']",,
2762,2720,projected ESTIMATED EFFECTS,预计 估计效果,,[],[],2720,['可预测的效应'],,[],[],,
2763,2721,"canagliflozin treatment would also prevent 22 hospitalizations for heart failure ( NNT , 46 ; 95 % CI , 29 to 124 ) and 25 composite events of cardiovascular death , myocardial infarction , or stroke ( NNT , 40 ; 95 % CI , 23 to 165 ) .",canagliflozin 治疗还可预防 22 例因心力衰竭住院（NNT，46；95% CI，29 至 124）和 25 例心血管死亡、心肌梗塞或中风的复合事件（NNT，40；95% CI，23 至 165）。,0.6428571428571429,"['heart', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'failure', 'death', 'heart failure', 'treatment', 'prevent', 'canagliflozin', 'CI', 'to', 'and']","['heart', 'myocardial infarction', 'cardiovascular', 'stroke', 'failure', 'death', 'heart failure', 'treatment', 'prevent']",2721,['卡纳格利弗洛辛治疗还会预防22次心脏病发作(NNT、46、95%CI、29至124)和25次心血管死亡、心脏病发作或中风(NNT、40、95%CI、23至165)的合成事件。'],0.4285714285714285,"['heart', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'failure', 'death', 'heart failure', 'treatment', 'prevent', 'canagliflozin', 'CI', 'to', 'and']","['heart', 'cardiovascular', 'stroke', 'death', 'treatment', 'prevent']",,
2764,2722,these results indicate that canagliflozin may be an effective treatment option for renal and cardiovascular protection in patients with type 2 diabetes with chronic kidney disease .,这些结果表明，canagliflozin 可能是 2 型糖尿病伴慢性肾脏病患者肾脏和心血管保护的有效治疗选择。,0.5625,"['diabetes', 'type', 'kidney', 'disease', 'cardiovascular', '2', 'protection', 'indicate', 'treatment', 'chronic', 'renal', 'option', 'with', 'canagliflozin', 'that', 'and']","['diabetes', 'type', 'kidney', 'disease', 'cardiovascular', '2', 'protection', 'treatment', 'chronic']",2722,"['这些结果表明,Canagliflozin可能是一种有效的肾和心血管保护治疗选项,在患有慢性肾疾病的2型糖尿病患者中。']",0.5625,"['diabetes', 'type', 'kidney', 'disease', 'cardiovascular', '2', 'protection', 'indicate', 'treatment', 'chronic', 'renal', 'option', 'with', 'canagliflozin', 'that', 'and']","['diabetes', 'type', 'kidney', 'disease', 'cardiovascular', '2', 'protection', 'treatment', 'chronic']",,
2765,2723,"the significantly lower rates of cardiovascular outcomes , including the composite of cardiovascular death , myocardial infarction , or stroke , in the canagliflozin group in our trial are consistent with those observed with canagliflozin in the CANVAS ( Canagliflozin Cardiovascular Assessment Study ) Program , 5 despite the smaller differences in glycemic control .",在我们的试验中，卡格列净组的心血管结局（包括心血管死亡、心肌梗死或卒中的复合事件）发生率显着降低，这与 CANVAS（卡格列净心血管评估研究）计划中观察到的卡格列净结果一致， 5 尽管规模较小血糖控制的差异。,0.625,"['group', 'myocardial infarction', 'composite', '5', 'control', 'cardiovascular', 'stroke', 'program', 'death', 'study', 'lower', 'assessment', 'trial', 'with', 'despite', 'canagliflozin']","['group', 'myocardial infarction', '5', 'control', 'cardiovascular', 'stroke', 'program', 'death', 'assessment', 'canagliflozin']",2723,"['在我们的研究中,心血管结果的显著较低率,包括心血管死亡、心脏病发作或中风的组成,与Canagliflozin在CANVAS(Canagliflozin Cardiovascular Assessment Study)计划中观察到的相一致。']",0.3125,"['group', 'myocardial infarction', 'composite', '5', 'control', 'cardiovascular', 'stroke', 'program', 'death', 'study', 'lower', 'assessment', 'trial', 'with', 'despite', 'canagliflozin']","['group', 'cardiovascular', 'stroke', 'program', 'death']",,
2766,2724,"the similar rates of amputation and fracture that we observed with canagliflozin and placebo are reassuring and consistent with trials of other SGLT2 inhibitors6,7,20 but differ from the CANVAS Program findings.5",我们观察到卡格列净和安慰剂的截肢率和骨折率相似，这令人安心，并且与其他 SGLT2 抑制剂的试验6、7、20 一致，但与 CANVAS 计划的结果不同。 5,0.5,"['fracture', 'placebo', 'program', 'amputation', 'differ', 'with', 'canagliflozin', 'that', 'but', 'and', 'similar', 'we']","['fracture', 'placebo', 'program', 'amputation', 'canagliflozin', 'but']",2724,"['与其他 SGLT2 抑制剂的测试相似的 amputation 和 fracture 率,我们观察到 canagliflozin 和 placebo 是令人安慰和一致的,但与 CANVAS 计划的结果不同。']",0.25,"['fracture', 'placebo', 'program', 'amputation', 'differ', 'with', 'canagliflozin', 'that', 'but', 'and', 'similar', 'we']","['program', 'but', 'similar']",,
2767,2725,whether the increased risk of lower limb amputation in the CANVAS Program was due to differing trial populations or protocols or to chance remains unclear .,CANVAS 计划中下肢截肢风险的增加是由于不同的试验人群或方案还是偶然性仍不清楚。,0.6666666666666666,"['program', 'limb', 'amputation', 'lower limb', 'risk', 'trial', 'due', 'in', 'to']","['program', 'limb', 'amputation', 'lower limb', 'risk', 'to']",2725,"['在CANVAS计划中是否由于不同试验人口或议定书而出现较低肢体折磨的风险增加,还是不清楚。']",0.4444444444444444,"['program', 'limb', 'amputation', 'lower limb', 'risk', 'trial', 'due', 'in', 'to']","['program', 'limb', 'risk', 'to']",,
2768,2726,the overall safety profile in our trial is otherwise consistent with the known adverse effects associated with canagliflozin .,在我们的试验中，总体安全性与卡格列净相关的已知不良反应在其他方面是一致的。,0.2857142857142857,"['safety', 'adverse', 'associated', 'trial', 'profile', 'with', 'canagliflozin']","['safety', 'canagliflozin']",2726,"['在我们的测试中,整体安全规格与已知与Canagliflozin相关的副作用相一致。']",0.1428571428571428,"['safety', 'adverse', 'associated', 'trial', 'profile', 'with', 'canagliflozin']",['safety'],,
2769,2727,this trial has certain limitations .,本试验具有一定的局限性。,0.0,"['trial', 'certain', 'this']",[],2727,['这个审判有某些限制。'],0.3333333333333333,"['trial', 'certain', 'this']",['trial'],,
2770,2728,"first , the trial was stopped early at a planned interim analysis , which may have limited the power for some secondary outcomes and may increase the risk of overestimating effect sizes.21",首先，试验在计划的中期分析中提前停止，这可能限制了一些次要结果的功效，并可能增加高估效应量的风险。 21,0.2857142857142857,"['a', 'analysis', 'power', 'early', 'risk', 'secondary', 'trial', 'effect', 'increase', 'at', 'limited', 'have', 'and', 'first']","['analysis', 'risk', 'effect', 'first']",2728,"['首先,试验在计划的临时分析中早些时候停止,这可能会限制某些次要结果的功率,并可能增加过度估计效果大小的风险。']",0.4285714285714285,"['a', 'analysis', 'power', 'early', 'risk', 'secondary', 'trial', 'effect', 'increase', 'at', 'limited', 'have', 'and', 'first']","['analysis', 'power', 'early', 'risk', 'effect', 'first']",,
2771,2729,"however , the precision of the effect and the consistency with the findings of previous large trials of SGLT2 inhibitors suggest that this limitation is unlikely to have a major effect on our findings .",然而，效果的精确性以及与之前 SGLT2 抑制剂大型试验结果的一致性表明，这种局限性不太可能对我们的研究结果产生重大影响。,0.2,"['a', 'precision', 'consistency', 'previous', 'large', 'major', 'limitation', 'effect', 'suggest', 'with', 'have', 'this', 'that', 'to', 'and']","['consistency', 'effect', 'and']",2729,"['然而,效果的准确性和与SGLT2抑制剂以前的大型试验的发现一致性表明,这种限制不太可能对我们的发现产生重大影响。']",0.2666666666666666,"['a', 'precision', 'consistency', 'previous', 'large', 'major', 'limitation', 'effect', 'suggest', 'with', 'have', 'this', 'that', 'to', 'and']","['consistency', 'previous', 'effect', 'and']",,
2772,2730,retrospective cohort data from Korea support H. pylori eradication for cancer prevention .,来自韩国的回顾性队列数据支持根除幽门螺杆菌以预防癌症。,0.8333333333333334,"['eradication', 'cancer', 'support', 'data', 'prevention', 'cohort']","['eradication', 'cancer', 'support', 'data', 'prevention']",2730,"['朝鲜支持H. pylori灭绝,以预防癌症。']",0.5,"['eradication', 'cancer', 'support', 'data', 'prevention', 'cohort']","['cancer', 'support', 'prevention']",,
2773,2731,"although Helicobacter pylori is a known risk factor for the development of gastric cancer , cohort studies and randomized , controlled trials have failed to show a significantly reduced risk for de novo gastric cancer with H. pylori eradication .",尽管幽门螺杆菌是胃癌发展的已知危险因素，但队列研究和随机对照试验未能显示根除幽门螺杆菌后新发胃癌的风险显着降低。,0.4,"['de novo', 'eradication', 'cancer', 'gastric', 'factor', 'helicobacter', 'controlled', 'risk', 'risk factor', 'development', 'cohort', 'with', 'gastric cancer', 'have', 'and']","['eradication', 'cancer', 'factor', 'risk', 'development', 'gastric cancer']",2731,"['虽然Helicobacter pylori是胃癌发育的已知风险因素,但随机测试和随机测试未能显著降低胃癌的风险。']",0.4,"['de novo', 'eradication', 'cancer', 'gastric', 'factor', 'helicobacter', 'controlled', 'risk', 'risk factor', 'development', 'cohort', 'with', 'gastric cancer', 'have', 'and']","['cancer', 'factor', 'risk', 'risk factor', 'development', 'gastric cancer']",,
2774,2732,"31 de novo gastric cancers were detected : 4 among 200 patients with successful H. pylori eradication ( 0.2 % ) , 6 among 5000 patients without H. pylori ( 0.1 % ) , and 21 among 3500 patients without eradication ( 0.6 % ) .",共检出31例新发胃癌：200例成功根除H. pylori的患者中有4例（0.2%），5000例未成功根除H. pylori的患者中有6例（0.1%），3500例未根除的患者中有21例（0.6%）。,0.1428571428571428,"['de novo', 'eradication', 'gastric', '4', 'with', 'and', 'without']",['eradication'],2732,"['已被检测到31个胃癌:H. pylori 消除成功的 200 名患者中有 4 名( 0.2% ),没有 H. pylori 的 5000 名患者中有 6 名( 0.1% ),没有 H. pylori 的 3500 名患者中有 21 名( 0.6% ) 。']",0.0,"['de novo', 'eradication', 'gastric', '4', 'with', 'and', 'without']",[],,
2775,2733,"eradication of H. pylori was associated with a 70 % reduced risk for de novo gastric cancer compared with no eradication ( hazard ratio , 0.3 ) .",与未根除相比，根除幽门螺杆菌可将原发性胃癌的风险降低 70%（风险比 0.3）。,0.6,"['de novo', 'eradication', 'cancer', 'gastric', 'ratio', 'hazard ratio', 'associated', 'risk', 'with', 'gastric cancer']","['eradication', 'cancer', 'ratio', 'hazard ratio', 'risk', 'gastric cancer']",2733,"['H. pylori 的灭绝与不灭绝相比,胃癌的风险减少了70%(危险比例,0.3)。']",0.4,"['de novo', 'eradication', 'cancer', 'gastric', 'ratio', 'hazard ratio', 'associated', 'risk', 'with', 'gastric cancer']","['cancer', 'ratio', 'risk', 'gastric cancer']",,
2776,2734,"in an adjusted analysis , de novo gastric cancer was also associated with older age , presence of atrophic gastritis , and a family history of gastric cancer .",在调整后的分析中，新发胃癌还与年龄较大、萎缩性胃炎的存在以及胃癌家族史有关。,0.5625,"['de novo', 'presence', 'family', 'cancer', 'gastric', 'atrophic', 'analysis', 'family history', 'associated', 'age', 'gastritis', 'atrophic gastritis', 'with', 'gastric cancer', 'in', 'and']","['presence', 'family', 'cancer', 'analysis', 'family history', 'age', 'gastritis', 'atrophic gastritis', 'gastric cancer']",2734,"['在调整的分析中,胃癌也与老年人、异常胃炎的存在以及胃癌的家庭史有关。']",0.375,"['de novo', 'presence', 'family', 'cancer', 'gastric', 'atrophic', 'analysis', 'family history', 'associated', 'age', 'gastritis', 'atrophic gastritis', 'with', 'gastric cancer', 'in', 'and']","['presence', 'family', 'cancer', 'analysis', 'gastritis', 'gastric cancer']",,
2777,2735,this large study supports eradication of H. pylori detected on upper endoscopy for prevention of future gastric cancer .,这项大型研究支持根除上消化道内窥镜检测到的幽门螺杆菌，以预防未来的胃癌。,0.4,"['eradication', 'cancer', 'gastric', 'upper', 'study', 'prevention', 'large', 'endoscopy', 'gastric cancer', 'this']","['eradication', 'cancer', 'prevention', 'gastric cancer']",2735,"['这项大型研究支持在顶部内分泌中发现的H. pylori的消灭,以预防未来的胃癌。']",0.3,"['eradication', 'cancer', 'gastric', 'upper', 'study', 'prevention', 'large', 'endoscopy', 'gastric cancer', 'this']","['cancer', 'prevention', 'gastric cancer']",,
2778,2736,the clinical significance of the observed association between low serum HDL level and de novo gastric cancer is uncertain .,所观察到的低血清 HDL 水平与新发胃癌之间关联的临床意义尚不确定。,0.6153846153846154,"['de novo', 'cancer', 'gastric', 'association', 'uncertain', 'HDL', 'serum', 'low', 'clinical', 'significance', 'level', 'gastric cancer', 'and']","['cancer', 'association', 'serum', 'low', 'clinical', 'significance', 'level', 'gastric cancer']",2736,['血清低水平HDL和胃癌之间观察到的联系的临床意义不确定。'],0.6153846153846154,"['de novo', 'cancer', 'gastric', 'association', 'uncertain', 'HDL', 'serum', 'low', 'clinical', 'significance', 'level', 'gastric cancer', 'and']","['cancer', 'association', 'serum', 'low', 'clinical', 'significance', 'level', 'gastric cancer']",,
2779,2737,"the U.S. FDA approved Dengvaxia , a dengue vaccine , for use in a restricted population .",美国 FDA 批准登革热疫苗 Dengvaxia 用于受限人群。,0.75,"['population', 'vaccine', 'FDA', 'dengue']","['population', 'vaccine', 'dengue']",2737,"['美国FDA批准了Dengvaxia,一种<unk>虫疫苗,用于有限人口使用。']",0.5,"['population', 'vaccine', 'FDA', 'dengue']","['population', 'vaccine']",,
2780,2738,"development of a vaccine has been challenging because of wide circulation of four antigenically distinct dengue virus serotypes : dengue 1 , 2 , 3 , and 4 .",由于四种抗原性不同的登革热病毒血清型（登革热 1、2、3 和 4）的广泛传播，疫苗的开发一直具有挑战性。,0.3846153846153846,"['virus', 'a', 'circulation', '1', '2', 'dengue virus', 'vaccine', 'wide', '3', '4', 'development', 'distinct', 'and']","['virus', '1', '2', 'dengue virus', 'vaccine']",2738,['疫苗的开发是由于四种抗生素分离的<unk>疹病毒类型的广泛循环而具有挑战性:<unk>疹1、2、3和4。'],0.4615384615384615,"['virus', 'a', 'circulation', '1', '2', 'dengue virus', 'vaccine', 'wide', '3', '4', 'development', 'distinct', 'and']","['virus', 'circulation', '1', '2', 'vaccine', 'and']",,
2781,2739,"the vaccine is given as three subcutaneous injections at 0 , 6 , and 12 months .",疫苗在 0、6 和 12 个月分 3 次皮下注射。,0.1428571428571428,"['vaccine', 'subcutaneous', 'as', 'at', 'injections', 'three', 'and']",['vaccine'],2739,['接种疫苗为0、6、12个月的三种子注射。'],0.1428571428571428,"['vaccine', 'subcutaneous', 'as', 'at', 'injections', 'three', 'and']",['vaccine'],,
2782,2740,it is contraindicated in individuals with severe immunodeficiency or immunosuppression .,严重免疫缺陷或免疫抑制患者禁用。,0.4,"['immunosuppression', 'immunodeficiency', 'contraindicated', 'with', 'severe']","['immunosuppression', 'immunodeficiency']",2740,['它在患有严重免疫缺陷或免疫抑郁症的患者中被禁止使用。'],0.2,"['immunosuppression', 'immunodeficiency', 'contraindicated', 'with', 'severe']",['immunodeficiency'],,
2783,2741,safety in pregnancy has not been established .,怀孕期间的安全性尚未确定。,0.6666666666666666,"['safety', 'pregnancy', 'in pregnancy']","['safety', 'pregnancy']",2741,['怀孕安全尚未确定。'],0.6666666666666666,"['safety', 'pregnancy', 'in pregnancy']","['safety', 'pregnancy']",,
2784,2742,the vaccine also prevents asymptomatic infection ( NEJM JW Infect Dis Dec 2016 and J Infect Dis 2016 Oct 1 ; 214 : 994 ) .,该疫苗还可以预防无症状感染（NEJM JW Infect Dis 2016 年 12 月和 J Infect Dis 2016 年 10 月 1 日；214：994）。,0.8,"['infection', '1', 'vaccine', 'asymptomatic', 'and']","['infection', '1', 'vaccine', 'asymptomatic']",2742,['疫苗还防止无症状感染(NEJM JW Infect Dis Dec 2016 和 J Infect Dis 2016 Oct 1 ; 214 : 994 )。'],0.8,"['infection', '1', 'vaccine', 'asymptomatic', 'and']","['infection', '1', 'vaccine', 'asymptomatic']",,
2785,2743,"adverse effects : the most commonly reported side effects were headache , injection site pain , malaise , asthenia , and myalgia .",副作用：最常报告的副作用是头痛、注射部位疼痛、不适、乏力和肌痛。,0.6,"['asthenia', 'injection', 'headache', 'site', 'myalgia', 'side effects', 'adverse', 'pain', 'malaise', 'and']","['injection', 'headache', 'myalgia', 'side effects', 'pain', 'malaise']",2743,['副作用:最常见的副作用是头痛、注射场所疼痛、恶心、哮喘和神经病。'],0.5,"['asthenia', 'injection', 'headache', 'site', 'myalgia', 'side effects', 'adverse', 'pain', 'malaise', 'and']","['injection', 'headache', 'site', 'side effects', 'pain']",,
2786,2744,individuals with a severe allergic reaction to Dengvaxia should not receive additional doses .,对 Dengvaxia 有严重过敏反应的个人不应接受额外剂量。,0.3333333333333333,"['reaction', 'allergic reaction', 'additional', 'with', 'severe', 'to']","['reaction', 'allergic reaction']",2744,['患有严重对Dengvaxia过敏反应的人不应服用额外剂量。'],0.3333333333333333,"['reaction', 'allergic reaction', 'additional', 'with', 'severe', 'to']","['reaction', 'allergic reaction']",,
2787,2745,persons with no previous dengue infection are at increased risk for severe disease after Dengvaxia vaccination if they are subsequently infected with any dengue serotype .,以前没有感染登革热的人如果随后感染任何登革热血清型，在接种登革热疫苗后患重病的风险就会增加。,0.5714285714285714,"['serotype', 'infection', 'disease', 'vaccination', 'previous', 'no', 'infected', 'dengue', 'risk', 'after', 'with', 'severe', 'severe disease', 'if']","['serotype', 'infection', 'disease', 'vaccination', 'dengue', 'risk', 'after', 'severe disease']",2745,"['未曾感染 dengue 的人在 Dengvaxia 疫苗接种后患有严重疾病的风险增加,如果他们随后感染任何 dengue 类型。']",0.3571428571428571,"['serotype', 'infection', 'disease', 'vaccination', 'previous', 'no', 'infected', 'dengue', 'risk', 'after', 'with', 'severe', 'severe disease', 'if']","['infection', 'disease', 'vaccination', 'risk', 'after']",,
2788,2746,Dengvaxia may cause temporary depression of sensitivity to tuberculin purified protein derivative ( PPD ) .,Dengvaxia 可能会暂时抑制对结核菌素纯化蛋白衍生物 (PPD) 的敏感性。,0.4285714285714285,"['derivative', 'depression', 'temporary', 'protein', 'cause', 'sensitivity', 'to']","['derivative', 'depression', 'protein']",2746,['Dengvaxia 可能导致临时抑郁症对 tuberculin 净化蛋白质衍生物(PPD)的敏感性。'],0.4285714285714285,"['derivative', 'depression', 'temporary', 'protein', 'cause', 'sensitivity', 'to']","['derivative', 'depression', 'protein']",,
2789,2747,"although the dengue vaccine has been approved 19 countries and the European Union , its use in some countries has sparked controversy because of its initial administration without screening for evidence of previous dengue infection .",尽管登革热疫苗已获得 19 个国家和欧盟的批准，但它在一些国家的使用引发了争议，因为它在最初接种时没有筛查以前是否感染过登革热的证据。,0.5454545454545454,"['infection', 'screening', 'administration', 'previous', 'vaccine', 'initial', 'dengue', 'evidence', 'union', 'and', 'without']","['infection', 'screening', 'vaccine', 'initial', 'dengue', 'evidence']",2747,"['尽管该疫苗已被19个国家和欧盟批准,但其在某些国家的使用引发了争议,因为它的初始应用没有检查,以证明以前的 dengue 感染。']",0.3636363636363636,"['infection', 'screening', 'administration', 'previous', 'vaccine', 'initial', 'dengue', 'evidence', 'union', 'and', 'without']","['infection', 'previous', 'vaccine', 'initial']",,
2790,2748,most countries have approved its use up to age 45 years .,大多数国家都批准其使用至 45 岁。,0.0,"['age', 'up', 'have', 'to']",[],2748,"['大多数国家已批准其使用,高达45岁。']",0.0,"['age', 'up', 'have', 'to']",[],,
2791,2749,"more than 13,000 participants ( mean age , 64 ; 70 % overweight or obese ; 50 % current or former smokers ) , without baseline CHD , stroke history , or type 2 diabetes , were assessed .","超过 13,000 名参与者（平均年龄 64 岁；70% 超重或肥胖；50% 现在或以前吸烟）没有基线 CHD、中风史或 2 型糖尿病，接受了评估。",0.5333333333333333,"['diabetes', 'type', 'stroke', 'mean', 'baseline', '2', 'history', 'obese', 'former', 'age', 'current', 'CHD', 'overweight', 'without', 'assessed']","['diabetes', 'type', 'stroke', 'mean', 'baseline', '2', 'age', 'overweight']",2749,"['超过13000名参与者(平均年龄,64;70%超重或肥胖;50%当前或前吸烟者),没有基因CHD,中风史或2型糖尿病,被评估。']",0.4666666666666667,"['diabetes', 'type', 'stroke', 'mean', 'baseline', '2', 'history', 'obese', 'former', 'age', 'current', 'CHD', 'overweight', 'without', 'assessed']","['diabetes', 'type', 'stroke', 'mean', '2', 'age', 'overweight']",,
2792,2750,"the authors conducted a wide range of analyses in which they adjusted for many sociodemographic , behavioral , and dietary risk factors .",作者进行了广泛的分析，其中他们针对许多社会人口学、行为和饮食风险因素进行了调整。,0.2857142857142857,"['a', 'range', 'wide', 'risk', 'dietary', 'in', 'and']","['wide', 'risk']",2750,"['作者进行了广泛的分析,他们对许多社会人口、行为和饮食风险因素进行了调整。']",0.2857142857142857,"['a', 'range', 'wide', 'risk', 'dietary', 'in', 'and']","['wide', 'risk']",,
2793,2751,one possible reason is that their similar sugar content has the same adverse metabolic effects on lipids and central fat deposition .,一个可能的原因是它们相似的糖含量对脂质和中心脂肪沉积具有相同的不利代谢作用。,0.5454545454545454,"['deposition', 'fat deposition', 'sugar', 'content', 'reason', 'central', 'adverse', 'metabolic', 'that', 'and', 'similar']","['deposition', 'fat deposition', 'sugar', 'content', 'reason', 'similar']",2751,"['其中一个可能的原因是,其类似的糖含量对脂肪和中央脂肪存储具有相同的负面代谢效应。']",0.2727272727272727,"['deposition', 'fat deposition', 'sugar', 'content', 'reason', 'central', 'adverse', 'metabolic', 'that', 'and', 'similar']","['sugar', 'content', 'reason']",,
2794,2752,"another explanation is that sugary beverages , including fruit juice , could replace calories from foods with higher nutritional value .",另一种解释是，包括果汁在内的含糖饮料可以替代营养价值更高的食物中的卡路里。,0.25,"['value', 'fruit', 'juice', 'replace', 'nutritional', 'with', 'explanation', 'that']","['value', 'juice']",2752,"['另一个解释是,含糖饮料,包括水果汁,可以从更高的营养价值的食物中取代卡路里。']",0.375,"['value', 'fruit', 'juice', 'replace', 'nutritional', 'with', 'explanation', 'that']","['value', 'fruit', 'juice']",,
2795,2753,new data confirm elevation of cholesterol but show no increase in cardiovascular events .,新数据证实胆固醇升高，但心血管事件并未增加。,0.625,"['cholesterol', 'elevation', 'cardiovascular', 'data', 'no', 'increase', 'but', 'new']","['cholesterol', 'cardiovascular', 'data', 'but', 'new']",2753,"['新数据证实了胆固醇的上升,但没有显示心血管事件的上升。']",0.75,"['cholesterol', 'elevation', 'cardiovascular', 'data', 'no', 'increase', 'but', 'new']","['cholesterol', 'elevation', 'cardiovascular', 'data', 'but', 'new']",,
2796,2754,a known side effect of this drug class is an elevation in lipid levels .,此类药物的一个已知副作用是血脂水平升高。,0.4285714285714285,"['elevation', 'side effect', 'class', 'lipid', 'drug', 'this', 'in']","['side effect', 'drug', 'this']",2754,['这种药物类的一个已知的副作用是脂肪水平的上升。'],0.5714285714285714,"['elevation', 'side effect', 'class', 'lipid', 'drug', 'this', 'in']","['elevation', 'side effect', 'drug', 'this']",,
2797,2755,"it is unclear whether this elevation is seen in patients taking tofacitinib for ulcerative colitis and , if so , whether it has any clinical consequence .",目前尚不清楚服用托法替尼治疗溃疡性结肠炎的患者是否会出现这种升高情况，如果出现这种情况，是否会产生任何临床后果。,0.5,"['elevation', 'taking', 'colitis', 'ulcerative', 'ulcerative colitis', 'clinical', 'consequence', 'tofacitinib', 'this', 'so', 'if', 'and']","['colitis', 'ulcerative', 'ulcerative colitis', 'clinical', 'tofacitinib', 'this']",2755,"['目前尚不清楚这种上升是否在服用Tofacitinib的患者中被观察到,如果有的话,是否有任何临床后果。']",0.25,"['elevation', 'taking', 'colitis', 'ulcerative', 'ulcerative colitis', 'clinical', 'consequence', 'tofacitinib', 'this', 'so', 'if', 'and']","['elevation', 'clinical', 'this']",,
2798,2756,over 1000 patients with tofacitinib exposure of up to 61 weeks were included .,超过 1000 名接受托法替布暴露长达 61 周的患者被纳入。,0.4,"['exposure', 'up', 'with', 'tofacitinib', 'over']","['exposure', 'over']",2756,['包括1000多名患有高达61周的托法西蒂尼布暴露的患者。'],0.2,"['exposure', 'up', 'with', 'tofacitinib', 'over']",['exposure'],,
2799,2757,"after 8 weeks of treatment , there was greater increase from baseline in total cholesterol , HDL , and LDL levels in patients on tofacitinib versus placebo , and these levels remained elevated through week 61 .",治疗 8 周后，与安慰剂组相比，托法替尼组患者的总胆固醇、HDL 和 LDL 水平较基线增加更多，并且这些水平在第 61 周内一直保持升高。,0.5384615384615384,"['cholesterol', 'placebo', 'baseline', 'HDL', 'total', 'LDL', 'treatment', 'week', 'after', 'increase', 'tofacitinib', 'on', 'and']","['cholesterol', 'placebo', 'baseline', 'treatment', 'week', 'after', 'tofacitinib']",2757,"['经过8周的治疗后,在托法西蒂尼布患者的整体胆固醇、HDL和LDL水平从基层上涨,这些水平在61周内保持高。']",0.3076923076923077,"['cholesterol', 'placebo', 'baseline', 'HDL', 'total', 'LDL', 'treatment', 'week', 'after', 'increase', 'tofacitinib', 'on', 'and']","['cholesterol', 'treatment', 'week', 'after']",,
2800,2758,the mean change in total cholesterol was approximately 35 mg / dL at week 8 .,第 8 周总胆固醇的平均变化约为 35 mg/dL。,0.4444444444444444,"['cholesterol', 'mean', '/', 'total', 'week', 'change', 'at', 'approximately', 'in']","['cholesterol', 'mean', 'week', 'change']",2758,['总胆固醇的平均变化在8周约为35 mg / dL。'],0.4444444444444444,"['cholesterol', 'mean', '/', 'total', 'week', 'change', 'at', 'approximately', 'in']","['cholesterol', 'mean', 'week', 'change']",,
2801,2759,the safety profile of any new medication is always of great interest to clinicians and patients .,临床医生和患者总是对任何新药的安全性非常感兴趣。,0.2857142857142857,"['safety', 'medication', 'profile', 'great', 'to', 'and', 'new']","['safety', 'new']",2759,['任何新药的安全性是临床医生和患者总是非常感兴趣的。'],0.2857142857142857,"['safety', 'medication', 'profile', 'great', 'to', 'and', 'new']","['safety', 'new']",,
2802,2760,this large observational review of registration trial data does show that there is a sustained increase in all components of lipids .,这项对注册试验数据的大型观察性审查确实表明，脂质的所有成分都在持续增加。,0.3,"['a', 'data', 'review', 'registration', 'large', 'trial', 'increase', 'all', 'this', 'that']","['data', 'review', 'registration']",2760,"['这一大观察审查登记试验数据表明,所有脂肪组件的持续增加。']",0.3,"['a', 'data', 'review', 'registration', 'large', 'trial', 'increase', 'all', 'this', 'that']","['data', 'review', 'registration']",,
2803,2761,"also , the majority of major adverse cardiovascular events occurred in those with multiple risk factors .",此外，大多数主要不良心血管事件发生在具有多种危险因素的人群中。,0.375,"['cardiovascular', 'multiple', 'major', 'adverse', 'risk', 'majority', 'with', 'in']","['cardiovascular', 'risk', 'majority']",2761,"['此外,大多数主要的心血管不良事件发生在有多个风险因素的人。']",0.375,"['cardiovascular', 'multiple', 'major', 'adverse', 'risk', 'majority', 'with', 'in']","['cardiovascular', 'risk', 'majority']",,
2804,2762,it remains to be seen who the ideal patient is for this type of therapy .,谁是这种疗法的理想患者还有待观察。,0.5,"['type', 'who', 'ideal', 'therapy', 'be', 'patient', 'this', 'to']","['ideal', 'therapy', 'patient', 'this']",2762,['仍然可以看到谁是理想的病人这种类型的治疗。'],0.625,"['type', 'who', 'ideal', 'therapy', 'be', 'patient', 'this', 'to']","['type', 'ideal', 'therapy', 'patient', 'this']",,
2805,2763,neither was more effective than placebo .,两者都不比安慰剂更有效。,1.0,['placebo'],['placebo'],2763,['没有比 placebo 更有效。'],0.0,['placebo'],[],,
2806,2764,"a composite asthma score ( which encompassed lung function and symptoms ) , was similar in all three groups among patients without eosinophilia .",没有嗜酸性粒细胞增多症的所有三组患者的综合哮喘评分（包括肺功能和症状）相似。,0.3333333333333333,"['asthma', 'composite', 'lung', 'eosinophilia', 'function', 'symptoms', 'score', 'all', 'three', 'and', 'without', 'similar']","['asthma', 'lung', 'eosinophilia', 'function']",2764,"['合成哮喘分数(包括肺功能和症状),在所有三个群体中,没有eosinophilia的患者中都是相似的。']",0.4166666666666667,"['asthma', 'composite', 'lung', 'eosinophilia', 'function', 'symptoms', 'score', 'all', 'three', 'and', 'without', 'similar']","['asthma', 'lung', 'function', 'score', 'similar']",,
2807,2765,"as expected , patients with sputum eosinophilia of ≥ 2 % improved while using mometasone but not while using tiotropium or placebo .",正如预期的那样，痰嗜酸性粒细胞增多 ≥ 2% 的患者在使用 mometasone 时有所改善，但在使用 tiotropium 或安慰剂时没有改善。,0.8571428571428571,"['placebo', 'sputum', 'eosinophilia', '2', 'as', 'with', 'but']","['placebo', 'sputum', 'eosinophilia', '2', 'as', 'but']",2765,"['如预期,患有<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>性<unk>。']",0.1428571428571428,"['placebo', 'sputum', 'eosinophilia', '2', 'as', 'with', 'but']",['as'],,
2808,2766,"soon , we might be checking eosinophil counts in our mild asthmatic patients to see if they will be responsive to ICS .",很快，我们可能会检查轻度哮喘患者的嗜酸性粒细胞计数，看他们是否对 ICS 有反应。,0.2222222222222222,"['checking', 'eosinophil', 'be', 'asthmatic', 'will', 'mild', 'if', 'to', 'we']","['checking', 'mild']",2766,"['很快,我们可能会在我们的轻微哮喘患者中检查eosinophil数,以确定他们是否会对ICS作出反应。']",0.2222222222222222,"['checking', 'eosinophil', 'be', 'asthmatic', 'will', 'mild', 'if', 'to', 'we']","['checking', 'be']",,
2809,2767,dosages in the studies ranged from 300 to 3600 mg daily .,研究中的剂量范围为每天 300 至 3600 毫克。,0.0,"['in', 'to']",[],2767,['研究中的剂量在每日300至3600毫克之间。'],0.0,"['in', 'to']",[],,
2810,2768,"also in this trial , no serious adverse events were associated with gabapentin , but in the metanalysis , the rate of adverse events was 10 % higher with gabapentin than placebo .",同样在该试验中，没有严重的不良事件与加巴喷丁相关，但在荟萃分析中，加巴喷丁的不良事件发生率比安慰剂高 10%。,0.2727272727272727,"['placebo', 'rate', 'adverse', 'associated', 'no', 'trial', 'with', 'serious', 'this', 'in', 'but']","['placebo', 'rate', 'but']",2768,"['在此研究中,没有严重的副作用与Gabapentin相关,但在甲状腺分析中,与Gabapentin的副作用率比 placebo高10%。']",0.1818181818181818,"['placebo', 'rate', 'adverse', 'associated', 'no', 'trial', 'with', 'serious', 'this', 'in', 'but']","['rate', 'but']",,
2811,2769,whether the level of clinical risk of breast cancer recurrence adds prognostic information to the recurrence score is not known .,乳腺癌复发的临床风险水平是否为复发评分增加了预后信息尚不清楚。,0.6,"['cancer', 'breast cancer', 'information', 'clinical', 'prognostic', 'risk', 'score', 'level', 'recurrence', 'to']","['cancer', 'breast cancer', 'information', 'clinical', 'risk', 'level']",2769,['是否乳腺癌重复的临床风险水平添加预测信息到重复率尚不清楚。'],0.7,"['cancer', 'breast cancer', 'information', 'clinical', 'prognostic', 'risk', 'score', 'level', 'recurrence', 'to']","['cancer', 'breast cancer', 'information', 'clinical', 'prognostic', 'risk', 'level']",,
2812,2770,the initial endocrine therapy was tamoxifen alone in the majority of the premenopausal women who were 50 years of age or younger .,大多数 50 岁或以下的绝经前妇女的初始内分泌治疗是他莫昔芬单独治疗。,0.6,"['who', 'endocrine', 'therapy', 'initial', 'endocrine therapy', 'premenopausal', 'age', 'majority', 'tamoxifen', 'alone']","['endocrine', 'therapy', 'initial', 'majority', 'tamoxifen', 'alone']",2770,['初始内分泌疗法仅适用于大多数50岁或更年轻的早期女性的Tamoxifen。'],0.5,"['who', 'endocrine', 'therapy', 'initial', 'endocrine therapy', 'premenopausal', 'age', 'majority', 'tamoxifen', 'alone']","['endocrine', 'therapy', 'initial', 'endocrine therapy', 'majority']",,
2813,2771,"among women who were 50 years of age or younger who had received endocrine therapy alone , the estimated ( ± SE ) rate of distant recurrence at 9 years was less than 5 % ( ≤ 1.8 ± 0.9 % ) with a low recurrence score ( a score of 0 to 10 ) , irrespective of clinical risk , and 4.7 ± 1.0 % with an intermediate recurrence score and low clinical risk .",在 50 岁或以下仅接受内分泌治疗的女性中，9 年时远处复发的估计 ( ± SE ) 率低于 5 % ( ≤ 1.8 ± 0.9 % )，且复发评分较低（评分0 至 10)，不考虑临床风险，以及 4.7 ± 1.0% 的中等复发评分和低临床风险。,0.3809523809523809,"['5', 'a', 'who', 'rate', 'endocrine', 'therapy', 'endocrine therapy', 'low', 'clinical', 'age', 'risk', 'distant', 'score', 'recurrence', 'irrespective', 'with', 'intermediate', 'SE', 'to', 'and', 'alone']","['5', 'rate', 'endocrine', 'therapy', 'low', 'clinical', 'risk', 'to']",2771,"['在50岁或未成年女性中,仅接受内分泌治疗的估计( ± SE )在9岁时的遥远复发率低于5%( ≤ 1.8 ± 0.9% )与低复发率( 0 到 10 ),无论临床风险,和 4.7 ± 1.0%与中间复发率和低临床风险。']",0.3809523809523809,"['5', 'a', 'who', 'rate', 'endocrine', 'therapy', 'endocrine therapy', 'low', 'clinical', 'age', 'risk', 'distant', 'score', 'recurrence', 'irrespective', 'with', 'intermediate', 'SE', 'to', 'and', 'alone']","['5', 'rate', 'endocrine', 'therapy', 'low', 'clinical', 'risk', 'to']",,
2814,2772,"in this age group , the estimated distant recurrence at 9 years exceeded 10 % among women with a high clinical risk and an intermediate recurrence score who received endocrine therapy alone ( 12.3 ± 2.4 % ) and among those with a high recurrence score who received chemoendocrine therapy ( 15.2 ± 3.3 % ) .",在这个年龄组中，在具有高临床风险和中度复发评分且仅接受内分泌治疗的女性（ 12.3 ± 2.4 % ）和接受化学内分泌治疗的高复发评分女性中，估计的 9 年远处复发率超过 10 % 。 (15.2±3.3%)。,0.3684210526315789,"['group', 'a', 'who', 'endocrine', 'therapy', 'endocrine therapy', 'clinical', 'age', 'risk', 'distant', 'score', 'recurrence', 'with', 'at', 'intermediate', 'this', 'and', 'alone', 'high']","['group', 'endocrine', 'therapy', 'clinical', 'age', 'risk', 'high']",2772,"['在这个年龄组中,在9岁时的远程重复率估计超过10%的女性,患有高临床风险和中间重复率,仅接受内分泌疗法(12.3 ± 2.4 % )和接受化内分泌疗法(15.2 ± 3.3 % )的高重复率。']",0.4210526315789473,"['group', 'a', 'who', 'endocrine', 'therapy', 'endocrine therapy', 'clinical', 'age', 'risk', 'distant', 'score', 'recurrence', 'with', 'at', 'intermediate', 'this', 'and', 'alone', 'high']","['group', 'endocrine', 'therapy', 'endocrine therapy', 'clinical', 'age', 'risk', 'high']",,
2815,2773,"a high score has been defined as 31 or higher on the basis of the prospective validation National Surgical Adjuvant Breast and Bowel Project ( NSABP ) B20 and Southwest Oncology Group S8814 trial cohorts3,4 or 26 or higher on the basis of the NSABP B20 trial cohort.5,6","根据国家外科辅助乳腺和肠道项目 (NSABP) B20 和西南肿瘤组 S8814 试验队列 3,4 的前瞻性验证，高分被定义为 31 分或更高；或者根据 NSABP B20 试验队列，高分被定义为 26 分或更高.5,6",0.2857142857142857,"['group', 'a', 'defined', 'adjuvant', 'validation', 'basis', 'surgical', 'bowel', 'breast', 'trial', 'project', 'score', 'and', 'high']","['group', 'bowel', 'project', 'high']",2773,"['基于国家手术补助乳房和肠道项目(NSABP)B20和南西肿瘤集团S8814试点3、4或26或以上的预期验证,基于NSABPB20试点5、6。']",0.2857142857142857,"['group', 'a', 'defined', 'adjuvant', 'validation', 'basis', 'surgical', 'bowel', 'breast', 'trial', 'project', 'score', 'and', 'high']","['group', 'bowel', 'breast', 'project']",,
2816,2774,an exploratory analysis indicated some benefit of chemotherapy in women 50 years of age or younger who had a recurrence score of 16 to 25 .,一项探索性分析表明，化疗对复发评分为 16 至 25 分的 50 岁或以下女性有一定益处。,0.2222222222222222,"['chemotherapy', 'who', 'analysis', 'exploratory', 'age', 'score', 'recurrence', 'benefit', 'in']","['chemotherapy', 'analysis']",2774,"['研究分析表明,在50岁或更年轻的妇女中,化疗的某些好处,其重复率为16至25。']",0.2222222222222222,"['chemotherapy', 'who', 'analysis', 'exploratory', 'age', 'score', 'recurrence', 'benefit', 'in']","['chemotherapy', 'analysis']",,
2817,2775,"the trial also showed a low percentage of women with distant recurrence ( 3 % ) at 9 years with endocrine therapy alone if the recurrence score was 0 to 15 , irrespective of age.7,8","该试验还显示，如果复发评分为 0 至 15 分，无论年龄大小，仅接受内分泌治疗 9 年时远处复发率较低 ( 3 % )。 7,8",0.1875,"['percentage', 'endocrine', 'therapy', 'endocrine therapy', 'low', 'distant', 'trial', '3', 'score', 'recurrence', 'irrespective', 'with', 'at', 'if', 'to', 'alone']","['endocrine', 'therapy', 'low']",2775,"['研究还显示,在9年内仅接受内分泌疗法的女性与远程重复率(3%)的比例较低,如果重复率为0至15,无论年龄如何。']",0.25,"['percentage', 'endocrine', 'therapy', 'endocrine therapy', 'low', 'distant', 'trial', '3', 'score', 'recurrence', 'irrespective', 'with', 'at', 'if', 'to', 'alone']","['endocrine', 'therapy', 'endocrine therapy', 'low']",,
2818,2776,we further examined the relationship between age and the absolute chemotherapy benefit in women who were 50 years of age or younger and had a recurrence score of 16 to 25 .,我们进一步检查了 50 岁或以下且复发评分为 16 至 25 分的女性的年龄与绝对化疗获益之间的关系。,0.25,"['chemotherapy', 'relationship', 'who', 'absolute', 'age', 'score', 'recurrence', 'benefit', 'in', 'to', 'and', 'we']","['chemotherapy', 'absolute', 'age']",2776,"['我们进一步研究了年龄与化疗的绝对好处之间的关系,在50岁或更年轻的妇女中,重复率为16至25。']",0.25,"['chemotherapy', 'relationship', 'who', 'absolute', 'age', 'score', 'recurrence', 'benefit', 'in', 'to', 'and', 'we']","['chemotherapy', 'absolute', 'age']",,
2819,2777,objective AND DEFINITION OF CLINICAL RISK,临床风险的目的和定义,0.0,['objective'],[],2777,['临床风险的目标和定义'],0.0,['objective'],[],,
2820,2778,"a prespecified secondary trial objective was to determine whether clinical risk , as assessed with the use of the Adjuvant ! algorithm , added information regarding prognosis for recurrence and prediction of chemotherapy benefit to that projected by the Oncotype DX test.7",预先指定的次要试验目的是确定临床风险是否与使用 Adjuvant! 时评估的一样。算法，在 Oncotype DX 测试预测的结果中添加了有关复发预后和化疗获益预测的信息。 7,0.3333333333333333,"['chemotherapy', 'objective', 'algorithm', 'adjuvant', 'prognosis', 'regarding', 'information', 'clinical', 'risk', 'secondary', 'trial', 'recurrence', 'benefit', 'as', 'with', 'that', 'by', 'to', 'and', 'determine', 'assessed']","['chemotherapy', 'algorithm', 'prognosis', 'regarding', 'information', 'clinical', 'risk']",2778,"['预定二次试验的目标是确定是否临床风险,根据使用Adjuvant!算法的评估,添加了关于重复预测和预测化疗的好处的信息,与 Oncotype DX测试所预测的。']",0.3809523809523809,"['chemotherapy', 'objective', 'algorithm', 'adjuvant', 'prognosis', 'regarding', 'information', 'clinical', 'risk', 'secondary', 'trial', 'recurrence', 'benefit', 'as', 'with', 'that', 'by', 'to', 'and', 'determine', 'assessed']","['chemotherapy', 'algorithm', 'prognosis', 'regarding', 'information', 'clinical', 'risk', 'to']",,
2821,2779,classic pathologic information and outcome results were also used to refine models based on classic information and genomic tests .,经典病理信息和结果结果也用于改进基于经典信息和基因组测试的模型。,0.5714285714285714,"['outcome', 'refine', 'classic', 'information', 'pathologic', 'to', 'and']","['outcome', 'classic', 'information', 'to']",2779,['古典病理信息和结果也被用来精化基于古典信息和基因测试的模型。'],0.4285714285714285,"['outcome', 'refine', 'classic', 'information', 'pathologic', 'to', 'and']","['outcome', 'information', 'to']",,
2822,2780,"the statistical analysis was performed by the second author , the manuscript was written by the first author , and a final version of the manuscript , incorporating changes recommended by the coauthors , was reviewed and approved by all the authors , who vouch for the accuracy and completeness of the data and the adherence of the trial to the protocol ( available with the full text of this article at NEJM.org ) .",统计分析由第二作者完成，手稿由第一作者撰写，手稿的最终版本合并了合著者建议的修改，并得到所有作者的审阅和批准，他们保证准确性和完整性。数据和试验对试验方案的依从性（与本文全文可在 NEJM.org 获取）。,0.4583333333333333,"['a', 'data', 'who', 'analysis', 'author', 'accuracy', 'protocol', 'version', 'article', 'available', 'manuscript', 'trial', 'text', 'statistical analysis', 'completeness', 'with', 'adherence', 'full', 'all', 'second', 'this', 'by', 'and', 'first']","['data', 'analysis', 'accuracy', 'protocol', 'version', 'manuscript', 'statistical analysis', 'completeness', 'full', 'by', 'first']",2780,"['统计分析是由第二作者进行的,手稿是由第一作者写的,最后版本的手稿,包含由共同作者推荐的变更,被所有作者审查和批准,谁渴望数据的准确性和完整性和审判的遵守的议定书(可在NEJM.org上找到完整的文章文本)。']",0.5416666666666666,"['a', 'data', 'who', 'analysis', 'author', 'accuracy', 'protocol', 'version', 'article', 'available', 'manuscript', 'trial', 'text', 'statistical analysis', 'completeness', 'with', 'adherence', 'full', 'all', 'second', 'this', 'by', 'and', 'first']","['data', 'analysis', 'accuracy', 'protocol', 'version', 'manuscript', 'trial', 'statistical analysis', 'completeness', 'full', 'this', 'by', 'first']",,
2823,2781,no one who is not an author contributed to the manuscript .,没有作者以外的人对手稿做出贡献。,0.2,"['who', 'author', 'no', 'manuscript', 'to']",['manuscript'],2781,"['没有人是作家,没有人为手稿做出贡献。']",0.2,"['who', 'author', 'no', 'manuscript', 'to']",['manuscript'],,
2824,2782,no corrections for multiple comparisons were made .,没有对多重比较进行更正。,0.0,"['multiple', 'no']",[],2782,['没有对多个比较进行修正。'],0.0,"['multiple', 'no']",[],,
2825,2783,the trial was conducted from April 2006 to October 2010 .,该试验于 2006 年 4 月至 2010 年 10 月进行。,0.5,"['trial', 'to']",['to'],2783,['审判是在2006年4月至2010年10月进行的。'],0.5,"['trial', 'to']",['trial'],,
2826,2784,the recurrence score was high ( a score of 26 to 100 ) in 589 patients ( 8.9 % ) with low clinical risk and in 770 patients ( 27.4 % ) with high clinical risk ; these distributions were also similar according to age .,589 名低临床风险患者 (8.9%) 和 770 名 (27.4%) 高临床风险患者的复发评分较高（评分为 26 至 100）；根据年龄，这些分布也相似。,0.4166666666666667,"['a', 'low', 'clinical', 'age', 'risk', 'score', 'recurrence', 'with', 'to', 'and', 'high', 'similar']","['low', 'clinical', 'age', 'risk', 'high']",2784,['重复率高(26至100分)在589名患有低临床风险的患者(8.9%)和770名患有高临床风险的患者(27.4%)中;这些分布也根据年龄相似。'],0.4166666666666667,"['a', 'low', 'clinical', 'age', 'risk', 'score', 'recurrence', 'with', 'to', 'and', 'high', 'similar']","['low', 'clinical', 'age', 'risk', 'high']",,
2827,2785,"weaker associations between clinical risk and distant recurrence were observed in older women who had a low recurrence score ( a score of 0 to 10 ) than among those who had a higher recurrence score , and no association was observed in younger women with a low recurrence score , which may be explained at least partly by the lower event rate among younger women and the smaller sample size .",与复发评分较高的女性相比，复发评分较低（评分为0至10）的老年女性临床风险与远处复发之间的关联较弱，而复发评分较低的年轻女性则未观察到相关性。 ，这至少可以部分解释为年轻女性的事件发生率较低和样本量较小。,0.4210526315789473,"['sample', 'who', 'rate', 'association', 'lower', 'be', 'size', 'no', 'clinical', 'risk', 'distant', 'sample size', 'score', 'recurrence', 'with', 'event', 'by', 'to', 'and']","['sample', 'rate', 'association', 'lower', 'clinical', 'risk', 'by', 'and']",2785,"['临床风险和遥远的复发之间的较弱的联系在年龄较低的复发率(0到10的分数)的老妇女中被观察到,而在较低的复发率的年轻妇女中没有联系,这至少部分可以由年轻妇女的较低的事件率和较小的样品大小解释。']",0.631578947368421,"['sample', 'who', 'rate', 'association', 'lower', 'be', 'size', 'no', 'clinical', 'risk', 'distant', 'sample size', 'score', 'recurrence', 'with', 'event', 'by', 'to', 'and']","['sample', 'rate', 'association', 'lower', 'be', 'size', 'clinical', 'risk', 'distant', 'score', 'by', 'and']",,
2828,2786,estimated treatment hazard ratios for 6496 women with an intermediate recurrence score who were randomly assigned to endocrine or chemoendocrine therapy are shown in Figure 2 .,图 2 显示了 6496 名具有中间复发评分的女性被随机分配到内分泌或化学内分泌治疗的估计治疗风险比。,0.4166666666666667,"['who', '2', 'endocrine', 'figure', 'therapy', 'treatment', 'hazard', 'score', 'recurrence', 'with', 'intermediate', 'to']","['2', 'endocrine', 'figure', 'therapy', 'treatment']",2786,"['可估计的治疗风险比例为6496名中等重复率的妇女,随机分配给内分泌或化内分泌治疗,显示在图2。']",0.4166666666666667,"['who', '2', 'endocrine', 'figure', 'therapy', 'treatment', 'hazard', 'score', 'recurrence', 'with', 'intermediate', 'to']","['2', 'endocrine', 'figure', 'therapy', 'treatment']",,
2829,2787,an estimated hazard ratio of greater than 1 indicates a higher recurrence rate with endocrine therapy alone than with chemoendocrine therapy .,估计的风险比大于 1 表明单独内分泌治疗的复发率高于化学内分泌治疗。,0.5833333333333334,"['a', 'rate', '1', 'ratio', 'hazard ratio', 'endocrine', 'therapy', 'endocrine therapy', 'recurrence', 'with', 'alone', 'recurrence rate']","['rate', '1', 'ratio', 'hazard ratio', 'endocrine', 'therapy', 'alone']",2787,['估计超过1的风险比例表明内分泌治疗的重复率高于化内分泌治疗的重复率。'],0.5,"['a', 'rate', '1', 'ratio', 'hazard ratio', 'endocrine', 'therapy', 'endocrine therapy', 'recurrence', 'with', 'alone', 'recurrence rate']","['rate', '1', 'ratio', 'hazard ratio', 'endocrine', 'therapy']",,
2830,2788,"the level of clinical risk was not predictive of chemotherapy benefit in women who had an intermediate recurrence score in the entire population , nor in the 4353 women who were older than 50 years of age or the 2143 women who were 50 years of age or younger ( Figure 2A ) .",临床风险水平不能预测整个人群中复发评分为中等的女性的化疗获益，也不能预测 4353 名 50 岁以上的女性或 2143 名 50 岁或以下的女性（图 2A)。,0.3846153846153846,"['chemotherapy', 'population', 'who', 'figure', 'clinical', 'age', 'risk', 'score', 'level', 'recurrence', 'predictive', 'benefit', 'intermediate']","['chemotherapy', 'population', 'clinical', 'risk', 'level']",2788,"['临床风险水平在整个人口中有中等重复率的妇女中没有预测化疗益处,也没有在50岁以上的4353名妇女或50岁以上的2143名妇女中有预测化疗益处(图2A)。']",0.3846153846153846,"['chemotherapy', 'population', 'who', 'figure', 'clinical', 'age', 'risk', 'score', 'level', 'recurrence', 'predictive', 'benefit', 'intermediate']","['chemotherapy', 'population', 'clinical', 'risk', 'level']",,
2831,2789,"trends suggested a chemotherapy benefit in 476 women who were younger than 50 years of age and had a recurrence score of 21 to 25 , but these trends did not vary according to clinical risk ( Figure 2B ) .",趋势表明化疗对 476 名年龄小于 50 岁且复发评分为 21 至 25 的女性有益，但这些趋势并未因临床风险而异（图 2B）。,0.5833333333333334,"['chemotherapy', 'who', 'figure', 'clinical', 'age', 'risk', 'score', 'recurrence', 'benefit', 'but', 'to', 'and']","['chemotherapy', 'clinical', 'age', 'risk', 'but', 'to', 'and']",2789,"['趋势表明,在50岁以下的476名妇女中,化疗有好处,并且有21至25的重复率,但这些趋势不因临床风险而有所不同(图2B)。']",0.4166666666666667,"['chemotherapy', 'who', 'figure', 'clinical', 'age', 'risk', 'score', 'recurrence', 'benefit', 'but', 'to', 'and']","['chemotherapy', 'clinical', 'risk', 'but', 'and']",,
2832,2790,age AND CHEMOTHERAPY BENEFIT,年龄和化疗获益,1.0,['age'],['age'],2790,['年龄和化疗的好处'],1.0,['age'],['age'],,
2833,2791,we further evaluated chemotherapy benefit as a function of age and menopausal status in 4338 women with a recurrence score of 16 to 25 ( Figure 3 ) .,我们进一步评估了 4338 名复发评分为 16 至 25 分的女性的化疗获益作为年龄和绝经状态的函数（图 3）。,0.25,"['chemotherapy', 'figure', 'function', 'status', 'menopausal', 'age', '3', 'score', 'recurrence', 'benefit', 'as', 'with', 'in', 'to', 'and', 'we']","['chemotherapy', 'function', 'status', 'age']",2791,"['我们进一步评估化疗益处作为年龄和更年期状态的功能,在4338妇女中,重复率为16至25(图3)。']",0.25,"['chemotherapy', 'figure', 'function', 'status', 'menopausal', 'age', '3', 'score', 'recurrence', 'benefit', 'as', 'with', 'in', 'to', 'and', 'we']","['chemotherapy', 'function', 'status', 'age']",,
2834,2792,"event RATES AT 9 YEARS , STRATIFIED ACCORDING TO AGE",9 岁时的事件发生率，根据年龄分层,0.0,['event'],[],2792,"['活动时间为9年,与年龄相适应']",0.0,['event'],[],,
2835,2793,"in 6469 women who were older than 50 years of age ( two thirds of the trial population ) , the mean ( ± SE ) distant recurrence rate at 9 years was similar , irrespective of use or nonuse of chemotherapy , in the cohort with an intermediate recurrence score , regardless of whether the clinical risk was low ( 4.0 ± 0.7 % vs. 3.5 ± 0.6 % ) or high ( 8.3 ± 1.5 % vs. 9.3 ± 1.9 % ) .",在6469名50岁以上的女性中（试验人群的三分之二） ，9年时的平均（ ± SE ）远处复发率在中间复发队列中相似，无论是否使用化疗。评分，无论临床风险是低（4.0 ± 0.7% 对 3.5 ± 0.6%）还是高（8.3 ± 1.5% 对 9.3 ± 1.9%）。,0.3636363636363636,"['chemotherapy', 'population', 'mean', 'who', 'rate', 'low', 'clinical', 'age', 'risk', 'distant', 'trial', 'score', 'recurrence', 'irrespective', 'cohort', 'with', 'intermediate', 'SE', 'two', 'high', 'similar', 'recurrence rate']","['chemotherapy', 'population', 'mean', 'rate', 'low', 'clinical', 'risk', 'high']",2793,"['在6469名超過50歲的婦女(試驗人口的三分之二)中,在9年中,平均(±SE)距離重複率相似,無論使用或不使用化學療法,在中間重複率的同步,無論臨床風險低( 4.0 ± 0.7 % 與 3.5 ± 0.6 % )或高( 8.3 ± 1.5 %與 9.3 ± 1.9 % )。']",0.2272727272727272,"['chemotherapy', 'population', 'mean', 'who', 'rate', 'low', 'clinical', 'age', 'risk', 'distant', 'trial', 'score', 'recurrence', 'irrespective', 'cohort', 'with', 'intermediate', 'SE', 'two', 'high', 'similar', 'recurrence rate']","['population', 'mean', 'rate', 'low', 'high']",,
2836,2794,the level of clinical risk also added prognostic information with regard to distant recurrence in the 1359 women ( both younger and older women ) with a high recurrence score who received chemoendocrine therapy .,临床风险水平还增加了关于 1359 名接受化学内分泌治疗且复发评分高的女性（包括年轻和年长女性）远处复发的预后信息。,0.4666666666666667,"['a', 'who', 'therapy', 'information', 'clinical', 'prognostic', 'risk', 'distant', 'score', 'level', 'recurrence', 'with', 'to', 'and', 'high']","['therapy', 'information', 'clinical', 'risk', 'level', 'to', 'high']",2794,['临床风险水平也增加了关于远程重复的预测信息在1359妇女(年轻和老年妇女)与高重复率接受化内分泌疗法。'],0.5333333333333333,"['a', 'who', 'therapy', 'information', 'clinical', 'prognostic', 'risk', 'distant', 'score', 'level', 'recurrence', 'with', 'to', 'and', 'high']","['therapy', 'information', 'clinical', 'prognostic', 'risk', 'level', 'to', 'high']",,
2837,2795,distant recurrence rates were also low among 589 women with a high recurrence score and low clinical risk who received chemotherapy ( 7.0 ± 2.4 % among older women and 6.2 ± 2.5 % among younger women ) and were similar to those among older women with a low recurrence score and high clinical risk ( 7.4 ± 3.4 % ) who received endocrine therapy alone .,在接受化疗的 589 名复发评分高、临床风险低的女性中，远处复发率也很低（老年女性为 7.0 ± 2.4 % ，年轻女性为 6.2 ± 2.5 % ），与复发率低的老年女性相似单独接受内分泌治疗的评分和高临床风险 (7.4 ± 3.4%)。,0.4375,"['chemotherapy', 'who', 'endocrine', 'endocrine therapy', 'low', 'clinical', 'risk', 'distant', 'score', 'recurrence', 'with', 'to', 'and', 'alone', 'high', 'similar']","['chemotherapy', 'endocrine', 'low', 'clinical', 'risk', 'alone', 'high']",2795,"['距离重复率也低于接受化疗的589名高重复率和低临床风险的妇女(7.0 ± 2.4 % 老年妇女和 6.2 ± 2.5 % 年轻妇女),与接受内分泌治疗的老年妇女(7.4 ± 3.4 % )较低的重复率和高临床风险的妇女(7.4 ± 3.4 % )相似。']",0.4375,"['chemotherapy', 'who', 'endocrine', 'endocrine therapy', 'low', 'clinical', 'risk', 'distant', 'score', 'recurrence', 'with', 'to', 'and', 'alone', 'high', 'similar']","['chemotherapy', 'endocrine', 'low', 'clinical', 'risk', 'to', 'high']",,
2838,2796,"in contrast , among 770 women with a high recurrence score and high clinical risk , distant recurrence rates were high among both older and younger women despite the use of chemotherapy ( 19.8 ± 3.9 % and 15.2 ± 3.3 % , respectively ) .",相比之下，在 770 名具有高复发评分和高临床风险的女性中，尽管使用了化疗，但老年和年轻女性的远处复发率都很高（分别为 19.8 ± 3.9% 和 15.2 ± 3.3%）。,0.3636363636363636,"['chemotherapy', 'contrast', 'clinical', 'risk', 'distant', 'score', 'recurrence', 'with', 'despite', 'and', 'high']","['chemotherapy', 'clinical', 'risk', 'high']",2796,"['相比之下,770名具有高重复率和高临床风险的妇女中,老年妇女和年轻妇女之间的遥远重复率尽管使用化疗(19.8 ± 3.9% 和 15.2 ± 3.3% 相应)。']",0.3636363636363636,"['chemotherapy', 'contrast', 'clinical', 'risk', 'distant', 'score', 'recurrence', 'with', 'despite', 'and', 'high']","['chemotherapy', 'clinical', 'risk', 'high']",,
2839,2797,estimation OF CHEMOTHERAPY BENEFIT IN REDUCING DISTANT RECURRENCE AT 9 YEARS,9 年时化疗在减少远距离复发方面的获益评估,0.0,['estimation'],[],2797,['化疗效益估计在9年内减少远程复发'],1.0,['estimation'],['estimation'],,
2840,2798,"in 476 women with a recurrence score of 21 to 25 , the absolute chemotherapy benefit in the subgroup with low clinical risk ( 6.4 ± 4.9 percentage points ) was similar to that in the subgroup with high clinical risk ( 8.7 ± 6.2 percentage points ) .",在 476 名复发评分为 21 至 25 的女性中，低临床风险亚组的绝对化疗获益 (6.4 ± 4.9 个百分点) 与高临床风险亚组 (8.7 ± 6.2 个百分点) 相似。,0.4,"['percentage', 'chemotherapy', 'absolute', 'low', 'clinical', 'risk', 'score', 'recurrence', 'subgroup', 'benefit', 'with', 'that', 'to', 'high', 'similar']","['chemotherapy', 'absolute', 'low', 'clinical', 'risk', 'high']",2798,"['在 476 名女性中,重复率为 21 至 25,低临床风险( 6.4 ± 4.9 个百分点)的子组中,绝对化疗的好处与高临床风险( 8.7 ± 6.2 个百分点)的子组中相似。']",0.4,"['percentage', 'chemotherapy', 'absolute', 'low', 'clinical', 'risk', 'score', 'recurrence', 'subgroup', 'benefit', 'with', 'that', 'to', 'high', 'similar']","['chemotherapy', 'absolute', 'low', 'clinical', 'risk', 'high']",,
2841,2799,"in the 886 women with a recurrence score of 16 to 20 , there was an estimated chemotherapy benefit with high clinical risk ( 6.5 ± 4.9 % ) but not with low clinical risk ( − 0.2 ± 2.1 % ) .",在复发评分为 16 至 20 的 886 名女性中，估计化疗获益具有高临床风险 (6.5 ± 4.9%)，但并非具有低临床风险 (-0.2 ± 2.1%)。,0.5454545454545454,"['chemotherapy', 'low', 'clinical', 'risk', 'score', 'recurrence', 'benefit', 'with', 'but', 'to', 'high']","['chemotherapy', 'low', 'clinical', 'risk', 'but', 'high']",2799,"['在886名女性中,重复率为16至20,有高临床风险(6.5 ± 4.9 %)但不低临床风险( − 0.2 ± 2.1 %)的化疗好处。']",0.5454545454545454,"['chemotherapy', 'low', 'clinical', 'risk', 'score', 'recurrence', 'benefit', 'with', 'but', 'to', 'high']","['chemotherapy', 'low', 'clinical', 'risk', 'but', 'high']",,
2842,2800,the sample size was small in some of the subgroups examined ; this contributed to higher standard errors than estimates for the entire cohort with a recurrence score of 11 to 25 .,在一些被检查的子组中，样本量很小；这导致标准误差高于复发评分为 11 至 25 的整个队列的估计值。,0.2727272727272727,"['sample', 'standard', 'size', 'sample size', 'score', 'recurrence', 'cohort', 'with', 'this', 'in', 'to']","['sample', 'standard', 'to']",2800,"['样品大小在一些被审查的子组中很小;这有助于比整个组的估计更高的标准错误,重复率为11至25。']",0.3636363636363636,"['sample', 'standard', 'size', 'sample size', 'score', 'recurrence', 'cohort', 'with', 'this', 'in', 'to']","['sample', 'standard', 'size', 'to']",,
2843,2801,prognosis IN WOMEN 50 YEARS OF AGE OR YOUNGER,50 岁或以下女性的预后,0.5,"['prognosis', 'OR']",['prognosis'],2801,['女性50岁或年轻的预测'],0.5,"['prognosis', 'OR']",['prognosis'],,
2844,2802,"among women who were 50 years of age or younger , most of whom were premenopausal and treated with tamoxifen alone or followed sequentially with an aromatase inhibitor , the distant recurrence rate at 9 years was less than 5 % ( ≤ 1.8 ± 0.9 % ) among those with a low recurrence score , irrespective of clinical risk , and an intermediate recurrence score with low clinical risk ( 4.7 ± 1.0 % ) ( Table 1 ) .",在年龄在 50 岁或以下的女性中，其中大多数是绝经前且仅接受他莫昔芬治疗或后续接受芳香化酶抑制剂治疗的女性，9 年时的远处复发率低于 5 % ( ≤ 1.8 ± 0.9 % ) 。低复发评分，无论临床风险如何，中等复发评分，低临床风险 (4.7 ± 1.0%)（表 1）。,0.4166666666666667,"['inhibitor', '5', 'a', 'aromatase', 'table', 'who', 'rate', '1', 'low', 'premenopausal', 'clinical', 'age', 'risk', 'distant', 'score', 'recurrence', 'irrespective', 'with', 'tamoxifen', 'intermediate', 'aromatase inhibitor', 'and', 'alone', 'recurrence rate']","['inhibitor', '5', 'table', 'rate', '1', 'low', 'clinical', 'age', 'risk', 'tamoxifen']",2802,"['在50岁或更年轻的妇女中,其中大多数是临床前期,单独服用tamoxifen或连续服用 aromatase 抑制剂的妇女中,在9年间的遥远复发率低于5%( ≤ 1.8 ± 0.9% )在低复发率的妇女中,无论临床风险如何,以及低临床风险的中间复发率( 4.7 ± 1.0 % )( 表 1 )。']",0.375,"['inhibitor', '5', 'a', 'aromatase', 'table', 'who', 'rate', '1', 'low', 'premenopausal', 'clinical', 'age', 'risk', 'distant', 'score', 'recurrence', 'irrespective', 'with', 'tamoxifen', 'intermediate', 'aromatase inhibitor', 'and', 'alone', 'recurrence rate']","['inhibitor', '5', 'table', 'rate', '1', 'low', 'clinical', 'risk', 'alone']",,
2845,2803,"in contrast , the rate of distant recurrence at 9 years exceeded 10 % among women with high clinical risk and an intermediate recurrence score who received endocrine therapy alone ( 12.3 ± 2.4 % ) and in those with a high recurrence score who received chemoendocrine therapy ( 15.2 ± 3.3 % ) .",相比之下，9 年时远处复发率超过 10 %，在具有高临床风险和中度复发评分且仅接受内分泌治疗的女性 ( 12.3 ± 2.4 % ) 和具有高复发评分且接受化学内分泌治疗的女性 ( 15.2 ) 中± 3.3%）。,0.3529411764705882,"['a', 'who', 'rate', 'contrast', 'endocrine', 'therapy', 'endocrine therapy', 'clinical', 'risk', 'distant', 'score', 'recurrence', 'with', 'intermediate', 'and', 'alone', 'high']","['rate', 'endocrine', 'therapy', 'clinical', 'risk', 'high']",2803,"['相比之下,在9年间的遥远复发率超过了高临床风险和中间复发率的女性10%,仅接受内分泌疗法(12.3 ± 2.4%)和接受化内分泌疗法(15.2 ± 3.3%)的高复发率的女性。']",0.4117647058823529,"['a', 'who', 'rate', 'contrast', 'endocrine', 'therapy', 'endocrine therapy', 'clinical', 'risk', 'distant', 'score', 'recurrence', 'with', 'intermediate', 'and', 'alone', 'high']","['rate', 'endocrine', 'therapy', 'endocrine therapy', 'clinical', 'risk', 'high']",,
2846,2804,the integration of genomic and clinical information may provide a more accurate estimation of prognosis for individual patients than could be provided by either the genomic or clinical information alone.16,基因组和临床信息的整合可能比基因组或临床信息单独提供更准确的个体患者预后估计。 16,0.6363636363636364,"['a', 'estimation', 'integration', 'individual', 'prognosis', 'accurate', 'be', 'information', 'clinical', 'by', 'and']","['estimation', 'integration', 'individual', 'prognosis', 'accurate', 'information', 'clinical']",2804,"['基因组和临床信息的集成可能为个人患者提供更准确的预测估计,而仅仅基因组或临床信息可以提供。']",0.8181818181818182,"['a', 'estimation', 'integration', 'individual', 'prognosis', 'accurate', 'be', 'information', 'clinical', 'by', 'and']","['estimation', 'integration', 'individual', 'prognosis', 'accurate', 'information', 'clinical', 'by', 'and']",,
2847,2805,"although TAILORx showed that endocrine therapy was noninferior to chemoendocrine therapy in women with an intermediate recurrence score ( a score of 11 to 25 ) , 7 we performed an exploratory analysis in accordance with recommended guidelines in order to determine whether any subgroup might derive some benefit from adjuvant chemotherapy.17",尽管 TAILORx 显示内分泌治疗在中度复发评分（评分为 11 至 25）的女性中不劣于化学内分泌治疗 7 ，但我们还是根据推荐的指南进行了探索性分析，以确定是否有任何亚组可能从中获益。辅助化疗。 17,0.2222222222222222,"['a', 'analysis', 'order', 'adjuvant', 'endocrine', 'therapy', 'endocrine therapy', 'exploratory', 'score', 'recurrence', 'subgroup', 'benefit', 'with', 'intermediate', 'that', 'in order to', 'determine', 'we']","['analysis', 'endocrine', 'therapy', 'in order to']",2805,"['虽然TAILORx 表明,内分泌疗法与中间重复率(11至25分)的妇女的内分泌疗法不低,但我们根据推荐的指导方针进行了探索分析,以确定任何子组是否可以从补充化疗中获得某种好处。']",0.2777777777777778,"['a', 'analysis', 'order', 'adjuvant', 'endocrine', 'therapy', 'endocrine therapy', 'exploratory', 'score', 'recurrence', 'subgroup', 'benefit', 'with', 'intermediate', 'that', 'in order to', 'determine', 'we']","['analysis', 'endocrine', 'therapy', 'endocrine therapy', 'in order to']",,
2848,2806,"the interaction among age , recurrence score , and chemotherapy benefit observed in TAILORx is therefore consistent with the greater treatment effect of adjuvant chemotherapy in younger women .",因此，在 TAILORx 中观察到的年龄、复发评分和化疗获益之间的相互作用与辅助化疗对年轻女性的更大治疗效果一致。,0.3846153846153846,"['chemotherapy', 'adjuvant', 'treatment', 'age', 'interaction', 'effect', 'score', 'recurrence', 'treatment effect', 'benefit', 'with', 'therefore', 'and']","['chemotherapy', 'treatment', 'age', 'effect', 'treatment effect']",2806,"['因此,在 TAILORx 中观察到的年龄、重复率和化疗益处之间的相互作用与年轻妇女的辅助化疗的更大的治疗效应一致。']",0.3076923076923077,"['chemotherapy', 'adjuvant', 'treatment', 'age', 'interaction', 'effect', 'score', 'recurrence', 'treatment effect', 'benefit', 'with', 'therefore', 'and']","['chemotherapy', 'treatment', 'age', 'effect']",,
2849,2807,"given the incremental benefits observed with ovarian suppression plus tamoxifen or an aromatase inhibitor as compared with tamoxifen alone in premenopausal women21,22 and the low percentage of premenopausal women who received ovarian suppression in TAILORx , it is possible that similar incremental benefits observed in younger women who received chemotherapy and had a recurrence score of 16 to 25 could be achieved with ovarian suppression and an aromatase inhibitor , as observed in other trials.21,22","鉴于在绝经前女性 21,22 中观察到卵巢抑制加他莫昔芬或芳香化酶抑制剂与单用他莫昔芬相比的增量获益，以及在 TAILORx 中接受卵巢抑制的绝经前女性所占比例较低，有可能在接受卵巢抑制的年轻女性中观察到类似的增量获益接受化疗并且复发评分为 16 到 25 可以通过卵巢抑制和芳香化酶抑制剂实现，正如在其他试验中观察到的那样。 21,22",0.35,"['inhibitor', 'percentage', 'chemotherapy', 'suppression', 'aromatase', 'who', 'plus', 'be', 'low', 'premenopausal', 'score', 'recurrence', 'with', 'achieved', 'tamoxifen', 'aromatase inhibitor', 'that', 'and', 'alone', 'similar']","['inhibitor', 'chemotherapy', 'suppression', 'plus', 'be', 'low', 'tamoxifen']",2807,"['鉴于卵巢抑制以及<unk>化<unk>或<unk>化<unk>抑制剂与<unk>化<unk>单独相比的卵巢抑制剂的增加效益21,22和在甲状腺抑制剂中服用卵巢抑制剂的甲状腺抑制剂中服用卵巢抑制剂的低百分比,可能类似的增加效益在接受化疗的年轻妇女中服用,并且有16至25的重复率可以通过卵巢抑制剂和<unk>化<unk>抑制剂获得,如其他研究所观察到的。']",0.35,"['inhibitor', 'percentage', 'chemotherapy', 'suppression', 'aromatase', 'who', 'plus', 'be', 'low', 'premenopausal', 'score', 'recurrence', 'with', 'achieved', 'tamoxifen', 'aromatase inhibitor', 'that', 'and', 'alone', 'similar']","['inhibitor', 'chemotherapy', 'suppression', 'plus', 'be', 'low', 'alone']",,
2850,2808,"estimation of an absolute chemotherapy benefit requires tools to estimate the underlying risk of recurrence and the treatment effect of chemotherapy , which may vary in magnitude according to tumor biologic features .",评估化疗的绝对获益需要工具来评估复发的潜在风险和化疗的治疗效果，这可能会根据肿瘤生物学特征的不同而有所不同。,0.5625,"['chemotherapy', 'estimation', 'tools', 'tumor', 'biologic', 'absolute', 'treatment', 'risk', 'effect', 'estimate', 'magnitude', 'recurrence', 'treatment effect', 'benefit', 'in', 'and']","['chemotherapy', 'tools', 'tumor', 'absolute', 'treatment', 'risk', 'effect', 'treatment effect', 'and']",2808,"['对绝对化疗益处的估计需要工具来估计基于重复的风险和化疗的治疗效果,这可能因肿瘤的生物特征而有所不同。']",0.625,"['chemotherapy', 'estimation', 'tools', 'tumor', 'biologic', 'absolute', 'treatment', 'risk', 'effect', 'estimate', 'magnitude', 'recurrence', 'treatment effect', 'benefit', 'in', 'and']","['chemotherapy', 'estimation', 'tools', 'tumor', 'absolute', 'treatment', 'risk', 'effect', 'treatment effect', 'and']",,
2851,2809,"when the recurrence score was further stratified according to clinical risk among TAILORx patients as described here , there was no evidence of chemotherapy benefit at 9 years in the subgroup with a low clinical risk and a recurrence score of 16 to 20 , whereas the addition of chemotherapy was associated with lower rates of distant recurrence ranging from approximately 6 to 8 percentage points among women with a recurrence score of 21 to 25 , irrespective of clinical risk , and a recurrence score of 16 to 20 with high clinical risk .",如本文所述，当根据 TAILORx 患者的临床风险对复发评分进一步分层时，没有证据表明临床风险低且复发评分为 16 至 20 的亚组在 9 年时化疗获益，而加入化疗在复发评分为 21 至 25 分的女性（无论临床风险如何）和复发评分为 16 至 20 分的高临床风险女性中，远处复发率降低约 6 至 8 个百分点。,0.35,"['percentage', 'chemotherapy', 'addition', 'lower', 'associated', 'no', 'clinical', 'risk', 'distant', 'score', 'evidence', 'recurrence', 'irrespective', 'subgroup', 'benefit', 'with', 'approximately', 'to', 'and', 'high']","['chemotherapy', 'addition', 'clinical', 'risk', 'evidence', 'and', 'high']",2809,"['当重复率按临床风险进一步分类时,如下所述,在低临床风险和16至20重复率的子组中9年没有化疗益处的证据,而化疗的补充与距离重复率较低,从21至25重复率的女性中约6至8个百分点,无论临床风险如何,以及高临床风险的16至20重复率。']",0.35,"['percentage', 'chemotherapy', 'addition', 'lower', 'associated', 'no', 'clinical', 'risk', 'distant', 'score', 'evidence', 'recurrence', 'irrespective', 'subgroup', 'benefit', 'with', 'approximately', 'to', 'and', 'high']","['chemotherapy', 'addition', 'clinical', 'risk', 'evidence', 'and', 'high']",,
2852,2810,"the level of clinical risk also added prognostic information for women with a high recurrence score who were receiving chemoendocrine therapy , irrespective of age , and thus could be used to identify patients with very high risk for whom testing of new therapeutic approaches in clinical trials is warranted .",临床风险水平还为接受化学内分泌治疗的复发评分高的女性增加了预后信息，无论年龄大小，因此可用于识别需要在临床试验中测试新治疗方法的高风险患者。 .,0.5238095238095238,"['a', 'who', 'high risk', 'therapy', 'be', 'information', 'therapeutic', 'clinical', 'age', 'prognostic', 'thus', 'score', 'level', 'identify', 'recurrence', 'irrespective', 'testing', 'with', 'to', 'and', 'new']","['therapy', 'be', 'information', 'therapeutic', 'clinical', 'age', 'thus', 'level', 'identify', 'to', 'new']",2810,"['临床风险水平还添加了高重复率的妇女的预测信息,这些妇女无论年龄如何接受化内分泌疗法,因此可以用来识别患有非常高的风险的患者,他们在临床试验中可以测试新的治疗方法。']",0.4761904761904761,"['a', 'who', 'high risk', 'therapy', 'be', 'information', 'therapeutic', 'clinical', 'age', 'prognostic', 'thus', 'score', 'level', 'identify', 'recurrence', 'irrespective', 'testing', 'with', 'to', 'and', 'new']","['therapy', 'be', 'information', 'clinical', 'age', 'prognostic', 'thus', 'level', 'identify', 'new']",,
2853,2811,the addition of this information enabled more precise identification of subgroups of younger women who may derive some benefit from more effective antiestrogen therapy than a course of tamoxifen .,添加此信息可以更准确地识别年轻女性亚群，她们可能会从比他莫昔芬疗程更有效的抗雌激素治疗中获益。,0.6,"['antiestrogen', 'who', 'identification', 'addition', 'therapy', 'information', 'benefit', 'course', 'tamoxifen', 'this']","['antiestrogen', 'identification', 'addition', 'therapy', 'information', 'tamoxifen']",2811,"['这些信息的添加使得更准确地识别年轻妇女的子群,这些妇女可能从更有效的抗雌激素治疗中获得一些好处,而不是托米西芬的治疗。']",0.6,"['antiestrogen', 'who', 'identification', 'addition', 'therapy', 'information', 'benefit', 'course', 'tamoxifen', 'this']","['antiestrogen', 'identification', 'addition', 'therapy', 'information', 'this']",,
2854,2812,the noninferiority margin was a risk difference of 6 percentage points .,非劣效性界值是 6 个百分点的风险差异。,0.5,"['percentage', 'margin', 'difference', 'risk']","['difference', 'risk']",2812,['非低利率差距为6个百分点的风险差距。'],0.25,"['percentage', 'margin', 'difference', 'risk']",['risk'],,
2855,2813,"in symptomatic patients with risk factors for coronary artery disease , two strategies are predominantly used to establish the diagnosis and guide management of care .",在有冠状动脉疾病危险因素的有症状患者中，主要使用两种策略来确定诊断和指导护理管理。,0.5714285714285714,"['disease', 'coronary', 'diagnosis', 'guide', 'risk', 'symptomatic', 'management', 'care', 'with', 'coronary artery', 'in', 'and', 'establish', 'two']","['disease', 'coronary', 'diagnosis', 'guide', 'risk', 'management', 'coronary artery', 'two']",2813,"['在患有冠状动脉疾病风险因素的症状患者中,主要使用两种策略来确定诊断和指导护理管理。']",0.5714285714285714,"['disease', 'coronary', 'diagnosis', 'guide', 'risk', 'symptomatic', 'management', 'care', 'with', 'coronary artery', 'in', 'and', 'establish', 'two']","['disease', 'coronary', 'diagnosis', 'guide', 'risk', 'management', 'coronary artery', 'two']",,
2856,2814,"the first uses invasive angiography visualizing the presence and distribution of coronary artery disease , supported by assessment of fractional flow reserve ( FFR ) to guide the need for subsequent revascularization.3,4","第一种方法是使用侵入性血管造影术可视化冠状动脉疾病的存在和分布，并通过评估血流储备分数 ( FFR ) 来指导后续血运重建的需要。 3,4",0.75,"['presence', 'angiography', 'disease', 'need', 'reserve', 'flow', 'coronary', 'assessment', 'distribution', 'guide', 'subsequent', 'coronary artery', 'by', 'to', 'and', 'first']","['presence', 'angiography', 'disease', 'need', 'reserve', 'flow', 'coronary', 'assessment', 'distribution', 'guide', 'coronary artery', 'first']",2814,"['第一次使用侵入性天文图,可视化冠状动脉疾病的存在和分布,支持分裂流备(FFR)的评估,以指导后续复发的需要。']",0.6875,"['presence', 'angiography', 'disease', 'need', 'reserve', 'flow', 'coronary', 'assessment', 'distribution', 'guide', 'subsequent', 'coronary artery', 'by', 'to', 'and', 'first']","['presence', 'disease', 'need', 'flow', 'coronary', 'assessment', 'distribution', 'guide', 'coronary artery', 'by', 'first']",,
2857,2815,"the second uses noninvasive functional stress testing , followed by invasive angiography and revascularization in patients with a positive test .",第二种采用无创功能压力测试，随后对测试呈阳性的患者进行有创血管造影和血运重建。,0.3333333333333333,"['angiography', 'test', 'functional', 'stress', 'revascularization', 'testing', 'with', 'positive', 'second', 'by', 'and', 'noninvasive']","['angiography', 'test', 'stress', 'revascularization']",2815,"['第二次使用非侵入性功能压力测试,随后在受积极测试的患者中进行侵入性 angiography 和 revascularization。']",0.25,"['angiography', 'test', 'functional', 'stress', 'revascularization', 'testing', 'with', 'positive', 'second', 'by', 'and', 'noninvasive']","['test', 'stress', 'second']",,
2858,2816,"international guidelines differ in their recommendations for noninvasive testing.1,2","国际指南对无创检测的建议各不相同。 1,2",0.3333333333333333,"['differ', 'in', 'noninvasive']",['differ'],2816,['国际指南在其非侵略性测试的建议中有所不同。'],0.0,"['differ', 'in', 'noninvasive']",[],,
2859,2817,"however , there is consensus that revascularization should be guided by ischemia testing5 unless the left main coronary artery is involved.6",然而，一致认为血运重建应以缺血检测为指导 5 ，除非左主干冠状动脉受累 6 。,0.75,"['consensus', 'ischemia', 'coronary', 'be', 'revascularization', 'coronary artery', 'that', 'by']","['consensus', 'ischemia', 'coronary', 'revascularization', 'coronary artery', 'by']",2817,"['然而,有一个共识,重振应由伊什米亚测试引导5除非左主要冠状动脉参与。']",0.5,"['consensus', 'ischemia', 'coronary', 'be', 'revascularization', 'coronary artery', 'that', 'by']","['consensus', 'coronary', 'coronary artery', 'by']",,
2860,2818,cardiovascular MRI has been associated with a lower incidence of invasive angiography than testing based on clinical risk assessment.10,心血管 MRI 与基于临床风险评估的测试相比，侵入性血管造影的发生率较低。 10,0.4545454545454545,"['angiography', 'incidence', 'cardiovascular', 'lower', 'MRI', 'associated', 'clinical', 'risk', 'testing', 'with', 'on']","['angiography', 'incidence', 'cardiovascular', 'clinical', 'risk']",2818,"['心血管MRI与基于临床风险评估的测试相比,侵入性安吉格拉的发病率较低。']",0.3636363636363636,"['angiography', 'incidence', 'cardiovascular', 'lower', 'MRI', 'associated', 'clinical', 'risk', 'testing', 'with', 'on']","['incidence', 'cardiovascular', 'clinical', 'risk']",,
2861,2819,the trial design and methods have been published previously.11,试验设计和方法之前已发表。 11,0.25,"['trial', 'design', 'have', 'and']",['design'],2819,['试验设计和方法已公布。11'],0.25,"['trial', 'design', 'have', 'and']",['design'],,
2862,2820,the trial was approved by the United Kingdom National Research Ethics Service and local institutional review boards .,该试验得到了英国国家研究伦理服务局和当地机构审查委员会的批准。,0.2222222222222222,"['research', 'review', 'service', 'ethics', 'local', 'kingdom', 'trial', 'by', 'and']","['research', 'review']",2820,['审判由英国国家研究伦理局和地方机构审查委员会批准。'],0.4444444444444444,"['research', 'review', 'service', 'ethics', 'local', 'kingdom', 'trial', 'by', 'and']","['research', 'review', 'trial', 'by']",,
2863,2821,"trial investigators and committees are presented in the Supplementary Appendix , available with the full text of this article at NEJM.org .",试验研究者和委员会在补充附录中介绍，补充附录与本文全文可在 NEJM.org 获取。,0.0769230769230769,"['appendix', 'article', 'supplementary', 'available', 'trial', 'text', 'committees', 'with', 'at', 'full', 'this', 'in', 'and']",['committees'],2821,"['审判调查人员和委员会在附件中提交,可在NEJM.org上找到本文的完整文本。']",0.3076923076923077,"['appendix', 'article', 'supplementary', 'available', 'trial', 'text', 'committees', 'with', 'at', 'full', 'this', 'in', 'and']","['appendix', 'trial', 'committees', 'full']",,
2864,2822,an independent data and safety monitoring board monitored the progress of all aspects of the trial .,一个独立的数据和安全监督委员会监督了试验各个方面的进展。,0.3333333333333333,"['safety', 'monitoring', 'data', 'board', 'trial', 'independent', 'progress', 'all', 'and']","['safety', 'data', 'independent']",2822,['一个独立的数据和安全监测委员会监测了审判的各个方面的进展。'],0.5555555555555556,"['safety', 'monitoring', 'data', 'board', 'trial', 'independent', 'progress', 'all', 'and']","['safety', 'monitoring', 'data', 'trial', 'independent']",,
2865,2823,"after database closure , an independent trial statistician analyzed the data .",数据库关闭后，一位独立的试验统计学家分析了数据。,0.6,"['database', 'closure', 'after', 'trial', 'independent']","['closure', 'after', 'independent']",2823,"['数据库关闭后,一个独立的试验统计学家分析了数据。']",0.6,"['database', 'closure', 'after', 'trial', 'independent']","['closure', 'after', 'independent']",,
2866,2824,all procedures were carried out in accordance with Good Clinical Practice guidelines and the principles of the Declaration of Helsinki .,所有程序均按照良好临床实践指南和赫尔辛基宣言的原则进行。,0.0,"['good clinical practice', 'with', 'all', 'out', 'and']",[],2824,['所有程序都按照好临床实践指南和赫尔辛基宣言的原则进行。'],0.0,"['good clinical practice', 'with', 'all', 'out', 'and']",[],,
2867,2825,"funders had no role in the design of the trial ; the collection , analysis or interpretation of the data ; or the writing and review of the manuscript .",资助者在试验设计中没有任何作用；数据的收集、分析或解释；或稿件的撰写和审阅。,0.5833333333333334,"['data', 'analysis', 'review', 'collection', 'interpretation', 'role', 'no', 'manuscript', 'writing', 'trial', 'design', 'and']","['data', 'analysis', 'review', 'collection', 'interpretation', 'role', 'design']",2825,['资助者在审判的设计中没有任何作用;数据的收集、分析或解释;或手稿的写作和审查。'],0.8333333333333334,"['data', 'analysis', 'review', 'collection', 'interpretation', 'role', 'no', 'manuscript', 'writing', 'trial', 'design', 'and']","['data', 'analysis', 'review', 'collection', 'interpretation', 'role', 'manuscript', 'writing', 'trial', 'design']",,
2868,2826,the authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol ( available at NEJM.org ) .,作者保证数据的完整性和准确性，以及试验对方案（可在 NEJM.org 获取）的忠实度。,0.375,"['fidelity', 'data', 'accuracy', 'protocol', 'available', 'trial', 'completeness', 'and']","['data', 'accuracy', 'completeness']",2826,['作者保证数据的完整性和准确性以及审判对议定书的忠诚性(可在NEJM.org上提供)。'],0.625,"['fidelity', 'data', 'accuracy', 'protocol', 'available', 'trial', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
2869,2827,"patients were enrolled at 16 sites in the United Kingdom , Portugal , Germany , and Australia ( Table S1 in the Supplementary Appendix ) .",患者在英国、葡萄牙、德国和澳大利亚的 16 个地点入组（补充附录表 S1）。,0.25,"['appendix', 'australia', 'table', 'supplementary', 'kingdom', 'at', 'S1', 'and']","['australia', 'table']",2827,['患者在英国、葡萄牙、德国和澳大利亚的16个地点注册(附件中的S1表)。'],0.375,"['appendix', 'australia', 'table', 'supplementary', 'kingdom', 'at', 'S1', 'and']","['appendix', 'australia', 'table']",,
2870,2828,no systematic effort was made to maximize medical therapy for angina before screening for enrollment .,在入组筛选之前，没有系统地努力最大限度地对心绞痛进行药物治疗。,0.5555555555555556,"['screening', 'medical', 'angina', 'therapy', 'systematic', 'no', 'effort', 'before', 'to']","['screening', 'angina', 'therapy', 'effort', 'before']",2828,"['没有系统的努力,以最大限度地治疗腹泻,在注册之前进行筛查。']",0.5555555555555556,"['screening', 'medical', 'angina', 'therapy', 'systematic', 'no', 'effort', 'before', 'to']","['screening', 'therapy', 'systematic', 'effort', 'before']",,
2871,2829,management STRATEGY,管理策略,1.0,['management'],['management'],2829,['管理策略'],1.0,['management'],['management'],,
2872,2830,"randomization was performed with fixed block sizes , stratified according to center and sex within center .",随机化以固定的区组大小进行，根据中心和中心内的性别分层。,0.7142857142857143,"['center', 'randomization', 'block', 'sex', 'fixed', 'with', 'to center']","['center', 'randomization', 'block', 'sex', 'fixed']",2830,"['随机化是以固定区块大小进行的,根据中心和中心内的性别分布。']",0.5714285714285714,"['center', 'randomization', 'block', 'sex', 'fixed', 'with', 'to center']","['center', 'randomization', 'block', 'sex']",,
2873,2831,"all the randomly assigned diagnostic tests were performed and interpreted by senior local physicians , who made all subsequent clinical management decisions .",所有随机分配的诊断测试均由当地高级医师进行和解释，他们做出所有后续的临床管理决定。,0.2727272727272727,"['who', 'senior', 'local', 'clinical', 'subsequent', 'diagnostic', 'management', 'all', 'by', 'and', 'physicians']","['clinical', 'management', 'by']",2831,"['所有随机分配的诊断测试都是由高级当地医生进行和解释的,他们做出了所有随后的临床管理决策。']",0.2727272727272727,"['who', 'senior', 'local', 'clinical', 'subsequent', 'diagnostic', 'management', 'all', 'by', 'and', 'physicians']","['clinical', 'management', 'by']",,
2874,2832,"patients assigned to the FFR group underwent invasive coronary angiography and FFR testing in all coronary arteries with a caliber of 2.5 mm or more and a stenosis severity of 40 % or more , if technically feasible .",如果技术可行，分配到 FFR 组的患者在所有直径为 2.5 毫米或以上且狭窄严重程度为 40% 或以上的冠状动脉中接受侵入性冠状动脉造影和 FFR 测试。,0.25,"['group', 'angiography', 'stenosis', 'caliber', 'coronary', 'coronary angiography', 'testing', 'with', 'all', 'if', 'to', 'and']","['group', 'stenosis', 'coronary']",2832,"['FFR 组的患者在所有 2.5 毫米或以上的冠状动脉中进行了侵入性冠状安吉格和 FFR 测试,如果技术上可行,则患有 40 % 或以上的<unk>性硬度。']",0.1666666666666666,"['group', 'angiography', 'stenosis', 'caliber', 'coronary', 'coronary angiography', 'testing', 'with', 'all', 'if', 'to', 'and']","['group', 'coronary']",,
2875,2833,details of the FFR procedure have been described previously.11,FFR 程序的细节已在前面描述过。 11,0.5,"['procedure', 'have']",['procedure'],2833,['FFR程序的详细信息已被描述。11'],0.5,"['procedure', 'have']",['procedure'],,
2876,2834,revascularization was recommended in all vessels with an FFR of 0.8 or less .,建议对 FFR 为 0.8 或更低的所有血管进行血运重建。,0.4,"['revascularization', 'with', 'vessels', 'all', 'in']","['revascularization', 'vessels']",2834,"['在所有具有 0.8 或更低 FFR 的船舶中,建议进行重新吸收。']",0.0,"['revascularization', 'with', 'vessels', 'all', 'in']",[],,
2877,2835,the decision to proceed to PCI or CABG was made in line with practice guidelines.1,进行 PCI 或 CABG 的决定是根据实践指南做出的。 1,0.4285714285714285,"['in line', 'proceed', 'CABG', 'practice', 'decision', 'with', 'to']","['proceed', 'practice', 'decision']",2835,"['决定向 PCI 或 CABG 提交,按照实践指导方针作出。']",0.2857142857142857,"['in line', 'proceed', 'CABG', 'practice', 'decision', 'with', 'to']","['practice', 'decision']",,
2878,2836,patients in this group also underwent a cardiovascular MRI study ( including assessment of myocardial perfusion ) before the invasive study .,该组患者在侵入性研究之前还接受了心血管 MRI 检查（包括心肌灌注评估）。,0.4545454545454545,"['group', 'perfusion', 'a', 'cardiovascular', 'study', 'MRI', 'assessment', 'myocardial', 'this', 'before', 'in']","['group', 'perfusion', 'cardiovascular', 'assessment', 'before']",2836,['该群体的患者在入侵性研究之前也接受了心血管MRI研究(包括心血管注射的评估)。'],0.3636363636363636,"['group', 'perfusion', 'a', 'cardiovascular', 'study', 'MRI', 'assessment', 'myocardial', 'this', 'before', 'in']","['group', 'cardiovascular', 'assessment', 'before']",,
2879,2837,"this scan was not reported , and all results were blinded .",这次扫描没有被报告，所有的结果都是盲目的。,0.3333333333333333,"['all', 'this', 'and']",['this'],2837,"['这个扫描没有被报告,所有结果都是盲目的。']",0.3333333333333333,"['all', 'this', 'and']",['this'],,
2880,2838,the cardiovascular MRI protocol has been described previously.11,之前已经描述了心血管 MRI 方案。 11,0.3333333333333333,"['cardiovascular', 'protocol', 'MRI']",['cardiovascular'],2838,['心血管MRI协议已被描述。'],0.6666666666666666,"['cardiovascular', 'protocol', 'MRI']","['cardiovascular', 'protocol']",,
2881,2839,"in brief , myocardial perfusion was assessed with the first pass of gadobutrol ( in the form of Gadovist , from Bayer , Leverkusen , Germany ) at a dose of 0.075 mmol per kilogram of body weight during adenosine infusion at a rate of 140 to 210 μg per kilogram per minute for up to 6 minutes , followed by assessment of resting perfusion after 10 minutes and scar imaging .",简而言之，在腺苷输注期间，以每千克体重 140 至 210 微克的速率，首次通过钆布醇（以 Gadovist 的形式，来自德国勒沃库森拜耳公司）来评估心肌灌注。公斤每分钟最多 6 分钟，然后在 10 分钟和疤痕成像后评估静息灌注。,0.5909090909090909,"['adenosine', 'perfusion', 'body weight', 'form', 'scar', 'rate', 'infusion', 'minute', 'kilogram', 'assessment', 'pass', 'after', 'myocardial', 'up', 'with', 'dose', 'imaging', 'by', 'to', 'and', 'first', 'assessed']","['adenosine', 'perfusion', 'body weight', 'form', 'scar', 'rate', 'infusion', 'minute', 'assessment', 'pass', 'after', 'by', 'and']",2839,"['简而言之,心血管注射被评估在第一个通过Gadobutrol(在Gadovist的形式,从Bayer,Liverkusen,德国)的剂量为0.075 mmol 每公斤体重,在注射Adenosine的速度为 140 至 210 μg 每公斤每分钟,最多为 6 分钟,随后评估休息注射10 分钟后和扫描图像。']",0.5,"['adenosine', 'perfusion', 'body weight', 'form', 'scar', 'rate', 'infusion', 'minute', 'kilogram', 'assessment', 'pass', 'after', 'myocardial', 'up', 'with', 'dose', 'imaging', 'by', 'to', 'and', 'first', 'assessed']","['body weight', 'form', 'infusion', 'minute', 'assessment', 'pass', 'after', 'dose', 'by', 'and', 'first']",,
2882,2840,"clinically significant inducible ischemia was defined as involving any of the following : two or more neighboring segments , two adjacent slices , or a single transmural segment ( approximately 6 % of the myocardium ) .11",具有临床意义的可诱导缺血被定义为涉及以下任何一项：两个或多个相邻节段、两个相邻切片或单个透壁节段（大约 6 % 的心肌） .11,0.4545454545454545,"['segment', 'a', 'defined', 'myocardium', 'ischemia', 'as', 'approximately', 'single', 'two', 'transmural', 'following']","['segment', 'myocardium', 'ischemia', 'single', 'two']",2840,"['临床上显著的引发性腹泻被定义为涉及两个或多个邻近的部分,两个邻近的粘膜,或一个单一的转移性部分(约6%的心脏)。']",0.2727272727272727,"['segment', 'a', 'defined', 'myocardium', 'ischemia', 'as', 'approximately', 'single', 'two', 'transmural', 'following']","['segment', 'single', 'two']",,
2883,2841,"ischemic burden was calculated semiquantitatively , as described in the Supplementary Appendix .",如补充附录中所述，以半定量方式计算缺血负荷。,0.1666666666666666,"['appendix', 'supplementary', 'as', 'in', 'ischemic', 'burden']",['as'],2841,"['以色列的重量被计算为半量,如附件中所描述。']",0.3333333333333333,"['appendix', 'supplementary', 'as', 'in', 'ischemic', 'burden']","['appendix', 'as']",,
2884,2842,"patients with clinically significant inducible ischemia underwent invasive angiography , and revascularization was recommended , guided by the localization of the ischemic territory .",具有临床显着可诱导缺血的患者接受了侵入性血管造影，并建议在缺血区域定位的指导下进行血运重建。,0.4444444444444444,"['angiography', 'territory', 'ischemia', 'localization', 'revascularization', 'with', 'by', 'and', 'ischemic']","['angiography', 'ischemia', 'localization', 'revascularization']",2842,"['患有临床上显著的引发性腹泻的患者接受了侵入性腹泻,并建议进行重复腹泻,由腹泻区域的定位引导。']",0.2222222222222222,"['angiography', 'territory', 'ischemia', 'localization', 'revascularization', 'with', 'by', 'and', 'ischemic']","['localization', 'by']",,
2885,2843,the final decision on need for and type of revascularization and the target vessel or vessels was left to the performing interventional cardiologist .,关于血运重建的需要和类型以及目标血管的最终决定留给了介入心脏病专家。,0.6363636363636364,"['vessel', 'type', 'need', 'cardiologist', 'revascularization', 'target', 'decision', 'performing', 'vessels', 'to', 'and']","['type', 'need', 'revascularization', 'target', 'decision', 'vessels', 'to']",2843,['最终决定需要和类型的再生和目标船或船只留给执行干预心脏病学家。'],0.4545454545454545,"['vessel', 'type', 'need', 'cardiologist', 'revascularization', 'target', 'decision', 'performing', 'vessels', 'to', 'and']","['type', 'need', 'target', 'decision', 'performing']",,
2886,2844,FFR was not permitted in this group .,该组不允许 FFR。,0.3333333333333333,"['group', 'this', 'in']",['group'],2844,['FFR 不允许在这个群体。'],0.3333333333333333,"['group', 'this', 'in']",['group'],,
2887,2845,all the patients undergoing coronary revascularization received dual antiplatelet therapy .,所有接受冠状动脉血运重建的患者均接受双重抗血小板治疗。,0.5,"['antiplatelet', 'coronary', 'therapy', 'revascularization', 'dual', 'all']","['coronary', 'therapy', 'revascularization']",2845,['所有患有冠状复发症的患者都接受了双重抗膜治疗。'],0.3333333333333333,"['antiplatelet', 'coronary', 'therapy', 'revascularization', 'dual', 'all']","['coronary', 'therapy']",,
2888,2846,"in the case of persistent chest pain , antianginal therapy was increased .",在持续性胸痛的情况下，增加抗心绞痛治疗。,0.6,"['persistent', 'chest', 'chest pain', 'therapy', 'case']","['chest', 'chest pain', 'therapy']",2846,"['在持久的胸部疼痛的情况下,抗阴道治疗增加。']",0.4,"['persistent', 'chest', 'chest pain', 'therapy', 'case']","['chest', 'therapy']",,
2889,2847,subsequent invasive angiography was performed at the discretion of the responsible physician for patients with refractory symptoms .,随后的有创血管造影术由负责医师酌情对难治性症状患者进行。,0.2857142857142857,"['angiography', 'refractory', 'physician', 'symptoms', 'subsequent', 'with', 'at']","['angiography', 'physician']",2847,"['随后的侵入性安吉奥格拉是由负责医生的判断下进行的,对于患有反射性症状的患者。']",0.2857142857142857,"['angiography', 'refractory', 'physician', 'symptoms', 'subsequent', 'with', 'at']","['physician', 'at']",,
2890,2848,the quality and completeness of data entry were monitored with a combination of site visits and remote monitoring .,数据输入的质量和完整性通过现场访问和远程监控相结合的方式进行监控。,0.4545454545454545,"['monitoring', 'combination', 'site', 'data', 'quality', 'remote', 'completeness', 'entry', 'with', 'remote monitoring', 'and']","['combination', 'site', 'data', 'quality', 'completeness']",2848,['数据输入的质量和完整性通过网站访问和远程监测的组合进行监测。'],0.4545454545454545,"['monitoring', 'combination', 'site', 'data', 'quality', 'remote', 'completeness', 'entry', 'with', 'remote monitoring', 'and']","['monitoring', 'combination', 'data', 'quality', 'completeness']",,
2891,2849,clinical OUTCOME,临床结果,1.0,['clinical'],['clinical'],2849,['临床外科'],1.0,['clinical'],['clinical'],,
2892,2850,each component of the primary outcome was analyzed separately as a secondary outcome .,主要结局的每个组成部分作为次要结局单独分析。,0.0,"['component', 'a', 'outcome', 'primary', 'secondary', 'as', 'separately', 'each']",[],2850,['每个初始结果的组成部分分别被分析为次要结果。'],0.125,"['component', 'a', 'outcome', 'primary', 'secondary', 'as', 'separately', 'each']",['outcome'],,
2893,2851,the frequency of invasive coronary angiography that was not performed according to the protocol was assessed .,评估了未根据方案进行的有创冠状动脉造影的频率。,0.2857142857142857,"['angiography', 'frequency', 'protocol', 'coronary', 'coronary angiography', 'that', 'assessed']","['frequency', 'coronary']",2851,['根据协议未进行的侵入性冠状安吉格拉的频率被评估。'],0.4285714285714285,"['angiography', 'frequency', 'protocol', 'coronary', 'coronary angiography', 'that', 'assessed']","['frequency', 'protocol', 'coronary']",,
2894,2852,definitions of outcomes are provided in the Supplementary Appendix .,补充附录中提供了结局的定义。,0.0,"['appendix', 'supplementary', 'in']",[],2852,['结果的定义在附件中列出。'],0.3333333333333333,"['appendix', 'supplementary', 'in']",['appendix'],,
2895,2853,a 10 % incidence in the FFR group and a noninferiority margin of 6 percentage points were assumed on the basis of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation ( FAME ) trial.4,FFR 组的发生率为 10%，非劣效性界限为 6 个百分点，这是基于分数流量储备与血管造影多血管评估 (FAME) 试验的结果。 4,0.6,"['group', 'percentage', 'angiography', 'incidence', 'margin', 'reserve', 'evaluation', 'flow', 'basis', 'and']","['group', 'angiography', 'incidence', 'margin', 'reserve', 'flow']",2853,"['在FFR群体中有10%的发病率和6个百分点的非低率边缘,根据Fractional Flow Reserve vs. Angiography for Multivessel Evaluation(FAME)试验。']",0.3,"['group', 'percentage', 'angiography', 'incidence', 'margin', 'reserve', 'evaluation', 'flow', 'basis', 'and']","['group', 'incidence', 'margin']",,
2896,2854,"with allowance for 10 % of the patients withdrawing , a sample size of 918 patients was chosen .",考虑到 10% 的患者退出，选择了 918 名患者的样本量。,0.2,"['sample', 'size', 'allowance', 'sample size', 'with']",['sample'],2854,"['与退休患者的10%的补贴,选择了918名患者的样品大小。']",0.4,"['sample', 'size', 'allowance', 'sample size', 'with']","['sample', 'size']",,
2897,2855,no interim analyses were performed .,没有进行中期分析。,0.0,['no'],[],2855,['没有进行过时分析。'],0.0,['no'],[],,
2898,2856,no other imputation was performed .,没有进行其他插补。,0.0,['no'],[],2856,['没有其他指控。'],0.0,['no'],[],,
2899,2857,the primary and all secondary efficacy variables were analyzed descriptively .,对主要和所有次要功效变量进行了描述性分析。,0.2,"['primary', 'secondary', 'efficacy', 'all', 'and']",['efficacy'],2857,['所有初级和二级效能变量都被描述分析。'],0.2,"['primary', 'secondary', 'efficacy', 'all', 'and']",['efficacy'],,
2900,2858,"for the primary outcome , differences in proportions and asymptotic 95 % confidence intervals were calculated to test for noninferiority .",对于主要结果，计算比例差异和渐近 95% 置信区间以检验非劣效性。,0.25,"['test', 'outcome', 'primary', 'asymptotic', 'confidence', 'in', 'and', 'intervals']","['test', 'outcome']",2858,"['对于初始结果,比例差异和无与伦比的95%信任间隔被计算为非低效测试。']",0.125,"['test', 'outcome', 'primary', 'asymptotic', 'confidence', 'in', 'and', 'intervals']",['outcome'],,
2901,2859,the pretest likelihood of coronary artery disease was calculated according to a modified Diamond and Forrester score.12,根据修改后的 Diamond 和 Forrester 评分计算冠状动脉疾病的预测试可能性。 12,0.5,"['disease', 'coronary', 'diamond', 'coronary artery', 'to', 'and']","['disease', 'coronary', 'coronary artery']",2859,['冠状动脉疾病的预期概率根据修改的钻石和福雷斯特分数计算。'],0.6666666666666666,"['disease', 'coronary', 'diamond', 'coronary artery', 'to', 'and']","['disease', 'coronary', 'diamond', 'coronary artery']",,
2902,2860,"all analyses were performed with the use of SAS software , version 9.4 ( SAS Institute ) .",所有分析均使用 SAS 软件 9.4 版（SAS Institute）进行。,0.1666666666666666,"['version', 'software', 'institute', 'with', 'SAS', 'all']",['software'],2860,"['所有分析都使用SAS软件,版本 9.4(SAS研究所)进行。']",0.5,"['version', 'software', 'institute', 'with', 'SAS', 'all']","['version', 'software', 'institute']",,
2903,2861,"baseline CHARACTERISTICS , DIAGNOSTIC PROCEDURES , AND THERAPY",基线特征、诊断程序和治疗,1.0,['baseline'],['baseline'],2861,"['基因特征,诊断程序,和治疗']",0.0,['baseline'],[],,
2904,2862,"a total of 16,620 patients were assessed for eligibility between December 2 , 2010 , and August 8 , 2015 ; of these , 918 were deemed to be eligible and enrolled in the trial .","2010 年 12 月 2 日至 2015 年 8 月 8 日期间，共有 16,620 名患者接受了资格评估；其中，918 人被认为符合条件并参加了试验。",0.1111111111111111,"['a', '2', 'total', 'be', 'trial', 'in', 'and', 'assessed', 'eligible']",['2'],2862,"['在2010年12月2日至2015年8月8日期间,共有16620名患者被评为合格,其中918人被认为是合格的,并被列入审查。']",0.3333333333333333,"['a', '2', 'total', 'be', 'trial', 'in', 'and', 'assessed', 'eligible']","['2', 'be', 'eligible']",,
2905,2863,recruitment numbers according to center are presented in Table S1 in the Supplementary Appendix ; reasons for the exclusion of ineligible patients are shown in Figure S1 in the Supplementary Appendix .,补充附录表 S1 中列出了各中心的招募人数；排除不合格患者的原因见补充附录图 S1。,0.3,"['center', 'appendix', 'table', 'figure', 'supplementary', 'exclusion', 'recruitment', 'to center', 'S1', 'in']","['center', 'table', 'recruitment']",2863,['根据中心的招聘号码在附件中的表 S1 显示;不合格患者排除的原因在附件中的图 S1 显示。'],0.3,"['center', 'appendix', 'table', 'figure', 'supplementary', 'exclusion', 'recruitment', 'to center', 'S1', 'in']","['center', 'appendix', 'table']",,
2906,2864,patient characteristics are summarized in Table 1 .,表 1 总结了患者特征。,0.8,"['table', '1', 'characteristics', 'patient', 'in']","['table', '1', 'characteristics', 'patient']",2864,['患者的特征在表1中总结。'],0.8,"['table', '1', 'characteristics', 'patient', 'in']","['table', '1', 'characteristics', 'patient']",,
2907,2865,baseline medications and risk factors also did not differ significantly between the two groups ( Table S2 in the Supplementary Appendix ) .,基线用药和危险因素在两组之间也没有显着差异（补充附录表 S2）。,0.4444444444444444,"['appendix', 'table', 'baseline', 'supplementary', 'differ', 'risk', 'S2', 'and', 'two']","['table', 'baseline', 'risk', 'two']",2865,['基本药物和风险因素在两组之间也没有显著的差异(附件中的S2表)。'],0.4444444444444444,"['appendix', 'table', 'baseline', 'supplementary', 'differ', 'risk', 'S2', 'and', 'two']","['appendix', 'table', 'risk', 'two']",,
2908,2866,the results of the diagnostic tests as well as the subsequent management strategies are shown in Figure 1 .,诊断测试的结果以及随后的管理策略如图 1 所示。,0.375,"['1', 'figure', 'well', 'subsequent', 'diagnostic', 'management', 'as', 'in']","['1', 'management', 'as']",2866,['诊断测试的结果以及随后的管理策略在图1中显示。'],0.25,"['1', 'figure', 'well', 'subsequent', 'diagnostic', 'management', 'as', 'in']","['1', 'management']",,
2909,2867,secondary AND EXPLORATORY OUTCOMES,次要和探索性结果,0.0,['secondary'],[],2867,['二级和探险室'],0.0,['secondary'],[],,
2910,2868,"the secondary outcomes for each component of the primary outcome are summarized in Table 2 , with a detailed description of the patients who died provided in Table S4 in the Supplementary Appendix .",表 2 总结了主要结局的每个组成部分的次要结局，补充附录表 S4 中提供了死亡患者的详细描述。,0.2,"['component', 'a', 'appendix', 'table', 'who', '2', 'outcome', 'supplementary', 'primary', 'secondary', 'description', 'with', 'S4', 'each', 'in']","['table', '2', 'description']",2868,"['初始结果的每个组成部分的次要结果在表2中总结,详细描述已死亡的患者在附件表S4中提供。']",0.3333333333333333,"['component', 'a', 'appendix', 'table', 'who', '2', 'outcome', 'supplementary', 'primary', 'secondary', 'description', 'with', 'S4', 'each', 'in']","['appendix', 'table', '2', 'outcome', 'description']",,
2911,2869,the occurrence of events according to the results of the index test and the performance of revascularization is shown in Figure 3 .,根据指标测试结果的事件发生情况和血运重建的表现如图3所示。,0.3333333333333333,"['test', 'figure', 'occurrence', 'index', 'revascularization', '3', 'performance', 'to', 'and']","['occurrence', 'index', 'revascularization']",2869,"['根据指数测试结果的事件的发生,以及回归的表现,在图3中显示。']",0.2222222222222222,"['test', 'figure', 'occurrence', 'index', 'revascularization', '3', 'performance', 'to', 'and']","['occurrence', 'index']",,
2912,2870,there was a significant reduction in the average CCS class in both groups from baseline to 1 year ( Table S5 in the Supplementary Appendix ) .,从基线到 1 年，两组的平均 CCS 等级均显着降低（补充附录表 S5）。,0.5833333333333334,"['a', 'class', 'appendix', 'table', 'average', 'year', 'baseline', '1', 'supplementary', 'reduction', 'CCS', 'to']","['class', 'table', 'average', 'year', 'baseline', '1', 'reduction']",2870,"['在两组中,从基线到1年中,平均CCS级的显著下降(附件中的S5表)。']",0.5833333333333334,"['a', 'class', 'appendix', 'table', 'average', 'year', 'baseline', '1', 'supplementary', 'reduction', 'CCS', 'to']","['class', 'appendix', 'table', 'average', 'year', 'baseline', '1']",,
2913,2871,"serious adverse events , which occurred in similar numbers of patients in each group , are presented in Table S7 in the Supplementary Appendix .",补充附录表 S7 列出了每组中发生类似数量患者的严重不良事件。,0.2222222222222222,"['group', 'appendix', 'table', 'supplementary', 'adverse', 'serious', 'each', 'in', 'similar']","['group', 'table']",2871,"['严重的副作用,发生在每个群体的患者类似数量,在补充附件中的S7表中呈现。']",0.3333333333333333,"['group', 'appendix', 'table', 'supplementary', 'adverse', 'serious', 'each', 'in', 'similar']","['group', 'appendix', 'table']",,
2914,2872,the use of cardiovascular MRI was associated with a significantly lower incidence of invasive coronary angiography and coronary revascularization than was the use of FFR .,与使用 FFR 相比，使用心血管 MRI 可显着降低侵入性冠状动脉造影和冠状动脉血运重建的发生率。,0.3636363636363636,"['angiography', 'incidence', 'cardiovascular', 'coronary', 'lower', 'MRI', 'revascularization', 'associated', 'coronary angiography', 'with', 'and']","['incidence', 'cardiovascular', 'coronary', 'revascularization']",2872,"['心血管MRI的使用与侵入性冠状安吉格拉和冠状复发的显著较低的发病率有关,而不是FFR的使用。']",0.4545454545454545,"['angiography', 'incidence', 'cardiovascular', 'coronary', 'lower', 'MRI', 'revascularization', 'associated', 'coronary angiography', 'with', 'and']","['incidence', 'cardiovascular', 'coronary', 'lower', 'and']",,
2915,2873,current guidelines on the management of the care of patients with suspected coronary artery disease separate diagnostic strategies from therapeutic strategies owing to a lack of evidence comparing combined diagnostic and therapeutic pathways.13,由于缺乏比较综合诊断和治疗途径的证据，目前关于疑似冠状动脉疾病患者护理管理的指南将诊断策略与治疗策略分开。 13,0.5,"['lack', 'disease', 'coronary', 'therapeutic', 'diagnostic', 'current', 'management', 'evidence', 'care', 'with', 'coronary artery', 'separate', 'to', 'and']","['disease', 'coronary', 'management', 'evidence', 'coronary artery', 'separate', 'to']",2873,"['目前对患有可疑冠状动脉疾病患者的护理管理的指导方针,因缺乏比较综合诊断和治疗途径的证据而与治疗策略分开的诊断策略。']",0.5,"['lack', 'disease', 'coronary', 'therapeutic', 'diagnostic', 'current', 'management', 'evidence', 'care', 'with', 'coronary artery', 'separate', 'to', 'and']","['disease', 'coronary', 'management', 'evidence', 'coronary artery', 'separate', 'and']",,
2916,2874,"it is notable that three of four deaths from cardiac causes in the current trial occurred in patients with severe ischemia on the index examination while on the waiting list for bypass surgery , with one death from cardiac causes occurring in a patient who had a myocardial infarction before index angiography .",值得注意的是，在目前的试验中，四分之三的心脏原因死亡发生在在旁路手术等候名单上进行指标检查时出现严重缺血的患者，其中一名心脏原因死亡发生在之前有过心肌梗塞的患者中。指数血管造影。,0.55,"['myocardial infarction', 'cardiac', 'angiography', 'bypass', 'who', 'death', 'ischemia', 'surgery', 'examination', 'index', 'patient', 'bypass surgery', 'trial', 'list', 'current', 'with', 'severe', 'three', 'that', 'before']","['myocardial infarction', 'cardiac', 'angiography', 'bypass', 'death', 'ischemia', 'surgery', 'examination', 'index', 'patient', 'before']",2874,"['值得注意的是,目前试验中心脏病导致的死亡人数中有三人发生在指数检查中患有严重腹泻的患者中,等待手术的名单上,心脏病导致的死亡人数中有一个人在指数手术前患有心脏病发作的患者中死亡。']",0.35,"['myocardial infarction', 'cardiac', 'angiography', 'bypass', 'who', 'death', 'ischemia', 'surgery', 'examination', 'index', 'patient', 'bypass surgery', 'trial', 'list', 'current', 'with', 'severe', 'three', 'that', 'before']","['cardiac', 'death', 'surgery', 'examination', 'index', 'patient', 'before']",,
2917,2875,the most important limitation of the trial is that the incidences of outcome events at 1 year were lower than expected on the basis of data from the FAME trial ( which enrolled only patients with documented multivessel disease ) .4,该试验最重要的局限性是 1 年时结果事件的发生率低于根据 FAME 试验（该试验仅纳入有记录的多支血管疾病的患者）的数据预期的结果 .4,0.4545454545454545,"['disease', 'data', 'year', '1', 'outcome', 'basis', 'lower', 'limitation', 'trial', 'with', 'that']","['disease', 'data', 'year', '1', 'outcome']",2875,"['试验中最重要的限制是,1年后结果事件的发病率低于预期的数据,根据FAME试验的数据(仅注册有多细胞疾病的患者)。']",0.4545454545454545,"['disease', 'data', 'year', '1', 'outcome', 'basis', 'lower', 'limitation', 'trial', 'with', 'that']","['disease', 'data', 'year', '1', 'outcome']",,
2918,2876,"as a result , the noninferiority margin was large relative to the incidence of major adverse cardiac events .",因此，相对于主要不良心脏事件的发生率，非劣效性界值较大。,0.3,"['cardiac', 'incidence', 'margin', 'relative', 'large', 'major', 'adverse', 'result', 'as', 'to']","['cardiac', 'incidence', 'to']",2876,"['因此,非较低的边界与主要心脏病发作的发病率相对较大。']",0.3,"['cardiac', 'incidence', 'margin', 'relative', 'large', 'major', 'adverse', 'result', 'as', 'to']","['cardiac', 'incidence', 'margin']",,
2919,2877,"thus , noninferiority of cardiovascular MRI would have been shown even if the incidence was twice as high as that in the FFR group .",因此，即使发生率是 FFR 组的两倍，心血管 MRI 的非劣效性也会被证明。,0.4,"['group', 'incidence', 'cardiovascular', 'MRI', 'thus', 'have', 'that', 'if', 'twice', 'high']","['group', 'incidence', 'cardiovascular', 'thus']",2877,"['因此,心血管MRI的非低,即使发病率比FFR群体高两倍。']",0.5,"['group', 'incidence', 'cardiovascular', 'MRI', 'thus', 'have', 'that', 'if', 'twice', 'high']","['group', 'incidence', 'cardiovascular', 'thus', 'high']",,
2920,2878,"the actual incidences in the two groups , however , were similar .",然而，两组的实际发生率相似。,0.25,"['actual', 'in', 'two', 'similar']",['two'],2878,"['然而,实际情况在两组中是相似的。']",0.5,"['actual', 'in', 'two', 'similar']","['two', 'similar']",,
2921,2879,this may have caused some bias since interventional cardiologists may have had greater confidence in one index examination over the other .,这可能会造成一些偏差，因为介入心脏病专家可能对一项指标检查比另一项指标更有信心。,0.7142857142857143,"['bias', 'examination', 'index', 'confidence', 'have', 'this', 'over']","['bias', 'examination', 'index', 'confidence', 'have']",2879,"['這可能導致了一些混亂,因為介入心臟科學家可能在一個指數檢查中對另一個有更大的信心。']",0.2857142857142857,"['bias', 'examination', 'index', 'confidence', 'have', 'this', 'over']","['confidence', 'have']",,
2922,2880,"similarly , a bias toward revascularization in the FFR group cannot be fully ruled out , since conversion from a diagnostic to a therapeutic procedure was easier in this group .",同样，不能完全排除 FFR 组偏向血运重建的可能性，因为在该组中从诊断性操作转变为治疗性操作更容易。,0.3846153846153846,"['group', 'conversion', 'bias', 'procedure', 'be', 'revascularization', 'therapeutic', 'diagnostic', 'this', 'in', 'out', 'to', 'toward']","['group', 'conversion', 'be', 'revascularization', 'toward']",2880,"['同样,在FFR群体中对复发的偏见不能完全排除,因为从诊断到治疗程序的转换在这个群体中更容易。']",0.3076923076923077,"['group', 'conversion', 'bias', 'procedure', 'be', 'revascularization', 'therapeutic', 'diagnostic', 'this', 'in', 'out', 'to', 'toward']","['group', 'conversion', 'procedure', 'be']",,
2923,2881,additional limitations should also be considered .,还应考虑额外的限制。,0.5,"['be', 'additional']",['additional'],2881,['还要考虑额外的限制。'],0.5,"['be', 'additional']",['additional'],,
2924,2882,"systematic maximization of antianginal therapy was not performed before screening for enrollment , so patients who might have been asymptomatic after medication adjustment may have been enrolled in the trial .",在入组筛选前未进行系统的最大程度抗心绞痛治疗，因此药物调整后可能无症状的患者可能已入组试验。,0.5,"['who', 'screening', 'adjustment', 'therapy', 'systematic', 'medication', 'asymptomatic', 'after', 'trial', 'have', 'so', 'before']","['screening', 'therapy', 'systematic', 'asymptomatic', 'after', 'before']",2882,"['抗阴道治疗的系统性最大化在注册前没有进行,因此在药物调整后可能无症状的患者可能已被注册在测试中。']",0.4166666666666667,"['who', 'screening', 'adjustment', 'therapy', 'systematic', 'medication', 'asymptomatic', 'after', 'trial', 'have', 'so', 'before']","['therapy', 'asymptomatic', 'after', 'have', 'before']",,
2925,2883,the patient population was primarily male and white .,患者群体主要是男性和白人。,0.8,"['population', 'male', 'white', 'patient', 'and']","['population', 'male', 'white', 'patient']",2883,['患者人口主要是男性和白人。'],0.8,"['population', 'male', 'white', 'patient', 'and']","['population', 'male', 'white', 'patient']",,
2926,2884,an Anticoagulation Forum guideline provides recommendations on the use of DOAC reversal agents .,抗凝论坛指南提供了有关使用 DOAC 逆转剂的建议。,1.0,['anticoagulation'],['anticoagulation'],2884,"['关于使用 DOAC 逆转剂的建议,关于使用 DOAC 逆转剂的建议。']",0.0,['anticoagulation'],[],,
2927,2885,sponsoring Organization : the Anticoagulation Forum,主办机构：抗凝论坛,0.5,"['anticoagulation', 'organization']",['anticoagulation'],2885,['赞助组织 : 抗分裂论坛'],0.5,"['anticoagulation', 'organization']",['organization'],,
2928,2886,"previously , some physicians and patients were reluctant to use DOACs because of the unavailability of an antidote .",以前，由于无法获得解毒剂，一些医生和患者不愿使用 DOAC。,0.5,"['antidote', 'to', 'and', 'physicians']","['antidote', 'to']",2886,"['此前,一些医生和患者因抗剂无法使用而拒绝使用DOAC。']",0.25,"['antidote', 'to', 'and', 'physicians']",['and'],,
2929,2887,"however , idarucizumab has recently been approved as a reversal agent for the DOAC dabigatran , and andexanet alfa has been approved as a reversal agent for the DOACs rivaroxaban and apixaban .",然而，idarucizumab 最近已被批准作为 DOAC 达比加群的逆转剂，andexanet alfa 已被批准作为 DOAC 利伐沙班和阿哌沙班的逆转剂。,0.5,"['a', 'as', 'dabigatran', 'idarucizumab', 'rivaroxaban', 'agent', 'apixaban', 'and']","['dabigatran', 'rivaroxaban', 'apixaban', 'and']",2887,"['然而, idarucizumab 最近已被批准为DOAC dabigatran的逆转剂,而 andexanet alfa 已被批准为DOAC rivaroxaban 和 apixaban 的逆转剂。']",0.125,"['a', 'as', 'dabigatran', 'idarucizumab', 'rivaroxaban', 'agent', 'apixaban', 'and']",['and'],,
2930,2888,"now , members of the Anticoagulation Forum have provided indications for proper use of these reversing agents .",现在，抗凝论坛的成员已经提供了正确使用这些逆转剂的适应症。,0.3333333333333333,"['anticoagulation', 'members', 'have']",['anticoagulation'],2888,"['现在,抗麻疹论坛的成员已经提供了适当使用这些逆转剂的指示。']",0.0,"['anticoagulation', 'members', 'have']",[],,
2931,2889,reversing agents are not indicated in patients with DOAC overdose without bleeding or in those presenting with trauma without bleeding .,逆转剂不适用于 DOAC 过量但未出血的患者或出现外伤但未出血的患者。,0.6,"['bleeding', 'trauma', 'overdose', 'with', 'without']","['bleeding', 'trauma', 'overdose']",2889,['逆转物质不适用于无出血的DOAC过量患者或无出血的创伤患者。'],0.8,"['bleeding', 'trauma', 'overdose', 'with', 'without']","['bleeding', 'trauma', 'overdose', 'without']",,
2932,2890,"although it is reassuring that DOAC reversal agents are now available , guidance on their rational use is needed , given their cost , limited availability , and associated risk for thrombosis .",尽管现在可以使用 DOAC 逆转剂令人欣慰，但考虑到它们的成本、可用性有限和相关的血栓形成风险，仍需要对其合理使用的指导。,0.2727272727272727,"['thrombosis', 'associated', 'available', 'risk', 'rational', 'availability', 'cost', 'limited', 'that', 'and', 'guidance']","['thrombosis', 'risk', 'cost']",2890,"['尽管确保 DOAC 逆转剂现在可用,但由于其成本、可用性有限以及相关风险,需要对其合理使用的指导。']",0.1818181818181818,"['thrombosis', 'associated', 'available', 'risk', 'rational', 'availability', 'cost', 'limited', 'that', 'and', 'guidance']","['risk', 'cost']",,
2933,2891,the authors suggest a need for multidisciplinary stewardship programs to assist with proper use of reversing agents .,作者建议需要多学科管理计划来协助正确使用逆转剂。,0.1666666666666666,"['a', 'need', 'suggest', 'with', 'assist', 'to']",['need'],2891,"['作者提出了多学科管理计划的必要性,以帮助适当使用逆转代理。']",0.0,"['a', 'need', 'suggest', 'with', 'assist', 'to']",[],,
2934,2892,"ideally , hospital systems will help with the evolution of the Coumadin clinic toward broader anticoagulation monitoring services that support patients treated with DOACs .",理想情况下，医院系统将帮助 Coumadin 诊所向更广泛的抗凝监测服务方向发展，以支持接受 DOAC 治疗的患者。,0.7,"['monitoring', 'anticoagulation', 'support', 'evolution', 'clinic', 'hospital', 'will', 'with', 'that', 'toward']","['monitoring', 'anticoagulation', 'support', 'evolution', 'clinic', 'hospital', 'toward']",2892,"['理想情况下,医院系统将有助于科马丁诊所的进化,向支持用DOAC治疗的患者提供更广泛的抗凝固监测服务。']",0.7,"['monitoring', 'anticoagulation', 'support', 'evolution', 'clinic', 'hospital', 'will', 'with', 'that', 'toward']","['monitoring', 'anticoagulation', 'support', 'evolution', 'clinic', 'hospital', 'toward']",,
2935,2893,"although laboratory monitoring is seldom needed , patients treated with DOACs still require careful monitoring and guidance with difficult decisions , including regarding the need for urgent reversal .",虽然很少需要实验室监测，但接受 DOAC 治疗的患者仍需要仔细监测和指导，并做出艰难的决定，包括是否需要紧急逆转。,0.3636363636363636,"['monitoring', 'need', 'still', 'regarding', 'laboratory', 'urgent', 'with', 'careful', 'and', 'difficult', 'guidance']","['monitoring', 'need', 'laboratory', 'difficult']",2893,"['虽然实验室监测很少需要,但用DOAC治疗的患者仍然需要仔细监测和引导困难的决策,包括紧急逆转的必要性。']",0.3636363636363636,"['monitoring', 'need', 'still', 'regarding', 'laboratory', 'urgent', 'with', 'careful', 'and', 'difficult', 'guidance']","['monitoring', 'need', 'laboratory', 'difficult']",,
2936,2894,numerous nonclinical factors are associated with excess risk .,许多非临床因素与过度风险有关。,0.25,"['excess', 'associated', 'risk', 'with']",['risk'],2894,['许多非临床因素与过度风险有关。'],0.25,"['excess', 'associated', 'risk', 'with']",['risk'],,
2937,2895,"eleven social and behavioral risk factors were evaluated , including race , financial worry , intimate partner violence , neighborhood poverty , and depressive symptoms .",评估了 11 个社会和行为风险因素，包括种族、经济担忧、亲密伴侣暴力、邻里贫困和抑郁症状。,0.4444444444444444,"['symptoms', 'risk', 'violence', 'depressive', 'worry', 'race', 'partner', 'and', 'eleven']","['risk', 'violence', 'depressive', 'race']",2895,"['11个社会和行为风险因素被评估,包括种族、财务担忧、亲密伴侣暴力、邻居贫困和抑郁症状。']",0.4444444444444444,"['symptoms', 'risk', 'violence', 'depressive', 'worry', 'race', 'partner', 'and', 'eleven']","['risk', 'violence', 'depressive', 'race']",,
2938,2896,patients who were widowed had 38 % higher risk for developing hypertension than did married patients .,丧偶患者患高血压的风险比已婚患者高 38%。,0.5,"['hypertension', 'who', 'developing', 'risk']","['hypertension', 'risk']",2896,['已婚患者患高血压的风险比已婚患者更高38%。'],0.5,"['hypertension', 'who', 'developing', 'risk']","['hypertension', 'risk']",,
2939,2897,studies assessing the clinical effect of social and behavioral interventions would be appropriate .,评估社会和行为干预的临床效果的研究是适当的。,0.4,"['be', 'clinical', 'effect', 'and', 'appropriate']","['clinical', 'effect']",2897,['对社会和行为干预的临床影响进行评估的研究是适当的。'],0.2,"['be', 'clinical', 'effect', 'and', 'appropriate']",['clinical'],,
2940,2898,ongoing surveillance for tickborne disease has identified a previously unknown segmented RNA virus in northern China .,对蜱传疾病的持续监测在中国北方发现了一种以前不为人知的分段 RNA 病毒。,1.0,"['RNA', 'virus', 'disease', 'china', 'surveillance']","['RNA', 'virus', 'disease', 'china', 'surveillance']",2898,['甲状腺疾病的持续监测已在中国北部发现前所未知的分区RNA病毒。'],1.0,"['RNA', 'virus', 'disease', 'china', 'surveillance']","['RNA', 'virus', 'disease', 'china', 'surveillance']",,
2941,2899,"the relatively recent recognition of tickborne infection due to Borrelia miyamotoi , Borrelia mayonii , and Powassan virus have highlighted the limits of our understanding of the breadth of pathogens that can be transmitted by ticks .",最近对宫本疏螺旋体、马约氏疏螺旋体和 Powassan 病毒引起的蜱传感染的认识凸显了我们对可通过蜱传播的病原体范围的了解的局限性。,0.1538461538461538,"['infection', 'virus', 'recent', 'borrelia', 'be', 'limits', 'recognition', 'due', 'have', 'that', 'by', 'to', 'and']","['infection', 'virus']",2899,"['由于Borrelia miyamotoi、Borrelia mayonii 和Pawassan 病毒引起的甲状腺感染的相对较近的认知,突出了我们对甲状腺可以传播的病原体的宽度的理解的界限。']",0.3076923076923077,"['infection', 'virus', 'recent', 'borrelia', 'be', 'limits', 'recognition', 'due', 'have', 'that', 'by', 'to', 'and']","['infection', 'virus', 'by', 'to']",,
2942,2900,ongoing surveillance for tickborne infections in China has now identified yet another previously unidentified RNA virus as a cause of acute human febrile illness .,中国对蜱传感染的持续监测现已确定另一种以前未发现的 RNA 病毒是引起人类急性发热性疾病的原因。,0.6363636363636364,"['RNA', 'virus', 'a', 'febrile', 'illness', 'china', 'surveillance', 'cause', 'acute', 'human', 'as']","['RNA', 'virus', 'illness', 'china', 'surveillance', 'cause', 'human']",2900,['中国正在进行的<unk>虫感染的监测现在已经确定了另一个以前未识别的RNA病毒作为急性人类发烧性疾病的原因。'],0.6363636363636364,"['RNA', 'virus', 'a', 'febrile', 'illness', 'china', 'surveillance', 'cause', 'acute', 'human', 'as']","['RNA', 'virus', 'illness', 'china', 'surveillance', 'cause', 'human']",,
2943,2901,"the index case was a female farmer from the town of Alongshan who presented in April 2017 to a hospital in Inner Mongolia with fever , headache , and a history of tick bites .",指示病例是阿龙山镇的一名女农民，她于 2017 年 4 月因发烧、头痛和被蜱叮咬病史到内蒙古一家医院就诊。,0.2857142857142857,"['a', 'headache', 'index case', 'female', 'who', 'tick', 'inner', 'farmer', 'history', 'town', 'fever', 'hospital', 'with', 'and']","['headache', 'female', 'tick', 'hospital']",2901,"['该指数案例是一名来自阿隆森市的农民,她于2017年4月被送往内蒙古一家医院,患有发烧、头痛和<unk>疹的历史。']",0.2142857142857142,"['a', 'headache', 'index case', 'female', 'who', 'tick', 'inner', 'farmer', 'history', 'town', 'fever', 'hospital', 'with', 'and']","['headache', 'history', 'hospital']",,
2944,2902,"when initial testing did not identify a known cause of infection , further workup was undertaken , including viral culture , electron microscopy , and subsequent genetic and serologic analyses .",当最初的测试没有确定感染的已知原因时，进行了进一步的检查，包括病毒培养、电子显微镜检查以及随后的遗传和血清学分析。,0.4285714285714285,"['infection', 'culture', 'electron', 'electron microscopy', 'a', 'genetic', 'serologic', 'initial', 'cause', 'viral', 'subsequent', 'identify', 'testing', 'and']","['infection', 'culture', 'electron', 'electron microscopy', 'initial', 'cause']",2902,"['当初检测未确定已知感染原因时,还进行了进一步的工作,包括病毒文化、电子显微镜以及随后的遗传和血管分析。']",0.4285714285714285,"['infection', 'culture', 'electron', 'electron microscopy', 'a', 'genetic', 'serologic', 'initial', 'cause', 'viral', 'subsequent', 'identify', 'testing', 'and']","['infection', 'culture', 'electron', 'electron microscopy', 'initial', 'cause']",,
2945,2903,"the clinical symptoms of infection were nonspecific but most commonly included headache , fever , and fatigue .",感染的临床症状是非特异性的，但最常见的包括头痛、发烧和疲劳。,0.6666666666666666,"['infection', 'headache', 'fatigue', 'nonspecific', 'symptoms', 'clinical symptoms', 'fever', 'but', 'and']","['infection', 'headache', 'fatigue', 'nonspecific', 'clinical symptoms', 'but']",2903,"['感染的临床症状是不具体的,但最常见的是头痛、发烧和疲劳。']",0.5555555555555556,"['infection', 'headache', 'fatigue', 'nonspecific', 'symptoms', 'clinical symptoms', 'fever', 'but', 'and']","['infection', 'headache', 'fatigue', 'clinical symptoms', 'but']",,
2946,2904,"a minority of patients had coma , nausea , myalgia , arthralgia , rash , petechiae , or other symptoms .",少数患者有昏迷、恶心、肌痛、关节痛、皮疹、瘀点或其他症状。,0.6666666666666666,"['coma', 'myalgia', 'rash', 'symptoms', 'nausea', 'arthralgia']","['coma', 'myalgia', 'nausea', 'arthralgia']",2904,['少数患者患有昏迷、恶心、神经病、关节炎、发作、皮特基亚或其他症状。'],0.3333333333333333,"['coma', 'myalgia', 'rash', 'symptoms', 'nausea', 'arthralgia']","['coma', 'nausea']",,
2947,2905,the incubation period was generally 3 to 7 days .,潜伏期一般为3～7天。,0.5,"['period', 'incubation period', '3', 'to']","['period', 'incubation period']",2905,['孵化期通常为3至7天。'],0.25,"['period', 'incubation period', '3', 'to']",['period'],,
2948,2906,"all patients were treated empirically with intravenous ribavirin and intramuscular benzylpenicillin ; the duration of illness with treatment was approximately 6 to 8 days , and all patients had complete recovery .",所有患者均接受静脉利巴韦林和肌肉注射苄青霉素的经验性治疗；病程约6～8天，全部痊愈。,0.3076923076923077,"['intramuscular', 'illness', 'complete', 'recovery', 'treatment', 'ribavirin', 'intravenous', 'duration', 'with', 'approximately', 'all', 'to', 'and']","['illness', 'recovery', 'treatment', 'ribavirin']",2906,"['所有患者都接受了内血管里巴维林和内肌本西尔佩尼西林的实验性治疗;与治疗的疾病持续时间约为6至8天,所有患者都得到了完全恢复。']",0.3076923076923077,"['intramuscular', 'illness', 'complete', 'recovery', 'treatment', 'ribavirin', 'intravenous', 'duration', 'with', 'approximately', 'all', 'to', 'and']","['illness', 'recovery', 'treatment', 'duration']",,
2949,2907,"the authors note that I. persulcatus is widely distributed in Asia and eastern Europe and most mammals are common hosts , so ALSV may have a relatively wide distribution in Asia .",作者指出，I. persulcatus广泛分布于亚洲和东欧，大多数哺乳动物是共同宿主，因此ALSV可能在亚洲有相对广泛的分布。,0.2727272727272727,"['mammals', 'ALSV', 'wide', 'common', 'distribution', 'note', 'have', 'that', 'so', 'in', 'and']","['wide', 'distribution', 'have']",2907,"['作者指出,I. persulcatus在亚洲和东欧广泛分布,大多数哺乳动物是常见的主人,因此ALSV可能在亚洲有相对广泛的分布。']",0.2727272727272727,"['mammals', 'ALSV', 'wide', 'common', 'distribution', 'note', 'have', 'that', 'so', 'in', 'and']","['wide', 'distribution', 'have']",,
2950,2908,using sitting devices for routine sleep puts infants at risk .,使用坐姿装置进行常规睡眠会使婴儿处于危险之中。,0.8,"['routine', 'sitting', 'risk', 'sleep', 'at']","['routine', 'risk', 'sleep', 'at']",2908,"['使用座位设备为日常睡眠,将婴儿置于危险之中。']",0.6,"['routine', 'sitting', 'risk', 'sleep', 'at']","['risk', 'sleep', 'at']",,
2951,2909,in 2016 the American Academy of Pediatrics updated its recommendations for creating a safe infant sleep environment .,2016 年，美国儿科学会更新了其关于创造安全婴儿睡眠环境的建议。,0.6666666666666666,"['a', 'environment', 'pediatrics', 'infant', 'academy', 'sleep']","['environment', 'pediatrics', 'infant', 'sleep']",2909,"['2016年,美国儿科学院更新了其建议,以创造一个安全的婴儿睡眠环境。']",0.6666666666666666,"['a', 'environment', 'pediatrics', 'infant', 'academy', 'sleep']","['environment', 'pediatrics', 'infant', 'sleep']",,
2952,2910,"using data from the National Center for Fatality Review and Prevention from 2004 to 2014 , researchers studied the circumstances associated with infant death in sitting devices .",研究人员使用国家死亡审查和预防中心 2004 年至 2014 年的数据，研究了坐式装置导致婴儿死亡的相关情况。,0.5384615384615384,"['center', 'fatality', 'data', 'review', 'death', 'sitting', 'prevention', 'infant', 'associated', 'infant death', 'with', 'to', 'and']","['center', 'data', 'review', 'death', 'prevention', 'infant', 'infant death']",2910,"['使用2004年至2014年国家死亡审查和预防中心的数据,研究人员研究了与婴儿死亡在座位设备相关的情况。']",0.5384615384615384,"['center', 'fatality', 'data', 'review', 'death', 'sitting', 'prevention', 'infant', 'associated', 'infant death', 'with', 'to', 'and']","['center', 'data', 'review', 'death', 'prevention', 'infant', 'infant death']",,
2953,2911,"of these , 63 % occurred in car seats , 35 % in bouncers , swings , and other sitting devices , and 2 % in strollers .",其中，63% 发生在汽车座椅中，35% 发生在摇椅、秋千和其他坐姿装置中，2% 发生在婴儿车中。,0.5,"['2', 'sitting', 'car', 'and']","['2', 'car']",2911,"['其中,63%发生在汽车座位上,35%发生在滑板、滑板和其他座位设备上,2%发生在行人座位上。']",0.5,"['2', 'sitting', 'car', 'and']","['2', 'car']",,
2954,2912,fewer than 10 % of deaths in car seats occurred in infants being properly transported .,不到 10% 的汽车安全座椅死亡发生在婴儿被正确运输的情况下。,0.5,"['car', 'being']",['car'],2912,['汽车座位死亡人数不到10%发生在适当运送的婴儿中。'],0.5,"['car', 'being']",['car'],,
2955,2913,at least one risk factor was identified in 82 % of the deaths .,在 82% 的死亡病例中至少确定了一个危险因素。,0.4,"['factor', 'risk', 'risk factor', 'at', 'in']","['factor', 'risk']",2913,"['在死亡人数的82%中,至少有一种风险因素被确定。']",0.6,"['factor', 'risk', 'risk factor', 'at', 'in']","['factor', 'risk', 'risk factor']",,
2956,2914,the most common risk factor was the supervising person being asleep .,最常见的风险因素是监督人睡着了。,0.7142857142857143,"['factor', 'person', 'common', 'risk', 'risk factor', 'asleep', 'being']","['factor', 'person', 'risk', 'risk factor', 'asleep']",2914,['最常见的风险因素是监督者正在睡觉。'],0.4285714285714285,"['factor', 'person', 'common', 'risk', 'risk factor', 'asleep', 'being']","['factor', 'risk', 'risk factor']",,
2957,2915,"after adjusting for age , sex , and race / ethnicity , deaths in sitting devices were twice as likely to occur during nonparental than parental supervision .",在针对年龄、性别和种族/族裔进行调整后，在没有父母监督的情况下，坐姿死亡的可能性是父母监督期间的两倍。,0.2666666666666666,"['parental', 'sex', '/', 'sitting', 'supervision', 'age', 'after', 'race', 'ethnicity', 'as', 'occur', 'to', 'and', 'twice', 'adjusting']","['sex', 'age', 'after', 'race']",2915,"['根据年龄、性别和种族/种族的调整,座位设备中的死亡率在非父母的监测期间比父母的监测期间多两倍。']",0.2,"['parental', 'sex', '/', 'sitting', 'supervision', 'age', 'after', 'race', 'ethnicity', 'as', 'occur', 'to', 'and', 'twice', 'adjusting']","['sex', 'age', 'race']",,
2958,2916,most infants ( 64 % ) died in their homes .,大多数婴儿 (64%) 死于家中。,0.0,['in'],[],2916,['大多数婴儿(64%)在家中死亡。'],0.0,['in'],[],,
2959,2917,this study shows that most infants who died in car safety seats were not being transported .,这项研究表明，大多数死于汽车安全座椅的婴儿并不是在运输过程中。,0.4285714285714285,"['safety', 'who', 'study', 'car', 'being', 'this', 'that']","['safety', 'car', 'this']",2917,"['这项研究表明,大多数死于汽车安全座位的婴儿都没有被运送。']",0.2857142857142857,"['safety', 'who', 'study', 'car', 'being', 'this', 'that']","['safety', 'car']",,
2960,2918,we should advise parents that car seats are safe and should be used for travel but are not safe and should not be used for infant sleeping .,我们应该告诉父母，汽车安全座椅是安全的，应该用于旅行，但不安全，不应该用于婴儿睡觉。,0.2727272727272727,"['parents', 'sleeping', 'be', 'infant', 'car', 'travel', 'advise', 'that', 'but', 'and', 'we']","['infant', 'car', 'but']",2918,"['我们应该建议父母,汽车座位是安全的,应该用于旅行,但不安全,不应该用于婴儿睡眠。']",0.2727272727272727,"['parents', 'sleeping', 'be', 'infant', 'car', 'travel', 'advise', 'that', 'but', 'and', 'we']","['infant', 'car', 'but']",,
2961,2919,the incidence of colorectal cancer in individuals younger than 50 is rising in several developed countries .,在一些发达国家，50 岁以下人群的结直肠癌发病率正在上升。,0.5,"['incidence', 'cancer', 'colorectal cancer', 'rising']","['incidence', 'cancer']",2919,['五十岁以下的人患有染色性癌症的发病率在多个发达国家越来越高。'],0.5,"['incidence', 'cancer', 'colorectal cancer', 'rising']","['incidence', 'cancer']",,
2962,2920,epidemiologic data from the United States show rising colorectal cancer ( CRC ) incidence in individuals younger than 50 .,来自美国的流行病学数据显示，50 岁以下人群的结直肠癌 (CRC) 发病率呈上升趋势。,0.6,"['incidence', 'cancer', 'data', 'colorectal cancer', 'rising']","['incidence', 'cancer', 'data']",2920,"['来自美国的流行病学数据显示,在50岁以下的个人中,染色性癌症(CRC)的发病率上升。']",0.6,"['incidence', 'cancer', 'data', 'colorectal cancer', 'rising']","['incidence', 'cancer', 'data']",,
2963,2921,"in one study , investigators assessed CRC incidence and mortality in about 144 million people aged 20 to 49 years from 20 European countries .",在一项研究中，研究人员评估了 20 个欧洲国家约 1.44 亿 20 至 49 岁人群的 CRC 发病率和死亡率。,0.25,"['incidence', 'study', 'mortality', 'aged', 'to', 'and', 'assessed', 'million']","['incidence', 'mortality']",2921,"['在一项研究中,研究人员评估了来自20个欧洲国家的20至49岁的约144百万人患有CRC的发病率和死亡率。']",0.25,"['incidence', 'study', 'mortality', 'aged', 'to', 'and', 'assessed', 'million']","['incidence', 'mortality']",,
2964,2922,"in individuals aged 20 to 29 , CRC incidence increased from 0.8 to 2.3 cases per 100,000 persons between 1990 and 2016 .","在 20 至 29 岁的人群中，CRC 发病率在 1990 年至 2016 年间从每 100,000 人 0.8 例增加到 2.3 例。",0.25,"['incidence', 'aged', 'to', 'and']",['incidence'],2922,"['在20至29岁的个人中,CRC的发病率在1990年至2016年间每10万人中增加了0.8至2.3例。']",0.25,"['incidence', 'aged', 'to', 'and']",['incidence'],,
2965,2923,"overall , colon cancer incidence rose more than rectal cancer incidence .",总体而言，结肠癌发病率上升幅度超过直肠癌发病率。,0.8333333333333334,"['incidence', 'cancer', 'rose', 'rectal cancer', 'colon', 'colon cancer']","['incidence', 'cancer', 'rectal cancer', 'colon', 'colon cancer']",2923,"['总体而言,肠道癌的发病率高于直肠癌的发病率。']",0.5,"['incidence', 'cancer', 'rose', 'rectal cancer', 'colon', 'colon cancer']","['incidence', 'cancer', 'rectal cancer']",,
2966,2924,"the CRC incidence increases in the 30 to 39 and 40 to 49 age groups started 10 to 20 years after incidence rose in the 20 to 29 group , consistent with a birth cohort effect .",在 20 至 29 岁年龄组的发病率上升 10 至 20 年后，30 至 39 岁和 40 至 49 岁年龄组的 CRC 发病率开始上升，这与出生队列效应一致。,0.3846153846153846,"['group', 'incidence', 'a', 'rose', 'birth', 'age', 'increases', 'after', 'effect', 'birth cohort', 'with', 'to', 'and']","['group', 'incidence', 'age', 'after', 'effect']",2924,"['在30至39和40至49年龄段的CRC发病率增加开始10至20年后,发病率在20至29组增加,一致与出生调节效应。']",0.3846153846153846,"['group', 'incidence', 'a', 'rose', 'birth', 'age', 'increases', 'after', 'effect', 'birth cohort', 'with', 'to', 'and']","['group', 'incidence', 'age', 'after', 'effect']",,
2967,2925,"while the mechanisms driving these trends remain unclear , there are several likely contributing and interrelated factors , such as overweight , red and processed meat consumption , smoking , lack of physical activity , gut microbiome alterations , and environmental factors .",虽然驱动这些趋势的机制仍不清楚，但有几个可能的促成因素和相互关联的因素，例如超重、食用红肉和加工肉类、吸烟、缺乏体力活动、肠道微生物组改变和环境因素。,0.4285714285714285,"['microbiome', 'lack', 'gut', 'consumption', 'gut microbiome', 'activity', 'driving', 'physical', 'red', 'as', 'overweight', 'physical activity', 'processed', 'and']","['microbiome', 'gut', 'gut microbiome', 'activity', 'as', 'overweight']",2925,"['虽然引发这些趋势的机制仍然不清楚,但有几个可能有助于和相互关联的因素,如体重过重、红肉和加工肉食、吸烟、缺乏身体活动、肠道微生物变化和环境因素。']",0.2857142857142857,"['microbiome', 'lack', 'gut', 'consumption', 'gut microbiome', 'activity', 'driving', 'physical', 'red', 'as', 'overweight', 'physical activity', 'processed', 'and']","['gut', 'activity', 'as', 'overweight']",,
2968,2926,"the epidemiologic trends do not support universal CRC screening in younger persons , because the absolute rates remain significantly lower than in those 50 and older , although some argue that decreasing the screening start age is an inevitability in the long run .",流行病学趋势不支持对年轻人进行普遍的 CRC 筛查，因为绝对率仍然明显低于 50 岁及以上的人群，尽管一些人认为从长远来看，降低筛查开始年龄是不可避免的。,0.4545454545454545,"['support', 'screening', 'absolute', 'lower', 'age', 'universal', 'argue', 'long run', 'start', 'that', 'and']","['support', 'screening', 'absolute', 'age', 'universal']",2926,"['流行病学趋势不支持普遍的CRC筛查在年轻人,因为绝对率仍然显著低于50岁以上的人,虽然有些人认为,减少筛查开始年龄是长期不可避免的。']",0.4545454545454545,"['support', 'screening', 'absolute', 'lower', 'age', 'universal', 'argue', 'long run', 'start', 'that', 'and']","['support', 'screening', 'absolute', 'age', 'universal']",,
2969,2927,"COPD exacerbations occurred at similar rates in all groups , despite marked reductions in median blood and sputum eosinophil levels in the benralizumab groups .",尽管贝那利珠单抗组的血液和痰嗜酸性粒细胞水平中值显着降低，但所有组的 COPD 恶化发生率相似。,0.25,"['eosinophil', 'COPD', 'median', 'sputum', 'blood', 'marked', 'despite', 'benralizumab', 'at', 'all', 'and', 'similar']","['COPD', 'sputum', 'blood']",2927,"['在所有群体中,COPD的加剧发生在相同的速度,尽管在本拉利苏马布群体中中间血液和斑点的eosinophil 水平显著下降。']",0.1666666666666666,"['eosinophil', 'COPD', 'median', 'sputum', 'blood', 'marked', 'despite', 'benralizumab', 'at', 'all', 'and', 'similar']","['COPD', 'blood']",,
2970,2928,the current investigators speculate that more patients in that study had concomitant asthma .,目前的研究人员推测，该研究中更多的患者伴有哮喘。,0.1666666666666666,"['asthma', 'study', 'concomitant', 'current', 'that', 'in']",['asthma'],2928,"['目前的研究人员猜测,该研究中的更多患者患有同步哮喘。']",0.1666666666666666,"['asthma', 'study', 'concomitant', 'current', 'that', 'in']",['asthma'],,
2971,2929,"prophylactic antibiotics can prevent infections after cesarean delivery , but whether antibiotics should be administered for operative vaginal delivery ( i.e. , forceps or vacuum ) is not known .",预防性使用抗生素可以预防剖宫产后的感染，但对于手术阴道分娩（即产钳或真空吸引）是否应该使用抗生素尚不清楚。,0.5384615384615384,"['vacuum', 'cesarean', 'vaginal', 'delivery', 'forceps', 'be', 'operative', 'cesarean delivery', 'after', 'antibiotics', 'prevent', 'prophylactic', 'but']","['vacuum', 'delivery', 'forceps', 'after', 'antibiotics', 'prevent', 'but']",2929,"['预防性抗生素可以预防凯撒分娩后感染,但是否应服用抗生素进行手术阴道分娩(即,强化剂或真空)尚不清楚。']",0.4615384615384615,"['vacuum', 'cesarean', 'vaginal', 'delivery', 'forceps', 'be', 'operative', 'cesarean delivery', 'after', 'antibiotics', 'prevent', 'prophylactic', 'but']","['vacuum', 'delivery', 'after', 'antibiotics', 'prevent', 'but']",,
2972,2930,"endpoints included new prescription of antibiotics for documented systemic infection , endometritis , or perineal wound infection .",终点包括为记录的全身感染、子宫内膜炎或会阴伤口感染开出新的抗生素处方。,0.75,"['infection', 'systemic infection', 'endometritis', 'wound', 'prescription', 'perineal', 'antibiotics', 'new']","['infection', 'endometritis', 'wound', 'prescription', 'antibiotics', 'new']",2930,"['终点包括新的抗生素处方,用于记录的系统感染、内分泌炎或阴道伤口感染。']",0.625,"['infection', 'systemic infection', 'endometritis', 'wound', 'prescription', 'perineal', 'antibiotics', 'new']","['infection', 'wound', 'prescription', 'antibiotics', 'new']",,
2973,2931,"in the antibiotic group , significantly fewer women reported perineal pain , use of pain medication , perineal discomfort leading to difficulty with infant feeding ; fewer healthcare provider visits were also reported .",在抗生素组中，报告会阴疼痛、使用止痛药、会阴不适导致婴儿喂养困难的女性明显减少；还报告了更少的医疗保健提供者访问。,0.4166666666666667,"['group', 'antibiotic', 'feeding', 'discomfort', 'medication', 'infant', 'pain', 'perineal', 'difficulty', 'leading', 'with', 'to']","['group', 'antibiotic', 'infant', 'pain', 'difficulty']",2931,"['在抗生素群体中,显著较少的妇女报告了腹部疼痛,使用疼痛药物,腹部不舒服导致婴儿喂养困难;医疗保健提供商的访问也报告了较少。']",0.5,"['group', 'antibiotic', 'feeding', 'discomfort', 'medication', 'infant', 'pain', 'perineal', 'difficulty', 'leading', 'with', 'to']","['group', 'antibiotic', 'discomfort', 'infant', 'pain', 'difficulty']",,
2974,2932,"in this large trial , maternal infections after operative delivery were more common than anticipated ; nonetheless , antibiotics ( even after delivery ) significantly reduced risk for perineal or systemic infection .",在这项大型试验中，手术分娩后的母体感染比预期更常见；尽管如此，抗生素（甚至在分娩后）显着降低了会阴部或全身感染的风险。,0.4615384615384615,"['infection', 'maternal', 'systemic infection', 'delivery', 'large', 'common', 'operative', 'risk', 'after', 'trial', 'perineal', 'antibiotics', 'this']","['infection', 'maternal', 'delivery', 'risk', 'after', 'antibiotics']",2932,"['在这项大试验中,手术产后母亲感染比预期的更为常见;然而,抗生素(即使在产后)显著降低了阴道或系统感染的风险。']",0.3846153846153846,"['infection', 'maternal', 'systemic infection', 'delivery', 'large', 'common', 'operative', 'risk', 'after', 'trial', 'perineal', 'antibiotics', 'this']","['infection', 'maternal', 'risk', 'after', 'antibiotics']",,
2975,2933,dexmedetomidine produces sedation while maintaining a degree of arousability and may reduce the duration of mechanical ventilation and delirium among patients in the intensive care unit ( ICU ) .,右美托咪定产生镇静作用，同时保持一定程度的唤醒能力，并可能减少重症监护病房 (ICU) 患者机械通气和谵妄的持续时间。,0.6666666666666666,"['ventilation', 'mechanical', 'reduce', 'unit', 'delirium', 'mechanical ventilation', 'degree', 'intensive care unit', 'sedation', 'duration', 'dexmedetomidine', 'and']","['ventilation', 'delirium', 'mechanical ventilation', 'degree', 'intensive care unit', 'sedation', 'duration', 'dexmedetomidine']",2933,"['Dexmedetomidine 产生放松,同时保持一种刺激性程度,并可能在强度护理单位(ICU)的患者中减少机械通风和<unk>的持续时间。']",0.4166666666666667,"['ventilation', 'mechanical', 'reduce', 'unit', 'delirium', 'mechanical ventilation', 'degree', 'intensive care unit', 'sedation', 'duration', 'dexmedetomidine', 'and']","['ventilation', 'unit', 'mechanical ventilation', 'degree', 'duration']",,
2976,2934,the use of dexmedetomidine as the sole or primary sedative agent in patients undergoing mechanical ventilation has not been extensively studied .,尚未对接受机械通气的患者使用右美托咪定作为唯一或主要镇静剂进行广泛研究。,0.4444444444444444,"['ventilation', 'mechanical', 'mechanical ventilation', 'primary', 'sedative', 'sole', 'as', 'dexmedetomidine', 'agent']","['ventilation', 'mechanical ventilation', 'sedative', 'dexmedetomidine']",2934,"['在机械通风患者中,德克塞米多米丁作为唯一或主要的放松剂的使用尚未广泛研究。']",0.3333333333333333,"['ventilation', 'mechanical', 'mechanical ventilation', 'primary', 'sedative', 'sole', 'as', 'dexmedetomidine', 'agent']","['ventilation', 'mechanical ventilation', 'primary']",,
2977,2935,the primary outcome was the rate of death from any cause at 90 days .,主要结果是 90 天时全因死亡率。,0.6,"['rate', 'outcome', 'death', 'primary', 'cause']","['rate', 'outcome', 'death']",2935,['主要结果是任何原因死亡率在90天。'],0.8,"['rate', 'outcome', 'death', 'primary', 'cause']","['rate', 'outcome', 'death', 'cause']",,
2978,2936,we enrolled 4000 patients at a median interval of 4.6 hours between eligibility and randomization .,我们招募了 4000 名患者，从合格到随机化的中位间隔时间为 4.6 小时。,0.4,"['median', 'interval', 'randomization', 'median interval', 'we']","['interval', 'randomization']",2936,['我们注册了4000名患者在资格和随机化之间的平均间隔为4.6小时。'],0.4,"['median', 'interval', 'randomization', 'median interval', 'we']","['interval', 'randomization']",,
2979,2937,bradycardia and hypotension were more common in the dexmedetomidine group .,心动过缓和低血压在右美托咪定组更常见。,0.6666666666666666,"['group', 'bradycardia', 'hypotension', 'common', 'dexmedetomidine', 'and']","['group', 'bradycardia', 'hypotension', 'dexmedetomidine']",2937,['布拉迪卡迪和低血压在德克塞米多米丁群体中更为常见。'],0.3333333333333333,"['group', 'bradycardia', 'hypotension', 'common', 'dexmedetomidine', 'and']","['group', 'hypotension']",,
2980,2938,"sedation is a component of the care of critically ill patients who are undergoing mechanical ventilation , 1,2 but the appropriate choice of a primary sedative agent remains uncertain .","sedation is a component of the care of critically ill patients who are undergoing mechanical ventilation , 1,2 but the appropriate choice of a primary sedative agent remains uncertain .",0.0,"['component', 'ventilation', 'mechanical', 'who', 'uncertain', 'mechanical ventilation', 'primary', 'ill', 'sedation', 'sedative', 'care', 'choice', 'agent', 'but', 'appropriate', 'critically']",[],2938,"['放松是经过机械通风的关键病患者的护理组成部分,但基本放松剂的适当选择仍然不确定。']",0.25,"['component', 'ventilation', 'mechanical', 'who', 'uncertain', 'mechanical ventilation', 'primary', 'ill', 'sedation', 'sedative', 'care', 'choice', 'agent', 'but', 'appropriate', 'critically']","['ventilation', 'mechanical ventilation', 'choice', 'but']",,
2981,2939,"hypotension and bradycardia are common side effects.5,6","低血压和心动过缓是常见的副作用。 5,6",0.5,"['bradycardia', 'hypotension', 'common', 'and']","['bradycardia', 'hypotension']",2939,['催眠和布拉迪卡迪是常见的副作用。'],0.0,"['bradycardia', 'hypotension', 'common', 'and']",[],,
2982,2940,"the trial was conducted in 74 ICUs in eight countries ( Australia , Ireland , Italy , Malaysia , New Zealand , Saudi Arabia , Switzerland , and the United Kingdom ) .",该试验在 8 个国家（澳大利亚、爱尔兰、意大利、马来西亚、新西兰、沙特阿拉伯、瑞士和英国）的 74 个 ICU 进行。,0.3333333333333333,"['arabia', 'australia', 'kingdom', 'trial', 'and', 'new']","['australia', 'new']",2940,['审判在八个国家(澳大利亚、爱尔兰、意大利、马来西亚、新西兰、沙特阿拉伯、瑞士和英国)的74个国际刑事法院进行。'],0.5,"['arabia', 'australia', 'kingdom', 'trial', 'and', 'new']","['australia', 'trial', 'new']",,
2983,2941,"a complete list of trial sites is provided in the Supplementary Appendix , available with the full text of this article at NEJM.org .",补充附录中提供了试验地点的完整列表，补充附录与本文全文可在 NEJM.org 上获取。,0.0714285714285714,"['a', 'appendix', 'article', 'supplementary', 'complete', 'available', 'trial', 'text', 'list', 'with', 'at', 'full', 'this', 'in']",['full'],2941,"['测试网站的完整列表在附件中提供,可在NEJM.org上找到本文的完整文本。']",0.1428571428571428,"['a', 'appendix', 'article', 'supplementary', 'complete', 'available', 'trial', 'text', 'list', 'with', 'at', 'full', 'this', 'in']","['appendix', 'full']",,
2984,2942,"the protocol and statistical analysis plan , also available at NEJM.org , have been published previously.19",方案和统计分析计划也可在 NEJM.org 上获得，之前已发表。 19,0.3333333333333333,"['analysis', 'protocol', 'available', 'statistical analysis', 'have', 'and']","['analysis', 'statistical analysis']",2942,"['该议定书和统计分析计划,也可在NEJM.org上公布。']",0.5,"['analysis', 'protocol', 'available', 'statistical analysis', 'have', 'and']","['analysis', 'protocol', 'statistical analysis']",,
2985,2943,"the trial was designed by the authors , who wrote the manuscript and attest to the accuracy and completeness of the data , the statistical analyses , adherence to the protocol , and complete reporting of adverse events .",该试验由作者设计，他们撰写了手稿并证明数据的准确性和完整性、统计分析、对方案的遵守以及不良事件的完整报告。,0.3846153846153846,"['data', 'who', 'accuracy', 'protocol', 'complete', 'adverse', 'manuscript', 'trial', 'attest', 'completeness', 'adherence', 'by', 'and']","['data', 'accuracy', 'manuscript', 'completeness', 'by']",2943,"['审查是由作者设计的,谁写了手稿,并证实了数据的准确性和完整性,统计分析,遵守协议,并完整报告不良事件。']",0.5384615384615384,"['data', 'who', 'accuracy', 'protocol', 'complete', 'adverse', 'manuscript', 'trial', 'attest', 'completeness', 'adherence', 'by', 'and']","['data', 'accuracy', 'protocol', 'manuscript', 'attest', 'completeness', 'by']",,
2986,2944,approval was obtained from the institutional review board at each participating institution .,每个参与机构都获得了机构审查委员会的批准。,0.5,"['review', 'approval', 'institution', 'board', 'at', 'each']","['review', 'approval', 'institution']",2944,['批准由各参与机构的机构审计委员会获得。'],0.6666666666666666,"['review', 'approval', 'institution', 'board', 'at', 'each']","['review', 'approval', 'institution', 'each']",,
2987,2945,"prior informed consent or consent to continue to participate in the trial was obtained from all patients or their proxies , according to local regulatory requirements .",根据当地监管要求，已获得所有患者或其代理人的事先知情同意或继续参与试验的同意。,0.25,"['local', 'prior', 'trial', 'consent', 'informed consent', 'continue', 'all', 'to']","['consent', 'continue']",2945,"['此前已知的同意或同意继续参加试验,根据当地的监管要求,从所有患者或他们的亲属获得。']",0.375,"['local', 'prior', 'trial', 'consent', 'informed consent', 'continue', 'all', 'to']","['local', 'consent', 'continue']",,
2988,2946,an independent data and safety monitoring committee provided oversight of the trial .,一个独立的数据和安全监督委员会对试验进行了监督。,0.5714285714285714,"['safety', 'monitoring', 'data', 'committee', 'trial', 'independent', 'and']","['safety', 'data', 'committee', 'independent']",2946,['一个独立的数据和安全监测委员会提供审判的监督。'],0.8571428571428571,"['safety', 'monitoring', 'data', 'committee', 'trial', 'independent', 'and']","['safety', 'monitoring', 'data', 'committee', 'trial', 'independent']",,
2989,2947,"a single interim analysis was planned and performed after 2000 patients had been evaluated for the primary outcome , as described in the Supplementary Appendix .",如补充附录所述，在对 2000 名患者的主要结局进行评估后，计划并进行了一次中期分析。,0.2727272727272727,"['a', 'appendix', 'analysis', 'outcome', 'supplementary', 'primary', 'after', 'as', 'in', 'single', 'and']","['analysis', 'after', 'as']",2947,"['一个单一的临时分析是在2000名患者对初始结果进行评估后进行的,如附件中所描述。']",0.5454545454545454,"['a', 'appendix', 'analysis', 'outcome', 'supplementary', 'primary', 'after', 'as', 'in', 'single', 'and']","['appendix', 'analysis', 'outcome', 'after', 'as', 'single']",,
2990,2948,"the National Health and Medical Research Council of Australia , the Health Research Council of New Zealand , and the Institut Jantung Negara Foundation of Malaysia funded the trial .",澳大利亚国家卫生与医学研究委员会、新西兰卫生研究委员会和马来西亚国家卫生研究院基金会资助了该试验。,0.5,"['australia', 'research', 'health', 'medical', 'trial', 'foundation', 'and', 'new']","['australia', 'research', 'health', 'new']",2948,['澳大利亚国家卫生和医学研究理事会、新西兰卫生研究理事会和马来西亚Jantung Negara基金会资助了审判。'],0.625,"['australia', 'research', 'health', 'medical', 'trial', 'foundation', 'and', 'new']","['australia', 'research', 'health', 'trial', 'new']",,
2991,2949,"Pfizer and Orion Pharma supplied dexmedetomidine but had no role in the design or conduct of the trial , analysis of the data , or writing or review of the manuscript .",辉瑞和 Orion Pharma 提供了右美托咪定，但没有参与试验的设计或实施、数据分析或手稿的撰写或审阅。,0.5,"['data', 'analysis', 'review', 'role', 'no', 'manuscript', 'writing', 'trial', 'conduct', 'design', 'dexmedetomidine', 'orion', 'but', 'and']","['data', 'analysis', 'review', 'manuscript', 'design', 'dexmedetomidine', 'but']",2949,['Pfizer 和 Orion Pharma 供应了 dexmedetomidine 但在设计或进行测试、数据分析或写作或审查手稿中没有任何作用。'],0.5714285714285714,"['data', 'analysis', 'review', 'role', 'no', 'manuscript', 'writing', 'trial', 'conduct', 'design', 'dexmedetomidine', 'orion', 'but', 'and']","['data', 'analysis', 'review', 'role', 'manuscript', 'writing', 'design', 'but']",,
2992,2950,"patients were eligible for inclusion if they were receiving mechanical ventilation through an endotracheal tube , were expected to continue to receive ventilatory support beyond the next full calendar day , and were receiving sedatives for safety and comfort .",如果患者正在通过气管插管接受机械通气，预计将在下一个完整日历日之后继续接受通气支持，并且正在接受镇静剂以确保安全和舒适，则他们符合入选条件。,0.5294117647058824,"['safety', 'ventilation', 'support', 'mechanical', 'inclusion', 'mechanical ventilation', 'endotracheal tube', 'comfort', 'calendar', 'sedatives', 'full', 'continue', 'if', 'to', 'and', 'next', 'eligible']","['safety', 'ventilation', 'support', 'mechanical ventilation', 'comfort', 'calendar', 'sedatives', 'full', 'continue']",2950,"['患者可以通过内分泌管获得机械通风,预计将继续接收通风支持超过下一天,并为安全和舒适提供放松剂。']",0.3529411764705882,"['safety', 'ventilation', 'support', 'mechanical', 'inclusion', 'mechanical ventilation', 'endotracheal tube', 'comfort', 'calendar', 'sedatives', 'full', 'continue', 'if', 'to', 'and', 'next', 'eligible']","['safety', 'ventilation', 'support', 'mechanical ventilation', 'comfort', 'continue']",,
2993,2951,"key exclusion criteria were an age under 18 years , invasive ventilation in the ICU for longer than 12 hours before enrollment , and suspected or proven acute primary brain injury ( Table S1 in the Supplementary Appendix ) .",关键的排除标准是年龄在 18 岁以下、入组前在 ICU 中有创通气时间超过 12 小时，以及疑似或证实为急性原发性脑损伤（补充附录表 S1）。,0.5333333333333333,"['injury', 'ventilation', 'key', 'appendix', 'table', 'brain', 'supplementary', 'exclusion', 'primary', 'age', 'acute', 'brain injury', 'S1', 'before', 'and']","['injury', 'ventilation', 'key', 'table', 'brain', 'age', 'brain injury', 'before']",2951,"['关键排除标准是18岁以下的年龄,在注册前超过12小时在ICU中进行侵入性通风,以及怀疑或证明急性初级脑损伤(附件中的S1表)。']",0.6,"['injury', 'ventilation', 'key', 'appendix', 'table', 'brain', 'supplementary', 'exclusion', 'primary', 'age', 'acute', 'brain injury', 'S1', 'before', 'and']","['injury', 'ventilation', 'key', 'appendix', 'table', 'brain', 'age', 'brain injury', 'before']",,
2994,2952,"the patients were randomly assigned in a 1 : 1 ratio to receive dexmedetomidine or usual care , as described below .",患者按 1:1 的比例随机分配接受右美托咪定或常规治疗，如下所述。,0.5714285714285714,"['a', '1', 'ratio', 'usual', 'care', 'as', 'dexmedetomidine']","['1', 'ratio', 'as', 'dexmedetomidine']",2952,"['病人随机分配在1:1的比例接受德克梅多米丁或常规护理,如下所述。']",0.4285714285714285,"['a', '1', 'ratio', 'usual', 'care', 'as', 'dexmedetomidine']","['1', 'ratio', 'as']",,
2995,2953,"randomization was stratified according to trial site and the presence or absence of suspected or proven sepsis , 20 as determined by the treating clinician .",随机分组根据试验地点和是否存在疑似或证实的脓毒症 20 由治疗临床医生确定。,0.5,"['presence', 'randomization', 'site', 'sepsis', 'absence', 'clinician', 'trial', 'as', 'by', 'to']","['presence', 'randomization', 'site', 'sepsis', 'by']",2953,"['随机化根据试验地点和怀疑或被证明的塞普西斯的存在或缺席,根据治疗诊所的确定。']",0.4,"['presence', 'randomization', 'site', 'sepsis', 'absence', 'clinician', 'trial', 'as', 'by', 'to']","['presence', 'randomization', 'site', 'absence']",,
2996,2954,trial INTERVENTIONS AND MEASUREMENTS,试验干预和测量,0.0,['trial'],[],2954,['审判干预与测量'],1.0,['trial'],['trial'],,
2997,2955,sedation Goals,镇静目标,1.0,['sedation'],['sedation'],2955,['安静目标'],0.0,['sedation'],[],,
2998,2956,patients received adequate analgesia as determined by the treating clinician according to the results of pain assessments performed at least every 4 hours with the use of validated scales.21,根据至少每 4 小时使用经过验证的量表进行的疼痛评估结果，患者接受了足够的镇痛。 21,0.3333333333333333,"['analgesia', 'pain', 'clinician', 'adequate', '4', 'as', 'with', 'by', 'to']","['analgesia', 'pain', 'adequate']",2956,"['患者接受了按治疗诊所确定的适当疼痛,根据至少每4小时进行的疼痛评估结果,使用验证规模。']",0.1111111111111111,"['analgesia', 'pain', 'clinician', 'adequate', '4', 'as', 'with', 'by', 'to']",['pain'],,
2999,2957,"the sedation target was light sedation , unless it was deemed to be unsafe or contraindicated by the treating clinician , as defined by the Richmond Agitation and Sedation Scale ( RASS ) , which ranges from − 5 ( unresponsive ) to + 4 ( combative ) .",镇静目标是轻度镇静，除非治疗的临床医生认为它不安全或禁忌，如里士满激越和镇静量表 (RASS) 所定义，范围从 - 5（无反应）到 + 4（好斗）。,0.4117647058823529,"['5', 'agitation', 'defined', 'scale', 'contraindicated', 'be', 'target', 'clinician', 'sedation', 'light', '4', 'unresponsive', 'combative', 'as', 'by', 'to', 'and']","['5', 'scale', 'contraindicated', 'target', 'sedation', 'as', 'by']",2957,['静静的目标是轻静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静静。'],0.0588235294117647,"['5', 'agitation', 'defined', 'scale', 'contraindicated', 'be', 'target', 'clinician', 'sedation', 'light', '4', 'unresponsive', 'combative', 'as', 'by', 'to', 'and']",['target'],,
3000,2958,"the sedation goal was a RASS score of − 2 ( lightly sedated ) to + 1 ( restless ) , as assessed at least every 4 hours.22",镇静目标是 RASS 评分为 − 2（轻度镇静）至 + 1（不安），至少每 4 小时评估一次。 22,0.3636363636363636,"['a', '1', '2', 'restless', 'sedation', '4', 'score', 'goal', 'as', 'to', 'assessed']","['1', '2', 'sedation', 'goal']",2958,"['定位目标为 − 2 (轻度定位) 到 + 1 (无休息) 的 RASS 分数,估计至少每 4 小时。']",0.3636363636363636,"['a', '1', '2', 'restless', 'sedation', '4', 'score', 'goal', 'as', 'to', 'assessed']","['1', '2', 'score', 'goal']",,
3001,2959,the presence or absence of delirium was assessed daily with the use of the Confusion Assessment Method for the Intensive Care Unit ( positive or negative ) 23 when the RASS score was − 2 or higher .,当 RASS 评分为 - 2 或更高时，每天使用重症监护病房的意识模糊评估方法（阳性或阴性）23 评估是否存在谵妄。,0.3571428571428571,"['presence', '2', 'unit', 'delirium', 'intensive care unit', 'negative', 'confusion', 'assessment', 'absence', 'method', 'score', 'with', 'positive', 'assessed']","['presence', '2', 'delirium', 'intensive care unit', 'assessment']",2959,"['每日使用密集护理单位(积极或消极)的混乱评估方法来评估德里亚的存在或缺席,当RASS分数为 − 2 或更高时。']",0.5,"['presence', '2', 'unit', 'delirium', 'intensive care unit', 'negative', 'confusion', 'assessment', 'absence', 'method', 'score', 'with', 'positive', 'assessed']","['presence', '2', 'unit', 'confusion', 'assessment', 'absence', 'score']",,
3002,2960,weaning of sedation and ventilation was conducted according to local clinical practices .,根据当地临床实践进行镇静和通气的撤除。,0.4285714285714285,"['ventilation', 'local', 'clinical', 'sedation', 'weaning', 'to', 'and']","['ventilation', 'clinical', 'sedation']",2960,['耐受静静和通风按照当地的临床实践进行。'],0.4285714285714285,"['ventilation', 'local', 'clinical', 'sedation', 'weaning', 'to', 'and']","['ventilation', 'local', 'clinical']",,
3003,2961,dexmedetomidine,右美托咪定,1.0,['dexmedetomidine'],['dexmedetomidine'],2961,['德克梅德托米丁'],0.0,['dexmedetomidine'],[],,
3004,2962,"in the dexmedetomidine group , the goal was to administer dexmedetomidine as the primary sedating agent or , once the sedation target was achieved , the sole sedating agent .",在右美托咪定组中，目标是将右美托咪定作为主要镇静剂给药，或者在达到镇静目标后，作为唯一的镇静剂给药。,0.4545454545454545,"['group', 'primary', 'target', 'sedation', 'sole', 'goal', 'administer', 'as', 'achieved', 'dexmedetomidine', 'agent']","['group', 'target', 'sedation', 'goal', 'dexmedetomidine']",2962,"['在德克塞米多米丁群体中,目标是将德克塞米多米丁作为主要的放松剂或,一旦达到放松目标,唯一的放松剂。']",0.3636363636363636,"['group', 'primary', 'target', 'sedation', 'sole', 'goal', 'administer', 'as', 'achieved', 'dexmedetomidine', 'agent']","['group', 'primary', 'target', 'goal']",,
3005,2963,"intravenous dexmedetomidine was started at a dose of 1 μg per kilogram of body weight per hour without a loading dose and adjusted ( maximum dose , 1.5 μg per kilogram per hour ) to achieve a RASS score in the target range .",静脉注射右美托咪定起始剂量为每小时每公斤体重 1 微克，无负荷剂量，并调整（最大剂量，每小时每公斤体重 1.5 微克）以达到目标范围内的 RASS 评分。,0.5,"['loading', 'body weight', 'maximum dose', 'range', '1', 'kilogram', 'target', 'intravenous', 'score', 'dexmedetomidine', 'at', 'hour', 'and', 'without']","['body weight', 'range', '1', 'target', 'dexmedetomidine', 'hour', 'without']",2963,"['体重每公斤1 μg的剂量开始,无负载剂量,并调整(最大剂量,每公斤1,5 μg),以达到目标范围中的RASS分数。']",0.4285714285714285,"['loading', 'body weight', 'maximum dose', 'range', '1', 'kilogram', 'target', 'intravenous', 'score', 'dexmedetomidine', 'at', 'hour', 'and', 'without']","['body weight', 'range', '1', 'target', 'score', 'without']",,
3006,2964,"previous data had suggested that dexmedetomidine as the sole agent might not achieve the target sedation in all patients or in all clinical situations , particularly when deep sedation ( RASS score of − 3 or less ) was indicated.9,12","以前的数据表明，右美托咪定作为唯一药物可能无法在所有患者或所有临床情况下实现目标镇静，特别是在需要深度镇静（RASS 评分为 − 3 或更低）时。 9,12",0.4285714285714285,"['data', 'previous', 'target', 'clinical', 'sedation', 'sole', '3', 'score', 'deep', 'as', 'dexmedetomidine', 'agent', 'all', 'that']","['data', 'previous', 'target', 'clinical', 'sedation', 'dexmedetomidine']",2964,"['以前的数据表明,作为唯一的药物,德克塞米多米丁可能无法在所有患者或所有临床情况下达到目标放松,特别是在深度放松(RASS分为 − 3 或更低)时。']",0.2857142857142857,"['data', 'previous', 'target', 'clinical', 'sedation', 'sole', '3', 'score', 'deep', 'as', 'dexmedetomidine', 'agent', 'all', 'that']","['data', 'previous', 'target', 'clinical']",,
3007,2965,"thus , the use of propofol at the lowest possible dose was allowed when the maximum dose of dexmedetomidine was insufficient and during the initial adjustment of the dexmedetomidine dose .",因此，当右美托咪定的最大剂量不足时和右美托咪定剂量的初始调整期间，允许以尽可能低的剂量使用异丙酚。,0.6666666666666666,"['maximum dose', 'adjustment', 'initial', 'thus', 'propofol', 'dexmedetomidine', 'at', 'and', 'insufficient']","['initial', 'thus', 'propofol', 'dexmedetomidine', 'at', 'insufficient']",2965,"['因此,在达克梅多多米丁的最大剂量不足时,在达克梅多米丁剂量的初始调整期间,允许使用最低的剂量。']",0.3333333333333333,"['maximum dose', 'adjustment', 'initial', 'thus', 'propofol', 'dexmedetomidine', 'at', 'and', 'insufficient']","['initial', 'thus', 'insufficient']",,
3008,2966,"the use of benzodiazepines was discouraged , although administration was permitted for specific indications of uncontrolled agitation or delirium , seizures , palliative comfort , and procedural sedation or if concomitant neuromuscular blockade was used .",不鼓励使用苯二氮卓类药物，但允许对不受控制的激越或谵妄、癫痫发作、姑息性安慰和程序性镇静等特定指征进行给药，或者如果同时使用神经肌肉阻滞剂。,0.4166666666666667,"['agitation', 'administration', 'delirium', 'concomitant', 'sedation', 'comfort', 'specific', 'neuromuscular', 'uncontrolled', 'blockade', 'and', 'seizures']","['delirium', 'sedation', 'neuromuscular', 'blockade', 'seizures']",2966,"['使用本佐迪亚塞宾被拒绝,尽管允许给出不受控制的刺激或<unk>疹的具体指示,冲击,放松舒适和程序安静,或者如果使用同步的神经肌肉阻塞。']",0.1666666666666666,"['agitation', 'administration', 'delirium', 'concomitant', 'sedation', 'comfort', 'specific', 'neuromuscular', 'uncontrolled', 'blockade', 'and', 'seizures']","['comfort', 'neuromuscular']",,
3009,2967,usual Care,日常护理,0.0,"['usual', 'care']",[],2967,['常见的护理'],0.0,"['usual', 'care']",[],,
3010,2968,"patients who were assigned to receive usual care were given propofol , midazolam , or other sedatives , as directed by the treating physician , and with the intention of excluding dexmedetomidine .",被分配接受常规治疗的患者按照主治医师的指示给予异丙酚、咪达唑仑或其他镇静剂，并打算排除右美托咪定。,0.3846153846153846,"['who', 'physician', 'usual', 'intention', 'care', 'as', 'sedatives', 'with', 'propofol', 'midazolam', 'dexmedetomidine', 'by', 'and']","['physician', 'sedatives', 'propofol', 'midazolam', 'dexmedetomidine']",2968,"['被授予接受常规护理的患者被授予propofol、midazolam或其他放松剂,如治疗医生指示,并有意排除dexmedetomidine。']",0.1538461538461538,"['who', 'physician', 'usual', 'intention', 'care', 'as', 'sedatives', 'with', 'propofol', 'midazolam', 'dexmedetomidine', 'by', 'and']","['physician', 'as']",,
3011,2969,rescue dexmedetomidine was permitted for uncontrolled agitation after failure of initial conventional therapies .,在初始常规治疗失败后，允许使用右美托咪定来治疗无法控制的躁动。,0.5714285714285714,"['agitation', 'failure', 'initial', 'after', 'uncontrolled', 'dexmedetomidine', 'rescue']","['failure', 'initial', 'after', 'dexmedetomidine']",2969,['救生德克塞米多米丁被允许在初始常规治疗失败后不受控制的刺激。'],0.4285714285714285,"['agitation', 'failure', 'initial', 'after', 'uncontrolled', 'dexmedetomidine', 'rescue']","['failure', 'initial', 'after']",,
3012,2970,intravenous clonidine and remifentanil were prohibited in both groups .,两组均禁用静脉可乐定和瑞芬太尼。,0.5,"['clonidine', 'intravenous', 'remifentanil', 'and']","['clonidine', 'remifentanil']",2970,"['在两组中,内膜克隆尼丁和雷米芬坦尼尔都被禁止。']",0.0,"['clonidine', 'intravenous', 'remifentanil', 'and']",[],,
3013,2971,"antipsychotic drugs , including haloperidol and quetiapine , were allowed for the treatment of agitated delirium if the currently administered sedative agents were not sufficient to achieve the target levels of sedation in either group .",如果当前使用的镇静剂不足以达到任一组的目标镇静水平，则允许使用包括氟哌啶醇和喹硫平在内的抗精神病药来治疗躁动性谵妄。,0.6428571428571429,"['group', 'antipsychotic', 'drugs', 'delirium', 'haloperidol', 'treatment', 'target', 'sedation', 'sedative', 'agitated', 'quetiapine', 'if', 'to', 'and']","['group', 'antipsychotic', 'delirium', 'haloperidol', 'treatment', 'target', 'sedation', 'sedative', 'quetiapine']",2971,"['抗精神药物,包括Haloperidol和Quetiapine,被允许用来治疗被刺激的<unk>,如果目前服用的放松剂不足以达到每个群体的目标放松水平。']",0.2857142857142857,"['group', 'antipsychotic', 'drugs', 'delirium', 'haloperidol', 'treatment', 'target', 'sedation', 'sedative', 'agitated', 'quetiapine', 'if', 'to', 'and']","['group', 'drugs', 'treatment', 'target']",,
3014,2972,"other aspects of care , including mobilization and nonpharmacologic interventions to promote comfort , reduce anxiety , and facilitate sleep , were prescribed by the treating clinician in both groups .",其他方面的护理，包括促进舒适、减少焦虑和促进睡眠的动员和非药物干预，由两组的治疗临床医生规定。,0.5,"['mobilization', 'anxiety', 'reduce', 'clinician', 'comfort', 'sleep', 'care', 'by', 'to', 'and']","['mobilization', 'anxiety', 'comfort', 'sleep', 'by']",2972,"['其他护理方面,包括动员和非药物干预,以促进舒适、减少焦虑和促进睡眠,由治疗诊所在两组中处方。']",0.5,"['mobilization', 'anxiety', 'reduce', 'clinician', 'comfort', 'sleep', 'care', 'by', 'to', 'and']","['mobilization', 'anxiety', 'comfort', 'sleep', 'by']",,
3015,2973,the primary outcome was the rate of death from any cause at 90 days after randomization .,主要结果是随机化后 90 天的全因死亡率。,0.7142857142857143,"['randomization', 'rate', 'outcome', 'death', 'primary', 'cause', 'after']","['randomization', 'rate', 'outcome', 'death', 'after']",2973,['主要结果是随机化后90天发生的任何原因死亡率。'],0.8571428571428571,"['randomization', 'rate', 'outcome', 'death', 'primary', 'cause', 'after']","['randomization', 'rate', 'outcome', 'death', 'cause', 'after']",,
3016,2974,adverse events and serious adverse events were reported by site investigators and were not collected systematically or adjudicated independently .,不良事件和严重不良事件由研究中心调查员报告，未系统收集或独立裁定。,0.2,"['site', 'adverse', 'serious', 'by', 'and']",['by'],2974,"['现场调查人员报告了不良事件和严重不良事件,并未经系统收集或独立招标。']",0.2,"['site', 'adverse', 'serious', 'by', 'and']",['site'],,
3017,2975,the stopping rules for an interim analysis are provided in the Supplementary Appendix .,补充附录中提供了期中分析的停止规则。,0.25,"['appendix', 'analysis', 'supplementary', 'stopping']",['analysis'],2975,['暂时分析的停止规则在附件中列出。'],0.5,"['appendix', 'analysis', 'supplementary', 'stopping']","['appendix', 'analysis']",,
3018,2976,details regarding the post hoc sensitivity analysis with respect to missing data and truncation due to death are provided in the Supplementary Appendix .,补充附录中提供了关于缺失数据和因死亡截断的事后敏感性分析的详细信息。,0.4,"['truncation', 'appendix', 'data', 'analysis', 'death', 'supplementary', 'regarding', 'post', 'due', 'with', 'respect', 'sensitivity', 'to', 'and', 'missing']","['data', 'analysis', 'death', 'regarding', 'to', 'missing']",2976,['关于因死亡而失踪的数据以及因死亡而失踪的敏感性分析的详细信息在附件中提供。'],0.4666666666666667,"['truncation', 'appendix', 'data', 'analysis', 'death', 'supplementary', 'regarding', 'post', 'due', 'with', 'respect', 'sensitivity', 'to', 'and', 'missing']","['appendix', 'data', 'analysis', 'death', 'regarding', 'to', 'and']",,
3019,2977,"we conducted prespecified subgroup analyses of the primary outcome for six baseline variables : clinically suspected or proven sepsis , geographic region , surgical versus medical admission , an age that was older or younger than the median , a score on the APACHE ( Acute Physiology and Chronic Health Evaluation ) II that was higher or lower than the median , 27 and the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen .",我们对六个基线变量的主要结果进行了预先指定的亚组分析：临床怀疑或证实败血症、地理区域、手术入院与药物入院、年龄大于或小于中位数、APACHE（急性生理学和慢性健康）评分评价) II 即高于或低于中位数、27 和动脉血氧分压与吸入氧分压之比。,0.4285714285714285,"['median', 'pressure', 'physiology', 'baseline', 'ratio', 'outcome', 'evaluation', 'health', 'admission', 'medical', 'surgical', 'region', 'lower', 'sepsis', 'chronic', 'primary', 'age', 'fraction', 'partial', 'geographic', 'acute', 'score', 'subgroup', 'oxygen', 'that', 'to', 'and', 'inspired']","['physiology', 'baseline', 'ratio', 'outcome', 'evaluation', 'health', 'region', 'sepsis', 'chronic', 'age', 'oxygen', 'to']",2977,['我们对六个基因变量的初始结果进行了预定分组分析:临床上怀疑或被证明的塞普西斯、地理区域、手术与医学入学、年龄较老或较年轻的中等、高于中等或较低的APACHE(急性生理学和慢性健康评估)II的分数27和血液氧气的部分压力与灵感氧气的分数的比例。'],0.4642857142857143,"['median', 'pressure', 'physiology', 'baseline', 'ratio', 'outcome', 'evaluation', 'health', 'admission', 'medical', 'surgical', 'region', 'lower', 'sepsis', 'chronic', 'primary', 'age', 'fraction', 'partial', 'geographic', 'acute', 'score', 'subgroup', 'oxygen', 'that', 'to', 'and', 'inspired']","['pressure', 'physiology', 'ratio', 'outcome', 'health', 'region', 'lower', 'chronic', 'age', 'fraction', 'score', 'oxygen', 'to']",,
3020,2978,"risk differences for subgroups were determined with the use of binomial identity regression , and potential heterogeneity was determined with the use of logistic regression , with the fitting of main effects for sepsis , trial group , subgroup , and an interaction between trial group and subgroup .",使用二项式恒等回归确定亚组的风险差异，并使用逻辑回归确定潜在异质性，拟合脓毒症、试验组、亚组的主效应以及试验组和亚组之间的交互作用。,0.4285714285714285,"['group', 'logistic regression', 'heterogeneity', 'potential', 'sepsis', 'binomial', 'risk', 'interaction', 'trial', 'subgroup', 'fitting', 'with', 'and', 'identity']","['group', 'heterogeneity', 'sepsis', 'binomial', 'risk', 'fitting']",2978,"['对子群的风险差异通过使用二元身份回归来确定,并通过使用物流回归来确定潜在的异常性,通过对塞普西斯、试验组、子群和试验组和子群之间的相互作用来确定。']",0.2857142857142857,"['group', 'logistic regression', 'heterogeneity', 'potential', 'sepsis', 'binomial', 'risk', 'interaction', 'trial', 'subgroup', 'fitting', 'with', 'and', 'identity']","['group', 'potential', 'risk', 'subgroup']",,
3021,2979,"on each day , the RASS score was determined in one of three categories : − 3 to − 5 , target sedation ( − 2 to + 1 ) , or more than + 1 .",在每一天，RASS 评分被确定为三个类别之一：- 3 至- 5，目标镇静（- 2 至+ 1），或超过+ 1。,0.4166666666666667,"['5', '1', '2', 'categories', 'target', 'sedation', '3', 'score', 'three', 'each', 'in', 'to']","['5', '1', '2', 'target', 'sedation']",2979,"['每日,RASS分数分为三个类别之一: − 3 至 − 5,目标定位( − 2 至 + 1 ),或超过 + 1 。']",0.4166666666666667,"['5', '1', '2', 'categories', 'target', 'sedation', '3', 'score', 'three', 'each', 'in', 'to']","['5', '1', '2', 'target', 'score']",,
3022,2980,comparisons were performed with the use of multinomial logistic regression with robust sandwich errors clustered at an individual patient level .,比较是通过使用多项逻辑回归进行的，其中稳健的三明治误差聚集在个体患者水平。,0.4285714285714285,"['logistic regression', 'individual', 'patient', 'level', 'multinomial', 'with', 'sandwich']","['individual', 'patient', 'level']",2980,['比较是通过使用多层物流回归与强大的三明治错误分类在一个个体患者水平进行的。'],0.4285714285714285,"['logistic regression', 'individual', 'patient', 'level', 'multinomial', 'with', 'sandwich']","['individual', 'patient', 'level']",,
3023,2981,"all statistical analyses were performed with the use of SAS software , version 9.4 ( SAS Institute ) .",所有统计分析均使用 SAS 软件 9.4 版（SAS Institute）进行。,0.1666666666666666,"['version', 'software', 'institute', 'with', 'SAS', 'all']",['software'],2981,"['所有统计分析都使用SAS软件,版本 9.4(SAS研究所)进行。']",0.5,"['version', 'software', 'institute', 'with', 'SAS', 'all']","['version', 'software', 'institute']",,
3024,2981,"all statistical analyses were performed with the use of SAS software , version 9.4 ( SAS Institute ) .",所有统计分析均使用 SAS 软件 9.4 版（SAS Institute）进行。,0.1666666666666666,"['version', 'software', 'institute', 'with', 'SAS', 'all']",['software'],2981,"['所有统计分析都使用SAS软件,版本 9.4(SAS研究所)进行。']",0.5,"['version', 'software', 'institute', 'with', 'SAS', 'all']","['version', 'software', 'institute']",,
3025,2982,"from November 2013 through February 2018 , we screened 29,502 patients who were being treated in the ICU and randomly assigned 4000 patients to receive either dexmedetomidine ( 2001 patients ) or usual care ( 1999 patients ) ( Table S2 in the Supplementary Appendix ) .","从 2013 年 11 月到 2018 年 2 月，我们筛选了 29,502 名在 ICU 接受治疗的患者，并随机分配 4000 名患者接受右美托咪定（2001 名患者）或常规治疗（1999 名患者）（补充附录表 S2）。",0.1666666666666666,"['appendix', 'table', 'who', 'supplementary', 'usual', 'november', 'being', 'care', 'dexmedetomidine', 'S2', 'and', 'we']","['table', 'dexmedetomidine']",2982,"['从2013年11月至2018年2月,我们检查了29502名在ICU中接受治疗的患者,并随机分配了4000名患者接受德克塞米多米丁(2001年患者)或普通护理(1999年患者)(附件中的S2表)。']",0.1666666666666666,"['appendix', 'table', 'who', 'supplementary', 'usual', 'november', 'being', 'care', 'dexmedetomidine', 'S2', 'and', 'we']","['appendix', 'table']",,
3026,2983,"the median time from eligibility to randomization was 4.6 hours ( interquartile range , 1.8 to 8.7 ) .",从合格到随机分组的中位时间为 4.6 小时（四分位数范围，1.8 至 8.7）。,0.6,"['median', 'range', 'randomization', 'time', 'to']","['range', 'randomization', 'time']",2983,"['从可选性到随机化的平均时间为4.6小时(区间范围,1.8到8.7)。']",0.6,"['median', 'range', 'randomization', 'time', 'to']","['range', 'randomization', 'time']",,
3027,2984,this result did not change after adjustment for baseline covariates or in a sensitivity analysis that accounted for missing data ( see the Supplementary Appendix ) .,在对基线协变量进行调整后或在对缺失数据进行解释的敏感性分析中（见补充附录），该结果没有改变。,0.4285714285714285,"['a', 'appendix', 'data', 'analysis', 'baseline', 'adjustment', 'supplementary', 'after', 'result', 'change', 'sensitivity', 'this', 'that', 'missing']","['data', 'analysis', 'baseline', 'after', 'result', 'missing']",2984,['此结果在基线科瓦里亚特调整后或在缺乏数据的敏感性分析中没有变化(参见附件)。'],0.5714285714285714,"['a', 'appendix', 'data', 'analysis', 'baseline', 'adjustment', 'supplementary', 'after', 'result', 'change', 'sensitivity', 'this', 'that', 'missing']","['appendix', 'data', 'analysis', 'baseline', 'after', 'result', 'change', 'missing']",,
3028,2985,"there was no significant difference in the primary outcome between the subgroup of patients with suspected or proven sepsis at randomization and those without sepsis ( risk difference favoring the dexmedetomidine group , 1.1 percentage points ; 95 % CI , − 2.6 to 4.8 ) .",随机分组时疑似或确诊脓毒症患者亚组与无脓毒症患者亚组的主要结局无显着差异（右美托咪定组的风险差异为 1.1 个百分点；95% CI，- 2.6 至 4.8）。,0.4666666666666667,"['group', 'percentage', 'randomization', 'outcome', 'difference', 'sepsis', 'primary', 'no', 'risk', 'subgroup', 'with', 'dexmedetomidine', 'significant difference', 'CI', 'without']","['group', 'randomization', 'difference', 'sepsis', 'risk', 'dexmedetomidine', 'without']",2985,"['在初始结果中,怀疑或被证实的塞普西斯患者的子群和没有塞普西斯患者之间没有显著的差异(有利于德克塞米多米丁群体的风险差异,1.1个百分点;95%的CI, −2.6到4.8)。']",0.3333333333333333,"['group', 'percentage', 'randomization', 'outcome', 'difference', 'sepsis', 'primary', 'no', 'risk', 'subgroup', 'with', 'dexmedetomidine', 'significant difference', 'CI', 'without']","['group', 'outcome', 'difference', 'risk', 'subgroup']",,
3029,2986,"tertiary outcomes including tracheostomy , reintubation , use of restraints , unplanned extubation , and lengths of stay in both the ICU and hospital are shown in Table S7 in the Supplementary Appendix .",补充附录表 S7 显示了包括气管切开术、再插管、约束使用、计划外拔管以及 ICU 和医院住院时间在内的三级结局。,0.4444444444444444,"['appendix', 'table', 'supplementary', 'tracheostomy', 'extubation', 'hospital', 'in', 'and', 'stay']","['table', 'tracheostomy', 'extubation', 'hospital']",2986,"['第三方结果,包括特拉切奥斯托米亚、重新入侵、使用限制、未计划的灭绝以及住在ICU和医院的长度,在附加附件中的S7表中显示。']",0.3333333333333333,"['appendix', 'table', 'supplementary', 'tracheostomy', 'extubation', 'hospital', 'in', 'and', 'stay']","['appendix', 'table', 'hospital']",,
3030,2987,sedation LEVELS,镇静水平,1.0,['sedation'],['sedation'],2987,['安静级别'],0.0,['sedation'],[],,
3031,2988,the percentage of patients who had an indication for deep sedation as determined by the treating clinician is shown in Figure 1B .,图 1B 显示了由主治临床医生确定的具有深度镇静指征的患者百分比。,0.3333333333333333,"['percentage', 'indication', 'who', 'figure', 'clinician', 'sedation', 'deep', 'as', 'by']","['indication', 'sedation', 'by']",2988,['由治疗诊所确定的患有深静的患者的百分比显示在图1B。'],0.2222222222222222,"['percentage', 'indication', 'who', 'figure', 'clinician', 'sedation', 'deep', 'as', 'by']","['indication', 'by']",,
3032,2989,use OF ADDITIONAL SEDATIVES,使用额外的镇静剂,,[],[],2989,['使用额外的润滑剂'],,[],[],,
3033,2990,"overall , 1910 of 1954 patients ( 97.7 % ) in the dexmedetomidine group received the trial agent for a median duration of 2.56 days ( interquartile range , 1.10 to 5.23 ) .",总体而言，右美托咪定组 1954 名患者中有 1910 名 (97.7%) 接受了试验药物治疗，中位持续时间为 2.56 天（四分位距，1.10 至 5.23）。,0.4285714285714285,"['group', 'median', 'range', 'trial', 'duration', 'dexmedetomidine', 'agent']","['group', 'duration', 'dexmedetomidine']",2990,"['总体而言,1910年1954年患者(97.7%)在德克塞米多米丁群体中接受了试用剂的平均时间为2.56天(四分之一间范围,1.10至5.23)。']",0.2857142857142857,"['group', 'median', 'range', 'trial', 'duration', 'dexmedetomidine', 'agent']","['group', 'range']",,
3034,2991,"among the 1931 patients who received usual care , 1161 ( 60.1 % ) received propofol , 230 ( 11.9 % ) received midazolam , and 386 ( 20.0 % ) received both as primary sedatives .",在接受常规治疗的 1931 名患者中，1161 名 (60.1%) 接受异丙酚，230 名 (11.9%) 接受咪达唑仑，386 名 (20.0%) 接受两种主要镇静剂。,0.3333333333333333,"['who', 'usual', 'primary', 'care', 'as', 'sedatives', 'propofol', 'midazolam', 'and']","['sedatives', 'propofol', 'midazolam']",2991,"['在1931年接受常用护理的患者中,1161人(60.1%)接受了propofol,230人(11.9%)接受了midazolam,386人(20.0%)接受了初级放松剂。']",0.0,"['who', 'usual', 'primary', 'care', 'as', 'sedatives', 'propofol', 'midazolam', 'and']",[],,
3035,2992,analyses were performed in six prespecified subgroups ( Figure 3 ) .,分析在六个预先指定的亚组中进行（图 3）。,0.0,"['figure', '3', 'in']",[],2992,['分析是在六个预定子组(图3)进行的。'],0.0,"['figure', '3', 'in']",[],,
3036,2993,episodes of sinus arrest led to the administration of atropine or epinephrine or cardiac massage ( in seven events ) or resolved spontaneously ( Table S9 in the Supplementary Appendix ) .,窦性停搏发作导致给予阿托品或肾上腺素或心脏按摩（在 7 起事件中）或自行缓解（补充附录表 S9）。,0.5,"['atropine', 'cardiac', 'sinus', 'arrest', 'appendix', 'table', 'epinephrine', 'administration', 'supplementary', 'massage', 'episodes', 'to', 'spontaneously', 'led']","['atropine', 'cardiac', 'sinus', 'table', 'epinephrine', 'massage', 'episodes']",2993,['阴道停止的事件导致阿特罗宾或癫痫或心脏按摩(在七个事件中)或自发解决(附件中的S9表)。'],0.3571428571428571,"['atropine', 'cardiac', 'sinus', 'arrest', 'appendix', 'table', 'epinephrine', 'administration', 'supplementary', 'massage', 'episodes', 'to', 'spontaneously', 'led']","['cardiac', 'arrest', 'appendix', 'table', 'massage']",,
3037,2994,"early in the course of the critical illness , most patients who were treated with dexmedetomidine received supplemental sedatives .",在危重病程早期，大多数接受右美托咪定治疗的患者接受补充镇静剂。,0.5555555555555556,"['who', 'illness', 'early', 'supplemental', 'critical', 'course', 'sedatives', 'with', 'dexmedetomidine']","['illness', 'early', 'critical', 'sedatives', 'dexmedetomidine']",2994,"['在关键疾病的早期,大多数用德克塞米多米丁治疗的患者接受了额外的放松剂。']",0.2222222222222222,"['who', 'illness', 'early', 'supplemental', 'critical', 'course', 'sedatives', 'with', 'dexmedetomidine']","['illness', 'early']",,
3038,2995,"although the target level of light sedation was observed more frequently in the dexmedetomidine group , deep sedation was frequently reported in the two groups .",尽管在右美托咪定组中更频繁地观察到达到目标水平的轻度镇静，但两组中都经常报告深度镇静。,0.7777777777777778,"['group', 'frequently', 'target', 'sedation', 'light', 'level', 'deep', 'dexmedetomidine', 'two']","['group', 'frequently', 'target', 'sedation', 'level', 'dexmedetomidine', 'two']",2995,"['尽管在德克塞米多米丁群体中更频繁地观察到轻度放松的目标水平,但在两组中,深度放松经常被报告。']",0.5555555555555556,"['group', 'frequently', 'target', 'sedation', 'light', 'level', 'deep', 'dexmedetomidine', 'two']","['group', 'frequently', 'target', 'level', 'two']",,
3039,2996,"adverse and serious adverse events , mainly bradycardia and hypotension , some of which led to cardiac massage , were reported more frequently during dexmedetomidine sedation than during usual care .",不良和严重不良事件，主要是心动过缓和低血压，其中一些导致心脏按摩，在右美托咪定镇静期间比在常规护理期间更频繁地报告。,0.5384615384615384,"['cardiac', 'bradycardia', 'frequently', 'hypotension', 'usual', 'massage', 'adverse', 'sedation', 'care', 'dexmedetomidine', 'serious', 'and', 'led']","['cardiac', 'bradycardia', 'frequently', 'hypotension', 'massage', 'sedation', 'dexmedetomidine']",2996,"['副作用和严重的副作用,主要是乳腺炎和低血压,其中一些导致心脏按摩,在德克塞米多米丁放松期间报告得更频繁,而不是在常见护理期间。']",0.3076923076923077,"['cardiac', 'bradycardia', 'frequently', 'hypotension', 'usual', 'massage', 'adverse', 'sedation', 'care', 'dexmedetomidine', 'serious', 'and', 'led']","['cardiac', 'hypotension', 'massage', 'and']",,
3040,2997,"these trials , however , had several limitations , including delayed intervention ( up to 96 hours ) , 12 an unspecified target sedation level , 11 targeting deeper levels of sedation ( RASS score of − 3 to 0 ) than currently recommended , 13 a relatively short duration of treatment , and lack of daily data on sedation levels.11,13","然而，这些试验有一些局限性，包括延迟干预（最多 96 小时） 12 未指定目标镇静水平 11 目标镇静水平比目前推荐的更深（ RASS 评分为 - 3 至 0） 13 持续时间相对较短的治疗，并且缺乏关于镇静水平的日常数据。 11,13",0.6,"['lack', 'data', 'short', 'treatment', 'target', 'intervention', 'sedation', '3', 'score', 'level', 'duration', 'up', 'delayed', 'to', 'and']","['data', 'treatment', 'target', 'sedation', 'level', 'duration', 'delayed', 'to', 'and']",2997,"['然而,这些试验有几个限制,包括延迟的干预(高达96小时),12个未确定的目标放松水平,11个目标深度放松水平(RASS分为 − 3 到 0 )比目前推荐,13个相对较短的治疗时间,以及缺乏日常放松水平的数据。']",0.4,"['lack', 'data', 'short', 'treatment', 'target', 'intervention', 'sedation', '3', 'score', 'level', 'duration', 'up', 'delayed', 'to', 'and']","['data', 'treatment', 'target', 'level', 'delayed', 'and']",,
3041,2998,"the biologic rationale for a potential benefit of dexmedetomidine is based on experimental evidence of protective effects against neuronal , myocardial , and renal injury , 28,29 along with a reduction in inflammatory mediators after cardiopulmonary bypass30 and reduced mortality in animal models.31","右美托咪定潜在益处的生物学原理基于对神经元、心肌和肾损伤的保护作用 28,29 以及体外循环后炎症介质减少 30 和动物模型死亡率降低的实验证据。 31",0.4761904761904761,"['neuronal', 'injury', 'potential', 'cardiopulmonary', 'biologic', 'experimental', 'reduction', 'rationale', 'mortality', 'along', 'animal', 'renal', 'after', 'inflammatory', 'myocardial', 'protective', 'evidence', 'benefit', 'with', 'dexmedetomidine', 'and']","['neuronal', 'injury', 'reduction', 'rationale', 'mortality', 'along', 'animal', 'after', 'evidence', 'dexmedetomidine']",2998,"['德克梅多米丁的潜在益处的生物合理性是基于对神经、心血管和肾脏损伤的保护作用的实验证据,28、29以及心肺过渡后的炎症调节剂的减少30以及动物模型的死亡率的减少。']",0.2857142857142857,"['neuronal', 'injury', 'potential', 'cardiopulmonary', 'biologic', 'experimental', 'reduction', 'rationale', 'mortality', 'along', 'animal', 'renal', 'after', 'inflammatory', 'myocardial', 'protective', 'evidence', 'benefit', 'with', 'dexmedetomidine', 'and']","['injury', 'reduction', 'mortality', 'animal', 'after', 'evidence']",,
3042,2999,"several studies and trials have shown lower mortality associated with dexmedetomidine than with other agents in patients with sepsis17,18 along with lower rates and shorter durations of coma and delirium , 12,16,17 both of which are associated with increased mortality.32,33","几项研究和试验表明，与其他药物相比，右美托咪定在脓毒症患者中的死亡率较低17,18，昏迷和谵妄的发生率较低且持续时间较短，12,16,17 这两者都与死亡率增加有关。32,33",0.5,"['coma', 'delirium', 'lower', 'associated', 'mortality', 'along', 'with', 'dexmedetomidine', 'have', 'and']","['coma', 'delirium', 'mortality', 'dexmedetomidine', 'have']",2999,"['多项研究和研究表明,与德克塞米多米丁相关的死亡率低于与塞普西斯病患者的其他药物的死亡率17,18 以及较低的病率和昏迷和<unk>病的短期,12,16,17 两者都与死亡率增加有关。']",0.4,"['coma', 'delirium', 'lower', 'associated', 'mortality', 'along', 'with', 'dexmedetomidine', 'have', 'and']","['coma', 'lower', 'mortality', 'have']",,
3043,3000,"however , in our trial , we found no difference in overall mortality with the use of dexmedetomidine as compared with usual care .",然而，在我们的试验中，我们发现使用右美托咪定与常规治疗相比，总死亡率没有差异。,0.3,"['usual', 'difference', 'mortality', 'no', 'trial', 'care', 'as', 'with', 'dexmedetomidine', 'we']","['difference', 'mortality', 'dexmedetomidine']",3000,"['然而,在我们的研究中,我们没有发现与常见护理相比使用德克塞米多米丁的总死亡率的差异。']",0.2,"['usual', 'difference', 'mortality', 'no', 'trial', 'care', 'as', 'with', 'dexmedetomidine', 'we']","['difference', 'mortality']",,
3044,3001,"there was heterogeneity with respect to the treatment effect on mortality for an age above or below the median of 63.7 years , with lower mortality in older patients and higher mortality in younger patients , but the significance of the difference could not be determined .",对于高于或低于 63.7 岁中位数的死亡率，治疗效果存在异质性，老年患者死亡率较低，年轻患者死亡率较高，但无法确定差异的显着性。,0.5,"['median', 'heterogeneity', 'difference', 'lower', 'be', 'treatment', 'mortality', 'age', 'significance', 'effect', 'treatment effect', 'with', 'respect', 'on', 'in', 'but', 'to', 'and']","['heterogeneity', 'difference', 'be', 'treatment', 'mortality', 'effect', 'treatment effect', 'but', 'to']",3001,"['与治疗对死亡率的影响有关异常性,年龄超过或低于平均年龄63.7年,年龄较老患者死亡率较低,年龄较年轻患者死亡率较高,但差异的重要性无法确定。']",0.3888888888888889,"['median', 'heterogeneity', 'difference', 'lower', 'be', 'treatment', 'mortality', 'age', 'significance', 'effect', 'treatment effect', 'with', 'respect', 'on', 'in', 'but', 'to', 'and']","['difference', 'treatment', 'mortality', 'age', 'significance', 'but', 'to']",,
3045,3002,patients who were treated with dexmedetomidine received additional drugs to achieve the target level of sedation .,接受右美托咪定治疗的患者接受了额外的药物以达到目标镇静水平。,0.75,"['who', 'drugs', 'target', 'sedation', 'additional', 'level', 'with', 'dexmedetomidine']","['drugs', 'target', 'sedation', 'additional', 'level', 'dexmedetomidine']",3002,"['接受德克塞米多米丁治疗的患者接受了额外的药物,以达到目标放松水平。']",0.5,"['who', 'drugs', 'target', 'sedation', 'additional', 'level', 'with', 'dexmedetomidine']","['drugs', 'target', 'additional', 'level']",,
3046,3003,"the use of multiple agents , however , was common in both groups .",然而，使用多种药物在这两个群体中都很常见。,0.0,"['multiple', 'common', 'in']",[],3003,"['然而,多元化物的使用在两组中都是常见的。']",0.0,"['multiple', 'common', 'in']",[],,
3047,3004,this may reflect sedation requirements during the acute phase of a critical illness .,这可能反映了危重疾病急性期的镇静需求。,0.75,"['a', 'phase', 'illness', 'reflect', 'sedation', 'acute', 'critical', 'this']","['phase', 'illness', 'reflect', 'sedation', 'acute', 'critical']",3004,['这可能反映在关键疾病的急性阶段的安静要求。'],0.375,"['a', 'phase', 'illness', 'reflect', 'sedation', 'acute', 'critical', 'this']","['phase', 'illness', 'reflect']",,
3048,3005,the administration of medications in our trial was unblinded .,在我们的试验中，药物管理是公开的。,0.5,"['administration', 'trial']",['administration'],3005,"['在我们的试验中,药物的应用是无视的。']",0.0,"['administration', 'trial']",[],,
3049,3006,"we did not exclude patients who required deep sedation , a factor that might have influenced the overall RASS scores and the need for sedative agents administered after randomization .",我们没有排除需要深度镇静的患者，该因素可能会影响总体 RASS 评分以及随机化后对镇静剂的需求。,0.5384615384615384,"['a', 'randomization', 'need', 'who', 'factor', 'sedation', 'sedative', 'after', 'deep', 'exclude', 'have', 'that', 'we']","['randomization', 'need', 'factor', 'sedation', 'sedative', 'after', 'have']",3006,"['我们没有排除需要深度放松的患者,这可能影响了RASS总分数和随机化后服用的放松剂的需求。']",0.3076923076923077,"['a', 'randomization', 'need', 'who', 'factor', 'sedation', 'sedative', 'after', 'deep', 'exclude', 'have', 'that', 'we']","['randomization', 'need', 'after', 'have']",,
3050,3007,"we did not mandate a daily interruption in sedation or adherence to a particular strategy for managing sedation or delirium in the ICU ( e.g. , the ABCDEF bundle ) .39,40","我们没有强制每天中断镇静或坚持在 ICU 中管理镇静或谵妄的特定策略（例如 ABCDEF 集束化）.39,40",0.5,"['bundle', 'a', 'strategy', 'delirium', 'interruption', 'particular', 'sedation', 'adherence', 'to', 'we']","['bundle', 'strategy', 'delirium', 'interruption', 'sedation']",3007,"['我們沒有命令每日中断座位或遵守一個特定的策略,以管理座位或 delirium 在 ICU (例如, ABCDEF 包 ).39,40']",0.2,"['bundle', 'a', 'strategy', 'delirium', 'interruption', 'particular', 'sedation', 'adherence', 'to', 'we']","['strategy', 'interruption']",,
3051,3008,dexmedetomidine was insufficient alone or as the primary agent to achieve clinically desired target sedation levels and was associated with more reported adverse events than usual care .,右美托咪定单独使用或作为主要药物不足以达到临床所需的目标镇静水平，并且与常规治疗相比报告的不良事件更多。,0.3846153846153846,"['usual', 'adverse', 'associated', 'primary', 'target', 'sedation', 'care', 'with', 'dexmedetomidine', 'agent', 'and', 'alone', 'insufficient']","['target', 'sedation', 'dexmedetomidine', 'alone', 'insufficient']",3008,"['Dexmedetomidine 单独或作为主要物质不足以达到临床上所需的目标放松水平,并与比常见护理更已知的副作用有关。']",0.2307692307692307,"['usual', 'adverse', 'associated', 'primary', 'target', 'sedation', 'care', 'with', 'dexmedetomidine', 'agent', 'and', 'alone', 'insufficient']","['target', 'alone', 'insufficient']",,
3052,3009,brain activation in response to spoken motor commands can be detected by electroencephalography ( EEG ) in clinically unresponsive patients .,在临床反应迟钝的患者中，可以通过脑电图 (EEG) 检测对口头运动命令做出反应的大脑激活。,0.8888888888888888,"['brain', 'motor', 'activation', 'be', 'electroencephalography', 'response', 'EEG', 'unresponsive', 'by']","['brain', 'motor', 'activation', 'be', 'electroencephalography', 'response', 'EEG', 'by']",3009,['反对发动机命令的脑激活可以通过电解体(EEG)在临床上不响应的患者中检测到。'],0.6666666666666666,"['brain', 'motor', 'activation', 'be', 'electroencephalography', 'response', 'EEG', 'unresponsive', 'by']","['brain', 'motor', 'activation', 'be', 'response', 'by']",,
3053,3010,the prevalence and prognostic importance of a dissociation between commanded motor behavior and brain activation in the first few days after brain injury are not well understood .,在脑损伤后的头几天，指令性运动行为与大脑激活之间的分离的普遍性和预后重要性尚不清楚。,0.6153846153846154,"['behavior', 'injury', 'dissociation', 'brain', 'motor', 'prevalence', 'activation', 'well', 'prognostic', 'after', 'brain injury', 'and', 'first']","['behavior', 'injury', 'dissociation', 'brain', 'motor', 'activation', 'after', 'brain injury']",3010,"['脑损伤后的前几天,指定的发动行为和大脑激活之间的分离的普及和预测重要性不清楚。']",0.6153846153846154,"['behavior', 'injury', 'dissociation', 'brain', 'motor', 'prevalence', 'activation', 'well', 'prognostic', 'after', 'brain injury', 'and', 'first']","['behavior', 'injury', 'dissociation', 'brain', 'activation', 'prognostic', 'after', 'brain injury']",,
3054,3011,"we studied a prospective , consecutive series of patients in a single intensive care unit who had acute brain injury from a variety of causes and who were unresponsive to spoken commands , including some patients with the ability to localize painful stimuli or to fixate on or track visual stimuli .",我们在一个重症监护室研究了一系列前瞻性、连续的患者，这些患者因各种原因患有急性脑损伤并且对口头命令没有反应，包括一些能够定位疼痛刺激或注视或跟踪视觉的患者。刺激。,0.3636363636363636,"['injury', 'track', 'who', 'series', 'variety', 'localize', 'brain', 'unit', 'painful', 'intensive care unit', 'consecutive', 'visual', 'acute', 'ability', 'stimuli', 'unresponsive', 'brain injury', 'with', 'single', 'to', 'and', 'we']","['injury', 'series', 'localize', 'brain', 'consecutive', 'visual', 'stimuli', 'brain injury']",3011,"['我们研究了一系列连续的患者在一个单一的强烈护理单位,他们患有各种原因的急性脑损伤,并且不响应发言命令,包括一些患者有能力找到疼痛刺激或固定或跟踪视觉刺激的能力。']",0.4090909090909091,"['injury', 'track', 'who', 'series', 'variety', 'localize', 'brain', 'unit', 'painful', 'intensive care unit', 'consecutive', 'visual', 'acute', 'ability', 'stimuli', 'unresponsive', 'brain injury', 'with', 'single', 'to', 'and', 'we']","['injury', 'series', 'brain', 'unit', 'consecutive', 'ability', 'stimuli', 'brain injury', 'single']",,
3055,3012,machine learning was applied to EEG recordings to detect brain activation in response to commands that patients move their hands .,机器学习被应用于脑电图记录，以检测响应患者移动双手命令的大脑活动。,0.7272727272727273,"['brain', 'activation', 'response', 'detect', 'applied', 'EEG', 'machine', 'learning', 'move', 'that', 'to']","['brain', 'response', 'detect', 'EEG', 'machine', 'learning', 'move', 'to']",3012,"['机器学习被应用到EEG录制,以检测大脑激活,以回应患者移动手的命令。']",0.5454545454545454,"['brain', 'activation', 'response', 'detect', 'applied', 'EEG', 'machine', 'learning', 'move', 'that', 'to']","['brain', 'activation', 'detect', 'machine', 'learning', 'move']",,
3056,3013,a total of 16 of 104 unresponsive patients ( 15 % ) had brain activation detected by EEG at a median of 4 days after injury .,在 104 名无反应的患者中，共有 16 名 (15%) 在受伤后中位数 4 天时通过 EEG 检测到大脑激活。,0.5,"['injury', 'median', 'brain', 'total', 'activation', 'after', 'EEG', '4', 'unresponsive', 'by']","['injury', 'brain', 'activation', 'after', 'unresponsive']",3013,"['在104名不响应患者中,共有16人(15%)在受伤后4天中间发现了EEG的脑激活。']",0.4,"['injury', 'median', 'brain', 'total', 'activation', 'after', 'EEG', '4', 'unresponsive', 'by']","['injury', 'brain', 'activation', 'after']",,
3057,3014,the condition in 8 of these 16 patients ( 50 % ) and in 23 of 88 patients ( 26 % ) without brain activation improved such that they were able to follow commands before discharge .,这 16 名患者中的 8 名 (50%) 和 88 名患者中的 23 名 (26%) 的情况在没有大脑激活的情况下有所改善，以至于他们能够在出院前遵循命令。,0.5,"['discharge', 'brain', 'condition', 'activation', 'that', 'follow', 'before', 'to', 'and', 'without']","['brain', 'activation', 'follow', 'before', 'to']",3014,"['在这些16名患者中,8人(50%)和88名患者中,23人(26%)没有大脑激活的状况有所改善,以便在排放前能够遵循命令。']",0.4,"['discharge', 'brain', 'condition', 'activation', 'that', 'follow', 'before', 'to', 'and', 'without']","['brain', 'activation', 'follow', 'before']",,
3058,3015,a dissociation between the absence of behavioral responses to motor commands and the evidence of brain activation in response to these commands in EEG recordings was found in 15 % of patients in a consecutive series of patients with acute brain injury . ( supported by the Dana Foundation and the James S. McDonnell Foundation . ),在一系列连续的急性脑损伤患者中，15% 的患者发现在 EEG 记录中，对运动命令缺乏行为反应与大脑对这些命令作出反应的证据之间存在分离。 （由 Dana 基金会和 James S. McDonnell 基金会支持。）,0.6470588235294118,"['injury', 'dissociation', 'series', 'brain', 'motor', 'activation', 'consecutive', 'absence', 'response', 'acute', 'EEG', 'evidence', 'brain injury', 'with', 'foundation', 'by', 'and']","['injury', 'dissociation', 'series', 'brain', 'motor', 'consecutive', 'absence', 'response', 'evidence', 'brain injury', 'by']",3015,"['在EEG记录中发现了对发动机命令缺乏行为反应和对这些命令反应的大脑激活的证据之间的分离,15%的患者在连续一系列患有急性脑损伤的患者中发现(由Dana基金会和James S. McDonnell基金会支持)。']",0.6470588235294118,"['injury', 'dissociation', 'series', 'brain', 'motor', 'activation', 'consecutive', 'absence', 'response', 'acute', 'EEG', 'evidence', 'brain injury', 'with', 'foundation', 'by', 'and']","['injury', 'dissociation', 'series', 'brain', 'motor', 'activation', 'absence', 'response', 'evidence', 'brain injury', 'by']",,
3059,3016,"however , the prevalence and prognostic relevance of this dissociation , if detected in the days soon after brain injury , are not well understood .",然而，如果在脑损伤后不久检测到这种分离的发生率和预后相关性，则尚不清楚。,0.5,"['injury', 'dissociation', 'brain', 'prevalence', 'well', 'prognostic', 'after', 'relevance', 'brain injury', 'this', 'if', 'and']","['injury', 'dissociation', 'brain', 'after', 'brain injury', 'and']",3016,"['然而,这种分裂的发病率和预测相关性,如果在脑损伤后的几天内被发现,则不清楚。']",0.5833333333333334,"['injury', 'dissociation', 'brain', 'prevalence', 'well', 'prognostic', 'after', 'relevance', 'brain injury', 'this', 'if', 'and']","['injury', 'dissociation', 'brain', 'prognostic', 'after', 'brain injury', 'and']",,
3060,3017,we studied the prevalence and prognostic importance of brain activation detected by EEG in response to spoken commands to perform a motor task .,我们研究了脑电图检测到的大脑激活的普遍性和预后重要性，以响应执行运动任务的口头命令。,0.5833333333333334,"['a', 'brain', 'task', 'motor', 'prevalence', 'activation', 'prognostic', 'response', 'EEG', 'by', 'and', 'we']","['brain', 'task', 'motor', 'activation', 'response', 'EEG', 'by']",3017,"['我们研究了由EEG检测的大脑激活的普及和预测重要性,以回应发言的命令进行发动任务。']",0.4166666666666667,"['a', 'brain', 'task', 'motor', 'prevalence', 'activation', 'prognostic', 'response', 'EEG', 'by', 'and', 'we']","['brain', 'task', 'activation', 'prognostic', 'by']",,
3061,3018,"from July 2014 through September 2017 , we prospectively screened all patients who were admitted with acute brain injury to the neuroscience ICU of our hospital ; screening was performed within 3 days after admission .",2014年7月至2017年9月，我们前瞻性筛查了所有入住我院神经科学ICU的急性脑损伤患者；入院后3天内进行筛查。,0.4,"['injury', 'who', 'screening', 'brain', 'admission', 'after', 'acute', 'neuroscience', '3', 'brain injury', 'hospital', 'with', 'all', 'to', 'we']","['injury', 'screening', 'brain', 'after', 'neuroscience', 'brain injury']",3018,"['从2014年7月到2017年9月,我们预期检查了所有患有急性脑损伤的患者到我们医院的神经科学ICU;检查在入院后3天内进行。']",0.4,"['injury', 'who', 'screening', 'brain', 'admission', 'after', 'acute', 'neuroscience', '3', 'brain injury', 'hospital', 'with', 'all', 'to', 'we']","['injury', 'brain', 'after', 'neuroscience', 'brain injury', 'hospital']",,
3062,3019,"in keeping with our routine practice and in accordance with guidelines regarding EEG monitoring of patients in the ICU , 9 unresponsive patients either were monitored by continuous EEG or were anticipated to be connected to monitoring within 12 hours after screening , unless imminent death was expected .",按照我们的常规做法并根据关于 ICU 患者脑电图监测的指南，9 名无反应的患者要么接受连续脑电图监测，要么预计在筛查后 12 小时内连接到监测，除非预计即将死亡。,0.7142857142857143,"['monitoring', 'death', 'screening', 'continuous', 'routine', 'regarding', 'be', 'after', 'practice', 'EEG', 'unresponsive', 'with', 'by', 'and']","['monitoring', 'death', 'screening', 'continuous', 'routine', 'regarding', 'be', 'after', 'EEG', 'unresponsive']",3019,"['根據我們的日常實踐,並根據關於ICU患者的EEG監視的指示,9名不負責任的患者,無論是由持續的EEG監視,還是預計在檢查後12小時內連接到監視,除非預計即將死亡。']",0.2142857142857142,"['monitoring', 'death', 'screening', 'continuous', 'routine', 'regarding', 'be', 'after', 'practice', 'EEG', 'unresponsive', 'with', 'by', 'and']","['death', 'be', 'by']",,
3063,3020,"the exclusion criteria were an age of less than 18 years , a preexisting disorder of consciousness before the onset of the acute brain injury that resulted in the current admission , pregnancy , deafness before the acute brain injury , clinical recovery of the ability to follow commands before enrollment , patients or families who did not want to participate in the study , or logistic reasons ( details are provided in the Supplementary Appendix ) .",排除标准是年龄小于 18 岁，导致当前入院的急性脑损伤发作前存在意识障碍，怀孕，急性脑损伤前耳聋，临床恢复之前的命令能力。入组、不想参加研究的患者或家属，或后勤原因（详细信息在补充附录中提供）。,0.52,"['injury', 'pregnancy', 'appendix', 'who', 'disorder', 'consciousness', 'brain', 'admission', 'study', 'supplementary', 'exclusion', 'recovery', 'onset', 'clinical', 'age', 'acute', 'deafness', 'current', 'ability', 'brain injury', 'want', 'that', 'follow', 'before', 'to']","['injury', 'pregnancy', 'disorder', 'consciousness', 'brain', 'recovery', 'clinical', 'age', 'deafness', 'ability', 'brain injury', 'before', 'to']",3020,"['排除标准为18岁以下的年龄,在急性脑损伤开始前存在的意识障碍,导致当前入学、怀孕、急性脑损伤前失明、临床恢复在登记前遵循命令的能力、不愿意参加研究的患者或家庭或物流原因(详细信息在附件中提供)。']",0.6,"['injury', 'pregnancy', 'appendix', 'who', 'disorder', 'consciousness', 'brain', 'admission', 'study', 'supplementary', 'exclusion', 'recovery', 'onset', 'clinical', 'age', 'acute', 'deafness', 'current', 'ability', 'brain injury', 'want', 'that', 'follow', 'before', 'to']","['injury', 'pregnancy', 'appendix', 'disorder', 'consciousness', 'brain', 'recovery', 'onset', 'clinical', 'age', 'current', 'ability', 'brain injury', 'follow', 'before']",,
3064,3021,"patients , families , and treating physicians were unaware of the results of the EEG recordings , and these results were not made available to treating clinicians in relation to decisions regarding the withdrawal of care .",患者、家属和主治医生都不知道脑电图记录的结果，并且这些结果也不会提供给主治医生以决定是否停止治疗。,0.2,"['withdrawal', 'relation', 'regarding', 'available', 'EEG', 'unaware', 'care', 'to', 'and', 'physicians']","['relation', 'EEG']",3021,"['病人、家庭和治疗医生不了解EEG记录的结果,这些结果并未向治疗诊所医生提供有关退休的决定。']",0.1,"['withdrawal', 'relation', 'regarding', 'available', 'EEG', 'unaware', 'care', 'to', 'and', 'physicians']",['regarding'],,
3065,3022,demographic data and data on complications that occurred during the hospital stay and on outcomes were prospectively collected .,前瞻性收集了人口统计数据和住院期间发生的并发症以及结果的数据。,0.1666666666666666,"['data', 'hospital', 'on', 'that', 'and', 'stay']",['data'],3022,['人口数据和在医院住宿期间发生的并发症以及结果的数据被预期收集。'],0.3333333333333333,"['data', 'hospital', 'on', 'that', 'and', 'stay']","['data', 'hospital']",,
3066,3023,"in addition , we recorded EEGs from 10 healthy volunteers with a mean age of 31 years , using the same EEG protocol as in the patients ( see the Supplementary Appendix ) .",此外，我们还记录了 10 名平均年龄为 31 岁的健康志愿者的脑电图，使用与患者相同的脑电图方案（见补充附录）。,0.3571428571428571,"['a', 'appendix', 'mean', 'protocol', 'addition', 'supplementary', 'age', 'EEG', 'as', 'with', 'volunteers', 'in', 'healthy', 'we']","['mean', 'addition', 'age', 'EEG', 'healthy']",3023,"['此外,我们记录了10名健康志愿者的EEG,平均年龄为31岁,使用与患者相同的EEG协议(参见附件)。']",0.3571428571428571,"['a', 'appendix', 'mean', 'protocol', 'addition', 'supplementary', 'age', 'EEG', 'as', 'with', 'volunteers', 'in', 'healthy', 'we']","['appendix', 'mean', 'protocol', 'age', 'healthy']",,
3067,3024,the study was approved for patients and healthy volunteers by the local institutional review board .,该研究得到了当地机构审查委员会的批准，适用于患者和健康志愿者。,0.25,"['review', 'study', 'local', 'board', 'volunteers', 'by', 'and', 'healthy']","['review', 'healthy']",3024,['该研究是由当地机构审计委员会批准的病人和健康志愿者。'],0.375,"['review', 'study', 'local', 'board', 'volunteers', 'by', 'and', 'healthy']","['review', 'by', 'healthy']",,
3068,3025,the first and last authors are responsible for the study design and drafting of the manuscript .,第一和最后一位作者负责研究设计和文稿起草。,0.3333333333333333,"['study', 'manuscript', 'design', 'and', 'first', 'drafting']","['design', 'first']",3025,['第一和最后的作者负责研究设计和编写手稿。'],0.5,"['study', 'manuscript', 'design', 'and', 'first', 'drafting']","['manuscript', 'design', 'first']",,
3069,3026,there was no industry involvement in or support for the study .,没有工业界参与或支持这项研究。,0.4,"['support', 'study', 'no', 'industry', 'involvement']","['support', 'industry']",3026,['没有行业参与或支持该研究。'],0.2,"['support', 'study', 'no', 'industry', 'involvement']",['support'],,
3070,3027,"the authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol , available at NEJM.org .",作者保证数据的准确性和完整性，以及试验对试验方案的忠实度，试验方案可在 NEJM.org 获取。,0.5,"['fidelity', 'data', 'accuracy', 'protocol', 'available', 'trial', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'completeness']",3027,"['作者保证数据的准确性和完整性,以及对本协议的审判忠诚性,可在NEJM.org上提供。']",0.625,"['fidelity', 'data', 'accuracy', 'protocol', 'available', 'trial', 'completeness', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
3071,3028,the results are reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology ( STROBE ) guidelines for reporting observational studies.11,结果是根据加强流行病学观察研究报告 (STROBE) 观察研究报告指南报告的。 11,0.25,"['epidemiology', 'with', 'in', 'strengthening']",['epidemiology'],3028,['根据《强化观测研究报告在流行病学(STROBE)》报告观测研究的指导方针。'],0.25,"['epidemiology', 'with', 'in', 'strengthening']",['epidemiology'],,
3072,3029,study PROCEDURES,研究程序,0.0,['study'],[],3029,['研究程序'],0.0,['study'],[],,
3073,3030,"for the daily neurologic assessment , sedated patients underwent interruption or reduction of sedation if it was deemed safe by the attending physician during rounds.15",对于每日神经系统评估，如果主治医师在查房期间认为镇静是安全的，镇静患者会中断或减少镇静。 15,0.75,"['physician', 'interruption', 'reduction', 'assessment', 'sedation', 'if', 'by', 'neurologic']","['physician', 'interruption', 'reduction', 'assessment', 'sedation', 'neurologic']",3030,"['对于每日神经学评估,在参观的医生在参观期间认为安全的情况下,静静的患者遭受静静的中断或减少。']",0.625,"['physician', 'interruption', 'reduction', 'assessment', 'sedation', 'if', 'by', 'neurologic']","['physician', 'interruption', 'reduction', 'assessment', 'neurologic']",,
3074,3031,both the behavioral and the EEG assessments were performed during interruption of sedation whenever possible .,行为和脑电图评估都尽可能在镇静中断期间进行。,0.75,"['interruption', 'sedation', 'EEG', 'and']","['interruption', 'sedation', 'EEG']",3031,"['无论是行为和EEG评估,都随时在停滞中进行。']",0.0,"['interruption', 'sedation', 'EEG', 'and']",[],,
3075,3032,motor COMMAND PROTOCOL,电机命令协议,0.0,['motor'],[],3032,['发动机命令协议'],1.0,['motor'],['motor'],,
3076,3033,the total duration of the motor command session was approximately 25 minutes .,运动命令会话的总持续时间约为 25 分钟。,0.6,"['motor', 'total', 'command', 'duration', 'approximately']","['motor', 'command', 'duration']",3033,['发动机控制时间约为25分钟。'],0.4,"['motor', 'total', 'command', 'duration', 'approximately']","['motor', 'command']",,
3077,3034,EEG ACQUISITION AND PROCESSING,脑电图采集和处理,1.0,['EEG'],['EEG'],3034,['EEG 采购与处理'],0.0,['EEG'],[],,
3078,3035,"statistical analyses were performed with R statistical software , version 3.4.1 ( R Project for Statistical Computing ) .24",使用 R 统计软件 3.4.1 版（R 统计计算项目）.24 进行统计分析,0.5,"['version', 'software', 'project', 'with']","['software', 'project']",3035,"['统计分析使用 R 统计软件, 版本 3.4.1 ( 统计计算的 R 项目 ).24']",0.75,"['version', 'software', 'project', 'with']","['version', 'software', 'project']",,
3079,3036,patients AND VOLUNTEERS,患者和志愿者,,[],[],3036,['病人和志愿者'],,[],[],,
3080,3037,"a total of 401 unresponsive patients with acute brain injury were screened , and 104 met the criteria for inclusion and were enrolled ( Table 1 and Figure 2 ) .",共筛选了 401 名无反应的急性脑损伤患者，其中 104 名符合纳入标准并入组（表 1 和图 2）。,0.4666666666666667,"['injury', 'a', 'table', 'inclusion', '1', '2', 'figure', 'brain', 'total', 'acute', 'unresponsive', 'brain injury', 'with', 'met', 'and']","['injury', 'table', '1', '2', 'brain', 'unresponsive', 'brain injury']",3037,"['共有401名患有急性脑损伤的不响应患者被检查,104人符合入学标准,并被注册(图1和图2)。']",0.3333333333333333,"['injury', 'a', 'table', 'inclusion', '1', '2', 'figure', 'brain', 'total', 'acute', 'unresponsive', 'brain injury', 'with', 'met', 'and']","['injury', '1', '2', 'brain', 'brain injury']",,
3081,3038,"enrolled patients were similar to those who were not enrolled with respect to age , sex , and admission Glasgow Coma Scale score ( Table S1 in the Supplementary Appendix ) .",入组患者与未入组患者在年龄、性别和入院格拉斯哥昏迷量表评分方面相似（补充附录表 S1）。,0.2941176470588235,"['coma', 'appendix', 'table', 'who', 'sex', 'scale', 'admission', 'supplementary', 'age', 'score', 'with', 'respect', 'S1', 'in', 'to', 'and', 'similar']","['coma', 'table', 'sex', 'scale', 'age']",3038,['注册的患者类似于未注册的年龄、性别和入学Glasgow Coma Scale分数(附件中的S1表)。'],0.4117647058823529,"['coma', 'appendix', 'table', 'who', 'sex', 'scale', 'admission', 'supplementary', 'age', 'score', 'with', 'respect', 'S1', 'in', 'to', 'and', 'similar']","['appendix', 'table', 'sex', 'scale', 'age', 'score', 'to']",,
3082,3039,the healthy volunteers all had EEG evidence of brain activation in response to motor commands .,健康的志愿者都有脑电图显示大脑响应运动命令而激活的证据。,0.7777777777777778,"['brain', 'motor', 'activation', 'response', 'EEG', 'evidence', 'volunteers', 'all', 'healthy']","['brain', 'motor', 'activation', 'response', 'EEG', 'evidence', 'healthy']",3039,"['所有健康的志愿者都有EEG的脑激活的证据,以应对发动机命令。']",0.5555555555555556,"['brain', 'motor', 'activation', 'response', 'EEG', 'evidence', 'volunteers', 'all', 'healthy']","['brain', 'motor', 'activation', 'evidence', 'healthy']",,
3083,3040,"we obtained a total of 240 EEG recordings from the 104 patients ( median number of recordings per patient , 2 ; interquartile range , 1 to 3 ) a median of 6 days ( interquartile range , 3 to 10 ) after the injury .",我们从 104 名患者中获得了总共 240 次脑电图记录（每位患者记录的中位数为 2；四分位间距为 1 至 3），中位时间为受伤后 6 天（四分位间距为 3 至 10）。,0.5833333333333334,"['injury', 'median', 'range', '1', '2', 'total', 'number', 'patient', 'after', 'EEG', '3', 'we']","['injury', '1', '2', 'number', 'patient', 'after', 'EEG']",3040,"['我们从104名患者中获得了总计240个EEG记录(每患者中间记录数量,2个;间隔范围,1至3个),受伤后平均6天(间隔范围,3至10个)。']",0.5833333333333334,"['injury', 'median', 'range', '1', '2', 'total', 'number', 'patient', 'after', 'EEG', '3', 'we']","['injury', 'range', '1', '2', 'number', 'patient', 'after']",,
3084,3041,"this dissociation was detected at a median of 4.0 days ( interquartile range , 2.0 to 5.3 ) after admission to the ICU .",在入住 ICU 后的中位数 4.0 天（四分位距，2.0 至 5.3）检测到这种分离。,0.2857142857142857,"['median', 'dissociation', 'range', 'admission', 'after', 'this', 'to']","['dissociation', 'after']",3041,"['这种分离在进入ICU后平均为 4.0 天(区间范围, 2.0 至 5.3)。']",0.5714285714285714,"['median', 'dissociation', 'range', 'admission', 'after', 'this', 'to']","['dissociation', 'range', 'admission', 'after']",,
3085,3042,"among these 16 patients , the causes of the acute brain injury were subarachnoid hemorrhage ( 5 patients ) , traumatic brain injury ( 3 ) , intracerebral hemorrhage ( 4 ) , cardiac arrest ( 2 ) , neurosarcoidosis ( 1 ) , and bupropion overdose ( 1 ) ( Table 2 ) .",这16例患者中，急性脑损伤的原因为蛛网膜下腔出血（5例） 、颅脑外伤（3例） 、脑出血（4例） 、心脏骤停（2例） 、神经结节病（1例） 、安非他酮过量（ 1例） 。 （表2）。,0.65,"['injury', 'cardiac', '5', 'arrest', 'table', '1', '2', 'hemorrhage', 'brain', 'traumatic', 'overdose', 'intracerebral', 'cardiac arrest', 'subarachnoid', 'subarachnoid hemorrhage', 'acute', '3', '4', 'brain injury', 'and']","['injury', 'cardiac', '5', 'table', '1', '2', 'hemorrhage', 'brain', 'traumatic', 'overdose', 'subarachnoid', 'subarachnoid hemorrhage', 'brain injury']",3042,"['在这些16名患者中,急性脑损伤的原因是子宫血液(5名患者),创伤性脑损伤(3),内脑血液(4),心脏停止(2),神经糖尿病(1),和布普罗皮昂过量(1)(图2)。']",0.5,"['injury', 'cardiac', '5', 'arrest', 'table', '1', '2', 'hemorrhage', 'brain', 'traumatic', 'overdose', 'intracerebral', 'cardiac arrest', 'subarachnoid', 'subarachnoid hemorrhage', 'acute', '3', '4', 'brain injury', 'and']","['injury', 'cardiac', '5', 'arrest', '1', '2', 'brain', 'traumatic', 'overdose', 'brain injury']",,
3086,3043,"we found that 15 % of patients in a consecutive series of patients with acute brain injury who were clinically unresponsive - some of whom had motor localization to pain stimuli , visual fixation , or visual tracking - had evidence of brain activation in response to spoken motor commands , as determined on the basis of EEG activity .",我们发现，在一系列临床上无反应的急性脑损伤患者中，有 15 % 的患者有对疼痛刺激、视觉固定或视觉追踪的运动定位 - 有大脑激活对口头运动命令做出反应的证据，根据 EEG 活动确定。,0.5833333333333334,"['injury', 'fixation', 'who', 'series', 'localization', 'brain', 'activity', 'basis', 'motor', 'activation', 'consecutive', 'pain', 'response', 'visual', 'acute', 'EEG', 'evidence', 'stimuli', 'unresponsive', 'brain injury', 'with', '-', 'that', 'we']","['injury', 'fixation', 'series', 'localization', 'brain', 'activity', 'motor', 'activation', 'pain', 'response', 'evidence', 'stimuli', 'unresponsive', 'brain injury']",3043,"['我们发现,15%的连续一系列患有急性脑损伤的患者,他们是临床上不响应的 - 其中一些有发动机定位到疼痛刺激,视觉固定,或视觉跟踪 - 有脑激活的证据,以应对发动机命令,根据EEG活动确定。']",0.5416666666666666,"['injury', 'fixation', 'who', 'series', 'localization', 'brain', 'activity', 'basis', 'motor', 'activation', 'consecutive', 'pain', 'response', 'visual', 'acute', 'EEG', 'evidence', 'stimuli', 'unresponsive', 'brain injury', 'with', '-', 'that', 'we']","['injury', 'fixation', 'series', 'localization', 'brain', 'activity', 'motor', 'activation', 'pain', 'response', 'evidence', 'stimuli', 'brain injury']",,
3087,3044,"our findings support those of previous studies that have shown that EEG or functional MRI can in some cases reflect activation of parts of the brain in response to spoken commands in unresponsive patients , 1,4,26 but whether the detected signal represents recognition or comprehension of commands is uncertain .","我们的研究结果支持之前的研究，这些研究表明 EEG 或功能性 MRI 在某些情况下可以反映无反应患者响应口头命令时大脑部分的激活， 1,4,26 但检测到的信号是否代表识别或理解命令不确定。",0.4705882352941176,"['support', 'brain', 'functional', 'previous', 'uncertain', 'activation', 'reflect', 'MRI', 'response', 'signal', 'EEG', 'recognition', 'unresponsive', 'have', 'that', 'but', 'to']","['support', 'brain', 'activation', 'reflect', 'response', 'signal', 'recognition', 'but']",3044,"['我們的發現支持以前的研究表明,EEG或功能MRI在某些情況下可能反映了大腦部位的啟動,以回應在不响應的病人發言命令,但是否發現的信號代表命令的認識或理解是不確定的。']",0.2352941176470588,"['support', 'brain', 'functional', 'previous', 'uncertain', 'activation', 'reflect', 'MRI', 'response', 'signal', 'EEG', 'recognition', 'unresponsive', 'have', 'that', 'but', 'to']","['support', 'previous', 'reflect', 'but']",,
3088,3045,patients who had an EEG response to spoken commands more often had later recovery than those who did not have this pattern .,与没有这种模式的患者相比，对口头命令有脑电图反应的患者恢复得更晚。,0.5555555555555556,"['pattern', 'who', 'recovery', 'response', 'EEG', 'have', 'this', 'later', 'to']","['pattern', 'recovery', 'response', 'EEG', 'have']",3045,['患有对发言命令的EEG反应的患者比没有这种模式的人更频繁地恢复后期。'],0.5555555555555556,"['pattern', 'who', 'recovery', 'response', 'EEG', 'have', 'this', 'later', 'to']","['pattern', 'recovery', 'response', 'have', 'later']",,
3089,3046,limitations of our study include the varied causes of brain injuries among the patients .,我们研究的局限性包括患者脑损伤的不同原因。,0.3333333333333333,"['brain', 'study', 'varied']",['brain'],3046,['我们研究的限制包括患者脑损伤的多样原因。'],0.3333333333333333,"['brain', 'study', 'varied']",['brain'],,
3090,3047,"sedation is a potential confounder in the classification of patients as being in a comatose , vegetative , or minimally conscious state ; however , we were able to detect brain activation in response to motor commands in some lightly sedated patients .",在将患者分类为处于昏迷、植物人或最低意识状态时，镇静是一个潜在的混杂因素；然而，我们能够检测到一些轻度镇静患者的大脑对运动指令的反应。,0.6875,"['a', 'state', 'classification', 'potential', 'brain', 'vegetative', 'motor', 'activation', 'comatose', 'conscious', 'sedation', 'response', 'detect', 'being', 'conscious state', 'we']","['state', 'classification', 'potential', 'brain', 'motor', 'comatose', 'conscious', 'sedation', 'response', 'detect', 'conscious state']",3047,"['沉默是患者分类为处于昏迷、植物性或最小意识状态的潜在混乱;然而,我们能够在某些轻度沉默的患者中检测到大脑激活,以应对发动机命令。']",0.5625,"['a', 'state', 'classification', 'potential', 'brain', 'vegetative', 'motor', 'activation', 'comatose', 'conscious', 'sedation', 'response', 'detect', 'being', 'conscious state', 'we']","['state', 'classification', 'brain', 'motor', 'activation', 'comatose', 'conscious', 'detect', 'conscious state']",,
3091,3048,"in conclusion , early after brain injury , 15 % of clinically unresponsive patients who did not follow commands had EEG evidence of brain activation in response to spoken motor commands recorded at the bedside in the ICU .",总之，在脑损伤后早期，15% 的临床反应迟钝且不服从指令的患者在 ICU 床边记录到脑电图显示大脑对口头运动指令有反应。,0.5714285714285714,"['injury', 'who', 'brain', 'motor', 'early', 'activation', 'response', 'after', 'EEG', 'evidence', 'conclusion', 'unresponsive', 'brain injury', 'follow']","['injury', 'brain', 'motor', 'early', 'response', 'after', 'EEG', 'brain injury']",3048,"['在结论中,早在脑损伤后,15%的临床上不响应的患者没有遵循命令,有EEG脑激活的证据,以回应在ICU的床边记录的发动机命令。']",0.7857142857142857,"['injury', 'who', 'brain', 'motor', 'early', 'activation', 'response', 'after', 'EEG', 'evidence', 'conclusion', 'unresponsive', 'brain injury', 'follow']","['injury', 'brain', 'motor', 'early', 'activation', 'response', 'after', 'evidence', 'conclusion', 'brain injury', 'follow']",,
3092,3049,"among 22,651 patients ( 9604 in the derivation data set and 13,047 in the validation data set ) , the prevalence of myocardial infarction was 15.3 % .","在 22,651 名患者（推导数据集中 9604 名和验证数据集中 13,047 名）中，心肌梗死的患病率为 15.3%。",0.5,"['derivation', 'myocardial infarction', 'data', 'validation', 'prevalence', 'set', 'and', 'data set']","['derivation', 'myocardial infarction', 'data', 'data set']",3049,"['在22651名患者中(衍生数据集中的9604人和验证数据集中的13.047人)中,心脏病发作的发病率为15.3%。']",0.375,"['derivation', 'myocardial infarction', 'data', 'validation', 'prevalence', 'set', 'and', 'data set']","['derivation', 'data', 'data set']",,
3093,3050,these findings were confirmed in an external validation data set .,这些发现在外部验证数据集中得到了证实。,0.5,"['external', 'data', 'validation', 'set', 'in', 'data set']","['data', 'validation', 'data set']",3050,['这些发现在外部验证数据集中得到确认。'],0.3333333333333333,"['external', 'data', 'validation', 'set', 'in', 'data set']","['data', 'data set']",,
3094,3051,chest pain suggestive of myocardial infarction is a leading cause of presentation to the emergency department worldwide.1,提示心肌梗死的胸痛是全球急诊科就诊的主要原因。 1,0.5,"['presentation', 'myocardial infarction', 'chest', 'chest pain', 'department', 'emergency', 'cause', 'emergency department', 'leading', 'to']","['myocardial infarction', 'chest', 'chest pain', 'department', 'cause']",3051,['胸部疼痛提示心脏病发作是全球紧急部门提交的主要原因1'],0.4,"['presentation', 'myocardial infarction', 'chest', 'chest pain', 'department', 'emergency', 'cause', 'emergency department', 'leading', 'to']","['chest', 'department', 'emergency', 'cause']",,
3095,3052,"however , some challenges remain .",然而，一些挑战仍然存在。,,[],[],3052,"['然而,有些挑战仍然存在。']",,[],[],,
3096,3053,"second , although it is generally accepted that the initial blood sample for troponin measurement should be obtained immediately on presentation , the appropriate timing of obtaining the second blood sample is a matter of debate , and recommendations vary between 1 hour and 6 hours.2,4,9,11,13,16","其次，虽然人们普遍认为应在就诊时立即获取用于肌钙蛋白测量的初始血样，但获取第二份血样的适当时间仍有争议，建议在 1 小时到 6 小时之间变化。 2,4 ,9,11,13,16",0.4117647058823529,"['sample', 'presentation', '1', 'blood', 'be', 'initial', 'measurement', 'matter', 'accepted', 'debate', 'timing', 'hour', 'troponin', 'second', 'that', 'and', 'appropriate']","['1', 'be', 'initial', 'measurement', 'hour', 'troponin', 'second']",3053,"['其次,虽然一般认为初步血液样本应在提交时立即获得,但获得第二个血液样本的适当时间是讨论问题,建议在1小时至6小时之间。']",0.4117647058823529,"['sample', 'presentation', '1', 'blood', 'be', 'initial', 'measurement', 'matter', 'accepted', 'debate', 'timing', 'hour', 'troponin', 'second', 'that', 'and', 'appropriate']","['sample', '1', 'blood', 'be', 'initial', 'hour', 'second']",,
3097,3054,comparing outcomes in such patients with those in the general population may increase the understanding of individual risk.17,将此类患者的结果与一般人群的结果进行比较可能会增加对个体风险的理解。 17,0.4,"['population', 'individual', 'general', 'increase', 'with']","['population', 'individual']",3054,"['与一般人口患者的结果进行比较,可以提高个人风险的理解。']",0.4,"['population', 'individual', 'general', 'increase', 'with']","['population', 'individual']",,
3098,3055,"the authors vouch for the accuracy and completeness of the data and all analyses and for the fidelity of the study to the protocol , which is available with the full text of this article at NEJM.org .",作者保证数据和所有分析的准确性和完整性，以及研究对方案的忠实度，该方案与本文全文可在 NEJM.org 获取。,0.2857142857142857,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'study', 'available', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'completeness', 'full']",3055,"['作者对数据和所有分析的准确性和完整性以及对该协议的研究的忠诚性表示赞赏,该协议可在NEJM.org上提供本文的完整文本。']",0.3571428571428571,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'study', 'available', 'text', 'completeness', 'with', 'full', 'all', 'this', 'and']","['data', 'accuracy', 'protocol', 'completeness', 'full']",,
3099,3056,"the Standards for Reporting of Diagnostic Accuracy ( STARD ) checklist for this study is provided in Table S1 in Supplementary Appendix 1 , available at NEJM.org .",本研究的诊断准确性报告标准 (STARD) 检查表见补充附录 1 中的表 S1，补充附录 1 可在 NEJM.org 获取。,0.2307692307692307,"['checklist', 'appendix', 'table', '1', 'accuracy', 'study', 'supplementary', 'available', 'diagnostic', 'at', 'S1', 'this', 'in']","['table', '1', 'accuracy']",3056,"['该研究的标准报告诊断准确性(STARD)检查列表在附件1的表 S1中提供,可在NEJM.org上找到。']",0.3076923076923077,"['checklist', 'appendix', 'table', '1', 'accuracy', 'study', 'supplementary', 'available', 'diagnostic', 'at', 'S1', 'this', 'in']","['appendix', 'table', '1', 'accuracy']",,
3100,3057,study POPULATION WITH SUSPECTED ACUTE MYOCARDIAL INFARCTION,疑似急性心肌梗死的研究人群,0.0,['study'],[],3057,['研究患有急性心脏病发作的人口'],0.0,['study'],[],,
3101,3058,patients who presented to the emergency department with acute symptoms suggestive of myocardial infarction were considered the acute study population .,因急性症状提示心肌梗死而到急诊室就诊的患者被认为是急性研究人群。,0.3,"['myocardial infarction', 'population', 'who', 'study', 'department', 'emergency', 'symptoms', 'emergency department', 'acute', 'with']","['myocardial infarction', 'population', 'department']",3058,['患有心脏病发作的急性症状的患者被视为急性研究人口。'],0.1,"['myocardial infarction', 'population', 'who', 'study', 'department', 'emergency', 'symptoms', 'emergency department', 'acute', 'with']",['population'],,
3102,3059,"patients 18 years of age or older were recruited in 13 countries in three geographic regions ( Europe , North America , and Australasia ) .",在三个地理区域（欧洲、北美和澳大拉西亚）的 13 个国家/地区招募了 18 岁或以上的患者。,0.1428571428571428,"['america', 'north', 'age', 'geographic', 'three', 'in', 'and']",['north'],3059,['18岁及以上的患者在三个地理区域(欧洲、北美和澳大利亚)的13个国家被招募。'],0.1428571428571428,"['america', 'north', 'age', 'geographic', 'three', 'in', 'and']",['north'],,
3103,3060,all the participating studies were approved by local ethics committees and complied with the principles of the Declaration of Helsinki .,所有参与研究均获得当地伦理委员会的批准，并符合赫尔辛基宣言的原则。,0.1428571428571428,"['ethics', 'local', 'committees', 'with', 'all', 'by', 'and']",['committees'],3060,"['所有参与研究都由当地伦理委员会批准,并遵守赫尔辛基宣言的原则。']",0.2857142857142857,"['ethics', 'local', 'committees', 'with', 'all', 'by', 'and']","['committees', 'by']",,
3104,3061,"the diagnosis of myocardial infarction that was originally assigned to each study patient in each cohort was used as the basis for assigning the diagnosis for our study ( that is , the diagnosis was not reassessed as part of our analysis ) .",最初分配给每个队列中每个研究患者的心肌梗死诊断被用作分配我们研究诊断的基础（也就是说，诊断没有作为我们分析的一部分重新评估）。,0.4166666666666667,"['part', 'myocardial infarction', 'analysis', 'study', 'basis', 'diagnosis', 'patient', 'cohort', 'that', 'each', 'originally', 'to']","['part', 'myocardial infarction', 'analysis', 'diagnosis', 'patient']",3061,"['首先,对每个研究患者的心脏病发作的诊断,作为我们研究的诊断的基础(即诊断没有作为我们分析的一部分重新评估)。']",0.3333333333333333,"['part', 'myocardial infarction', 'analysis', 'study', 'basis', 'diagnosis', 'patient', 'cohort', 'that', 'each', 'originally', 'to']","['part', 'analysis', 'diagnosis', 'patient']",,
3105,3062,additional information regarding the troponin assays and the diagnosis of myocardial infarction in the acute study population is provided in Supplementary Appendix 1 .,补充附录 1 中提供了有关急性研究人群中肌钙蛋白检测和心肌梗死诊断的更多信息。,0.5384615384615384,"['myocardial infarction', 'population', 'appendix', '1', 'study', 'supplementary', 'regarding', 'diagnosis', 'information', 'additional', 'acute', 'troponin', 'and']","['myocardial infarction', 'population', '1', 'regarding', 'diagnosis', 'information', 'troponin']",3062,"['有关急性研究人口中甲状腺发作的特洛波因测量和诊断的额外信息,如附件1所示。']",0.4615384615384615,"['myocardial infarction', 'population', 'appendix', '1', 'study', 'supplementary', 'regarding', 'diagnosis', 'information', 'additional', 'acute', 'troponin', 'and']","['population', 'appendix', '1', 'regarding', 'diagnosis', 'information']",,
3106,3063,evaluation OF DIAGNOSTIC PERFORMANCE IN THE ACUTE STUDY POPULATION,评估急性研究人群的诊断性能,0.0,['evaluation'],[],3063,['急诊人口的诊断性能评估'],0.0,['evaluation'],[],,
3107,3064,"the selected cutoff concentrations were chosen to represent a wide range of diagnostic performances.9,11,12,14,22","选定的截止浓度代表广泛的诊断性能。 9,11,12,14,22",0.2857142857142857,"['cutoff', 'a', 'range', 'represent', 'wide', 'diagnostic', 'concentrations']","['represent', 'wide']",3064,['选择的<unk>浓度被选为代表广泛的诊断表现。9、11、12、14、22'],0.2857142857142857,"['cutoff', 'a', 'range', 'represent', 'wide', 'diagnostic', 'concentrations']","['represent', 'wide']",,
3108,3065,"to identify patients at low risk for myocardial infarction , the negative predictive value and the sensitivity for myocardial infarction , as well as the proportion of patients with troponin levels below the selected cutoff level , were calculated .",为识别心肌梗死低风险患者，计算了心肌梗死的阴性预测值和敏感性，以及肌钙蛋白水平低于选定临界值的患者比例。,0.4117647058823529,"['proportion', 'myocardial infarction', 'cutoff', 'value', 'negative', 'low', 'well', 'risk', 'level', 'identify', 'predictive', 'as', 'with', 'sensitivity', 'predictive value', 'troponin', 'and']","['proportion', 'myocardial infarction', 'low', 'risk', 'level', 'identify', 'troponin']",3065,['确定患心脏病发作风险较低的患者、负预测值和心脏病发作敏感度以及患心脏病发作水平低于所选择的心脏病发作水平的患者比例。'],0.2352941176470588,"['proportion', 'myocardial infarction', 'cutoff', 'value', 'negative', 'low', 'well', 'risk', 'level', 'identify', 'predictive', 'as', 'with', 'sensitivity', 'predictive value', 'troponin', 'and']","['proportion', 'low', 'risk', 'level']",,
3109,3066,a patient was deemed to be at low risk when both C1 and C2 were below the selected cutoff concentrations .,当 C1 和 C2 均低于选定的截止浓度时，患者被视为低风险。,0.375,"['cutoff', 'a', 'be', 'low', 'risk', 'patient', 'concentrations', 'and']","['low', 'risk', 'patient']",3066,"['患者被认为处于低风险状态,当C1和C2都低于所选择的<unk>浓度时。']",0.375,"['cutoff', 'a', 'be', 'low', 'risk', 'patient', 'concentrations', 'and']","['low', 'risk', 'patient']",,
3110,3067,"to identify patients at high risk for myocardial infarction , the positive predictive value and the specificity for myocardial infarction , as well as the proportion of patients with troponin levels greater than or equal to the selected cutoff concentration , were calculated .",为识别心肌梗死高危患者，计算了心肌梗死的阳性预测值和特异性，以及肌钙蛋白水平大于或等于所选截止浓度的患者比例。,0.4705882352941176,"['proportion', 'myocardial infarction', 'cutoff', 'specificity', 'concentration', 'high risk', 'value', 'well', 'identify', 'predictive', 'equal', 'as', 'with', 'predictive value', 'positive', 'troponin', 'and']","['proportion', 'myocardial infarction', 'specificity', 'concentration', 'high risk', 'identify', 'equal', 'troponin']",3067,['确定患有高心脏病发作风险的患者、积极的预测值和心脏病发作的特性以及患有高或等于所选择的心脏病发作浓度的患者的比例。'],0.1764705882352941,"['proportion', 'myocardial infarction', 'cutoff', 'specificity', 'concentration', 'high risk', 'value', 'well', 'identify', 'predictive', 'equal', 'as', 'with', 'predictive value', 'positive', 'troponin', 'and']","['proportion', 'concentration', 'equal']",,
3111,3068,a patient was deemed to be at high risk when either C1 or C2 was greater than or equal to the selected cutoff concentration .,当 C1 或 C2 大于或等于选定的截止浓度时，患者被视为高风险。,0.4285714285714285,"['cutoff', 'a', 'concentration', 'high risk', 'be', 'patient', 'equal']","['concentration', 'patient', 'equal']",3068,"['患者被认为处于高风险状态,当C1或C2高于或相当于所选择的<unk>浓度时。']",0.2857142857142857,"['cutoff', 'a', 'concentration', 'high risk', 'be', 'patient', 'equal']","['concentration', 'patient']",,
3112,3069,"in the APACE , BACC , Heidelberg , ProsPECTUS ( Prospektive Kohortenstudie zur Evaluation der Diagnostik und der therapeutischen Strategien in der Chest Pain Unit ) , and stenoCardia studies , patients were followed for 2 years .",在 APACE、BACC、海德堡、ProsPECTUS（Prospektive Kohortenstudie zur Evaluation der Diagnostik und der therapeutischen Strategien in der Chest Pain Unit）和 stenoCardia 研究中，对患者进行了为期 2 年的随访。,0.1666666666666666,"['chest', '2', 'evaluation', 'chest pain', 'unit', 'and']",['2'],3069,"['在APACE、BACC、Heidelberg、ProsPECTUS(Prospektive Kohortenstudie zur Evaluation der Diagnostik und der therapeutischen Strategien in der Chest Pain Unit)和StenoCardia研究中,患者被监测了2年。']",0.1666666666666666,"['chest', '2', 'evaluation', 'chest pain', 'unit', 'and']",['2'],,
3113,3070,general POPULATION STUDIES,一般人口研究,0.0,['general'],[],3070,['一般人口研究'],0.0,['general'],[],,
3114,3071,details of the included studies are provided in Supplementary Appendix 1 .,补充附录 1 中提供了纳入研究的详细信息。,0.25,"['appendix', '1', 'supplementary', 'in']",['1'],3071,['所包含的研究的详细信息在附件1中提供。'],0.5,"['appendix', '1', 'supplementary', 'in']","['appendix', '1']",,
3115,3072,details of the risk prediction and the methods for matching are provided in Supplementary Appendix 1 .,补充附录 1 中提供了风险预测和匹配方法的详细信息。,0.5,"['appendix', '1', 'supplementary', 'risk', 'matching', 'and']","['1', 'risk', 'matching']",3072,['风险预测和匹配方法的详细信息如附件1所示。'],0.6666666666666666,"['appendix', '1', 'supplementary', 'risk', 'matching', 'and']","['appendix', '1', 'risk', 'matching']",,
3116,3073,the characteristics of the patients were described according to quartiles for continuous variables and according to absolute and relative frequencies for binary variables .,连续变量按四分位数描述患者特征，二元变量按绝对频率和相对频率描述患者特征。,0.4285714285714285,"['binary', 'continuous', 'absolute', 'relative', 'characteristics', 'to', 'and']","['continuous', 'absolute', 'characteristics']",3073,['患者的特性根据连续变量的四分之一和二进制变量的绝对和相对频率进行描述。'],0.4285714285714285,"['binary', 'continuous', 'absolute', 'relative', 'characteristics', 'to', 'and']","['continuous', 'absolute', 'characteristics']",,
3117,3074,"for the evaluation of diagnostic performance , the negative predictive value , sensitivity , positive predictive value , and specificity were calculated for multiple combinations of initial troponin concentrations and serial changes in troponin concentrations ( C1 and C2 , as described above ) .",为了评估诊断性能，计算了初始肌钙蛋白浓度和肌钙蛋白浓度连续变化（C1 和 C2，如上所述）的多种组合的阴性预测值、敏感性、阳性预测值和特异性。,0.2941176470588235,"['specificity', 'evaluation', 'value', 'multiple', 'negative', 'initial', 'serial', 'diagnostic', 'predictive', 'performance', 'as', 'sensitivity', 'predictive value', 'concentrations', 'positive', 'troponin', 'and']","['specificity', 'initial', 'performance', 'as', 'troponin']",3074,"['对于诊断性能的评估,计算了负预测值、敏感性、积极预测值和特性,用于初始特洛波因浓度的多组和特洛波因浓度的序列变化(如上所述,C1和C2)。']",0.1764705882352941,"['specificity', 'evaluation', 'value', 'multiple', 'negative', 'initial', 'serial', 'diagnostic', 'predictive', 'performance', 'as', 'sensitivity', 'predictive value', 'concentrations', 'positive', 'troponin', 'and']","['initial', 'performance', 'as']",,
3118,3075,"to examine the generalizability of our findings , the diagnostic performance of these combinations was assessed in a derivation data set and confirmed in a validation data set .",为了检查我们研究结果的普遍性，这些组合的诊断性能在推导数据集中进行了评估，并在验证数据集中进行了确认。,0.3333333333333333,"['derivation', 'data', 'validation', 'set', 'diagnostic', 'performance', 'in', 'to', 'and', 'examine', 'assessed', 'data set']","['derivation', 'data', 'performance', 'data set']",3075,"['为了检查我们发现的普遍性,这些组合的诊断性能在衍生数据集中被评估,并在验证数据集中得到确认。']",0.3333333333333333,"['derivation', 'data', 'validation', 'set', 'diagnostic', 'performance', 'in', 'to', 'and', 'examine', 'assessed', 'data set']","['derivation', 'data', 'performance', 'data set']",,
3119,3076,no adjustment for multiple testing was performed .,没有对多重测试进行调整。,0.0,"['multiple', 'adjustment', 'no', 'testing']",[],3076,['没有进行多次测试的调整。'],0.0,"['multiple', 'adjustment', 'no', 'testing']",[],,
3120,3076,no adjustment for multiple testing was performed .,没有对多重测试进行调整。,0.0,"['multiple', 'adjustment', 'no', 'testing']",[],3076,['没有进行多次测试的调整。'],0.0,"['multiple', 'adjustment', 'no', 'testing']",[],,
3121,3077,"all statistical methods were implemented in R statistical software , version 3.5.0 .",所有统计方法均在 R 统计软件 3.5.0 版中实施。,0.25,"['version', 'software', 'all', 'in']",['software'],3077,"['所有统计方法都在 R 统计软件中实施,版本 3.5.0。']",0.5,"['version', 'software', 'all', 'in']","['version', 'software']",,
3122,3078,details of the statistical methods are provided in Supplementary Appendix 1 .,补充附录 1 中提供了统计方法的详细信息。,0.25,"['appendix', '1', 'supplementary', 'in']",['1'],3078,['统计方法的详细信息如附件1所示。'],0.5,"['appendix', '1', 'supplementary', 'in']","['appendix', '1']",,
3123,3079,study POPULATION WITH SUSPECTED MYOCARDIAL INFARCTION,疑似心肌梗死的研究人群,0.0,['study'],[],3079,['研究患有心脏病发作的人口'],0.0,['study'],[],,
3124,3080,"evaluation of diagnostic performance was performed in 9604 patients and validated in 13,047 patients .","对 9604 名患者进行了诊断性能评估，并在 13,047 名患者中进行了验证。",0.2,"['evaluation', 'diagnostic', 'performance', 'in', 'and']",['performance'],3080,"['在9604名患者中进行了诊断性能评估,并在13.047名患者中进行了验证。']",0.2,"['evaluation', 'diagnostic', 'performance', 'in', 'and']",['performance'],,
3125,3081,"the characteristics of the patients at baseline are presented in Table 1 for all patients , and in Table S2 in Supplementary Appendix 1 for each contributing study separately .",所有患者的基线患者特征见表 1，每项参与研究分别见补充附录 1 的表 S2。,0.3076923076923077,"['appendix', 'table', 'baseline', '1', 'study', 'supplementary', 'characteristics', 'at', 'S2', 'all', 'separately', 'each', 'and']","['table', 'baseline', '1', 'characteristics']",3081,"['基线上的患者的特点在图1中为所有患者介绍,并在补充附件1中的图S2中为每个参与研究分别介绍。']",0.2307692307692307,"['appendix', 'table', 'baseline', '1', 'study', 'supplementary', 'characteristics', 'at', 'S2', 'all', 'separately', 'each', 'and']","['appendix', 'baseline', '1']",,
3126,3082,"the final diagnosis of myocardial infarction was adjudicated in 3455 of 22,651 patients ( 15.3 % ) .","22,651 名患者中有 3455 名 (15.3%) 最终被诊断为心肌梗死。",1.0,"['myocardial infarction', 'diagnosis']","['myocardial infarction', 'diagnosis']",3082,['心脏病发作的最终诊断在22651名患者中获得了3455名患者(153%)。'],0.5,"['myocardial infarction', 'diagnosis']",['diagnosis'],,
3127,3083,patients AT LOW RISK FOR MYOCARDIAL INFARCTION,心肌梗死低风险患者,,[],[],3083,['患心脏病发作风险较低'],,[],[],,
3128,3084,"in addition , these patients were at very low risk for myocardial infarction or death from any cause at 30 days .",此外，这些患者在 30 天时发生心肌梗塞或全因死亡的风险非常低。,0.6666666666666666,"['myocardial infarction', 'death', 'addition', 'low', 'cause', 'risk']","['myocardial infarction', 'death', 'low', 'risk']",3084,"['此外,这些患者在30天内患心脏病发作或任何原因死亡的风险非常低。']",0.6666666666666666,"['myocardial infarction', 'death', 'addition', 'low', 'cause', 'risk']","['death', 'low', 'cause', 'risk']",,
3129,3085,patients AT HIGH RISK FOR MYOCARDIAL INFARCTION,心肌梗死高危患者,,[],[],3085,['患心脏病发作风险较高'],,[],[],,
3130,3086,prognosis IN PERSONS WITHOUT MYOCARDIAL INFARCTION,无心肌梗死患者的预后,1.0,['prognosis'],['prognosis'],3086,['没有心脏病发作的人的预测'],1.0,['prognosis'],['prognosis'],,
3131,3087,"however , owing to the higher analytic sensitivity of these assays , clinical management decisions have become more challenging .",然而，由于这些检测的分析灵敏度更高，临床管理决策变得更具挑战性。,0.5714285714285714,"['analytic', 'clinical', 'management', 'sensitivity', 'have', 'become', 'to']","['clinical', 'management', 'sensitivity', 'to']",3087,"['然而,由于这些估计的分析敏感性较高,临床管理决策变得更加挑战性。']",0.4285714285714285,"['analytic', 'clinical', 'management', 'sensitivity', 'have', 'become', 'to']","['clinical', 'management', 'to']",,
3132,3088,"consequently , algorithms have been developed to triage patients with suspected myocardial infarction efficiently .",因此，已经开发出算法来有效地对疑似心肌梗塞的患者进行分类。,0.4,"['myocardial infarction', 'triage', 'with', 'have', 'to']","['myocardial infarction', 'have']",3088,"['因此,算法已经开发,以有效地测试患有心脏病发作的患者。']",0.2,"['myocardial infarction', 'triage', 'with', 'have', 'to']",['have'],,
3133,3089,these algorithms have inflexible rules for the timing of troponin resampling and cutoff levels for the diagnosis of myocardial infarction .,这些算法对肌钙蛋白重采样的时间和诊断心肌梗死的截止水平有不灵活的规则。,0.5714285714285714,"['myocardial infarction', 'cutoff', 'diagnosis', 'timing', 'troponin', 'have', 'and']","['myocardial infarction', 'diagnosis', 'troponin', 'have']",3089,"['这些算法具有不灵活的规则,以便在心脏病发作的诊断中进行特洛波因重新采集和切割水平的时间。']",0.2857142857142857,"['myocardial infarction', 'cutoff', 'diagnosis', 'timing', 'troponin', 'have', 'and']","['diagnosis', 'have']",,
3134,3090,"therefore , the majority of these patients are candidates for early invasive strategies .",因此，这些患者中的大多数是早期侵入性策略的候选者。,0.6666666666666666,"['early', 'majority', 'therefore']","['early', 'majority']",3090,"['因此,大多数这些患者是早期侵入策略的候选人。']",0.6666666666666666,"['early', 'majority', 'therefore']","['early', 'majority']",,
3135,3091,"to estimate risk among such persons , we compared the incidence of myocardial infarction or death in the acute study population of patients in whom myocardial infarction had been ruled out with the incidence in the matched general population .",为了估计这些人的风险，我们比较了已排除心肌梗死的急性研究人群与匹配的一般人群的心肌梗死或死亡发生率。,0.3846153846153846,"['myocardial infarction', 'population', 'incidence', 'death', 'general', 'study', 'risk', 'acute', 'estimate', 'with', 'out', 'to', 'we']","['myocardial infarction', 'population', 'incidence', 'death', 'risk']",3091,"['为了在这些人中估计风险,我们比较了心脏病发作或死亡的发病率,与心脏病发作被排除的患者的急性研究人口的发病率与相匹配的总体人口的发病率。']",0.3076923076923077,"['myocardial infarction', 'population', 'incidence', 'death', 'general', 'study', 'risk', 'acute', 'estimate', 'with', 'out', 'to', 'we']","['population', 'incidence', 'death', 'risk']",,
3136,3092,some limitations of the study merit consideration .,该研究的一些局限性值得考虑。,0.0,"['study', 'consideration']",[],3092,['研究的一些限制值得考虑。'],0.0,"['study', 'consideration']",[],,
3137,3093,"the diagnosis of myocardial infarction , which was based on adjudication within each cohort , did not involve a harmonized standard operating procedure .",心肌梗死的诊断基于每个队列的判断，不涉及统一的标准操作程序。,0.5714285714285714,"['myocardial infarction', 'standard', 'procedure', 'diagnosis', 'involve', 'cohort', 'each']","['myocardial infarction', 'standard', 'procedure', 'diagnosis']",3093,"['心脏病发作的诊断,该诊断是基于在每个团体内分配的,并没有包括一个统一的标准操作程序。']",0.5714285714285714,"['myocardial infarction', 'standard', 'procedure', 'diagnosis', 'involve', 'cohort', 'each']","['standard', 'procedure', 'diagnosis', 'involve']",,
3138,3094,"in addition , our analyses included study populations that had different pretest probabilities of myocardial infarction .",此外，我们的分析包括了具有不同心肌梗塞预测概率的研究人群。,0.25,"['myocardial infarction', 'addition', 'study', 'that']",['myocardial infarction'],3094,"['此外,我们的分析包括研究人口,有不同预期的心脏病发作的可能性。']",0.0,"['myocardial infarction', 'addition', 'study', 'that']",[],,
3139,3095,this might lead to overestimation or underestimation of diagnostic probabilities in different scenarios .,这可能会导致高估或低估不同情况下的诊断概率。,0.0,"['lead', 'diagnostic', 'this', 'in', 'to']",[],3095,['这可能会导致在不同的场景中过估或低估诊断概率。'],0.0,"['lead', 'diagnostic', 'this', 'in', 'to']",[],,
3140,3096,"minimally invasive surgery may reduce operative morbidity , recovery time , and length of hospital stay .",微创手术可以减少手术并发症、恢复时间和住院时间。,0.3333333333333333,"['morbidity', 'reduce', 'surgery', 'time', 'recovery', 'minimally invasive surgery', 'operative', 'length', 'recovery time', 'hospital', 'and', 'stay']","['surgery', 'time', 'recovery', 'recovery time']",3096,['最小侵入性手术可以减少手术病率、恢复时间和住院时间。'],0.3333333333333333,"['morbidity', 'reduce', 'surgery', 'time', 'recovery', 'minimally invasive surgery', 'operative', 'length', 'recovery time', 'hospital', 'and', 'stay']","['surgery', 'time', 'recovery', 'recovery time']",,
3141,3097,"of the 1056 patients randomized , the median age was 56 , the majority were male , and half had clinical node positive disease .",在随机分配的 1056 名患者中，中位年龄为 56 岁，大多数为男性，其中一半患有临床淋巴结阳性疾病。,0.6363636363636364,"['median', 'disease', 'half', 'male', 'node', 'clinical', 'age', 'majority', 'median age', 'positive', 'and']","['disease', 'half', 'male', 'node', 'clinical', 'age', 'majority']",3097,"['在1056名随机病人中,平均年龄为56岁,大多数是男性,一半患有临床节点积极性疾病。']",0.6363636363636364,"['median', 'disease', 'half', 'male', 'node', 'clinical', 'age', 'majority', 'median age', 'positive', 'and']","['disease', 'half', 'male', 'node', 'clinical', 'age', 'majority']",,
3142,3098,at surgery tumors were downstaged to T1 in 22.4 % in the laparoscopic group and in 25.4 % in the open distal gastrectomy group .,在手术中，腹腔镜组和开腹远端胃切除术组分别有 22.4% 和 25.4% 的肿瘤降期至 T1。,0.3333333333333333,"['group', 'surgery', 'distal', 'open', 'T1', 'at', 'in', 'to', 'and']","['group', 'surgery', 'distal']",3098,"['在手术中,肿瘤在拉帕罗斯科小组中下降到T1的22.4%和开放式分裂性结核小组中下降到25.4%。']",0.2222222222222222,"['group', 'surgery', 'distal', 'open', 'T1', 'at', 'in', 'to', 'and']","['group', 'surgery']",,
3143,3099,"however , adjusting for age , tumor size , pathologic T stage , N stage , and adjuvant chemotherapy supported noninferiority of laparoscopic distal gastrectomy ( hazard ratio , of 1.1 ( P = 0.49 ) .",然而，调整年龄、肿瘤大小、病理 T 分期、N 分期和辅助化疗支持腹腔镜远端胃切除术的非劣效性（风险比为 1.1 (P = 0.49)）。,0.6428571428571429,"['stage', 'chemotherapy', 'ratio', 'hazard ratio', 'adjuvant', 'tumor', 'distal', 'pathologic', 'size', 'N', 'T', 'P', 'and', 'adjusting']","['stage', 'chemotherapy', 'ratio', 'hazard ratio', 'tumor', 'distal', 'size', 'T', 'and']",3099,"['然而,适应年龄、肿瘤大小、病理 T 阶段、N 阶段和辅助化疗,支持了拉帕罗斯科性分裂性(风险比例,为 1.1(P = 0.49)。']",0.5,"['stage', 'chemotherapy', 'ratio', 'hazard ratio', 'adjuvant', 'tumor', 'distal', 'pathologic', 'size', 'N', 'T', 'P', 'and', 'adjusting']","['chemotherapy', 'ratio', 'hazard ratio', 'tumor', 'size', 'T', 'and']",,
3144,3100,this approach is increasingly being used as the primary surgical approach for resectable gastric cancer .,这种方法越来越多地被用作可切除胃癌的主要手术方法。,0.25,"['approach', 'cancer', 'gastric', 'surgical', 'primary', 'being', 'gastric cancer', 'this']","['cancer', 'gastric cancer']",3100,['这种方法越来越多地被用作可恢复胃癌的主要手术方法。'],0.25,"['approach', 'cancer', 'gastric', 'surgical', 'primary', 'being', 'gastric cancer', 'this']","['cancer', 'gastric cancer']",,
3145,3101,a systematic review shows no obvious benefit of treatment .,系统评价显示治疗没有明显的好处。,0.1666666666666666,"['a', 'review', 'systematic', 'treatment', 'no', 'benefit']",['treatment'],3101,['系统的审查没有显而易见的治疗好处。'],0.5,"['a', 'review', 'systematic', 'treatment', 'no', 'benefit']","['review', 'systematic', 'treatment']",,
3146,3102,"for this guideline , researchers reviewed 21 randomized controlled trials that involved more than 2000 adults with subclinical hypothyroidism who received thyroid hormone treatment or placebo .",对于该指南，研究人员回顾了 21 项随机对照试验，这些试验涉及 2000 多名接受甲状腺激素治疗或安慰剂治疗的亚临床甲状腺功能减退症成人。,0.4545454545454545,"['thyroid', 'placebo', 'thyroid hormone', 'who', 'hypothyroidism', 'subclinical', 'controlled', 'treatment', 'with', 'this', 'that']","['thyroid', 'placebo', 'thyroid hormone', 'hypothyroidism', 'treatment']",3102,"['为此指导方针,研究人员审查了21个随机控制的研究,其中涉及2000多名患有临床甲状腺炎的成年人,他们接受了甲状腺激素治疗或 placebo。']",0.3636363636363636,"['thyroid', 'placebo', 'thyroid hormone', 'who', 'hypothyroidism', 'subclinical', 'controlled', 'treatment', 'with', 'this', 'that']","['thyroid', 'thyroid hormone', 'controlled', 'treatment']",,
3147,3103,many adults with subclinical hypothyroidism do not benefit from thyroid hormone treatment .,许多患有亚临床甲状腺功能减退症的成年人无法从甲状腺激素治疗中获益。,0.5714285714285714,"['thyroid', 'thyroid hormone', 'hypothyroidism', 'subclinical', 'treatment', 'benefit', 'with']","['thyroid', 'thyroid hormone', 'hypothyroidism', 'treatment']",3103,['许多患有临床甲状腺炎的成年人不受甲状腺激素治疗的好处。'],0.4285714285714285,"['thyroid', 'thyroid hormone', 'hypothyroidism', 'subclinical', 'treatment', 'benefit', 'with']","['thyroid', 'thyroid hormone', 'treatment']",,
3148,3104,"notably , about 60 % of adults with subclinical hypothyroidism and TSH levels between 4 and 10 mIU / L experience spontaneous normalization of TSH levels within 5 years .",值得注意的是，大约 60% 的患有亚临床甲状腺功能减退症且 TSH 水平在 4 到 10 mIU/L 之间的成年人在 5 年内经历了 TSH 水平的自发正常化。,0.2727272727272727,"['5', 'spontaneous', '/', 'hypothyroidism', 'TSH', 'subclinical', 'normalization', '4', 'experience', 'with', 'and']","['5', 'hypothyroidism', 'normalization']",3104,"['显而易见的是,大约60%的成年人患有临床甲状腺炎和TSH水平在4至10mIU / L之间,在5年内经历了TSH水平的自发正常化。']",0.2727272727272727,"['5', 'spontaneous', '/', 'hypothyroidism', 'TSH', 'subclinical', 'normalization', '4', 'experience', 'with', 'and']","['5', 'normalization', 'and']",,
3149,3105,"in contrast , those with higher TSH levels or antibodies to thyroid peroxidase have elevated risk for developing overt hypothyroidism .",相比之下，TSH 水平较高或甲状腺过氧化物酶抗体较高的人患明显甲状腺功能减退症的风险较高。,0.3636363636363636,"['peroxidase', 'thyroid', 'contrast', 'hypothyroidism', 'TSH', 'developing', 'risk', 'overt', 'with', 'have', 'to']","['peroxidase', 'thyroid', 'hypothyroidism', 'risk']",3105,"['相比之下,患有高 TSH 或甲状腺甲状腺过氧化物的抗体的人患甲状腺甲状腺炎的风险较高。']",0.2727272727272727,"['peroxidase', 'thyroid', 'contrast', 'hypothyroidism', 'TSH', 'developing', 'risk', 'overt', 'with', 'have', 'to']","['thyroid', 'risk', 'have']",,
3150,3106,intensive glycemic control did not result in persistent cardiovascular benefit .,强化血糖控制不会导致持久的心血管益处。,0.3333333333333333,"['persistent', 'control', 'cardiovascular', 'intensive', 'result', 'benefit']","['control', 'cardiovascular']",3106,['强烈的血糖控制并没有导致持久的心血管益处。'],0.3333333333333333,"['persistent', 'control', 'cardiovascular', 'intensive', 'result', 'benefit']","['control', 'cardiovascular']",,
3151,3107,the VA Diabetes Trial was one of three randomized trials published in 2008 and 2009 in which intensive glycemic control did not significantly lower the incidence of major adverse cardiovascular ( CV ) events in older patients with longstanding type 2 diabetes ( NEJM JW Gen Med Jan 15 2009 and N Engl J Med 2009 ; 360 : 129 ) .,VA 糖尿病试验是 2008 年和 2009 年发表的三项随机试验之一，在这些试验中，强化血糖控制并未显着降低患有长期 2 型糖尿病的老年患者主要不良心血管 (CV) 事件的发生率（NEJM JW Gen Med 2009 年 1 月 15 日和 N Engl J Med 2009；360：129）。,0.3529411764705882,"['diabetes', 'type', 'incidence', 'control', 'cardiovascular', '2', 'lower', 'major', 'adverse', 'intensive', 'trial', 'gen', 'N', 'with', 'three', 'and', 'med']","['diabetes', 'type', 'incidence', 'control', 'cardiovascular', '2']",3107,"['VA糖尿病试验是2008年和2009年发表的三项随机试验之一,其中强烈的血糖控制并没有显著降低患有长期患有2型糖尿病的老年患者的主要心血管不良(CV)事件的发病率(NEJM JW Gen Med 2009年1月15日和N Engl J Med 2009年;360:129)。']",0.3529411764705882,"['diabetes', 'type', 'incidence', 'control', 'cardiovascular', '2', 'lower', 'major', 'adverse', 'intensive', 'trial', 'gen', 'N', 'with', 'three', 'and', 'med']","['diabetes', 'type', 'incidence', 'control', 'cardiovascular', '2']",,
3152,3108,"now , the researchers provide additional data .",现在，研究人员提供了额外的数据。,1.0,"['data', 'additional']","['data', 'additional']",3108,"['现在,研究人员提供了额外的数据。']",1.0,"['data', 'additional']","['data', 'additional']",,
3153,3109,"during these 5 latest years , HbA1c levels were the same in the two groups .",最近5年，两组HbA1c水平相同。,0.6666666666666666,"['5', 'in', 'two']","['5', 'two']",3109,"['在过去的5年里,HbA1c水平在两组中是相同的。']",0.6666666666666666,"['5', 'in', 'two']","['5', 'two']",,
3154,3110,"nearly 500 such patients were randomized to a daily dose of dapagliflozin ( 10 mg ) plus saxagliptin ( 2.5 mg ) , dapagliflozin alone ( 10 mg ) , or placebo .",将近 500 名此类患者随机接受每日剂量的达格列净 (10 mg) 加沙克列汀 (2.5 mg)、单独达格列净 (10 mg) 或安慰剂。,0.5714285714285714,"['placebo', 'plus', 'daily dose', 'saxagliptin', 'dapagliflozin', 'to', 'alone']","['placebo', 'plus', 'dapagliflozin', 'alone']",3110,"['大约有500名患者随机服用每日剂量达帕格利弗洛辛(10毫克)加上萨卡格利普丁(2.5毫克),达帕格利弗洛辛单独(10毫克)或 placebo。']",0.2857142857142857,"['placebo', 'plus', 'daily dose', 'saxagliptin', 'dapagliflozin', 'to', 'alone']","['plus', 'alone']",,
3155,3111,"at 24 weeks , outcomes with active treatment , compared with placebo , were as follows :",在 24 周时，与安慰剂相比，积极治疗的结果如下：,0.6,"['placebo', 'active', 'treatment', 'as', 'with']","['placebo', 'treatment', 'as']",3111,"['在24周,与 placebo 相比,活性治疗的结果如下:']",0.4,"['placebo', 'active', 'treatment', 'as', 'with']","['treatment', 'as']",,
3156,3112,"mean UACR decreased significantly , by 21 % with dapagliflozin alone and by 38 % with combined therapy ( from a baseline of about 250 mg / g ) .",平均 UACR 显着下降，单独使用达格列净降低 21%，联合治疗降低 38%（从基线约 250 mg/g）。,0.5454545454545454,"['a', 'mean', 'baseline', '/', 'therapy', 'combined therapy', 'with', 'dapagliflozin', 'by', 'and', 'alone']","['mean', 'baseline', 'therapy', 'dapagliflozin', 'by', 'alone']",3112,"['平均UACR显著下降,只有Dapagliflozin的21%和结合治疗的38%(从约250mg/g的基线)。']",0.3636363636363636,"['a', 'mean', 'baseline', '/', 'therapy', 'combined therapy', 'with', 'dapagliflozin', 'by', 'and', 'alone']","['mean', 'baseline', 'therapy', 'by']",,
3157,3113,"mean GFR fell significantly , by 2.4 mL / minute / 1.73 m2 in both active treatment groups ( from a baseline of about 50 mL / minute / 1.73 m2 ) .",两个积极治疗组的平均 GFR 显着下降 2.4 mL/minute/1.73 m2（基线值约为 50 mL/minute/1.73 m2）。,0.2727272727272727,"['a', 'mean', 'baseline', '/', 'active', 'minute', 'treatment', 'ml', 'fell', 'GFR', 'by']","['mean', 'baseline', 'treatment']",3113,"['平均GFR在两种活性治疗群体中显著下降,为2.4 mL / 分钟 / 1.73 m2(从约50 mL / 分钟 / 1.73 m2的基线)。']",0.4545454545454545,"['a', 'mean', 'baseline', '/', 'active', 'minute', 'treatment', 'ml', 'fell', 'GFR', 'by']","['mean', 'baseline', 'minute', 'treatment', 'by']",,
3158,3114,mean HbA1c decreased significantly ( from a baseline of about 8.4 % ) by 0.6 % with combined therapy but not with dapagliflozin alone .,平均 HbA1c 显着（从约 8.4% 的基线）下降 0.6% 联合治疗，但不是单独使用达格列净。,0.7,"['a', 'mean', 'baseline', 'therapy', 'combined therapy', 'with', 'dapagliflozin', 'by', 'but', 'alone']","['mean', 'baseline', 'therapy', 'dapagliflozin', 'by', 'but', 'alone']",3114,"['平均 HbA1c 显著下降(从大约 8.4 % 的基线) 0.6% 与结合治疗,但不仅仅是 dapagliflozin 。']",0.5,"['a', 'mean', 'baseline', 'therapy', 'combined therapy', 'with', 'dapagliflozin', 'by', 'but', 'alone']","['mean', 'baseline', 'therapy', 'by', 'but']",,
3159,3115,UACR and GFR returned to baseline by 3 weeks after the trial was completed .,试验结束后 3 周 UACR 和 GFR 恢复到基线水平。,0.25,"['baseline', 'after', 'trial', '3', 'GFR', 'by', 'to', 'and']","['baseline', 'after']",3115,['UACR和GFR在审判结束后3周返回基线。'],0.375,"['baseline', 'after', 'trial', '3', 'GFR', 'by', 'to', 'and']","['baseline', 'after', 'trial']",,
3160,3116,"in this brief study , dapagliflozin - both as monotherapy and when combined with saxagliptin - reduced albuminuria in diabetic patients with chronic kidney disease .",在这项简短的研究中，dapagliflozin - 无论是作为单一疗法还是与沙格列汀联合使用，都可以减少伴有慢性肾病的糖尿病患者的白蛋白尿。,0.4615384615384615,"['kidney', 'disease', 'study', 'diabetic', 'chronic', 'albuminuria', 'with', 'saxagliptin', 'dapagliflozin', '-', 'combined with', 'this', 'and']","['kidney', 'disease', 'diabetic', 'chronic', 'saxagliptin', 'this']",3116,"['在这项简短的研究中,Dapagliflozin - 作为单疗法和与萨卡格利普丁相结合 - 在患有慢性肾脏疾病的糖尿病患者中减少了阿尔布米努里亚。']",0.3076923076923077,"['kidney', 'disease', 'study', 'diabetic', 'chronic', 'albuminuria', 'with', 'saxagliptin', 'dapagliflozin', '-', 'combined with', 'this', 'and']","['kidney', 'disease', 'diabetic', 'chronic']",,
3161,3117,its cash price is roughly US $ 7000 annually .,其现金价格约为每年 7000 美元。,1.0,['price'],['price'],3117,['其现金价格每年约为7000美元。'],1.0,['price'],['price'],,
3162,3118,participants had ≥ 3 traditional risk factors for cardiovascular disease ( CVD ) .,参与者有 ≥ 3 个传统的心血管疾病 (CVD) 危险因素。,0.6666666666666666,"['disease', 'cardiovascular', 'cardiovascular disease', 'risk', '3', 'CVD']","['disease', 'cardiovascular', 'cardiovascular disease', 'risk']",3118,['參與者有 ≥ 3 傳統心血管疾病(CVD)的風險因素。'],0.5,"['disease', 'cardiovascular', 'cardiovascular disease', 'risk', '3', 'CVD']","['disease', 'cardiovascular', 'cardiovascular disease']",,
3163,3119,median fasting and nonfasting levels were similar for total cholesterol ( 215 mg / dL ) and LDL cholesterol ( 132 mg / dL ) ; the median nonfasting triglyceride level was significantly higher than the median fasting level ( 159 mg / dL vs. 124 mg / dL ) .,总胆固醇 (215 mg/dL) 和 LDL 胆固醇 (132 mg/dL) 的中位空腹和非空腹水平相似；中位非空腹甘油三酯水平显着高于中位空腹水平（159 mg/dL 对 124 mg/dL）。,0.3,"['cholesterol', 'triglyceride', 'median', 'LDL cholesterol', '/', 'total', 'fasting', 'level', 'and', 'similar']","['cholesterol', 'triglyceride', 'level']",3119,['平均禁食和非禁食水平与总胆固醇(215 mg / dL )和LDL胆固醇(132 mg / dL )相似;平均禁食三酯水平比平均禁食水平(159 mg / dL 相比124 mg / dL )显著高。'],0.3,"['cholesterol', 'triglyceride', 'median', 'LDL cholesterol', '/', 'total', 'fasting', 'level', 'and', 'similar']","['cholesterol', 'LDL cholesterol', 'level']",,
3164,3120,"in analyses adjusted for traditional CVD risk factors , hazard ratios for the association of various lipid components with incident CVD events were nearly identical for fasting and nonfasting measurements .",在针对传统 CVD 危险因素进行调整的分析中，各种脂质成分与 CVD 事件关联的风险比对于空腹和非空腹测量几乎相同。,0.4545454545454545,"['lipid', 'association', 'various', 'hazard', 'fasting', 'risk', 'identical', 'with', 'incident', 'CVD', 'and']","['lipid', 'association', 'hazard', 'risk', 'incident']",3120,"['在对传统CVD风险因素进行调整的分析中,对各种脂肪组成部分与事件CVD事件的结合的风险比率对于禁食和不受伤害的测量来说是相同的。']",0.3636363636363636,"['lipid', 'association', 'various', 'hazard', 'fasting', 'risk', 'identical', 'with', 'incident', 'CVD', 'and']","['association', 'risk', 'identical', 'incident']",,
3165,3121,"for example , adjusted HRs for each 40 mg / dL LDL cholesterol increase were about 1.3 for both fasting and nonfasting measurements .",例如，对于空腹和非空腹测量，LDL 胆固醇每升高 40 mg/dL 的调整后 HR 约为 1.3。,0.25,"['cholesterol', 'LDL cholesterol', '/', 'fasting', 'increase', 'example', 'each', 'and']","['cholesterol', 'example']",3121,"['例如,每 40 mg / dL LDL 胆固醇增加的调整 HR 约为 1.3 为禁食和非禁食测量。']",0.25,"['cholesterol', 'LDL cholesterol', '/', 'fasting', 'increase', 'example', 'each', 'and']","['cholesterol', 'example']",,
3166,3122,this study suggests that nonfasting lipid levels are comparable to fasting lipid levels in predicting CVD events .,这项研究表明，非空腹血脂水平在预测 CVD 事件方面与空腹血脂水平相当。,0.0,"['lipid', 'study', 'fasting', 'CVD', 'this', 'that', 'to']",[],3122,"['这项研究表明,非营养脂肪水平与预测CVD事件的禁食脂肪水平相似。']",0.0,"['lipid', 'study', 'fasting', 'CVD', 'this', 'that', 'to']",[],,
3167,3123,"adherence to lipid screening is improved when patients can have blood drawn at the time of their office visits , without an overnight fast .",如果患者可以在就诊时抽血，而无需隔夜禁食，则患者对血脂筛查的依从性会有所提高。,0.3636363636363636,"['lipid', 'screening', 'blood', 'office', 'time', 'fast', 'at', 'adherence', 'have', 'to', 'without']","['screening', 'time', 'have', 'without']",3123,"['对脂肪筛查的坚持是改善的,当患者在他们的办公室访问时可能有血液拖动,而无需过夜快。']",0.5454545454545454,"['lipid', 'screening', 'blood', 'office', 'time', 'fast', 'at', 'adherence', 'have', 'to', 'without']","['screening', 'blood', 'time', 'at', 'have', 'without']",,
3168,3124,"even 4000 to 5000 steps were associated with benefit , with no evidence of benefit for more than 7500 steps daily .",即使是 4000 到 5000 步也有益处，但没有证据显示每天 7500 步以上有益处。,0.1666666666666666,"['associated', 'no', 'evidence', 'benefit', 'with', 'to']",['evidence'],3124,"['甚至有4000到5000步与福利有关,每天没有超过7500步的福利证据。']",0.3333333333333333,"['associated', 'no', 'evidence', 'benefit', 'with', 'to']","['evidence', 'benefit']",,
3169,3125,"the public widely believes that 10,000 steps daily are necessary to achieve health benefits .","公众普遍认为每天需要走 10,000 步才能获得健康益处。",0.2,"['health', 'public', 'necessary', 'that', 'to']",['health'],3125,"['公众普遍认为,每天需要10万步,以实现健康益处。']",0.2,"['health', 'public', 'necessary', 'that', 'to']",['health'],,
3170,3126,"to explore the optimal number of daily steps and stepping intensity required to promote health , researchers conducted an observational study of 16,700 women ( mean age , 72 ) who used accelerometers for at least 10 hours daily and for at least 4 days at study entry .","为了探索促进健康所需的最佳每日步数和步进强度，研究人员对 16,700 名女性（平均年龄 72 岁）进行了一项观察性研究，她们每天至少使用加速度计 10 小时，并且在研究开始时使用加速度计至少 4 天。",0.4615384615384615,"['mean', 'who', 'health', 'observational study', 'number', 'optimal', 'age', 'intensity', '4', 'explore', 'entry', 'to', 'and']","['mean', 'health', 'observational study', 'number', 'age', 'explore']",3126,"['研究人员对16700名女性(平均年龄,72岁)进行了观测研究,他们每天至少使用加速器10小时,并在入学时至少使用加速器4天。']",0.1538461538461538,"['mean', 'who', 'health', 'observational study', 'number', 'optimal', 'age', 'intensity', '4', 'explore', 'entry', 'to', 'and']","['mean', 'age']",,
3171,3127,participants were categorized into quartiles and assessed annually for a wide range of clinical and sociodemographic variables .,参与者被分为四分位数，并每年根据广泛的临床和社会人口统计学变量进行评估。,0.3333333333333333,"['a', 'range', 'wide', 'clinical', 'and', 'assessed']","['wide', 'clinical']",3127,"['参与者被分类为四分之一,并每年对广泛的临床和社会人口变量进行评估。']",0.3333333333333333,"['a', 'range', 'wide', 'clinical', 'and', 'assessed']","['wide', 'clinical']",,
3172,3128,"in adjusted analyses , mortality correlated inversely with number of daily steps ( median steps / day , 5500 ) .",在调整后的分析中，死亡率与每日步数呈负相关（平均步数/天，5500）。,0.3333333333333333,"['median', '/', 'mortality', 'number', 'with', 'in']","['mortality', 'number']",3128,"['在调整的分析中,死亡率与每日步骤的数量相匹配(平均步骤/日,5500)。']",0.3333333333333333,"['median', '/', 'mortality', 'number', 'with', 'in']","['mortality', 'number']",,
3173,3129,mortality and walking speed were not correlated .,死亡率和步行速度没有相关性。,0.75,"['walking', 'mortality', 'speed', 'and']","['walking', 'mortality', 'speed']",3129,['死亡率和步行速度与此无关。'],0.75,"['walking', 'mortality', 'speed', 'and']","['walking', 'mortality', 'speed']",,
3174,3130,"patients might walk more or less than these levels for many reasons , but these results give clinicians a more empirical foundation for providing basic exercise advice .",出于多种原因，患者步行可能会多于或少于这些水平，但这些结果为临床医生提供基本锻炼建议提供了更多的经验基础。,0.4444444444444444,"['a', 'exercise', 'advice', 'basic', 'empirical', 'walk', 'foundation', 'give', 'but']","['exercise', 'walk', 'foundation', 'but']",3130,"['由于许多原因,患者可能比这些水平走得多或少,但这些结果为诊所提供了一个更实验性的基础,以提供基本的锻炼建议。']",0.4444444444444444,"['a', 'exercise', 'advice', 'basic', 'empirical', 'walk', 'foundation', 'give', 'but']","['exercise', 'basic', 'foundation', 'but']",,
3175,3131,ticagrelor is a reversible inhibitor of platelet aggregation via antagonism of adenosine diphosphate receptor type P2Y12 .,替格瑞洛是一种可逆的血小板聚集抑制剂，通过拮抗腺苷二磷酸受体 P2Y12 型来抑制。,0.9090909090909092,"['adenosine', 'aggregation', 'receptor', 'antagonism', 'inhibitor', 'type', 'diphosphate', 'via', 'reversible', 'platelet', 'platelet aggregation']","['adenosine', 'aggregation', 'receptor', 'antagonism', 'inhibitor', 'type', 'diphosphate', 'reversible', 'platelet', 'platelet aggregation']",3131,"['Ticagrelor 是一种通过 P2Y12 类型 adenosine diphosphate 受体的反动性,可以逆转的阻塞器。']",0.1818181818181818,"['adenosine', 'aggregation', 'receptor', 'antagonism', 'inhibitor', 'type', 'diphosphate', 'via', 'reversible', 'platelet', 'platelet aggregation']","['receptor', 'type']",,
3176,3132,it is used to prevent thrombotic events in patients with acute coronary syndromes .,它用于预防急性冠脉综合征患者的血栓事件。,0.5,"['coronary', 'thrombotic', 'acute', 'with', 'prevent', 'in', 'to', 'syndromes']","['coronary', 'prevent', 'to', 'syndromes']",3132,['它用于预防患有急性冠状综合征的患者的血管现象。'],0.5,"['coronary', 'thrombotic', 'acute', 'with', 'prevent', 'in', 'to', 'syndromes']","['coronary', 'prevent', 'to', 'syndromes']",,
3177,3133,ticagrelor was also assayed for its ability to inhibit biofilm formation in vitro and in vivo .,还检测了替格瑞洛在体外和体内抑制生物膜形成的能力。,0.7142857142857143,"['biofilm', 'in vivo', 'in vitro', 'formation', 'ability', 'to', 'and']","['biofilm', 'in vivo', 'in vitro', 'formation', 'ability']",3133,['ticagrelor 也被评估为其抑制生物电影形成的能力 in vitro 和 in vivo 。'],0.2857142857142857,"['biofilm', 'in vivo', 'in vitro', 'formation', 'ability', 'to', 'and']","['formation', 'ability']",,
3178,3134,"ticagrelor increased the bactericidal activities of vancomycin , rifampin , and ciprofloxacin .",替格瑞洛增加万古霉素、利福平和环丙沙星的杀菌活性。,0.6,"['vancomycin', 'bactericidal', 'rifampin', 'ciprofloxacin', 'and']","['vancomycin', 'rifampin', 'ciprofloxacin']",3134,"['ticagrelor 增加了 vancomycin, rifampin, 和 ciprofloxacin 的细菌活性。']",0.0,"['vancomycin', 'bactericidal', 'rifampin', 'ciprofloxacin', 'and']",[],,
3179,3135,giving mice the standard oral antiplatelet dosage of ticagrelor inhibited S. aureus growth on and local tissue dissemination from preinfected implants .,给予小鼠标准口服抗血小板剂量的替格瑞洛可抑制金黄色葡萄球菌在预感染植入物上的生长和局部组织传播。,0.5,"['growth', 'standard', 'dosage', 'tissue', 'oral', 'antiplatelet', 'local', 'dissemination', 'implants', 'inhibited']","['standard', 'dosage', 'tissue', 'local', 'implants']",3135,['给老鼠的标准口服抗<unk>剂量Ticagrelor抑制S. aureus的生长和从预感染的植入物的本地组织传播。'],0.4,"['growth', 'standard', 'dosage', 'tissue', 'oral', 'antiplatelet', 'local', 'dissemination', 'implants', 'inhibited']","['standard', 'dosage', 'tissue', 'implants']",,
3180,3136,future clinical studies investigating the use of ticagrelor in endovascular infections would be of interest .,将来调查替格瑞洛在血管内感染中使用的临床研究会很有趣。,1.0,"['be', 'clinical']","['be', 'clinical']",3136,['未来的临床研究研究使用Ticagrelor在内血管感染将是有趣的。'],1.0,"['be', 'clinical']","['be', 'clinical']",,
3181,3137,"if ongoing studies provide an affirmative answer , it will be difficult to justify BMS for any patients undergoing PCI .",如果正在进行的研究提供肯定的答案，则很难证明 BMS 对任何接受 PCI 的患者都是合理的。,0.4,"['be', 'will', 'if', 'to', 'difficult']","['be', 'difficult']",3137,"['如果正在进行的研究提供一个可靠的答案,将很难为任何患有PCI的患者证明BMS。']",0.4,"['be', 'will', 'if', 'to', 'difficult']","['be', 'difficult']",,
3182,3138,"the BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia ( CLL ) , but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known .",BCL2 抑制剂 venetoclax 在慢性淋巴细胞白血病 (CLL) 患者中显示出活性，但其与其他药物联合治疗 CLL 和合并症的疗效尚不清楚。,0.5454545454545454,"['inhibitor', 'combination', 'leukemia', 'activity', 'lymphocytic', 'chronic', 'efficacy', 'with', 'CLL', 'but', 'and']","['inhibitor', 'combination', 'leukemia', 'activity', 'chronic', 'but']",3138,"['BCL2 抑制剂 venetoclax 已在患有慢性淋巴细胞白血病(CLL)的患者中表现出活性,但其与其他药物相结合的有效性在患有 CLL 和同存在条件的患者中尚不清楚。']",0.6363636363636364,"['inhibitor', 'combination', 'leukemia', 'activity', 'lymphocytic', 'chronic', 'efficacy', 'with', 'CLL', 'but', 'and']","['inhibitor', 'combination', 'leukemia', 'activity', 'chronic', 'efficacy', 'but']",,
3183,3139,the safety of each regimen was also evaluated .,还评估了每种方案的安全性。,0.5,"['safety', 'each']",['safety'],3139,['每个政权的安全性也被评估。'],0.5,"['safety', 'each']",['safety'],,
3184,3140,"in total , 432 patients ( median age , 72 years ; median Cumulative Illness Rating Scale score , 8 ; median creatinine clearance , 66.4 ml per minute ) underwent randomization , with 216 assigned to each group .",总共有 432 名患者（中位年龄 72 岁；中位累积疾病评定量表评分 8 分；中位肌酐清除率 66.4 毫升/分钟）接受随机分组，每组 216 人。,0.4705882352941176,"['group', 'creatinine', 'median', 'randomization', 'scale', 'illness', 'total', 'minute', 'cumulative', 'age', 'clearance', 'score', 'ml', 'with', 'rating scale', 'median age', 'each']","['group', 'randomization', 'scale', 'illness', 'minute', 'age', 'clearance', 'rating scale']",3140,"['总共,432名患者(平均年龄,72岁;平均累积疾病评级分数,8;平均创造素清分,每分钟66.4毫升)遭到随机化,每组分为216人。']",0.3529411764705882,"['group', 'creatinine', 'median', 'randomization', 'scale', 'illness', 'total', 'minute', 'cumulative', 'age', 'clearance', 'score', 'ml', 'with', 'rating scale', 'median age', 'each']","['group', 'randomization', 'illness', 'minute', 'age', 'score']",,
3185,3141,these differences were not significant .,这些差异并不显着。,,[],[],3141,['这些差异并不重要。'],,[],[],,
3186,3142,most patients with chronic lymphocytic leukemia ( CLL ) are older than 70 years of age and have clinically relevant coexisting conditions.1,大多数慢性淋巴细胞白血病 ( CLL ) 患者的年龄超过 70 岁，并且有临床相关的合并症。 1,0.5,"['leukemia', 'lymphocytic', 'chronic', 'age', 'with', 'CLL', 'have', 'and']","['leukemia', 'chronic', 'age', 'have']",3142,"['大多数患有慢性淋巴细胞白血病(CLL)的患者年龄超过70岁,并且具有临床相关的共同存在条件。']",0.5,"['leukemia', 'lymphocytic', 'chronic', 'age', 'with', 'CLL', 'have', 'and']","['leukemia', 'chronic', 'age', 'have']",,
3187,3143,such patients require more effective but less toxic regimens.2,此类患者需要更有效但毒性更小的治疗方案。 2,0.5,"['toxic', 'but']",['but'],3143,['这些患者需要更有效但更少的毒性饮食。'],0.5,"['toxic', 'but']",['but'],,
3188,3144,"venetoclax is an orally administered , BCL2 homology domain 3 ( BH3 ) -mimetic compound that disrupts antiapoptotic signaling through BCL2 , thereby inducing programmed cell death of CLL cells.8",venetoclax 是一种口服给药的 BCL2 同源结构域 3 ( BH3 ) 模拟化合物，可通过 BCL2 破坏抗凋亡信号，从而诱导 CLL 细胞的程序性细胞死亡。 8,0.6666666666666666,"['domain', 'cell', 'cell death', 'homology', 'compound', 'programmed cell death', '3', 'CLL', 'that']","['domain', 'cell', 'cell death', 'homology', 'compound', 'programmed cell death']",3144,"['venetoclax 是一种口服管理的,BCL2 homology domain 3(BH3) - 微化合物,通过BCL2干扰抗光学信号,从而导致CLL细胞的编程细胞死亡。']",0.3333333333333333,"['domain', 'cell', 'cell death', 'homology', 'compound', 'programmed cell death', '3', 'CLL', 'that']","['cell', 'cell death', 'compound']",,
3189,3145,a notification letter to all the investigators about the enrollment of such patients is shown in the Supplementary Appendix .,补充附录中显示了致所有研究者的关于此类患者入组的通知函。,0.1428571428571428,"['a', 'appendix', 'supplementary', 'letter', 'all', 'in', 'to']",['to'],3145,"['向所有调查人员提交有关这些病人登记的通知信,如附件中所示。']",0.2857142857142857,"['a', 'appendix', 'supplementary', 'letter', 'all', 'in', 'to']","['appendix', 'letter']",,
3190,3146,additional eligibility criteria are summarized in the Supplementary Appendix .,补充附录总结了额外的资格标准。,0.25,"['appendix', 'supplementary', 'additional', 'in']",['additional'],3146,['额外的可选性标准在附件中总结。'],0.5,"['appendix', 'supplementary', 'additional', 'in']","['appendix', 'additional']",,
3191,3147,the trial was approved by the institutional review board or independent health authorities at each participating institution and was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice .,该试验由各参与机构的机构审查委员会或独立卫生当局批准，并根据赫尔辛基宣言和国际临床试验协调指南会议进行。,0.5,"['review', 'good clinical practice', 'health', 'institution', 'board', 'trial', 'independent', 'with', 'at', 'each', 'by', 'and']","['review', 'health', 'institution', 'at', 'each', 'by']",3147,"['审查由各参与机构的机构审查委员会或独立卫生机构批准,并按照赫尔辛基宣言和国际临床实践协调指南会议进行。']",0.4166666666666667,"['review', 'good clinical practice', 'health', 'institution', 'board', 'trial', 'independent', 'with', 'at', 'each', 'by', 'and']","['review', 'health', 'institution', 'each', 'by']",,
3192,3148,"the authors collected the data during the trial , with oversight by an independent data and safety monitoring committee .",作者在试验期间收集数据，并由独立的数据和安全监测委员会监督。,0.6666666666666666,"['safety', 'monitoring', 'data', 'committee', 'trial', 'independent', 'with', 'by', 'and']","['safety', 'monitoring', 'data', 'committee', 'independent', 'by']",3148,"['作者在审判期间收集了数据,由独立的数据和安全监测委员会监督。']",0.7777777777777778,"['safety', 'monitoring', 'data', 'committee', 'trial', 'independent', 'with', 'by', 'and']","['safety', 'monitoring', 'data', 'committee', 'trial', 'independent', 'by']",,
3193,3149,the sponsors and the German CLL Study Group analyzed the data .,主办方和德国 CLL 研究小组对数据进行了分析。,0.4,"['group', 'data', 'study', 'CLL', 'and']","['group', 'data']",3149,['赞助商和德国CLL研究集团分析了数据。'],0.4,"['group', 'data', 'study', 'CLL', 'and']","['group', 'data']",,
3194,3150,"all the authors had access to the data and vouch for the completeness and accuracy of the data and for the adherence of the trial to the protocol , available at NEJM.org .",所有作者都可以访问数据并保证数据的完整性和准确性，并保证试验遵守试验方案，试验方案可在 NEJM.org 获取。,0.4,"['data', 'accuracy', 'protocol', 'access', 'available', 'trial', 'completeness', 'adherence', 'all', 'and']","['data', 'accuracy', 'protocol', 'completeness']",3150,"['所有作者都可以访问数据,并为数据的完整性和准确性以及审判与协议的遵守提供在NEJM.org。']",0.5,"['data', 'accuracy', 'protocol', 'access', 'available', 'trial', 'completeness', 'adherence', 'all', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
3195,3151,the manuscript was written by four of the academic authors and was reviewed critically and revised by all the authors .,手稿由四位学术作者撰写，并由所有作者进行了严格审查和修改。,0.4,"['manuscript', 'all', 'by', 'and', 'critically']","['manuscript', 'by']",3151,"['手稿由四位学术作家撰写,并被所有作家批评和审查。']",0.4,"['manuscript', 'all', 'by', 'and', 'critically']","['manuscript', 'by']",,
3196,3152,all the authors contributed to the writing and critical revision of the manuscript for intellectual content .,所有作者都为手稿的知识内容的撰写和重要修订做出了贡献。,0.1111111111111111,"['content', 'manuscript', 'writing', 'intellectual', 'critical', 'revision', 'all', 'to', 'and']",['manuscript'],3152,['所有作者都为知识内容的手稿的写作和批判性审查做出了贡献。'],0.2222222222222222,"['content', 'manuscript', 'writing', 'intellectual', 'critical', 'revision', 'all', 'to', 'and']","['manuscript', 'writing']",,
3197,3153,the trial was conducted in 21 countries at 196 sites .,该试验在 21 个国家/地区的 196 个地点进行。,0.0,"['trial', 'at', 'in']",[],3153,['审判在21个国家在196个地点进行。'],0.3333333333333333,"['trial', 'at', 'in']",['trial'],,
3198,3154,a block size of six was used to balance the randomization .,使用块大小为 6 来平衡随机化。,0.8,"['balance', 'randomization', 'block', 'size', 'to']","['balance', 'randomization', 'block', 'size']",3154,['一块六块的尺寸被用来平衡随机化。'],0.8,"['balance', 'randomization', 'block', 'size', 'to']","['balance', 'randomization', 'block', 'size']",,
3199,3155,patients were stratified according to Binet stage and geographic region .,根据 Binet 分期和地理区域对患者进行分层。,0.4,"['stage', 'region', 'geographic', 'to', 'and']","['stage', 'region']",3155,['病人按Binet阶段和地理区域分布。'],0.2,"['stage', 'region', 'geographic', 'to', 'and']",['region'],,
3200,3156,the treatment duration in both groups consisted of 12 cycles lasting 28 days each ; no crossover was allowed .,两组的治疗时间均为12个周期，每个周期持续28天；不允许交叉。,0.4,"['treatment', 'no', 'duration', 'each', 'in']","['treatment', 'duration']",3156,"['两组的治疗时间为12个周期,每个周期为28天;没有交叉。']",0.2,"['treatment', 'no', 'duration', 'each', 'in']",['treatment'],,
3201,3157,"obinutuzumab was administered intravenously for 6 cycles starting with 100 mg on day 1 and 900 mg on day 2 ( or 1000 mg on day 1 ) , 1000 mg on day 8 and 1000 mg on day 15 of cycle 1 , and subsequently 1000 mg on day 1 of cycles 2 through 6 .",obinutuzumab 静脉给药 6 个周期，第 1 天 100 mg 和第 2 天 900 mg（或第 1 天 1000 mg） ，第 1 周期第 8 天 1000 mg 和第 15 天 1000 mg ，随后第 1 天 1000 mg第 2 至 6 周期中的第 1 个。,0.375,"['1', '2', 'intravenously', 'cycle', 'with', 'obinutuzumab', 'on', 'and']","['1', '2', 'cycle']",3157,"['obinutuzumab 服用了 6 个周期,从 1 天 100 mg 到 2 天 900 mg (或 1 天 1000 mg ), 8 天 1000 mg 到 1 天 1000 mg 到 1 周期 15 日,随后 1 天 2 至 6 周期 1000 mg 。']",0.375,"['1', '2', 'intravenously', 'cycle', 'with', 'obinutuzumab', 'on', 'and']","['1', '2', 'cycle']",,
3202,3158,chlorambucil was administered orally at 0.5 mg per kilogram of body weight on days 1 and 15 of each cycle until completion of 12 cycles .,苯丁酸氮芥在每个周期的第 1 天和第 15 天以每公斤体重 0.5 mg 的剂量口服给药，直至完成 12 个周期。,0.5,"['body weight', '1', 'cycle', 'kilogram', 'completion', 'at', 'each', 'and']","['body weight', '1', 'cycle', 'completion']",3158,"['每周1日至15日,每体重每公斤 0.5 毫克的氯<unk>被口服服用,直到12个周期完成。']",0.5,"['body weight', '1', 'cycle', 'kilogram', 'completion', 'at', 'each', 'and']","['body weight', '1', 'cycle', 'completion']",,
3203,3159,"disease was assessed in all patients at baseline and at similar time points in both treatment groups during the trial , including an assessment of the response to therapy 3 months after the completion of treatment , with complete and partial response defined in accordance with International Workshop on CLL guidelines as of 2008 ( see the Supplementary Appendix ) .12",在试验期间，在两个治疗组的基线和相似时间点对所有患者的疾病进行了评估，包括在治疗完成后 3 个月评估对治疗的反应，根据 CLL 国际研讨会定义的完全和部分反应截至 2008 年的指南（见补充附录）.12,0.375,"['disease', 'appendix', 'defined', 'baseline', 'supplementary', 'time', 'therapy', 'complete', 'assessment', 'treatment', 'response', 'partial', 'after', 'trial', '3', 'completion', 'with', 'CLL', 'all', 'to', 'and', 'assessed', 'similar', 'workshop']","['disease', 'baseline', 'time', 'therapy', 'assessment', 'treatment', 'response', 'after', 'completion']",3159,"['研究期间,所有患者在基线和同等时间点的病情被评估,包括在治疗完成后3个月对治疗的反应的评估,并根据2008年国际CLL指令研讨会定义的完整和部分反应(参见补充附件)。']",0.4166666666666667,"['disease', 'appendix', 'defined', 'baseline', 'supplementary', 'time', 'therapy', 'complete', 'assessment', 'treatment', 'response', 'partial', 'after', 'trial', '3', 'completion', 'with', 'CLL', 'all', 'to', 'and', 'assessed', 'similar', 'workshop']","['disease', 'appendix', 'baseline', 'time', 'therapy', 'assessment', 'treatment', 'response', 'after', 'completion']",,
3204,3160,"after the completion of treatment , patients were followed for progression and safety every 3 months for 2 years , and then every 6 months .",治疗完成后，每 3 个月随访一次患者的进展和安全性，持续 2 年，然后每 6 个月随访一次。,0.75,"['safety', '2', 'treatment', 'progression', 'after', '3', 'completion', 'and']","['safety', '2', 'treatment', 'progression', 'after', 'completion']",3160,"['完成治疗后,患者每3个月进行进展和安全,两年,然后每6个月进行监测。']",0.625,"['safety', '2', 'treatment', 'progression', 'after', '3', 'completion', 'and']","['safety', 'treatment', 'progression', 'after', 'completion']",,
3205,3161,"in patients with a treatment response , minimal residual disease in bone marrow was assessed at cycle 9 and 3 months after completion of treatment .",在治疗有反应的患者中，在第 9 个周期和治疗完成后 3 个月评估骨髓中的微小残留病灶。,0.5714285714285714,"['bone', 'bone marrow', 'disease', 'cycle', 'treatment', 'response', 'after', 'minimal', '3', 'completion', 'residual', 'with', 'and', 'assessed']","['bone', 'bone marrow', 'disease', 'cycle', 'treatment', 'response', 'after', 'completion']",3161,"['在患有治疗反应的患者中,在治疗结束后9个月和3个月的周期中评估了骨髓中最小残留性疾病。']",0.5,"['bone', 'bone marrow', 'disease', 'cycle', 'treatment', 'response', 'after', 'minimal', '3', 'completion', 'residual', 'with', 'and', 'assessed']","['bone', 'bone marrow', 'disease', 'cycle', 'treatment', 'response', 'after']",,
3206,3162,an independent data and safety monitoring committee reviewed safety regularly ( see the Supplementary Appendix ) .,一个独立的数据和安全监测委员会定期审查安全性（见补充附录）。,0.625,"['safety', 'monitoring', 'appendix', 'data', 'supplementary', 'committee', 'independent', 'and']","['safety', 'monitoring', 'data', 'committee', 'independent']",3162,['一个独立的数据和安全监测委员会定期审查安全(参见附件)。'],0.75,"['safety', 'monitoring', 'appendix', 'data', 'supplementary', 'committee', 'independent', 'and']","['safety', 'monitoring', 'appendix', 'data', 'committee', 'independent']",,
3207,3163,an interim analysis was planned to be performed after 110 of 170 events ( 65 % ) had occurred .,计划在 170 起事件中的 110 起 (65%) 发生后进行中期分析。,0.75,"['analysis', 'be', 'after', 'to']","['analysis', 'be', 'after']",3163,['临时分析计划在170起事件(65%)中发生后进行。'],0.75,"['analysis', 'be', 'after', 'to']","['analysis', 'be', 'after']",,
3208,3164,"therefore , the independent data and safety monitoring committee recommended conducting the primary analysis of the primary and secondary end points .",因此，独立数据和安全监测委员会建议对主要和次要终点进行初步分析。,0.5454545454545454,"['safety', 'monitoring', 'data', 'analysis', 'end points', 'primary', 'committee', 'secondary', 'independent', 'therefore', 'and']","['safety', 'monitoring', 'data', 'analysis', 'end points', 'committee']",3164,"['因此,独立的数据和安全监测委员会建议对初级和二级终点进行初级分析。']",0.6363636363636364,"['safety', 'monitoring', 'data', 'analysis', 'end points', 'primary', 'committee', 'secondary', 'independent', 'therefore', 'and']","['safety', 'monitoring', 'data', 'analysis', 'end points', 'committee', 'independent']",,
3209,3165,"in the analysis of minimal residual disease negativity and response to treatment , patients without a sample or response assessment that could be evaluated were counted as not being negative for residual disease or as not having a response , respectively .",在微小残留病阴性和对治疗反应的分析中，没有可评估样本或反应评估的患者分别被计为残留病阴性或无反应。,0.5333333333333333,"['sample', 'disease', 'analysis', 'negative', 'be', 'assessment', 'treatment', 'response', 'minimal', 'being', 'residual', 'that', 'to', 'and', 'without']","['sample', 'disease', 'analysis', 'be', 'assessment', 'treatment', 'response', 'without']",3165,"['在分析最低剩余疾病的负面性和对治疗的反应时,没有样品或应对评估的患者被计算为对剩余疾病不负面或没有应对的患者。']",0.5333333333333333,"['sample', 'disease', 'analysis', 'negative', 'be', 'assessment', 'treatment', 'response', 'minimal', 'being', 'residual', 'that', 'to', 'and', 'without']","['sample', 'disease', 'analysis', 'be', 'assessment', 'treatment', 'response', 'residual']",,
3210,3166,"the demographic and disease characteristics were well balanced between the two treatment groups ( Table 1 , and Table S1 in the Supplementary Appendix ) .",两个治疗组之间的人口统计学和疾病特征得到很好的平衡（表 1 和补充附录中的表 S1）。,0.5,"['disease', 'appendix', 'table', '1', 'supplementary', 'treatment', 'well', 'characteristics', 'S1', 'in', 'and', 'two']","['disease', 'table', '1', 'treatment', 'characteristics', 'two']",3166,['人口和疾病特征在两组治疗之间平衡良好(附件中的表1和表S1)。'],0.5833333333333334,"['disease', 'appendix', 'table', '1', 'supplementary', 'treatment', 'well', 'characteristics', 'S1', 'in', 'and', 'two']","['disease', 'appendix', 'table', '1', 'treatment', 'characteristics', 'two']",,
3211,3167,"the median age of the patients was 72 years ( range , 41 to 89 ) , the median Cumulative Illness Rating Scale score was 8 ( range , 0 to 28 ) ( Table S2 in the Supplementary Appendix ) , and the median creatinine clearance was 66.4 ml per minute ( range , 0.1 to 3670.0 ) .",患者的中位年龄为 72 岁（范围，41 至 89 岁），中位累积疾病评定量表评分为 8（范围，0 至 28 分）（补充附录表 S2），中位肌酐清除率为 66.4 ml每分钟（范围，0.1 至 3670.0）。,0.4210526315789473,"['creatinine', 'median', 'appendix', 'range', 'table', 'scale', 'illness', 'supplementary', 'minute', 'cumulative', 'age', 'clearance', 'score', 'ml', 'rating scale', 'median age', 'S2', 'to', 'and']","['range', 'table', 'scale', 'illness', 'minute', 'age', 'clearance', 'rating scale']",3167,"['患者的平均年龄为72年(范围,41至89年),平均积累性疾病评级分数为8(范围,0至28年)(附件中的S2表),平均创造素清分为每分钟66.4毫升(范围,0.1至3670.0)。']",0.4210526315789473,"['creatinine', 'median', 'appendix', 'range', 'table', 'scale', 'illness', 'supplementary', 'minute', 'cumulative', 'age', 'clearance', 'score', 'ml', 'rating scale', 'median age', 'S2', 'to', 'and']","['appendix', 'range', 'table', 'scale', 'illness', 'minute', 'age', 'score']",,
3212,3168,"altogether , 13.8 % of the patients had TP53 deletion , mutation , or both and 59.8 % had unmutated IGHV .",总共有 13.8% 的患者有 TP53 缺失、突变或两者都有，59.8% 有未突变的 IGHV。,0.75,"['mutation', 'deletion', 'altogether', 'and']","['mutation', 'deletion', 'altogether']",3168,"['总体而言, 13.8% 的患者患有 TP53 删除、突变或两者,而 59.8% 的患者患有未经指示的 IGHV。']",0.5,"['mutation', 'deletion', 'altogether', 'and']","['mutation', 'and']",,
3213,3169,the safety population included 426 patients ( Figure 1 ) .,安全人群包括 426 名患者（图 1）。,0.75,"['safety', 'population', '1', 'figure']","['safety', 'population', '1']",3169,['安全人口包括426名患者(图1)。'],0.75,"['safety', 'population', '1', 'figure']","['safety', 'population', '1']",,
3214,3170,"the median relative dose intensity was 95.1 % ( range , 21 to 100 ) for venetoclax , 95.4 % ( range , 4 to 111 ) for chlorambucil , and 100 % ( range , 0 to 111 ) for obinutuzumab , with dose modifications in 43.3 % , 26.9 % , and 38.3 % of patients , respectively .",维奈托克的中位相对剂量强度为 95.1 %（范围，21 至 100 ），苯丁酸氮芥为 95.4 %（范围，4 至 111 ），奥比妥珠单抗为 100 %（范围，0 至 111 ），剂量调整为 43.3 % ，分别为 26.9% 和 38.3% 的患者。,0.2,"['median', 'range', 'relative', 'intensity', '4', 'with', 'obinutuzumab', 'dose', 'to', 'and']","['range', 'dose']",3170,"['平均相对剂量强度为95.1 %(范围,21至100)为 venetoclax,95.4 %(范围,4至111)为chlorambucil,100 %(范围,0至111)为obinutuzumab,剂量变化为43.3 %、26.9 %和38.3 %的患者。']",0.2,"['median', 'range', 'relative', 'intensity', '4', 'with', 'obinutuzumab', 'dose', 'to', 'and']","['range', 'dose']",,
3215,3171,the results for all key secondary end points in accordance with the hierarchical testing procedure are summarized in Table S5 in the Supplementary Appendix .,根据分层测试程序，所有关键次要终点的结果总结在补充附录的表 S5 中。,0.4,"['procedure', 'key', 'appendix', 'table', 'supplementary', 'end points', 'secondary', 'testing procedure', 'with', 'all']","['procedure', 'key', 'table', 'end points']",3171,"['根据序列测试程序,所有关键二级终点的结果在附件S5表中总结。']",0.5,"['procedure', 'key', 'appendix', 'table', 'supplementary', 'end points', 'secondary', 'testing procedure', 'with', 'all']","['procedure', 'key', 'appendix', 'table', 'end points']",,
3216,3172,the most common grade 3 or 4 adverse event was neutropenia ( Table 2 ) .,最常见的 3 级或 4 级不良事件是中性粒细胞减少症（表 2）。,0.4444444444444444,"['table', '2', 'grade', 'neutropenia', 'common', 'adverse', 'adverse event', '3', '4']","['table', '2', 'neutropenia', 'adverse event']",3172,['最常见的3级或4级不良事件是中风(图2)。'],0.2222222222222222,"['table', '2', 'grade', 'neutropenia', 'common', 'adverse', 'adverse event', '3', '4']","['2', 'adverse event']",,
3217,3173,"none of these events met the Howard criteria for clinical tumor lysis syndrome ( i.e. , the presence of specific electrolyte changes and clinical manifestations ; see the Supplementary Appendix ) .19",这些事件均不符合临床肿瘤溶解综合征的霍华德标准（即存在特定的电解质变化和临床表现；见补充附录）19,0.5454545454545454,"['lysis', 'presence', 'appendix', 'electrolyte', 'syndrome', 'tumor', 'supplementary', 'clinical', 'specific', 'met', 'and']","['lysis', 'presence', 'electrolyte', 'syndrome', 'tumor', 'clinical']",3173,['这些事件中没有一个符合霍华德临床肿瘤利西斯综合征的标准(即特定电解质变化和临床表现的存在;参见附件)。'],0.5454545454545454,"['lysis', 'presence', 'appendix', 'electrolyte', 'syndrome', 'tumor', 'supplementary', 'clinical', 'specific', 'met', 'and']","['presence', 'appendix', 'electrolyte', 'syndrome', 'tumor', 'clinical']",,
3218,3174,a summary of the serious adverse events is provided in Table S7 in the Supplementary Appendix .,补充附录表 S7 中提供了严重不良事件的总结。,0.1428571428571428,"['a', 'appendix', 'table', 'supplementary', 'adverse', 'serious', 'in']",['table'],3174,['对严重不良事件的概述在附件S7表中提供。'],0.2857142857142857,"['a', 'appendix', 'table', 'supplementary', 'adverse', 'serious', 'in']","['appendix', 'table']",,
3219,3175,"with a median age of 72 years and a median Cumulative Illness Rating Scale score of 8 , the trial population was representative of most patients with CLL.20",中位年龄为 72 岁，中位累积疾病评定量表得分为 8，试验人群代表了大多数 CLL 患者。 20,0.4166666666666667,"['population', 'median', 'scale', 'illness', 'cumulative', 'age', 'trial', 'score', 'with', 'rating scale', 'median age', 'and']","['population', 'scale', 'illness', 'age', 'rating scale']",3175,"['平均年龄为72岁,平均累积疾病评级分数为8分,试验人口代表了大多数患有CLL的患者。']",0.4166666666666667,"['population', 'median', 'scale', 'illness', 'cumulative', 'age', 'trial', 'score', 'with', 'rating scale', 'median age', 'and']","['population', 'scale', 'illness', 'age', 'score']",,
3220,3176,"however , these percentages were observed in smaller numbers of patients and in patients with fewer coexisting conditions .",然而，这些百分比是在少数患者和合并症较少的患者中观察到的。,0.3333333333333333,"['with', 'in', 'and']",['and'],3176,"['然而,这些百分比在较少的患者和较少的共同存在条件的患者中被观察到。']",0.3333333333333333,"['with', 'in', 'and']",['and'],,
3221,3177,the safety profile of both treatments in this trial showed no new safety signals or higher incidences of known toxic effects .,该试验中两种治疗的安全性概况均未显示出新的安全信号或已知毒性作用的发生率更高。,0.25,"['safety', 'toxic', 'no', 'trial', 'profile', 'this', 'in', 'new']","['safety', 'new']",3177,"['在这项试验中,两种治疗的安全规格没有显示新的安全信号或已知毒性影响的更高的发病率。']",0.25,"['safety', 'toxic', 'no', 'trial', 'profile', 'this', 'in', 'new']","['safety', 'new']",,
3222,3178,"the toxic effects in the two treatment groups were similar in severity , and significant differences were detected only in the incidence of metabolism disorders and gastrointestinal disorders .",两个治疗组的毒性反应严重程度相似，仅在代谢紊乱和胃肠道紊乱的发生率上有显着差异。,0.5555555555555556,"['metabolism', 'incidence', 'toxic', 'gastrointestinal', 'treatment', 'disorders', 'and', 'two', 'similar']","['metabolism', 'incidence', 'gastrointestinal', 'treatment', 'two']",3178,"['两组治疗的毒性影响在严重程度上是相似的,只有在代谢障碍和肠道障碍的发病率上才发现显著差异。']",0.6666666666666666,"['metabolism', 'incidence', 'toxic', 'gastrointestinal', 'treatment', 'disorders', 'and', 'two', 'similar']","['metabolism', 'incidence', 'treatment', 'disorders', 'two', 'similar']",,
3223,3179,"although the difference did not reach significance , it bears monitoring going forward ; the overall percentage of patients with fatal adverse events was similar to those in the CLL11 trial ( 4 to 9 % ) .3",差异虽未达到显着性，但值得进一步观察；发生致命不良事件的患者的总体百分比与 CLL11 试验中的相似（4% 至 9%）.3,0.0833333333333333,"['monitoring', 'percentage', 'difference', 'adverse', 'fatal', 'significance', 'forward', 'trial', '4', 'with', 'reach', 'similar']",['difference'],3179,"['雖然差異沒有達到意義,但它帶來監視進步;患有致命副作用的患者的總百分比與CLL11試驗(4至9%)相似。']",0.0,"['monitoring', 'percentage', 'difference', 'adverse', 'fatal', 'significance', 'forward', 'trial', '4', 'with', 'reach', 'similar']",[],,
3224,3180,"we observationally followed enrolled participants ( complete cohort ) after the conclusion of the original clinical trial by using central databases to identify cardiovascular events , hospitalizations , and deaths .",在最初的临床试验结束后，我们通过使用中央数据库来识别心血管事件、住院和死亡，对登记的参与者（完整队列）进行了观察性跟踪。,0.3076923076923077,"['clinical trial', 'cardiovascular', 'complete', 'central', 'after', 'original', 'identify', 'conclusion', 'cohort', 'by', 'to', 'and', 'we']","['clinical trial', 'cardiovascular', 'after', 'identify']",3180,"['在完成原始临床试验后,我们观察地跟踪了注册的参与者(完整的组合),使用中央数据库来识别心血管事件、入院和死亡。']",0.3846153846153846,"['clinical trial', 'cardiovascular', 'complete', 'central', 'after', 'original', 'identify', 'conclusion', 'cohort', 'by', 'to', 'and', 'we']","['clinical trial', 'cardiovascular', 'complete', 'after', 'identify']",,
3225,3181,participants were asked whether they would be willing to provide additional data by means of surveys and chart reviews ( survey cohort ) .,参与者被问及他们是否愿意通过调查和图表审查（调查队列）的方式提供额外的数据。,0.4,"['chart', 'data', 'be', 'survey', 'additional', 'means', 'cohort', 'by', 'to', 'and']","['chart', 'data', 'survey', 'additional']",3181,['参与者被问及他们是否愿意通过调查和图表评论(调查组)提供额外的数据。'],0.4,"['chart', 'data', 'be', 'survey', 'additional', 'means', 'cohort', 'by', 'to', 'and']","['chart', 'data', 'survey', 'additional']",,
3226,3182,"the prespecified primary outcome was a composite of major cardiovascular events , including nonfatal myocardial infarction , nonfatal stroke , new or worsening congestive heart failure , amputation for ischemic gangrene , and death from cardiovascular causes .",预设的主要结局是主要心血管事件的复合，包括非致死性心肌梗死、非致死性中风、新发或恶化的充血性心力衰竭、因缺血性坏疽截肢以及心血管原因死亡。,0.6111111111111112,"['heart', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'gangrene', 'failure', 'outcome', 'death', 'amputation', 'major', 'heart failure', 'primary', 'congestive', 'congestive heart failure', 'and', 'new', 'ischemic']","['heart', 'myocardial infarction', 'cardiovascular', 'stroke', 'gangrene', 'failure', 'death', 'amputation', 'heart failure', 'congestive heart failure', 'new']",3182,"['预定的初始结果是主要心血管事件的组合,包括非致命心脏病发作、非致命心脏病发作、新或恶化凝固心脏衰竭、催化性<unk>疹的折磨和心血管原因导致的死亡。']",0.3888888888888889,"['heart', 'myocardial infarction', 'composite', 'cardiovascular', 'stroke', 'gangrene', 'failure', 'outcome', 'death', 'amputation', 'major', 'heart failure', 'primary', 'congestive', 'congestive heart failure', 'and', 'new', 'ischemic']","['heart', 'cardiovascular', 'stroke', 'failure', 'outcome', 'death', 'new']",,
3227,3183,death from any cause was a prespecified secondary outcome .,全因死亡是预先指定的次要结局。,0.2,"['a', 'outcome', 'death', 'cause', 'secondary']",['death'],3183,['任何原因的死亡都是预定的次要结果。'],0.6,"['a', 'outcome', 'death', 'cause', 'secondary']","['outcome', 'death', 'cause']",,
3228,3184,there were 1655 participants in the complete cohort and 1391 in the survey cohort .,完整队列中有 1655 名参与者，调查队列中有 1391 名参与者。,0.2,"['complete', 'survey', 'cohort', 'in', 'and']",['survey'],3184,['共有1655名参与者参加了全集和1391名参与了调查集。'],0.2,"['complete', 'survey', 'cohort', 'in', 'and']",['survey'],,
3229,3185,"the risk of major cardiovascular disease outcomes was reduced , however , during an extended interval of separation of the glycated hemoglobin curves ( hazard ratio , 0.83 ; 95 % CI , 0.70 to 0.99 ) , but this benefit did not continue after equalization of the glycated hemoglobin levels ( hazard ratio , 1.26 ; 95 % CI , 0.90 to 1.75 ) .",然而，在糖化血红蛋白曲线分离的延长间隔期间，主要心血管疾病结局的风险降低（风险比，0.83 ； 95 % CI，0.70 至 0.99 ） ，但在糖化血红蛋白均衡后，这种益处并未持续水平（风险比，1.26；95% CI，0.90 至 1.75）。,0.7222222222222222,"['disease', 'cardiovascular', 'interval', 'ratio', 'hazard ratio', 'hemoglobin', 'equalization', 'major', 'separation', 'cardiovascular disease', 'risk', 'after', 'benefit', 'CI', 'continue', 'this', 'but', 'to']","['disease', 'cardiovascular', 'interval', 'ratio', 'hazard ratio', 'hemoglobin', 'equalization', 'separation', 'cardiovascular disease', 'risk', 'after', 'continue', 'but']",3185,"['然而,主要心血管疾病结果的风险在加糖血球曲线分离的延长间隔(危险比例,0.83;95% CI,0.70至0.99),但这种好处在加糖血球水平平衡后没有继续(危险比例,1.26;95% CI,0.90至1.75)。']",0.5555555555555556,"['disease', 'cardiovascular', 'interval', 'ratio', 'hazard ratio', 'hemoglobin', 'equalization', 'major', 'separation', 'cardiovascular disease', 'risk', 'after', 'benefit', 'CI', 'continue', 'this', 'but', 'to']","['disease', 'cardiovascular', 'interval', 'ratio', 'separation', 'cardiovascular disease', 'risk', 'after', 'continue', 'but']",,
3230,3186,participants with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had a lower risk of cardiovascular events than those who received standard therapy only during the prolonged period in which the glycated hemoglobin curves were separated .,被随机分配到强化血糖控制组 5.6 年的 2 型糖尿病参与者发生心血管事件的风险低于仅在糖化血红蛋白曲线分离的长时间内接受标准治疗的参与者。,0.5882352941176471,"['diabetes', 'type', 'standard', 'period', 'glucose', 'control', 'cardiovascular', 'who', '2', 'hemoglobin', 'lower', 'therapy', 'intensive', 'risk', 'with', 'prolonged', 'to']","['diabetes', 'type', 'standard', 'control', 'cardiovascular', '2', 'hemoglobin', 'therapy', 'risk', 'to']",3186,"['患有2型糖尿病的参与者,随机被分配到强烈的葡萄糖控制5年6年,患心血管事件的风险低于接受标准治疗的患者,仅在加糖血糖曲线分离的延长期间。']",0.6470588235294118,"['diabetes', 'type', 'standard', 'period', 'glucose', 'control', 'cardiovascular', 'who', '2', 'hemoglobin', 'lower', 'therapy', 'intensive', 'risk', 'with', 'prolonged', 'to']","['diabetes', 'type', 'standard', 'period', 'glucose', 'control', 'cardiovascular', '2', 'therapy', 'risk', 'to']",,
3231,3187,"there was no evidence of a legacy effect or a mortality benefit with intensive glucose control . ( Funded by the VA Cooperative Studies Program ; VADT ClinicalTrials.gov number , NCT00032487 . )",没有证据表明强化血糖控制会产生遗留效应或降低死亡率。 （由 VA 合作研究计划资助；VADT ClinicalTrials.gov 编号，NCT00032487。）,0.5,"['a', 'glucose', 'control', 'cooperative', 'program', 'mortality', 'no', 'intensive', 'number', 'effect', 'evidence', 'benefit', 'with', 'by']","['control', 'program', 'mortality', 'number', 'effect', 'evidence', 'by']",3187,"['没有证据表明有遗传效应或有强烈糖控制的死亡效应(由VA合作研究计划资助;VADT ClinicalTrials.gov号,NCT00032487 )。']",0.4285714285714285,"['a', 'glucose', 'control', 'cooperative', 'program', 'mortality', 'no', 'intensive', 'number', 'effect', 'evidence', 'benefit', 'with', 'by']","['control', 'program', 'number', 'effect', 'evidence', 'by']",,
3232,3188,"in brief , the original trial included 1791 military veterans with type 2 diabetes who were randomly assigned to receive either intensive or standard glucose control .",简而言之，最初的试验包括 1791 名患有 2 型糖尿病的退伍军人，他们被随机分配接受强化或标准血糖控制。,0.4615384615384615,"['diabetes', 'type', 'standard', 'glucose', 'control', 'who', '2', 'military', 'intensive', 'trial', 'original', 'with', 'to']","['diabetes', 'type', 'standard', 'control', '2', 'military']",3188,"['简而言之,最初的试验包括1791名患有2型糖尿病的军事退伍军人,他们随机被任命接受强度或标准糖尿病控制。']",0.4615384615384615,"['diabetes', 'type', 'standard', 'glucose', 'control', 'who', '2', 'military', 'intensive', 'trial', 'original', 'with', 'to']","['diabetes', 'type', 'standard', 'control', '2', 'military']",,
3233,3189,"detailed descriptions of these cohorts and assessments , as previously reported , 13,16 are provided in Methods Sections A through I in the Supplementary Appendix ( available with the full text of this article at NEJM.org ) .","这些队列和评估的详细描述，如先前报道，13,16 在补充附录的方法部分 A 至 I 中提供（与本文全文可在 NEJM.org 获取）。",0.0666666666666666,"['appendix', 'article', 'supplementary', 'available', 'text', 'A', 'cohorts', 'as', 'with', 'at', 'full', 'I', 'this', 'in', 'and']",['as'],3189,"['这些协调和评估的详细描述,如上所述,1316在补充附件中提供的方法 A 通过 I 部分(可在 NEJM.org 找到本文的完整文本)。']",0.2,"['appendix', 'article', 'supplementary', 'available', 'text', 'A', 'cohorts', 'as', 'with', 'at', 'full', 'I', 'this', 'in', 'and']","['appendix', 'as', 'full']",,
3234,3190,two authors who are statisticians vouch for the completeness and accuracy of the data and analyses .,两位统计学家作者保证数据和分析的完整性和准确性。,0.6666666666666666,"['data', 'who', 'accuracy', 'completeness', 'and', 'two']","['data', 'accuracy', 'completeness', 'two']",3190,"['两位作家是统计学家,对数据和分析的完整性和准确性表示赞扬。']",0.6666666666666666,"['data', 'who', 'accuracy', 'completeness', 'and', 'two']","['data', 'accuracy', 'completeness', 'two']",,
3235,3191,the authors vouch for the fidelity of the study to the protocol ( available at NEJM.org ) .,作者保证该研究忠实于方案（可在 NEJM.org 获取）。,0.2,"['fidelity', 'protocol', 'study', 'available', 'at']",['at'],3191,['作者对研究对议定书的忠诚度(可在NEJM.org上找到)。'],0.2,"['fidelity', 'protocol', 'study', 'available', 'at']",['protocol'],,
3236,3192,"the first author wrote the manuscript , with all the coauthors approving the final version for submission .",第一作者撰写了手稿，所有合著者都同意提交最终版本。,0.4285714285714285,"['author', 'version', 'manuscript', 'submission', 'with', 'all', 'first']","['version', 'manuscript', 'first']",3192,"['第一位作者写了手稿,所有共同作者都批准了最终版本。']",0.4285714285714285,"['author', 'version', 'manuscript', 'submission', 'with', 'all', 'first']","['version', 'manuscript', 'first']",,
3237,3193,the statistical analysis plan was prespecified by the lead investigators before data access or knowledge of results .,统计分析计划由主要研究人员在访问数据或了解结果之前预先确定。,0.625,"['lead', 'data', 'analysis', 'knowledge', 'access', 'statistical analysis', 'before', 'by']","['data', 'analysis', 'statistical analysis', 'before', 'by']",3193,['统计分析计划在数据访问或结果的知识之前由主要调查人员预定。'],0.75,"['lead', 'data', 'analysis', 'knowledge', 'access', 'statistical analysis', 'before', 'by']","['data', 'analysis', 'knowledge', 'statistical analysis', 'before', 'by']",,
3238,3194,the protocol was approved by the Hines and Ann Arbor Veterans Affairs ( VA ) health system institutional review boards and was reviewed annually by a data and safety monitoring committee .,该协议得到海因斯和安阿伯退伍军人事务部 (VA) 卫生系统机构审查委员会的批准，并每年由数据和安全监督委员会审查。,0.7272727272727273,"['safety', 'monitoring', 'arbor', 'data', 'system', 'review', 'protocol', 'health', 'committee', 'by', 'and']","['safety', 'data', 'system', 'review', 'protocol', 'health', 'committee', 'by']",3194,"['该议定书由Hines和Ann Arbor Veterans Affairs(VA)卫生系统机构审查委员会批准,由数据和安全监测委员会每年审查。']",0.8181818181818182,"['safety', 'monitoring', 'arbor', 'data', 'system', 'review', 'protocol', 'health', 'committee', 'by', 'and']","['safety', 'monitoring', 'data', 'system', 'review', 'protocol', 'health', 'committee', 'by']",,
3239,3195,"as previously described , 16 four national data registries - the central VA medical files , the Centers for Medicare and Medicaid Services ( CMS ) claims files , the VA death files , and the National Death Index ( NDI ) - were used to collect data and information about outcomes .",如前所述，16 四个国家数据登记处——中央 VA 医疗档案、医疗保险和医疗补助服务中心 ( CMS ) 索赔档案、 VA 死亡档案和国家死亡指数 ( NDI ) - 被用来收集数据和信息。关于结果。,0.5454545454545454,"['data', 'centers for medicare and medicaid services', 'death', 'index', 'medical', 'information', 'central', 'as', 'NDI', '-', 'to']","['data', 'death', 'index', 'information', 'as', 'to']",3195,"['如上所述,16个国家数据记录 - 中央VA医疗文件、医疗和医疗服务中心(CMS)声明文件、VA死亡文件和国家死亡指数(NDI) - 被用来收集数据和结果信息。']",0.4545454545454545,"['data', 'centers for medicare and medicaid services', 'death', 'index', 'medical', 'information', 'central', 'as', 'NDI', '-', 'to']","['data', 'death', 'index', 'information', 'as']",,
3240,3196,medical records were reviewed and adjudicated as previously described16 ( see the Methods Sections and Table S1 in the Supplementary Appendix ) for participants younger than 65 years of age ( CMS ineligible ) reporting an event outside the VA system .,对于 65 岁以下（不符合 CMS 资格）报告 VA 系统外事件的参与者，如前所述16（见补充附录中的方法部分和表 S1）审查和裁定医疗记录。,0.25,"['appendix', 'table', 'system', 'medical', 'supplementary', 'outside', 'age', 'as', 'event', 'S1', 'in', 'and']","['table', 'system', 'as']",3196,['医学记录被审查并按前所述提交(参见补充附件中的方法部分和表 S1 )为65岁以下的参与者(CMS不适用)报告VA系统以外的事件。'],0.25,"['appendix', 'table', 'system', 'medical', 'supplementary', 'outside', 'age', 'as', 'event', 'S1', 'in', 'and']","['appendix', 'table', 'system']",,
3241,3197,"models examined the effect of treatment group ( intensive therapy or standard therapy ) on the primary outcome in an unadjusted analysis ( model 1 ) or while accounting for baseline , most recent , or cumulative mean glycated hemoglobin level ( models 2 , 3 , and 4 , respectively ) .",模型检查治疗组（强化治疗或标准治疗）对未经调整的分析（模型 1 ）中的主要结果的影响，或在考虑基线、最近或累积平均糖化血红蛋白水平时（模型 2 、 3 和 4 ，分别 ） 。,0.5652173913043478,"['group', 'standard', 'mean', 'model', 'analysis', 'baseline', '1', '2', 'recent', 'outcome', 'hemoglobin', 'therapy', 'hemoglobin level', 'cumulative', 'treatment', 'primary', 'intensive', 'effect', '3', '4', 'unadjusted', 'treatment group', 'on']","['group', 'standard', 'mean', 'model', 'analysis', 'baseline', '1', '2', 'outcome', 'hemoglobin', 'therapy', 'treatment', 'treatment group']",3197,"['模型研究了治疗组(强度治疗或标准治疗)对不调整分析(模型1)的初始结果的影响,或者考虑到基层,最新的或累积的血糖血糖水平(模型2、3、4、相应)。']",0.4782608695652174,"['group', 'standard', 'mean', 'model', 'analysis', 'baseline', '1', '2', 'recent', 'outcome', 'hemoglobin', 'therapy', 'hemoglobin level', 'cumulative', 'treatment', 'primary', 'intensive', 'effect', '3', '4', 'unadjusted', 'treatment group', 'on']","['group', 'standard', 'model', 'analysis', '1', '2', 'outcome', 'therapy', 'cumulative', 'treatment', 'treatment group']",,
3242,3198,the last observation of the glycated hemoglobin level was carried forward in these analyses owing to slow changes in glycated hemoglobin values over time and the low frequency of missing data .,由于糖化血红蛋白值随时间变化缓慢且缺失数据的频率较低，因此在这些分析中延续了对糖化血红蛋白水平的最后一次观察。,0.5384615384615384,"['frequency', 'data', 'hemoglobin', 'low frequency', 'time', 'hemoglobin level', 'forward', 'values', 'observation', 'over', 'to', 'and', 'missing']","['frequency', 'data', 'hemoglobin', 'time', 'observation', 'to', 'missing']",3198,"['在这些分析中,Glycated Hemoglobin 水平的最后观测是由于随着时间的推移,Glycated Hemoglobin 值的缓慢变化以及缺乏数据的低频率而进行的。']",0.6153846153846154,"['frequency', 'data', 'hemoglobin', 'low frequency', 'time', 'hemoglobin level', 'forward', 'values', 'observation', 'over', 'to', 'and', 'missing']","['frequency', 'data', 'low frequency', 'time', 'observation', 'to', 'and', 'missing']",,
3243,3199,"proportionality assumptions held for 10 years but not thereafter , but relaxing the assumptions did not substantially affect any results .",比例假设保持 10 年但此后不再保持，但放宽假设不会对任何结果产生实质性影响。,1.0,"['affect', 'proportionality', 'but']","['affect', 'proportionality', 'but']",3199,"['比例性假设持续了10年,但不随后,但放松假设没有显著影响任何结果。']",1.0,"['affect', 'proportionality', 'but']","['affect', 'proportionality', 'but']",,
3244,3200,"we estimated that data collection in the larger , complete cohort missed less than 6 % of the outcomes owing to delays in the availability of CMS and NDI data ( see Methods Section B in the Supplementary Appendix ) .",我们估计，由于 CMS 和 NDI 数据的可用性延迟，更大的完整队列中的数据收集遗漏了不到 6% 的结果（参见补充附录中的方法部分 B）。,0.25,"['appendix', 'data', 'section', 'collection', 'B', 'supplementary', 'complete', 'availability', 'data collection', 'cohort', 'NDI', 'that', 'in', 'to', 'and', 'we']","['data', 'collection', 'data collection', 'to']",3200,"['我们估计数据收集在更大、完整的集合中失去了不到6%的结果,因为CMS和NDI数据的可用性延迟(参见补充附件中的方法B部分)。']",0.3125,"['appendix', 'data', 'section', 'collection', 'B', 'supplementary', 'complete', 'availability', 'data collection', 'cohort', 'NDI', 'that', 'in', 'to', 'and', 'we']","['appendix', 'data', 'collection', 'complete', 'data collection']",,
3245,3201,characteristics OF THE PARTICIPANTS AT BASELINE,基线参与者的特征,1.0,['characteristics'],['characteristics'],3201,['巴塞罗那参与者的特点'],0.0,['characteristics'],[],,
3246,3202,"according to the baseline characteristics , most of the participants were men , were overweight or obese , and had a mean duration of diabetes of approximately 12 years ( Table 1 ) .",根据基线特征，大多数参与者为男性，超重或肥胖，糖尿病平均病程约为 12 年（表 1）。,0.5833333333333334,"['diabetes', 'mean', 'table', 'baseline', '1', 'obese', 'characteristics', 'duration', 'overweight', 'approximately', 'to', 'and']","['diabetes', 'mean', 'table', 'baseline', '1', 'characteristics', 'overweight']",3202,"['根据基因特征,大多数参与者是男性,体重过重或肥胖,糖尿病的平均持续时间约为12年(图1)。']",0.5,"['diabetes', 'mean', 'table', 'baseline', '1', 'obese', 'characteristics', 'duration', 'overweight', 'approximately', 'to', 'and']","['diabetes', 'mean', '1', 'characteristics', 'duration', 'overweight']",,
3247,3203,no meaningful differences were observed between the baseline characteristics of the complete and survey cohorts or between the treatment groups ( Table S2 in the Supplementary Appendix ) .,在完整队列和调查队列或治疗组之间的基线特征之间未观察到有意义的差异（补充附录表 S2）。,0.4615384615384615,"['appendix', 'table', 'baseline', 'supplementary', 'complete', 'survey', 'treatment', 'no', 'characteristics', 'cohorts', 'meaningful', 'S2', 'and']","['table', 'baseline', 'survey', 'treatment', 'characteristics', 'meaningful']",3203,['没有观察到完整和调查组的基本特征或治疗组之间的有意义差异(附件中的S2表)。'],0.3846153846153846,"['appendix', 'table', 'baseline', 'supplementary', 'complete', 'survey', 'treatment', 'no', 'characteristics', 'cohorts', 'meaningful', 'S2', 'and']","['appendix', 'table', 'survey', 'treatment', 'characteristics']",,
3248,3204,"the separation of the glycated hemoglobin curves gradually diminished to 0.2 to 0.3 % in the 3 years after trial completion , and the glycated hemoglobin levels subsequently stabilized at a median of approximately 8 % in both groups .",糖化血红蛋白曲线的分离在试验完成后的 3 年内逐渐减小至 0.2 至 0.3%，随后两组的糖化血红蛋白水平稳定在约 8% 的中位数。,0.4,"['median', 'hemoglobin', 'separation', 'after', 'trial', '3', 'completion', 'approximately', 'to', 'and']","['hemoglobin', 'separation', 'after', 'completion']",3204,"['在测试完成后3年间,血糖化血糖曲线的分离逐渐下降到0.2 至 0.3%,血糖化血糖水平随后稳定到两组中平均约8%。']",0.3,"['median', 'hemoglobin', 'separation', 'after', 'trial', '3', 'completion', 'approximately', 'to', 'and']","['separation', 'after', 'completion']",,
3249,3205,results for the individual components of the above composite outcomes are provided in Tables S7 through S9 in the Supplementary Appendix .,补充附录表 S7 至表 S9 中提供了上述综合结局的各个组成部分的结果。,0.0,"['composite', 'appendix', 'individual', 'supplementary']",[],3205,['上述合成结果的个体组件的结果在附件中的表 S7 至 S9 中提供。'],0.5,"['composite', 'appendix', 'individual', 'supplementary']","['appendix', 'individual']",,
3250,3206,"to examine the robustness of these findings , we repeated analyses for the primary outcome using the larger , complete cohort and found similar results ( hazard ratio , 0.95 ; 95 % CI , 0.83 to 1.09 ) .",为了检查这些发现的稳健性，我们使用更大的完整队列对主要结果进行了重复分析，并发现了相似的结果（风险比，0.95；95% CI，0.83 至 1.09）。,0.3571428571428571,"['ratio', 'hazard ratio', 'outcome', 'complete', 'primary', 'cohort', 'CI', 'robustness', 'repeated', 'to', 'and', 'examine', 'similar', 'we']","['ratio', 'hazard ratio', 'outcome', 'robustness', 'similar']",3206,"['为了检查这些发现的强度,我们重复了使用更大的,完整的组合的初始结果的分析,并发现了类似的结果(风险比例,0.95;95% CI,0.83到1.09)。']",0.2857142857142857,"['ratio', 'hazard ratio', 'outcome', 'complete', 'primary', 'cohort', 'CI', 'robustness', 'repeated', 'to', 'and', 'examine', 'similar', 'we']","['ratio', 'hazard ratio', 'outcome', 'complete']",,
3251,3207,"we found no evidence that treatment effects varied across our three prespecified risk factors of duration of diabetes , history of cardiovascular disease , or cardiovascular disease risk ( Table S10 in the Supplementary Appendix ) .",我们没有发现任何证据表明治疗效果因糖尿病持续时间、心血管疾病史或心血管疾病风险这三个预先指定的风险因素而异（补充附录表 S10）。,0.45,"['diabetes', 'disease', 'cardiovascular', 'appendix', 'table', 'supplementary', 'history', 'cardiovascular disease', 'treatment', 'no', 'across', 'risk', 'evidence', 'duration', 'S10', 'three', 'that', 'in', 'varied', 'we']","['diabetes', 'disease', 'cardiovascular', 'table', 'cardiovascular disease', 'treatment', 'risk', 'evidence', 'duration']",3207,"['我们没有发现任何证据表明治疗效果在我们三个预定风险因素的持续时间糖尿病,心血管疾病的历史,或心血管疾病的风险(附件中的S10表)。']",0.55,"['diabetes', 'disease', 'cardiovascular', 'appendix', 'table', 'supplementary', 'history', 'cardiovascular disease', 'treatment', 'no', 'across', 'risk', 'evidence', 'duration', 'S10', 'three', 'that', 'in', 'varied', 'we']","['diabetes', 'disease', 'cardiovascular', 'appendix', 'table', 'history', 'cardiovascular disease', 'treatment', 'risk', 'evidence', 'duration']",,
3252,3208,glucose CONTROL AS A MEDIATOR OF RISK AND A LEGACY EFFECT,血糖控制作为风险和遗留效应的中介,0.0,"['glucose', 'A', 'AS']",[],3208,['葡萄糖控制作为风险调节器和传奇效应'],0.3333333333333333,"['glucose', 'A', 'AS']",['glucose'],,
3253,3209,we first compared the event rates of major outcomes during and after the VADT ( Table S12 in the Supplementary Appendix ) .,我们首先比较了 VADT 期间和之后主要结局的事件发生率（补充附录表 S12）。,0.3,"['appendix', 'table', 'supplementary', 'major', 'after', 'event', 'in', 'and', 'first', 'we']","['table', 'after', 'first']",3209,['我们首先比较了VADT期间和之后的主要结果的事件率(附件中的S12表)。'],0.5,"['appendix', 'table', 'supplementary', 'major', 'after', 'event', 'in', 'and', 'first', 'we']","['appendix', 'table', 'after', 'event', 'first']",,
3254,3210,we then evaluated the treatment effect in the period before and after glycemic control nearly equalized in the two groups .,然后我们评估了两组血糖控制接近均衡前后的治疗效果。,0.6363636363636364,"['period', 'control', 'treatment', 'after', 'effect', 'treatment effect', 'before', 'in', 'and', 'two', 'we']","['control', 'treatment', 'after', 'effect', 'treatment effect', 'before', 'two']",3210,"['然后,我们评估了在前和后期间的治疗效果,在两组中报告的血糖控制相当。']",0.8181818181818182,"['period', 'control', 'treatment', 'after', 'effect', 'treatment effect', 'before', 'in', 'and', 'two', 'we']","['period', 'control', 'treatment', 'after', 'effect', 'treatment effect', 'before', 'in', 'two']",,
3255,3211,"in a sensitivity analysis that used the larger , complete cohort , similar results were seen .",在使用更大的完整队列的敏感性分析中，我们看到了类似的结果。,0.125,"['a', 'analysis', 'complete', 'cohort', 'sensitivity', 'that', 'in', 'similar']",['analysis'],3211,"['在使用更大、完整的集合的敏感性分析中,相似的结果被观察到。']",0.375,"['a', 'analysis', 'complete', 'cohort', 'sensitivity', 'that', 'in', 'similar']","['analysis', 'complete', 'similar']",,
3256,3212,this finding highlighted the importance of overall differences in glucose control between groups in mediating this outcome .,这一发现强调了各组之间血糖控制总体差异在调节这一结果中的重要性。,0.4,"['glucose', 'control', 'outcome', 'this', 'in']","['control', 'outcome']",3212,"['这一发现强调了在调解这一结果时,群体之间的葡萄糖控制中的总体差异的重要性。']",0.6,"['glucose', 'control', 'outcome', 'this', 'in']","['glucose', 'control', 'outcome']",,
3257,3213,these results did not vary according to baseline cardiovascular disease risk .,这些结果不会因基线心血管疾病风险而有所不同。,0.8333333333333334,"['disease', 'cardiovascular', 'baseline', 'cardiovascular disease', 'risk', 'to']","['disease', 'cardiovascular', 'baseline', 'cardiovascular disease', 'risk']",3213,['这些结果不因基因心血管疾病风险而有所不同。'],0.6666666666666666,"['disease', 'cardiovascular', 'baseline', 'cardiovascular disease', 'risk', 'to']","['disease', 'cardiovascular', 'cardiovascular disease', 'risk']",,
3258,3214,"in contrast , there was no continued benefit with regard to the risk of cardiovascular disease after glycated hemoglobin levels equalized in the treatment groups .",相比之下，在糖化血红蛋白水平在治疗组中保持平衡后，心血管疾病风险方面没有持续获益。,0.5833333333333334,"['disease', 'cardiovascular', 'contrast', 'hemoglobin', 'cardiovascular disease', 'treatment', 'no', 'risk', 'after', 'benefit', 'with', 'to']","['disease', 'cardiovascular', 'hemoglobin', 'cardiovascular disease', 'treatment', 'risk', 'after']",3214,"['相比之下,在治疗群体中平等的血糖血糖水平后,心血管疾病的风险没有持续的好处。']",0.5,"['disease', 'cardiovascular', 'contrast', 'hemoglobin', 'cardiovascular disease', 'treatment', 'no', 'risk', 'after', 'benefit', 'with', 'to']","['disease', 'cardiovascular', 'cardiovascular disease', 'treatment', 'risk', 'after']",,
3259,3215,"in fact , there was a decline in benefit with regard to the risk of cardiovascular disease that coincided with equalization of glucose control within treatment groups and this continued during the 5 ( or more ) years of equal glycemic control that followed .",事实上，在心血管疾病风险方面的获益下降与治疗组内血糖控制的均衡同时发生，并且在随后的 5 年（或更长时间）血糖控制均等期间持续存在。,0.5625,"['5', 'decline', 'disease', 'glucose', 'control', 'cardiovascular', 'equalization', 'cardiovascular disease', 'treatment', 'risk', 'benefit', 'with', 'this', 'that', 'to', 'and']","['5', 'decline', 'disease', 'control', 'cardiovascular', 'equalization', 'cardiovascular disease', 'treatment', 'risk']",3215,"['事实上,对心血管疾病风险的利润下降,与治疗组内的葡萄糖控制的平衡相匹配,这在5年(或更多)的平等葡萄糖控制的后续持续。']",0.625,"['5', 'decline', 'disease', 'glucose', 'control', 'cardiovascular', 'equalization', 'cardiovascular disease', 'treatment', 'risk', 'benefit', 'with', 'this', 'that', 'to', 'and']","['5', 'decline', 'disease', 'glucose', 'control', 'cardiovascular', 'cardiovascular disease', 'treatment', 'risk', 'benefit']",,
3260,3216,"in addition , almost all the association between glucose control and major cardiovascular events was explained by the mean glycated hemoglobin level in the 3 most recent years , with no evidence that earlier years of glucose control had a carryover effect .",此外，几乎所有血糖控制与主要心血管事件之间的关联都可以用最近 3 年的平均糖化血红蛋白水平来解释，没有证据表明早年的血糖控制有遗留效应。,0.4090909090909091,"['a', 'glucose', 'control', 'cardiovascular', 'mean', 'recent', 'association', 'hemoglobin', 'addition', 'major', 'hemoglobin level', 'no', 'effect', '3', 'evidence', 'with', 'all', 'that', 'earlier', 'by', 'and', 'almost all']","['control', 'cardiovascular', 'mean', 'association', 'hemoglobin', 'effect', 'evidence', 'by', 'almost all']",3216,"['除此之外,几乎所有的糖控制与主要心血管事件之间的联系都由近3年中糖化血球的平均水平解释,没有证据表明糖控制的早期几年具有携带作用。']",0.3636363636363636,"['a', 'glucose', 'control', 'cardiovascular', 'mean', 'recent', 'association', 'hemoglobin', 'addition', 'major', 'hemoglobin level', 'no', 'effect', '3', 'evidence', 'with', 'all', 'that', 'earlier', 'by', 'and', 'almost all']","['control', 'cardiovascular', 'mean', 'association', 'effect', 'evidence', 'by', 'almost all']",,
3261,3217,several sensitivity analyses showed no evidence that 5.6 years of tight glucose control resulted in a legacy effect in our study population .,几项敏感性分析表明，没有证据表明 5.6 年的严格血糖控制对我们的研究人群产生了遗留效应。,0.3636363636363636,"['population', 'glucose', 'control', 'study', 'no', 'effect', 'evidence', 'tight', 'sensitivity', 'that', 'in']","['population', 'control', 'effect', 'evidence']",3217,"['几次敏感性分析显示没有任何证据表明,5.6年严格的葡萄糖控制导致我们研究人口的遗传效应。']",0.5454545454545454,"['population', 'glucose', 'control', 'study', 'no', 'effect', 'evidence', 'tight', 'sensitivity', 'that', 'in']","['population', 'glucose', 'control', 'effect', 'evidence', 'tight']",,
3262,3218,"however , these benefits must be weighed against adverse effects such as hypoglycemia and weight gain .",然而，必须权衡这些好处和副作用，如低血糖和体重增加。,0.5,"['gain', 'must', 'weight', 'hypoglycemia', 'be', 'adverse', 'as', 'and']","['gain', 'weight', 'as', 'and']",3218,"['然而,这些好处必须对抗不良影响,如低血糖和体重增加。']",0.5,"['gain', 'must', 'weight', 'hypoglycemia', 'be', 'adverse', 'as', 'and']","['gain', 'weight', 'as', 'and']",,
3263,3219,it is possible that underlying atherosclerosis and cardiovascular injury were too advanced in these participants to be effectively altered by glucose lowering .,这些参与者的潜在动脉粥样硬化和心血管损伤可能已经发展到无法通过降低葡萄糖有效改变的程度。,0.4545454545454545,"['injury', 'atherosclerosis', 'glucose', 'cardiovascular', 'be', 'advanced', 'lowering', 'that', 'by', 'to', 'and']","['injury', 'atherosclerosis', 'glucose', 'cardiovascular', 'be']",3219,"['在这些参与者中,基本的甲状腺硬化和心血管损伤可能过于先进,以便通过糖分降低有效地改变。']",0.4545454545454545,"['injury', 'atherosclerosis', 'glucose', 'cardiovascular', 'be', 'advanced', 'lowering', 'that', 'by', 'to', 'and']","['injury', 'cardiovascular', 'be', 'by', 'to']",,
3264,3220,it is plausible that the cardiovascular protective effects of tight glycemic control have diminishing returns once other cardiovascular disease risk factors are well controlled by medications that may also have vasoactive properties .,一旦其他心血管疾病危险因素被可能也具有血管活性的药物很好地控制，严格血糖控制的心血管保护作用的回报递减似乎是合理的。,0.5384615384615384,"['disease', 'control', 'cardiovascular', 'controlled', 'properties', 'cardiovascular disease', 'well', 'risk', 'protective', 'tight', 'have', 'that', 'by']","['disease', 'control', 'cardiovascular', 'controlled', 'cardiovascular disease', 'risk', 'have']",3220,"['可靠的是,紧密的血糖控制的心血管保护作用会减少回报,因为其他心血管疾病风险因素被药物控制得很好,这些药物也可能具有血管活性特性。']",0.5384615384615384,"['disease', 'control', 'cardiovascular', 'controlled', 'properties', 'cardiovascular disease', 'well', 'risk', 'protective', 'tight', 'have', 'that', 'by']","['disease', 'control', 'cardiovascular', 'controlled', 'cardiovascular disease', 'risk', 'have']",,
3265,3221,there are several limitations to the current study .,目前的研究有几个局限性。,0.0,"['study', 'current', 'to']",[],3221,['对目前的研究有几个限制。'],0.0,"['study', 'current', 'to']",[],,
3266,3222,the cohort in our original trial consisted largely of older men .,我们最初试验中的队列主要由老年男性组成。,0.0,"['trial', 'original', 'cohort']",[],3222,"['我們原來的審判中,大多是由老年人組成的。']",0.0,"['trial', 'original', 'cohort']",[],,
3267,3223,"however , patterns of outcomes between treatment groups did not vary notably during the transition from the active trial phase to the observation period , which suggests that these constraints did not alter the results .",然而，在从积极试验阶段到观察阶段的过渡期间，治疗组之间的结果模式没有显着差异，这表明这些限制并没有改变结果。,0.5555555555555556,"['period', 'transition', 'phase', 'active', 'treatment', 'trial', 'observation', 'that', 'to']","['period', 'transition', 'phase', 'treatment', 'observation']",3223,"['然而,治疗组之间的结果模式在从活跃试验阶段到观测期间的过渡期间并没有显著变化,这表明这些限制并没有改变结果。']",0.5555555555555556,"['period', 'transition', 'phase', 'active', 'treatment', 'trial', 'observation', 'that', 'to']","['period', 'transition', 'phase', 'treatment', 'observation']",,
3268,3224,"although there was a significantly lower risk of major cardiovascular events during the 7.1 years of separation of the glycated hemoglobin curves ( during the trial and observation periods ) , there was no evidence of a beneficial legacy effect after this period of improved glucose control .",尽管在糖化血红蛋白曲线分离的 7.1 年期间（在试验和观察期间），主要心血管事件的风险显着降低，但没有证据表明在改善血糖控制的这段时间后有有益的遗留效应。,0.5263157894736842,"['period', 'a', 'glucose', 'control', 'cardiovascular', 'hemoglobin', 'lower', 'major', 'separation', 'no', 'risk', 'after', 'trial', 'effect', 'evidence', 'observation', 'periods', 'this', 'and']","['period', 'control', 'cardiovascular', 'hemoglobin', 'separation', 'risk', 'after', 'effect', 'evidence', 'observation']",3224,"['虽然在 7.1 年的分离期间显著降低了主要心血管事件的风险(在测试和观测期间),但在这种改善葡萄糖控制期间没有有益的遗传效应的证据。']",0.4736842105263157,"['period', 'a', 'glucose', 'control', 'cardiovascular', 'hemoglobin', 'lower', 'major', 'separation', 'no', 'risk', 'after', 'trial', 'effect', 'evidence', 'observation', 'periods', 'this', 'and']","['period', 'glucose', 'control', 'cardiovascular', 'separation', 'risk', 'effect', 'evidence', 'observation']",,
3269,3225,patients presenting 4.5 to about 9 hours after stroke onset had better functional outcomes but more symptomatic intracranial hemorrhage with alteplase than placebo .,卒中发作后 4.5 至约 9 小时就诊的患者与安慰剂相比，使用阿替普酶后功能结果更好，但症状性颅内出血更多。,0.5454545454545454,"['placebo', 'stroke', 'hemorrhage', 'functional', 'intracranial', 'intracranial hemorrhage', 'onset', 'symptomatic', 'after', 'with', 'but']","['placebo', 'stroke', 'hemorrhage', 'intracranial hemorrhage', 'after', 'but']",3225,"['在发作开始后4,5至9小时的患者表现良好功能性结果,但患有阿尔特普拉斯的内分泌出血症状比 placebo 更为明显。']",0.4545454545454545,"['placebo', 'stroke', 'hemorrhage', 'functional', 'intracranial', 'intracranial hemorrhage', 'onset', 'symptomatic', 'after', 'with', 'but']","['stroke', 'hemorrhage', 'onset', 'after', 'but']",,
3270,3226,current guidelines recommend that intravenous ( IV ) alteplase should only be administered for patients with acute stroke who meet criteria and can be treated within 4.5 hours .,目前的指南建议静脉内 (IV) 阿替普酶只能用于符合标准且可在 4.5 小时内治疗的急性卒中患者。,0.2727272727272727,"['stroke', 'who', 'recommend', 'be', 'acute', 'intravenous', 'current', 'with', 'IV', 'that', 'and']","['stroke', 'recommend', 'be']",3226,"['目前的指导方针建议, intravenous(IV) alteplase 应仅适用于符合标准的急性发作患者,可在 4.5 小时内进行治疗。']",0.2727272727272727,"['stroke', 'who', 'recommend', 'be', 'acute', 'intravenous', 'current', 'with', 'IV', 'that', 'and']","['stroke', 'recommend', 'be']",,
3271,3227,"however , some patients with salvageable brain tissue beyond the current time window might benefit from IV alteplase .",然而，一些脑组织可挽救超过当前时间窗的患者可能受益于静脉注射阿替普酶。,0.5,"['tissue', 'brain', 'time', 'window', 'current', 'benefit', 'with', 'IV']","['tissue', 'brain', 'time', 'window']",3227,"['然而,一些患有超越当前时间窗外可挽救的大脑组织的患者可能受益于IV alteplase。']",0.5,"['tissue', 'brain', 'time', 'window', 'current', 'benefit', 'with', 'IV']","['tissue', 'brain', 'time', 'window']",,
3272,3228,"of those who underwent advanced brain imaging , 225 had a proven disparity between the infarct core and volume of hypoperfused tissue ( radiologic mismatch ) .",在接受高级脑成像的患者中，有 225 名患者的梗塞核心和低灌注组织体积之间存在已证实的差异（放射学不匹配）。,0.4615384615384615,"['volume', 'a', 'tissue', 'core', 'mismatch', 'who', 'infarct', 'brain', 'disparity', 'radiologic', 'advanced', 'imaging', 'and']","['volume', 'tissue', 'core', 'infarct', 'brain', 'disparity']",3228,"['经过先进的大脑图像的人中,225人发现心脏病发作核心和催眠组织(放射性混合)的容量之间存在明显的差异。']",0.3076923076923077,"['volume', 'a', 'tissue', 'core', 'mismatch', 'who', 'infarct', 'brain', 'disparity', 'radiologic', 'advanced', 'imaging', 'and']","['tissue', 'core', 'brain', 'disparity']",,
3273,3229,stroke with unknown onset time occurred in 65 % .,65% 的中风发生时间不详。,0.4,"['stroke', 'time', 'onset', 'with', 'in']","['stroke', 'time']",3229,['不知不觉的发作时间发生在65%。'],0.4,"['stroke', 'time', 'onset', 'with', 'in']","['stroke', 'time']",,
3274,3230,large vessel occlusion was present in 69 % of alteplase and 72 % of placebo patients .,69% 的阿替普酶患者和 72% 的安慰剂患者存在大血管闭塞。,0.1428571428571428,"['vessel', 'occlusion', 'placebo', 'large', 'present', 'in', 'and']",['placebo'],3230,['大型海洋排泄物在69%的阿尔特普拉斯和72%的 placebo 患者中存在。'],0.0,"['vessel', 'occlusion', 'placebo', 'large', 'present', 'in', 'and']",[],,
3275,3231,"after adjustment for baseline imbalances , an excellent outcome was observed in 35.4 % of alteplase patients and 29.5 % of placebo patients , a significant difference .",调整基线失衡后，35.4% 的阿替普酶患者和 29.5% 的安慰剂患者观察到良好结果，差异显着。,0.5555555555555556,"['placebo', 'excellent', 'baseline', 'outcome', 'adjustment', 'difference', 'after', 'significant difference', 'and']","['placebo', 'baseline', 'outcome', 'difference', 'after']",3231,"['在对基层不平衡进行调整后,在35.4%的阿尔特普拉斯病人和29.5%的 placebo病人中获得了优秀的结果,这是一个显著的差异。']",0.4444444444444444,"['placebo', 'excellent', 'baseline', 'outcome', 'adjustment', 'difference', 'after', 'significant difference', 'and']","['excellent', 'outcome', 'difference', 'after']",,
3276,3232,reperfusion of at least 50 % of the hypoperfused territory occurred in 72 % of alteplase and 52 % of placebo recipients .,72% 的阿替普酶接受者和 52% 的安慰剂接受者发生了至少 50% 的低灌注区域的再灌注。,0.1666666666666666,"['territory', 'placebo', 'at', 'in', 'and', 'reperfusion']",['placebo'],3232,"['在阿尔特普拉斯的72%和 placebo受体的52%中,至少有50%的催眠区域发生了重新融合。']",0.0,"['territory', 'placebo', 'at', 'in', 'and', 'reperfusion']",[],,
3277,3233,symptomatic intracranial hemorrhage was more common with alteplase than with placebo ( 6.2 % vs. 0.9 % ) .,有症状的颅内出血在阿替普酶组比安慰剂组更常见（6.2% 对 0.9%）。,0.5714285714285714,"['placebo', 'hemorrhage', 'intracranial', 'intracranial hemorrhage', 'common', 'symptomatic', 'with']","['placebo', 'hemorrhage', 'intracranial hemorrhage', 'symptomatic']",3233,['症状性内分泌出血在阿尔特普拉斯比 placebo 更常见(6.2% 与 0.9% )。'],0.1428571428571428,"['placebo', 'hemorrhage', 'intracranial', 'intracranial hemorrhage', 'common', 'symptomatic', 'with']",['hemorrhage'],,
3278,3234,mortality did not differ between the two groups .,死亡率在两组之间没有差异。,0.6666666666666666,"['mortality', 'differ', 'two']","['mortality', 'two']",3234,['死亡率在两组之间没有区别。'],0.6666666666666666,"['mortality', 'differ', 'two']","['mortality', 'two']",,
3279,3235,"given the increased rate of hemorrhage , many of the patients who met study criteria are likely to be better off with mechanical thrombectomy only .",鉴于出血率增加，许多符合研究标准的患者可能仅接受机械血栓切除术效果会更好。,0.3333333333333333,"['mechanical', 'who', 'rate', 'hemorrhage', 'study', 'be', 'thrombectomy', 'with', 'met']","['rate', 'hemorrhage', 'thrombectomy']",3235,"['鉴于出血率的增加,许多满足研究标准的患者很可能只有机械血管细胞才会更好。']",0.2222222222222222,"['mechanical', 'who', 'rate', 'hemorrhage', 'study', 'be', 'thrombectomy', 'with', 'met']","['rate', 'hemorrhage']",,
3280,3236,"in a trial that involved older black women , supplementation did not improve any measure of physical conditioning .",在一项涉及年长黑人女性的试验中，补充剂并未改善任何身体调节措施。,0.2857142857142857,"['conditioning', 'a', 'physical', 'black', 'trial', 'measure', 'that']","['conditioning', 'black']",3236,"['在涉及老年黑人妇女的研究中,补充剂没有改善身体调节的任何措施。']",0.2857142857142857,"['conditioning', 'a', 'physical', 'black', 'trial', 'measure', 'that']","['conditioning', 'black']",,
3281,3237,"at 3 years , bone density had not improved with supplementation compared with placebo , even though the mean 25 ( OH ) D level had increased to 47 ng / mL in the vitamin D group and was unchanged in the placebo group ( NEJM JW Gen Med Mar 1 2019 and J Bone Miner Res 2018 ; 33 : 1916 , and J Am Geriatr Soc 2019 ; 67 : 81 ) .",在 3 年时，与安慰剂相比，骨密度没有因补充剂而改善，即使维生素 D 组的平均 25 ( OH ) D 水平增加到 47 ng / mL 而安慰剂组没有变化（ NEJM JW Gen Med Mar 1 2019 和 J Bone Miner Res 2018；33：1916，以及 J Am Geriatr Soc 2019；67：81)。,0.45,"['group', 'bone', 'placebo', 'density', 'mean', 'vitamin', '1', '/', 'D', 'gen', '3', 'level', 'ml', 'with', 'vitamin D', 'at', 'to', 'and', 'med', 'miner']","['group', 'bone', 'placebo', 'density', 'mean', 'vitamin', '1', 'level', 'and']",3237,"['在3年,骨密度与补充剂相比没有改善,尽管平均25(OH)D水平在维生素D组中增加到47 ng / mL,并且在 placebo组中没有变化(NEJM JW Gen Med Mar 1 2019和J Bone Miner Res 2018;33 : 1916,和J Am Geriatr Soc 2019;67 : 81)。']",0.4,"['group', 'bone', 'placebo', 'density', 'mean', 'vitamin', '1', '/', 'D', 'gen', '3', 'level', 'ml', 'with', 'vitamin D', 'at', 'to', 'and', 'med', 'miner']","['group', 'bone', 'density', 'mean', 'vitamin', '1', 'level', 'vitamin D']",,
3282,3238,"now , these researchers report the effect of vitamin D supplementation on physical performance in this study .",现在，这些研究人员在这项研究中报告了补充维生素 D 对身体表现的影响。,0.2,"['vitamin', 'report', 'physical', 'study', 'D', 'effect', 'performance', 'vitamin D', 'on', 'this']","['vitamin', 'report']",3238,"['现在,这些研究人员报告了维生素D补充剂对身体性能的影响。']",0.4,"['vitamin', 'report', 'physical', 'study', 'D', 'effect', 'performance', 'vitamin D', 'on', 'this']","['vitamin', 'report', 'performance', 'vitamin D']",,
3283,3239,"at 3 years , investigators noted no differences between the vitamin D and placebo groups for any of these outcomes .",在 3 年时，研究人员注意到维生素 D 组和安慰剂组之间的任何这些结果都没有差异。,0.25,"['placebo', 'vitamin', 'no', 'D', '3', 'vitamin D', 'at', 'and']","['placebo', 'vitamin']",3239,"['3岁时,研究人员没有注意到维生素D和 placebo群体之间的差异,这些结果中的任何一个。']",0.25,"['placebo', 'vitamin', 'no', 'D', '3', 'vitamin D', 'at', 'and']","['vitamin', 'vitamin D']",,
3284,3240,"in recent years , experts have disagreed on whether the target for vitamin D supplementation should be a serum 25 ( OH ) D level of 20 ng / mL or 30 ng / mL .",近年来，对于补充维生素D的目标应该是血清25(OH)D水平为20 ng/mL还是30 ng/mL，专家们意见不一。,0.3846153846153846,"['a', 'vitamin', 'recent', '/', 'serum', 'be', 'target', 'D', 'level', 'ml', 'vitamin D', 'on', 'have']","['vitamin', 'serum', 'target', 'level', 'vitamin D']",3240,"['近年来,专家们不同意维生素D补充的目标是否应该是血清25(OH)D水平为20 ng / mL或30 ng / mL。']",0.3846153846153846,"['a', 'vitamin', 'recent', '/', 'serum', 'be', 'target', 'D', 'level', 'ml', 'vitamin D', 'on', 'have']","['vitamin', 'serum', 'target', 'level', 'vitamin D']",,
3285,3241,this study suggests that targeting the higher level confers no advantage - at least in terms of improving bone density and physical performance .,这项研究表明，以更高的水平为目标并没有任何优势——至少在提高骨密度和身体机能方面是这样。,0.3571428571428571,"['bone', 'density', 'physical', 'study', 'no', 'advantage', 'level', 'performance', 'at', '-', 'this', 'that', 'in', 'and']","['bone', 'density', 'advantage', 'level', 'this']",3241,"['这项研究表明,瞄准更高的水平没有任何好处 - 至少在改善骨密度和身体性能方面。']",0.2857142857142857,"['bone', 'density', 'physical', 'study', 'no', 'advantage', 'level', 'performance', 'at', '-', 'this', 'that', 'in', 'and']","['bone', 'density', 'level', 'performance']",,
3286,3242,"although the study was conducted exclusively in older black women , it seems unlikely that results would be different in other populations .",尽管这项研究专门针对年长的黑人女性进行，但其他人群的结果似乎不太可能有所不同。,0.2,"['study', 'black', 'be', 'that', 'in']",['black'],3242,"['虽然这项研究仅在老年黑人妇女中进行,但在其他人口中,结果似乎不太可能不同。']",0.4,"['study', 'black', 'be', 'that', 'in']","['black', 'be']",,
3287,3243,the latest observational study showed no excess risk .,最新的观察性研究表明没有额外的风险。,0.5,"['excess', 'observational study', 'no', 'risk']","['observational study', 'risk']",3243,['最近的观察研究没有显示过度风险。'],0.25,"['excess', 'observational study', 'no', 'risk']",['risk'],,
3288,3244,some - but not all - observational studies have suggested an association between statins and polyneuropathy .,一些（但不是全部）观察性研究表明他汀类药物与多发性神经病之间存在关联。,0.375,"['association', 'statins', 'polyneuropathy', '-', 'have', 'all', 'but', 'and']","['association', 'statins', 'but']",3244,"['一些 - 但不是所有 - 观察研究表明,静态与多元病之间的联系。']",0.375,"['association', 'statins', 'polyneuropathy', '-', 'have', 'all', 'but', 'and']","['association', 'have', 'but']",,
3289,3245,"these cases were compared with 283 healthy controls who had neither polyneuropathy nor its common risk factors ( e.g. , diabetes , excessive alcohol use ) .",这些病例与 283 名既没有多发性神经病也没有其常见危险因素（例如糖尿病、过度饮酒）的健康对照者进行了比较。,0.4,"['alcohol', 'diabetes', 'who', 'common', 'risk', 'polyneuropathy', 'controls', 'with', 'excessive', 'healthy']","['alcohol', 'diabetes', 'risk', 'healthy']",3245,"['这些病例与283个没有聚因欧病或其常见风险因素(例如,糖尿病,过量饮酒)的健康检查进行了比较。']",0.4,"['alcohol', 'diabetes', 'who', 'common', 'risk', 'polyneuropathy', 'controls', 'with', 'excessive', 'healthy']","['alcohol', 'diabetes', 'risk', 'healthy']",,
3290,3246,statin use prior to onset of symptoms was noted in 13 % of cases and in 21 % of controls .,13% 的病例和 21% 的对照组注意到在症状出现前使用他汀类药物。,0.0,"['statin', 'symptoms', 'onset', 'prior', 'controls', 'and']",[],3246,"['在症状出现之前,在13%的病例和21%的检查中被注意到使用静素。']",0.0,"['statin', 'symptoms', 'onset', 'prior', 'controls', 'and']",[],,
3291,3247,"in analyses adjusted for numerous potentially confounding variables , statin use was not associated with excess risk for polyneuropathy .",在针对许多潜在混杂变量进行调整后的分析中，他汀类药物的使用与多发性神经病的过度风险无关。,0.2857142857142857,"['statin', 'excess', 'associated', 'risk', 'polyneuropathy', 'confounding variables', 'with']","['risk', 'confounding variables']",3247,"['在对多种潜在混乱变量进行调整的分析中,静素的使用与多元病的过度风险无关。']",0.1428571428571428,"['statin', 'excess', 'associated', 'risk', 'polyneuropathy', 'confounding variables', 'with']",['risk'],,
3292,3248,"in a recent American Heart Association scientific statement on adverse effects of statins , the authors noted that an association between statins and neuropathy had been noted in some observational studies but not in randomized trials ( NEJM JW Gen Med Mar 1 2019 and Arterioscler Thromb Vasc Biol 2019 ; 39 : 38 ) .",在美国心脏协会最近关于他汀类药物不良反应的科学声明中，作者指出，他汀类药物与神经病变之间的关联已在一些观察性研究中被注意到，但在随机试验中并未被注意到（NEJM JW Gen Med 2019 年 3 月 1 日和 Arterioscler Thromb Vasc Biol 2019 ；39：38）。,0.4615384615384615,"['heart', '1', 'recent', 'neuropathy', 'association', 'statins', 'scientific', 'adverse', 'gen', 'that', 'but', 'and', 'med']","['heart', '1', 'neuropathy', 'association', 'statins', 'but']",3248,"['在美国心脏协会最近的一份关于静脉的副作用的科学声明中,作者指出,静脉与神经病之间的联系在某些观测研究中被注意到,但不是随机测试中(NEJM JW Gen Med Mar 1 2019和Arterioscler Thromb Vasc Biol 2019 ; 39 : 38 )。']",0.3846153846153846,"['heart', '1', 'recent', 'neuropathy', 'association', 'statins', 'scientific', 'adverse', 'gen', 'that', 'but', 'and', 'med']","['heart', '1', 'neuropathy', 'association', 'but']",,
3293,3249,this new study tilts the scale further against a causal association .,这项新研究使比例进一步向因果关系倾斜。,0.1428571428571428,"['a', 'association', 'scale', 'study', 'causal', 'this', 'new']",['new'],3249,['这项新研究将其扩展到进一步对抗因果关系的范围。'],0.2857142857142857,"['a', 'association', 'scale', 'study', 'causal', 'this', 'new']","['causal', 'new']",,
3294,3250,women who took high doses of both B6 and B12 had 50 % higher risk than those who had low intake .,服用高剂量维生素 B6 和维生素 B12 的女性比摄入量低的女性患病风险高 50%。,0.375,"['intake', 'who', 'low', 'risk', 'B6', 'and', 'high', 'B12']","['low', 'risk', 'high']",3250,['服用高剂量B6和B12的妇女比服用低剂量的妇女更有50%的风险。'],0.375,"['intake', 'who', 'low', 'risk', 'B6', 'and', 'high', 'B12']","['low', 'risk', 'high']",,
3295,3251,"in prior studies of B6 and B12 supplementation , researchers reported excess hip fracture risk among supplement users .",在之前对维生素 B6 和维生素 B12 补充剂的研究中，研究人员报告说补充剂使用者的髋部骨折风险过高。,0.4,"['fracture', 'excess', 'hip', 'supplement', 'risk', 'prior', 'B6', 'in', 'and', 'B12']","['fracture', 'hip', 'supplement', 'risk']",3251,"['在以前的B6和B12补充剂的研究中,研究人员在补充剂的用户中报告过度的骨折风险。']",0.3,"['fracture', 'excess', 'hip', 'supplement', 'risk', 'prior', 'B6', 'in', 'and', 'B12']","['fracture', 'supplement', 'risk']",,
3296,3252,"median intakes ( dietary plus supplements ) of vitamins B6 and B12 were 3.6 mg / day and 12.1 µg / day , respectively .",维生素 B6 和 B12 的中位数摄入量（膳食加补充剂）分别为 3.6 毫克/天和 12.1 微克/天。,0.25,"['median', '/', 'plus', 'dietary', 'vitamins', 'B6', 'and', 'B12']","['plus', 'vitamins']",3252,['维生素B6和B12的平均摄入量(饮食加上补充剂)分别为3.6 mg/天和12.1 μg/天。'],0.25,"['median', '/', 'plus', 'dietary', 'vitamins', 'B6', 'and', 'B12']","['plus', 'vitamins']",,
3297,3253,about 9 % of the population had high intake of B6 ( ≥ 35 mg / day ) and about 24 % had high intake of B12 ( ≥ 20 µg / day ) .,大约 9% 的人群摄入大量 B6（≥ 35 毫克/天），约 24% 的人群摄入大量维生素 B12（≥ 20 微克/天）。,0.1428571428571428,"['population', 'intake', '/', 'B6', 'and', 'high', 'B12']",['population'],3253,"['大约9%的人口摄入了高B6( ≥35毫克/天),大约24%的人口摄入了高B12( ≥20毫克/天)。']",0.2857142857142857,"['population', 'intake', '/', 'B6', 'and', 'high', 'B12']","['population', 'high']",,
3298,3254,Nonpathological hip fractures occurred in 2300 participants .,2300 名参与者发生了非病理性髋部骨折。,0.6666666666666666,"['hip', 'fractures', 'in']","['hip', 'fractures']",3254,['非病理骨折发生在2300名参与者。'],0.3333333333333333,"['hip', 'fractures', 'in']",['fractures'],,
3299,3255,"however , nutritional supplements do not seem to benefit people without diagnosed nutritional deficiencies , and excessive intake of some vitamins and minerals can be harmful .",然而，营养补充剂似乎对未诊断出营养缺乏症的人没有任何好处，而且某些维生素和矿物质的过量摄入可能有害。,0.2,"['intake', 'minerals', 'be', 'nutritional', 'benefit', 'vitamins', 'to', 'and', 'excessive', 'without']","['vitamins', 'and']",3255,"['然而,营养补充剂似乎不会有利于没有诊断的营养缺陷的人,过量摄入某些维生素和矿物质可能会有害。']",0.4,"['intake', 'minerals', 'be', 'nutritional', 'benefit', 'vitamins', 'to', 'and', 'excessive', 'without']","['benefit', 'vitamins', 'to', 'and']",,
3300,3256,"therefore , this study reminds us to question patients explicitly about nutritional supplement use and counsel them accordingly .",因此，这项研究提醒我们要明确询问患者有关营养补充剂使用的问题，并相应地向他们提供建议。,0.2,"['question', 'study', 'supplement', 'nutritional', 'counsel', 'nutritional supplement', 'therefore', 'this', 'to', 'and']","['question', 'supplement']",3256,"['因此,这项研究提醒我们明确询问患者关于营养补充剂的使用,并根据此咨询他们。']",0.3,"['question', 'study', 'supplement', 'nutritional', 'counsel', 'nutritional supplement', 'therefore', 'this', 'to', 'and']","['supplement', 'counsel', 'to']",,
3301,3257,"Fournier gangrene ( FG ) is a rare necrotizing fasciitis of the perineal soft tissue and organs with high rates of complications ( e.g. , fecal diversion ) and death and prolonged recovery times .",Fournier 坏疽 (FG) 是一种罕见的会阴软组织和器官坏死性筋膜炎，并发症（例如粪便改道）和死亡发生率高，恢复时间长。,0.4285714285714285,"['a', 'tissue', 'gangrene', 'death', 'fasciitis', 'fecal', 'necrotizing', 'recovery', 'diversion', 'perineal', 'with', 'prolonged', 'and', 'high']","['tissue', 'gangrene', 'death', 'fasciitis', 'recovery', 'high']",3257,['Fournier gangrene(FG)是一種罕見的<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>化性<unk>。'],0.0,"['a', 'tissue', 'gangrene', 'death', 'fasciitis', 'fecal', 'necrotizing', 'recovery', 'diversion', 'perineal', 'with', 'prolonged', 'and', 'high']",[],,
3302,3258,"although approximately half of cases are in patients with diabetes , specific triggers of this disease are not identifiable .",虽然大约一半的病例是糖尿病患者，但无法确定该病的具体诱因。,0.5,"['diabetes', 'disease', 'half', 'specific', 'with', 'approximately', 'this', 'in']","['diabetes', 'disease', 'half', 'this']",3258,"['虽然大约一半的病例发生在糖尿病患者中,但这种疾病的具体发病因无法识别。']",0.375,"['diabetes', 'disease', 'half', 'specific', 'with', 'approximately', 'this', 'in']","['diabetes', 'disease', 'half']",,
3303,3259,"median time to onset of FG after SGLT2 initiation was 4.5 months ( range , 5 days to 4 years ) .",SGLT2 启动后至 FG 发作的中位时间为 4.5 个月（范围，5 天至 4 年）。,0.5555555555555556,"['median', '5', 'initiation', 'range', 'time', 'onset', 'after', '4', 'to']","['5', 'initiation', 'range', 'time', 'after']",3259,"['在 SGLT2 启动后 FG 的平均起始时间为 4.5 个月(范围, 5 天至 4 年)。']",0.6666666666666666,"['median', '5', 'initiation', 'range', 'time', 'onset', 'after', '4', 'to']","['5', 'initiation', 'range', 'time', 'onset', 'after']",,
3304,3260,approximately two thirds of cases were in men .,大约三分之二的病例发生在男性身上。,0.0,"['approximately', 'in', 'two']",[],3260,['大约三分之二的病例是男性。'],0.0,"['approximately', 'in', 'two']",[],,
3305,3261,the recent FDA warning about FG in this drug class should lead clinicians to discuss this risk with patients .,最近 FDA 对这类药物中 FG 的警告应该引导临床医生与患者讨论这种风险。,0.2727272727272727,"['lead', 'class', 'recent', 'warning', 'FDA', 'risk', 'discuss', 'with', 'drug', 'this', 'to']","['warning', 'risk', 'drug']",3261,['最近的FDA警告关于FG在这种药物类应该引导诊所医生与患者讨论这种风险。'],0.3636363636363636,"['lead', 'class', 'recent', 'warning', 'FDA', 'risk', 'discuss', 'with', 'drug', 'this', 'to']","['warning', 'risk', 'drug', 'to']",,
3306,3262,"in vitro and mouse studies show that triclosan , an antibacterial compound used in consumer products , protects bacteria from antibiotics at typically used concentrations .",体外和小鼠研究表明，三氯生是一种用于消费品的抗菌化合物，可以保护细菌免受通常使用浓度的抗生素的侵害。,0.6,"['in vitro', 'mouse', 'antibacterial', 'compound', 'antibiotics', 'triclosan', 'at', 'concentrations', 'that', 'and']","['in vitro', 'mouse', 'compound', 'antibiotics', 'triclosan', 'at']",3262,"['in vitro 和鼠标研究表明,在消费品中使用的抗菌化合物,特里克洛桑在通常使用的浓度中保护细菌免受抗生素。']",0.3,"['in vitro', 'mouse', 'antibacterial', 'compound', 'antibiotics', 'triclosan', 'at', 'concentrations', 'that', 'and']","['mouse', 'compound', 'antibiotics']",,
3307,3263,"compounds with antimicrobial activity in consumer goods have increasingly been recognized to impose selective pressure on bacteria in the environment , influencing the activity of antimicrobial therapeutics .",人们越来越多地认识到消费品中具有抗菌活性的化合物会对环境中的细菌施加选择压力，从而影响抗菌疗法的活性。,0.5454545454545454,"['bacteria', 'pressure', 'environment', 'activity', 'antimicrobial', 'therapeutics', 'with', 'compounds', 'have', 'in', 'to']","['bacteria', 'pressure', 'environment', 'activity', 'therapeutics', 'have']",3263,"['在消费品中具有抗微生物活动的化合物越来越被认可,对环境中的细菌施加选择性压力,影响抗微生物疗法的活动。']",0.5454545454545454,"['bacteria', 'pressure', 'environment', 'activity', 'antimicrobial', 'therapeutics', 'with', 'compounds', 'have', 'in', 'to']","['bacteria', 'pressure', 'environment', 'activity', 'therapeutics', 'have']",,
3308,3264,"triclosan , a polychlorinated aromatic compound that targets fatty acid synthesis , is one such compound that is found in common household items , such as toothpaste , shaving cream , and deodorants .",三氯生是一种以脂肪酸合成为目标的多氯芳香族化合物，常见于牙膏、剃须膏和除臭剂等日常用品中。,0.3076923076923077,"['aromatic compound', 'synthesis', 'fatty', 'toothpaste', 'common', 'shaving', 'cream', 'household', 'triclosan', 'acid', 'shaving cream', 'that', 'and']","['synthesis', 'toothpaste', 'triclosan', 'acid']",3264,"['特里克洛桑,一个聚氯化的香味化合物,针对脂肪酸合成,是这种化合物之一,在常见的家庭用品,如牙膏,切割霜和消化剂。']",0.3076923076923077,"['aromatic compound', 'synthesis', 'fatty', 'toothpaste', 'common', 'shaving', 'cream', 'household', 'triclosan', 'acid', 'shaving cream', 'that', 'and']","['synthesis', 'toothpaste', 'household', 'acid']",,
3309,3265,microbiologically relevant concentrations of triclosan are found in the urine of at least 10 % of people in the U.S .,在美国至少 10% 的人的尿液中发现了微生物相关浓度的三氯生。,0.5,"['urine', 'triclosan', 'at', 'concentrations']","['urine', 'triclosan']",3265,['微生物学上相关的三克洛桑浓度在美国至少10%的人的尿液中发现。'],0.25,"['urine', 'triclosan', 'at', 'concentrations']",['urine'],,
3310,3266,researchers now describe experiments demonstrating that triclosan induces significant antibiotic tolerance in Escherichia coli and Staphylococcus aureus .,研究人员现在描述的实验证明三氯生在大肠杆菌和金黄色葡萄球菌中诱导显着的抗生素耐受性。,0.6,"['escherichia', 'antibiotic', 'escherichia coli', 'staphylococcus', 'staphylococcus aureus', 'tolerance', 'triclosan', 'that', 'in', 'and']","['antibiotic', 'escherichia coli', 'staphylococcus', 'staphylococcus aureus', 'tolerance', 'triclosan']",3266,"['研究人员现在描述的实验表明,三克洛桑在Escherichia coli和Staphylococcus aureus中引发了显著的抗生素耐受性。']",0.2,"['escherichia', 'antibiotic', 'escherichia coli', 'staphylococcus', 'staphylococcus aureus', 'tolerance', 'triclosan', 'that', 'in', 'and']","['antibiotic', 'tolerance']",,
3311,3267,this survival was dependent on induction of persister cells via the induction of synthesis of the alarmone guanosine tetraphosphate .,这种存活依赖于通过诱导四磷酸鸟苷酮的合成来诱导持久细胞。,0.5,"['induction', 'synthesis', 'survival', 'guanosine', 'via', 'this']","['induction', 'synthesis', 'survival']",3267,"['这种生存依赖于恒久细胞的引发,通过引发警报<unk><unk><unk><unk><unk>的合成。']",0.3333333333333333,"['induction', 'synthesis', 'survival', 'guanosine', 'via', 'this']","['synthesis', 'survival']",,
3312,3268,"although the U.S. FDA has banned triclosan in household soap , that is not the case worldwide , and triclosan remains in many products that we use daily .",尽管美国 FDA 已禁止在家用肥皂中使用三氯生，但世界范围内并非如此，我们日常使用的许多产品中仍然存在三氯生。,0.2222222222222222,"['soap', 'FDA', 'case', 'household', 'triclosan', 'that', 'in', 'and', 'we']","['soap', 'triclosan']",3268,"['尽管美国联邦调查局禁止在家用肥皂中使用三克洛桑,但这不是世界各地的情况,而三克洛桑仍然存在于我们每天使用的许多产品中。']",0.2222222222222222,"['soap', 'FDA', 'case', 'household', 'triclosan', 'that', 'in', 'and', 'we']","['soap', 'and']",,
3313,3269,tyrosine kinase inhibitors ( TKIs ) such as sunitinib that target vascular endothelial growth factor ( VEGF ) are widely used and are frequently active in patients with advanced renal cancer .,靶向血管内皮生长因子 (VEGF) 的酪氨酸激酶抑制剂 (TKI)，例如舒尼替尼，被广泛使用，并且经常在晚期肾癌患者中发挥作用。,0.5384615384615384,"['vascular endothelial growth factor', 'VEGF', 'tyrosine', 'cancer', 'tyrosine kinase', 'frequently', 'renal cancer', 'active', 'target', 'advanced', 'with', 'that', 'and']","['vascular endothelial growth factor', 'VEGF', 'tyrosine', 'cancer', 'tyrosine kinase', 'renal cancer', 'target']",3269,['针对血管内分泌生长因素(VEGF)的Sunitinib等甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺甲状腺'],0.0,"['vascular endothelial growth factor', 'VEGF', 'tyrosine', 'cancer', 'tyrosine kinase', 'frequently', 'renal cancer', 'active', 'target', 'advanced', 'with', 'that', 'and']",[],,
3314,3270,"however , these agents do not result in cure and have substantial toxicity burdens for patients .",然而，这些药物不能治愈并且对患者有很大的毒性负担。,0.5714285714285714,"['toxicity', 'cure', 'result', 'have', 'in', 'and', 'substantial']","['toxicity', 'cure', 'have', 'and']",3270,"['然而,这些物质不会导致治疗,并且对患者有显著的毒性负担。']",0.5714285714285714,"['toxicity', 'cure', 'result', 'have', 'in', 'and', 'substantial']","['toxicity', 'cure', 'have', 'and']",,
3315,3271,"the rate of grade 3 or 4 adverse events was lower among patients receiving combination therapy ( 40 % vs. 54 % ) , as was the rate of treatment discontinuation ( 5 % vs. 8 % ) .",接受联合治疗的患者中 3 级或 4 级不良事件的发生率较低（40% 对 54%），停止治疗的发生率也较低（5% 对 8%）。,0.4,"['combination therapy', '5', 'rate', 'grade', 'lower', 'adverse', 'treatment', '3', '4', 'as']","['combination therapy', '5', 'rate', 'treatment']",3271,"['在接受结合治疗的患者中,3级或4级副作用的发病率较低(40%与54%),如治疗中断率(5%与8%)。']",0.4,"['combination therapy', '5', 'rate', 'grade', 'lower', 'adverse', 'treatment', '3', '4', 'as']","['5', 'rate', 'treatment', 'as']",,
3316,3272,editorialists note that it is increasingly important that studies lead to improvements in achieving a durable complete response .,编辑指出，越来越重要的是，研究会导致改善实现持久的完全缓解。,0.0,"['lead', 'complete', 'response', 'note', 'that', 'in', 'to']",[],3272,"['编辑学家指出,研究导致实现可持续完整的回应的改进越来越重要。']",0.1428571428571428,"['lead', 'complete', 'response', 'note', 'that', 'in', 'to']",['complete'],,
3317,3273,both the treatment and toxicity burden for patients as well as the economic costs to the health system mandate that we raise the bar of expectations for future progress in this disease .,患者的治疗和毒性负担以及卫生系统的经济成本要求我们提高对该疾病未来进展的预期标准。,0.4285714285714285,"['disease', 'toxicity', 'system', 'health', 'raise', 'treatment', 'well', 'bar', 'progress', 'this', 'that', 'in', 'and', 'burden']","['disease', 'toxicity', 'system', 'health', 'raise', 'treatment']",3273,['治疗和毒性对患者的负担以及医疗保健系统的经济成本都要求我们提高对这种疾病的未来进展的期望。'],0.3571428571428571,"['disease', 'toxicity', 'system', 'health', 'raise', 'treatment', 'well', 'bar', 'progress', 'this', 'that', 'in', 'and', 'burden']","['disease', 'toxicity', 'system', 'raise', 'treatment']",,
3318,3274,aclidinium did not worsen cardiovascular outcomes in patients with chronic obstructive pulmonary disease .,阿地溴铵不会使慢性阻塞性肺病患者的心血管结局恶化。,0.4285714285714285,"['disease', 'cardiovascular', 'obstructive', 'pulmonary', 'chronic', 'with', 'in']","['disease', 'cardiovascular', 'chronic']",3274,['aclidinium 不会在慢性阻塞性肺疾病患者中恶化心血管结果。'],0.4285714285714285,"['disease', 'cardiovascular', 'obstructive', 'pulmonary', 'chronic', 'with', 'in']","['disease', 'cardiovascular', 'chronic']",,
3319,3275,"researchers examined the LAMA aclidinium ( Pressair ) and its effect on major adverse cardiovascular events ( MACE ) , as well its efficacy in preventing moderate to severe COPD exacerbations .",研究人员检查了 LAMA aclidinium (Pressair) 及其对主要不良心血管事件 (MACE) 的影响，以及它在预防中度至重度 COPD 恶化方面的功效。,0.3846153846153846,"['COPD', 'cardiovascular', 'moderate', 'major', 'adverse', 'well', 'effect', 'efficacy', 'severe', 'on', 'in', 'to', 'and']","['COPD', 'cardiovascular', 'effect', 'efficacy', 'severe']",3275,['研究人员研究了LAMA aclidinium(Pressair)及其对主要不良心血管事件(MACE)的影响以及其在预防中等至严重的COPD恶化方面的有效性。'],0.2307692307692307,"['COPD', 'cardiovascular', 'moderate', 'major', 'adverse', 'well', 'effect', 'efficacy', 'severe', 'on', 'in', 'to', 'and']","['COPD', 'cardiovascular', 'efficacy']",,
3320,3276,"during 3 years , MACE rates were similar in the two groups .",3 年期间，两组的 MACE 发生率相似。,0.25,"['3', 'in', 'two', 'similar']",['two'],3276,"['在3年中,MACE率在两组中是相似的。']",0.5,"['3', 'in', 'two', 'similar']","['two', 'similar']",,
3321,3277,"coupled with results from the UPLIFT trial of tiotropium ( Spiriva ; NEJM JW Gen Med Nov 1 2008 and N Engl J Med 2008 ; 359 : 1543 ) , these findings increase our confidence that LAMAs do not confer risk for cardiovascular disease in patients with COPD .",结合噻托溴铵的 UPLIFT 试验（Spiriva；NEJM JW Gen Med 2008 年 11 月 1 日和 N Engl J Med 2008 年；359:1543），这些发现增强了我们的信心，即 LAMA 不会给 COPD 患者带来心血管疾病的风险。,0.4375,"['coupled', 'COPD', 'disease', 'cardiovascular', '1', 'cardiovascular disease', 'risk', 'trial', 'gen', 'N', 'increase', 'with', 'confidence', 'that', 'and', 'med']","['COPD', 'disease', 'cardiovascular', '1', 'cardiovascular disease', 'risk', 'confidence']",3277,"['与 UPLIFT 测试的结果相结合( Spiriva ; NEJM JW Gen Med Nov 1 2008 和 N Engl J Med 2008 ; 359 : 1543 ),这些发现增加了我们的信心,LAMAs 不会在患有 COPD 的患者中提供心血管疾病的风险。']",0.4375,"['coupled', 'COPD', 'disease', 'cardiovascular', '1', 'cardiovascular disease', 'risk', 'trial', 'gen', 'N', 'increase', 'with', 'confidence', 'that', 'and', 'med']","['COPD', 'disease', 'cardiovascular', '1', 'cardiovascular disease', 'risk', 'confidence']",,
3322,3278,bleeding in early pregnancy is strongly associated with pregnancy loss .,早孕出血与流产密切相关。,0.3333333333333333,"['bleeding', 'pregnancy', 'early', 'associated', 'loss', 'with']","['bleeding', 'early']",3278,['早期怀孕的出血与怀孕损失密切相关。'],0.6666666666666666,"['bleeding', 'pregnancy', 'early', 'associated', 'loss', 'with']","['bleeding', 'pregnancy', 'early', 'loss']",,
3323,3279,progesterone is essential for the maintenance of pregnancy .,黄体酮对于维持妊娠至关重要。,0.75,"['pregnancy', 'progesterone', 'essential', 'maintenance']","['pregnancy', 'progesterone', 'maintenance']",3279,['素对怀孕的维持至关重要。'],0.5,"['pregnancy', 'progesterone', 'essential', 'maintenance']","['pregnancy', 'maintenance']",,
3324,3280,several small trials have suggested that progesterone therapy may improve pregnancy outcomes in women who have bleeding in early pregnancy .,几项小型试验表明，黄体酮治疗可以改善早孕出血妇女的妊娠结局。,0.625,"['bleeding', 'pregnancy', 'progesterone', 'who', 'early', 'therapy', 'have', 'that']","['bleeding', 'pregnancy', 'progesterone', 'early', 'therapy']",3280,"['一些小型研究表明, progesterone 治疗可以改善怀孕结果的妇女在怀孕早期出血。']",0.5,"['bleeding', 'pregnancy', 'progesterone', 'who', 'early', 'therapy', 'have', 'that']","['bleeding', 'pregnancy', 'early', 'therapy']",,
3325,3281,"women were randomly assigned to receive vaginal suppositories containing either 400 mg of progesterone or matching placebo twice daily , from the time at which they presented with bleeding through 16 weeks of gestation .",妇女被随机分配接受含有 400 毫克黄体酮或匹配安慰剂的阴道栓剂，每天两次，从她们出现出血的时间到妊娠 16 周。,0.7,"['bleeding', 'placebo', 'progesterone', 'gestation', 'vaginal', 'time', 'matching', 'with', 'suppositories', 'twice']","['bleeding', 'placebo', 'progesterone', 'gestation', 'time', 'matching', 'suppositories']",3281,"['女性随机被命令接收含有400毫克的阴道<unk>,或每天两次匹配<unk>丸<unk>,从出血到16周的怀孕。']",0.3,"['bleeding', 'placebo', 'progesterone', 'gestation', 'vaginal', 'time', 'matching', 'with', 'suppositories', 'twice']","['bleeding', 'gestation', 'matching']",,
3326,3282,the primary analysis was performed in all participants for whom data on the primary outcome were available .,主要分析是在所有可获得主要结果数据的参与者中进行的。,0.375,"['data', 'analysis', 'outcome', 'primary', 'available', 'on', 'all', 'in']","['data', 'analysis', 'outcome']",3282,"['初级分析是在所有参与者中进行的,初级结果的数据可用。']",0.375,"['data', 'analysis', 'outcome', 'primary', 'available', 'on', 'all', 'in']","['data', 'analysis', 'outcome']",,
3327,3283,a sensitivity analysis of the primary outcome that included all the participants was performed with the use of multiple imputation to account for missing data .,对包括所有参与者在内的主要结果进行了敏感性分析，并使用多重插补来解释缺失数据。,0.3333333333333333,"['a', 'data', 'analysis', 'outcome', 'multiple', 'primary', 'with', 'sensitivity', 'all', 'that', 'to', 'missing']","['data', 'analysis', 'outcome', 'missing']",3283,"['包括所有参与者在内的初始结果的敏感性分析是通过使用多种假设进行的,以计算缺失的数据。']",0.3333333333333333,"['a', 'data', 'analysis', 'outcome', 'multiple', 'primary', 'with', 'sensitivity', 'all', 'that', 'to', 'missing']","['data', 'analysis', 'outcome', 'missing']",,
3328,3284,"a total of 4153 women , recruited at 48 hospitals in the United Kingdom , were randomly assigned to receive progesterone ( 2079 women ) or placebo ( 2074 women ) .",在英国 48 家医院招募的总共 4153 名女性被随机分配接受黄体酮（2079 名女性）或安慰剂（2074 名女性）。,0.4,"['placebo', 'progesterone', 'total', 'kingdom', 'at']","['placebo', 'progesterone']",3284,"['在英国48家医院招聘的4153名妇女,随机被分配给受益者(2079名妇女)或受益者(2074名妇女)。']",0.0,"['placebo', 'progesterone', 'total', 'kingdom', 'at']",[],,
3329,3285,the percentage of women with available data for the primary outcome was 97 % ( 4038 of 4153 women ) .,具有主要结果可用数据的女性百分比为 97%（4153 名女性中的 4038 名）。,0.3333333333333333,"['percentage', 'data', 'outcome', 'primary', 'available', 'with']","['data', 'outcome']",3285,['对于初级结果的可用数据的女性比例为97%(4153名女性中有4038人)。'],0.3333333333333333,"['percentage', 'data', 'outcome', 'primary', 'available', 'with']","['data', 'outcome']",,
3330,3286,"the sensitivity analysis , in which missing primary outcome data were imputed , resulted in a similar finding ( relative rate , 1.03 ; 95 % CI , 1.00 to 1.07 ; P = 0.08 ) .",对缺失的主要结果数据进行估算的敏感性分析得出了类似的结果（相对率，1.03；95% CI，1.00 至 1.07；P = 0.08）。,0.3571428571428571,"['a', 'data', 'analysis', 'rate', 'outcome', 'relative', 'primary', 'sensitivity', 'P', 'CI', 'in', 'to', 'missing', 'similar']","['data', 'analysis', 'rate', 'outcome', 'missing']",3286,"['敏感性分析,在其中缺乏的初始结果数据被指示,导致类似的发现(相对率, 1.03 ; 95 % CI, 1.00 到 1.07 ; P = 0.08 )。']",0.3571428571428571,"['a', 'data', 'analysis', 'rate', 'outcome', 'relative', 'primary', 'sensitivity', 'P', 'CI', 'in', 'to', 'missing', 'similar']","['data', 'analysis', 'rate', 'outcome', 'missing']",,
3331,3287,the incidence of adverse events did not differ significantly between the groups .,不良事件的发生率在各组之间没有显着差异。,0.3333333333333333,"['incidence', 'adverse', 'differ']",['incidence'],3287,['副作用的发病率在各个群体之间没有显著的差异。'],0.3333333333333333,"['incidence', 'adverse', 'differ']",['incidence'],,
3332,3288,"among women with bleeding in early pregnancy , progesterone therapy administered during the first trimester did not result in a significantly higher incidence of live births than placebo . ( Funded by the United Kingdom National Institute for Health Research Health Technology Assessment program ; PRISM Current Controlled Trials number , ISRCTN14163439 . )",在早孕出血的妇女中，在妊娠早期给予黄体酮治疗并没有导致比安慰剂显着更高的活产率。 （由英国国家卫生研究所卫生技术评估计划资助；PRISM 当前对照试验编号，ISRCTN14163439。）,0.6363636363636364,"['bleeding', 'pregnancy', 'placebo', 'incidence', 'progesterone', 'research', 'program', 'health', 'early', 'therapy', 'controlled', 'assessment', 'number', 'kingdom', 'institute', 'technology', 'result', 'current', 'with', 'live', 'by', 'first']","['bleeding', 'pregnancy', 'placebo', 'progesterone', 'research', 'program', 'health', 'early', 'therapy', 'assessment', 'number', 'institute', 'technology', 'by']",3288,"['在怀孕早期出血的妇女中,在第一季度服用的<unk>丸激素治疗并没有导致活生生的发病率显著高于<unk>丸激素(由英国国家卫生研究卫生技术评估计划资助;PRISM当前控制测试号,ISRCTN14163439 )。']",0.6363636363636364,"['bleeding', 'pregnancy', 'placebo', 'incidence', 'progesterone', 'research', 'program', 'health', 'early', 'therapy', 'controlled', 'assessment', 'number', 'kingdom', 'institute', 'technology', 'result', 'current', 'with', 'live', 'by', 'first']","['bleeding', 'pregnancy', 'incidence', 'research', 'program', 'health', 'early', 'therapy', 'controlled', 'assessment', 'number', 'technology', 'by', 'first']",,
3333,3289,miscarriage affects one in five pregnancies.1,流产影响五分之一的怀孕。 1,0.3333333333333333,"['miscarriage', 'five', 'in']",['miscarriage'],3289,['怀孕不良影响每五次怀孕1'],0.0,"['miscarriage', 'five', 'in']",[],,
3334,3290,"progesterone , which is produced by the corpus luteum in the ovary , is necessary to prepare the endometrium for implantation of the embryo and thus is an essential hormone for a successful pregnancy .",黄体酮由卵巢中的黄体产生，是子宫内膜为胚胎着床做准备所必需的，因此是成功怀孕的必需激素。,0.7058823529411765,"['implantation', 'pregnancy', 'embryo', 'ovary', 'hormone', 'progesterone', 'essential', 'corpus', 'necessary', 'corpus luteum', 'thus', 'endometrium', 'in', 'by', 'to', 'and', 'prepare']","['implantation', 'pregnancy', 'embryo', 'ovary', 'hormone', 'progesterone', 'necessary', 'corpus luteum', 'thus', 'endometrium', 'by', 'prepare']",3290,"['由卵巢中的<unk>体产生的<unk>素,需要为胚胎植入的内分泌物做好准备,因此是成功怀孕的必需激素。']",0.4705882352941176,"['implantation', 'pregnancy', 'embryo', 'ovary', 'hormone', 'progesterone', 'essential', 'corpus', 'necessary', 'corpus luteum', 'thus', 'endometrium', 'in', 'by', 'to', 'and', 'prepare']","['implantation', 'pregnancy', 'embryo', 'ovary', 'hormone', 'thus', 'by', 'prepare']",,
3335,3291,additional progesterone is produced when an embryo implants in the endometrium and during early placental development .,当胚胎植入子宫内膜和早期胎盘发育过程中会产生额外的黄体酮。,0.8,"['embryo', 'progesterone', 'placental', 'early', 'additional', 'development', 'endometrium', 'implants', 'in', 'and']","['embryo', 'progesterone', 'placental', 'early', 'additional', 'development', 'endometrium', 'in']",3291,['额外的<unk>素在胚胎植入内分泌器和早期胎儿发育期间产生。'],0.4,"['embryo', 'progesterone', 'placental', 'early', 'additional', 'development', 'endometrium', 'implants', 'in', 'and']","['embryo', 'early', 'additional', 'development']",,
3336,3292,"subsequently , beginning at approximately 12 weeks of pregnancy , the placenta becomes the dominant source of progesterone.5",随后，从大约怀孕 12 周开始，胎盘成为黄体酮的主要来源。 5,0.5,"['pregnancy', 'dominant', 'placenta', 'source', 'at', 'approximately']","['pregnancy', 'placenta', 'source']",3292,"['接下来,从大约12周的怀孕开始,胎盘成为主流的<unk>素来源。']",0.5,"['pregnancy', 'dominant', 'placenta', 'source', 'at', 'approximately']","['pregnancy', 'placenta', 'source']",,
3337,3293,"the physiological importance of progesterone has prompted researchers , physicians , and patients to consider progesterone supplementation during early pregnancy to prevent miscarriages .",黄体酮的生理重要性促使研究人员、医生和患者考虑在早孕期间补充黄体酮以防止流产。,0.25,"['pregnancy', 'progesterone', 'early', 'physiological', 'prevent', 'to', 'and', 'physicians']","['progesterone', 'early']",3293,"['益生素的重要性促使研究人员、医生和患者在早期怀孕期间考虑益生素补充,以防止不适。']",0.25,"['pregnancy', 'progesterone', 'early', 'physiological', 'prevent', 'to', 'and', 'physicians']","['pregnancy', 'early']",,
3338,3294,"progesterone supplementation in early pregnancy has been attempted in two contexts : the first is to prevent miscarriages in asymptomatic women who have a history of recurrent miscarriages , and the second is to rescue a pregnancy in women who have started to bleed during early pregnancy.6",曾在两种情况下尝试过在早孕期间补充黄体酮：第一种是防止有反复流产史的无症状妇女流产，第二种是挽救在早孕期间开始流血的妇女的妊娠。 6,0.4375,"['pregnancy', 'progesterone', 'who', 'early', 'history', 'recurrent', 'asymptomatic', 'prevent', 'bleed', 'have', 'second', 'in', 'and', 'rescue', 'first', 'two']","['pregnancy', 'progesterone', 'early', 'asymptomatic', 'have', 'first', 'two']",3294,"['早期怀孕期间的 progesterone 补充已在两种情况下进行尝试:第一种是预防在无症状的妇女中出现重复出现的麻烦的麻烦,第二种是在早期怀孕期间开始出血的妇女中恢复怀孕。']",0.375,"['pregnancy', 'progesterone', 'who', 'early', 'history', 'recurrent', 'asymptomatic', 'prevent', 'bleed', 'have', 'second', 'in', 'and', 'rescue', 'first', 'two']","['pregnancy', 'early', 'asymptomatic', 'prevent', 'first', 'two']",,
3339,3295,we addressed the first scenario in a previous issue of the Journal7 and found no beneficial effect of progesterone in women with a history of unexplained recurrent miscarriages .,我们在上一期《期刊》7 中讨论了第一种情况，发现黄体酮对有不明原因反复流产史的女性没有任何有益作用。,0.2307692307692307,"['a', 'progesterone', 'issue', 'previous', 'history', 'recurrent', 'no', 'effect', 'unexplained', 'with', 'and', 'first', 'we']","['progesterone', 'effect', 'first']",3295,"['我们在《杂志7》之前的一篇文章中讨论了第一个场景,并且没有发现<unk>酮对未解释的重复性麻烦的女性有任何有益影响。']",0.1538461538461538,"['a', 'progesterone', 'issue', 'previous', 'history', 'recurrent', 'no', 'effect', 'unexplained', 'with', 'and', 'first', 'we']","['unexplained', 'first']",,
3340,3296,the current trial focuses on women with vaginal bleeding in early pregnancy .,目前的试验主要针对妊娠早期阴道流血的妇女。,0.4444444444444444,"['bleeding', 'pregnancy', 'vaginal', 'early', 'trial', 'current', 'with', 'vaginal bleeding', 'on']","['bleeding', 'pregnancy', 'early', 'current']",3296,['目前的研究专注于怀孕早期阴道出血的妇女。'],0.4444444444444444,"['bleeding', 'pregnancy', 'vaginal', 'early', 'trial', 'current', 'with', 'vaginal bleeding', 'on']","['bleeding', 'pregnancy', 'early', 'vaginal bleeding']",,
3341,3297,"the PRISM trial was approved by the United Kingdom Medicines and Healthcare Products Regulatory Agency , the United Kingdom National Research Ethics Service Committee ( South Central Oxford ) , and the National Health Service research and development department at each participating hospital .",PRISM 试验获得了英国药品和保健品监管机构、英国国家研究伦理服务委员会（牛津中南部）以及各参与医院的国家卫生服务研发部门的批准。,0.5,"['research and development', 'health', 'service', 'department', 'ethics', 'central', 'kingdom', 'committee', 'trial', 'agency', 'hospital', 'at', 'each', 'by']","['research and development', 'health', 'department', 'committee', 'hospital', 'each', 'by']",3297,['PRISM审查由英国医药和医疗保健产品监管机构、英国国家研究伦理服务委员会(南中央牛津)和全国卫生服务研究与发展部门在每个参与医院批准。'],0.3571428571428571,"['research and development', 'health', 'service', 'department', 'ethics', 'central', 'kingdom', 'committee', 'trial', 'agency', 'hospital', 'at', 'each', 'by']","['health', 'department', 'committee', 'hospital', 'by']",,
3342,3298,progesterone and placebo were purchased from Besins Healthcare .,黄体酮和安慰剂购自 Besins Healthcare。,0.6666666666666666,"['placebo', 'progesterone', 'and']","['placebo', 'progesterone']",3298,['Progesterone 和 Placebo 从 Besins Healthcare 购买。'],0.0,"['placebo', 'progesterone', 'and']",[],,
3343,3299,"this company had no role in the design of the trial ; in the collection , analysis , or interpretation of the data ; or in the preparation of the manuscript .",该公司未参与试验设计；在数据的收集、分析或解释中；或在准备手稿。,0.6363636363636364,"['data', 'analysis', 'preparation', 'collection', 'interpretation', 'role', 'no', 'manuscript', 'trial', 'design', 'this']","['data', 'analysis', 'preparation', 'collection', 'interpretation', 'manuscript', 'design']",3299,['该公司在审判的设计中没有任何作用;在数据的收集、分析或解释中;或在手稿的编制中。'],0.7272727272727273,"['data', 'analysis', 'preparation', 'collection', 'interpretation', 'role', 'no', 'manuscript', 'trial', 'design', 'this']","['data', 'analysis', 'collection', 'interpretation', 'role', 'manuscript', 'trial', 'design']",,
3344,3300,trial oversight and monitoring were provided by a trial steering committee and by an independent data and safety monitoring committee .,试验监督和监测由一个试验指导委员会和一个独立的数据和安全监测委员会提供。,0.6666666666666666,"['safety', 'monitoring', 'data', 'steering', 'committee', 'trial', 'independent', 'by', 'and']","['safety', 'monitoring', 'data', 'committee', 'independent', 'by']",3300,['审判监督和监测由审判管理委员会和独立的数据和安全监测委员会提供。'],0.7777777777777778,"['safety', 'monitoring', 'data', 'steering', 'committee', 'trial', 'independent', 'by', 'and']","['safety', 'monitoring', 'data', 'committee', 'trial', 'independent', 'by']",,
3345,3301,"the first , second , and last authors vouch for the accuracy and completeness of the data and analyses and for the fidelity of the trial to the protocol , available with the full text of this article at NEJM.org .",第一、第二和最后一位作者保证数据和分析的准确性和完整性，以及试验对方案的忠实度，方案与本文全文可在 NEJM.org 获取。,0.3333333333333333,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'second', 'this', 'and', 'first']","['data', 'accuracy', 'completeness', 'full', 'first']",3301,"['第一、第二、最后的作者为数据和分析的准确性和完整性以及对议定书的审判的忠诚性,可在NEJM.org上提供本文的完整文本。']",0.4666666666666667,"['fidelity', 'data', 'accuracy', 'protocol', 'article', 'available', 'trial', 'text', 'completeness', 'with', 'full', 'second', 'this', 'and', 'first']","['data', 'accuracy', 'protocol', 'trial', 'completeness', 'full', 'first']",,
3346,3302,the participants in the PRISM trial were recruited at 48 hospitals in the United Kingdom .,PRISM 试验的参与者是在英国的 48 家医院招募的。,0.0,"['kingdom', 'trial', 'at']",[],3302,['PRISM试验的参与者被招募到英国48家医院。'],0.0,"['kingdom', 'trial', 'at']",[],,
3347,3303,"women were eligible for enrollment in the trial if they were 16 to 39 years of age , if they had completed less than 12 weeks of pregnancy , if they presented with vaginal bleeding , and if they had an intrauterine gestational sac that was visible on ultrasonography .",如果女性年龄在 16 至 39 岁之间，如果她们完成的妊娠不足 12 周，如果她们出现阴道流血，并且如果她们有超声检查可见的宫内孕囊，则她们有资格参加试验。,0.3529411764705882,"['bleeding', 'pregnancy', 'sac', 'intrauterine', 'vaginal', 'gestational', 'age', 'trial', 'ultrasonography', 'visible', 'with', 'vaginal bleeding', 'that', 'if', 'to', 'and', 'eligible']","['bleeding', 'pregnancy', 'sac', 'age', 'ultrasonography', 'visible']",3303,"['如果他们16至39岁,如果他们完成了不到12周的怀孕,如果他们出现了阴道出血,如果他们有一个子宫内怀孕袋,这是可见的超声波。']",0.3529411764705882,"['bleeding', 'pregnancy', 'sac', 'intrauterine', 'vaginal', 'gestational', 'age', 'trial', 'ultrasonography', 'visible', 'with', 'vaginal bleeding', 'that', 'if', 'to', 'and', 'eligible']","['bleeding', 'pregnancy', 'sac', 'ultrasonography', 'visible', 'vaginal bleeding']",,
3348,3304,"the upper threshold of 39 years for maternal age was chosen because the probability of miscarriages due to chromosomal abnormalities increases with advancing age , 10 and progesterone treatment could not be expected to prevent such miscarriages .",之所以选择 39 岁作为产妇年龄的上限，是因为染色体异常导致的流产概率会随着年龄的增长而增加， 10 而黄体酮治疗无法预防此类流产。,0.4285714285714285,"['threshold', 'maternal', 'progesterone', 'probability', 'upper', 'be', 'treatment', 'age', 'increases', 'due', 'with', 'prevent', 'to', 'and']","['progesterone', 'probability', 'treatment', 'age', 'prevent', 'and']",3304,"['由于由于由于染色体异常导致失育的可能性随着年龄的推移而增加,所以选择了39年的母亲年龄的上限,10和<unk>酮治疗可能无法预防这种失育的可能性。']",0.5,"['threshold', 'maternal', 'progesterone', 'probability', 'upper', 'be', 'treatment', 'age', 'increases', 'due', 'with', 'prevent', 'to', 'and']","['maternal', 'probability', 'treatment', 'age', 'prevent', 'to', 'and']",,
3349,3305,trial ASSIGNMENTS,试用作业,0.0,['trial'],[],3305,['审判签名'],1.0,['trial'],['trial'],,
3350,3306,"participants were randomly assigned , in a 1 : 1 ratio , to administer to themselves vaginal suppositories containing either 400 mg of micronized progesterone ( Utrogestan , Besins Healthcare ) or matching placebo twice daily , from the time of randomization through 16 completed weeks of gestation ( or earlier if pregnancy ended before 16 weeks ) .",参与者被随机分配，以 1 ： 1 的比例，从随机化时间到 16 个完整的妊娠周（或如果妊娠在 16 周之前结束，则更早）。,0.4375,"['pregnancy', 'placebo', 'progesterone', 'randomization', '1', 'ratio', 'gestation', 'vaginal', 'time', 'matching', 'administer', 'suppositories', 'before', 'earlier', 'if', 'twice']","['pregnancy', 'randomization', '1', 'ratio', 'gestation', 'time', 'before']",3306,"['参与者随机分配,在1:1的比例,给自己阴道补充剂含有400毫克的微化<unk>(Utrogestan,Besins Healthcare)或匹配 placebo每天两次,从随机化到16周完成的怀孕(或更早,如果怀孕结束之前16周)。']",0.4375,"['pregnancy', 'placebo', 'progesterone', 'randomization', '1', 'ratio', 'gestation', 'vaginal', 'time', 'matching', 'administer', 'suppositories', 'before', 'earlier', 'if', 'twice']","['pregnancy', 'randomization', '1', 'ratio', 'gestation', 'matching', 'before']",,
3351,3307,"if vaginal administration was not preferred , participants could administer the suppositories rectally .",如果阴道给药不是首选，参与者可以直肠给药栓剂。,0.2,"['administration', 'vaginal', 'administer', 'suppositories', 'if']",['suppositories'],3307,"['如果阴道服用不受偏好,则参与者可以直接服用<unk>剂。']",0.0,"['administration', 'vaginal', 'administer', 'suppositories', 'if']",[],,
3352,3308,"the appearance , route , and timing of administration of progesterone and placebo were identical .",黄体酮和安慰剂给药的外观、途径和时间是相同的。,0.4285714285714285,"['placebo', 'progesterone', 'administration', 'identical', 'appearance', 'timing', 'and']","['placebo', 'progesterone', 'identical']",3308,['投注前列腺素和 placebo 的外观、路径和时间是相同的。'],0.1428571428571428,"['placebo', 'progesterone', 'administration', 'identical', 'appearance', 'timing', 'and']",['identical'],,
3353,3309,"secondary outcomes included the time from conception to the end date of pregnancy , ongoing pregnancy at 12 weeks of gestation , miscarriage ( defined as loss of pregnancy before 24 weeks of gestation ) , live birth before 34 weeks of gestation , ectopic pregnancy , stillbirth ( defined as intrauterine death after at least 24 weeks of gestation ) , termination of pregnancy , the week of gestation at delivery , birth weight , size ( small or large ) for gestational age , preeclampsia , Apgar scores , survival at 28 days of neonatal life , and congenital abnormalities , as well as other antenatal , intrapartum , postpartum , and neonatal outcomes .",次要结果包括从受孕到妊娠结束日期的时间、妊娠 12 周时的持续妊娠、流产（定义为妊娠 24 周前流产） 、妊娠 34 周前活产、异位妊娠、死产（定义妊娠至少 24 周后宫内死亡） 、终止妊娠、分娩时的妊娠周数、出生体重、胎龄大小（小或大）、先兆子痫、Apgar 评分、新生儿 28 天时的存活率，以及先天性异常，以及其他产前、产时、产后和新生儿结果。,0.5384615384615384,"['pregnancy', 'life', 'conception', 'neonatal', 'defined', 'weight', 'congenital', 'intrauterine', 'survival', 'birth weight', 'death', 'gestation', 'date', 'ectopic', 'ectopic pregnancy', 'preeclampsia', 'delivery', 'large', 'time', 'size', 'loss', 'gestational', 'termination', 'postpartum', 'well', 'antenatal', 'age', 'week', 'secondary', 'after', 'live birth', 'intrapartum', 'end', 'as', 'miscarriage', 'gestational age', 'stillbirth', 'before', 'and']","['pregnancy', 'conception', 'weight', 'survival', 'death', 'gestation', 'date', 'ectopic pregnancy', 'preeclampsia', 'delivery', 'time', 'size', 'termination', 'postpartum', 'week', 'after', 'live birth', 'intrapartum', 'miscarriage', 'stillbirth', 'before']",3309,"['二次结果包括从怀孕到怀孕结束日期的时间,在怀孕12周的持续怀孕,失业(定义为怀孕24周前的失业),在怀孕34周前的生育(定义为怀孕24周后的子宫内死亡),怀孕结束,怀孕周在怀孕期间,出生重量,尺寸(小或大)为怀孕年龄,预发光,阿普加分数,生存28天的新生儿寿命,并生育异常,以及其他内分子,内分子,产后和新生儿的结果。']",0.3846153846153846,"['pregnancy', 'life', 'conception', 'neonatal', 'defined', 'weight', 'congenital', 'intrauterine', 'survival', 'birth weight', 'death', 'gestation', 'date', 'ectopic', 'ectopic pregnancy', 'preeclampsia', 'delivery', 'large', 'time', 'size', 'loss', 'gestational', 'termination', 'postpartum', 'well', 'antenatal', 'age', 'week', 'secondary', 'after', 'live birth', 'intrapartum', 'end', 'as', 'miscarriage', 'gestational age', 'stillbirth', 'before', 'and']","['pregnancy', 'weight', 'survival', 'birth weight', 'death', 'gestation', 'date', 'time', 'size', 'termination', 'postpartum', 'age', 'week', 'after', 'before']",,
3354,3310,"a detailed list of all secondary outcomes is provided in the Supplementary Appendix , available at NEJM.org .",补充附录中提供了所有次要结局的详细列表，补充附录可在 NEJM.org 获取。,0.0,"['a', 'appendix', 'supplementary', 'available', 'secondary', 'list', 'at', 'all', 'in']",[],3310,"['详细的所有次要结果列表在附件中提供,可在NEJM.org上找到。']",0.1111111111111111,"['a', 'appendix', 'supplementary', 'available', 'secondary', 'list', 'at', 'all', 'in']",['appendix'],,
3355,3311,this minimally important difference was chosen on the basis of a national survey of clinical practitioners in the United Kingdom .,这一最低限度的重要差异是根据对英国临床从业者的全国调查选择的。,0.5,"['a', 'basis', 'difference', 'survey', 'clinical', 'kingdom', 'national survey', 'this']","['difference', 'survey', 'clinical', 'this']",3311,['这个最小重要差异是基于英国临床实践者的全国调查选择的。'],0.5,"['a', 'basis', 'difference', 'survey', 'clinical', 'kingdom', 'national survey', 'this']","['difference', 'survey', 'clinical', 'this']",,
3356,3312,this method has been shown to be appropriate and to be less prone to convergence issues than other similar methods.13,这种方法已被证明是合适的，并且比其他类似方法更不容易出现收敛问题。 13,0.2222222222222222,"['convergence', 'be', 'prone', 'method', 'this', 'to', 'and', 'appropriate', 'similar']","['convergence', 'this']",3312,"['这种方法已被证明是合适的,并且比其他类似方法更不容易接触接近问题。']",0.1111111111111111,"['convergence', 'be', 'prone', 'method', 'this', 'to', 'and', 'appropriate', 'similar']",['this'],,
3357,3313,the statistical analysis plan did not include a provision for correction for multiplicity when the analyses of the secondary outcomes were performed .,统计分析计划不包括在对次要结果进行分析时对多重性进行校正的规定。,0.7142857142857143,"['a', 'correction', 'analysis', 'provision', 'secondary', 'multiplicity', 'statistical analysis']","['correction', 'analysis', 'provision', 'multiplicity', 'statistical analysis']",3313,['统计分析计划不包括在进行二次结果分析时对多样性进行纠正的规定。'],0.4285714285714285,"['a', 'correction', 'analysis', 'provision', 'secondary', 'multiplicity', 'statistical analysis']","['analysis', 'provision', 'statistical analysis']",,
3358,3314,"therefore , the results are reported as point estimates and 95 % confidence intervals , without P values .",因此，结果报告为点估计值和 95% 置信区间，没有 P 值。,0.1111111111111111,"['values', 'point', 'as', 'confidence', 'P', 'therefore', 'and', 'without', 'intervals']",['point'],3314,"['因此,结果以点估计和95%的信任间隔报告,没有P值。']",0.1111111111111111,"['values', 'point', 'as', 'confidence', 'P', 'therefore', 'and', 'without', 'intervals']",['point'],,
3359,3315,"for continuous outcomes , a linear regression model was used to estimate mean differences , with the same adjustment that was used in the analysis of the primary outcome .",对于连续结果，使用线性回归模型估计平均差异，并使用与主要结果分析相同的调整。,0.5333333333333333,"['a', 'mean', 'model', 'analysis', 'outcome', 'continuous', 'adjustment', 'linear', 'linear regression', 'primary', 'estimate', 'with', 'that', 'to', 'regression model']","['mean', 'model', 'analysis', 'outcome', 'continuous', 'linear regression', 'to', 'regression model']",3315,"['对于持续的结果,一个线性退缩模型用于估计平均差异,与同样的调整,用于分析的初始结果。']",0.3333333333333333,"['a', 'mean', 'model', 'analysis', 'outcome', 'continuous', 'adjustment', 'linear', 'linear regression', 'primary', 'estimate', 'with', 'that', 'to', 'regression model']","['mean', 'model', 'analysis', 'outcome', 'to']",,
3360,3316,"the widths of the confidence intervals were not adjusted for multiplicity , so the intervals should not be used to infer definitive treatment effects .",置信区间的宽度未针对多重性进行调整，因此不应使用区间来推断明确的治疗效果。,0.25,"['definitive', 'be', 'treatment', 'multiplicity', 'confidence', 'so', 'to', 'intervals']","['treatment', 'multiplicity']",3316,"['信任间隔的宽度不适用于多样性,因此不应使用间隔来确定最终的治疗效果。']",0.25,"['definitive', 'be', 'treatment', 'multiplicity', 'confidence', 'so', 'to', 'intervals']","['treatment', 'to']",,
3361,3317,interim analyses of principal safety and effectiveness outcomes were performed on behalf of the data and safety monitoring committee by the trial statistician ( who remained unaware of the treatment assignments ) on two occasions .,主要安全性和有效性结果的期中分析由试验统计学家（他们仍然不知道治疗分配）代表数据和安全监测委员会进行了两次。,0.6153846153846154,"['safety', 'monitoring', 'effectiveness', 'data', 'who', 'principal', 'treatment', 'committee', 'trial', 'unaware', 'by', 'and', 'two']","['safety', 'monitoring', 'effectiveness', 'data', 'treatment', 'committee', 'by', 'two']",3317,['主要安全和有效性结果的临时分析由审查统计学家(未知处理任务)两次代表数据和安全监测委员会进行。'],0.6153846153846154,"['safety', 'monitoring', 'effectiveness', 'data', 'who', 'principal', 'treatment', 'committee', 'trial', 'unaware', 'by', 'and', 'two']","['safety', 'monitoring', 'effectiveness', 'data', 'treatment', 'committee', 'by', 'two']",,
3362,3318,"because these analyses were performed with the use of the Peto principle , 14 no adjustment was made in the final P values to determine significance .",由于这些分析是根据 Peto 原理进行的，14 因此未对最终 P 值进行调整以确定显着性。,0.1111111111111111,"['adjustment', 'no', 'principle', 'significance', 'values', 'with', 'P', 'to', 'determine']",['to'],3318,"['由于这些分析是用Peto原则进行的,所以在最终P值中没有进行任何调整,以确定意义。']",0.3333333333333333,"['adjustment', 'no', 'principle', 'significance', 'values', 'with', 'P', 'to', 'determine']","['principle', 'significance', 'to']",,
3363,3319,"from May 19 , 2015 , through July 27 , 2017 , a total of 12,862 women were identified as being eligible for the PRISM trial ; of these women , 4153 were randomly assigned to receive either progesterone ( 2079 women ) or placebo ( 2074 women ) ( Figure 1 ) .","从 2015 年 5 月 19 日到 2017 年 7 月 27 日，共有 12,862 名女性被确定为符合 PRISM 试验的资格；在这些女性中，有 4153 人被随机分配接受黄体酮（2079 名女性）或安慰剂（2074 名女性）（图 1）。",0.3333333333333333,"['placebo', 'progesterone', '1', 'figure', 'total', 'trial', 'being', 'as', 'eligible']","['placebo', 'progesterone', '1']",3319,"['2015 年 5 月 19 日至 2017 年 7 月 27 日,共有 12 862 名妇女被确定为受益于 PRISM 试验;其中 4153 名妇女被随机分配给受益于 progesterone (2079 名妇女) 或 placebo (2074 名妇女) (图 1 ) 。']",0.1111111111111111,"['placebo', 'progesterone', '1', 'figure', 'total', 'trial', 'being', 'as', 'eligible']",['1'],,
3364,3320,"demographic and baseline characteristics were similar in the two trial groups ( Table 1 , and Table S1 in the Supplementary Appendix ) .",两个试验组的人口统计学和基线特征相似（表 1 和补充附录中的表 S1）。,0.4545454545454545,"['appendix', 'table', 'baseline', '1', 'supplementary', 'characteristics', 'trial', 'S1', 'and', 'two', 'similar']","['table', 'baseline', '1', 'characteristics', 'two']",3320,['人口和基层特征在两个测试组中是相似的(图1和附件S1的图)。'],0.4545454545454545,"['appendix', 'table', 'baseline', '1', 'supplementary', 'characteristics', 'trial', 'S1', 'and', 'two', 'similar']","['appendix', '1', 'characteristics', 'two', 'similar']",,
3365,3321,information on the route of administration was available for 88 % ( 3662 of 4153 ) of the women : 99 % ( 3611 of 3662 women ) administered the suppositories vaginally and 1 % ( 51 of 3662 women ) administered them rectally .,88%（4153 名女性中的 3662 名）的女性可以获得有关给药途径的信息：99%（3662 名女性中的 3611 名）阴道给予栓剂，1%（3662 名女性中的 51 名）直肠给予栓剂。,0.5714285714285714,"['1', 'administration', 'information', 'available', 'route of administration', 'suppositories', 'and']","['1', 'information', 'route of administration', 'suppositories']",3321,"['已有88%(3662名女性中4153名):99%(3611名女性中3662名女性)按阴道服用药物,1%(3662名女性中51名女性)按直径服用药物。']",0.1428571428571428,"['1', 'administration', 'information', 'available', 'route of administration', 'suppositories', 'and']",['1'],,
3366,3322,"the incidence of live births after at least 34 weeks of gestation was 75 % ( 1513 of 2025 women ) in the progesterone group and 72 % ( 1459 of 2013 women ) in the placebo group ( relative rate , 1.03 ; 95 % CI , 1.00 to 1.07 ; P = 0.08 ) .",妊娠至少 34 周后活产的发生率在黄体酮组为 75%（2025 名女性中的 1513 名），在安慰剂组为 72%（2013 名女性中的 1459 名）（相对率 1.03 ； 95% CI 1.00 至1.07；P=0.08）。,0.5384615384615384,"['group', 'placebo', 'incidence', 'progesterone', 'rate', 'gestation', 'relative', 'after', 'P', 'live', 'CI', 'to', 'and']","['group', 'placebo', 'incidence', 'progesterone', 'rate', 'gestation', 'after']",3322,"['在怀孕至少34周后,生育的发病率为75%(2025年妇女中1513人)在 progesterone 群体和72%(2013年妇女中1459人)在 placebo 群体(相对率, 1.03; 95% CI, 1.00 至 1.07; P = 0.08 )。']",0.3846153846153846,"['group', 'placebo', 'incidence', 'progesterone', 'rate', 'gestation', 'relative', 'after', 'P', 'live', 'CI', 'to', 'and']","['group', 'incidence', 'rate', 'gestation', 'after']",,
3367,3323,"the sensitivity analysis , in which multiple imputation was used for missing data , did not change the findings ( relative rate , 1.03 ; 95 % CI , 1.00 to 1.07 ; P = 0.08 ) .",对缺失数据使用多重插补的敏感性分析没有改变结果（相对率，1.03；95% CI，1.00 至 1.07；P = 0.08）。,0.3333333333333333,"['data', 'analysis', 'rate', 'multiple', 'relative', 'change', 'sensitivity', 'P', 'CI', 'in', 'to', 'missing']","['data', 'analysis', 'rate', 'missing']",3323,"['敏感性分析,其中用于失踪数据的多种假设,并没有改变发现(相对率, 1.03 ; 95 % CI, 1.00 到 1.07 ; P = 0.08 )。']",0.3333333333333333,"['data', 'analysis', 'rate', 'multiple', 'relative', 'change', 'sensitivity', 'P', 'CI', 'in', 'to', 'missing']","['data', 'analysis', 'rate', 'to']",,
3368,3324,"the incidence of ongoing pregnancy at 12 weeks was 83 % ( 1672 of 2025 women ) in the progesterone group and 80 % ( 1602 of 2013 women ) in the placebo group ( relative rate , 1.04 ; 95 % CI , 1.01 to 1.07 ) .",孕酮组 12 周继续妊娠的发生率为 83%（2025 名女性中的 1672 名），安慰剂组为 80%（2013 名女性中的 1602 名）（相对率，1.04；95% CI，1.01 至 1.07）。,0.6,"['group', 'pregnancy', 'placebo', 'incidence', 'progesterone', 'rate', 'relative', 'CI', 'to', 'and']","['group', 'pregnancy', 'placebo', 'incidence', 'progesterone', 'rate']",3324,"['在12周的持续怀孕的发病率为Progesterone组的83%(1672名2025年妇女)和Placebo组的80%(1602名2013年妇女)(相对率,1.04;95%CI,1.01至1.07)。']",0.4,"['group', 'pregnancy', 'placebo', 'incidence', 'progesterone', 'rate', 'relative', 'CI', 'to', 'and']","['group', 'pregnancy', 'incidence', 'rate']",,
3369,3325,"the incidence of miscarriage was 20 % ( 410 of 2025 women ) in the progesterone group and 22 % ( 451 of 2013 women ) in the placebo group ( relative rate , 0.91 ; 95 % CI , 0.81 to 1.01 ) .",黄体酮组的流产发生率为 20%（2025 名女性中的 410 名），安慰剂组为 22%（2013 名女性中的 451 名）（相对率，0.91；95% CI，0.81 至 1.01）。,0.6,"['group', 'placebo', 'incidence', 'progesterone', 'rate', 'relative', 'miscarriage', 'CI', 'to', 'and']","['group', 'placebo', 'incidence', 'progesterone', 'rate', 'miscarriage']",3325,"['失育的发病率为20%(2025年女性中有410人)在<unk>丸激素群体和22%(2013年女性中有451人)在<unk>丸激素群体(相对率,0.91;95%的CI,0.81至1.01)。']",0.3,"['group', 'placebo', 'incidence', 'progesterone', 'rate', 'relative', 'miscarriage', 'CI', 'to', 'and']","['group', 'incidence', 'rate']",,
3370,3326,"the results of all the other secondary outcomes are presented in Table 2 , and in Table S2 in the Supplementary Appendix .",所有其他次要结局的结果列于表 2 和补充附录的表 S2 中。,0.2222222222222222,"['appendix', 'table', '2', 'supplementary', 'secondary', 'S2', 'all', 'in', 'and']","['table', '2']",3326,['所有其他次要结果的结果在表2和附件S2表中呈现。'],0.3333333333333333,"['appendix', 'table', '2', 'supplementary', 'secondary', 'S2', 'all', 'in', 'and']","['appendix', 'table', '2']",,
3371,3327,a significant subgroup effect was identified for only 1 of the 10 prespecified subgroups - the subgroup of participants defined according to the number of previous miscarriages .,仅在 10 个预先指定的亚组中的一个亚组中发现了显着的亚组效应——参与者亚组是根据先前的流产次数定义的。,0.3333333333333333,"['a', 'defined', '1', 'previous', 'number', 'effect', 'subgroup', '-', 'to']","['1', 'number', 'effect']",3327,['一个显著的子组效应被确定仅为10个预定子组中的1个 - 根据以前的错误数量定义的参与者子组。'],0.4444444444444444,"['a', 'defined', '1', 'previous', 'number', 'effect', 'subgroup', '-', 'to']","['1', 'previous', 'number', 'effect']",,
3372,3328,"the incidence of live births in the subgroup of women who had no previous miscarriages was 74 % in the progesterone group and 75 % in the placebo group ( relative rate , 0.99 ; 95 % CI , 0.95 to 1.04 ) ; the incidence among women who had one or two previous miscarriages was 76 % and 72 % , respectively ( relative rate 1.05 ; 95 % CI , 1.00 to 1.12 ) ; and the incidence among women who had three or more previous miscarriages was 72 % and 57 % , respectively ( relative rate , 1.28 ; 95 % CI , 1.08 to 1.51 ) ( P = 0.007 for the interaction between trial group and the number of miscarriages ) ( Figure 2 ) .",在没有流产史的女性亚组中，活产率在黄体酮组为 74%，在安慰剂组为 75%（相对率，0.99；95% CI，0.95 至 1.04）；有过一次或两次流产史的女性的发生率分别为 76% 和 72%（相对率 1.05；95% CI，1.00 至 1.12）；有过三次或以上流产史的女性的发生率分别为 72 % 和 57 % （相对率 1.28 ； 95 % CI 1.08 至 1.51 ）（试验组与流产次数之间的交互作用 P = 0.007 ） （图2）。,0.3636363636363636,"['group', 'placebo', 'incidence', 'progesterone', 'who', 'rate', '2', 'figure', 'previous', 'relative', 'no', 'number', 'interaction', 'trial', 'subgroup', 'P', 'live', 'CI', 'three', 'to', 'and', 'two']","['group', 'placebo', 'incidence', 'progesterone', 'rate', '2', 'number', 'two']",3328,"['在未曾有过不孕的妇女的子组中,生育的发病率为74%在 progesterone 组和75%在 placebo 组(相对率,0.99;95% CI,0.95 至 1.04);在曾经有过一个或两个不孕的妇女中,发病率为76%和72%,分别(相对率 1.05;95% CI,1.00 至 1.12);在未曾有过三个或多个不孕的妇女中,发病率为72%和57%,分别(相对率,1.28;95% CI,1.08 至 1.51 )(P = 0.007 对试验组和不孕的数量之间的相互作用)。']",0.2727272727272727,"['group', 'placebo', 'incidence', 'progesterone', 'who', 'rate', '2', 'figure', 'previous', 'relative', 'no', 'number', 'interaction', 'trial', 'subgroup', 'P', 'live', 'CI', 'three', 'to', 'and', 'two']","['group', 'incidence', 'rate', '2', 'number', 'two']",,
3373,3329,the results of two post hoc subgroup analyses in which we categorized the number of previous miscarriages differently from the subgroup analysis described here are provided in Figure S1 in the Supplementary Appendix .,补充附录图 S1 中提供了两项事后亚组分析的结果，在这些分析中，我们对既往流产次数进行了不同于此处描述的亚组分析的分类。,0.25,"['appendix', 'analysis', 'figure', 'previous', 'supplementary', 'post', 'number', 'subgroup', 'S1', 'in', 'two', 'we']","['analysis', 'number', 'two']",3329,"['两次随时分组分析的结果,其中我们不同于这里描述的分组分析,分类了以前的错误的数量,在附加附件中的图 S1 显示。']",0.4166666666666667,"['appendix', 'analysis', 'figure', 'previous', 'supplementary', 'post', 'number', 'subgroup', 'S1', 'in', 'two', 'we']","['appendix', 'analysis', 'previous', 'number', 'two']",,
3374,3330,a summary of serious adverse events is provided in Table S3 in the Supplementary Appendix .,补充附录表 S3 中提供了严重不良事件的总结。,0.125,"['a', 'appendix', 'table', 'supplementary', 'adverse', 'S3', 'serious', 'in']",['table'],3330,['严重不良事件的概述在附件 S3 表中提供。'],0.25,"['a', 'appendix', 'table', 'supplementary', 'adverse', 'S3', 'serious', 'in']","['appendix', 'table']",,
3375,3331,there was also no significant difference between the groups in the incidence of miscarriage or stillbirth .,流产或死产的发生率在两组之间也没有显着差异。,0.6666666666666666,"['incidence', 'difference', 'no', 'miscarriage', 'stillbirth', 'significant difference']","['incidence', 'difference', 'miscarriage', 'stillbirth']",3331,"['此外,群体之间没有显著的差异,即出生或失育的发病率。']",0.3333333333333333,"['incidence', 'difference', 'no', 'miscarriage', 'stillbirth', 'significant difference']","['incidence', 'difference']",,
3376,3332,"although there appeared to be slightly more ongoing pregnancies at 12 weeks in the progesterone group than in the placebo group , an inference of benefit cannot be drawn because the confidence interval for the relative rate was not adjusted for multiplicity of testing .",尽管孕酮组在 12 周时继续怀孕的人数似乎略高于安慰剂组，但无法推断出获益，因为相对率的置信区间未针对多重测试进行调整。,0.6923076923076923,"['group', 'placebo', 'progesterone', 'interval', 'rate', 'relative', 'be', 'inference', 'confidence interval', 'multiplicity', 'testing', 'benefit', 'to']","['group', 'placebo', 'progesterone', 'interval', 'rate', 'be', 'inference', 'confidence interval', 'to']",3332,['虽然在12周的 progesterone 群体中出现的怀孕比在 placebo 群体中出现的怀孕比在12周的 progesterone 群体中出现的怀孕比在12周的 progesterone 群体中出现的怀孕比在12周的 progesterone 群体中出现的怀孕比在12周的 progesterone 群体中出现的怀孕比在12周的 progesterone 群体中出现的怀孕比在12周的 progesterone 群体中出现的怀孕比在12周的 progesterone 群体中出现的怀孕比在12周的 progesterone 群体中出现的怀孕比在12周的 progesterone 群体中出现的怀孕比在12周的 progesterone 群体中出现的怀孕比在12周的 progesterone'],0.1538461538461538,"['group', 'placebo', 'progesterone', 'interval', 'rate', 'relative', 'be', 'inference', 'confidence interval', 'multiplicity', 'testing', 'benefit', 'to']","['group', 'be']",,
3377,3333,the large sample size in our trial allowed investigation of the primary outcome in prespecified subgroups .,我们试验中的大样本量允许在预先指定的亚组中调查主要结果。,0.375,"['sample', 'investigation', 'outcome', 'large', 'size', 'primary', 'trial', 'sample size']","['sample', 'investigation', 'outcome']",3333,"['在我们的试验中,大样品大小允许在预先指定的子组中对初始结果进行调查。']",0.5,"['sample', 'investigation', 'outcome', 'large', 'size', 'primary', 'trial', 'sample size']","['sample', 'investigation', 'outcome', 'size']",,
3378,3334,"among the 10 subgroup analyses , 1 showed differential effects of progesterone : the effect of progesterone in women with bleeding in early pregnancy differed according to the number of previous miscarriages , with a suggestion of benefit among women who had had three or more previous miscarriages .",在 10 项亚组分析中，1 项显示了黄体酮的不同影响：黄体酮对早孕出血妇女的影响因既往流产次数的不同而不同，这表明有 3 次或以上流产经历的妇女受益。,0.3125,"['bleeding', 'suggestion', 'pregnancy', 'differential', 'progesterone', 'who', '1', 'previous', 'early', 'number', 'effect', 'subgroup', 'benefit', 'with', 'three', 'to']","['bleeding', 'progesterone', '1', 'early', 'number']",3334,"['在10个子组分析中,1显示了 progesterone 的差异效应:在怀孕早期出血的妇女中, progesterone 的效应根据前几次出血的数量有所不同,并且在三次或多次出血的妇女中有好处的建议。']",0.4375,"['bleeding', 'suggestion', 'pregnancy', 'differential', 'progesterone', 'who', '1', 'previous', 'early', 'number', 'effect', 'subgroup', 'benefit', 'with', 'three', 'to']","['bleeding', 'suggestion', 'pregnancy', '1', 'early', 'number', 'effect']",,
3379,3335,"previous reports have indicated a steep and proportionate increase in the loss of chromosomally normal pregnancies ( i.e. , euploid miscarriages ) with increasing number of previous miscarriages.15",先前的报告表明，随着先前流产次数的增加，染色体正常妊娠（即整倍体流产）的流失率急剧增加并成比例增加。 15,0.1818181818181818,"['a', 'euploid', 'previous', 'normal', 'loss', 'number', 'increase', 'with', 'have', 'steep', 'and']","['euploid', 'number']",3335,"['以前的报告表明,染色体正常怀孕的损失(即卵巢不良)的急剧和比例增加,以前的不良怀孕的数量增加。']",0.2727272727272727,"['a', 'euploid', 'previous', 'normal', 'loss', 'number', 'increase', 'with', 'have', 'steep', 'and']","['previous', 'loss', 'number']",,
3380,3336,"given that the potential benefit of progesterone therapy would be expected to be specific to euploid pregnancies , an increasing level of benefit in women with increasing number of previous miscarriages is consistent with our understanding of the biologic factors associated with risk of miscarriage .",考虑到黄体酮治疗的潜在益处预计对整倍体妊娠具有特异性，因此随着先前流产次数的增加，女性的益处水平增加与我们对与流产风险相关的生物学因素的理解是一致的。,0.4444444444444444,"['progesterone', 'potential', 'euploid', 'biologic', 'previous', 'therapy', 'be', 'associated', 'number', 'risk', 'specific', 'level', 'benefit', 'with', 'miscarriage', 'that', 'in', 'to']","['progesterone', 'euploid', 'therapy', 'be', 'number', 'risk', 'level', 'miscarriage']",3336,"['鉴于 progesterone 治疗的潜在好处预计将是具体的结婚怀孕,在妇女的益处水平的增加与以前的失育的数量的增加一致,我们的理解与失育的风险相关的生物因素。']",0.3888888888888889,"['progesterone', 'potential', 'euploid', 'biologic', 'previous', 'therapy', 'be', 'associated', 'number', 'risk', 'specific', 'level', 'benefit', 'with', 'miscarriage', 'that', 'in', 'to']","['previous', 'therapy', 'be', 'number', 'risk', 'level', 'to']",,
3381,3337,"however , we did not identify this subgroup as one of special interest a priori in our statistical analysis plan , 17 and multiple comparisons were performed ( without adjustment for multiplicity ) ; thus , this observation requires validation .",然而，在我们的统计分析计划中，我们并没有先验地将这个亚组确定为特别感兴趣的亚组，17 并进行了多重比较（没有针对多重性进行调整）；因此，这一观察需要验证。,0.3888888888888889,"['a', 'analysis', 'validation', 'multiple', 'adjustment', 'thus', 'identify', 'multiplicity', 'subgroup', 'statistical analysis', 'observation', 'as', 'this', 'in', 'and', 'special', 'without', 'we']","['analysis', 'thus', 'multiplicity', 'statistical analysis', 'observation', 'and', 'special']",3337,"['然而,我们没有确定这个子组是我们统计分析计划中的特殊兴趣之一,17和多次比较进行了(没有对多样性进行调整),因此,这种观察需要验证。']",0.3888888888888889,"['a', 'analysis', 'validation', 'multiple', 'adjustment', 'thus', 'identify', 'multiplicity', 'subgroup', 'statistical analysis', 'observation', 'as', 'this', 'in', 'and', 'special', 'without', 'we']","['analysis', 'thus', 'statistical analysis', 'observation', 'this', 'and', 'special']",,
3382,3338,some limitations of our trial should be considered .,应考虑我们试验的一些局限性。,0.0,"['be', 'trial']",[],3338,['我们审判的某些限制必须考虑。'],0.5,"['be', 'trial']",['trial'],,
3383,3339,"first , we studied a vaginal preparation of progesterone , at a dose of 400 mg twice daily , and it is possible that the results observed with this regimen are not generalizable to women receiving other doses and preparations by other routes .",首先，我们研究了一种孕酮阴道制剂，剂量为 400 毫克，每天两次，使用该方案观察到的结果可能无法推广到通过其他途径接受其他剂量和制剂的女性。,0.3333333333333333,"['a', 'progesterone', 'preparation', 'vaginal', 'with', 'dose', 'preparations', 'this', 'that', 'by', 'to', 'and', 'first', 'twice', 'we']","['progesterone', 'preparation', 'dose', 'preparations', 'first']",3339,"['首先,我们研究了每日两次400毫克的阴道预测剂量,并且可能与此计划所观察的结果在接受其他剂量和其他路径的妇女中无法普遍化。']",0.1333333333333333,"['a', 'progesterone', 'preparation', 'vaginal', 'with', 'dose', 'preparations', 'this', 'that', 'by', 'to', 'and', 'first', 'twice', 'we']","['dose', 'first']",,
3384,3340,"micronized vaginal progesterone has an identical molecular structure to natural progesterone , whereas other formulations of progestational agents have a different molecular structure and therefore potentially different mechanisms of action and pharmacologic features .",微粉化阴道黄体酮与天然黄体酮具有相同的分子结构，而其他促孕剂制剂具有不同的分子结构，因此可能具有不同的作用机制和药理学特征。,0.6153846153846154,"['a', 'progesterone', 'molecular', 'vaginal', 'action', 'natural', 'molecular structure', 'identical', 'pharmacologic', 'have', 'therefore', 'to', 'and']","['progesterone', 'molecular', 'action', 'molecular structure', 'identical', 'pharmacologic', 'have', 'and']",3340,"['微化阴道<unk>素具有与天然<unk>素相同的分子结构,而其他<unk>素的配方具有不同的分子结构,因此可能有不同的作用机制和药物特征。']",0.4615384615384615,"['a', 'progesterone', 'molecular', 'vaginal', 'action', 'natural', 'molecular structure', 'identical', 'pharmacologic', 'have', 'therefore', 'to', 'and']","['molecular', 'action', 'molecular structure', 'identical', 'have', 'and']",,
3385,3341,"furthermore , trials that have evaluated vaginal progesterone in the prevention of preterm birth have shown its effectiveness when administered by this route.21,22","此外，评估阴道黄体酮预防早产的试验表明，通过这种途径给药时其有效性。 21,22",0.4444444444444444,"['progesterone', 'effectiveness', 'birth', 'vaginal', 'prevention', 'have', 'this', 'that', 'by']","['progesterone', 'effectiveness', 'prevention', 'have']",3341,"['此外,在预防早产时对阴道 progesterone 进行评估的研究表明,在通过此路径进行的测试中,它是有效的。']",0.3333333333333333,"['progesterone', 'effectiveness', 'birth', 'vaginal', 'prevention', 'have', 'this', 'that', 'by']","['prevention', 'have', 'this']",,
3386,3342,"second , we started progesterone treatment only in women who had an intrauterine sac ; therefore , our trial cannot provide evidence on the effects of earlier use of progesterone , before a pregnancy sac is visible on an ultrasound examination .",其次，我们只对有宫内囊的女性开始黄体酮治疗；因此，我们的试验无法提供证据证明在超声检查可见妊娠囊之前早期使用黄体酮的效果。,0.5625,"['pregnancy', 'progesterone', 'sac', 'intrauterine', 'who', 'examination', 'ultrasound', 'treatment', 'trial', 'evidence', 'visible', 'second', 'therefore', 'before', 'earlier', 'we']","['pregnancy', 'progesterone', 'sac', 'examination', 'ultrasound', 'treatment', 'evidence', 'second', 'before']",3342,"['其次,我们只开始在妇女中使用<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk>丸<unk']",0.0625,"['pregnancy', 'progesterone', 'sac', 'intrauterine', 'who', 'examination', 'ultrasound', 'treatment', 'trial', 'evidence', 'visible', 'second', 'therefore', 'before', 'earlier', 'we']",['second'],,
3387,3343,"third , the participants discontinued progesterone at 16 weeks of gestation ; however , we consider it to be unlikely that therapy beyond this time would have affected the outcomes related to miscarriage .",第三，参与者在妊娠16周时停用黄体酮；但是，我们认为超过此时间的治疗不太可能影响与流产相关的结果。,0.6666666666666666,"['progesterone', 'gestation', 'time', 'therapy', 'be', 'miscarriage', 'have', 'this', 'that', 'to', 'third', 'we']","['progesterone', 'gestation', 'time', 'therapy', 'be', 'miscarriage', 'this', 'third']",3343,"['第三,参与者在怀孕16周中断了<unk>酮;然而,我们认为不太可能在此期间的治疗会影响与怀孕相关的结果。']",0.3333333333333333,"['progesterone', 'gestation', 'time', 'therapy', 'be', 'miscarriage', 'have', 'this', 'that', 'to', 'third', 'we']","['gestation', 'therapy', 'be', 'third']",,
3388,3344,"finally , although we found no increase in the risk of congenital abnormalities among babies of women treated with progesterone , the trial was not powered for such rare outcomes .",最后，虽然我们发现接受黄体酮治疗的妇女所生婴儿的先天性畸形风险没有增加，但该试验的功效不足以证明这种罕见的结果。,0.25,"['progesterone', 'congenital', 'no', 'risk', 'trial', 'increase', 'with', 'we']","['progesterone', 'risk']",3344,"['最后,虽然我们发现没有增加出生异常的风险在婴儿的妇女用 progesterone 治疗,但试验没有得到如此罕见的结果。']",0.125,"['progesterone', 'congenital', 'no', 'risk', 'trial', 'increase', 'with', 'we']",['risk'],,
3389,3345,"in conclusion , treatment with progesterone did not result in significant improvement in the incidence of live births among women with vaginal bleeding during the first 12 weeks of pregnancy .",总之，孕酮治疗并未显着改善妊娠前 12 周阴道出血妇女的活产率。,0.4615384615384615,"['bleeding', 'pregnancy', 'improvement', 'incidence', 'progesterone', 'vaginal', 'treatment', 'result', 'conclusion', 'with', 'vaginal bleeding', 'live', 'first']","['bleeding', 'pregnancy', 'improvement', 'progesterone', 'treatment', 'vaginal bleeding']",3345,"['在结论中,用 progesterone 治疗并没有导致在怀孕的前 12 周内患有阴道出血的妇女中生育的发病率显著改善。']",0.5384615384615384,"['bleeding', 'pregnancy', 'improvement', 'incidence', 'progesterone', 'vaginal', 'treatment', 'result', 'conclusion', 'with', 'vaginal bleeding', 'live', 'first']","['bleeding', 'pregnancy', 'improvement', 'incidence', 'treatment', 'conclusion', 'vaginal bleeding']",,
3390,3346,the time to initiate intravenous thrombolysis for acute ischemic stroke is generally limited to within 4.5 hours after the onset of symptoms .,急性缺血性脑卒中开始静脉溶栓的时间一般限制在症状出现后4.5小时内。,0.5,"['stroke', 'thrombolysis', 'symptoms', 'time', 'onset', 'after', 'acute', 'intravenous', 'limited', 'ischemic']","['stroke', 'thrombolysis', 'time', 'onset', 'after']",3346,"['急性腹泻发作时间通常仅限于症状出现后的4,5小时内。']",0.3,"['stroke', 'thrombolysis', 'symptoms', 'time', 'onset', 'after', 'acute', 'intravenous', 'limited', 'ischemic']","['stroke', 'time', 'after']",,
3391,3347,some trials have suggested that the treatment window may be extended in patients who are shown to have ischemic but not yet infarcted brain tissue on imaging .,一些试验表明，在成像显示脑组织缺血但尚未梗塞的患者中，治疗窗口可能会延长。,0.5,"['tissue', 'who', 'brain', 'window', 'be', 'treatment', 'on', 'imaging', 'have', 'that', 'but', 'to', 'infarcted', 'ischemic']","['tissue', 'brain', 'window', 'be', 'treatment', 'but', 'infarcted']",3347,"['一些研究表明,治疗窗口可能被扩展给那些在图像上显示有骨质但尚未发病的大脑组织的患者。']",0.5,"['tissue', 'who', 'brain', 'window', 'be', 'treatment', 'on', 'imaging', 'have', 'that', 'but', 'to', 'infarcted', 'ischemic']","['tissue', 'brain', 'window', 'be', 'treatment', 'have', 'but']",,
3392,3348,the patients were randomly assigned to receive intravenous alteplase or placebo between 4.5 and 9.0 hours after the onset of stroke or on awakening with stroke ( if within 9 hours from the midpoint of sleep ) .,患者被随机分配到中风发作后 4.5 至 9.0 小时或因中风醒来时（如果在睡眠中点后 9 小时内）接受静脉内阿替普酶或安慰剂。,0.3636363636363636,"['placebo', 'stroke', 'onset', 'after', 'sleep', 'intravenous', 'awakening', 'with', 'if', 'to', 'and']","['placebo', 'stroke', 'after', 'sleep']",3348,['病人随机在发作后 4.5 至 9.0 小时内接受 intravenous alteplase 或 placebo 或在发作中醒时(如果在中间睡眠时间为 9 小时内)。'],0.2727272727272727,"['placebo', 'stroke', 'onset', 'after', 'sleep', 'intravenous', 'awakening', 'with', 'if', 'to', 'and']","['stroke', 'after', 'sleep']",,
3393,3349,"the primary outcome was a score of 0 or 1 on the modified Rankin scale , on which scores range from 0 ( no symptoms ) to 6 ( death ) , at 90 days .",主要结果是 90 天时，改良 Rankin 量表的评分为 0 分或 1 分，评分范围为 0（无症状）至 6（死亡）。,0.4545454545454545,"['a', 'range', '1', 'outcome', 'death', 'scale', 'symptoms', 'primary', 'no', 'score', 'on']","['range', '1', 'outcome', 'death', 'scale']",3349,"['初始结果是修正的Rankin规模的0或1分,在90天内,分数从0(没有症状)到6(死亡)。']",0.3636363636363636,"['a', 'range', '1', 'outcome', 'death', 'scale', 'symptoms', 'primary', 'no', 'score', 'on']","['1', 'outcome', 'death', 'score']",,
3394,3350,the risk ratio for the primary outcome was adjusted for age and clinical severity at baseline .,主要结果的风险比根据基线时的年龄和临床严重程度进行了调整。,0.75,"['baseline', 'ratio', 'outcome', 'primary', 'clinical', 'age', 'risk', 'and']","['baseline', 'ratio', 'outcome', 'clinical', 'age', 'risk']",3350,['初始结果的风险比例根据年龄和临床严重性进行调整。'],0.625,"['baseline', 'ratio', 'outcome', 'primary', 'clinical', 'age', 'risk', 'and']","['ratio', 'outcome', 'clinical', 'age', 'risk']",,
3395,3351,"after 225 of the planned 310 patients had been enrolled , the trial was terminated because of a loss of equipoise after the publication of positive results from a previous trial .",在计划招募 310 名患者中的 225 名患者后，该试验因先前试验的阳性结果公布后失去平衡而终止。,0.2857142857142857,"['a', 'previous', 'publication', 'loss', 'after', 'trial', 'positive']","['publication', 'after']",3351,"['在计划的310名患者中有225人被注册后,试验因先前试验的积极结果发布后损失而终止。']",0.2857142857142857,"['a', 'previous', 'publication', 'loss', 'after', 'trial', 'positive']","['loss', 'after']",,
3396,3352,a total of 113 patients were randomly assigned to the alteplase group and 112 to the placebo group .,共有 113 名患者被随机分配到阿替普酶组，112 名患者被随机分配到安慰剂组。,0.5,"['group', 'placebo', 'total', 'and']","['group', 'placebo']",3352,['总共有113名病人随机分配到阿尔特普拉斯群体和112名病人分配到 placebo群体。'],0.25,"['group', 'placebo', 'total', 'and']",['group'],,
3397,3353,"symptomatic intracerebral hemorrhage occurred in 7 patients ( 6.2 % ) in the alteplase group and in 1 patient ( 0.9 % ) in the placebo group ( adjusted risk ratio , 7.22 ; 95 % CI , 0.97 to 53.5 ; P = 0.05 ) .",阿替普酶组 7 例患者 (6.2%) 和安慰剂组 1 例患者 (0.9%) 发生有症状的脑内出血（调整后的风险比，7.22；95% CI，0.97 至 53.5；P = 0.05）。,0.75,"['group', 'placebo', '1', 'ratio', 'hemorrhage', 'intracerebral', 'risk', 'symptomatic', 'patient', 'P', 'CI', 'and']","['group', 'placebo', '1', 'ratio', 'hemorrhage', 'intracerebral', 'risk', 'symptomatic', 'patient']",3353,"['症状性脑内出血发生在7名患者(6.2% )在阿尔特普拉斯群体和1名患者(0.9% )在 placebo群体(调整风险比例,7.22;95% CI,0.97至53.5;P=0.05 )。']",0.5833333333333334,"['group', 'placebo', '1', 'ratio', 'hemorrhage', 'intracerebral', 'risk', 'symptomatic', 'patient', 'P', 'CI', 'and']","['group', '1', 'ratio', 'hemorrhage', 'intracerebral', 'risk', 'patient']",,
3398,3354,"among the patients in this trial who had ischemic stroke and salvageable brain tissue , the use of alteplase between 4.5 and 9.0 hours after stroke onset or at the time the patient awoke with stroke symptoms resulted in a higher percentage of patients with no or minor neurologic deficits than the use of placebo .",在本试验中患有缺血性中风且脑组织可挽救的患者中，在中风发作后 4.5 至 9.0 小时或患者因中风症状醒来时使用阿替普酶可导致更高比例的患者没有神经功能缺损或有轻微神经功能缺损。比使用安慰剂。,0.4444444444444444,"['percentage', 'placebo', 'tissue', 'stroke', 'who', 'brain', 'minor', 'symptoms', 'time', 'onset', 'patient', 'after', 'trial', 'with', 'this', 'and', 'neurologic', 'ischemic']","['placebo', 'tissue', 'stroke', 'brain', 'time', 'patient', 'after', 'neurologic']",3354,"['在这项研究中患有催化学中风和可挽救的脑组织的患者中,在中风开始后 4.5 至 9.0 小时之间使用 alteplase 或在患者醒来时与中风症状导致没有或较少的神经缺陷的患者的比例高于使用 placebo 。']",0.4444444444444444,"['percentage', 'placebo', 'tissue', 'stroke', 'who', 'brain', 'minor', 'symptoms', 'time', 'onset', 'patient', 'after', 'trial', 'with', 'this', 'and', 'neurologic', 'ischemic']","['tissue', 'stroke', 'brain', 'time', 'onset', 'patient', 'after', 'neurologic']",,
3399,3355,"there were more cases of symptomatic cerebral hemorrhage in the alteplase group than in the placebo group . ( Funded by the Australian National Health and Medical Research Council and others ; EXTEND ClinicalTrials.gov numbers , NCT00887328and NCT01580839 . )",阿替普酶组中有症状的脑出血病例多于安慰剂组。 （由澳大利亚国家健康与医学研究委员会和其他机构资助；扩展 ClinicalTrials.gov 编号，NCT00887328 和 NCT01580839。）,0.6666666666666666,"['group', 'placebo', 'research', 'hemorrhage', 'health', 'cerebral', 'medical', 'symptomatic', 'cerebral hemorrhage', 'in', 'by', 'and']","['group', 'placebo', 'research', 'hemorrhage', 'health', 'symptomatic', 'cerebral hemorrhage', 'by']",3355,"['阿尔特普拉斯群体中有更多的症状性脑出血病例,而不是 placebo群体(由澳大利亚国家卫生和医学研究委员会和其他机构资助;EXTEND ClinicalTrials.gov 号码,NCT00887328和NCT01580839 )。']",0.6666666666666666,"['group', 'placebo', 'research', 'hemorrhage', 'health', 'cerebral', 'medical', 'symptomatic', 'cerebral hemorrhage', 'in', 'by', 'and']","['group', 'research', 'hemorrhage', 'health', 'cerebral', 'cerebral hemorrhage', 'by', 'and']",,
3400,3356,"current guidelines for ischemic stroke limit the time to initiate intravenous thrombolytic therapy to within 4.5 hours after the onset of stroke.1,2","目前的缺血性中风指南将开始静脉溶栓治疗的时间限制在中风发作后 4.5 小时内。 1,2",0.5454545454545454,"['stroke', 'time', 'therapy', 'onset', 'thrombolytic', 'after', 'intravenous', 'current', 'limit', 'to', 'ischemic']","['stroke', 'time', 'therapy', 'onset', 'after', 'limit']",3356,"['目前的伊斯基米中风指南限制在中风中风治疗开始的时间,在中风开始后4,5小时内。']",0.5454545454545454,"['stroke', 'time', 'therapy', 'onset', 'thrombolytic', 'after', 'intravenous', 'current', 'limit', 'to', 'ischemic']","['stroke', 'time', 'therapy', 'onset', 'after', 'limit']",,
3401,3357,"the selection of patients for reperfusion therapies on the basis of tissue viability rather than the time from the onset of stroke has also resulted in better outcomes than medical therapy in trials of thrombectomy.9,10","在血栓切除术试验中，根据组织活力而不是中风发作时间来选择再灌注治疗患者也比药物治疗取得了更好的结果。 9,10",0.4,"['tissue', 'stroke', 'viability', 'basis', 'medical', 'time', 'therapy', 'onset', 'in', 'reperfusion']","['tissue', 'stroke', 'time', 'therapy']",3357,"['基于组织可行性而不是自中风开始时的患者的选择,也导致了更好的结果,而不是在血管细胞检测中进行的医学治疗。']",0.5,"['tissue', 'stroke', 'viability', 'basis', 'medical', 'time', 'therapy', 'onset', 'in', 'reperfusion']","['tissue', 'stroke', 'time', 'therapy', 'onset']",,
3402,3358,"the benefit of endovascular thrombectomy in patients with imaging evidence of salvageable brain tissue up to 24 hours after stroke onset has resulted in a disparity between the time windows used for thrombolytic therapy and thrombectomy.1,2","血管内血栓切除术对脑卒中发作后 24 小时内有可挽救脑组织影像学证据的患者的益处导致了用于溶栓治疗和血栓切除术的时间窗之间的差异。 1,2",0.5294117647058824,"['a', 'tissue', 'stroke', 'brain', 'disparity', 'time', 'therapy', 'onset', 'thrombectomy', 'thrombolytic', 'after', 'evidence', 'up', 'benefit', 'with', 'imaging', 'and']","['tissue', 'stroke', 'brain', 'disparity', 'time', 'therapy', 'thrombectomy', 'after', 'evidence']",3358,['心血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管血管'],0.0,"['a', 'tissue', 'stroke', 'brain', 'disparity', 'time', 'therapy', 'onset', 'thrombectomy', 'thrombolytic', 'after', 'evidence', 'up', 'benefit', 'with', 'imaging', 'and']",[],,
3403,3359,we tested the hypothesis that intravenous thrombolysis with alteplase initiated between 4.5 and 9.0 hours after stroke onset or on awakening with stroke symptoms ( for which the time of onset was not known ) would provide a benefit in patients who had a small core volume of cerebral infarction that was disproportionate to a larger area of hypoperfusion.11,我们检验了以下假设：在卒中发作后 4.5 至 9.0 小时或醒来时出现卒中症状（发作时间未知）时开始静脉溶栓阿替普酶对小体积脑梗塞患者有益。这与更大面积的低灌注不成比例。 11,0.4545454545454545,"['volume', 'a', 'core', 'stroke', 'who', 'hypothesis', 'infarction', 'cerebral', 'thrombolysis', 'cerebral infarction', 'symptoms', 'time', 'area', 'onset', 'after', 'intravenous', 'benefit', 'awakening', 'with', 'that', 'and', 'we']","['volume', 'stroke', 'hypothesis', 'infarction', 'thrombolysis', 'cerebral infarction', 'time', 'area', 'onset', 'after']",3359,"['我们测试了假设,在发作后 4.5 到 9.0 小时内启动的 intravenous thrombolysis with alteplase 或在发作症状的觉醒时(发作时间尚不清楚)将为患有较小核心大脑发作的患者提供好处。']",0.3181818181818182,"['volume', 'a', 'core', 'stroke', 'who', 'hypothesis', 'infarction', 'cerebral', 'thrombolysis', 'cerebral infarction', 'symptoms', 'time', 'area', 'onset', 'after', 'intravenous', 'benefit', 'awakening', 'with', 'that', 'and', 'we']","['core', 'stroke', 'hypothesis', 'cerebral', 'time', 'after', 'awakening']",,
3404,3360,"the trial methods have been published previously , 11 and the protocol is available with the full text of this article at NEJM.org .",试验方法之前已发表，11 实验方案与本文全文可在 NEJM.org 上获取。,0.0,"['protocol', 'article', 'available', 'trial', 'text', 'with', 'at', 'full', 'have', 'this', 'and']",[],3360,"['试验方法已经公布,11和协议与本文的完整文本在NEJM.org上可用。']",0.1818181818181818,"['protocol', 'article', 'available', 'trial', 'text', 'with', 'at', 'full', 'have', 'this', 'and']","['protocol', 'full']",,
3405,3361,"the design of the trial , the analysis and collection of the data , and the writing of the manuscript were performed by the members of the executive committee and by the investigators at the trial sites listed in the Supplementary Appendix , available at NEJM.org .",试验的设计、数据的分析和收集以及手稿的撰写由执行委员会成员和补充附录所列试验地点的研究人员完成，补充附录可在 NEJM.org 获取。,0.5,"['members', 'appendix', 'data', 'analysis', 'collection', 'supplementary', 'available', 'manuscript', 'writing', 'committee', 'trial', 'design', 'by', 'and']","['data', 'analysis', 'collection', 'manuscript', 'committee', 'design', 'by']",3361,"['审判的设计、分析和数据收集以及手稿的编写由执行委员会成员和调查人员在附件中列出的审判场所进行,可在NEJM.org上找到。']",0.6428571428571429,"['members', 'appendix', 'data', 'analysis', 'collection', 'supplementary', 'available', 'manuscript', 'writing', 'committee', 'trial', 'design', 'by', 'and']","['appendix', 'data', 'analysis', 'collection', 'manuscript', 'committee', 'trial', 'design', 'by']",,
3406,3362,"all the authors vouch for the accuracy and completeness of the data , for the fidelity of the trial to the protocol , and for the reporting of adverse events .",所有作者保证数据的准确性和完整性、试验对方案的忠实度以及不良事件的报告。,0.3333333333333333,"['fidelity', 'data', 'accuracy', 'protocol', 'adverse', 'trial', 'completeness', 'all', 'and']","['data', 'accuracy', 'completeness']",3362,"['所有作者都保证数据的准确性和完整性,审判对议定书的忠诚性,以及报告不良事件。']",0.5555555555555556,"['fidelity', 'data', 'accuracy', 'protocol', 'adverse', 'trial', 'completeness', 'all', 'and']","['data', 'accuracy', 'protocol', 'trial', 'completeness']",,
3407,3363,Boehringer Ingelheim provided the alteplase and matching placebo used in this trial .,勃林格殷格翰提供了本试验中使用的阿替普酶和匹配的安慰剂。,0.4,"['placebo', 'matching', 'trial', 'this', 'and']","['placebo', 'matching']",3363,['Boehringer Ingelheim 提供了在本试验中使用的 alteplase 和匹配 placebo 。'],0.2,"['placebo', 'matching', 'trial', 'this', 'and']",['matching'],,
3408,3364,a research version of RAPID software was provided free of charge to the trial sites by iSchemaView .,iSchemaView 向试用网站免费提供了 RAPID 软件的研究版。,0.3333333333333333,"['charge', 'research', 'version', 'free', 'free of charge', 'software', 'trial', 'by', 'to']","['research', 'free of charge', 'software']",3364,['RAPID 软件的研究版本是由 iSchemaView 免费提供的测试网站。'],0.5555555555555556,"['charge', 'research', 'version', 'free', 'free of charge', 'software', 'trial', 'by', 'to']","['research', 'version', 'free of charge', 'software', 'by']",,
3409,3365,"neither company was involved in the design , conduct , or reporting of the trial .",两家公司均未参与试验的设计、实施或报告。,0.25,"['trial', 'conduct', 'design', 'in']",['design'],3365,['没有公司参与了审判的设计、执行或报告。'],0.5,"['trial', 'conduct', 'design', 'in']","['trial', 'design']",,
3410,3366,no confidentiality agreements were in place between the authors and either commercial entity .,作者与任一商业实体之间均未签订保密协议。,0.3333333333333333,"['confidentiality', 'entity', 'no', 'agreements', 'in', 'and']","['confidentiality', 'entity']",3366,['作者和任何商业实体之间没有任何隐私协议。'],0.1666666666666666,"['confidentiality', 'entity', 'no', 'agreements', 'in', 'and']",['entity'],,
3411,3367,"recruitment was suspended on June 6 , 2018 .",2018年6月6日停止招聘。,0.0,"['recruitment', 'on']",[],3367,['招聘已于2018年6月6日暂停。'],0.0,"['recruitment', 'on']",[],,
3412,3368,occlusion of a large cerebral vessel was not a prerequisite for inclusion .,大脑血管的闭塞不是纳入的先决条件。,0.2857142857142857,"['vessel', 'occlusion', 'a', 'inclusion', 'prerequisite', 'cerebral', 'large']","['prerequisite', 'cerebral']",3368,['一个大脑船的封锁并不是包含的前提条件。'],0.4285714285714285,"['vessel', 'occlusion', 'a', 'inclusion', 'prerequisite', 'cerebral', 'large']","['inclusion', 'prerequisite', 'cerebral']",,
3413,3369,patients were not eligible if the investigator was considering the use of endovascular thrombectomy at the time of enrollment .,如果研究者在入组时考虑使用血管内血栓切除术，则患者不符合条件。,0.6,"['investigator', 'time', 'thrombectomy', 'if', 'eligible']","['investigator', 'time', 'thrombectomy']",3369,['如果研究人员考虑在登记时使用内血管血管细胞。'],0.2,"['investigator', 'time', 'thrombectomy', 'if', 'eligible']",['time'],,
3414,3370,the trial was approved by the institutional ethics committee at each participating site .,该试验得到了每个参与地点的机构伦理委员会的批准。,0.2857142857142857,"['site', 'ethics', 'committee', 'trial', 'at', 'each', 'by']","['site', 'committee']",3370,['审判由各参与场所的机构道德委员会批准。'],0.7142857142857143,"['site', 'ethics', 'committee', 'trial', 'at', 'each', 'by']","['site', 'committee', 'trial', 'each', 'by']",,
3415,3371,written informed consent was obtained from all the patients or their legal representatives before enrollment .,入组前已获得所有患者或其法定代理人的书面知情同意书。,0.5,"['consent', 'informed consent', 'all', 'before']","['consent', 'before']",3371,['所有患者或其法定代表在登记前获得了书面通知的同意。'],0.5,"['consent', 'informed consent', 'all', 'before']","['consent', 'before']",,
3416,3372,additional details of the inclusion and exclusion criteria are provided in the Supplementary Appendix .,补充附录中提供了纳入和排除标准的更多详细信息。,0.0,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'additional', 'and']",[],3372,['包括和排除标准的详细信息在附件中提供。'],0.1666666666666666,"['appendix', 'inclusion', 'supplementary', 'exclusion', 'additional', 'and']",['appendix'],,
3417,3373,"from 2010 through February 2018 , the guidelines did not include the use of endovascular thrombectomy in extended time windows .",从 2010 年到 2018 年 2 月，该指南不包括在延长时间窗内使用血管内血栓切除术。,0.6666666666666666,"['time', 'thrombectomy', 'in']","['time', 'thrombectomy']",3373,"['从2010年至2018年2月,指南不包括在延长时间的窗口中使用内血管血管细胞。']",0.3333333333333333,"['time', 'thrombectomy', 'in']",['time'],,
3418,3374,the primary outcome was a score of 0 or 1 on the modified Rankin scale at 90 days ( indicating an excellent functional outcome with a return to all usual activities ) .,主要结果是 90 天时改良 Rankin 量表的得分为 0 或 1（表明恢复所有日常活动的良好功能结果）。,0.2142857142857142,"['a', 'excellent', '1', 'outcome', 'scale', 'functional', 'usual', 'primary', 'score', 'with', 'at', 'return', 'all', 'to']","['1', 'outcome', 'scale']",3374,"['初始结果在90天修改的Rankin尺寸上得分为0或1(指向出色的功能结果,并返回所有常规活动)。']",0.1428571428571428,"['a', 'excellent', '1', 'outcome', 'scale', 'functional', 'usual', 'primary', 'score', 'with', 'at', 'return', 'all', 'to']","['1', 'outcome']",,
3419,3375,the risk ratio for the primary outcome was adjusted for age and clinical severity of stroke ( NIHSS score ) at baseline .,主要结果的风险比根据年龄和基线时卒中的临床严重程度（NIHSS 评分）进行了调整。,0.7,"['stroke', 'baseline', 'ratio', 'outcome', 'primary', 'clinical', 'age', 'risk', 'score', 'and']","['stroke', 'baseline', 'ratio', 'outcome', 'clinical', 'age', 'risk']",3375,['初始结果的风险比例按年龄和临床发作严重性(NIHSS分数)进行调整。'],0.7,"['stroke', 'baseline', 'ratio', 'outcome', 'primary', 'clinical', 'age', 'risk', 'score', 'and']","['stroke', 'ratio', 'outcome', 'clinical', 'age', 'risk', 'score']",,
3420,3376,"the secondary clinical outcomes were the score ( 0 to 6 ) on the modified Rankin scale at 90 days ( with the distribution of scores in each trial group used in an ordinal analysis to assess functional improvement ) ; a score of 0 to 2 on the modified Rankin scale at 90 days ( indicating functional independence ) ; and percentages of reperfusion of at least 50 % and of at least 90 % at 24 hours after the intervention ( defined as ≥ 50 % and ≥ 90 % reductions , respectively , in the volume of the perfusion lesion in which there had been a delayed arrival of an injected tracer agent exceeding 6 seconds ) .19",次要临床结果是 90 天时改良 Rankin 量表的评分（0 至 6 分）（每个试验组的评分分布用于顺序分析以评估功能改善）； 90 天时改良 Rankin 量表评分为 0 至 2（表示功能独立）；干预后 24 小时再灌注百分比至少为 50 % 和至少 90 % （定义为延迟到达的灌注损伤体积分别减少 ≥ 50 % 和 ≥ 90 % ）注射示踪剂超过 6 秒）.19,0.5333333333333333,"['group', 'lesion', 'perfusion', 'improvement', 'volume', 'a', 'defined', 'analysis', '2', 'scale', 'ordinal', 'functional', 'tracer', 'distribution', 'clinical', 'intervention', 'secondary', 'after', 'trial', 'independence', 'assess', 'score', 'with', 'at', 'agent', 'delayed', 'each', 'to', 'and', 'reperfusion']","['group', 'lesion', 'perfusion', 'improvement', 'volume', 'analysis', '2', 'scale', 'distribution', 'clinical', 'after', 'independence', 'assess', 'at', 'delayed', 'to']",3376,"['二次临床结果是90天修复的Rankin规模的分数(每个测试组的分数分配用于评估功能改善的常规分析),90天修复的Rankin规模的分数为0至2(表明功能独立性),24小时后至少有50%和至少有90%的反射率(定义为 ≥50%和 ≥90%的减少,相应地,在注射器的延迟到达超过6秒的注射损伤量中。']",0.5,"['group', 'lesion', 'perfusion', 'improvement', 'volume', 'a', 'defined', 'analysis', '2', 'scale', 'ordinal', 'functional', 'tracer', 'distribution', 'clinical', 'intervention', 'secondary', 'after', 'trial', 'independence', 'assess', 'score', 'with', 'at', 'agent', 'delayed', 'each', 'to', 'and', 'reperfusion']","['group', 'lesion', 'improvement', 'analysis', '2', 'scale', 'distribution', 'clinical', 'after', 'independence', 'assess', 'score', 'at', 'delayed', 'to']",,
3421,3377,this analysis confirmed a final intended sample size of 310 patients.23,该分析确认了 310 名患者的最终预期样本量。 23,0.4,"['sample', 'analysis', 'size', 'sample size', 'this']","['sample', 'analysis']",3377,['此分析确认了310名患者的最终预定样品大小。'],0.6,"['sample', 'analysis', 'size', 'sample size', 'this']","['sample', 'analysis', 'size']",,
3422,3378,"the statistical analysis plan , available in the protocol , was finalized before the database was locked.23",协议中提供的统计分析计划在数据库锁定之前完成 23 。,0.5714285714285714,"['database', 'analysis', 'protocol', 'available', 'statistical analysis', 'before', 'in']","['analysis', 'protocol', 'statistical analysis', 'before']",3378,['议定书中可用的统计分析计划在数据库被锁定之前完成。'],0.7142857142857143,"['database', 'analysis', 'protocol', 'available', 'statistical analysis', 'before', 'in']","['analysis', 'protocol', 'available', 'statistical analysis', 'before']",,
3423,3379,"statistical analyses were performed with the use of Stata software , version 13 ( StataCorp ) .",使用 Stata 软件 13 版 (StataCorp) 进行统计分析。,0.3333333333333333,"['version', 'software', 'with']",['software'],3379,"['统计分析是使用Stata软件,版本13(StataCorp)进行的。']",0.6666666666666666,"['version', 'software', 'with']","['version', 'software']",,
3424,3380,treatment effects for secondary outcomes are presented as adjusted risk ratios with 95 % confidence intervals .,次要结果的治疗效果以调整后的风险比和 95% 置信区间表示。,0.2857142857142857,"['treatment', 'risk', 'secondary', 'as', 'with', 'confidence', 'intervals']","['treatment', 'risk']",3380,['二进制结果的治疗效果以95%的信任间隔进行调整的风险比例。'],0.2857142857142857,"['treatment', 'risk', 'secondary', 'as', 'with', 'confidence', 'intervals']","['treatment', 'risk']",,
3425,3381,"because the analyses of the secondary or tertiary outcomes did not include adjustment for multiple comparisons , the results are reported as point estimates with unadjusted 95 % confidence intervals .",由于对次要或三级结果的分析不包括多重比较调整，结果报告为具有未调整的 95% 置信区间的点估计值。,0.2222222222222222,"['multiple', 'adjustment', 'secondary', 'unadjusted', 'point', 'as', 'with', 'confidence', 'intervals']","['unadjusted', 'point']",3381,"['由于二级或三级结果的分析不包括对多个比较进行调整,结果以不调整的95%信任间隔的点估计报告。']",0.1111111111111111,"['multiple', 'adjustment', 'secondary', 'unadjusted', 'point', 'as', 'with', 'confidence', 'intervals']",['point'],,
